<SEC-DOCUMENT>0001558370-23-009707.txt : 20230515
<SEC-HEADER>0001558370-23-009707.hdr.sgml : 20230515
<ACCEPTANCE-DATETIME>20230515092755
ACCESSION NUMBER:		0001558370-23-009707
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		109
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230515
DATE AS OF CHANGE:		20230515

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			iBio, Inc.
		CENTRAL INDEX KEY:			0001420720
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				262797813
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35023
		FILM NUMBER:		23919012

	BUSINESS ADDRESS:	
		STREET 1:		600 MADISON AVENUE, SUITE 1601
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022-1737
		BUSINESS PHONE:		302 355-0650

	MAIL ADDRESS:	
		STREET 1:		600 MADISON AVENUE, SUITE 1601
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022-1737

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	iBioPharma, Inc.
		DATE OF NAME CHANGE:	20080806

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	InB:Biotechnologies, Inc.
		DATE OF NAME CHANGE:	20071210
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ibio-20230331x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.2.5.9 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 5/15/2023 1:23:24 PM -->
      <!-- iXBRL Library version: 1.0.8476.13996 -->
      <!-- iXBRL Service Job ID: 0feb4e6a-2e11-4ecf-b69e-ff06b9538fce -->

  <html xmlns:ibio="http://www.ibioinc.com/20230331" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" xs:nil="true" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" name="us-gaap:PreferredStockValue" id="Hidden_Mmhw1Jx8RkCtn1jI8k-39w"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" xs:nil="true" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" name="us-gaap:PreferredStockValue" id="Hidden_N_j11tLD2kCEU98JvTtlWA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" sign="-" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" id="Hidden_uMJ7rDsFFEe-PYrwZsUJbg">0.47</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" sign="-" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" id="Hidden_4R874yyR00-lQ-gPK5aVDQ">0.77</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" sign="-" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" id="Hidden_4cohup_Xe0im-EU-Ng1hmQ">2.30</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" sign="-" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" id="Hidden_alkmQJ0-3EK_SSHZA_FGwg">2.20</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" sign="-" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" id="Hidden_s2ZDVjJuBUuX5ocrOsoaJA">0.08</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" sign="-" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" id="Hidden_pvbUml_Xr02ereqyMzgIaA">0.65</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" sign="-" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" id="Hidden_tZ68DHnAh0ewkHu2Z17AYg">3.27</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" sign="-" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" id="Hidden_UcSIW9AD8UiR_O8CKdfyGg">1.62</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" sign="-" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_KoisN5HwMUirJemjndgMlQ">0.55</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" sign="-" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_3P92l1MxxUySgIWVF8sauw">1.42</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" sign="-" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_CHdwpyqz5UmsdxMQu01lmA">5.57</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" sign="-" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_Y9WTzYNp-UiQOB98sjcuIw">3.82</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_X1igTQcX2UyKMX7R8gIL5Q">13184000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_H4VP7sY7u0-Nc2YmbPLNbg">8719000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_d1Pfavst9UCfkWrvh4C2fA">10592000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_N_ufrc8wzUOepnKRl3ROPA">8719000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_L-Jh2gUQ20aXNcKW4O9D8A">13184000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_Sd0Sn95nhESiByEw7rkSOw">8719000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_8NBIqXmdCESiQWM1l4UUWw">10592000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="Duration_7_1_2021_To_9_30_2021_vL3rOPanq0GYnPOprKHLGg" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_cDAb6ZuFx0WK18wMCd_ivg">8719000</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" sign="-" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" id="Hidden_wjVHAja0hk-ujBowM-xKHQ">0.47</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" sign="-" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" id="Hidden_yQjZFWrye0SmP2jIiPGrBA">0.77</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" sign="-" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" id="Hidden_-JF8WUqQSkmfxC0R_OaSQA">2.30</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" sign="-" contextRef="Duration_7_1_2021_To_9_30_2021_vL3rOPanq0GYnPOprKHLGg" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" id="Hidden_PwsJbaSoOUORrCdM232mAA">2.20</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" sign="-" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" id="Hidden_9HqUV2MAckqjZOnis6YfZg">0.08</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" sign="-" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" id="Hidden_U0bOGUWDzkuEeJ29Nf_EjQ">0.65</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" sign="-" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" id="Hidden_TmWH34FMsECu90mrUdyfXg">3.27</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" sign="-" contextRef="Duration_7_1_2021_To_9_30_2021_vL3rOPanq0GYnPOprKHLGg" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" id="Hidden_kDRlUx8GmUabgAhq5k_vvQ">1.62</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" sign="-" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_Zp0MkR-0tUq910UPmXzGpA">0.55</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" sign="-" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_acVcgEcpAUW-LaSF7a3TxQ">1.42</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" sign="-" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_wBTFuchxW0eQbgh0co0GoQ">5.57</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" sign="-" contextRef="Duration_7_1_2021_To_9_30_2021_vL3rOPanq0GYnPOprKHLGg" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_tJo2ezbm1Eau_et1XorUuA">3.82</ix:nonFraction><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_srt_RangeAxis_srt_MinimumMember_iZJ0-KgMMEWGQBeszyazgg" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Hidden_Eet2cSErQUWYG2NYDDLIPA">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_7qvwM12szUub7e7UoiuztA" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Hidden_5A4l74BAAkGpy-k8y3HFLw">P23Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="dei:EntityCentralIndexKey" id="Tc_s0P44FTMQESws8USVI0JYA_2_1">0001420720</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="dei:CurrentFiscalYearEndDate" id="Tc_zckhK2d-j0mrNXCfAWreBQ_3_1">--06-30</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="dei:DocumentFiscalYearFocus" id="Tc_hZBWLIhR80OijMhMqCjy_g_4_1">2023</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="dei:DocumentFiscalPeriodFocus" id="Tc_9tqFbpgFckS4rj5HeafPtw_5_1">Q3</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="dei:AmendmentFlag" id="Tc_nDMQDrLQsE-wJcCtxBXxPg_6_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" id="Hidden_ALMi0aoiGEux0RbmMQwClg">422000</ix:nonFraction><ix:nonNumeric contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="Hidden_UQCuo_IgjkapUCQ_dOiKtg">P0Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_srt_StatementScenarioAxis_ibio_NoBiosimilarProductHasBeenApprovedMember_us-gaap_TypeOfArrangementAxis_ibio_CollaborationOptionAndLicenseAgreementMember_ou4zV9VwTU-c00lddvVKIg" name="ibio:CollaborationAndLicenseAgreementRoyaltyPaymentTerm" id="Hidden_oSXmWjkN2kiwoY8AqAXFYw">P10Y</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentOneMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_NmtkHB0kdUyIGd_4OxJpew" decimals="0" name="us-gaap:SettlementAssetsCurrent" id="Hidden_PJle0PEsI0uXVu8jrliU2w">5100000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_1_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentOneMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_-rTyVybeQkylV5wAH1QWrQ" decimals="0" name="ibio:CashPaymentsReceivablesRelatedToLitigationSettlement" id="Hidden__ic71Y4ppUShPuWLdTGl2Q">900000</ix:nonFraction><ix:nonNumeric contextRef="Duration_9_10_2021_To_9_10_2021_srt_RangeAxis_srt_MinimumMember_FVB8Duxb3Eaig4ikvWE2OQ" name="ibio:BaseRentAbatementInFirstYearPeriod" id="Hidden_fzpg5j2sZU2ExYr4_xtclw">P2Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_9_10_2021_To_9_10_2021_srt_RangeAxis_srt_MaximumMember_mW7qNF6ZRUyagUbuT2sblQ" name="ibio:BaseRentAbatementInFirstYearPeriod" id="Hidden_JKyPk5I8s0q_VC6f1fzo2Q">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="us-gaap:LeasePracticalExpedientsPackage" id="Hidden_eZ239xUFfk2aM5khbNy0yg">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg" contextRef="Duration_10_7_2022_To_10_7_2022_Slp385Pip0S6eRadEDIyaA" decimals="2" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden_C8lqvEAS3E6y7jI9fK0gaA">0.04</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_WwbDRZXCKEm0c75aLXR51A">1000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_N7VJDuA9s0SBMrSoQpnaMA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" id="Hidden_iQoKre6X4UGSKRq8g3fedQ">2786000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_4-uRaCb8LEyTO1qExlEmGw">8727158</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_x71a3m4K-ki3BoetvIms3g">12368287</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg" contextRef="Duration_10_7_2022_To_10_7_2022_Slp385Pip0S6eRadEDIyaA" decimals="2" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden_L9F1YPW0H0e_OcCFkVLlag">0.04</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg" contextRef="Duration_10_7_2022_To_10_7_2022_Slp385Pip0S6eRadEDIyaA" decimals="2" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden_QTQry_EgBE-Zf0eAMcyRBw">0.04</ix:nonFraction><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_ibio_TwoThousandEighteenOmnibusEquityIncentivePlanMember_RgnWTUvfSUmaNbGh5cYapQ" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Hidden_nzLgsplRfUCEtBruJ2QfKQ">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_BcLE-e5aOUawYtWYzbYpuQ" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Hidden_6UlFUOUwakC1Lx6RTBBOdg">P10Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_ConsultantsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_yuIW9ztkf0mAQBCgQQaTxw" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Hidden_PqrGwNIVNUKtOSk9GN3hkQ">P10Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_7N6sRqj9kEWZRTEMclg2yA" name="ibio:SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary" id="Hidden_H20oJhWZMkiyeILxAMoOWg">P24M</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_7N6sRqj9kEWZRTEMclg2yA" name="ibio:SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus" id="Hidden_3XETezoZoE2Gln_IFI6pTg">P24M</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_7N6sRqj9kEWZRTEMclg2yA" name="ibio:SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct" id="Hidden_YRBOV4wB5E2sgYw7SZXbjg">P18M</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_7N6sRqj9kEWZRTEMclg2yA" name="ibio:SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod" id="Hidden_eUgWy76apU6hIb4U9tpWXg">P18M</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="ibio-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_7_1_2022_To_3_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_GWDLoqc91Eylj7aqLB53AA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_3_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_OScbop6D_EyFbi9oWinyQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uJ57OeAa6Em8d-wBmehB4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7S5LrOv4UU-uYc7t0vEohw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ydfUDabqlkij0w-BBn4BJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_6_2022_To_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_KH2r3-L2ZEmEEfMT1ZNKKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-06</xbrli:startDate><xbrli:endDate>2022-12-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_qNVa23oLakSTWA8v85-VDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_7_2022_To_10_7_2022_Slp385Pip0S6eRadEDIyaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-07</xbrli:startDate><xbrli:endDate>2022-10-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_a8XYRnY0YEqjr3LZjT16ww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Dq6r99N510C1DCNhsL8h9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_aXxc-Org7Umr-wR0vxLYGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ljAxJwch6kazqell6E9urQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Zo82mtQMNE2WG6FBhO9Gxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_OyKJ3tL-Q06qZ-tFHs9gXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_btFG4i_i4UifFBqeFaAOYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tl2lar8KpUyhhXZisj7IKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Pbu5fuCUvkqtV3iKXcXZgg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_FQYWefjPT06gXbntJAGaLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_JyoJW5xFA02SvXgMgzGBBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sIGvof6AoUegd5YJhRXoGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_eeBEWZpzDEuzNagWju7iXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_abZOLroj_UO6rIP7k3Bifg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tF8wULMhbkG99rPul9KSrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_PWObTblql0OvdhYq9X8sSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZL8l8ThJZ0-W7M_aNkuPyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_XTKrAoBNIEahMhTSx3nvGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_q6a6n0hytkGjctTlsPRp-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_3LjjH4Oi8EqKlNswnjVbLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_gOfCh-hUOkaoojsAe2NwmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_eTEPnd7U0k2A3wEuB687aA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_hsH-C_nn7UGLsToocSuw0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_jVGpJMpt70iwB6r1klHOKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_6xZdpSuxG02KaCdJhSlZ7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HFSiWMrWY0ej62GFJxBZIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_3WIr_ndZqka5CsSKIRQ3fA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_oxzaYxve7U-k1xy12FFQvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_pVa8MvgG4kWQa5aMi-i-SQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_G5vLxz-NeEqgDIsG6nvKaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8ASi2S5ht0qWY7QQf1HPIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_84GMwaIsm0KxnvZMEZe9PA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_302kYRWtf0SLrzPv4HomVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_UH3i88_6M0mId27kV_1YRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_swlXLlVROkCjZl5I0-C9RQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vSAxS0YAgUqgjKsUyRNznw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QXzbdBTf7UyvyFsCyM5MpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__ZOGluhSl0G7K2wu1sD4IQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember__h4euJzls0O2OyXOl4zqpA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_vETdeXuor0693SHSOmu6TA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_PlanNameAxis_ibio_OmnibusIncentivePlanMember_KOZgQdvqsU-8te5q0_AgpA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:OmnibusIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_BcLE-e5aOUawYtWYzbYpuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2022_To_12_1_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_hQgfyxu2uUOmIRU8B4Fklw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_23_2022_To_8_23_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_lmnxjWAiuES8yulA3DkvLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-23</xbrli:startDate><xbrli:endDate>2022-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_20_2023_To_1_20_2023_srt_TitleOfIndividualAxis_ibio_Dr.MartinBrennerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_N9G2vRJjBkiY4CVMVYrH_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:Dr.MartinBrennerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-20</xbrli:startDate><xbrli:endDate>2023-01-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_3_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_ibio_TwoThousandEighteenOmnibusEquityIncentivePlanMember_RgnWTUvfSUmaNbGh5cYapQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:TwoThousandEighteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_3_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_ibio_TwoThousandEighteenOmnibusEquityIncentivePlanMember_B8y79W7GIkih4LgR3vQBOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:TwoThousandEighteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_fmpgVBKP1km0zpZ63FGixw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_OhlEn2kqNUmaT0Hh--g1yg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_ConsultantsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_yuIW9ztkf0mAQBCgQQaTxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:ConsultantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentOneMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_NmtkHB0kdUyIGd_4OxJpew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndMaintenanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioPlanExpectedPaymentOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_25_2022_To_8_17_2022_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_ggLswlBXtkqHIYFVDHZ-Zg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CantorFitzgeraldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-25</xbrli:startDate><xbrli:endDate>2022-08-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_9_2022_To_5_9_2022_us-gaap_StatementClassOfStockAxis_ibio_Series2022ConvertiblePreferredStockMember_IRKi-LuHkUq15KpdZkL8TA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:Series2022ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-09</xbrli:startDate><xbrli:endDate>2022-05-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditTermLoanMember_pkYNKGm7FE-AjzorOXr0XA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ibio:LetterOfCreditTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditSanDiegoLeaseMember_wcNGCEcPbEm21StpOapKJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ibio:LetterOfCreditSanDiegoLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_CompanyPurchasingCardMember_ZTE2EhC6DUi3V8Us5_uTEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ibio:CompanyPurchasingCardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditTermLoanMember_ZKZXpDTWYkGA9VMDpyQWng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ibio:LetterOfCreditTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditSanDiegoLeaseMember_yPkVHgiNf0eqnma-vd44Og"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ibio:LetterOfCreditSanDiegoLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_CompanyPurchasingCardMember_jAg6eAzyCE6hspA3-EkVZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ibio:CompanyPurchasingCardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_3_31_2023_srt_RangeAxis_srt_MinimumMember_iZJ0-KgMMEWGQBeszyazgg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_3_31_2023_srt_RangeAxis_srt_MaximumMember_qkTv4t_oSEqp0FIe4NY8bw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_6QB18MmXqEK9CBa2yX9t0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_yqfA3UgBD0GxUlVv1J1aZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_lgu0RKVqRUy0scLhwVYi5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_ThM6Q7i9IU-hcgFbdInU_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_NSlKXkd1_ky6H3FWqPfqaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_6pSybpjm2Em9u1qgqtHc8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_1_2021_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_Nh5Sltvg50S1MDQaPh-wrw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:PreferredTrackingStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_23_2017_lMLzTmFjFUeEaGVOB1WIPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_9_2022_vsP8EMdp9kqoJCsGc37KdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-05-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_31_2021_To_10_31_2021_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_47o5yRKDNE6T9LQPWz8erA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:PreferredTrackingStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-31</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_23_2017_To_2_23_2017_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_hlhl6dJdp0if7Q1n3P67xA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:PreferredTrackingStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-02-23</xbrli:startDate><xbrli:endDate>2017-02-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_10_2022_To_10_10_2022_us-gaap_TypeOfArrangementAxis_ibio_CroAgreementMember_58YO1TPUFEKbnaIFe8Kesw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:CroAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-10</xbrli:startDate><xbrli:endDate>2022-10-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_1_2021_klJV-onJz0KrNHSyhYX8GA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_1HkfNu-AM0mxZ7COThJZjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_gf874UKLE0GViq4jrr0myw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_s9UOO5awBEKLVvHLUhhOvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_QiAZnlfbxEmMw0lCHMl5EA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZuedCxHLfEuQdq1I8bADJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ll59BJ1LzUSofhSUma-j9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ogcZKKYW_Eir0iTTRpyFTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_reQq62UAKUWWMC0PAA6-mQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_aWjmWshK0UmxjFzpIuJKUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_srt_StatementScenarioAxis_ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_1x-cfjUThkKbcg8PyPRDEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ibio:IbioCdmoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:PreferredTrackingStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibio:ExchangeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_srt_StatementScenarioAxis_ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ibio_EasternAffiliateMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_qFx6baRFl0K1AnDbITGYjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ibio:IbioCdmoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibio:EasternAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:PreferredTrackingStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibio:ExchangeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_16_2020_us-gaap_DebtInstrumentAxis_ibio_PppLoanCaresActMember_arEPE-gVxE-EC-ffEJt_Mw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:PppLoanCaresActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_2_9_2022_To_2_9_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_jUBQVMVhmEuilj8unuIy3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndMaintenanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-09</xbrli:startDate><xbrli:endDate>2022-02-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_3ufJCLpgP0Khx5n03TYFHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_3_31_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_WSwD-_QeQUyXYX-UiYDXDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_AXcDgcQQBEGgUeelykng1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_3_31_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_7hfM841DCUy3t_UYmcPmTA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ibio_SecondEasternAffiliateMember_KNUp6QEjNk2k0RVdB9kesQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibio:SecondEasternAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_3_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ibio_SecondEasternAffiliateMember_NrQUiMJSu0yMjFFmZyMHLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibio:SecondEasternAffiliateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_14_2023_To_2_14_2023_TnhaetjjP06Trcv9WL2o_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-14</xbrli:startDate><xbrli:endDate>2023-02-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_10_2021_us-gaap_GuaranteeObligationsByNatureAxis_us-gaap_FinancialStandbyLetterOfCreditMember_KIF7AjbiKESPVs3YPPPkKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">us-gaap:FinancialStandbyLetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_DniZqopZZkSjp3fXCv6SrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_3_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_7qvwM12szUub7e7UoiuztA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_5pgV7l8BAkeLqa2TtOfOrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_3xQ4GPFAFEWXC_8Y-7ecig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_h4ptg2J5jEab7-ozoqAPPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementMember_k1dUagvh-06HXU6xBQefUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_FGJtC-Cca0ywdM4SzNVWpg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_JJDtYxXNZUqTS9r_Ytu0CA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_huTLj4Tyh0uE8TfHbS9zCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_wmQZYW3PoEyWWUp8Dmyyyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Tqrr8xcQvkaRlWyBfJNZbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_11_2022_To_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_uQ72oafLtUqgFnnzbdiAsw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-11</xbrli:startDate><xbrli:endDate>2022-10-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_11_2022_To_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_DateOfAmendmentMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_ymy8A_X8_EK1tvCrHTVuEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:DateOfAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-11</xbrli:startDate><xbrli:endDate>2022-10-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_11_2022_To_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_SmV5R4SrNkmUCX3FsbIGLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-11</xbrli:startDate><xbrli:endDate>2022-10-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_co4oLbGgmE-T18TcXR1zRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:SecuredTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_Vft8wC26KU20m86L9BIQqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:SecuredTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_jDRo_Tn2dEiaxaJsfTrTaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CollegeStationInvestorsLlcAndBryanCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:SecuredTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_1_2021_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_LgWNkAEXrEOd4Kk1fbDdsQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:SecuredTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_ibio_PppLoanCaresActMember_fyRImC3heEeL4wSzPLvcgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:PppLoanCaresActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_19_2022_us-gaap_StatementClassOfStockAxis_ibio_Series2022ConvertiblePreferredStockMember_qeFYBi3PAUWnjNGHYNci7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:Series2022ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentContinuingOperationsMember_Cex7NDVXOEO89CLJRQZTuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_3_31_2022_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentContinuingOperationsMember_h7DRj5r8q0CCEDp9Wg0n4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_ELLu56FrAUeDrqmkxHQWOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibio:InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_19_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_8ARQ_UpEmkSNVg45b4FndQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_J-u4uOUfG0ORoIm4jvgctQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_cBAtqPpEJUqEJd0c0GaR7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesBWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_InpkTkfz_02nABMpU6azWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_A4kvDn5x20q7_8fIvjOF-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_BCjemMCehUOFvWDV-Z5NgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_nMTFluJjHUGsVU2uJ_O6bQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_MA5Y7fHH4E6vZRFVAPWBvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_RepresentativeWarrantsMember_L0HxhOr8_0eWqjfa9gKftw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:RepresentativeWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_PreFundedWarrantsMember_AmjIXMsiE020WBD4cpXPjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_xGREzJg85k2rOyE5lH-V2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_3_31_2023_us-gaap_AssetAcquisitionAxis_ibio_StockPurchaseAgreementMember_3-07kxSNOkaDZSJYQDyQdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibio:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_3_31_2023_us-gaap_AssetAcquisitionAxis_ibio_AssetPurchaseAgreementMember_W13nwak_50mao3LDEg0jzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibio:AssetPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_16_2022_To_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionIntangibleAssetsMember_yQ9fxKqDbkGLPQucgu0SgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibio:AssetAcquisitionIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-16</xbrli:startDate><xbrli:endDate>2022-09-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_16_2022_To_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionFixedAssetsMember_vLthqkkiPEekVSsXm4z-Wg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibio:AssetAcquisitionFixedAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-16</xbrli:startDate><xbrli:endDate>2022-09-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_23_2021_To_8_23_2021_ibio_AssetAcquisitionAxis_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionPrepaidExpensesMember_ZiSAVMfDE0OuOIvWRTPOkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibio:AssetAcquisitionPrepaidExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-23</xbrli:startDate><xbrli:endDate>2021-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_23_2021_To_8_23_2021_ibio_AssetAcquisitionAxis_us-gaap_FiniteLivedIntangibleAssetsMember_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionIntangibleAssetsMember__yJ7v5TK2km2wwhoqTq5Cw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibio:AssetAcquisitionIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-23</xbrli:startDate><xbrli:endDate>2021-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_23_2021_To_8_23_2021_ibio_AssetAcquisitionAxis_ibio_Series2PreferredStockMember_us-gaap_AssetAcquisitionAxis_ibio_Series2PreferredStockMember_VOoG9DcOHkek5MqvabkkeA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibio:Series2PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-23</xbrli:startDate><xbrli:endDate>2021-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_23_2021_To_8_23_2021_HiZIlu8ubEeyewTLP3230g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-23</xbrli:startDate><xbrli:endDate>2021-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_10_2021_fOp8nNM7xESd6X0-jbcuDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_3_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_-vyQFO66V0-VnP5O63-I_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_3_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_gE-bXUQhFkqJyMBuH9S0rQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_3_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_uH1aZ6v5zUW5U0OYeCYCVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_3_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_zQX7x8UMbk6gJSsI7k7Ecw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_3_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_52A2X6mgk0CFvchRmy-_Xw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_3_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_wGAzW97TrUSXKPZdUccZUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_qwQKiC4qEkiqgQ5177TkpA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_0YZIOq7O40ivJtfSHHkoMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_qY2IkD16B0qsnL9JdcbhWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_3_31_2023_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_uXNvRGR-RESDya9s9QmQmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_j5YNxf9-9UOgFjDrRr3Uog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_8W6InNkO50yKpr_pjkqq9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_RaNGnKpnsEaTsjOvOslUxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_qBMqGNRQFUWB9ZObqlDu1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_e_Rq4byCpkSvRJ7e4WS-Ew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_3_31_2022_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_GqDXZ6lLOEyUlH87AA2kZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_T5bdyp2yw0iUue1_r7FPew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_aJI5vfPiSkWbqmmaBoEKtQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_PuLylut6L0y-PztjYjnBWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gnv2jc0O2EKruqChBGMUTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_vL3rOPanq0GYnPOprKHLGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_-w0U61DdKUWU0kwbv1xmfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_RvsAx0CeVUiEHjFvD-Jmkw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_vI4fmkUg3kuCuyZ_zK8brg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ibio:ImmuneOncologyAntibodiesRtx003Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_us-gaap_StatementClassOfStockAxis_ibio_Series2PreferredStockMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementMember_YCIyuJUGskWd66faz53YYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ibio:ImmuneOncologyAntibodiesRtx003Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:Series2PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-23</xbrli:startDate><xbrli:endDate>2021-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_o6HWlvHmjUS2rzS8fnoWuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MWdz4lqoIEShu4AoC1KFyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_9_2020_srt_StatementScenarioAxis_ibio_ScenarioTwoMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_JVZ6u6vkRkGYKXk3HmaqFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_9_2020_srt_StatementScenarioAxis_ibio_ScenarioOneMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_tZmDg9QDo0iz01RbPbZOcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_9_2020_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_x5WH3KDAZkGbq_aE3REdDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_3_31_2023_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_7N6sRqj9kEWZRTEMclg2yA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:SeparationAgreementAndGeneralReleaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentTwoMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_KtCuFsBjc0WIUmqqIyBxaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndMaintenanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioPlanExpectedPaymentTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_YZMShz8Rh0u-FmqZPOXdfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_4_2021_To_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_eCKkBDi1PUu1tOF1oLvpIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-04</xbrli:startDate><xbrli:endDate>2021-05-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_R1fh5LInTEmTcImaZYCq4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_3_31_2023_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_ARnE75gvP0qnPbmgOAREKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_7ZRgVsYP8kOQ3Ji8AiOywQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_3_31_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_yRWAOjfd2Ue7tGm5AdoU8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_23_2017_To_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_oc0tqqFKsk-LEKQxwyeAOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ibio:IbioCdmoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:PreferredTrackingStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibio:ExchangeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-02-23</xbrli:startDate><xbrli:endDate>2017-02-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_aNeIbxhhIUWzr_C1HYpBqQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_t_boUVr6WkyudoVlOiImcQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_10_1_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_zTgxHY80r0C6Oan6do8BOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_1_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_VyVmxesCq0KMm1BWB8Egcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_4_1_2021_34XjF-RfakO2aPg-6ZHbIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_10_2021_To_9_10_2021_nXnIcEGZ8UGqkU29lvwVJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-10</xbrli:startDate><xbrli:endDate>2021-09-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_GnYUgnieSE-ivQH2Syhl-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_us-gaap_StatementClassOfStockAxis_ibio_Series2PreferredStockMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementMember_GiIiWNIPGEib_sv1KnwHFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ibio:ImmuneOncologyAntibodiesRtx003Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:Series2PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_3_31_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_9dyJeVMv1ki5yRGsbgJw-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_3_31_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_V386ndKYUkuQBZjgR9D61w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_05inVfs2x0qofUiIplZIZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_12_31_2022_cYAWIZbIyEWUA55EtH7XHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uUZOjGeySkC0V7oyrpt9UA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ibio_FacilityMember_K0EB_c8dT0OHjVuRMWJAdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ibio:FacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_p-vKhEHGAUG72E1kGh9gmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CollegeStationInvestorsLlcAndBryanCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_10_2022_us-gaap_TypeOfArrangementAxis_ibio_CroAgreementMember_Bo_t44xgLU28rjco1A0Xvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:CroAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2021_To_11_1_2021_dei_LegalEntityAxis_ibio_IbioCmoPreferredTrackingStockMember_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_Fd00xECGqUS_feybjJADgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibio:IbioCmoPreferredTrackingStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CollegeStationInvestorsLlcAndBryanCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_12_2022_To_10_12_2022_fUvngAqb2k-xursF14pifg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-12</xbrli:startDate><xbrli:endDate>2022-10-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_12_2022_0w4cNGT5qUGNwBnB1qrjUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-10-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_11_3_2022_To_11_3_2022_B-3zxmk-RECRSqI6e6Ttyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-03</xbrli:startDate><xbrli:endDate>2022-11-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_ECHSceNMpEGQENNfII3BMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_c19oJcuBhUqWIDNcmlXJ7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_LfJb0Ctu7kiams8KPEcLPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_OccurrenceOfSpecificMilestoneMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_RDzgSGSsy0qENkxPgtYl4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:OccurrenceOfSpecificMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_O-zm2Doh6EmpqJ14OI8KEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_10_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_dl3OmSiDBEKFtrzke4LxUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_87cTBGu9gE-x613iWJyDyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_Q7qov9TaRUq6PVlJRwP10w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibio:PrincipalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_12_6_2022_To_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_sbC4xz-l302ta9iq3YNsng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-06</xbrli:startDate><xbrli:endDate>2022-12-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VgtORRQXUEmi1Rl7s04fXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_goiPae-IiUSx1NtZV7V7cg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HD3iLrT9BUSp3VUMVRBnVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_19_2022_To_9_19_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_wXZQoYO-rEO6uGxtBLB7Ag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-19</xbrli:startDate><xbrli:endDate>2022-09-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_srt_StatementScenarioAxis_ibio_NoBiosimilarProductHasBeenApprovedMember_us-gaap_TypeOfArrangementAxis_ibio_CollaborationOptionAndLicenseAgreementMember_ou4zV9VwTU-c00lddvVKIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ibio:ImmuneOncologyAntibodiesRtx003Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:NoBiosimilarProductHasBeenApprovedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-23</xbrli:startDate><xbrli:endDate>2021-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_us-gaap_TypeOfArrangementAxis_ibio_CollaborationOptionAndLicenseAgreementMember_ajEqmB0rDEiBS1559tP2SQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ibio:ImmuneOncologyAntibodiesRtx003Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-23</xbrli:startDate><xbrli:endDate>2021-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_1_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentTwoMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_d6E-TSK80kuu0sljeRCUGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioPlanExpectedPaymentTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_1_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentOneMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_-rTyVybeQkylV5wAH1QWrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioPlanExpectedPaymentOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_CoaZKFcMoUunX2IienHmqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_iqiKw6Sqfk-mWIZ8WFtzQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedLegalFeesMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_c-4YxyJ_jk-9z62ejKBbXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioPlanExpectedLegalFeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_0-dXyj2LIE2MJCZBHgv0hw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CollegeStationInvestorsLlcAndBryanCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_10_2021_To_9_10_2021_srt_RangeAxis_srt_MinimumMember_FVB8Duxb3Eaig4ikvWE2OQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-10</xbrli:startDate><xbrli:endDate>2021-09-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_10_2021_To_9_10_2021_srt_RangeAxis_srt_MaximumMember_mW7qNF6ZRUyagUbuT2sblQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-10</xbrli:startDate><xbrli:endDate>2021-09-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_16_2022_To_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_QdOFAORoNkObDq7whbxqtQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-16</xbrli:startDate><xbrli:endDate>2022-09-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_25_2020_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_R42dgLYX1k2Ix5l9AuMByA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CantorFitzgeraldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_Xf6pRLT-l0WeqW9gCVshUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_h7U0v0axEUSvtq7AMRXwhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2021_To_12_31_2021_WNPh7gwO_06OGSGOzOxzNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_10_2023_1kydZmm4_EeBJVujDl0wBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_position_V29P0pRPvUyM5A0t2OFq5g"><xbrli:measure>ibio:position</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_D_NZPLSJv9m0GC4_X7zPjKmg"><xbrli:measure>ibio:D</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_lease_8Woavb0ETUO8s9ODCurHtQ"><xbrli:measure>ibio:lease</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_customer_yQcExGHKGkW8YXSDfuntYQ"><xbrli:measure>ibio:customer</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_ITzkWC4v7UGBZiwOGBFemw"><xbrli:measure>ibio:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_sqft_3kWp_fWhaEWbENPWsKzOnw"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:7.2pt;min-height:20.15pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1px solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_e4f47eb1_71a3_4d75_9ca4_11bd0a77993f"></a><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Washington</b>, <b style="font-weight:bold;">D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-size:9pt;font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="dei:DocumentType" id="Narr_o6mHoMtUw0WMff6IvdNl2Q"><b style="font-size:9pt;font-weight:bold;">10-Q</b></ix:nonNumeric></p><a id="_78f9c99e_4a1c_46a6_993a_898c0bdb85de"></a><a id="Tc_NhZNl0RBDEST7OTwZQSR3w_1_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:3.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:96.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="dei:DocumentQuarterlyReport" id="Tc_VZNONDB5FUuis5CS4w0q2w_1_0"><b style="font-family:'Segoe UI Symbol';font-size:9pt;font-weight:bold;">&#9746;</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:96.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><span style="font-size:9pt;">For the quarterly period ended </span><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="dei:DocumentPeriodEndDate" id="Narr_Y0tpL-Ffik-sQokYvqLFhQ">March&#160;31,&#160;2023</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">OR</b></p><a id="_2426db59_d74c_4e48_8938_15e2dadd7a8b"></a><a id="Tc_Z8mlf5xv9kmyQcuv-zy4EQ_1_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:3.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:96.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="dei:DocumentTransitionReport" id="Tc_2itkjY7XMUeAjEISSFlWfA_1_0"><b style="font-family:'Segoe UI Symbol';font-size:9pt;font-weight:bold;">&#9744;</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:96.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 10pt 0pt;">For the transition period from ___ to ___</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-size:9pt;font-weight:bold;">Commission File Number </b><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="dei:EntityFileNumber" id="Narr_Az8vKbcouUCLfy21djprjg"><b style="font-size:9pt;font-weight:bold;">001-35023</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="dei:EntityRegistrantName" id="Narr_TrK5w7J6wkGoiKHtNsg4iw"><b style="font-weight:bold;">iBio,&#160;Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 10pt 0pt;">(Exact name of registrant as specified in its charter)</p><a id="_64cc32ea_03df_4de5_8b97_e3f1a1a0de16"></a><a id="Tc_n_m_xNAgkkKNnT8d6p4AWA_1_0"></a><a id="Tc_OS-zqVpdcUa8p1UG0aot_g_1_2"></a><a id="Tc_6N1SXoK1xUKxN_9KMhAXug_3_0"></a><a id="Tc_-iFLMDs0rE6sCu0v3erOUQ_3_2"></a><a id="Tc_L_vkTzz5uke3OxPBG3M7_Q_4_0"></a><a id="Tc_1u4A4ugRFk-9DaD3xg0WZg_4_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="dei:EntityIncorporationStateCountryCode" id="Tc_39qpsAOIak-X5WYqVUMYow_0_0"><b style="font-size:9pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="dei:EntityTaxIdentificationNumber" id="Tc_lDMOM0k3yEuCut1p3YVwIA_0_2"><b style="font-size:9pt;font-weight:bold;">26-2797813</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(State or other jurisdiction of incorporation or organization)</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(I.R.S. Employer Identification No.)</p></td></tr><tr><td style="vertical-align:bottom;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="dei:EntityAddressAddressLine1" id="Narr_ETTPvafiCkKvBG-c4CoXow"><b style="font-size:9pt;font-weight:bold;">8800 HSC Parkway</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="dei:EntityAddressCityOrTown" id="Narr_l8HydpBPbkSN5WVARUZHyw"><b style="font-size:9pt;font-weight:bold;">Bryan</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="dei:EntityAddressStateOrProvince" id="Narr_OEnZ6w8CyUeF4b1hCx7JMg"><b style="font-size:9pt;font-weight:bold;">TX</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="dei:EntityAddressPostalZipCode" id="Narr_lHXH4Ypnf0iQMp6MT2JzNw"><b style="font-size:9pt;font-weight:bold;">77807</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">-1107</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Address of principal executive offices)</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Zip Code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="dei:CityAreaCode" id="Narr_72Ucj5zaP0afitPp-eFeVg"><b style="font-size:9pt;font-weight:bold;">979</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="dei:LocalPhoneNumber" id="Narr___VyigrJuk-pSzwjQoQwTg"><b style="font-size:9pt;font-weight:bold;">446-0027</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 10pt 0pt;">(Registrant&#8217;s telephone number, including area code)</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 10pt 0pt;">(Former name, former address and former fiscal year, if changed since last report)</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 10pt 0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><a id="_69468a9e_bc59_40b1_bd61_01c8e498cc01"></a><a id="Tc_OdtYQgE5iU2ZnplZrFn8dQ_1_0"></a><a id="Tc_xsRPmJLUyU-0JuS_b4BmRQ_1_2"></a><a id="Tc_DQtbrqgQ8kKU2NlfEFQxgg_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:26%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:19.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:52%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:26%;background:#ffffff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:bottom;width:0.99%;background:#ffffff;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:19.99%;background:#ffffff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading symbol(s)</b></p></td><td style="vertical-align:bottom;width:0.99%;background:#ffffff;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:52%;background:#ffffff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:bottom;width:26%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="dei:Security12bTitle" id="Tc_M9LtKRTFwUGF-r9UiW1z6Q_2_0"><span style="font-size:9pt;">Common Stock</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:0.99%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:19.99%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="dei:TradingSymbol" id="Tc_Hb12vT3VRk23NCZ-e7G3yQ_2_2"><span style="font-size:9pt;">IBIO</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:0.99%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:52%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="dei:SecurityExchangeName" id="Tc_0_mnYiUsN02DTEcVbGLOyQ_2_4"><span style="font-size:9pt;">NYSE American</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="dei:EntityCurrentReportingStatus" id="Narr_0aHOd91z00GexDLWRKzgjQ"><span style="font-size:9pt;">Yes</span></ix:nonNumeric><span style="font-size:9pt;">&#160; </span><span style="font-family:Times New Roman;font-size:9pt;">&#8999;</span><span style="font-size:9pt;"> &#160;&#160;No </span><span style="font-family:'Times New Roman';font-size:9pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="dei:EntityInteractiveDataCurrent" id="Narr_jTqVCzMAuUGf2tSEVkwNWA"><span style="font-size:9pt;">Yes</span></ix:nonNumeric><span style="font-size:9pt;">&#160; </span><span style="font-family:Times New Roman;font-size:9pt;">&#8999;</span><span style="font-size:9pt;"> &#160;&#160;No </span><span style="font-family:'Times New Roman';font-size:9pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Indicate by check mark whether the registrant is a large, accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large, accelerated filer,&#8221; &#8220;accelerated filer&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;white-space:nowrap;width:27.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Large accelerated Filer&#160; <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Accelerated Filer&#160; <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:27.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="dei:EntityFilerCategory" id="Narr_erVoDxhSc02HkvYhUnLzVg"><span style="font-size:9pt;">Non-accelerated Filer</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160; </span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">Smaller reporting company&#160;&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="dei:EntitySmallBusiness" id="Narr_NZ2O17yy2EGwyaCS8fM0qQ"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:27.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">Emerging growth&#160;company&#160;&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="dei:EntityEmergingGrowthCompany" id="Narr_FjbMm_xHu0uQm5t66_uKjw"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Times New Roman';">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-size:9pt;">Yes </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="dei:EntityShellCompany" id="Narr_UCbSYMbLtk-omf1nKapTWA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;"> &#160;&#160; No&#160; </span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Shares of Common Stock outstanding as of May 10, 2023:&#160;<ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_5_10_2023_1kydZmm4_EeBJVujDl0wBA" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_W42B6utcREK6zJHJcIpNxA">16,798,014</ix:nonFraction></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1px solid #000000;margin:0pt 0pt 10pt 0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_10e5e096_de04_41f3_b7fb_a459e1afc4ba"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">iBio, Inc.</b></p><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:6.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:87.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:5.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:94.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIFINANCIALINFORMATION_616298"><span style="font-style:normal;font-weight:normal;">PART&#160;I. FINANCIAL INFORMATION</span></a></p></td><td style="vertical-align:top;width:5.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:94.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:6.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1FinancialStatements_863395"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:top;width:87.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Consolidated <a href="#Item1FinancialStatements_863395"><span style="font-style:normal;font-weight:normal;">Financial Statements (Unaudited)</span></a></p></td><td style="vertical-align:top;width:5.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></td></tr><tr><td style="vertical-align:top;width:6.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Item&#160;2.</span></a></p></td><td style="vertical-align:top;width:87.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:top;width:5.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">37</p></td></tr><tr><td style="vertical-align:top;width:6.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-style:normal;font-weight:normal;">Item&#160;3</span></a>.</p></td><td style="vertical-align:top;width:87.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:top;width:5.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">45</p></td></tr><tr><td style="vertical-align:top;width:6.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4ControlsandProcedures_545173"><span style="font-style:normal;font-weight:normal;">Item&#160;4.</span></a></p></td><td style="vertical-align:top;width:87.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4ControlsandProcedures_545173"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:top;width:5.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">45</p></td></tr><tr><td style="vertical-align:top;width:6.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:94.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIIOTHERINFORMATION_600713"><span style="font-style:normal;font-weight:normal;">PART&#160;II. OTHER INFORMATION</span></a></p></td><td style="vertical-align:top;width:5.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">46</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:94.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:6.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1LegalProceedings_731318"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:top;width:87.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1LegalProceedings_731318"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:top;width:5.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">46</p></td></tr><tr><td style="vertical-align:top;width:6.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_275295"><span style="font-style:normal;font-weight:normal;">Item&#160;1A.</span></a></p></td><td style="vertical-align:top;width:87.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_275295"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:top;width:5.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">46</p></td></tr><tr><td style="vertical-align:top;width:6.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5OtherInformation_186239"><span style="font-style:normal;font-weight:normal;">Item&#160;5.</span></a></p></td><td style="vertical-align:top;width:87.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5OtherInformation_186239"><span style="font-style:normal;font-weight:normal;">Other Information</span></a></p></td><td style="vertical-align:top;width:5.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">51</p></td></tr><tr><td style="vertical-align:top;width:6.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Exhibits_377876"><span style="font-style:normal;font-weight:normal;">Item&#160;6.</span></a></p></td><td style="vertical-align:top;width:87.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Exhibits_377876"><span style="font-style:normal;font-weight:normal;">Exhibits</span></a></p></td><td style="vertical-align:top;width:5.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">51</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:94.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:94.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SIGNATURES_117481"><span style="font-style:normal;font-weight:normal;">SIGNATURES</span></a></p></td><td style="vertical-align:top;width:5.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">52</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e31b7acb_1b53_4713_a703_640c879db98d"></a><a id="PARTIFINANCIALINFORMATION_616298"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">PART&#160;I&#160;- FINANCIAL INFORMATION</p><a id="Item1FinancialStatements_863395"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Item&#160;1. &#160; Consolidated Financial Statements (Unaudited).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">iBio,&#160;Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Condensed Consolidated Balance Sheets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(In thousands, except share and per share amounts)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_75250c54_ee0d_4efe_b108_30bf3749ae52"></a><a id="Tc_iMcq8Zs8rUyKKwVGdKs76g_1_2"></a><a id="Tc_hBcYfewvG0SX-7e17gJJ6g_1_5"></a><a id="Tc_xhMix_BzqEaHfRzE-t7iEA_2_2"></a><a id="Tc_cLixNDTMy0q9_MzZ_RMSBQ_2_5"></a><a id="Tc_XBD0eJWv1kK_guq1PahHUQ_3_2"></a><a id="Tc_VafXDcSAxEOKEouLWQApBg_3_5"></a><a id="Tc_4nXRcUqE6k274RSm8lcSzw_4_0"></a><a id="Tc_H4NNVqvyC0u0vpzRaReHKg_5_0"></a><a id="Tc_he0hI7l7nk2TMZEBQWM7uQ_6_0"></a><a id="Tc_XiJx4CZxZEir6LDfJc4yAw_6_2"></a><a id="Tc_FeoLwn78eEe_5Yyrn53VRg_6_5"></a><a id="Tc_bGN9_yzgO0uv2dL16WAqtA_7_0"></a><a id="Tc_r7cXt00Akk6Uz2K4vVLALw_7_3"></a><a id="Tc_E2IbbK8d8U2ko7QEzw7YFg_8_0"></a><a id="Tc_pKKp1hC9EEGO_j-3YBScbg_9_0"></a><a id="Tc_socQG1DHI0W3MXO8RMLccw_9_6"></a><a id="Tc_gwrdMToF-kyRTblJdkDHgw_10_0"></a><a id="Tc_3fOmKH1290WP6jBv_xiUtw_10_3"></a><a id="Tc_eijDQzShPUCxet9eFsosag_11_0"></a><a id="Tc_v7PwMUA6AUeyIVJeiDuYsg_11_6"></a><a id="Tc_8ItfCvkkoUOf3-Pw2gB3xw_12_0"></a><a id="Tc_88qnP7BGU0C9hp6-JXX6bw_13_0"></a><a id="Tc_MbISB2giBECzNK7IEdo3nQ_14_0"></a><a id="Tc_yyzygDQGUEi9xD1Nra1ehA_16_0"></a><a id="Tc_OH-jImYmbEyXcSndD38GOw_17_0"></a><a id="Tc_oJI_0-WGKE-OGuJJtCPB9w_18_0"></a><a id="Tc_9aNpBNty9Um3uPxu9zGWVw_18_6"></a><a id="Tc_sAHJOSMNR0uAi6VZAom99Q_19_0"></a><a id="Tc_mbUAK7zvLk2Tgjgk2PegNA_20_0"></a><a id="Tc_N-d7_GYUFkGWL2bz36EBDQ_21_0"></a><a id="Tc_lYpqj1bZY06NPMjXP--MHA_22_0"></a><a id="Tc_SZ5RmLRLfUCd8EaknZkmFg_23_0"></a><a id="Tc_bUi9F5-KRU6F_DGrPjEcQA_23_3"></a><a id="Tc_R68tRV7un0K4aNEUYsGAcQ_24_0"></a><a id="Tc_eaE3RkCjG0S7aVc58WztPg_24_3"></a><a id="Tc_3EAgUwafpECIfraCUHQZfg_25_0"></a><a id="Tc_4_SAPkLmn0CnUXLjqgqY-Q_25_2"></a><a id="Tc_7wFTT4ruD0OXY9pavNvcog_25_5"></a><a id="Tc_iFmmqhsKgEGTG2HBtATaCg_27_0"></a><a id="Tc_w_TaNL3lwUO_d4RXGMzKGw_28_0"></a><a id="Tc_OgfQeiaHfEKxF5FazYjd5w_29_0"></a><a id="Tc_IwCuYnf1ZUaRau2OSE-eLg_29_2"></a><a id="Tc_gtFTdK3mB0mytqVlzXDowg_29_5"></a><a id="Tc_BEXXcU9Wk0yaNOdhbXrlag_30_0"></a><a id="Tc_8jDulb_HmUGbqObwDT8xyw_31_0"></a><a id="Tc_ND_Jh-CcpEuVRN9dzFJL5g_31_6"></a><a id="Tc_cgZbh12BIkmlDVAVbEC1ew_32_0"></a><a id="Tc_Kw5g3Z_ZE0WPoJDAyG7nuA_33_0"></a><a id="Tc_5I--yIOdSkqyxSNxWAb1SA_33_6"></a><a id="Tc_mNQ5XFlVfUi3AA8wIk0W6g_34_0"></a><a id="Tc_kh17Qf1zb0y7_cwRYyTVzw_35_0"></a><a id="Tc_X0sUpKAFEUCasutt7XhbtQ_35_3"></a><a id="Tc_0tv9HNMEXk6m5X7uomoeVg_36_0"></a><a id="Tc_3TcSbPk8GEGzpF1UuOPk_g_37_0"></a><a id="Tc_Ti2BXkGoX0areHuYRJRhSg_39_0"></a><a id="Tc_S5lIsQnUQUans0y9UTfIDQ_39_6"></a><a id="Tc_Wq8majHRhE2m0ToFesl78w_40_0"></a><a id="Tc_pItZPbrFN0C3rYBRVcnSHw_41_0"></a><a id="Tc_U-1kAoOyfEWhHbRL8_1SnQ_41_6"></a><a id="Tc_ATJeQ9VPN0OqWwIwUzLZoQ_42_0"></a><a id="Tc_wCJ-pHy9UEueAxpaqgIJGQ_42_6"></a><a id="Tc_IMA4c1Dh9UCIHlyD8x8bjQ_43_0"></a><a id="Tc_AMmv2-h7N0CEjPF00GCe5A_43_3"></a><a id="Tc_S7nN7NqSvUqF-jo7lR_BGQ_45_0"></a><a id="Tc_wbgcDBR1kE-HbmqmXZ2_nw_47_0"></a><a id="Tc_-Z5EGnoZwkqHrPADFVNKcg_48_0"></a><a id="Tc_1FMds4FcR0mx9hQQYJ8Ing_49_0"></a><a id="Tc_MWq-NlTKF0OhSNyd8pEw9w_50_0"></a><a id="Tc_lUYp4tHJJEOtwlpA94vjTA_51_0"></a><a id="Tc_h0CYP8TsHkeShlJ1EH9SuQ_51_3"></a><a id="Tc_nu3rXIqOxUCztDuza7cvTw_52_0"></a><a id="Tc_OYsaCRTS2kayLp7HpqinOg_53_0"></a><a id="Tc_2IdCcZfsGU6aPQbAsygcJA_54_0"></a><a id="Tc_a2XqDcBLikKsBBhgGS88bA_54_2"></a><a id="Tc_qqTC6d6Hok2Sksg6lRotEw_54_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.07870102%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">March&#160;31,&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">June&#160;30,&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:66.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2022</p></td></tr><tr><td style="vertical-align:bottom;width:66.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">(Unaudited)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">(See Note 2)</p></td></tr><tr><td style="vertical-align:bottom;width:66.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_s88ototjB0aqygIcjYTuAw_6_3">6,562</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_CULjBccjlEaHD75wz6RHtw_6_6">22,676</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Investments in debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesCurrent" scale="3" id="Tc_xwy80zCLFkypVh67Bj53Kw_7_6">10,845</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Accounts receivable - trade</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_I1S7eWhn-k2n9Z2c7RJdKA_8_3">70</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_VjsmiIs0p02Ho5cu5-2gIQ_8_6">1,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Subscription receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="ibio:SubscriptionReceivableCurrent" scale="3" id="Tc_15OaVR0rm0a-CIhnBuL7iw_9_3">260</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Settlement receivable - current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SettlementAssetsCurrent" scale="3" id="Tc_86pKZoc0fEmQWuZzygFm0Q_10_6">5,100</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Convertible promissory note receivable and accrued interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesAndLoansReceivableNetCurrent" scale="3" id="Tc_DKhoXoLRiEK4q8g2CUghfg_11_3">912</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_WnMcTMmBlkKJ3KGjbVTuVA_12_3">921</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_aLYME3ls8keFQoQUrrUI_w_12_6">1,549</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Current assets held for sale</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent" scale="3" id="Tc_NTrYaEtJGkmeiXwOmDMZAQ_13_3">18,368</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent" scale="3" id="Tc_KeR5umeqXE67BIQRqQp-Gw_13_6">3,900</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Total Current Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_3lMiRGtndUSBWStZiRvXJg_14_3">27,093</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_FrDU-cVJ5Eyh2Tz2pdaFjQ_14_6">45,070</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="Tc_kkh_YvD6t0KUr_rLPlN7Lg_16_3">3,253</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="Tc_a7w3eGeb6UqZufRUxZm9kg_16_6">5,996</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Convertible promissory note receivable and accrued interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="ibio:ConvertiblePromissoryNoteReceivableAndAccruedInterest" scale="3" id="Tc_e0-OmfxZ9EaWGpY-Jfydwg_17_3">775</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="ibio:ConvertiblePromissoryNoteReceivableAndAccruedInterest" scale="3" id="Tc_SjOIZAlpQkOTcoa7251CkA_17_6">1,631</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease right-of-use assets, net of accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="Tc_tppJfvfOXk2Rnb0hgMhvVQ_18_3">678</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease right-of-use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_jyVooTVfhEmt8c3inY-YUg_19_3">2,786</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_7CHtNIQU6UCEAf5CxhRHxw_19_6">3,068</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Fixed assets, net of accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_9mHx-Imi40-b0UQYmuiFqQ_20_3">4,358</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_JPnH5m0xuUiMfJPHXRv_nA_20_6">1,373</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:66.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Intangible assets, net of accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="Tc_vGXg5Jie3EeePAWzTKgCBQ_21_3">5,393</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="Tc_F58MpnjqgES5MNaGW8aIpA_21_6">4,851</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Security deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SecurityDeposit" scale="3" id="Tc__PmeNcZLFEOyy-zDF3voPw_22_3">50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SecurityDeposit" scale="3" id="Tc_0EXT15_DPky9XT1I5ZThrA_22_6">29</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:66.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid expenses - noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseNoncurrent" scale="3" id="Tc_PnRMyidZ0UqLRVM-ovxbdA_23_6">74</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:66.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Noncurrent assets held for sale</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" scale="3" id="Tc_yXMUt5o-qUOg_i8D2tBwhg_24_6">37,314</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Total Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_6WvFgPmtrU2UZ9Azm1AEfw_25_3">44,386</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_2bH3OutPIEO7ZFQ7jaGQEA_25_6">99,406</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Liabilities and Stockholders&#39; Equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_vzpN7AvfxkyIw73sShaIYQ_29_3">2,013</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_eiF9apP5nUG6FvduHeoYlw_29_6">4,264</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_w7iucYSoRkKgNPyQ3b3BUw_30_3">3,821</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_HWM3ykO6NkiDQdRbmKTs4g_30_6">3,764</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Finance lease obligations - current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="Tc_JmyrWKkuWUOMUnZe9xYgYQ_31_3">265</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Operating lease obligation - current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_kqITfLuYTESU9UXNFPib5A_32_3">377</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_xdVumVfIZUOuqKWYIR09cw_32_6">91</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Equipment financing payable - current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="ibio:EquipmentFinancingPayableCurrent" scale="3" id="Tc_Y6d-ErsAlEiPtE76Qo4Zsg_33_3">156</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Term note payable - net of deferred financing costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesPayableCurrent" scale="3" id="Tc_JOxp3uu29Ue5v1anSIQl8w_34_3">13,700</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesPayableCurrent" scale="3" id="Tc_8XSx77QBWEOerH82bZPlnw_34_6">22,161</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Contract liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueCurrent" scale="3" id="Tc_0AN5D-wuP06_qKeuEoQUoA_35_6">100</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Current liabilities related to assets held for sale</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="ibio:CurrentLiabilitiesRelatedToAssetsHeldForSale" scale="3" id="Tc_zYIwHpHTk0WzaKFnUQbJLA_36_3">1,944</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="ibio:CurrentLiabilitiesRelatedToAssetsHeldForSale" scale="3" id="Tc_x0ZyHdAb5kimjvdcHl2zPA_36_6">56</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Total Current Liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_ou9xvJYdj02Q9Aku65jEiQ_37_3">22,276</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_Dk-wsZ3dVUyVsuFLrpk8vA_37_6">30,436</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease obligations - net of current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="Tc_hAO25xUyQUCTiArslGnAZA_39_3">422</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease obligation - net of current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_3LnICue8Jkqs5zAx1CTksQ_40_3">3,225</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_ZDRFtsm8vU2TSEz9AWklEg_40_6">3,514</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Equipment financing payable - net of current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="ibio:EquipmentFinancingPayableNoncurrent" scale="3" id="Tc_zcULuyMaBUWjfTVN-gKm2g_41_3">283</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses - noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="ibio:AccruedLiabilitiesNoncurrent" scale="3" id="Tc_Y7NuIiY3_0OXX6oUQ5oUAQ_42_3">791</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Noncurrent liabilities related to assets held for sale</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="ibio:NoncurrentLiabilitiesRelatedToAssetsHeldForSale" scale="3" id="Tc_7FxhGJGA00SKu4sgrkZmcw_43_6">1,971</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Total Liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_CC1ykaf4UEOv3m4-OwxPhg_45_3">26,997</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_oMaGSxazK0O_HgowJr8oyA_45_6">35,921</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders&#39; Equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:8pt;">Series 2022 Convertible Preferred Stock - </span><span style="font-size:8pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_p9rb5jJIhUaDss0l0UYP6w"><ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_QyAo8U5xXkS-StafUPgp-Q">0.001</ix:nonFraction></ix:nonFraction></span><span style="font-size:8pt;"> par value; </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_DX8CGX1xHECHWjc1dCRSQA"><ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_KPGveXqpV0eWR1BuZJ4JVw">1,000,000</ix:nonFraction></ix:nonFraction></span><span style="font-size:8pt;"> shares authorized; </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_YG-Eswwbyk26gW_K0Gfzcw">0</ix:nonFraction></span><span style="font-size:8pt;"> and </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_ZPl3Z4lwH0OQ8axNSOZVyA">1,000</ix:nonFraction></span><span style="font-size:8pt;"> shares </span><span style="-sec-ix-hidden:Hidden_N7VJDuA9s0SBMrSoQpnaMA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">issued</span></span><span style="font-size:8pt;"> and </span><span style="-sec-ix-hidden:Hidden_WwbDRZXCKEm0c75aLXR51A;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">outstanding</span></span><span style="font-size:8pt;"> as of March 31, 2023 and June 30, 2022, respectively</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_Mmhw1Jx8RkCtn1jI8k-39w;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_N_j11tLD2kCEU98JvTtlWA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:66.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:8pt;">Common Stock - </span><span style="font-size:8pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_ftuKYvVLKk-oxoU6HLYP9Q"><ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_K2Zbi1wiPE6wQRHbva8MNA">0.001</ix:nonFraction></ix:nonFraction></span><span style="font-size:8pt;"> par value; </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_Ah8Z8hI9_kChEO0IWg8u7Q"><ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_wlqE7fdn40utyCKmpWU4Xg">275,000,000</ix:nonFraction></ix:nonFraction></span><span style="font-size:8pt;"> shares authorized at March 31, 2023 and June 30, 2022; </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_FVPCoeSXvEK3_cfOHfDZqg">15,818,149</ix:nonFraction></span><span style="font-size:8pt;"> and </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_cj-9Av5pikCC7_6VCJYIFQ">8,727,158</ix:nonFraction></span><span style="font-size:8pt;"> shares </span><span style="-sec-ix-hidden:Hidden_4-uRaCb8LEyTO1qExlEmGw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">issued</span></span><span style="font-size:8pt;"> and </span><span style="-sec-ix-hidden:Hidden_x71a3m4K-ki3BoetvIms3g;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">outstanding</span></span><span style="font-size:8pt;"> as of March 31, 2023 and June 30,&#160;2022, respectively</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_YlE-INmkE0uc31WbXvLjrg_49_3">16</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_vKmQJKujrEeP7E0ptTz0IQ_49_6">9</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_IQuUFxVCuEmRUnby06fy9A_50_3">300,280</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_-UL7-cxMBEyJg9OPQzXESw_50_6">287,619</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Accumulated other comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_hVsQU8DXA0-m2OkBmiLTNw_51_6">213</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_q41KgZWxJkKM7KGMiyQunw_52_3">282,907</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_1xKzZJye6kyWxDv-sLvLqA_52_6">223,930</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Total Stockholders&#8217; Equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_BH_TcF4ZVkaLmYyh3wNaEA_53_3">17,389</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Zz6flBgPTk66PEGS5n5tPA_53_6">63,485</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Total Liabilities and Stockholders&#39; Equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_aN47aWwzmkOIrPlWj-OYgA_54_3">44,386</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_WQ4hf6WHfUW5PyMkgmqCMQ_54_6">99,406</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_3346d1c0_7c38_460d_b5ad_6f93201e5b18"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">iBio,&#160;Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Condensed Consolidated Statements of Operations and Comprehensive Loss</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited; in thousands, except per share amounts)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_c5321d8f_6e23_495d_85a2_b363ce9c7edb"></a><a id="Tc_auWFiouu_0CPkrLSWw43rQ_1_2"></a><a id="Tc_zcbU4ZiK00WBZN0nxshGxg_1_8"></a><a id="Tc_OvYmJCOG7Uys3oMUbMolsw_2_2"></a><a id="Tc_rDnugrXPy0-9TW2oFRoakg_2_8"></a><a id="Tc_j7gkWNodaUaaBIWNePkjEA_3_2"></a><a id="Tc_8GXH8j-4B0qxccMZx8HZaA_3_5"></a><a id="Tc_81YqxgPlH0mIUp3DygIlmw_3_8"></a><a id="Tc_BkGZDwaY80GwSCIRpadzpw_3_11"></a><a id="Tc_j0MDcTIaJEGy_m_Rie9U2w_5_0"></a><a id="Tc_XnAGPPmw30uWYi-BDDzC8w_5_2"></a><a id="Tc_s2yAsKI5skmjjaumUzI2xg_5_5"></a><a id="Tc_hE9AxqXsZkiL0BBT8AETMg_5_8"></a><a id="Tc_yELfJzcB7UKx2nhHWlOOhQ_5_9"></a><a id="Tc_8ScpxemUfEOi0QdUfe4l9A_5_11"></a><a id="Tc_QJQZ7awkRkWN1oz4YVFKTw_7_0"></a><a id="Tc_fzGpRhxHgUGIPAcxLV9GnQ_8_0"></a><a id="Tc_q6_zfw82S0mAI_Xldh2kmQ_9_0"></a><a id="Tc_sPVLz3l1UUeqRZVTbUfUEA_10_0"></a><a id="Tc_0w4p8VrfwUynE14R_XOcWA_12_0"></a><a id="Tc_PxPQT7AFVUmc632p1c9H-w_14_0"></a><a id="Tc_yj5-tfR-BU2EJfSqRsN3XA_15_0"></a><a id="Tc_Y4orFNPWnEmBMTZKBZZtMg_15_12"></a><a id="Tc_PUXDvAeLYEysWOLAUH-VnA_16_0"></a><a id="Tc_VQ36ty8lj02CjW_r-WVFRw_17_0"></a><a id="Tc_rhAXGzYmkUi0U-c_9MID9g_17_12"></a><a id="Tc_KEbz52E7iE22Us1VUY1ppA_18_0"></a><a id="Tc_iE69QlObe06D9LRp0NuyNg_18_9"></a><a id="Tc_B2envCwVrkuI4JaBGj0luA_19_0"></a><a id="Tc_M73IB6GvPU6vv9vIwyDUyg_21_0"></a><a id="Tc_8PeDU5vglEGxVCcrZEyv3g_22_0"></a><a id="Tc_ahDv8zC-PkGH7wZkxTvlaw_22_9"></a><a id="Tc_j7VWeM-pbkaSMwMlYo0s-w_23_0"></a><a id="Tc_O1gX-pG7JEaExrMurWxNzA_25_0"></a><a id="Tc_0QLWikUKaEuUJLiuzkgd4w_25_9"></a><a id="Tc_HLEQVtZMfEeX37fXKw_rEg_26_0"></a><a id="Tc_uyQ_l4cALk6OrSh5qsDwaw_28_0"></a><a id="Tc_pgWRMpOtgUuFf_Q6Xs5AHA_30_0"></a><a id="Tc_gTqI-7XnaUWso-73twmVZA_30_2"></a><a id="Tc_DqjsO6z090CSRTskqfMJ2Q_30_5"></a><a id="Tc_fAgpgt0BFkGvoQaBJkNxyA_30_8"></a><a id="Tc_1RONr7P5hEucvf_JedL7WA_30_11"></a><a id="Tc_UObNyNR7_0udsQhR2kZl0w_32_0"></a><a id="Tc_-eaNYBmQLkeQHbMoSOtg0A_33_0"></a><a id="Tc_1W8s6gUrhUOkBvHo4LYdTg_33_2"></a><a id="Tc_pmvr2rddZ0WWvtS6MPL6QQ_33_5"></a><a id="Tc_ekVmGeZRFEu9hhmRsj3ETg_33_8"></a><a id="Tc_eCYSUnBF6UqQ3qCEi0s0lg_33_11"></a><a id="Tc_1MaSaNMe8k6RqBRVX-8kpQ_34_0"></a><a id="Tc_mdzPncKKW0iq7duToQ0H0Q_35_0"></a><a id="Tc_7BFyKPaQlUKbrfFui0BR7A_35_12"></a><a id="Tc_FYDfTz6ynkq_wRvw5s4PWg_37_0"></a><a id="Tc_zdks_GRmJUuGulrOE6N22w_37_2"></a><a id="Tc_96P0qi8qNUm5VxSVAwUnSg_37_5"></a><a id="Tc_wOt2zU7lqkGrGORzUqFdIQ_37_8"></a><a id="Tc_FW5_-lkD7ku_mLtbI_rmfA_37_11"></a><a id="Tc_di17N_Rcc0mOM_wVS0kzKA_39_0"></a><a id="Tc_xydSVZZSGEGcztqoWpYzWw_40_0"></a><a id="Tc_J7UcQDrzakmHGOYRlIJ4jQ_41_0"></a><a id="Tc_R-G2TdT0A0qdbDPgmjipzg_43_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.20833588%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="Tc_Pdqvlad84EqCs5rzRaQ3lg_5_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_19Dgy2otzUKIaPDqoz5EFw_5_6">1,800</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_FMbLgsOhOUOfG1gHJujK3g_5_12">1,884</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_yliNjXUcO0mnxP6edm9W9A_8_3">2,644</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_83IOdDjjp0yYIw811NRLCg_8_6">3,272</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_4QqqwxXsS0SQIlfuLoCuYA_8_9">7,971</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_Bzi8_YIJk06ZGr6rd23I6A_8_12">6,265</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_CW7Njiutp0-LlK909WSwRQ_9_3">3,525</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_i5Ibdp7FsUmGaeKbn6kwhw_9_6">5,316</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_qqJ6XKIsZEyOqXCGIUR38w_9_9">16,407</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_24nbE7BJD0ivq6TEDYHsZQ_9_12">14,863</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 18pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_XWDbNuqNPUKVTfc_-L5KyQ_10_3">6,169</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_i00J9cW4OESUOLCW5vPGIg_10_6">8,588</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_DOAC88r1hEOZIIsQwy0Dmg_10_9">24,378</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_gbmNwuDCs06Kxl-5gzqxnA_10_12">21,128</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Operating loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_iVHTVYEeO0C-r84Kd042YQ_12_3">6,169</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_FRQIOuev6EKOVgpHHhtTkw_12_6">6,788</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_T2ZHlopK20CJwNcLlKgWwQ_12_9">24,378</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_b0MNztITmkSD6imhB8IEcg_12_12">19,244</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Other income (expense):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_fJPC63O9bkGZ65ppd_IMuA_15_3">35</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="-3" format="ixt:zerodash" name="us-gaap:InterestExpense" scale="3" id="Tc_oXEMjdiIfE6oGTZ9O8Mc7A_15_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_KgWFf1t94UazeBXQGDERMw_15_9">66</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_1n3U72d5g0quO4W7Ofl7KA_16_3">23</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_AA85FXXzAkSoFibrVZCPnw_16_6">40</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_MDsivovyu0mtyyhlal36mQ_16_9">163</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_0cnkO7hhz0aR7sU4Tfa5uw_16_12">111</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Loss on sale of debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleGainLoss" sign="-" scale="3" id="Tc_tydLgSwpQ0KxNeAtY4Tpsw_17_3">98</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleGainLoss" scale="3" id="Tc_l09Dhs9zREKc8a57PMLOEw_17_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleGainLoss" sign="-" scale="3" id="Tc_V4uHOfnha0qD86-K2SBfog_17_9">98</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Royalty income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" format="ixt:zerodash" name="us-gaap:RoyaltyIncomeNonoperating" scale="3" id="Tc_uho2-HG7A0aY2J1fXx0KYQ_18_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RoyaltyIncomeNonoperating" scale="3" id="Tc_Wwa10ZgyqUCQoR3_pX3qKA_18_6">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RoyaltyIncomeNonoperating" scale="3" id="Tc_S1KUGCvB-UOgMTAANebsqg_18_12">7</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 18pt;">Total other income (expense)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_pvxWTkROl0as6ba0s0UT2g_19_3">110</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_WWK8mDcbIkmxmuMb3-6n9Q_19_6">42</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_4wY12rA-lEGsGYjJ4X-Xaw_19_9">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_wPhf1aXNpUexg-xK5kCpww_19_12">118</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Consolidated net loss from continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_YgS82KFCd0CANUghMGOFiA_21_3">6,279</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_7qJr5DkzxkSjD4mVfEzymQ_21_6">6,746</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_mCFD-SeWJEqtTQVp5O8HKQ_21_9">24,379</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_TgVXC2n-LUmD96QjUvbMDA_21_12">19,126</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Net loss attributable to noncontrolling interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="3" id="Tc_VgWU5qJjO0uSPkE44lSIPg_22_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="3" id="Tc_c5_VwaTQpUCzZ3V5TJwc1g_22_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" sign="-" scale="3" id="Tc_wNnvhtQGJESeofnfZMepuQ_22_12">1</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to iBio, Inc. from continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperations" sign="-" scale="3" id="Tc_Ppl2nqQf3EGjmCD9gDiKPA_23_3">6,279</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperations" sign="-" scale="3" id="Tc_Jt1DV4iXF0mzDJBkayoX9g_23_6">6,746</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperations" sign="-" scale="3" id="Tc_xAQgv45p_kmQPDMCJRsMGw_23_9">24,379</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperations" sign="-" scale="3" id="Tc_OhxST6aiN0yPQpqh8MuATw_23_12">19,125</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Preferred stock dividends - iBio CDMO Tracking Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" format="ixt:zerodash" name="us-gaap:DividendsPreferredStockStock" scale="3" id="Tc_yypIbOim8EikM39QIf6LKA_25_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="-3" format="ixt:zerodash" name="us-gaap:DividendsPreferredStockStock" scale="3" id="Tc_zNoQYLNEG0-CnshffoZMZg_25_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStockStock" scale="3" id="Tc_P3mOBGtx9ESa92OoOvtN7Q_25_12">88</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Net loss available to iBio, Inc. stockholders from continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" format="ixt:numdotdecimal" name="ibio:NetLossAvailableToStockholdersFromContinuingOperations" sign="-" scale="3" id="Tc_OeKAkTvz50GA0s0Tb6DWpA_26_3">6,279</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="-3" format="ixt:numdotdecimal" name="ibio:NetLossAvailableToStockholdersFromContinuingOperations" sign="-" scale="3" id="Tc_LAZ6MsUZ6UuSM4ROyBQenA_26_6">6,746</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="ibio:NetLossAvailableToStockholdersFromContinuingOperations" sign="-" scale="3" id="Tc_eR2cFR4f7EKWLwCepiHITg_26_9">24,379</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:NetLossAvailableToStockholdersFromContinuingOperations" sign="-" scale="3" id="Tc_AWOO-nrav0qpxILH4EUeGA_26_12">19,213</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Loss from discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" sign="-" scale="3" id="Tc_UPxQ8KETdkazLR1ES0MJ_g_28_3">1,015</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" sign="-" scale="3" id="Tc_vVZ_Q8KblUO5zIXz7tFTwQ_28_6">5,644</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" sign="-" scale="3" id="Tc_gZt0vZjWu0CNLlYXoLegVQ_28_9">34,598</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" sign="-" scale="3" id="Tc_PsHr1B6lmU2_r-NHp8ueNQ_28_12">14,124</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Net loss available to iBio, Inc. stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" format="ixt:numdotdecimal" name="ibio:UnconsolidatedGainLossAttributableToStockholders" sign="-" scale="3" id="Tc_o2Owa36fJUCRat9-otlhJQ_30_3">7,294</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="-3" format="ixt:numdotdecimal" name="ibio:UnconsolidatedGainLossAttributableToStockholders" sign="-" scale="3" id="Tc_gqyCwbilXUaAavP8WCcxTA_30_6">12,390</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="ibio:UnconsolidatedGainLossAttributableToStockholders" sign="-" scale="3" id="Tc_5wVDvzJhqku-0Kk6IZwIrg_30_9">58,977</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:UnconsolidatedGainLossAttributableToStockholders" sign="-" scale="3" id="Tc_zUeYebMud06IbpJkt_JVJA_30_12">33,337</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Comprehensive loss:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Consolidated net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_wJeTQDGEEECcVgmfavvXZQ_33_3">7,294</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_LWR_BJTC7kium3eirPY49g_33_6">12,390</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_T2_qpgstWU67lMNjdcl1xw_33_9">58,977</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_l1ZJSYGsM0GhGkRCkdWmPw_33_12">33,250</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Other comprehensive income (loss) - unrealized gain (loss) on debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="Tc_fG8e_sJQnUuZAzdtWvlGLg_34_3">134</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" sign="-" scale="3" id="Tc_SoklsFCDrU2SxgInve6mJQ_34_6">103</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="Tc_suoD5akzh0mHi9LfrLCHiQ_34_9">180</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" sign="-" scale="3" id="Tc_RMovBs15wkaYgwhgC0KiAQ_34_12">131</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Other comprehensive income - foreign currency adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="Tc_ncQKXytNN0eamBV3EtvAVQ_35_3">33</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="Tc_xW792NPVqUSKJ931fBTXHg_35_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="Tc_d916kj6HyEyyfhcVGEIQsg_35_9">33</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_spTeRAjiK0eXbc-J2MxqAQ_37_3">7,127</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_Wkto6q4lhUq9kE9FJH7qVw_37_6">12,493</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_XM_m5Py68Uq7xxc4mjFdDQ_37_9">58,764</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_-qxBKxrFLU-syo-oPmH5wg_37_12">33,381</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Loss per common share attributable to iBio, Inc. stockholders - basic and diluted - continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_uMJ7rDsFFEe-PYrwZsUJbg;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" sign="-" scale="0" id="Tc_RilchKoS4UCJaPFwuDZM1A_39_3">0.47</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_4R874yyR00-lQ-gPK5aVDQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" sign="-" scale="0" id="Tc_5G6DgJzK7ESE_RaTei5-Sg_39_6">0.77</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_4cohup_Xe0im-EU-Ng1hmQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" sign="-" scale="0" id="Tc_oBuy8t_nzka5lH2_gjqYvA_39_9">2.30</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_alkmQJ0-3EK_SSHZA_FGwg;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" sign="-" scale="0" id="Tc_VUbiBod6ukK1c330zq7CfQ_39_12">2.20</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Loss per common share attributable to iBio, Inc. stockholders - basic and diluted - discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_s2ZDVjJuBUuX5ocrOsoaJA;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" sign="-" scale="0" id="Tc_re-rJSKGDk-ia_p_-3l5ag_40_3">0.08</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_pvbUml_Xr02ereqyMzgIaA;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" sign="-" scale="0" id="Tc_Ed24NtwATES_S41t6SC_ew_40_6">0.65</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_tZ68DHnAh0ewkHu2Z17AYg;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" sign="-" scale="0" id="Tc__gF5KQ2JL0mmdw1b8ZG_bQ_40_9">3.27</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_UcSIW9AD8UiR_O8CKdfyGg;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" sign="-" scale="0" id="Tc_uTpEwlUeQ0mWV6XUFoHIxA_40_12">1.62</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Loss per common share attributable to iBio, Inc. stockholders - basic and diluted - total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_KoisN5HwMUirJemjndgMlQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_Tw6nnJ6DUk6LCWnDIy5A0Q_41_3">0.55</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_3P92l1MxxUySgIWVF8sauw;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_SqmavZBF9kyRCWsanPSJgg_41_6">1.42</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_CHdwpyqz5UmsdxMQu01lmA;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_6GGqdelwYEqoCYRXMXKn5g_41_9">5.57</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_Y9WTzYNp-UiQOB98sjcuIw;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_avtP0lVylEyRn117FbNoNg_41_12">3.82</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average common shares outstanding - basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_bFu57BPFek2kZ-K-6wqZMg_43_3">13,184</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_gZ9FgyqWxUGMW-ouf22GfQ_43_6">8,719</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_I2yZAS3AwEqPM-8kN4rx-g_43_9">10,592</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_l112lJjdHkGW3My9bqHyjg_43_12">8,719</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_815ebba6_b959_461c_97b1_f7e784538779"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">iBio, Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Condensed Consolidated Statements of Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited; in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Nine Months Ended March 31, 2023</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_2e8a0b0c_723f_45eb_951a_9d7bc96275a4"></a><a id="Tc_ZxCH9sqzOU2wBeVVAjLOPw_1_16"></a><a id="Tc_SSq5NyWbRU6EeOeAqJqhFg_2_13"></a><a id="Tc_qNK958G4zUKe_EktrmuIbQ_2_16"></a><a id="Tc_mWg5YPVRW02205I--BpPmg_3_2"></a><a id="Tc_foLJ1LXK3UiQGWk1BWaqzw_3_8"></a><a id="Tc_9DC9Qku3M02IyX1B9Sq9Bg_3_13"></a><a id="Tc_tIB50va0SUSRYs7cZ4CHvg_3_16"></a><a id="Tc_8_nWiJUd4EKOsToYF6BizA_3_19"></a><a id="Tc_F-wI5iMqjU2Vu8u6EyPo4A_4_2"></a><a id="Tc_1SpoMsrJZUKSKdfuzm085g_4_5"></a><a id="Tc_FUBnYQk1v0mBreqYZrRsAA_4_8"></a><a id="Tc_ivOvDHifAk64yE-kuVdhzA_4_10"></a><a id="Tc_A2uuYwF8-UebNhhtyskuHw_4_13"></a><a id="Tc_myQO_UBljk-EpU8ZS5zEVw_4_16"></a><a id="Tc_kYja2HhoZkCIAo8PxYPcxw_4_19"></a><a id="Tc_QVNCWhcePU--JRHQKZzQNA_4_22"></a><a id="Tc_58FGiVAh-02w9T9fZsVvYA_5_0"></a><a id="Tc_X_EW1wRZTEG5NGByx8GDXA_5_5"></a><a id="Tc_JKA8cqJgQE2CIW0GlMtiQA_5_6"></a><a id="Tc_3UChdS9ViECoa_fS4FfxPA_5_10"></a><a id="Tc_QS01SmrchkC8-_DNrQPYnw_5_13"></a><a id="Tc_4ZDTRtb1l0m4d-ezrqP5hw_5_16"></a><a id="Tc_lH52SjQWQUGapvY9TlGqDQ_5_19"></a><a id="Tc_nN21Ig1JmEWaHCvWvhqjgg_5_22"></a><a id="Tc_x0reua0sEUyGolV9rkqpqA_7_0"></a><a id="Tc_bm4m_nhnPUSgv5ABmmzqHA_7_3"></a><a id="Tc_yGpkyw_ulkqcBOVqihNAYQ_7_6"></a><a id="Tc_gSmG_merFUyZb4qIFsC7vw_7_11"></a><a id="Tc_f9UaBn9f70OP67hAKFUEeQ_7_17"></a><a id="Tc_2h966nTBP0avopIGom6V1w_7_20"></a><a id="Tc_1RZ-00G7QU-hYYAeIcITNQ_8_0"></a><a id="Tc_lBBQW8fazUCgDoZSwDS30A_8_6"></a><a id="Tc_HYBf3OelDEqyN9VODnOs4g_8_8"></a><a id="Tc_HR3vrPnuaESYjG_Gio3_og_8_11"></a><a id="Tc_cpm3SHWkXkybMP7IPKFIbw_8_14"></a><a id="Tc_4Po4p58A_0eQ93g7--RcjA_8_17"></a><a id="Tc_lfNJ1OSWd06fNSyxvlxnwg_8_20"></a><a id="Tc_B0oO9iM6fEuFOpFI_oxnxw_8_23"></a><a id="Tc_CzmEVgGIXUWwTWU0_DQLTg_9_0"></a><a id="Tc_GsgHNoBXVU6TSOVTrGj0_A_9_3"></a><a id="Tc_JQwZrk5sc0i4jGw4MYleHg_9_6"></a><a id="Tc_p9Wx94GzWEipefxZiu7IcQ_9_11"></a><a id="Tc_g8yawIwmJECVSfznyFQ3qQ_9_17"></a><a id="Tc_Duy-pc0VikuR7ZlpKmO9nw_9_20"></a><a id="Tc_XoF4lze810OwcNxLG_tFag_10_0"></a><a id="Tc_xny_Hw_LQUCxhgQRQYxsGA_10_3"></a><a id="Tc_GEaBFTdBhUKDQjKHAaUKgA_10_6"></a><a id="Tc_FUA9jvXm4kyKfR_d2ACf1Q_10_11"></a><a id="Tc_9folBaFXWUuyJkFXpwBYYA_10_14"></a><a id="Tc_IwYk1j-j1kqs1bW8DxuDww_10_17"></a><a id="Tc_3y56dbT-wEavkUh5td6M_Q_10_20"></a><a id="Tc_lIyzn4eP1UCE2rj9W49l6A_10_23"></a><a id="Tc_2Ra5cVMfP0CdfQP24882Cw_11_0"></a><a id="Tc_aaGckC8K9ki5M4PAiyPq-w_11_3"></a><a id="Tc_7Sj0eBTEWE-CSAYUzLzBwg_11_6"></a><a id="Tc_T1N0A76cDUeGijdzXrMnnA_11_8"></a><a id="Tc_Q47XZTQcB0CisXBEg5dmow_11_11"></a><a id="Tc_yQWgMcp68Uudbm1KfzclNQ_11_17"></a><a id="Tc_Y5ekTFP1bUq_RPLnaz_3SA_11_20"></a><a id="Tc_o27qcx7lY0W4P3kgbiTjdQ_12_0"></a><a id="Tc_gaJ85CUHUkOP8XBn7h1_Xg_12_3"></a><a id="Tc_NkQ53JOz4EeDoN_VQpBOkQ_12_6"></a><a id="Tc_XAoLFhZhUE2R3ctPKXJuLw_12_8"></a><a id="Tc_vwfMuzY5gkyhIL07XpoZ1w_12_11"></a><a id="Tc_1grDO_C2L0Wlr2kAv-5r-A_12_14"></a><a id="Tc_yTgxF7Gz20OkENYuJIrsWA_12_20"></a><a id="Tc_gD90yceowUivORppjI5f8g_13_0"></a><a id="Tc_yO7AsDOlCkCY_pR4syyPrA_13_3"></a><a id="Tc_jigUNHpFukWQxCMd4Ar4cw_13_6"></a><a id="Tc_cYswTCdYu0m0MbU9nrxb3A_13_8"></a><a id="Tc_kpz0VC42E0CYvyByZN7oiw_13_11"></a><a id="Tc_pSiITOveI0SUNc-oAVFWkA_13_14"></a><a id="Tc_sF6RMc5M_0qhnOw9QJAa3w_13_17"></a><a id="Tc_vzXDHn9cgk-kUEOpkCZAqA_15_0"></a><a id="Tc_WginCTCXM0WyJ_82caeSrg_15_3"></a><a id="Tc_AQNIXh0HsUCWproPINNoCg_15_5"></a><a id="Tc_0i29PK4DJ0SElLXBaaEVWQ_15_6"></a><a id="Tc_K9eNtTJV1UeqI2BTQCJAQQ_15_10"></a><a id="Tc_awIsNJtyvUmN67fcgPHhfA_15_13"></a><a id="Tc_88gJL26QOUKzw2L6hgOuDg_15_16"></a><a id="Tc_BWi0jJWkEEO8RhgVRrIXEw_15_19"></a><a id="Tc_cz_8az-_DkKTBi1poS37Kg_15_22"></a><a id="Tc_vm2agwB_5kWs_RVw3xpKXg_17_0"></a><a id="Tc_td4DCtj3yEmU9CW66MlWBg_17_3"></a><a id="Tc_MQK1tX6V5k6CPsSHaxuAnA_17_6"></a><a id="Tc_U_NQOAp0qkiAXNAE-jvj9w_17_17"></a><a id="Tc_uxPugE8VmkqlFaN6TpwjDg_17_20"></a><a id="Tc_mMIvj3FMAESvf56dg_FdjQ_18_0"></a><a id="Tc_8Uoykngg-Eqs8c-5rW18AQ_18_3"></a><a id="Tc_DzIzlf2fi0GDdkJBIloFFg_18_6"></a><a id="Tc_Zu_X2kObQkODGBr8S258dw_18_8"></a><a id="Tc_UjXh4Rq1E0m_TfXl7-IsQw_18_11"></a><a id="Tc_NhsSMysI7ku17U0NT0byrw_18_17"></a><a id="Tc_l389Rb87QE-v87JFDylwuA_18_20"></a><a id="Tc_a6OsHOaIbkS50q4OGm_W3g_19_0"></a><a id="Tc_-i5nhNyDSEyGy-Tzxs1fcA_19_3"></a><a id="Tc_ynhb5tZiNESs1yWhzGxqiw_19_6"></a><a id="Tc_lRYwon_NaUi24ZP4rjc06Q_19_11"></a><a id="Tc_7a80sp8ISEmsIHlfdqCHHw_19_17"></a><a id="Tc_R3KBXz5mzkuKu6CPy3bVpg_19_20"></a><a id="Tc_9nY4FISg0kS_Nu9kjTV_gA_20_0"></a><a id="Tc_4coW0GPnsEq2b-yocJA3-A_20_3"></a><a id="Tc_s1hTrQriDUe-YvdPuiNH9Q_20_6"></a><a id="Tc_I9_mvde_SUCwrDVLkRKFOw_20_11"></a><a id="Tc_GwZZxPsBNE2tQ1jLIfSE8Q_20_14"></a><a id="Tc_CXOzr5itcUyVYABSQFJQxg_20_17"></a><a id="Tc_Mwv0jGbeV0egLdgO84h0NQ_20_20"></a><a id="Tc_3njxxO7Sz0-B6F2NAFd7iA_20_23"></a><a id="Tc_itI0ZsrnS0elGRKa2LAUCQ_21_0"></a><a id="Tc_tT4erJ9Ygkiwi7DGiCioNg_21_3"></a><a id="Tc_aAr4CjdSt0qB_zgcFobQLg_21_6"></a><a id="Tc_D3JaE-1fm0O3BB6zv4iy1Q_21_8"></a><a id="Tc_bYCmPj4EdUCaBfOI-zSVJg_21_11"></a><a id="Tc_FVMe9RaDNEirksU2ObdHPg_21_17"></a><a id="Tc_25f8dyOxf0iQp-CcZdtPyg_21_20"></a><a id="Tc_I4-E2R5vq0aLrOysuHYYBA_22_0"></a><a id="Tc_UgtrLkAodkuX6ZexDmDZZA_22_3"></a><a id="Tc_ULkQ1ouNiECwAity1ByGBg_22_6"></a><a id="Tc_O7usFzddGEatuc_uEUYFaQ_22_8"></a><a id="Tc_dllOYvyHY0yN-EW3RqwFFw_22_11"></a><a id="Tc_IBPWijGxB0CXf1jqCKzFrw_22_14"></a><a id="Tc_psN-zDaN6U6F1AR46lHOCw_22_20"></a><a id="Tc_uD5BqJoHHUycc_DCZLxv2w_23_0"></a><a id="Tc_ke4z6J39Vk2DEI_OIEGjSw_23_3"></a><a id="Tc_kvUI2da5H0af-6Ztp14ZPw_23_6"></a><a id="Tc__D-UIycP5Um5lJJQM-u23A_23_8"></a><a id="Tc_57S34QZXKE2u3Y7SDVe9Dw_23_11"></a><a id="Tc_yMciPuTNL0eYMUbHFuiyMg_23_14"></a><a id="Tc_V07jUvRR_UqP3S4KJ8Wkyg_23_17"></a><a id="Tc_ymZYFMyybUG37vg84KUQVw_25_0"></a><a id="Tc_alKE0oKzIUizwMCT86CnuQ_25_3"></a><a id="Tc_nPl7q9u2Kk65_u9dYS5-cg_25_5"></a><a id="Tc_Fd3icQfPsESqoBjX0VUDPw_25_6"></a><a id="Tc_WsRMKOysNUe2JGyRNHGfgQ_25_10"></a><a id="Tc_PrKi2vrdcEmhsSPMxQuZmA_25_13"></a><a id="Tc_D9e2qTE9rEuOnjIPNRLBwA_25_16"></a><a id="Tc_R2JI5O29FEWuqTdg5w6S6Q_25_19"></a><a id="Tc_8btalIcYe0K2pFWbYdPVoQ_25_22"></a><a id="Tc_jZa6cm8OS0KXq4NaWNXvkA_27_0"></a><a id="Tc_7psJ31fR2EeodO7vEa0txw_27_3"></a><a id="Tc_i-8-nBpJOkiMJrCjULl4IA_27_6"></a><a id="Tc_y6IdC7kOVEyqFoVzDCI-dw_27_11"></a><a id="Tc_UKoq_u5k_UCw3sX-tZ4HqQ_27_14"></a><a id="Tc_iGFmKhZyyka2fb4o50aYMQ_27_17"></a><a id="Tc_1pQwTkBmXESwBEx7jZBZeA_27_20"></a><a id="Tc_rmMQ7IArAE6qMFQySH-1xQ_27_23"></a><a id="Tc_sRm6pa65gE64boW949ElPw_28_0"></a><a id="Tc_wUYl_YLA8EKu1WVo0V7n6A_28_3"></a><a id="Tc_RyYy_sz6ekeNDoczKgU4kw_28_6"></a><a id="Tc_EEHnWkvv0U-Uzi6C1JBnFg_28_17"></a><a id="Tc_LfJThLxBsU6YKQlpiCP4Zw_28_20"></a><a id="Tc_hN5dWoBBTkemiqzYjRPbQw_29_0"></a><a id="Tc_WhCvWmfDnUarhxhv6vA15g_29_3"></a><a id="Tc_8BVhk3ShXk683Cx8bz93SA_29_6"></a><a id="Tc_MvUiAkgWg0SGdiXbIISpWA_29_8"></a><a id="Tc_UlulZO2Uc0SB7GfsXlfDzg_29_11"></a><a id="Tc_PViU1IV-zEWGpPkwPHc1WA_29_17"></a><a id="Tc_DjFxOmQV3kCEOWOTI4Sczg_29_20"></a><a id="Tc_OXH_eFuCjUWKSaNnm624Zw_30_0"></a><a id="Tc_CTFt316g-EKI3DeRUjF6Fw_30_3"></a><a id="Tc_bDRn90NO-UGAEIIYJ0NF9Q_30_6"></a><a id="Tc_OYiC2mhGhEWGOF_pmZk6sQ_30_8"></a><a id="Tc_CAn6VaUlCk23gfIieGCPIQ_30_11"></a><a id="Tc_NGP6qdIyuUixy0GPFl0HTQ_30_14"></a><a id="Tc_Ztd_MLZGk0W1KCgG7q7UKA_30_20"></a><a id="Tc_oHk7DUfLMkq9HF8bThXzmA_31_0"></a><a id="Tc_nG6OdKAcv0yT89fVY1vLuQ_31_3"></a><a id="Tc_xep71svxg0CG8S_G-iILgQ_31_6"></a><a id="Tc_k5sH7Urn6k-skpKhjqdbow_31_8"></a><a id="Tc_7ReV8QwHB0OWaXd46MYHIA_31_11"></a><a id="Tc_hJ2tCUZd-EiDD9zSUpRsqQ_31_14"></a><a id="Tc_dlIhYHV5jUGoXN819-WOSg_31_20"></a><a id="Tc_tb37ze8G6UWSAOREjiKyJg_32_0"></a><a id="Tc_5mx1gDcEDkOCLCrazYUZFg_32_3"></a><a id="Tc_bjVosWomikaddYhtRnSoGQ_32_6"></a><a id="Tc_gn8trrjQjE-Ye7-tQ7XTOg_32_8"></a><a id="Tc_Ou2yY7-EW0ir9wac73yLlw_32_11"></a><a id="Tc_5f2GC077J02nxb3yDTf7wQ_32_14"></a><a id="Tc_2H7YJmuF7EizlV7Ubvt2bg_32_20"></a><a id="Tc_Ap3iXRobe0CGl0ZYwo3UjQ_33_0"></a><a id="Tc_BoQsyE5YlkWFSbkqYXeaYQ_33_3"></a><a id="Tc_do_Qltr-kU2zE8MFEv-TQg_33_6"></a><a id="Tc_bWdXGTGjAEO9QwT3w-jQIQ_33_8"></a><a id="Tc_kdNRujDgjEC9tJScIArW6A_33_11"></a><a id="Tc_kiovuzEVHkWUr2D-ggyIVA_33_14"></a><a id="Tc_PU-ayL_f5UCtQtEJ0NqbNQ_33_17"></a><a id="Tc_Icl26a7sU0uZAF9ViaawSg_35_0"></a><a id="Tc_qKbRpjE7zEmZVkGVLPvVMQ_35_3"></a><a id="Tc_ho1ZFjZL90iVUYmWkyQ_yA_35_5"></a><a id="Tc_RkBG1xGK-kKaWMWgAGE9yQ_35_6"></a><a id="Tc_hb_MOuPg30yHUWhoCGQa_A_35_10"></a><a id="Tc_tbncnihVJkCobR0heQPvEQ_35_13"></a><a id="Tc_FwGYoGhOjkaNd17vZ_ZnUw_35_16"></a><a id="Tc_xTpVZHsEDUSlhU_VNIREGg_35_17"></a><a id="Tc_S4IjNtJsfkeDm3ssWrZbiw_35_19"></a><a id="Tc_skNaqKQv2Uy3blOEeifimA_35_22"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preferred&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:16.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of July 1, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_302kYRWtf0SLrzPv4HomVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_UEQD0GJzPkW7yjNYWVirWA_5_3">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_UH3i88_6M0mId27kV_1YRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_KqWt_9FeZUqwb0SfUDANqg_5_8">8,727</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_UH3i88_6M0mId27kV_1YRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_kMsKjbE0dEuGWDue5bP-cQ_5_11">9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sIGvof6AoUegd5YJhRXoGA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_APQ5V8oVIkidHETHsr_F9Q_5_14">287,619</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_eeBEWZpzDEuzNagWju7iXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_Dt0U_qo5hkKRUuIrWnadog_5_17">213</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_JyoJW5xFA02SvXgMgzGBBQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_QkJ66Rh4FE6UbSw1mM2YCw_5_20">223,930</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_jXB0mJimHkK9bgFzYBz_Mg_5_23">63,485</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Capital raise</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HD3iLrT9BUSp3VUMVRBnVA" decimals="-3" format="ixt:numdotdecimal" name="ibio:StockIssuedDuringPeriodSharesCapitalRaise" scale="3" id="Tc_LXUOzDdCm0i2CRtj3yrndg_7_8">176</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VgtORRQXUEmi1Rl7s04fXA" decimals="-3" format="ixt:numdotdecimal" name="ibio:StockIssuedDuringPeriodValueCapitalRaise" scale="3" id="Tc_DT3n_LaSq0-rjUhxFDEOdw_7_14">1,151</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_9_30_2022_goiPae-IiUSx1NtZV7V7cg" decimals="-3" format="ixt:numdotdecimal" name="ibio:StockIssuedDuringPeriodValueCapitalRaise" scale="3" id="Tc_AJT33ejfz0adv6NmiAl2Fw_7_23">1,151</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Conversion of preferred stock to common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_qNVa23oLakSTWA8v85-VDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" sign="-" scale="3" id="Tc_IhRHdtm2vkGLXm040I-MNQ_8_3">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:25.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Common stock issued - RubrYc transaction</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HD3iLrT9BUSp3VUMVRBnVA" decimals="-3" format="ixt:numdotdecimal" name="ibio:CommonStockIssuedInRubrycTransactionInShares" scale="3" id="Tc_vzFSCcALUU-_-fT3xo8pmQ_9_8">102</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VgtORRQXUEmi1Rl7s04fXA" decimals="-3" format="ixt:numdotdecimal" name="ibio:CommonStockIssuedInRubrycTransactionValue" scale="3" id="Tc_RkS8cV8V4EWEw5Jv4DR1Lw_9_14">650</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_9_30_2022_goiPae-IiUSx1NtZV7V7cg" decimals="-3" format="ixt:numdotdecimal" name="ibio:CommonStockIssuedInRubrycTransactionValue" scale="3" id="Tc_LJVbZRr9M0SXaebi3Cos1w_9_23">650</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Vesting of RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HD3iLrT9BUSp3VUMVRBnVA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="Tc_moXR8fWTZ0Ss3iSTSTqVQw_10_8">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VgtORRQXUEmi1Rl7s04fXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_FF1rq18Fn0yLg7Wc_jaxzQ_11_14">1,222</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_9_30_2022_goiPae-IiUSx1NtZV7V7cg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_8RPSpzupPEGNphu9xYn9kw_11_23">1,222</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Unrealized loss on available-for-sale debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_JJDtYxXNZUqTS9r_Ytu0CA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" sign="-" scale="3" id="Tc_18VTyRga4kKTF74w_Iyc2g_12_17">10</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_9_30_2022_goiPae-IiUSx1NtZV7V7cg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" sign="-" scale="3" id="Tc_VB98PcRaGECsXOH2rKMmcg_12_23">10</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ll59BJ1LzUSofhSUma-j9g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_WZk5HBniCkaiH-kouHDybw_13_20">18,130</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_9_30_2022_goiPae-IiUSx1NtZV7V7cg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_ertEIEyeNU22xh2kOPDSLQ_13_23">18,130</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of September 30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_84GMwaIsm0KxnvZMEZe9PA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_6oyE0u7h5kqgwHkzuCfnIg_15_8">9,006</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_84GMwaIsm0KxnvZMEZe9PA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_LyGtaUgWI06rmt1ChMP87w_15_11">9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tl2lar8KpUyhhXZisj7IKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_IKiwHBL4I0KoitcIYJDwJA_15_14">290,642</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Pbu5fuCUvkqtV3iKXcXZgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_9FbEgwGeTkOjgdhOP9ciLQ_15_17">223</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_btFG4i_i4UifFBqeFaAOYw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_tFfmu65RN0yusd03e-AlUA_15_20">242,060</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_9_30_2022_FQYWefjPT06gXbntJAGaLQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_oodOclsf6UWEoUChA_JB5A_15_23">48,368</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Capital raise</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="Duration_10_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uUZOjGeySkC0V7oyrpt9UA" decimals="-3" format="ixt:numdotdecimal" name="ibio:StockIssuedDuringPeriodSharesCapitalRaise" scale="3" id="Tc_J-lyjXVGcU-3b4-2rdsxFQ_17_8">3,366</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_10_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uUZOjGeySkC0V7oyrpt9UA" decimals="-3" format="ixt:numdotdecimal" name="ibio:StockIssuedDuringPeriodValueCapitalRaise" scale="3" id="Tc_W0JDAbLnH0qj7FfsDE4wrA_17_11">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_10_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_05inVfs2x0qofUiIplZIZw" decimals="-3" format="ixt:numdotdecimal" name="ibio:StockIssuedDuringPeriodValueCapitalRaise" scale="3" id="Tc_GrlKzva4EE6Lyviw6zEtMg_17_14">3,497</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_10_1_2022_To_12_31_2022_cYAWIZbIyEWUA55EtH7XHg" decimals="-3" format="ixt:numdotdecimal" name="ibio:StockIssuedDuringPeriodValueCapitalRaise" scale="3" id="Tc_m2Y47du4Okupnd6aAZtJ9A_17_23">3,500</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Cost to raise capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_10_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_05inVfs2x0qofUiIplZIZw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="Tc_l2K7b2N9nkyTBnJgALXaTQ_18_14">636</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_10_1_2022_To_12_31_2022_cYAWIZbIyEWUA55EtH7XHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="Tc_u7etNgEqv0WTZ5DoMpuY5g_18_23">636</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Payment for fractional shares after reverse stock split</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="Duration_10_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uUZOjGeySkC0V7oyrpt9UA" decimals="-3" format="ixt:numdotdecimal" name="ibio:FractionalShareIssuedAfterReverseStockSplitShares" sign="-" scale="3" id="Tc_k1umYGO_30mKtRmnFp0uRA_19_8">8</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_10_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_05inVfs2x0qofUiIplZIZw" decimals="-3" format="ixt:numdotdecimal" name="ibio:FractionalShareIssuedAfterReverseStockSplitValue" sign="-" scale="3" id="Tc_sv2Q6jxnBkWZWVkuefQOyA_19_14">39</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_10_1_2022_To_12_31_2022_cYAWIZbIyEWUA55EtH7XHg" decimals="-3" format="ixt:numdotdecimal" name="ibio:FractionalShareIssuedAfterReverseStockSplitValue" sign="-" scale="3" id="Tc_YACjxM1loUClsOcAJOPaww_19_23">39</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Vesting of RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="Duration_10_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uUZOjGeySkC0V7oyrpt9UA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="Tc_-kMxTgJA6E68P38tcprqNA_20_8">4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_10_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_05inVfs2x0qofUiIplZIZw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_zPQbotzf7kKhKhNrwWQuqw_21_14">1,127</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_10_1_2022_To_12_31_2022_cYAWIZbIyEWUA55EtH7XHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_hxT0VfUH30yD2U7FcFfiwg_21_23">1,127</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Unrealized gain on available-for-sale debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_10_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_FGJtC-Cca0ywdM4SzNVWpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" scale="3" id="Tc_voRmpczuSUWz09HtgayIcQ_22_17">56</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_10_1_2022_To_12_31_2022_cYAWIZbIyEWUA55EtH7XHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" scale="3" id="Tc_2dxLH-n9_EeD3RGX2T8giA_22_23">56</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_10_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZuedCxHLfEuQdq1I8bADJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_4w4snGLOLUaWz-kp_dbB2Q_23_20">33,553</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_10_1_2022_To_12_31_2022_cYAWIZbIyEWUA55EtH7XHg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_Ai2dAuPAfUihWY5mPl9wUg_23_23">33,553</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8ASi2S5ht0qWY7QQf1HPIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_7u7VS-R7S0aH1K6oMnQGuQ_25_8">12,368</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8ASi2S5ht0qWY7QQf1HPIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_EWwh0UeZT0GbAU1epGGLLw_25_11">12</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ljAxJwch6kazqell6E9urQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_oarCkqXZ7ka4O1LKUYZ_JA_25_14">294,591</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Zo82mtQMNE2WG6FBhO9Gxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_P_q0hcn8TkGLtPhE8WhNLQ_25_17">167</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_aXxc-Org7Umr-wR0vxLYGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_Eufh1h0gw0yU0Wv3mNPXFQ_25_20">275,613</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_12_31_2022_OyKJ3tL-Q06qZ-tFHs9gXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_BJpC_fePFkOFQQkbP86avg_25_23">18,823</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Vesting of RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MWdz4lqoIEShu4AoC1KFyw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="Tc__WEjtC_I30C6eWIpRvg6_Q_27_8">28</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Capital raise</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MWdz4lqoIEShu4AoC1KFyw" decimals="-3" format="ixt:numdotdecimal" name="ibio:StockIssuedDuringPeriodSharesCapitalRaise" scale="3" id="Tc_Q1Iosb-GXkWTSR6haHio9Q_28_8">3,422</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MWdz4lqoIEShu4AoC1KFyw" decimals="-3" format="ixt:numdotdecimal" name="ibio:StockIssuedDuringPeriodValueCapitalRaise" scale="3" id="Tc_0COs9epdt0eQFq88HYVPNw_28_11">4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_o6HWlvHmjUS2rzS8fnoWuw" decimals="-3" format="ixt:numdotdecimal" name="ibio:StockIssuedDuringPeriodValueCapitalRaise" scale="3" id="Tc_F2SDmEzkWUuVASRc4x1baw_28_14">4,093</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" format="ixt:numdotdecimal" name="ibio:StockIssuedDuringPeriodValueCapitalRaise" scale="3" id="Tc_tdGxeJvQWE2JcyC1aBjI7g_28_23">4,097</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_o6HWlvHmjUS2rzS8fnoWuw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_kkV9HLQtqkiBl1m2QwVbaw_29_14">1,596</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_tMmR8II-oU6zZPzwV6HrCQ_29_23">1,596</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Unrealized gain on debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_YZMShz8Rh0u-FmqZPOXdfA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" scale="3" id="Tc_F-klo3k5x0C2g3HbpffCwQ_30_17">113</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" scale="3" id="Tc_Rm-foUWBOU-C5qJi-hy_UQ_30_23">113</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Reclassification adjustment for loss on available-for-sale debt securities realized in net income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_YZMShz8Rh0u-FmqZPOXdfA" decimals="-3" format="ixt:numdotdecimal" name="ibio:ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities" scale="3" id="Tc_tEYOAHBJ9E-s0qCB7h4_rw_31_17">21</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" format="ixt:numdotdecimal" name="ibio:ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities" scale="3" id="Tc_sbeXa_3RgkK2HRYCyfApsg_31_23">21</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Foreign currency translation adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_YZMShz8Rh0u-FmqZPOXdfA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="Tc_7lOVEYLmikymQoHBQjT4Dg_32_17">33</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="Tc_4q5T7TFfT0q1H3yWu_Tcow_32_23">33</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_QiAZnlfbxEmMw0lCHMl5EA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_3jGDbbRq50axmyZ-0NA7OQ_33_20">7,294</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_G5jLXeM43kyL8HjGSBSSwA_33_23">7,294</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of March 31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_G5vLxz-NeEqgDIsG6nvKaA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_NRWjaij06UKQ60HNf8szKg_35_8">15,818</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_G5vLxz-NeEqgDIsG6nvKaA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_b7J3U6a_4kemXh8DhJ6_wA_35_11">16</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Dq6r99N510C1DCNhsL8h9g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_J21wzIsDpU-JryeexKsakA_35_14">300,280</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_a8XYRnY0YEqjr3LZjT16ww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_zHsDbcuTu0GCZkSKZnXhqA_35_20">282,907</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_DmhBoT7zlU-HV0ioP1liyg_35_23">17,389</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">iBio, Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Condensed Consolidated Statements of Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited; in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Nine Months Ended March 31, 2022</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_c6f7d3f6_c336_473e_9c70_22cbb0026f2e"></a><a id="Tc_RkvVTAOQjUWvXB79U7kFzQ_1_16"></a><a id="Tc_n_RyJH0aJEewm-pZpC4i0A_2_13"></a><a id="Tc_uBd3SRB_WUyZZdR3hMVKCQ_2_16"></a><a id="Tc_dpnyPpA3y0SNWlQ9azBGLg_3_2"></a><a id="Tc_6jBkpost6EaP_xGgmEyaZg_3_8"></a><a id="Tc_J9f0ZUgqJkWzAF7-P9TZRg_3_13"></a><a id="Tc_Yr7BccEbLU27iu_gjj1SVQ_3_16"></a><a id="Tc_e47eV8IJskqxLa8lTwXHfw_3_19"></a><a id="Tc_iTtbWRfl_0K9pB46J1lXvA_3_22"></a><a id="Tc_rWwm5t7CU0a-DE1TWJGYrg_4_2"></a><a id="Tc_s0_D4LDIgUmWTtfGM-jAaw_4_5"></a><a id="Tc_HwL_6Dx38EWx48re9fCBMw_4_8"></a><a id="Tc_DC7fVu-DhkyjlOj0dn3xDg_4_10"></a><a id="Tc_5jXhQt3fTUuFI0DXo1ck8A_4_13"></a><a id="Tc_z7GWAza0CECkWzr048nw-A_4_16"></a><a id="Tc_V6NC_veenUO5FyU98j3vMA_4_19"></a><a id="Tc_6-_dKGCAIkGHX2qF_81NdQ_4_22"></a><a id="Tc_P3FugzkvXkmiVkqbgZQhnA_4_25"></a><a id="Tc_mGbSTBntNUKBlngW_g6VLg_5_0"></a><a id="Tc_FRlsC271ckuy7j2he4D1tg_5_3"></a><a id="Tc_nGD9KfYE20WEMc-UuDLSBw_5_5"></a><a id="Tc_yyZyHxKS10C471Oj31BkkQ_5_6"></a><a id="Tc_fyXYOQWLaUuG_FeTjQJ6xg_5_10"></a><a id="Tc_3mvNblRA_kuhKmyfQWtz3Q_5_13"></a><a id="Tc_pGoGM8mXeEudO_ngz6wfKQ_5_16"></a><a id="Tc_l1gyPdjkPkepykFsZpnvwQ_5_19"></a><a id="Tc_oaEiuQBzUUa6C00PWl5P-g_5_22"></a><a id="Tc_NnfRP1OuGEuJAPQ1gRYCDw_5_25"></a><a id="Tc_ua31NRYL7k6kHBZlGfw9RA_7_0"></a><a id="Tc_R3WFtTLeE0GDoHCJgFJvxQ_7_3"></a><a id="Tc_7LYB_lgRV0qGwFwhL0kCbg_7_6"></a><a id="Tc_Mg9DEl0j1E-mmV6U-BADhQ_7_11"></a><a id="Tc_oFj3v573oEyIDTuykyc5aA_7_17"></a><a id="Tc_D3Ii5_yaeUWra4aAXq7XBw_7_20"></a><a id="Tc_gvj5r-x9TUqLZrOeCn4NRA_7_23"></a><a id="Tc_zxyYotS0OEqC1F3sLorXgw_8_0"></a><a id="Tc_0R63LZ6ZEUyMMrvwRDtxjA_8_3"></a><a id="Tc_ewkRb5qUa0m3-V31D6n_Rg_8_6"></a><a id="Tc_CEERfYTbNUWpA25EJMrMZg_8_8"></a><a id="Tc_YwjZhHOIrEK07msCcOf5-w_8_11"></a><a id="Tc_x2v93UHlM0uz22EuncYdDQ_8_17"></a><a id="Tc_tTmWk3uankOmZutrPqMf5A_8_20"></a><a id="Tc_ek072JDH7k-Zqf9bwruhUw_8_23"></a><a id="Tc_teSmg5aAaUykAw5qTJSC2A_9_0"></a><a id="Tc_PDGHvgUUy0iFavsStSMLyA_9_3"></a><a id="Tc_PLcV1t8ZGki51ha5Xfd7VA_9_6"></a><a id="Tc_s6MkLS2L7E6fAuz-_gWa4A_9_8"></a><a id="Tc_E32BAJJDdUC7yxVV9r945A_9_11"></a><a id="Tc_6xYg7K7kVUy7bIMMD1_V5w_9_14"></a><a id="Tc_g3AbdUJryEaNjlbchAXZXw_9_20"></a><a id="Tc_mvzrVIaoSkOAujbjEZ9HTA_9_23"></a><a id="Tc_wLS0gwaWmUGlySdITVMgHQ_10_0"></a><a id="Tc_VfKLCmTQeUqwls49mTk9ow_10_3"></a><a id="Tc_GzEvAsBdTkmHic6HPXsrNg_10_6"></a><a id="Tc_bMN_qXBun0qnjglfVBDsTA_10_8"></a><a id="Tc_a0qsR37JUUCQmHxY-3b0Cw_10_11"></a><a id="Tc_vQq5DZoLGUK9fX-SCEANVA_10_14"></a><a id="Tc_TWmik1VmQUK23Q4SNSli0A_10_17"></a><a id="Tc_CJpFSBuKO0uNI5JcVnkXug_12_0"></a><a id="Tc_irzfPoMd3EWlQ-IQEpAN7A_12_3"></a><a id="Tc_SxQUf6CMSEmCNBWMccfFrg_12_5"></a><a id="Tc_u3rUBBQl3kGS_Fg7SPaa0A_12_6"></a><a id="Tc_UkKYtbY-ukmsYkc2FiEk8A_12_10"></a><a id="Tc_z5dGdj2wAk6KX-GrL2by5g_12_13"></a><a id="Tc_MdL7nyWgsE6nMH7DCB0SXg_12_16"></a><a id="Tc_PQDT5y49lE2zDj_DPF54ZQ_12_19"></a><a id="Tc_YtJYXFc-Ck67sDhgsbvvXw_12_22"></a><a id="Tc_X0vcv50RY0KwdNKrwOngSw_12_25"></a><a id="Tc_YCxmQD4qwU-Cm9ie7mxFlg_14_0"></a><a id="Tc_pXZ8AH3hB0e41edtoY2R7w_14_3"></a><a id="Tc_MUBMRF4T7Em93DGp8_WOEQ_14_6"></a><a id="Tc_WiPfCxXQqkSWx4YPmx-1Og_14_11"></a><a id="Tc__XfeSltYt0-PjQY19RHEdQ_14_14"></a><a id="Tc_0Dk7TXTzhUOqQNq62OnbDQ_14_17"></a><a id="Tc_7bP_og7ZokqF-9H_4GdSWg_14_20"></a><a id="Tc_owecVfqyj06T3hnxBouxgw_14_23"></a><a id="Tc_tITqVAOw_UCBOL5vX13YNg_14_26"></a><a id="Tc_4gdoUA9s7UuTOEtOppAg-g_15_0"></a><a id="Tc_c8d5e4xXukKFvMywC72b3A_15_3"></a><a id="Tc_utfSicDYiEGVs_HWp_wmog_15_6"></a><a id="Tc_NIsNpsDPVUGEQTpf3UXDvQ_15_8"></a><a id="Tc_ouhoZUQE_Euzi9yA4aDqQg_15_11"></a><a id="Tc_rMf1NrXJn0G4n4YzjHvfwQ_15_17"></a><a id="Tc_ucE6IrukwkuVxV-fflLCGw_15_20"></a><a id="Tc_WANtI8i2rUmhJpDO8Qf9oA_15_23"></a><a id="Tc_iDXbf9YqwkimtrqOC3ZqJw_16_0"></a><a id="Tc_UFcavKg-cUujA6qzR8Chpw_16_3"></a><a id="Tc_Sx79EGNpr02WkAjZwzGRYA_16_6"></a><a id="Tc_fBv-8Dy8GUqag7TBD965NQ_16_8"></a><a id="Tc_JyTKj6mv_UK8V3oe0N2AOg_16_11"></a><a id="Tc_bXQwfiG1wkiuWnTmp_Vz4Q_16_17"></a><a id="Tc_kmL2lAbO8US7IF9gttgEGA_16_20"></a><a id="Tc_nFQ8vA-AwEKzurlOROjJrA_17_0"></a><a id="Tc_F58xgsy560iuEOblldhq0Q_17_3"></a><a id="Tc_M26Kjs_NO0K83gT_q4mPNw_17_6"></a><a id="Tc_IVGWItJmC0uPrUKfABBRtA_17_8"></a><a id="Tc_uhRbWi0Oakqlubz8lBSbfQ_17_11"></a><a id="Tc_Qwg4PPXgDE-TvGT4N_IOmQ_17_17"></a><a id="Tc_QO0RQkS9y0Wjrfftl8tm0g_17_20"></a><a id="Tc_FiGBIYn-w0en7JnoJSCLFg_17_23"></a><a id="Tc_VPEPea0j0E6BXGB85Fc6Yg_18_0"></a><a id="Tc_HvF-nWeBQUOWs7ovoZhrIg_18_3"></a><a id="Tc_2O7563rkS0-d13YxPNmj0A_18_6"></a><a id="Tc_1E7j_5czmk2G3I3kviAppQ_18_8"></a><a id="Tc_jChbv8Rs70u9IjHY4hJ_Bg_18_11"></a><a id="Tc_CQllCl5TSUGQbFZI24RgIw_18_14"></a><a id="Tc_ZD8qYzeQ7E-Dfs8ck8tK4w_18_20"></a><a id="Tc_H0tes4bv-UiAViFkPuYNPA_18_23"></a><a id="Tc_7dyA_bwoPUqq7G1lWtBicw_19_0"></a><a id="Tc_TTvNkko4sE2IunHmRgHSbQ_19_3"></a><a id="Tc_VoP-lhwiZ0ii5x21K2QPkA_19_6"></a><a id="Tc_WXGN4Iur3U-TC0HvUQJUAQ_19_8"></a><a id="Tc_yaH6VIwAJU-p_Jy27g2ppQ_19_11"></a><a id="Tc_PIgdOtrKlkSoZ25kyKEeWA_19_14"></a><a id="Tc_Cr-04pSEAEC_-XnMDH6Fog_19_17"></a><a id="Tc_hMqiUnbFqkeqLuwEMNi_DA_19_23"></a><a id="Tc_h0iwXYUuIUaZiRmFIB76sQ_21_0"></a><a id="Tc_QPJSRcwDV0m1iQq7-S1uCA_21_3"></a><a id="Tc_6gjklySXhkqAFJbboJtsSQ_21_5"></a><a id="Tc_-nYHbpa5zEioU1s8UaojcA_21_6"></a><a id="Tc_xrlpCa7XxUaqiVL1tR6ovw_21_10"></a><a id="Tc_nHmfyKB9GEmT3uua6YmCwg_21_13"></a><a id="Tc_nGwRHKxoxEy9rfvI3sxXyA_21_16"></a><a id="Tc_kZCHEGKA_0SpEK_vxe0uNw_21_19"></a><a id="Tc_g4pX4QTqR0662h6xT2-m7g_21_22"></a><a id="Tc_jXy25XS3xEqC7i9fow8dbA_21_23"></a><a id="Tc_hh6CPeHcs0a27Xr1Q93tlQ_21_25"></a><a id="Tc_xsTKd5-6x0K78CDCaXyW6A_23_0"></a><a id="Tc_muRn0K-A80eEPTel1PvZWg_23_3"></a><a id="Tc_pYIxaMMH50CTM_p2Omm9ew_23_6"></a><a id="Tc_wyXudqxtx0-wlyEx0m2EUw_23_11"></a><a id="Tc_5eh8EB2B6Uq-U7JaTHOf8g_23_17"></a><a id="Tc_jZq4kLuDhECS26iA7NS-Eg_23_20"></a><a id="Tc_6D16UHIOTUOPoVl_IoVzrA_23_23"></a><a id="Tc_ZYW4rSOS3EW-AJlIjBbm0Q_24_0"></a><a id="Tc_BqgbTBy0Ok2KJa1qiugEOw_24_3"></a><a id="Tc_R1uFIhDev0CoQmMP5tpS7Q_24_6"></a><a id="Tc_e4kDkAuDzEOgb2E4Es-3ww_24_8"></a><a id="Tc_vcq1gbQFM0yqGQbPtvHr8Q_24_11"></a><a id="Tc_gx2malIPpU2lXrk3cMXIjg_24_14"></a><a id="Tc_ZnVmP-xqME-lPrUxRLMd7Q_24_17"></a><a id="Tc_O1_CYNbsBU2kPGWm_o5D6A_24_20"></a><a id="Tc_0HWG0X1sS0OthYLB2JUnig_24_23"></a><a id="Tc_fWO5ZckDYEKq6iVokMQQTw_24_26"></a><a id="Tc_kBBMFiLVYUOARHNICSuSpA_25_0"></a><a id="Tc_ZGB8O4y8KkW8Fnf5KG8LDg_25_3"></a><a id="Tc_iy5dthQmg0KlP4KcQwn3VA_25_6"></a><a id="Tc_b4a8XdlnOUOXXptxcWelJQ_25_8"></a><a id="Tc_FpWA20YWEEy8KS1M_Zmstg_25_11"></a><a id="Tc_uCFZM3wrTEWY9LnDxmcoeA_25_14"></a><a id="Tc_NdS7TxslsUGxphUqItVzDg_25_17"></a><a id="Tc_s--pTyn7j0S32iVrX54ETQ_25_20"></a><a id="Tc_1_yJh-9y_E-lMcjUn_Xh2w_25_23"></a><a id="Tc_2kKXGh4upEKSHeEmMAnVYw_25_26"></a><a id="Tc_UlxMONhMNEyun0qGi5V3-Q_26_0"></a><a id="Tc_w0C_LMS8kUuQPxtOLjNUBg_26_3"></a><a id="Tc_a1gf3WQ2G0iGGVqxkyBOtQ_26_6"></a><a id="Tc_gXD3HiArf0SVpSW19rZDqg_26_8"></a><a id="Tc_o8ahcrbQfEabVpZObR1mHw_26_11"></a><a id="Tc_T-b9kawTQkaXUUv0B0hVyw_26_17"></a><a id="Tc_AHmiInFb30CLDGwAfcRAYw_26_20"></a><a id="Tc_TrkNPQzD1UGUlV7Vfs7xOA_26_23"></a><a id="Tc_yjiRl-VEDUucSvPDkg-FQQ_27_0"></a><a id="Tc_L-j8HCmrdEupjvNYwxP5oQ_27_3"></a><a id="Tc_SEtFva-hu0K8jZ7rPkfXXQ_27_6"></a><a id="Tc_aI1y0ZlVjU2DmHfkiI-Uyg_27_8"></a><a id="Tc_2PUEJt4Jlk-hNNvq5G2J-Q_27_11"></a><a id="Tc_u6ldwY1ewka87jYIVGkb1g_27_14"></a><a id="Tc_E77MdXOjQEqu9qOAfyGnqw_27_17"></a><a id="Tc_guNHCLlVMkavSmEAALFhxw_27_20"></a><a id="Tc_lEGLugLhO0yZ7ryTBX1BSg_27_23"></a><a id="Tc_gUVoTfywL0u2e7FTspyacQ_27_26"></a><a id="Tc_rN8IckL1y0OewSEGt_l3Fg_28_0"></a><a id="Tc_9e5u1c9HrUqF73YZ-n3-PQ_28_3"></a><a id="Tc_H97n-Nw4B0usUUS3YjhaGw_28_6"></a><a id="Tc_ZeGHy_vmV0K1HFj7egJEkw_28_8"></a><a id="Tc_bSSqV5R5NkKqZhHOUy3L6Q_28_11"></a><a id="Tc_CWaqLD7ZQEi4JhWFLk3Fig_28_14"></a><a id="Tc_MeIIv_Seo0mqiGFkGE8zNA_28_20"></a><a id="Tc_XhKe0nXMBk60p2FctLo87Q_28_23"></a><a id="Tc_FQVGCa4LaES9AWK4dfbhXA_29_0"></a><a id="Tc_vTFesws3wkyfMxa_nqGqMA_29_3"></a><a id="Tc_xchc78PrKU6kFbKts67eJw_29_6"></a><a id="Tc_V-rhNHO_hE6AGqt_nBUO3w_29_8"></a><a id="Tc_sx0IJbshaEKwiD9FzOI1ug_29_11"></a><a id="Tc_8jEPxowB_ESMKpDMgLcvJA_29_14"></a><a id="Tc_6zPJ243DeUmObfjf7Nm8iw_29_17"></a><a id="Tc__AajH2g1wk2BXZtHgODsXg_29_23"></a><a id="Tc_Se400FUFNESOZQuCXy5N5w_31_0"></a><a id="Tc_M2GJl0pFM0-G70XAYwaZ1w_31_3"></a><a id="Tc_SwGsQWHnV0-DNuXT0rXddw_31_5"></a><a id="Tc_l99OsCLvsk6EuyxrR5qsNg_31_6"></a><a id="Tc_mSYo7YwhWkWhrDAZyiRbtA_31_10"></a><a id="Tc__3a9EAupQ0-ag-PMP_J_cA_31_13"></a><a id="Tc_J-ELVrCBa02IKP0HMNpRHw_31_16"></a><a id="Tc_v_iLKItYZ0Kt2ZsYhyVXZw_31_19"></a><a id="Tc_huN1ne0Ec0mi05lviFGXDA_31_22"></a><a id="Tc_xRgmCTutlkugKFnoD1qQdw_31_23"></a><a id="Tc_GdBNeKMNAkOuGnFFBf84iQ_31_25"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:16.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:16.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:16.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:16.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preferred&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:16.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Noncontrolling</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:16.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of July 1, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__ZOGluhSl0G7K2wu1sD4IQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_3NR69hkmJkuV3anSFyN8-g_5_8">8,715</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__ZOGluhSl0G7K2wu1sD4IQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_EjBcch8DJ06uz5zjhq9Xxg_5_11">9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_oxzaYxve7U-k1xy12FFQvw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_66dfaVOvG0WXmuYTHDIh_A_5_14">282,266</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_pVa8MvgG4kWQa5aMi-i-SQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_Km7v8l9yP0qbIxflPgByrA_5_17">63</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HFSiWMrWY0ej62GFJxBZIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_6wIqzY5CYE2j3TDLQYZkFQ_5_20">173,627</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_3WIr_ndZqka5CsSKIRQ3fA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_qc89S7guoEmda5oXX19i1g_5_23">17</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2021_RvsAx0CeVUiEHjFvD-Jmkw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_x1UFppHhB0u45pg4AXC3yw_5_26">108,568</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:16.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uJ57OeAa6Em8d-wBmehB4A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="Tc_9BmMk-ZZskqn1MUJGySciw_7_8">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gnv2jc0O2EKruqChBGMUTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_rJFxwCKwMUe_ncAirJbsQQ_7_14">77</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_9_30_2021_vL3rOPanq0GYnPOprKHLGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_AkLOSIEf30CGbGFdFSTStQ_7_26">77</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:16.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gnv2jc0O2EKruqChBGMUTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_6449CZetDUi6suTkaiWx5Q_8_14">821</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_9_30_2021_vL3rOPanq0GYnPOprKHLGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_6RCtt1totEaXgCWkj2znJA_8_26">821</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Unrealized loss on debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Tqrr8xcQvkaRlWyBfJNZbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" sign="-" scale="3" id="Tc_SkIvZv-03UCt7krk3nUHlQ_9_17">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_9_30_2021_vL3rOPanq0GYnPOprKHLGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" sign="-" scale="3" id="Tc_v68lyXQsg0OpU1A4bbGkMw_9_26">1</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:16.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_aWjmWshK0UmxjFzpIuJKUg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_x7OP3GSh20CfW1htQpoyig_10_20">8,939</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_s9UOO5awBEKLVvHLUhhOvQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="Tc_ATirVQlqQUGXqRc8MyXWlA_10_23">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_9_30_2021_vL3rOPanq0GYnPOprKHLGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_7RO69URuQ0-EXiCK74oqSg_10_26">8,940</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:16.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of September&#160;30,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QXzbdBTf7UyvyFsCyM5MpQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_TSsD94KmrUmPquF5HCSfnQ_12_8">8,718</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QXzbdBTf7UyvyFsCyM5MpQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_0admOlRw5EixuAj1Bnloqg_12_11">9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_hsH-C_nn7UGLsToocSuw0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_d76U8Q1u3U-Rvqfdq0WR7A_12_14">283,164</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_jVGpJMpt70iwB6r1klHOKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_3uq5jPgSyUS4IUchTIOolw_12_17">64</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_gOfCh-hUOkaoojsAe2NwmQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_PEm66rYnoku6woNQhmNZyA_12_20">182,566</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_eTEPnd7U0k2A3wEuB687aA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_-Zvmbch2fU-XbcGxWI4kPQ_12_23">18</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_9_30_2021_6xZdpSuxG02KaCdJhSlZ7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_Sr06ebgs406ZuDc6FET-IA_12_26">100,525</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:16.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Vesting of RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="Duration_10_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ydfUDabqlkij0w-BBn4BJA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="Tc_jb-WS4aXZUOZ-OuLtkj0cQ_14_8">4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Warrant issued for Transaction</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_10_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_h7U0v0axEUSvtq7AMRXwhw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="Tc_sMRBOJX0ZUmv2wJWyU3kYg_15_14">967</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_10_1_2021_To_12_31_2021_WNPh7gwO_06OGSGOzOxzNw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="Tc_5zBictjKAkyf3SDMIT5XuQ_15_26">967</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:16.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Acquisition of remaining portion of iBio CDMO</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_10_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_h7U0v0axEUSvtq7AMRXwhw" decimals="-3" format="ixt:numdotdecimal" name="ibio:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate" scale="3" id="Tc_YxJAX4G5D0-17EVMnacbow_16_14">68</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_10_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_Xf6pRLT-l0WeqW9gCVshUA" decimals="-3" format="ixt:numdotdecimal" name="ibio:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate" sign="-" scale="3" id="Tc_J2d28V-xF0W4qiLc6ThAVw_16_23">18</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_10_1_2021_To_12_31_2021_WNPh7gwO_06OGSGOzOxzNw" decimals="-3" format="ixt:numdotdecimal" name="ibio:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate" scale="3" id="Tc_QcgGt0jUPEe773tHCyoALg_16_26">50</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_10_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_h7U0v0axEUSvtq7AMRXwhw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_VmzKG3VRGUGfSZZdtmPYSg_17_14">1,103</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_10_1_2021_To_12_31_2021_WNPh7gwO_06OGSGOzOxzNw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_5tkeuA-60066K9XlQmP3TA_17_26">1,103</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:16.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Unrealized loss on debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_10_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_wmQZYW3PoEyWWUp8Dmyyyg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" sign="-" scale="3" id="Tc_me3JV3yei0CVxDefjkFL9A_18_17">27</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_10_1_2021_To_12_31_2021_WNPh7gwO_06OGSGOzOxzNw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" sign="-" scale="3" id="Tc_l7YiXkoIp0O5wfo21vNZow_18_26">27</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_10_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_reQq62UAKUWWMC0PAA6-mQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_i_Cehr8NsUKBp99AU4RkgA_19_20">11,920</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_10_1_2021_To_12_31_2021_WNPh7gwO_06OGSGOzOxzNw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_SmTXp2qTQ0uL8kEs-UAgDA_19_26">11,920</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:16.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vSAxS0YAgUqgjKsUyRNznw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_ak7ImX92w0uxEawUbf_faw_21_8">8,722</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vSAxS0YAgUqgjKsUyRNznw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_bm2MtIiFAE-Ma8REYscohA_21_11">9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_XTKrAoBNIEahMhTSx3nvGA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_Wr9-2RTRWE2fxX1fO9OAKg_21_14">285,166</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_q6a6n0hytkGjctTlsPRp-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_Jn1TslrH_UuF2Y6RCsID9w_21_17">91</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZL8l8ThJZ0-W7M_aNkuPyg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_vHdlJAuL00W3HcHkgAlejQ_21_20">194,486</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_12_31_2021_3LjjH4Oi8EqKlNswnjVbLw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_IWjVIZxsvkS36Yf8AxnbGA_21_26">90,598</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:16.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Vesting of RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7S5LrOv4UU-uYc7t0vEohw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="Tc_hZgMQ8qjqEKFFJfQU9YdbQ_23_8">4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_PuLylut6L0y-PztjYjnBWw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="Tc_4-Ow8-Vo3kGS6G8jE0b-og_23_14">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="Tc_za685tnvvku0BEtXAab4Ig_23_26">1</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:16.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Cost to raise capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:16.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_PuLylut6L0y-PztjYjnBWw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_7qbIWAfEFUS-A-QJ4d5p7g_26_14">1,274</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_fefUCcOSCE2mJDHLCLouTQ_26_26">1,274</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Foreign currency translation adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:16.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Unrealized loss on debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_huTLj4Tyh0uE8TfHbS9zCQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" sign="-" scale="3" id="Tc_LSZijCzi_Ei02Hj36wbYfQ_28_17">103</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" sign="-" scale="3" id="Tc_1llsh3wFb0e5PrhSmoMqRA_28_26">103</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ogcZKKYW_Eir0iTTRpyFTw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc__8mZTU2BJkKLS9O4WHTsLQ_29_20">12,390</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_bzUCZS8eEEKmXLJUc4DDVA_29_26">12,390</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:16.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:16.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of March&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_swlXLlVROkCjZl5I0-C9RQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_gCM0iQ72vECVC_YdxIPnzw_31_8">8,726</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_swlXLlVROkCjZl5I0-C9RQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_20qDUDdaI02GYXikX5WPsg_31_11">9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tF8wULMhbkG99rPul9KSrQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_zC3Flss6SUmK9Q7wuJ9N1g_31_14">286,441</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_PWObTblql0OvdhYq9X8sSA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_GvL954xfU0uh49oeef4Eiw_31_17">194</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_abZOLroj_UO6rIP7k3Bifg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_YetIzcIeYU6WDX5nui40wg_31_20">206,876</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2022_-w0U61DdKUWU0kwbv1xmfg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_bqCNOF3hHE-ePClQjuXbFw_31_26">79,380</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_2f285abd_250c_40eb_8c93_2f028b1276c3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">iBio,&#160;Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Condensed Consolidated Statements of Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited; in Thousands)</p><a id="_3e80e45b_99d0_4606_bf62_ac31d4e8f20c"></a><a id="Tc_-YAek3qiQkmih8rsEUdJ1A_1_2"></a><a id="Tc_4qYUP83v9ES7XLzUDohUGQ_2_2"></a><a id="Tc_XVSG81WyQ0-VOkY5nAzbUw_3_2"></a><a id="Tc_Uv_gqxKRBEKRb9X2rbtzgA_3_5"></a><a id="Tc_2S6dlvKaAEOURfVKp457XQ_5_0"></a><a id="Tc_ORS8b4NE4U6EfL5Yjq-edw_6_0"></a><a id="Tc_WjJ98x5OgEiar-7YRnC_vA_6_2"></a><a id="Tc_DbibM_vRskGOLRPbW4M1Ag_6_5"></a><a id="Tc_1JcXmO8wRUqWwFHbFxKIqQ_7_0"></a><a id="Tc_YTy8EcKSdkqqnlyFY5siZA_8_0"></a><a id="Tc_7jsTPXjmB0upbDGDuG-Ncg_9_0"></a><a id="Tc_mrpWGiuhzEehy_f0T1XEbg_10_0"></a><a id="Tc_ESqr684PRkm7EfWSdz-cHw_11_0"></a><a id="Tc_SXQXtMr850W0eiosMgUr4Q_12_0"></a><a id="Tc_MGSnv2qlfUaFdgUkqMVrtQ_13_0"></a><a id="Tc_wJ6yCdO4XkGb8sOBH9RwpQ_14_0"></a><a id="Tc_t2lP7_EKuU-w7R-G5qCGaA_15_0"></a><a id="Tc_UyQPcWBo-UKowVv4rY4LzA_16_0"></a><a id="Tc_3eMTmPFb00erSKirvTAxvQ_17_0"></a><a id="Tc_ZdtZI12EkEiYC_bQAQPMMQ_18_0"></a><a id="Tc_YSvOkbS5z0afmEP6u3HQkQ_19_0"></a><a id="Tc_zuCz40KFH0eO5IYpA1PQ2g_20_0"></a><a id="Tc_9jjuw-ajBkKx-MWLznY7dw_21_0"></a><a id="Tc_wOcgWiPL2Eixr_Bp-izZaQ_22_0"></a><a id="Tc_fFOyszchJkiqRVPilZHvig_22_3"></a><a id="Tc_gqoaY8bjXUyefS4zKQD_fw_23_0"></a><a id="Tc_OJ0lfeAFRkGNmAKrhLC-mw_23_3"></a><a id="Tc_Lht-oMPMykmX-MVHjmfeZA_24_0"></a><a id="Tc_WUKewR95REW2-241S8y-tQ_25_0"></a><a id="Tc_6e86PVyjrEeF5RjoQx1hHw_26_0"></a><a id="Tc_iK0aD--m00-LV0PDP0ppxg_27_0"></a><a id="Tc_cZx2MUVqPEam9HSOmXVCIg_28_0"></a><a id="Tc_SIKGFLpqQkeZBQLTVZUhcw_29_0"></a><a id="Tc_4jZWEpS4-kmua2gte07Phw_30_0"></a><a id="Tc_avYD-99oLkeLWfXPPEHIsw_31_0"></a><a id="Tc_t-dEzxOt4EeS02onNW82BA_32_0"></a><a id="Tc_A1WTJlW7EECi5CrIcCTTmg_33_0"></a><a id="Tc_cam7khAyWkSNr0kdYHyxzw_34_0"></a><a id="Tc_JU-7r6-YV0WeSl631C--rw_35_0"></a><a id="Tc_nSS7eqvaF0m2pdcGrOBz6Q_36_0"></a><a id="Tc_ExYLOOz40ESs7JKrb_TQ_Q_38_0"></a><a id="Tc_71-gfLn340qLxF-MCRRXWQ_39_0"></a><a id="Tc_RxDBISATT0aBiVd1-Zp8AA_39_3"></a><a id="Tc_sB5DqqN2AEmlDqfHKMO34Q_40_0"></a><a id="Tc_dQkGF0CQqk-AL4kl8UgJug_41_0"></a><a id="Tc_sWoeit5xhkS9eMfHvKKerw_42_0"></a><a id="Tc_lOqcgZGeUUW4wb3gqkZ3pA_42_3"></a><a id="Tc_-97_f3kS2EyCqn0ENaiSHg_43_0"></a><a id="Tc_7eVYg7rEI0uAILQsL9ikKQ_43_3"></a><a id="Tc_2v51PvI65E6o9M0lphq_bQ_44_0"></a><a id="Tc_53BkHycSLEuA7yoIgUW7Jg_45_0"></a><a id="Tc_yfIUxSP_VU-Y6cTGruqd-Q_46_0"></a><a id="Tc_eHbNTBXDokmrW8o881K9pw_48_0"></a><a id="Tc_G2wiV-5ArkuOhPphXqP-YA_50_0"></a><a id="Tc_EBec_VU7NE2Pg7Kj82uzmg_51_0"></a><a id="Tc_bB4zIiu4MUGaXMd34eTyEw_52_0"></a><a id="Tc_Ow9SDnMmpUK9E5j_mh6Cog_53_0"></a><a id="Tc_hAq4JYButEqYRNYiyCk3HA_53_3"></a><a id="Tc_tPoPkUlSFE2peMc3h0BaTg_54_0"></a><a id="Tc_9DnFvv-c7E6TlIoaqzHrRw_55_0"></a><a id="Tc_i7exTv1da02qUdkGPnrwRg_56_0"></a><a id="Tc_aA5cj09vl0iz5jLPEDi91g_57_0"></a><a id="Tc_OqXn-Gv-uECFhXQM3jDAvw_57_3"></a><a id="Tc_opLbpq7ubUm_G3aqeOnV-w_58_0"></a><a id="Tc_krR2d8zYekSamqmjx9XWig_59_0"></a><a id="Tc_zEmZlv4nPk-t2Lhfv2z7fw_60_0"></a><a id="Tc_VaGRfXaUtU66Yxsa8dcWzg_62_0"></a><a id="Tc_gBYgDFmMJkiOR-rA1wh18g_64_0"></a><a id="Tc_GnSkcVCNWU2nlejVX_l8Dw_65_0"></a><a id="Tc_A6FrCjD980aI_nAoAhjaog_66_0"></a><a id="Tc_aadDUWCcaUKkGz6O19rVbA_66_2"></a><a id="Tc_kAU5TWFq50OxarkttS4vpQ_66_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows from operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Consolidated net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_khQgursIN0yO8ahkh-ZaZA_6_3">58,977</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_a5wNQa9RlkyVWGRsLCPLaw_6_6">33,250</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Adjustments to reconcile consolidated net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_lxWZozlJ5kuNIw19qftGtA_8_3">3,945</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_TFYBbxBd7kGsqYtaS6Qbdw_8_6">3,198</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Amortization of intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="Tc_kTPQ1XIt4U66J6cn749--A_9_3">121</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="Tc__vohrUfukkSnhG_jc5LLgA_9_6">333</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Amortization of finance lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="Tc_2FUegZtetUa3dSPgClZwyg_10_3">156</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="Tc_5mmZXfcVhkmxxfuoyrlJDw_10_6">587</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Amortization of operating lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="Tc_DcdHbHF74UWa1KwnlcIm0g_11_3">290</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="Tc_PVl7Ig5SsECvuWkIlSvvTQ_11_6">386</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Depreciation of fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_BKkZaT7qF0aTTsUmqrdwGw_12_3">508</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_BOU5Ucl43Ui4OLK5zax6ug_12_6">1,532</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Gain on sale of fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="3" id="Tc_w_G_FCcUlUCtbzqE_p55hA_13_3">732</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="3" id="Tc_fuMFGqXxkkCtkv3-g2G3tA_13_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Accrued interest receivable on convertible promissory note receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="ibio:AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable" scale="3" id="Tc_xGzevSI4tEm5CnohzUWjbQ_14_3">56</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable" scale="3" id="Tc_mMM5TI4a3EuK6tyIyumchw_14_6">56</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Amortization of premiums on debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="Tc_cp0iTU4mykmBMJxfRJI0DA_15_3">67</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="Tc_VZNl-8iWnEe0SaKnpewVgw_15_6">269</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Loss on sale of debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleGainLoss" sign="-" scale="3" id="Tc_MrkGoOqDrEWWYwUT85SkgQ_16_3">98</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleGainLoss" scale="3" id="Tc_drGrEsIGBkiHO_gX1C4LjA_16_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Amortization of deferred financing costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="ibio:DeferredFinancingCostsAmortizationExpense" scale="3" id="Tc_uDHgnP3OGEGYZMM0vL2xtw_17_3">160</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:DeferredFinancingCostsAmortizationExpense" scale="3" id="Tc_dSkSB4QvTkOU7K1xRCoqpw_17_6">67</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Inventory reserve</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="ibio:IncreaseDecreaseInInventoryReserve" scale="3" id="Tc_ITeJCo4eWkmEvHq-kmbkYQ_18_3">4,915</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:zerodash" name="ibio:IncreaseDecreaseInInventoryReserve" scale="3" id="Tc_zkG8Ukfd4067GilNBRCuxA_18_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Impairment of fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TangibleAssetImpairmentCharges" scale="3" id="Tc_bdBQHKdgYUK7Wa_3U6UsKg_19_3">17,600</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:zerodash" name="us-gaap:TangibleAssetImpairmentCharges" scale="3" id="Tc_cj5zSDDXOUissqJUtVhwzA_19_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Impairment of intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="3" id="Tc_wJKRChNLIkOE3jHR1vje0w_20_3">565</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:zerodash" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="3" id="Tc_aXeC-RpywEOywOUUaUwaZg_20_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Gain on disposition of finance lease ROU assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfLeasedAssetsNetOperatingLeases" scale="3" id="Tc_HeyXR5OU4EOEQXQS8GSlxg_21_3">5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnSaleOfLeasedAssetsNetOperatingLeases" scale="3" id="Tc_mLgjY5wIrE-x6-rDsLxMuQ_21_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Forgiveness of note payable and accrued interest - SBA loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:ForgivenessOfNotePayableAndAccruedInterestSbaLoan" scale="3" id="Tc_XKNnOOK2AkiRHj5fw18_oQ_22_6">607</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Settlement of revenue contract</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:SettlementOfRevenueContract" scale="3" id="Tc_Rf2eBNLshE6ucP_vbEvy2Q_23_6">84</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 24pt;">Accounts receivable - trade</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" sign="-" scale="3" id="Tc_CDgSNW2P5kGCa9ctP-16Ug_25_3">931</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_3PUV-7tzBU-JZtnC7IMeQg_25_6">890</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 24pt;">Settlement receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="ibio:IncreaseDecreaseInSettlementAssets" sign="-" scale="3" id="Tc_ttqIZYalJUyYErgM4Iv7oQ_26_3">5,100</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:IncreaseDecreaseInSettlementAssets" sign="-" scale="3" id="Tc_erDNxm4dIEu4nlR9o5sPmQ_26_6">5,100</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 24pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories" scale="3" id="Tc_XktYm1aN4U-61om_eu9yNg_27_3">1,015</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories" scale="3" id="Tc_Aov-fiO1oU-hQiw3N7o4HA_27_6">3,257</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 24pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="3" id="Tc_KvihGiut1EGcICpXdZVAoA_28_3">627</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_h07VThkxnUuswDwxw9k_pg_28_6">494</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 24pt;">Prepaid expenses - noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" sign="-" scale="3" id="Tc_4UmB4ilivkK38k211EiBtA_29_3">74</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" id="Tc_6V9sPJN2TUeeJ2q86EUzcQ_29_6">975</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 24pt;">Security deposit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInSecurityDeposits" sign="-" scale="3" id="Tc_4s7XHKNtK02Y62eZxkqbKg_30_3">21</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInSecurityDeposits" sign="-" scale="3" id="Tc_i77-31WBdkGPqXiDjfOyeA_30_6">5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 24pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" sign="-" scale="3" id="Tc_BWmcU63IuEiEF43fuDmarw_31_3">481</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="Tc_OGV0xpNODkey0gr0UGYCwg_31_6">1,649</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 24pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" sign="-" scale="3" id="Tc_Aso4Wf7gXkWFEXl325eoGw_32_3">18</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="Tc_MIWLCdeOKU2Lka3nM8k_Og_32_6">618</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 24pt;">Accrued expenses - noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="ibio:IncreaseDecreaseInAccruedLiabilitiesNoncurrent" scale="3" id="Tc_hQ43xbZ800GAOyoigJgXGw_33_3">791</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:zerodash" name="ibio:IncreaseDecreaseInAccruedLiabilitiesNoncurrent" scale="3" id="Tc_L3RH-cJsKUeLQ0dspuWkVw_33_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 24pt;">Operating lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="3" id="Tc_Dx__jB5TJEmsHcgSO4CFpg_34_3">9</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="3" id="Tc_e0zqImcLWkePpyUUTSCjZA_34_6">12</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 24pt;">Contract liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" sign="-" scale="3" id="Tc__mK7zt4x0UiIYuRs6udM0g_35_3">100</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" sign="-" scale="3" id="Tc_RmuYADqX-Uuh4_6BMYeQSg_35_6">86</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 24pt;"><span style="white-space:pre-wrap;">     Net cash used in operating activities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_gw9OIxyrkE60KWZDLssHfw_36_3">25,466</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_WCXVteXIxU2ep7fovcCITw_36_6">25,977</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows from investing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Purchases of debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="Tc_xRMZO3LQA0OM0pdB2Or3uQ_39_6">5,355</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Redemption of debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="3" id="Tc_RsQhyDlqokOBPSFZ9IRhxA_40_3">4,100</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="3" id="Tc_pirdJLxm8kuxKnZDr_lPwQ_40_6">9,711</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Sale of debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="3" id="Tc_satvE27kxUOXRnjYhvS0Yg_41_3">6,739</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="3" id="Tc_cyq6BC91406QaLezJ9buiA_41_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Purchase of equity security</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" scale="3" id="Tc_11cs0S7dakK2pN8ExprQGA_42_6">1,760</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Additions to intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="Tc_JGHWux3tkU-N3l979gartw_43_6">4,300</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Purchases of fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_cMLinalO-U6cPHno6FysEA_44_3">5,232</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_pw_eChb00kKFKEN9xKiQnw_44_6">3,900</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Sales proceeds for fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="Tc_34Gp_WfJYk6b5gsW2NngPg_45_3">2,100</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="Tc_VEvn-BJpBkm_hDojpD6YkA_45_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Payment for RubrYc asset acquisition</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="Tc_XNktqvMOj0KI62knRg7iag_46_3">692</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="Tc_Q11mQSU5KEmBc1hfXHT0Xw_46_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 24pt;"><span style="white-space:pre-wrap;">     Net cash provided by (used in) investing activities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="Tc_pX7LSInpq0mD9S8D-_IzpA_48_3">7,015</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_GmtREfiBrU2lB15Qo7p_Mw_48_6">5,604</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows from financing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from sales of common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="ibio:ProceedsFromIssuanceOfPreferredAndCommonStock" scale="3" id="Tc_MvoMFo3naUCrOJwqPp4DuQ_51_3">7,851</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:zerodash" name="ibio:ProceedsFromIssuanceOfPreferredAndCommonStock" scale="3" id="Tc_S8XyFADNiE-ew3eED9ztPg_51_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Payments for fractional shares after reverse stock split</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="ibio:PaymentsForFractionalSharesAfterReverseStockSplit" scale="3" id="Tc_fs_AqQRIUkGSZ_oAHqVq4g_52_3">39</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:zerodash" name="ibio:PaymentsForFractionalSharesAfterReverseStockSplit" scale="3" id="Tc__E5TH91jwkuirnrvlA4VFw_52_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Acquisition of noncontrolling interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToMinorityShareholders" scale="3" id="Tc__lRG6lp7yk6ZRkJyb_6QBA_53_6">50</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from equipment financing loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="ibio:ProceedsFromEquipmentFinancingLoan" scale="3" id="Tc_NGsSOzcWl0m9-wTmtSnCXA_54_3">500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:zerodash" name="ibio:ProceedsFromEquipmentFinancingLoan" scale="3" id="Tc_AYpP1kOiFUG0VfpWCL-c_w_54_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Payment of equipment financing loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="ibio:PaymentOfEquipmentFinancingLoan" scale="3" id="Tc_OCWVxn743kCU6S8KfiNsyw_55_3">62</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:zerodash" name="ibio:PaymentOfEquipmentFinancingLoan" scale="3" id="Tc_1R3B_IeSSk-3Hc1crXUjYg_55_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Payment of term note payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="3" id="Tc_ge3XwCFEXUexe8ib6prx4Q_56_3">8,523</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:zerodash" name="us-gaap:RepaymentsOfNotesPayable" scale="3" id="Tc_j41puXX25E-8rJbCLz8Erw_56_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_8WM6D5I_0EaKV1t3nV12Jw_57_6">77</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Costs to attain term note</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="ibio:PaymentsToAttainTermNote" scale="3" id="Tc_zA-u05S5S06YU9Dmx-DrdQ_58_3">22</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:PaymentsToAttainTermNote" scale="3" id="Tc_MuD4RQQYe0GXQk9K_2ZFpw_58_6">322</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Payment of finance lease obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="Tc_doi9Gi1IS0OnJldRudu-8A_59_3">144</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="Tc_BMgW_GAqq0KaciR_Se5D0w_59_6">5,820</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 24pt;"><span style="white-space:pre-wrap;">     Net cash used in financing activities </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" sign="-" scale="3" id="Tc_3k4axUkP1EaDKGtvgoBDuA_60_3">439</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" sign="-" scale="3" id="Tc_3vZ8TdlVYEuh4rHqqxPHXQ_60_6">6,115</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Effect of exchange rate changes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="Tc_VLhUnPoSyUC4vFa_3PKJ1g_62_3">33</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:zerodash" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="Tc_swKqIuDrUU2W8bj12FcyhQ_62_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net decrease in cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_e_kJ8s8AqkWmTvEcQbgv1w_64_3">18,857</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_EvHH-KIpAkeJXvzxEP9afQ_64_6">37,696</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Cash, cash equivalents and restricted cash - beginning </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_4FYGDuxHJ0eReM-3hdMItg_65_3">28,672</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2021_RvsAx0CeVUiEHjFvD-Jmkw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_SEzVfgqzT0ePJcOGgHghCA_65_6">77,404</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Cash, cash equivalents and restricted cash - end </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_UyO2Zj5IK0W_vpgjlXrXEg_66_3">9,815</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2022_-w0U61DdKUWU0kwbv1xmfg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_lE0287lz3ECXZ-lQDavldA_66_6">39,708</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">iBio,&#160;Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Condensed Consolidated Statements of Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited; in Thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_8f6f63e7_b1d2_465e_878f_4b32ffb4565d"></a><a id="Tc_w52u7hdpKEythZlO6Z9N2Q_1_2"></a><a id="Tc_OXBx7MtWNkCJ-nF0_MKG5Q_2_2"></a><a id="Tc_OEPBsOZw1kayuRa7iMEHxA_3_2"></a><a id="Tc_hWo9dnGTY02307hO7bq8MA_3_5"></a><a id="Tc_sZIEXUk7j0eQtXnqwvf1fw_4_0"></a><a id="Tc_nFCRr66akEixOJRIBE2pbw_5_0"></a><a id="Tc_7Tt_DxMvcE2A98l5ZaHnFQ_5_2"></a><a id="Tc_xmUx4Zctp0KpbjEc9QexuA_5_5"></a><a id="Tc_i-CWnfIId0G2rCpuvdQCcQ_6_0"></a><a id="Tc_8Rgbp2dEgUypo-RihQ9oDQ_6_2"></a><a id="Tc_--SrpV0WbUC7ElqvJp9hKQ_6_5"></a><a id="Tc__j9J_V2M40eFtHM2qnbo0Q_7_0"></a><a id="Tc_nvozwFd0gEiVHYOjTT6POQ_7_2"></a><a id="Tc_xxCTQtjTDk2fnadpa_3unQ_7_5"></a><a id="Tc_r75KBcK8rEu718cMVem1SA_8_0"></a><a id="Tc_zGKAGA-RL06fL3qXM4K-oQ_8_2"></a><a id="Tc_XCz8Ep6ZHE6XiIvAnMIIQA_8_5"></a><a id="Tc_7LpkN4POckCu4W8M6pyx2A_9_0"></a><a id="Tc_BUql7di_ekaNAdr1VUo3ww_9_2"></a><a id="Tc_hXK38AYpckSNoFrwjCmXRQ_9_5"></a><a id="Tc_DmaUsmf7YkOQHbQe9L_KBA_10_0"></a><a id="Tc_1wrGEVYEfkKOaOIdu-nq3g_10_2"></a><a id="Tc_zxFnEzi6ykuESIZv9y3VdQ_10_3"></a><a id="Tc_TFp_-CwW_kapna6S48zidQ_10_5"></a><a id="Tc_8r3n_Umh90226quVtACrHw_10_6"></a><a id="Tc_FANKz1DRUkin_aPz3oWsHg_11_0"></a><a id="Tc_MH870hjffkyH1HBxyeDilQ_11_2"></a><a id="Tc_dATtWVdi_0iy01xswkosOQ_11_3"></a><a id="Tc_QgDdMa2R_Eu9YUF7OXORsg_11_5"></a><a id="Tc_ETckehcPQUG6OHU42UhxMg_11_6"></a><a id="Tc_cjELtwURT0OIY8CCS5CCvg_12_0"></a><a id="Tc_TaIJfnNl6kyR2fZWj_H7Cw_12_2"></a><a id="Tc_a-HupxPG10CkIMZ0wHtVkw_12_3"></a><a id="Tc_a-RG_Zyfv0KFZjNREZppCQ_12_5"></a><a id="Tc_uxClabcNe0ukjtlvB3S28w_12_6"></a><a id="Tc_rJ8QCHuzKEiNjt9SwgCCtA_13_0"></a><a id="Tc_b6vPyu4gMkealS9CtYd4fQ_13_2"></a><a id="Tc_hduzhupyskCtPxlTzMegHw_13_3"></a><a id="Tc_UtGcddrJeki2GVUxu5KMEA_13_5"></a><a id="Tc_pmLPhYWEPUuSiXazAeaD4w_13_6"></a><a id="Tc_njsik4piukyLyremUJ61Uw_14_0"></a><a id="Tc_SNh_tM0EUkeFdXeFtXptDw_14_2"></a><a id="Tc_uo_Lo4CiFkO-6ZoWa5e_dQ_14_5"></a><a id="Tc_Gt8Vp8gMb0-P6o7edrJs_g_15_0"></a><a id="Tc_37lNxglnR0qFaXb1oP97fw_15_2"></a><a id="Tc_fwrTDgs7_0q1NlSibyL-cQ_15_5"></a><a id="Tc_9LRrR64G6EG-RKXi1nw1eQ_16_0"></a><a id="Tc_Kcdyu8qRH0WbScBg-2BrEQ_16_2"></a><a id="Tc_rNNyP4qMEkWojUTxGnHfwA_16_5"></a><a id="Tc_P_VReekPrEilTC4xy9Dh7A_17_0"></a><a id="Tc_KqH6SEH1mEewVxchzDOZ3Q_17_2"></a><a id="Tc_J3VQlMLl_0y9fBJdxvxZ_w_17_5"></a><a id="Tc_au97iT0KBkyRpV9oTmtW6w_18_0"></a><a id="Tc_JyHRzcT-30OVN3ey9ECMOg_18_2"></a><a id="Tc_9MIajNnBykuAzxXsHjvyfw_18_5"></a><a id="Tc_fTuL1teB3U-WvqY76aU20g_19_0"></a><a id="Tc_ionx1Mv4W0yOsfLhzTT7QQ_19_2"></a><a id="Tc_OvAl6U6JzE2RimY-Mn7iUg_19_5"></a><a id="Tc_ne8lU9fSpESfDcqN2S_lYQ_20_0"></a><a id="Tc_WKcq-f5ZDE-X1ZBSILqUDw_20_2"></a><a id="Tc_En__0wbpnUeP30l0hcqnCQ_20_5"></a><a id="Tc_SYGwX42LzUi385OdqPdS3g_21_0"></a><a id="Tc_5bMMiMCPZ0ec8v-0s1zX_g_21_2"></a><a id="Tc_heshfl83UkezsD-wc9y_pg_21_5"></a><a id="Tc_ZGlOOj8mQk-Phmnut9edwg_22_0"></a><a id="Tc_x_dIrSN4FUi0qKfteeJNMA_23_0"></a><a id="Tc_H8u0rzfxDkmSANXQC_bfcQ_23_2"></a><a id="Tc_AWX6G6Sv_kS_j6X8syEEnw_23_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Schedule of non-cash activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Fixed assets included in accounts payable in prior period, paid in current period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="ibio:CapitalExpenditureIncurredForIntangibleAssetsPaid" scale="3" id="Tc_OsQt9lfZa0iBk_p5VjI1Ug_5_3">1,769</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:CapitalExpenditureIncurredForIntangibleAssetsPaid" scale="3" id="Tc_FLuB7YrU70iVrk-KSoVpIw_5_6">791</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Increase in finance lease ROU assets for new leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="Tc_9heWDc-dTUaKs5KZvlA1CA_6_3">814</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="Tc_NBeABZ7p_k6qsmcqHqA5Qw_6_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Increase in finance lease obligation for new leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="ibio:IncreaseDecreaseInFinanceLeaseObligationsForNewLeases" scale="3" id="Tc_w3Zb3S8TyUu2RpZ5MHv_7w_7_3">814</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:zerodash" name="ibio:IncreaseDecreaseInFinanceLeaseObligationsForNewLeases" scale="3" id="Tc_Q-e5CEzFPk-dCMyFi2JPsw_7_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">RubrYc asset acquisition by issuance of common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="ibio:CommonStockIssuedInRubrycTransactionValue" scale="3" id="Tc_GrbdDPlQ2U2BEWhSoa-JBA_8_3">650</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:zerodash" name="ibio:CommonStockIssuedInRubrycTransactionValue" scale="3" id="Tc_-Buic0FefUWk1iX9G9XRsg_8_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Costs to raise capital paid directly from gross proceeds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="ibio:CostToRaiseCapitalPaidDirectlyFromGrossProceeds" scale="3" id="Tc_ytpeX1Zr-EGcGbOtyRuAKg_9_3">636</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:zerodash" name="ibio:CostToRaiseCapitalPaidDirectlyFromGrossProceeds" scale="3" id="Tc_lAYcHpqjoEeJehf420dIgA_9_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Sales of fixed assets receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 460</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Subscription receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 260</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Cost accrued to amend term note payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Unpaid fixed assets included in accounts payable </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,193</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Termination of finance ROU assets including issuance of warrant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:zerodash" name="ibio:TerminationOfFinanceLeaseRightOfUseAssetIncludingIssuanceOfWarrant" scale="3" id="Tc_senshscGSke7Dp0zVR65TQ_14_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:TerminationOfFinanceLeaseRightOfUseAssetIncludingIssuanceOfWarrant" scale="3" id="Tc_axE8hBNV5ESmMdP2NGPUJg_14_6">25,386</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Note payable to acquire Facility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:zerodash" name="us-gaap:NotesIssued1" scale="3" id="Tc_lWHlQ3Z0LEqWVJgRxsUzfA_15_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesIssued1" scale="3" id="Tc_aB1jma_l_k2uvHzADP9lEA_15_6">22,375</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Increase in operating lease ROU assets for new lease - net of lease incentive</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:zerodash" name="ibio:NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities" scale="3" id="Tc_3w_wZgF8qkWD6VEjKjeQkw_16_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities" scale="3" id="Tc_e7_L-7Z7q0eyBrVqcKUyug_16_6">5,570</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Settlement of revenue contract</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:zerodash" name="ibio:NonCashSettlementOfRevenueContract" scale="3" id="Tc_csxh8rSsr06kCSuRWj_NjA_17_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:NonCashSettlementOfRevenueContract" scale="3" id="Tc_NOsl1V2wZk-rMqU2swMsnw_17_6">580</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Issuance of warrant for final finance lease obligation payment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:zerodash" name="ibio:WarrantsIssuedForFinanceLeasePayment" scale="3" id="Tc_6aDcdT2xI0-rbDOsnCdzzg_18_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:WarrantsIssuedForFinanceLeasePayment" scale="3" id="Tc_qdV-eVfdEUKd_4dLAvutWw_18_6">217</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Lease incentive for construction in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:zerodash" name="ibio:LeaseIncentiveForConstructionInProgress" scale="3" id="Tc_Y7Ae9kfP80KLs8VQdRHkeQ_19_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:LeaseIncentiveForConstructionInProgress" scale="3" id="Tc_cFSlIqmPK0GzMhsWZltTyg_19_6">82</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Acquisition of noncontrolling interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:zerodash" name="ibio:NoncashOrPartNoncashAcquisitionNonControllingInterestAssumed" scale="3" id="Tc_MTtcGTTSC0uiotrjLcw63w_20_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:NoncashOrPartNoncashAcquisitionNonControllingInterestAssumed" scale="3" id="Tc_NkJ8zFzrL0Wa49yVEV6OGQ_20_6">18</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Unrealized (gain) loss on available-for-sale debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" scale="3" id="Tc_v8lBuw1bvUObFCamQjMV6Q_21_3">159</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" scale="3" id="Tc_zlf2qVqIWEGpwMM1qvwvCg_21_6">131</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Supplemental cash flow information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Cash paid during the period for interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_dAFo8lmVoUKvrrhWtf0T1A_23_3">523</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_cheu2D2nE0qYxOn_o1wlyw_23_6">860</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:270.03pt;"><a id="_38aaeb69_a4db_4b80_a5cd_bda07833987d"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">iBio,&#160;Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes&#160;to Condensed Consolidated Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">(Unaudited)</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" name="us-gaap:NatureOfOperations" id="Tb_-XgXDlkNEUaEbuvFCo_11g" continuedAt="Tb_-XgXDlkNEUaEbuvFCo_11g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">1.&#160;&#160;&#160;Nature of Business </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">iBio, Inc. (&#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;, &#8220;iBio&#8221;, &#8220;iBio, Inc&#8221; or the &#8220;Company&#8221;) is an Artificial Intelligence (&#8220;AI&#8221;)-driven innovator of precision antibody immunotherapies. The Company has a pipeline of innovative primarily immuno-oncology antibodies against hard-to-drug targets where it may face reduced competition and with antibodies that may be more selective. The Company plans to use its AI-driven discovery platform to continue adding antibodies against hard-to-drug targets or to work with partners on AI-driven drug development. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Therapeutics Pipeline </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><img src="ibio-20230331x10q001.jpg" alt="Graphic" style="display:inline-block;height:269.68pt;left:0%;padding-bottom:0.35pt;position:relative;top:0pt;width:531.75pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">IBIO-101: </b>an anti-CD25 molecule that works by depletion of immunosuppressive T-regulatory cells (&#8220;Tregs&#8221;) via antibody-dependent cellular cytotoxicity (&#8220;ADCC&#8221;), without disrupting activation of effector T-cells (&#8220;Teffs&#8221;) in the tumor microenvironment. IBIO-101 could potentially be used to treat solid tumors, hairy cell leukemia, relapsed multiple myeloma, lymphoma, or head and neck cancer. IBIO-101 is currently in the Investigational New Drug (&#8220;IND&#8221;) enabling stage. We have contracted with a contract research organization (&#8220;CRO&#8221;) to assist with the development of the manufacturing process, which includes but is not limited to process and cell line development for the production of the drug substance and drug product. IBIO-101 is strategically positioned as a fast follower to Hoffman-La Roche&#8217;s RG6292 molecule that recently released Phase 1 clinical data. While RG6292 showed signs of efficacy, especially in combination with PD-L1 monoclonal antibody, and was well tolerated, we anticipate additional clinical research will be needed to determine whether different cancer types are more efficacious than others. As a result, we have decided to pause the IND enabling studies until additional data is released on RG6292. This approach will allow us to gather more information, thoroughly evaluate the market potential and optimize our financial resources and the development plan for IBIO-101 to maximize its potential for success.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">CCR8:</b> targets depletion of highly immunosuppressive CCR8+ Tregs in the tumor microenvironment via an ADCC mechanism with selective binding to CCR8 over its closely related cousin, CCR4, to avoid off-target effects. A CCR8 program could potentially be broadly applicable in solid tumors and/or as a prospective combination therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">EGFRvIII: </b>binds a tumor-specific mutation of EGFR variant III with an afucosylated antibody for high ADCC. Because of its specificity binding to the tumor-specific mutation, it could potentially reduce toxicity and/or expand the therapeutic window compared to simple broad EGFR-targeted alternatives. EGFRvIII is constantly &#8220;switched on&#8221; which can lead to the development of a range of different cancers. An EGFRvIII antibody could potentially be used to treat glioblastoma, head and neck cancer or non-small cell lung cancer.</p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_-XgXDlkNEUaEbuvFCo_11g_cont1" continuedAt="Tb_-XgXDlkNEUaEbuvFCo_11g_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">CD3 antibody panel:</b> provides a range of CD3 affinities with cross-reactivity to non-human primates and increased the humanness of the antibody sequences. The antibody panel is intended to serve as one arm of T-cell-redirecting bispecific antibodies, a new class of therapeutic antibodies designed to simultaneously bind to T-cells via CD3 and to tumor cells via tumor-specific antigens or tumor-associated antigens, inducing T-cell-mediated killing of tumor cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">MUC16:</b> a highly expressed target on ovarian cancer cells and an attractive tumor associated target for therapeutic antibodies. However, antibodies targeting MUC16 are prone to tumor resistance via epitope shedding and dysregulated glycosylation. Epitope-steered antibodies that bind to an epitope that avoids both of these tumor resistance mechanisms could potentially be used to treat MUC16 positive tumors, particularly those tumors that are resistant to other MUC16 antibodies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">PD-1 Agonist: </b>selectively binds PD-1 to suppress auto-reactive T-cells without PD-L1/PD-L2 blocking. A PD-1 agonist could potentially be used to treat inflammatory bowel disease, systemic lupus erythematosus, multiple sclerosis or other inflammatory diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In addition to the programs described above, the Company also has three additional early discovery programs that have the potential to advance into later stages of preclinical development and are designed to tackle hard-to-drug targets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">IBIO-100 and Endostatin E4</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our preclinical anti-fibrotic program, IBIO-100, has been undergoing a review process as part of our ongoing effort to prioritize our resources and focus on the most promising opportunities. The IBIO-100 program design is based upon work by Dr. Carol Feghali-Bostwick, Professor of Medicine at the Medical University of South Carolina and Vice-Chair of the Scleroderma Foundation. Her initial work was conducted at the University of Pittsburgh, and we have licensed the patents relevant for the continued development of the molecule from the university. &#160;After careful consideration, in February 2023, the Company terminated all efforts on IBIO-100 anti-fibrotic program and provided a six (6) month notice of termination of the license agreement to the University of Pittsburgh, as required by the license agreement. Pursuant to the license agreement with the University of Pittsburgh, the Company&#8217;s financial obligations for the management of the patents under the license will cease on August 14, 2023, and at such time, will transition back to the University of Pittsburgh.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As part of this decision, we are intending to complete the pre-clinical cancer studies we are conducting in collaboration with University of Texas Southwestern using E4 endostatin peptide, which is derived from IBIO-100. After the pre-clinical studies are completed, we will re-assess whether to further pursue the oncology program and have further discussions with the University of Pittsburgh. This approach allows us to gather valuable data and insights that will inform our future decisions regarding the potential of E4 endostatin peptide as an oncology program. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">AI Drug Discovery Platform</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In September 2022, the Company purchased substantially all of the assets of RubrYc Therapeutics (for a complete description of the transaction please see Note 6 &#8211; Significant Transactions). The AI Drug Discovery platform technology is designed to be used to discover antibodies that bind to hard-to-target subdominant and conformational epitopes for further development within our existing portfolio or in partnership with outside entities. The RubrYc AI platform is built upon three key technologies. </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Epitope Targeting Engine:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> A patented machine-learning platform that combines computational biology and 3D-modeling to identify molecules that mimic hard-to-target binding sites on target proteins, specifically, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">subdominant and conformational epitopes.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The creation of these small mimics enables the engineering of therapeutic antibody candidates that can selectively bind immune and cancer cells better than &#8221;trial and error&#8221; antibody engineering and screening methods that are traditionally focused on dominant epitopes.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">RubrYcHu</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">TM</sup><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"> Library:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> An </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">AI-generated human antibody library free of significant sequence liabilities that provides a unique pool of antibodies to screen. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The combination of the Epitope Targeting Engine and screening with the </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">RubrYcHu</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Library has been shown to reduce the discovery time from ideation to </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">in vivo</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> proof-of-concept (&#8220;PoC&#8217;) by up to four months. This has the potential to enable more, and better, therapeutic candidates to reach the clinic faster. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">StableHu</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">TM</sup><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"> Library:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> An </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">AI-powered sequence optimization library used to improve antibody performance</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. Once an antibody has been advanced to the lead optimization stage, </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">StableHu</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> allows precise and rapid optimization of the antibody binding regions to rapidly move a candidate molecule into the IND-enabling stage.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On January 3, 2023, the United States Patent and Trademark Office issued U.S. Patent No. 11,545,238, entitled &#8220;Machine Learning Method for Protein Modelling to Design Engineered Peptides,&#8221; which, among other claims, covers a machine learning model for </p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_-XgXDlkNEUaEbuvFCo_11g_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">engineering peptides, including antibody epitope therapeutics. &#160;Subject to any potential patent term extensions, the patent will expire on May 13, 2040.</p></ix:continuation><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Tb_4RTLL7EZIE2-SZCqH8ijHg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">2.&#160;&#160;&#160;Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Interim Consolidated Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The accompanying unaudited condensed consolidated financial statements have been prepared from the books and records of the Company and include all normal and recurring adjustments which, in the opinion of management, are necessary for a fair presentation in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) for interim consolidated financial information and Rule 8-03 of Regulation S-X promulgated by the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;). Accordingly, these interim financial statements do not include all of the information and footnotes required for complete annual consolidated financial statements. Interim results are not necessarily indicative of the results that may be expected for the full year. Interim unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and the notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the prior year ended June&#160;30,&#160;2022, filed with the SEC on October 11, 2022 (the &#8220;Annual Report&#8221;), from which the accompanying condensed consolidated balance sheet dated June&#160;30,&#160;2022 was derived.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Principles of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated as part of the consolidation. Non-controlling interest in the consolidated financial statements represented the share of the loss in iBio CDMO, LLC (&#8220;iBio CDMO&#8221;) for an affiliate of Eastern Capital Limited (&#8220;Eastern Capital&#8221;) through November 1, 2021, the date the Company acquired the remaining interest in iBio CDMO. &#160;See Note 6 &#8211; Significant Transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Going Concern </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The history of significant losses, the negative cash flow from operations, the limited cash resources on hand and the dependence by the Company on its ability to obtain additional financing to fund its operations after the current cash resources are exhausted raise substantial doubt about the Company&#39;s ability to continue as a going concern. In an effort to remain a going concern and increase cash reserves, the Company completed a public equity offering, reduced its work force by approximately 60% (a reduction of approximately 69 positions) in November 2022, and ceased operations of its CDMO facility thereby reducing annual spend on expenses by approximately 50%. &#160;Additionally, in July 2022, the Company initiated the selling of the CDMO assets and facility, and since then has sold a substantial portion of the CDMO assets. (See Note 3 &#8211; Discontinued Operations for more information.) Additional potential options being considered&#160;to further increase liquidity include lowering the Company&#8217;s expenses further, focusing product development on a select number of product candidates, the sale of the CDMO, the sale or out-licensing of certain product candidates, additional equipment sales, raising money from capital markets, grant revenue or collaborations, or a combination thereof. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">The Company&#8217;s cash, cash equivalents, and restricted cash of </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-5" format="ixt:numdotdecimal" name="ibio:CashAndCashEquivalentsPlusDebtSecurities" scale="6" id="Narr_8vn33m0oh0C8DGH5Xv-gJw">9.8</ix:nonFraction></span><span style="font-size:10pt;"> million</span> <span style="font-size:10pt;">as of March&#160;31,&#160;2023, is not anticipated to be sufficient to support operations through the first quarter of Fiscal 2024</span><b style="font-size:10pt;font-weight:bold;"> </b><span style="font-size:10pt;">unless the Company reduces its burn rate further, sells the CDMO facility for amounts above its term note payable, or increases its capital as described above. Regardless of whether the Company is able to reduce its burn rate or sell or out-license certain assets or parts of the business, the Company will need to raise additional capital in order to fully execute its near and long-term business plan. It is the Company&#8217;s goal to implement one or more potential options described above to allow the Company to have a cash runway for at least 12 months from the date of the filing of this Quarterly Report on Form 10-Q. However, there can be no assurance that the Company will be successful in implementing any of the options that it is evaluating.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Reverse Stock Split </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 22, 2022, the Company&#39;s Board of Directors approved the implementation of a reverse stock split (the &#8220;Reverse Split&#8221;) at a ratio of one-for-twenty five (1:<span style="-sec-ix-hidden:Hidden_C8lqvEAS3E6y7jI9fK0gaA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">25</span></span>) shares of the Company&#39;s common stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_TQ2Ei7lmZUWTCFjqX1MX1g">0.001</ix:nonFraction> (the &#8220;Common Stock&#8221;). The Reverse Split was effective as of October 7, 2022. All share and per share amounts of the Common Stock presented have been retroactively adjusted to reflect the Reverse Split. See Note 16 &#8211; Stockholders&#8217; Equity for more information. </p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_075b834f_ea6e_4b6d_918f_dab5057ef1cf"></a><a id="Tc_XREI6MaW0kimF42qx9FETQ_1_2"></a><a id="Tc_hY-Ri585aU6hIMMoMlwfKA_1_5"></a><a id="Tc_aCxSFsKNv0qj7ueB-_BfoQ_2_2"></a><a id="Tc_j8KiDUpdZk6eXosTKIvamQ_2_5"></a><a id="Tc_I4Zb1cLwR0GQqAV0e0CxQw_3_2"></a><a id="Tc_UbkQXdv6k0e2OIi0Hj8HFA_3_5"></a><a id="Tc_9M9v-_9T4k-Q3jhGnoHluw_4_0"></a><a id="Tc_o6BadAFcUECQzLsch0j5cA_4_1"></a><a id="Tc_4DH4FZdZn0C9rdTrfF9TiA_4_2"></a><a id="Tc_oCE3gktabEKxRrgiuQq6Ng_4_5"></a><a id="Tc_Snlf2v1kKEGlidoo1jE3zw_5_0"></a><a id="Tc_odvTmScSU0G1tJwEwL1_qg_6_0"></a><a id="Tc_aKFc3apyAU-GiK1rn6hcFQ_7_0"></a><a id="Tc_XzQ1SIj_fkm19kSmKVhLpA_8_0"></a><a id="Tc_hlcB96-lqUeZAlQpBVqrQg_9_0"></a><a id="Tc_ZKOjaQbBvUOolFejDQRbVA_10_0"></a><a id="Tc_HbcuGkRljkmpYWUzmFZGzw_10_6"></a><a id="Tc_3i8PyCW_ZEq7mhzpMc4NkQ_11_0"></a><a id="Tc_ufyPBbk3GUynemp27wgCNw_13_0"></a><a id="Tc_mzLoarMtjk6y_aX9Vq0LuQ_14_0"></a><a id="Tc_X6OkdBnUBkib6YOE14UDZA_15_0"></a><a id="Tc_PHE7KcQZrkmZEaQPJBm0uQ_16_0"></a><a id="Tc_2m0O47XSqk6xC1Q50xX2iQ_16_1"></a><a id="Tc_RzWZXtic7kWCSILhMGKTdg_18_0"></a><a id="Tc_oAAF6AI0LUq027lMYhScLQ_18_1"></a><a id="Tc_AWTWbrUHjkmtjoc3vQgUkg_18_2"></a><a id="Tc_qGEJo1_t_0Ooc96V4BPtmw_18_5"></a><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="Tb_vjNUY7z2SEqlEKH3y7Z5Vg" continuedAt="Tb_vjNUY7z2SEqlEKH3y7Z5Vg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">3.&#160;&#160;&#160;Discontinued Operations </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On November 3, 2022, the Company announced it is seeking to divest its contract development and manufacturing organization (iBio CDMO, LLC) in order to complete its transformation into an antibody discovery and development company. In conjunction with the divestment, the Company commenced a workforce reduction of approximately <ix:nonFraction unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg" contextRef="Duration_11_3_2022_To_11_3_2022_B-3zxmk-RECRSqI6e6Ttyg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="Narr_1fBedorh_0WhkDGZfaEFuQ">60</ix:nonFraction>% of the current Company staffing levels (a reduction of approximately <ix:nonFraction unitRef="Unit_Standard_position_V29P0pRPvUyM5A0t2OFq5g" contextRef="Duration_11_3_2022_To_11_3_2022_B-3zxmk-RECRSqI6e6Ttyg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" scale="0" id="Narr_pOGDtvayTEuzxUujXdhAMQ">69</ix:nonFraction> positions). The Company substantially completed the employee reduction by January 2, 2023. Through the process of seeking to divest its contract development and manufacturing organization, the Company continues to market for sale the 130,000-square-foot cGMP facility location in Bryan, Texas (the &#8220;Facility&#8221;). Additionally, on February 10, 2021, the Company, entered into an Auction Sale Agreement (the &#8220;Auction Sale Agreement&#8221;) with Holland Industrial Group, together with Federal Equipment Company and Capital Recovery Group LLC (collectively, the &#8220;Auctioneers&#8221;) for the sale at public auction of equipment and other tangible personal property (the &#8220;Equipment&#8221;) located at the Facility. &#160;The Auctioneer guaranteed an amount of gross proceeds from the sale of the equipment of $2.1 million, which was paid to the Company on February 17, 2023. The auction, which commenced on March 24, 2023 and concluded on March 30, 2023, resulted in total proceeds of approximately $2.9 million. &#160;In accordance with the Auction Sale Agreement, the Company received 80% of the excess proceeds, after Holland Industrial Group&#8217;s $0.2 million fee, which approximated $0.5 million during the fourth quarter of Fiscal 2023 and is included in prepaid and other assets as of March 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company incurred pre-tax charges of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_11_3_2022_To_11_3_2022_B-3zxmk-RECRSqI6e6Ttyg" decimals="-5" format="ixt:numdotdecimal" name="ibio:EmployeeReductionExpenses" scale="6" id="Narr_kvXmfJdPE0uCp-t1jspnPQ">1.9</ix:nonFraction> million for the employee reduction which consisted of severance obligations, continuation of salaries and benefits over a 60-day transitional period during which impacted employees remain employed but were not expected to provide active service, and other customary employee benefit payments in connection with an employee reduction. &#160;At March&#160;31,&#160;2023, $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" scale="6" id="Narr__ZEcBVa8FkGpFde_CTtQng">0.1</ix:nonFraction> million remains in accrued expenses as a current liability. &#160;The Company recorded a charge in discontinued operations for $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-5" format="ixt:numdotdecimal" name="ibio:EmployeeReductionExpenses" scale="6" id="Narr_NrFLBXXwpkCAbU5aKKxRTw">34.6</ix:nonFraction> million for the nine months ended March&#160;31,&#160;2023, of which approximately $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TangibleAssetImpairmentCharges" scale="6" id="Narr_Q5kOWRKjykiCEjswWhTwNg">17.6</ix:nonFraction> million was the result of a fixed asset impairment charge (see Note 11 &#8211; Fixed Assets for more information), approximately $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-5" format="ixt:numdotdecimal" name="ibio:DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown" scale="6" id="Narr_xwRr7BMujEe0x6dZTl7fMQ">4.9</ix:nonFraction> million to write down inventory to its net realizable value, approximately $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-5" format="ixt:numdotdecimal" name="ibio:DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance" scale="6" id="Narr_DVjv9HDNtE-vznpcyU9EEA">7.5</ix:nonFraction> million of personnel costs including severance and the balance related to operational costs related to winding down the CDMO business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As such, the results of iBio CDMO&#39;s operations are reported as discontinued operations for the three and nine months ended March&#160;31,&#160;2023. The Company has retrospectively recast its condensed consolidated statement of operations for the three and nine months ended March&#160;31,&#160;2022 presented. In addition, those assets and liabilities associated with the discontinued operations of the CDMO that the Company intends to sell have been classified as &#8220;held for sale&#8221; as of March 31, 2023. The Company has retrospectively recast its consolidated balance sheet as of June 30, 2022 for assets and liabilities held for sale. The Company has chosen not to segregate the cash flows of iBio CDMO in the consolidated statement of cash flows. &#160;Supplemental disclosures related to discontinued operations for the statements of cash flows have been provided below. Unless noted otherwise, discussion in the Notes to the Condensed Consolidated Financial Statements refers to the Company&#39;s continuing operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="Tb_fhkmsCG_B0a91HXa6X0jKA" continuedAt="Tb_fhkmsCG_B0a91HXa6X0jKA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">The following table presents a reconciliation of the major financial lines constituting the results of operations for discontinued operations to the loss from discontinued operations presented separately in the condensed consolidated statements of operations (in thousands):</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:61.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:0.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:15.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:61.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues</p></td><td style="vertical-align:middle;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:15.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="3" id="Tc_X3VbJSYQ-0-_6YfEISLeSA_4_3">205</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="3" id="Tc_MITVCm85VEuybu2KUSLBTQ_4_6">143</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of goods sold</p></td><td style="vertical-align:middle;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="3" id="Tc_iV5NOnh0AESI9pSyWDjKrw_5_3">25</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="3" id="Tc_0b3TJmyyNUmE29RsZzR1dw_5_6">48</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross profit</p></td><td style="vertical-align:middle;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" scale="3" id="Tc_ZNBojOkqJEyJ2d6yy73wAg_6_3">180</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" scale="3" id="Tc_2TvSrgx0bUCdw96CZWr35Q_6_6">95</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:middle;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Research and development</span></p></td><td style="vertical-align:middle;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" format="ixt:numdotdecimal" name="ibio:DiscontinuedOperationsResearchAndDevelopmentExpenses" scale="3" id="Tc_kSVrGv72L0SXa4LzPj5wIA_8_3">837</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="-3" format="ixt:numdotdecimal" name="ibio:DiscontinuedOperationsResearchAndDevelopmentExpenses" scale="3" id="Tc_Vncq_hslbkmU1bee_e_9vA_8_6">2,278</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    General and administrative</span></p></td><td style="vertical-align:middle;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" scale="3" id="Tc_cj9cxxOvgk6p90qvhXuzWw_9_3">929</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" scale="3" id="Tc_Wiveo7HxtkavTRORVEpouw_9_6">3,211</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Gain on sale of fixed assets</span></p></td><td style="vertical-align:middle;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown" sign="-" scale="3" id="Tc_bpMIncSDzkmh2an40preTw_10_3">732</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:61.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total operating expenses</p></td><td style="vertical-align:middle;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" scale="3" id="Tc_iHCAYFCoNk-9eVR9jDEwPA_11_3">1,034</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" scale="3" id="Tc_-SYNbbot-U60n9dd1TfEOA_11_6">5,489</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other expenses:</p></td><td style="vertical-align:middle;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Interest expense - term note payable</span></p></td><td style="vertical-align:middle;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense" scale="3" id="Tc_IwhO18AvXUits91JF-Lb3A_14_3">158</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense" scale="3" id="Tc_5F_TNv_ki0CfPbJscwFCOQ_14_6">249</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:61.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Other</span></p></td><td style="vertical-align:middle;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" format="ixt:numdotdecimal" name="ibio:DiscontinuedOperationsMiscellaneousExpensesIncome" scale="3" id="Tc_4ZenPpYICkmA5LhDDr88GA_15_3">3</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="-3" format="ixt:numdotdecimal" name="ibio:DiscontinuedOperationsMiscellaneousExpensesIncome" scale="3" id="Tc_rdOrXJRlK0Ssynqcvk_yiQ_15_6">1</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:61.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total other expenses</p></td><td style="vertical-align:middle;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" scale="3" id="Tc_UdO0U6YXS02vU23F0Xe7xg_16_3">161</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" scale="3" id="Tc_huyzL1WyXE691q0b19XFOQ_16_6">250</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:61.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from discontinued operations</p></td><td style="vertical-align:middle;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:15.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" sign="-" scale="3" id="Tc_W3TTPyCEtUunHkbMyOm92g_18_3">1,015</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" sign="-" scale="3" id="Tc_Rf4MwXqG7kyxdMrWRlyQTA_18_6">5,644</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_77fb9156_f0fe_4f33_b0af_69c87be0721a"></a><a id="Tc_HHeMLY37T0SNHJq3nCOoBA_1_2"></a><a id="Tc_KF7LR7G0Q0qHUwq6zt192Q_1_5"></a><a id="Tc_DSbMRWZAf0ujSBC6zZVIAQ_2_2"></a><a id="Tc_zZcYvJqS5UWHK1-ytwwexw_2_5"></a><a id="Tc_LtafjDwmrECC7IRx4v7W7A_3_2"></a><a id="Tc_V0Mo8vffekGVWv-jihuW3w_3_5"></a><a id="Tc_VReh5oii8kmmx8n1LrbcJw_4_0"></a><a id="Tc_MreGs4HtREW_gRcz_WaLxw_4_1"></a><a id="Tc__2yaqzMtpE6Rc2bTAKQhgQ_4_2"></a><a id="Tc_0kr5bkebyEurSMKQzdbDrg_4_5"></a><a id="Tc_vDmezVYeP0aUd0ieRlFxhw_5_0"></a><a id="Tc_jb3Kc_mN00yAzG8t3obk7A_6_0"></a><a id="Tc_PLJ3l9_yuU6_G3IyePVVFw_7_0"></a><a id="Tc_uuhGfHVOJkSgQXMTGzkspQ_8_0"></a><a id="Tc_mFREqdEXxUejfoR0H9HnPA_9_0"></a><a id="Tc_DM2iQKB-Y0CG8mszTR4ljw_10_0"></a><a id="Tc_A7RGnBiBr0OvxxINnoVKIw_10_6"></a><a id="Tc_b87DEIuX7E-XH7vDc5bF_g_11_0"></a><a id="Tc_z5pateRRPEy9qDNFuITm3g_11_3"></a><a id="Tc_tnf8GMwr5ke6uAOx_6uAYA_11_6"></a><a id="Tc_teXd02bnmkGh16rUiGXNLA_12_0"></a><a id="Tc_TQ4AsZhtZ06k7dvv249JdQ_12_6"></a><a id="Tc_nmLJi1t77k-lnNVvCnWYTg_13_0"></a><a id="Tc_AWAtSTjZ0kW0w8V9KsgVoA_15_0"></a><a id="Tc_wEJnECD_sUKSLhQBI-wotQ_16_0"></a><a id="Tc_V4ykzvoPyUyKb-TVhvOqWA_17_0"></a><a id="Tc_mPrizJTok0CYvUsSue0v4g_17_3"></a><a id="Tc_FLBfjGGw7Emx9ETLTCs-IQ_18_0"></a><a id="Tc_-NvD4t6xb0qsXZlER5uj2w_18_3"></a><a id="Tc_auLDP0VpiEuhfp3kpRYvhQ_19_0"></a><a id="Tc_GVVoKjtlsUaY07I59nc-_Q_20_0"></a><a id="Tc_zrnGzeBPF0CQXHponsr6Nw_20_1"></a><a id="Tc_Ytdg_czL8USHYtvJoI2uGg_22_0"></a><a id="Tc_4RZOy_G5kEe-qX6dXNSPiw_22_1"></a><a id="Tc_EfFhEqPtlUK1G3m2mVcq1A_22_2"></a><a id="Tc_h754wq83gEWVAlpy-7LRJg_22_5"></a><a id="_33dc10ed_cfbb_4f9f_89c5_fea575d6012f"></a><a id="Tc_4Bl-8VNH_kGTmjrEfJZQYg_1_2"></a><a id="Tc_ET2kLzwI20ObSz2Bs-55Mw_1_5"></a><a id="Tc_NL9OiO9Dl0q30GRGAtMpGQ_2_2"></a><a id="Tc_w0xcPMRhn0yK1Hm6gPdpUA_2_5"></a><a id="Tc_oJPHMaFdVUm7phZYLT2Ddg_3_0"></a><a id="Tc_3KdmO23qyECg8Wu9UhdVkg_4_0"></a><a id="Tc_PthQyJOdVk29QVmkkNqCBA_4_2"></a><a id="Tc_owINy07YS0emoUD97sQnaA_4_3"></a><a id="Tc_RZvSDkQwsU2KfU5c7p8hrg_4_5"></a><a id="Tc_p-dOXevybkuZUV_UEk1hjw_5_0"></a><a id="Tc_k_ftVp8DE02_l7WrUVwb8w_5_6"></a><a id="Tc_kHJBJ_LMTUmxTntTseUpAA_6_0"></a><a id="Tc_IYdyxfqPn0yWw_tnLuGYyw_6_6"></a><a id="Tc_DVmdH3E5hE-eG3J6CBFDSw_7_0"></a><a id="Tc_TLl1-ewHL0OiI69DF2mmIw_7_2"></a><a id="Tc_k6ja1kpTvUGctsi3i-y7uw_7_5"></a><a id="Tc_5VD4uvxza0-syDhxHp7Npw_9_0"></a><a id="Tc_MGcAhzJFNkOVG7F-oUgRGw_10_0"></a><a id="Tc_oJ0Jmd5XlEm8GO0L3xgIiw_10_2"></a><a id="Tc_xwwQ1Erhv0KgA9JEWuUcow_10_3"></a><a id="Tc_PZ35v7WYRESqMMQhrTKj6g_10_5"></a><a id="Tc_Lsy_GZ5IqUqmzv22JfeekQ_11_0"></a><a id="Tc_S_vL86bJlU6IMV-4ywZlYw_11_3"></a><a id="Tc_pDWB7Yf-9EW9Qph4rnbeLQ_12_0"></a><a id="Tc_Nwmj4NrYc0itz0ajIfdFOA_12_3"></a><a id="Tc_FQlHu8X1NUmCtMNO_XeCkA_13_0"></a><a id="Tc__ikE7fp07UqNADp1Dwngew_13_2"></a><a id="Tc_ky2FKwg5_kGIJJoenicvFA_13_3"></a><a id="Tc_p5n8TJZLR0KR0nS7Rv_nDQ_13_5"></a><a id="Tc_YgAWfhOrIUqcERKiO1O7BA_15_0"></a><a id="Tc_wHWoA0G0AEunNWR3AUE0Dg_16_0"></a><a id="Tc_NSoGFGiMg0K-wMZ-Ppp1PQ_16_2"></a><a id="Tc_ovrVZP56ykuiI0AJ0870dA_16_3"></a><a id="Tc_zTut9yNdn0WhJDEXadzXtg_16_5"></a><a id="Tc_o-fVqQlvBEqtVtL3ThMd0g_17_0"></a><a id="Tc_q6lr0YPfl0K2Jo2PNzaWEw_18_0"></a><a id="Tc_j4HiQhhv_ESjfyW5fDZNIQ_18_2"></a><a id="Tc_yIrHxtu130aQ6Gh3P8qVSA_18_5"></a><a id="Tc_D37TJlBlI0OnLQlOOgri0Q_20_0"></a><a id="Tc_KRh_iudLlUSMZd6fgsOWMA_21_0"></a><a id="Tc_cV5oPRHwY02ZjuS-zyRVHg_21_2"></a><a id="Tc_NEfDKD9D1Ui8V7UhaPxIMw_21_3"></a><a id="Tc_Nr2ICtINmkK7RgCBm51uRg_21_5"></a><a id="Tc_--WGjIAaX0a6R9QxCfDs1A_22_0"></a><a id="Tc_ofrU0GoFSkmHkh4ggn8M_A_22_3"></a><a id="Tc_twyRu6Al_kKF7ul7_tzdIA_23_0"></a><a id="Tc_EXoTglek30W6QFBqEfoX4Q_23_2"></a><a id="Tc_yFBCMcvhzk2w7WER9Durwg_23_3"></a><a id="Tc_l23omx5XYEuZz_cKP8TEqg_23_5"></a><ix:continuation id="Tb_vjNUY7z2SEqlEKH3y7Z5Vg_cont1" continuedAt="Tb_vjNUY7z2SEqlEKH3y7Z5Vg_cont2"><ix:continuation id="Tb_fhkmsCG_B0a91HXa6X0jKA_cont1" continuedAt="Tb_fhkmsCG_B0a91HXa6X0jKA_cont2"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:14.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues</p></td><td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="3" id="Tc_XAXuG185rk68azDa1vNy_Q_4_3">391</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="3" id="Tc_YOBSZZGpukGVFcYMdY8EoQ_4_6">438</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of goods sold</p></td><td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="3" id="Tc_9GDse8Auz0iKU2paFf05qg_5_3">52</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="3" id="Tc_ZWI4mxp590W2s4PxYbmv6A_5_6">201</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross profit</p></td><td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" scale="3" id="Tc_j1IiUkEZFUSijrpI7w-BwQ_6_3">339</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" scale="3" id="Tc_dB-qaSKgNUmAvbgpD-Lgpg_6_6">237</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Research and development</span></p></td><td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="ibio:DiscontinuedOperationsResearchAndDevelopmentExpenses" scale="3" id="Tc_mEjE1IqdmUerf_4U_O6MHg_8_3">6,361</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:DiscontinuedOperationsResearchAndDevelopmentExpenses" scale="3" id="Tc_qvKaRf4Rskm0MErLirlctw_8_6">5,128</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    General and administrative</span></p></td><td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" scale="3" id="Tc_t7CBEMVWlEWS-fCbuWhCMw_9_3">6,165</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" scale="3" id="Tc_l-_WtYqjjECBebYyoDMUZw_9_6">8,659</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Fixed asset impairments</span></p></td><td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="ibio:TangibleAssetImpairmentChargesDiscontinuedOperations" scale="3" id="Tc_MXhCvYbaAkGEapvNR9M5Vg_10_3">17,600</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Gain on sale of fixed assets</span></p></td><td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (732)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Inventory reserve</span></p></td><td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown" scale="3" id="Tc_aCNReGcpyUGEaaoLiY_QtA_12_3">4,933</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total operating expenses</p></td><td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" scale="3" id="Tc_KRxrRsk4akatUz05pX2kZQ_13_3">34,327</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" scale="3" id="Tc_pB9Z_HP1vkaaMSfU0meImA_13_6">13,787</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other income (expenses):</p></td><td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Interest expense - term note payable</span></p></td><td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense" scale="3" id="Tc_7NjoyUaP40GkniATxT_jmw_16_3">606</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense" scale="3" id="Tc_Ct7GyEbMr0mnjHhrEQPEMQ_16_6">372</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Interest expense - related party</span></p></td><td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupInterestExpenseRelatedParty" scale="3" id="Tc_K_edmUvdF0KF3F5WZzj5aQ_17_6">810</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Forgiveness of note payable and accrued interest - SBA loan</span></p></td><td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupGainOnDebtForgiveness" scale="3" id="Tc_SvzoSoCYJU2E1vjuTdVb-Q_18_6">607</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Other</span></p></td><td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="ibio:DiscontinuedOperationsMiscellaneousExpensesIncome" scale="3" id="Tc_oSugKgwZP0KzIFJnZmwKHA_19_3">4</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:DiscontinuedOperationsMiscellaneousExpensesIncome" sign="-" scale="3" id="Tc_-5X8K-L35EKZFw4HcH9xSA_19_6">1</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total other income (expenses)</p></td><td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" scale="3" id="Tc_HJqw12rxrEyARg97U3a_dQ_20_3">610</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" scale="3" id="Tc_36w7PYWQWEq1iH1gB6mM9w_20_6">574</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from discontinued operations</p></td><td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:14.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" sign="-" scale="3" id="Tc_ygupZ6luQ02CAuyXBEqWWw_22_3">34,598</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" sign="-" scale="3" id="Tc_bAngYwK1VEmpUMwkeDedbg_22_6">14,124</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table presents net carrying values related to the major classes of assets that were classified as held for sale at March&#160;31,&#160;2023 and June&#160;30,&#160;2022 (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Inventory</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" scale="3" id="Tc_7ZGc89kQfkKtjv3-Q0i1xA_4_6">3,900</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Operating lease right-of-use assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupOperatingLeaseRightOfUseAssets" scale="3" id="Tc_CCs6R1m5QUSuqDe4qbKPqw_5_3">1,944</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Property and equipment, net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" scale="3" id="Tc_rT4iqBjLdEOK_4rVlxz1TA_6_3">16,424</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:14.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="3" id="Tc_RR7AXOBXl02oURYtXzaSIw_7_3">18,368</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="3" id="Tc_MfEafO9YkU6jTQkQztVXHQ_7_6">3,900</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Property and equipment, net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" scale="3" id="Tc_YwGmWKbD8Eefu-etn4KrRg_10_6">35,289</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Finance lease right-of-use assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupNonCurrentAssetsFinanceLeaseRightOfUseAssets" scale="3" id="Tc_5WSzUR_W9k-pnmV_nvyBJA_11_6">74</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Operating lease right-of-use assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent" scale="3" id="Tc_IvuP5Uc-d0KP7_W0ANVBXA_12_6">1,951</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" scale="3" id="Tc_0HrPalRgd0ehLPUbsVHwKA_13_6">37,314</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Finance lease obligation</span></p></td><td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupCurrentLiabilitiesFinanceLeaseObligations" scale="3" id="Tc_0R3REXoidUm7qI-_rTPhaA_16_6">46</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Operating lease obligation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupCurrentLiabilitiesOperatingLeaseObligations" scale="3" id="Tc_37IrJ6QnLEGf4dXsmwG_Yg_17_3">1,944</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupCurrentLiabilitiesOperatingLeaseObligations" scale="3" id="Tc_ZYodlYOsfUuD_CeH1TRgZw_17_6">10</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:14.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="3" id="Tc_v6s8JJw-2kmKqJxSuuJByQ_18_3">1,944</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="3" id="Tc_bl2_IU5a9UKaK1mNcvNx-g_18_6">56</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Finance lease obligation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupNoncurrentLiabilitiesFinanceLeaseObligations" scale="3" id="Tc_5jnBGlaaHUegVzpu6lOu0w_21_6">30</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Operating lease obligation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupNoncurrentOperatingLeaseObligations" scale="3" id="Tc_H5E9ZRLRNEygKIT-Q87kbA_22_6">1,941</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total long-term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" scale="3" id="Tc_tyBWYoqgjEiTela-q4nyvA_23_6">1,971</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_47db2472_f34f_4a92_9f5f_763468402716"></a><a id="Tc_5TWjXDaf0ESGvbwV1ua1dA_1_2"></a><a id="Tc_Hvp6bobsJUSwTGw37RdFDA_1_5"></a><a id="Tc_RhTNIsByLkKLnMZki4t_cQ_2_2"></a><a id="Tc_mEVdwY-SgUySdZ_Di0g8Gw_2_5"></a><a id="Tc_SETXt2t_L0y2KcmrESgTfQ_3_2"></a><a id="Tc_wIiOLk4AmEOPWhaf2V5fhg_3_5"></a><a id="Tc_P-0MMbfM6kK4ePUHJVEBaQ_4_0"></a><a id="Tc_ADOyLcr_oU26s6dX6kAl5Q_4_1"></a><a id="Tc_q1Yj27yKiU2NgJs7p3tsog_4_2"></a><a id="Tc_cA4zN9-QJ0S4S3QarHbX0g_4_5"></a><a id="Tc_fvC4vG8neEmVC4ebybmHYQ_5_0"></a><a id="Tc_lmbUBw1JcUChgwMsSHaNJA_6_0"></a><a id="Tc_Dsp4WqkDqEi1jIzb_RxNcg_7_0"></a><a id="Tc_TIpRZup3N0u22fc2QXb_TQ_7_6"></a><a id="Tc_lloxI4I5ZECF_9du9PEIRQ_8_0"></a><a id="Tc_d-RY9odnlE6cAkbTTGODzQ_8_6"></a><a id="Tc_jE_eWYzcO02JM6PEUzifDQ_9_0"></a><a id="Tc_GqtTQpdeb0OWUVStIv97Jw_9_3"></a><a id="Tc_2-JFptg7IEqbsnKU7i8FaQ_9_6"></a><a id="Tc_kYBXCXdUmkyh9INqx70Z1Q_10_0"></a><a id="Tc_h2_mo_ZX_0O4c9UKExcX7Q_11_0"></a><a id="Tc_i_eKfLp4EkygHwoZAZsRSQ_12_0"></a><a id="Tc_u8xRQElDT0qe9VKY9r8-hg_12_3"></a><a id="Tc_cf8QwJHby0qbNZ-fP7jUUA_12_6"></a><a id="Tc_NZlZfXu40EuS3mx4l4MJYw_13_0"></a><a id="Tc_zamoQrMu0kusNhhrbLLxDw_13_6"></a><ix:continuation id="Tb_vjNUY7z2SEqlEKH3y7Z5Vg_cont2"><ix:continuation id="Tb_fhkmsCG_B0a91HXa6X0jKA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table presents the supplemental disclosures related to discontinued operations for the statements of cash flows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Depreciation expense</p></td><td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortizationDiscontinuedOperations" scale="3" id="Tc_fwACq1u-ZEq1H3GxdtJhfA_4_3">273</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortizationDiscontinuedOperations" scale="3" id="Tc_1nmPxrb5ak-kriRJTsGYzA_4_6">1,532</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization of finance lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets" scale="3" id="Tc_o4Vm7RARJUCIMq5Pt8thQQ_5_3">20</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets" scale="3" id="Tc_GM37i_NetE-dQ4-ZWIuM7g_5_6">587</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Purchase of fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpenditureDiscontinuedOperations" scale="3" id="Tc_txSwrvhrh0qxcqTJG33kYw_6_3">1,041</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpenditureDiscontinuedOperations" scale="3" id="Tc_1i_4kEHfikiA835VTncrpQ_6_6">28,384</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fixed asset impairments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="ibio:TangibleAssetImpairmentChargesDiscontinuedOperations" scale="3" id="Tc_bIZlkdVyNkSn5orWAZ0mhw_7_3">17,600</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Inventory reserve</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown" scale="3" id="Tc_xiZ8PZAGEUqjVNpJHF37Fg_8_3">4,933</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sales proceeds of fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 2,100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Investing non-cash transactions:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Fixed assets included in accounts payable in prior period, paid in current period</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod" scale="3" id="Tc_ocl9q5wYF02Pw3qPyc7rYQ_11_3">1,542</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod" scale="3" id="Tc_g6yRetR-aEm5bUjO95ogjQ_11_6">791</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Unpaid fixed assets included in accounts payable</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 2,193</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Sales of fixed assets receivable</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="ibio:UnpaidFixedAssetsAttributableToDiscontinuedOperations" scale="3" id="Tc_bDzkbhsVL0yTsduFsXzGAA_13_3">460</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_adn3R_PFpki_rEn3dlfjdg" continuedAt="Tb_adn3R_PFpki_rEn3dlfjdg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">4.&#160;&#160;&#160;Summary of Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s significant accounting policies are described in Note&#160;3 of the Notes&#160;to Consolidated Financial Statements in the Annual Report.</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="us-gaap:UseOfEstimates" id="Tb_azSXl0Y530OdIghiWsHDDQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include liquidity assertions, the valuation of intellectual property and fixed assets held for sale, the incremental borrowing rate utilized in the finance and operating lease calculations, legal and contractual contingencies and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="Tb_UHQRFwr6EU6rNOScFO_5BA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Accounts Receivable</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Accounts receivable are reported at their outstanding unpaid principal balances net of allowances for uncollectible accounts. The Company provides for allowances for uncollectible receivables based on its estimate of uncollectible amounts considering age, collection history, and other factors considered appropriate. Management&#8217;s policy is to write off accounts receivable against the allowance for doubtful accounts when a balance is determined to be uncollectible. At March&#160;31,&#160;2023 and June&#160;30,&#160;2022, the Company determined that an allowance for doubtful accounts was not needed. &#160;The Company had accounts receivable of $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2021_RvsAx0CeVUiEHjFvD-Jmkw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="Narr_V-lVNi1WpkW1d4bjhYNUQw">426,000</ix:nonFraction> at June&#160;30,&#160;2021. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="Tb_q_XWXtJTlE-_lyjuxQVZyg" continuedAt="Tb_q_XWXtJTlE-_lyjuxQVZyg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company accounts for its revenue recognition under Accounting Standards Codification (&quot;ASC&quot;) 606, <i style="font-style:italic;">Revenue from Contracts with Customers</i>. Under this standard, the Company recognizes revenue when a customer obtains control of promised services or goods in an amount that reflects the consideration to which the Company expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer contracts. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s contract revenue consists primarily of amounts earned under contracts with third-party customers and reimbursed expenses under such contracts. The Company analyzes its agreements to determine whether the elements can be separated and accounted for individually or as a single unit of accounting. Allocation of revenue to individual elements that qualify for separate accounting is based on the separate selling prices determined for each component, and total contract consideration is then allocated pro rata across the components of the arrangement. If separate selling prices are not available, the Company will use its best estimate of such selling prices, consistent with the overall pricing strategy and after consideration of relevant market factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In general, the Company applies the following steps when recognizing revenue from contracts with customers: (i)&#160;identify the contract, (ii)&#160;identify the performance obligations, (iii)&#160;determine the transaction price, (iv)&#160;allocate the transaction price to the performance obligations and (v)&#160;recognize revenue when a performance obligation is satisfied. &#160;</p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_adn3R_PFpki_rEn3dlfjdg_cont1" continuedAt="Tb_adn3R_PFpki_rEn3dlfjdg_cont2"><ix:continuation id="Tb_q_XWXtJTlE-_lyjuxQVZyg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Recognition of revenue is driven by satisfaction of the performance obligations using one of two methods: revenue is either recognized over time or at a point in time. Contracts containing multiple performance obligations classify those performance obligations into separate units of accounting either as standalone or combined units of accounting. For those performance obligations treated as a standalone unit of accounting, revenue is generally recognized based on the method appropriate for each standalone unit. For those performance obligations treated as a combined unit of accounting, revenue is generally recognized as the performance obligations are satisfied, which generally occurs when control of the goods or services have been transferred to the customer or client or once the client or customer is able to direct the use of those goods and/or services as well as obtaining substantially all of its benefits. As such, revenue for a combined unit of accounting is generally recognized based on the method appropriate for the last delivered item but due to the specific nature of certain project and contract items, management may determine an alternative revenue recognition method as appropriate, such as a contract whereby one deliverable in the arrangement clearly comprises the overwhelming majority of the value of the overall combined unit of accounting. Under this circumstance, management may determine revenue recognition for the combined unit of accounting based on the revenue recognition guidance otherwise applicable to the predominant deliverable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">If a loss on a contract is anticipated, such loss is recognized in its entirety when the loss becomes evident. When the current estimates of the amount of consideration that is expected to be received in exchange for transferring promised goods or services to the customer indicates a loss will be incurred, a provision for the entire loss on the contract is made. At March&#160;31,&#160;2023 and June&#160;30,&#160;2022, the Company had no contract loss provisions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Fixed-Fee </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Under a fixed-fee contract, the Company charges a fixed agreed upon amount for a deliverable. Fixed-fee contracts have fixed deliverables upon completion of the project. Typically, the Company recognizes revenue for fixed-fee contracts after projects are completed, delivery is made and title transfers to the customer, and collection is reasonably assured.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Revenue can be recognized either 1) over time or 2) at a point in time. &#160;All revenue was recognized at a point in time for all periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the three months ended March 31, 2022, revenue was recognized from a license agreement and for the nine months ended March&#160;31,&#160;2022, revenue was recognized from a license agreement and the settlement of a revenue contract. &#160;No revenue was recognized for all other periods presented. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Time and Materials</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Under a time and materials contract, the Company charges customers an hourly rate plus reimbursement for other project specific costs. The Company recognizes revenue for time and material contracts based on the number of hours devoted to the project multiplied by the customer&#8217;s billing rate plus other project specific costs incurred.</p></ix:continuation><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="ibio:ContractAssetsPolicyTextBlock" id="Tb_R6Ywaxw_R0mSwl_kxgI62A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;">Contract Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">A contract asset is an entity&#8217;s right to payment for goods and services already transferred to a customer if that right to payment is conditional on something other than the passage of time. Generally, an entity will recognize a contract asset when it has fulfilled a contract obligation but must perform other obligations before being entitled to payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Contract assets consist primarily of the cost of project contract work performed by third parties for which the Company expects to recognize any related revenue at a later date, upon satisfaction of the contract obligations. At March&#160;31,&#160;2023 and June&#160;30,&#160;2022, contract assets were $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2021_RvsAx0CeVUiEHjFvD-Jmkw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="0" id="Narr_OAlu573U3ky6lx_Ld3glTg"><ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="0" id="Narr_EYTru7PojEiyxXVzf5G2_g"><ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="0" id="Narr_S5jYEx3AzUevf9K1xYOGCQ">0</ix:nonFraction></ix:nonFraction></ix:nonFraction>.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="ibio:ContractLiabilitiesPolicyTextBlock" id="Tb_ZPCk-06WHUyJ6--qXvzlUQ" continuedAt="Tb_ZPCk-06WHUyJ6--qXvzlUQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Contract Liabilities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">A contract liability is an entity&#8217;s obligation to transfer goods or services to a customer at the earlier of (1) when the customer prepays consideration or (2) the time that the customer&#8217;s consideration is due for goods and services the entity will yet provide. Generally, an entity will recognize a contract liability when it receives a prepayment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Contract liabilities consist primarily of consideration received, usually in the form of payment, on project work to be performed whereby the Company expects to recognize any related revenue at a later date, upon satisfaction of the contract obligations. At March&#160;31,&#160;2023, June&#160;30,&#160;2022, and June&#160;30,&#160;2021, contract liabilities w<span style="background:#ffffff;">ere </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueCurrent" scale="0" id="Narr_IFbkSUQjhk-wskYYsFI-Rg">0</ix:nonFraction></span><span style="background:#ffffff;">, </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueCurrent" scale="0" id="Narr__hQl1FflmkSM1zkRAvyoZQ">100,000</ix:nonFraction></span><span style="background:#ffffff;"> and </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2021_RvsAx0CeVUiEHjFvD-Jmkw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueCurrent" scale="0" id="Narr_TfdeV_r890GVh9_tgy0Qew">423,000</ix:nonFraction></span><span style="background:#ffffff;">, r</span>espectively. The Company recognized revenue of $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_qwQKiC4qEkiqgQ5177TkpA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" id="Narr_NEo0qFwncECSgETdXnBj4Q">53,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_uXNvRGR-RESDya9s9QmQmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" id="Narr_YJ0oW45npE6WAdRseDvq4A">100,000</ix:nonFraction> during the three and nine months ended March&#160;31,&#160;2023, respectively, that was included in the contract liabilities balance as of June 30, 2022 and was reported in discontinued operations. The Company recognized revenue of $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_RaNGnKpnsEaTsjOvOslUxA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" id="Narr_iLWJ8v-qhEG3vbDUxpTYdg">52,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_GqDXZ6lLOEyUlH87AA2kZw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" id="Narr_C9E32KKbL0eNuCjXmbBZkw">178,000</ix:nonFraction> during the three and nine months ended March&#160;31,&#160;2022, respectively, that was included in the contract liabilities balance as of June&#160;30,&#160;2021 and was reported in discontinued operations. The Company recognized revenue of $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentContinuingOperationsMember_Cex7NDVXOEO89CLJRQZTuQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" id="Narr_NL2uS3D_tkGX9TwrAs58-g">0</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentContinuingOperationsMember_h7DRj5r8q0CCEDp9Wg0n4A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" id="Narr_ng8ZsqgAIkybbHVlmG94ew">84,000</ix:nonFraction> during the three </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d1abb17b_0533_4c11_b9df_85ab01e76140"></a><a id="Tc_Rw8Q34IORUuzy8vSk9bKlg_1_2"></a><a id="Tc_qmFfroL4jkGUecZd2B8JAA_1_5"></a><a id="Tc_73bvcGzr2Ems6jm1U-pjEQ_2_2"></a><a id="Tc_AuD-eypfeUmaU6i4SOajWQ_2_5"></a><a id="Tc_26Lh-wEna0qGNcEO3lEYfg_3_0"></a><a id="Tc_b3dZf5tvD0GGk_JNjOsgZQ_3_1"></a><a id="Tc_T5klerT_OEOMCAUPlMh7Ig_3_2"></a><a id="Tc_EOOeyzsLHUWeZ3AqN7erMw_3_5"></a><a id="Tc_tEhB_yfsvkGJUL7se4gikQ_4_0"></a><a id="Tc_ovymw47_DUaD07ax1ADc6g_5_0"></a><a id="Tc_yxjhFBwPv0y10T_kHXrNJA_6_0"></a><a id="Tc_PGy3FB8DaUK67RbZIzjNTw_6_1"></a><a id="Tc_7D22CKFMWU6mVK6jxvzG0w_7_0"></a><a id="Tc_1jssrFVSwEKuKbOPejhCNw_7_1"></a><a id="Tc_yT59n5MxZ0efyAfTyEIV9Q_7_2"></a><a id="Tc_KXtux2puX0uKOu5x0DEeHQ_7_5"></a><ix:continuation id="Tb_adn3R_PFpki_rEn3dlfjdg_cont2" continuedAt="Tb_adn3R_PFpki_rEn3dlfjdg_cont3"><ix:continuation id="Tb_ZPCk-06WHUyJ6--qXvzlUQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">and nine months ended March&#160;31,&#160;2022 that was included in the contract liabilities balance as of June&#160;30,&#160;2021 and reported as part of continuing operations.</p></ix:continuation><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="us-gaap:LesseeLeasesPolicyTextBlock" id="Tb_mVnt28z-aUGz6gPcHfhjHw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Leases</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company accounts for leases under the guidance of Accounting Standards Codification (&quot;ASC&quot;) 842, <i style="font-style:italic;">Leases</i> (&quot;ASC 842&quot;). The standard established a right-of-use (&#8220;ROU&#8221;) model requiring a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months and classified as either an operating or finance lease. The adoption of ASC 842 had a significant effect on the Company&#8217;s balance sheet, resulting in an increase in non-current assets and both current and non-current liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In accordance with ASC 842, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether the Company obtains the right to substantially all the economic benefit from the use of the asset, and whether the Company has the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. For contracts with lease and non-lease components, <span style="-sec-ix-hidden:Hidden_eZ239xUFfk2aM5khbNy0yg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Company has elected not to allocate the contract consideration and to account for the lease and non-lease components as a single lease component</span></span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The lease liabilities and the corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. The implicit rate within the Company&#8217;s existing finance (capital) lease was determinable and, therefore, used at the adoption date of ASC 842 to determine the present value of lease payments under the finance lease. The implicit rate within the Company&#8217;s operating lease was not determinable and, therefore, the Company used the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Company&#8217;s incremental borrowing rate requires judgment. The Company will determine the incremental borrowing rate for each new lease using its estimated borrowing rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain the Company will exercise that option. An option to terminate is considered unless it is reasonably certain the Company will not exercise the option.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_LkhtSHTHGkulumI0VGTBOg" continuedAt="Tb_LkhtSHTHGkulumI0VGTBOg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Cash, Cash Equivalents and Restricted Cash</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company considers all highly-liquid instruments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents at March&#160;31,&#160;2023 and June&#160;30,&#160;2022 consisted of money market accounts. Restricted cash consisted of $3.0 million held within a Company account at Woodforest Bank for the term note payable (see Note 6 &#8211; Significant Transactions and Note 13 - Debt), collateral for a letter of credit obtained related to the San Diego operating lease (see Note 15 &#8211; Operating Lease Obligations) and collateral for a Company purchasing card. The Company&#8217;s bank required an additional <ix:nonFraction unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="INF" format="ixt:numdotdecimal" name="ibio:PercentageOfCollateralRequired" scale="-2" id="Narr_DQ4OuCTaB0iw3tKJzxuEYQ">5</ix:nonFraction>% collateral held above the actual letters of credit issued for the San Diego lease and Company purchasing card. Restricted cash was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="Narr_1i70k72QH0edboQnRqkyfA">3.3</ix:nonFraction> million at &#160;March&#160;31,&#160;2023 and $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="Narr_vjIgHb6Ka0WIHLLcFrnoaA">6.0</ix:nonFraction> million on June&#160;30,&#160;2022. The reduction to the restricted cash occurred because on October 11, 2022, the Company, as part of the First Amendment to the Credit Agreement with Woodforest National Bank (&#8220;Woodforest&#8221;), paid down $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_10_11_2022_To_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_SmV5R4SrNkmUCX3FsbIGLA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="6" id="Narr_c0uoj2eKzUy7ZULPYBRLAg">5.5</ix:nonFraction> million of the term loan and subsequently Woodforest cancelled the irrevocable letter of credit issued by JPMorgan Chase Bank upon closing of the amendment. &#160;In accordance with the Fourth Amendment with Woodforest, the Company deposited $3 million in a restricted account at Woodforest. (For a complete description of the transaction please see Note 6 &#8211; Significant Transactions and Note 13 - Debt). </p><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="Tb_W6UuzIWN2UeSrrcPK9eEgQ" continuedAt="Tb_W6UuzIWN2UeSrrcPK9eEgQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table summarizes the components of total cash, cash equivalents and restricted cash in the condensed consolidated statements of cash flows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:58.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:16.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:58.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Cash and equivalents</p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_y-nwbhNzlU6IrRk6o8df9g_3_3">6,562</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_LAKoUBSkZkyMUr8_O8NNVw_3_6">22,676</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:58.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Collateral held for letter of credit - term note payable</p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditTermLoanMember_pkYNKGm7FE-AjzorOXr0XA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_dVh5rk2GvkmcZYwyyUVxKQ_4_3">3,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditTermLoanMember_ZKZXpDTWYkGA9VMDpyQWng" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_8-LbPHEcmkOkhcB_0Bk0TA_4_6">5,743</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:58.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Collateral held for letter of credit - San Diego lease</p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditSanDiegoLeaseMember_wcNGCEcPbEm21StpOapKJw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_Okp55T8ALk-B9TxBy72cBw_5_3">198</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditSanDiegoLeaseMember_yPkVHgiNf0eqnma-vd44Og" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_mhJ9jDA9c0qegenXeSPuag_5_6">198</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:58.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Collateral held for Company purchasing card</p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_CompanyPurchasingCardMember_ZTE2EhC6DUi3V8Us5_uTEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_ooAwW-2nbkWhsZVO5yrmCA_6_3">55</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_CompanyPurchasingCardMember_jAg6eAzyCE6hspA3-EkVZw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_yyuV7Ddzj0arkhjZQTRwQw_6_6">55</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:58.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Total cash, cash equivalents and restricted cash</p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="3" id="Tc_gXuEleZ0_EW5XykaBlWpMQ_7_3">9,815</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="3" id="Tc_1WqZkojip0m6TAgln9pdWw_7_6">28,672</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_adn3R_PFpki_rEn3dlfjdg_cont3" continuedAt="Tb_adn3R_PFpki_rEn3dlfjdg_cont4"><ix:continuation id="Tb_LkhtSHTHGkulumI0VGTBOg_cont1"><ix:continuation id="Tb_W6UuzIWN2UeSrrcPK9eEgQ_cont1"></ix:continuation></ix:continuation><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="us-gaap:AvailableForSaleSecuritiesPurchasedOptionsPricePolicy" id="Tb_Q7YpYezfakqnoxt2R7eT7Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Investments in Debt Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:normal;">Debt investments were classified as available-for-sale. Changes in fair value are recorded in other comprehensive income (loss). Fair value was calculated based on publicly available market information. Discounts and/or premiums paid when the debt securities were acquired are amortized to interest income over the terms of the debt securities. See Note 8 &#8211; Investments in Debt Securities.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="us-gaap:InventoryPolicyTextBlock" id="Tb_VzsQ913b2kuNm4rpzLa54w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Inventory</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'TimesNewRomanPSMT';">Inventory is stated at the lower of cost or net realizable value on the first-in, first-out basis. &#160;Inventory held is related to the CDMO business and has been classified as held for sale. &#160;See Note 3 &#8211; Discontinued Operations for information on inventory reserved reflected in the period ended March&#160;31,&#160;2023.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'TimesNewRomanPSMT';visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_AUVWTs1jJ0yn9AScW39HpQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Research and Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company accounts for research and development costs in accordance with the Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 730-10, <i style="font-style:italic;">Research and Development</i> (&#8220;ASC 730-10&#8221;). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved. For the nine months ended March&#160;31,&#160;2023 and 2022, research and development expense was reported in both continuing and discontinued operations.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="ibio:RightOfUseAssetsPolicyPolicyTextBlock" id="Tb_cDBqCxaQz0-Tuz_ZWYZuAQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Right-of-Use Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">Assets held under the terms of finance (capital) leases are amortized on a straight-line basis over the terms of the leases or the economic lives of the assets. Obligations for future lease payments under finance (capital) leases are shown within liabilities and are analyzed between amounts falling due within and after one year. See Note 9 </span><i style="font-family:'TimesNewRomanPSMT';">&#8211;</i><span style="font-style:normal;"> Finance Lease ROU Assets and Note 14 </span><i style="font-family:'TimesNewRomanPSMT';">&#8211;</i><span style="font-style:normal;"> Finance Lease Obligations for additional information.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Tb_5KkxvNm4Nkmv_L55GrQLSA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Fixed Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Fixed assets are stated at cost net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets ranging from <span style="-sec-ix-hidden:Hidden_Eet2cSErQUWYG2NYDDLIPA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> to <ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_srt_RangeAxis_srt_MaximumMember_qkTv4t_oSEqp0FIe4NY8bw" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_e959wg9ykEuCujOYmJE7bQ">39 years</ix:nonNumeric>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company monitors fixed assets for impairment indicators throughout the year. &#160;When necessary, charges for impairments of long-lived assets are recorded for the amount by which the fair value is less than the carrying value of these assets. &#160;Changes in the Company&#8217;s business strategy or adverse changes in market conditions could impact impairment analyses and require the recognition of an impairment charge. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">See Note 11 &#8211; Fixed Assets for additional information.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" id="Tb_u-now5XBekGI7cFpD6sZBw" continuedAt="Tb_u-now5XBekGI7cFpD6sZBw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Intangible Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Identifiable intangible assets are comprised of definite life intangible assets and indefinite life intangible assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company accounts for definite life intangible assets at either their historical cost or allocated purchase price at asset acquisition and records amortization utilizing the straight-line method based upon their estimated useful lives. Intellectual property is amortized over <span style="-sec-ix-hidden:Hidden_5A4l74BAAkGpy-k8y3HFLw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">20&#160;years</span></span>. The Company reviews the carrying value of its definite life intangible assets for impairment whenever events or changes in business circumstances indicate the carrying amount of such assets may not be fully recoverable. &#160;The carrying value is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. An impairment loss is measured as the amount by which the carrying amount exceeds it fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For indefinite life intangible assets, the Company performs an impairment test annually and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. &#160;The Company determines the fair value of the asset quarterly or when triggering events are present, based on discounted cash flows and records an impairment loss if book value exceeds fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Evaluating for impairment requires judgment, including the estimation of future cash flows, future growth rates and profitability and the expected life over which cash flows will occur. Changes in the Company&#8217;s business strategy or adverse changes in market conditions could impact impairment analyses and require the recognition of an impairment charge. Although management bases its estimates on </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_adn3R_PFpki_rEn3dlfjdg_cont4" continuedAt="Tb_adn3R_PFpki_rEn3dlfjdg_cont5"><ix:continuation id="Tb_u-now5XBekGI7cFpD6sZBw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">See Note 12 &#8211; Intangible Assets for additional information.</p></ix:continuation><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Tb_06wvhCAEeEWyEhNo-zW2pQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Share-based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company recognizes the cost of all share-based payment transactions at fair value. Compensation cost, measured by the fair value of the equity instruments issued, adjusted for estimated forfeitures, is recognized in the financial statements as the respective awards are earned over the performance or service period. The Company uses historical data to estimate forfeiture rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The impact that share-based payment awards will have on the Company&#8217;s results of operations is a function of the number of shares awarded, the trading price of the Company&#8217;s stock at the date of grant or modification, the vesting schedule and forfeitures. Furthermore, the application of the Black-Scholes option pricing model employs weighted-average assumptions for expected volatility of the Company&#8217;s stock, expected term until exercise of the options, the risk-free interest rate, and dividends, if any, to determine fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Expected volatility is based on historical volatility of the Common Stock; the expected term until exercise represents the weighted-average period of time that options granted are expected to be outstanding giving consideration to vesting schedules and the Company&#8217;s historical exercise patterns; and the risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. The Company has not paid any dividends since its inception and does not anticipate paying any dividends for the foreseeable future, so the dividend yield is assumed to be <ix:nonFraction unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="2" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_dZRlZm_3dEyetEjhbq3AjQ">zero</ix:nonFraction>. In addition, the Company estimates forfeitures at each reporting period, rather than electing to record the impact of such forfeitures as they occur. See Note 18 <span style="font-family:'TimesNewRomanPSMT';">&#8211;</span> Share-Based Compensation for additional information.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_8DWFv54dVES3pvyTAya_AA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Concentrations of Credit Risk</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cash</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company maintains principally all cash balances in two financial institutions which, at times, may exceed the insured amounts. The exposure to the Company is solely dependent upon daily balances and the strength of the financial institutions. The Company has not incurred any losses on these accounts. At March&#160;31,&#160;2023 and June&#160;30,&#160;2022, amounts in excess of insured limits were approximately $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashUninsuredAmount" scale="0" id="Narr_530hsNS8aUGfSGj7B0_Dgg">6,300,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashUninsuredAmount" scale="0" id="Narr_h69Rm3lLdkCvNIcsKaaxdw">18,200,000</ix:nonFraction>, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Revenue</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the three months ended March&#160;31,&#160;2023, the Company reported no revenue from continuing operations and generated 100% of its revenue reported in discontinued operations from <ix:nonFraction unitRef="Unit_Standard_customer_yQcExGHKGkW8YXSDfuntYQ" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_R1fh5LInTEmTcImaZYCq4w" decimals="0" format="ixt-sec:numwordsen" name="ibio:NumberOfMajorCustomers" scale="0" id="Narr_aI4Q-qCcvk6NezyHvWlCNw">two</ix:nonFraction> customers. During the three months ended March&#160;31,&#160;2022, the Company reported $1.8 million of license revenue from continuing operations and generated $144,000 of revenue reported in discontinued operations from <ix:nonFraction unitRef="Unit_Standard_customer_yQcExGHKGkW8YXSDfuntYQ" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_7ZRgVsYP8kOQ3Ji8AiOywQ" decimals="0" format="ixt-sec:numwordsen" name="ibio:NumberOfMajorCustomers" scale="0" id="Narr__Wm0JN7HhkyhmKvk2ynWHA">two</ix:nonFraction> customers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the nine months ended March&#160;31,&#160;2023, the Company reported no revenue from continuing operations and generated 100% of its revenue reported in discontinued operations from <ix:nonFraction unitRef="Unit_Standard_customer_yQcExGHKGkW8YXSDfuntYQ" contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_ARnE75gvP0qnPbmgOAREKg" decimals="0" format="ixt-sec:numwordsen" name="ibio:NumberOfMajorCustomers" scale="0" id="Narr_Pg_RCsQcV0yt7kOArtYgYg">two</ix:nonFraction> customers. During the nine months ended March&#160;31,&#160;2022, the Company reported revenue from continuing operations related to a license agreement and a settlement of a revenue contract. &#160;The Company also generated $438,000 of revenue reported in discontinued operations from <ix:nonFraction unitRef="Unit_Standard_customer_yQcExGHKGkW8YXSDfuntYQ" contextRef="Duration_7_1_2021_To_3_31_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_yRWAOjfd2Ue7tGm5AdoU8A" decimals="0" format="ixt-sec:numwordsen" name="ibio:NumberOfMajorCustomers" scale="0" id="Narr_LUt5ipb340ea-p4c833KYQ">six</ix:nonFraction> customers.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_qutn5niG2UO4thm5VBO6-Q" continuedAt="Tb_qutn5niG2UO4thm5VBO6-Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Recently Issued Accounting Pronouncements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In June 2016, the FASB issued ASU 2016-13, <i style="font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i> (&#8220;ASU 2016-13&#8221;), which requires an entity to assess impairment of its financial instruments based on its estimate of expected credit losses. Since the issuance of ASU 2016-13, the FASB released several amendments to improve and clarify the implementation guidance. In November 2019, the FASB issued ASU 2019-10, <i style="font-style:italic;">Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates</i>, which amended the effective date of the various topics. As the Company is a smaller reporting company, the provisions of ASU 2016-13 and the related amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022 (quarter ending September 30, 2023, for the Company). Entities are required to apply these changes through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The Company does not expect the adoption of ASU 2016-13 to have a significant impact on the Company&#8217;s consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying condensed consolidated financial statements. Most of the newer standards issued represent </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_adn3R_PFpki_rEn3dlfjdg_cont5"><ix:continuation id="Tb_qutn5niG2UO4thm5VBO6-Q_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">technical corrections to the accounting literature or application to specific industries which have no effect on the Company&#8217;s condensed consolidated financial statements.</p></ix:continuation></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_c154a48b_dde1_4116_81a8_7d3237accc10"></a><a id="Tc_045taNn2f0Wv5MKRW47oAQ_1_3"></a><a id="Tc_3xIzEjwey0-qDFEQVjc7xg_2_3"></a><a id="Tc_7clGVSmmgU-oRaoxSdQ-ng_3_3"></a><a id="Tc_h_VgauOptUWE42_eh2S8UA_3_6"></a><a id="Tc_Wa8C6dgdsk60xlIbNk9L1A_3_9"></a><a id="Tc_OwvJHQbbhUWZNdHN2vC9Cw_3_12"></a><a id="Tc_5Kg8VHwilU2vGcguXbhUww_3_15"></a><a id="Tc_IKS7zpdZrE6-k3SPaNCjDA_4_0"></a><a id="Tc_wqius-FhEUuCQEQo4tzHCA_4_2"></a><a id="Tc_q5Getv0WjEyX-N2ClQE2MQ_4_3"></a><a id="Tc_gr0qW8us_0-JJEkt6uIWtw_4_5"></a><a id="Tc_xJ3zjk8yN0STh2nE5iVkqg_4_6"></a><a id="Tc_-uX2bEHmOUqYJHMy3GA6pA_4_8"></a><a id="Tc_zpss2OXn602lwSlrqscnRw_4_11"></a><a id="Tc_BiQri7EtRUKSPVpDdnpbOg_4_14"></a><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_rxpXPlWmVkiM7wUPu5gvHA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">5.&#160;&#160;&#160;Financial Instruments and Fair Value Measurement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The carrying values of cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and term note payable in the Company&#8217;s condensed consolidated balance sheets approximated their fair values as of March&#160;31,&#160;2023 and June&#160;30,&#160;2022 due to their short-term nature. The carrying value of the convertible promissory note receivable, the term note payable and finance lease obligation approximated to fair value as of March&#160;31,&#160;2023 and June&#160;30,&#160;2022 as the interest rates related to the financial instruments approximated to market value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company accounts for its investments in debt securities at fair value. The following provides a description of the three levels of inputs that may be used to measure fair value under the standard, the types of investments that fall under each category, and the valuation methodologies used to measure these investments at fair value. </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Level 1</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8211; Inputs are based upon unadjusted quoted prices for identical instruments in active markets. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Level 2</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8211; Inputs to the valuation include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in inactive markets, inputs other than quoted prices that are observable for the asset or liability, and inputs that are derived principally from or corroborated by observable market data by correlation or other means. If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability. &#160;All debt securities were valued using Level 2 inputs.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Level 3</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8211; Inputs to the valuation methodology are unobservable and significant to the fair value measurement.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company&#8217;s fixed assets and amortizable intangible assets are measured at fair value on a nonrecurring basis; that is, these assets are not measured at fair value on an ongoing basis, but are subject to fair value adjustments in certain circumstances, such as when there is evidence of&#160;impairment. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company initially marketed the CDMO business and during the second quarter of Fiscal 2023, changed its strategy to selling the stand-alone CDMO assets. &#160;These assets were assessed for impairment and the analysis resulted in the expected future cash flows from the sale of the property and equipment falling below its current carrying value. The Company utilized a market approach, using independent third-party appraisals, including comparable assets, in addition to bids received from prospective buyers, to estimate the fair value of the property and equipment. As a result, the carrying value of the building and equipment was reduced to their estimated fair values of $16,350,000 and $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_c19oJcuBhUqWIDNcmlXJ7Q" decimals="0" format="ixt:numdotdecimal" name="ibio:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure" scale="0" id="Narr_w4vNATbkrEaXs4QUDqykMg">2,100,000</ix:nonFraction>, respectively. &#160;In the second quarter of Fiscal 2023, impairment charges were recorded in discontinued operations under general and administrative expense of $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_OScbop6D_EyFbi9oWinyQQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TangibleAssetImpairmentCharges" scale="0" id="Narr_q5CjbeTfpkWUEpMrlr7OpQ">6,300,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_GWDLoqc91Eylj7aqLB53AA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TangibleAssetImpairmentCharges" scale="0" id="Narr_phSRxINAEka9wpDwrrSh2w">11,300,000</ix:nonFraction> for the building and machinery and equipment, respectively. &#160;The machinery and equipment were sold during the third quarter of Fiscal 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="Tb_rsNfdSjvIUS9KYs4qarwoQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table shows the fair value of the Company&#39;s fixed assets included in Current Assets Held For Sale measured at fair value on a non-recurring basis as of March&#160;31,&#160;2023 (amounts in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:26.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:12.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:12.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:14.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:6.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">March 31, 2023</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Fair Value Hierarchy</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Quoted Prices in Active Markets for Identical Assets (Level 1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Significant Other Observable Inputs (Level 2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Significant Unobservable Inputs (Level 3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Total Fair Value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Total Impairments</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Building in Bryan, Texas</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_ECHSceNMpEGQENNfII3BMg" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure" scale="3" id="Tc_LS8gMm8kN0O95Nq_RSvajg_4_9">16,364</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_LfJb0Ctu7kiams8KPEcLPg" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure" scale="3" id="Tc_D8L3LM_Z5kKhANNNL-b-Bg_4_12">16,364</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_OScbop6D_EyFbi9oWinyQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TangibleAssetImpairmentCharges" scale="3" id="Tc_cBzCXWyopECfPMVBc_bCRQ_4_15">6,300</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the second quarter of Fiscal 2023, the Company re-evaluated its business strategy and reviewed its product portfolio. After such review, the Company identified intellectual property, patent and licenses that would no longer be utilized and therefore were fully impaired (Level 3). &#160;See Note 12 &#8211; Intangible Assets for additional information.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="ibio:SignificantTransactionsTextBlock" id="Tb_I9DG71wPZUW0G9l5TM2FcA" continuedAt="Tb_I9DG71wPZUW0G9l5TM2FcA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">6.   Significant Transactions </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Affiliates of Eastern Capital Limited</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 1, 2021, the Company and its subsidiary, iBio CDMO (&#8220;iBio CDMO&#8221;, and collectively with the Company, the &#8220;Purchaser&#8221;) entered into a series of agreements (the &#8220;Transaction&#8221;) with College Station Investors LLC (&#8220;College Station&#8221;), and Bryan Capital Investors LLC (&#8220;Bryan Capital&#8221; and, collectively with College Station, &#8220;Seller&#8221;), each affiliates of Eastern Capital Limited (&#8220;Eastern,&#8221; a former significant stockholder of the Company) described in more detail below whereby in exchange for a certain cash payment and a warrant the Company:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acquired both the Facility where iBio CDMO at that time and currently conducts business and also the rights as the tenant in the Facility&#8217;s ground lease;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acquired all of the equity owned by one of the affiliates of Eastern in the Company and iBio CDMO; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(iii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">otherwise terminated all agreements between the Company and the affiliates of Eastern.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Facility is a life sciences building located on land owned by the Board of Regents of the Texas A&amp;M University System (&#8220;Texas A&amp;M&#8221;) and is designed and equipped for the manufacture of plant-made biopharmaceuticals. iBio CDMO had held a sublease for the Facility through 2050, subject to extension until 2060 (the &#8220;Sublease&#8221;) until the purchase of the Facility described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The Purchase and Sale Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 1, 2021, the Purchaser entered into a Purchase and Sale Agreement (the &#8220;Purchase and Sale Agreement&#8221;) with the Seller pursuant to which: (i) the Seller sold to Purchaser all of its rights, title and interest as the tenant in the Ground Lease Agreement (the &#8220;Ground Lease Agreement&#8221;) that it entered into with Texas A&amp;M (the &#8220;Landlord&#8217;&#8217;) related to the property at which the Facility is located together with all improvements pertaining thereto (the &#8220;Property&#8221;), which previously had been the subject of the Sublease; (ii) the Seller sold to Purchaser all of its rights, title and interest to any tangible personal property owned by Seller and located on the Property including the Facility; (iii) the Seller sold to Purchaser all of its rights, title and interest to all licensed, permits and authorization for use of the Property; and (iv) College Station and iBio CDMO terminated the Sublease. The total purchase price for the Property, the termination of the Sublease and other agreements among the parties, and the equity described below is $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_p-vKhEHGAUG72E1kGh9gmg" decimals="0" format="ixt:numdotdecimal" name="ibio:PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest" scale="0" id="Narr_c35m5Rq9hUmL7KGY2l9mag">28,750,000</ix:nonFraction>, which was paid $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_0-dXyj2LIE2MJCZBHgv0hw" decimals="0" format="ixt:numdotdecimal" name="ibio:PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment" scale="0" id="Narr_wyXaGY1hj0-jbxEUk5urmg">28,000,000</ix:nonFraction> in cash and by the issuance to Seller of warrants (the &#8220;Warrant&#8221;) described below. As part of the transaction, iBio CDMO became the tenant under the Ground Lease Agreement for the Property until 2060 upon exercise of available extensions. The base rent payable under the Ground Lease Agreement, which was $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_p-vKhEHGAUG72E1kGh9gmg" decimals="0" format="ixt:numdotdecimal" name="ibio:FairMarketValueOfProperty" scale="0" id="Narr_SE3oJopWBUy2AkE-Yjvbkw">151,450</ix:nonFraction> for the current year, is <ix:nonFraction unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg" contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_0-dXyj2LIE2MJCZBHgv0hw" decimals="3" format="ixt:numdotdecimal" name="ibio:BaseRentPercentageOfFairMarketValueOfProperty" scale="-2" id="Narr_7eNyzIYL5UiqlVXsUtGP9A">6.5</ix:nonFraction>% of the Fair Market Value (as defined in the Ground Lease Agreement) of the Property. The Ground Lease Agreement includes various covenants, indemnities, defaults, termination rights, and other provisions customary for lease transactions of this nature.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As discussed above, iBio CDMO is being accounted for as a discontinued operation. &#160;As such, the assets acquired and/or leased are now classified as assets held for sale on the March&#160;31,&#160;2023 and June&#160;30,&#160;2022 condensed consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The Equity Purchase Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company also entered into an Equity Purchase Agreement with Bryan Capital on November 1, 2021 (the &#8220;Equity Purchase Agreement&#8221;) pursuant to which the Company acquired for $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_0-dXyj2LIE2MJCZBHgv0hw" decimals="0" format="ixt:numdotdecimal" name="ibio:EquityAgreementConsiderationTransferredEquityInterestsAcquired" scale="0" id="Narr_VZMHv9wYW0mXMudRrP9VVw">50,000</ix:nonFraction> cash, plus the Warrant, the <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="Duration_11_1_2021_To_11_1_2021_dei_LegalEntityAxis_ibio_IbioCmoPreferredTrackingStockMember_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_Fd00xECGqUS_feybjJADgA" decimals="INF" format="ixt-sec:numwordsen" name="ibio:EquityAgreementWarrantsIssuedOrIssuable" scale="0" id="Narr_Dbujxdiw_kqusUM3gFSIpA">one</ix:nonFraction> (1) share of iBio CMO Preferred Tracking Stock and the <ix:nonFraction unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg" contextRef="Duration_11_1_2021_To_11_1_2021_dei_LegalEntityAxis_ibio_IbioCmoPreferredTrackingStockMember_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_Fd00xECGqUS_feybjJADgA" decimals="4" format="ixt:numdotdecimal" name="ibio:EquityAgreementPercentageOfEquityInterestIssuedOrIssuable" scale="-2" id="Narr_0uqWqpHSz0eTcbhtKXxulA">0.01</ix:nonFraction>% interest in iBio CDMO owned by Bryan Capital. As a result, iBio CDMO is now a wholly-owned subsidiary of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The Credit Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the Purchase and Sale Agreement, iBio CDMO entered into a Credit Agreement, dated November 1, 2021, with Woodforest pursuant to which Woodforest provided iBio CDMO a $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_jDRo_Tn2dEiaxaJsfTrTaQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_HuC1-zR7xku2xtT4c6UXkw">22,375,000</ix:nonFraction> secured term loan to purchase the Facility, which Term Loan is evidenced by a term note. The term loan was advanced in full on the closing date. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">See Note 13 &#8211; Debt for further information of the Term Loan.</p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_510a9d62_c474_4755_bd29_abe8ac2e0e02"></a><a id="Tc_Ly_4CDDyBEulELC7BWBKDw_1_0"></a><a id="Tc_vAx4vycQ60OHr8wtaIhIMg_1_1"></a><a id="Tc_9x9Mlze6LkWVrsb38PVkVw_1_2"></a><a id="Tc_t92ooBgU90WRxuuo2Y1P6g_2_0"></a><a id="Tc_1mwHeVWqQEa2opYMa9qJNw_3_0"></a><a id="Tc_GG23qJudZU6qMqE3ojRigA_3_1"></a><a id="Tc_YTx5Vp5OqEOmQk8ZBnIB3Q_4_1"></a><a id="Tc_1mEvqKuGM0Ghn4aeNwYLUw_4_2"></a><ix:continuation id="Tb_I9DG71wPZUW0G9l5TM2FcA_cont1" continuedAt="Tb_I9DG71wPZUW0G9l5TM2FcA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The Warrant</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As part of the consideration for the purchase and sale of the rights set forth above, the Company issued to Bryan Capital a Warrant to purchase <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_p-vKhEHGAUG72E1kGh9gmg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_IKmk-eOCj0Snmgruk4OxVQ">51,583</ix:nonFraction> shares of the Common Stock at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_p-vKhEHGAUG72E1kGh9gmg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_pwVB13hfPkG3orWZJeAxSg">33.25</ix:nonFraction> per share. The Warrant expires October 10, 2026, is exercisable immediately, provides for a cashless exercise at any time and automatic cashless exercise on the expiration date if on such date the exercise price of the Warrant exceeds its fair market value as determined in accordance with the terms of the Warrant and adjustments in the case of stock dividends and stock splits. Of the shares issued under the Warrant, <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_0-dXyj2LIE2MJCZBHgv0hw" decimals="INF" format="ixt:numdotdecimal" name="ibio:WarrantsIssuedForFinalPaymentOfSubleaseRent" scale="0" id="Narr_r4MaBUzh0EK8GRDq1mfJ7g">11,583</ix:nonFraction>, which were originally valued at $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_p-vKhEHGAUG72E1kGh9gmg" decimals="0" format="ixt:numdotdecimal" name="ibio:WarrantsIssuedForFinalPaymentOfSubleaseRentValue" scale="0" id="Narr_CLMuDV2410mw6hlmw0-Esw">217,255</ix:nonFraction>, reflected the final payment of rent due under the Sublease. The Warrant, as shown on the condensed consolidated statements of equity, was recorded in additional paid-in capital with the corresponding activity included in the basis of the purchase price allocation of the Property acquired. &#160;See Note 16 &#8211; Stockholders&#8217; Equity for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">RubrYc</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On August 23, 2021, the Company entered into a series of agreements with RubrYc Therapeutics, Inc. (&#8220;RubrYc&#8221;) described in more detail below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Collaboration and License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company entered into a collaboration and licensing agreement (the &#8220;RTX-003 License Agreement&#8221;) with RubrYc to further develop RubrYc&#8217;s immune-oncology antibodies in its RTX-003 campaign. &#160;Under the terms of the agreement, the Company is solely responsible for worldwide research and development activities for development of the RTX-003 antibodies for use in pharmaceutical products in all fields<span style="color:#0000ff;">. &#160;</span>RubrYc was also entitled to receive royalties in the mid-single digits on net sales of RTX-003 antibodies, subject to adjustment under certain circumstances. The RTX-003 License Agreement was terminated when the Company acquired substantially all of the assets of RubrYc in September 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Collaboration, Option and License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company entered into an agreement with RubrYc (the &#8220;Collaboration, Option and License Agreement&#8221;) to collaborate for up to <ix:nonNumeric contextRef="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_us-gaap_TypeOfArrangementAxis_ibio_CollaborationOptionAndLicenseAgreementMember_ajEqmB0rDEiBS1559tP2SQ" format="ixt-sec:durwordsen" name="ibio:CollaborationAndLicenseAgreementAgreementTerm" id="Narr_LucSxRjHIUaXli40Nremaw">five years</ix:nonNumeric> to discover and develop novel antibody therapeutics using RubrYc&#8217;s artificial intelligence discovery platform. The Company agreed to pay RubrYc for each Selected Compound as it achieves various milestones in addition to royalties if the Selected Compounds are commercialized. &#160;RubrYc was also entitled to receive tiered royalties ranging from low- to mid-single digits on net sales of Collaboration Products, subject to adjustment under certain circumstances. Royalties are payable on a country-by-country and collaboration product-by-collaboration product basis until the latest to occur of: (i) the last-to-expire of specified patent rights in such country; (ii) expiration of marketing or regulatory exclusivity in such country; or (iii) <span style="-sec-ix-hidden:Hidden_oSXmWjkN2kiwoY8AqAXFYw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ten</span></span> (10) years after the first commercial sale of a product in such country, provided that no biosimilar product has been approved in such country. &#160;With the exception of any obligations that survive the termination, the Collaboration, Option and License Agreement was terminated when the Company acquired substantially all of the assets of RubrYc in September 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 4.5pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock Purchase Agreement </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;padding-bottom:10pt;text-align:justify;margin:0pt;">In connection with the entry into the Collaboration, Option and License Agreement and RTX-003 License Agreement, the Company also entered into a Stock Purchase Agreement (&#8220;Stock Purchase Agreement&#8221;) with RubrYc whereby the Company purchased a total of <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_us-gaap_StatementClassOfStockAxis_ibio_Series2PreferredStockMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementMember_YCIyuJUGskWd66faz53YYA" decimals="INF" format="ixt:numdotdecimal" name="ibio:StockPurchaseAgreementNumberOfSharesPurchased" scale="0" id="Narr_PF3bV4dPpEGw5Fx2T7XsJQ">2,864,345</ix:nonFraction> shares of RubrYc&#8217;s Series A-2 preferred stock (&#8220;Series A-2 Preferred&#8221;) for $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_us-gaap_StatementClassOfStockAxis_ibio_Series2PreferredStockMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementMember_YCIyuJUGskWd66faz53YYA" decimals="0" format="ixt:numdotdecimal" name="ibio:StockPurchaseAgreementValueOfSharesPurchased" scale="0" id="Narr_tdFTjayjfkyxFwaWSgVYpg">7,500,000</ix:nonFraction>. </p><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_AssetAcquisitionAxis_ibio_StockPurchaseAgreementMember_3-07kxSNOkaDZSJYQDyQdQ" name="us-gaap:AssetAcquisitionTableTextBlock" id="Tb_THO5zO_xZUe_EXmMFNHfAA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">The Company accounted for the agreements as an asset purchase and allocated the purchase price of $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_8_23_2021_To_8_23_2021_HiZIlu8ubEeyewTLP3230g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="0" id="Narr_ZkhmKvNjrUqSSaxOMOAAJQ">7,500,000</ix:nonFraction> as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:74.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:17.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:74.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Preferred stock</p></td><td style="vertical-align:middle;width:4.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:4.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:17.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_8_23_2021_To_8_23_2021_ibio_AssetAcquisitionAxis_ibio_Series2PreferredStockMember_us-gaap_AssetAcquisitionAxis_ibio_Series2PreferredStockMember_VOoG9DcOHkek5MqvabkkeA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="0" id="Tc_5cOdzhs_RUmDKqNo9aeW8A_1_3">1,760,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:74.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Intangible assets</p></td><td style="vertical-align:middle;width:4.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_8_23_2021_To_8_23_2021_ibio_AssetAcquisitionAxis_us-gaap_FiniteLivedIntangibleAssetsMember_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionIntangibleAssetsMember__yJ7v5TK2km2wwhoqTq5Cw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="0" id="Tc_t4cXIBNH20uALgAFeBypBQ_2_3">4,300,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:74.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid expenses</p></td><td style="vertical-align:middle;width:4.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:4.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_8_23_2021_To_8_23_2021_ibio_AssetAcquisitionAxis_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionPrepaidExpensesMember_ZiSAVMfDE0OuOIvWRTPOkA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="0" id="Tc_VqpN7vCtn0mlyM0vbHOrsw_3_3">1,440,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:74.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:4.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:17.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_8_23_2021_To_8_23_2021_HiZIlu8ubEeyewTLP3230g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="0" id="Tc_jrIfCXwOCEKhkr6nSyrQvg_4_3">7,500,000</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Subsequently after the Company acquired substantially all of the assets of RubrYc in September 2022, RubrYc ceased its operations, and accordingly, the Company recorded an impairment of the investment in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_6_30_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_us-gaap_StatementClassOfStockAxis_ibio_Series2PreferredStockMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementMember_GiIiWNIPGEib_sv1KnwHFw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfInvestments" scale="0" id="Narr_Fvww1RpDzkem6ij8dpmcgA">1,760,000</ix:nonFraction> during the year ended June 30, 2022. The amount was recorded in the condensed consolidated statement of operations and comprehensive loss under general and administrative expense. The Company also recorded an impairment of current and non-current prepaid expense of $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_6_30_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_us-gaap_StatementClassOfStockAxis_ibio_Series2PreferredStockMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementMember_GiIiWNIPGEib_sv1KnwHFw" decimals="0" format="ixt:numdotdecimal" name="ibio:ImpairmentOfPrepaidExpensesCurrent" scale="0" id="Narr_mFjSXLYA4UepuFAdsQn9ww">288,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_6_30_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_us-gaap_StatementClassOfStockAxis_ibio_Series2PreferredStockMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementMember_GiIiWNIPGEib_sv1KnwHFw" decimals="0" format="ixt:numdotdecimal" name="ibio:ImpairmentOfPrepaidExpensesNonCurrent" scale="0" id="Narr_tMeA9GimhEevEGsKbe8y4A">864,000</ix:nonFraction>, respectively, during the year ended June 30, 2022. The amount was recorded in the condensed consolidated statement of operations and comprehensive loss under research and development expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_7920b4be_edc0_4f66_92f3_6bf7c9890f36"></a><a id="Tc_-ZmbcfYz2Eyp0W7ssw7GYQ_1_0"></a><a id="Tc_EwyL5FVzukaAPTwoV8xfGA_1_1"></a><a id="Tc_50uJs9ZjsE67W0c1GnOngw_1_2"></a><a id="Tc_cEy0BnrvZUml2QuTIW1CSA_2_0"></a><a id="Tc_CeeiFpXpf06hpmbo0awEwg_2_1"></a><a id="Tc_aec_8eX65kmvKJYuJwB56A_3_1"></a><a id="Tc_lfNuUdDPFEakfGGLrARJ1g_3_2"></a><ix:continuation id="Tb_I9DG71wPZUW0G9l5TM2FcA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 16, 2022, the Company entered an Asset Purchase Agreement with RubrYc pursuant to which it acquired substantially all of the assets of RubrYc. &#160;The Company issued <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="Duration_9_19_2022_To_9_19_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_wXZQoYO-rEO6uGxtBLB7Ag" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="Narr_vPqpfdpcl0q76nU-8R49gQ">102,354</ix:nonFraction> shares of the Common Stock to RubrYc with an approximate market value of $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_9_19_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_8ARQ_UpEmkSNVg45b4FndQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="Narr_G_ehDlbqSUmAZijeIzvmIw">1,000,000</ix:nonFraction> (the &#8220;Closing Shares&#8221;). Pursuant to the Asset Purchase Agreement, the shares are subject to an initial lockup period and the estimated fair value was calculated as $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_xGREzJg85k2rOyE5lH-V2A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Narr_f0pDy_8eFE26JeGv8CspZQ">650,000</ix:nonFraction>. The Company also agreed to make potential additional payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_9_19_2022_To_9_19_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_wXZQoYO-rEO6uGxtBLB7Ag" decimals="0" format="ixt:numdotdecimal" name="ibio:CollaborativeArrangementMilestonePayments" scale="0" id="Narr_x6FByO4HAkGC_GEynDvp-w">5,000,000</ix:nonFraction> upon the achievement of specified developmental milestones on or before the fifth anniversary of the closing date, payable in cash or shares of the Common Stock, at the Company&#8217;s option. In addition, the Company had advanced RubrYc $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_9_16_2022_To_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_QdOFAORoNkObDq7whbxqtQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForAdvanceToAffiliate" scale="3" id="Narr_UXrcC-Kf-0u5gQ8yxwv86A">484,000</ix:nonFraction> to support their operation costs during the negotiation period and incurred transaction costs totaling $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_9_16_2022_To_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_QdOFAORoNkObDq7whbxqtQ" decimals="0" format="ixt:numdotdecimal" name="ibio:AssetAcquisitionTransactionCosts" scale="3" id="Narr_D9bsrdWi3UqNuAqjy0ifew">208,000</ix:nonFraction>, which were also capitalized as part of the assets acquired. &#160;The assets acquired include the patented AI drug discovery platform, all rights with no future milestone payments or royalty obligations, to IBIO-101, in addition to CCR8, EGFRvIII, MUC16, CD3 and one additional immuno-oncology candidate plus a PD-1 agonist. The Purchase Agreement contained representations, warranties and covenants of RubrYc and the Company. &#160;The acquisition closed on September 19, 2022 after receipt of approval of the NYSE American.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_AssetAcquisitionAxis_ibio_AssetPurchaseAgreementMember_W13nwak_50mao3LDEg0jzw" name="us-gaap:AssetAcquisitionTableTextBlock" id="Tb_QNviURTzA0Ka3CzH1HjRBg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">The Company accounted for the agreements as an asset purchase and allocated the purchase price of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_9_16_2022_To_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_QdOFAORoNkObDq7whbxqtQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="0" id="Narr_iZw4Mx31nEyk1lBs0PJeRA">1,342,000</ix:nonFraction> as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:74.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:17.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:74.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible assets</p></td><td style="vertical-align:middle;width:4.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:4.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:17.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_9_16_2022_To_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionIntangibleAssetsMember_yQ9fxKqDbkGLPQucgu0SgA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="0" id="Tc_H8d0HaEcZkyMb7uXzNLkGg_1_3">1,228,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:74.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fixed assets</p></td><td style="vertical-align:middle;width:4.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:4.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_9_16_2022_To_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionFixedAssetsMember_vLthqkkiPEekVSsXm4z-Wg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="0" id="Tc_QgTrzYdDfUObgDu6tU-O2A_2_3">114,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:74.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:4.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:17.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_9_16_2022_To_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_QdOFAORoNkObDq7whbxqtQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="0" id="Tc_XsGkA4D-Lki2Nl0gmrumZw_3_3">1,342,000</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, the Company assumed three equipment leases that were accounted for as finance leases totaling approximately $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementMember_k1dUagvh-06HXU6xBQefUQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiability" scale="0" id="Narr_fLAbKmyBLkGYM6q62vsaRw">814,000</ix:nonFraction>. &#160;See Note 9 &#8211; Finance Lease ROU Assets and Note 14 &#8211; Finance Lease Obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Former CEO Departure</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Effective December 1, 2022, the Company and Mr. Thomas F. Isett, the former Chief Executive Officer (the &#8220;CEO) and former member of the Board of Directors (the &#8220;Board&#8221;), agreed for Mr. Isett to resign as a member of the Board and relinquish his duties, rights and obligations as the CEO of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Separation Agreement and General Release </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">In connection with Mr. Isett&#8217;s resignation, the Company entered into a separation agreement and general release with Mr. Isett effective December 1, 2022 (the &#8220;Agreement&#8221;). &#160;Pursuant to the Agreement, Mr. Isett resigned as CEO of the Company effective December 1, 2022, and will remain an employee of the Company until December 31, 2022, on which date his employment with the Company will automatically terminate. &#160;Following Mr. Isett&#8217;s termination of employment with the Company, pursuant to the Agreement, Mr. Isett will receive the severance benefits set forth in his employment agreement, as previously disclosed by the Company, including (i) an amount equal to his current base salary in equal bi-monthly installments for <span style="-sec-ix-hidden:Hidden_H20oJhWZMkiyeILxAMoOWg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">twenty-four</span></span> (24) months; (ii) an amount equal to a pro rata share of his target bonus for the current fiscal year; (iii) an amount equal to the target bonus in equal bi-monthly installments for the <span style="-sec-ix-hidden:Hidden_3XETezoZoE2Gln_IFI6pTg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">twenty-four</span></span> (24) month severance period and (iv) provided that he elects continuation coverage for health insurance under the Consolidated Omnibus Budget Reconciliation Act of 1985 (&#8220;COBRA&#8221;), the Company will pay the full cost of this benefit for up to <span style="-sec-ix-hidden:Hidden_YRBOV4wB5E2sgYw7SZXbjg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">eighteen</span></span> (18) months, or if he has not obtained alternative employer-provided health coverage by the end of the <span style="-sec-ix-hidden:Hidden_eUgWy76apU6hIb4U9tpWXg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">eighteen</span></span> (18) month COBRA subsidy period, the Company will provide him with a lump-sum cash payment equal to <ix:nonFraction unitRef="Unit_Standard_item_ITzkWC4v7UGBZiwOGBFemw" contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_7N6sRqj9kEWZRTEMclg2yA" decimals="INF" format="ixt-sec:numwordsen" name="ibio:SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct" scale="0" id="Narr_g0ndatGlE0Ki-cfkEHQ3rQ">six</ix:nonFraction> (6) times the monthly amount paid by the Company for the COBRA subsidy. &#160;The Agreement includes a general release of claims by Mr. Isett. &#160;The Company accrued approximately $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_7N6sRqj9kEWZRTEMclg2yA" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="Narr_3JCmJT_BBkyazUcvFSNifA">2.13</ix:nonFraction> million to general and administrative expenses in the second quarter of Fiscal 2023. As of March 31, 2023, approximately $1.1 million is recorded in accrued expenses and $791,000 in accrued expenses &#8211; noncurrent. </p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" id="Tb_Ef67qn-mQEWTXAhKiIfGgA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">7.&#160;&#160;&#160;Convertible Promissory Note Receivable </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On October 1, 2020, the Company entered into a master services agreement with Safi Biosolutions, Inc. (&#8220;Safi&#8221;). In addition, the Company invested $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_10_1_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_VyVmxesCq0KMm1BWB8Egcw" decimals="-5" format="ixt:numdotdecimal" name="ibio:LoansReceivableAmountInvested" scale="6" id="Narr_2sXQ1GcXUkiNLJRRWnMgjQ">1.5</ix:nonFraction> million in Safi in the form of a convertible promissory note (the &quot;Note&quot;). The Note bears interest at the rate of <ix:nonFraction unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg" contextRef="Duration_10_1_2020_To_10_1_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_zTgxHY80r0C6Oan6do8BOw" decimals="2" format="ixt:numdotdecimal" name="ibio:LoansReceivableFixedRatesOfInterest" scale="-2" id="Narr_s9yp0QZHnUe6UPPLoZgF5Q">5</ix:nonFraction>% per annum and is convertible into shares of Safi&#8217;s common stock (as defined). Principal and accrued interest mature on October 1, 2023. &#160;For the three months ended March&#160;31,&#160;2023 and 2022, interest income amounted to $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_AXcDgcQQBEGgUeelykng1A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="Narr_vZ2jtgBZX0i-APs96KuMBg"><ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_3ufJCLpgP0Khx5n03TYFHw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="Narr_0DR1Rpk9zEKYvrlHxDU3ZA">18,000</ix:nonFraction></ix:nonFraction>. For the nine months ended March&#160;31,&#160;2023 and 2022, interest income amounted to $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_7hfM841DCUy3t_UYmcPmTA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="Narr_mLocBu93u0ybE0Cwm4xE-A"><ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_WSwD-_QeQUyXYX-UiYDXDA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="Narr_6W0Vcb1UBkCyI8Y_K67yxw">56,000</ix:nonFraction></ix:nonFraction>. As of March&#160;31,&#160;2023 and June&#160;30,&#160;2022, the Note balance and accrued interest totaled $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_1HkfNu-AM0mxZ7COThJZjg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesAndLoansReceivableNetNoncurrent" scale="0" id="Narr_0stJSXljr0OYE6WiXtdCqA">1,687,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_gf874UKLE0GViq4jrr0myw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesAndLoansReceivableNetNoncurrent" scale="0" id="Narr_5eSMpjQiR0CM01qBVLpSbQ">1,631,000</ix:nonFraction>, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company is currently renegotiating the terms of the Note with Safi, which are expected to be finalized in the fourth quarter of Fiscal 2023. &#160;Proceeds expected to be received in the next twelve months are approximately $912,000 and accordingly, $775,000 has been classified to long term.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b3aa3e97_bcf0_437c_bcc9_201d17d46763"></a><a id="Tc_i5PvlYBcBEmMdMECIpdcVw_1_2"></a><a id="Tc_Yhgy2sc8bkul0Ezv2RDyKg_1_5"></a><a id="Tc_55OgNvZrBkebKhFd-q0j6g_2_2"></a><a id="Tc_MMhSi4-tgUuthLnGKbLuQw_2_5"></a><a id="Tc_To_2fBVNVUiTC6rVczEX8w_3_0"></a><a id="Tc_hD99MqJFVUaRQ94l0w-u5A_3_1"></a><a id="Tc_CwPWNmHOU0mXG2AU3KQulA_3_2"></a><a id="Tc_ySyuxOx6hEim_wVNAolAzQ_3_3"></a><a id="Tc_wXW0AxRgJEGAXLnkpTSWAA_3_5"></a><a id="Tc_ivlMh1Qzv0e-BI8nP-EjDw_4_0"></a><a id="Tc_lEcGEpPIXEae61XOt7Pxxw_4_1"></a><a id="Tc_noBY5ag9REWxmGIUFYJxfg_4_3"></a><a id="Tc_Noa0_u7G-EecaeDdiCXOrA_5_0"></a><a id="Tc_nBieTJiN1UGGnLuV8IGz1A_5_1"></a><a id="Tc_gZ9_ID0SuU6bMEgrXcPbfg_5_2"></a><a id="Tc_QGWN6F4jmkqq5Xb9sVmcxg_5_3"></a><a id="Tc_Lw-PhBhVCUSLZzdly68NQw_5_5"></a><a id="_baf04a13_255f_46b1_ba8a_feaaeef4ab79"></a><a id="Tc_XT1zGOgeZEyEFTBfQEYL9w_1_2"></a><a id="Tc_PQ392wWzm0iUuFsXsEQhJg_1_5"></a><a id="Tc_c-vrZXLt_E6YO6VSmicSdw_2_0"></a><a id="Tc_zUFc13DctUyCfiWjKI2VsA_2_1"></a><a id="Tc_p-13tFn8106dKGMFIZofHA_2_2"></a><a id="Tc_l3Nako53tEWj7jdF7Rsu2Q_2_5"></a><a id="Tc_d9h-wXtBQEyr3iwY9eW1DA_3_0"></a><a id="Tc_MjMzBnqHakG6tHlX-4_4ZA_3_1"></a><a id="Tc_X9t6xfJc10eAmMnotwZpCw_3_2"></a><a id="Tc_qPPWP5Kez0-Izi_oXHeOpQ_3_3"></a><a id="Tc_3Sh-1xd5vk6PG1ZxBHoeNg_3_5"></a><a id="Tc_LgG7AqaYo0CH8ZwMJH0Rfg_4_0"></a><a id="Tc_N6Rm4YuQ-E-7nWalixj-0Q_4_3"></a><a id="Tc_63Fv9JDQzESUWQq23EJF8w_5_1"></a><a id="Tc_jU85fYJ-2UCJ3RQ19-QeFA_5_2"></a><a id="Tc_abiJtzUKBEWNqbMv0HlrUg_5_3"></a><a id="Tc_E0mHyGnBZkaRbHtdStTWRg_5_5"></a><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="Tb_DXSGjOiLakGW3cX2lxBW4w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">8.&#160;&#160;&#160;Investments in Debt Securities </p><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="Tb_9YYy015_hUyeosoAaZQrzw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company did not hold any investments in debt securities at March 31, 2023. The components of investments in debt securities are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:58.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:16.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:58.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Adjusted cost</p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:16.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_ig0Kbjcg5UaWjbTb_SxfMg_3_6">11,029</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:58.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Gross unrealized losses</p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_N2vdO0cxTU-lHyJs0D3WAQ_4_6">184</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:58.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Fair value</p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:16.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesCurrent" scale="3" id="Tc_1F_uO6gXC06SrX47LOvydg_5_6">10,845</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="Tb_6oFlvpvV-0u64XdiVcugDQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The fair value of available-for-sale debt securities, by contractual maturity, was as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:59.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:15.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Fiscal period ending:</b></p></td><td style="vertical-align:middle;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:59.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2023</p></td><td style="vertical-align:middle;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:15.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" scale="3" id="Tc_nkkYPyQxd06aHTAvp5jj2w_3_6">8,054</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:59.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2024</p></td><td style="vertical-align:middle;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" scale="3" id="Tc_xl3-0FThQ0merF-UPWMbJQ_4_6">2,791</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:59.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:15.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesCurrent" scale="3" id="Tc_czerRu9kwE64lHYgALZrjQ_5_6">10,845</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Amortization of premiums paid on the debt securities amounted to $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="0" id="Narr_0VHYOx-KL0O59hepQipT3Q">7,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="0" id="Narr_B7raERMHkk-8rKsBAGDgWA">74,000</ix:nonFraction> for the three months ended March&#160;31,&#160;2023 and 2022, respectively, and $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="0" id="Narr__7yyJg5AOUewT-eMwV2CXg">67,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="0" id="Narr_nRWfrlf-mEy6yTti8e80mA">269,000</ix:nonFraction> for the nine months ended March 31, 2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="ibio:AvaliableForSaleDebtSecuritiesRealizedGainsLossesTableTextBlock" id="Tb_wSknUKOhaUOvu2vrPEiPXA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Realized gains on available-for-sale debt securities are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Proceeds from sale of debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,943</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Cost of debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,036</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Realized loss on sale of debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (93)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Proceeds from sale of debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,739</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Cost of debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,837</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Realized loss on sale of debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (98)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="ibio:FinanceLeaseRightOfUseAssetDisclosureTextBlock" id="Tb_l6QJ4jhuAUSvf0rCP8bgFA" continuedAt="Tb_l6QJ4jhuAUSvf0rCP8bgFA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">9.&#160;&#160;&#160;Finance Lease ROU Assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As discussed above, the Company assumed three equipment leases as part of the RubrYc asset acquisition. &#160;In addition, the Company leased a mobile office trailer which is classified as part of assets held for sale. &#160;The lease was terminated in December 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">See Note 14 &#8211; Finance Lease Obligations for more details of the terms of the leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_af606e7e_a5ff_4638_b67a_c1940e015287"></a><a id="Tc_CPY4XaPZ2EmuNY3i-1YbVA_1_2"></a><a id="Tc_cr5J0dxRTEiNTA03hHI5VA_1_5"></a><a id="Tc_LiJ7etncvUy_k6sUk9okOQ_2_2"></a><a id="Tc_WxLsuAE_MEeL3tn3VwaHQQ_2_5"></a><a id="Tc_SC9E9RG_mkOKtVSUsP0rbw_3_0"></a><a id="Tc_JzXCpA-hskmzrENKCw602A_3_2"></a><a id="Tc_jbtugi3MhUeVukQ2sartSw_3_5"></a><a id="Tc_RiNSpHGohE-NJMhhTGL6iQ_3_6"></a><a id="Tc_eHKvjOJqyUejbvynzd2oQQ_4_0"></a><a id="Tc_Irrst77vW0CkFHU5gNNbdg_4_6"></a><a id="Tc_-cQxwFb3SkWmlAWKZOSahA_5_0"></a><a id="Tc_mkFwnCgf3EKqhtF8qIXZtw_5_2"></a><a id="Tc_HK47tw4eRU6z9G80manUpw_5_5"></a><a id="Tc_IaXMYv8UoUGK_B8qn4K8UQ_5_6"></a><ix:continuation id="Tb_l6QJ4jhuAUSvf0rCP8bgFA_cont1"><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="ibio:SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock" id="Tb_kfzKjlcBOUSRyqLvbwAcUg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes by category the gross carrying value and accumulated amortization of finance lease ROU (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ROU - Equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ibio_FacilityMember_K0EB_c8dT0OHjVuRMWJAdA" decimals="-3" format="ixt:numdotdecimal" name="ibio:FinanceLeaseRightOfUseAssetGross" scale="3" id="Tc_GFeo5LTQ_UWht7BCE8FuXw_3_3">814</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" scale="3" id="Tc_7RHg-X7zJkKzU1FV6q0yhA_4_3">136</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net finance lease ROU</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="Tc_FI826uy3KUO-m9EixjDxWA_5_3">678</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Amortization of finance lease ROU assets was approximately $68,000 and $0 for the three months ended March&#160;31,&#160;2023 and 2022, respectively, and $136,000 and $0 for the nine months ended March&#160;31,&#160;2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="ibio:OperatingLeaseRightOfUseAssetDisclosureTextBlock" id="Tb_uGtKOkXz2EuS2MIqLh385Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">10.&#160;&#160;&#160;Operating Lease ROU Assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">San Diego, California</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 10, 2021, the Company entered into a lease for approximately <ix:nonFraction unitRef="Unit_Standard_sqft_3kWp_fWhaEWbENPWsKzOnw" contextRef="As_Of_9_10_2021_fOp8nNM7xESd6X0-jbcuDQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="Narr_B846z8ldt0iIgq9_ETtgSA">11,383</ix:nonFraction> square feet of space in San Diego, California. &#160;Based on the terms of the lease payments, the Company recorded an operating lease ROU asset of $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_9_10_2021_fOp8nNM7xESd6X0-jbcuDQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Narr_hsRo-_cZI0K_ZlEzy--RaQ">3,603,000</ix:nonFraction>. &#160;The net carrying amount of this ROU operating lease asset was <span style="-sec-ix-hidden:Hidden_iQoKre6X4UGSKRq8g3fedQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$2,798,000</span></span> and $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Narr_bZZlgiZPOUashncbb3B9CQ">3,068,000</ix:nonFraction> at March&#160;31,&#160;2023 and June&#160;30,&#160;2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Bryan, Texas</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On November 1, 2021, as discussed above, iBio CDMO acquired the Facility and became the tenant under the ground lease for the Property upon which the Facility is located. Based on the terms of the lease payments, the Company recorded an operating lease ROU asset of $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_11_1_2021_klJV-onJz0KrNHSyhYX8GA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Narr_FHQXFrY2cEWRg4s83-4ybg">1,967,000</ix:nonFraction>. The net amount of this ROU operating lease asset is included in assets held for sale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> &#160; &#160;<span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">See Note 15 - Operating Lease Obligation for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_57b3f682_4a22_4370_9ff9_eb8f23d1d182"></a><a id="Tc_cgHk1sU58Eq8Rn4mRjUJOg_1_2"></a><a id="Tc_13fn_O4cEEqqv_EZFdpTeQ_1_5"></a><a id="Tc_M-6bk83PHU-M41hlu8CwuA_2_2"></a><a id="Tc_tmw93gdhwUyF-amKysFXCg_2_5"></a><a id="Tc_YiAUjgh5nUeE22GH8mVUvg_4_0"></a><a id="Tc_JO1ZeqF8R0uW99mJJxlKCw_4_2"></a><a id="Tc_oMwcirh6L0GK8BffeBegwQ_4_5"></a><a id="Tc_ounatZbmfUStBEBGLqOhLQ_4_6"></a><a id="Tc_Po5f3E3L5UmTiBKPAThDNw_5_0"></a><a id="Tc_SKdc2Itcf0GT2qsSfgMTKQ_5_6"></a><a id="Tc_RSjwHKuQfkyCkmVOg1vsHg_6_0"></a><a id="Tc_eVth7K0Z4kuMjmzrCDISQw_6_6"></a><a id="Tc_hr4Hs6AdeUi5niS_yPTrdg_7_0"></a><a id="Tc_Jc2hWA4E8U2_7QWF7ZWrLw_9_0"></a><a id="Tc_O3PBB3jfq0Ke66JiWtSfsg_9_6"></a><a id="Tc_zZoJAWmmRkKh2Xit_UvKUg_10_0"></a><a id="Tc_ymQsarXi5UKotwBom6x6Yw_10_2"></a><a id="Tc_vAsk78IKDUqCALU__ObReQ_10_5"></a><a id="Narr_amX5M4MZW0e_zjFI-BSkgA"></a><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Tb_vdfruBHf60i889TOzr5V_Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11.&#160;&#160;&#160;Fixed Assets</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb_ugQyFffa7029J342EhdZ9Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes by category the gross carrying value and accumulated depreciation of fixed assets (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Building and improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_ThM6Q7i9IU-hcgFbdInU_Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_h9ZDwiArxk6xsONmYwVYLA_4_3">695</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:61.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Machinery and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_yqfA3UgBD0GxUlVv1J1aZg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_7P5Mdj-4b060qRMd-T9QWg_5_3">3,461</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Office equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_6QB18MmXqEK9CBa2yX9t0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_SJk8PlZhtEu91Wbft_dRwA_6_3">403</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:61.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Construction in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_lgu0RKVqRUy0scLhwVYi5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_KNEj4gqndk6MaN3GhChFbw_7_3">34</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_NSlKXkd1_ky6H3FWqPfqaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_zOkCdUCwTU-ovzBum4h9ZQ_7_6">1,373</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_xiWADLT9JUSXXhY4HnsmzA_8_3">4,593</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_1iUMKj_1fkeCO6sCPiXpTA_8_6">1,373</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_bjQnmRqB4UilTtedXHIJDg_9_3">235</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_ImyBH8dAYEOt_Kb8kn1tPQ_10_3">4,358</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_qwA0jErzF0uBmLsoKDs5Wg_10_6">1,373</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Depreciation expense reported in continuing operations was approximately $120,000 and $235,000 for the three and nine months ended March&#160;31,&#160;2023, respectively, and $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2022_-w0U61DdKUWU0kwbv1xmfg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" id="Narr_kJg3iZDObkyzV99IDY7Ngw"><ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2022_-w0U61DdKUWU0kwbv1xmfg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" id="Narr_ck2tWKIuOkS853pAMtmBsg">0</ix:nonFraction></ix:nonFraction> for both the three and nine months ended March&#160;31,&#160;2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Fixed assets held for sale at March&#160;31,&#160;2023 and June&#160;30,&#160;2022 in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="0" format="ixt:numdotdecimal" name="ibio:FixedAssetsHeldForSale" scale="0" id="Narr__5QW1rgNvECycQVQnZz5ug">16,424,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="0" format="ixt:numdotdecimal" name="ibio:FixedAssetsHeldForSale" scale="0" id="Narr_Rh7CKI_44UWqw4YXJwxXlg">35,289,000</ix:nonFraction>, respectively, are included in assets held for sale. &#160;The depreciation expense for the three months ended March&#160;31,&#160;2023 and 2022 and the nine months ended March&#160;31,&#160;2023 and 2022 is classified as part of loss from discontinued operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the third quarter of Fiscal 2023, the Company re-evaluated its business strategy and reviewed its product portfolio. After such review, the Company recorded an impairment charge of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TangibleAssetImpairmentCharges" scale="6" id="Narr_onZblSPmYUeP3OEbWSgLKQ">17.6</ix:nonFraction> million for the three and nine months ended March&#160;31,&#160;2023, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">See Note 5 - Financial Instruments and Fair Value Measurement for more information.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_5b04936d_c3ad_4c09_8985_f22a5bb0676d"></a><a id="Tc_TFlQ9ieolkydrqk_efdAuA_1_2"></a><a id="Tc_tT67cEfk90GhVOgnx4D3QQ_1_14"></a><a id="Tc_wZMl6Jq2iUOy2H52AV4oOw_2_2"></a><a id="Tc_qfVksBQV-0GCdR9HV6Bl-g_2_5"></a><a id="Tc_Yl3nAtrOT0OdtCy2ZDT01g_2_8"></a><a id="Tc_1dkD513dqEyKiqXI0ZwS4g_2_11"></a><a id="Tc_poZZk8UYGkSY2uHdwsoSog_2_14"></a><a id="Tc_P7CpSOfoCUSy2CQT-ZQ8Dg_3_0"></a><a id="Tc_C7acAThOjESfYoYGVeI50Q_3_2"></a><a id="Tc_s9mSbQu6LkKd9j7NHfKZ7A_3_5"></a><a id="Tc_xnesTDOyukGbkeqvi1g00w_3_6"></a><a id="Tc_R3XNNuLP9UqpiYFB5h_Jsw_3_8"></a><a id="Tc_0Nk-36mTFUqCIyzOlbAETw_3_11"></a><a id="Tc_wbAqQg0h6kOP554bo0p26Q_3_14"></a><a id="Tc_1JbjJmy3iE6n0pjb7X4UZg_4_0"></a><a id="Tc_Gn4Mck1m6UGfYPJn8iCk3g_4_6"></a><a id="Tc_Sui72GG45EqwX6Le16hAHQ_4_9"></a><a id="Tc_SoTwPrdVnku7OxQariYTiA_4_15"></a><a id="Tc_PmSbrNQX-0ewwTQboUDTmQ_5_6"></a><a id="Tc_dy6xVIgy7kOedsWykyggbw_6_0"></a><a id="Tc_GJMeKhzKJkmM7kEZi9iDqg_6_9"></a><a id="Tc_JiTwAkIrfk2ZiYcK7zfYCw_7_0"></a><a id="Tc_BA1Qs-l7JUq3fyl0SpC7vA_7_9"></a><a id="Tc_UPCEq2tm-E2f8bZ4k4-TYw_7_15"></a><a id="Tc_ktPMnr48W0qfjfJDzKSUYQ_8_9"></a><a id="Tc_g_hNVLjVBEWAkDaZTSMQ-w_9_0"></a><a id="Tc_TwZZTV5H7EK4d6gRpDsZVg_9_2"></a><a id="Tc_icDKOzHfTE2AHtV5aLVxqA_9_5"></a><a id="Tc_2OHm-yVk30aO3DuZdJHR_g_9_8"></a><a id="Tc_pt270A6_iEql_pycQbAV0w_9_11"></a><a id="Tc_8LDguzrY2kWZwfW4AN9d9A_9_14"></a><a id="Tc_G9j20_PwLUqhwkeWwLgddw_11_0"></a><a id="Tc_7fB5euSVCkCzARytPLZC3w_11_2"></a><a id="Tc_V_a2SORM1kSyICcIXIuvaQ_11_6"></a><a id="Tc_EqPbgF7j3UKhBHb6ZT_HrA_11_8"></a><a id="Tc_CXxRVerQg0yZtEZe_-D9Ng_11_12"></a><a id="Tc_WR--_kM730y0u5rkfLE97A_11_14"></a><a id="Tc_5IbX6sSPpUW1v63FSG56Cw_13_0"></a><a id="Tc_b6cx-LdhgU2hw_O0TZkGsQ_13_2"></a><a id="Tc_1rqtI69YxE2TWgWfskNGsQ_13_3"></a><a id="Tc_nMU9n1F4PUe_o0lObfSTBw_13_8"></a><a id="Tc_0JjaRnI-vU2iOvfa29WWgQ_13_9"></a><a id="Tc_dpSELJBWS0qFl_z8zYVaCA_13_14"></a><a id="Tc_BpALnKYGRUCsWpqJYjzrtA_13_15"></a><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="Tb_aB5KzA-dWkGaYz1o51HWhg" continuedAt="Tb_aB5KzA-dWkGaYz1o51HWhg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">12.&#160;&#160;&#160;Intangible Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has two categories of intangible assets&#160;&#8211; intellectual property and patents. Intellectual property consists of all technology, know-how, data, and protocols for producing targeted proteins in plants and related to any products and product formulations for pharmaceutical uses and for other applications. Intellectual property includes, but is not limited to, certain technology for the development and manufacture of novel vaccines and therapeutics for humans and certain veterinary applications acquired in December&#160;2003 from Fraunhofer USA&#160;Inc., acting through its Center for Molecular Biotechnology (&#8220;Fraunhofer&#8221;), pursuant to a Technology Transfer Agreement, as amended (the &#8220;TTA&#8221;). The Company designates such technology further developed and acquired from Fraunhofer as <i style="font-style:italic;">iBioLaunch</i><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> or <i style="font-style:italic;">LicKM</i><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> or <i style="font-style:italic;">FastPharming</i> Technology. The value on the Company&#8217;s books attributed to patents owned or controlled by the Company is based only on payments for services and fees related to the protection of the Company&#8217;s patent portfolio. The intellectual property also includes certain trademarks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On August 23, 2021, the Company entered into a series of agreements with RubrYc described in more detail above (see Note 6 &#8211; Significant Transactions) whereby in exchange for a $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_vI4fmkUg3kuCuyZ_zK8brg" decimals="-5" format="ixt:numdotdecimal" name="ibio:StockPurchaseAgreementTotalInvestment" scale="6" id="Narr_M9z9BGqBR0yWut7pSW7RKA">7.5</ix:nonFraction> million investment in RubrYc, the Company acquired a worldwide exclusive license to certain antibodies that RubrYc develops under what it calls its RTX-003 campaign, which are promising immuno-oncology antibodies that bind to the CD25 protein without interfering with the IL-2 signaling pathway thereby potentially depleting T-regulatory (Tregs) cells while enhancing T effector (Teffs) cells and encouraging the immune system to attack cancer cells. The Company accounted for this license as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development efforts. &#160;In addition, the Company also received preferred shares and an option for future collaboration licenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 16, 2022, the Company entered into an Asset Purchase Agreement with RubrYc described in more detail above (see Note 6 &#8211; Significant Transactions) pursuant to which it acquired substantially all of the assets of RubrYc. &#160;The assets acquired include the patented AI drug discovery platform, all rights with no future milestone payments or royalty obligations, to IBIO-101, in addition to CCR8, EGFRvIII, MUC16, CD3, and one additional immuno-oncology candidate, plus a PD-1 agonist.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In January 2014, the Company entered into a license agreement with the University of Pittsburgh<i style="font-style:italic;"> </i>whereby the Company acquired exclusive worldwide rights to certain issued and pending patents covering specific candidate products for the treatment of fibrosis (the &quot;Licensed Technology&quot;) which license agreement was amended in August 2016 and again in December 2020 and February 2022. The license agreement provides for payment by the Company of a license issue fee, annual license maintenance fees, reimbursement of prior patent costs incurred by the university, payment of a milestone payment upon regulatory approval for sale of a first product, and annual royalties on product sales. In addition, the Company has agreed to meet certain diligence milestones related to product development benchmarks. As part of its commitment to the diligence milestones, the Company successfully commenced production of a plant-made peptide comprising the Licensed Technology before March 31, 2014. The next milestone &#8211; filing an Investigational New Drug Application with the FDA or foreign equivalent covering the Licensed Technology (&quot;IND&quot;) &#8211; initially was required to be met by December 1, 2015, and on November 2, 2020, was extended to be required to be met by December 31, 2021 and on February 8, 2022, was further extended to December 31, 2023. In addition, the amounts of the annual license maintenance fee and payment upon completion of various regulatory milestones were amended. On February 14, 2023, the Company provided notification to the University of Pittsburgh terminating the license agreement. Pursuant to the termination of the license agreement with the University of Pittsburgh, the Company&#8217;s financial obligations for the management of the patents under the license will cease on August 14, 2023, and at such time, will transition back to the University of Pittsburgh. As a result of the termination of the license agreement, the Company recorded a full impairment of the related intangible asset associated with IBIO-100 in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_2_14_2023_To_2_14_2023_TnhaetjjP06Trcv9WL2o_A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="0" id="Narr_gabpU9Y0GUm7DxEP8okS4w">25,000</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">See Note 4 - Summary of Significant Accounting Policies for more information.</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="Tb_zhQLQdvP6EWVMnhhpRTsHQ" continuedAt="Tb_zhQLQdvP6EWVMnhhpRTsHQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table reflects changes in the carrying amount of intangible assets (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">June&#160;30,&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">March 31,</p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Additions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Impairments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2023</p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Intellectual property &#8211; gross carrying value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_h4ptg2J5jEab7-ozoqAPPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_uDuiqWzM4UW6j3A5fqy9Tw_3_3">3,100</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_V386ndKYUkuQBZjgR9D61w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" scale="3" id="Tc_sQiZCLyJaE-8zgvliyZk6w_3_9">400</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_V386ndKYUkuQBZjgR9D61w" decimals="-3" format="ixt:numdotdecimal" name="ibio:ImpairmentOfIntangibleAssetsGrossOfReversals" scale="3" id="Tc_gD8vjbiKi0OZeU-qnQBxPQ_3_12">3,100</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_5pgV7l8BAkeLqa2TtOfOrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_3dEqidnwKUmElk3-GZnBAA_3_15">400</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Patents and licenses &#8211; gross carrying value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_3xQ4GPFAFEWXC_8Y-7ecig" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_QMd3MYnh_Emcfg-hZ15lbQ_4_3">2,846</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_9dyJeVMv1ki5yRGsbgJw-Q" decimals="-3" format="ixt:numdotdecimal" name="ibio:ImpairmentOfIntangibleAssetsGrossOfReversals" scale="3" id="Tc_3EFnOQnsfEGnleHXbsr5qw_4_12">2,846</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_VtLxoXRTqU2SA2qBwvHXVQ_5_3">5,946</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" scale="3" id="Tc__hMYb9q8P0yjchJrWWvZqg_5_9">400</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="ibio:ImpairmentOfIntangibleAssetsGrossOfReversals" scale="3" id="Tc_H2bECi1sSUq3wNq_dUMb0Q_5_12">5,946</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_rwVC6hrXTUWaFsbpYTCoRQ_5_15">400</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Intellectual property &#8211; accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_h4ptg2J5jEab7-ozoqAPPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_r4fFPv4dMkeivKIv67f4Ug_6_3">2,867</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_V386ndKYUkuQBZjgR9D61w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="Tc_ECv8lsjGyUuSO-zYV0GXQw_6_6">74</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_V386ndKYUkuQBZjgR9D61w" decimals="-3" format="ixt:numdotdecimal" name="ibio:ReversalOfIntangibleAssetImpairment" scale="3" id="Tc_BkVM9LOO306UyMphs6HjIA_6_12">2,931</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_5pgV7l8BAkeLqa2TtOfOrg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_f5lZALBgV0GbGqGmfj-mXg_6_15">10</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Patents and licenses &#8211; accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_3xQ4GPFAFEWXC_8Y-7ecig" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_u-S9-y0xpUWLPLAY4wOItQ_7_3">2,403</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_9dyJeVMv1ki5yRGsbgJw-Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="Tc_4D0nYfD3606yo0FR6Z0z4Q_7_6">47</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_9dyJeVMv1ki5yRGsbgJw-Q" decimals="-3" format="ixt:numdotdecimal" name="ibio:ReversalOfIntangibleAssetImpairment" scale="3" id="Tc_Z-x4mpFS8UGObFy2JY-7Xg_7_12">2,450</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_kR_IUoa_Mkiwgw9foyTM3Q_8_3">5,270</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="Tc_1hClUXxaqU6SBWScluCa4g_8_6">121</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="ibio:ReversalOfIntangibleAssetImpairment" scale="3" id="Tc_vCnyQSY-uk-psyNwv_GPHQ_8_12">5,381</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_NVaJFduVD0mKVQJHQA-7AQ_8_15">10</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Total definite lived intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_UyUKdLoCvk6r9vCsAAM8dg_9_3">676</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="Tc_QQSAS4Je70O4sgiPG8awFA_9_6">121</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" scale="3" id="Tc_Uku7jNr8zkqRB3JNQbV85Q_9_9">400</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="3" id="Tc_6MHbE5Aq40WzHQQJUrSNLw_9_12">565</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_AzAkt6XVs0CrXKRL2yReZg_9_15">390</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">License - indefinite lived</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="Tc_snc7Ig2CPE6zVUxRF3Gcow_11_3">4,175</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IndefinitelivedIntangibleAssetsAcquired" scale="3" id="Tc_vAxMAWzxg0ejjTCIiZp0LA_11_9">828</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="Tc_r1lNqFFe8UGoscuTpLp8SA_11_15">5,003</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Total net intangible</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 4,851</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,228</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 5,393</p></td></tr></table></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_aB5KzA-dWkGaYz1o51HWhg_cont1"><ix:continuation id="Tb_zhQLQdvP6EWVMnhhpRTsHQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Amortization expense was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="Narr_-KEMU6FAq0SAc2AZqepQaQ">5,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="Narr_Fi_fyesQAkiNY9dwLLajFQ">122,000</ix:nonFraction> for the three months ended March&#160;31,&#160;2023 and 2022, respectively. Amortization expense was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="Narr_ckxgk6jYfkSMHk9BY63kWA">121,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="Narr_bZUudpfNtU-LHZGf_USidw">333,000</ix:nonFraction> for the nine months ended March&#160;31,&#160;2023 and 2022, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> <span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the second quarter of Fiscal 2023, the Company re-evaluated its business strategy and reviewed its product portfolio. After such review, the Company identified intellectual property, patent and licenses that will no longer be utilized and therefore were fully impaired. &#160;The Company recorded an impairment charge in general and administrative expenses of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="0" id="Narr_ucdLRNlvPk6j8-oM8J0Ogw">565,000</ix:nonFraction> for the nine months ended March&#160;31,&#160;2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">See Note 4 - Summary of Significant Accounting Policies and Note 5 &#8211; Financial Instruments and Fair Value Measurement for more information.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="us-gaap:DebtDisclosureTextBlock" id="Tb_BFnhxF-yiE2VcEa8tBDnkQ" continuedAt="Tb_BFnhxF-yiE2VcEa8tBDnkQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">13.&#160;&#160;&#160;Debt</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The Credit Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the Purchase and Sale Agreement, iBio CDMO entered into a Credit Agreement, dated November 1, 2021, with Woodforest pursuant to which Woodforest provided iBio CDMO a $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_11_1_2021_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_LgWNkAEXrEOd4Kk1fbDdsQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_ZtqYl9pyrEOQZQWx1IhakQ">22,375,000</ix:nonFraction> secured term loan (the &#8220;Term Loan&#8221;) to purchase the Facility, which Term Loan is evidenced by a term note (the &#8220;Term Note&#8221;) (for a complete description of the transaction please see Note 6 &#8211; Significant Transactions). The Term Loan was advanced in full on the closing date. The Term Loan bears interest at a rate of <ix:nonFraction unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg" contextRef="As_Of_11_1_2021_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_LgWNkAEXrEOd4Kk1fbDdsQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_zqXUcwvD0UKvnHWS-_DG2g">3.25</ix:nonFraction>%, with higher interest rates upon an event of default, which interest is payable monthly beginning November 5, 2021. Principal on the Term Loan was originally payable on November 1, 2023, subject to early termination upon events of default. The Term Loan provides that it may be prepaid by iBio CDMO at any time and provides for mandatory prepayment upon certain circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On October 11, 2022, iBio CDMO and Woodforest amended the Credit Agreement to: (i) include a payment of $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_10_11_2022_To_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_DateOfAmendmentMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_ymy8A_X8_EK1tvCrHTVuEQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" scale="0" id="Narr_WUnC40JDfE6jX1M8NPdAqQ">5,500,000</ix:nonFraction> of the outstanding principal balance owed under the Credit Agreement on the date of the amendment, (ii) include a payment of $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_10_11_2022_To_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_uQ72oafLtUqgFnnzbdiAsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" scale="0" id="Narr_f28vH5JCpk-M4trV9KWheg">5,100,000</ix:nonFraction> of the outstanding principal balance owed under the Credit Agreement within two (2) business days upon our receipt of such amount owed to us by Fraunhofer as part of our legal settlement with them (the &#8220;Fraunhofer Settlement Funds&#8221;) (see Note 19 &#8211; Fraunhofer Settlement for more information), (iii) include principal payments of $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_10_11_2022_To_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_SmV5R4SrNkmUCX3FsbIGLA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentPeriodicPayment" scale="0" id="Narr_BW2RdnQHYUqVP2jI1pmWKg">250,000</ix:nonFraction> per month in debt amortization for a six-month period commencing the date of the amendment through March 2023, (iv) include an amendment fee of $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_O-zm2Doh6EmpqJ14OI8KEw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFeeAmount" scale="0" id="Narr_vM9ewdRhhUWxrPGyS-uRpQ">22,375</ix:nonFraction> and all costs and expenses, (v) require delivery of a report detailing cash flow expenditures every two (2) weeks for the period prior to the delivery of the last report and a monthly 12-month forecast, (vi) reduce the liquidity covenant (the &#8220;Liquidity Covenant&#8221;) in the Guaranty (as defined in the Credit Agreement) from $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_10_10_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_dl3OmSiDBEKFtrzke4LxUw" decimals="-6" format="ixt:numdotdecimal" name="ibio:DebtCovenantLiquidityAmount" scale="6" id="Narr_BvaL5Qacr0O0dRFb2fc5Lw">10</ix:nonFraction> million to $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_O-zm2Doh6EmpqJ14OI8KEw" decimals="-5" format="ixt:numdotdecimal" name="ibio:DebtCovenantLiquidityAmount" scale="6" id="Narr_RudUF6_0u0WdrCkTAt9J6w">7.5</ix:nonFraction> million with the ability to lower the liquidity covenant to $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_OccurrenceOfSpecificMilestoneMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_RDzgSGSsy0qENkxPgtYl4w" decimals="-5" format="ixt:numdotdecimal" name="ibio:DebtCovenantLiquidityAmount" scale="6" id="Narr_WW8db3gWcUGzP7OywFMYgQ">5.0</ix:nonFraction> million upon the occurrence of a specific milestone in the Credit Agreement, and (vii) change the annual filing requirement solely for the fiscal year ended June 30, 2022, such that the filing is acceptable with or without a &#8220;going concern&#8221; designation. &#160;In addition, Woodforest cancelled the irrevocable letter of credit issued by JPMorgan Chase Bank upon closing of the amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In January 2023, the Company&#8217;s unrestricted cash decreased below the required $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_1_31_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_87cTBGu9gE-x613iWJyDyg" decimals="0" format="ixt:numdotdecimal" name="ibio:CreditAgreementThresholdLimitUnrestrictedCash" scale="0" id="Narr_7rvypUBypkemXf40ShuFXw">7,500,000</ix:nonFraction>, which created an event of default under the Credit Agreement and Guaranty as a result of not complying with the Liquidity Covenant. As a result, on February 9, 2023, iBio CDMO and Woodforest entered into a second amendment to the Credit Agreement (the &#8220;Second Amendment&#8221;), which amended, among other things, added a milestone that had to be met by a specified date, the failure of which would be an event of default. &#160;In addition, on February 9, 2023, the Company, as guarantor, entered into a second amendment to the Guaranty, which amended, among other things, allowed the Company to account for the Fraunhofer Settlement Funds in determining whether the Company is in compliance with the Liquidity Covenant until a specified period dependent upon the occurrence of a specific milestone in the Credit Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On February 20, 2023, iBio CDMO entered into a third amendment to the Credit Agreement (the &#8220;Third Amendment&#8221;), which removed the added milestone specified in the Second Amendment, the failure of which would be an event of default. &#160;In addition, the Guaranty was amended to allow the Company until February 28, 2023, to account for the Fraunhofer Settlement Funds in determining whether the Company is in compliance with the Liquidity Covenant without being dependent upon a specified milestone. &#160;In addition, the Company agreed that each time it consummates an at-the-market issuance of Equity Interests (as defined within the Credit Agreement), no later than five (5) days following such issuance of Equity Interests, it will (i) pay to Woodforest in immediately available cash funds, without setoff or counterclaim of any kind, forty percent (40%) of the Net Proceeds (as defined within the Credit Agreement) received by the Company for such issuance of Equity Interests; provided, any such payment would cease upon payment obligations in full and (ii) provide Woodforest with a detailed accounting of each such issuance of Equity Interests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On March 24, 2023, iBio CDMO and Woodforest entered into a fourth amendment to the Credit Agreement (the &#8220;Fourth Amendment&#8221;), which within the Fourth Amendment Woodforest agreed to (i) reduce the percentage of any payment to Woodforest the Company is required to make from the proceeds of sales of its common stock under its at-the-market facility from 40% to 20%, (ii) reduce the percentage of any payment to Woodforest the Company is required to make from the proceeds of sales of its equipment from 40% to </p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Narr_-c4Snp0UGk6fmfQXR9EODA"></a><a id="_98dfabd9_d0e3_4595_bbd3_ed68c560ea7e"></a><a id="Tc_plg2VYHH10um2u83oJQWog_1_0"></a><a id="Tc_MspsLMsIp0eR1HJ09y41ig_1_2"></a><a id="Tc_8pTom3VVvUGfCd4Rgq_F-w_1_5"></a><a id="Tc_faG7Nb-XtU6sMnAj-Z47Sw_1_8"></a><a id="Tc_oRCMBJvfgUeZRBt0xVBQDQ_2_0"></a><a id="Tc_6rHOkWCAsUSAKHicN66aTQ_2_2"></a><a id="Tc__DuMmRc8_U-KVkyxQcHljg_2_5"></a><a id="Tc_tpQ6b0Ac7023b4m4bF5ZfQ_2_8"></a><a id="Tc_MPWxRt10h0itL_-UVKVc1Q_3_0"></a><a id="Tc_AXqC2fmJ-k2hLH7EzjNeow_4_0"></a><a id="Tc_A5_u0hoSbkWpPibJEEa6vQ_6_0"></a><a id="Tc_c5i4KmgX5EqTBYFd-nu8WQ_6_5"></a><a id="Tc_RzWJWIBJiEezFWFNsqsi_A_6_8"></a><a id="Tc_h8aCQTHZPk-g0Ypfp-Ra7Q_7_0"></a><a id="Tc_bnILVwfI2kuD79HPiDTV6A_8_0"></a><a id="Tc_3opKiV2b3UymIrrVCnIuVg_8_2"></a><ix:continuation id="Tb_BFnhxF-yiE2VcEa8tBDnkQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">20%, and (iii) allowed the Company to retain $2,000,000 million of the $5,100,000 million that the Company received from the Fraunhofer Settlement Funds, with the remaining $3,000,000 million being held in a Company account at Woodforest. &#160;In addition, the Company is obligated to (y) deliver to Woodforest an executed copy of a purchase agreement (the &#8220;Purchase Agreement&#8221;) for the sale of the Facility, no later than April 14, 2023, and (z) pay to Woodforest a fee in the amount of $75,000 on the earlier of the date of the closing of the Purchase Agreement, or the Maturity Date (as defined in the Credit Agreement). &#160;In addition, on March 24, 2023, the Company, as guarantor, entered into a fourth amendment to the Guaranty, which reduced the Liquidity Covenant from $7,500,000 to $1,000,000. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On May 10, 2023, iBio CDMO and Woodforest entered into a fifth amendment to the Credit Agreement (the &#8220;Fifth Amendment&#8221;), which within the Fifth Amendment Woodforest agreed to: (i) waive our obligation to deliver to Woodforest an executed copy of a Purchase Agreement for the sale of the Facility no later than April 14, 2023 and, (ii) release $500,000 of the $3.0 million being held in a Company account at Woodforest when the outstanding principal amount is reduced to $10.0 million and for each additional $2.5 million reduction of the outstanding principal amount, an additional $750,00 will be released from the Company account at Woodforest.&#160; In addition, starting on the effective date of the Fifth Amendment, the interest on the Term Loan increased to 5.25%, and the Term Loan shall further accrue interest, payable in kind and added to the balance of the outstanding principal amount at a fixed rate per annum equal to (a) 1.00%, if the Facility is sold on or before June 30, 2023, (b) 2.00% if the Facility is sold after June 2023, but on or before September 30, 2023, or (c) 3:00%, if the Facility is sold after September 30, 2023, or not sold prior to the maturity date.&#160; The Company also agreed to pay Woodforest a fee in the amount of (x) $75,000 if the Facility is sold on or before June 30, 2023, (y) $100,000 if the Facility is sold after June 2023, but on or before September 30, 2023, or (x) $125,000, if the Facility is sold after September 30, 2023, or not sold prior to the maturity date. As of the date of the filing of this Quarterly Report on Form 10-Q, the Company is not in negotiations on a Purchase Agreement with a potential buyer of the Facility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">At March&#160;31,&#160;2023, the balance of the Term Loan was $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_co4oLbGgmE-T18TcXR1zRA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="0" id="Narr_4IOUiGH_jEe3yHB3khQFuA">13,700,000</ix:nonFraction> which consisted of the Term Note of $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_co4oLbGgmE-T18TcXR1zRA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_lbv1tpIZ_E6glF8_J3EKKA">13,852,000</ix:nonFraction>, net of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_co4oLbGgmE-T18TcXR1zRA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="0" id="Narr_LiWuh9-4S0ubSOwKTX04lg">152,000</ix:nonFraction> of deferred finance costs. &#160;At June&#160;30,&#160;2022, the balance was $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_Vft8wC26KU20m86L9BIQqA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="0" id="Narr_0XhaGohGLE6j1khbtgtT4A">22,161,000</ix:nonFraction> which consisted of the Term Note of $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_Vft8wC26KU20m86L9BIQqA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_G15SqtPMHU21METdl-0dNQ">22,375,000</ix:nonFraction>, net of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_Vft8wC26KU20m86L9BIQqA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="0" id="Narr_80y2Hfv7gkq-kGEBh_bbfg">214,000</ix:nonFraction> of deferred finance costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Equipment Financing</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On October 12, 2022, the Company entered into an equipment financing master lease agreement and a lease supplement whereby $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_10_12_2022_0w4cNGT5qUGNwBnB1qrjUA" decimals="0" format="ixt:numdotdecimal" name="ibio:EquipmentFinancingAmountBorrowed" scale="0" id="Narr_zrCS5fiZnE-WA86tWFFM1A">500,000</ix:nonFraction> was borrowed over <ix:nonNumeric contextRef="Duration_10_12_2022_To_10_12_2022_fUvngAqb2k-xursF14pifg" format="ixt-sec:durwordsen" name="ibio:LesseeEquipmentLeaseTermOfContract" id="Narr_Kj3Rc964-0-Sv2iQEnJR3Q">36 months</ix:nonNumeric> at an imputed interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg" contextRef="Duration_10_12_2022_To_10_12_2022_fUvngAqb2k-xursF14pifg" decimals="4" format="ixt:numdotdecimal" name="ibio:EquipmentFinancingLeaseImputedInterestRate" scale="-2" id="Narr_IIn3ZyLRSEuN6sPi8vmwyw">10.62</ix:nonFraction>% and securitized by certain assets purchased for the San Diego research site. &#160;The financing is payable in monthly installments of $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_10_12_2022_0w4cNGT5qUGNwBnB1qrjUA" decimals="0" format="ixt:numdotdecimal" name="ibio:EquipmentLeasingMonthlyInstallmentPayable" scale="0" id="Narr_gScY4u1Y60etIss3r0A08Q">16,230</ix:nonFraction> through October 2025. &#160;At March&#160;31,&#160;2023, the balance owed under the financing was $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="0" format="ixt:numdotdecimal" name="ibio:EquipmentFinancingBalance" scale="0" id="Narr__EtQVjIykkC24lRmvCsm4Q">438,000</ix:nonFraction>. &#160;Interest incurred under the financing for the three and nine months ended March&#160;31,&#160;2023 totaled approximately $12,000 and $19,000, respectively.</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock" id="Tb_O4z0w5hcUEWH-JcsCPR7UQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Future minimum payments under the finance lease obligation are due as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fiscal period ending on March 31:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_Q7qov9TaRUq6PVlJRwP10w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractualObligationDueInNextTwelveMonths" scale="0" id="Tc_T8gW3oO93UGgX23FETHzDg_2_3">156</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_ELLu56FrAUeDrqmkxHQWOw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractualObligationDueInNextTwelveMonths" scale="0" id="Tc_ovITMRoH90imcAJwO9uc8w_2_6">39</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractualObligationDueInNextTwelveMonths" scale="0" id="Tc_kyyFWRWOkEq1rmA5iCK-1Q_2_9">195</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_Q7qov9TaRUq6PVlJRwP10w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractualObligationDueInSecondYear" scale="0" id="Tc__n8dMwhngkGH06u5Y7MnSQ_3_3">173</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_ELLu56FrAUeDrqmkxHQWOw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractualObligationDueInSecondYear" scale="0" id="Tc_vvCh3Rz-jkSAe6OWwHYqdA_3_6">22</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractualObligationDueInSecondYear" scale="0" id="Tc_APz5CILUjkuhPHcrsaYf0w_3_9">195</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_Q7qov9TaRUq6PVlJRwP10w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractualObligationDueInThirdYear" scale="0" id="Tc_Ot9pNXknv0qNCoIMsKeTUw_4_3">110</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_ELLu56FrAUeDrqmkxHQWOw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractualObligationDueInThirdYear" scale="0" id="Tc_Wte3AIHnxky-sUrVTbGNSw_4_6">4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractualObligationDueInThirdYear" scale="0" id="Tc_MgQ5bVy3406nuC9a5f5VCw_4_9">114</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum equipment financing payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_Q7qov9TaRUq6PVlJRwP10w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractualObligation" scale="0" id="Tc_GYBS3uZ9Kk6My2y2dmuC6Q_6_3">439</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_ELLu56FrAUeDrqmkxHQWOw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractualObligation" scale="0" id="Tc_WehArT2Hp0C8D6hzEX6O9A_6_6">65</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractualObligation" scale="0" id="Tc_2-jUOS9bb0y89OU5rbPc_A_6_9">504</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_Q7qov9TaRUq6PVlJRwP10w" decimals="0" format="ixt:numdotdecimal" name="ibio:ContractualObligationCurrent" scale="0" id="Tc_6GJUzt5Afk2mhz1m42DO6Q_7_3">156</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term portion of minimum equipment financing obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_Q7qov9TaRUq6PVlJRwP10w" decimals="0" format="ixt:numdotdecimal" name="ibio:ContractualObligationNoncurrent" scale="0" id="Tc_Rk3bTzdPd0eST75acaCiVQ_8_3">283</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Note Payable &#8211; PPP Loan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On April 16, 2020, the Company received $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_4_16_2020_us-gaap_DebtInstrumentAxis_ibio_PppLoanCaresActMember_arEPE-gVxE-EC-ffEJt_Mw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermNotesPayable" scale="0" id="Narr_3UeAXG6ahk-z5hylcU3PaA">600,000</ix:nonFraction> related to its filing under the Paycheck Protection Program (&#8220;PPP&#8221;) and Coronavirus Aid, Relief, and Economic Security Act (the &quot;CARES Act&quot;). The Company elected to treat the Small Business Administration (&#8220;SBA&#8221;) loans as debt under ASC 470, <i style="font-style:italic;">Debt</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On July 21, 2021, iBio was granted forgiveness in repaying the loan. &#160;In accordance with ASC 405-20-40, <i style="font-style:italic;">Liabilities - Extinguishments of Liabilities &#8211; Derecognition</i>, the Company derecognized the liability and accrued interest of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_ibio_PppLoanCaresActMember_fyRImC3heEeL4wSzPLvcgw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentDecreaseForgiveness" scale="0" id="Narr_LMEh6iFXh0i6jO0DvkdOqA">7,000</ix:nonFraction> in the first quarter of Fiscal 2022. &#160;The forgiveness is included in loss from discontinued operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">See Note 3 &#8211; Discontinued Operations.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e46749a7_c456_4fe1_83d5_d7498426c6b9"></a><a id="Tc_zjYAu4QBzkCUM5uo6I2xFw_1_2"></a><a id="Tc_jLBSwZogJ02Aa4nuirF27Q_1_5"></a><a id="Tc_GqEMFH2CjkaFmVbd8-kI4A_2_2"></a><a id="Tc_ON-1aZIAXUaPMBZP5gA1vw_2_5"></a><a id="Tc_aDAOc7QhDkOeN3LJN2rRLw_3_2"></a><a id="Tc_a-WMSpLvm0WgVmUSXC_Sqg_3_5"></a><a id="Tc_Jqv_LIQmdkihHwW4APc3ag_4_0"></a><a id="Tc_MTWTAcddTE28I35HCRd0JA_5_0"></a><a id="Tc_Vpz5dbcrGkCqJp4fXe2ypw_5_2"></a><a id="Tc_ghJMXG7Gv0Kyjt0Y9d6yJA_5_5"></a><a id="Tc_zsyLlnrlHECWZLrtqxOjDg_5_6"></a><a id="Tc_GA8iEakTqkK3qOOQRhCfZg_6_0"></a><a id="Tc_eqcn1jDroEK5T96DXy69tw_6_6"></a><a id="Tc_m0gZPlpRwUa0c6priVcz0A_7_0"></a><a id="Tc_JrvTEKOJA0WvXp90R86ikA_7_2"></a><a id="Tc_ntzeObkKI06cSKHDuFIUcQ_7_5"></a><a id="Tc_eXiwXQq2a0yQ1ftFlaQp0w_7_6"></a><a id="Tc_xWBzVd7Zv0SIhg1KCQvXvg_9_0"></a><a id="Tc_aRAY66vG9kaBIjivD2cPzg_10_0"></a><a id="Tc_U5f6ub_CIUqIdLajIU0hAg_11_0"></a><a id="Tc_f14SnTs9oEqsJm0tK6WiyA_11_2"></a><a id="Tc_2PTNU-9UfU-whlyrLj08LQ_11_3"></a><a id="Tc_lmIf8LsTjEmzDJuAwW9gXA_11_5"></a><a id="Tc_HgputE-1aU-7K7QjYpK-VA_11_6"></a><a id="Tc_f8O4XFgFDU6_Id0sIZfMFA_12_0"></a><a id="Tc_JcRMvlZFeUWWN_BBD5ixDw_12_2"></a><a id="Tc_ao_sv7ql30ed92M2dQpN8w_12_5"></a><a id="Tc_k-INW74QAU-ulE8Vq-aErw_12_6"></a><a id="_b20209bd_9e0d_40b3_abda_c4cf412e5808"></a><a id="Tc_h24npepEpkqkUn9nd_hypg_1_2"></a><a id="Tc_4JTqDp5MDU-w1ADh7ngKbA_1_5"></a><a id="Tc_YLw1SqwUnEKeE3sBKIZRcA_2_2"></a><a id="Tc_0Q31xqUlE0KAAWlP_VUJyQ_2_5"></a><a id="Tc_GFbA_4UWsEqxSFOBpsJQUw_3_2"></a><a id="Tc_p8LHWkN-MkmJXk8qwuUPjQ_3_5"></a><a id="Tc_21rEX6T62km5f4--c-UQ-g_4_0"></a><a id="Tc_o5cBRc1khEegicQY-AdZdg_5_0"></a><a id="Tc_yqny3-SBW0Ofmo_5Z6MdvQ_5_2"></a><a id="Tc_7whFE_sRBkKh4DhhwYhueg_5_5"></a><a id="Tc_dgxhhoS8jEieriW7Re58Ag_5_6"></a><a id="Tc_EOqeib-zcUW4dySUTcNtIw_6_0"></a><a id="Tc_mXnTl0lI4k2Uz6ytCbYiAA_6_6"></a><a id="Tc_TsEEOpbR3kCrayj4ROfN6Q_7_0"></a><a id="Tc_ep1bUPPdgEyaKpJ3GmVotw_7_2"></a><a id="Tc_uGye0RkClE2-FgG-nzO-lg_7_5"></a><a id="Tc_OPryupgWnUOtmigDCBYpBw_7_6"></a><a id="Tc_Y7bt-jD_uU2J9s09huF9pA_9_0"></a><a id="Tc_qOBXmnQFREaXxz--rACY4w_10_0"></a><a id="Tc_9HXQQDw4nkKg_bfpAgbc7Q_11_0"></a><a id="Tc_yIF4aX_Z8US8sci6O7clLA_11_2"></a><a id="Tc_R4wd6XTvYEWb0coxOjxcVQ_11_3"></a><a id="Tc_bNgHcs8BM02nWX2ZaS6L5Q_11_5"></a><a id="Tc_OfrukKDLRkGX5Z-WzccjqA_11_6"></a><a id="Tc_izVY35qXdkmxJJofgAJadw_12_0"></a><a id="Tc_YvitsgcYmEijxfK1ryhKLg_12_2"></a><a id="Tc_NHDUDHB9zEqWQPYL4veT2w_12_5"></a><a id="Tc_V7TSIEYqjUC4GaMUMbaHRw_12_6"></a><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="us-gaap:LesseeFinanceLeasesTextBlock" id="Tb_MCSuS7GO2UymFneAPFtn9w" continuedAt="Tb_MCSuS7GO2UymFneAPFtn9w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">14.&#160;&#160;&#160;Finance Lease Obligations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sublease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As discussed above, until November 1, 2021, iBio CDMO leased the Facility as well as certain equipment from College Station under the Sublease. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Sublease was terminated on November 1, 2021, when iBio CDMO acquired the Facility and became the tenant under the ground lease for the property upon which the Facility is located. &#160;See Note 15 &#8211; Operating Lease Obligations for additional information related to the ground lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">General and administrative expenses related to College Station, including rent related to the increases in the Consumer Price Index (&#8220;CPI&#8221;) and real estate taxes, were approximately $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ibio_SecondEasternAffiliateMember_KNUp6QEjNk2k0RVdB9kesQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="0" id="Narr_vffNdhoDPUSeHmqJWGVysA">0</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ibio_SecondEasternAffiliateMember_NrQUiMJSu0yMjFFmZyMHLQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="0" id="Narr_J_oqSF9jzESyo9JHtNExZQ">250,000</ix:nonFraction> for the three and nine months ended March 31, 2022, respectively. Interest expense related to College Station was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ibio_SecondEasternAffiliateMember_KNUp6QEjNk2k0RVdB9kesQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="0" id="Narr_aJfX-5vb9kWt3nFIq9rXag">0</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ibio_SecondEasternAffiliateMember_NrQUiMJSu0yMjFFmZyMHLQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="0" id="Narr_-Ubh6uVdEEiNkawVPWNamA">810,000</ix:nonFraction> for the three and nine months ended March 31, 2022, respectively. Such expenses were classified as part of loss from discontinued operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Equipment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As discussed above, the Company assumed <ix:nonFraction unitRef="Unit_Standard_lease_8Woavb0ETUO8s9ODCurHtQ" contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_aNeIbxhhIUWzr_C1HYpBqQ" decimals="0" format="ixt-sec:numwordsen" name="ibio:NumberOfEquipmentLeases" scale="0" id="Narr_mQlZ9iByLkO5o8cPEzkyxA">three</ix:nonFraction> equipment leases that were accounted for as finance leases totaling $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_aNeIbxhhIUWzr_C1HYpBqQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiability" scale="0" id="Narr_wzZgRp8zo0-aO82swz_3uQ">813,822</ix:nonFraction> as part of the RubrYc Asset Purchase Agreement. &#160;The monthly rental for the <ix:nonFraction unitRef="Unit_Standard_lease_8Woavb0ETUO8s9ODCurHtQ" contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_aNeIbxhhIUWzr_C1HYpBqQ" decimals="0" format="ixt-sec:numwordsen" name="ibio:NumberOfEquipmentLeases" scale="0" id="Narr_QI9yY5RGnUONApCqkaJSrw">three</ix:nonFraction> leases is approximately $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_GnYUgnieSE-ivQH2Syhl-Q" decimals="0" format="ixt:numdotdecimal" name="ibio:LeaseRentExpensePerMonth" scale="0" id="Narr_Vh1Sr9_tJkeknjEMlKZLcg">14,000</ix:nonFraction> per month and all <ix:nonFraction unitRef="Unit_Standard_lease_8Woavb0ETUO8s9ODCurHtQ" contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_aNeIbxhhIUWzr_C1HYpBqQ" decimals="0" format="ixt-sec:numwordsen" name="ibio:NumberOfEquipmentLeases" scale="0" id="Narr_BaVTKOA_LUywjY-Kb_SJmg">three</ix:nonFraction> expire on August 1, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Mobile Office Trailer</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Commencing April 1, 2021, the Company leased a mobile office trailer that was located at the Facility in Bryan, Texas, at a monthly rental of $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_4_1_2021_To_4_1_2021_34XjF-RfakO2aPg-6ZHbIA" decimals="0" format="ixt:numdotdecimal" name="ibio:LessorFinanceLeaseMonthlyRent" scale="0" id="Narr_4_Fc4XR1XU--g2Ng5pXQkg">3,819</ix:nonFraction> through March 31, 2024. &#160;In December 2022, the Company terminated the lease and returned the mobile office trailer. Expenses related to the lease prior to its termination are included in discontinued operations.</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock" id="Tb_KZw9oG81OUCwOnq9fYqECg" continuedAt="Tb_KZw9oG81OUCwOnq9fYqECg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following tables present the components of lease expense and supplemental balance sheet information related to the finance lease obligation (in thousands).</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Amortization of ROU assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="Tc_SLTufxOjhk2h0WzJKbuyuw_5_3">68</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest on lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="Tc_2JLXvhy9Ak2cg1q0gclHWg_6_3">16</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_IHQOy81d1kyh95cL5sRKYw_7_3">84</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for amounts included in the measurement lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating cash flows from finance lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Financing cash flows from finance lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" format="ixt:numdotdecimal" name="ibio:FinancingCashFlowsFromFinanceLeaseObligation" scale="3" id="Tc_ubI8cPr_4Uq09pmBiBngEg_12_3">62</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finance lease cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Amortization of ROU assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="Tc_Trt3xKPH80qnq0tW8tqJdA_5_3">156</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest on lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="Tc_pWHlL015mECuTqQO6VmTnA_6_3">33</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_id_5qfFj_kSKM8mT8BAVuA_7_3">189</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash paid for amounts included in the measurement lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating cash flows from finance lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Financing cash flows from finance lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="ibio:FinancingCashFlowsFromFinanceLeaseObligation" scale="3" id="Tc_7A9J8k72I02YgR-4jbgOOA_12_3">144</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_HJhpIINPwUy94h0A0bhPmA_1_2"></a><a id="Tc_7KHI9FpKbUColjxJgrTHnQ_1_6"></a><a id="Tc_wY8KSdVHtU6dSok_lf80ZA_2_2"></a><a id="Tc_qIcU-CwlcUCmSW8M-75ybA_2_6"></a><a id="Tc_os2ZHvkap0aI3T6ttTWCpw_3_0"></a><a id="Tc_gHkcyyW1YEi0MukIKt3Yzg_3_2"></a><a id="Tc_qupEfSg6ik-y07Oh-CrVlw_3_6"></a><a id="Tc_VBrhg1lXck-btp6r1Xywiw_3_7"></a><a id="Tc_9FbLdyVtAkGj-y0sEW2RtA_4_0"></a><a id="Tc_wWxlbmAcLUKznmedMCNC5Q_4_2"></a><a id="Tc_k0YtmA9WEEykIu1MkdN88A_4_6"></a><a id="Tc_MqmQgUdeb06FZ713daSrKw_4_7"></a><a id="Tc_O3LPqslyVUS9GjM5P0GnqA_5_0"></a><a id="Tc_3hvz66OZ70KVn4XtBMRqGQ_5_2"></a><a id="Tc_BKsPbV5DokujAaTOmZ4UiQ_5_6"></a><a id="Tc_exCjj-fZYUKi2_zUeKazyA_5_7"></a><a id="Tc_dDO2RyvKqEGew8a1lAUvkg_6_0"></a><a id="Tc_VpqG6FqWMEqKdGu2uxNpJQ_6_4"></a><a id="Tc_NiOFBl083UKMwYJoYuD2DA_6_8"></a><a id="Tc_RuMIir-UfUmqXjzBLHPPHw_7_0"></a><a id="Tc_bpNG0BWveUCWYP6tvwnmLg_7_4"></a><a id="Tc_quxrdSH8kU6XpHhYsxg6oA_7_7"></a><a id="Tc_459iuWinpEyvkHL87TkulQ_7_8"></a><a id="_ed0a8d6d_4c25_47ca_a4df_817b0fafa129"></a><a id="Tc_p_IxIexBQkKHzwpWLDN89w_1_0"></a><a id="Tc_DO8Bqy8m4EGeZvm6ddMzyA_1_2"></a><a id="Tc_HhukoJM_8UunaE8KuGTJag_1_5"></a><a id="Tc_o-kWAnDF9U6D7o1K-CzoPg_1_8"></a><a id="Tc_zhFBGIP400qK84qCEPuMGw_2_0"></a><a id="Tc_OZDiyoXHO0iFjYwQxf04ug_2_2"></a><a id="Tc_LSuoQWRc1kWdcfJOSOOEXw_2_5"></a><a id="Tc_BAytqK5Ifkahih_5ebTLyQ_2_8"></a><a id="Tc_bYlJO18V-kat8Ykr__7rYA_3_0"></a><a id="Tc_POdMNASQ-0Ogp78fnk2RvA_4_0"></a><a id="Tc_8l9mNRXEl0uagFK54If59Q_6_0"></a><a id="Tc_N65m1V2G6k-dOhD8cKbDdA_6_5"></a><a id="Tc_Qz8YY-EZr0mUeAknK94slQ_6_8"></a><a id="Tc_0pCFYJRjpkm8hfABrzI19Q_7_0"></a><a id="Tc_kxYpu8ElIU6sWbZV9HR35Q_8_0"></a><a id="Tc_ypG41Vnl5k6SPnELFSMUUQ_8_2"></a><ix:continuation id="Tb_MCSuS7GO2UymFneAPFtn9w_cont1"><ix:continuation id="Tb_KZw9oG81OUCwOnq9fYqECg_cont1"><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="ibio:ScheduleOfFinanceLeaseRightOfUseAssetsAndObligationAndWeightedAverageInformationTableTextBlock" id="Tb_PKRUVgdyvkCPffEBu_ESGA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finance lease ROU assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="Tc_lZ2wf76nOk2lqd-6ECGkTw_3_3">678</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finance lease obligation - current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="Tc_K70LcCwwF0WBUZf4DmeNKg_4_3">265</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finance lease obligation - noncurrent portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_ALMi0aoiGEux0RbmMQwClg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> 421</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average remaining lease term - finance lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonNumeric contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_A2T_pWSg5EC7IZoPCGZJzA_6_3">2.34</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_UQCuo_IgjkapUCQ_dOiKtg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;width:54.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average discount rate - finance lease obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_MdaMg13aREmov-Xx-Jz8Ng_7_3">9.50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="Tb__4z9wyJVvU29zPpfOzqoIw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Future minimum payments under the finance lease obligation are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fiscal period ending on March 31:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_Q7qov9TaRUq6PVlJRwP10w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_D0UCSQb2ZUWNNgFDwff04w_2_3">265</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_ELLu56FrAUeDrqmkxHQWOw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_Q_yEt2gfUEGJLnqZMzEA2w_2_6">54</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_kt_KNPWmIUSg6WoSr9Wmlg_2_9">319</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_Q7qov9TaRUq6PVlJRwP10w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_HAeS69HCI0yC5JqeaA9yXg_3_3">292</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_ELLu56FrAUeDrqmkxHQWOw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_wcGHaXS4YEiYK1fU6ZD5Cw_3_6">28</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_H8v6lhCL4UaieSj2GtJPRA_3_9">320</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_Q7qov9TaRUq6PVlJRwP10w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_saiMO_xSZUmBAxl3zJgBpA_4_3">130</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_ELLu56FrAUeDrqmkxHQWOw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_MulEN7xmRUipgd4VX3dUVQ_4_6">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_nJ57tnhebk-qjkOr28U7tw_4_9">133</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_Q7qov9TaRUq6PVlJRwP10w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="3" id="Tc_52oIY6b-r0GnQDOhPtmHSg_6_3">687</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_ELLu56FrAUeDrqmkxHQWOw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="3" id="Tc_XuOmy2P1fUK0F-jyBdRgDQ_6_6">85</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="3" id="Tc_lQvoaMc3IUmExWHFJr2DTw_6_9">772</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_Q7qov9TaRUq6PVlJRwP10w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="Tc_h5MzqZ4F_k2Q4-10kMj9vg_7_3">265</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term portion of minimum lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_Q7qov9TaRUq6PVlJRwP10w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="Tc_221yWiw8r0Wb6LuJ86GEbw_8_3">422</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="us-gaap:LesseeOperatingLeasesTextBlock" id="Tb_4FruKkOrYkKh_FrP_hF0wA" continuedAt="Tb_4FruKkOrYkKh_FrP_hF0wA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">15.&#160;&#160;&#160;Operating Lease Obligations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Texas Ground Lease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As discussed above, as part of the Transaction, iBio CDMO became the tenant under the Ground Lease Agreement for the Property until 2060 upon exercise of available extensions. The base rent payable under the Ground Lease Agreement, which was $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_0-dXyj2LIE2MJCZBHgv0hw" decimals="0" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseMonthlyRent" scale="0" id="Narr_hexVf_8etUe4a4O0r-CWuA">151,450</ix:nonFraction> for the prior year, is <ix:nonFraction unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg" contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_0-dXyj2LIE2MJCZBHgv0hw" decimals="3" format="ixt:numdotdecimal" name="ibio:BaseRentPercentageOfFairMarketValueOfProperty" scale="-2" id="Narr_iBsKxPpld0C9gBlYcATSlA">6.5</ix:nonFraction>% of the Fair Market Value (as defined in the Ground Lease Agreement) of the Property. The Ground Lease Agreement includes various covenants, indemnities, defaults, termination rights, and other provisions customary for lease transactions of this nature.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">San Diego</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;">On September 10, 2021, the Company entered into a lease for approximately <ix:nonFraction unitRef="Unit_Standard_sqft_3kWp_fWhaEWbENPWsKzOnw" contextRef="As_Of_9_10_2021_fOp8nNM7xESd6X0-jbcuDQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="Narr_ESwvanexM0uDPvfOtlaKDg">11,383</ix:nonFraction> square feet of space in San Diego, California. &#160;Terms of the lease include the following: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:14pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The length of term of the lease is </span><ix:nonNumeric contextRef="As_Of_9_10_2021_fOp8nNM7xESd6X0-jbcuDQ" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Narr_hctCYZ27JEmg_oNBRnY3YQ"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">88 months</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> from the lease commencement date (as defined).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The lease commencement date was estimated to be on or around January 1, 2022.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The monthly rent for the first year of the lease is </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_9_10_2021_To_9_10_2021_nXnIcEGZ8UGqkU29lvwVJQ" decimals="0" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseMonthlyRent" scale="0" id="Narr_tFJIA75J5kOF5Tc-Dc_r-g">51,223</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and increases approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg" contextRef="Duration_9_10_2021_To_9_10_2021_nXnIcEGZ8UGqkU29lvwVJQ" decimals="2" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent" scale="-2" id="Narr_pwzJpv-GUUufLrU8GhfZVQ">3</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per year.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The lease provides for a base rent abatement for months </span><span style="-sec-ix-hidden:Hidden_fzpg5j2sZU2ExYr4_xtclw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> through </span><span style="-sec-ix-hidden:Hidden_JKyPk5I8s0q_VC6f1fzo2Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five</span></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> in the first year of the lease.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The landlord is providing a tenant improvement allowance of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_9_10_2021_fOp8nNM7xESd6X0-jbcuDQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TenantImprovements" scale="0" id="Narr_Q1q5uqu9AkufnjDkhL2Pfg">81,860</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> to be used for improvements as specified in the lease.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company is responsible for other expenses such as electric, janitorial, etc.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company opened an irrevocable letter of credit in the amount of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_9_10_2021_us-gaap_GuaranteeObligationsByNatureAxis_us-gaap_FinancialStandbyLetterOfCreditMember_KIF7AjbiKESPVs3YPPPkKQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GuaranteeObligationsMaximumExposure" scale="0" id="Narr_bWZtxsCAP0utvWtsp297bQ">188,844</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> in favor of the landlord. &#160;The letter of credit expires on October 8, 2023 and renews annually as required.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As discussed above, the lease provides for scheduled increases in base rent and scheduled rent abatements. Rent expense is charged to operations using the straight-line method over the term of the lease which results in rent expense being charged to operations at inception of the lease in excess of required lease payments. This excess (formerly classified as deferred rent) is shown as a reduction of the operating lease ROU asset in the accompanying balance sheet. &#160;As the Company has already started making improvements to the facility, the rent expense will be recognized.</p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_3a7d19da_b1b9_4ebb_b22e_d2e08e764ab9"></a><a id="Tc_4TjZ6oTXCkGSsF4Nj8Vqww_1_1"></a><a id="Tc_PGKM8EQKu0-g8TobkmoKqg_1_4"></a><a id="Tc_cdLntbLIb0G_KdCSKuKq1w_2_1"></a><a id="Tc_YAg7EdkipkiH0HeLOpmHFg_2_4"></a><a id="Tc_-YGik9YeakWrbqysh8uPhw_3_1"></a><a id="Tc_28cp7A_aAUaMIMdPXaR7yg_3_4"></a><a id="Tc_gwVOPJqP7UO_I5hCpF0AqA_4_0"></a><a id="Tc_q7K6NBcSkUyjAv1M0s472w_4_1"></a><a id="Tc_tZ6NDsR1-EKrgzfTH2mIqQ_4_4"></a><a id="Tc_W-eeSQv8bUqTncaZtG7F0Q_5_0"></a><a id="Tc_kGaYxoTOF0SHIl64QZIPQw_5_1"></a><a id="Tc_4R8zwraaGEKH-0rUJKdt8w_5_4"></a><a id="Tc_lFhMcNiVG0ms79yu-5cx0A_7_0"></a><a id="Tc_Km40OQsgi02_KFl_3YoRqw_8_0"></a><a id="Tc_CQ-Wm1Zc00OLl2e3iLWZ7w_9_0"></a><a id="Tc_cN0g-iRzpkOwXdph4qC-6A_9_1"></a><a id="Tc__d4tLIqmPEu-ciNY2V3FbQ_9_2"></a><a id="Tc_mOQWayxQO0ySQG5eQBLpeA_9_4"></a><a id="Tc_CVAOXItprUConYFriOSn4g_9_5"></a><a id="Tc_pBLdJukspUOre4FXk5_wjA_10_0"></a><a id="Tc_Is5SdT-OFUKgMB1yrnfDpA_10_1"></a><a id="Tc_ggDvlU9el0eghjGwJUD8Ng_10_4"></a><a id="Tc_cfZpdhJSnUufhuzxfh8csg_10_5"></a><a id="Tc_x9H18pqWgUKQDdxY-b6deA_13_1"></a><a id="Tc_oI60MiUIgEKGUchg-tE2Wg_13_4"></a><a id="Tc_WEKOyxick0e09a6Akk_16g_14_1"></a><a id="Tc_939-u6D0Jk2JpDF7p84S7A_14_4"></a><a id="Tc_2aEjJQyJhka7FNMIvDFSag_15_1"></a><a id="Tc_R7bOEKwRpUuAevJ1jPHRVw_15_4"></a><a id="Tc_sL3lJQcH206tuPuJuFxkVA_16_0"></a><a id="Tc_aAjnaWhg4UK-fAEX-bBhaA_16_1"></a><a id="Tc_DfiM_d73akennLyECWjxVw_16_4"></a><a id="Tc_9wC721qTFkm90SqYFyu89A_17_0"></a><a id="Tc_HzU-9w9tREaGCrQzROslCA_17_1"></a><a id="Tc_RZkuMaQ7lEOPxeIZNrjnKA_17_4"></a><a id="Tc_sJbHCVXKx0mXc4_0Xh9GKw_19_0"></a><a id="Tc_AozqNkn-kkmiqAJR8ug66Q_20_0"></a><a id="Tc_E8-QGWA2n0OKpcEcO-5EYw_21_0"></a><a id="Tc_jDfv2tuXq0-ebXAVDpR0zg_21_1"></a><a id="Tc_mNv2X1H_Tka3eaJDeYmL0w_21_2"></a><a id="Tc_VwBdilYfHkKTWhNtIBlO3A_21_4"></a><a id="Tc_KhGVVZn3IUOmTeqz496ahw_21_5"></a><a id="Tc_S6pGKSzJFUqZMKd41AMSaQ_22_0"></a><a id="Tc_66R0IcxckEm6hV5iAK7Q4Q_22_1"></a><a id="Tc_7VyNJiqvp0ixLJB0Omwn0w_22_4"></a><a id="Tc_k5CAlRLqHk2TZJpCbl7nQQ_22_5"></a><a id="_9968eb3a_9e76_47d9_87e1_96477970609c"></a><a id="Tc_wq7ajW4RtUqZYoQmEoTsZw_1_0"></a><a id="Tc_bmmdOTEhKUiBrr4Mpk8JQw_1_2"></a><a id="Tc_mMep0mN53UWPQBLx3f3wpw_1_5"></a><a id="Tc_7XKzl0h0k02_3UZWjjE9rw_1_8"></a><a id="Tc_zvQPbdiQOUCztGEByjOkSw_2_0"></a><a id="Tc_XFPelYIp206InU5bMnBmAQ_2_2"></a><a id="Tc_YQyrTmnnQ0m9P5Axm22-iQ_2_5"></a><a id="Tc_1tPtNO8P6EejOc6gYleArA_2_8"></a><a id="Tc_zewTCt8CEk6_umAyZS2hxg_3_0"></a><a id="Tc_UHPBMEGd90a8_lqWZDylXw_4_0"></a><a id="Tc_XecxR9ofw0abFlyvTwa2lQ_5_0"></a><a id="Tc_w6t6s-7ZYUWDk8zMBC5wjg_6_0"></a><a id="Tc_jFkQcTxrM0e08FEYMXGpUA_7_0"></a><a id="Tc_NazfWTTRu0qFL4m-BrHYRQ_9_0"></a><a id="Tc_vNGQSE5QzEGg-HORg0hYow_9_5"></a><a id="Tc_R9--YOyCWUiRCjQBIub4fQ_9_8"></a><a id="Tc_6yKPnN7hekCLlgsnvNxGXw_10_0"></a><a id="Tc_20Z33cY8O0y-UfojWX5jag_11_0"></a><a id="Tc_UQtYcCjZg0yR9JMVfhAQ9g_11_2"></a><ix:continuation id="Tb_4FruKkOrYkKh_FrP_hF0wA_cont1"><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock" id="Tb_MSo5llzMu0ObY48RKasMOA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following tables present the components of lease expense and supplemental balance sheet information related to the operating lease obligation (in thousands).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_rSD0SXh9-EWiKbzVbYWnYg_4_2">141</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc__peCmcUscEWjhBOWu9qtGg_4_5">141</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" format="ixt:numdotdecimal" name="ibio:TotalOperatingLeaseCosts" scale="3" id="Tc_ME-SQiAVpU62kh46EDGTUQ_5_2">141</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="-3" format="ixt:numdotdecimal" name="ibio:TotalOperatingLeaseCosts" scale="3" id="Tc_ChtO1kPlEk2t83I-IzFzBg_5_5">141</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for amounts included in the measurement lease liability:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating cash flows from operating lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 141</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 141</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating cash flows from operating lease obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" format="ixt:numdotdecimal" name="ibio:OperatingCashFlowsFromOperatingLeaseObligation" scale="3" id="Tc_oGOSYYXv00OQqZGKCdJQkw_10_2">103</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_Gml3MSjWQE-ztk6sVU5tlg_16_2">422</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_qpCEx-vwy02U_fjCVKT6qQ_16_5">313</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="ibio:TotalOperatingLeaseCosts" scale="3" id="Tc_IfvwFib4qEayE1fIQ7E-Ag_17_2">422</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:TotalOperatingLeaseCosts" scale="3" id="Tc_Z0I9wlHXXkKckAT6BCt1og_17_5">313</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for amounts included in the measurement lease liability:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating cash flows from operating lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 422</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 313</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating cash flows from operating lease obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="ibio:OperatingCashFlowsFromOperatingLeaseObligation" scale="3" id="Tc_ir5a-q8FmU2v_mSbccaniQ_22_2">154</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb_Bd9JXPMWFU6UiRug0OWNfA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Future minimum payments under the operating lease obligation are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fiscal period ending on December&#160;31:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Imputed Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_LZPd_PGF3kylVKbzYW4qFQ_2_3">377</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseImputedInterestToBePaidYearOne" scale="3" id="Tc__sSaDB4PiEqwmIrkJ6_K8w_2_6">249</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne" scale="3" id="Tc_SDgPe1zRn061O5V4vr-Kqg_2_9">626</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_aPKNd8yR00WcBRZ_lcSZjQ_3_3">424</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseImputedInterestToBePaidYearTwo" scale="3" id="Tc_2ZFTu9WYGkyEFzd_ZKhU-g_3_6">220</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo" scale="3" id="Tc_eBTYeX1odUiE8Xk4KeORfA_3_9">644</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_yykC0QNx-kuwQnCo7X9jIQ_4_3">476</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseImputedInterestToBePaidYearThree" scale="3" id="Tc_AwI3CGIulUOaih78T4kzIA_4_6">188</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree" scale="3" id="Tc_K6U1QRmEFkCYz3HKDxS4VA_4_9">664</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="Tc_49HELDPt_UOdIS4iYsqbdw_5_3">532</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseImputedInterestToBePaidYearFour" scale="3" id="Tc_EekqHlKgvU2endLujYQReA_5_6">151</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour" scale="3" id="Tc_2dZhyU3gIEWLXLigVywHvQ_5_9">683</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="Tc_U292ARCeHEWXDcP8NIXbzw_6_3">593</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseImputedInterestToBePaidYearFive" scale="3" id="Tc_iRuSTDYNRkmdB6IgeA5klQ_6_6">111</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive" scale="3" id="Tc_vcdTjkV5pUOqcx0UHX822w_6_9">704</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="Tc_UgXXLvX7EECkaYO39rg0Ow_7_3">1,200</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive" scale="3" id="Tc_zthvIJ5N3kWoe85DOkuR0Q_7_6">82</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive" scale="3" id="Tc_hZ-Te9Qdwk-1EZX00aUM-Q_7_9">1,282</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_Inm78xIa-06a5ZDxlAHWPQ_9_3">3,602</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseImputedInterestToBePaidTotal" scale="3" id="Tc_5O4tvu8hSE--xoXOuRHttw_9_6">1,001</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" scale="3" id="Tc_MuNtJjg0kkqW2yOD1ev0dg_9_9">4,603</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_rZItyn40KkurpnECMmI5Wg_10_3">377</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term portion of minimum lease obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_vcZ7zFjzn0-IxopJyO3n7g_11_3">3,225</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_loV9x29FtEyJx_azkAKJ0g" continuedAt="Tb_loV9x29FtEyJx_azkAKJ0g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">16.&#160;&#160;&#160;Stockholders&#8217; Equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s Board is authorized to issue, at any time, without further stockholder approval, up to <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="Narr_9i9VV6pF7kq3Kctbf0-Sug">1</ix:nonFraction> million shares of preferred stock. The Board has the authority to fix and determine the voting rights, rights of redemption and other rights and preferences of preferred stock.</p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_loV9x29FtEyJx_azkAKJ0g_cont1" continuedAt="Tb_loV9x29FtEyJx_azkAKJ0g_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Series 2022 Convertible Preferred Stock (&#8220;Series 2022 Preferred&#8221;)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May 9, 2022, the Board of the Company created the Series 2022 Preferred, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" contextRef="As_Of_5_9_2022_vsP8EMdp9kqoJCsGc37KdQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_GIw5xluf0Ue_k5DQ_V4PKQ">0.001</ix:nonFraction> per share, out of the Company&#8217;s <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="As_Of_5_9_2022_vsP8EMdp9kqoJCsGc37KdQ" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="Narr_gmdXwquc4keoie0kuef9uQ">1</ix:nonFraction> million authorized shares of preferred stock. &#160;Each share of Series 2022 Preferred was convertible at a ratio of one-for-one (<ix:nonFraction unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg" contextRef="Duration_5_9_2022_To_5_9_2022_us-gaap_StatementClassOfStockAxis_ibio_Series2022ConvertiblePreferredStockMember_IRKi-LuHkUq15KpdZkL8TA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="Narr_2KjXBoiT7k6cw2YYecJcNA">1</ix:nonFraction>:1) shares of the Common Stock on a pre-split basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company issued <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="Duration_5_9_2022_To_5_9_2022_us-gaap_StatementClassOfStockAxis_ibio_Series2022ConvertiblePreferredStockMember_IRKi-LuHkUq15KpdZkL8TA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_0tfQ5g_BSUmVRIDSBe6_mw">1,000</ix:nonFraction> shares of Series 2022 Preferred and received proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_5_9_2022_To_5_9_2022_us-gaap_StatementClassOfStockAxis_ibio_Series2022ConvertiblePreferredStockMember_IRKi-LuHkUq15KpdZkL8TA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="0" id="Narr_F_GTJgT2nUSX80LULqpjGA">270</ix:nonFraction>. &#160;Pursuant to the terms of the preferred stock, the Company&#8217;s Board converted the Preferred Stock to <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="As_Of_7_19_2022_us-gaap_StatementClassOfStockAxis_ibio_Series2022ConvertiblePreferredStockMember_qeFYBi3PAUWnjNGHYNci7Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="Narr_GPCXa8UxFEyqSii9wjmHzQ">40</ix:nonFraction> shares of Common Stock on July 19, 2022, on a post-split basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">iBio CMO Preferred Tracking Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On February 23, 2017, the Company entered into an exchange agreement with Bryan Capital pursuant to which the Company acquired substantially all of the interest in iBio CDMO held by Bryan Capital and issued <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="Duration_2_23_2017_To_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_oc0tqqFKsk-LEKQxwyeAOw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" id="Narr_fob72mPae0qRrsGQZNXP9Q">one</ix:nonFraction> share of a newly created Preferred Tracking Stock, in exchange for <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="Duration_2_23_2017_To_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_oc0tqqFKsk-LEKQxwyeAOw" decimals="INF" format="ixt:numdotdecimal" name="ibio:NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock" scale="0" id="Narr_qklJg84qa0Wd8DEGwTdWBA">29,990,000</ix:nonFraction> units of limited liability company interests of iBio CDMO held by Bryan Capital at an original issue price of $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_2_23_2017_To_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_oc0tqqFKsk-LEKQxwyeAOw" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="Narr_zaSPK_9O1k2JQxhPE2MkgQ">13</ix:nonFraction> million. After giving effect to the transaction, the Company owned <ix:nonFraction unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg" contextRef="As_Of_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_srt_StatementScenarioAxis_ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_1x-cfjUThkKbcg8PyPRDEg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="Narr_RSJVANoWF0SD6lFBp8SrCA">99.99</ix:nonFraction>% and Bryan Capital owned <ix:nonFraction unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg" contextRef="As_Of_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_srt_StatementScenarioAxis_ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ibio_EasternAffiliateMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_qFx6baRFl0K1AnDbITGYjg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="Narr_yJJPB7Ei_0KYEleNz24_4g">0.01</ix:nonFraction>% of iBio CDMO.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On February 23, 2017, the Board of the Company created the Preferred Tracking Stock out of the Company&#8217;s <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="As_Of_2_23_2017_lMLzTmFjFUeEaGVOB1WIPA" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="Narr_VPaQc1_aUUq1ZBGMCIPmmA">1</ix:nonFraction> million authorized shares of preferred stock. The Preferred Tracking Stock accrued dividends at the rate of <ix:nonFraction unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg" contextRef="Duration_2_23_2017_To_2_23_2017_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_hlhl6dJdp0if7Q1n3P67xA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" id="Narr_D6u7FMk_-ka86-2PeXuSkw">2</ix:nonFraction>% per annum on the original issue price. Accrued dividends were cumulative and were payable if and when declared by the Board, upon an exchange of the shares of Preferred Tracking Stock and upon a liquidation, winding up or deemed liquidation (such as a merger) of the Company. <ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" contextRef="Duration_10_31_2021_To_10_31_2021_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_47o5yRKDNE6T9LQPWz8erA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockDividendsPerShareDeclared" scale="0" id="Narr_dwbDH7vudE6QbxEcysrbEA">No</ix:nonFraction> dividends were declared through October 31, 2021. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On November 1, 2021, iBio purchased the iBio CMO Preferred Tracking Stock held by Bryan Capital. <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="As_Of_11_1_2021_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_Nh5Sltvg50S1MDQaPh-wrw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_yr6g1TC1q0yXaaAChy64yw">No</ix:nonFraction> iBio CMO Preferred Tracking Stock remains outstanding. As a result, the iBio CDMO subsidiary and its intellectual property are now wholly owned by iBio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The number of authorized shares of the Common Stock is <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="Narr_kfLYRjfMsUKgvDDa2R64hQ">275</ix:nonFraction> million. In addition, the Company has reserved <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="As_Of_3_31_2023_us-gaap_PlanNameAxis_ibio_OmnibusIncentivePlanMember_KOZgQdvqsU-8te5q0_AgpA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_AeUkr_RI4Eqbd6QcDtCU-g">1,280,000</ix:nonFraction> shares of Common Stock for issuance pursuant to the grant of new awards under the Company&#8217;s 2020 Omnibus Incentive Plan (the &#8220;2020 Plan&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Reverse Stock Split</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On June 30, 2022, the Company held a special meeting of its stockholders at which the stockholders approved a proposal to affect an amendment to the Company&#39;s certificate of incorporation, as amended, to implement a reverse stock split at a ratio of <span style="-sec-ix-hidden:Hidden_L9F1YPW0H0e_OcCFkVLlag;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span>-for-twenty-five (1:25). On September 22, 2022, the Company&#39;s Board approved the implementation of the reverse stock split of the Common Stock. As a result of the reverse stock split, every twenty-five (25) shares of the Common Stock either issued and outstanding or held by the Company in its treasury immediately prior to the effective time was, automatically and without any action on the part of the respective holders thereof, combined and converted into one (1) share of the Common Stock. No fractional shares were issued in connection with the reverse stock split. Stockholders who otherwise were entitled to receive a fractional share in connection with the reverse stock split instead were eligible to receive a cash payment, which was not material in the aggregate, instead of shares. On October 7, 2022, the Company filed a Certificate of Amendment of its Certificate of Incorporation, as amended with the Secretary of State of Delaware effecting a <span style="-sec-ix-hidden:Hidden_QTQry_EgBE-Zf0eAMcyRBw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span>-for-twenty-five (1:25) reverse stock split of the shares of the Common Stock, either issued or outstanding, effective October 7, 2022. The Common Stock began trading on a reverse split adjusted basis when the market opened Monday, October 10, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Recent issuances of Common Stock include the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;">Cantor Fitzgerald Underwriting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On November 25, 2020, the Company entered into a Controlled Equity Offering SM Sales Agreement (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald &amp; Co. (&quot;Cantor Fitzgerald&quot;) to sell shares of Common Stock, from time to time, through an &#8220;at the market offering&#8221; program having an aggregate offering price of up to $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_11_25_2020_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_R42dgLYX1k2Ix5l9AuMByA" decimals="0" format="ixt:numdotdecimal" name="ibio:AggregateCommonStockPurchased" scale="0" id="Narr_xdPINAI6NkKJlzPBkmEgGQ">100,000,000</ix:nonFraction> through which Cantor Fitzgerald would act as sales agent. &#160;Between July 25, 2022, and March 31, 2023, Cantor Fitzgerald sold as sales agent pursuant to the Sales Agreement <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="Duration_7_25_2022_To_8_17_2022_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_ggLswlBXtkqHIYFVDHZ-Zg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="Narr_rhZQCatEh0OtATyVjThQhg">1,551,879</ix:nonFraction> shares of Common Stock. The Company received net proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_25_2022_To_8_17_2022_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_ggLswlBXtkqHIYFVDHZ-Zg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="Narr_DAOTiRlO0kCs8LUewOuBJQ">2.9</ix:nonFraction> million during the nine months ended March 31, 2023 and holds a subscription receivable for $260,000 at March 31, 2023 for proceeds received on April 4, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk87152699"></a><ix:continuation id="Tb_loV9x29FtEyJx_azkAKJ0g_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">RubrYc Transaction</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 19, 2022, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="Duration_9_19_2022_To_9_19_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_wXZQoYO-rEO6uGxtBLB7Ag" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="Narr_l87vlbKHxUyocHNadFC8Cw">102,354</ix:nonFraction> shares valued at approximately $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_9_19_2022_To_9_19_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_wXZQoYO-rEO6uGxtBLB7Ag" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Narr_2x_xAp8J_Uy16xOdLEq_Og">1,000,000</ix:nonFraction> to RubrYc as part of the payment for purchasing the assets of RubrYc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Wainwright Underwriting</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On December 6, 2022, the Company entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with H.C. Wainwright &amp; Co., LLC (&#8220;Wainwright&#8221;). Pursuant to the Underwriting Agreement, the Company agreed to sell to Wainwright, in a firm commitment underwritten offering (the &#8220;Offering&#8221;) (i) <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="Duration_12_6_2022_To_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_KH2r3-L2ZEmEEfMT1ZNKKw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_IYolcbaWj0KAzUIGbGXmaA">1,530,769</ix:nonFraction> shares of the Company&#8217;s Common Stock, (ii) pre-funded warrants (the &#8220;Pre-Funded Warrants&#8221;) to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_InpkTkfz_02nABMpU6azWQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_FklHTk98D0y3-4a0bBvZGg">1,834,616</ix:nonFraction> shares of Common Stock, (iii) Series A Common Stock purchase warrants (the &#8220;Series A Warrants&#8221;) to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_J-u4uOUfG0ORoIm4jvgctQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_F_xkh3b4cUuoMJagkKPr5w">3,365,385</ix:nonFraction> shares of Common Stock and (iv) Series B Common Stock purchase warrants (the &#8220;Series B Warrants&#8221; and together with the Series A Warrants, the &#8220;Common Warrants&#8221;) to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_cBAtqPpEJUqEJd0c0GaR7w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_XT_XaaZm7UOnKLdpmoj-9Q">3,365,385</ix:nonFraction> shares of Common Stock. &#160;The offering closed on December 9, 2022. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Wainwright acted as the sole book-running manager for the Offering. The Company paid Wainwright an underwriting discount equal to <ix:nonFraction unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg" contextRef="Duration_12_6_2022_To_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_sbC4xz-l302ta9iq3YNsng" decimals="3" format="ixt:numdotdecimal" name="ibio:PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering" scale="-2" id="Narr_sHJFjA2fU0aKizQcrvJSEQ">7.0</ix:nonFraction>% of the gross proceeds of the offering, and reimbursed Wainwright for the legal fees and certain expenses of the underwriter. &#160;Pursuant to the Underwriting Agreement, the Company has granted Wainwright a <ix:nonFraction unitRef="Unit_Standard_D_NZPLSJv9m0GC4_X7zPjKmg" contextRef="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_t_boUVr6WkyudoVlOiImcQ" decimals="INF" format="ixt:numdotdecimal" name="ibio:NumberOfDaysOptionToPurchaseAdditionalShares" scale="0" id="Narr_WehFIvXP3Ey6KYU8IG99ug">30</ix:nonFraction>-day option to purchase up to an additional <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="Duration_12_6_2022_To_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_sbC4xz-l302ta9iq3YNsng" decimals="INF" format="ixt:numdotdecimal" name="ibio:NumberOfAdditionalSharesIssued" scale="0" id="Narr_71YaRJSkCk6rl16z_SdJMQ">504,807</ix:nonFraction> shares of Common Stock and/or Common Warrants to purchase up to an additional <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="Duration_12_6_2022_To_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_sbC4xz-l302ta9iq3YNsng" decimals="INF" format="ixt:numdotdecimal" name="ibio:CommonWarrantsToPurchaseAdditionalShares" scale="0" id="Narr_pMKZ9Uw5AUqR_N4jecmmnQ">1,009,614</ix:nonFraction> shares of Common Stock at the public offering price, less the underwriting discounts and commissions, solely to cover over-allotments. Wainwright elected to purchase <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_A4kvDn5x20q7_8fIvjOF-g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_kC3Wn3vdFUONp8wJkeQmPg">504,807</ix:nonFraction> Series A Warrants and <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_BCjemMCehUOFvWDV-Z5NgA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_RgYzDgBVIk-LgBjMqnDO5g">504,807</ix:nonFraction> Series B Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company has also agreed to issue to Wainwright, as the representative of the underwriters, warrants (the &#8220;Representative&#8217;s Warrants&#8221;) to purchase a number of shares of Common Stock equal to <ix:nonFraction unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg" contextRef="Duration_12_6_2022_To_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_sbC4xz-l302ta9iq3YNsng" decimals="3" format="ixt:numdotdecimal" name="ibio:PercentageOfAggregateNumberOfSharesOfCommonStock" scale="-2" id="Narr_Y5KuARgib0iRtalxW3sUUg">6.0</ix:nonFraction>% of the aggregate number of shares of Common Stock and Pre-Funded Warrants being offered in the offering. Wainwright received warrants to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_t_boUVr6WkyudoVlOiImcQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_lRtDPabCp0SniP2x0VvoLw">201,923</ix:nonFraction> shares of Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company received net proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_12_6_2022_To_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_sbC4xz-l302ta9iq3YNsng" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="0" id="Narr_vxg1YmiXmUandO8TNmnw4Q">2,864,000</ix:nonFraction> after deducting underwriting discounts, commissions and other issuance costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Vesting of Restricted Stock Units &#8220;RSUs&#8221;</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On August 23, 2022, RSUs for <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="Duration_8_23_2022_To_8_23_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_lmnxjWAiuES8yulA3DkvLA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Narr_m7pNGF3dzkGi9dFIRCS90w">1,057</ix:nonFraction> shares of Common Stock were vested. On December 1, 2022, RSUs for <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="Duration_12_1_2022_To_12_1_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_hQgfyxu2uUOmIRU8B4Fklw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Narr_xjuK8UcN8k-puL1U4_ChOQ">4,120</ix:nonFraction> shares of Common Stock were vested. &#160;In addition, RSUs for 27,740 of Common Stock vested during the third quarter of Fiscal 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Warrants</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Bryan Capital </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> <span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As discussed above, the Company issued to Bryan Capital a Warrant to purchase <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_p-vKhEHGAUG72E1kGh9gmg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_7HX1cxRmB0OeO4Ou9dbhQA">51,583</ix:nonFraction> shares of the Common Stock of the Company at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_p-vKhEHGAUG72E1kGh9gmg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_7Tabihv1HkOJKPb8uczZ_A">33.25</ix:nonFraction> per share. The Warrant expires October 10, 2026, is exercisable immediately, provides for a cashless exercise at any time and automatic cashless exercise on the expiration date if on such date the exercise price of the Warrant exceeds its fair market value as determined in accordance with the terms of the Warrant and adjustments in the case of stock dividends and stock splits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Wainwright</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> <span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As discussed above, the Company issued various warrants with the following terms:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Pre-Funded Warrants &#8211; Immediately exercisable at an exercise price of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" contextRef="As_Of_3_31_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_PreFundedWarrantsMember_AmjIXMsiE020WBD4cpXPjg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_BS7l0T1UnkWJ7PMFT_W4_w">0.001</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per share. &#160;All of the Pre-Funded Warrants were exercised in December 2022.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Class A Warrants &#8211; Immediately exercisable at an exercise price of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" contextRef="As_Of_3_31_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_nMTFluJjHUGsVU2uJ_O6bQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_o-2KTPyYIEmtHYDjVk5QDw">1.04</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per share for a term of </span><ix:nonNumeric contextRef="As_Of_3_31_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_nMTFluJjHUGsVU2uJ_O6bQ" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_9Zac9cb3vEC3yjGa-34Smg"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five years</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Class B Warrants &#8211; Immediately exercisable at an exercise price of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" contextRef="As_Of_3_31_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_MA5Y7fHH4E6vZRFVAPWBvA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_xFRdUBF3TUStkCKmcJ_rPQ">1.04</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per share for a term of </span><ix:nonNumeric contextRef="As_Of_3_31_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_MA5Y7fHH4E6vZRFVAPWBvA" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_io3MZFnexkiTo45E9NuJ3g"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two years</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Representative Warrants &#8211; Immediately exercisable at an exercise price of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" contextRef="As_Of_3_31_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_RepresentativeWarrantsMember_L0HxhOr8_0eWqjfa9gKftw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_DSNqOUOU1EK6G0HApVcRpQ">1.30</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per share for a term of </span><ix:nonNumeric contextRef="As_Of_3_31_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_RepresentativeWarrantsMember_L0HxhOr8_0eWqjfa9gKftw" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_GXfBT0qO_EO_3H7LZnJx8Q"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five years</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the third quarter of Fiscal 2023, 341,300 Class A Warrants and 1,704,916 Class B Warrants were exercised. &#160;On April 3, 2023, an additional 76,300 Class B Warrants were exercised. &#160;The total proceeds from Class A and B Warrants exercised during the third quarter of Fiscal 2023 and on April 3, 2023 were $2,207,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_dtW3O3oX406yrmLcqGqNKQ_1_2"></a><a id="Tc_dw_54q50xUqpUOVCl93W5Q_1_8"></a><a id="Tc_GOI7qUYkREal-tZHN_1_eg_2_2"></a><a id="Tc_JdqYLbZPeEaY4hDW7napNQ_2_8"></a><a id="Tc_VcxV88LsPU-QIjLMEbWjHw_3_2"></a><a id="Tc_9MRJ2ZpioEqKXc5gr1qaXg_3_5"></a><a id="Tc_7RpvO52VeEWhAHBwH7vhYg_3_8"></a><a id="Tc_1rtvTw39XEqH2w0ixJh-Og_3_11"></a><a id="Tc_muarCRbr2EWl4s8TnO7sdw_4_0"></a><a id="Tc_9cJuQ52lwkyvBd0t7XVVDQ_6_0"></a><a id="Tc_wOXUdHZc6UyCjIZY44aeGQ_6_2"></a><a id="Tc_0N_8Sme_1UWfdWECvtq-Ng_6_5"></a><a id="Tc_eQugqKipQEKGL40zBz9ufQ_6_8"></a><a id="Tc_9BlLCQBXrEG9iTQ8FhmIaQ_6_11"></a><a id="Tc_5w1ApP_dLkWUpV5iw5uLUw_7_0"></a><a id="Tc_RJJwZY40XkWa2UBn1JcKmg_7_3"></a><a id="Tc_qgzK91QUPUWyrnNU4tezNQ_7_6"></a><a id="Tc_Hs-sgisJk0i_qoQBCaojmA_8_0"></a><a id="Tc_ztHKj5qXCU6-jvjAlrenoA_8_2"></a><a id="Tc_V1_suX-zo02QN2S8r0QO0g_8_5"></a><a id="Tc_sj7ngWQxGU60n4NgPyn4OA_8_8"></a><a id="Tc_dZM8E3yo_UCqB4Q5SD-7Kg_8_11"></a><a id="Tc_lWJoQ6ajnUe8nNQeajXdcg_10_0"></a><a id="Tc_0OKgAvOrr0CDC5Cwrs_Pag_10_2"></a><a id="Tc_rUVosKDwdE-dfO34qC1DMA_10_5"></a><a id="Tc_W8uE2bKBeki9fI0jzrUd9g_10_8"></a><a id="Tc_osPMUN5nMke2N5oEaatjcw_10_11"></a><a id="Tc_IRWOvFbCxES4mbloS6X3aA_12_0"></a><a id="Tc_K-ydAiV_fE2fknODdf709A_12_2"></a><a id="Tc_dWZLaasVuk2XpgPd0sI9PA_12_5"></a><a id="Tc_zixRfykYukqQdaYrMA_7zA_12_8"></a><a id="Tc_Otlhr7LRCU2komwWT5ickg_12_11"></a><a id="Tc_W0CL9GWYikW6MuCGJ1lzdA_14_0"></a><a id="Tc_RdxwXWKkV0CRNdOjOWgcCg_16_0"></a><a id="Tc_lTe4WWLxs0ifnZ9giLIvIQ_18_0"></a><a id="Tc_trlDLvrAxU-ooICm1aVvoQ_19_0"></a><a id="Tc_kSTw6MIc-kyj08t4f3emWQ_20_0"></a><a id="Tc_nqDsjmr9tk6IQbfQ7qdMhQ_1_2"></a><a id="Tc_XOnEN_JAfUuGoro5-FroEQ_2_2"></a><a id="Tc_vlAtgdcJRUa_B6SUSLLnIA_2_4"></a><a id="Tc_ELV2IyuzIUi_ZH208dP_hw_3_2"></a><a id="Tc_DEqR_WEr-kqW3z2c6ZfH5A_4_0"></a><a id="Tc_OVg6GAwvzEybZECMSR4grw_5_0"></a><a id="Tc_VvLHE8LBxU6sfIOTk41L9Q_6_0"></a><a id="Tc_7YEdkuLVH0-N33t9hpqWag_7_0"></a><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="us-gaap:EarningsPerShareTextBlock" id="Tb_Fb7R_KTVVU2ZCgrio0GBBw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">17.&#160;&#160;&#160;Earnings (Loss) Per Common Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Basic earnings (loss) per common share is computed by dividing the net income (loss) allocated to common stockholders by the weighted-average number of shares of Common Stock outstanding during the period. For purposes of calculating diluted earnings (loss) per common share, the denominator includes both the weighted-average number of shares of Common Stock outstanding during the period and the number of common stock equivalents if the inclusion of such common stock equivalents is dilutive. Dilutive common stock equivalents potentially include stock options and warrants using the treasury stock method. The following table summarizes the components of the earnings (loss) per common share calculation (in thousands, except per share amounts):</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Tb_GOEnFK17Vkm0o6xMm9Mhig" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to iBio, Inc. from continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperations" sign="-" scale="3" id="Tc_hzVmml4HYESwaYILa0wC3Q_6_3">6,279</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperations" sign="-" scale="3" id="Tc_-n2mFY4t8UaLSt05w02FQQ_6_6">6,746</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperations" sign="-" scale="3" id="Tc_5RheRb5Jk0Guw6NDAs0FvA_6_9">24,379</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperations" sign="-" scale="3" id="Tc_5bmaJJiR6kCOjd0GsiqvnA_6_12">19,125</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Preferred stock dividends &#8211; iBio CMO Preferred Tracking Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:zerodash" name="us-gaap:DividendsPreferredStockStock" scale="3" id="Tc_7bKjXxcsWEiAn5YUSlY0-g_7_9">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStockStock" scale="3" id="Tc_Yw6kWRvqj062X5TDoi8FNQ_7_12">88</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss available to iBio, Inc. stockholders from continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_eq_NG0pTqk2fzjcbhynN7g_8_3">6,279</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_OVVQ0QqRbk6RoxZ6IKbZcw_8_6">6,746</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_cI2y7cxPck2jKe_Z2nOgXw_8_9">24,379</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_WlbLXj1kq0CiA449_iKktw_8_12">19,213</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss available to iBio, Inc. stockholders from discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" sign="-" scale="3" id="Tc_qdn-WhX9KkeuMBRAK4fYAw_10_3">1,015</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" sign="-" scale="3" id="Tc_qj_JDBLdM0q-3evr4D9Z2A_10_6">5,644</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" sign="-" scale="3" id="Tc__yTeiC9ZC0uzgDC2xzRiiA_10_9">34,598</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" sign="-" scale="3" id="Tc_yprmAT0-YUK57VFsrkDCcw_10_12">14,124</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss available to iBio, Inc. stockholders - total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" format="ixt:numdotdecimal" name="ibio:UnconsolidatedGainLossAttributableToStockholders" sign="-" scale="3" id="Tc_GvpYuHBdsUGnWyrzvfmYdg_12_3">7,294</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="-3" format="ixt:numdotdecimal" name="ibio:UnconsolidatedGainLossAttributableToStockholders" sign="-" scale="3" id="Tc_0teAQDP3tkK6MY4RPr_Ulg_12_6">12,390</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="ibio:UnconsolidatedGainLossAttributableToStockholders" sign="-" scale="3" id="Tc_1vJsmrMybk-4FdiPTrOIPw_12_9">58,977</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:UnconsolidatedGainLossAttributableToStockholders" sign="-" scale="3" id="Tc_-tx0-E5b2kalbs8Uyu2Wgw_12_12">33,337</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average common shares outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_ayL3huDlXE66wzyy_DgCjw_16_3">13,184</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_9zILRcazVkGWeJCkHOZc1g_16_6">8,719</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_NaaOtZZfI0mvwrDOY7nBAA_16_9">10,592</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_H7x__8YIcUySjiGvbbJvzQ_16_12">8,719</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Per share amount - continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_wjVHAja0hk-ujBowM-xKHQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" sign="-" scale="0" id="Tc_lWWloV0UtkyBfBiiNRSaRg_18_3">0.47</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_yQjZFWrye0SmP2jIiPGrBA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" sign="-" scale="0" id="Tc_EDGauNFFBkaqU6uAL3d_0A_18_6">0.77</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_-JF8WUqQSkmfxC0R_OaSQA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" sign="-" scale="0" id="Tc_wLQqonYOtE-EAqJ7RAyVXg_18_9">2.30</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_PwsJbaSoOUORrCdM232mAA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" sign="-" scale="0" id="Tc_KzFjCg6hoUSzoZZHMJcbYQ_18_12">2.20</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Per share amount - discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_9HqUV2MAckqjZOnis6YfZg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" sign="-" scale="0" id="Tc_Mmee8DqHxUS55T7RRwXHgA_19_3">0.08</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_U0bOGUWDzkuEeJ29Nf_EjQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" sign="-" scale="0" id="Tc_8zcMN0DjXkOvj_7-hCoRCg_19_6">0.65</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_TmWH34FMsECu90mrUdyfXg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" sign="-" scale="0" id="Tc_GULP1gfMZk2tWGjb_G0FZg_19_9">3.27</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_kDRlUx8GmUabgAhq5k_vvQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" sign="-" scale="0" id="Tc_s8roW3CkL0uKtNusmA2L2g_19_12">1.62</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Per share amount - total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_Zp0MkR-0tUq910UPmXzGpA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_CC1jkLFcB0WipDJMD-8N6Q_20_3">0.55</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_acVcgEcpAUW-LaSF7a3TxQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_ubyF2mtHpUCD0gqp86cnxA_20_6">1.42</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_wBTFuchxW0eQbgh0co0GoQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_hAcacMq6QUmWewMnshMIwQ_20_9">5.57</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_tJo2ezbm1Eau_et1XorUuA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_S21jD0LPzk2PPdPTEO7EHQ_20_12">3.82</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In Fiscal year 2023 and Fiscal year 2022, the Company incurred net losses which cannot be diluted; therefore, basic and diluted loss per common share is the same. As of March&#160;31,&#160;2023 and 2022, shares issuable which could potentially dilute future earnings were as follows:</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_rLy__zaz8kixEBQ575DJYw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:76.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_uH1aZ6v5zUW5U0OYeCYCVA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_FhGoM2nwo06qU1S4gPBRjQ_4_2">457</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="Duration_7_1_2021_To_3_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_wGAzW97TrUSXKPZdUccZUQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_HFt7PkZSJk6JVQ0TPC4gjA_4_4">625</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_gE-bXUQhFkqJyMBuH9S0rQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_626QYxhVzUSS-EKoP80GHg_5_2">443</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="Duration_7_1_2021_To_3_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_52A2X6mgk0CFvchRmy-_Xw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_EpqNH86j0UKnnYJymfbN1Q_5_4">22</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_-vyQFO66V0-VnP5O63-I_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_WF0zSk5jC0COELd5xIAyjg_6_2">5,948</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="Duration_7_1_2021_To_3_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_zQX7x8UMbk6gJSsI7k7Ecw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_kE_xkF9ai0uGhsMr2nPXAQ_6_4">52</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Shares excluded from the calculation of diluted loss per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_VblNbVliK0-SJvrFIqMMXQ_7_2">6,848</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_kN_eLP3NYEqD5vWP12cwEA_7_4">699</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_7071743d_7dd8_40a4_80b7_69f59ecab8fa"></a><a id="Tc_xqooNMl_sUOOo29hPorafQ_1_2"></a><a id="Tc_H8889CVVS0KAxk9Hl15DOA_2_2"></a><a id="Tc_yX0Ig4luLECb76oq7R3JXw_3_2"></a><a id="Tc_xjsTD95a-USkOYqo00RivA_3_5"></a><a id="Tc_ubY7AHU4fUWKxU1bXMp2Pg_4_0"></a><a id="Tc_VH7HcCL9KE-dGaQE7G7Nmg_4_2"></a><a id="Tc_J6-kE8PyFU-lbbJddc-daA_4_5"></a><a id="Tc_Z-aR5Jlw_kaIJ4mWLdORUQ_5_0"></a><a id="Tc_Bx4JZP5W50-LkDVLY3O-Wg_6_0"></a><a id="Tc_Kq5FwDEkIUyef1klrTRHKA_6_2"></a><a id="Tc_N8_HmrwPYU2D_Tas9yZi0Q_6_5"></a><a id="_d477453a_e0a6_41cf_8916_acd71ab546c7"></a><a id="Tc_zSXS79yeIkCYP18GHprTRQ_1_2"></a><a id="Tc_1ZkPo_CexkqEdWi2VYhA5Q_2_2"></a><a id="Tc_RC_NzykUMUuaWUIBi8xyag_3_2"></a><a id="Tc_caujJwzb8Ey-TtmP7L3leA_3_5"></a><a id="Tc_ioPL3wpnUE6YsJUM2LMYBg_4_0"></a><a id="Tc_juY4oujIH0Gvqz0oYlNyDw_4_2"></a><a id="Tc_Z9F8ZF4ISk2ckdgmyLvUUw_4_5"></a><a id="Tc_4dmePw8hd0KyhKQXTLJ6Vg_5_0"></a><a id="Tc_m2UaReygPkeYfTb7ERQyGg_6_0"></a><a id="Tc_hEE0hEzCzUyLMx7lUzdW7A_6_2"></a><a id="Tc__EVIQjnRy0WY1LhfwOY17A_6_5"></a><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_xvNkkpsGMEeCBidFKktokw" continuedAt="Tb_xvNkkpsGMEeCBidFKktokw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">18.</b>&#160;&#160;&#160;<b style="font-weight:bold;">Share-Based Compensation</b></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_jhpVZGYF-UaFMIbuFiJv1w" continuedAt="Tb_jhpVZGYF-UaFMIbuFiJv1w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes the components of share-based compensation expense in the condensed consolidated statements of operations (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_0YZIOq7O40ivJtfSHHkoMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_Zg77W993pk2G9Lo0OBtQ-Q_4_3">40</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_qBMqGNRQFUWB9ZObqlDu1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_rsx-TzYqNkq9nxGov2RIbw_4_6">101</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_qY2IkD16B0qsnL9JdcbhWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_T7exz_sUPEOLOGUv6hSFPQ_5_3">345</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_e_Rq4byCpkSvRJ7e4WS-Ew" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_XCKMQrNsyEivcfNNbLHp6w_5_6">1,112</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_Lg96nj-F80WP0q0uVj1D3g_6_3">385</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_ly4BAtGc3U67bdZXw9zuVA_6_6">1,213</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_j5YNxf9-9UOgFjDrRr3Uog" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_qDhbGuMFfk6FtgJmZpCSWA_4_3">96</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_T5bdyp2yw0iUue1_r7FPew" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_lR6_WHVZFESuFRUz5V-PcQ_4_6">132</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_8W6InNkO50yKpr_pjkqq9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_CkpUNS83A0qxU-2x9_-E_Q_5_3">2,330</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_aJI5vfPiSkWbqmmaBoEKtQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_2-Hnh9GOUkCGWkwi5v1K4w_5_6">2,761</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_ztZc-lQvJkaIgTdwQtDM-A_6_3">2,426</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_2WeVYxtStEO86fYfU2hJsg_6_6">2,893</ix:nonFraction></p></td></tr></table></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b417457f_4ab4_4cf4_9aa9_2f5c7f74f284"></a><a id="Tc_yMq2_Nm2dUStgYGys-85MQ_2_0"></a><a id="Tc_u2hy1UXlzkSEgIK_w91eyQ_2_3"></a><a id="Tc_Gf9PdQY4UEWhHfdQh8YGLw_2_4"></a><a id="Tc_7Wjg-ulI40eR48WSVAch5Q_3_0"></a><a id="Tc_dP1ExuJylUuhNTCpTagL2A_3_4"></a><a id="Tc_LW_3_KUCwkOvqRprgY3FJQ_4_0"></a><a id="Tc_TGiAGAeWW02V_uqhSKZs9g_4_3"></a><a id="Tc_P6MhyXlKeUaW9GGxDM4p2w_4_4"></a><a id="Tc_3req3qGCDk2-8RUtbs0dVw_5_0"></a><ix:continuation id="Tb_xvNkkpsGMEeCBidFKktokw_cont1" continuedAt="Tb_xvNkkpsGMEeCBidFKktokw_cont2"><ix:continuation id="Tb_jhpVZGYF-UaFMIbuFiJv1w_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In addition, share-based compensation expense included in loss from discontinued operations totaled approximately $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_qwQKiC4qEkiqgQ5177TkpA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Narr_41fSsTjaE0qNQu4s5FfmpA">1,211,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_RaNGnKpnsEaTsjOvOslUxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Narr_h60vEgQkukKa6Dp826HlKQ">62,000</ix:nonFraction> for the three months ended March&#160;31,&#160;2023 and 2022, respectively, and $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_uXNvRGR-RESDya9s9QmQmA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Narr_LpqAGMr9Ik-odSxMH8FX7A">1,519,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_GqDXZ6lLOEyUlH87AA2kZw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Narr_yIoe3tvbQkebTFys6wMpYw">305,000</ix:nonFraction> for the nine months ended March&#160;31,&#160;2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Stock Options</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">iBio, Inc. 2020 Omnibus Equity Incentive Plan (the &#8220;2020 Plan&#8221;)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On December 9, 2020, the Company adopted the 2020 Plan for employees, officers, directors and external service providers. The total number of shares of Common Stock reserved under the 2020 Plan is <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="As_Of_12_9_2020_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_x5WH3KDAZkGbq_aE3REdDQ" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="6" id="Narr_-W_uzhzydke7ZmAR4tOlGg">1,280,000</ix:nonFraction> shares of Common Stock for issuance pursuant to the grant of new awards under the 2020 Plan. The 2020 Plan allows for the award of stock options, stock appreciation rights, restricted stock, restricted stock units, unrestricted stock, cash-based awards, and dividend equivalent rights. The value of all awards awarded under the 2020 Plan and all other cash compensation paid by the Company to any non-employee director in any calendar year may not exceed $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_12_9_2020_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_x5WH3KDAZkGbq_aE3REdDQ" decimals="0" format="ixt:numdotdecimal" name="ibio:ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized" scale="0" id="Narr_o1FOSSg8P0ezJ3LrOAL8Yg">500,000</ix:nonFraction>; provided, however, that such amount shall be $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_12_9_2020_srt_StatementScenarioAxis_ibio_ScenarioOneMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_tZmDg9QDo0iz01RbPbZOcw" decimals="0" format="ixt:numdotdecimal" name="ibio:ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized" scale="0" id="Narr_PBT6RlAIFU2833263GTwgQ">750,000</ix:nonFraction> for the calendar year in which the applicable non-employee director is initially elected or appointed to the Board and $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_12_9_2020_srt_StatementScenarioAxis_ibio_ScenarioTwoMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_JVZ6u6vkRkGYKXk3HmaqFA" decimals="2" format="ixt:numdotdecimal" name="ibio:ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized" scale="0" id="Narr_amt07L16IEKMNbf7-nSQBg">1,500,000</ix:nonFraction> for any non-executive chair of our Board should one be appointed. Notwithstanding the foregoing, the independent members of the Board may make exceptions to such limits in extraordinary circumstances. The term of the 2020 Plan will expire on the tenth anniversary of the date the Plan is approved by the stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Vesting of service awards are determined by the Board and stated in the award agreements. In general, vesting occurs ratably on the anniversary of the grant date over the service period, generally <span style="-sec-ix-hidden:Hidden_nzLgsplRfUCEtBruJ2QfKQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> or <ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_ibio_TwoThousandEighteenOmnibusEquityIncentivePlanMember_B8y79W7GIkih4LgR3vQBOw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_CSKU14zRB0OxTP_bZzVSAA">five years</ix:nonNumeric>, as determined at the time of grant. Vesting of performance awards occurs when the performance criteria is satisfied. The Company uses historical data to estimate forfeiture rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock options issued</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the first quarter of Fiscal year 2023, the Company granted stock option agreements to various employees to purchase <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_BcLE-e5aOUawYtWYzbYpuQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_ZId_ow8qvkm_0n_SdS4YEw">303,869</ix:nonFraction> shares of the Common Stock at exercise prices between $<ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" contextRef="Duration_7_1_2022_To_9_30_2022_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember__h4euJzls0O2OyXOl4zqpA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_j3PbY3C2l0Cyk8W3SwTp1A">6.75</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" contextRef="Duration_7_1_2022_To_9_30_2022_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_vETdeXuor0693SHSOmu6TA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_4MnaGkxf50mK2KbmfE-qJw">9.50</ix:nonFraction> per share. The options vest <ix:nonFraction unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg" contextRef="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_OhlEn2kqNUmaT0Hh--g1yg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_09Qlycs3aEKW0Am7I2eofA">25</ix:nonFraction>% after <ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_OhlEn2kqNUmaT0Hh--g1yg" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_vVulWTfSDEWaII7V344YMg">one year</ix:nonNumeric> and then in equal quarterly installments over a <ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_fmpgVBKP1km0zpZ63FGixw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_VFV09sjlq0OdGnoTTM0mzg">36-month</ix:nonNumeric> period and expire on the <span style="-sec-ix-hidden:Hidden_6UlFUOUwakC1Lx6RTBBOdg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">tenth</span></span> anniversary of the grant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the first quarter of Fiscal year 2023, the Company granted a stock option agreement to a consultant to purchase <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_ConsultantsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_yuIW9ztkf0mAQBCgQQaTxw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_1VcjwvBUq0WnX0MiO1Hwvg">4,000</ix:nonFraction> shares of the Common Stock at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA" contextRef="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_ConsultantsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_yuIW9ztkf0mAQBCgQQaTxw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_iSnLRz9Cc0eHBlXI2lKksw">6.75</ix:nonFraction> per share. The options vest in equal monthly installments, over a period of <ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_ConsultantsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_yuIW9ztkf0mAQBCgQQaTxw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_UirB_vocvkCuPeq1a6fnSA">twelve months</ix:nonNumeric>, starting after the second month and expire on the <span style="-sec-ix-hidden:Hidden_PqrGwNIVNUKtOSk9GN3hkQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">tenth</span></span> anniversary of the grant date. &#160;During the third quarter of Fiscal year 2023, the Company terminated the consultant&#8217;s services. &#160;As a result, none of the 4,000 shares pursuant to the stock option agreement were exercised and as such, all 4,000 shares will be forfeited. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">No stock options were granted in the second or third quarter of Fiscal year 2023.</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_hT2YZ3L5oUmhKKFafj4Dnw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company estimated the fair value of options granted using the Black-Scholes option pricing model with the following assumptions:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_VtlcwNPlo065-EY0TDiG6Q">3.21</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_KZ7epdNEokKo93Wq0Yt5lw">3.61</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_FrcaXW2gAUW5-3ztwH2J3Q_3_3">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_Y8cG6sW2lEayYU4r9GYzlg">115.52</ix:nonFraction> - <ix:nonFraction unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_kmx9GDiHt0K5Dt8LzBuKcg">116.93</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_d2qNBBkwrkembDdRz3OvJQ_5_3">7</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">RSUs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On August 29, 2022, the Company issued RSUs to acquire 6,954 shares of common stock to various employees at a market value of $7.06 per share. &#160;The RSUs vest over a four-year period. &#160;The grant date fair value of the RSUs totaled approximately $49,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On November 10, 2022, as previously disclosed in relation to the Employment Agreement with Mr. Isett, the Company&#8217;s former CEO, dated April 30, 2021, the Company granted Mr. Isett RSUs to acquire 200,000 shares of Common Stock, on a post-split basis.&#160; The RSUs vest over a three-year period commencing April 30, 2021 provided the vesting is subject to the following performance conditions: (i) submission to the U.S. Food and Drug Administration (FDA) of an Investigational New Drug (IND) application, or alternatively, if the Board approves not to file an IND, (ii) consummation of a disposition of iBio CDMO, LLC, or (iii) out-licensing, with full global rights, any of its investigational product candidates prior to the submission to the FDA an IND application.&#160; The grant-date fair value of the RSUs totaled approximately $296,000. The performance conditions were not met and the RSUs did not vest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_xvNkkpsGMEeCBidFKktokw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On November 11, 2022, the Company granted Mr. Robert Lutz, the Company&#8217;s Chief Financial and Business Officer at the time, RSUs to acquire 100,057 shares of the Company&#8217;s Common Stock in exchange for Mr. Lutz&#8217;s agreement to continue employment with the Company through July 1, 2023. &#160;The RSUs vest the earlier of: (i) July 1, 2023, or (ii) the successful achievement of the Company&#8217;s 2023 objectives, as defined by the Board. The grant-date fair value of the RSUs totaled approximately $175,100. Mr. Lutz resigned from the Company and was no longer an employee of the Company effective February 10, 2023; accordingly, the RSUs did not vest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 11, 2022, the Company granted Dr. Martin Brenner, the Company&#8217;s Chief Scientific Officer, RSUs to acquire 95,348 shares of the Company&#8217;s Common Stock in exchange for Mr. Brenner&#8217;s agreement to continue employment with the Company through July 1, 2023. &#160;The RSUs vest the earlier of: (i) July 1, 2023, or (ii) the successful achievement of the Company&#8217;s 2023 objectives, as defined by the Board. The grant-date fair value of the RSUs totaled approximately $167,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On January 20, 2023, the Board of the Company appointed Dr. Brenner to the position of Interim Chief Executive Officer, effective immediately. Dr. Brenner was granted RSUs to acquire <ix:nonFraction unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA" contextRef="Duration_1_20_2023_To_1_20_2023_srt_TitleOfIndividualAxis_ibio_Dr.MartinBrennerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_N9G2vRJjBkiY4CVMVYrH_Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_xOrb0Io2SE227kIwVO4pJQ">130,000</ix:nonFraction> shares of the Company&#8217;s Common Stock, which RSUs shall vest pro rata over a <ix:nonNumeric contextRef="Duration_1_20_2023_To_1_20_2023_srt_TitleOfIndividualAxis_ibio_Dr.MartinBrennerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_N9G2vRJjBkiY4CVMVYrH_Q" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_L1M1gvHvF0mtkcegsegemg">twelve-month</ix:nonNumeric> period, such vesting to terminate if Dr. Brenner is no longer the Company&#8217;s Interim Chief Executive Officer. The grant-date fair value of the RSUs totaled approximately $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_20_2023_To_1_20_2023_srt_TitleOfIndividualAxis_ibio_Dr.MartinBrennerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_N9G2vRJjBkiY4CVMVYrH_Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="0" id="Narr_QqsuvscWy0mnYtvNfbz3aQ">91,000</ix:nonFraction>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 31, 2023, the Compensation Committee (the &#8220;Committee&#8221;) of the Board of the Company approved a special equity award program pursuant to which it awarded to its employees an aggregate of 225,000 RSUs under the Company&#8217;s 2020 Omnibus Equity Incentive Plan, as amended (the &#8220;Plan&#8221;), which awards included a grant of 50,000 and 37,500 restricted stock units to each of Dr. Brenner, and Felipe Duran, the Company&#8217;s Interim, Chief Financial Officer, respectively, vesting quarterly over 12 months commencing April 1, 2023. The grant-date fair value of the RSUs totaled approximately $468,000.</p></ix:continuation><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="ibio:GainLossRelatedToLitigationSettlementTextBlock" id="Tb_VgWcfGoqO0iG_HgKRmcSpQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">19.&#160;&#160;&#160;Fraunhofer Settlement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May 4, 2021, the Company and Fraunhofer USA, Inc. (&#8220;FhUSA&#8221;) entered into a Confidential Settlement Agreement and Mutual Release (the &#8220;Settlement Agreement&#8221;) to settle all claims and counterclaims in the litigation captioned iBio, Inc. v. Fraunhofer USA, Inc. (Case No. 10256-VCF) in Delaware Chancery Court (the &#8220;Lawsuit&#8221;). The Settlement Agreement, among other things, resolves the Company&#8217;s claims to ownership of certain plant-based technology developed by FhUSA from 2003 through 2014, and sets forth the terms of a license of intellectual property. The Lawsuit was commenced against FhUSA by the Company in March 2015 in the Court of Chancery of the State of Delaware and is described in more detail in the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended December 31, 2020. The Settlement Agreement is not an admission of liability or fault of the parties. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The terms of the Settlement Agreement provide for cash payments to the Company of $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_iqiKw6Sqfk-mWIZ8WFtzQA" decimals="0" format="ixt:numdotdecimal" name="ibio:CashPaymentsReceivablesRelatedToLitigationSettlement" scale="0" id="Narr_z1YkMoNMP0mEsN-lQHOMog">28,000,000</ix:nonFraction> as follows: (i) $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedLegalFeesMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_c-4YxyJ_jk-9z62ejKBbXQ" decimals="0" format="ixt:numdotdecimal" name="ibio:CashPaymentsReceivablesRelatedToLitigationSettlement" scale="0" id="Narr_Fg78nAsSX0yHCH9uhDa3KQ">16,000,000</ix:nonFraction> to be paid no later than May 14, 2021 (which is expected to be paid <ix:nonFraction unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg" contextRef="Duration_5_4_2021_To_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_eCKkBDi1PUu1tOF1oLvpIQ" decimals="2" format="ixt:numdotdecimal" name="ibio:PercentageOfLegalFeesExpectedToBeReceived" scale="-2" id="Narr_uYeaL_wTsECIU534LyvGjw">100</ix:nonFraction>% to cover legal fees and expenses); (ii) <span style="-sec-ix-hidden:Hidden_PJle0PEsI0uXVu8jrliU2w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span> payments of $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_31_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentTwoMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_KtCuFsBjc0WIUmqqIyBxaQ" decimals="0" format="ixt:numdotdecimal" name="ibio:SettlementAssetsNonCurrent" scale="0" id="Narr_CroCfNCc9kmeZIvs8pMmDA">5,100,000</ix:nonFraction> payable by March 31, 2022 and 2023 and (iii) as additional consideration for a license agreement, <span style="-sec-ix-hidden:Hidden__ic71Y4ppUShPuWLdTGl2Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span> payments of $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_3_1_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentTwoMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_d6E-TSK80kuu0sljeRCUGw" decimals="0" format="ixt:numdotdecimal" name="ibio:CashPaymentsReceivablesRelatedToLitigationSettlement" scale="0" id="Narr_cQS5iSwvpUqrS5WJcDK78w">900,000</ix:nonFraction> due on March 1, 2022 and 2023. The license provides for a nonexclusive, nontransferable, worldwide, fully paid-up license to all intellectual property rights in and to certain plant-based technology developed by FhUSA from 2003 through 2014 that were the subject of the Lawsuit. After payment of the fees and expenses of its attorneys and others retained by the Company, including the litigation funding company, the Company&#8217;s estimated aggregate net cash recovery as a result of the Settlement Agreement will be approximately $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_DniZqopZZkSjp3fXCv6SrQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GainContingencyUnrecordedAmount" scale="0" id="Narr_5V4ZKpiSr0efxipuhN-bUw">10,200,000</ix:nonFraction>. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of June 30, 2021, the Company held receivables related to the settlement in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_6_30_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_CoaZKFcMoUunX2IienHmqw" decimals="0" format="ixt:numdotdecimal" name="ibio:CashPaymentsReceivablesRelatedToLitigationSettlement" scale="0" id="Narr_qdhUZGjOqk6Jt025sPAdaw">10,200,000</ix:nonFraction>. This amount was recorded in the consolidated statement of operations and comprehensive loss as settlement income in Fiscal 2021. &#160;During the quarter ended March 31, 2022, the Company received the first payment of $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_6pSybpjm2Em9u1qgqtHc8Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLegalSettlements" scale="0" id="Narr_iCr0GgwzZUS0VJKxjcilIQ">5,100,000</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 17, 2023, the Company received a payment of $5,100,000 from Fraunhofer related to the Fraunhofer Settlement Funds and in accordance with the Fourth Amendment to the Credit Agreement with Woodforest, transferred $3,000,0000 to a Company account at Woodforest on March 24, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company would recognize the $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_2_9_2022_To_2_9_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_jUBQVMVhmEuilj8unuIy3A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LitigationSettlementAmountAwardedFromOtherParty" scale="6" id="Narr_mIz43m0XN0uOxN6BvhdiIg">1.8</ix:nonFraction> million of license revenue when it determines the collection of the license fees was reasonably assured in accordance with ASC 606. On February 9, 2022, the Company received the first $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_2_9_2022_To_2_9_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_jUBQVMVhmEuilj8unuIy3A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLegalSettlements" scale="0" id="Narr_Md8xcyGbDESuekoScqDDSQ">900,000</ix:nonFraction> payment under the license agreement. &#160;As such, the Company determined that the collection of the license fees was reasonably assured, and the Company recognized license revenue related to the license fees and recorded a receivable for the second payment in the third quarter of 2022. &#160;The second $900,000 payment was received on February 17, 2023.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_o_FytRbVLU6Rza4WS8kABA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">20.&#160;&#160;&#160;Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company recorded <ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="Narr_c4C_PvL6IEuUXkF0mSDY1g">no</ix:nonFraction> income tax expense for the three months ended March&#160;31,&#160;2023 because the estimated annual effective tax rate was <ix:nonFraction unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="2" format="ixt-sec:numwordsen" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Narr_fKFBYkIMyUqfULLClhlJ8Q">zero</ix:nonFraction>. As of March&#160;31,&#160;2023, the Company continues to provide a valuation allowance against its net deferred tax assets since the Company believes it is more likely than not that its deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_srLb1d2QX06KtPNaSlsgQw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">21.&#160;&#160;Commitments and Contingencies </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">CRO Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On October 10, 2022, the Company entered into an agreement with a CRO for cell line development and master cell banking to produce iBio-101 in addition to process development and GMP manufacturing of iBio-101 drug substance and drug product to support GLP toxicology and Phase 1 clinical studies. &#160;The Company has incurred costs totaling approximately $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_10_10_2022_To_10_10_2022_us-gaap_TypeOfArrangementAxis_ibio_CroAgreementMember_58YO1TPUFEKbnaIFe8Kesw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="0" id="Narr_CRjdnlbwe0a-crjUFDhTsQ">422,000</ix:nonFraction> through March 31, 2023. &#160;The Company is committed to additional costs totaling approximately $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="As_Of_10_10_2022_us-gaap_TypeOfArrangementAxis_ibio_CroAgreementMember_Bo_t44xgLU28rjco1A0Xvw" decimals="0" format="ixt:numdotdecimal" name="ibio:EstimatedAdditionalCostOnDevelopment" scale="0" id="Narr_FMymwXG7bU6arr6cvuxV0w">958,000</ix:nonFraction> as of the date of the filing of this report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Inflation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Although the Company has not experienced any material adverse effects on our business due to increasing inflation, it has raised operating costs for many businesses and, in the future, could impact demand or pricing of manufacturing services, foreign exchange rates or employee wages. We are actively monitoring the effects these disruptions and increasing inflation could have on the Company&#8217;s operations. </p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="Tb_60M6jZsajUGVZTVm2gDyuQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">22.&#160;&#160;&#160;Employee 401(K)&#160;Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Commencing January&#160;1, 2018, the Company established the iBio,&#160;Inc. 401(K)&#160;Plan (the &#8220;Plan&#8221;). Eligible employees of the Company may participate in the Plan, whereby they may elect to make elective deferral contributions pursuant to a salary deduction agreement and receive matching contributions upon meeting age and length-of-service requirements. The Company will make a <ix:nonFraction unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="Narr_RgckjiRlJUq03TKkZkvPEg">100</ix:nonFraction>% matching contribution that is not in excess of <ix:nonFraction unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="Narr_5xxuElLbVEq0TMjWoaEtqg">5</ix:nonFraction>% of an eligible employee&#8217;s compensation. In addition, the Company may make qualified non-elective contributions at its discretion. For the three months ended March&#160;31,&#160;2023 and 2022, employer contributions made to the Plan totaled approximately $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="0" id="Narr_rnQROXfy4Uu8mKFMHf9vdg">56,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="0" id="Narr_O1kOYbXnxUeedfrbccqtXg">54,000</ix:nonFraction>, respectively. For the nine months ended March&#160;31,&#160;2023 and 2022, employer contributions made to the Plan totaled approximately $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="0" id="Narr_tSqUaUVqe0u2ws-CcB_rMA">200,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="0" id="Narr_txulreCGR0GjfatJGBUO1w">116,000</ix:nonFraction>, respectively. In addition, employer contributions included in loss from discontinued operations totaled approximately $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_qwQKiC4qEkiqgQ5177TkpA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="0" id="Narr_ZBaVg6nGH0SFioOmzcZNKw">17,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_RaNGnKpnsEaTsjOvOslUxA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="0" id="Narr_yS2wBaL_IUqwE91qwIDsMQ">41,000</ix:nonFraction> for the three months ended March&#160;31,&#160;2023 and 2022, respectively, and approximately $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_uXNvRGR-RESDya9s9QmQmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="0" id="Narr_PnJZyYKbik6du6s3dMCXbA">129,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog" contextRef="Duration_7_1_2021_To_3_31_2022_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_GqDXZ6lLOEyUlH87AA2kZw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="0" id="Narr_VYijXZXIEEO6CxeRWQ-eNQ">110,000</ix:nonFraction> for the nine months ended March&#160;31,&#160;2023 and 2022, respectively.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg" name="us-gaap:SubsequentEventsTextBlock" id="Tb_YqPnqmpEeUuR2j64PGMYGw" continuedAt="Tb_YqPnqmpEeUuR2j64PGMYGw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">23.&#160;&#160;&#160;Subsequent Events </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On April 3, 2023, 76,300 Class B Warrants were exercised, which resulted in proceeds of $79,352. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Between April 3 and April 17, 2023, Cantor Fitzgerald sold as sales agent pursuant to the Sales Agreement 892,194 shares of Common Stock. The Company received net proceeds of approximately $1.1 million during April 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May 10, 2023, iBio CDMO and Woodforest entered into a fifth amendment to the Credit Agreement (the &#8220;Fifth Amendment&#8221;), which within the Fifth Amendment Woodforest agreed to: (i) waive the obligation to deliver to Woodforest an executed copy of a Purchase Agreement for the sale of the 130,000 square foot cGMP manufacturing facility in Bryan, Texas, no later than April 14, 2023 and, (ii) release $500,000 of the $3.0 million being held in a Company account at Woodforest when the outstanding principal amount is reduced to $10.0 million and for each additional $2.5 million reduction of the outstanding principal amount, an additional $750,000 will be released from the Company account at Woodforest. &#160;In addition, starting on the effective date of the Fifth Amendment, the interest on the Term Loan increased to 5.25%, and the Term Loan shall further accrue interest, payable in kind and added to the balance of the outstanding principal amount at a fixed rate per annum equal to (a) 1.00%, if the Facility is sold on or before June 30, 2023, (b) 2.00% if the Facility is sold after June 2023, but on or before September 30, 2023, or (c) 3:00%, if the Facility is sold after September 30, 2023, or not sold prior to the maturity date. &#160;The Company also agreed to pay Woodforest a fee in the amount of (x) $75,000 if the Facility is sold on or before June 30, 2023, (y) $100,000 if the Facility is sold after June 2023, but on or before September 30, 2023, or (x) $125,000, if the Facility is sold after September 30, 2023, or not sold prior to the maturity date. &#160;After marketing the Facility with a real estate firm for approximately six months, in May 2023, the Company entered into a new agreement with a new global commercial real estate firm to remarket the Facility. &#160;As of the date of the filing of this Quarterly Report on Form 10-Q, the Company is not in negotiations on a Purchase Agreement with a potential buyer of the Facility.</p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_YqPnqmpEeUuR2j64PGMYGw_cont1"></ix:continuation><a id="_d71e1f95_83c5_47f3_96f3_d13352a95c63"></a><a id="Item2ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;2.&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The following information should be read together with the consolidated financial statements and the notes thereto and other information included elsewhere in this Quarterly Report on Form&#160;10-Q (this &#8220;Report&#8221;) and in our Annual Report on Form&#160;10-K for the&#160;year ended June&#160;30, 2022, as filed with the SEC on October 11, 2022 (the &#8220;Annual Report&#8221;). Unless the context requires otherwise, references in this Report to &#8220;iBio,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221; and similar terms mean iBio,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Forward-Looking Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">This Report contains &#8220;forward-looking statements&#8221; within the meaning of Section&#160;27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section&#160;21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). For this purpose, any statements contained herein regarding our strategy, future operations, financial position, future revenues, projected costs and expenses, prospects, plans and objectives of management, other than statements of historical facts, are forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements reflect our current views with respect to future events. Because these forward-looking statements involve known and unknown risks and uncertainties, actual results, performance or achievements could differ materially from those expressed or implied by these forward-looking statements for a number of important reasons, including those discussed in this &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and elsewhere in this Report, as well as in the section titled &#8220;Risk Factors&#8221; in the Company&#8217;s Annual Report. We cannot guarantee any future results, levels of activity, performance or achievements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this Report as anticipated, believed, estimated or expected. The forward-looking statements contained in this Report represent our estimates as of the date of this Report (unless another date is indicated) and should not be relied upon as representing our expectations as of any other date. While we may elect to update these forward-looking statements, we specifically disclaim any obligation to do so unless otherwise required by securities laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Overview </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We are an AI-driven innovator of precision antibody immunotherapies. We have a pipeline of innovative primarily immuno-oncology antibodies against hard-to-drug targets where we may face reduced competition and with antibodies that may be more selective. We </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:274.62pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">plan to use our AI-driven discovery platform to continue adding antibodies against hard-to-drug targets or to work with partners on AI-driven drug development. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Therapeutics Pipeline </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><img src="ibio-20230331x10q002.jpg" alt="Graphic" style="display:inline-block;height:274.62pt;width:541.5pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">IBIO-101: </b>an anti-CD25 molecule that works by depletion of immunosuppressive T-regulatory cells (&#8220;Tregs&#8221;) via antibody-dependent cellular cytotoxicity (&#8220;ADCC&#8221;), without disrupting activation of effector T-cells (&#8220;Teffs&#8221;) in the tumor microenvironment. IBIO-101 could potentially be used to treat solid tumors, hairy cell leukemia, relapsed multiple myeloma, lymphoma, or head and neck cancer. IBIO-101 is currently in the Investigational New Drug (&#8220;IND&#8221;) enabling stage. We have contracted with a contract research organization (&#8220;CRO&#8221;) to assist with the development of the manufacturing process, which includes but is not limited to process and cell line development for the production of the drug substance and drug product. IBIO-101 is strategically positioned as a fast follower to Hoffman-La Roche&#8217;s RG6292 molecule that recently released Phase 1 clinical data. While RG6292 showed signs of efficacy, especially in combination with PD-L1 monoclonal antibody, and was well tolerated, we anticipate additional clinical research will be needed to determine whether different cancer types are more efficacious than others. As a result, we have decided to pause the IND enabling studies until additional data is released on RG6292. This approach will allow us to gather more information, thoroughly evaluate the market potential and optimize our financial resources and the development plan for IBIO-101 to maximize its potential for success.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">CCR8:</b> targets depletion of highly immunosuppressive CCR8+ Tregs in the tumor microenvironment via an ADCC mechanism with selective binding to CCR8 over its closely related cousin, CCR4, to avoid off-target effects. A CCR8 program could potentially be broadly applicable in solid tumors and/or as a prospective combination therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">EGFRvIII: </b>binds a tumor-specific mutation of EGFR variant III with an afucosylated antibody for high ADCC. Because of its specificity binding to the tumor-specific mutation, it could potentially reduce toxicity and/or expand the therapeutic window compared to simple broad EGFR-targeted alternatives. EGFRvIII is constantly &#8220;switched on&#8221; which can lead to the development of a range of different cancers. An EGFRvIII antibody could potentially be used to treat glioblastoma, head and neck cancer or non-small cell lung cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">CD3 antibody panel:</b> provides a range of CD3 affinities with cross-reactivity to non-human primates and increased the humanness of the antibody sequences. The antibody panel is intended to serve as one arm of T-cell-redirecting bispecific antibodies, a new class of therapeutic antibodies designed to simultaneously bind to T-cells via CD3 and to tumor cells via tumor-specific antigens or tumor-associated antigens, inducing T-cell-mediated killing of tumor cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">MUC16:</b> a highly expressed target on ovarian cancer cells and an attractive tumor associated target for therapeutic antibodies. However, antibodies targeting MUC16 are prone to tumor resistance via epitope shedding and dysregulated glycosylation. Epitope-steered </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">antibodies that bind to an epitope that avoids both of these tumor resistance mechanisms could potentially be used to treat MUC16 positive tumors, particularly those tumors that are resistant to other MUC16 antibodies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">PD-1 Agonist: </b>selectively binds PD-1 to suppress auto-reactive T-cells without PD-L1/PD-L2 blocking. A PD-1 agonist could potentially be used to treat inflammatory bowel disease, systemic lupus erythematosus, multiple sclerosis or other inflammatory diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In addition to the programs described above, the Company also has three additional early discovery programs that have the potential to advance into later stages of preclinical development and are designed to tackle hard-to-drug targets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">IBIO-100 and Endostatin E4</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our preclinical anti-fibrotic program, IBIO-100, has been undergoing a review process as part of our ongoing effort to prioritize our resources and focus on the most promising opportunities. The IBIO-100 program design is based &#160;upon work by Dr. Carol Feghali-Bostwick, Professor of Medicine at the Medical University of South Carolina and Vice-Chair of the Scleroderma Foundation. Her initial work was conducted at the University of Pittsburgh, and we have licensed the patents relevant for the continued development of the molecule from the university. &#160;After careful consideration, in February 2023, we terminated all efforts on IBIO-100 anti-fibrotic program and provided a six (6) month notice of termination of the license agreement to the University of Pittsburgh, as required by the license agreement. Pursuant to termination of the license agreement with the University of Pittsburgh, our financial obligations for the management of the patents under the license will cease on August 14, 2023, and at such time, will transition back to the University of Pittsburgh.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As part of this decision, we are intending to complete the pre-clinical cancer studies we are conducting in collaboration with University of Texas Southwestern using E4 endostatin peptide, which is derived from IBIO-100. After the pre-clinical studies are completed, we will re-assess whether to further pursue the oncology program and have further discussions with the University of Pittsburgh. This approach allows us to gather valuable data and insights that will inform our future decisions regarding the potential of E4 endostatin peptide as an oncology program. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">AI Drug Discovery Platform</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In September 2022, we purchased substantially all of the assets of RubrYc Therapeutics (for a complete description of the transaction please see Note 6 &#8211; Significant Transactions). The AI Drug Discovery platform technology is designed to be used to discover antibodies that bind to hard-to-target subdominant and conformational epitopes for further development within our existing portfolio or in partnership with outside entities. The RubrYc AI platform is built upon three key technologies. </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Epitope Targeting Engine:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> A proprietary machine-learning platform that combines computational biology and 3D-modeling to identify molecules that mimic hard-to-target binding sites on target proteins, specifically, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">subdominant and conformational epitopes.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The creation of these small mimics enables the engineering of therapeutic antibody candidates that can selectively bind immune and cancer cells better than &#8221;trial and error&#8221; antibody engineering and screening methods that are traditionally focused on dominant epitopes.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">RubrYcHu</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">TM</sup><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"> Library:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> An </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">AI-generated human antibody library free of significant sequence liabilities that provides a unique pool of antibodies to screen. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The combination of the Epitope Targeting Engine and screening with the </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">RubrYcHu</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Library has been shown to reduce the discovery time from ideation to </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">in vivo</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> proof-of-concept (PoC) by up to four months. This has the potential to enable more, and better, therapeutic candidates to reach the clinic faster. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">StableHu</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">TM</sup><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"> Library:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> An </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">AI-powered sequence optimization library used to improve antibody performance</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. Once an antibody has been advanced to the lead optimization stage, </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">StableHu</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> allows precise and rapid optimization of the antibody binding regions to rapidly move a candidate molecule into the IND-enabling stage.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On January 3, 2023, the United States Patent and Trademark Office issued U.S. Patent No. 11,545,238, entitled &#8220;Machine Learning Method for Protein Modelling to Design Engineered Peptides,&#8221; which, among other claims, covers a machine learning model for engineering peptides, including antibody epitope therapeutics. Subject to any potential patent term extensions, the patent will expire on May 13, 2040. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Recent Developments  </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On January 17, 2023, we announced the resignation of Mr. Robert Lutz, the Chief Financial and Business Officer<span style="background:#ffffff;">, effective February 10, 2023. On January 25, 2023, we announced the Board of Directors appointed Dr. Martin Brenner to the position of Interim Chief Executive Officer, effective January 20, 2023, and Mr. Felipe Duran, to the position of Interim Chief Financial Officer, effective as of February 13, 2023. We are continuing the search for a successor Chief Executive Officer and as such, Dr. Brenner&#8217;s position of Interim Chief Executive Officer will end when the Company appoints a successor.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On February 9, 2023, we and Woodforest entered into the Second Amendment to the Credit Agreement and amended the Credit Agreement to: (i) waive any current or prior default of the Liquidity Covenant until a period specified in such amendment which is dependent upon the occurrence of a specific milestone in the Credit Agreement, (ii) in addition to our unrestricted cash, until such period dependent upon the occurrence of a specific milestone in the Credit Agreement, we can account for all amounts owed to us by Fraunhofer as part of our legal settlement with them (see Note 19 &#8211; Fraunhofer Settlement for more information) in determining whether we are in compliance with the Liquidity Covenant, (iii) permit us to sell certain equipment located at the Facility, whereby forty percent (40%) of the net proceeds will be paid to Woodforest within ten (10) days following the end of the month of when the sales occurred, and (iv) remove any affirmative obligation on the part of the iBio CDMO to continue conducting its primary business. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On February 20, 2023, we and Woodforest entered into a third amendment to the Credit Agreement (the &#8220;Third Amendment&#8221;), which removed the added milestone specified in the Second Amendment, the failure of which would be an event of default. &#160;In addition, the Guaranty was amended to allow us until February 28, 2023, to account for the Fraunhofer Settlement Funds in determining whether we are in compliance with the Liquidity Covenant without being dependent upon a specified milestone. &#160;In addition, we agreed that each time we consummate an at-the-market issuance of Equity Interests (as defined within the Credit Agreement), no later than five (5) days following such issuance of Equity Interests, we will (i) pay to Woodforest in immediately available cash funds, without setoff or counterclaim of any kind, forty percent (40%) of the Net Proceeds (as defined within the Credit Agreement) received by us for such issuance of Equity Interests; provided, any such payment would cease upon payment obligations in full and (ii) provide Woodforest with a detailed accounting of each such issuance of Equity Interests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On March 24, 2023, we and Woodforest entered into a fourth amendment to the Credit Agreement (the &#8220;Fourth Amendment&#8221;), which within the Fourth Amendment Woodforest agreed to (i) reduce the percentage of any payment to Woodforest we are required to make from the proceeds of sales of its common stock under its at-the-market facility from 40% to 20%, (ii) reduce the percentage of any payment to Woodforest we are required to make from the proceeds of sales of its equipment from 40% to 20%, and (iii) allow us to retain $2,000,000 million of the $5,100,000 million that the Company received from the Fraunhofer Settlement Funds, with the remaining $3,000,000 million being held in a Company account at Woodforest. &#160;In addition, we are obligated to (y) deliver to Woodforest an executed copy of a purchase agreement (the &#8220;Purchase Agreement&#8221;) for the sale of the 130,000 square foot cGMP manufacturing facility in Bryan, Texas (&#8220;Facility&#8221;), no later than April 14, 2023, and (z) pay to Woodforest a fee in the amount of $75,000 on the earlier of the date of the closing of the Purchase Agreement, or the Maturity Date (as defined in the Credit Agreement). &#160;In addition, on March 24, 2023, we entered into a fourth amendment to the Guaranty, which reduced the Liquidity Covenant from $7,500,000 to $1,000,000. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_Hlk133939629"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On May 10, 2023, we and Woodforest entered into a fifth amendment to the Credit Agreement (the &#8220;Fifth Amendment&#8221;), which within the Fifth Amendment Woodforest agreed to: (i) waive our obligation to deliver to Woodforest an executed copy of a Purchase Agreement for the sale of the Facility no later than April 14, 2023 and, (ii) release $500,000 of the $3.0 million being held in a Company account at Woodforest when the outstanding principal amount is reduced to $10.0 million and for each additional $2.5 million reduction of the outstanding principal amount, an additional $750,00 will be released from the Company account at Woodforest. &#160;In addition, starting on the effective date of the Fifth Amendment, the interest on the Term Loan increased to 5.25%, and the Term Loan shall further accrue interest, payable in kind and added to the balance of the outstanding principal amount at a fixed rate per annum equal to (a) 1.00%, if the Facility is sold on or before June 30, 2023, (b) 2.00% if the Facility is sold after June 2023, but on or before September 30, 2023, or (c) 3:00%, if the Facility is sold after September 30, 2023, or not sold prior to the maturity date. &#160;The Company also agreed to pay Woodforest a fee in the amount of (x) $75,000 if the Facility is sold on or before June 30, 2023, (y) $100,000 if the Facility is sold after June 2023, but on or before September 30, 2023, or (x) $125,000, if the Facility is sold after September 30, 2023, or not sold prior to the maturity date. After marketing the Facility with a real estate firm for approximately six months, in May 2023, we entered into an agreement with a global commercial real estate firm to market the Facility. As of the date of the filing of this Quarterly Report on Form 10-Q, we are not in negotiations on a Purchase Agreement with a potential buyer of the Facility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity and Capital Resources </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The history of significant losses, the negative cash flow from operations, the limited cash resources on hand and the dependence by the Company on its ability to obtain additional financing to fund its operations after the current cash resources are exhausted raises substantial doubt about the Company&#39;s ability to continue as a going concern. <span style="background:#ffffff;">Our management concluded that our recurring losses from operations and the fact that we have&#160;not generated significant revenue or positive cash flows from operations raise substantial doubt </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="background:#ffffff;">about our ability to continue as a going concern for the next 12 months after issuance of our financial statements. Our auditors also included an explanatory paragraph in its report on our consolidated financial statements as of and for the year ended June 30, 2022 with respect to this uncertainty.</span> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In an effort to remain a going concern and increase cash reserves, we completed a public offering in December 2022, reduced our work force by approximately 60% (a reduction of approximately 69 positions) in November 2022, and ceased operations of our CDMO facility thereby reducing annual spend on expenses by approximately 50%. Additionally, we continue our efforts to sell our CDMO assets and facility that were initiated by management in July 2022; however, there can be no assurance that we will be successful in selling the CDMO assets and facility at favorable prices, if at all. (See Note 3 &#8211; Discontinued Operations for more information.) Additional potential options being considered&#160;to further increase liquidity include lowering our expenses further, focusing product development on a select number of product candidates, the sale or out-licensing of certain product candidates, sell the CDMO, equipment sales, raising money from capital markets, grant revenue or collaborations, or a combination thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the first quarter of Fiscal year 2023, we completed at-the-market offerings and sold 175,973 shares of Common Stock. We received net proceeds of approximately $1.2 million. During the second quarter of Fiscal year 2023, we completed a public offering and raised gross proceeds of approximately $3.5 million selling an aggregate of 3,365,385 shares of its common stock (or pre-funded warrants in lieu thereof), Series A warrants to purchase up to 3,870,192 shares of common stock and Series B warrants to purchase up to 3,870,192 shares of common stock. Subsequently after the public offering, during the third quarter of Fiscal year 2023, 341,300 Class A Warrants and 1,704,916 Class B Warrants were exercised. On April 3, 2023, an additional 76,300 Class B Warrants were exercised. &#160;The total proceeds from Class A and B Warrants exercised during the third quarter of Fiscal 2023 and on April 3, 2023 were $2,207,000. Also, during the third quarter of Fiscal year 2023, we completed at-the-market offerings and sold 1,375,906 shares for which we received approximately $2.0 million. &#160;Additionally, between April 3 and April 17, 2023, we completed at-the-market offerings and sold 892,194 shares of which we received approximately $1.1 million. (See Note 16 &#8211; Stockholder&#8217;s Equity for more information.) </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;">Our cash, cash equivalents and restricted cash of $9.8 million</span> <span style="font-size:10pt;">as of March&#160;31,&#160;2023, is not anticipated to be sufficient to support operations through the first quarter of fiscal year 2024,</span><b style="font-size:10pt;font-weight:bold;"> </b><span style="font-size:10pt;">unless we further reduce our burn rate, sell the CDMO assets or the facility for amounts above the debt on the facility, or increase our capital as described above. Regardless of whether we are able to reduce our burn rate or sell or out-license certain assets or parts of the business, we will need to raise additional capital in order to fully execute our longer-term business plan. It is our goal to implement one or more potential options described above to allow us to have a cash runway for at least 12 months from the date of the filing of this Quarterly Report on Form 10-Q. However, there can be no assurance that we will be successful in implementing any of the options that we are evaluating.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our liquidity and operations could also be impacted by our obligations under the Woodforest Credit Agreement. As described in detail in Section 6. Significant Transactions, to avoid violating the Liquidity Covenant associated with the parent guarantee of the debt we need to pay off the debt through the sale of the facility or we need to raise additional capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;text-align:justify;margin:0pt;">Results of Operations&#160;- Comparison of the three months ended March&#160;31,&#160;2023 and 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Revenue</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Revenue from the CDMO operations is now included in discontinued operations and not broken out separately on the financial statements. Our ongoing business is primarily focused on i) development of our pipeline for which we do not expect revenue and ii) on our AI-driven discovery platform. We may have revenue with the AI-driven discovery platform in the future. Revenue for the three months ended March 31, 2022 was related to a licensing agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Research and Development Expenses (&#8220;R&amp;D&#8221;)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">R&amp;D expenses for the three months ended March&#160;31,&#160;2023 and 2022 were $2.6 million and $3.3 million, respectively, a reduction of approximately ($0.7) million. The decrease in R&amp;D expenses is mainly due to certain tasks and assays being performed in-house which were previously outsourced, and a decrease in spending for consultants or outside services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">General and Administrative Expenses&#160;(&#8220;G&amp;A&#8221;)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">G&amp;A expenses for the three months ended March&#160;31,&#160;2023 and 2022 were approximately $3.5 million and $5.3 million, respectively, a decrease of ($1.8) million. The decrease in expenses is primarily attributable to the reduction in personnel costs, a decrease in spending for consultants or outside services, and reduced amortization of intangible assets impaired during Q2 of Fiscal year 2023.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Total Operating Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Total operating expenses, consisting primarily of R&amp;D and G&amp;A expenses, for the three months ended March&#160;31,&#160;2023 were approximately $6.2 million, compared to approximately $8.6 million in Fiscal year 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Discontinued Operations</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 2, 2022, we announced our plans to divest our contract development and manufacturing organization (iBio CDMO, LLC) in order to complete its transformation into an AI-driven precision antibody discovery and development company. In conjunction with the divestment, we completed a workforce reduction of approximately 60% and discontinued CDMO operations. &#160;CDMO operations remain treated as a discontinued operation on our financial statements. Losses for Discontinued Operations for the three months ended March&#160;31,&#160;2023 and 2022 were approximately ($1.0) million and ($5.6) million, respectively. &#160;In the three months ended March&#160;31,&#160;2023, we had a reduction in consumable supplies expenses of approximately ($1.1) million, decrease of approximately ($1.1) million for consultants and outside services, decrease in depreciation expense of ($0.7) million, decrease in personnel costs ($0.6) million and a net gain of approximately $0.5 million from auction of machinery and equipment. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Net Loss Available to iBio,&#160;Inc. Stockholders</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net loss available to iBio,&#160;Inc. stockholders for the three months ended March&#160;31,&#160;2023 was ($7.3) million, or ($0.55) per share. Net loss available to iBio,&#160;Inc. stockholders for the three months ended March&#160;31,&#160;2022 was approximately ($12.4) million or ($1.42) per share. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;text-align:justify;margin:0pt;">Results of Operations&#160;- Comparison of the nine months ended March&#160;31,&#160;2023 and 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Revenue</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Revenue from the CDMO operations is now included in discontinued operations and not broken out separately on the financial statements. Revenue was otherwise immaterial. Our ongoing business is primarily focused on i) development of our pipeline for which we do not expect revenue and ii) on our AI-driven discovery platform. We may have revenue with the AI-driven discovery platform in the future. Revenue for the nine months ended March 31, 2022 was mainly related to a licensing agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Research and Development Expenses (&#8220;R&amp;D&#8221;)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">R&amp;D expenses for the nine months ended March&#160;31,&#160;2023 and 2022 were $8.0 million and $6.3 million, respectively, an increase of approximately $1.7 million. The increase was primarily driven by the investments into our pipeline including IBIO-101, CCR8, and EGFRvIII, and the expansion of our AI-driven discovery platform to include increases in R&amp;D personnel at the San Diego facility, increased spend on lab supplies, lab equipment/maintenance, and facility rent for the San Diego team. &#160;This increase was partially offset by a reduction in spending on consultants and outside services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">General and Administrative Expenses&#160;(&#8220;G&amp;A&#8221;)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">G&amp;A expenses for the nine months ended March&#160;31,&#160;2023 and 2022 were approximately $16.4 million and $14.9 million, respectively, an increase of $1.5 million. The increase is primarily from the increase in personnel costs for severance and retention expenses offset by a reduction in spending for legal and consulting fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Total Operating Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Total operating expenses, consisting primarily of R&amp;D and G&amp;A expenses, for the nine months ended March&#160;31,&#160;2023, were approximately $24.4 million, compared to approximately $21.1 million in the same period of 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Discontinued Operations</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 2, 2022, we announced our plans to divest its contract development and manufacturing organization (iBio CDMO, LLC) in order to complete its transformation into an AI-driven precision antibody discovery and development company. In conjunction with the divestment, we completed a workforce reduction of approximately 60% and discontinued CDMO operations. &#160;CDMO operations are now treated as a discontinued operation on our financial statements. Losses for Discontinued Operations for the nine months ended March&#160;31,&#160;2023 and 2022 were approximately ($34.6) million and ($14.1) million, respectively. &#160;For the nine months ended March&#160;31,&#160;2023, the loss included impairments of fixed assets of approximately ($17.6) million, consumables and inventory of approximately ($4.9) million, personnel related costs of ($7.5) million including severance, and the remaining costs were operational.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Net Loss Available to iBio,&#160;Inc. Stockholders from Continuing Operations</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net loss available to iBio,&#160;Inc. stockholders for the nine months ended March&#160;31,&#160;2023 was ($59.0) million, or ($5.57) per share. Net loss available to iBio,&#160;Inc. stockholders for the nine months ended March&#160;31,&#160;2022 was approximately ($33.3) million or ($3.82) per share. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Uses of Cash and Funding Requirements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Net Cash Used in Operating Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net cash used in operating activities was approximately ($25.5) million for the nine months ended March&#160;31,&#160;2023. The use of cash was primarily attributable to funding our net loss for the period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Net Cash Provided by Investing Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net cash provided by investing activities of approximately $7.0 million for the nine months ended March&#160;31,&#160;2023 was primarily attributable to the redemption and sale of debt securities of $11.0 million and to a lesser extent $2.1 million from the sale of fixed assets in an auction process which was offset by the purchase of fixed assets of ($5.2) million. (Refer to Note 6 &#8211; Significant Transactions for details.) </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Net Cash Used in Financing Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net cash used in financing activities during the nine months ended March&#160;31,&#160;2023, was approximately ($0.4) million and was mainly attributable to the proceeds from the sale of common stock, warrants exercised, offset by payments towards the term note made to Woodforest (see Note 13 &#8211; Debt for further details).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Funding Requirements </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have incurred significant losses and negative cash flows from operations since our spin-off from Integrated BioPharma in August&#160;2008. As of March&#160;31,&#160;2023, our accumulated deficit was approximately $(282.9) million and we used approximately ($24.8) million of cash for operating activities during the nine months ended March&#160;31,&#160;2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We plan to fund our future business operations using cash on hand, through proceeds realized in connection with the commercialization of our technologies, through proceeds from the sale of the CDMO entity or the facility, through the proceeds from our license agreement with Fraunhofer, through potential proceeds from the sale or out-licensing of assets, and through proceeds from the sale of additional equity or other securities. However, there can be no assurance that we will be successful in implementing these plans, many of which will take several years before we will realize proceeds. The Term Loan with Woodforest and the Guaranty requires we maintain an unrestricted cash balance of $1.0 million, which limits our ability to use our funds for operations. &#160;If we should default on the Credit Agreement and Woodforest does not waive the default, and if Woodforest makes a demand for the acceleration of all payments due to this default, it could result in all obligations that are guaranteed being due and payable immediately without further notice. We cannot be certain that such funding will be available on favorable terms or available at all. If we are unable to raise funds when required or on favorable terms, this assumption may no longer be operative, and we may have to: a) significantly delay, scale back, or discontinue the product application and/or commercialization of our proprietary technologies; b) seek collaborators for our technology and product candidates on terms that are less favorable than might otherwise be available; c) relinquish or otherwise dispose of rights to technologies, product candidates, or products that we would otherwise seek to develop or commercialize; or d) possibly cease operations. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">See Liquidity and Capital Resources above for further information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Off-Balance Sheet Arrangements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As part of our ongoing business, we do not participate in transactions that generate relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities (&#8220;SPE&#8221;s), which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually limited purposes. As of March&#160;31,&#160;2023, we were not involved in any SPE transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Critical Accounting Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our condensed consolidated financial statements are presented in accordance with U.S. GAAP, and all applicable U.S. GAAP accounting standards effective as of March 31, 2023, have been taken into consideration in preparing the condensed consolidated </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">financial statements. The preparation of condensed consolidated financial statements requires estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures. Some of those estimates are subjective and complex, and, consequently, actual results could differ from those estimates. We base our estimates, to the extent possible, on historical experience. Historical information is modified as appropriate based on current business factors and various assumptions that we believe are necessary to form a basis for making judgments about the carrying value of assets and liabilities. We evaluate our estimates on an ongoing basis and make changes when necessary. Actual results could differ from our estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Critical accounting estimates are those estimates made in accordance with U.S. GAAP that involve a significant level of estimation uncertainty and have had or are reasonably likely to have a material impact on the financial condition or results of operations of the Company. The following accounting estimate had a material impact on the results of operations of the Company for the three and nine months ended March&#160;31,&#160;2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Impairment of Fixed Assets </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We monitor fixed assets for impairment indicators throughout the year. &#160;When necessary, charges for impairments of long-lived assets are recorded for the amount by which the fair value is less than the carrying value of these assets. &#160;Changes in the Company&#8217;s business strategy or adverse changes in market conditions could impact impairment analyses and require the recognition of an impairment charge. Although we base our estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 3, 2022, we announced we are seeking to divest our contract development and manufacturing organization (iBio CDMO) in order to complete our transformation into an antibody discovery and development company. Through the process of seeking to divest its contract development and manufacturing organization, we continue to market for sale the 130,000-square-foot cGMP facility location in Bryan, Texas (the &#8220;Facility&#8221;). The decision to divest triggered a quantitative impairment analysis of our CDMO fixed assets of the building in Bryan, Texas totaling $22.65 million and machinery and equipment totaling $13.4 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We utilized a market approach, using independent third-party appraisals, including comparable assets, in addition to bids received from prospective buyers, to estimate the fair value of the property and equipment. &#160;We recorded an impairment charge of $6.3 million for the building and $11.3 million for the machinery and equipment in the quarter ended December 31, 2022. &#160;The key assumption in the valuation analysis is the expected sale price of $21.1 million for the Bryan, Texas facility and the associated machinery and equipment less approximate costs to sell of $2.7 million. The carrying amount of the CDMO fixed assets after impairment at December 31, 2022 was $18.5 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On February 10, 2021, the &#8220;Company, entered into an Auction Sale Agreement (the &#8220;Auction Sale Agreement&#8221;) with Holland Industrial Group, together with Federal Equipment Company and Capital Recovery Group LLC (collectively, the &#8220;Auctioneers&#8221;) for the sale at public auction of equipment and other tangible personal property (the &#8220;Equipment&#8221;) located at the Facility. &#160;The Auctioneer guaranteed an amount of gross proceeds from the sale of the equipment of $2.1 million, which was paid to the Company on February 17, 2023. The auction, which commenced on March 24, 2023 and concluded on March 30, 2023, resulted in total proceeds of approximately $2.9 million. &#160;In accordance with the Auction Sale Agreement, the Company received 80% of the excess proceeds, after Holland was paid a fixed amount of $0.2 million for expenses, which was approximately $0.5 million and was received on May 2, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may have to record a further, potentially material, impairment to the fair value of this asset group if we do not realize a sale transaction for the expected amount of $19 million less costs to sell in the near term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Impairment of Indefinite-Lived Intangible Assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For indefinite life intangible assets, we perform an impairment test annually and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Evaluating for impairment requires judgment, including the estimation of future cash flows, future growth rates and profitability and the expected life over which cash flows will occur. Changes in the Company&#8217;s business strategy or adverse changes in market conditions could impact impairment analyses and require the recognition of an impairment charge. Although we base our estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We tested for impairment of the IBIO-101 therapeutic technology (or &#8220;IP&#8221;), classified as an indefinite-lived intangible asset, which had a carrying amount of $5 million at December 31, 2022. The key impairment trigger was the decline in the Common Stock price over the month of December 2022. We did not record an impairment charge to the IP as of December 31, 2022. No triggering events were identified during the third quarter of Fiscal 2023 requiring additional testing. &#160;We will continue to monitor the value of the IP, since we </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">believe it is at risk for impairment, and will perform our annual impairment testing in the fourth quarter of Fiscal 2023. The primary impairment indicators that may arise in the near future are (1) any sustained decline in our common stock market price and (2) FDA decisions on similar competing technologies that are applying for Phase 1 approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The December 31, 2022 impairment analysis on the IP is considered a critical accounting estimate because it entailed management preparing highly uncertain cash flow projections and valuation assumptions of significant complexity and subjectivity. One fair value indicator was developed using a discounted cash flow (&#8220;DCF&#8221;) analysis, where the most subjective assumptions were the estimated probability of obtaining Phase 1 approval of the IBIO-101 technology from the FDA of 65% and a discount rate of 12%. These two key assumptions remained the same with those we included in our June 30, 2022 impairment analysis for the IP. We provide the following quantitative sensitivity analysis only to allow our investors to obtain a better understanding of the degree and direction of potential material change in the fair value estimate developed using the DCF approach:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A hypothetical increase in the discount rate to 15% alone (all other assumptions kept constant) would not lead to an impairment of the intangible. However, a hypothetical increase in the discount rate to 16% would lead to an impairment of $1 million to the intangible.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A decrease in the estimated probability of clearing Phase 1 FDA approval to 45% (all other assumptions kept constant) would not lead to an impairment of the intangible. However, a hypothetical decrease in the estimated probability of clearing Phase 1 FDA approval to 35% would lead to an impairment charge of $1.4 million to the intangible.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A second fair value indicator was developed using a market approach. &#160;We reviewed public pharma/biotech company acquisitions &amp; mergers completed from 2018-2023 with deal value less than $1 billion from the GlobalData database. The equity premium observed in merger and acquisition transactions that closed during 2022 for similar therapeutic technologies was in the 50% to 125% range. We selected an equity market premium of 100% as the most appropriate assumption at December 31, 2022, which was consistent with the 20-day median premium of the comparable pulled. A hypothetical decrease in the observable equity market premiums of 5% would lead to the estimated fair value attributable to the IP under the market approach to decline materially and result in an approximate $1 million impairment amount.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We continue to operate in a highly competitive environment, rising interest rates (and cost of capital) and experiences liquidity challenges. Accordingly, we may have to adjust our cash flow projections and valuation assumptions in the near future to account for market trends and any changes to our research and development plans. Any such future adjustments may lead to material future impairments in the IP and other related assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our remaining critical accounting estimates remain consistent with the information disclosed in the same section in our last annual report on Form 10-K for the year ended June 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_1d24a094_a427_4b91_aea0_e31303962a6c"></a><a id="Item3QuantitativeandQualitativeDisclosur"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;3.&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As a smaller reporting company, we are not required to provide the information required by this Item&#160;3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_bae7a397_e2da_4da0_807f_3cec0c0ea073"></a><a id="Item4ControlsandProcedures_545173"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;4.&#160;&#160;Controls and Procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;margin:0pt;">Evaluation of Disclosure Controls and Procedures </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-align:justify;background:#ffffff;margin:0pt;">Our management, under the direction of our interim Chief Executive Officer&#160;(our Principal Executive Officer) and interim Chief Financial Officer (our Principal Financial Officer) have evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Exchange Act, as amended, as of March 31,&#160;2023. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules&#160;and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company&#8217;s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. The Company&#8217;s disclosure controls and procedures are also designed to ensure that such information is accumulated and communicated to management to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 10pt 0pt;">Based on our evaluation, our Principal Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures were ineffective as of March 31,2023 due to the material weakness identified below.&#160; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">During the preparation of the Quarterly Report for the quarter ended March 31, 2023, we identified a material weakness in our controls relating to accounting for stock-based compensation expense relating to the vesting of severed employees&#8217; awards.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;margin:0pt;">Changes in Internal Control over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">There were no changes in our internal control over financial reporting, as such term is defined in Rules&#160;13a-15(f)&#160;and 15d-15(f)&#160;under the Exchange Act, during the quarter ended March 31, 2023, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Plans to Remediate Internal Control over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Management is currently assessing the actions that need to be taken to remediate the material weakness identified above. The material weakness will only be deemed to have been remediated after the new controls and procedures have been in place and management has concluded through appropriate testing that the controls are operating effectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_0de26404_5c2a_444f_ae72_3fe18572a2a0"></a><a id="PARTIIOTHERINFORMATION_600713"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">PART&#160;II.&#160;&#160;OTHER INFORMATION</p><a id="Item1LegalProceedings_731318"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1.&#160;&#160;Legal Proceedings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">We are not subject to any material legal proceedings. &#160;From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. &#160;We are not currently a party to any legal proceedings that, in the opinion of management, are likely to have a material adverse effect on our business. &#160;Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors</span>.</p><a id="_f7e13ade_3273_4e06_bfab_edfe23bb77ff"></a><a id="Item1ARiskFactors_275295"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1A.&#160;&#160;Risk Factors </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Our business is subject to risks and events that, if they occur, could adversely affect our financial condition and results of operations and the trading price of our securities.&#160;</i><i style="color:#222222;font-style:italic;">The following information updates, and should be read in conjunction with, the information disclosed in Part&#160;I,&#160;Item&#160;1A, &#8220;Risk Factors,&#8221; contained in the</i><i style="font-style:italic;"> Annual Report. Except as described below, our risk factors as of the date of this Report have not changed materially from those described in &#8220;Part&#160;I, Item&#160;1A. Risk Factors&#8221;&#160;of our Annual Report.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We are reviewing potential options to extend our cash runway. This review could impact our future operations and financial position.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">We are currently evaluating a number of potential options to expand our cash runway, the implementation of which will impact the Company&#8217;s liquidity. In an effort to improve liquidity and runway, we recently announced that we were selling our CDMO business and Facility, reducing our work force by approximately 60%, and ceasing operations of our CDMO, thereby reducing annual spend on expenses by approximately 50%. Potential options being considered&#160;to further increase liquidity include lowering our expenses further, focusing product development on a select number of product candidates, the sale or out-licensing of certain product candidates, raising money from capital markets, grant revenue or collaborations, or a combination thereof. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Our cash, cash equivalents and restricted cash of $9.8 million as of March 31, 2023, is not anticipated to be sufficient to support our operations for at least 12 months from the date of the filing of this Quarterly Report on Form 10-Q unless we reduce our burn rate further, sell the CDMO facility for amounts above its term note payable, or increase our capital. Regardless of whether we are able to reduce our burn rate or sell or out-licensing certain assets or parts of the business, we will need to raise additional capital in order to fully execute our near and long-term business plans. In fact, we do not believe that our current cash, cash equivalents and restricted cash as of March 31, 2023 will be sufficient to support our operations through first quarter of Fiscal 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 1pt 0pt 0pt;">There can be no assurance that we will be able to sell the CDMO assets or that if we are able to do so that we do so on favorable terms or that he exploration of potential options will result in any agreements or transactions, or that, if completed, any agreements or transactions will be successful or on attractive terms. Although we expect to be able to sell the CDMO assets in 2023, no guaranteed timetable has been established for the completion of this process, and we do not expect to disclose developments unless and until we have a material update to provide or the Board of Directors has concluded that disclosure is appropriate or required. If we determine to change our business strategy, our future business, prospects, financial position and operating results could be significantly different than those in historical periods or projected by our management. Because of the significant uncertainty regarding our future plans, we are not able to accurately predict the impact of a potential change in our business strategy and future funding requirements.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 1pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our historical operating results indicate substantial doubt exists related to our ability to operate as a going concern.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">We have incurred net losses and used significant cash in operating activities since inception, and we expect to continue to generate operating losses for the foreseeable future. As of March 31, 2023, we have an accumulated deficit of ($282.9) million. In addition, our projections regarding our cash runway are based upon certain assumptions, including that payments owed to us under outstanding notes receivable are paid at maturity.&#160; Accordingly, these assumptions are based upon the financial positions of the&#160;parties from which we are owed payments, for which there can be no guarantee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">We held cash, cash equivalents and restricted cash of $9.8 million as of March 31, 2023. Based on current trends and activities, there is significant doubt that we can continue as a going concern through the first quarter of fiscal year 2024. We have announced that we have implemented and are continuing to implement cost savings measures to expand our cash runway, the implementation of which will impact our liquidity, but these measures alone will not be sufficient to provide the financing needed to meet our near and long-term goals. Potential options being considered&#160;to increase liquidity include further lowering our expenses through decreasing spending and focusing product development on a select number of product candidates, the sale or out-licensing of certain product candidates or parts of the business, raising money from capital markets, grant revenue or collaborations, or a combination thereof. Regardless of whether we are able to reduce our burn rate or sell or out-licensing certain assets or parts of the business, we will need to raise additional capital in order to fully execute our longer-term business plan. We believe based on input from expert advisors, that it is likely we will be able to implement one or more options that will extend our cash runway for 12 months or more from the date of the filing of this Quarterly Report on Form 10-Q. However, there can be no assurance that we will be successful in implementing any of the options that we are evaluating.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Our condensed consolidated financial statements as of and for the period ended March 31, 2023, have been prepared under the assumption that we will continue as a going concern for the next 12 months. Our management concluded that our recurring losses from operations and the fact that we have&#160;not generated significant revenue or positive cash flows from operations raise substantial doubt about our ability to continue as a going concern for the next 12 months after issuance of our financial statements. Our auditors also included an explanatory paragraph in its report on our consolidated financial statements as of and for the year ended June 30, 2022 with respect to this uncertainty.&#160;If we continue to experience operating losses, and we are not able to generate additional liquidity through a capital raise or other cash infusion, we might need to secure additional sources of funds, which may or may not be available to us. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to further scale back or discontinue the development of our product candidates or other research and development initiatives or initiate steps to cease operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We need additional funding to fully execute our business plan, which funding may not be available on commercially acceptable terms or at all. If we are unable to raise capital when needed, we may be forced to delay, reduce or eliminate the commercialization of our development and manufacturing services and efforts for our product development programs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-align:justify;background:#ffffff;margin:0pt;">Even if we are able to sell the CDMO assets or the facility upon favorable terms, we will need additional capital to fully implement our near and long-term business, operating and development plans as we do not anticipate that any of our product candidates will generate revenue in the next few years, if at all. To the extent that we initiate or continue clinical development without securing collaborator or licensee funding, our research and development expenses could increase substantially.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-align:justify;background:#ffffff;margin:0pt;">When we elect to raise additional funds or additional funds are required, we may raise such funds from time to time through public or private equity offerings, debt financings, corporate collaboration and licensing arrangements or other financing alternatives. Additional equity or debt financing or corporate collaboration and licensing arrangements may not be available on acceptable terms, if at all. We currently have no committed sources of funding. &#160;On November 25, 2020, we entered into a Controlled Equity Offering SM Sales Agreement (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald &amp; Co. (&quot;Cantor Fitzgerald&quot;) to sell shares of common stock, from time to time, through an &#8220;at the market offering&#8221; program having an aggregate offering price of up to $100,000,000 through which Cantor Fitzgerald would act as sales agent (the &#8220;Sales Agent&#8221;). There can be no assurance that we will meet the requirements to be able to sell securities pursuant to the Sales Agreement, of if we meet the requirements that we will be able to raise sufficient funds on favorable terms. If we are unable to raise capital in sufficient amounts when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or commercialization efforts and our ability to generate revenues and achieve or sustain profitability will be substantially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:6pt;text-align:justify;background:#ffffff;margin:0pt;">If we are unable to raise funds when required or on favorable terms, this assumption may no longer be operative, and we may have to: a) significantly delay, scale back, or discontinue the product application and/or commercialization of our proprietary technologies; b) seek collaborators for our technology and product candidates on terms that are less favorable than might otherwise be available; c) relinquish or otherwise dispose of rights to technologies, product candidates, or products that we would otherwise seek to develop or commercialize; or d) possibly cease operations.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The failure to comply with the terms of the Credit Agreement, as amended, could result in a default under the terms of the&#160;Credit Agreement, as amended,&#160;and,&#160;if&#160;uncured,&#160;it&#160;could potentially result in action against our pledged assets. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There is no assurance that iBio CDMO or we will generate sufficient revenue or raise sufficient capital to be able to make the required principal payment under the Term Loan that iBio CDMO entered into with Woodforest National Bank (&#8220;Woodforest&#8221;). The Term Loan with Woodforest is secured by (a) a leasehold deed of trust on our sole manufacturing facility (the &#8220;Facility&#8221;), (b) a letter of credit issued by JPMorgan Chase Bank and (c) a first lien on all assets of iBio CDMO including the Facility. &#160;We have also guaranteed the payment of all iBio CDMO&#8217;s obligations under the Credit Agreement. &#160;On March 24, 2023, we and Woodforest entered into a fourth amendment to the Credit Agreement (the &#8220;Fourth Amendment&#8221;), which within the Fourth Amendment Woodforest agreed to (i) reduce the percentage of any payment to Woodforest we are required to make from the proceeds of sales of its common stock under its at-the-market facility from 40% to 20%, (ii) reduce the percentage of any payment to Woodforest we are required to make from the proceeds of sales of its equipment from 40% to 20%, and (iii) allow us to retain $2,000,000 million of the $5,100,000 million that the Company received from the Fraunhofer Settlement Funds, with the remaining $3,000,000 million being held in a Company account at Woodforest. &#160;In addition, we are obligated to (y) deliver to Woodforest an executed copy of a purchase agreement (the &#8220;Purchase Agreement&#8221;) for the sale of the 130,000 square foot cGMP manufacturing facility in Bryan, Texas, no later than April 14, 2023, and (z) pay to Woodforest a fee in the amount of $75,000 on the earlier of the date of the closing of the Purchase Agreement, or the Maturity Date (as defined in the Credit Agreement). &#160;In addition, on March 24, 2023, we entered into a fourth amendment to the Guaranty, which reduced the Liquidity Covenant from $7,500,000 to $1,000,000. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May 10, 2023, iBio CDMO and Woodforest entered into a fifth amendment to the Credit Agreement (the &#8220;Fifth Amendment&#8221;), which within the Fifth Amendment Woodforest agreed to: (i) waive the obligation to deliver to Woodforest an executed copy of a Purchase Agreement for the sale of the 130,000 square foot cGMP manufacturing facility in Bryan, Texas, no later than April 14, 2023 and, (ii) release $500,000 of the $3.0 million being held in a Company account at Woodforest when the outstanding principal amount is reduced to $10.0 million and for each additional $2.5 million reduction of the outstanding principal amount, an additional $750,00 will be released from the Company account at Woodforest. &#160;In addition, starting on the effective date of the Fifth Amendment, the interest on the Term Loan increased to 5.25%, and the Term Loan shall further accrue interest, payable in kind and added to the balance of the outstanding principal amount at a fixed rate per annum equal to (a) 1.00%, if the Facility is sold on or before June 30, 2023, (b) 2.00% if the Facility is sold after June 2023, but on or before September 30, 2023, or (c) 3:00%, if the Facility is sold after September 30, 2023, or not sold prior to the maturity date. &#160;The Company also agreed to pay Woodforest a fee in the amount of (x) $75,000 if the Facility is sold on or before June 30, 2023, (y) $100,000 if the Facility is sold after June 2023, but on or before September 30, 2023, or (x) $125,000, if the Facility is sold after September 30, 2023, or not sold prior to the maturity date. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we fail to successfully extend our cash runway via strategic options, not sell the Facility by the end of the first quarter of Fiscal 2024, or other alternatives as described, we would be in violation of the Liquidity Covenant in the first quarter of Fiscal 2024. &#160;If we or iBio CDMO fails to comply with the terms of the Term Loans and/or the related agreements, including the affirmative and negative covenants contained therein and fails to meet the Liquidity Covenant, Woodforest could declare a default, accelerate the payment of all amounts owed by us to Woodforest and if the default were to remain uncured, Woodforest would have the right to proceed against any or all of the collateral securing their Term Loan. Our failure to make such payments when due could result in our loss of the Facility. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;">The Credit Agreement with Woodforest originally included an affirmative covenant that required us to provide to Woodforest within 120 days of our fiscal year end, our consolidated financial statements, audited by independent certified public accountants without a &#8220;going concern&#8221; qualification. The consolidated financial statements for the year ended June 30, 2022 include a qualification that raises substantial doubt about our ability to continue as a going concern. &#160;As a result, without the amendment to the Credit Agreement, we would have been in violation of the covenant after the expiration of the cure period. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Covenant restrictions in the Credit Agreement, as amended, may limit our ability to operate our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">The Credit Agreement with Woodforest contains, and our future indebtedness agreements may contain covenants that restrict our ability to finance future operations or capital needs or to engage in other business activities. The Credit Agreement, as amended, currently requires maintaining $1,000,000 of unrestricted cash and cash equivalents and restricts iBio CDMO&#8217;s ability to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:200%;background:#ffffff;"><tr><td style="vertical-align:middle;width:1.66%;background:#ffffff;margin:0pt;padding:0.75pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.74%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#9679;</p></td><td style="vertical-align:middle;width:96.59%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">incur, assume or guarantee additional Debt (as defined in the Credit Agreement);</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:200%;background:#ffffff;"><tr><td style="vertical-align:middle;width:1.66%;background:#ffffff;margin:0pt;padding:0.75pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.74%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#9679;</p></td><td style="vertical-align:middle;width:96.59%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">repurchase capital stock;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:200%;background:#ffffff;"><tr><td style="vertical-align:middle;width:1.66%;background:#ffffff;margin:0pt;padding:0.75pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.74%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#9679;</p></td><td style="vertical-align:middle;width:96.59%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">make other restricted payments including, without limitation, paying dividends and making investments;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:200%;background:#ffffff;"><tr><td style="vertical-align:middle;width:1.66%;background:#ffffff;margin:0pt;padding:0.75pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.74%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#9679;</p></td><td style="vertical-align:middle;width:96.59%;background:#ffffff;margin:0pt;padding:0.75pt 0pt 0.75pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">sell or otherwise dispose of assets other than as specified in the Credit Agreement, as amended.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If our acquired intangible assets become impaired, we may be required to record a significant charge to earnings.</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;">We regularly review acquired intangible assets for impairment when events or changes in circumstances indicate that the carrying value may not be recoverable. We test indefinite-lived intangible assets for impairment at least annually. Factors that may be considered a change in circumstances, indicating that the carrying value of the intangible assets may not be recoverable, include: macroeconomic conditions, such as deterioration in general economic conditions; industry and market considerations, such as deterioration in the environment in which we operate; cost factors, such as increases in labor or other costs that have a negative effect on earnings and cash flows; our financial performance, such as negative or declining cash flows or a decline in actual or planned revenue or earnings compared with actual and projected results of relevant prior periods; the decision not to further develop certain pipeline assets; other relevant entity-specific events, such as changes in management, key personnel, strategy, or customers; and sustained decreases in share price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_Hlk134792396"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We have identified </span><span style="font-style:italic;font-weight:bold;">material</span><span style="font-style:italic;font-weight:bold;"> weaknesses in our internal controls, and we cannot provide assurances that these material weaknesses will be effectively remediated or that additional weaknesses will not occur in the future. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;">Our management is responsible for establishing and maintaining adequate internal control over our financial reporting, as defined in Rule 13a- 15(f) under the Exchange Act. During the preparation of the Quarterly Report for the quarter ended March 31, 2023, we identified a material weakness in our controls relating to accounting for stock-based compensation expense. &#160;Specifically, stock-based compensation expense was overstated by $1.2 million in the fiscal quarter ended March 31, 2023 and was understated by the same amount in the fiscal quarter ended December 31, 2022, as a result of an equity awards expense of approximately $1.2 million being incorrectly recorded in the fiscal quarter ended March 31, 2023 &#160;upon the immediate vesting of severed employees&#8217; awards on January 2, 2023, instead of accelerating the stock-based compensation expense in accordance with ASC 718-10-55-77 - Share-Based Compensation over the period between giving the employees their notice and their last day of service (i.e., November 3, 2022 &#8211; January 2, 2023). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;">While we plan to take remedial action to address the material weakness in our internal controls, we cannot provide any assurance that such remedial measures, or any other remedial measures we take, will be effective. In addition, a material weakness will not be considered remediated until the applicable controls operate for a sufficient period of time and management has concluded, through testing, that these controls are designed and operate effectively. Although management believes that the material weakness in our internal controls will be remediated, there can be no assurance that the deficiencies will be remediated in the near future or that the internal control over financial reporting, as modified, will enable us to identify or avoid material weaknesses in our internal controls in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">As a result of our failure to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, security holders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Effective internal control over financial reporting is necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, is designed to prevent fraud. Our failure to maintain an effective system of internal controls, and any failure by us to implement required new or improved internal controls or difficulties encountered in their implementation, could cause us to fail to meet our reporting obligations. In addition, any testing by us, as and when required, conducted in connection with Section 404 of the Sarbanes-Oxley Act, or Section 404, or any subsequent testing by our independent registered public accounting firm, as and when required, may reveal deficiencies in our internal control over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. As a growing company, implementing and maintaining effective controls may require more resources, and we may encounter internal control integration difficulties. Our failure to maintain effective internal controls over financial reporting, may result in us not being able to accurately report our financial results, detect or prevent fraud, or file our periodic reports in a timely manner, which may, among other adverse consequences, cause investors to lose confidence in our reported financial information and lead to a decline in the trading price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Pursuant to Section 404, we will be required to furnish a report by our management on our internal control over financial reporting. However, as a smaller reporting company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm until we are no longer a smaller reporting company. To achieve compliance with Section 404 within the prescribed period, we are engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude within the prescribed timeframe that our internal control over financial reporting is effective as required by Section 404. This could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Changes in general economic conditions, geopolitical conditions, domestic and foreign trade policies, monetary policies and other factors beyond our control may adversely impact our business and operating results.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.22;text-align:justify;margin:0pt 5.2pt 0pt 2pt;"><span style="background:#ffffff;">The uncertain financial markets, disruptions in supply chains, mobility restraints, and changing priorities as well as volatile asset values could impact our business in the future. We and our third-party contract manufacturers, contract research organizations, and clinical sites may also face disruptions in procuring items that are essential to our research and development activities, including, for example, medical and laboratory supplies used in our clinical trials or preclinical studies, in each case, that are sourced from abroad or for which there are shortages because of ongoing efforts to address the outbreak.</span> These minor disruptions have had an immaterial effect on business, which we have been able to address with minimal impact to our business operations to date. Further, although we have not experienced any material adverse effects on our business due to increasing inflation, it has raised operating costs for many businesses and, in the future, could impact demand or pricing manufacturing of our drug candidates or services providers, foreign exchange rates or employee wages. We are actively monitoring the effects these disruptions and increasing inflation could have on our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.22;text-align:justify;margin:0pt 5.2pt 0pt 2pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.22;text-align:justify;margin:0pt 5.2pt 0pt 2pt;">Our<span style="letter-spacing:0.65pt;"> </span>operations<span style="letter-spacing:0.65pt;"> </span>and<span style="letter-spacing:0.65pt;"> </span>performance<span style="letter-spacing:0.65pt;"> </span>depend<span style="letter-spacing:0.65pt;"> </span>on<span style="letter-spacing:0.65pt;"> </span>global,<span style="letter-spacing:0.65pt;"> </span>regional<span style="letter-spacing:0.65pt;"> </span>and<span style="letter-spacing:0.65pt;"> </span>U.S.<span style="letter-spacing:0.65pt;"> </span>economic<span style="letter-spacing:0.65pt;"> </span>and<span style="letter-spacing:0.65pt;"> </span>geopolitical<span style="letter-spacing:0.65pt;"> </span>conditions.<span style="letter-spacing:-0.05pt;"> </span>Russia&#8217;s<span style="letter-spacing:1.05pt;"> </span>invasion<span style="letter-spacing:1.05pt;"> </span>and<span style="letter-spacing:1.05pt;"> </span>military<span style="letter-spacing:1.05pt;"> </span>attacks<span style="letter-spacing:1.05pt;"> </span>on<span style="letter-spacing:1.05pt;"> </span>Ukraine<span style="letter-spacing:1.05pt;"> </span>have<span style="letter-spacing:1.05pt;"> </span>triggered<span style="letter-spacing:1.05pt;"> </span>significant<span style="letter-spacing:1.05pt;"> </span>sanctions<span style="letter-spacing:1.05pt;"> </span>from<span style="letter-spacing:1.05pt;"> </span>U.S.<span style="letter-spacing:1.05pt;"> </span>and<span style="letter-spacing:1.05pt;"> </span>European<span style="letter-spacing:1.05pt;"> </span>leaders.<span style="letter-spacing:-0.05pt;"> </span>These<span style="letter-spacing:0.55pt;"> </span>events<span style="letter-spacing:0.55pt;"> </span>are<span style="letter-spacing:0.55pt;"> </span>currently<span style="letter-spacing:0.55pt;"> </span>escalating<span style="letter-spacing:0.55pt;"> </span>and<span style="letter-spacing:0.55pt;"> </span>creating<span style="letter-spacing:0.55pt;"> </span>increasingly<span style="letter-spacing:0.55pt;"> </span>volatile<span style="letter-spacing:0.55pt;"> </span>global<span style="letter-spacing:0.55pt;"> </span>economic<span style="letter-spacing:0.55pt;"> </span>conditions.<span style="letter-spacing:0.55pt;"> </span>Resulting<span style="letter-spacing:0.55pt;"> </span>changes<span style="letter-spacing:0.55pt;"> </span>in U.S.<span style="letter-spacing:1.75pt;"> </span>trade<span style="letter-spacing:1.75pt;"> </span>policy<span style="letter-spacing:1.75pt;"> </span>could<span style="letter-spacing:1.75pt;"> </span>trigger<span style="letter-spacing:1.75pt;"> </span>retaliatory<span style="letter-spacing:1.75pt;"> </span>actions<span style="letter-spacing:1.75pt;"> </span>by<span style="letter-spacing:1.75pt;"> </span>Russia,<span style="letter-spacing:1.75pt;"> </span>its<span style="letter-spacing:1.75pt;"> </span>allies<span style="letter-spacing:1.75pt;"> </span>and<span style="letter-spacing:1.75pt;"> </span>other<span style="letter-spacing:1.75pt;"> </span>affected<span style="letter-spacing:1.75pt;"> </span>countries,<span style="letter-spacing:1.75pt;"> </span>including<span style="letter-spacing:1.75pt;"> </span>China,<span style="letter-spacing:-0.1pt;"> </span>resulting<span style="letter-spacing:0.5pt;"> </span>in<span style="letter-spacing:0.5pt;"> </span>a<span style="letter-spacing:0.5pt;"> </span>&#8220;trade<span style="letter-spacing:0.5pt;"> </span>war.&#8221;<span style="letter-spacing:0.5pt;"> </span>Furthermore,<span style="letter-spacing:-0.05pt;"> </span>if<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>conflict<span style="letter-spacing:-0.05pt;"> </span>between<span style="letter-spacing:-0.05pt;"> </span>Russia<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>Ukraine<span style="letter-spacing:-0.05pt;"> </span>continues<span style="letter-spacing:-0.05pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>long<span style="letter-spacing:-0.05pt;"> </span>period<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>time,<span style="letter-spacing:0.6pt;"> </span>or<span style="letter-spacing:0.6pt;"> </span>if<span style="letter-spacing:0.6pt;"> </span>other<span style="letter-spacing:0.6pt;"> </span>countries,<span style="letter-spacing:0.6pt;"> </span>including<span style="letter-spacing:0.6pt;"> </span>the<span style="letter-spacing:0.6pt;"> </span>U.S.,<span style="letter-spacing:0.6pt;"> </span>become<span style="letter-spacing:0.6pt;"> </span>further<span style="letter-spacing:0.6pt;"> </span>involved<span style="letter-spacing:0.6pt;"> </span>in<span style="letter-spacing:0.6pt;"> </span>the<span style="letter-spacing:0.6pt;"> </span>conflict,<span style="letter-spacing:0.6pt;"> </span>we<span style="letter-spacing:0.6pt;"> </span>could<span style="letter-spacing:0.6pt;"> </span>face<span style="letter-spacing:0.6pt;"> </span>significant<span style="letter-spacing:0.6pt;"> </span>adverse effects to our business and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.22;text-align:justify;margin:0pt 5.1pt 12pt 0pt;">The<span style="letter-spacing:1.5pt;"> </span>above<span style="letter-spacing:1.5pt;"> </span>factors,<span style="letter-spacing:1.5pt;"> </span>including<span style="letter-spacing:1.5pt;"> </span>a<span style="letter-spacing:1.5pt;"> </span>number<span style="letter-spacing:1.5pt;"> </span>of<span style="letter-spacing:1.5pt;"> </span>other<span style="letter-spacing:1.5pt;"> </span>economic<span style="letter-spacing:1.5pt;"> </span>and<span style="letter-spacing:1.5pt;"> </span>geopolitical<span style="letter-spacing:1.5pt;"> </span>factors<span style="letter-spacing:1.5pt;"> </span>both<span style="letter-spacing:1.5pt;"> </span>in<span style="letter-spacing:1.5pt;"> </span>the<span style="letter-spacing:1.5pt;"> </span>U.S.<span style="letter-spacing:1.5pt;"> </span>and<span style="letter-spacing:1.5pt;"> </span>abroad,<span style="letter-spacing:1.5pt;"> </span>could ultimately have material adverse effects on our business, financial condition, results of operations or cash flows, including the<span style="letter-spacing:-0.05pt;"> </span>following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.22;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:16.2pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">effects of significant changes in economic, monetary and fiscal policies in the U.S. and abroad including currency fluctuations, inflationary pressures and significant income tax changes;</span></td><td style="width:6.1pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.22;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:16.2pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">supply chain disruptions;</span></td><td style="width:6.1pt;"></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:19.45pt;margin-top:0.05pt;padding-left:19.8pt;text-indent:-19.8pt;"><span style="display:inline-block;font-size:9pt;min-width:16.55pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>a global or regional economic slowdown in any of our market segments;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:19.45pt;margin-top:0.44pt;padding-left:19.8pt;text-indent:-19.8pt;"><span style="display:inline-block;font-size:9pt;min-width:16.55pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>changes in government policies and regulations affecting the Company or its significant customers;</div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.22;margin-bottom:0pt;margin-top:0.44pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:16.2pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">industrial policies in various countries that favor domestic industries over multinationals or that restrict foreign companies altogether;</span></td><td style="width:5.85pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.22;margin-bottom:0pt;margin-top:0.1pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:16.2pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">new or stricter trade policies and tariffs enacted by countries, such as China, in response to changes in U.S. trade policies and tariffs;</span></td><td style="width:5.85pt;"></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:19.45pt;margin-top:0.05pt;padding-left:19.8pt;text-indent:-19.8pt;"><span style="display:inline-block;font-size:9pt;min-width:16.55pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>postponement of spending, in response to tighter credit, financial market volatility and other factors;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:19.45pt;margin-top:0.44pt;padding-left:19.8pt;text-indent:-19.8pt;"><span style="display:inline-block;font-size:9pt;min-width:16.55pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>rapid material escalation of the cost of regulatory compliance and litigation;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:19.45pt;margin-top:0.44pt;padding-left:19.8pt;text-indent:-19.8pt;"><span style="display:inline-block;font-size:9pt;min-width:16.55pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>difficulties protecting intellectual property;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:19.45pt;margin-top:0.44pt;padding-left:19.8pt;text-indent:-19.8pt;"><span style="display:inline-block;font-size:9pt;min-width:16.55pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>longer payment cycles;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:19.45pt;margin-top:0.44pt;padding-left:19.8pt;text-indent:-19.8pt;"><span style="display:inline-block;font-size:9pt;min-width:16.55pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>credit risks and other challenges in collecting accounts receivable; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:19.45pt;margin-top:0.44pt;padding-left:19.8pt;text-indent:-19.8pt;"><span style="display:inline-block;font-size:9pt;min-width:16.55pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the impact of each of the foregoing on outsourcing and procurement arrangements.</div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.44pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may maintain our cash assets at certain financial institutions in the U.S. in amounts that may be in excess of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insurance limit of $250,000</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.44pt 0pt 0pt 19.45pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><a id="_Hlk133874778"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We may maintain our cash assets at certain financial institutions in the U.S. in amounts that may be in excess of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insurance limit of $250,000. In the event of a failure of any financial institutions where we maintain our deposits or other assets, we may incur a loss to the extent such loss exceeds the FDIC insurance limitation, which could have a material adverse effect upon our liquidity, financial condition and our results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Due to the discontinuance of the CDMO business, we will not be generating material revenue from CDMO operations going forward.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As a result of the discontinuance of the CDMO business, we will not generate material revenue from the CDMO operations any longer.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We have experienced turnover in our senior management team, and the loss of one or more of our executive officers or key employees or an inability to attract and retain highly skilled employees could adversely affect our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Our success depends largely upon the continued services of our key executive officers. We have in the past and may in the future experience changes in our executive management team resulting from the departure of executives, which may be disruptive to our </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">business. To continue to develop our pipeline and execute our strategy, we also must attract and retain highly skilled personnel in our industry.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_d52fab56_7575_44b5_8a21_e8d73d105ee5"></a><a id="Item5OtherInformation_186239"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Item&#160;5. Other Information </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On May 10, 2023, iBio CDMO and Woodforest entered into a fifth amendment to the Credit Agreement (the &#8220;Fifth Amendment&#8221;), which within the Fifth Amendment Woodforest agreed to: (i) waive the obligation to deliver to Woodforest an executed copy of a Purchase Agreement for the sale of the Facility no later than April 14, 2023 and, (ii) release $500,000 of the $3.0 million being held in a Company account at Woodforest when the outstanding principal amount is reduced to $10.0 million and for each additional $2.5 million reduction of the outstanding principal amount, an additional $750,00 will be released from the Company account at Woodforest. &#160;In addition, starting on the effective date of the Fifth Amendment, the interest on the Term Loan increased to 5.25%, and the Term Loan shall further accrue interest, payable in kind and added to the balance of the outstanding principal amount at a fixed rate per annum equal to (a) 1.00%, if the Facility is sold on or before June 30, 2023, (b) 2.00% if the Facility is sold after June 2023, but on or before September 30, 2023, or (c) 3:00%, if the Facility is sold after September 30, 2023, or not sold prior to the maturity date. &#160;The Company also agreed to pay Woodforest a fee in the amount of (x) $75,000 if the Facility is sold on or before June 30, 2023, (y) $100,000 if the Facility is sold after June 2023, but on or before September 30, 2023, or (x) $125,000, if the Facility is sold after September 30, 2023, or not sold prior to the maturity date. After marketing the Facility with a real estate firm for approximately six months, in May 2023, the Company entered into a new agreement with a new global commercial real estate firm to remarket the Facility. As of the date of the filing of this Quarterly Report on Form 10-Q, the Company is not in negotiations on a Purchase Agreement with a potential buyer of the Facility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_2a269750_8ef5_4c22_b296_f709ca599b7b"></a><a id="Item6Exhibits_377876"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Item&#160;6.&#160;&#160;Exhibits. </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.55pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">HIDDEN_ROW</p></div></div></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.55pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:86.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.55pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.55pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;No.</b></p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.55pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:86.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.55pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:top;width:11.26%;background:#ffffff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.81%;background:#ffffff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.91%;background:#ffffff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:86.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1420720/000114420418027689/tv493469_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Incorporation of iBio,&#160;Inc., Certificate of Merger, Certificate of Ownership and Merger, Certificate of Amendment of the Certificate of Incorporation (incorporated herein by reference to Exhibit&#160;3.1 to the Quarterly Report on Form&#160;10-Q filed with the Securities and Exchange Commission on May&#160;11, 2018&#160;&#8211; File No.&#160;001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">3.2</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1420720/000114420418009023/tv484918_ex3-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment of the Certificate of Incorporation of iBio,&#160;Inc. (incorporated herein by reference to Exhibit&#160;3.2 to the Quarterly Report on Form&#160;10-Q filed with the Securities and Exchange Commission on February&#160;14, 2018&#160;&#8211; File No.&#160;001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">3.3</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1420720/000114420418033574/tv496218_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment of the Certificate of Incorporation of iBio,&#160;Inc. (incorporated herein by reference to the Company&#8217;s Current Report on Form&#160;8-K filed with the Securities and Exchange Commission on June&#160;8, 2018&#160;&#8211; File No.&#160;001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">3.4</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1420720/000110465922009994/tm224794d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amended and Restated Bylaws of iBio,&#160;Inc. (incorporated herein by reference to Exhibit&#160;3.1 to the Company&#8217;s Current Report on Form&#160;8-K filed with the Securities and Exchange Commission on February 1, 2022&#160;&#8211; File No.&#160;000-53125)</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">3.5</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1420720/000142072022000062/ibio-20221007xex3d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment of the Certificate of Incorporation if iBio, Inc. (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 7, 2022 &#8211; File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1420720/000142072023000004/ibio-20230120xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Offer Letter by and between iBio, Inc. and Felipe Duran dated January 23, 2023 (incorporated herein by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on January 25, 2023 &#8211; File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000142072023000009/ibio-20221231xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment to Credit Agreement dated February 21, 2023 by and between iBio, Inc. and Woodforest National Bank &#160;(incorporated herein by reference to Exhibit 10.2 to the Company&#8217;s Current Quarterly Report on Form 8-K10-Q filed with the Securities and Exchange Commission on December 2, 2022 February 14, 2023 &#8211; File No. &#160;001-35023)</span></a> </p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.3+</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1420720/000142072023000009/ibio-20221231xex10d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;white-space:pre-wrap;">Special Incentive Bonus Agreement dated January 26, 2023 by and between iBio, Inc. and Martin Brenner (incorporated herein by reference to Exhibit 10.3 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on February 14, 2023 &#8211; File No.  001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.4+</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000142072023000009/ibio-20221231xex10d4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Special Incentive Bonus Agreement dated January 26, 2023 by and between iBio, Inc. and Felipe Duran (incorporated herein by reference to Exhibit 10.4 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on February 14, 2023 &#8211; File No. &#160;001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.5</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1420720/000142072023000017/ibio-20230220xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Third Amendment to Credit Agreement dated February 21, 2023 between iBio CDMO LLC and Woodforest National Bank and Third Amended Guaranty of iBio, Inc. (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8 K filed with the Securities and Exchange Commission on February 21, 2023 &#8211; File No. 000 35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.6</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1420720/000142072023000022/ibio-20230324xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fourth Amendment to Credit Agreement dated March 24, 2023 between iBio CDMO LLC and Woodforest National Bank and Fourth Amended Guaranty of iBio, Inc. (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8 K filed with the Securities and Exchange Commission on March 30, 2023 &#8211; File No. 000 35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.7*</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="ibio-20230331xex10d7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Auction Sale Agreement between iBio, Inc. and Holland Industrial Group, Federal Equipment Company and Capital Recovery Group LLC dated as of February 10, 2023</span></a> </p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.8*</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="ibio-20230331xex10d8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fifth Amendment to the Credit Agreement dated May 10, 2023 between iBio CDMO LLC and Woodforest National Bank and Fifth Amended Guaranty of iBio, Inc.</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">31.1*</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="ibio-20230331xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Periodic Report by Principal Executive Officer Pursuant to Rule&#160;13a-14 and 15d-14 of the Securities Exchange Act of 1934, as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</span></a> </p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">31.2*</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="ibio-20230331xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Periodic Report by Principal Financial Officer Pursuant to Rule&#160;13a-14 and 15d-14 of the Securities Exchange Act of 1934, as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</span></a> </p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">32.1*</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="ibio-20230331xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Periodic Report by Principal Executive Officer Pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</span></a> </p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">32.2*</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="ibio-20230331xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Periodic Report by Principal Financial Officer Pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">101.INS</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:0.3pt;margin:0pt 0pt 0pt -0.3pt;">&#160; </p></td><td style="vertical-align:top;width:86.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Inline &#160; XBRL Instance*</p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">101.SCH</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Inline XBRL Taxonomy Extension Schema*</p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">101.CAL</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Inline XBRL Taxonomy Extension Calculation*</p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">101.DEF</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Inline XBRL Taxonomy Extension Definition*</p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">101.LAB</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Inline XBRL Taxonomy Extension Labeled*</p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">101.PRE</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Inline XBRL Taxonomy Extension Presentation*</p></td></tr><tr style="height:6.7pt;"><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">104</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Cover page Interactive Data File (embedded within the Inline XBRL document)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">*&#160;&#160;&#160;Filed herewith.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">+  Certain portions of this exhibit indicated therein by [**] have been omitted in accordance with Item 601(b)(10) of Regulation 8-K.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_7d306a60_52a0_4475_a072_db92f8acdb29"></a><a id="SIGNATURES_117481"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:52.49%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:47.5%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:52.49%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.5%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">iBio,&#160;Inc.</p></td></tr><tr><td style="vertical-align:top;width:52.49%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.5%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Registrant)</p></td></tr><tr><td style="vertical-align:top;width:52.49%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.5%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:52.49%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; May 15, 2023</p></td><td style="vertical-align:top;width:47.5%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Martin Brenner</p></td></tr><tr><td style="vertical-align:top;width:52.49%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.5%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Martin Brenner</p></td></tr><tr><td style="vertical-align:top;width:52.49%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interim Chief Executive Officer and Chief Scientific Officer<br />Principal Executive Officer</p></td></tr><tr><td style="vertical-align:top;width:52.49%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"></td><td style="vertical-align:top;width:47.5%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:52.49%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; May 15, 2023</p></td><td style="vertical-align:top;width:47.5%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Felipe Duran</p></td></tr><tr><td style="vertical-align:top;width:52.49%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.5%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Felipe Duran</p></td></tr><tr><td style="vertical-align:top;width:52.49%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.5%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interim Chief Financial Officer</p></td></tr></table></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:52.49%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.5%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Principal Financial Officer and Principal Accounting Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>2
<FILENAME>ibio-20230331xex10d7.htm
<DESCRIPTION>EX-10.7
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 5/15/2023 01:23:28 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 8pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Exhibit 10.7</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">AUCTION SALE AGREEMENT</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">HOLLAND INDUSTRIAL GROUP LLC, </b><font style="font-size:12pt;">together with </font><b style="font-size:12pt;font-weight:bold;">FEDERAL EQUIPMENT COMPANY</b><font style="font-size:12pt;">, and </font><b style="font-size:12pt;font-weight:bold;">CAPITAL RECOVERY GROUP LLC </b><font style="font-size:12pt;">(collectively, the &#8220;Auctioneers&#8221;) which will act jointly and severally as the exclusive agents on behalf of </font><b style="font-size:12pt;font-weight:bold;">IBIO INC </b><font style="font-size:12pt;">(&#8220;IBIO&#8221;) pursuant to this agreement &#160;(the &#8220;Agreement&#8221;), dated February 10, 2023 (the &#8220;Effective Date&#8221;) for the sale at public auction (the &#8220;Auction&#8221;) or by negotiated sales (&#8220;Negotiated Sales&#8221;) of equipment and other tangible personal property (collectively, the &#8220;Equipment&#8221;) located at IBIO&#8217;s facility at 8800 Health Science Center Pkwy, Bryan TX 77807 (the &#8220;Facility&#8221;) upon the following terms and conditions:</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:12pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">AUCTION &amp; AUCTION DATES</b><font style="font-size:12pt;">.</font></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">The Auction will be conducted as an online Auction on the Internet through an Internet provider selected by Auctioneers (the &#8220;Internet Provider&#8221;) commencing on a mutually agreed upon date to be scheduled following the Effective Date of this Agreement.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">2.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EQUIPMENT TO BE SOLD</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">The Equipment to be sold shall include all of the Equipment at the Facility designated by &#160;IBIO for sale as per Exhibit A. Once an item of Equipment is advertised for sale by Auctioneers it shall remain available for sale unless otherwise agreed in writing by Auctioneers, which shall not be unreasonably withheld, conditioned or delayed.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">AUCTION PROMOTION &amp; ADVERTISING</b><font style="font-size:12pt;">.</font></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">Prior to the Auction, Auctioneers will conduct a promotional marketing campaign for the sale of the Equipment utilizing digital publication on Industry websites, Internet publication on Auctioneers&#8217; Websites and the Internet Provider&#8217;s Website, emails to Auctioneers&#8217; subscriber lists and by such other means as Auctioneers deem appropriate in their professional judgment.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">Auctioneers&#8217; customer lists, which have been developed over years of auction selling to customers throughout the world will be used for marketing the sale of the Equipment.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">A detailed catalog listing each item of Equipment with photographs and a description will be prepared by Auctioneers, posted on Auctioneers&#8217; Websites and the Internet Provider&#8217;s Website.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">4.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SALE PREPARATION; LABOR &amp; ACCESS TO FACILITY</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">Auctioneers will supervise and direct the preparation of the Equipment for sale no later than [DATE]. &#160;IBIO, at its expense, shall provide at least one (1) person, upon a mutually agreed upon date for a period not to exceed two (2) business days, reasonably familiar with the Equipment at the Facility to answer questions from Auctioneers relating to all matters relating to the preparation, inspection, sale and removal of the Equipment.</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">Auctioneers and their representatives shall, at no additional cost and expense be permitted reasonable access to the Facility during IBIO&#8217;s standard business hours starting upon a mutually agreed upon date through the Removal Period (as defined in Section 7 below) and provided with normal utility service for water, sewer, heat and electricity (collectively, the &#8220;Utilities&#8221;) to prepare for and conduct the Auction and for the removal of the Equipment by the purchasers (the &#8220;Purchaser&#8221;) and their riggers following its sale. &#160;Prospective purchasers are to be permitted to inspect the Equipment at the Facility on the day before commencement of the Auction and at other times by appointment made in advance with IBIO.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">Prior to the sale of any of the Equipment, IBIO, at its sole cost and expense, shall remove all chemicals, hazardous materials and toxic substances as defined in any applicable environmental laws, rules and regulations (&#8220;Hazardous Materials&#8221;) contained in the Equipment and in any of the lines running to and from the Equipment, with the exception for any lines, lubricants or other materials reasonable required for the storage, operation and maintenance of the Equipment, as reasonably determined by IBIO.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">5.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXPENSES</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">All marketing expenses for promoting the sale and all labor, travel, lodging and other necessary expenses for Auctioneers&#8217; personnel to prepare for and conduct the Auction and conclude the sale of the Equipment have been budgeted not to exceed Two Hundred Thousand Dollars ($200,000) (the &#8220;Expenses&#8221;). &#160;The Expenses will be advanced by Auctioneers and reimbursed out of the proceeds from the sale of the Equipment as provided in Section 10 below.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">6.</font></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SALE PROCEDURES &amp; TERMS</b><font style="font-size:12pt;">.</font></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">The Equipment to be sold at the Auction will be sold to the highest bidders for cash. At the time of the Auction, IBIO represents, warrants and covenants that IBIO is authorized to execute and perform its obligations under this Agreement, has the right to sell the Equipment, has good and marketable title to the Equipment, and, to its knowledge, all Equipment will be free and clear of all liens, claims and encumbrances of any kind or nature. Auctioneers will be auctioning the Equipment on an &#8220;as is,&#8221; &#8220;where is&#8221; and &#8220;with all faults&#8221; basis. &#160;Auctioneers will consult with IBIO regarding the manner and method of Auction but shall have the right to present the Equipment and conduct the Auction using their best efforts provided, however in the manner, and utilizing the methods, that they deem in their professional judgment to be appropriate.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">All bidders will be required to register with Auctioneers and the Internet Provider prior to bidding and agree to be bound by the Terms of Sale established by Auctioneers and the Internet Provider; provided, however, such Terms of Sale shall not provide any representations, warrants or covenants from IBIO without its express prior consent.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">With the prior written approval of IBIO, Equipment may be sold by Negotiated Sales before the Auction.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">The sale of an item of will be considered final once the item has been paid for at the Auction (or in a Negotiated Sale). &#160;In the event payment is not made for an item bid upon at the Auction, the item shall be considered a &#8220;non-sale.&#8221; &#160;Auctioneers in conjunction with IBIO shall use their best efforts to resell any non-sale item following the Auction by Negotiated Sales.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">7.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">REMOVAL</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">Removal of the Equipment shall be done by qualified riggers at the expense, risk and liability of the Purchasers, including, without limitation, liability for any damages to the Facility or for any environmental conditions that may be caused or exacerbated in connection with the removal of the Equipment. &#160;Auctioneers will assist in identifying qualified riggers with the understanding that the riggers will not be employees or agents of Auctioneers, and &#160;will be engaged by the Purchasers, perhaps as independent contractors. &#160;Removal parameters for the removal by the selected riggers will be pursuant to terms and conditions mutually agreed to in writing by Auctioneer and IBIO. &#160;Neither Auctioneers nor IBIO shall have any liability for any damages or injuries to persons or property in connection with removal of the Equipment. &#160; Purchasers will be required to remove all Equipment following the Auction within a period no later than April 28</font><sup style="font-size:9pt;vertical-align:top;">th</sup><font style="font-size:12pt;"> 2023 (the &#8220;Removal Period&#8221;). &#160;All riggers prior to commencement of removal will be required to furnish a certificate of insurance for general liability insurance with limits of no less than Two Million Dollars ($2,000,000) per occurrence with financially sound, duly licensed and reputable insurers on account of injury or damage to persons or property at the Facility, naming IBIO and Auctioneers as additional insureds. &#160;During the Removal Period, the Purchasers and their riggers, while in coordination with Auctioneers, shall be given access to the Facility by IBIO during IBIO&#8217;s normal business hours with 48 hours in advance notice and provided with the utilities at no cost to remove their purchases. &#160;If the Purchaser or their riggers do not show after the confirmation by IBIO of a pick-up date, IBIO may reschedule an alternative date in their reasonable discretion. &#160;If a Purchaser, or their riggers, never picks up their items from the Auction after &#160;reasonable efforts by IBIO to make these arrangements (a &#8220;No-Show&#8221;), the proceeds from any sale of a No Show shall be credited towards the Sales Proceeds regardless of whether the Purchaser ever takes possession of those items or not. &#160;The Auctioneers will supervise the Purchasers are removing only the Equipment they purchased, and be present at the Facility when the Purchasers and their riggers remove their purchases. &#160;Notwithstanding the foregoing, if any Purchaser does not remove their purchases prior to the end of the Removal Period, the Auctioneers will remove such purchases from the facility no later than May 1, 2023.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">8.</font></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SECURITY &amp; RISK OF LOSS</b><font style="font-size:12pt;">.</font></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">From the Effective Date until the Removal Period, IBIO shall be responsible, at its sole cost and expense, for all reasonable security at the Facility before, during and through the Removal Period, and shall be responsible for all risk of loss or damage to the Equipment until it is paid for by the Purchasers and removed by the Purchasers, except for any loss or damage to either: (i) the Equipment caused by Auctioneers or their employees, agents or representatives, or (ii) the Facility or the Equipment caused by the Purchasers or their employees, agents, or representatives, including but not limited to the rigger removing items on behalf of any Purchaser.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">9.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">AUCTIONEERS&#8217; COMPENSATION</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">a.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Guaranteed Amount</u><font style="font-size:12pt;">. &#160;Auctioneer hereby guarantees that the aggregate amount of the gross proceeds from the sale of the Equipment (&#8220;Sale Proceeds&#8221;) shall be an amount at least equal to Two Million One Hundred Thousand Dollars ($2,100,000) (the &#8220;Guaranteed Amount&#8221;). &#160;As used herein, &#8220;Sale Proceeds&#8221; excludes any and all Buyer&#8217;s Premium (as that term is defined </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">in Section 9c below).</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">b.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Initial Deposit; Balance of Remaining Guaranteed Amount</u><font style="font-size:12pt;">. Within five (5) business days after IBIO provides Auctioneer with evidence reasonably satisfactory to Auctioneer that IBIO will deliver free and clear title to the Equipment, including the payment of any Personal Property Taxes as set forth in Section 9e below, if any, Auctioneer shall pay to IBIO as an advance the sum of by certified check or wire transfer of immediately available funds, representing one hundred percent (100 %) of the Guaranteed Amount &#160;(&#8220;Initial Deposit&#8221;). IBIO shall have the right to terminate this Agreement effective immediately if Auctioneer fails to pay IBIO in accordance with this Section 9b.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">c.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Auctioneer&#39;s Compensation</u><font style="font-size:12pt;">. &#160;Provided that Auctioneer has paid the Initial Deposit to IBIO pursuant to the terms of the immediately preceding Section 9b, IBIO hereby agrees that: (i) Auctioneer shall retain the portion of the Sale Proceeds in an amount not to exceed the Guaranteed Amount; and (ii) Auctioneer shall retain the portion of Sale Proceeds, if any, after subtracting the Guaranteed Amount there from, in the amount not to exceed the Expenses, as defined in Section 5. &#160;Auctioneer shall also charge Purchasers and retain a buyer&#8217;s premium (the &#8220;Buyer&#8217;s Premium&#8221;) equal to a percent to be determined by Auctioneer of the gross purchase price as compensation to Auctioneer for all Equipment sold prior to, during and after the Auction (including any Negotiated Sales), which shall be payable by each Purchaser in addition to the purchase price bid. Auctioneer intends to charge a Buyer&#8217;s Premium of eighteen percent (18%), which shall not be increased without the prior written consent of IBIO.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">d.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sale Expenses</u><font style="font-size:12pt;">. &#160;Subject to Section 5 above and in accordance with Section 9a-c above, Auctioneer shall be entitled to be reimbursed for Expenses. &#160;Notwithstanding the foregoing, expenses related to the use of the Facility (for example, utilities, trash removal, internet service, rent, insurance for the Subject Premises, etc.), shall be paid for solely by IBIO and not be part of the Expenses reimbursed to Auctioneer. &#160;For purposes of clarification, IBIO shall be entitled to charge any costs or expense related to the disposal of any Equipment purchased by the Purchaser and not removed prior to the Removal Period &#160;and which are incurred after the Removal Period to the Purchaser as a condition of the removal of any Equipment purchased.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">e.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Personal Property Taxes</u><font style="font-size:12pt;">. &#160;If applicable, IBIO is responsible for paying all Personal Property Taxes on the Equipment for taxes due and owing but unpaid </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">and</u><font style="font-size:12pt;"> taxes for the entire calendar year 2022/2023 which have been assessed against IBIO for the Equipment for the year 2022/2023 but may not yet be due and owing (collectively the &#8220;Personal Property Taxes&#8221;). &#160;Before Auctioneer directs final payment of the Sales Proceeds, as provided in this Agreement, IBIO will provide Auctioneer paid receipts from the taxing municipality evidencing IBIO&#8217;s payment of all Personal Property Taxes. &#160;In the event that Auctioneer receives evidence of IBIO not paying all Personal Property Taxes on the Equipment for taxes due and owing pursuant to this Section 9e, Auctioneer shall provide such evidence promptly to IBIO, and Auctioneer may deduct from the Sales Proceeds the amount of such Personal Property Taxes and pay them to the taxing authority directly within 10 business days after the Auction has ended.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">f.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Upside Sharing</u><font style="font-size:12pt;">. In addition to Auctioneer&#8217;s obligation to deliver the Guaranteed Amount pursuant to Section 9a hereof, if applicable, Auctioneer agrees to deliver to IBIO per the </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">following formula:</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">i.</font></font><font style="font-size:12pt;">the Guaranteed Amount;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 18pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">ii.</font></font><font style="font-size:12pt;">Any Sale Proceeds over </font><b style="font-size:12pt;font-weight:bold;">$2,300,000</b><font style="font-size:12pt;"> will be split 80:20 in favor of IBIO (with Sales Proceeds between $2,100,000 and $2,300,000 remitted to Auctioneer for Expenses); and</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0pt 18pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">iii.</font></font><font style="font-size:12pt;">Auctioneer shall be entitled to the Buyer&#8217;s Premium on the sale of all items.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">10.</font></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ACCOUNTING &amp; SETTLEMENT</b><font style="font-size:12pt;">.</font></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">Auctioneers will maintain accurate records of the bidding during the Auction and accurate records of all Negotiated Sales. &#160;A preliminary accounting for all items sold at the Auction will be provided to IBIO immediately following the Auction.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">All Sales Proceeds from the Auction of the Equipment will be collected by Auctioneers. &#160;Auctioneers will deliver to IBIO an itemized accounting setting forth the purchase price for each item sold together with an itemization of Sale Expenses within Fourteen (14) calendar days of the Auction. &#160; At the time of the delivery of the accounting, remittance will be made to IBIO of the Sales Proceeds, less the Guaranteed Amount, Expenses, and the portion of Sales Proceeds due to Auctioneer (which are over $2,300,000) pursuant to Section 9f (iii). All amounts in this Agreement are to be paid in U.S. Dollars.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">Copies of all records of the sale of the Equipment shall be maintained at Auctioneers&#8217; offices for a period of one (1) year following completion of the Auction and at all times during that one (1) year period shall be available to IBIO upon reasonable advance notice.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">11.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">UTILITY DISCONNECTION AND EQUIPMENT REMOVAL.</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">The Purchasers at the Auction shall be solely responsible for disconnecting any utilities from the Equipment and rigging and shipping the purchased Equipment. &#160;Under no circumstances shall IBIO be responsible for Equipment removal or utility disconnection unless IBIO specifically is requested and agrees to do so. All Equipment purchased must be removed from the Facility by the end of the Removal Period. &#160;The Equipment shall be removed in a workmanlike manner under Auctioneers&#8217; direct supervision, provided however, Auctioneer has no responsibility for supervising the Facility or providing security to protect the Facility or any of its contents, including the Equipment, from theft, vandalism, casualty or other damage at any time before, during or after the Removal Period. &#160;Subject to the limitations of liability set forth in Section 19, Auctioneer will instruct all Purchasers to remove oils or other fluids that any such Purchaser drained or caused to be drained from any of the Equipment before such Purchaser removes such Equipment from the Facility. Any oils or other fluids taken from any Equipment, if not removed by the Purchaser, will remain the responsibility of Auctioneer to store and/or remove from the Facility. Unless included in Exhibit A, under no circumstances will Auctioneer ever be responsible for draining, collecting, cleaning, storing or removing any oils, fluids or any other Hazardous Materials which is located on the Facility, whether as part of Equipment or separately contained or occurring.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">12.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">USE OF PREMISES</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">IBIO authorizes Auctioneer and its representatives to enter upon and use the Facility for the purposes of a) storing the Equipment thereupon; b) preparing for and conducting the Auction (or Negotiated Sales); c) otherwise exhibiting the Equipment to prospective purchasers; and d) with IBIO&#8217;s prior consent, for such other purposes as are reasonably and necessary to conduct the Auction and all manner of sales public or private. &#160;IBIO agrees that Auctioneer will have rent-free use of the Facility until completion of the project but in no event beyond the Removal Period. &#160;IBIO further agrees that it will furnish utilities, heating and proper lighting necessary to prepare for and conduct the Auction at IBIO&#8217;s sole expense. The Auctioneer will leave the Facility in the same general condition that the Facility is in currently (wear and tear excepted). &#160;Notwithstanding the foregoing, IBIO acknowledges that Auctioneer shall remove all items in EXHIBIT A on or before May 1, 2023 .</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">13.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ENVIRONMENTAL MATTERS</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">Auctioneers shall have no liability or responsibility with respect to any environmental conditions or matters or Hazardous Materials with respect to the Equipment and the Facility, including, without limitation, any responsibility for any Hazardous Materials contained in any of the Equipment or for any environmental conditions that may be caused or exacerbated in connection with the removal of the Equipment. &#160;IBIO will undertake all reasonable precautions to ensure that Hazardous Materials, if any, at the Facility and in the Equipment do not become exposed to the Purchasers or Auctioneers&#8217; personnel.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">14.</font></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">TITLE TO EQUIPMENT; CONSENTS</b><font style="font-size:12pt;">.</font></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">If requested by the Purchaser, IBIO will provide a bill of sale in order to warrant to the Purchasers of the Equipment that IBIO has the right to sell the Equipment and that to its knowledge, the Equipment will be sold with good and marketable title to the Purchasers free and clear of all liens, claims, restrictions and encumbrances of any kind or nature.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">15.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">INSURANCE</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">Auctioneers shall carry general liability insurance with limits of no less than Two Million Dollars ($2,000,000) in the aggregate with financially sound, duly licensed and reputable insurers on account of injury or damage to persons or property at the Facility, naming IBIO as an additional insured. Prior to entering the Facility to prepare for the sale of the Equipment, Auctioneers shall furnish IBIO with a certificate evidencing such coverage. &#160;Throughout the duration of this Agreement, IBIO shall maintain property and casualty insurance on the Equipment and any insurance required on the Facility, naming Auctioneer as additional insured. &#160;Should an insurance claim be required due to damage to any of the Equipment (sold pursuant to Section 6) because of fire, theft, flood, etc., IBIO will be solely responsible for filing any such claim and any insurance proceeds due shall be deemed part of the Sales Proceeds of the Auction and distributed in accordance with Section 9 above. &#160;Risk of loss to the Equipment due to theft or vandalism remains with IBIO until the Equipment is paid for at the Auction by a Purchaser.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">16. </font></font><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">INDEMNIFICATION</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;">IBIO agrees to indemnity and hold Auctioneer, their members, directors, officers, shareholders, agents and employees (each an &#8220;Auctioneer Indemnitee&#8221;) harmless from any third </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">party claims, causes of action, damages and liabilities of any kind (each a &#8220;Claim&#8221;) arising from or in connection with: (i) any breach of the warranties contained in Section 6 directly relating to the Equipment made by IBIO to Auctioneer, or (ii) any material breach of the remaining provisions of this Agreement by IBIO, except if and to the extent that any such Claim has resulted from any fraud, intentional misconduct, willful misconduct, or failure to comply with applicable laws by any Auctioneer Indemnitees in connection with the performance of this Agreement.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Auctioneer agrees to indemnify and hold IBIO, its subsidiary iBio CDMO LLC, and their respective directors, officers, employees, shareholders, agents and advisors (each an &#8220;IBIO Indemnitee&#8221;) harmless from any Claims arising from or in connection with (i) any material breach of the Agreement by Auctioneer, or (ii) any fraud, intentional misconduct, willful misconduct, or failure to comply with applicable laws by any Auctioneer Indemnitees in connection with the performance of this Agreement.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">In the event an Indemnitee seeks indemnification hereunder, it shall (a) inform the indemnifying party of the Claim as soon as reasonably practicable after it receives notice of the same, (b) permit the indemnifying party to assume direction and control of the defense or investigation of the Claim at the expense of the indemnifying party (including the right to settle the claim solely for monetary consideration provided that the Indemnitee receives a full and unconditional release of the Claim in connection therewith) and (c) cooperate as requested (at the expense of the indemnifying party) in the defense of the Claim. The failure of an </font><font style="font-size:12pt;">I</font><font style="font-size:12pt;">ndemnitee to perform any obligations under this Section shall not relieve the indemnifying party of its obligations under this Section, except to the extent that the indemnifying party can demonstrate that defense of the Claim has been materially affectedy as a result of such failure.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">17.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">GOVERNING LAW.</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">This Agreement is executed in and shall be governed by and construed under, the laws of the State of Delaware.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">18. </font></font><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">BINDING ARBITRATION CLAUSE</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">THE PARTIES HEREBY WAIVE THEIR RIGHT TO A JURY TRIAL. ANY CONTROVERSY OR CLAIM ARISING OUT OF CONTRACT, TORT, STATUTE OR OTHERWISE (INCLUDING THE INTERPRETATION OF THIS ARBITRATION CLAUSE, AND THE ARBITRABILITY OF THIS CLAIM OR DISPUTE BETWEEN THE PARTIES HERETO AND/OR ANY OF THEIR RESPECTIVE EMPLOYEES, AGENTS, SUCCESSORS, ASSIGNS, OR CONSIGNORS, SHALL BE SETTLED BY ARBITRATION ADMINISTERED BY JUDICIAL ARBITRATION AND MEDIATION SERVICES, INC., UNDER JAMS COMPREHENSIVE ARBITRATION RULES &amp; PROCEDURES. THE NUMBER OF ARBITRATORS SHALL BE ONE (1). THE PARTIES AGREE THAT THEY SHALL EACH BE RESPONSIBLE FOR THEIR OWN ARBITRATION FEES AND COSTS UNTIL SUCH TIME AS THE ARBITRATOR AWARDS ARBITRATION COSTS TO THE PREVAILING PARTY. THE ARBITRATION SHALL BE HELD NEW CASTLE COUNTY, DELAWARE. JUDGMENT ON THE AWARD RENDERED BY THE ARBITRATOR MAY BE ENTERED IN ANY COURT HAVING JURISDICTION THEREOF. THIS AGREEMENT SHALL BE CONSTRUED AND INTERPRETED ACCORDING TO THE LAWS OF THE STATE OF DELAWARE. IF ANY ACTION BASED ON THE PERFORMANCE, BREACH OR INTERPRETATION OF THIS CONTRACT IS BROUGHT, THE PREVAILING PARTY IN SUCH ACTION AS DETERMINED BY THE ARBITRATOR SHALL BE ENTITLED TO RECOVER FROM </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">THE LOSING PARTY ALL ACTUAL AND DOCUMENTED COSTS, EXPENSES OF ARBITRATION, AND REASONABLE ATTORNEY&#39;S FEES. ANY AWARD OF THE ARBITRATOR SHALL BE IN WRITING AND WILL BE FINAL AND BINDING ON ALL PARTIES, SUBJECT TO ANY LIMITED RIGHT OF APPEAL UNDER THE FEDERAL ARBITRATION ACT.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">19.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">LIMITATION OF LIABILITY</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">Auctioneer has the obligations set forth in this Agreement but in no event, and regardless of any undertaking by Auctioneer in this Agreement, in any other document, or made without a writing, shall Auctioneer have any liability to IBIO which exceeds the amount equal to the total Sales Proceeds retained by Auctioneer plus the amount of Buyer&#8217;s Premium collected by the Auctioneer.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, IN NO EVENT SHALL EITHER PARTY BE RESPONSIBLE OR HAVE ANY LIABILITY UNDER THIS AGREEMENT FOR ANY INDIRECT, SPECIAL, EXEMPLARY, INCIDENTAL, PUNITIVE OR CONSEQUENTIAL DAMAGES OR ANY LOST PROFITS OR LOSS OF REVENUE ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT EVEN IF ADVISED OF THE POSSIBILITY THEREOF.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">20.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">DISCLAIMER OF WARRANTIES</b><b style="font-size:12pt;font-weight:bold;">.</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">WITH THE EXCEPTION OF THE EXPRESS WARRANTIES OR REPRESENTATIONS CONTAINED IN SECTION 6 OF THIS AGREEMENT, IBIO HAS NOT HERETOFORE MADE AND DOES NOT HEREBY MAKE ANY WARRANTIES OR REPRESENTATIONS OF ANY KIND, EXPRESS OR IMPLIED, WITH RESPECT TO THE EQUIPMENT, INCLUDING, WITHOUT LIMITATION, WITH RESPECT TO THE QUALITY, QUANTITY, CONDITION, VALUE, QUIET ENJOYMENT, MERCHANTABILITY, OR FITNESS FOR ANY PURPOSE WHATSOEVER. &#160;THE EQUIPMENT IS SOLD AND ASSIGNED &#8220;AS IS,&#8221; &#8220;WHERE IS&#8221;.</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">21.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">COUNTERPARTS; FACSIMILE SIGNATURES</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">This Agreement may be executed in any number of counterparts, each of which, when executed, will be deemed to be an original and all of which, when taken together, will be deemed to be but one and the same legally enforceable and binding instrument.&#160; </font><font style="font-size:12pt;">Delivering signatures via facsimile&#160; or electronic transmission in .pdf format shall be an acceptable means of executing this Agreement and signatures so delivered shall be treated as originals and be fully binding on the signing party.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">22.</font></font><font style="font-size:12pt;"> </font><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SEVERABILITY</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">The provisions of this Agreement shall be severable.&#160; </font><font style="font-size:12pt;">Should any part, term or provision of this Agreement be construed by any court of competent jurisdiction to be illegal, invalid or unenforceable for any reason, the legality, validity and enforceability of the remaining parts, terms and provisions shall not be affected thereby.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">23.</font></font><font style="font-size:12pt;"> </font><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">INDEPENDENT CONTRACTOR</b><b style="font-size:12pt;font-weight:bold;">.</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">Nothing contained in this Agreement will be construed as creating any agency, partnership, joint enterprise or other similar relationship between the parties. &#160;The relationship between the parties will at all times be that of independent contractors. &#160;Neither party will have authority to contract for or bind the other in any manner whatsoever. &#160;This Agreement confers no rights upon either party except those expressly granted herein and does not confer any right upon either party to make any representations or commitment on behalf of the other.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">24.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">FORCE MAJEURE</b><b style="font-size:12pt;font-weight:bold;">.</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">Neither party will be liable or responsible to the other party, nor be deemed to have defaulted or breached this Agreement, for any failure or delay in fulfilling or performing any term of this Agreement when and to the extent such failure or delay is caused by or results from acts of God, flood, fire, earthquake, explosion, governmental actions, war, invasion or hostilities (whether war is declared or not), terrorist threats or acts, riot, or other civil unrest, national emergency, revolution, insurrection, epidemic, pandemic, lock-outs, strikes or other labor disputes (whether or not relating to either party&#8217;s workforce), or restraints or delays affecting carriers or inability or delay or telecommunication breakdown or power outage, provided that, if the event in question continues for a continuous period in excess of thirty (30) days, either party shall be entitled to give notice in writing to the other to terminate this Agreement. Neither party will be liable for any loss, injury, delays or damages suffered or incurred by the other party due to the above causes or to the termination of the Agreement pursuant to this Section.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">25.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">COMPLETE AGREEMENT; ASSIGNMENT</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">This Agreement constitutes the entire understanding between the parties and replaces any and all prior agreements related to the Auction.&#160; </font><font style="font-size:12pt;">This Agreement may not be modified or amended except in writing signed by the parties.&#160; This Agreement may not be assigned to any party without the written consent of the other parties.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">26.</font></font><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">AUCTIONEER&#8217;S TERMS AND CONDITIONS</b><b style="font-size:12pt;font-weight:bold;">.</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;">Attached here as Exhibit B are the terms and conditions Auctioneers provide Purchasers and other participants to its auctions and sales. &#160;These terms and conditions will be used for the Auction. &#160; The terms and conditions include terms which give to the Purchasers the same responsibilities as those described in Sections 7 and 11 of this Agreement as being performed by Purchasers, and not IBIO or Auctioneers.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;">We thank you for the opportunity to present this Agreement. &#160;Please indicate your acceptance by signing and returning a copy of this Agreement to us and we will schedule the Auction and commence our promotional campaign.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr><td colspan="3" style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">HOLLAND INDUSTRIAL GROUP LLC</b></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:30.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">DATED: </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">February 9, 2023</u></p></td><td style="vertical-align:bottom;width:22.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">By:</font></p></td><td colspan="2" style="vertical-align:bottom;width:44.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">/s/ Brian Holland</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:44.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Brian Holland, Authorized Signatory</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">FEDERAL EQUIPMENT COMPANY</b></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">DATED: </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">February 9, 2023</u></p></td><td colspan="2" style="vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:bottom;width:34.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">/s/ Adam Covitt</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:bottom;width:34.16%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">President</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Print Name:</font></p></td><td style="vertical-align:bottom;width:34.16%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Adam Covitt</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">CAPITAL RECOVERY GROUP LLC</b></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">DATED: </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">February 9, 2023</u></p></td><td colspan="2" style="vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:bottom;width:34.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">/s/ William Firestone</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:bottom;width:34.16%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Chief Executive Officer</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Print Name:</font></p></td><td style="vertical-align:bottom;width:34.16%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">William Firestone</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Agreed and accepted this 10th day of</font></p></td><td colspan="3" style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">February, 2023</font></p></td><td colspan="3" style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">IBIO, Inc.</b></p></td><td colspan="3" style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">By:</font></p></td><td colspan="2" style="vertical-align:bottom;width:38.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">/s/ Marc Banjak</font></p></td><td colspan="3" style="vertical-align:bottom;width:47.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Title:</font></p></td><td colspan="2" style="vertical-align:bottom;width:38.33%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">General Counsel</font></p></td><td colspan="3" style="vertical-align:bottom;width:47.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:14.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Print Name:</font></p></td><td colspan="2" style="vertical-align:bottom;width:38.33%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Marc Banjak</font></p></td><td colspan="3" style="vertical-align:bottom;width:47.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-size:12pt;font-weight:bold;">EXHIBIT A</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;">[List of Equipment]</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:18pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">iBio Tag #</b></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Equipment </b><b style="font-size:12pt;font-weight:bold;"><br></b><b style="font-size:12pt;font-weight:bold;">Type</b></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Equipment </b><b style="font-size:12pt;font-weight:bold;"><br></b><b style="font-size:12pt;font-weight:bold;">Description </b></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Vendor / </b><b style="font-size:12pt;font-weight:bold;"><br></b><b style="font-size:12pt;font-weight:bold;">Manufacturer</b></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Model #</b></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Serial #</b></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">A-501</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Part; Motor</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Homogenizer Motor</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">108705200260</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">61738H001-4</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">ALIC-25</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Other</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Seeder Emergency Stop</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">PWS4PDRC5000</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">JJPWS4PDRCP50003</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">ALID-30-32</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Other</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Wyckoma UV Water Purifier</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">N/A</font></p></td></tr><tr style="height:33pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">AM-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Benchtop pH/Conductivity Meter</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Orion Versa Star Pro pH/Conductivity Benchtop Meter</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Thermo Scientific</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Orion VeraStar Pro</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">V10865</font></p></td></tr><tr style="height:27.95pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-size:12pt;font-style:italic;">AM-01_PR-01</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Benchtop pH/Conductivity Meter; Printer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Orion versa printer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">SNBC</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">BTP-M300</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">1912610956</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">AM-02</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Benchtop pH/Conductivity Meter</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">PH/conductivity meter (Thermo VSTAR50)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Thermo Scientific </font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Orion VeraStar Pro</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">V10372</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">AM-03</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Handheld pH/Conductivity Meter</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Benchtop pH/conductivity meter</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Thermo Scientific </font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Orion Star A329</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">G08221</font></p></td></tr><tr style="height:33pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">AM-04</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Handheld pH/Conductivity Meter</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Benchtop pH/conductivity meter</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Thermo Scientific </font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Orion Star A329</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">G08479</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">AM-05</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Handheld pH/Conductivity Meter</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Benchtop pH/conductivity meter</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Thermo Scientific </font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Orion Star A329</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">G07509</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">AM-06</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Handheld pH/Conductivity Meter</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Benchtop pH/conductivity meter</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Thermo Scientific </font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Orion Star A329</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">G08220</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">AM-07</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Handheld pH/Conductivity Meter</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">pH/EC Meter</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Thermo Scientific </font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Orion Star A329</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">G08790</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">AM-08</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Benchtop pH/Conductivity Meter</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">PH/Conductivity meter (Thermo VSTAR50)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Thermo Scientific </font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Orion VeraStar Pro</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">V13929</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">AM-10</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Benchtop pH/Conductivity Meter</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">PH Meter </font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">THERMO FISHER</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Orion VeraStar Pro (VSTAR90)</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">V16639</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">AM-11</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Benchtop pH/Conductivity Meter</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Benchtop pH/conductivity meter</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Thermo Scientific</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Orion VeraStar Pro</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">V16857</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">AM-12</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Benchtop pH/Conductivity Meter</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Benchtop pH/conductivity meter</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">MU6100L</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">21230692</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">BC-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">BSC</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Bio Safety Cabinet (SterilGARD SC403A-HE)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Baker</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">SterilGARD SC403A-HE</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">97741</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">BC-02</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">BSC</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Biosafety Cabinet</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">THE BAKER COMPANY</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">SG403A-HE</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">98461</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">BC-03</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">BSC</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Biological Safety Cabinet </font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Baker Company</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">SG403A-HE</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">103026</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">BC-04</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">BSC</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Biosafety Cabinet</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">BAKER SterilGard</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">SG603A-HE</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">103270</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">BC-05</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">BSC</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Bio Safety Cabinet (SterilGARD SG404)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">THE BAKER COMPANY</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">SG404</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">121145</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">BC-06</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">BSC</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Biosafety Cabinet</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">BAKER SterilGard</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">SG604</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">121144</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">BC-07</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">BSC</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Biosafety Cabinet</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">BAKER SterilGard</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">SG404</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">125223</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">BC-08</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">BSC</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Biosafety Cabinet</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Baker</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">SterilGARD SC-404</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:27.95pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">BIO-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Analyzer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Agilent 2100 Bioanalyzer; Computer: IBIOAGILENT</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Agilent</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">G2939B</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">DEDAE01028</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">BL-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Other</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Compactor; Bailer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Marathon</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">4224</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">2091883</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">BLI-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Analyzer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Biolayer Interferometer (BLItz)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Pall Forte-bio</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Blitz</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">FB-60066</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">BLOT-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Gel Box</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Blotter</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Bio-Rad</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Criterion Blotter</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">560BR 00926</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:9.95%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:22.12%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:25.44%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:15.87%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:12.7%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">BLOT-02</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Gel Box</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Blotter</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Invitrogen by Thermo Scientific</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">iBlot</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">10069096</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">BLOT-03</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Gel Box</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Blotter</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Invitrogen by Thermo Scientific</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">iBlot</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">10060140</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">BR-04</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Bioreactor</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Bio Flo Controller; Computer: DT-72a</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">BioFlo 320</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">B320HP001718</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">BR-05</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Bioreactor</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Bio Flo Controller; Computer: DT-72a</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">BioFlo 320</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">B320HP001719</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">BR-06</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Bioreactor</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">BioFlo 320, configured controller</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">BIOFLO_320_CS</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:30pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-size:12pt;font-style:italic;">BR-06 &amp; BR-07_N/A</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Bioreactor</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">DO Cable, with T-82 connector for BioFlo 320</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">M1379-8106</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:25.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-size:12pt;font-style:italic;">BR-06 &amp; BR-07_N/A</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Bioreactor</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">DO Sensor, Mettler Toledo InPro 6820, 225mm, straight T-82 connector</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">P0720-6526</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-size:12pt;font-style:italic;">BR-06 &amp; BR-07_N/A</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Bioreactor</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Single-Use Vessel Bundle for BioFlo 320</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">M1379-0322</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">BR-07</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Bioreactor</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">BioFlo 320, configured controller</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">BIOFLO_320_CS</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:30.6pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">BR-N/A (BIOFLO-110)</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Bioreactor</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">New Brunswick Power Controller and System</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">BIOFLO-110</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">301062575</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-size:12pt;font-style:italic;">BR-N/A (BIOFLO-110)</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Bioreactor</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">New Brunswick Controller</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">BIOFLO-110</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">301048357</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-size:12pt;font-style:italic;">BR-N/A (BIOFLO-110)</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Bioreactor</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">New Brunswick </font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">BIOFLO-110</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">301062554</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:9.95%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:22.12%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:25.44%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:15.87%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:12.7%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-style:italic;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Liquid Addition Pump</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-size:12pt;font-style:italic;">BR-N/A (BIOFLO-110)</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Bioreactor</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">New Brunswick Heat Jacket</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">DO302</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">R0723681</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-size:12pt;font-style:italic;">BR-N/A (BIOFLO-110)</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Bioreactor</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">New Brunswick Vessel (5L)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">N/A</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-size:12pt;font-style:italic;">BR-N/A (BIOFLO-110)</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Bioreactor</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">New Brunswick DO/PH Controller</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">BIOFLO-110</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">300847316</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-size:12pt;font-style:italic;">BR-N/A (BIOFLO-110)</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Bioreactor</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">New Brunswick Foam Level Controller</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">BIOFLO-110</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">301162598</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-size:12pt;font-style:italic;">BR-N/A (BIOFLO-110)</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Bioreactor</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">New Brunswick Gas Mix Controller Bus</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">BIOFLO-110</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">301062566</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">BR-N/A (Holloway)</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Holloway America Bioreactor (200L)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">609458</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">30527</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">BR-N/A (Holloway)</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Holloway America Bioreactor (50L)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">608719</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">30129</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">BR-N/A (Holloway)</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Holloway America Heat Jacket</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">30437</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">10453C37</font></p></td></tr><tr style="height:30pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">C-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Other</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Hoopman Seed Coater and Power Switch (pan coater)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">HOOPMAN EQUIPMENT AND ENGINEERING</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">PC-S</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">20E60-0275</font></p></td></tr><tr style="height:31.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">CAP-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Capillary Electrophoresis</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">ESI Separation System; Capillary Electrophoresis</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">deltaDOT</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Peregrine 1</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">PER00128</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:40.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CAP-02</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Capillary Electrophoresis</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CESI 8000 plus; HIGH PERFORMANCE SEPARATION ESI MODULE; Computer: ABSCIEX-TTOATVR</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SCIEX</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CESI 8000 PLUS</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">B038775072</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CBTK-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CO2 FYRITE Gas Analyzer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Combustion Test Kit</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">BACHARACH</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">0011-7032</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20100735</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CC-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Analyzer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Countess Automated Cell Counter</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Invitrogen by Thermo Scientific</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">C10281</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">13011-032</font></p></td></tr><tr style="height:32.45pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CC-101</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Part; Column</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Axichrom Chromatography Column 70/300; B1</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CYTIVA</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">28901840</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2851549</font></p></td></tr><tr style="height:33.95pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CC-102</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Part; Column</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Axichrom Chromatography Column 70/300; B1</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CYTIVA</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">28901840</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2865490</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CE-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Handheld Conductivity Meter</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Handheld Conductivity Meter</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Fisher Scientific</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">15-077-977</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">170038251</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CF-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Centrifuge</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Centrifuge - Roto evaporator/concentrator </font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Labconco</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">7810010</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">120559385 C</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CF-02</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Centrifuge</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf 5417R Centrifuge</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">5417R</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">5407ZO031839</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CF-03</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Centrifuge</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Centrifuge (Avanti J-265 XPI)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Beckman Coulter</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">AVANTI J-26S XPI</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">JST12G01</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CF-04</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Centrifuge</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Table Top Centrifuge 5804R, 15amp version</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">5804R</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">5805CP064983</font></p></td></tr><tr style="height:29.1pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CF-05</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Centrifuge</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Centrifuge (benchtop) - Microcentrifuge C1603</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">5427R</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">5409FL804956</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CF-06</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Centrifuge</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Microcentrifuge 210A</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">DENVILL SCIENTIFIC</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">C0210</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">4097</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CF-07</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Centrifuge</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Mini Centrifuge</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">10067-588</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2015120240</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CF-08</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Centrifuge</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Galaxy Mini Centrifuge</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">C1413</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">10060863</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CF-09</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Centrifuge</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Galaxy Mini Centrifuge</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">C1413</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1008 0515</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CF-10</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Centrifuge</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Allegra X-30 Centrifuge</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Beckman Coulter</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Allegra X-30</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">ALT12K047 </font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CF-11</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Centrifuge</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Mini Centrifuge</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">10067-588</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2015120239</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CF-13</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Centrifuge</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Mini Centrifuge (MySPIN 6)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">THERMO SCIENTIFIC</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">75004061</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">HSF6029 (or HSF56029)</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CF-14</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Centrifuge</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Mini Centrifuge</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">C0803</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">179-16031-19120149</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CF-15</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Centrifuge</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Benchtop Centrifuge</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Fisherbrand</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">14955300</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">14955300-1659</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CF-16</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Centrifuge</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Centrifuge (swing bucket)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">5810 R</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">5811IN188964</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CF-17</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Centrifuge</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Centrifuge 5420</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">5420</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">5420KH204129</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CF-18</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Centrifuge</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Centrifuge (benchtop)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Beckman Coulter</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Microfuge 20R</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MRB20L15</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CF-N/A </font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Centrifuge</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Digital High Speed Microcentrifuge</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">C1603</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">110-18031-19110088</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CF-N/A (Grundfos Centrifuge)</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Grundfos Centrifuge Pump</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">A96523265-P11101546</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CF-N/A (Grundfos Centrifuge)</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Grundfos Centrifuge Pump</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">A96523265-P11101547</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CF-N/A (New)</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Centrifuge</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Mini Centrifuge</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">C0803</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">179-16031-21080274</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CF-N/A (New)</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Centrifuge</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Mini Centrifuge</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">C0803</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">179-16031-21120277</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CF-N/A (New)</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Centrifuge</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Mini Centrifuge</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">C0803</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">179-16031-21120280</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CF-N/A (New)</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Centrifuge</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Mini Centrifuge</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">C0803</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">179-16031-21120281</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CIP-01_CE-104</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CIP SKID WASH CONDUCTIVITY SENSOR</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Mettler Thornton</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">244-634</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">10060571</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CM-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Handheld Colorimeter</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Handheld Colorimeter</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Hach</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">DR/890</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Unknown</font></p></td></tr><tr style="height:29.1pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CMR-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Camera/Microscope</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">FLUORESCENCE IMAGING CAMERA; Computer: DT-75</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Tucsen</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">FL-20BW</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">KBLF06520003</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">CMR-01_DT-75</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Desktop; Instrument: CMR-01</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Dell</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CRSY-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Condensate Recirculator</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Condensate Recirculator</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Caron</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CRSY102-1</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CRSY102-1-1799</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CRYO-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CryoPod Carrier</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CryoPod Carrier</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">biocision</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CP3L</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CP001109</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CWT-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Weight Set</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1 mg to 10 kg ASTM Class 1 Weight Set</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Troemner</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">30391383</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">4000020171</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CWT-02</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Weight Set</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20 kg ASTM Class 1 Weight</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Troemner</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">30391454</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1000145468</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CWT-03</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Weight Set</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1 mg Class 1 Weight</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Troemner</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">80781102</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1000145467</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CWT-04</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Weight Set</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">100 g ASTM Class 1 Weight</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Troemner</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">80781142</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1000179174</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CWT-05</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Weight Set</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1 mg to 500 g ASTM Class 1 Weight Set</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Troemner</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">30390154</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">4000029090</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CWT-06</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Weight Set</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1 kg ASTM Class 1 Weight</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Troemner</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">30390261</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">4000029090-1</font></p></td></tr><tr style="height:24.95pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CWT-08</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Weight Set</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">50 g and 1000 g ASTM Class 1 CarePac Weight Set</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Mettler Toledo</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">11123108</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">4000029799</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CWT-09</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Weight Set</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">5 kg ASTM Class 4 Stainless Weight</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Troemner</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">30391187</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1000234156</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CWT-10</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Weight Set</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">10 kg ASTM Class 4 Stainless Weight</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Troemner</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">30391324</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1000234258</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CWT-11</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Weight Set</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">25 kg ASTM Class 4 Stainless Weight</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Troemner</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">30391193</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1000235582</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CWT-12</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Weight Set</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">25 kg ASTM Class 4 Stainless Weight</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Troemner</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">30391193</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1000235583</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CWT-13</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Weight Set</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">25 kg ASTM Class 4 Stainless Weight</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Troemner</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">30391193</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1000235584</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CWT-14</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Weight Set</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">25 kg ASTM Class 4 Stainless Weight</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Troemner</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">30391193</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1000235585</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CWT-15</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Weight Set</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">25 kg ASTM Class 4 Stainless Weight</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Troemner</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">30391193</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1000235586</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CWT-16</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Weight Set</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">25 kg ASTM Class 4 Stainless Weight</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Troemner</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">30391193</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1000235587</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CWT-17</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Weight Set</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">25 kg ASTM Class 4 Stainless Weight</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Troemner</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">30391193</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1000235588</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CWT-18</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Weight Set</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">25 kg ASTM Class 4 Stainless Weight</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Troemner</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">30391193</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1000235589</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CWT-19</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Weight Set</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">25 kg ASTM Class 4 Stainless Weight</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Troemner</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">30391193</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1000235590</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CWT-N/A (New)</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Weight Set</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">10 g and 200 g ASTM Class 1 Weight Set</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Mettler Toledo</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">11123101</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">4000026048</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">DA-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Meter</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Digital Anemmometer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">EMD MILLIPORE</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">DA-100-NT</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">16268</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">DB-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Dry/Heat Block</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">ThermoMixer 5350</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">5350</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">5350BJ036961</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">DB-02</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Dry/Heat Block</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Digital Mini Dry Bath</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">BioExpress</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">BSH200-HL</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">AS-BSH200-5643</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">DB-04</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Dry/Heat Block</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Digital Mini Dry Bath</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">BioExpress</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">BSH200-HL</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">AS-BSH200-5879</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">DB-05</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Dry/Heat Block</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Digital Drybath (ISOTEMP 145D)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Fisher Scientific</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1450</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">102N0028</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">DB-06</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Dry/Heat Block</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Digital Mini Heat Block</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Fisherbrand</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">14955218</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">A37-00746</font></p></td></tr><tr style="height:33pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">DB-07</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Dry/Heat Block</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Digital Drybath (Drybath Stdrd 1 blck 100-120V)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermo Scientific</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">88870001</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">JCBT70001083</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">DB-08</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Dry/Heat Block</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Digital Mini Heat Block</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Fisherbrand</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">14955218</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">137-16031-19120177</font></p></td></tr><tr style="height:33pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">DL-01-MT/TT-04</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Data Logger</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TraceableGO Bluetooth Temperature/Humidity Monitor</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">76214-378</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">200782720</font></p></td></tr><tr style="height:33pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">DL-01-MT/TT-05</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Data Logger</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TraceableGO Bluetooth Temperature/Humidity Monitor</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">76214-378</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">200782721</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">ELPC-02</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Electronic Pipette Aid</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Electronic Pipette Aid</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Sartorius</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Midi Plus</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">4539404876</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">ELPC-03</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Electronic Pipette Aid</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Electronic Pipette Aid</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Sartorius</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Midi Plus</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">4539604192</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">ELPC-04</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Electronic Pipette Aid</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Electronic Pipette Aid</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Sartorius</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Midi Plus</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">4539604190</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:9.95%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:22.12%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:25.44%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:15.87%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:12.7%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">ELPC-05</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Electronic Pipette Aid</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Electronic Pipette Aid</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermo Scientific</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">S1 Pipet Filler</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">211391</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">ELPC-06</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Electronic Pipette Aid</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Pipet-Aid XP</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Drummond Scientific</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIPET AID XP</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">236470L</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">ELPC-07</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Electronic Pipette Aid</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Electronic Pipette Aid</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Fisherbrand</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Unknown</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MJ759512</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">ELPC-08</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Electronic Pipette Aid</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Pipette Controller</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Jencons</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">POWERPETTE PLUS</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">AD7182</font></p></td></tr><tr style="height:33pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">ELPC-11</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Electronic Pipette Aid</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">ELECTRONIC PIPETTE CONTROLLER, ELPC-11</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Cole Parmer</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">25300-96</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">J0900072</font></p></td></tr><tr style="height:33pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">ELPC-12</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Electronic Pipette Aid</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">ELECTRONIC PIPETTE CONTROLLER, ELPC-12</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Cole Parmer</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">25300-96</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">J0900075</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">ELPC-13</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Electronic Pipette Aid</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Electronic Pipette Aid</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Cole-Parmer</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Omega Zen</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">J0900079</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">ELPC-14</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Electronic Pipette Aid</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">FB MOTORIZED PIPET FILLER, ELPC-14</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Fisherbrand</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">FB14955202</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">None</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">ELPC-15</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Electronic Pipette Aid</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">FB MOTORIZED PIPET FILLER, ELPC-15</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Fisherbrand</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">FB14955202</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">None</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">ELPC-16</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Electronic Pipette Aid</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Electronic Pipette Aid</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Sartorius</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Midi Plus</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">4542404808</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">ELPC-17</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Electronic Pipette Aid</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Electronic Pipette Aid</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Sartorius</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Midi Plus</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">4542404807</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">ELPC-18</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Electronic Pipette Aid</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Electronic Pipette Aid</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermo Scientific</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">S1 Pipet Filler</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">210637</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">ELPC-N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Electronic Pipette Aid</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Pipet-Aid XP</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Drummond Scientific</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Pipet Aid XP</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">255733L</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">ENDO-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Endotoxin System; Computer: DT-60</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Charles Rivers</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Nexgen MCS 150</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">21381257</font></p></td></tr><tr style="height:33pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">ENDO-01_DT-60</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Dell Desktop/Charles Rivers; </font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Dell</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:9.95%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:22.12%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:25.44%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:15.87%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:12.7%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Instrument: ENDO-01</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">EPLC-12</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Electronic Pipette Aid</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Electronic Pipette Aid</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermo Scientific</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">S1 Pipet Filler</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">233593</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">EPWR-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Electrophoresis Power Supply</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Electrophoresis Power Supply</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Bio-Rad</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PowerPac HC</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">043BR40278</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">EPWR-02</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Electrophoresis Power Supply</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Electrophoresis Power Supply</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Bio-Rad</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PowerPac Basic</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">041BR156066</font></p></td></tr><tr style="height:33pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">EPWR-03</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Electrophoresis Power Supply</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Power source, Electrophoresis Power Supply</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">BIO-RAD</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PowerPac HC</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">043BR38975</font></p></td></tr><tr style="height:33pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">EPWR-04</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Electrophoresis Power Supply</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PowerEase Touch 90W, Electrophoresis Power Supply</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Invitrogen by Thermo Scientific</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">ZP10001</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">19A31A014</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">EPWR-05</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Electrophoresis Power Supply</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Electrophoresis Power Supply</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Bio-Rad</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PowerPac HC</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">043BR38969</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">EPWR-N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Electrophoresis Power Supply</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Electrophoresis Power Supply</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Invitrogen by Thermo Scientific</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PS0120</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PS0120200919003</font></p></td></tr><tr style="height:33pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">EPWR-N/A (New)</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Electrophoresis Power Supply</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Gel Power Supply Adapter; ZOOM IPGRunner</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Invitrogen by Thermo Scientific</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">ZM0002</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">202008-0008</font></p></td></tr><tr style="height:33pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">FBD-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Other</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Hoopman Tank and Power Switch, SEED COATING FLUID BED DRYER, FBD-01</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">HOOPMAN EQUIPMENT AND ENGINEERING</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">FBL</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20E63-0287</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">FH-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">BSC</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">AMS Chemical Fume Hood</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">AIR MASTER SYSTEMS</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">AIR MASTER SYSTEMS</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">FIT-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Filter Integrity Tester</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Milipore Integritest 4; B1</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">EMD MILLIPORE</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">XIT450001</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">IT40138</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">FIT-N/A (New)</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Filter Integrity Tester</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Filter Integrity Tester</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Millipore</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">IT5INS001</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">IT506223115</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">FM-100</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Fill Machine</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Proface Control Panel (For Flexicon)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">M&amp;O Perry</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">P1540</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">P-1052</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">FM-100_HEPA-01</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Fill Machine</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Magnhelic HEPA Filter Housing</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">M&amp;O Perry</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SAM 24 CRF/LI</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;">36500  [1052 B4 (2x4x6&quot; - 7.03ft2)]</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">FM-200</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Fill Machine</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Flexicon Filling Machine (Pump)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">FLEXICON</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">91-060-00A</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">190311-213120</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">FM-200_CC-01</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Fill Machine</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Flexicon (Air Compressor)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">FLEXICON</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">93-100-100</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">181214-002255</font></p></td></tr><tr style="height:33pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">FM-200_N/A</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Fill Machine</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Burket Pilot 80-100 PSI (on fill finish machine)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">98124608</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1000</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">FM-200_N/A</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Fill Machine</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Burket Pilot 80-100 PSI (on fill finish machine)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">98124608</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1001</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">GCEL-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Electrophoresis Gel Box</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Xcell SureLock</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Novex by Life Technologies</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">EI0001</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">009436691</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">GCEL-02</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Electrophoresis Gel Box</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Xcell SureLock</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Novex by Life Technologies</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">EI0001</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">009489764</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">GCEL-03</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Electrophoresis Gel Box</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Electrophoresis Gel Cell; Mini PROTEAN Tetra </font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Bio-Rad</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Mini PROTEAN Tetra Cell</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">552BR112534</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">GCEL-04</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Electrophoresis Gel Box</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Electrophoresis Gel Cell; Mini PROTEAN Tetra </font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Bio-Rad</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Mini PROTEAN Tetra Cell</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">552BR160175</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">GCEL-05</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Electrophoresis Gel Box</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Electrophoresis Gel Cell; Mini PROTEAN Tetra </font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Bio-Rad</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Mini PROTEAN Tetra Cell</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">552BR165669</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">GCEL-06</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Electrophoresis Power Supply</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Mini-Gel Electrophoresis Power Supply</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Life Technologies</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PowerEase 90W PS0090</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">0900532107</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">GCEL-07</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Electrophoresis Gel Box</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Mini Gel Tank</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Invitrogen by Thermo Scientific</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">None</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">None</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">GCEL-N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">E-Gel Power Snap Electrophoresis</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Invitrogen </font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">G8100</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2848021070066</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">HBLK-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Digital Heatblock</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Digital Heatblock</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">NO75838-294</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">210616003</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">HBLK-02</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Digital Heatblock</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Digital Mini Heat Block</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Fisherbrand</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">14955218</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">137-16031-19120036</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">HBLK-03</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Digital Heatblock</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Digital Mini Heat Block</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Fisherbrand</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">14955218</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">137-16031-19120035</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">HM-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Mixer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Homogenator</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">WARING LABORATORY</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">38BL54</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">120315</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">HM-02</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Mixer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Homogenator</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">WARING LABORATORY</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">38BL54</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">100913</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">HM-03</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Mixer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Homogenator; Heavy Duty Blender</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">WARING LABORATORY</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CB15</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">101105</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">HM-04</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Mixer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">High Shear Laboratory Mixer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Silverson Machines Ltd</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">L5M-A</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">38022</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">HM-05</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Mixer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Disintegrator Motor</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Bepex-Reitz</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Angle Disintegrator RP Series</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2010041824</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Hoist</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Other</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Pittsburgh Centrifuge Lift</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Pittsburgh</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Heavy Duty 2Ton Folding Engine Crane</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">367821634</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:39pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">HPLC-03</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">HPLC</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">HPLC, ANALYTICAL SCIENCES HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) SYSTEM</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Shimadzu</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">LC-20AD</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">L20105357031</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">HPLC-04</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">HPLC</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">HPLC LC Infinity 1260IIE; Computer: DT-74</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Agilent</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SYS-LC-1260IIE</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">DEAEW06746</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">HPLC-04_ DT-74</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">HPLC</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Dell Desktop; Instrument: HPLC-04</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Dell</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">HPLC-05</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">HPLC</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">HPLC DAD/FLD; Computer: DT-73</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Agilent</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SYS-LC-1260IIE</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">DEAEW06594</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">HPLC-06</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">HPLC</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">HPLC 1260 Infinity II Vial Sampler G7129A</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Agilent</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Agilent 1260 Infinity II</font><font style="font-size:12pt;"><br></font><font style="font-size:12pt;">Vial sampler G7129A (DEADQ34684);</font><font style="font-size:12pt;"><br></font><font style="font-size:12pt;">Quat Pump G7111B (DEADW06782);</font><font style="font-size:12pt;"><br></font><font style="font-size:12pt;">MCT G7116A (DEADM06266);</font><font style="font-size:12pt;"><br></font><font style="font-size:12pt;">DAD WR G7115A (DEAC611667);</font><font style="font-size:12pt;"><br></font><font style="font-size:12pt;">FLD Spectra G7121B </font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">DEAEW06782</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:41.45pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">(DEAEJ01869);</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">FS-AC G1364F (DEAGS00935)</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:41.45pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">HPLC-07</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">HPLC</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">HPLC, ANALYTICAL SCIENCES LAB HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY SYSTEM</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SCIEX</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Exion LC</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">ABRES5803372</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">HRV-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Hedge Trimmer (For Harvest)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Stihl</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">HSE 70 Hedge Trimmer</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">HRV-01_A-501</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Tank 501 Agitator</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Brawn Mixer, Inc.</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">BGMF75</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">110003</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">HRV-01_A-503</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Tank 503 Agitator Blade</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Brawn Mixer, Inc.</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">BGMF75</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">110101</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">ICE-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Other</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Ice Maker</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">IMGR-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Gel Imager</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Gel Doc XR+ Imager; Computer: WRoom2</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Bio-Rad</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1708195</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">721BR13736</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">IMGR-02</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Gel Imager</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Gel Imager, ZOE</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Bio-Rad</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">ZOE Fluorescent Cell Imager</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">742BR2344</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">INC-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Incubator</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">28 C INCUBATOR, INC-01</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SANYO</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MIR-262</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">10080233</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">INC-02</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Incubator</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">37 C INCUBATOR, INC-02</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SANYO</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MIR-262</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">11040095</font></p></td></tr><tr style="height:30pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">INC-03</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Incubator</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">32.5 C IncuCell 404 INCUBATOR (32.5 deg C +/-2.5 deg C)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">BMT</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">LSIS-B2V/1C 404</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">D132099</font></p></td></tr><tr style="height:29.1pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">INC-03-TE-01</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Incubator</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">32.5 C IncuCell INCUBATOR, </font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">ENDRESS + HAUSER</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TH12-A8ADX2A1BK1</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">S50407232A1</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:35.45pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">INC-03, EMS TEMPERATURE SENSOR</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:35.45pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">INC-04</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Incubator</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">22.5 C FrioCell 404 INCUBATOR (22.5 deg C +/-2.5 deg C)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">BMT</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">FC-B2V-M/FC404</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">E150801</font></p></td></tr><tr style="height:27.6pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">INC-04-TE-01</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Incubator</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">22.5 C FrioCell INCUBATOR, INC-04, EMS TEMPERATURE SENSOR</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Endress Hauser</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TH12-A8ADX2A1BK1</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">S50411232A1</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">INC-05</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Incubator</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Cell Culture CO2 Incubator</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PHCBI</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MCO-170AICUVL-PA</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">190160106</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">INC-06</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Incubator</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Incubator</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Sanyo</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MIR-262</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">10080230</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">INC-07</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Incubator</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Incubator Max Q 6000</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">THERMO SCIENTIFIC</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">4353</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">107548-28</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">INC-08</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Incubator</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Refrigerated Incubator Shaker</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">New Brunswick Innova 43R</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">110355172</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">INC-09</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Incubator</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Incubator Shaker</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Labnet</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">I5311DS</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">10038810</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">INC-10</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Incubator</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Refrigerated Incubator Shaker</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">New Brunswick Innova 42R</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SI42HR204111</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">INC-11</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Incubator</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Biological Indicator Incubator</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Steris</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">S3271</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20012863</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">INC-12</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Incubator</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Digital Microplate Incubator</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">BT LabSystems</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">BT1101</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MU2018010455</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">INC-13</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Incubator</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Refrigerated Incubator Shaker</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">New Brunswick Innova 43R</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SI43JH2000928</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">INC-16</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Incubator</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Refrigerated Incubator Shaker</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">New Brunswick Innova 43R</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">S142KL305802</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">INC-17 (New)</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Incubator</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SRS CO2 Incubator</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PHCBI</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MC0-1708ICUVL</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">220160007</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">INC-N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Incubator</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">New Brunswick Incubator Galaxy 170S</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">C0170S-120-1000</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">40233</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">INC-N/A (Lab Companion Incubator)</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Lab Companion Incubator</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SI600</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">INC-N/A (Lab Companion Incubator)</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Lab Companion Incubator holder rack</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SI600</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">INC-N/A (Lab Companion Incubator)</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Lab Companion Shaker Rack</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SI600</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">INC-N/A (TBD)</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Incubator</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Microplate Incubator</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">BT LabSystems</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">BT1101</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">BL-E28-1032</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">INF-02</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Other</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Small-Scale Infiltrator</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">APF</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">None</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">None</font></p></td></tr><tr style="height:45.95pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">LC-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Liquid Chromatography</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Cytiva AKTA Pure 150; FPLC--Pure (AKTA Pure 150 BENCHTOP CHROMATOGRAPHY SYSTEM); Computer: DT-94</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CYTIVA</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">29046665</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1803232</font></p></td></tr><tr style="height:41.45pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">LC-01_DT-94</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Liquid Chromatography</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Desktop; Instrument: LC-01</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:39.95pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">LC-02</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Liquid Chromatography</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Cytiva AKTA Process (Gradient </font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">GE Healthcare </font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">IQ150FPW</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">28980354</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:42.6pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">System); LC-02; AKTA Chromatography Skid (Gradient System)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Bio-Sciences</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:42.6pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">LC-03</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Liquid Chromatography</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Cytiva AKTA Pilot 400; LC-03; AKTA Pilot Chromatography Skid (GE AKTA Pilot 400); Computer: DT-78</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">GE Healthcare Bio-Sciences</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">56317181</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1465844</font></p></td></tr><tr style="height:40.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">LC-03_DT-78</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Liquid Chromatography</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Desktop; Instrument: LC-03</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:46.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">LC-04</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Liquid Chromatography</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Cytiva AKTA Process (Isocratic System); LC-04; AKTA Chromatography Skid (Isocratic System)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">GE Healthcare Bio-Sciences</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">IQ150FPW</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">28980355</font></p></td></tr><tr style="height:40.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">LC-05</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Liquid Chromatography</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Cytiva AKTA FPLC - Avant; Computer: DT-93</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">GE Healthcare Bio-Sciences</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">28930842</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1521342</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">LC-05_DT-93</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Liquid Chromatography</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Desktop; Instrument: LC-05</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:34.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">LC-06</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Liquid Chromatography</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Cytiva AKTA Avant 25 CHROMATOGRAPHY SYSTEM; Computer: DT-61</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">GE Healthcare Bio-Sciences</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">28930842</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2584237</font></p></td></tr><tr style="height:29.1pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">LC-06_DT-61</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Liquid Chromatography</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Desktop; Instrument: LC-06</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:23.1pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">LC-07</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Liquid Chromatography</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Cytiva AKTA 25 LIQUID CHROMATOGRAPHY, BUILDING 1 MB/PD LAB; Computer: DT-67</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">GE Healthcare Bio-Sciences</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">28930842</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2626667</font></p></td></tr><tr style="height:25.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">LC-07_DT-67</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Liquid Chromatography</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Desktop; Instrument: LC-07</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:38.1pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">LC-08</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Liquid Chromatography</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Cytiva AKTA 25 LIQUID CHROMATOGRAPHY, BUILDING 1 MB/PD LAB; Computer: DT-68</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">GE Healthcare Bio-Sciences</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">28930842</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2628404</font></p></td></tr><tr style="height:30pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">LC-08_DT-68</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Liquid Chromatography</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Desktop; Instrument: LC-08</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:26.1pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">LC-09</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Liquid Chromatography</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Cytiva AKTA Avant 25 FPLC - Avant; Computer: LP-AKTA-124</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">GE Healthcare Bio-Sciences</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">28930842</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2814045</font></p></td></tr><tr style="height:24pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">LC-10</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Liquid Chromatography</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Cytiva AKTA FPLC - Avant 150; Computer: DESKTOP-JADJOEO</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CYTIVA</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">28976337</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2825681</font></p></td></tr><tr style="height:27.6pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">LC-11</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Liquid Chromatography</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Cytiva AKTA Pilot 600 R; B1; Computer: LP-Akta-127</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CYTIVA</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">29704661</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2843929</font></p></td></tr><tr style="height:30pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">LC-12</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Liquid Chromatography</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Cytiva AKTA Avant 25 CHROMATOGRAPHY SYSTEM; Computer: LP-AKTA-125</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CYTIVA</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">28930842</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2881938</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:24.95pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">LSH-503</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Tank 503 Sensor, HIGH LEVEL SWITCH</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">ROSEMOUNT</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2120D2RBCSX211</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MSKK74800K0000</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">LT-501</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Tank 501 Sensor</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">OMEGA</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">LV01503-LP</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">110214</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">LT-503</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Tank 503 Sensor, LEVEL TRANSMITTER</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Omega Engineering</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">LVU1505-LP</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">11D217</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MA-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Moisture Analyzer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">BENCHTOP MOISTURE ANALYZER, MA-01</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Mettler Toledo</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">HE73/03</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">C129191478</font></p></td></tr><tr style="height:40.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MANF-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Filtration Manifold</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Millipore EZ-Fit Manifold (Vacuum manifolds support simultaneous filtration of three test samples)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Millipore</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">EZFITBASE3</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">BM7AA9924</font></p></td></tr><tr style="height:26.45pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MANF-02</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Filtration Manifold</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Millipore EZ-Fit Manifold (Vacuum manifolds support simultaneous filtration of six test samples)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Millipore</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">EZFITBASE6</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">None</font></p></td></tr><tr style="height:23.1pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MIC-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Microscope</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Microscope</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Olympus</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">BX43F</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">0M11045</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MIC-02</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Microscope</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Microscope</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Jenco</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CP-2A1</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">V206116</font></p></td></tr><tr style="height:36pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MPR-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">BioTek Synergy H1, SYNERGY H1 HYBRID MULTI-MODE PLATEREADER; Computer: DT-65</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">BioTek</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">H1M</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">253156</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:27.6pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">MPR-01_DT-65</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Dell Desktop; Instrument: MPR-01 (plate reader)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Dell</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:24.95pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MPR-02</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Microplate Reader; Computer: DT-39</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">BioTek</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">EPOCH 2</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">18041929</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">MPR-02_DT-39</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Desktop; Instrument: MPR-02</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MPS-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MicroPulser Electroporator</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MicroPulser Electroporator</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Bio-Rad</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">165-2100</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">411BR7412</font></p></td></tr><tr style="height:32.45pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MS-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Mass Spec</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">QQQ TOF Mass Spec; Computer: Desktop-O0MS0BV</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SCIEX</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Triple TOF 5600</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">AY22791203</font></p></td></tr><tr style="height:27.95pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">MS-01_NG-02</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Nitrogen Generator</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Peak Scientific</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Genius 1024 230v</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">721110550</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">MS-01-UPS</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Mass Spec</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">UPS</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Powervar</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">42052-108R</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">42052108R-2210082</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MS-02</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">QTOF Mass Spec; Computer: SCIEX-X500B</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SCIEX</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">X500 QTOX</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">DN230022002</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">MS-02_NG-01</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Nitrogen Generator</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Peak Scientific</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Genius 1024 230v</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">771061676</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">MS-02-UPS</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">UPS</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Powervar</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">42080-72R</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">4208072R-2040003</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MX-02</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Mixer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Analog Stir Plate</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermo Scientific</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SP18425</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">C1725110102729</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MX-03</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Mixer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Digital Magnetic Mixer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">12621-054</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">160629002</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MX-07</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Mixer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Magnetic Stirrer Mixer (Midi MR1)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">IKA</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">IP21</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">None</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MX-08</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Mixer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Analog Magnetic Stirrer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermo Scientific</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">88880009</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">K3KT09034</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MX-10</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Vortex mixer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Analog Vortex mixer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">58816-121</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">110310030</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MX-11</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Mixer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Magnetic Stirrer Mixer (Midi MR1)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">IKA</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">IP21</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">None</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MX-12</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Vortex mixer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Analog Vortex Mixer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">58816-121</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">101011006</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MX-N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">heater/mixer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermal heater/mixer; ThermoMixer F1.5</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">5384</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">5384KO708635</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MX-N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">heater/mixer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermal heater/mixer; ThermoMixer F1.5</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">5384</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">5384LI309238</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MX-N/A (New)</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Mixer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Compact Digital Mixer System</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Cole-Parmer</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">50006-01</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">250CP30717</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Stainless Steel Square Table</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">5.5 ft Stainless Steel Bench</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Furniture</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;white-space:pre-wrap;">3 ft  Stainless Steel Bench</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Storage</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">30 gallon flammable cabinet</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Diaphragm Pump</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">3HJW3B</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MF654921</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">DYMO Label Writer 450</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">DYMO</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1750110</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1841021750110</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Sanyo Incubator</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SANYO</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MIR262</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">10080232</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Rheometer (in box)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">LungBio</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Filter Cart (used)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Repligen</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Boegthin Flow Monitor Sensor Probe</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">401565</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">502398-1-004</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Cleanrooms International Filter Fan</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SAM-24</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">36500</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Contec 6.5x2 Roller</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">284EPJ</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">3667</font></p></td></tr><tr style="height:38.1pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Donaldson Filter (Sterile Tank Filtering complete housing)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">P-BE0576</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">73903488</font></p></td></tr><tr style="height:48pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">6 ft Desk</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Gray Desk</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Envircon Filters</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20L Carboys</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermo Scientific </font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Bioreactor</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Whatman Bioreactor Bioreactor Vessel (8L)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Contec 10x2 Roller</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">284EPJ</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">3667</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">0.5mL tube Heatblock, 1 each</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">13259-000</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Z10709001</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2mL tube Heatblock, 3 each</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">12985-048</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">210602001</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Dry Heat Block</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">75838-294</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">APC Uniterruptable Power Supply</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SRT8KRMXLT</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">AS1641272199</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Boxes of single-use coveralls, expired</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">3M</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Grow racks (10 shelves, 1 unit)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CC Pharming</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:29.45pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Durachill (2-3 HP DuraChill&#8482; Chiller, Air-Cooled, Water-Cooled)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PolyScience</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">DCA304D1XC-101</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1A10D1373</font></p></td></tr><tr style="height:29.1pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Automatic Paper Towel Dispensors</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Uline</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Pallet of single-use coveralls</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Ultraguard</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Control Inc Bioreactor Control Panel </font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">WATSON-MARLOW</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CSD363612SS6R</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">A-1958</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">AAF Air Filter Housing</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">WE2717</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SA090154</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Agronomy Biohazard Dumpster </font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">American Lifts Elevator Platform</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">36525</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">APC Uniterruptable Power Supply</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">RW500DR</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">AS1029143523</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Auto Up Lift</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">STE30-25-4</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">211108791</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Baldor Electrical Pump</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">K070079</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Beckman Coulter Rotor</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">12U57022</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Beckman Coulter Rotor</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">12U57053</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Beckman Coulter Rotor</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">18U41966</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Beckman Coulter Rotor</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">18U41972</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Beckman Coulter Rotor</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">18U41975</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Beckman Coulter Rotor</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">18U41981</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Bioractor Rack</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Black Chemical Locker</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Burket Flow Switch for centrifuge</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">429136</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Centrifuge Base</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Depth Filter</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Envirco fan filter</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">11156-001</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">S08-IQ-01750</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Envirco fan filter</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">11156-001</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">S08-IQ-01753</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Envirco fan filter</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">11156-001</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">S08-IQ-01757</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Envirco fan filter</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">11156-001</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">S08-IQ-01783</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Evoguard Disc Valve</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">09022001740001170072</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Evoguard Disc Valve</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">0902200174001170107</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Evoguard Disc Valve</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">0902205170001173427</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Evoguard Disc Valve</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">09022051790001173430</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Evoguard Disc Valve</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">09041007270001171051</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Evoguard Disc Valve</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">09041607270001171054</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Evoguard Disc Valve</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">09041607460001173840</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Evoguard Disc Valve</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">09041607460001173840</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Evoguard Valve</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">0-903-355-331</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">9033553310001170000</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">GE Thermal Motor (on Mixer)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">5KH36PNB050T</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">D07J170126</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Newman Lanelling Power Supply</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">NV2</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">10450</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Parker Door Lift</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">02.00HB2ALU34A</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CC607668C</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Polyscience recirculator</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">5870T87XC751</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1C1081640</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Sartorius Pump (on the bioreactor)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">8843415</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">D02101088</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Sartorius Servomotor</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">AKM23D-ANBNC-00</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">80396035</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Sartorius Servomotor</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">AKM23D-ANBNC-00</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">80396036</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Scrubbing Tank</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Stackup Homogenizer and Disintegrator </font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Sump pump (under grate) Post Infiltration</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Sump pump fuse box</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Sump Pump Germ</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Sump Pump Harvest</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Sump Pump Infiltration</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Sump pump on/off switch</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Sump pump on/off switch</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Tablecraft Kenkut 3 </font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Tray Racks for growing plants</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td></tr><tr style="height:20.45pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Pallet washer (used as tray washer)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TRUDO DO Sensor</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">DOS-OFF-VP-225</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">477</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TRUDO DO Sensor</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">DOS-OFF-VP-225</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">697</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TRUDO DO Sensor</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">DOS-OFF-VP-225</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">698</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR Recirculator </font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1177MD</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">108800807</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR Recirculator </font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1177PD</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">108C00855</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR Recirculator </font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1177PD</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">3F1081196</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Wave Tube Sealer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">28411704</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1146852</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A (Column)</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">BPG Column (BPG 100/500)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CYTIVA</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TO 80405</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">56116562</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A (Column)</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">AXI-CHROM 300-1000</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">28903963</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">44</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A (Intermec Label Printer A)</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Intermec Label Printer; Computer: IBIODT-10</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Intermec</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PC43t</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">116C1730219</font></p></td></tr><tr style="height:26.1pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">N/A (Intermec Label Printer A)_DT-10</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Dell Desktop Workstation, Instrument: Intermec Label Printer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Dell</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:25.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A (Intermec Label Printer B)</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Intermec Label Printer; Computer: IBIODT55</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Intermec</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:25.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">N/A (Intermec Label Printer B)_DT-55</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Dell Desktop/Intermec; Instrument: Label Printer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Dell</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:27.6pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A (Lenze Labeler)</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Lenze Labeler Motor</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">13019972</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1786089</font></p></td></tr><tr style="height:14.1pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A (Lenze Labeler)</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Lenze Labeler Motor</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">13020623</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1785062</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A (Lowara)</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Lowara Water Pump (for centrifuge)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20171215</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">7520560967</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A (Lowara)</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Lowara water pump motor</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20171215</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">13304R002F</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">N/A (New)</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">Fluorescence Test Plate</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">BioTek Instruments</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">1400501</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">531367</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">N/A (Peristaltic Pump)</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">Control Inc Bioreactor Control Panel </font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">WATSON-MARLOW</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">010.NS22.210</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">10195787</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><i style="font-size:12pt;font-style:italic;">N/A (Proteus)</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">Glas-Col Temperature Control (On Proteus)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">099ARD4512</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">474933</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">N/A (Proteus)</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">Proteus 2000</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">590</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">N/A (Rosemont)</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">Rosemont Heat Jacket</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">1116C-43</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">20006</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">N/A (Siemens Centrifuge)</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">Siemens Centrifuge Motor</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">1705/1933953-001</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">N/A (Supply)</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">Spool Printer (Tape)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">PC43t</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">116c1730061</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">N/A (Westfalia Centrifuge)</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">Westfalia Centrifuge</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">CSA19-06-476</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">1694-995</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">N/A (Wiegmann Mixer)</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">Wiegmann Mixer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">B141206CH</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">E6924</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">N/A (Xcellerex Bioreactor System)</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">Xcellerex Bioreactor System</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">XD-50</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">X0212010</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">N/A? (PP-10?)</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">Masterflex L/S (Pump Head)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">MASTER FLEX</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">77200-60</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">New</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">Sterilizer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">Glass Bead Sterilizer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">B1205</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">172-16031-21060065</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">New</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">Test Plate</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">Absorbance Test Plate</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">BioTek Instruments</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">7260522</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">531361</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">NF-02</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">Baby Nutsche Filter (5L)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">Pope Scientific</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">C276-1.5FVTR150-FL</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><font style="font-size:12pt;">147671-1-3</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">OV-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Microwave Oven</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Danby</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">DMW111KBLDB</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">4720000000000</font></p></td></tr><tr style="height:49.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">P-303</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Hydrovar Pump System; GERMINATION ROOM IRRIGATION DISTRIBUTION PUMP, P-303</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Goulds</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">5SV5FA30</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">K1609123</font></p></td></tr><tr style="height:25.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">P-304</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Goulds Hydrovar Pump, Irrigation; (IRR-01-VFD-P-304), VARIABLE FREQUENCY DRIVE</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VEM3555</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td></tr><tr style="height:25.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">P-402</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">peristaltic pump; INOCULATION SOLUTION TRANSFER PUMP</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">WATSON MARLOW</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">520DUS/REM</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">L020910</font></p></td></tr><tr style="height:25.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">P-803</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Sump pump (under grate) Post Infiltration</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td></tr><tr style="height:26.45pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PC-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Laser Particle Counter</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Lighthouse Worldwide Solutions</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Solair 3100</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">161104042</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PC-02</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Laser Particle Counter</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Lighthouse Worldwide Solutions</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Solair 3100</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">161104043</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PC-03</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Laser Particle Counter</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Lighthouse Worldwide Solutions</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Solair 3100</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">101204044</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PC-04</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Laser Particle Counter</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Lighthouse Worldwide Solutions</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Solair 3100</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">200404034</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PC-05</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Laser Particle Counter</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Lighthouse Worldwide Solutions</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Solair 3100</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">210604006</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PC-06</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Laser Particle Counter</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Lighthouse Worldwide Solutions</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Solair 3100</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">210604010</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PC-07</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Laser Particle Counter</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Lighthouse Worldwide Solutions</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Solair 3100</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">210604007</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PC-08</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Laser Particle Counter</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Lighthouse Worldwide Solutions</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Solair 3100</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">210604009</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PC-09</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Laser Particle Counter</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Lighthouse Worldwide Solutions</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Solair 3100</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">210604011</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PC-10</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Laser Particle Counter</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Lighthouse Worldwide Solutions</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Solair 3100</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">210604008</font></p></td></tr><tr style="height:30pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PCR-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">QPCR THERMAL CYCLER, BUILDING 1 MB/PD LAB</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">THERMO FISHER</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">QUANTSTUDIO 5 REAL-TIME PCR (CATALOG #: A28138)</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">272511703</font></p></td></tr><tr style="height:24.95pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PCR-02</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PCR Workstation Cabinet</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">10783-132</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">31102-02F 00351</font></p></td></tr><tr style="height:25.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PCR-03</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermocycler</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Nexus GX2 Mastercycler</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">6336JL526723</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PCR-N/A (New)</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">UV Cabinet (PCR)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Grant Instruments</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">UVC/T-M-AR</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">04010422010009</font></p></td></tr><tr style="height:35.1pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PGCH-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">gBrite LED PLANT GROWTH CHAMBER, PGCH-01</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CARON</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">7312-50-2</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">7312-50-2-013</font></p></td></tr><tr style="height:27.6pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PGCH-02</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">gBrite LED PLANT GROWTH CHAMBER, PGCH-02</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CARON</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">7312-50-2</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">7312-50-2-014</font></p></td></tr><tr style="height:30.6pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PH-02</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Benchtop pH Meter</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermo Scientific</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Orion 4 STAR</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">B32770</font></p></td></tr><tr style="height:26.45pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PH-03</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Benchtop pH Meter</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SympHony SB70P</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">D05492</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-002</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">100 to 1000 uL SINGLE CHANNEL PIPETTE, PIP-02</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Signature Variable 1000uL</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">42764417</font></p></td></tr><tr style="height:27.95pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-003</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2 to 20 uL SINGLE CHANNEL PIPETTE, PIP-03</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Signature 20&#181;L</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">42731744</font></p></td></tr><tr style="height:31.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-004</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20 to 200 uL SINGLE CHANNEL PIPETTE, PIP-04</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Signature EHP Variable 200 uL</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">42753091</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-005</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">12-Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">30 to 300 uL 12 CHANNEL PIPETTE, PIP-05</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Research Plus</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">M18968B</font></p></td></tr><tr style="height:30pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-006</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">100 to 1000 uL SINGLE CHANNEL PIPETTE, PIP-06</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Research Plus 1000 uL</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">156701A</font></p></td></tr><tr style="height:27.95pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-007</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">0.5 to 10 uL SINGLE CHANNEL PIPETTE, PIP-07</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Research Plus 10 uL</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">163850A</font></p></td></tr><tr style="height:27.6pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-008</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">10 to 100 uL SINGLE CHANNEL PIPETTE, PIP-08</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Research Plus</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">159502A</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-009</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">8-Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">0.5 to 10 uL 8 CHANNEL PIPETTE, PIP-09</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Finnpipette</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">8ch 4510</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">C70350</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-010</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">12-Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20 to 200 uL 12 CHANNEL PIPETTE, PIP-10</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Signature EHP Variable 200 uL</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">153870016</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:35.45pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-011</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">100 to 1000 uL SINGLE CHANNEL PIPETTE, PIP-11</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Gilson</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">P1000L</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">NK73657</font></p></td></tr><tr style="height:30.6pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-012</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">100 to 1000 uL SINGLE CHANNEL PIPETTE, PIP-12</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Signature 1000&#181;L</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">242763608</font></p></td></tr><tr style="height:27.95pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-013</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">100 to 1000 uL SINGLE CHANNEL PIPETTE, PIP-13</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Signature 1000&#181;L</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">42764592</font></p></td></tr><tr style="height:25.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-014</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2 to 20 uL SINGLE CHANNEL PIPETTE, PIP-14</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Signature 20&#181;L</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">42732892</font></p></td></tr><tr style="height:23.1pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-015</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2 to 20 uL SINGLE CHANNEL PIPETTE, PIP-15</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Signature 20&#181;L</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">242732436</font></p></td></tr><tr style="height:26.45pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-016</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20 to 200 uL SINGLE CHANNEL PIPETTE, PIP-16</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Signature 200&#181;L</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">242751755</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-017</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">12-Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20 to 200 uL 12 CHANNEL PIPETTE, PIP-17</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Gilson</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">LP12X200L</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MC70193</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-018</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">12-Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20 to 200 uL 12 CHANNEL PIPETTE, PIP-18</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Gilson</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">P12x200L</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MC71420</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-019</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1 to 10 uL SINGLE CHANNEL PIPETTE, PIP-19</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Gilson</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIPETMAN P10</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">T69789G</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:30pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-020</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">10 to 100 uL SINGLE CHANNEL PIPETTE, PIP-20</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Gilson</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIPETMAN P100</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">T63429E</font></p></td></tr><tr style="height:29.45pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-021</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">100 to 1000 uL SINGLE CHANNEL PIPETTE, PIP-21</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Rainin</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">E4 XLS 1000</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">B624604126</font></p></td></tr><tr style="height:26.45pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-022</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20 to 200 uL SINGLE CHANNEL PIPETTE, PIP-22</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Rainin</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">E4 XLS 200</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">B625647698</font></p></td></tr><tr style="height:30.6pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-023</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2 to 20 uL SINGLE CHANNEL PIPETTE, PIP-23</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Rainin</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">E4 XLS</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">B619464014</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-024</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">0.5 to 10 uL SINGLE CHANNEL PIPETTE, PIP-24</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Rainin</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Pipet-Lite SL-10 XLS</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">B615353398</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-026</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">12-Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">50 to 300 uL 12 CHANNEL PIPETTE, PIP-26</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Signature 300uL x12</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">053880021</font></p></td></tr><tr style="height:27pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-027</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20 to 200 uL SINGLE CHANNEL PIPETTE, PIP-27</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Gilson</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">P200</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">NK71010</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-028</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">0.5 to 10 uL SINGLE CHANNEL PIPETTE, PIP-28</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Signature EHP Variable 10uL</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">42722247</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-029</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">0.5 to 10 uL SINGLE CHANNEL PIPETTE, PIP-29</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Signature EHP Variable 10uL</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">242722188</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:9.95%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:22.12%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:25.44%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:15.87%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:12.7%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-030</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">100 to 1000 uL SINGLE CHANNEL PIPETTE, PIP-30</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Gilson</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">P1000</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">NK72771</font></p></td></tr><tr style="height:24.95pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-031</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2 to 20 uL SINGLE CHANNEL PIPETTE, PIP-31</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Signature EHP Variable 20uL</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">242731580</font></p></td></tr><tr style="height:25.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-032</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2 to 20 uL SINGLE CHANNEL PIPETTE, PIP-32</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Signature EHP Variable 20uL</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">42732814</font></p></td></tr><tr style="height:27pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-033</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20 to 200 uL SINGLE CHANNEL PIPETTE, PIP-33</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Gilson</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">P200</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">NK71001</font></p></td></tr><tr style="height:27.95pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-034</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20 to 200 uL SINGLE CHANNEL PIPETTE, PIP-34</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Signature 200&#181;L</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">42753009</font></p></td></tr><tr style="height:25.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-035</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">100 to 1000 uL SINGLE CHANNEL PIPETTE, PIP-36</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Signature 200&#181;L</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">242753411</font></p></td></tr><tr style="height:25.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-037</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">0.1 to 2.5 uL SINGLE CHANNEL PIPETTE, PIP-37</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Reference</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">402107A</font></p></td></tr><tr style="height:33.6pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-038</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2 to 20 uL SINGLE CHANNEL PIPETTE, PIP-38</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Reference</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">395817A</font></p></td></tr><tr style="height:34.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-039</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">50 to 200 uL SINGLE CHANNEL </font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Reference</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">398159A</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:9.95%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:22.12%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:25.44%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:15.87%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:12.7%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIPETTE, PIP-39</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-040</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">0.1 to 2.5 uL SINGLE CHANNEL PIPETTE, PIP-40</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Reference 2</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">G17616F</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-041</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2 to 20 uL SINGLE CHANNEL PIPETTE, PIP-41</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Reference 2</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">K48791J</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-042</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20 to 200 uL SINGLE CHANNEL PIPETTE, PIP-42</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Reference 2</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">H12806F</font></p></td></tr><tr style="height:22.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-043</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">100 to 1000 uL SINGLE CHANNEL PIPETTE, PIP-43</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Reference 2</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">I10393F</font></p></td></tr><tr style="height:24pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-044</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">100 to 1000 uL SINGLE CHANNEL PIPETTE, PIP-44</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Research Plus</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N20509B</font></p></td></tr><tr style="height:22.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-045</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20ul Single Channel Pipette</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Research Plus</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N17220B</font></p></td></tr><tr style="height:26.45pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-046</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20 to 200 uL SINGLE CHANNEL PIPETTE, PIP-46</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Research Plus</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N19398B</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-047</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">0.5 to 10 uL SINGLE CHANNEL PIPETTE, PIP-47</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Signature Variable 10uL</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">42722243</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-048</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">0.5 to 10 uL SINGLE CHANNEL </font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Signature Variable 10uL</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">42721230</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:9.95%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:22.12%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:25.44%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:15.87%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:12.7%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIPETTE, PIP-48</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-050</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">0.5 to 10 uL SINGLE CHANNEL PIPETTE, PIP-50</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Signature Variable 10uL</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">242722478</font></p></td></tr><tr style="height:27pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-051</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">100 to 1000 uL SINGLE CHANNEL PIPETTE, PIP-51</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Gilson</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Pipetman P1000</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">NL71701</font></p></td></tr><tr style="height:24pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-052</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">100 to 1000 uL SINGLE CHANNEL PIPETTE, PIP-52</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Signature Variable 1000uL</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">242764691</font></p></td></tr><tr style="height:24.95pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-053</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">100 to 1000 uL SINGLE CHANNEL PIPETTE, PIP-53</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Signature 1000&#181;L</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">242764693</font></p></td></tr><tr style="height:24pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-054</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">100 to 1000 uL SINGLE CHANNEL PIPETTE, PIP-54</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Signature 1000&#181;L</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">242764712</font></p></td></tr><tr style="height:31.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-055</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">100 to 1000 uL SINGLE CHANNEL PIPETTE, PIP-55</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Gilson</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Pipetman P1000</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">NL71702</font></p></td></tr><tr style="height:24pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-057</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2 to 20 uL SINGLE CHANNEL PIPETTE, PIP-57</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Signature Variable 20uL</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">924733690</font></p></td></tr><tr style="height:29.1pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-058</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2 to 20 uL SINGLE CHANNEL PIPETTE, PIP-58</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Signature Variable 20uL</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">242732461</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-059</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2 to 20 uL SINGLE CHANNEL PIPETTE, PIP-59</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Signature Variable 20uL</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">242732416</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-060</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2 to 20 uL SINGLE CHANNEL PIPETTE, PIP-60</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Signature Variable 20uL</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">42731683</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-061</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2 to 20 uL SINGLE CHANNEL PIPETTE, PIP-61</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Signature Variable 20uL</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">42732744</font></p></td></tr><tr style="height:25.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-062</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20 to 200 uL SINGLE CHANNEL PIPETTE, PIP-62</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Signature 200&#181;L</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">42751747</font></p></td></tr><tr style="height:21.95pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-063</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20 to 200 uL SINGLE CHANNEL PIPETTE, PIP-63</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Signature Variable 200uL</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">242753406</font></p></td></tr><tr style="height:32.1pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-064</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20 to 200 uL SINGLE CHANNEL PIPETTE, PIP-64</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Signature Variable 200uL</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">242753412</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-065</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20 to 200 uL SINGLE CHANNEL PIPETTE, PIP-65</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Signature Variable 200uL</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">42750938</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-066</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20 to 200 uL SINGLE CHANNEL PIPETTE, PIP-66</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Signature Variable 200uL</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">42751732</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-067</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">12-Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">50 to 300 uL 12 CHANNEL PIPETTE, PIP-67</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Fisherbrand</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Finnpipette 4510</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">E47292</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-068</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2 to 20 uL SINGLE CHANNEL PIPETTE, PIP-68</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Rainin</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Pipet-Lite XLS</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">B648361415</font></p></td></tr><tr style="height:30pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-069</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20 to 200 uL SINGLE CHANNEL PIPETTE, PIP-69</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Rainin</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Pipet-Lite XL-200 XLS</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">B648359909</font></p></td></tr><tr style="height:31.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-070</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">100 to 1000 uL SINGLE CHANNEL PIPETTE, PIP-70</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Rainin</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Pipet-Lite XLS</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">B646316130</font></p></td></tr><tr style="height:27.95pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-071</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">0.5 to 10 uL SINGLE CHANNEL PIPETTE, PIP-71</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Rainin</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Pipet-Lite XLS</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">B648362151</font></p></td></tr><tr style="height:24.95pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-072</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Repeater Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">100 to 500 uL SINGLE CHANNEL PIPETTE, PIP-72</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">75836-686</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">127343</font></p></td></tr><tr style="height:29.1pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-073</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Repeater Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">10mL Repeating Pipette</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Repeater Plus</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N11121C</font></p></td></tr><tr style="height:27.6pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-074</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">0.5 to 10 uL SINGLE CHANNEL PIPETTE, PIP-74</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Research Plus</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">L48870H</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-075</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2 to 20 uL SINGLE CHANNEL PIPETTE, PIP-75</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Research Plus</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">M29111H</font></p></td></tr><tr style="height:31.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-076</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20 to 200 uL SINGLE CHANNEL PIPETTE, PIP-76</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Research Plus</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">M29436H</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:9.95%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:22.12%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:25.44%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:15.87%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:12.7%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:30.95pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-077</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">100 to 1000 uL SINGLE CHANNEL PIPETTE, PIP-77</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Research Plus</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">H427178J</font></p></td></tr><tr style="height:25.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-078</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">0.1 to 2.5 uL SINGLE CHANNEL PIPETTE, PIP-78</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Research Plus</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">H26175I</font></p></td></tr><tr style="height:27.6pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-079</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2 to 20 uL SINGLE CHANNEL PIPETTE, PIP-79</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Research Plus</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">P40110H</font></p></td></tr><tr style="height:27.6pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-080</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20 to 200 uL SINGLE CHANNEL PIPETTE, PIP-80</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Research Plus</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">O22719H</font></p></td></tr><tr style="height:31.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-083</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">500 to 5000 uL SINGLE CHANNEL PIPETTE, PIP-83</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Research Plus</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">P58717I</font></p></td></tr><tr style="height:24pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-084</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">0.1 to 2.5 uL SINGLE CHANNEL PIPETTE, PIP-84</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Research Plus</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">O24096I</font></p></td></tr><tr style="height:24pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-085</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2 to 20 uL SINGLE CHANNEL PIPETTE, PIP-85</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Research Plus</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N44888I</font></p></td></tr><tr style="height:26.1pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-086</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20 to 200 uL SINGLE CHANNEL PIPETTE, PIP-86</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Research Plus</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N17768I</font></p></td></tr><tr style="height:17.45pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-087</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">0.5 to 10 uL SINGLE CHANNEL </font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Research Plus</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">H23849I</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:9.95%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:22.12%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:25.44%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:15.87%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:12.7%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:27pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIPETTE, PIP-87</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:27pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-088</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">10 to 100 uL SINGLE CHANNEL PIPETTE, PIP-88</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Research Plus</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">I22938I</font></p></td></tr><tr style="height:33pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-089</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">100 to 1000 uL SINGLE CHANNEL PIPETTE, PIP-89</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Research Plus</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">I44926I</font></p></td></tr><tr style="height:30pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-090</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">12-Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">10 to 100 uL 12 CHANNEL PIPETTE, PIP-90</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Research Plus</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">M49917I</font></p></td></tr><tr style="height:26.45pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-091</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">12-Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">0.5 to 10 uL 12 CHANNEL PIPETTE, PIP-91</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Research Plus</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">G54609I</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-092</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">0.1 to 2.5 uL SINGLE CHANNEL PIPETTE, PIP-92</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Research Plus</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N28417I</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-093</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2 to 20 uL SINGLE CHANNEL PIPETTE, PIP-93</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Research Plus</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">K46043I</font></p></td></tr><tr style="height:24.6pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-094</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20 to 200 uL SINGLE CHANNEL PIPETTE, PIP-94</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Research Plus</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">P36012I</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-095</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">0.5 to 10 uL SINGLE CHANNEL PIPETTE, PIP-95</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Research Plus</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">I48244I</font></p></td></tr><tr style="height:33.6pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-096</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">10 to 100 uL SINGLE CHANNEL </font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Research Plus</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">H37818I</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:9.95%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:22.12%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:25.44%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:15.87%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:12.7%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:32.1pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIPETTE, PIP-96</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:32.1pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-097</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">100 to 1000 uL SINGLE CHANNEL PIPETTE, PIP-97</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Research Plus</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">H45953I</font></p></td></tr><tr style="height:33pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-098</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">0.5 to 10 uL SINGLE CHANNEL PIPETTE, PIP-98</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Reference 2</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">G29123J</font></p></td></tr><tr style="height:31.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-099</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">100 to 1000 uL SINGLE CHANNEL PIPETTE, PIP-99</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Reference 2</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">H24626J</font></p></td></tr><tr style="height:33pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-100</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20 to 200 uL SINGLE CHANNEL PIPETTE, PIP-100</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Reference 2</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">G17609J</font></p></td></tr><tr style="height:24.95pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-101</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">100 to 1000 uL SINGLE CHANNEL PIPETTE, PIP-101</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Repeater E3x</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">O42195I</font></p></td></tr><tr style="height:28.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-102</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">12-Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">30 to 300 uL 12 CHANNEL PIPETTE, PIP-102</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Xplorer plus</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Q39708I</font></p></td></tr><tr style="height:26.45pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-104</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">12-Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">50 to 1200 uL 12 CHANNEL PIPETTE, PIP-104</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Xplorer</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">J77942J</font></p></td></tr><tr style="height:35.45pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-106</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">50 to 1000 uL SINGLE CHANNEL PIPETTE, PIP-106</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Xplorer plus</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N46608I</font></p></td></tr><tr style="height:30pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-107</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Repeater Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">100 to 1000 uL SINGLE CHANNEL </font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Repeater M4</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">H54341J</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:9.95%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:22.12%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:25.44%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:15.87%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:12.7%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:25.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIPETTE, PIP-107</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:25.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-108</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">10 to 100 uL SINGLE CHANNEL PIPETTE, PIP-108</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Gilson</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">P100</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">QN73615</font></p></td></tr><tr style="height:29.1pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-109</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2 to 20 uL SINGLE CHANNEL PIPETTE, PIP-109</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Reference 2</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Q11258H</font></p></td></tr><tr style="height:24.95pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-110</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20 to 200 uL SINGLE CHANNEL PIPETTE, PIP-110</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Research Plus</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">G29737J</font></p></td></tr><tr style="height:24.95pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-111</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">100 to 1000 uL SINGLE CHANNEL PIPETTE, PIP-111</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Research Plus</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">J43098J</font></p></td></tr><tr style="height:27.6pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-112</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">0.5 to 10 uL SINGLE CHANNEL PIPETTE, PIP-112</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Reference 2</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">P41973I</font></p></td></tr><tr style="height:31.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-113</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">10 to 100 uL SINGLE CHANNEL PIPETTE, PIP-113</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Reference 2</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N12835I</font></p></td></tr><tr style="height:27.6pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-114</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">100 to 1000 uL SINGLE CHANNEL PIPETTE, PIP-114</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Reference 2</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Q32149I</font></p></td></tr><tr style="height:27.95pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-115</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">0.1 to 2.5 uL SINGLE CHANNEL PIPETTE, PIP-115</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Reference 2</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">R31901I</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:26.45pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-116</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2 to 20 uL SINGLE CHANNEL PIPETTE, PIP-116</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Reference 2</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">M10785H</font></p></td></tr><tr style="height:24.95pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-117</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20 to 200 uL SINGLE CHANNEL PIPETTE, PIP-117</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Reference 2</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">H13218J</font></p></td></tr><tr style="height:29.1pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-118</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">100 to 1000 uL SINGLE CHANNEL PIPETTE, PIP-118</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Rainin</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Pipet-Lite XLS</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">C037046735</font></p></td></tr><tr style="height:29.1pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-119</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20 to 200 uL SINGLE CHANNEL PIPETTE, PIP-119</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Rainin</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Pipet-Lite XL-200 XLS</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">C038113434</font></p></td></tr><tr style="height:29.1pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-120</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2 to 20 uL SINGLE CHANNEL PIPETTE, PIP-120</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Rainin</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Pipet-Lite XLS</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">C038111669</font></p></td></tr><tr style="height:31.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-121</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">12-Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">30 to 300 uL 12 CHANNEL PIPETTE, PIP-121</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Research Plus</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">O48187J</font></p></td></tr><tr style="height:25.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-122</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2 to 20 uL SINGLE CHANNEL PIPETTE, PIP-122</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Research Plus</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">J30097J</font></p></td></tr><tr style="height:25.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-123</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20 to 200 uL SINGLE CHANNEL PIPETTE, PIP-123</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Research Plus</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">I23667J</font></p></td></tr><tr style="height:22.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-124</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">100 to 1000 uL SINGLE CHANNEL PIPETTE, PIP-124</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Research Plus</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">I45909J</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:25.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-125</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2 to 20 uL SINGLE CHANNEL PIPETTE, PIP-125</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Research Plus</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">G46301J</font></p></td></tr><tr style="height:24.95pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-126</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20 to 200 uL SINGLE CHANNEL PIPETTE, PIP-126</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Research Plus</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">G20345J</font></p></td></tr><tr style="height:24.95pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-130</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">100 to 1000 uL SINGLE CHANNEL PIPETTE, PIP-130</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Research Plus</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">L45794J</font></p></td></tr><tr style="height:29.45pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-131</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">0.5 to 10 uL SINGLE CHANNEL PIPETTE, PIP-131</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Research Plus</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">O20588J</font></p></td></tr><tr style="height:30.6pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-132</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">0.5 to 10 uL SINGLE CHANNEL PIPETTE, PIP-132</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Research Plus</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">K36581J</font></p></td></tr><tr style="height:24.95pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-134</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Repeater Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">50mL Single Channel Pipette</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Repeater E3</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">R37240J</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-135</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">0.2 to 2 uL SINGLE CHANNEL PIPETTE, PIP-135</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Gilson</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Pipetman P2</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MK71943</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-136</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">0.2 to 2 uL SINGLE CHANNEL PIPETTE, PIP-136</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Gilson</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Pipetman P2</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">QK71741</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-137</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1 to 10 uL SINGLE CHANNEL PIPETTE, PIP-137</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Gilson</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Pipetman P10</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">QH53528</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-138</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1 to 10 uL SINGLE CHANNEL PIPETTE, PIP-138</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Gilson</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Pipetman P10</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">QC52021</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-139</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1 to 10 uL SINGLE CHANNEL PIPETTE, PIP-139</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Gilson</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Pipetman P10</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">QH53524</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-140</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1 to 10 uL SINGLE CHANNEL PIPETTE, PIP-140</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Gilson</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIPETMAN P10</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PK53604</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-141</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1 to 10 uL SINGLE CHANNEL PIPETTE, PIP-141</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Gilson</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIPETMAN P10</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">QH53534</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-142</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1 to 10 uL SINGLE CHANNEL PIPETTE, PIP-142</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Gilson</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIPETMAN G P10G</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">QH53523</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-143</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2 to 20 uL SINGLE CHANNEL PIPETTE, PIP-143</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Gilson</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Pipetman P20</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">RC72611</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-144</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2 to 20 uL SINGLE CHANNEL PIPETTE, PIP-144</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Gilson</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Pipetman P20</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">RA73937</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-145</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2 to 20 uL SINGLE CHANNEL PIPETTE, PIP-145</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Gilson</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Pipetman P20</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">RA73987</font></p></td></tr><tr style="height:34.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-146</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">10 to 100 uL SINGLE CHANNEL </font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Gilson</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIPETMAN P100</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">QK20542</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:15.7pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIPETTE, PIP-146</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:27.95pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-147</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20 to 200 ul SINGLE CHANNEL PIPETTE, PIP-147</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Gilson</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Pipetman P200</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PC71724</font></p></td></tr><tr style="height:24pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-148</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20 to 200 uL SINGLE CHANNEL PIPETTE, PIP-148</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Gilson</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Pipetman P200</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">RC74689</font></p></td></tr><tr style="height:24pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-149</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20 to 200 uL SINGLE CHANNEL PIPETTE, PIP-149</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Gilson</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Pipetman P200</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">RC74663</font></p></td></tr><tr style="height:24pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-150</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20 to 200 uL SINGLE CHANNEL PIPETTE, PIP-150</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Gilson</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Pipetman P200</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">RC73454</font></p></td></tr><tr style="height:29.1pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-151</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">100 to 1000 ul SINGLE CHANNEL PIPETTE, PIP-151</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Gilson</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Pipetman P1000</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">RA73605</font></p></td></tr><tr style="height:27.95pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-152</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">100 to 1000 uL SINGLE CHANNEL PIPETTE, PIP-152</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Gilson</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Pipetman P1000</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">NK71861</font></p></td></tr><tr style="height:26.45pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-153</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">100 to 1000 uL SINGLE CHANNEL PIPETTE, PIP-153</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Gilson</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Pipetman P1000</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">RC71364</font></p></td></tr><tr style="height:32.1pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-154</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">12-Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20 to 200 uL 12 CHANNEL PIPETTE, PIP-154</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Gilson</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIPETMAN L P200</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">RK71274</font></p></td></tr><tr style="height:26.45pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-155</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">12-Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20 to 300 uL 12 CHANNEL </font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Gilson</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIPETMAN L P300</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">RH71310</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:16.7pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><div style="height:16.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><div style="height:16.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><div style="height:16.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIPETTE, PIP-155</font></p></div></div></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><div style="height:16.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><div style="height:16.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><div style="height:16.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:25.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-156</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">100 to 1000 uL SINGLE CHANNEL PIPETTE, PIP-156</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">ERGONOMIC HP</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">B42761319</font></p></td></tr><tr style="height:26.45pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-157</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">0.5 to 10 uL SINGLE CHANNEL PIPETTE, PIP-157</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">ERGONOMIC HP</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">B42720414</font></p></td></tr><tr style="height:29.1pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-158</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20 to 200 uL SINGLE CHANNEL PIPETTE, PIP-158</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">ERGONOMIC HP</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">B42750380</font></p></td></tr><tr style="height:27.6pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-159</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">0.1 to 2 uL SINGLE CHANNEL PIPETTE, PIP-159</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">ERGONOMIC HP</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">A42710726</font></p></td></tr><tr style="height:27.6pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-160</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2 to 20 uL SINGLE CHANNEL PIPETTE, PIP-160</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">ERGONOMIC HP</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">B42730230</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-162</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">8-Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">10 to 100 uL 8 CHANNEL PIPETTE, PIP-162</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Research Plus</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">K69935K</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-163</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">8-Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">0.5 to 10 uL 8 CHANNEL PIPETTE, PIP-163</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Research Plus</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">L50080K</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-164</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20 to 200 uL SINGLE CHANNEL PIPETTE, PIP-164</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Research Plus</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">M60331K</font></p></td></tr><tr style="height:29.1pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-165</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2 to 20 uL SINGLE CHANNEL </font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Research Plus</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">M28841K</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:29.1pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIPETTE, PIP-165</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:29.1pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-166</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2 to 20 uL SINGLE CHANNEL PIPETTE, PIP-166</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Research Plus</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">M28795K</font></p></td></tr><tr style="height:33.6pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-167</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20 to 200 uL SINGLE CHANNEL PIPETTE, PIP-167</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Research Plus</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">M60330K</font></p></td></tr><tr style="height:23.1pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-168</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">100 to 1000 uL SINGLE CHANNEL PIPETTE, PIP-168</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Research Plus</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">M56124K</font></p></td></tr><tr style="height:26.45pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-169</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">100 to 1000 uL SINGLE CHANNEL PIPETTE, PIP-169</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Research Plus</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">M56442K</font></p></td></tr><tr style="height:24pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-170</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20 to 200 uL SINGLE CHANNEL PIPETTE, PIP-170</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Rainin</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Pipet-Lite SL-200 XLS</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">C038113533</font></p></td></tr><tr style="height:24.95pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-171</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2 to 20 uL SINGLE CHANNEL PIPETTE, PIP-171</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Rainin</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Pipet-Lite SL-20 XLS</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">C038111643</font></p></td></tr><tr style="height:30.6pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-172</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">100 to 1000 uL SINGLE CHANNEL PIPETTE, PIP-172</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Rainin</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Pipet-Lite SL-1000 XLS</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">C037046686</font></p></td></tr><tr style="height:25.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-173</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2 to 20 uL SINGLE CHANNEL PIPETTE, PIP-173</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Catalog No. 76169-234</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">21k0085</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:25.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-174</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">100 to 10000 uL SINGLE CHANNEL PIPETTE, PIP-174</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Catalog No. 76169-240</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">22B0203</font></p></td></tr><tr style="height:33.95pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-175</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20 to 200 uL SINGLE CHANNEL PIPETTE, PIP-175</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Catalog No. 76169-238</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">22B0735</font></p></td></tr><tr style="height:27.6pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-176</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1 to 10 uL SINGLE CHANNEL PIPETTE, PIP-176</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Catalog No. 76169-232</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">21K0226</font></p></td></tr><tr style="height:25.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-177</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">12-Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20 to 200 uL 12 CHANNEL PIPETTE, PIP-177</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Catalog No. 89079-956</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">C53870050</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-178</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">0.2 to 2 uL SINGLE CHANNEL PIPETTE, PIP-178</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Catalog No. 76169-274</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">22A1179</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-179</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1 to 10 uL SINGLE CHANNEL PIPETTE, PIP-179</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Catalog No. 76169-232</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">22B0348</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-180</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2 to 20 uL SINGLE CHANNEL PIPETTE, PIP-180</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Catalog No. 76169-234</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">22B0787</font></p></td></tr><tr style="height:27pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-181</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20 to 200 uL SINGLE CHANNEL PIPETTE, PIP-181</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Catalog No. 76169-238</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">22B0689</font></p></td></tr><tr style="height:27.6pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-182</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">100 to 1000 uL SINGLE CHANNEL PIPETTE, PIP-182</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Catalog No. 76169-240</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">22B0158</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:25.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-184</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Repeater Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">HandyStep S 500 uL REPETITIVE PIPETTE, PIP-184</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">BRAND</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">DE-M22</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">22D58959</font></p></td></tr><tr style="height:30pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-185</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">0.5 to 5 mL SINGLE CHANNEL PIPETTE, PIP-185</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">EPPENDORF</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">G37495L</font></p></td></tr><tr style="height:23.1pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-186</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">12-Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20 to 300 uL 12 CHANNEL PIPETTE, PIP-186</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">76169-260</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">22C0106</font></p></td></tr><tr style="height:36pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-187</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">0.5 to 5 mL SINGLE CHANNEL PIPETTE, PIP-187</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Research Plus</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">G37503L</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Repeater Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Repeater Pipet</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Repeater Plus</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">L18883C</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">12-Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Pipette (1200uL 12 Channel)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Xplorer Plus</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">I36933L</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">10uL Single Channel Pipette</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Research Plus</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N69392K</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">10uL Single Channel Pipette</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Research Plus</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N69471K</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">200uL Single Channel Pipette</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Research Plus</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">P42051K</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-N/A (New)</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1200uL 12 Channel Pipette</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Xplorer Plus</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">J27483L</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-N/A (New)</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">200uL Single Channel Pipette</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">76169-238</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">22H0507</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-N/A (New)</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">10uL Single Channel Pipette</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">76189-232</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">22H0705</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-N/A (New)</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20uL Single Channel Pipette</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">76189-234</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">22H0297</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-N/A (New)</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1000uL Single Channel Pipette</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">76189-240</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">22G1014</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PIP-N/A (New)</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Pipette</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2uL Single Channel Pipette</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">76189-274</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">22A1186</font></p></td></tr><tr style="height:28.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PP-03</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">KrosFlo Research II Pump</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">KrosFlo Research II Pump (Used for Depth Filtration)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Spectrum Laboratories</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">900-1612</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">E10003074</font></p></td></tr><tr style="height:26.45pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PP-06</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Peristaltic Pump</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Masterflex L/S Pump</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Masterflex by Cole-Parmer Instrument Co.</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">7524-40</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">M10001213</font></p></td></tr><tr style="height:30.6pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PP-07</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Peristaltic Pump</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Peristaltic Pump</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Masterflex by Cole-Parmer Instrument Co.</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">77410-10</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">F11000873</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PP-08</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Peristaltic Pump</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Peristaltic Pump</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Masterflex by Cole-Parmer Instrument Co.</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">77410-10</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">F11000868</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PP-09</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Peristaltic Pump</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Peristaltic Pump </font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Masterflex by Cole-Parmer Instrument Co.</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">950-0000</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">K10002589</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PP-10</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Peristaltic Pump</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Peristaltic Pump </font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Watson Marlow</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">520Du</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">L020909</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PP-12</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Peristaltic Pump</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Peristaltic Pump</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Watson Marlow</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">323S/D</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">K100409</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PP-13</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Peristaltic Pump</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Masterflex VP</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Masterflex by Cole-Parmer Instrument Co.</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">77410-10</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">E11000743</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PP-14</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Peristaltic Pump</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Masterflex L/P</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Masterflex by Cole-Parmer Instrument Co.</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">77601-10</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PP-15</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Peristaltic Pump</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Masterflex I/P Pump</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Masterflex by Cole-Parmer Instrument Co.</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">77601-10</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">G11004421</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PP-16</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Peristaltic Pump</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Peristaltic Pump</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Spectrum Laboratories</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">708-13197-000</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">C16001928</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PP-17</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Peristaltic Pump</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MasterFlex 15/24/35/36 L/S Pump</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Masterflex by Cole-Parmer Instrument Co.</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">07522-20</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">D19004907</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PP-19</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Peristaltic Pump</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Peristaltic Pump</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Masterflex by Cole-Parmer Instrument Co.</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">77602-10</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">D20000965</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PP-20</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Peristaltic Pump</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Peristaltic Pump</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Masterflex by Cole-Parmer Instrument Co.</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">77410-10</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">D20000964</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PP-21</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Peristaltic Pump</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Peristaltic Pump</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Watson Marlow</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">323E/D</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">200605-301958</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PRC-03</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Mastercycle</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Eppendorf</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">nexus GX2</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">6336JL526723</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PS-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Electrophoresis Power Supply</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Mini-Gel Electrophoresis Power Supply</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Life Technologies</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PowerEase 90W PS0090</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">090091217</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PS-02</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Electrophoresis Power Supply</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Mini-Gel Electrophoresis Power Supply</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Life Technologies</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PowerEase 90W PS0090</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">090091217</font></p></td></tr><tr style="height:31.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PSS-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PROTEIN STAINING SYSTEM, </font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">GENSCRIPT</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">L00657</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:27.6pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">BUILDING 1 MB/PD LAB</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:27.6pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PU-18</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Peristaltic Pump</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MasterFlex 73/82 L/S Pump; B1</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Masterflex by Cole-Parmer Instrument Co.</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">77420-10</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">F19003722</font></p></td></tr><tr style="height:29.1pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PU-502</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Centrifugal Pump (Sanitary Centrifugal Pump)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Fristam</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">FZX2150</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">FZX21502002648</font></p></td></tr><tr style="height:24.95pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PW-02</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">ELGA Pure Water System </font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">ELGA</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Purelab Ultra</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">UGG279578</font></p></td></tr><tr style="height:24.95pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">RH-09</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Temperature element; TraceableGO DATALOGGING HYGROMETER</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Control Company</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">15-027-679</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">181361790</font></p></td></tr><tr style="height:31.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">RH-15</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermometer/Clock/Humidity Monitor</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermometer/Clock/Humidity Monitor</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">36934-164</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">192263914</font></p></td></tr><tr style="height:30.6pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">RH-17</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermometer/Clock/Humidity Monitor</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermometer/Clock/Humidity Monitor</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">36934-164</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">192263885</font></p></td></tr><tr style="height:25.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">RH-36</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermometer/Clock/Humidity Monitor</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermometer/Clock/Humidity Monitor</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">62344-734</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">170009673</font></p></td></tr><tr style="height:32.45pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">RH-37</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermometer/Clock/Humidity Monitor</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermometer/Clock/Humidity Monitor</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">62344-734</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">170009667</font></p></td></tr><tr style="height:29.1pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">ROTO-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Centrifuge Rotor</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Beckman Coulter</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SX4400</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">13D 1054</font></p></td></tr><tr style="height:39pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">ROTO-02</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Centrifuge Rotor</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Beckman Coulter</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">S096</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">12D 1116</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">ROTO-03</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Centrifuge Rotor</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Beckman Coulter</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">21D 1128</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">RS-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Hoopman Seed Sifter</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">HOOPMAN EQUIPMENT AND </font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">RS-480</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20E64-0297</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">ENGINEERING</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">RT-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Rotap Sifter (RO-TAP SIEVE SHAKER)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">WSTyler</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">RX-29</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">16924</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SC-02</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Scale/Balance</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1200g ANALYTICAL BALANCE, SC-02</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Mettler Toledo</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">XP1203S (VWR 11277-142)</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">B104107101</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SC-03</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Scale/Balance</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">400 g Benchtop Scale</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Ohaus</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SP402</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">7131450513</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SC-05</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Scale/Balance</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">400 g Benchtop Scale</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Ohaus</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SP402</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">7131450567</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SC-06</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Scale/Balance</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">4000 g Benchtop Scale</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Ohaus</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SP4001</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">B615338640</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SC-07</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Scale/Balance</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">400 g Benchtop Scale</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Ohaus</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SP402</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">7131250842</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SC-08</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Scale/Balance</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">4000 g Benchtop Scale</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Ohaus</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SP4001</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">7131282198</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SC-09</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Scale/Balance</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">4000 g Benchtop Scale</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Ohaus</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SP4001</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">7130210631</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SC-10</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Scale/Balance</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">300 kg Floor Scale</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Ohaus</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">T32XW</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">0048381-6JM</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SC-11</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Scale/Balance</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">200 kg Floor Scale</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Arlyn Scales</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SAW-KMPI-201-3</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">38382G</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SC-12</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Scale/Balance</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">60,000 g Benchtop Scale</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Arlyn Scales</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SAW-KML-12</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">39243A</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SC-15</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Scale/Balance</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">6200 g Benchtop Scale</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Ohaus</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SPX6201</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">B620493261</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SC-16</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Scale/Balance</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">32100 g Benchtop Scale</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Mettler Toledo</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">XS32001L (VWR 62410-854)</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">B63806041</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SC-17</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Scale/Balance</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">5000 lb Portable Floor </font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Mettler Toledo</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Deckmate 2888 with </font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1175478-1AN with </font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Scale with Indicator</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">IND570 Harsh</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">04553356MM</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SC-18</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Scale/Balance</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">5000 lb Portable Floor Scale with Indicator</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Mettler Toledo</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Deckmate 2888 with IND570 Harsh</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1175483-1AN with 04553326MM</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SC-19</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Scale/Balance</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">300 kg Floor Scale</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Ohaus</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">3000 Series T31P</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">004221-6HM</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SC-20</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Scale/Balance</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20 kg Benchtop Scale</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">AND</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SK-20K</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">M4131280</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SC-21</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Scale/Balance</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">200 g Benchtop Scale</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Ohaus</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CS200</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Unknown</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SC-22</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Scale/Balance</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">30000 g Benchtop Scale</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Ohaus</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">V71P30T</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">8337390095</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SC-23</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Scale/Balance</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">100 kg Floor Scale</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Ohaus</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Defender 5000 T51XW</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">B644224624</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SC-24</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Scale/Balance</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">30000 g Benchtop Scale</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Ohaus</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">V71P30T</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">8337470178</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SC-25</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Scale/Balance</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">5000 lb Floor Scale with Indicator</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Mettler Toledo</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PUA579 with IND570 Harsh</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">B71493420 with B651462092</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SC-26</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Scale/Balance</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">60 kg Floor Scale with Indicator</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Mettler Toledo</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PBA655-CC60 with IND246</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">B721166690 with B742830324</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SC-27</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Scale/Balance</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">220 g Benchtop Scale</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Mettler Toledo</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">ME204TE/00</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">B919631364</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SC-28</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Scale/Balance</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">6200 g Benchtop Scale</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Mettler Toledo</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">ML6001T/00</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">C030759821</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SC-29</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Scale/Balance</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">600 kg Portable Floor Scale with Indicator</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Mettler Toledo</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Deckmate 2888 with IND236</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">C048577386 with C032837773</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SC-30</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Scale/Balance</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">120 g Portable Toploading Balance</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR-123P</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">10282020121</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SC-33</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Scale/Balance</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1500 kg Portable Floor Scale with Indicator</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Mettler Toledo</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Deckmate 2888 with IND570 Harsh</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">C219032181 with C129189754</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SC-N/A (New)</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Scale/Balance</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">60 kg KrosFlo Scale</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Repligen</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">ACSS-60K</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">633495</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SC-N/A (New)</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Scale/Balance</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">60 kg KrosFlo Scale</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Repligen</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">ACSS-60K</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">633501</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SC-N/A (New)</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Scale/Balance</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1500 kg Portable Floor Scale with Indicator</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Mettler Toledo</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Deckmate 2888 with IND570 Harsh</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">C210670680 with C208578114</font></p></td></tr><tr style="height:30pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SCN-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Electrophoresis Gel Scanner</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Electropherisis Gel Scanner; Computer: DT-99</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Microtek</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Bio-5000 plus</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SK6A2100119</font></p></td></tr><tr style="height:25.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">SCN-01_DT-99</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Electrophoresis Gel Scanner</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Desktop; Instrument: SCN-01</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Dell</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:23.1pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SD-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SMC Seeder (Seeder Portion)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CXSM20-50-273L</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SHK-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Shaker</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Low speed orbital shaker</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CORNING</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">S2030-LS-COR</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">16103390</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SHK-02</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Shaker</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Digital Variable Speed Nutating Mixer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Fisher Scientific</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">88861043</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">G4CF61043015</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SHK-03</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Shaker</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Digital MicroPlate Shaker</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermo Scientific</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">88882005</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">K3CT82005021</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SHK-04</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Shaker</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Digital Microplate Shaker</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermo Scientific</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">88882005</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">KBCT82005172</font></p></td></tr><tr style="height:39.95pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SHK-05</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Shaker</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Analog Low Speed Orbital Shaker (LES Orbital Shaker 120V)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Corning</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">6780-FP</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20040169</font></p></td></tr><tr style="height:25.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SHK-06</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Shaker</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Analog Titer Plate Shaker</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermo Scientific</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">4625</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">C1882110311321</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:31.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SHK-07</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Shaker</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Shaker (tilt)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">THERMO SCIENTIFIC</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">4630</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">C1668101034877</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SHK-08</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Shaker</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">LSE Low Speed Orbital Shaker</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CORNING</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">S2030-LS-COR</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">16033191</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SHK-N/A (New)</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Shaker</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Digital MicroPlate Shaker</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermo Scientific</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">88882005</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">KBCT82005184</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SP-06</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Stir Plate</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Analog Magnetic Stir Plate</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermo Scientific</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SP18425Q</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">C1725160405796</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SP-07</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Stir Plate</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Analog Magnetic Stir Plate</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermo Scientific</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SP18425Q</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">C1725160405797</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SP-08</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Stir Plate</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Digital Magnetic Stir Plate</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">97042-748</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">160419001</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SP-09</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Stir Plate</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Stir Plate; B1</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">COLE PARMER</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">04661-29</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">010212C04714</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SP-10</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Stir Plate</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Analog Magnetic Stirrer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">12620-994</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">110505009</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SP-11</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Stir Plate</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Digital Magnetic Stir Plate</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Corning</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">6795-610D</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">133710018020</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SPC-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Spectrophotometer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Beckman Coulter</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">DU 730</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1321276</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SPC-02</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Spectrophotometer; Computer: LAB05</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Beckman Coulter</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">DU 800</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1096311</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">SPC-02_DT-32</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Desktop CPU; Instrument: SPC-02</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Dell</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Optiplex 980</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">397BNN1</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SPC-04</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Chlorophyll Meter</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Konica Minolta</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SPAD-502 Plus</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20009831</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SPC-05</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Handheld Wavelength Light Meter</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Wave Illumination</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">WAVEGO-VIS-50</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">W119040274</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SPC-06</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Spectrophotometer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">THERMOSCIENTIFIC</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">GENESYS 30</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">9A1Y121114</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:9.95%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:22.12%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:25.44%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:15.87%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:12.7%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SPC-07</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Spectrophotometer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">THERMOSCIENTIFIC</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">GENESYS 30</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">9A1Y121108</font></p></td></tr><tr style="height:43.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SPC-08</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Evolution 260 Bio UV-VISIBLE SPECTROPHOTOMETER, SPC-08; Computer: DT-70</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">THERMO FISHER SCIENTIFIC</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">840-211000</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">5A6Y 073105</font></p></td></tr><tr style="height:24.6pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">SPC-08_DT-70</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Dell Desktop; Instrument: SPC-08</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Dell</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:46.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SPC-N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Fluorometer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Qubit 4 Fluorometer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermo Fisher Scientific</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Qubit 4 Fluorometer</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2322621070191</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SPST-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Certified Reference Materials</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Hellma Analytics</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Type 667-UV003</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">None</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SPST-02</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Certified Reference Materials</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Hellma Analytics</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Type 666-F3</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">None</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SPST-03</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Certified Reference Materials</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Hellma Analytics</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Type 666-F290</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">None</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SPST-04</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Certified Reference Materials</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Starna Scientific</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">87288-87293</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">33083</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SPST-05</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Certified Reference Materials</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Starna Scientific</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">87311-87312</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">33084</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SS-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Autoclave</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PRIMUS Autoclave; B1</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PRIMUS</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PSS8-B-SPSD</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">17603</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SS-02</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Autoclave</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Autoclave</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Sanyo</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MLS-3781-L</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">30641</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SS-03</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Autoclave</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Autoclave</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Sanyo</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MLS-3781-L</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">30642</font></p></td></tr><tr style="height:26.45pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">STAB-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Incubator</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Stability Chamber (25 C / 60% RH STABILITY CHAMBER)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">BAHNSON ENVIRONMENTAL SPECIALTIES</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">ES2000 CDM-C</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2107234827</font></p></td></tr><tr style="height:30.6pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">STAB-02</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Incubator</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Stability Chamber (25 </font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">BAHNSON ENVIRON</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">ES2000 CDM-C</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2107234826</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:9.95%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:22.12%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:25.44%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:15.87%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:12.7%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:30.6pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">C / 60% RH STABILITY CHAMBER)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MENTAL SPECIALTIES</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:30.6pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SW-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Other</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Slide Warmer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Premiere</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">XH-2002</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">C&amp;AU110161</font></p></td></tr><tr style="height:33.95pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TE-36</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TempAlert TEMPERATURE SENSOR, TE-36</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SMART SENSE by DIGI</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">AC-TMP5PINDIN6</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">28FA96D4090000</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TE-37</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TempAlert TEMPERATURE SENSOR, TE-37</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SMART SENSE by DIGI</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">AC-TMP5PINDIN6</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">289022D4090000</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TE-503</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Tank 503 Regulator</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TFF-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TFF</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Spectrum KTF-1000 System</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">REPLIGEN</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SYTF-1000</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2016-12-20-002</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TFF-01_TK-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TFF</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Spectrum TFF-01 Surge Tank </font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">REPLIGEN</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">ZA1234289</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">80601138</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TFF-02</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TFF</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Spectrum KTF-1000 System</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">REPLIGEN</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SYTF-1000</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2016-12-20-001</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TFF-02_TK-02</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TFF</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Spectrum TFF-02 Surge Tank </font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">REPLIGEN</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">ZA014860</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">80601115</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TFF-03</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TFF</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">KrosFlo KMPi TFF System</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">REPLIGEN</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">S/N: C1600469</font><font style="font-size:12pt;"><br></font><font style="font-size:12pt;">Large Pump (PP-02) S/N: C16003088</font><font style="font-size:12pt;"><br></font><font style="font-size:12pt;">Small Pump (PP-01) S/N: C16001924 (Model 900-1613)</font><font style="font-size:12pt;"><br></font><font style="font-size:12pt;">Back Pressure Valve S/N: N/A</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TFF-04</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TFF</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">KrosFlo KR2i TFF System</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">REPLIGEN</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">900-1893</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Pump S/N: B16004036</font><font style="font-size:12pt;"><br></font><font style="font-size:12pt;">Back Pressure Valve S/N: PCV160161512</font><font style="font-size:12pt;"><br></font><font style="font-size:12pt;">Scale: B615338640</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TFF-05</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TFF</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">KrosFlo KR2i TFF System</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">REPLIGEN</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">900-1893</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">J19004878</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TFF-06</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TFF</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">KrosFlo KMPi TFF System</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">REPLIGEN</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">900-1939</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">L19003012</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TFF-07</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TFF</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">KrosFlo KMPi TFF System</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">REPLIGEN</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">900-1939</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">L19003011</font></p></td></tr><tr style="height:27.6pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TFF-08</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TFF</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TFF Skid (MasterFlex); KrosFlo LDF37 TFF System</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">REPLIGEN</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SYKL-121-01N or SYKL-122-01N</font><font style="font-size:12pt;"><br></font><font style="font-size:12pt;">(TFF-08_PU-01) Permeate Pump: ACPU-021-01N (Leeson Washguard Design; Model C4017NK570)</font><font style="font-size:12pt;"><br></font><font style="font-size:12pt;">(TFF-08_VA-01) Backpressure Valve: ACPU-F82-01N</font><font style="font-size:12pt;"><br></font><font style="font-size:12pt;">(TFF-08_GA-01) Digital Pressure Monitor: ACPU-201-</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">A11000474 (Masterflex B/T Digital Modular Drive)</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:26.45pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">01N (SpectrumLabs; Model: 900-1607)</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:26.45pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TFF-09</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TFF</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Repligen KTF-250 System</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">REPLIGEN</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SYTF-250</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">200626-001</font></p></td></tr><tr style="height:27.6pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TFF-10</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TFF</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Repligen KTF-600 System </font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">REPLIGEN</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SYTF-600</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">200625-001</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TFF-11</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TFF</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">KrosFlo KR2i TFF System</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">REPLIGEN</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">900-1893</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">L19005530</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TFF-12</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TFF</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Repligen KTF-2000 System</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">REPLIGEN</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SYTF-2000</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">200323-001</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TFF-13</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TFF</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">KrosFlo KR2i TFF System</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">REPLIGEN</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">900-1893</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Unknown</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TFF-14</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TFF</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Repligen KTF-200 System</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">REPLIGEN</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SYTF-200</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20059865-001</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TM-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermometer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Digital Thermocouple Thermometer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Fluke</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">52</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">72840145</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TM-02</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermometer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Digital Thermometer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Fluke</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">51 II</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">13550436</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TM-06</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermometer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">LONG-STEM DIGITAL THERMOMETER, TM-06</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">61220-416</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">160381824</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TM-09</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermometer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Single Channel Datalogging Thermometer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Control Company</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">61161-336</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">111515290</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TM-15</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermometer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2 Channel Datalogging Thermometer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">10048-650</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">170320475</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TM-17</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermometer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2 Channel Datalogging Thermometer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">10048-650</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">170372115</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TM-18</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermometer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2 Channel Datalogging Thermometer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">10048-650</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">170372116</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TM-19</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermometer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2 Channel Datalogging Thermometer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">10048-660</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">170407774</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TM-22</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermometer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Liquid in Glass Thermometer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">61014-920</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">None</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TM-25</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermometer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Liquid in Glass Thermometer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">61014-920</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">None</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TM-26</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermometer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Liquid in Glass Thermometer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">H-B</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">61014-920</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">None</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TM-28</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermometer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Liquid in Glass Thermometer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">H-B</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">60 to 120 deg F</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">L58439</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TM-30</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermometer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Long-Stem Digital Thermometer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Digi-Sense</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">61220-416</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">191952722</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TM-32</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermometer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Long-Stem Digital Thermometer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">(Cole-Parmer) Digi-Sense</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">90205-00</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Unknown</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TM-40</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermometer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Temperature Monitoring Datalogger</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Sensitech</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TempTale Ultra Dry Ice Probe</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">GH22S003H0</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TM-41</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermometer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Temperature Monitoring Datalogger</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Sensitech</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TempTale Ultra Dry Ice Probe</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">GH22S003D0</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TM-42</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermometer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Temperature Monitoring Datalogger</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Sensitech</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TempTale Ultra Dry Ice Probe</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">GDS2S007V0</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TM-43</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermometer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Temperature Monitoring Datalogger</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Sensitech</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TempTale Ultra Dry Ice Probe</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">GDS2S007E0</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TM-44</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermometer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Temperature Monitoring Datalogger</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Sensitech</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TempTale Ultra Dry Ice Probe</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">GDS2S007B0</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TM-46</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermometer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Long-Stem Digital Thermometer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">(Cole-Parmer) Digi-Sense</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">90205-00</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">200543970</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TM-48</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermometer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Long-Stem Digital Thermometer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">(Cole-Parmer) Digi-Sense</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">90205-00</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">200110485</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TM-49</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermometer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Long-Stem Digital Thermometer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">(Cole-Parmer) Digi-Sense</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">90205-00</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">200544006</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TM-50</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermometer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Long-Stem Digital Thermometer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">(Cole-Parmer) Digi-Sense</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">90205-00</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">210369473</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TM-51</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermometer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Long-Stem Digital Thermometer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">(Cole-Parmer) Digi-Sense</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">90205-00</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">210369451</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TM-52</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermometer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Long-Stem Digital Thermometer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">(Cole-Parmer) Digi-Sense</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">90205-00</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Unknown</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TM-53</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermometer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Long-Stem Digital Thermometer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">(Cole-Parmer) Digi-Sense</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">90205-00</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">210369458</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TM-54</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermometer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Long-Stem Digital Thermometer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">(Cole-Parmer) Digi-Sense</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">90205-00</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">210369476</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TM-55</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermometer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Long-Stem Digital Thermometer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">(Cole-Parmer) Digi-Sense</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">90205-00</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">210369460</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TM-56</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermometer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Long-Stem Digital Thermometer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">(Cole-Parmer) Digi-Sense</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">90205-00</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">210369465</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TM-57</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermometer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Long-Stem Digital Thermometer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">(Cole-Parmer) Digi-Sense</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">90205-00</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">210369454</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TM-58</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermometer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Long-Stem Digital Thermometer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">(Cole-Parmer) Digi-Sense</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">90205-00</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">210369523</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TM-59</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermometer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Long-Stem Digital Thermometer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">(Cole-Parmer) Digi-Sense</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">90205-00</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">210369468</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TM-60</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermometer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Total Immersion Liquid in Glass Thermometer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">89095-612</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">725753</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TM-61</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermometer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Total Immersion Liquid in Glass Thermometer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">89095-612</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">725870</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TM-62</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Thermometer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Total Immersion Liquid in Glass Thermometer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">89095-612</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">725944</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TOC-02</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TOC Analyzer; Computer: DT-59</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SUEZ</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">M9 Laboratory </font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">21036186</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">TOC-02_AUTO-01</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TOC Autosampler</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SUEZ</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">AUTOSAMPLER</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">A2EE-698B-43A9-94D1-0C2645DF294D</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">TOC-02_DT-59</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Dell Desktop/Sievers M9, TOC-02 (TOC)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Dell</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TP-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Schneider Control Panel</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TSW-20</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Timer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">3 Channel Timer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Fisherbrand</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">06-662-46</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">181141321</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TSW-22</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Timer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Jumbo 2 Channel Digital Timer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">61161-346</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">191972038</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TSW-31</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Timer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Jumbo 2 Channel Digital Timer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">61161-346</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">181582595</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TSW-33</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Timer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Jumbo 2 Channel Digital Timer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">61161-346</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">181582673</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TSW-34</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Timer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Nano Timer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">21800-064</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">192577090</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TSW-38</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Timer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Jumbo 2 Channel Digital Timer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">61161-346</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">200398677</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TSW-41</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Timer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Jumbo 2 Channel Digital Timer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">61161-346</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">200398710</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TSW-42</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Timer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Jumbo 2 Channel Digital Timer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Fisherbrand</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">06-662-47</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">200398665</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TSW-43</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Timer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Jumbo 2 Channel Digital Timer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">61161-346</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">200398670</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TSW-45</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Timer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Jumbo 2 Channel Digital Timer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">61161-346</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">200398735</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TSW-48</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Timer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">4 Channel Timer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Control Company</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">5004</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">200486051</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TSW-51</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Timer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">4 Channel Timer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Control Company</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">5004</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">200486056</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:9.95%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:22.12%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:25.44%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:15.87%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:12.7%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt 0pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TSW-52</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Timer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">4 Channel Timer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Control Company</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">5004</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">200486054</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TSW-54</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Timer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">4 Channel Timer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Control Company</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">5004</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">200486052</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TSW-58</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Timer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Digital Stopwatch</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">82023-864</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">WA07906</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TSW-60</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Timer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Digital Stopwatch</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">82023-864</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">WA07914</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TSW-64</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Timer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Nano Timer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">21800-064</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">210931180</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TSW-65</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Timer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Nano Timer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">21800-064</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">210727529</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TSW-66</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Timer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Nano Timer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">21800-064</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">210931190</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TSW-67</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Timer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Timer (Nano 2 Channel)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">21800-064</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">210931191</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TSW-68</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Timer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Nano Timer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">21800-064</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">210931189</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TSW-69</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Timer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Nano Timer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">21800-064</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">210931195</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TSW-70</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Timer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Timer (Nano 2 Channel)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">21800-064</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">210931185</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TSW-71</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Timer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Nano Timer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">21800-064</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">210931177</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TSW-72</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Timer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Nano Timer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">21800-064</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">210931198</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TSW-73</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Timer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Nano Timer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">21800-064</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">210931245</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TSW-74</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Timer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Nano Timer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">21800-064</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">210931182</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TSW-75</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Timer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Timer (Nano 2 Channel)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">21800-064</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">210931200</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TSW-77</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Timer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Timer (Nano 2 Channel)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">21800-064</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">210727543</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TSW-78</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Timer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Timer (Nano 2 Channel)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">21800-064</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">210931201</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TSW-80</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Timer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Nano Timer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">21800-064</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">210931179</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TSW-81</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Timer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Timer (Nano 2 Channel)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">21800-064</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">210931205</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TSW-82</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Timer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Timer (Nano 2 Channel)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">21800-064</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">210931176</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TSW-83</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Timer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Timer (Nano 2 Channel)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">21800-064</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">210727550</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TT-25</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Temperature Alert</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">DIGI</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TM-ZP300-SREVA</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">11666000000168690138</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TT-27</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Temperature Alert</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">DIGI</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TM-ZP300-SREVA</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">11666000000168690138</font></p></td></tr><tr style="height:33pt;"><td style="vertical-align:top;width:9.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TT-38</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TempAlert WIRELESS TEMPERATURE </font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SMART SENSE by DIGI</font></p></td><td style="vertical-align:top;width:12.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TM-ZP300-S Rev A</font></p></td><td style="vertical-align:top;width:13.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">11666000000-178600001</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:33pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TRANSMITTER, TT-38</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:33pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TT-43</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TempAlert WIRELESS TEMPERATURE TRANSMITTER, TT-43</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SMART SENSE by DIGI</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TM-ZP300-DS Rev B</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">11666000000-189718014</font></p></td></tr><tr style="height:33pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TT-45</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TempAlert WIRELESS TEMPERATURE TRANSMITTER, TT-45</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SMART SENSE by DIGI</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TM-ZP300-DS Rev B</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">11666000000-189753969</font></p></td></tr><tr style="height:33pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TT-46</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TempAlert WIRELESS TEMPERATURE TRANSMITTER, TT-46</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SMART SENSE by DIGI</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TM-ZP300-DS Rev B</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1.1666E+19</font></p></td></tr><tr style="height:33pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TT-48</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TempAlert WIRELESS TEMPERATURE TRANSMITTER, TT-48</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SMART SENSE by DIGI</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TM-ZP300-DS Rev B</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">11666000000-189680788</font></p></td></tr><tr style="height:24pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TT-51</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TempAlert WIRELESS TEMPERATURE TRANSMITTER, TT-51</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SMART SENSE by DIGI</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TM-ZP300-DS Rev B</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1.1666E+19</font></p></td></tr><tr style="height:31.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TT-52</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Smart Sense Moisture Sensor</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SMART SENSE by DIGI</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TM-ZP300-DS Rev B</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">11666000000-189702013</font></p></td></tr><tr style="height:27.95pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TURB-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Handheld Turbidity Meter</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Handheld Turbidity Meter</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Hach</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">LPG439.01.0002</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">12070C018761</font></p></td></tr><tr style="height:26.45pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TY-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Tally Counter</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Tally Counter</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Cole Parmer</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20610-00</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">3128-201</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TY-02</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Tally Counter</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Tally Counter</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Cole Parmer</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">20610-00</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TY-04</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Tally Counter</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Handheld Tally Counter</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Uline</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">H-7350</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">None</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">UB-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Ultrasonic waterbath</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Water Bath (Ultrasonic)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">97043-972</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1015A0217</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">UB-02</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Ultrasonic waterbath</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Digital Ultrasonic Cleaner</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">97043-936</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1013E041X</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VAC-FH-324</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SFI Vacuum Tank</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">855955-1-1</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">5475-1</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VC-01 (ANZL-01)</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Cell Counter</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Vi-Cell BLU Cell Viability Analyzer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Beckman Coulter</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">ViCell Blu</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">C1919622C077</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VC-100</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Perry Industries Recirculation Table </font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VA-1200</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">P1053</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VP-02</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Dry Vacuum Pump/Compressor</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">DRY VACUUM PUMP/COMPRESSOR, VP-02</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Welch</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2511B-75 B</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">21600001068</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VP-03</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Dry Vacuum Pump/Compressor</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Vacuum Pump</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VACUUBRAND</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MZ 2C NT</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">41194003</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VP-04</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Dry Vacuum Pump/Compressor</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Dry Vacuum Pump/Compressor</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Welch</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">25118-75 B</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">041200000866</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VP-05</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Dry Vacuum Pump/Compressor</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Vacuum Pump</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Welch</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2511B-75 C</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">042000001173</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VPC-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Air Sampler</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Viable Air Sampler, QC EM Devices</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MILLIPORE SIGMA</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MAS-100VF</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">201288</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VPC-02</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Air Sampler</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Viable Air Sampler, QC EM Devices</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MILLIPORE SIGMA</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MAS-100VF</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">201289</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VPC-03</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Air Sampler</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Viable Air Sampler, QC EM Devices</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">EMD Millipore</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MAS-100 VF</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">201290</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VPC-04</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Air Sampler</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Viable Air Sampler, QC EM Devices</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">EMD Millipore</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MAS-100 VF</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">202390</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VPC-05</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Air Sampler</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Viable Air Sampler, QC EM Devices</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MILLIPORE SIGMA</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MAS-100VF</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">202722</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VPC-06</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Air Sampler</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Viable Air Sampler, QC EM Devices</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">EMD Millipore</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MAS-100 VF</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">202723</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VPC-07</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Air Sampler</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Viable Air Sampler, QC EM Devices</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MILLIPORE SIGMA</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MAS-100VF</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">202724</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VPC-08</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Air Sampler</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Viable Air Sampler, QC EM Devices</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MILLIPORE SIGMA</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MAS-100VF</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">202725</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VPC-09</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Air Sampler</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Viable Air Sampler, QC EM Devices</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MILLIPORE SIGMA</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MAS-100VF</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">202726</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VPC-10</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Air Sampler</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Viable Air Sampler, QC EM Devices</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">EMD Millipore</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MAS-100 VF</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">202727</font></p></td></tr><tr style="height:32.45pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VPE-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Spectrometer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SoloVPE SPECTROMETER, VPE-01; Computer: BCS-SOLOVPE-01</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">C TECHNOLOGIES, Inc</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">IN-VPE-SOLO5</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CTS2201049</font></p></td></tr><tr style="height:29.1pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VX-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Vortex mixer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Analog Vortex Mixer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">58816-121</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">101216023</font></p></td></tr><tr style="height:24.95pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VX-02</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Vortex mixer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR Vortex Mixer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">10153-688</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">018133022489</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VX-03</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Vortex mixer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR Vortex Mixer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">14005-824 (945303)</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">70111001</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VX-05</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Vortex mixer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Vortexer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">THERMO SCIENTIFIC</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">88882009</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">JBCT82009043</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VX-06</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Vortex mixer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Vortexer (9454FIDGUS)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Fisher Scientific</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">02215418</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">200811005</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VX-07</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Vortex mixer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR Advanced Vortex Mixer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">97043-564</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">200708001</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VX-08</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Vortex mixer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Analog Vortex Mixer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">58816-121</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">100729032</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VX-N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">IKA MS 3 Vortexer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">IKA</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MS 3 B S36</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">03.527864</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VX-N/A (New)</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Vortex mixer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR Digital Vortex Mixer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">10153-842</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">C224266120</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VX-N/A (New)</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Vortex mixer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR Digital Vortex Mixer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">10153-842</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">C224266141</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VX-N/A (New)</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Vortex mixer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Advanced Vortex Mixer </font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">10153-842</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">C224266119</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VX-N/A (New)</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Vortex mixer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Advanced Vortex Mixer</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">9453VWHDUSA</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">C234665787</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">WB-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Water Bath</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Heating Bath 10LA</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">97025-118</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1H1120169</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">WB-02</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Water Bath</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Water Bath (General Purpose)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">WB-02 (or WB20)</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">W41681341</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">WB-04 (New)</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Water Bath</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Digital Water Bath</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Benchmark Scientific</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">B2000-08</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MBG6119U-707</font></p></td></tr><tr style="height:14.1pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">WB-N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Water Bath</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Digital Water Bath</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PolyScience</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">WBE05</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">E12170211</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">WPW-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Microplate Reader</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Well Plate Washer BioTek ELX 508</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">BioTek</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">05404-0998</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">254624</font></p></td></tr><tr style="height:14.1pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">WS-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Glassware Washer, QC EM Devices</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Miele Professional</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">74350297</font></p></td></tr><tr style="height:33pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><b style="font-size:12pt;font-weight:bold;">FZ-04</b></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Ultra Low-Temp Upright Freezer Panasonic MDF-DU502VXC-PA</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">-80</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Panasonic</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">U76VA-PA</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">16117N0304</font></p></td></tr><tr style="height:26.45pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><b style="font-size:12pt;font-weight:bold;">FZ-06</b></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Ultra Low-Temp Upright Freezer Panasonic MDF-DU502VXC-PA</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">-70</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Panasonic</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MDF-U76VA-PA</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">16067N0208</font></p></td></tr><tr style="height:33pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><b style="font-size:12pt;font-weight:bold;">FRZ-18</b></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Dual Chamber Freezer (18-1 and 18-2)</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">-20</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PHCBI</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MDF-MU549DHL-PA</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">210460070</font></p></td></tr><tr style="height:33pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">FZ-03</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SANYO Biomedical Freezer (-20C)</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">-20</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Sanyo</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MDF-U730</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">10099311</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><b style="font-size:12pt;font-weight:bold;">FZ-05</b></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Freezer (-20C)</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">-20</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Panasonic</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MDF-U731M-PA</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">16089305</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">FZ-07</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">-20</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SCBMF-1420</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SYM-WB20961796</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><b style="font-size:12pt;font-weight:bold;">STAB-05</b></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Freezer (-20C)</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">-20</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PHCBI</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MDF-MU549DHL-PA</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">210360005</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><b style="font-size:12pt;font-weight:bold;">STAB-03</b></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Refrigerator</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2 to 8 DEG C</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PHCBI</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MIR-554-PA</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">21040077</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">FRZ-22-TE-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Temperature probe</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">BURNS ENGINEERING, Inc.</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">23435-10A-035-120</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">4268334</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><b style="font-size:12pt;font-weight:bold;">STAB-04</b></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Refrigerator</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2 to 8 DEG C</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PHCBI</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MIR-554-PA</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">21040079</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">FRZ-20</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">-20 deg C Setpoint +/-5 deg C</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VECTOR LAB PRODUCTS</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VFZR25-LB-RSD</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">21POP 003477</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">FRZ-21</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">-20 deg C Setpoint +/-5 deg C</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VECTOR LAB PRODUCTS</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VFZR25-LB-RSD</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">21POP 003469</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">FZ-01-TE-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Temperature probe</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:33pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><b style="font-size:12pt;font-weight:bold;">FZ-15</b></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Combination Refrigerator/Freezer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">-20 deg C Setpoint +/-5 deg C</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PHCBI</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MPR-715F-PA</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">191090101</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">FZ-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Freezer (-20C)</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">-23 deg C Setpoint +/-5 deg C</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Sanyo</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MDF-U730M</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">10119429</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><b style="font-size:12pt;font-weight:bold;">REF-10</b></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Refrigerator</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">5 deg C Setpoint +/-3 deg C</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VECTOR LAB PRODUCTS</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VREF25-LB-RSD</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">21POP 028904</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><b style="font-size:12pt;font-weight:bold;">REF-11</b></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Refrigerator</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">5 deg C Setpoint +/-3 deg C</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VECTOR LAB PRODUCTS</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VREF25-LB-RSD</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">21POP 019802</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><b style="font-size:12pt;font-weight:bold;">RF-07</b></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Refrigerator</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">5 deg C Setpoint +/-3 deg C</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PANASONIC</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MPR-721-PA</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">16120850</font></p></td></tr><tr style="height:33pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">RF-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Sanyo Refrigerator</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">5 deg C Setpoint +/-3 deg C, double </font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SANYO</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MPR-1410</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">8120328</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:33pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">door refrigerator</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:33pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">RF-02</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Sanyo Refrigerator</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">5 deg C Setpoint +/-3 deg C, double door refrigerator</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SANYO</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MPR-1411</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">10110326</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><b style="font-size:12pt;font-weight:bold;">FRZ-22</b></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Freezer (-80C)</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">-80 deg C Setpoint +/-10 deg C</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">HAIER</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">DW-86L729BPT</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">BE0GY 6EBA0 0QGMA E0010</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><b style="font-size:12pt;font-weight:bold;">FRZ-23</b></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Freezer (GMP)</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">-80 deg C Setpoint +/-10 deg C</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">HAIER</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">DW-86L729BPT</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">BE0GY 6EBA0 0QGMA E0020</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">FZ-02</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Ultra-Low Temperature Freezer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">-80 to -60 deg C</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Sanyo</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MDF-U74VC</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">10090862</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">FZ-08</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Ultra-Low Temperature Freezer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">-80 to -60 deg C</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Sanyo</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MDF-U53VC</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">8110241</font></p></td></tr><tr style="height:33pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><b style="font-size:12pt;font-weight:bold;">FZ-09</b></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Ultra Low-Temp Upright Freezer Panasonic MDF-DU502VXC-PA</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">-80 to -60 deg C</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PHCBI</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MDF-DU502VXC-PA</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">18070036</font></p></td></tr><tr style="height:33pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><b style="font-size:12pt;font-weight:bold;">FZ-10</b></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Ultra Low-Temp Upright Freezer Panasonic MDF-DU502VXC-PA</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">-80 to -60 deg C</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PHCBI</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MDF-DU502VXC-PA</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">18100058</font></p></td></tr><tr style="height:33pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><b style="font-size:12pt;font-weight:bold;">FZ-11</b></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Ultra Low-Temp Upright Freezer Panasonic MDF-DU502VXC-PA</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">-80 to -60 deg C</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PHCBI</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MDF-DU702VXC-PA</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">19020098</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:33pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><b style="font-size:12pt;font-weight:bold;">FZ-13</b></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Ultra Low-Temp Upright Freezer Panasonic MDF-DU502VXC-PA</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">-80 to -60 deg C</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PHCBI</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MDF-DU702VXC-PA</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">18120545</font></p></td></tr><tr style="height:33pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><b style="font-size:12pt;font-weight:bold;">FZ-14</b></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Ultra Low-Temp Upright Freezer Panasonic MDF-DU502VXC-PA</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">-80 to -60 deg C</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PHCBI</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MDF-DU702VXC-PA</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">19010021</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">RF-01-TE-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">temperature probe</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:33pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><b style="font-size:12pt;font-weight:bold;">FZ-19</b></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Ultra Low-Temp Upright Freezer Panasonic MDF-DU502VXC-PA</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">-80 to -60 deg C</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PHCBI</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MDF-DU702VXC</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2180472</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">RF-02-TE-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Temperature probe</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:33pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><b style="font-size:12pt;font-weight:bold;">STAB-06</b></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Ultra Low-Temp Upright Freezer Panasonic MDF-DU502VXC-PA</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">-80 to -60 deg C</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PHCBI</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MDF-DU702VXC-PA</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">21050263</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">RF-03-TE-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Temperature probe</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">RF-03</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR Refrigerator</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Double Door Refrigerator</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">GDM-49-SCI-HC-LD</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">9049901</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><b style="font-size:12pt;font-weight:bold;">RF-06</b></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Refrigerator</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Double Door Refrigerator</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SCCP-49</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SYM-7468326-1207</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><b style="font-size:12pt;font-weight:bold;">RF-08</b></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Refrigerator</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Double Door Refrigerator</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">GDM-49-SCI-HS-TSL01</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">10005976</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><b style="font-size:12pt;font-weight:bold;">RF-09</b></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Refrigerator</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Double Door Refrigerator</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">VWR</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">GDM-49-SCI-HS-TSL01</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">10009572</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PGCH-01</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Plant Grow Chamber</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">gBrite LED PLANT GROWTH CHAMBER</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CARON</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">7312-50-2</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">7312-50-2-013</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PGCH-02</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Plant Grow Chamber</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">gBrite LED PLANT GROWTH CHAMBER</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CARON</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">7312-50-2</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">7312-50-2-014</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">RF-04</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Refrigerator</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Refrigerator</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SANYO</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MPR-311D(H)</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">10110824</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CR-114.1</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Walk-in cold room (Room 114)</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:33pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">FRZ-24</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Combination Refrigerator/Freezer</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PHCBI</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MPR-715F-PA</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">211290288</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Chart Liquid Nitrogen Tank</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Chart Inc</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">MVE512</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CAB2116450639</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">LA-10</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Labeler</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Newman Stainless steel labeler</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Newman Labelling</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">NV2</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">10450</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">FKL-01</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Forklift</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Raymond electric forklift</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Raymond</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">960-CSR30T</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">960-10-01406</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">FKL-02</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Forklift</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Raymond electric forklift</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Raymond</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">960-CSR30T</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">960-10-01407</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">FKL-03</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Forklift</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Raymond electric forklift</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Raymond</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">960-CSR30T</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">960-10-01408</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">BR-03</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Controller/chiller</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Bioreactor controller/Chiller</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Sartorius/Polyscience</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">8843415/DCA304D1VX-U01</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">07172/1A10B1373</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">BR-03_TCU-01</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Chiller</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">VWR Chilled Recirculator </i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">VWR</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">1177PD</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">3F1081196</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">BR-03_TCU-03</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Chiller</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">VWR Chilled Recirculator </i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">VWR</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">1177MD</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">108800807</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">BR-01_TCU-01</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Chiller</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Polyscience Chilled Recirculator </i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">VWR</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">5870T87XC751</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">1C10A1640</i></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">BR-03_TCU-02</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Chiller</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">VWR Chilled Recirculator </i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">VWR</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">1177PD</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">108C00855</i></p></td></tr><tr style="height:30pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Electric Forklift</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Raymond electric forklift walk behind, 2020</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Raymond</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">6210</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">###-##-####</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Crane</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Vestil aluminum rolling gantry crane</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Vestil</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Pump</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Busch rolling vacuum pump cart</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">RS-Ra-0100F</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Cabinet</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">All flammable cabinets</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Cabinet</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">All corrosive cabinets</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Bin</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">All PVC rolling trash bins</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Ladder</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">All rolling ladders</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Lockers</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Two cylinder lockers</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Racks</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">All Rolling multi tier metro racks</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:30pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Shelving</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">three stainless steel multi shelf wall units, bookshelves</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Tables</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">All stainless steel tables</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Ladders</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">All fiberglass/aluminum step ladders</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Carts</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">All stainless rolling carts</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Jacks</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">All hydraulic pallet jacks</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Lift</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">hydraulic die lifting cart</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Benches</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">All Rolling lab benches</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Lifts/Dollies</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">All Rolling barrel lifts/dollies</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:30pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Columns</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">All rolling stainless chromotography columns</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:30pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Scrubber</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Tennant ECH2 walk behind floor scrubber</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Tennant</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">ECH2</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Totes</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">All collapsible totes/bag holders</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:30pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Columns</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Pallet of glass Columns in the warehouse</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Pump</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Goulds pump</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Goulds</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">5SVFA30</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Racking</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">five stainless tray racks</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Racking</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">All wire racks</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:30pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Compressor</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Air compressor mounted on stainless table, warehouse</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Conveyors</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Two rolling conveyors</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Glassware</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Lab Glassware</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Vacuums</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Two shop vaccs in warehouse</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Fans</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Two Fans in warehouse</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Lights</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">All Grow lights in warehouse</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Tank</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Carbon steel mixing tank in warehouse</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Sealer</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Hot lips sealer</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Wave</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">28411704</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">1446852</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Pump</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Mini peristaltic pump</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Krosflo</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Minikro pilot</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">G10000004</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Transformers</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">All transformers in warehouse</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Switchboxes</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Pallet of Switch boxes</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Pumps</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Two Grundfos pumps in warehouse</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Lift</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">rolling boom lift</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Filter</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Donaldson Stainless filter</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Filter</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">New in crate Donaldson stainless filter</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Filter</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Stainless steel filter</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Pentair</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">ES22NA-15</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">HPLC-01</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">VWR Refrigerator</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Hewlett Packard HPLC</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Hewlett packard</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">1100</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">UV-Vis</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">UV Vision unit</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Cary</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">60 UV-Vis</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">G6860A</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Shaker</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Incubated shaker</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Jeio Tech</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">SI-600</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">M039118</i></p></td></tr><tr style="height:30pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Lift</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Autoquip 1,000 lb capacity lift in warehouse</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">TA System</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">New in box TA System</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Waters</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">P/N 533002.901</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">5332-3071</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Lift</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Autoquip 2,500 lb lift</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Autoquip</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">STE30-25-4</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">211108791</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Controller</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Axichrom Master controller</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Axichrom</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">300-1000</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">44</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Cabinet</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Stainless steel cabinet</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Collector</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Fraction collector</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">GE Healthcare</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">F9-R</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">1779850</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Cryo rack</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Cryo rack system</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">VWR</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">BR-3</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">NPB2012200846</i></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Tank</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Cryo tank</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">MVE</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">SC 4/2V</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">CV-100</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Table</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Accumulation table</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">M&amp;O perry</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">VA-1200</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">P-1053</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">FTP-01</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">FTP Unit</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Lab FTP unit</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Sinks</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">All stainless steel sinks</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">ICE-02</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Ice machine</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Ice machine</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">TK-3441-A</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Tank</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Plastic mixing tank</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">TK-3441-B</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Tank</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Plastic mixing tank</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">TK-3441-C</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Tank</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Plastic mixing tank</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Charger</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Forklift Battery Charger</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Enersys</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">EQ3-15-1</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">IJ70608</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Charger</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Forklift Battery Charger</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Enersys</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">EQ3-15-1</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">IJ70606</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Charger</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Forklift Battery Charger</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Enersys</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">EQ3-15-1</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">IJ70607</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Charger</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Forklift Battery Charger</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Enersys</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">EQ3-15-1</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">IJ70605</i></p></td></tr><tr style="height:30pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">TK-401</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">SS Tank</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">T&amp;C 200 gallon pressurized tank with pump</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">T&amp;C Stainless</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">TC7354</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TK-501</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Harvest T&amp;C Tank Vessel (TK-501)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">T&amp;C STAINLESS</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TC7355</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">TK-501_TT-501</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Tank 501 Sensor TT-501</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">ROSEMOUNT</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">644HANAJ6M5Q4F6</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">287705</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TK-503</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Harvest T&amp;C Tank Vessel (TK-503)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">T&amp;C STAINLESS</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SN: TC7363, NB: 1092</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TK-503</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">T&amp;C Tank (503)</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TC7354</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">TK-503_ TT-503</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Tank 503 Temperature Sensor</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">ROSEMOUNT</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">644HANAJ6M5Q4F6</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">285370</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CF-502</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Centrifuge</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">HARVEST CENTRIFUGE, CF-502</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">FLOTTWEG</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">AC1200-420 HYG Disc Stack </font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">200017880</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;font-style:italic;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Sep 2 Phase</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">CF-502_FI-01</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Centrifuge</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Endress-Hauser Sensor, Flow Indicator</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Endress+Hauser</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Promag 10 Transmitter Model No.: 10H40-UFOA1AA</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N3031119000</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">CF-502_PI-01</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Centrifuge</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Pressure Sensor </font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Endress+Hauser</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PTP33B-IEW0/0</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N303AA0116E</font></p></td></tr><tr style="height:30.6pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">CF-502_PI-02</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Centrifuge</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Endress-Hauser Sensor, Pressure Indicator</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Endress+Hauser</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">PTP33B-IEW0/0</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N303180116E</font></p></td></tr><tr style="height:30.6pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">CF-502_PI-03</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Centrifuge</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Filter Regulator </font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Festo</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">356 759 JN</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">CF-502_PI-04</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Centrifuge</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Murr Sensor, Pressure Indicator</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2.56953E+17</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">CF-502_TRB-02</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Centrifuge</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">SELI Sensor, Turbidity Meter</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2172756910</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">CF-502-TRB-01</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Centrifuge</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Turbidity Sensor </font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">2172465703</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">UV-302</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Water Purifier</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">UV Purification System</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Wyckomar Inc</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">UV-301</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Water Purifier</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">UV Purification System</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Wyckomar Inc</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">SK-3441, P 3441-F</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Pump skid</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Irrigation skid with pump</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">TK-310</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Tank</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Plastic tank</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">TK-311</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Tank</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Plastic tank</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">TK-321</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Tank</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Plastic tank</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">TK-320</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Tank</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Plastic tank</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">TK-312</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Tank</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Plastic tank</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">TK-309</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Tank</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Plastic tank</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">P-310</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Pump</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">1/2HP convertible well pump. </i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Wayne</i></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TK-304</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Germination Tank</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CHEMTAINER</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TC3581IC-BLA</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1.9002E+11</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TK-305</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Germination Tank</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CHEMTAINER</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TC3581IC-BLA</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1.9002E+11</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TK-306</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Germination Tank</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CHEMTAINER</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TC3581IC-BLA</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1.9002E+11</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TK-307</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Germination Tank</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CHEMTAINER</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TC3581IC-BLA</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1.9002E+11</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TK-308</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Germination Return Tank</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CHEMTAINER</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TC3581IC-BLA</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">1.9002E+11</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TK-313</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Post Infiltration Tank</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TK-314</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Post Infiltration Tank</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TK-318</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Seeder Tank</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">N/A</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TK-319</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Transplant Tank</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">CHEMTAINER</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">TC3581IC-BLA</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">NONE</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">Softwalls (2) one in germ, one in warehouse</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:16.5pt;"><td colspan="6" style="vertical-align:top;white-space:normal;width:100%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Equipment to be sold at seller&#39;s discretion</b></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">POD</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Growing pod, approximately 7&#39; x 12&#39;</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">POD</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Growing pod, approximately 7&#39; x 12&#39;</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">POD</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Growing pod, approximately 7&#39; x 12&#39;</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">POD</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Growing pod, approximately 7&#39; x 12&#39;</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">POD</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Growing pod, approximately 7&#39; x 12&#39;</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:3.6pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">POD</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Green house. 12&#39; x 42&#39; approximately</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"></td></tr><tr style="height:30pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Infiltrator</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Plant infiltrator system from Autoquip lift to autoquip lift</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Pallet elevator</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">pallet elevator</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:9.96%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">&#160;</i></p></td><td style="vertical-align:top;width:22.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">Pallet elevator</i></p></td><td style="vertical-align:top;width:25.44%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><i style="font-size:12pt;font-style:italic;">pallet elevator</i></p></td><td style="vertical-align:top;width:15.87%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"></td><td style="vertical-align:top;width:12.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"></td><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt -0.25pt 0pt 3.34pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><font style="font-size:12pt;">&#160;</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-size:12pt;font-weight:bold;">EXHIBIT B</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;">[Purchaser Terms of Sale]</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-size:12pt;font-weight:bold;">An 18% Buyer&#39;s Premium will apply.</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-size:12pt;font-weight:bold;">PAYMENT TIMES: WITHIN 48 HOURS OF COMPLETION OF THE SALE.</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;">ALL BIDS ARE MADE AND RECEIVED UNDER THE TERMS HEREINAFTER SET FORTH TO WHICH TERMS BIDDERS AGREE BY MAKING THEIR BID AT THE SALE. THESE TERMS CANNOT BE ALTERED EXCEPT BY THE AUCTIONEER. NO EMPLOYEE HAS AUTHORITY TO MODIFY SAME. THE OWNER AND/OR AUCTIONEER RESERVE THE RIGHT TO ADD TO OR MODIFY THE TERMS OF THE SALES.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">This auction may require a credit or debit card 100% refundable deposit. Your credit/debit card added through the Bidspotter.com fully secure and PCI compliant registration process will be assessed a 100% refundable $1,000.00 (US Bidder) or $2,500.00 (International Bidder) deposit in order to be approved to bid online within this auction. If you are unsuccessful in the auction, your card will be refunded of your deposit within 24 hours post auction.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;">Holland Industrial Group LLC.&#160;</font><b style="font-size:12pt;font-weight:bold;">DOES NOT&#160;TAKE DEBIT CARDS OR CREDIT CARDS FOR AUCTION INVOICE PAYMENTS.</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;">All payments must be made by Wire Transfer or Company Check with Bank Letter of Guarantee to Holland Industrial Group LLC. Here is an example of what your letter should be: [Mr. &#8220;Customer Name&#8221; is a customer of this bank. This bank will guarantee unqualified payment of Holland Industrial Group LLC. on the account listed herein up to the amount of $. This letter is good until (insert expiration date 30 days from sale date)]. By registering, the Bidder hereby expressly authorizes HIG to charge the Credit Card if the Bidder fails to pay any invoice within forty-eight (48) hours after each such invoice is issued to Bidder.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">All bidders are required to give full name, address, phone, fax, and bank information when registering. All bidders must register before bidding.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;">All bids must be paid in full within two business days after the bids have closed. The Auctioneer shall determine the bidding increments. Some items may be auctioned with reserve.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;">All purchases must be removed within two weeks after the bids have closed. No lot can, on any account, be removed prior to HIG having been paid in full. Purchases will be delivered only on presentation of paid bill. Auctioneer shall not be responsible for goods not removed within the aforesaid time.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Purchasers must remove equipment at their expense, risk, and liability. Purchasers must engage the riggers. Riggers, movers, electricians, or buyer performing work at the Auction Sites must provide Auctioneer with evidence of insurance. The insurance </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">coverage must be at a level acceptable to Auctioneer and to the Seller. The insurance must name both Holland Industrial Group LLC and IBIO INC as additional insured. Purchaser is required to remove all the equipment within a period not later than April 28. Purchaser is required to get their riggers, before starting removal, to furnish a certificate of insurance with both IBIO and Auctioneers listed as additional insureds. Purchasers are agreeing that they&#8217;ll lose their equipment if it&#8217;s not removed by April 28.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Purchasers are solely responsible for disconnecting any utilities and for rigging and shipping the equipment. All the equipment has to be removed by the Purchasers from facility by April 28. Purchasers must get the equipment removed in a workmanlike manner. Purchasers must remove oils or other fluids in the equipment before removal.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;">All checks for deposits and balances due shall be payable to the order of Holland Industrial Group LLC. unless instructed otherwise. All bills must be paid to the Opa-locka headquarters offices of the Auctioneer at 13105 NW 42nd&#160;Ave Opa-locka FL 33054, or by wire transfer directly to the bank specified in the wire transfer instructions provided for this on-line auction. The full purchase price on all lots sold to the same buyer must be paid within the time fixed and before removal of any of the goods.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;">THE AUCTIONEER SHALL NOT BE RESPONSIBLE FOR THE CORRECT DESCRIPTION, GENUINENESS, AUTHENTICITY OF, OR DEFECT IN ANY LOT, AND MAKES NO WARRANTY IN CONNECTION THEREWITH. NO SALE SHALL BE SET ASIDE NOR ALLOWANCE MADE ON ACCOUNT OF ANY INCORRECTNESS, ERROR IN CATALOGING, OR ANY IMPERFECTION NOT NOTED. NO DEDUCTION ALLOWED ON DAMAGED ARTICLES, ALL ARTICLES BEING EXPOSED FOR PUBLIC EXHIBITION, AND SOLD &#8220;AS IS&#8221; AND WITHOUT RECOURSE. ARTICLES ARE NOT WARRANTED AS MERCHANTABLE OR FIT FOR ANY PARTICULAR PURPOSE, AND NO CLAIM MAY BE MADE BY PURCHASER RELATING TO THE CONDITION OR USE OF ARTICLES PURCHASED, OR FOR PROXIMATE OR CONSEQUENTIAL DAMAGES ARISING THEREFROM.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Articles purchased may not incorporate approved activating mechanisms, operating safety devices or safety guards, as required by OSHA or otherwise. It is Purchaser&#8217;s responsibility that articles purchased be so equipped and safeguarded to meet OSHA and any other requirements before placing such articles into operation.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;">Purchaser agrees to indemnify and hold Auctioneer harmless from and against all claims and liabilities relating to the condition or use of the articles purchased or failure of user to follow instructions, warnings or recommendations of the manufacturer, or to comply with federal, state and local laws applicable to such articles, including OSHA requirements, or for proximate or consequential damages, costs or legal expenses arising therefrom.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;">No claims will be allowed after removal of goods from premises.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Auctioneer shall not, in any event, be liable for non-delivery or any other matter or thing, to any Purchaser of any lot, other than for the return to the Purchaser of the deposit or sum paid on said lot, should the Purchaser be entitled thereto.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;">In default of payment of bills in full within the time therein specified, the Auctioneer in addition to all other remedies allowed by law, may retain all monies received as deposit or otherwise, as liquidated damages. Lots not paid for and removed within the time allowed herein may be resold at public or private sale without further notice, and any deficiency, together with all expenses and charges of re-sale, will be charged to the defaulting Purchaser.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;">Persons attending during exhibition, sale or removal of goods assume all risks of damage of or loss to person and property and specifically release the Auctioneer from liability therefor. Neither the Auctioneer nor his principal shall be liable by reason of defect in or condition of the premises on which the sale is held.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;">The Auctioneer reserves the right to withdraw from sale any of the property listed or to sell at this sale property not listed, and also reserves the right to group one or more lots into one or more selling lots or to subdivide into two or more selling lots. Whenever the best interest of a Seller will be served, the Auctioneer reserves the right to sell all the property listed, in bulk.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;">Where items are sold by estimated weight, count or measure, the Purchaser will be billed for and required to pay for the estimated weight, count or measure. If, upon delivery, any shortage exists, the Purchaser will receive a refund at the rate of purchase. If there be an excess, the Purchaser will be required to pay for such excess, at the rate of purchase.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;">The Auctioneer reserves the right to reject any and all bids, alter the order of sale, and accept bids made on behalf of the Seller. Auctioneer is not responsible for internet lags, delays, blackouts, or disconnects.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;">The record of sale kept by the Auctioneer and bookkeeper will be taken as final in the event of any dispute.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;">The Auctioneer is acting as agent only and is not responsible for the acts of its principals. Purchaser acknowledges, as an inducement to Seller to commit Purchaser to bid, that Purchaser has independently inspected the goods bid upon by the Purchaser, and acknowledges to the Seller that Purchaser is acquiring all goods &#8220;AS IS, WITH ALL </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20230331xex10d7001.jpg" alt="Graphic" style="display:inline-block;height:63.74pt;width:107.23pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;">FAULTS&#8221; and &#8220;WITH REMOVAL AT PURCHASERS&#8217; RISK AND EXPENSE&#8221; and agrees to protect, indemnify and hold harmless the Seller from any and all claims, demands, causes of actions, liabilities and judgments relating to the conditions or use of the goods.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Seller, if not the same as the Auctioneer, shall have the rights, protections and benefits afforded to the Auctioneer as set forth herein.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;">Although all information has been obtained from sources deemed reliable, the auctioneer and seller make no warranty or guarantee, expressed or implied, as to the accuracy of the information herein contained, or contained in our catalog. It is for this reason that buyers should avail themselves of the opportunity to make inspection prior to the auction. Although it is not likely, auction sales are subject to cancellation or postponement. Kindly contact auctioneer prior to attendance.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">ANY ADDITIONAL PROVISIONS OR AMENDMENTS TO THE ABOVE LISTED TERMS WILL BE POSTED BY THE AUCTIONEER PRIOR TO THE START OF BIDDING.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>3
<FILENAME>ibio-20230331xex10d8.htm
<DESCRIPTION>EX-10.8
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 5/15/2023 01:23:21 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Exhibit 10.8</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">FIFTH AMENDMENT TO CREDIT AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">THIS FIFTH AMENDMENT TO CREDIT AGREEMENT (this &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Fifth Amendment</font><font style="font-size:12pt;">&#8221;) is entered into as of the Fifth Amendment Closing Date (as defined below) by and between </font><b style="font-size:12pt;font-weight:bold;">IBIO CDMO LLC,</b><font style="font-size:12pt;"> a Delaware limited liability company (&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Borrower</font><font style="font-size:12pt;">&#8221;), and </font><b style="font-size:12pt;font-weight:bold;">WOODFOREST NATIONAL BANK</b><font style="font-size:12pt;">, a national banking association, as lender (in such capacity, &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Lender</font><font style="font-size:12pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">RECITALS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">A.</font></font><font style="font-size:12pt;">Borrower and Lender entered into that certain Credit Agreement dated November 1, 2021 (as amended by the First Amendment thereto dated as of October 11, 2022, the Second Amendment thereto dated as of February 9, 2023, the Third Amendment thereto dated as of February 20, 2023, the Fourth Amendment thereto dated as of March 24, 2023 and as otherwise amended, restated, supplemented or modified from time to time, the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Credit Agreement</font><font style="font-size:12pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">B.</font></font><font style="font-size:12pt;">On April 14, 2023, Borrower did not provide Lender with an executed Purchase Agreement with respect to the sale of the iBio Property, which resulted in a Default as of such date under and in accordance with the terms of Section 1(d) of the Fourth Amendment, without the benefit of any grace period otherwise provided under Section 11.2(b) of the Credit Agreement (herein, the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">PSA Default</font><font style="font-size:12pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">C.</font></font><font style="font-size:12pt;">Borrower has requested Lender to waive the PSA Default and Lender is willing to waive the PSA Default.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">D.</font></font><font style="font-size:12pt;">Borrower and Lender are willing to enter into the requested waiver and certain agreements and amendments set forth herein, subject to and conditioned upon the terms and conditions set forth in this Fifth Amendment.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">NOW, THEREFORE, in consideration of the promises herein contained, the mutual benefits to be derived herefrom and other good and valuable consideration received by each party, and each intending to be legally bound hereby, the parties agree as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">I.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreements and Amendments to Credit Agreement</u><font style="font-size:12pt;">. Borrower and Lender agree as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="font-size:12pt;">Section 1.1, </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definitions</u><font style="font-size:12pt;">, of the Credit Agreement is hereby amended by adding the following definitions in their proper alphabetical order:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Fifth Amendment</font><font style="font-size:12pt;">&#8221; means the Fifth Amendment to Credit Agreement dated as of the Fifth Amendment Closing Date by and between Borrower and Lender.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Fifth Amendment Closing Date</font><font style="font-size:12pt;">&#8221; means May 10, 2023.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Payment in Full</font><font style="font-size:12pt;">&#8221; means all Obligations (other than contingent Obligations with respect to indemnity and reimbursement of expenses as to which no claim has been made as of the time of determination) have been paid in full in cash.</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><font style="font-size:12pt;">Section 3.3, </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Interest</u><font style="font-size:12pt;">, of the Credit Agreement is hereby amended and restated by replacing such section in its entirety with the following language:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Interest</u><font style="font-size:12pt;">. &#160;From and after the Fifth Amendment Closing Date, the Term Loan shall accrue interest at a fixed rate per annum equal to 5.25%. &#160;In addition to the foregoing, from and after the Fifth Amendment Closing Date, the Term Loan shall further accrue additional interest, payable in kind and added to the balance of the Term Principal Amount, at a fixed rate per annum equal to (a) 1.00%, if Payment in Full occurs on or before June 30, 2023, (b) 2.00%, if Payment in Full occurs after June 30, 2023, but on or before September 30, 2023, or (c) 3.00%, if Payment in Full occurs after September 30, 2023, such interest accruing (at either 1.00%, 2.00% or 3.00%, as applicable, for the entirety of the accrual period), in each case, commencing on the Fifth Amendment Closing Date and continuing through and including the date that Payment in Full occurs.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(c)</font></font><font style="font-size:12pt;">Section I(d) of the Fourth Amendment of the Credit Agreement is hereby amended and restated in its entirety by replacing such section with the following language:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sale of iBio Property</u><font style="font-size:12pt;">. &#160;On or before the Maturity Date, if Borrower enters into a purchase and sale agreement between Borrower, as seller, and a third party, as buyer, regarding the purchase and sale of the iBio Property (a &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Purchase Agreement</font><font style="font-size:12pt;">&#8221;), Borrower shall deliver to Lender an executed copy of such Purchase Agreement and undertake all reasonable efforts to consummate the sale of the iBio Property. &#160;Upon the reasonable written request of Lender, Borrower shall provide Lender with copies of any other documents directly related to the sale of the iBio Property.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(e)</font></font><font style="font-size:12pt;">Section I(e) of the Fourth Amendment of the Credit Agreement is hereby amended and restated in its entirety by replacing such section with the following language:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 72pt;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fee</u><font style="font-size:12pt;">. &#160;On the earlier of (i) the date that Payment in Full occurs or (ii) the Maturity Date, Borrower shall pay to Lender, in immediately available funds, a fee, which fee, in any case, is fully earned as of the Fifth Amendment Closing Date, in the amount of (x) $75,000, if Payment in Full occurs on or before June 30, 2023, (y) $100,000, if Payment in Full occurs after June 30, 2023, but on or before September 30, 2023, or (z) $125,000, if Payment in Full does not occur in accordance with sub clauses (x) or (y) above.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(f)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Release of Reserved Funds</u><font style="font-size:12pt;">. &#160;Notwithstanding anything to the contrary in Section I(f) of the Fourth Amendment, so long as no Potential Default or Default exists or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">2</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">would be caused thereby and Borrower and Parent Guarantor are otherwise in compliance with the Loan Documents, (i) when the outstanding Term Principal Amount is reduced to $10,000,000, Lender shall release $500,000 of the Reserved Funds from the Reserved Funds Deposit Account to Borrower, and (ii) for each additional $2,500,000 reduction of the outstanding Term Principal Amount (i.e. the first reduction from $10,000,000 to $7,500,000), Lender shall release an additional $750,000 of the Reserved Funds from the Reserved Funds Deposit Account to Borrower, in each case, in immediately available funds.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(g)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payment in Full</u><font style="font-size:12pt;">. &#160;So long as Borrower provides reasonable notice to Lender of a payoff, Lender shall, at least one Business Day prior to the date Payment in Full occurs, provide Borrower with a written payoff letter, which shall, among other things, contain an itemized break down of all outstanding Obligations to be paid on the date that Payment in Full occurs.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">II.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waiver</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="font-size:12pt;">Lender hereby waives the PSA Default, including any failure to give notice thereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><font style="font-size:12pt;">The waiver granted by Lender hereunder does not indicate an intent to establish any course of dealing between Lender and Borrower with regard to future waivers, consents, agreements to forbear or any other modifications that may be requested. &#160;Lender&#8217;s agreement to the waiver set forth herein should not be construed as an indication that Lender would be willing to agree to any further or future consents, waivers, agreements to forbear or any modifications to any of the terms of the Credit Agreement, as amended hereby, or other Loan Documents, or in respect of any Potential Default or Default that may exist or that may occur.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">III.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Conditions Precedent to the Effectiveness of Fifth Amendment</u><font style="font-size:12pt;">. &#160;This Fifth Amendment shall be effective upon the satisfaction of the following conditions precedent:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="font-size:12pt;">Lender shall have received this Fifth Amendment duly executed by Borrower and Parent Guarantor;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><font style="font-size:12pt;">Lender shall have received an Officer&#8217;s Certificate and authorizing consent for each of Borrower and Parent Guarantor, in Proper Form;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(c)</font></font><font style="font-size:12pt;">To the extent outstanding and unpaid, the Borrower shall have paid to Lender (i) any fees and expenses due and owing under the Credit Agreement and (ii) all costs and expenses, including reasonable legal fees, payable in connection with this Fifth Amendment to the extent invoiced on or prior to the Fifth Amendment Closing Date; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(d)</font></font><font style="font-size:12pt;">After giving effect to this Fifth Amendment, no Potential Default or Default shall have occurred and be continuing.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">IV.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reaffirmation of Representations and Warranties</u><font style="font-size:12pt;">. &#160;To induce Lender to enter into this Fifth Amendment, Borrower hereby reaffirms, as of the Fifth Amendment Closing Date</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">3</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">(except as otherwise provided herein or to the extent such representations and warranties speak as to an earlier date or a date certain), its representations and warranties contained in </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7</u><font style="font-size:12pt;"> of the Credit Agreement (other than the representation set forth in the last sentence of </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.10</u><font style="font-size:12pt;"> of the Credit Agreement), and in all other documents executed pursuant thereto, and additionally represents and warrants as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="font-size:12pt;">The execution and delivery of this Fifth Amendment and the performance by Borrower of its obligations under this Fifth Amendment are within Borrower&#8217;s power, have been duly authorized by all necessary company action, have received all necessary governmental approval (if any shall be required), and do not and will not contravene or conflict with any provision of law or of the Organizational Documents of Borrower or of any agreement binding upon Borrower.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><font style="font-size:12pt;">This Fifth Amendment represents the legal, valid and binding obligations of Borrower enforceable against Borrower in accordance with its terms subject as to enforcement only to bankruptcy, insolvency, reorganization, moratorium or other similar laws affecting the enforcement of creditors&#8217; rights generally.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(c)</font></font><font style="font-size:12pt;">After giving effect to this Fifth Amendment, no change, event or state of affairs has occurred and is continuing which would constitute a Potential Default or a Default.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(d) </font></font><font style="font-size:12pt;">No exhibit or schedule to the Credit Agreement is required to be supplemented, amended or modified in connection with the transactions contemplated by this Fifth Amendment.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">V.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Defined Terms</u><font style="font-size:12pt;">. Terms used herein that are defined in the Credit Agreement, as amended hereby, shall have the same meanings herein, unless the context otherwise requires.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">VI.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reaffirmation of Credit Agreement</u><font style="font-size:12pt;">. This Fifth Amendment shall be deemed to be an amendment to the Credit Agreement, and the Credit Agreement, as amended hereby, is hereby ratified, adopted and confirmed in each and every respect.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">VII.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Ratification of Liens; Release</u><font style="font-size:12pt;">. The Borrower acknowledges and ratifies, as of the Fifth Amendment Closing Date, the existence and priority of the Liens granted by the Borrower in favor of Lender pursuant to the Security Documents in and to the Collateral and represents, warrants and covenants that such Liens are valid, existing and in full force and effect. &#160;THE BORROWER HEREBY RELEASES, DISCHARGES AND ACQUITS LENDER AND EACH AFFILIATE THEREOF AND THEIR RESPECTIVE DIRECTORS, OFFICERS, OWNERS, EMPLOYEES, AGENTS, REPRESENTATIVES AND ADVISORS AND THEIR RESPECTIVE SUCCESSORS AND ASSIGNS, FROM ANY AND ALL CLAIMS, DEMANDS, ACTIONS, CAUSES OF ACTION, REMEDIES, AND LIABILITIES OF EVERY KIND OR NATURE (INCLUDING WITHOUT LIMITATION, LENDER LIABILITY) ARISING OUT OF ANY ACT, OCCURRENCE, TRANSACTION OR OMISSION OCCURRING IN CONNECTION WITH THE CREDIT AGREEMENT AND THE OTHER LOAN DOCUMENTS PRIOR TO THE FIFTH AMENDMENT CLOSING DATE.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">VIII.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</u><font style="font-size:12pt;">. &#160;THIS FIFTH AMENDMENT SHALL BE GOVERNED BY</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">4</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF TEXAS.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">IX.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Invalid Provisions</u><font style="font-size:12pt;">. &#160;If any provision of this Fifth Amendment is held to be illegal, invalid or unenforceable, (a) the legality, validity and enforceability of the remaining provisions of this Fifth Amendment shall not be affected or impaired thereby and (b) the parties shall engage in good faith negotiations to replace the illegal, invalid or unenforceable provisions, with valid provisions the economic effect of which comes as close as possible to that of the illegal, invalid or unenforceable provisions. &#160;The invalidity of a provision in a particular jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">X.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Multiple Counterparts and Electronic Signatures</u><font style="font-size:12pt;">. &#160;This Fifth Amendment may be executed in any number of counterparts with the same effect as if all signatories had signed the same document. &#160;All counterparts must be construed together to constitute one and the same instrument. &#160;This Fifth Amendment may be transmitted and signed by facsimile, portable document format (PDF), or other electronic means, and shall have the same effect as manually-signed originals and shall be binding on the Loan Parties and Lender, with originals signatures to be delivered to Lender at Lender&#8217;s request.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">XI.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section Headings</u><font style="font-size:12pt;">. &#160;Section headings in this Fifth Amendment are included for convenience of reference only and shall not affect the interpretation of this Fifth Amendment.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">XII.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Successors and Assigns</u><font style="font-size:12pt;">. &#160;This Fifth Amendment is binding upon, and inures to the benefit of, the parties hereto and their respective successors and permitted assigns.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">XIII.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reservation of Rights; No Waiver of Defaults</u><font style="font-size:12pt;">. &#160;Lender hereby reserves all of its rights and remedies under the Credit Agreement and the other Loan Documents in all respects and for all purposes in addition to all other rights and remedies available to it under applicable Law or in equity. &#160;Other than as set forth herein, this Fifth Amendment is not intended to operate as a waiver of Lender&#8217;s rights and remedies, and, other than as set forth herein, does not constitute or operate as (a) a waiver of (or a consent to) any existing Potential Default or Default or any other violation of or noncompliance with any provision of the Credit Agreement, as amended hereby, or any other Loan Document, (b) an agreement to waive any existing or future Potential Default or Default, or (c) a waiver of Lender&#8217;s right to insist upon strict compliance with each term, covenant, condition and provision of the Credit Agreement, as amended hereby, and the other Loan Documents.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">XIV.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ENTIRETY</u><font style="font-size:12pt;">. &#160;THIS FIFTH AMENDMENT REPRESENTS THE FINAL AGREEMENT AMONG BORROWER, GUARANTORS AND LENDER AND MAY NOT BE CONTRADICTED BY EVIDENCE OF PRIOR, CONTEMPORANEOUS, OR SUBSEQUENT ORAL AGREEMENTS BY BORROWER, GUARANTORS AND LENDER. &#160;THERE ARE NO UNWRITTEN ORAL AGREEMENTS AMONG BORROWER, GUARANTORS AND LENDER.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">[Signature pages follow.]</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">5</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">IN WITNESS WHEREOF, the parties hereto have caused this Fifth Amendment to be duly executed on the Fifth Amendment Closing Date.</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.00925827%;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">BORROWER</b><font style="font-size:12pt;">:</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-size:12pt;">IBIO CDMO LLC,</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-size:12pt;">a Delaware limited liability company</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-size:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:bottom;width:46.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-size:12pt;">/s/ Felipe Duran</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:46.67%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-size:12pt;">Felipe Duran</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:46.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-size:12pt;">Authorized Person</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">Signature Page to Fifth Amendment to Credit Agreement</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">LENDER</b><font style="font-size:12pt;">:</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">WOODFOREST NATIONAL BANK</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:bottom;width:46.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">/s/ Cameron D. Jones</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:46.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-size:12pt;">Cameron D. Jones</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-size:12pt;">Senior Vice President</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">Signature Page to Fifth Amendment to Credit Agreement</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">GUARANTOR&#8217;S CONSENT AND AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">As an inducement to Lender to execute, and in consideration of Lender&#8217;s execution of, this Fifth Amendment, IBIO, INC., a Delaware corporation (&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Guarantor</font><font style="font-size:12pt;">&#8221;), hereby consents to this Fifth Amendment, and agrees that this Fifth Amendment shall in no way release, diminish, impair, reduce or otherwise adversely affect the obligations and liabilities of the undersigned under the Guaranty executed November 1, 2021 (as amended by the Guaranty First Amendment, the Guaranty Second Amendment, the Guaranty Third Amendment, the Guaranty Fourth Amendment and as otherwise amended, restated, supplemented or modified from time to time, the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Guaranty</font><font style="font-size:12pt;">&#8221;) executed by Guarantor in connection with the Credit Agreement. &#160;Guarantor further represents and warrants to Lender that (a) the representations and warranties in the Guaranty are true and correct in all material respects on and as of the Fifth Amendment Closing Date as though made on such date (except to the extent that such representations and warranties specifically relate to an earlier date), (b) it is in full compliance with all covenants and agreements contained in the Guaranty, (c)&#160;after giving effect to the Fifth Amendment, no Potential Default or Default has occurred and is continuing under the Guaranty and (d) the execution and delivery of this Guarantor&#8217;s Consent and Agreement are within Guarantor&#8217;s power and have been duly authorized by all necessary company action. &#160;This Guarantor&#8217;s Consent and Agreement shall be binding upon Guarantor, and its successors and permitted assigns, and shall inure to the benefit of Lender, and its successors and permitted assigns.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">[Signature page follows.]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">GUARANTOR</b><font style="font-size:12pt;">:</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">IBIO, INC.,</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">a Delaware corporation</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-size:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:bottom;width:46.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">/s/ Felipe Duran</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:46.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Felipe Duran</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:46.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Interim Chief Financial Officer</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">Signature Page to Guarantor&#8217;s Consent and Agreement to</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">Fifth Amendment to Credit Agreement</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>ibio-20230331xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 5/15/2023 01:23:21 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:9.56%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 7.2pt 0pt 7.2pt;"><b style="font-weight:bold;">Exhibit</b>&#160;<b style="font-weight:bold;">31.1 </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">Certification PURSUANT </b><b style="font-weight:bold;">TO RULE 13a-14(a)&#160;OR RULE 15d-14(a) </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OF THE SECURITIES EXCHANGE ACT OF 1934,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 7.2pt 0pt 7.2pt;"><b style="font-weight:bold;">AS ADOPTED </b><b style="font-weight:bold;text-transform:uppercase;">Pursuant to Section</b><font style="text-transform:uppercase;">&#160;</font><b style="font-weight:bold;text-transform:uppercase;">302 of </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 7.2pt 0pt 7.2pt;"><b style="font-weight:bold;text-transform:uppercase;">the Sarbanes-Oxley Act of 2002 </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 7.2pt;">I, Martin Brenner, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:89.98%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">1.</p></td><td style="vertical-align:top;width:89.98%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">I have reviewed this Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 (the &#8220;report&#8221;) of iBio, Inc. (the &#8220;registrant&#8221;);</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10.43%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">2.</p></td><td style="vertical-align:top;width:89.56%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10.43%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">3.</p></td><td style="vertical-align:top;width:89.56%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10.43%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">4.</p></td><td style="vertical-align:top;width:89.56%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:9.97%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.15%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">a.</p></td><td style="vertical-align:top;width:83.87%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:9.97%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.16%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">b.</p></td><td style="vertical-align:top;width:83.86%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:9.97%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.15%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">c.</p></td><td style="vertical-align:top;width:83.87%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:9.97%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.16%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">d.</p></td><td style="vertical-align:top;width:83.86%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10.43%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">5.</p></td><td style="vertical-align:top;width:89.56%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:9.97%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.15%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">a.</p></td><td style="vertical-align:top;width:83.87%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:9.97%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.15%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">b.</p></td><td style="vertical-align:top;width:83.87%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.4299507%;padding-left:0pt;padding-right:0pt;width:100.85%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:40.17%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3.1%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:56.71%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:11.3pt;"><td style="vertical-align:top;width:40.17%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: <a name="led148333F20215171623961419318"></a>May 15, 2023</p></td><td style="vertical-align:top;width:3.1%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:56.71%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr style="height:11.3pt;"><td style="vertical-align:top;width:40.17%;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.1%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:56.71%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Martin Brenner</p></td></tr><tr style="height:11.3pt;"><td style="vertical-align:top;width:40.17%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.1%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:56.71%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:&#160;Martin Brenner</p></td></tr><tr style="height:34.35pt;"><td style="vertical-align:top;width:40.17%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.1%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:56.71%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:&#160;  Interim Chief Executive Officer and Chief Scientific Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:9.56%;margin-top:30pt;page-break-after:avoid;width:84.56%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>ibio-20230331xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 5/15/2023 01:23:21 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 7.2pt 0pt 7.2pt;"><b style="font-weight:bold;">Exhibit</b>&#160;<b style="font-weight:bold;">31.2 </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">Certification PURSUANT </b><b style="font-weight:bold;">TO RULE 13a-14(a)&#160;OR RULE 15d-14(a) </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OF THE SECURITIES EXCHANGE ACT OF 1934,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 7.2pt 0pt 7.2pt;"><b style="font-weight:bold;">AS ADOPTED </b><b style="font-weight:bold;text-transform:uppercase;">Pursuant to Section</b><font style="text-transform:uppercase;">&#160;</font><b style="font-weight:bold;text-transform:uppercase;">302 of </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 7.2pt 0pt 7.2pt;"><b style="font-weight:bold;text-transform:uppercase;">the Sarbanes-Oxley Act of 2002 </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 7.2pt;">I, Felipe Duran, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 7.2pt;"><font style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:10%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:90%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">1.</p></td><td style="vertical-align:top;width:90%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">I have reviewed this Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 (the &#8220;report&#8221;) of iBio, Inc. (the &#8220;registrant&#8221;);</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">2.</p></td><td style="vertical-align:top;width:90%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">3.</p></td><td style="vertical-align:top;width:90%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:10%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:90%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">4.</p></td><td style="vertical-align:top;width:90%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.12%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">a.</p></td><td style="vertical-align:top;width:83.87%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.12%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">b.</p></td><td style="vertical-align:top;width:83.87%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.12%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">c.</p></td><td style="vertical-align:top;width:83.87%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.12%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">d.</p></td><td style="vertical-align:top;width:83.87%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">5.</p></td><td style="vertical-align:top;width:90%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.12%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">a.</p></td><td style="vertical-align:top;width:83.87%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.12%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">b.</p></td><td style="vertical-align:top;width:83.87%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: <a name="led148333F20215171623961419318"></a>May 15, 2023</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Felipe Duran</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:&#160;Felipe Duran</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:&#160;&#160;Interim Chief Financial Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Interim Principal Financial Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>ibio-20230331xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 5/15/2023 01:23:43 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">18 U.S.C. SECTION 1350</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the Quarterly Report on Form 10-Q of iBio, Inc. (the &#8220;Company&#8221;) for the quarterly period ended March 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Martin Brenner, Interim Chief Executive Officer and Chief Scientific Officer (Principal Executive Officer) of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:98.2%;"><tr><td style="vertical-align:middle;width:6.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">1.</p></td><td style="vertical-align:middle;width:89.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:6.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2.</p></td><td style="vertical-align:middle;width:90%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:6.66%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:top;width:44.16%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:1.25pt;"><td style="vertical-align:top;width:6.66%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"></td><td style="vertical-align:top;width:44.16%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"></td><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"></td></tr><tr style="height:15.7pt;"><td style="vertical-align:top;width:6.66%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:44.16%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">May 15, 2023</p></td><td style="vertical-align:top;width:49.16%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Martin Brenner</p></td></tr><tr style="height:14.1pt;"><td style="vertical-align:top;width:6.66%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"></td><td style="vertical-align:top;width:44.16%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"></td><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Martin Brenner</p></td></tr><tr style="height:14.1pt;"><td style="vertical-align:top;width:6.66%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"></td><td style="vertical-align:top;width:44.16%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"></td><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt 1.5pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interim Chief Executive Officer and Chief Scientific Officer</p></td></tr><tr style="height:14.1pt;"><td style="vertical-align:top;width:6.66%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"></td><td style="vertical-align:top;width:44.16%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"></td><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>ibio-20230331xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 5/15/2023 01:23:43 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">18 U.S.C. &#167;1350,</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the Quarterly Report on Form 10-Q of iBio, Inc. (the &#8220;Company&#8221;) for the quarterly period ended March 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Felipe Duran, Interim Chief Financial Officer (Principal Financial Officer) of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:98.2%;"><tr><td style="vertical-align:middle;width:6.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">1.</p></td><td style="vertical-align:middle;width:89.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:6.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2.</p></td><td style="vertical-align:middle;width:90%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:92.97%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:5.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:44.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:1.25pt;"><td style="vertical-align:top;width:5.23%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:44.71%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:50.04%;margin:0pt;padding:0pt;"></td></tr><tr style="height:15.7pt;"><td style="vertical-align:top;width:5.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:44.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">May 15, 2023</p></td><td style="vertical-align:top;width:50.04%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Felipe Duran </p></td></tr><tr style="height:14.1pt;"><td style="vertical-align:top;width:5.23%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:44.71%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:50.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Felipe Duran</p></td></tr><tr style="height:14.1pt;"><td style="vertical-align:top;width:5.23%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:44.71%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:50.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interim Chief Financial Officer</p></td></tr><tr style="height:14.1pt;"><td style="vertical-align:top;width:5.23%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:44.71%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:50.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Interim Principal Financial Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ibio-20230331x10q001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ibio-20230331x10q001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (>!"P# 2(  A$! Q$!_\0
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M4 +2444 +1244 &:6DHH 6BDHH 6C-)10 M%)10 M&:0T4 +1244 &:6DHH
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ML+S/V]_X2#XB_P#0C:1_X4I_^1*/^$@^(O\ T(VD?^%*?_D2OQ"_X:J^,_\
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M_P#16/&?_@[N/_BJ/J4O+\0^L+S/V]_X2'XB_P#0C:1_X4I_^1*/^$@^(O\
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ML+S/V]_X2#XB_P#0C:1_X4I_^1*/^$@^(O\ T(VD?^%*?_D2OQ"_X:J^,_\
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M_P#16/&?_@[N/_BJ/J4O+\0^L+S/V]_X2'XB_P#0C:1_X4I_^1*/^$@^(O\
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ML+S/V]_X2#XB_P#0C:1_X4I_^1*/^$@^(O\ T(VD?^%*?_D2OQ"_X:J^,_\
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M_P#16/&?_@[N/_BJ/J4O+\0^L+S/V]_X2#XB_P#0C:1_X4I_^1*/^$@^(O\
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ML+S/V]_X2#XB_P#0C:1_X4I_^1*/^$@^(O\ T(VD?^%*?_D2OQ"_X:J^,_\
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M_P#16/&?_@[N/_BJ/J4O+\0^L+S/V]_X2#XB_P#0C:1_X4I_^1*/^$@^(O\
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MD.X\ *<=ZXGQ%^T/X@UCQ?X@UNUT[1+*/5T2 V=SI5O?BWA1-D:1O<1NRD*
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MN%8\'::ZCXA_&+PG\3M)FU'6O MP?B#-9P6DFNVVM-'9LT2+&+C[)Y9_>E$
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M?<_%+!]#1@^AK]K?^%4_"'_HUJ?_ ,)K3?\ X_1_PJGX0_\ 1K4__A-:;_\
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M:TW_ ./T?6U_+^0>P?<_%+!]#1@^AK]K?^%4_"'_ *-:G_\ ":TW_P"/T?\
M"J?A#_T:U/\ ^$UIO_Q^CZVOY?R#V#[GXI8/H:,'T-?M;_PJGX0_]&M3_P#A
M-:;_ /'ZI6_@'X*W>IW>GQ?LPS/>6@1IXAX9T[*!AE>?.QR*?UM?R_D'L'W/
MQ?P?0T8/H:_:W_A5/PA_Z-:G_P#":TW_ ./T?\*I^$/_ $:U/_X36F__ !^E
M];7\OY![!]S\4L'T-&#Z&OVM_P"%4_"'_HUJ?_PFM-_^/T?\*I^$/_1K4_\
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M-:;_ /'Z/^%4_"'_ *-:G_\ ":TW_P"/T?6U_+^0>P?<_%+!]#1@^AK]K?\
MA5/PA_Z-:G_\)K3?_C]'_"J?A#_T:U/_ .$UIO\ \?H^MK^7\@]@^Y^*6#Z&
MC!]#7[6_\*I^$/\ T:U/_P"$UIO_ ,?H_P"%4_"'_HUJ?_PFM-_^/T?6U_+^
M0>P?<_%+!]#1@^AK]K?^%4_"'_HUJ?\ \)K3?_C]'_"J?A#_ -&M3_\ A-:;
M_P#'Z/K:_E_(/8/N?BE@^AHP?0U^UO\ PJGX0_\ 1K4__A-:;_\ 'Z/^%4_"
M'_HUJ?\ \)K3?_C]'UM?R_D'L'W/Q2P?0T8/H:_:W_A5/PA_Z-:G_P#":TW_
M ./T?\*I^$/_ $:U/_X36F__ !^CZVOY?R#V#[GXI8/H:,'T-?M;_P *I^$/
M_1K4_P#X36F__'Z/^%4_"'_HUJ?_ ,)K3?\ X_1];7\OY![!]S\4L'T-&#Z&
MOVM_X53\(?\ HUJ?_P )K3?_ (_1_P *I^$/_1K4_P#X36F__'Z/K:_E_(/8
M/N?BF <C@U^]G[(/_)KOPK_[%RR_]%+7G_\ PJGX0_\ 1K4__A-:;_\ 'Z^A
M?!EC8:;X3TBUTO1#X;TZ&UC2WTAH4A-F@7Y8MB$JNT<84D"N3$UU5BDD;4J?
M(V[FUC_.*3'^<4N*/\]:\\Z1<>U%.HQ0!XE^U_\ $_Q!\(/@M>^(_#-Q!:ZK
M%>VT*R7%NLRA7?#?*W'2O$_V(_VH/B#\;/BGJNB>+-1LKS3K?1Y+R-+>P2!A
M()H5!W+R1AVXKT+_ (*'?\FUZE_V$K+_ -&U\S?\$RO^2ZZ]_P!B[-_Z46]?
M9X/#49Y-6K2@G)-V=M>G4]NA3@\%.;6O?[C]-=H]!1M'H*6BOC#QA-H]!1M'
MH*6B@!-H]!1M'H*6B@!-H]!1M'H*6B@!-H]!1M'H*6B@!-H]!1M'H*6B@!-H
M]!1M'H*6B@!-H]!1M'H*6B@#S3XA*/\ A:OPOX'_ !_7O;_IQFKT+8/[H_*O
M/OB#_P E7^%__7]>_P#I#-7HE7+9$+J,V#^Z/RHV#^Z/RI]%0,9L']T?E1L'
M]T?E3Z* &;!_='Y4;!_='Y4^B@!FP?W1^5&P?W1^5/HH 9L']T?E1M'H/RI]
M% #-@_NC\J-@_NC\J?10!Y]\<E ^&^I?*!\\/_HU:[[8,GY1U/:N$^.7_).-
M2_WX?_1BUWWK]35/X4+J,V#^Z/RHV#^Z/RKG?&7Q+\)_#R!)?$WB/2]!23[G
MV^Z2(O\ 0$Y/X"N/A_:I^$%Q($C^(WAUW/0"^6M84*U17A!M>29JJ<Y*ZBSU
M+8/0?E1L']T?E7F#?M1_"193$?B)X>$@XV_;5S3&_:J^$"$AOB-X=!'4?;5J
M_JF(_P"?<ON97LJG\K^X]2V#^Z/RHV#^Z/RKRT_M5?" +N_X6-X=V^OVU::W
M[5_P=7K\2/#@^M\M'U3$?\^Y?<P]E4_E?W'JFP?W1^5&P>@_*O*O^&L/@YC/
M_"R?#F/7[<M,'[6WP9)Q_P ++\-Y_P"OY:7U6O\ \^W]S%[*I_*_N/6-@_NC
M\J-@_NC\J\J/[6/P< Y^)/AS_P #EJ:#]J3X1W.?*^(GAZ3')VWJ\4_JN(_Y
M]O[F'LJG\K^X]/V#^Z/RHV#^Z/RKRT?M5?" MM'Q&\.Y]/MRU/#^TY\*+@_N
M_B#H#_[MXIH^J8C_ )]R^YC]C4_E?W'I>P?W1^5&P?W1^5>5R?M7?!V)BK_$
MCPXK#@@WR\4W_AK/X-_]%*\.?^!RTOJM?_GV_N8O95/Y7]QZL$']T?E1L']T
M?E7E/_#6?P;_ .BE>'/_  .6D_X:S^#?_12O#G_@<M'U:O\ \^W]S#V53^5G
MJ^P?W1^5&P?W1^5>4?\ #6GP:_Z*5X;_ / Y:/\ AK3X-?\ 12_#?_@<M'U6
MO_S[?W,/95/Y6;7P24'P%'\H_P"/^][?]/,E=[L']T?E7SK\)/VG_A-HO@R.
MVOOB'X?M;@7EV_ERWJAMK3NRG'N"#^-=E_PUK\&O^BE^&_\ P.6JEAJ_,_<?
MW,2I5+?"SUC8/[H_*C8/[H_*O)_^&M?@U_T4OPW_ .!RT?\ #6OP:_Z*7X;_
M / Y:GZM7_D?W,?LY_RL]8V#^Z/RHV#^Z/RKR?\ X:U^#7_12_#?_@<M+_PU
MK\&O^BE^&_\ P.6CZM7_ )']S#V=3^5_<>K[!_='Y4;!_='Y5Y1_PUI\&O\
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M&[;[;LU]>U^1XZC'#XFI2ALGH?(5X*G5E&.R"BBBN$YPHHHH **** "BBB@
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MA6K<DOP_S-?[3I/H_P"OF?D1\0&MH+T6<"_-&Y<X_A!["N2Y]#7[*O\ L0?
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MK.US>>')UMHYI&RS0,,H#_NX(^F*^4S?*:>&A[>AHNJ/(Q>$C3C[2GL>Z_!
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M(U*LJ@;!Y8"D)]T'N%!/)KMJ*B51R7*QJ*3N<!\=/^2;ZC_OP_\ HQ:^+O\
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M;L**,48J!A103B@'- @HHQ1B@8448HH **,T4 %%&**!' ?'3_DF^H_[\/\
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M5Z8.E7+9$K=A11BC%04%%&*,4 %%&*,4 %%&*,4 %%&*,4 %%&** "BC%&*
M"BC%&* "N ^/O_)&?&'_ &#I?Z5W^*X#X^C_ (LSXP_[!TO]*J/Q(E['9Z/_
M ,@BR_ZX)_Z"*N54T<?\2BR_ZX)_Z"*MXJ2@HHHQ0 4444 %%&*,4 %%%&*
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M (__ /)&/&'_ &#I?Z54?B0GL=EHP_XE%C_UP3_T$5=Q5/1?^018_P#7!/\
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M (Y0?^"46F?]%)U#_P %,7_QRO79/^"B'P>C3>U]K6S^]_8L^/Y4R'_@HO\
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MW0C^R8L,/0CS.:].7_@H[\&'8*-2UG)_Z@L_^%3V_P#P42^#5S)Y8U35D?.
MKZ1.I/Z4_;YWVE_X"O\ (?/CNS^[_@'G#?\ !+_2F0H?'U[M/./[+CX/M^\J
MOJ'_  2VTV^6-1\1;^/8,9_LN,G'_?S KTZ7_@HG\'8) DE]K:%EWC.BS@%?
M4<<BDC_X*+?!F4C;JFK-G/31Y^,>O'%7]9SQ])?^ K_(KVN/??[O^ >3Q_\
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M&'_]$-7IHZ5YE\5O^1W^&O\ V&'_ /1#5Z:.E6]D2MV+1114%!1110 4444
M%%%% !1110 4444 %%%% !1110 5Y_\ '_\ Y(QXP_[!TO\ 2O0*\_\ C_\
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M&/\ Z_KW_P!*9*[^N ^!_P#R(4?_ %_7O_I3)7?UXTOB9P+9!1114E!1110
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MS?\ I1;U].?\%$?^3:M2_P"PC9?^C17S'_P3*_Y+KKW_ &+LW_I1;U]W@?\
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M8\8?]@Z7^E5'XD3+9G9Z+_R"+'_K@G_H(J[5+1?^018_]<$_]!%7:DH****
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M**DH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S'XK?\CO\-?\
ML,/_ .B&KTT=*\R^*W_([_#7_L,/_P"B&KTT=*M[(E;L6BBBH*"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ KS_X_P#_ "1CQA_V#I?Z5Z!7G_Q__P"2
M,>,/^P=+_2JC\2)ELSL]%_Y!%C_UP3_T$5=JEHO_ ""+'_K@G_H(J[4E!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?,O\
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M+_XJOQ(2X1;TEMH!<Y; '?UK5TM8;K4_LWF1H'!'FKAA@CWJ7PQ!:^U?W?\
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M_P#0UZ)_X,8?_BJ_"<HIZ_8S_P  '^%-$:9^Y9G_ ( /\*7^K%/_ )^O[O\
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M[C_@G5\(+F82/;Z[N' VZQ*,?3BIH_\ @GG\)(T"BWUOCO\ VM)G\\5Y7/\
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M_&?_ %PLO_19KRULSB>Z.^HHHJ2@HHHH **** "BBB@ HHHH **** "BBB@
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M)SSG(QE*_;;'U_.C'U_.KCQ+4C_RZ7W_ / &LRDOL_B?@O/\*_&JNX'@WQ$
M&X']D7'_ ,13#\+?&V6_XH[Q#S_U![GG_P <K]Z\?7\Z,?7\ZC_6*=_X:^__
M (!/]HR_E/P>T_X7>-!=*6\&Z^?E/WM'N, X]XZ<OP\\>#'_ !1NNC_N!S__
M !NOW?Q]?SHQ]?SJEQ)42_AK[_\ @#6927V?Q/PO_P"$.\=G2WLF\%:X49MV
M\:+<!OTCIC?#?QQNS%X9U^-3@[3I-R.<?]<Z_=/'U_.C'U_.K7$U3_GTOO\
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M_H(J[5+1?^018_\ 7!/_ $$5=J2@HHHH **** "BBB@ HHHH **** "BBB@
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MY0Q7S%(7L&P:]2HJ'.3W92BD?.GB?]C33_$6KZ]#'XW\0Z?X+\0ZB-5U?PI
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M#.#6HI =2M7^R7\>W;B4#[V.P8<_G7SV:91+ )5(2YH_BCS\5A'0]Z+NC?\
M@?\ \B%'_P!?U[_Z4R5W]<!\#_\ D0H_^OZ]_P#2F2N_KY^7Q,\U;(****D8
M4444 %%%% !1110 4444 %%%% !1110 4444 %<#X8_Y*WXS_P"N%E_Z+-=]
M7 ^&/^2M^,_^N%E_Z+-4MF2]T=]1114E!1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 >8_%;_D=_AK_V&'_]$-7IHZ5YE\5O^1W^&O\ V&'_ /1#
M5Z:.E6]D2MV+1114%!1110 4444 %%%% !1110 4444 %%%% !1110 5Y_\
M'_\ Y(QXP_[!TO\ 2O0*\_\ C_\ \D8\8?\ 8.E_I51^)$RV9V>B_P#((L?^
MN"?^@BKM4M%_Y!%C_P!<$_\ 015VI*"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH ^9?^"B/_)M6I?\ 81LO_1HKYC_X)E?\
MEUU[_L79O_2BWKZ<_P""B/\ R;5J7_81LO\ T:*^8_\ @F5_R777O^Q=F_\
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M]8?A)9WWA)HG\'GPBK(EU</<3G6S= N&\]0>+8G9E@,;2<'-?,UDK7A$;SK
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M0?\ UZ^6S[$4Z>&]C?WI6T\NYYF/J1C3Y.K-KX'_ /(A1_\ 7]>_^E,E=_7
M? __ )$*/_K^O?\ TIDKOZ_/)?$SYQ;(****D84444 %%%% !1110 4444 %
M%%% !1110 4444 %<#X8_P"2M^,_^N%E_P"BS7?5P/AC_DK?C/\ ZX67_HLU
M2V9+W1WU%%%24%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!YC\5
MO^1W^&O_ &&'_P#1#5Z:.E>9?%;_ )'?X:_]AA__ $0U>FCI5O9$K=BT445!
M04444 %%%% !1110 4444 %%%% !1110 4444 %>?_'_ /Y(QXP_[!TO]*]
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M'44W>O\ >'YT;U_O#\Z '44W>O\ >'YT;U_O#\Z '44W>O\ >'YT;U_O#\Z
M'44W>O\ >'YT;U_O#\Z '44W>O\ >'YT;U_O#\Z '44W>O\ >'YT;U_O#\Z
M'44W>O\ >'YT;U_O#\Z '44W>O\ >'YT;U_O#\Z /,_BM_R._P -?^PP_P#Z
M(:O31TKS'XK,/^$W^&O(_P"0P_?_ *8-7IH=<?>'YU;V1*W8ZBF[U_O#\Z-Z
M_P!X?G4%#J*;O7^\/SHWK_>'YT .HIN]?[P_.C>O]X?G0 ZBF[U_O#\Z-Z_W
MA^= #J*;O7^\/SHWK_>'YT .HIN]?[P_.C>O]X?G0 ZBF[U_O#\Z-Z_WA^=
M#J*;O7^\/SHWK_>'YT .KS_X_P#_ "1CQA_V#I?Z5WV]?[P_.O/_ (_.O_"F
M?&'(_P"0=+W^E5'XD3+9G:Z+_P @BQ_ZX)_Z"*NU1T9U_LBR^8?ZA._^R*N;
MU_O#\ZDH=13=Z_WA^=&]?[P_.@!U%-WK_>'YT;U_O#\Z '44W>O]X?G1O7^\
M/SH =13=Z_WA^=&]?[P_.@!U%-WK_>'YT;U_O#\Z '44W>O]X?G1O7^\/SH
M=13=Z_WA^=&]?[P_.@!U%-WK_>'YT;U_O#\Z '44W>O]X?G2]: %HHHH ***
M* .0^*E]I&G^$99M<\5S^#+ 2QAM5M[I+9U;=PN]U8?,>,8YKS+PA9^%/'^I
M2Z?X;^./B/6[Z*(SO;V.MVTKK&" 6($/3+*,^XK)_P""@?\ R;EJ'_81L_\
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M4(M[Y0_>_<]NU?0%<#X8_P"2M^,_^N%E_P"BS5*;LQ-+0H?\*5NO^BD>./\
MP8P__&*/^%*W7_12/''_ (,8?_C%>FT5/.Q\J/,O^%*W7_12/''_ (,8?_C%
M'_"E;K_HI'CC_P &,/\ \8KTVBCG8<J/,O\ A2MU_P!%(\<?^#&'_P",4?\
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M&'_XQ7IM%'.PY4>9?\*5NO\ HI'CC_P8P_\ QBC_ (4K=?\ 12/''_@QA_\
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MD_X*8?$^)BCZ'X;1QU#6\X/_ *,KPZU^!_Q TV[OY(M#EM7L55I));B%8V#
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M8M?'G_!4;P->NOA'Q="K26,'F6,Y"Y$;L0R$GL#@CZXK[#^.G_)-]1_WX?\
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M</\ #Z\0=<BZM,_3_75G];PK>E6/WHOV%>WP/[F>77/B6.2>%X;!(@J&-UW
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M^@G-_P""^Z_^-4?\+Q\&_P#03F_\%]U_\:HY9=@NNYWM%<%_PO'P;_T$YO\
MP7W7_P :H_X7CX-_Z"<W_@ONO_C5'++L%UW*?Q _Y*O\+_\ K^O?_2&:O2:\
M(\9_%3PYJ'Q%^']_;W5U-:6%W=O<RKIMT5B5K.5%+'RN,LP'U(KNO^%X^#?^
M@G-_X+[K_P"-5<HNRT)36IWM%<%_PO'P;_T$YO\ P7W7_P :H_X7CX-_Z"<W
M_@ONO_C51RR[%77<[VBN"_X7CX-_Z"<W_@ONO_C5'_"\?!O_ $$YO_!?=?\
MQJCEEV"Z[G>T5P7_  O'P;_T$YO_  7W7_QJC_A>/@W_ *"<W_@ONO\ XU1R
MR[!==SO:*X+_ (7CX-_Z"<W_ (+[K_XU1_PO'P;_ -!.;_P7W7_QJCEEV"Z[
MG>T5P7_"\?!O_03F_P#!?=?_ !JC_A>/@W_H)S?^"^Z_^-4<LNP77<[VBN"_
MX7CX-_Z"<W_@ONO_ (U1_P +Q\&_]!.;_P %]U_\:HY9=@NNXSXZ?\DWU'_?
MA_\ 1BUWZ]*\1^+OQ8\-:]X%OK.PN[FYN7:,K%'IMT6.'4G@1>@KL1\<?!P'
M_(3F_P#!?=?_ !JJY966A-U<[ZDP/05P?_"\?!O_ $$YO_!?=?\ QJC_ (7C
MX-_Z"<W_ (+[K_XU4\LNQ5UW.\P/048'H*X/_A>/@W_H)S?^"^Z_^-4?\+Q\
M&_\ 03F_\%]U_P#&J.678+KN=Y@>@HP/05P?_"\?!O\ T$YO_!?=?_&J/^%X
M^#?^@G-_X+[K_P"-4<LNP77<[S ]!1@>@K@_^%X^#?\ H)S?^"^Z_P#C5'_"
M\?!O_03F_P#!?=?_ !JCEEV"Z[G>8'H*,#T%<'_PO'P;_P!!.;_P7W7_ ,:H
M_P"%X^#?^@G-_P""^Z_^-4<LNP77<[S ]!1@>@K@_P#A>/@W_H)S?^"^Z_\
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MF_\ !?=?_&J.678+KN=[17!?\+Q\&_\ 03F_\%]U_P#&J/\ A>/@W_H)S?\
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M )M'O^=&T>_YTM% ";1[_G1M'O\ G2T4 )M'O^=&T>_YTM% ";1[_G1M'O\
MG2T4 )M'O^=&T>_YTM% ";1[_G1M'O\ G2T4 )M'O^=&T>_YTM% ";1[_G1M
M'O\ G2T4 )M'O^=&T>_YTM% ";1[_G1M'O\ G2T4 )M'O^=&T>_YTM% ";1[
M_G1M'O\ G2T4 )M'O^=&T>_YTM% ";1[_G1M'O\ G2T4 )M'O^=&T>_YTM%
M";1[_G1M'O\ G2T4 )M'O^=&T>_YTM% ";1[_G1M'O\ G2T4 )M'O^=&T>_Y
MTM% ";1[_G1M'O\ G2T4 )M'O^=&T>_YTM% ";1[_G1M'O\ G2T4 )M'O^=&
MT>_YTM% ";1[_G1M'O\ G2T4 )M'O^=&T>_YTM% ";1[_G1M'O\ G2T4 )M'
MO^=&T>_YTM% ";1[_G1M'O\ G2T4 )M'O^=&T>_YTM% ";1[_G1M'O\ G2T4
M )M'O^=&T>_YTM% ";1[_G1M'O\ G2T4 )M'O^=&T>_YTM% ";1[_G1M'O\
MG2T4 )M'O^=&T>_YTM% ";1[_G1M'O\ G2T4 )M'O^=&T>_YTM% ";1[_G1M
M'O\ G2T4 )M'O^=&T>_YTM% ";1[_G1M'O\ G2T4 )M'O^=&T>_YTM% ";1[
M_G1M'O\ G2T4 )M'O^=&T>_YTM% ";1[_G1M'O\ G2T4 )M'O^=&T>_YTM%
M";1[_G1M'O\ G2T4 )M'O^=&T>_YTM% ";1[_G1M'O\ G2T4 )M'O^=&T>_Y
MTM% ";1[_G1M'O\ G2T4 )M'O^=&T>_YTM% ";1[_G2T44 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44"N%<QX]\&'Q?X0N]&L[F/2Y)98IXY_(\Q%=)UFR4!7(++SR.IYKIZ*:=M0
MT9Y-K_P3O_%<TFJZMXE,WB%+FVFM9;6V>VM($A,A6/RTE\P[C+(6;S0V=A&
MN#);_ :SCU+P_<F_$-O8HQO["WA;R=0E$CRP2,9'=U,4LDCC+-DMST%>JT57
M/(FR/$+']F6UCTFSTZ[U@S162P6T%S''-]H-K&' B9I)G4$[P<HJ %2=OS8$
M6M_!GQ2NL>%]5MM7T^]U33[NSM_.33!#;P6<$<_S-$)<NY:4#Y6 7/RJ!G/N
ME%/GD'+$\73]G55U%;V76$NY+R/R]5@FAF2WN/\ 2))\Q1Q3H(_FE<8;>/ND
MY();8\.?!Z]T'Q+H5TVNQ7&D:(]\]G:?8=L[?:22?-F\P[MI9N0H+9!/(R?4
M**7/)A9'D\WP4OKL6^FW>O6UWX:LKR>_L]/ET[,OF2>852:3S,21HTK':%4L
M-H+<$F&P^ TZZGIUY?\ B%[H6,B-!:>5))%"BRV\@1#-+(X!-OG!8X+\8QSZ
M]11SR"R/GWXD?"3Q#IMIXA3PJ)=2NO$MO?6MP9+2%X85F<NJ[GG1H\%WRP#@
MCDKD+GTG4? FKPZQ;:QH&MPZ7J'V!-/NHKNS-U;SHA)1MH=&5U+/@YP0Q!'0
MCN:*'-L$DCQ34OV=)YK:[AL_$QB;5+=8M6FNK 2O<.+E[AI(\.HC):1UVX8!
M=N/N\]:WPGAE^&I\&/J4JV4TKFYFA3RWEADN&EEB&#\NX,R%@<\D]:[ZBASD
MPLCS:P^"MIH_C*VUFPU2[CLXKU=0:PN9)+G=.+:6W9A)(Y8;DD3(Y_U0]355
M/@YJ4LE]87/B*%_#5YJSZM+8Q:?MGD+.)!$TQD(V;E&<("1QD5ZG11S,+(\5
ME_9R:;3Y=-7Q ;.QG@$=Q]BMWC:[<1A%:9#*8GP0ISL#$*%+8Z[6J_"WQ#J]
MV=1E\1::NK3V<VFW,@T;= UO)L/R1M*2'!3.2Q4@X*G ->H44<\@LCQR\_9N
MT^XDU:--;O$L+K3EM+:T,:D6L^Q(WN0PP69TBB4CCHW/S&M'2/@W!HM\^LWI
MBU.^,%TMU#;Q2G[89$C3EIYI&W!8@OWL$$#C'/J5%'/+N%D>/^"/@]=Q?"#6
M-!U6;[-JVN0R12O,JSFVAV^7;PL </Y<013@X+;R#SFMW3?AC=1WVD3W=WI4
M,.ERS2P6VD:6;6,F6%XFR#*_/SYR,=,=Z]#HH<FPLCYSU/X,^(]%_LWPMHOF
M7FBS76G7-]?W%I %'V=UW%9/.#K\D:X0QMS]TC+8ZNU_9UM(?"=MH4FLS-%%
M=1W+SQP"-V"VBVQ4$'C(7.>V<5[#13]I(7*CAOAG\-O^$"BN7GN(+Z^FBAMF
MNXTG5WBB!"!O,FDZ;F.%V@9.!7<T45#;>K*5D%%%%(=PHHHH"X4444!<****
M N%%%% 7"BBB@+A1110%PHHHH"X4444!<**** N%%%% 7"BBB@+A1110%PHH
MHH"X4444!<**** N%%%% 7"BBB@+A1110%PHHHH"X4444!<**** N%%%% 7"
MBBB@+A1110%PHHHH"X4444!<**** N%%%% 7"BBB@+A1110%PHHHH"X4444!
M<**** N%%%% 7"BBB@+A1110%PHHHH"X4444!<**** N%%%% 7"BBB@+A111
M0%PHHHH"X4444!<**** N%%%% 7"BBB@+A1110%PHHHH"X4444!<**** N%%
&%% 7/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ibio-20230331x10q002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ibio-20230331x10q002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (F!#P# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]2*2BCZT
M+1244 +FBDHH 6BDHH 6C-)10 M%)Q10 M&:2B@!<T4E'% "T4E% "YHI*/I
M0 M)1Q10 M)110 M%)]*.* %S1244 %+24?2@!:,TE% "T4G%!]Z %S1244
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M_ >T_P#C-'_#>7Q__P"BH:K_ . ]I_\ &:W^IS\OQ,O;Q\_P/V&_X3;XC_\
M1,4_\*2V_P#C='_";?$?_HF*?^%);?\ QNOQY_X;R^/_ /T5#5?_  'M/_C-
M'_#>7Q__ .BH:K_X#VG_ ,9H^IS\OQ#V\?/\#]AO^$W^(_\ T3%/_"DMO_C=
M'_";_$;_ *)BG_A26_\ \;K\>?\ AO+X_P#_ $5#5?\ P'M/_C-'_#>7Q_\
M^BH:K_X#VG_QFCZG/R_$/;Q\_P #]AO^$W^(_P#T3%/_  I+;_XW1_PF_P 1
M_P#HF*?^%);?_&Z_'G_AO+X__P#14-5_\![3_P",T?\ #>7Q_P#^BH:K_P"
M]I_\9H^IS\OQ#V\?/\#]AO\ A-_B/_T3%/\ PI+?_P"-T?\ ";_$?_HF*?\
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M?\-Y?'__ **AJO\ X#VG_P 9H^IS\OQ#V\?/\#]AO^$W^(__ $3%/_"DM_\
MXW1_PF_Q'_Z)BG_A26W_ ,;K\>?^&\OC_P#]%0U7_P ![3_XS1_PWE\?_P#H
MJ&J_^ ]I_P#&:/J<_+\1_6(^?X'[#?\ ";_$?_HF*?\ A26__P ;H_X3?XC_
M /1,4_\ "DM__C=?CS_PWE\?_P#HJ&J_^ ]I_P#&:/\ AO+X_P#_ $5#5?\
MP'M/_C-'U.?E^(O;Q\_P/V&_X3;XC_\ 1,4_\*2V_P#C='_";_$;_HF*?^%)
M;_\ QNOQY_X;R^/_ /T5#5?_  'M/_C-'_#>7Q__ .BH:K_X#VG_ ,9H^IS\
MOQ#V\?/\#]AO^$W^(_\ T3%/_"DMO_C='_";_$?_ *)BG_A26_\ \;K\>?\
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M  WE\?\ _HJ&J_\ @/:?_&:/J<_+\0]O'S_ _8;_ (3?XC_]$Q3_ ,*2W_\
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MAO\ A-_B/_T3%/\ PI+?_P"-T?\ ";_$;_HF*?\ A26__P ;K\>?^&\OC_\
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MS_ _8;_A-OB/_P!$Q3_PI+;_ .-T?\)O\1_^B8I_X4EO_P#&Z_'G_AO+X_\
M_14-5_\  >T_^,T?\-Y?'_\ Z*AJO_@/:?\ QFCZG/R_$/;Q\_P/V&_X3?XC
M?]$Q3_PI+?\ ^-T?\)O\1_\ HF*?^%);_P#QNOQY_P"&\OC_ /\ 14-5_P#
M>T_^,T?\-Y?'_P#Z*AJO_@/:?_&:/J<_+\0]O'S_  /V&_X3?XC_ /1,4_\
M"DM__C='_";?$?\ Z)BG_A26W_QNOQY_X;R^/_\ T5#5?_ >T_\ C-'_  WE
M\?\ _HJ&J_\ @/:?_&:/J<_+\1_6(^?X'[#?\)O\1_\ HF*?^%);_P#QNC_A
M-_B/_P!$Q3_PI+?_ .-U^//_  WE\?\ _HJ&J_\ @/:?_&:/^&\OC_\ ]%0U
M7_P'M/\ XS1]3GY?B+V\?/\  _8;_A-_B/\ ]$Q3_P *2W_^-T?\)O\ $?\
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MV&_X3?XC_P#1,4_\*2W_ /C='_";?$?_ *)BG_A26W_QNOQY_P"&\OC_ /\
M14-5_P# >T_^,T?\-Y?'_P#Z*AJO_@/:?_&:/J<_+\1_6(^?X'[#?\)O\1_^
MB8I_X4EO_P#&Z/\ A-_B-_T3%/\ PI+?_P"-U^//_#>7Q_\ ^BH:K_X#VG_Q
MFC_AO+X__P#14-5_\![3_P",T?4Y^7XB]O'S_ _8;_A-_B/_ -$Q3_PI+?\
M^-T?\)M\1_\ HF*?^%);?_&Z_'G_ (;R^/\ _P!%0U7_ ,![3_XS1_PWE\?_
M /HJ&J_^ ]I_\9H^IS\OQ#V\?/\  _8;_A-OB/\ ]$Q3_P *2V_^-T?\)O\
M$?\ Z)BG_A26_P#\;K\>?^&\OC__ -%0U7_P'M/_ (S1_P -Y?'_ /Z*AJO_
M (#VG_QFCZG/R_$/;Q\_P/V&_P"$W^(W_1,4_P#"DM__ (W1_P )O\1_^B8I
M_P"%);__ !NOQY_X;R^/_P#T5#5?_ >T_P#C-'_#>7Q__P"BH:K_ . ]I_\
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M1_PF_P 1_P#HF*?^%);_ /QNOQY_X;R^/_\ T5#5?_ >T_\ C-'_  WE\?\
M_HJ&J_\ @/:?_&:/J<_+\0]O'S_ _8;_ (3;XC_]$Q3_ ,*2V_\ C='_  F_
MQ'_Z)BG_ (4EO_\ &Z_'G_AO+X__ /14-5_\![3_ .,T?\-Y?'__ **AJO\
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M3%/_  I+;_XW1_PF_P 1_P#HF*?^%);_ /QNOQY_X;R^/_\ T5#5?_ >T_\
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M !FCZG/R_$/;Q\_P/V&_X3?XC?\ 1,4_\*2W_P#C='_";_$?_HF*?^%);_\
MQNOQY_X;R^/_ /T5#5?_  'M/_C-'_#>7Q__ .BH:K_X#VG_ ,9H^IS\OQ#V
M\?/\#]AO^$V^(_\ T3%/_"DMO_C='_";_$?_ *)BG_A26_\ \;K\>?\ AO+X
M_P#_ $5#5?\ P'M/_C-'_#>7Q_\ ^BH:K_X#VG_QFCZG/R_$?UB/G^!^PW_"
M;_$;_HF*?^%);_\ QNC_ (3?XC?]$Q3_ ,*2W_\ C=?CS_PWE\?_ /HJ&J_^
M ]I_\9H_X;R^/_\ T5#5?_ >T_\ C-'U.?E^(O;Q\_P/V&_X3;XC_P#1,4_\
M*2V_^-T?\)M\1_\ HF*?^%);?_&Z_'G_ (;R^/\ _P!%0U7_ ,![3_XS1_PW
ME\?_ /HJ&J_^ ]I_\9H^IS\OQ#V\?/\  _8;_A-_B/\ ]$Q3_P *2W_^-T?\
M)O\ $;_HF*?^%);_ /QNOQY_X;R^/_\ T5#5?_ >T_\ C-'_  WE\?\ _HJ&
MJ_\ @/:?_&:/J<_+\0]O'S_ _8;_ (3?XC?]$Q3_ ,*2W_\ C=>A:?-<7%A;
MRW5M]CN7C5I;?S!)Y;$<KN'#8/&17X;_ /#>7Q__ .BGZK_X#VG_ ,9K]G?@
MQK5]XD^$7@O5=3N6O-1O='M;BYN' #22-$I9C@ 9)/85S5J#I)-V_$VIU%-N
MQV=%%)7(;BT444 ?+G_!2_\ Y,]\6_\ 7YIO_I;%7XKU^U'_  4O_P"3/O%O
M_7YIO_I;%7XKU[F"_A?,\[$?&%!(4$GH!DT4CKN1U'4J1^E=YRG87/PE\6V>
MIW^G3:.Z7MAHB^([F'SHR8]/:-)!.?FY&R1#@?-STIY^#WC :M'IAT607TFA
M?\),D/G1Y.F^29_M&=V,>6I;;][C&,\5[7KO[8BZS9Z]H_\ 917P_?> X_"\
M$?\ 9UFMXEXMM#$9GN0/,,.Z-SMWDX*_+Q@4H_VC_!W_  C<&LOH>NGXCP^"
M#X%4+-!_9#0>0UN+L_\ +;S!"Q'E@;=W.<<5AS5.QK:/<\RLOV??B'J.H>"[
M&V\+7<]SXSMS=:"J/&5OH@,LRMNPN!R=Y4@$$]:H>&O@WXT\8ZEXGT_1?#]S
MJ-YX:@FN=6BA9,VJ1,5D)RV&(*M\JY)VG .#7N'A_P#;7N/"VB^%M#T_2IFT
MW3--T>QEN9MGVJV-N_\ IWV0Y^5;F()&<D<)S5/P/^UKI/PRN=6U#1/!\>J:
MIK7C&;Q%?S:PS!4M@[?9H(O*D&6"S7&_>"A+C@XI<U370+0[GAEA\-_$NJ>
M[WQI::1-<^%[*]CTZYU*,J4AG=0R*PSN (9?FQMR0,Y-2/\ ##Q/'\23X ;2
MG'B\:@-*_LSS8]WVHD*(]^[9G)'.['O7LOA']I[0_AEH>JZ!X8T&]NO#5_XO
MN-4N=&U8Q^1>:++;>2;&;:Q_>*=K*PR%**P.>*YFY^..E7'[7+?%K^SKX:*W
MBE=>^P?N_M/DB16V?>V;\#^]CWJE*=WH*T=-3@]/^%?BG5;*.[M-)>>WDUQ?
M#:NLL?.HMTM_O=3Z_=]ZL_$3X-^*_A28!XFLK2S>::2W6.VU.UNW61/OJZP2
MN4(_V@.>.M>O7_[7(\2:/HMMKFF>9<:7X_A\51MINGVEDALD_P"6+"()OF_V
MF!_WJK_$#XS_  Q\7_&[P]X[?3O$VIVEMJ;WNH:5=Z7I=@LD0=IHHE-J1YA\
MT@.\GS%,\DTN:=]4.T;:,\PUOX%>//#?CO0?!FJ>&[FQ\3:ZMN^G:?,\8:X$
MQ*Q8;=M&2",,1@@@XK$\.> M;\6>+?\ A&=-MH6UG?+$8+F[AMD#1YW@R2NJ
M#&T]6Y[9KWV]_:[T?Q=XI^&OBKQ#X2^P>(O"'BI]7=M#8M%=V,LOVB:(F>4L
M)?/W,O.S#D?+P*\@^*U_\/-5UE=1\%-XJE>[NYKJ^B\306:*FY]ZB+R&;/);
M.[';'>G&4WHT)J/1E[Q-^S;\1?!_B/\ L'5= C@U@6=U?O9QZC:S/'#;1^9.
MSB.5MFU.<-@GL#7%:GX1U?1O#F@Z]>69ATC74G?3;K>K"X6%Q'*0 21M8@<@
M>V:]N7]IC2K/]J/QM\5K+2;M+36K;4H[.TGA@DECDN+0PQF5&)C95<@L/FR,
MC!Z5R/QD^.4GQ@\$_#O3[ZT2'6O#MO?0WL]M9V]I:S>=.LD9BBA"JN%7#949
M/KUH3G=70-1UL>3T445L9A1110 5Z5J_[./Q%T/P?_PE%WX=VZ,-/BU9Y(K^
MVEFCLY &2=H%E,JQD,IW%,#/.*\U/(->X?%#]I_5O%>AV&A>'H+?1=)_X173
M_#NH2OIEH+^Z$$*I*INE4RF%V0$(7' P0.E9RYKKE*5NIS&N_LY_$3PWX3?Q
M+?\ AX)I$5G#J,TD-_:S2P6TH4QS20I*941@Z_,R@#<,XI)OV=/B-!X)/BR3
MPO<+HHLQJ);SX3<+:'I<&VW^<(N^\IC'.<<UZ3XT_:LL/%O@?Q1X931I--CU
M#PUI&CVFIV=C:17WF6D<23Q7,X'F2VLI0G:6++MCP ,BGR?M(>"AK%Q\0(M
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MJ)O=C([B/:$^;.[&*-6^!?CG1-8?2[O076[73)-8!BN8)8I+.,$O-'*CLCJ
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M ,11_P ,I?LG?]"/K7_@%KG_ ,11];C_ "O[@]A+NC\A<48K]>O^&4OV3O\
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M_E?W!["7='Y"XHQ7Z]?\,I?LG?\ 0CZU_P" 6N?_ !%'_#*7[)W_ $(^M?\
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M2_9._P"A'UK_ , M<_\ B*/K<?Y7]P>PEW1^0N*,5^O7_#*7[)W_ $(^M?\
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M (BC_AE+]D[_ *$?6O\ P"US_P"(H^MQ_E?W!["7='Y"XHQ7Z]?\,I?LG?\
M0CZU_P" 6N?_ !%'_#*7[)W_ $(^M?\ @%KG_P 11];C_*_N#V$NZ/R%Q1BO
MUZ_X92_9._Z$?6O_  "US_XBC_AE+]D[_H1]:_\  +7/_B*/K<?Y7]P>PEW1
M^0N*,5^O7_#*7[)W_0CZU_X!:Y_\11_PRE^R=_T(^M?^ 6N?_$4?6X_RO[@]
MA+NC\A<48K]>O^&4OV3O^A'UK_P"US_XBC_AE+]D[_H1]:_\ M<_^(H^MQ_E
M?W!["7='Y"XHQ7Z]?\,I?LG?]"/K7_@%KG_Q%'_#*7[)W_0CZU_X!:Y_\11]
M;C_*_N#V$NZ/R%Q1BOUZ_P"&4OV3O^A'UK_P"US_ .(H_P"&4OV3O^A'UK_P
M"US_ .(H^MQ_E?W!["7='Y"XK^@O]GP?\6*^'W_8!LO_ $2M?-W_  RE^R=_
MT(^M?^ 6N?\ Q%?7?A#3-,T7PKH^GZ+ ]OH]K:10V<,@=62%5 0$/\P(&/O<
M^M<6*K*JDDFC>C3<&VS6Q1BE[4<^E>>=0N*,4[%&/>@1Y9^TM\6-2^"7P?U?
MQ=I%I:7U]9RVT:07N[RF$DR1G.T@\!B1SUKP_P#95_;5\6?'GXJ#POK.AZ-I
M]E]@FNO.L1-YFY"N!\SD8^8]J[K]OW_DU[Q-_P!?-A_Z5QU\@?\ !.3_ ).+
M'_8'N_YQU]C@<'0JY36KSA>:O9_)'M8>C3GA)U&M5?\ )'ZFXHQ2T5\<>.)B
MC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10!QWQDX^$G
MC3!(_P")+>_^B'KI;8DVT/S'_5KW]A7-?&3_ )))XT_[ M[_ .B'KIK7_CU@
M_P"N:_R%5T)ZC\G^\?SI<G^\?SI<48J0N)D_WC^=)D_WC^=.HQ0.XF3_ 'C^
M=)D_WC^=.HQ0*XW)_O'\Z7)_O'\Z7%% 7&Y/]X_G2Y/]X_G2XHH"XW)_O'\Z
M,G^\?SIV** N)D_WC^=>?^"F8_%#X@_,>NG=_P#I@U>@UY]X*_Y*C\0?KIW_
M *(:J6S$^AZ!D_WC^=)D_P!X_G3JHWFMZ=ITOEW5_:VTF,[)IT0_D2*23>Q2
MU+F3_>/YT9/]X_G6</$^CE=PU6QV^OVJ/'\Z3_A*-'QG^UK''K]JC_\ BJKD
MEV'9]C3R?[Q_.C)_O'\ZR_\ A*M&_P"@O8?^!4?_ ,51_P )5HW_ $%[#_P*
MC_\ BJ.278+,T\G^\?SHR?[Q_.LS_A*M%_Z#%A_X%1__ !5!\5Z*/^8Q8#_M
M[C_^*I<LNP69IY/]X_G2Y/\ >/YUE_\ "5Z(?^8Q8?\ @7'_ /%4?\)7HO\
MT&+#_P "H_\ XJCEEV"S-3)_O'\Z3)_O'\ZSO^$GT?;G^UK''K]JC_\ BJ0>
M*-&/_,6L3_V]1_\ Q5/DEV"S-+)_O'\Z,G^\?SK._P"$FTC&?[5L<>OVF/\
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M/^3BQ_V![O\ G'7WN6_\B/$>LOR1]#A?]QJ?/\D?J=1117P1X(4444 %%%%
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M^W[_ ,FO>)O^OFP_]*XZ^0/^"<G_ "<6/^P/=_SCK[W+?^1'B/67Y(^APO\
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MGUW6_P#\;KH7$&7[W?W&O]H8?O\ @? &G>*[VSFCNI-3NX=0C "7*W#B5<#
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M?5F8DD^YJB<FOU"U?_@F7X!U>[:=_$WB.(G^&,V^/UCJC_PZV^'W_0U^)O\
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M1U.*,5Y_\,OV@/A_\9+V^M/!OB.+7+BQC66XCC@FC,:,2%/SHN<D'I6GX?\
MBWX.\5^.-<\'Z1X@M-1\2Z&BOJ6GV[%GM0V -QQMSD@$ Y'?%-QDMT*Z.MQ7
MGW@G_DJ/Q!^NG?\ HAJ]#KSOP=(L/Q.^(;N=JK_9Y)/8>0U..S&^AUOB?Q3I
M'@O1;C5]=U*VTK3;<;I;JZD"(OXGJ?8<FOG74O\ @HO\'M/OIK>.YUR_CC8K
M]IM=+?RFP<9!8J<>^*^"OVLOVBM6^._Q.U":.]E3PMILSVVDV22$1[%.#.0.
M"[D9SV4J![^*2:E*_P!X[F'<\U]U@N'Z+IJ>*;YGT70^@H9?#EO5;N?JVO\
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MR++TKINWJO\ (B6 PZUU^\_3@_\ !3'X.C^#Q+_X*Q_\71_P\Q^#I_@\2_\
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M0KNM+_Y!MI_UQ3_T$5^18BK[:I*IW;?WGQ]27/-R[EJBBBN4S"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH \PL_^3D-3_[%F#_TJ>O3Z\PL_P#D
MY#4_^Q9@_P#2IZ]/JY=!(****@84444 %%%% !1110 4444 %%%% !1110 4
M444 %9_B#_D!:C_U[R?^@FM"L_Q!_P @+4?^O>3_ -!--;@<K\"O^2->"?\
ML#VO_HL5W5<+\"O^2->"?^P/:_\ HL5W55/XF"V"BBBH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "O/]>_Y+/X6_[!E]_.*O0*\_U[_DL_A7_L&7W\
MXJJ.X,] HHHJ0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH ^=?V_P#_ )->\3?]?-A_Z5Q5\??\$Y/^3BQ_V![O^<=?8/[?
M_P#R:]XF_P"OFP_]*XJ^/O\ @G)_R<6/^P/=_P XZ^]RW_D1XCUE^2/H<+_N
M-3Y_DC]3J***^"/!"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#COC)_R
M23QI_P!@6]_]$/74VG_'K#_N+_*N6^,G_))/&G_8%O?_ $0]=3:?\>L/^XO\
MJKH2]R6BBBI$%%%% !1110 4444#"BBB@04444 %>>^"?^2I?$'ZZ?\ ^B&K
MT*O/?!/_ "5+X@_73_\ T0U6MF#/0JYG5/AAX.UR\>[U+PGH>H73G+3W6G0R
M.Q]V*Y->9?M)_M<>$_V<K.*VO8Y-:\2W4?F6VC6KA6V9QYDKGB-,@C."3C@'
MFOC2Y_X*@_$JZO9#;:!X8LK8_<BD@GF9?JWFKG\A7KX/*\9B8^TI*R[MVN=U
M'"UJJYH:(_0W_A3/P_\ ^A&\-_\ @I@_^(I/^%,?#[_H1?#?_@I@_P#B*_.V
M3_@II\5=QVZ;X5"=BUA/T_[_ -5I_P#@I_\ %56Q%IGA5E_O-83C/_D>O0>2
M9C'>2_\  CI>!Q*Z_B?HY_PICX??]"+X;_\ !3!_\11_PIGX?_\ 0C>&_P#P
M4P?_ !%?GI9_\%*_BM-M,FE^%A&1DN+*<?\ M>KLO_!2+XFN4DBL?# AS@@Z
M?.S'W_U_%5_869=__)A_4,3W_$^_O^%,_#__ *$;PW_X*8/_ (BE_P"%-> /
M^A&\-_\ @I@_^(K\]+K_ (*4_%JRGE631O#)1>586,^".Q_U]4I_^"G7Q5^4
M0Z7X6'')>PGY_P#(])Y'F*^TO_ A?4<2NOXGZ,?\*:\ ?]"-X;_\%,'_ ,12
M?\*9^'__ $(WAO\ \%,'_P 17YP_\/._BW_T#/"?_@OG_P#DBD/_  4]^+8_
MYAGA/_P7S_\ R14?V-F/\W_DQ/U+$=_Q/TDC^$?@:%LQ^#/#Z'U72X!_[+0/
MA'X%'3P7X?'.>-+@Z_\ ?-?FR?\ @I_\6_\ H&>$_P#P7S__ "12C_@I]\7#
M_P PSPG_ ."^?_Y(H_L?,?YO_)@^IXCO^)^DI^$?@5F9CX+\/%FZDZ7!D_\
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MN%%%%9B"BBB@ HHHH **** /,+/_ ).0U/\ [%F#_P!*GKT^O,+/_DY#4_\
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M!)D')XXKJ9?V5OBEIKR/=>#Y_*@$C2;+JWD/[L$R( LA)=0"Q0 L!SC%<O\
M#3XF7WPSFUR2RLK:\.K6!T^47)8>6AE23<NTCG,8'/&":[W1OVDM6_X2VTU%
MM&TQ)5\0W_B!06DVB:[A\ITZYV*.0>N>IKDF\5[1^S2:\_3U74S;J\WNVL//
M[+7Q+O+:PN+3PU-.LZ(R$7=N%Q(H>,$&3*EP?E!P6/ R:Y_3_A9XIC$N[0;M
M9YK"6^6)F12((YC#(^"V0%D4J0><CI76WW[0.IR:C?2-H]E'YUQH\TAR^ =-
M7;%CGH_\7IVQ5W4OVJM1N;>\\WPCH[ZC);75G'J7G7 DBM[BY-R\80/L.'8X
M8C.#73S8U:N*?_#>O?0UO66Z7]?,JZC\ O'NB?9=%G\+W<U]J3RP0KOB<AT7
M,BNZN5CVKR=Y&!STKROQ;\.?$7@G69]+UG2;BRO(E5]A D5T895T="5=2.C*
M2#7JB?M8:S9SZN6T'2Y[/5]3O=2OK.0RA+A;J(QS0$A@RI@Y# [@0.:Q-9_:
M3\5:C):VFCZA=>#="ALH].AT;1KN58%MTW85BQ+2$EW)9B3\WI2IRQ7-:I%?
ME_G]UOGT"+JWM)+^OO+5W^S'<V\4NE#Q5IS^/H=-.JR>%!;3"01"+SC&+@CR
MS,(OG,?X9S7)ZG^SU\1=-M]*FE\*W;IJ<T-O:BWDBF=Y)DWQ*RHY9"ZG(W@9
MP?0UZ&O[26HW\4U__P (QHT?BV?36TI_%:O.;LQ>5Y6?++^4)#'\ID"YQ[UB
M:=^U/XBT77]1U:TTC2DN;Z;2Y9$?S&3%E;FW5,;LD2(3N[C/RD5RM8R'1/UM
MOY6Z=KZZ:F+5:/\ 7]:?B<W;?LW_ !(O-9NM+@\,O-=6T<<LACO+9HL.2$"R
MB38S,58!%8L2IP*MI^SAXPU"TT!M(L)-1N]1L);^YMW"VHT_9<O;^7*\K*H8
MNF ,@DG !-3Z/\>-,T*"ZTRV^&^@?\(W)=VVI0Z*]Y>&."]@#A+@2>9O8D.5
M*$[2 . >:T;S]J;5?$5I+8^*?#&C>)M,N4/VNTN'G@%Q-]KDNDFW1N"A5Y7&
MT<%3@\\U$I8N^D5_7S_5>K);J]%_7WG,:)^SS\1O$2WS6/A2[)LKF2SF2XDB
M@?SHQF1%61U+E1RVT' ZUK7/PN\1>&]!U22\TX6>F64=E)>7,A5E4W*AH7.T
MG<"#D 9X!]#7J'@7]J30]6NW\2_$>.VU#Q!IE[?7ND06FG3^;!]HAVF.*195
MCV;@O^M5BH!.3G%<]XQ^.UKXG^&?@3X?Z9?2W4NEV8:_U6>T\@7,RAA# 5))
M<0HQ17/4G@"G2KXEU>24%;O9Z=]>O;IJ_(<)U.:S1XA>:>L5O<R^;#&^20L&
M&27+9XYX'IZ=ZS?+ EVW+-@G)*GMZBNOOM0:QVWEM807ZNACF$L.>21R!_#W
MYK%E;>)IYHX<QPF!(G3D;L\\D<J3]>0<5ZST.MEO2D@:X6VBF2:-/WPDV''3
MIZYZ5F7EG?W<GGS+EG!V(6&XJ/1?2K&DW=QI,4#1LA$O+< D+[^U6XK1=D]S
M#*K1LH! (W YYQGI]:UMS(JUT85G"CW4'VC=';,X#28.,9YKJ-<>46!<11I'
M"P$)CYR@XSQGC\?6DN[/3WTVXV.8'D48.=T>1S[DGWJ86UQ:V2+)!YNGG8S*
M.?E(Y*D>XZ5"3B)*QS$;/>PW5U+,D8C 5(B?O$\$+Z #^E,CF.FN\>$GB;&X
M9RN?48Z'FK5]:6_]C"YM'D\LRE?*EY^I#< ]N, UE)+@&3SLLWRE#U-9W)-G
M2[6/49T5XY;> (RO-&=Y(ZYP!U /-4KW3;BTN)()Y?M&TA0\9+!_[I'YC\ZT
M-'U);$(557:/+J8B0=S  J?88["IKV\-[! 96,.TE2A)W,,]>G/0?E6BCS*[
M*2N4+,2:;JR !3+&0,.,#=CWZ'GK5B>[(DD>2?[074ASM(RPZ=?0]_:KTNGV
MD%HMS/<0.$ D"YQ(PW?=(SU/;TK&F",4<-YJ/T?L,>H/3Z52LM!K0@NIC)#&
MK<LK'!/7!_\ KU4?I4LLGFL#[8R:B8UA)W9D]SW#]BOXG7WPR_:$\,/!.RZ?
MK%RFE7T.3MDCE8*N0.I5RK#Z5^S8YK\4?V1_ M[X_P#VA_!5C:1,Z6NH1ZA<
MNO\ RSAA82,Q_P"^0/J17[7@<5^><0J"Q$6M[:_H?/9BDJBMO8*,4M)7RIY(
M8HQ12T )CZT4M% "8HQ12T >768_XR1U/_L6(/\ TJ>O4,?6O+[/_DY'4_\
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MDD\:?]@6]_\ 1#UU=I_QZ0_[B_RJNA+W)J***D04444 %%%% !1110 4444
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M_(/_ (Y6[X1_8%^-/BS4%@F\+IX>M]P#W>KW<2(H/<*A9F_ 5^PFQ?[H_*E
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M KS[7O\ DM'A7_L&7W\XJ]!KS[7O^2T>%?\ L&7W\XJJ.XF>@T445(PHHHH
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH*L?.?\ P4!_Y-=\2_\
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M3R723K<L/WSKM>3.<AV'!;N.#7V\?^"3]@1_R4R^_P#!-'_\=IO_  Z<T_\
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MP_'H*^(M5_L)#N72S>2&UZY_U6=N,\XQBMJ#QYJWB"Y=9M:U"VN96AE8I<R
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MJ1V"BBB@+!1110%@HHHH"P4444!8**** L%%%% 6"BBB@+!7G^O?\EG\*_\
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M,2F78OF%=N_'..N,^E)+!'-'LDC5TSG:R@CKGI3]JNPN1]SXGTOXH:WK5MX
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M%=U7"_ K_DC7@G_L#VO_ *+%=U3E\3$MD%%%%2,**** "BBB@ HHHH ****
M"BBB@ HHHH **** "O/]=_Y+/X6_[!E]_P"A0UZ!7G^N_P#)9_"W_8,OO_0H
M:J(F>@4445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** /G/_@H#_R:[XF_Z^;#_P!*XJ^/?^"<G_)Q8_[ ]W_..OL+_@H#
M_P FN^)O^OFP_P#2N*OCW_@G)_R<6/\ L#W?\XZ^]RW_ )$>(]9?DCWL-_N-
M3Y_DC]3J***^"/!"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#COC)_R2
M3QI_V!;W_P!$/75VG_'I#_N+_*N4^,G_ "23QI_V!;W_ -$/75VG_'I#_N+_
M "JN@NI-1114C.%^./Q3B^"GPH\1^-Y].DU:+1K;[0UE%*(FE^8+@,00.OI7
M$^$OCWXQN8KC5O&_POE\!^#[73Y-1N-?N?$%I=I$BIO ,4?S<C/Y5L_M4_#S
M6?BQ^S]XU\)>'HH9]9U6R\BVCN)1$C-O4\L>G ->+_#7]GK4F\#^*OAQ>?!O
M2?AOX<\4Z6]IJ>MZ5XL.HS-,(BL;"%HAW9CPP ]ZWBH<EWO_ %Y_YF4G+FT.
MU\$?M3>+O&]]H6H6WP/\5Q>!=<N$BL?$/VFV>7RG_P!7<2VFX21Q$8.XG@<^
MF4G_ &G?&VL^/O&OASP9\';SQ;!X6U!=.NM07Q!:VBO(8DD&$E /1QZUXOXG
M_9=^+GQ8T_PCX.\5Z%HFDGP_'#IC?$+2O$=TC3:?$1Q'IZ;0)G5<$R$@9.*]
M3^&_['VBP_&_Q[X]\8>';:[OW\06VH>&KY;Z4O##%;Q*I9%8#(="<,#FM&J:
MU_K\R4YO^O\ @%C5?VLO&*^.?%?AC0O@W?\ B"[\+6=G=:NT.O6L/D&>#S?+
M4. '*X=<J<';GN*]*^$/[17@GXT>'++4]$U6.&XFTQ-5GTR[8)<VL#,R[I%_
MNAD==P)&5ZUX#\2_V);[XM?$SXX:[JCOII\06%E%X9U"TU.6/9-' 5D\Z%&5
M67<%&'#<%L8JM\2_V8OB-XF\ ?#>[\'V&C^"/&%OH3^#_$=E97(6V33)@!(T
M#*,$HRF1!C/[PCJ*'&DTDG;_ (8$YJ[/1/&?[;?ASP\?%EQHVF?\)1I.A^$T
M\5PZE8WJK#?1M<-!Y2$J<8*D[N1[5W7PL^/=O\3_ (A>+?"L6C3:?)X?LM,O
M'NI)U=9A>6XF"A0!C8#@GO[5X3\8?V2O$VJ77C[3_!]A9KH-Y\-;7PCHR37:
MQMY\-P6",,?*NS!W=SFO3/@'\&_$WP_^,7Q"\1:Q!;1:9K6F:':V;PW D=I+
M6T$4VY<?* PX/>I:I\K:W_X8:<[ZGT#1117,;!7FGAF]CTWXB?$J[E.(H$L9
M7(]!;N3_ "KTNO+=(T\ZMXW^*-DK;6N8+.$-Z;K9QG]:TA;6_P#6HNJ/Q\^+
M?Q*U+XP_$GQ!XKU99GDU&5S"CL<00#/E1CL J@?CD]ZX8-#U\M\?[_\ ]:KG
MB+0;WPGKVHZ)J43P7^G7,EI<1G^%T8J?Y?K6=Q@]:_8X<L81C!:+8^SC9)*.
MQU_@KP!J'Q!L_$ THQHVB:>^JS1S,Q:5%=(]D8 ^^2ZXS@>];=Y^SW\3=&M;
M^6^\!:_:P6]L]S*\EDV$1#\S$CTP21UP,XQ5+X3?%$?#"?Q%(=-.I?VOIAT[
M'G^5Y69HY-_W3G_5XQQUZ\5Z+I_[4\@\3P:B- D*KXDU7Q!Y!U X(O+<PF#.
MS^'KNQ\W3 KEG/$JH_9Q37_ ]>YE*57F]U:'"VO[//Q.O(+*>#P#X@G@O(Q+
M!)'9EEE4J'# ^A4@CU[9K!M_A[XGN!$8] U!C+:/?H! 1FW20Q/+C^ZL@*D]
MB,5Z1+^TV[RW3IH<L0GN?#]P%6_(V?V6@7'W/^6F,Y_A_P!JMJ;]J[3+R"^N
M)_!4K:Y):7VFV]Y'JY6&.UN;QKO:T/E'=(K,R[PP!!Z UFJN+6\$_P#AO7Y$
M\U5?9_K[SSV^^!WQ!TG5-/TS4O!NO6NH:B[16-H]HQDN'7[RJ/51@GT'/2N:
M\3>'+_P7K4^D:]8WFCZI#@R6E['Y<@!&0<$\@CD$<&O9]._:JVW'B<3>&3<:
M?KNLZEJEY;G461_LUY"(9+>.0)E' Y$@],%<5R_BG]HS7-0>WLO#D:>'?#UI
MID6D6UC.D5_/Y$>_!DGECW,Y,C\J% R  ,5TTZN*;2G!??\ \/\ E\S6,ZO6
M)O6_[.&J0V:1SZ_HI\11::=4F\)+.QU);;9YN[;M\LN(SO,>_>!SBN/U/X1>
M-=$ATVZOO".L1VNIW"16+M:MBZ>10T:ICJ6!! [UW-M^T=IVH71\0/X5BMOB
M3/IQTJ3Q)]OD: *8/(-P+7;CSS'\I;=MZG;DUIV/[4TVA>)]6U*RT!9OM-SH
M\BQ2W;%0ME:FW8<*#F122&&"A/>B%3&K[*?W;^5GMU5]=-04JZZ' I\%/'L^
MKWNB0^ ];;5K6!;B:V%JQ>*-B0K^F"00,'D@CJ*U_#?P,\3:A+X;>TTVXUMM
M6L9=2^QV,+M+!'',T160$  EUQCW Z\5M^'/C%X5T.WNM&MO VJ-X;DO;34[
M6SFU^3[5'>0;MC-.(ANC.\@QA1T!!!R:[_6/CE%JOAZXM/%/A_\ M"&]A)OK
M;3M2-D[S?;)+I7C?8Q10TA4J0V0,Y!IU*^,5DH?EV_Q=_->KO<<IUEI;^OO/
M+H_!GCOQSIFIIH_@O5+FRL9C;W#0VS9@D3ED8'&& &2!T[UD>'/A1XTU/7UT
MJ'0IH+AY+:&5KZ/;% 9\>0SM_"'W#:>^:]P\$?M&^&?%=Z_BGX@3VNGZKI.H
M7UYI5I8FZ5B+B'!0HL;12\A0&=T8<D[A@5Y_\3_C+;>)?AAX$\$:3JD%[?6E
MK%-K6L6\,D'G21!EM8,N S&&-B"W0GH2!FIA6Q7/[+V=O/6RWUOUV\M6O449
MU;\O+;^OQ.4\3:7K'P8\6:OX7U6.VGU&SD42&&4M'R,@@X'4$5!J=S;^(-$>
M=HUBNXX_-7:<Y ZBN'U/6[G4KAGN7$]UN)>Y9BSRGN23USUS3++5WMDG0G*O
M&4 /;->FJ3LG+XNIU*.B;W+#*,?ZN;ZK4"G;/#@F/YQS)^/-4_MTR?=E(S[]
M*([QHQ',P$A63.&[\5O<NYHZY/(VH29NH&/J%Z_I6=Y[C_EO!_WR/\*34-4^
MV7,DQ@A4L?N@=*JFY /,,)[]#_C6=[$W+:M+,ZJLELS$X ('^%*UM<@@$6V3
MR!A?\*I+>[&#)#$&Z@X/'ZU6W$@?7UJ.8FY=.\=[0_\ ?--._P#NVI_%?\:I
MGG/ Z_E0>I^7H/7I4\Q-RV ZD$);Y'0AE_QJ!K=SUV')S]\?XU'@YY7MFD"Y
MQ\O7]:F]P'FW?GA?P<?XTHM'/\ _[Z%"HBPAF3<Q8@<XP*GCM4,RQM'AB,A5
M?<?8'TII)_U_P L>^?L4?$?4_A+\?O#MOYICTOQ!(FFWL!?Y'60XC<@?Q*Y!
M'U([U^P(K\;?V7_ =[XK^/7@FSBB\F2&_BNY0,2.(XF$C$]E "=1ZU^R0Z5^
M><20IQQ,''=K7]#Y_,HQ516WL+1117R)Y 4444 %%%% !1110!Y=9?\ )R6I
M_P#8L0?^E3UZC7EUE_R<EJ?_ &+$'_I4]>HU<NA,0HHHJ"@HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *S_$'_("U#_KWD_]!-:%9_B#_D!:A_U[R?\
MH)IK<#E?@5_R1KP3_P!@>U_]%BNZKA?@5_R1KP3_ -@>U_\ 18KNJ<OB8EL@
MHHHJ1A1110 4444 %%%% !1110 4444 %%%% !1110 5Y_KO_)9_"W_8,OO_
M $*&O0*\_P!=_P"2S^%O^P9??^A0U41,] HHHJ1A1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 ?.?_!0'_DUWQ-_U\V'_I7%
M7Q[_ ,$Y/^3BQ_V![O\ G'7V%_P4!_Y-=\3?]?-A_P"E<5?'O_!.3_DXL?\
M8'N_YQU][EO_ "(\1ZR_)'O8;_<:GS_)'ZG4445\$>"%%%% !1110 4444 %
M%%% !1110 4444 %%%% ''?&3_DDGC3_ + M[_Z(>NKM/^/2'_<7^5<I\9/^
M22>-/^P+>_\ HAZZNT_X](?]Q?Y57074FHHHJ1A1110 4444 %%%% !1110
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M@4445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW%[1;'WM17C7[)?CO7OB+\&;'5O$6J0ZO?B\N[9;H(D=R88YF6(7<2?+%<A
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M ).2U/\ [%B#_P!*GKU&O@Y=#Y^(4445!04444 %%%% !1110 4444 %%%%
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M2TUBZD&?B-;LN,MYFFN3G_OY5+_AU3K?/_%PK#/_ &#)/_CE']LX#I47W/\
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M[F AA9+%]FLV(Z;UW,SCVR >X-?9%K:PV-M%;V\206\2"..*)0JHH& H X
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M% !1110 4444 %%%% !1110 5G^(/^0%J'_7O)_Z":T*S_$'_("U#_KWD_\
M0336X'*_ K_DC7@G_L#VO_HL5W5<+\"O^2->"?\ L#VO_HL5W5.7Q,2V0444
M5(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH *\_UW_DL_A;_ +!E]_Z%
M#7H%>?Z[_P EG\+?]@R^_P#0H:J(F>@4445(PHHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** /G/\ X* _\FN^)O\ KYL/_2N*
MOCW_ ()R?\G%C_L#W?\ ..OL+_@H#_R:[XF_Z^;#_P!*XJ^/?^"<G_)Q8_[
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M-EMD:V\L=$\LC;M&!@8QQ4NB:#IGAG3(=.TC3[32M/A!$5I90+#%&,Y^5%
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M+X1Z=K1BFEOK/4WTJ*6:W\'S0W&D0W^'\R..28ERG^K/RE@"6 )P*\)2[A5
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MB@ HHHH **** "BBB@ HHHH *S_$'_("U#_KWD_]!-:%9_B#_D!:A_U[R?\
MH)IK<#E?@5_R1KP3_P!@>U_]%BNZKA?@5_R1KP3_ -@>U_\ 18KNJ<OB8EL@
MHHHJ1A1110 4444 %%%% !1110 4444 %%%% !1110 5Y_KO_)9_"W_8,OO_
M $*&O0*\_P!=_P"2S^%O^P9??^A0U41,] HHHJ1A1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 ?.?_!0'_DUWQ-_U\V'_I7%
M7Q[_ ,$Y/^3BQ_V![O\ G'7V%_P4!_Y-=\3?]?-A_P"E<5?'O_!.3_DXL?\
M8'N_YQU][EO_ "(\1ZR_)'O8;_<:GS_)'ZG4445\$>"%%%% !1110 4444 %
M%%% !1110 4444 %%%% ''?&3_DDGC3_ + M[_Z(>NKM/^/2'_<7^5<I\9/^
M22>-/^P+>_\ HAZZNT_X](?]Q?Y57074FHHHJ1A1110 4444 %%%% !1110
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M /':4_L(_ ENOP_MO_ ^[_\ CM?-EQ_P5$\1P'"_#6PE.2,+J\O_ ,8J8_\
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M_L6(/_2IZ]1JY="8A1114%!1110 4444 %%%% !1110 4444 %%%% !1110
M5G^(/^0%J'_7O)_Z":T*S_$'_("U#_KWD_\ 0336X'*_ K_DC7@G_L#VO_HL
M5W5<+\"O^2->"?\ L#VO_HL5W5.7Q,2V04445(PHHHH **** "BBB@ HHHH
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M-$T2TDTB#2(M'CF\26,&H:C(D8<"5[AU)#Y<X"X "J.<9KIA6Q+:4J:MZ_\
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MDM3_ .Q8@_\ 2IZ]1JY="8A1114%!1110 4444 %%%% !1110 4444 %%%%
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MK-YXX\ K"GB&X :_TB1A$EZX&/-C<\+)C&0>&QG(.<_G[K/P#^)>@7S6E_\
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MKNJ<OB8EL@HHHJ1A1110 4444 %%%% !1110 4444 %%%% !1110 5Y_KO\
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MA"Y!!"9!![UT]K\"_ALUM"3\/O"Q)0?\P:V]/]RG[MA:W.M_X2+2O^@E9_\
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MV_Z)]X6_\$UM_P#$4?\ "B?AM_T3[PM_X)K;_P"(J?='[QU'_"1:5_T$K/\
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M(NP )TR?W+>]=3IGB'2UTVU!U*SR(D_Y>$_NCWKS'XO_  4^'EC\*_%UQ;>
M_#5O<1:5=/'+%I%NK(PB8@@A,@CUKIM-^!GPW?3K5F^'_A<L8D))T:WY^4?[
M%5[O*+6YV/\ PD6E?]!*S_\  A/\:/\ A(M*_P"@E9_^!"?XUR__  HGX;?]
M$^\+?^":V_\ B*/^%$_#;_HGWA;_ ,$UM_\ $5/NC]XZC_A(M*_Z"5G_ .!"
M?XT?\)%I7_02L_\ P(3_ !KE_P#A1/PV_P"B?>%O_!-;?_$4?\*)^&W_ $3[
MPM_X)K;_ .(H]T/>.H_X2+2O^@E9_P#@0G^-'_"1:5_T$K/_ ,"$_P :Y?\
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MPHGX;?\ 1/O"W_@FMO\ XBCW0]XZC_A(M*_Z"5G_ .!"?XT?\)%I7_02L_\
MP(3_ !KE_P#A1/PV_P"B?>%O_!-;?_$4?\*)^&W_ $3[PM_X)K;_ .(H]T/>
M.H_X2+2O^@E9_P#@0G^-'_"1:5_T$K/_ ,"$_P :Y?\ X43\-O\ HGWA;_P3
M6W_Q%'_"B?AM_P!$^\+?^":V_P#B*/=#WCJ/^$BTK_H)6?\ X$)_C1_PD6E?
M]!*S_P# A/\ &N7_ .%$_#;_ *)]X6_\$UM_\11_PHGX;?\ 1/O"W_@FMO\
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MPD6E?]!*S_\  A/\:/\ A(M*_P"@E9_^!"?XUR__  HGX;?]$^\+?^":V_\
MB*/^%$_#;_HGWA;_ ,$UM_\ $4>Z'O'4?\)%I7_02L__  (3_&C_ (2+2O\
MH)6?_@0G^-<O_P *)^&W_1/O"W_@FMO_ (BC_A1/PV_Z)]X6_P#!-;?_ !%'
MNA[QU'_"1:5_T$K/_P "$_QH_P"$BTK_ *"5G_X$)_C7+_\ "B?AM_T3[PM_
MX)K;_P"(H_X43\-O^B?>%O\ P36W_P 11[H>\=1_PD6E?]!*S_\  A/\:/\
MA(M*_P"@E9_^!"?XUR__  HGX;?]$^\+?^":V_\ B*/^%$_#;_HGWA;_ ,$U
MM_\ $4>Z'O'4?\)%I7_02L__  (3_&N"US7=-/QD\+N-0M-@TV^!;STP.8O>
MM7_A1/PV_P"B?>%O_!-;?_$5PVM?!?X?1_%[PU;)X%\-+;2:=>L\(TFW",08
ML$C9@D9/YU4>43N>P_\ "1:5_P!!*S_\"$_QH_X2+2O^@E9_^!"?XUR__"B?
MAM_T3[PM_P"":V_^(H_X43\-O^B?>%O_  36W_Q%3[H_>.H_X2+2O^@E9_\
M@0G^-'_"1:5_T$K/_P "$_QKE_\ A1/PV_Z)]X6_\$UM_P#$4?\ "B?AM_T3
M[PM_X)K;_P"(H]T/>.H_X2+2O^@E9_\ @0G^-'_"1:5_T$K/_P "$_QKE_\
MA1/PV_Z)]X6_\$UM_P#$4?\ "B?AM_T3[PM_X)K;_P"(H]T/>.H_X2+2O^@E
M9_\ @0G^-'_"1:5_T$K/_P "$_QKE_\ A1/PV_Z)]X6_\$UM_P#$4?\ "B?A
MM_T3[PM_X)K;_P"(H]T/>.H_X2+2O^@E9_\ @0G^-'_"1:5_T$K/_P "$_QK
ME_\ A1/PV_Z)]X6_\$UM_P#$4?\ "B?AM_T3[PM_X)K;_P"(H]T/>.H_X2+2
MO^@E9_\ @0G^-'_"1:5_T$K/_P "$_QKE_\ A1/PV_Z)]X6_\$UM_P#$4?\
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M?!GU(4444 %%%% !1110 4444 %%%% !1110 4444 <=\9/^22>-/^P+>_\
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M):G_ -BQ!_Z5/7J->767_)R6I_\ 8L0?^E3UZC5RZ$Q"BBBH*"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ K/\0?\@+4/^O>3_T$UH5G^(/^0%J'_7O)
M_P"@FFMP.5^!7_)&O!/_ &![7_T6*[JN%^!7_)&O!/\ V![7_P!%BNZIR^)B
M6R"BBBI&%%%% !1110 4444 %%%% !1110 4444 %%%% !7G^N_\EG\+?]@R
M^_\ 0H:] KS_ %W_ )+/X6_[!E]_Z%#51$ST"BBBI&%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!\]_MY_\FS>)/^OFQ_\
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MAMO(R2:[#Q9^S'HWCBP\/Z=K&I7$VFZ9X7NO#$T$4:HUQ'.D"F8-GY'4P!@
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MI>RDWM<6BBBOECW HHHH **** "BBB@#RZR_Y.2U/_L6(/\ TJ>O4:\NLO\
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MV?WGYAM_P2X^)9<D>)O"A&3C,UUT_P"_-/M_^"7WQ.MY4<>)O"9*\_ZZZ_\
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M+XC*O_(S^%BV>07N<8^OE5^F%%']OXWNON#^RL-V?WGYAZQ_P3H\;^#='O\
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MM"L_Q!_R M0_Z]Y/_0336X'*_ K_ )(UX)_[ ]K_ .BQ7=5POP*_Y(UX)_[
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M51_PO9?^A!\=_P#@A;_XJO3MB_W1^5&Q?[H_*B\>P6?<\Q_X7LO_ $(/CO\
M\$+?_%4?\+V7_H0?'?\ X(6_^*KT[8O]T?E1L7^Z/RHO'L%GW/,?^%[+_P!"
M#X[_ /!"W_Q5'_"]E_Z$'QW_ ."%O_BJ].V+_='Y4;%_NC\J+Q[!9]SP_P"(
MOQ;G\2^ ?$FDV7P_\<M>7VFW-M"K:&R@N\3*H)+<<D<UO0?'-8X8T/@'QWE5
M _Y +>G^]7J6Q?[H_*C8O]T?E3YH[6"S[GF/_"]E_P"A!\=_^"%O_BJ/^%[+
M_P!"#X[_ /!"W_Q5>G;%_NC\J-B_W1^5*\>P6?<\Q_X7LO\ T(/CO_P0M_\
M%4?\+V7_ *$'QW_X(6_^*KT[8O\ ='Y4;%_NC\J+Q[!9]SS'_A>R_P#0@^._
M_!"W_P 51_PO9?\ H0?'?_@A;_XJO3MB_P!T?E1L7^Z/RHO'L%GW/,?^%[+_
M -"#X[_\$+?_ !5'_"]E_P"A!\=_^"%O_BJ].V+_ '1^5&Q?[H_*B\>P6?<\
MQ_X7LO\ T(/CO_P0M_\ %4?\+V7_ *$'QW_X(6_^*KT[8O\ ='Y4;%_NC\J+
MQ[!9]SS'_A>R_P#0@^.__!"W_P 51_PO9?\ H0?'?_@A;_XJO3MB_P!T?E1L
M7^Z/RHO'L%GW/,?^%[+_ -"#X[_\$+?_ !5<EX:^*-UI7CCQ;JD_@#QR+74C
M:?9R-#8D^7$5;(W\<FO>]B_W1^5&Q?[H_*GS)= L^YYC_P +V7_H0?'?_@A;
M_P"*H_X7LO\ T(/CO_P0M_\ %5Z=L7^Z/RHV+_='Y4KQ[!9]SS'_ (7LO_0@
M^.__  0M_P#%4?\ "]E_Z$'QW_X(6_\ BJ].V+_='Y4;%_NC\J+Q[!9]SS'_
M (7LO_0@^.__  0M_P#%4?\ "]E_Z$'QW_X(6_\ BJ].V+_='Y4;%_NC\J+Q
M[!9]SS'_ (7LO_0@^.__  0M_P#%4?\ "]E_Z$'QW_X(6_\ BJ].V+_='Y4;
M%_NC\J+Q[!9]SS'_ (7LO_0@^.__  0M_P#%4?\ "]E_Z$'QW_X(6_\ BJ].
MV+_='Y4;%_NC\J+Q[!9]SS'_ (7LO_0@^.__  0M_P#%4?\ "]E_Z$'QW_X(
M6_\ BJ].V+_='Y4;%_NC\J+Q[!9]SS'_ (7LO_0@^.__  0M_P#%4?\ "]E_
MZ$'QW_X(6_\ BJ].V+_='Y4;%_NC\J+Q[!9]SS'_ (7LO_0@^.__  0M_P#%
M4?\ "]E_Z$'QW_X(6_\ BJ].V+_='Y4;%_NC\J+Q[!9]SS'_ (7LO_0@^.__
M  0M_P#%4?\ "]E_Z$'QW_X(6_\ BJ].V+_='Y4;%_NC\J+Q[!9]SPWXD?%F
MX\3_  _\1Z19> /'+7E]I\]M"KZ&R@N\;*N26XY-;ME\<!;V<$3> ?'>Y(U4
M_P#$A;J !_>KU78O]T?E1L7^Z/RI\RM:P6?<\Q_X7LO_ $(/CO\ \$+?_%4?
M\+V7_H0?'?\ X(6_^*KT[8O]T?E1L7^Z/RI7CV"S[GF/_"]E_P"A!\=_^"%O
M_BJ/^%[+_P!"#X[_ /!"W_Q5>G;%_NC\J-B_W1^5%X]@L^YYC_PO9?\ H0?'
M?_@A;_XJC_A>R_\ 0@^._P#P0M_\57IVQ?[H_*C8O]T?E1>/8+/N>8_\+V7_
M *$'QW_X(6_^*H_X7LO_ $(/CO\ \$+?_%5Z=L7^Z/RHV+_='Y47CV"S[GF/
M_"]E_P"A!\=_^"%O_BJ/^%[+_P!"#X[_ /!"W_Q5>G;%_NC\J-B_W1^5%X]@
ML^YYC_PO9?\ H0?'?_@A;_XJC_A>R_\ 0@^._P#P0M_\57IVQ?[H_*C8O]T?
ME1>/8+/N>8_\+V7_ *$'QW_X(6_^*H_X7LO_ $(/CO\ \$+?_%5Z=L7^Z/RH
MV+_='Y47CV"S[GF/_"]E_P"A!\=_^"%O_BJ/^%[+_P!"#X[_ /!"W_Q5>G;%
M_NC\J-B_W1^5%X]@L^YYC_PO9?\ H0?'?_@A;_XJC_A>R_\ 0@^._P#P0M_\
M57IVQ?[H_*C8O]T?E1>/8+/N?/5M\2;V+XQWOB1OA_XX_LR71(K%6_L1MWFK
M.SD;=^<8(YKM_P#A>R_]"#X[_P#!"W_Q5>G;%_NC\J-B_P!T?E3<D^@DFNIY
MC_PO9?\ H0?'?_@A;_XJC_A>R_\ 0@^._P#P0M_\57IVQ?[H_*C8O]T?E2O'
ML.S[GF/_  O9?^A!\=_^"%O_ (JC_A>R_P#0@^.__!"W_P 57IVQ?[H_*C8O
M]T?E1>/8+/N>8_\ "]E_Z$'QW_X(6_\ BJ/^%[+_ -"#X[_\$+?_ !5>G;%_
MNC\J-B_W1^5%X]@L^YYC_P +V7_H0?'?_@A;_P"*H_X7LO\ T(/CO_P0M_\
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MY47CV"S[GA/PO^*UQX4^'7AK1K_X?^.5O;#3H+:94T-F =4 ;!#\\CK74?\
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M?^A!\=_^"%O_ (JO3MB_W1^5&Q?[H_*B\>P6?<\Q_P"%[+_T(/CO_P $+?\
MQ5'_  O9?^A!\=_^"%O_ (JO3MB_W1^5&Q?[H_*B\>P6?<\Q_P"%[+_T(/CO
M_P $+?\ Q5<IJGQ2N;OXC:'K4?@#QS]BM+*Z@E)T-LAG,>W W\_=->\[%_NC
M\J-B_P!T?E34DN@6?<\Q_P"%[+_T(/CO_P $+?\ Q5'_  O9?^A!\=_^"%O_
M (JO3MB_W1^5&Q?[H_*E>/8+/N>8_P#"]E_Z$'QW_P""%O\ XJC_ (7LO_0@
M^.__  0M_P#%5Z=L7^Z/RHV+_='Y47CV"S[GF/\ PO9?^A!\=_\ @A;_ .*H
M_P"%[+_T(/CO_P $+?\ Q5>G;%_NC\J-B_W1^5%X]@L^YYC_ ,+V7_H0?'?_
M ((6_P#BJ/\ A>R_]"#X[_\ !"W_ ,57IVQ?[H_*C8O]T?E1>/8+/N>8_P#"
M]E_Z$'QW_P""%O\ XJC_ (7LO_0@^.__  0M_P#%5Z=L7^Z/RHV+_='Y47CV
M"S[GF/\ PO9?^A!\=_\ @A;_ .*H_P"%[+_T(/CO_P $+?\ Q5>G;%_NC\J-
MB_W1^5%X]@L^YYC_ ,+V7_H0?'?_ ((6_P#BJ/\ A>R_]"#X[_\ !"W_ ,57
MIVQ?[H_*C8O]T?E1>/8+/N>8_P#"]E_Z$'QW_P""%O\ XJC_ (7LO_0@^.__
M  0M_P#%5Z=L7^Z/RHV+_='Y47CV"S[GF/\ PO9?^A!\=_\ @A;_ .*H_P"%
M[+_T(/CO_P $+?\ Q5>G;%_NC\J-B_W1^5%X]@L^YYC_ ,+V7_H0?'?_ ((6
M_P#BJ]'TV]_M+3[:Z\B>V\^-9/)N4V2)D9VLO8CN*GV+_='Y4ZDVGLAJX444
M5(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!BN8U/\ 9_?5M7EUVYUX2Z]<RSM=R&U=+66*6*&(QB&.967"V\7)D.?FW9!
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@FX4444!<**** N%%%
M% 7"BBB@+A1110%PHHHH"X4444!<**** N%%%% 7"BBB@+A1110%PHHHH"X4
M444!<**** N%%%% 7"BBB@+A1110%PHHHH"X4444!<**** N%%%% 7"BBB@+
MA1110%PHHHH"X4444!<**** N%%%% 7"BBB@+A1110%PHHHH"X4444!<****
M N%%%% 7"BBB@+A1110%PHHHH"X4444!<**** N%%%% 7"BBB@+A1110%PHH
MHH"X4444!<**** N%%%% 7"BBB@+A1110%PHHHH"X4444!<**** N%%%% 7"
MBBB@+A1110%PHHHH"X4444!<**** N%%%% 7"BBB@+A1110%PHHHH"X4444!
?<**** N%%%% 7"BBB@+A1110%PHHHH"X4444!<__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ibio-20230331xex10d7001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ibio-20230331xex10d7001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !5 (\# 2(  A$! Q$!_\0
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M+WPM^!?PB\8V/Q0O[J^\36I>]CDTVT5=SQ^<I!$?\(;9[@ ]<UY9_P %+?\
MDYR[_P"P)9_^U*U?VN;+Q)%^SO\  VYOM4L)_#,NGVJZ=I\-HR7,$HLD\QI)
M2Y#J>P"C'J:^MI4H.&';2UWTWT/FZDYJ5;5Z;>1]4?\ !/\ ^(?CCXL_#_7_
M !5XT\77&O$:@;""SEM88H[81HK-(&1026\S!!X&T8[UY/-^V1XL^/G[4?A[
MP!X-UM_"?@=]4:W-_90(]YJ"0AG=BS@A$<QE0% .ULDYX'2?\$]8KFX_9#\=
MQ66[[8]_J*P;>N\VL>W'OG%?'O[#BE?VH_AJIR&%U,"#P0?LTN16$</2=7$3
MM\-[(V=::A0C?XMSZ@\0?MA^+?V<_P!JKQ!X+\4ZS)XM\ B_C)EO(42[TZ*=
M5D!1T WK'OQM;.57J#U]E_;S\?>,?AK\(=.\8^"?%D^A26]]%;RPP6\,L=XD
MW"L6=25VXR,==QS7P7^WZ ?VJ/'H//R6O_I)'7US^VQ#<VW[!GA**]W?;$&B
MK,'^\'$0#9]\YJ:E"$98:HDO>M?ST'&K-JM"^VQ'_P $]?B[\1_C=K7B[4O&
M'C:ZU6PT>."WCTMK.!$D>7<?,+J@8%?+P .#N.>E?4_QM75U^%'BF?0=<F\.
MZO:6$MW;ZC!#'*T;1*9,;7!4A@NT\< G'-?&7_!)K_CS^)W_ %VT_P#]!FK[
M"\<^*](\7?"#Q]<:-J-OJ<%KI^I64TEM('6.>*)UDC)'\2L""*\_&Q4<7)15
MDFCLPLG+#)R>MF?G]^R=^TQ\8OC/\=O"GAG5_B'>1:9<^9=W"1V%L?-2*,R&
M(YCX#XVDCD Y%?J$N0.E?CS_ ,$[/^3J/!O_ %Y7O_I,U?KA%XLTBX\2W7AV
M+4;>37;:UCO9M/5QYT<#LRI(R]E+(P!]C6N:PC"NHPC96Z&>73E.DW)WU/$O
MVWOB=X@^&OP9O+SPAK8T?Q0C)>1E8DD=[6.6-;@J&!' E0DXZ&O)O^">'[2O
MC#XP:]XST#QMKKZW>VT$%]8RR0QQE(\E)5^11GDQGGUK7^/FL>%/%WQ?^(%K
MXOU_3=#T31/!S^&[*;4[E8HWU._5IW"EC@NL4,/'4!J^./V!_&[>"OVG/"8G
MDV0:PDVD3#. 6D3*?^1$2NBA0A/!U(\OO)7O^/\ 7J8U:THXF#OH]+?U_6A]
MW?MQZC\4/!7@M?&GP\\92Z1!IB[;_14M8)#<1\LTZ,ZEBR+R4'&T,>QKP_\
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MU.WWG<E]]GCA\R+C!5POS=.8P?XC7I&H?VU]I/V$6!M\#_CX+[\]^G&*K_\
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MI7_?4O\ A1_Q4O\ =TK_ +ZE_P *0%_1+N]OM.BFU&P&FW;9WVPF$P3GCYP
M#QS7#^(?#VNV'B76KW2K!-5LM=MX8KB-=0-E/:R1!E#K( 3L*D9VX92I(SGC
MJ?\ BI?[ND_]]2_X4?\ %2_W=*_[ZE_PH&<5-\.]7\0?#_P9HGB.2/5+VQO(
M9M4E:Y<^:J+("RR<,QRRX.0?6G6'PWO[/X9W/A.%K6"6QNUFTR\()6<1S+/$
MTX SO++M<\EL%^IQ79_\5+_=TK_OJ7_"E_XJ7^[I7_?4O^%.XK&#HVG>(/$/
MC*QUW7--M]$ATRTFM[>UANQ<R322F,N[,% " 1@ =222<8 K%C\(^)%NUT+[
M%:?V,NOG6O[6^U?,8_M!N/*\G;G?N^7.=N.<YXKM_P#BI?[NE?\ ?4O^%'_%
M2_W=*_[ZE_PI#.<U#X7V7B3QUK.JZW;FZT^XM;2"&!;J14<QF4N)8E8*XRZX
M# ]Z[]$"# Z=*P_^*E_NZ3_WU+_A6Q9B?[-']J\L7&/G\G.S/MGG% ',7NG>
M)X_$LE_;7R3:89(47320HV;3YC;BI.=W0=QWK%&@?$&8!9]<M45H)XW-N,$.
M?,:)U)3@@M&I!XPF>N<^CT4 <;J>E^+&UY7L-02/3%MXD(E=2S,&^?C8<,1_
M%G';'>LN+P_X[73R\FMHURRQ1BW1E&-J\R>84/);!*[<$ @8R*]&HH X6'1/
M&$KO]IU941;DR1^4X!=-['#?)TP5  ].3FJ,NA_$(L7AUFV1PZ%A(0R2C!#
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<B@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>ibio-20230331.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.5.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/15/2023 1:23:55 PM-->
<!--Modified on: 5/15/2023 1:23:55 PM-->
<xsd:schema xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" targetNamespace="http://www.ibioinc.com/20230331" elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:ibio="http://www.ibioinc.com/20230331" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:srt-roles="http://fasb.org/srt-roles/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:cef="http://xbrl.sec.gov/cef/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets" id="StatementCondensedConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>00200 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2" id="StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2">
        <link:definition>00201 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss CALC2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" id="StatementCondensedConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails">
        <link:definition>40402 - Disclosure - Summary of Significant Accounting Policies (Cash, Cash Equivalents and Restricted Cash) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesComponentsOfInvestmentsInDebtSecurities2Details" id="DisclosureInvestmentsInDebtAndEquitySecuritiesComponentsOfInvestmentsInDebtSecurities2Details">
        <link:definition>40702 - Disclosure - Investments in Debt and Equity Securities (Components of Investments in Debt Securities2) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesDebtSecuritiesContractualMaturityDetails" id="DisclosureInvestmentsInDebtSecuritiesDebtSecuritiesContractualMaturityDetails">
        <link:definition>40803 - Disclosure - Investments in Debt Securities (Debt Securities, Contractual Maturity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails" id="DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails">
        <link:definition>41102 - Disclosure - Fixed Assets (Carrying Value and Accumulated Depreciation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails" id="DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails">
        <link:definition>41202 - Disclosure - Intangible Assets (Carrying Value and Accumulated Amortization) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderFinanceLeaseObligationDetailsCalc2" id="DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderFinanceLeaseObligationDetailsCalc2">
        <link:definition>41304 - Disclosure - Finance Lease Obligation (Future Minimum Payments Under the Finance Lease Obligation) (Details) (Calc2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails" id="DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails">
        <link:definition>41403 - Disclosure - Finance Lease Obligation (Future Minimum Payments Under the Capitalized Lease Obligations) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc2" id="DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc2">
        <link:definition>41403 - Disclosure - Operating Lease Obligation (Future Minimum Payments under the Operating Lease Obligation) (Details) (Calc 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3" id="DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3">
        <link:definition>41403 - Disclosure - Operating Lease Obligation (Future Minimum Payments under the Operating Lease Obligation) (Details) (Calc 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails" id="DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails">
        <link:definition>41503 - Disclosure - Operating Lease Obligation (Future Minimum Payments under the Operating Lease Obligation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" id="StatementCondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity" id="StatementCondensedConsolidatedStatementsOfEquity">
        <link:definition>00300 - Statement - Condensed Consolidated Statements of Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureNatureOfBusiness" id="DisclosureNatureOfBusiness">
        <link:definition>10101 - Disclosure - Nature of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureBasisOfPresentation" id="DisclosureBasisOfPresentation">
        <link:definition>10201 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10401 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurement" id="DisclosureFinancialInstrumentsAndFairValueMeasurement">
        <link:definition>10501 - Disclosure - Financial Instruments and Fair Value Measurement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureSignificantTransactions" id="DisclosureSignificantTransactions">
        <link:definition>10601 - Disclosure - Significant Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureConvertiblePromissoryNoteReceivable" id="DisclosureConvertiblePromissoryNoteReceivable">
        <link:definition>10701 - Disclosure - Convertible Promissory Note Receivable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecurities" id="DisclosureInvestmentsInDebtSecurities">
        <link:definition>10801 - Disclosure - Investments in Debt Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssets" id="DisclosureFinanceLeaseRouAssets">
        <link:definition>10901 - Disclosure - Finance Lease ROU Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssets" id="DisclosureOperatingLeaseRouAssets">
        <link:definition>11001 - Disclosure - Operating Lease ROU Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFixedAssets" id="DisclosureFixedAssets">
        <link:definition>11101 - Disclosure - Fixed Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureIntangibleAssets" id="DisclosureIntangibleAssets">
        <link:definition>11201 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureDebt" id="DisclosureDebt">
        <link:definition>11301 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligation" id="DisclosureFinanceLeaseObligation">
        <link:definition>11401 - Disclosure - Finance Lease Obligation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligation" id="DisclosureOperatingLeaseObligation">
        <link:definition>11501 - Disclosure - Operating Lease Obligation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>11601 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShare" id="DisclosureEarningsLossPerCommonShare">
        <link:definition>11701 - Disclosure - Earnings (Loss) Per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensation" id="DisclosureShareBasedCompensation">
        <link:definition>11801 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFraunhoferSettlement" id="DisclosureFraunhoferSettlement">
        <link:definition>11901 - Disclosure - Fraunhofer Settlement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>12001 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>12101 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureEmployee401KPlan" id="DisclosureEmployee401KPlan">
        <link:definition>12201 - Disclosure - Employee 401(K) Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>12301 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20402 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>30403 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementTables" id="DisclosureFinancialInstrumentsAndFairValueMeasurementTables">
        <link:definition>30503 - Disclosure - Financial Instruments and Fair Value Measurement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables" id="DisclosureSignificantTransactionsTables">
        <link:definition>30603 - Disclosure - Significant Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesTables" id="DisclosureInvestmentsInDebtSecuritiesTables">
        <link:definition>30803 - Disclosure - Investments in Debt Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsTables" id="DisclosureFinanceLeaseRouAssetsTables">
        <link:definition>30903 - Disclosure - Finance Lease ROU Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFixedAssetsTables" id="DisclosureFixedAssetsTables">
        <link:definition>31103 - Disclosure - Fixed Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureIntangibleAssetsTables" id="DisclosureIntangibleAssetsTables">
        <link:definition>31203 - Disclosure - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationTables" id="DisclosureFinanceLeaseObligationTables">
        <link:definition>31403 - Disclosure - Finance Lease Obligation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsTables" id="DisclosureOperatingLeaseObligationsTables">
        <link:definition>31503 - Disclosure - Operating Lease Obligations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareTables" id="DisclosureEarningsLossPerCommonShareTables">
        <link:definition>31703 - Disclosure - Earnings (Loss) Per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationTables" id="DisclosureShareBasedCompensationTables">
        <link:definition>31803 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails" id="DisclosureBasisOfPresentationNarrativeDetails">
        <link:definition>40201 - Disclosure - Basis of Presentation (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails" id="DisclosureDiscontinuedOperationsNarrativeDetails">
        <link:definition>40301 - Disclosure - Discontinued Operations (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails" id="DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails">
        <link:definition>40302 - Disclosure - Discontinued Operations (Reconciliation and Classifications) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>40401 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails" id="DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails">
        <link:definition>40501 - Disclosure - Financial Instruments and Fair Value Measurement (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails" id="DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails">
        <link:definition>40502 - Disclosure - Financial Instruments and Fair Value Measurement (Non-recurring Basis) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails" id="DisclosureSignificantTransactionsNarrativeDetails">
        <link:definition>40601 - Disclosure - Significant Transactions (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails" id="DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails">
        <link:definition>40602 - Disclosure - Significant Transactions (Summary of Asset Acquisition) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureConvertiblePromissoryNoteReceivableNarrativeDetails" id="DisclosureConvertiblePromissoryNoteReceivableNarrativeDetails">
        <link:definition>40701 - Disclosure - Convertible Promissory Note Receivable (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesNarrativeDetails" id="DisclosureInvestmentsInDebtSecuritiesNarrativeDetails">
        <link:definition>40801 - Disclosure - Investments in Debt Securities (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesComponentsOfInvestmentsInDebtSecuritiesDetails" id="DisclosureInvestmentsInDebtSecuritiesComponentsOfInvestmentsInDebtSecuritiesDetails">
        <link:definition>40802 - Disclosure - Investments in Debt Securities (Components of Investments in Debt Securities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsNarrativeDetails" id="DisclosureFinanceLeaseRouAssetsNarrativeDetails">
        <link:definition>40901 - Disclosure - Finance Lease ROU Assets (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails" id="DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails">
        <link:definition>40902 - Disclosure - Finance Lease ROU Assets (Summary of Finance Lease ROU) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssetsNarrativeDetails" id="DisclosureOperatingLeaseRouAssetsNarrativeDetails">
        <link:definition>41001 - Disclosure - Operating Lease ROU Assets (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFixedAssetsNarrativeDetails" id="DisclosureFixedAssetsNarrativeDetails">
        <link:definition>41101 - Disclosure - Fixed Assets (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails" id="DisclosureIntangibleAssetsNarrativeDetails">
        <link:definition>41201 - Disclosure - Intangible Assets (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails" id="DisclosureDebtCreditAgreementDetails">
        <link:definition>41301 - Disclosure - Debt (The Credit Agreement) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails" id="DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails">
        <link:definition>41303 - Disclosure - Debt (Equipment Financing) (Future Minimum Payments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureDebtNotePayablePppLoanDetails" id="DisclosureDebtNotePayablePppLoanDetails">
        <link:definition>41304 - Disclosure - Debt (Note Payable - PPP Loan) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationNarrativeDetails" id="DisclosureFinanceLeaseObligationNarrativeDetails">
        <link:definition>41401 - Disclosure - Finance Lease Obligation (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails" id="DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails">
        <link:definition>41402 - Disclosure - Finance Lease Obligation (Finance Lease Cost and Other Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails" id="DisclosureOperatingLeaseObligationNarrativeDetails">
        <link:definition>41501 - Disclosure - Operating Lease Obligation (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails" id="DisclosureOperatingLeaseObligationLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails">
        <link:definition>41502 - Disclosure - Operating Lease Obligation (Lease Expense and Supplemental Balance Sheet Information Related to the Operating Lease Obligation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails" id="DisclosureStockholdersEquityNarrativeDetails">
        <link:definition>41601 - Disclosure - Stockholders' Equity (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails" id="DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails">
        <link:definition>41602 - Disclosure - Stockholders' Equity (Cantor Fitzgerald Underwriting and RubrYc Transaction) (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails" id="DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails">
        <link:definition>41603 - Disclosure - Stockholders' Equity (Wainwright Underwriting and Vesting of RSUs) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails" id="DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails">
        <link:definition>41701 - Disclosure - Earnings (Loss) Per Common Share (Components of the Earnings (Loss) per Common Share ) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" id="DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails">
        <link:definition>41702 - Disclosure - Earnings (Loss) Per Common Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails" id="DisclosureShareBasedCompensationNarrativeDetails">
        <link:definition>41801 - Disclosure - Share-Based Compensation (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" id="DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails">
        <link:definition>41802 - Disclosure - Share-Based Compensation (Share Based Compensation Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails" id="DisclosureShareBasedCompensationStockOptionActivityDetails">
        <link:definition>41803 - Disclosure - Share-Based Compensation (Stock Option Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationFairValueOfOptionsGrantedDetails" id="DisclosureShareBasedCompensationFairValueOfOptionsGrantedDetails">
        <link:definition>41805 - Disclosure - Share-Based Compensation (Fair Value of Options Granted) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationRsusDetails" id="DisclosureShareBasedCompensationRsusDetails">
        <link:definition>41806 - Disclosure - Share-Based Compensation (RSUs) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails" id="DisclosureFraunhoferSettlementNarrativeDetails">
        <link:definition>41901 - Disclosure - Fraunhofer Settlement (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureIncomeTaxesNarrativeDetails" id="DisclosureIncomeTaxesNarrativeDetails">
        <link:definition>42001 - Disclosure - Income Taxes (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" id="DisclosureCommitmentsAndContingenciesNarrativeDetails">
        <link:definition>42101 - Disclosure - Commitments and Contingencies (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureEmployee401KPlanNarrativeDetails" id="DisclosureEmployee401KPlanNarrativeDetails">
        <link:definition>42201 - Disclosure - Employee 401(K) Plan (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails" id="DisclosureSubsequentEventsNarrativeDetails">
        <link:definition>42301 - Disclosure - Subsequent Events (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureDiscontinuedOperations" id="DisclosureDiscontinuedOperations">
        <link:definition>10301 - Disclosure - Discontinued Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsTables" id="DisclosureDiscontinuedOperationsTables">
        <link:definition>30303 - Disclosure - Discontinued Operations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureDebtTables" id="DisclosureDebtTables">
        <link:definition>31303 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingDetails" id="DisclosureDebtEquipmentFinancingDetails">
        <link:definition>41302 - Disclosure - Debt (Equipment Financing) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="ibio-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ibio-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ibio-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ibio-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
  <xsd:element id="ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid" name="CapitalExpenditureIncurredForIntangibleAssetsPaid" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element name="ContractAssetsPolicyTextBlock" id="ibio_ContractAssetsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PurchaseAgreementAxis" id="ibio_PurchaseAgreementAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PurchaseAgreementDomain" id="ibio_PurchaseAgreementDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_EasternAffiliateMember" name="EasternAffiliateMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="SummaryOfSignificantAccountingPoliciesLineItems" id="ibio_SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockholdersEquityTable" id="ibio_StockholdersEquityTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PreferredTrackingStockMember" id="ibio_PreferredTrackingStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockholdersEquityLineItems" id="ibio_StockholdersEquityLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_AggregateCommonStockPurchased" name="AggregateCommonStockPurchased" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element name="EarningsLossPerCommonShareTable" id="ibio_EarningsLossPerCommonShareTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EarningsLossPerCommonShareLineItems" id="ibio_EarningsLossPerCommonShareLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_TwoThousandEighteenOmnibusEquityIncentivePlanMember" name="TwoThousandEighteenOmnibusEquityIncentivePlanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_PrincipalMember" name="PrincipalMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_InterestMember" name="InterestMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_SecondEasternAffiliateMember" name="SecondEasternAffiliateMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_BasisOfPresentationAbstract" name="BasisOfPresentationAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_ContractLiabilitiesPolicyTextBlock" name="ContractLiabilitiesPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_IbioCdmoMember" name="IbioCdmoMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_ProceedsFromIssuanceOfPreferredAndCommonStock" name="ProceedsFromIssuanceOfPreferredAndCommonStock" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="ibio_RightOfUseAssetsPolicyPolicyTextBlock" name="RightOfUseAssetsPolicyPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" name="FinanceLeaseRightOfUseAssetDisclosureAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock" name="FinanceLeaseRightOfUseAssetDisclosureTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock" name="SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_FinanceLeaseRightOfUseAssetDisclosureTable" name="FinanceLeaseRightOfUseAssetDisclosureTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_FacilityMember" name="FacilityMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems" name="FinanceLeaseRightOfUseAssetDisclosureLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_FinanceLeaseRightOfUseAssetGross" name="FinanceLeaseRightOfUseAssetGross" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock" name="ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_SeriesWarrantsMember" name="SeriesWarrantsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_SeriesBWarrantsMember" name="SeriesBWarrantsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_FinanceLeaseObligationOtherInformationAbstract" name="FinanceLeaseObligationOtherInformationAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract" name="CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_FinancingCashFlowsFromFinanceLeaseObligation" name="FinancingCashFlowsFromFinanceLeaseObligation" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="ibio_StockIssuedDuringPeriodValueCapitalRaise" name="StockIssuedDuringPeriodValueCapitalRaise" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="ibio_StockIssuedDuringPeriodSharesCapitalRaise" name="StockIssuedDuringPeriodSharesCapitalRaise" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_ScenarioTwoMember" name="ScenarioTwoMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_NumberOfMajorCustomers" name="NumberOfMajorCustomers" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_IbioInc.2020OmnibusEquityIncentivePlanMember" name="IbioInc.2020OmnibusEquityIncentivePlanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_ScenarioOneMember" name="ScenarioOneMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_PppLoanCaresActMember" name="PppLoanCaresActMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_CollaborativeArrangementMilestonePayments" name="CollaborativeArrangementMilestonePayments" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest" name="ConvertiblePromissoryNoteReceivableAndAccruedInterest" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable" name="AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="ibio_LoansReceivableAmountInvested" name="LoansReceivableAmountInvested" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LoansReceivableFixedRatesOfInterest" name="LoansReceivableFixedRatesOfInterest" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_SalesAgreementMember" name="SalesAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_ConsultantsMember" name="ConsultantsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_CantorFitzgeraldMember" name="CantorFitzgeraldMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_CashAndCashEquivalentsPlusDebtSecurities" name="CashAndCashEquivalentsPlusDebtSecurities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="ibio_OmnibusIncentivePlanMember" name="OmnibusIncentivePlanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_VariousEmployeesMember" name="VariousEmployeesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_SubscriptionReceivableCurrent" name="SubscriptionReceivableCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="ibio_ScheduleOfFinanceLeaseRightOfUseAssetsAndObligationAndWeightedAverageInformationTableTextBlock" name="ScheduleOfFinanceLeaseRightOfUseAssetsAndObligationAndWeightedAverageInformationTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_SettlementAssetsNonCurrent" name="SettlementAssetsNonCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan" name="ForgivenessOfNotePayableAndAccruedInterestSbaLoan" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="ibio_ExchangeAgreementMember" name="ExchangeAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_CollaborationOptionAndLicenseAgreementMember" name="CollaborationOptionAndLicenseAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_RubrycTheraputicsInc.Member" name="RubrycTheraputicsInc.Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm" name="CollaborationAndLicenseAgreementRoyaltyPaymentTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_ImmuneOncologyAntibodiesRtx003Member" name="ImmuneOncologyAntibodiesRtx003Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_StockPurchaseAgreementMember" name="StockPurchaseAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_Series2PreferredStockMember" name="Series2PreferredStockMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_StockPurchaseAgreementNumberOfSharesPurchased" name="StockPurchaseAgreementNumberOfSharesPurchased" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_StockPurchaseAgreementValueOfSharesPurchased" name="StockPurchaseAgreementValueOfSharesPurchased" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="ibio_CollaborationAndLicenseAgreementAgreementTerm" name="CollaborationAndLicenseAgreementAgreementTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_GainLossRelatedToLitigationSettlementTextBlock" name="GainLossRelatedToLitigationSettlementTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember" name="AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember" name="IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_CashPaymentsReceivablesRelatedToLitigationSettlement" name="CashPaymentsReceivablesRelatedToLitigationSettlement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="ibio_ScenarioPlanExpectedLegalFeesMember" name="ScenarioPlanExpectedLegalFeesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_ScenarioPlanExpectedPaymentOneMember" name="ScenarioPlanExpectedPaymentOneMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_ScenarioPlanExpectedPaymentTwoMember" name="ScenarioPlanExpectedPaymentTwoMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_PercentageOfLegalFeesExpectedToBeReceived" name="PercentageOfLegalFeesExpectedToBeReceived" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent" name="LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock" name="NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_SettlementOfRevenueContract" name="SettlementOfRevenueContract" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="ibio_LeaseIncentiveForConstructionInProgress" name="LeaseIncentiveForConstructionInProgress" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="ibio_NonCashSettlementOfRevenueContract" name="NonCashSettlementOfRevenueContract" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="ibio_SignificantTransactionsAbstract" name="SignificantTransactionsAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_SignificantTransactionsTextBlock" name="SignificantTransactionsTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_NoBiosimilarProductHasBeenApprovedMember" name="NoBiosimilarProductHasBeenApprovedMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock" name="OperatingLeaseRightOfUseAssetDisclosureTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock" name="ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_LessorFinanceLeaseMonthlyRent" name="LessorFinanceLeaseMonthlyRent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseMonthlyRent" name="LesseeOperatingLeaseMonthlyRent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="ibio_BaseRentAbatementInFirstYearPeriod" name="BaseRentAbatementInFirstYearPeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_OperatingLeaseObligationOtherInformationAbstract" name="OperatingLeaseObligationOtherInformationAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract" name="CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_OperatingCashFlowsFromOperatingLeaseObligation" name="OperatingCashFlowsFromOperatingLeaseObligation" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="ibio_TotalOperatingLeaseCosts" name="TotalOperatingLeaseCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" name="CollegeStationInvestorsLlcAndBryanCapitalMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_IbioCmoPreferredTrackingStockMember" name="IbioCmoPreferredTrackingStockMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_SecuredTermLoanMember" name="SecuredTermLoanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest" name="PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment" name="PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="ibio_BaseRentPercentageOfFairMarketValueOfProperty" name="BaseRentPercentageOfFairMarketValueOfProperty" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_FairMarketValueOfProperty" name="FairMarketValueOfProperty" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired" name="EquityAgreementConsiderationTransferredEquityInterestsAcquired" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="ibio_EquityAgreementWarrantsIssuedOrIssuable" name="EquityAgreementWarrantsIssuedOrIssuable" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable" name="EquityAgreementPercentageOfEquityInterestIssuedOrIssuable" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_CreditAgreementThresholdLimitUnrestrictedCash" name="CreditAgreementThresholdLimitUnrestrictedCash" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent" name="WarrantsIssuedForFinalPaymentOfSubleaseRent" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue" name="WarrantsIssuedForFinalPaymentOfSubleaseRentValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_StockPurchaseAgreementTotalInvestment" name="StockPurchaseAgreementTotalInvestment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="ibio_OperatingLeaseCostsAbstract" name="OperatingLeaseCostsAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract" name="LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne" name="LesseeOperatingLeaseImputedInterestToBePaidYearOne" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo" name="LesseeOperatingLeaseImputedInterestToBePaidYearTwo" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree" name="LesseeOperatingLeaseImputedInterestToBePaidYearThree" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour" name="LesseeOperatingLeaseImputedInterestToBePaidYearFour" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive" name="LesseeOperatingLeaseImputedInterestToBePaidYearFive" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive" name="LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" name="LesseeOperatingLeaseImputedInterestToBePaidTotal" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract" name="LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne" name="LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo" name="LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree" name="LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour" name="LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive" name="LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive" name="LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" name="LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate" name="AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="ibio_PaymentsToAttainTermNote" name="PaymentsToAttainTermNote" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="ibio_TerminationOfFinanceLeaseRightOfUseAssetIncludingIssuanceOfWarrant" name="TerminationOfFinanceLeaseRightOfUseAssetIncludingIssuanceOfWarrant" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="ibio_NoncashOrPartNoncashAcquisitionNonControllingInterestAssumed" name="NoncashOrPartNoncashAcquisitionNonControllingInterestAssumed" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="ibio_WarrantsIssuedForFinanceLeasePayment" name="WarrantsIssuedForFinanceLeasePayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="ibio_LetterOfCreditTermLoanMember" name="LetterOfCreditTermLoanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_LetterOfCreditSanDiegoLeaseMember" name="LetterOfCreditSanDiegoLeaseMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities" name="NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="ibio_DeferredFinancingCostsAmortizationExpense" name="DeferredFinancingCostsAmortizationExpense" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="ibio_IncreaseDecreaseInSettlementAssets" name="IncreaseDecreaseInSettlementAssets" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element name="PercentageOfCollateralRequired" id="ibio_PercentageOfCollateralRequired" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="CompanyPurchasingCardMember" id="ibio_CompanyPurchasingCardMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ImpairmentOfPrepaidExpensesCurrent" id="ibio_ImpairmentOfPrepaidExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ImpairmentOfPrepaidExpensesNonCurrent" id="ibio_ImpairmentOfPrepaidExpensesNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="Series2022ConvertiblePreferredStockMember" id="ibio_Series2022ConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AssetAcquisitionIntangibleAssetsMember" id="ibio_AssetAcquisitionIntangibleAssetsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AssetAcquisitionPrepaidExpensesMember" id="ibio_AssetAcquisitionPrepaidExpensesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WoodforestMember" id="ibio_WoodforestMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AmendedCreditAgreementMember" id="ibio_AmendedCreditAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DateOfAmendmentMember" id="ibio_DateOfAmendmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember" id="ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OccurrenceOfSpecificMilestoneMember" id="ibio_OccurrenceOfSpecificMilestoneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DebtCovenantLiquidityAmount" id="ibio_DebtCovenantLiquidityAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="CurrentLiabilitiesRelatedToAssetsHeldForSale" id="ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="NoncurrentLiabilitiesRelatedToAssetsHeldForSale" id="ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="UnconsolidatedGainLossAttributableToStockholders" id="ibio_UnconsolidatedGainLossAttributableToStockholders" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CommonStockIssuedInRubrycTransactionInShares" id="ibio_CommonStockIssuedInRubrycTransactionInShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CommonStockIssuedInRubrycTransactionValue" id="ibio_CommonStockIssuedInRubrycTransactionValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="IncreaseDecreaseInInventoryReserve" id="ibio_IncreaseDecreaseInInventoryReserve" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="IncreaseDecreaseInFinanceLeaseObligationsForNewLeases" id="ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="EmployeeReductionExpenses" id="ibio_EmployeeReductionExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DiscontinuedOperationsResearchAndDevelopmentExpenses" id="ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DisposalGroupInterestExpenseRelatedParty" id="ibio_DisposalGroupInterestExpenseRelatedParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DisposalGroupGainOnDebtForgiveness" id="ibio_DisposalGroupGainOnDebtForgiveness" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DiscontinuedOperationsMiscellaneousExpensesIncome" id="ibio_DiscontinuedOperationsMiscellaneousExpensesIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DisposalGroupOperatingLeaseRightOfUseAssets" id="ibio_DisposalGroupOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent" id="ibio_DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DisposalGroupCurrentLiabilitiesOperatingLeaseObligations" id="ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DisposalGroupNoncurrentOperatingLeaseObligations" id="ibio_DisposalGroupNoncurrentOperatingLeaseObligations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets" id="ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod" id="ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="UnpaidFixedAssetsAttributableToDiscontinuedOperations" id="ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AccruedLiabilitiesNoncurrent" id="ibio_AccruedLiabilitiesNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="IncreaseDecreaseInAccruedLiabilitiesNoncurrent" id="ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="PaymentsForFractionalSharesAfterReverseStockSplit" id="ibio_PaymentsForFractionalSharesAfterReverseStockSplit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ProceedsFromEquipmentFinancingLoan" id="ibio_ProceedsFromEquipmentFinancingLoan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="PaymentOfEquipmentFinancingLoan" id="ibio_PaymentOfEquipmentFinancingLoan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CostToRaiseCapitalPaidDirectlyFromGrossProceeds" id="ibio_CostToRaiseCapitalPaidDirectlyFromGrossProceeds" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="EquipmentFinancingPayableCurrent" id="ibio_EquipmentFinancingPayableCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="EquipmentFinancingPayableNoncurrent" id="ibio_EquipmentFinancingPayableNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="FractionalShareIssuedAfterReverseStockSplitValue" id="ibio_FractionalShareIssuedAfterReverseStockSplitValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="FractionalShareIssuedAfterReverseStockSplitShares" id="ibio_FractionalShareIssuedAfterReverseStockSplitShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance" id="ibio_DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown" id="ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DisposalGroupCurrentLiabilitiesFinanceLeaseObligations" id="ibio_DisposalGroupCurrentLiabilitiesFinanceLeaseObligations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DisposalGroupNoncurrentLiabilitiesFinanceLeaseObligations" id="ibio_DisposalGroupNoncurrentLiabilitiesFinanceLeaseObligations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure" id="ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AssetAcquisitionTransactionCosts" id="ibio_AssetAcquisitionTransactionCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AssetAcquisitionFixedAssetsMember" id="ibio_AssetAcquisitionFixedAssetsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AssetPurchaseAgreementMember" id="ibio_AssetPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SeparationAgreementAndGeneralReleaseMember" id="ibio_SeparationAgreementAndGeneralReleaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary" id="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus" id="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct" id="ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod" id="ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct" id="ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="FixedAssetsHeldForSale" id="ibio_FixedAssetsHeldForSale" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="EquipmentFinancingAmountBorrowed" id="ibio_EquipmentFinancingAmountBorrowed" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LesseeEquipmentLeaseTermOfContract" id="ibio_LesseeEquipmentLeaseTermOfContract" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="EquipmentLeasingMonthlyInstallmentPayable" id="ibio_EquipmentLeasingMonthlyInstallmentPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="EquipmentFinancingLeaseImputedInterestRate" id="ibio_EquipmentFinancingLeaseImputedInterestRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ContractualObligationCurrent" id="ibio_ContractualObligationCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ContractualObligationNoncurrent" id="ibio_ContractualObligationNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LeaseRentExpensePerMonth" id="ibio_LeaseRentExpensePerMonth" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="H.c.WainwrightCo.LlcMember" id="ibio_H.c.WainwrightCo.LlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PreFundedWarrantsMember" id="ibio_PreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering" id="ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="NumberOfDaysOptionToPurchaseAdditionalShares" id="ibio_NumberOfDaysOptionToPurchaseAdditionalShares" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="NumberOfAdditionalSharesIssued" id="ibio_NumberOfAdditionalSharesIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CommonWarrantsToPurchaseAdditionalShares" id="ibio_CommonWarrantsToPurchaseAdditionalShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PercentageOfAggregateNumberOfSharesOfCommonStock" id="ibio_PercentageOfAggregateNumberOfSharesOfCommonStock" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="RepresentativeWarrantsMember" id="ibio_RepresentativeWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="EquipmentFinancingBalance" id="ibio_EquipmentFinancingBalance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="Dr.MartinBrennerMember" id="ibio_Dr.MartinBrennerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NumberOfEquipmentLeases" id="ibio_NumberOfEquipmentLeases" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="EstimatedAdditionalCostOnDevelopment" id="ibio_EstimatedAdditionalCostOnDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CroAgreementMember" id="ibio_CroAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NetLossAvailableToStockholdersFromContinuingOperations" id="ibio_NetLossAvailableToStockholdersFromContinuingOperations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DisposalGroupNonCurrentAssetsFinanceLeaseRightOfUseAssets" id="ibio_DisposalGroupNonCurrentAssetsFinanceLeaseRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="TangibleAssetImpairmentChargesDiscontinuedOperations" id="ibio_TangibleAssetImpairmentChargesDiscontinuedOperations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ImpairmentOfIntangibleAssetsGrossOfReversals" id="ibio_ImpairmentOfIntangibleAssetsGrossOfReversals" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ReversalOfIntangibleAssetImpairment" id="ibio_ReversalOfIntangibleAssetImpairment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities" id="ibio_ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AvaliableForSaleDebtSecuritiesRealizedGainsLossesTableTextBlock" id="ibio_AvaliableForSaleDebtSecuritiesRealizedGainsLossesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>ibio-20230331_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.5.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/15/2023 1:23:55 PM-->
<!--Modified on: 5/15/2023 1:23:55 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2" roleURI="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureInvestmentsInDebtAndEquitySecuritiesComponentsOfInvestmentsInDebtSecurities2Details" roleURI="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesComponentsOfInvestmentsInDebtSecurities2Details" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureInvestmentsInDebtSecuritiesDebtSecuritiesContractualMaturityDetails" roleURI="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesDebtSecuritiesContractualMaturityDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails" roleURI="http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails" roleURI="http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderFinanceLeaseObligationDetailsCalc2" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderFinanceLeaseObligationDetailsCalc2" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc2" roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc2" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3" roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails" roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails" />
  <calculationLink xlink:role="http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Condensed Consolidated Balance Sheets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638197538275086293" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638197538275086293" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest" xlink:label="ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest_638197538275086293" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest_638197538275086293" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_638197538275086293" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_638197538275086293" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_638197538275086293" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_638197538275086293" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit_638197538275086293" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_SecurityDeposit_638197538275086293" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638197538275086293" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638197538275086293" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="us-gaap_PrepaidExpenseNoncurrent_638197538275086293" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_PrepaidExpenseNoncurrent_638197538275086293" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_638197538275086293" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_638197538275086293" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638197538275096367" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent_638197538275096367" order="9" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638197538275096367" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_638197538275096367" order="10" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638197538275096367" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638197538275096367" xlink:to="us-gaap_AccountsReceivableNetCurrent_638197538275096367" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638197538275096367" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638197538275096367" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638197538275096367" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638197538275096367" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638197538275096367" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638197538275096367" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesCurrent" xlink:label="us-gaap_DebtSecuritiesCurrent_638197538275096367" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638197538275096367" xlink:to="us-gaap_DebtSecuritiesCurrent_638197538275096367" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettlementAssetsCurrent" xlink:label="us-gaap_SettlementAssetsCurrent_638197538275096367" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638197538275096367" xlink:to="us-gaap_SettlementAssetsCurrent_638197538275096367" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesAndLoansReceivableNetCurrent" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent_638197538275106357" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638197538275096367" xlink:to="us-gaap_NotesAndLoansReceivableNetCurrent_638197538275106357" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:label="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_638197538275106357" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638197538275096367" xlink:to="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_638197538275106357" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SubscriptionReceivableCurrent" xlink:label="ibio_SubscriptionReceivableCurrent_638197538275106357" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638197538275096367" xlink:to="ibio_SubscriptionReceivableCurrent_638197538275106357" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638197538275106357" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638197538275106357" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_638197538275106357" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638197538275106357" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_638197538275106357" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_AccruedLiabilitiesNoncurrent" xlink:label="ibio_AccruedLiabilitiesNoncurrent_638197538275116366" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638197538275106357" xlink:to="ibio_AccruedLiabilitiesNoncurrent_638197538275116366" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638197538275116366" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638197538275106357" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638197538275116366" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale" xlink:label="ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale_638197538275116366" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638197538275106357" xlink:to="ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale_638197538275116366" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_EquipmentFinancingPayableNoncurrent" xlink:label="ibio_EquipmentFinancingPayableNoncurrent_638197538275116366" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638197538275106357" xlink:to="ibio_EquipmentFinancingPayableNoncurrent_638197538275116366" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638197538275116366" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638197538275106357" xlink:to="us-gaap_LiabilitiesCurrent_638197538275116366" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638197538275116366" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638197538275116366" xlink:to="us-gaap_AccountsPayableCurrent_638197538275116366" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638197538275126362" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638197538275116366" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638197538275126362" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638197538275126362" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638197538275116366" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638197538275126362" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent_638197538275126362" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638197538275116366" xlink:to="us-gaap_NotesPayableCurrent_638197538275126362" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_638197538275126362" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638197538275116366" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_638197538275126362" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_EquipmentFinancingPayableCurrent" xlink:label="ibio_EquipmentFinancingPayableCurrent_638197538275126362" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638197538275116366" xlink:to="ibio_EquipmentFinancingPayableCurrent_638197538275126362" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent_638197538275126362" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638197538275116366" xlink:to="us-gaap_DeferredRevenueCurrent_638197538275126362" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale" xlink:label="ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale_638197538275136375" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638197538275116366" xlink:to="ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale_638197538275136375" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638197538275136375" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638197538275136375" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638197538275136375" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638197538275136375" xlink:to="us-gaap_PreferredStockValue_638197538275136375" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638197538275145969" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638197538275136375" xlink:to="us-gaap_CommonStockValue_638197538275145969" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_638197538275145969" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638197538275136375" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_638197538275145969" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638197538275145969" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638197538275136375" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638197538275145969" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638197538275145969" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638197538275136375" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638197538275145969" order="5" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss">
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_UnconsolidatedGainLossAttributableToStockholders" xlink:label="ibio_UnconsolidatedGainLossAttributableToStockholders" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_638197538275156454" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_UnconsolidatedGainLossAttributableToStockholders" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_638197538275156454" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_NetLossAvailableToStockholdersFromContinuingOperations" xlink:label="ibio_NetLossAvailableToStockholdersFromContinuingOperations_638197538275156454" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_UnconsolidatedGainLossAttributableToStockholders" xlink:to="ibio_NetLossAvailableToStockholdersFromContinuingOperations_638197538275156454" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPreferredStockStock" xlink:label="us-gaap_DividendsPreferredStockStock_638197538275156454" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_NetLossAvailableToStockholdersFromContinuingOperations_638197538275156454" xlink:to="us-gaap_DividendsPreferredStockStock_638197538275156454" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="us-gaap_IncomeLossFromContinuingOperations_638197538275156454" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_NetLossAvailableToStockholdersFromContinuingOperations_638197538275156454" xlink:to="us-gaap_IncomeLossFromContinuingOperations_638197538275156454" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:label="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_638197538275156454" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperations_638197538275156454" xlink:to="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_638197538275156454" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_638197538275156454" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperations_638197538275156454" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_638197538275156454" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638197538275166279" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_638197538275156454" xlink:to="us-gaap_NonoperatingIncomeExpense_638197538275166279" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_638197538275166279" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638197538275166279" xlink:to="us-gaap_InterestExpense_638197538275166279" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638197538275166279" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638197538275166279" xlink:to="us-gaap_InvestmentIncomeInterest_638197538275166279" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyIncomeNonoperating" xlink:label="us-gaap_RoyaltyIncomeNonoperating_638197538275166279" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638197538275166279" xlink:to="us-gaap_RoyaltyIncomeNonoperating_638197538275166279" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleGainLoss_638197538275166279" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638197538275166279" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleGainLoss_638197538275166279" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638197538275166279" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_638197538275156454" xlink:to="us-gaap_OperatingIncomeLoss_638197538275166279" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638197538275166279" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638197538275166279" xlink:to="us-gaap_OperatingExpenses_638197538275166279" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638197538275166279" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638197538275166279" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638197538275166279" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638197538275176454" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638197538275166279" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638197538275176454" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638197538275176454" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638197538275166279" xlink:to="us-gaap_Revenues_638197538275176454" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2" xlink:type="extended" xlink:title="00201 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss CALC2">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_638197538275176454" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_638197538275176454" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_638197538275176454" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_638197538275176454" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638197538275176454" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ProfitLoss_638197538275176454" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Condensed Consolidated Statements of Cash Flows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638197538275186326" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638197538275186326" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638197538275186326" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638197538275186326" xlink:to="us-gaap_ProfitLoss_638197538275186326" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_IncreaseDecreaseInInventoryReserve" xlink:label="ibio_IncreaseDecreaseInInventoryReserve_638197538275186326" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638197538275186326" xlink:to="ibio_IncreaseDecreaseInInventoryReserve_638197538275186326" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable" xlink:label="ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable_638197538275186326" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638197538275186326" xlink:to="ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable_638197538275186326" order="3" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_638197538275186326" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638197538275186326" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_638197538275186326" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_DeferredFinancingCostsAmortizationExpense" xlink:label="ibio_DeferredFinancingCostsAmortizationExpense_638197538275186326" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638197538275186326" xlink:to="ibio_DeferredFinancingCostsAmortizationExpense_638197538275186326" order="5" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638197538275186326" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638197538275186326" xlink:to="us-gaap_ShareBasedCompensation_638197538275186326" order="6" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_638197538275186326" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638197538275186326" xlink:to="us-gaap_AmortizationOfIntangibleAssets_638197538275186326" order="7" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638197538275196349" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638197538275186326" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638197538275196349" order="8" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan" xlink:label="ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan_638197538275196349" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638197538275186326" xlink:to="ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan_638197538275196349" order="9" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638197538275196349" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638197538275186326" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638197538275196349" order="10" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SettlementOfRevenueContract" xlink:label="ibio_SettlementOfRevenueContract_638197538275196349" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638197538275186326" xlink:to="ibio_SettlementOfRevenueContract_638197538275196349" order="11" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="us-gaap_TangibleAssetImpairmentCharges_638197538275196349" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638197538275186326" xlink:to="us-gaap_TangibleAssetImpairmentCharges_638197538275196349" order="12" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_638197538275196349" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638197538275186326" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_638197538275196349" order="13" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases" xlink:label="us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases_638197538275206261" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638197538275186326" xlink:to="us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases_638197538275206261" order="14" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638197538275206261" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638197538275186326" xlink:to="us-gaap_Depreciation_638197538275206261" order="15" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638197538275206261" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638197538275186326" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638197538275206261" order="16" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_638197538275206261" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638197538275186326" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_638197538275206261" order="17" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_IncreaseDecreaseInSettlementAssets" xlink:label="ibio_IncreaseDecreaseInSettlementAssets_638197538275206261" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638197538275186326" xlink:to="ibio_IncreaseDecreaseInSettlementAssets_638197538275206261" order="18" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories" xlink:label="us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories_638197538275206261" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638197538275186326" xlink:to="us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories_638197538275206261" order="19" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638197538275216376" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638197538275186326" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638197538275216376" order="20" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits_638197538275216376" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638197538275186326" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits_638197538275216376" order="21" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638197538275216376" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638197538275186326" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638197538275216376" order="22" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:label="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_638197538275216376" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638197538275186326" xlink:to="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_638197538275216376" order="23" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent" xlink:label="ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent_638197538275216376" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638197538275186326" xlink:to="ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent_638197538275216376" order="24" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638197538275216376" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638197538275186326" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638197538275216376" order="25" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleGainLoss_638197538275226387" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638197538275186326" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleGainLoss_638197538275226387" order="26" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_638197538275226387" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638197538275186326" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_638197538275226387" order="27" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638197538275226387" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638197538275186326" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638197538275226387" order="28" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638197538275226387" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638197538275226387" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_638197538275236202" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638197538275226387" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_638197538275236202" order="1" use="optional" weight="-1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_638197538275236202" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638197538275226387" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_638197538275236202" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638197538275236202" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638197538275226387" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638197538275236202" order="3" use="optional" weight="-1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:label="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_638197538275245966" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638197538275226387" xlink:to="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_638197538275245966" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_638197538275245966" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638197538275226387" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_638197538275245966" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_638197538275245966" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638197538275226387" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_638197538275245966" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_638197538275245966" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638197538275226387" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_638197538275245966" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638197538275256373" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638197538275226387" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638197538275256373" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638197538275256373" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638197538275256373" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ProceedsFromIssuanceOfPreferredAndCommonStock" xlink:label="ibio_ProceedsFromIssuanceOfPreferredAndCommonStock_638197538275256373" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638197538275256373" xlink:to="ibio_ProceedsFromIssuanceOfPreferredAndCommonStock_638197538275256373" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_PaymentsToAttainTermNote" xlink:label="ibio_PaymentsToAttainTermNote_638197538275256373" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638197538275256373" xlink:to="ibio_PaymentsToAttainTermNote_638197538275256373" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ProceedsFromEquipmentFinancingLoan" xlink:label="ibio_ProceedsFromEquipmentFinancingLoan_638197538275256373" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638197538275256373" xlink:to="ibio_ProceedsFromEquipmentFinancingLoan_638197538275256373" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_PaymentOfEquipmentFinancingLoan" xlink:label="ibio_PaymentOfEquipmentFinancingLoan_638197538275266367" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638197538275256373" xlink:to="ibio_PaymentOfEquipmentFinancingLoan_638197538275266367" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable_638197538275266367" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638197538275256373" xlink:to="us-gaap_RepaymentsOfNotesPayable_638197538275266367" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638197538275266367" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638197538275256373" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638197538275266367" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_PaymentsForFractionalSharesAfterReverseStockSplit" xlink:label="ibio_PaymentsForFractionalSharesAfterReverseStockSplit_638197538275266367" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638197538275256373" xlink:to="ibio_PaymentsForFractionalSharesAfterReverseStockSplit_638197538275266367" order="7" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments_638197538275276346" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638197538275256373" xlink:to="us-gaap_FinanceLeasePrincipalPayments_638197538275276346" order="8" use="optional" weight="-1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="us-gaap_PaymentsToMinorityShareholders_638197538275276346" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638197538275256373" xlink:to="us-gaap_PaymentsToMinorityShareholders_638197538275276346" order="9" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638197538275276346" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638197538275276346" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Summary of Significant Accounting Policies (Cash, Cash Equivalents and Restricted Cash) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638197538275286440" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638197538275286440" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_638197538275286440" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_638197538275286440" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesComponentsOfInvestmentsInDebtSecurities2Details" xlink:type="extended" xlink:title="40702 - Disclosure - Investments in Debt and Equity Securities (Components of Investments in Debt Securities2) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_638197538275286440" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_638197538275286440" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesCurrent" xlink:label="us-gaap_DebtSecuritiesCurrent_638197538275286440" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_DebtSecuritiesCurrent_638197538275286440" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesDebtSecuritiesContractualMaturityDetails" xlink:type="extended" xlink:title="40803 - Disclosure - Investments in Debt Securities (Debt Securities, Contractual Maturity) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesCurrent" xlink:label="us-gaap_DebtSecuritiesCurrent" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_638197538275296375" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_638197538275296375" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_638197538275296375" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_638197538275296375" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Fixed Assets (Carrying Value and Accumulated Depreciation) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637045036842019774" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638197538275296375" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet_637045036842019774" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638197538275296375" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638197538275296375" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet_637045036842019774" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638197538275296375" order="2" use="optional" weight="-1" priority="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Intangible Assets (Carrying Value and Accumulated Amortization) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_638197538275296375" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_638197538275296375" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_638197538275296375" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet_638197538275296375" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_638197538275296375" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638197538275306383" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet_638197538275296375" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638197538275306383" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_638197538275306383" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_638197538275306383" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderFinanceLeaseObligationDetailsCalc2" xlink:type="extended" xlink:title="41304 - Disclosure - Finance Lease Obligation (Future Minimum Payments Under the Finance Lease Obligation) (Details) (Calc2)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_638197538275306383" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_638197538275306383" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_638197538275306383" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_638197538275306383" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails" xlink:type="extended" xlink:title="41403 - Disclosure - Finance Lease Obligation (Future Minimum Payments Under the Capitalized Lease Obligations) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_638197538275306383" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_638197538275306383" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_638197538275306383" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_638197538275306383" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_638197538275316351" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_638197538275316351" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc2" xlink:type="extended" xlink:title="41403 - Disclosure - Operating Lease Obligation (Future Minimum Payments under the Operating Lease Obligation) (Details) (Calc 2)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638197538275316351" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638197538275316351" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638197538275316351" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638197538275316351" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3" xlink:type="extended" xlink:title="41403 - Disclosure - Operating Lease Obligation (Future Minimum Payments under the Operating Lease Obligation) (Details) (Calc 3)">
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal_638197538275316351" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal_638197538275316351" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638197538275316351" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638197538275316351" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638197538275326362" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638197538275326362" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive_638197538275326362" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive_638197538275326362" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive_638197538275326362" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive_638197538275326362" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638197538275326362" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638197538275326362" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour_638197538275326362" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour_638197538275326362" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638197538275336362" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638197538275336362" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne_638197538275336362" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne_638197538275336362" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638197538275336362" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638197538275336362" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree_638197538275336362" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree_638197538275336362" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638197538275336362" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638197538275336362" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo_638197538275345975" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo_638197538275345975" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638197538275345975" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638197538275345975" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails" xlink:type="extended" xlink:title="41503 - Disclosure - Operating Lease Obligation (Future Minimum Payments under the Operating Lease Obligation) (Details)">
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive_638197538275345975" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive_638197538275345975" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive_638197538275345975" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive_638197538275345975" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour_638197538275356350" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour_638197538275356350" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne_638197538275356350" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne_638197538275356350" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree_638197538275356350" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree_638197538275356350" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo_638197538275356350" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo_638197538275356350" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive_638197538275356350" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive_638197538275356350" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive_638197538275356350" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive_638197538275356350" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour_638197538275356350" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour_638197538275356350" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne_638197538275366367" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne_638197538275366367" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree_638197538275366367" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree_638197538275366367" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo_638197538275366367" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo_638197538275366367" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638197538275366367" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638197538275366367" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638197538275366367" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638197538275366367" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638197538275366367" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638197538275366367" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638197538275376362" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638197538275376362" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638197538275376362" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638197538275376362" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638197538275376362" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638197538275376362" order="6" use="optional" weight="1" priority="2" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>ibio-20230331_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.5.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/15/2023 1:23:55 PM-->
<!--Modified on: 5/15/2023 1:23:55 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#StatementCondensedConsolidatedStatementsOfEquity" roleURI="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureSignificantTransactionsTables" roleURI="http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails" roleURI="http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureSignificantTransactionsNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails" roleURI="http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureConvertiblePromissoryNoteReceivableNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureConvertiblePromissoryNoteReceivableNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails" roleURI="http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureIntangibleAssetsNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails" roleURI="http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureDebtCreditAgreementDetails" roleURI="http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails" roleURI="http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureDebtNotePayablePppLoanDetails" roleURI="http://www.ibioinc.com/role/DisclosureDebtNotePayablePppLoanDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureFinanceLeaseObligationNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureOperatingLeaseObligationNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureStockholdersEquityNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails" roleURI="http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" roleURI="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureShareBasedCompensationNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureShareBasedCompensationRsusDetails" roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationRsusDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureFraunhoferSettlementNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureCommitmentsAndContingenciesNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureEmployee401KPlanNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureEmployee401KPlanNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureSubsequentEventsNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.ibioinc.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="ibio-20230331.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" />
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:title="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:title="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1 To us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_1" xlink:title="srt_MajorCustomersAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_1" xlink:title="srt_NameOfMajorCustomerDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_MajorCustomersAxis_1" xlink:to="srt_NameOfMajorCustomerDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_MajorCustomersAxis_1 To srt_NameOfMajorCustomerDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_1" xlink:title="us-gaap_ConcentrationRiskByBenchmarkAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_1" xlink:title="us-gaap_ConcentrationRiskBenchmarkDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis_1" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ConcentrationRiskByBenchmarkAxis_1 To us-gaap_ConcentrationRiskBenchmarkDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_1" xlink:title="us-gaap_ConcentrationRiskByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_1" xlink:title="us-gaap_ConcentrationRiskTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ConcentrationRiskByTypeAxis_1" xlink:to="us-gaap_ConcentrationRiskTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ConcentrationRiskByTypeAxis_1 To us-gaap_ConcentrationRiskTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_1" xlink:title="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" xlink:title="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_1" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_1 To us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_1" xlink:title="srt_ProductOrServiceAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_1" xlink:title="srt_ProductsAndServicesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ProductOrServiceAxis_1" xlink:to="srt_ProductsAndServicesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ProductOrServiceAxis_1 To srt_ProductsAndServicesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_1" xlink:title="us-gaap_DebtInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_1" xlink:title="us-gaap_DebtInstrumentNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentAxis_1" xlink:to="us-gaap_DebtInstrumentNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentAxis_1 To us-gaap_DebtInstrumentNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_1" xlink:title="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain_1" xlink:title="us-gaap_ReceivableTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_1" xlink:to="us-gaap_ReceivableTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_1 To us-gaap_ReceivableTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_1" xlink:title="srt_StatementGeographicalAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_1" xlink:title="srt_SegmentGeographicalDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementGeographicalAxis_1" xlink:to="srt_SegmentGeographicalDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementGeographicalAxis_1 To srt_SegmentGeographicalDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_1" xlink:title="us-gaap_RelatedPartyTransactionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_1" xlink:title="us-gaap_RelatedPartyTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionAxis_1" xlink:to="us-gaap_RelatedPartyTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionAxis_1 To us-gaap_RelatedPartyTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis_1" xlink:title="srt_OwnershipAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_1" xlink:title="srt_OwnershipDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_OwnershipAxis_1" xlink:to="srt_OwnershipDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_OwnershipAxis_1 To srt_OwnershipDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="us-gaap_RelatedPartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1 To us-gaap_RelatedPartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis_1" xlink:title="us-gaap_LeaseContractualTermAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_1" xlink:title="us-gaap_LeaseContractualTermDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LeaseContractualTermAxis_1" xlink:to="us-gaap_LeaseContractualTermDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LeaseContractualTermAxis_1 To us-gaap_LeaseContractualTermDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsByNatureAxis" xlink:label="us-gaap_GuaranteeObligationsByNatureAxis_1" xlink:title="us-gaap_GuaranteeObligationsByNatureAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsNatureDomain" xlink:label="us-gaap_GuaranteeObligationsNatureDomain_1" xlink:title="us-gaap_GuaranteeObligationsNatureDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GuaranteeObligationsByNatureAxis_1" xlink:to="us-gaap_GuaranteeObligationsNatureDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GuaranteeObligationsByNatureAxis_1 To us-gaap_GuaranteeObligationsNatureDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1" xlink:title="us-gaap_MeasurementInputTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1" xlink:title="us-gaap_MeasurementInputTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_MeasurementInputTypeAxis_1" xlink:to="us-gaap_MeasurementInputTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_MeasurementInputTypeAxis_1 To us-gaap_MeasurementInputTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis_1" xlink:title="srt_LitigationCaseAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain_1" xlink:title="srt_LitigationCaseTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_LitigationCaseAxis_1" xlink:to="srt_LitigationCaseTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_LitigationCaseAxis_1 To srt_LitigationCaseTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis" xlink:label="us-gaap_LitigationStatusAxis_1" xlink:title="us-gaap_LitigationStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain" xlink:label="us-gaap_LitigationStatusDomain_1" xlink:title="us-gaap_LitigationStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LitigationStatusAxis_1" xlink:to="us-gaap_LitigationStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LitigationStatusAxis_1 To us-gaap_LitigationStatusDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis_1" xlink:title="srt_ConsolidationItemsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain_1" xlink:title="srt_ConsolidationItemsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ConsolidationItemsAxis_1" xlink:to="srt_ConsolidationItemsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ConsolidationItemsAxis_1 To srt_ConsolidationItemsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis_1" xlink:title="us-gaap_StatementBusinessSegmentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_1" xlink:title="us-gaap_SegmentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementBusinessSegmentsAxis_1" xlink:to="us-gaap_SegmentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementBusinessSegmentsAxis_1 To us-gaap_SegmentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLocationAxis" xlink:label="us-gaap_OtherComprehensiveIncomeLocationAxis_1" xlink:title="us-gaap_OtherComprehensiveIncomeLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLocationDomain" xlink:label="us-gaap_OtherComprehensiveIncomeLocationDomain_1" xlink:title="us-gaap_OtherComprehensiveIncomeLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_OtherComprehensiveIncomeLocationAxis_1" xlink:to="us-gaap_OtherComprehensiveIncomeLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_OtherComprehensiveIncomeLocationAxis_1 To us-gaap_OtherComprehensiveIncomeLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationTypeAxis" xlink:label="us-gaap_ReclassificationTypeAxis_1" xlink:title="us-gaap_ReclassificationTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationTypeDomain" xlink:label="us-gaap_ReclassificationTypeDomain_1" xlink:title="us-gaap_ReclassificationTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ReclassificationTypeAxis_1" xlink:to="us-gaap_ReclassificationTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ReclassificationTypeAxis_1 To us-gaap_ReclassificationTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_1" xlink:title="srt_RestatementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_1" xlink:title="srt_RestatementDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RestatementAxis_1" xlink:to="srt_RestatementDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RestatementAxis_1 To srt_RestatementDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis_1" xlink:title="srt_ConsolidatedEntitiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain_1" xlink:title="srt_ConsolidatedEntitiesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ConsolidatedEntitiesAxis_1" xlink:to="srt_ConsolidatedEntitiesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ConsolidatedEntitiesAxis_1 To srt_ConsolidatedEntitiesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis_1" xlink:title="us-gaap_FairValueByAssetClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1" xlink:title="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByAssetClassAxis_1" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByAssetClassAxis_1 To us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_1" xlink:title="srt_CumulativeEffectPeriodOfAdoptionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_1" xlink:title="srt_CumulativeEffectPeriodOfAdoptionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis_1" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CumulativeEffectPeriodOfAdoptionAxis_1 To srt_CumulativeEffectPeriodOfAdoptionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:title="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_1" xlink:title="us-gaap_TypeOfAdoptionMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:to="us-gaap_TypeOfAdoptionMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1 To us-gaap_TypeOfAdoptionMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:label="us-gaap_TimingOfTransferOfGoodOrServiceAxis_1" xlink:title="us-gaap_TimingOfTransferOfGoodOrServiceAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:label="us-gaap_TimingOfTransferOfGoodOrServiceDomain_1" xlink:title="us-gaap_TimingOfTransferOfGoodOrServiceDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TimingOfTransferOfGoodOrServiceAxis_1" xlink:to="us-gaap_TimingOfTransferOfGoodOrServiceDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TimingOfTransferOfGoodOrServiceAxis_1 To us-gaap_TimingOfTransferOfGoodOrServiceDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_PurchaseAgreementAxis" xlink:label="ibio_PurchaseAgreementAxis_1" xlink:title="ibio_PurchaseAgreementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_PurchaseAgreementDomain" xlink:label="ibio_PurchaseAgreementDomain_1" xlink:title="ibio_PurchaseAgreementDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ibio_PurchaseAgreementAxis_1" xlink:to="ibio_PurchaseAgreementDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ibio_PurchaseAgreementAxis_1 To ibio_PurchaseAgreementDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_1" xlink:title="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_1" xlink:title="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_1" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_1 To us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1 To us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_1" xlink:title="us-gaap_FinancialInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FinancialInstrumentAxis_1" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FinancialInstrumentAxis_1 To us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemAxis" xlink:label="us-gaap_UnusualOrInfrequentItemAxis_1" xlink:title="us-gaap_UnusualOrInfrequentItemAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemDomain" xlink:label="us-gaap_UnusualOrInfrequentItemDomain_1" xlink:title="us-gaap_UnusualOrInfrequentItemDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_UnusualOrInfrequentItemAxis_1" xlink:to="us-gaap_UnusualOrInfrequentItemDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_UnusualOrInfrequentItemAxis_1 To us-gaap_UnusualOrInfrequentItemDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_1" xlink:title="us-gaap_TaxCreditCarryforwardAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_1" xlink:title="us-gaap_TaxCreditCarryforwardNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TaxCreditCarryforwardAxis_1" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TaxCreditCarryforwardAxis_1 To us-gaap_TaxCreditCarryforwardNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1" xlink:title="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="us-gaap_AdjustmentsForErrorCorrectionDomain_1" xlink:title="us-gaap_AdjustmentsForErrorCorrectionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1" xlink:to="us-gaap_AdjustmentsForErrorCorrectionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1 To us-gaap_AdjustmentsForErrorCorrectionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis_1" xlink:title="us-gaap_AssetAcquisitionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain_1" xlink:title="us-gaap_AssetAcquisitionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AssetAcquisitionAxis_1" xlink:to="us-gaap_AssetAcquisitionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AssetAcquisitionAxis_1 To us-gaap_AssetAcquisitionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:title="us-gaap_FairValueByMeasurementFrequencyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_1" xlink:title="us-gaap_FairValueMeasurementFrequencyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByMeasurementFrequencyAxis_1 To us-gaap_FairValueMeasurementFrequencyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:label="us-gaap_StatementOperatingActivitiesSegmentAxis_1" xlink:title="us-gaap_StatementOperatingActivitiesSegmentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentOperatingActivitiesDomain" xlink:label="us-gaap_SegmentOperatingActivitiesDomain_1" xlink:title="us-gaap_SegmentOperatingActivitiesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementOperatingActivitiesSegmentAxis_1" xlink:to="us-gaap_SegmentOperatingActivitiesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementOperatingActivitiesSegmentAxis_1 To us-gaap_SegmentOperatingActivitiesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_1" xlink:title="us-gaap_VestingAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_1" xlink:title="us-gaap_VestingDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VestingAxis_1" xlink:to="us-gaap_VestingDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VestingAxis_1 To us-gaap_VestingDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_1" xlink:title="us-gaap_GranteeStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_1" xlink:title="us-gaap_GranteeStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GranteeStatusAxis_1" xlink:to="us-gaap_GranteeStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GranteeStatusAxis_1 To us-gaap_GranteeStatusDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1" xlink:title="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1" xlink:title="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1 To us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity" xlink:type="extended" xlink:title="00300 - Statement - Condensed Consolidated Statements of Equity">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_StockIssuedDuringPeriodValueCapitalRaise" xlink:label="ibio_StockIssuedDuringPeriodValueCapitalRaise" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_StockIssuedDuringPeriodValueCapitalRaise" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_StockIssuedDuringPeriodSharesCapitalRaise" xlink:label="ibio_StockIssuedDuringPeriodSharesCapitalRaise" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_StockIssuedDuringPeriodSharesCapitalRaise" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_FractionalShareIssuedAfterReverseStockSplitValue" xlink:label="ibio_FractionalShareIssuedAfterReverseStockSplitValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_FractionalShareIssuedAfterReverseStockSplitValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_FractionalShareIssuedAfterReverseStockSplitShares" xlink:label="ibio_FractionalShareIssuedAfterReverseStockSplitShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_FractionalShareIssuedAfterReverseStockSplitShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CommonStockIssuedInRubrycTransactionValue" xlink:label="ibio_CommonStockIssuedInRubrycTransactionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_CommonStockIssuedInRubrycTransactionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CommonStockIssuedInRubrycTransactionInShares" xlink:label="ibio_CommonStockIssuedInRubrycTransactionInShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_CommonStockIssuedInRubrycTransactionInShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate" xlink:label="ibio_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities" xlink:label="ibio_ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables" xlink:type="extended" xlink:title="30603 - Disclosure - Significant Transactions (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AssetAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_StockPurchaseAgreementMember" xlink:label="ibio_StockPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="ibio_StockPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_AssetPurchaseAgreementMember" xlink:label="ibio_AssetPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="ibio_AssetPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTableTextBlock" xlink:label="us-gaap_AssetAcquisitionTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetAcquisitionTableTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IntellectualPropertyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="us-gaap_RevenueFromContractWithCustomerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_RevenueFromContractWithCustomerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:label="us-gaap_StatementOperatingActivitiesSegmentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementOperatingActivitiesSegmentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentOperatingActivitiesDomain" xlink:label="us-gaap_SegmentOperatingActivitiesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:to="us-gaap_SegmentOperatingActivitiesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentContinuingOperationsMember" xlink:label="us-gaap_SegmentContinuingOperationsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SegmentOperatingActivitiesDomain" xlink:to="us-gaap_SegmentContinuingOperationsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDiscontinuedOperationsMember" xlink:label="us-gaap_SegmentDiscontinuedOperationsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SegmentOperatingActivitiesDomain" xlink:to="us-gaap_SegmentDiscontinuedOperationsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_WoodforestMember" xlink:label="ibio_WoodforestMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_WoodforestMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_AmendedCreditAgreementMember" xlink:label="ibio_AmendedCreditAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ibio_AmendedCreditAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="ibio_SummaryOfSignificantAccountingPoliciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DeferredRevenueCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasePracticalExpedientsPackage" xlink:label="us-gaap_LeasePracticalExpedientsPackage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_LeasePracticalExpedientsPackage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RepaymentsOfDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashUninsuredAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_NumberOfMajorCustomers" xlink:label="ibio_NumberOfMajorCustomers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ibio_NumberOfMajorCustomers" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyIncomeNonoperating" xlink:label="us-gaap_RoyaltyIncomeNonoperating" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RoyaltyIncomeNonoperating" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Summary of Significant Accounting Policies (Cash, Cash Equivalents and Restricted Cash) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LetterOfCreditTermLoanMember" xlink:label="ibio_LetterOfCreditTermLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="ibio_LetterOfCreditTermLoanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LetterOfCreditSanDiegoLeaseMember" xlink:label="ibio_LetterOfCreditSanDiegoLeaseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="ibio_LetterOfCreditSanDiegoLeaseMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CompanyPurchasingCardMember" xlink:label="ibio_CompanyPurchasingCardMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="ibio_CompanyPurchasingCardMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_PercentageOfCollateralRequired" xlink:label="ibio_PercentageOfCollateralRequired" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="ibio_PercentageOfCollateralRequired" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Financial Instruments and Fair Value Measurement (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="us-gaap_TangibleAssetImpairmentCharges" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_TangibleAssetImpairmentCharges" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Financial Instruments and Fair Value Measurement (Non-recurring Basis) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="us-gaap_TangibleAssetImpairmentCharges" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_TangibleAssetImpairmentCharges" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Significant Transactions (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_Series2PreferredStockMember" xlink:label="ibio_Series2PreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="ibio_Series2PreferredStockMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CollaborationOptionAndLicenseAgreementMember" xlink:label="ibio_CollaborationOptionAndLicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ibio_CollaborationOptionAndLicenseAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_StockPurchaseAgreementMember" xlink:label="ibio_StockPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ibio_StockPurchaseAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SeparationAgreementAndGeneralReleaseMember" xlink:label="ibio_SeparationAgreementAndGeneralReleaseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ibio_SeparationAgreementAndGeneralReleaseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ImmuneOncologyAntibodiesRtx003Member" xlink:label="ibio_ImmuneOncologyAntibodiesRtx003Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ibio_ImmuneOncologyAntibodiesRtx003Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_NoBiosimilarProductHasBeenApprovedMember" xlink:label="ibio_NoBiosimilarProductHasBeenApprovedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ibio_NoBiosimilarProductHasBeenApprovedMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_RubrycTheraputicsInc.Member" xlink:label="ibio_RubrycTheraputicsInc.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_RubrycTheraputicsInc.Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" xlink:label="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_IbioCmoPreferredTrackingStockMember" xlink:label="ibio_IbioCmoPreferredTrackingStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="ibio_IbioCmoPreferredTrackingStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SecuredTermLoanMember" xlink:label="ibio_SecuredTermLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ibio_SecuredTermLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest" xlink:label="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment" xlink:label="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_FairMarketValueOfProperty" xlink:label="ibio_FairMarketValueOfProperty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_FairMarketValueOfProperty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_BaseRentPercentageOfFairMarketValueOfProperty" xlink:label="ibio_BaseRentPercentageOfFairMarketValueOfProperty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_BaseRentPercentageOfFairMarketValueOfProperty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired" xlink:label="ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_EquityAgreementWarrantsIssuedOrIssuable" xlink:label="ibio_EquityAgreementWarrantsIssuedOrIssuable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_EquityAgreementWarrantsIssuedOrIssuable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable" xlink:label="ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CreditAgreementThresholdLimitUnrestrictedCash" xlink:label="ibio_CreditAgreementThresholdLimitUnrestrictedCash" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_CreditAgreementThresholdLimitUnrestrictedCash" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent" xlink:label="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue" xlink:label="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CollaborativeArrangementMilestonePayments" xlink:label="ibio_CollaborativeArrangementMilestonePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_CollaborativeArrangementMilestonePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForAdvanceToAffiliate" xlink:label="us-gaap_PaymentsForAdvanceToAffiliate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsForAdvanceToAffiliate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_AssetAcquisitionTransactionCosts" xlink:label="ibio_AssetAcquisitionTransactionCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_AssetAcquisitionTransactionCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm" xlink:label="ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CollaborationAndLicenseAgreementAgreementTerm" xlink:label="ibio_CollaborationAndLicenseAgreementAgreementTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_CollaborationAndLicenseAgreementAgreementTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_StockPurchaseAgreementNumberOfSharesPurchased" xlink:label="ibio_StockPurchaseAgreementNumberOfSharesPurchased" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_StockPurchaseAgreementNumberOfSharesPurchased" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_StockPurchaseAgreementValueOfSharesPurchased" xlink:label="ibio_StockPurchaseAgreementValueOfSharesPurchased" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_StockPurchaseAgreementValueOfSharesPurchased" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfInvestments" xlink:label="us-gaap_ImpairmentOfInvestments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="28" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentOfInvestments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="29" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ImpairmentOfPrepaidExpensesCurrent" xlink:label="ibio_ImpairmentOfPrepaidExpensesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="30" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_ImpairmentOfPrepaidExpensesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ImpairmentOfPrepaidExpensesNonCurrent" xlink:label="ibio_ImpairmentOfPrepaidExpensesNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="31" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_ImpairmentOfPrepaidExpensesNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="32" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="33" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary" xlink:label="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="34" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus" xlink:label="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="35" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct" xlink:label="ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="36" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod" xlink:label="ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="37" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct" xlink:label="ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="38" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Significant Transactions (Summary of Asset Acquisition) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AssetAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_Series2PreferredStockMember" xlink:label="ibio_Series2PreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="ibio_Series2PreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_AssetAcquisitionIntangibleAssetsMember" xlink:label="ibio_AssetAcquisitionIntangibleAssetsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="ibio_AssetAcquisitionIntangibleAssetsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_AssetAcquisitionFixedAssetsMember" xlink:label="ibio_AssetAcquisitionFixedAssetsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="ibio_AssetAcquisitionFixedAssetsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_AssetAcquisitionPrepaidExpensesMember" xlink:label="ibio_AssetAcquisitionPrepaidExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="ibio_AssetAcquisitionPrepaidExpensesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_RubrycTheraputicsInc.Member" xlink:label="ibio_RubrycTheraputicsInc.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_RubrycTheraputicsInc.Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureConvertiblePromissoryNoteReceivableNarrativeDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Convertible Promissory Note Receivable (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableMember" xlink:label="us-gaap_NotesReceivableMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_NotesReceivableMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LoansReceivableAmountInvested" xlink:label="ibio_LoansReceivableAmountInvested" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="ibio_LoansReceivableAmountInvested" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LoansReceivableFixedRatesOfInterest" xlink:label="ibio_LoansReceivableFixedRatesOfInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="ibio_LoansReceivableFixedRatesOfInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_InvestmentIncomeInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:label="us-gaap_NotesAndLoansReceivableNetNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_NotesAndLoansReceivableNetNoncurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Finance Lease ROU Assets (Summary of Finance Lease ROU) (Details)">
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_FinanceLeaseRightOfUseAssetDisclosureTable" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_FacilityMember" xlink:label="ibio_FacilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ibio_FacilityMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems" xlink:to="ibio_FinanceLeaseRightOfUseAssetDisclosureTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_FinanceLeaseRightOfUseAssetGross" xlink:label="ibio_FinanceLeaseRightOfUseAssetGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems" xlink:to="ibio_FinanceLeaseRightOfUseAssetGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Fixed Assets (Carrying Value and Accumulated Depreciation) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Intangible Assets (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_RubrycTheraputicsInc.Member" xlink:label="ibio_RubrycTheraputicsInc.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_RubrycTheraputicsInc.Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ImmuneOncologyAntibodiesRtx003Member" xlink:label="ibio_ImmuneOncologyAntibodiesRtx003Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ibio_ImmuneOncologyAntibodiesRtx003Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IntellectualPropertyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_StockPurchaseAgreementTotalInvestment" xlink:label="ibio_StockPurchaseAgreementTotalInvestment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="ibio_StockPurchaseAgreementTotalInvestment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Intangible Assets (Carrying Value and Accumulated Amortization) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IntellectualPropertyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDeferredChargesAbstract" xlink:label="us-gaap_AmortizationOfDeferredChargesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AmortizationOfDeferredChargesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AmortizationOfDeferredChargesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="us-gaap_FinitelivedIntangibleAssetsAcquired1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:to="us-gaap_FinitelivedIntangibleAssetsAcquired1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:label="us-gaap_IndefinitelivedIntangibleAssetsAcquired" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:to="us-gaap_IndefinitelivedIntangibleAssetsAcquired" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetImpairmentAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairmentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_GoodwillAndIntangibleAssetImpairmentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ImpairmentOfIntangibleAssetsGrossOfReversals" xlink:label="ibio_ImpairmentOfIntangibleAssetsGrossOfReversals" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GoodwillAndIntangibleAssetImpairmentAbstract" xlink:to="ibio_ImpairmentOfIntangibleAssetsGrossOfReversals" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ReversalOfIntangibleAssetImpairment" xlink:label="ibio_ReversalOfIntangibleAssetImpairment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_GoodwillAndIntangibleAssetImpairmentAbstract" xlink:to="ibio_ReversalOfIntangibleAssetImpairment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_GoodwillAndIntangibleAssetImpairmentAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Debt (The Credit Agreement) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" xlink:label="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_WoodforestMember" xlink:label="ibio_WoodforestMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_WoodforestMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SecuredTermLoanMember" xlink:label="ibio_SecuredTermLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ibio_SecuredTermLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_AmendedCreditAgreementMember" xlink:label="ibio_AmendedCreditAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ibio_AmendedCreditAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_LitigationCaseAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember" xlink:label="ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_DateOfAmendmentMember" xlink:label="ibio_DateOfAmendmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ibio_DateOfAmendmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember" xlink:label="ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_OccurrenceOfSpecificMilestoneMember" xlink:label="ibio_OccurrenceOfSpecificMilestoneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ibio_OccurrenceOfSpecificMilestoneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CreditAgreementThresholdLimitUnrestrictedCash" xlink:label="ibio_CreditAgreementThresholdLimitUnrestrictedCash" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ibio_CreditAgreementThresholdLimitUnrestrictedCash" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFeeAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_DebtCovenantLiquidityAmount" xlink:label="ibio_DebtCovenantLiquidityAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ibio_DebtCovenantLiquidityAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLegalSettlements" xlink:label="us-gaap_ProceedsFromLegalSettlements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromLegalSettlements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails" xlink:type="extended" xlink:title="41303 - Disclosure - Debt (Equipment Financing) (Future Minimum Payments) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_PrincipalMember" xlink:label="ibio_PrincipalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ibio_PrincipalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_InterestMember" xlink:label="ibio_InterestMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ibio_InterestMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="us-gaap_ContractualObligationDueInSecondYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractualObligationDueInSecondYear" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="us-gaap_ContractualObligationDueInThirdYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractualObligationDueInThirdYear" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractualObligation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ContractualObligationCurrent" xlink:label="ibio_ContractualObligationCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_ContractualObligationCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ContractualObligationNoncurrent" xlink:label="ibio_ContractualObligationNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_ContractualObligationNoncurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureDebtNotePayablePppLoanDetails" xlink:type="extended" xlink:title="41304 - Disclosure - Debt (Note Payable - PPP Loan) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_PppLoanCaresActMember" xlink:label="ibio_PppLoanCaresActMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ibio_PppLoanCaresActMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermNotesPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentDecreaseForgiveness" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationNarrativeDetails" xlink:type="extended" xlink:title="41401 - Disclosure - Finance Lease Obligation (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SecondEasternAffiliateMember" xlink:label="ibio_SecondEasternAffiliateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="ibio_SecondEasternAffiliateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_RubrycTheraputicsInc.Member" xlink:label="ibio_RubrycTheraputicsInc.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_RubrycTheraputicsInc.Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_NumberOfEquipmentLeases" xlink:label="ibio_NumberOfEquipmentLeases" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ibio_NumberOfEquipmentLeases" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_FinanceLeaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LeaseRentExpensePerMonth" xlink:label="ibio_LeaseRentExpensePerMonth" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ibio_LeaseRentExpensePerMonth" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LessorFinanceLeaseMonthlyRent" xlink:label="ibio_LessorFinanceLeaseMonthlyRent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ibio_LessorFinanceLeaseMonthlyRent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails" xlink:type="extended" xlink:title="41403 - Disclosure - Finance Lease Obligation (Future Minimum Payments Under the Capitalized Lease Obligations) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_PrincipalMember" xlink:label="ibio_PrincipalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ibio_PrincipalMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_InterestMember" xlink:label="ibio_InterestMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ibio_InterestMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails" xlink:type="extended" xlink:title="41501 - Disclosure - Operating Lease Obligation (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" xlink:label="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsByNatureAxis" xlink:label="us-gaap_GuaranteeObligationsByNatureAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GuaranteeObligationsByNatureAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsNatureDomain" xlink:label="us-gaap_GuaranteeObligationsNatureDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_GuaranteeObligationsByNatureAxis" xlink:to="us-gaap_GuaranteeObligationsNatureDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialStandbyLetterOfCreditMember" xlink:label="us-gaap_FinancialStandbyLetterOfCreditMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GuaranteeObligationsNatureDomain" xlink:to="us-gaap_FinancialStandbyLetterOfCreditMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_BaseRentPercentageOfFairMarketValueOfProperty" xlink:label="ibio_BaseRentPercentageOfFairMarketValueOfProperty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_BaseRentPercentageOfFairMarketValueOfProperty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseMonthlyRent" xlink:label="ibio_LesseeOperatingLeaseMonthlyRent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_LesseeOperatingLeaseMonthlyRent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent" xlink:label="ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_BaseRentAbatementInFirstYearPeriod" xlink:label="ibio_BaseRentAbatementInFirstYearPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_BaseRentAbatementInFirstYearPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TenantImprovements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsMaximumExposure" xlink:label="us-gaap_GuaranteeObligationsMaximumExposure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GuaranteeObligationsMaximumExposure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails" xlink:type="extended" xlink:title="41601 - Disclosure - Stockholders' Equity (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_StockholdersEquityTable" xlink:label="ibio_StockholdersEquityTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ibio_StockholdersEquityTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ExchangeAgreementMember" xlink:label="ibio_ExchangeAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="ibio_ExchangeAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ibio_StockholdersEquityTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_EasternAffiliateMember" xlink:label="ibio_EasternAffiliateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="ibio_EasternAffiliateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ibio_StockholdersEquityTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_OmnibusIncentivePlanMember" xlink:label="ibio_OmnibusIncentivePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="ibio_OmnibusIncentivePlanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="ibio_StockholdersEquityTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="ibio_StockholdersEquityTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_PreferredTrackingStockMember" xlink:label="ibio_PreferredTrackingStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="ibio_PreferredTrackingStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_Series2022ConvertiblePreferredStockMember" xlink:label="ibio_Series2022ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="ibio_Series2022ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="ibio_StockholdersEquityTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_PreFundedWarrantsMember" xlink:label="ibio_PreFundedWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="ibio_PreFundedWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_RepresentativeWarrantsMember" xlink:label="ibio_RepresentativeWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="ibio_RepresentativeWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SeriesWarrantsMember" xlink:label="ibio_SeriesWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="ibio_SeriesWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SeriesBWarrantsMember" xlink:label="ibio_SeriesBWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="ibio_SeriesBWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="ibio_StockholdersEquityTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" xlink:label="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_H.c.WainwrightCo.LlcMember" xlink:label="ibio_H.c.WainwrightCo.LlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_H.c.WainwrightCo.LlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="8" xlink:from="ibio_StockholdersEquityTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember" xlink:label="ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="9" xlink:from="ibio_StockholdersEquityTable" xlink:to="srt_OwnershipAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_IbioCdmoMember" xlink:label="ibio_IbioCdmoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_OwnershipDomain" xlink:to="ibio_IbioCdmoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_StockholdersEquityLineItems" xlink:label="ibio_StockholdersEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="ibio_StockholdersEquityTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock" xlink:label="ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsPerShareDeclared" xlink:label="us-gaap_PreferredStockDividendsPerShareDeclared" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_PreferredStockDividendsPerShareDeclared" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails" xlink:type="extended" xlink:title="41602 - Disclosure - Stockholders' Equity (Cantor Fitzgerald Underwriting and RubrYc Transaction) (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SalesAgreementMember" xlink:label="ibio_SalesAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ibio_SalesAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CantorFitzgeraldMember" xlink:label="ibio_CantorFitzgeraldMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_CantorFitzgeraldMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_RubrycTheraputicsInc.Member" xlink:label="ibio_RubrycTheraputicsInc.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_RubrycTheraputicsInc.Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_AggregateCommonStockPurchased" xlink:label="ibio_AggregateCommonStockPurchased" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_AggregateCommonStockPurchased" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SubscriptionReceivableCurrent" xlink:label="ibio_SubscriptionReceivableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_SubscriptionReceivableCurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails" xlink:type="extended" xlink:title="41603 - Disclosure - Stockholders' Equity (Wainwright Underwriting and Vesting of RSUs) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_H.c.WainwrightCo.LlcMember" xlink:label="ibio_H.c.WainwrightCo.LlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_H.c.WainwrightCo.LlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_PreFundedWarrantsMember" xlink:label="ibio_PreFundedWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="ibio_PreFundedWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SeriesWarrantsMember" xlink:label="ibio_SeriesWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="ibio_SeriesWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SeriesBWarrantsMember" xlink:label="ibio_SeriesBWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="ibio_SeriesBWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering" xlink:label="ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_NumberOfDaysOptionToPurchaseAdditionalShares" xlink:label="ibio_NumberOfDaysOptionToPurchaseAdditionalShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_NumberOfDaysOptionToPurchaseAdditionalShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_NumberOfAdditionalSharesIssued" xlink:label="ibio_NumberOfAdditionalSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_NumberOfAdditionalSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CommonWarrantsToPurchaseAdditionalShares" xlink:label="ibio_CommonWarrantsToPurchaseAdditionalShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_CommonWarrantsToPurchaseAdditionalShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_PercentageOfAggregateNumberOfSharesOfCommonStock" xlink:label="ibio_PercentageOfAggregateNumberOfSharesOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_PercentageOfAggregateNumberOfSharesOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="extended" xlink:title="41702 - Disclosure - Earnings (Loss) Per Common Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)">
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_EarningsLossPerCommonShareTable" xlink:label="ibio_EarningsLossPerCommonShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ibio_EarningsLossPerCommonShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_EarningsLossPerCommonShareLineItems" xlink:label="ibio_EarningsLossPerCommonShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ibio_EarningsLossPerCommonShareLineItems" xlink:to="ibio_EarningsLossPerCommonShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ibio_EarningsLossPerCommonShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ibio_EarningsLossPerCommonShareLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails" xlink:type="extended" xlink:title="41801 - Disclosure - Share-Based Compensation (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ScenarioOneMember" xlink:label="ibio_ScenarioOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ibio_ScenarioOneMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ScenarioTwoMember" xlink:label="ibio_ScenarioTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ibio_ScenarioTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ConsultantsMember" xlink:label="ibio_ConsultantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ibio_ConsultantsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_VariousEmployeesMember" xlink:label="ibio_VariousEmployeesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ibio_VariousEmployeesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_TwoThousandEighteenOmnibusEquityIncentivePlanMember" xlink:label="ibio_TwoThousandEighteenOmnibusEquityIncentivePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="ibio_TwoThousandEighteenOmnibusEquityIncentivePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_IbioInc.2020OmnibusEquityIncentivePlanMember" xlink:label="ibio_IbioInc.2020OmnibusEquityIncentivePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="ibio_IbioInc.2020OmnibusEquityIncentivePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized" xlink:label="ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="41802 - Disclosure - Share-Based Compensation (Share Based Compensation Expense) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:label="us-gaap_StatementOperatingActivitiesSegmentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_StatementOperatingActivitiesSegmentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentOperatingActivitiesDomain" xlink:label="us-gaap_SegmentOperatingActivitiesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:to="us-gaap_SegmentOperatingActivitiesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDiscontinuedOperationsMember" xlink:label="us-gaap_SegmentDiscontinuedOperationsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SegmentOperatingActivitiesDomain" xlink:to="us-gaap_SegmentDiscontinuedOperationsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureShareBasedCompensationRsusDetails" xlink:type="extended" xlink:title="41806 - Disclosure - Share-Based Compensation (RSUs) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_Dr.MartinBrennerMember" xlink:label="ibio_Dr.MartinBrennerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ibio_Dr.MartinBrennerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails" xlink:type="extended" xlink:title="41901 - Disclosure - Fraunhofer Settlement (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_LitigationCaseAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember" xlink:label="ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis" xlink:label="us-gaap_LitigationStatusAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LitigationStatusAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain" xlink:label="us-gaap_LitigationStatusDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LitigationStatusAxis" xlink:to="us-gaap_LitigationStatusDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember" xlink:label="us-gaap_SettledLitigationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LitigationStatusDomain" xlink:to="us-gaap_SettledLitigationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ScenarioPlanExpectedLegalFeesMember" xlink:label="ibio_ScenarioPlanExpectedLegalFeesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ScenarioPlanMember" xlink:to="ibio_ScenarioPlanExpectedLegalFeesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ScenarioPlanExpectedPaymentOneMember" xlink:label="ibio_ScenarioPlanExpectedPaymentOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ScenarioPlanMember" xlink:to="ibio_ScenarioPlanExpectedPaymentOneMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ScenarioPlanExpectedPaymentTwoMember" xlink:label="ibio_ScenarioPlanExpectedPaymentTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ScenarioPlanMember" xlink:to="ibio_ScenarioPlanExpectedPaymentTwoMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ServiceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAndMaintenanceMember" xlink:label="us-gaap_LicenseAndMaintenanceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ServiceMember" xlink:to="us-gaap_LicenseAndMaintenanceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CashPaymentsReceivablesRelatedToLitigationSettlement" xlink:label="ibio_CashPaymentsReceivablesRelatedToLitigationSettlement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_CashPaymentsReceivablesRelatedToLitigationSettlement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_PercentageOfLegalFeesExpectedToBeReceived" xlink:label="ibio_PercentageOfLegalFeesExpectedToBeReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_PercentageOfLegalFeesExpectedToBeReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettlementAssetsCurrent" xlink:label="us-gaap_SettlementAssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SettlementAssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SettlementAssetsNonCurrent" xlink:label="ibio_SettlementAssetsNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_SettlementAssetsNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyUnrecordedAmount" xlink:label="us-gaap_GainContingencyUnrecordedAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainContingencyUnrecordedAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedFromOtherParty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LitigationSettlementAmountAwardedFromOtherParty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLegalSettlements" xlink:label="us-gaap_ProceedsFromLegalSettlements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromLegalSettlements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" xlink:type="extended" xlink:title="42101 - Disclosure - Commitments and Contingencies (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CroAgreementMember" xlink:label="ibio_CroAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ibio_CroAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_EstimatedAdditionalCostOnDevelopment" xlink:label="ibio_EstimatedAdditionalCostOnDevelopment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_EstimatedAdditionalCostOnDevelopment" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureEmployee401KPlanNarrativeDetails" xlink:type="extended" xlink:title="42201 - Disclosure - Employee 401(K) Plan (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:label="us-gaap_StatementOperatingActivitiesSegmentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementOperatingActivitiesSegmentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentOperatingActivitiesDomain" xlink:label="us-gaap_SegmentOperatingActivitiesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:to="us-gaap_SegmentOperatingActivitiesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDiscontinuedOperationsMember" xlink:label="us-gaap_SegmentDiscontinuedOperationsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SegmentOperatingActivitiesDomain" xlink:to="us-gaap_SegmentDiscontinuedOperationsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedBenefitPlanContributionsByEmployer" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails" xlink:type="extended" xlink:title="42301 - Disclosure - Subsequent Events (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_WoodforestMember" xlink:label="ibio_WoodforestMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_WoodforestMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentFeeAmount" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>ibio-20230331_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.5.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/15/2023 1:23:55 PM-->
<!--Modified on: 5/15/2023 1:23:55 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Document And Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US">Document Information [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US">Document Information [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Condensed Consolidated Balance Sheets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesCurrent" xlink:label="us-gaap_DebtSecuritiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesCurrent" xlink:to="us-gaap_DebtSecuritiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesCurrent_lbl" xml:lang="en-US">Debt Securities, Available-for-sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesCurrent_lbl" xml:lang="en-US">Fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DebtSecuritiesCurrent_lbl" xml:lang="en-US">Fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtSecuritiesCurrent_lbl" xml:lang="en-US">Investments in debt securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts Receivable, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable - trade</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SubscriptionReceivableCurrent" xlink:label="ibio_SubscriptionReceivableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SubscriptionReceivableCurrent" xlink:to="ibio_SubscriptionReceivableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SubscriptionReceivableCurrent_lbl" xml:lang="en-US">Amount of subscription receivables classified due within one year or the normal operating cycle, if longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SubscriptionReceivableCurrent_lbl" xml:lang="en-US">Subscription Receivable Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_SubscriptionReceivableCurrent_lbl" xml:lang="en-US">Subscription receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettlementAssetsCurrent" xlink:label="us-gaap_SettlementAssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SettlementAssetsCurrent" xlink:to="us-gaap_SettlementAssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SettlementAssetsCurrent_lbl" xml:lang="en-US">Settlement Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SettlementAssetsCurrent_lbl" xml:lang="en-US">Settlement receivable - current portion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesAndLoansReceivableNetCurrent" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesAndLoansReceivableNetCurrent" xlink:to="us-gaap_NotesAndLoansReceivableNetCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent_lbl" xml:lang="en-US">Financing Receivable, after Allowance for Credit Loss, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent_lbl" xml:lang="en-US">Convertible promissory note receivable and accrued interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:label="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:to="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_lbl" xml:lang="en-US">Assets Held-for-sale, Not Part of Disposal Group, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_lbl" xml:lang="en-US">Current assets held for sale</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US">Restricted Cash, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US">Restricted cash</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest" xlink:label="ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest" xlink:to="ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest_lbl" xml:lang="en-US">Amount of convertible Promissory Note Receivable and Accrued Interest.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest_lbl" xml:lang="en-US">Convertible Promissory Note Receivable and Accrued Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest_lbl" xml:lang="en-US">Convertible promissory note receivable and accrued interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US">Finance Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US">Finance lease right-of-use assets, net of accumulated amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US">Finance lease ROU assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Net fixed assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Fixed assets, net of accumulated depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Total net intangible assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net of accumulated amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security Deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security deposits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="us-gaap_PrepaidExpenseNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseNoncurrent" xlink:to="us-gaap_PrepaidExpenseNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl" xml:lang="en-US">Prepaid Expense, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl" xml:lang="en-US">Prepaid expenses - noncurrent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_lbl" xml:lang="en-US">Noncurrent assets held for sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_lbl" xml:lang="en-US">Total other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US">Finance Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US">Less: current portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US">Finance lease obligations - current portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US">Finance lease obligation - current portion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Less: current portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease obligation - current portion</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_EquipmentFinancingPayableCurrent" xlink:label="ibio_EquipmentFinancingPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_EquipmentFinancingPayableCurrent" xlink:to="ibio_EquipmentFinancingPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_EquipmentFinancingPayableCurrent_lbl" xml:lang="en-US">The amount of current portion of equipment financing payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_EquipmentFinancingPayableCurrent_lbl" xml:lang="en-US">Equipment Financing Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_EquipmentFinancingPayableCurrent_lbl" xml:lang="en-US">Equipment financing payable - current portion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Notes Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Term note payable - net of deferred financing costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Contract liabilities</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale" xlink:label="ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale" xlink:to="ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale_lbl" xml:lang="en-US">Current liabilities related to assets held for sale.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale_lbl" xml:lang="en-US">Current Liabilities Related To Assets Held For Sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale_lbl" xml:lang="en-US">Current liabilities related to assets held for sale</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Finance Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Long-term portion of minimum lease obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Finance lease obligation - non current portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Finance lease obligations - net of current portion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease obligation - net of current portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Long-term portion of minimum lease obligation</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_EquipmentFinancingPayableNoncurrent" xlink:label="ibio_EquipmentFinancingPayableNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_EquipmentFinancingPayableNoncurrent" xlink:to="ibio_EquipmentFinancingPayableNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_EquipmentFinancingPayableNoncurrent_lbl" xml:lang="en-US">The amount of noncurrent portion of equipment financing payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_EquipmentFinancingPayableNoncurrent_lbl" xml:lang="en-US">Equipment Financing Payable, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_EquipmentFinancingPayableNoncurrent_lbl" xml:lang="en-US">Equipment financing payable - net of current portion</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_AccruedLiabilitiesNoncurrent" xlink:label="ibio_AccruedLiabilitiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_AccruedLiabilitiesNoncurrent" xlink:to="ibio_AccruedLiabilitiesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_AccruedLiabilitiesNoncurrent_lbl" xml:lang="en-US">Carrying value of noncurrent portion of accrued expenses as at the end of the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_AccruedLiabilitiesNoncurrent_lbl" xml:lang="en-US">Accrued Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_AccruedLiabilitiesNoncurrent_lbl" xml:lang="en-US">Accrued expenses - noncurrent</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale" xlink:label="ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale" xlink:to="ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale_lbl" xml:lang="en-US">Noncurrent liabilities related to assets held for sale.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale_lbl" xml:lang="en-US">Noncurrent Liabilities Related To Assets Held For Sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale_lbl" xml:lang="en-US">Noncurrent liabilities related to assets held for sale</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xml:lang="en-US">Equity:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">iBio, Inc. Stockholders' Equity:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Series 2022 Convertible Preferred Stock - $0.001 par value; 1,000,000 shares authorized; 0 and 1,000 shares issued and outstanding as of March 31, 2023 and June 30, 2022, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Value of common stock issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock - $0.001 par value; 275,000,000 shares authorized at March 31, 2023 and June 30, 2022; 15,818,149 and 8,727,158 shares issued and outstanding as of March 31, 2023 and June 30, 2022, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US">Reverse stock split, shares received per share tendered</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Condensed Consolidated Statements of Operations and Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense):</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Investment Income, Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleGainLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleGainLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleGainLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleGainLoss_lbl" xml:lang="en-US">Debt Securities, Available-for-Sale, Gain (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleGainLoss_lbl" xml:lang="en-US">Loss on sale of debt securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleGainLoss_lbl" xml:lang="en-US">Loss on sale of debt securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyIncomeNonoperating" xlink:label="us-gaap_RoyaltyIncomeNonoperating" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyIncomeNonoperating" xlink:to="us-gaap_RoyaltyIncomeNonoperating_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyIncomeNonoperating_lbl" xml:lang="en-US">Royalty Income, Nonoperating</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RoyaltyIncomeNonoperating_lbl" xml:lang="en-US">Royalty income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income (expense)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Consolidated Gain (Loss) From Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Consolidated net loss from continuing operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:label="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:to="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_lbl" xml:lang="en-US">Net loss attributable to noncontrolling interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="us-gaap_IncomeLossFromContinuingOperations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperations" xlink:to="us-gaap_IncomeLossFromContinuingOperations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperations_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperations_lbl" xml:lang="en-US">Net loss attributable to iBio, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperations_lbl" xml:lang="en-US">Net loss attributable to iBio, Inc. from continuing operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPreferredStockStock" xlink:label="us-gaap_DividendsPreferredStockStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStockStock" xlink:to="us-gaap_DividendsPreferredStockStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPreferredStockStock_lbl" xml:lang="en-US">Dividends, Preferred Stock, Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DividendsPreferredStockStock_lbl" xml:lang="en-US">Preferred stock dividends - iBio CDMO Tracking Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:label="us-gaap_DividendsPreferredStockStock_lbl" xml:lang="en-US">Preferred stock dividends - iBio CMO Preferred Tracking Stock</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_NetLossAvailableToStockholdersFromContinuingOperations" xlink:label="ibio_NetLossAvailableToStockholdersFromContinuingOperations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_NetLossAvailableToStockholdersFromContinuingOperations" xlink:to="ibio_NetLossAvailableToStockholdersFromContinuingOperations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_NetLossAvailableToStockholdersFromContinuingOperations_lbl" xml:lang="en-US">Amount of net loss available to stockholders from continuing operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_NetLossAvailableToStockholdersFromContinuingOperations_lbl" xml:lang="en-US">Net Loss Available To Stockholders from Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ibio_NetLossAvailableToStockholdersFromContinuingOperations_lbl" xml:lang="en-US">Net loss available to iBio, Inc. stockholders from continuing operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl" xml:lang="en-US">Loss from discontinued operations</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_UnconsolidatedGainLossAttributableToStockholders" xlink:label="ibio_UnconsolidatedGainLossAttributableToStockholders" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_UnconsolidatedGainLossAttributableToStockholders" xlink:to="ibio_UnconsolidatedGainLossAttributableToStockholders_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_UnconsolidatedGainLossAttributableToStockholders_lbl" xml:lang="en-US">The unconsolidated net gain (loss) attributable to stockholders.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_UnconsolidatedGainLossAttributableToStockholders_lbl" xml:lang="en-US">Unconsolidated Gain (Loss) Attributable To Stockholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ibio_UnconsolidatedGainLossAttributableToStockholders_lbl" xml:lang="en-US">Net loss available to iBio, Inc. stockholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US">Comprehensive loss:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Consolidated net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss including portion attributable to noncontrolling interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Consolidated net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xml:lang="en-US">Other comprehensive income - unrealized gain (loss) on debt securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Foreign currency translation adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Other comprehensive income - foreign currency adjustment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl" xml:lang="en-US">Loss per common share attributable to iBio, Inc. stockholders - basic - continuing operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl" xml:lang="en-US">Loss per common share attributable to iBio, Inc. stockholders - diluted - continuing operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_lbl" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_lbl" xml:lang="en-US">Loss per common share attributable to iBio, Inc. stockholders - basic - discontinued operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_lbl" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_lbl" xml:lang="en-US">Loss per common share attributable to iBio, Inc. stockholders - diluted - discontinued operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Loss per common share attributable to iBio, Inc. stockholders - basic - total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Per share amount basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Loss per common share attributable to iBio, Inc. stockholders - diluted - total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Per share amount diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted-average common shares outstanding - basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted-average common shares outstanding - diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Consolidated Statements of Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated Other Comprehensive Loss [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xml:lang="en-US">Noncontrolling Interest [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in shares)</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_StockIssuedDuringPeriodValueCapitalRaise" xlink:label="ibio_StockIssuedDuringPeriodValueCapitalRaise" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_StockIssuedDuringPeriodValueCapitalRaise" xlink:to="ibio_StockIssuedDuringPeriodValueCapitalRaise_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_StockIssuedDuringPeriodValueCapitalRaise_lbl" xml:lang="en-US">Equity impact of the value of capital raise during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_StockIssuedDuringPeriodValueCapitalRaise_lbl" xml:lang="en-US">Stock Issued During Period, Value, Capital Raise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_StockIssuedDuringPeriodValueCapitalRaise_lbl" xml:lang="en-US">Capital raise</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Stock Options, Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options (in shares)</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_StockIssuedDuringPeriodSharesCapitalRaise" xlink:label="ibio_StockIssuedDuringPeriodSharesCapitalRaise" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_StockIssuedDuringPeriodSharesCapitalRaise" xlink:to="ibio_StockIssuedDuringPeriodSharesCapitalRaise_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_StockIssuedDuringPeriodSharesCapitalRaise_lbl" xml:lang="en-US">Number of new shares raised during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_StockIssuedDuringPeriodSharesCapitalRaise_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Capital Raise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_StockIssuedDuringPeriodSharesCapitalRaise_lbl" xml:lang="en-US">Capital raise (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US">Cost to raise capital</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_FractionalShareIssuedAfterReverseStockSplitValue" xlink:label="ibio_FractionalShareIssuedAfterReverseStockSplitValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_FractionalShareIssuedAfterReverseStockSplitValue" xlink:to="ibio_FractionalShareIssuedAfterReverseStockSplitValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_FractionalShareIssuedAfterReverseStockSplitValue_lbl" xml:lang="en-US">Value of fractional shares after reverse stock split issued during period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_FractionalShareIssuedAfterReverseStockSplitValue_lbl" xml:lang="en-US">Fractional Share Issued After Reverse Stock Split, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_FractionalShareIssuedAfterReverseStockSplitValue_lbl" xml:lang="en-US">Payment for fractional shares after reverse stock split</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_FractionalShareIssuedAfterReverseStockSplitShares" xlink:label="ibio_FractionalShareIssuedAfterReverseStockSplitShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_FractionalShareIssuedAfterReverseStockSplitShares" xlink:to="ibio_FractionalShareIssuedAfterReverseStockSplitShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_FractionalShareIssuedAfterReverseStockSplitShares_lbl" xml:lang="en-US">Number of fractional shares after reverse stock split issued during period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_FractionalShareIssuedAfterReverseStockSplitShares_lbl" xml:lang="en-US">Fractional Share Issued After Reverse Stock Split, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_FractionalShareIssuedAfterReverseStockSplitShares_lbl" xml:lang="en-US">Payment for fractional shares after reverse stock split (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of preferred stock to common stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CommonStockIssuedInRubrycTransactionValue" xlink:label="ibio_CommonStockIssuedInRubrycTransactionValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CommonStockIssuedInRubrycTransactionValue" xlink:to="ibio_CommonStockIssuedInRubrycTransactionValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CommonStockIssuedInRubrycTransactionValue_lbl" xml:lang="en-US">The value of common stock issued in the RubrYc transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CommonStockIssuedInRubrycTransactionValue_lbl" xml:lang="en-US">Common Stock Issued In RubrYc Transaction, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_CommonStockIssuedInRubrycTransactionValue_lbl" xml:lang="en-US">Common stock issued - RubrYc transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ibio_CommonStockIssuedInRubrycTransactionValue_lbl" xml:lang="en-US">RubrYc asset acquisition by issuance of common stock</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CommonStockIssuedInRubrycTransactionInShares" xlink:label="ibio_CommonStockIssuedInRubrycTransactionInShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CommonStockIssuedInRubrycTransactionInShares" xlink:to="ibio_CommonStockIssuedInRubrycTransactionInShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CommonStockIssuedInRubrycTransactionInShares_lbl" xml:lang="en-US">The number of shares of common stock issued in the RubrYc transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CommonStockIssuedInRubrycTransactionInShares_lbl" xml:lang="en-US">Common Stock Issued In RubrYc Transaction (In Shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_CommonStockIssuedInRubrycTransactionInShares_lbl" xml:lang="en-US">Common stock issued - RubrYc transaction (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Vesting of RSU's</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Vesting of RSU's (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Warrant issued for Transaction</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate" xlink:label="ibio_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate" xlink:to="ibio_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate_lbl" xml:lang="en-US">Adjustments to additional paid in capital acquisition of remaining portion of affiliate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate_lbl" xml:lang="en-US">Adjustments to additional paid in capital acquisition of remaining portion of affiliate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ibio_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate_lbl" xml:lang="en-US">Acquisition of remaining portion of iBio CDMO</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_lbl" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Gain (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_lbl" xml:lang="en-US">Unrealized gain (loss) on available-for-sale debt securities</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities" xlink:label="ibio_ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities" xlink:to="ibio_ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities_lbl" xml:lang="en-US">The reclassification adjustment for the period on gains (losses) on avaliable for sale debt securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities_lbl" xml:lang="en-US">Reclassficiation Adjustment, Gain (Loss) On Available For Sale Debt Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities_lbl" xml:lang="en-US">Reclassification adjustment for loss on available-for-sale debt securities realized in net income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Net loss attributable to noncontrolling interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Condensed Consolidated Statements of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile consolidated net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based Compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of definite lived intangible assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US">Amortization of ROU assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US">Amortization of finance lease right-of-use assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US">Amortization of finance lease ROU assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Amortization of operating lease right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation of fixed assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:label="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:to="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_lbl" xml:lang="en-US">Gain (Loss) on Sale of Assets and Asset Impairment Charges</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_lbl" xml:lang="en-US">Gain on sale of fixed assets</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable" xlink:label="ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable" xlink:to="ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable_lbl" xml:lang="en-US">Amount of accrued interest receivable on convertible promissory note receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable_lbl" xml:lang="en-US">Accrued Interest Receivable on Convertible Promissory Note Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable_lbl" xml:lang="en-US">Accrued interest receivable on convertible promissory note receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of Debt Discount (Premium)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of premiums on debt securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of premiums on debt securities</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_DeferredFinancingCostsAmortizationExpense" xlink:label="ibio_DeferredFinancingCostsAmortizationExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DeferredFinancingCostsAmortizationExpense" xlink:to="ibio_DeferredFinancingCostsAmortizationExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DeferredFinancingCostsAmortizationExpense_lbl" xml:lang="en-US">Amortization of loan and debt issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DeferredFinancingCostsAmortizationExpense_lbl" xml:lang="en-US">Deferred Financing Costs, Amortization Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DeferredFinancingCostsAmortizationExpense_lbl" xml:lang="en-US">Amortization of deferred financing costs</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_IncreaseDecreaseInInventoryReserve" xlink:label="ibio_IncreaseDecreaseInInventoryReserve" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IncreaseDecreaseInInventoryReserve" xlink:to="ibio_IncreaseDecreaseInInventoryReserve_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_IncreaseDecreaseInInventoryReserve_lbl" xml:lang="en-US">The increase (decrease) in inventory valuation reserve during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IncreaseDecreaseInInventoryReserve_lbl" xml:lang="en-US">Increase (Decrease) In Inventory Reserve</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_IncreaseDecreaseInInventoryReserve_lbl" xml:lang="en-US">Inventory reserve</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="us-gaap_TangibleAssetImpairmentCharges" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TangibleAssetImpairmentCharges" xlink:to="us-gaap_TangibleAssetImpairmentCharges_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TangibleAssetImpairmentCharges_lbl" xml:lang="en-US">Tangible Asset Impairment Charges</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TangibleAssetImpairmentCharges_lbl" xml:lang="en-US">Impairment of fixed assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TangibleAssetImpairmentCharges_lbl" xml:lang="en-US">Fixed assets impairments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US">Impairment of intangible assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US">Impairment of intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases" xlink:label="us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases" xlink:to="us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases_lbl" xml:lang="en-US">Gain (Loss) on Sale of Leased Assets, Net, Operating Leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases_lbl" xml:lang="en-US">Gain on disposition of finance lease ROU assets</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan" xlink:label="ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan" xlink:to="ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan_lbl" xml:lang="en-US">Forgiveness of note payable and accrued interest - SBA loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan_lbl" xml:lang="en-US">Forgiveness of note payable and accrued interest - SBA loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan_lbl" xml:lang="en-US">Forgiveness of note payable and accrued interest - SBA loan</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SettlementOfRevenueContract" xlink:label="ibio_SettlementOfRevenueContract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SettlementOfRevenueContract" xlink:to="ibio_SettlementOfRevenueContract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SettlementOfRevenueContract_lbl" xml:lang="en-US">Settlement of revenue contract.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SettlementOfRevenueContract_lbl" xml:lang="en-US">Settlement of revenue contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ibio_SettlementOfRevenueContract_lbl" xml:lang="en-US">Settlement of revenue contract</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable - trade</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_IncreaseDecreaseInSettlementAssets" xlink:label="ibio_IncreaseDecreaseInSettlementAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IncreaseDecreaseInSettlementAssets" xlink:to="ibio_IncreaseDecreaseInSettlementAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_IncreaseDecreaseInSettlementAssets_lbl" xml:lang="en-US">Increase (decrease) in cash received or short term receivables for unsettled money transfers, money orders, consumer payments, or business to business payments. Settlement assets include clearing and settling customers payments due to and from financial institutions and may include cash and cash equivalents.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IncreaseDecreaseInSettlementAssets_lbl" xml:lang="en-US">Increase (Decrease) In Settlement Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ibio_IncreaseDecreaseInSettlementAssets_lbl" xml:lang="en-US">Settlement receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories" xlink:label="us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories" xlink:to="us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories_lbl" xml:lang="en-US">Increase (Decrease) in Finished Goods and Work in Process Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories_lbl" xml:lang="en-US">Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses - noncurrent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits_lbl" xml:lang="en-US">Increase (Decrease) in Security Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits_lbl" xml:lang="en-US">Security deposit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent" xlink:label="ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent" xlink:to="ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent_lbl" xml:lang="en-US">The increase (decrease) during the reporting period in the aggregate amount of noncurrent expenses incurred but not yet paid.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent_lbl" xml:lang="en-US">Accrued expenses - noncurrent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease obligations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Contract liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xml:lang="en-US">Purchases of debt securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xml:lang="en-US">Redemption of debt securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-Sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl" xml:lang="en-US">Sale of debt securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:label="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:to="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_lbl" xml:lang="en-US">Payments to Acquire Equity Securities, FV-NI</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_lbl" xml:lang="en-US">Purchase of equity security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Payments to Acquire Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Additions to intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of fixed assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Sales of fixed assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xml:lang="en-US">Payment for RubrYc asset acquisition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ProceedsFromIssuanceOfPreferredAndCommonStock" xlink:label="ibio_ProceedsFromIssuanceOfPreferredAndCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ProceedsFromIssuanceOfPreferredAndCommonStock" xlink:to="ibio_ProceedsFromIssuanceOfPreferredAndCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ProceedsFromIssuanceOfPreferredAndCommonStock_lbl" xml:lang="en-US">The cash inflow from the additional capital contribution to the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ProceedsFromIssuanceOfPreferredAndCommonStock_lbl" xml:lang="en-US">Proceeds From Issuance Of Preferred And Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_ProceedsFromIssuanceOfPreferredAndCommonStock_lbl" xml:lang="en-US">Proceeds from sales of common stock</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_PaymentsForFractionalSharesAfterReverseStockSplit" xlink:label="ibio_PaymentsForFractionalSharesAfterReverseStockSplit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_PaymentsForFractionalSharesAfterReverseStockSplit" xlink:to="ibio_PaymentsForFractionalSharesAfterReverseStockSplit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_PaymentsForFractionalSharesAfterReverseStockSplit_lbl" xml:lang="en-US">The amount of cash outflow for fractional shares after reverse stock split.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_PaymentsForFractionalSharesAfterReverseStockSplit_lbl" xml:lang="en-US">Payments for Fractional Shares after Reverse Stock Split</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ibio_PaymentsForFractionalSharesAfterReverseStockSplit_lbl" xml:lang="en-US">Payments for fractional shares after reverse stock split</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="us-gaap_PaymentsToMinorityShareholders" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToMinorityShareholders" xlink:to="us-gaap_PaymentsToMinorityShareholders_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToMinorityShareholders_lbl" xml:lang="en-US">Payments to Noncontrolling Interests</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToMinorityShareholders_lbl" xml:lang="en-US">Acquisition of noncontrolling interest</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ProceedsFromEquipmentFinancingLoan" xlink:label="ibio_ProceedsFromEquipmentFinancingLoan" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ProceedsFromEquipmentFinancingLoan" xlink:to="ibio_ProceedsFromEquipmentFinancingLoan_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ProceedsFromEquipmentFinancingLoan_lbl" xml:lang="en-US">The amount of cash inflow from equipment financing loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ProceedsFromEquipmentFinancingLoan_lbl" xml:lang="en-US">Proceeds from Equipment Financing Loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_ProceedsFromEquipmentFinancingLoan_lbl" xml:lang="en-US">Proceeds from equipment financing loan</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_PaymentOfEquipmentFinancingLoan" xlink:label="ibio_PaymentOfEquipmentFinancingLoan" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_PaymentOfEquipmentFinancingLoan" xlink:to="ibio_PaymentOfEquipmentFinancingLoan_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_PaymentOfEquipmentFinancingLoan_lbl" xml:lang="en-US">The amount of cash outflow for equipment financing loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_PaymentOfEquipmentFinancingLoan_lbl" xml:lang="en-US">Payment of Equipment Financing Loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ibio_PaymentOfEquipmentFinancingLoan_lbl" xml:lang="en-US">Payment of equipment financing loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Repayments of Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Payment of term note payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_PaymentsToAttainTermNote" xlink:label="ibio_PaymentsToAttainTermNote" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_PaymentsToAttainTermNote" xlink:to="ibio_PaymentsToAttainTermNote_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_PaymentsToAttainTermNote_lbl" xml:lang="en-US">The cash outflow for cost incurred with attain term note.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_PaymentsToAttainTermNote_lbl" xml:lang="en-US">Payments To Attain Term Note</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ibio_PaymentsToAttainTermNote_lbl" xml:lang="en-US">Costs to attain term note</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US">Finance Lease, Principal Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US">Payment of finance lease obligation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash used in provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Effect of exchange rate changes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Amount released from restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net decrease in cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash - end</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash - beginning</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Other Noncash Investing and Financing Items [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Schedule of non-cash activities:</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid" xlink:label="ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid" xlink:to="ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid_lbl" xml:lang="en-US">The amount paid for capital expenditures incurred for intangible assets during the previous year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid_lbl" xml:lang="en-US">Capital Expenditure Incurred For Intangible Assets Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid_lbl" xml:lang="en-US">Fixed assets included in accounts payable in prior period, paid in current period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xml:lang="en-US">Increase in finance lease ROU assets for new leases</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases" xlink:label="ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases" xlink:to="ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases_lbl" xml:lang="en-US">The increase (decrease) in finance lease obligations for new leases incurred during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases_lbl" xml:lang="en-US">Increase (Decrease) In Finance Lease Obligations For New Leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases_lbl" xml:lang="en-US">Increase in finance lease obligation for new leases</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CostToRaiseCapitalPaidDirectlyFromGrossProceeds" xlink:label="ibio_CostToRaiseCapitalPaidDirectlyFromGrossProceeds" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CostToRaiseCapitalPaidDirectlyFromGrossProceeds" xlink:to="ibio_CostToRaiseCapitalPaidDirectlyFromGrossProceeds_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CostToRaiseCapitalPaidDirectlyFromGrossProceeds_lbl" xml:lang="en-US">The amount of cost incurred to raise capital directly from gross proceeds.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CostToRaiseCapitalPaidDirectlyFromGrossProceeds_lbl" xml:lang="en-US">Cost to Raise Capital paid Directly from Gross Proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_CostToRaiseCapitalPaidDirectlyFromGrossProceeds_lbl" xml:lang="en-US">Costs to raise capital paid directly from gross proceeds</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_TerminationOfFinanceLeaseRightOfUseAssetIncludingIssuanceOfWarrant" xlink:label="ibio_TerminationOfFinanceLeaseRightOfUseAssetIncludingIssuanceOfWarrant" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_TerminationOfFinanceLeaseRightOfUseAssetIncludingIssuanceOfWarrant" xlink:to="ibio_TerminationOfFinanceLeaseRightOfUseAssetIncludingIssuanceOfWarrant_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_TerminationOfFinanceLeaseRightOfUseAssetIncludingIssuanceOfWarrant_lbl" xml:lang="en-US">Amount of termination of finance lease right of use asset, including issuance of warrant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_TerminationOfFinanceLeaseRightOfUseAssetIncludingIssuanceOfWarrant_lbl" xml:lang="en-US">Termination Of Finance Lease Right Of Use Asset, Including Issuance Of Warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_TerminationOfFinanceLeaseRightOfUseAssetIncludingIssuanceOfWarrant_lbl" xml:lang="en-US">Termination of finance ROU assets including issuance of warrant</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesIssued1" xlink:label="us-gaap_NotesIssued1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesIssued1" xlink:to="us-gaap_NotesIssued1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesIssued1_lbl" xml:lang="en-US">Notes Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesIssued1_lbl" xml:lang="en-US">Note payable to acquire Facility</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities" xlink:label="ibio_NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities" xlink:to="ibio_NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities_lbl" xml:lang="en-US">The amount of increase in Right Of Use Assets under the ASU 842, for which no cash outflow was incurred.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities_lbl" xml:lang="en-US">Non Cash Transaction Increase In Right Of Use Assets And Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities_lbl" xml:lang="en-US">Increase in operating lease ROU assets for new lease - net of lease incentive</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_NonCashSettlementOfRevenueContract" xlink:label="ibio_NonCashSettlementOfRevenueContract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_NonCashSettlementOfRevenueContract" xlink:to="ibio_NonCashSettlementOfRevenueContract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_NonCashSettlementOfRevenueContract_lbl" xml:lang="en-US">Non cash Settlement of revenue contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_NonCashSettlementOfRevenueContract_lbl" xml:lang="en-US">Non cash Settlement of revenue contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ibio_NonCashSettlementOfRevenueContract_lbl" xml:lang="en-US">Settlement of revenue contract</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_WarrantsIssuedForFinanceLeasePayment" xlink:label="ibio_WarrantsIssuedForFinanceLeasePayment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_WarrantsIssuedForFinanceLeasePayment" xlink:to="ibio_WarrantsIssuedForFinanceLeasePayment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_WarrantsIssuedForFinanceLeasePayment_lbl" xml:lang="en-US">The fair value of warrants issued in noncash financing activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_WarrantsIssuedForFinanceLeasePayment_lbl" xml:lang="en-US">Warrants Issued for Finance Lease Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_WarrantsIssuedForFinanceLeasePayment_lbl" xml:lang="en-US">Issuance of warrant for final finance lease obligation payment</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LeaseIncentiveForConstructionInProgress" xlink:label="ibio_LeaseIncentiveForConstructionInProgress" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LeaseIncentiveForConstructionInProgress" xlink:to="ibio_LeaseIncentiveForConstructionInProgress_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LeaseIncentiveForConstructionInProgress_lbl" xml:lang="en-US">Lease incentive for construction in progress</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LeaseIncentiveForConstructionInProgress_lbl" xml:lang="en-US">Lease incentive for construction in progress</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_NoncashOrPartNoncashAcquisitionNonControllingInterestAssumed" xlink:label="ibio_NoncashOrPartNoncashAcquisitionNonControllingInterestAssumed" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_NoncashOrPartNoncashAcquisitionNonControllingInterestAssumed" xlink:to="ibio_NoncashOrPartNoncashAcquisitionNonControllingInterestAssumed_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_NoncashOrPartNoncashAcquisitionNonControllingInterestAssumed_lbl" xml:lang="en-US">The amount of non controlling interest that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_NoncashOrPartNoncashAcquisitionNonControllingInterestAssumed_lbl" xml:lang="en-US">Noncash or Part Noncash Acquisition, Non Controlling Interest Assumed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_NoncashOrPartNoncashAcquisitionNonControllingInterestAssumed_lbl" xml:lang="en-US">Acquisition of noncontrolling interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl" xml:lang="en-US">Unrealized (gain) loss on available-for-sale debt securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental cash flow information:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest Paid, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid during the period for interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Nature of Business [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">Nature of Operations [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">Nature of Business</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_BasisOfPresentationAbstract" xlink:label="ibio_BasisOfPresentationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_BasisOfPresentationAbstract" xlink:to="ibio_BasisOfPresentationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_BasisOfPresentationAbstract_lbl" xml:lang="en-US">Represents the information pertaining to Basis of Presentation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_BasisOfPresentationAbstract_lbl" xml:lang="en-US">Basis of Presentation [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_lbl" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl" xml:lang="en-US">Discontinued Operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Financial Instruments and Fair Value Measurement [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Financial Instruments and Fair Value Measurement</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SignificantTransactionsAbstract" xlink:label="ibio_SignificantTransactionsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SignificantTransactionsAbstract" xlink:to="ibio_SignificantTransactionsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SignificantTransactionsAbstract_lbl" xml:lang="en-US">Significant Transactions [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SignificantTransactionsAbstract_lbl" xml:lang="en-US">Significant Transactions [Abstract]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SignificantTransactionsTextBlock" xlink:label="ibio_SignificantTransactionsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SignificantTransactionsTextBlock" xlink:to="ibio_SignificantTransactionsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SignificantTransactionsTextBlock_lbl" xml:lang="en-US">Significant Transactions [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SignificantTransactionsTextBlock_lbl" xml:lang="en-US">Significant Transactions [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ibio_SignificantTransactionsTextBlock_lbl" xml:lang="en-US">Significant Transactions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ReceivablesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesAbstract_lbl" xml:lang="en-US">Convertible Promissory Note Receivable [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xml:lang="en-US">Loans, Notes, Trade and Other Receivables Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xml:lang="en-US">Convertible Promissory Note Receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xml:lang="en-US">Investments in Debt and Equity Securities [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Investments in Debt Securities</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" xlink:to="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract_lbl" xml:lang="en-US">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract_lbl" xml:lang="en-US">Finance Lease ROU [Abstract]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock" xlink:to="ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock_lbl" xml:lang="en-US">The entire disclosure for lessee's right to use underlying asset under finance lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock_lbl" xml:lang="en-US">Finance Lease, Right Of Use Asset, Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock_lbl" xml:lang="en-US">Finance Lease ROU Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureTextBlockAbstract_lbl" xml:lang="en-US">Operating Lease ROU Assets [Abstract]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock" xlink:label="ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock" xlink:to="ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock_lbl" xml:lang="en-US">The entire disclosure for lessee's right to use underlying asset under operating lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock_lbl" xml:lang="en-US">Operating Lease Right Of Use Asset Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock_lbl" xml:lang="en-US">Operating Lease ROU Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Fixed Assets [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Fixed Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Intangible Assets [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Intangible Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeDisclosureAbstract_lbl" xml:lang="en-US">Finance Lease Obligation [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeasesTextBlock" xlink:label="us-gaap_LesseeFinanceLeasesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="us-gaap_LesseeFinanceLeasesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeFinanceLeasesTextBlock_lbl" xml:lang="en-US">Lessee, Finance Leases [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeFinanceLeasesTextBlock_lbl" xml:lang="en-US">Finance Lease Obligation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract_lbl" xml:lang="en-US">Operating Lease, Liability [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Operating Lease Obligation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders' Equity [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings (Loss) Per Common Share [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Earnings (Loss) Per Common Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Compensation [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Share-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlementAbstract" xlink:label="us-gaap_GainLossRelatedToLitigationSettlementAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossRelatedToLitigationSettlementAbstract" xlink:to="us-gaap_GainLossRelatedToLitigationSettlementAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossRelatedToLitigationSettlementAbstract_lbl" xml:lang="en-US">Fraunhofer Settlement [Abstract]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_GainLossRelatedToLitigationSettlementTextBlock" xlink:label="ibio_GainLossRelatedToLitigationSettlementTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_GainLossRelatedToLitigationSettlementTextBlock" xlink:to="ibio_GainLossRelatedToLitigationSettlementTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_GainLossRelatedToLitigationSettlementTextBlock_lbl" xml:lang="en-US">Entire disclosure on gain (Loss) related to litigation settlement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_GainLossRelatedToLitigationSettlementTextBlock_lbl" xml:lang="en-US">Gain Loss Related To Litigation Settlement [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_GainLossRelatedToLitigationSettlementTextBlock_lbl" xml:lang="en-US">Fraunhofer Settlement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Taxes [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">Employee 401(K) Plan [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US">Pension and Other Postretirement Benefits Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US">Employee 401(K) Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Trade and Other Accounts Receivable, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Accounts Receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ContractAssetsPolicyTextBlock" xlink:label="ibio_ContractAssetsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ContractAssetsPolicyTextBlock" xlink:to="ibio_ContractAssetsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ContractAssetsPolicyTextBlock_lbl" xml:lang="en-US">Disclosure of accounting policy for contract assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ContractAssetsPolicyTextBlock_lbl" xml:lang="en-US">Contract Assets [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_ContractAssetsPolicyTextBlock_lbl" xml:lang="en-US">Contract Assets</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ContractLiabilitiesPolicyTextBlock" xlink:label="ibio_ContractLiabilitiesPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ContractLiabilitiesPolicyTextBlock" xlink:to="ibio_ContractLiabilitiesPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ContractLiabilitiesPolicyTextBlock_lbl" xml:lang="en-US">Disclosure of accounting policy for contract liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ContractLiabilitiesPolicyTextBlock_lbl" xml:lang="en-US">Contract Liabilities [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_ContractLiabilitiesPolicyTextBlock_lbl" xml:lang="en-US">Contract Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy" xlink:label="us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy" xlink:to="us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy_lbl" xml:lang="en-US">Debt Securities, Available-for-sale, Premium on Purchased Options [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy_lbl" xml:lang="en-US">Investments in Debt Securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_RightOfUseAssetsPolicyPolicyTextBlock" xlink:label="ibio_RightOfUseAssetsPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_RightOfUseAssetsPolicyPolicyTextBlock" xlink:to="ibio_RightOfUseAssetsPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_RightOfUseAssetsPolicyPolicyTextBlock_lbl" xml:lang="en-US">The disclosure of accounting policy for right-of-use assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_RightOfUseAssetsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Right Of Use Assets Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_RightOfUseAssetsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Right-of-Use Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Fixed Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xml:lang="en-US">Intangible Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentrations of Credit Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_lbl" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_lbl" xml:lang="en-US">Schedule of discontinued operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US">Schedule of of total cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of fixed assets measured at fair value on a non-recurring basis</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionAxis_lbl" xml:lang="en-US">Asset Acquisition [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="us-gaap_AssetAcquisitionDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionDomain_lbl" xml:lang="en-US">Asset Acquisition [Domain]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_StockPurchaseAgreementMember" xlink:label="ibio_StockPurchaseAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_StockPurchaseAgreementMember" xlink:to="ibio_StockPurchaseAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_StockPurchaseAgreementMember_lbl" xml:lang="en-US">Stock Purchase Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_StockPurchaseAgreementMember_lbl" xml:lang="en-US">Stock Purchase Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_AssetPurchaseAgreementMember" xlink:label="ibio_AssetPurchaseAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_AssetPurchaseAgreementMember" xlink:to="ibio_AssetPurchaseAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_AssetPurchaseAgreementMember_lbl" xml:lang="en-US">Asset Purchase Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_AssetPurchaseAgreementMember_lbl" xml:lang="en-US">Asset Purchase Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTableTextBlock" xlink:label="us-gaap_AssetAcquisitionTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionTableTextBlock" xlink:to="us-gaap_AssetAcquisitionTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionTableTextBlock_lbl" xml:lang="en-US">Asset Acquisition [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionTableTextBlock_lbl" xml:lang="en-US">Summary of Purchase Price Allocation of Asset Acquisition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of components of investments in debt securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xml:lang="en-US">Schedule of fair value of available-for-sale debt securities, by contractual maturity</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_AvaliableForSaleDebtSecuritiesRealizedGainsLossesTableTextBlock" xlink:label="ibio_AvaliableForSaleDebtSecuritiesRealizedGainsLossesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_AvaliableForSaleDebtSecuritiesRealizedGainsLossesTableTextBlock" xlink:to="ibio_AvaliableForSaleDebtSecuritiesRealizedGainsLossesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_AvaliableForSaleDebtSecuritiesRealizedGainsLossesTableTextBlock_lbl" xml:lang="en-US">Tabular disclosure of realized gains (losses) on available for sale debt securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_AvaliableForSaleDebtSecuritiesRealizedGainsLossesTableTextBlock_lbl" xml:lang="en-US">Avaliable For Sale Debt Securities Realized Gains (Losses) [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_AvaliableForSaleDebtSecuritiesRealizedGainsLossesTableTextBlock_lbl" xml:lang="en-US">Schedule of realized gains on available-for-sale debt securities</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock" xlink:label="ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock" xlink:to="ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock_lbl" xml:lang="en-US">The tabular disclosure for the gross carrying value and accumulated amortization of right-to-use assets under finance lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock_lbl" xml:lang="en-US">Summary Of Gross Carrying Value And Accumulated Amortization Of Finance Lease, Right Of Use Assets [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock_lbl" xml:lang="en-US">Summary of the gross carrying value and accumulated amortization of finance lease ROU</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of gross carrying value and accumulated depreciation of fixed assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Category the gross carrying value and accumulated amortization of intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableAbstract" xlink:label="us-gaap_NotesPayableAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_NotesPayableAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableAbstract_lbl" xml:lang="en-US">Notes Payable [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:to="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl" xml:lang="en-US">Contractual Obligation, Fiscal Year Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl" xml:lang="en-US">Schedule of future minimum payments under the finance lease obligation</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock" xlink:label="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock" xlink:to="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock_lbl" xml:lang="en-US">The tabular disclosure for components of lease expense and supplemental balance sheet information related to the finance lease obligation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock_lbl" xml:lang="en-US">Schedule Of Components Of Lease Expense And Supplemental Balance Sheet Information Related To Finance Lease Obligation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock_lbl" xml:lang="en-US">Schedule of components of lease expense and supplemental balance sheet information related to the finance lease obligation</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ScheduleOfFinanceLeaseRightOfUseAssetsAndObligationAndWeightedAverageInformationTableTextBlock" xlink:label="ibio_ScheduleOfFinanceLeaseRightOfUseAssetsAndObligationAndWeightedAverageInformationTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ScheduleOfFinanceLeaseRightOfUseAssetsAndObligationAndWeightedAverageInformationTableTextBlock" xlink:to="ibio_ScheduleOfFinanceLeaseRightOfUseAssetsAndObligationAndWeightedAverageInformationTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ScheduleOfFinanceLeaseRightOfUseAssetsAndObligationAndWeightedAverageInformationTableTextBlock_lbl" xml:lang="en-US">Represents information pertaining to schedule of finance lease right of use assets and obligation and weighted average information.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ScheduleOfFinanceLeaseRightOfUseAssetsAndObligationAndWeightedAverageInformationTableTextBlock_lbl" xml:lang="en-US">Schedule of Finance Lease Right of use Assets and Obligation and Weighted average Information [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_ScheduleOfFinanceLeaseRightOfUseAssetsAndObligationAndWeightedAverageInformationTableTextBlock_lbl" xml:lang="en-US">Schedule of finance lease and weighted average information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Finance Lease, Liability, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Future Minimum Payments Under the Finance Lease Obligation</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock" xlink:label="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock" xlink:to="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock_lbl" xml:lang="en-US">Schedule of components of lease expense and supplemental balance sheet information related to the Operating lease obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock_lbl" xml:lang="en-US">Schedule of components of lease expense and supplemental balance sheet information related to the Operating lease obligation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock_lbl" xml:lang="en-US">Lease Expense and Supplemental Balance Sheet Information Related to the Operating Lease Obligation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Future Minimum Payments under the Operating Lease Obligation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Earnings (loss) Per Share, Basic and Diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair value of options granted using the Black-Scholes option pricing model</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xml:lang="en-US">Percentage of workforce reduction</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:to="us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_lbl" xml:lang="en-US">Restructuring and Related Cost, Expected Number of Positions Eliminated</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_lbl" xml:lang="en-US">Number of positions reduced</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CashAndCashEquivalentsPlusDebtSecurities" xlink:label="ibio_CashAndCashEquivalentsPlusDebtSecurities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CashAndCashEquivalentsPlusDebtSecurities" xlink:to="ibio_CashAndCashEquivalentsPlusDebtSecurities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CashAndCashEquivalentsPlusDebtSecurities_lbl" xml:lang="en-US">Cash and cash equivalents plus debt securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CashAndCashEquivalentsPlusDebtSecurities_lbl" xml:lang="en-US">Cash and cash equivalents plus debt securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_CashAndCashEquivalentsPlusDebtSecurities_lbl" xml:lang="en-US">Cash and cash equivalents and marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_lbl" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_lbl" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_EmployeeReductionExpenses" xlink:label="ibio_EmployeeReductionExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_EmployeeReductionExpenses" xlink:to="ibio_EmployeeReductionExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_EmployeeReductionExpenses_lbl" xml:lang="en-US">Expected amount of expenses to be incurred due to employee reductions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_EmployeeReductionExpenses_lbl" xml:lang="en-US">Employee Reduction Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_EmployeeReductionExpenses_lbl" xml:lang="en-US">Expected employee reduction charges</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown" xlink:to="ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown_lbl" xml:lang="en-US">The amount inventory written down in a discontinued operation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Inventory Write down</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown_lbl" xml:lang="en-US">Inventory impairments</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance" xlink:to="ibio_DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance_lbl" xml:lang="en-US">The amount of personnel cost including severance incurred in a discontinuing operation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Personnel Costs Including Severance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance_lbl" xml:lang="en-US">Personnel costs including severance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" xlink:label="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" xlink:to="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_lbl" xml:lang="en-US">Results of operations for discontinued operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_lbl" xml:lang="en-US">Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_lbl" xml:lang="en-US">Revenue reported in discontinued operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Costs of Goods Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_lbl" xml:lang="en-US">Cost of goods sold</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Gross Profit (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_lbl" xml:lang="en-US">Gross profit</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses" xlink:label="ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses" xlink:to="ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Research and development expenses attributable to discontinued operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Discontinued Operations, Research And Development Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_TangibleAssetImpairmentChargesDiscontinuedOperations" xlink:label="ibio_TangibleAssetImpairmentChargesDiscontinuedOperations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_TangibleAssetImpairmentChargesDiscontinuedOperations" xlink:to="ibio_TangibleAssetImpairmentChargesDiscontinuedOperations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_TangibleAssetImpairmentChargesDiscontinuedOperations_lbl" xml:lang="en-US">The charge against earnings resulting from the aggregate write down of tangible assets of discontinued operations from their carrying value to their fair value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_TangibleAssetImpairmentChargesDiscontinuedOperations_lbl" xml:lang="en-US">Tangible Asset Impairment Charges, Discontinued Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_TangibleAssetImpairmentChargesDiscontinuedOperations_lbl" xml:lang="en-US">Fixed assets impairments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_lbl" xml:lang="en-US">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_lbl" xml:lang="en-US">Interest expense - term note payable</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_DisposalGroupInterestExpenseRelatedParty" xlink:label="ibio_DisposalGroupInterestExpenseRelatedParty" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DisposalGroupInterestExpenseRelatedParty" xlink:to="ibio_DisposalGroupInterestExpenseRelatedParty_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DisposalGroupInterestExpenseRelatedParty_lbl" xml:lang="en-US">Interest expense to related party from discontinued operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DisposalGroupInterestExpenseRelatedParty_lbl" xml:lang="en-US">Disposal Group, Interest Expense, Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ibio_DisposalGroupInterestExpenseRelatedParty_lbl" xml:lang="en-US">Interest expense - related party</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_DisposalGroupGainOnDebtForgiveness" xlink:label="ibio_DisposalGroupGainOnDebtForgiveness" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DisposalGroupGainOnDebtForgiveness" xlink:to="ibio_DisposalGroupGainOnDebtForgiveness_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DisposalGroupGainOnDebtForgiveness_lbl" xml:lang="en-US">Gain (loss) on forgiveness of debt to discontinued operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DisposalGroupGainOnDebtForgiveness_lbl" xml:lang="en-US">Disposal Group, Gain On Debt Forgiveness</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DisposalGroupGainOnDebtForgiveness_lbl" xml:lang="en-US">Forgiveness of note payable and accrued interest - SBA loan</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_DiscontinuedOperationsMiscellaneousExpensesIncome" xlink:label="ibio_DiscontinuedOperationsMiscellaneousExpensesIncome" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DiscontinuedOperationsMiscellaneousExpensesIncome" xlink:to="ibio_DiscontinuedOperationsMiscellaneousExpensesIncome_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DiscontinuedOperationsMiscellaneousExpensesIncome_lbl" xml:lang="en-US">Miscellaneous expenses (income) attributable to discontinued operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DiscontinuedOperationsMiscellaneousExpensesIncome_lbl" xml:lang="en-US">Discontinued Operations, Miscellaneous Expenses (Income)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ibio_DiscontinuedOperationsMiscellaneousExpensesIncome_lbl" xml:lang="en-US">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_lbl" xml:lang="en-US">Total other income (expenses)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Balance Sheet Disclosures [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_lbl" xml:lang="en-US">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Inventory, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_lbl" xml:lang="en-US">Inventory</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_DisposalGroupOperatingLeaseRightOfUseAssets" xlink:label="ibio_DisposalGroupOperatingLeaseRightOfUseAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DisposalGroupOperatingLeaseRightOfUseAssets" xlink:to="ibio_DisposalGroupOperatingLeaseRightOfUseAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DisposalGroupOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Current operating lease ROU assets attributable to discontinued operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DisposalGroupOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Disposal Group, Operating Lease Right Of Use Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DisposalGroupOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Operating lease right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_lbl" xml:lang="en-US">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_lbl" xml:lang="en-US">Other assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_lbl" xml:lang="en-US">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent" xlink:label="ibio_DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent" xlink:to="ibio_DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent_lbl" xml:lang="en-US">Noncurrent operating lease ROU assets attributable to discontinued operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent_lbl" xml:lang="en-US">Disposal Group, Operating Lease Right Of Use Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent_lbl" xml:lang="en-US">Operating lease right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_DisposalGroupNonCurrentAssetsFinanceLeaseRightOfUseAssets" xlink:label="ibio_DisposalGroupNonCurrentAssetsFinanceLeaseRightOfUseAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DisposalGroupNonCurrentAssetsFinanceLeaseRightOfUseAssets" xlink:to="ibio_DisposalGroupNonCurrentAssetsFinanceLeaseRightOfUseAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DisposalGroupNonCurrentAssetsFinanceLeaseRightOfUseAssets_lbl" xml:lang="en-US">Amount classified as non current  assets attributable to disposal group held for sale or disposed of, expected to be disposed of more than one year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DisposalGroupNonCurrentAssetsFinanceLeaseRightOfUseAssets_lbl" xml:lang="en-US">Disposal Group, Non Current Assets, Finance Lease Right of Use Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DisposalGroupNonCurrentAssetsFinanceLeaseRightOfUseAssets_lbl" xml:lang="en-US">Finance lease right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_DisposalGroupCurrentLiabilitiesFinanceLeaseObligations" xlink:label="ibio_DisposalGroupCurrentLiabilitiesFinanceLeaseObligations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DisposalGroupCurrentLiabilitiesFinanceLeaseObligations" xlink:to="ibio_DisposalGroupCurrentLiabilitiesFinanceLeaseObligations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DisposalGroupCurrentLiabilitiesFinanceLeaseObligations_lbl" xml:lang="en-US">Current finance lease obligations attributable to discontinued operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DisposalGroupCurrentLiabilitiesFinanceLeaseObligations_lbl" xml:lang="en-US">Disposal Group, Current Liabilities, Finance Lease Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DisposalGroupCurrentLiabilitiesFinanceLeaseObligations_lbl" xml:lang="en-US">Finance lease obligation</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations" xlink:label="ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations" xlink:to="ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations_lbl" xml:lang="en-US">Current operating lease obligations attributable to discontinued operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations_lbl" xml:lang="en-US">Disposal Group, Current Liabilities, Operating Lease Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations_lbl" xml:lang="en-US">Operating lease obligation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_lbl" xml:lang="en-US">Long-term liabilities:</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_DisposalGroupNoncurrentLiabilitiesFinanceLeaseObligations" xlink:label="ibio_DisposalGroupNoncurrentLiabilitiesFinanceLeaseObligations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DisposalGroupNoncurrentLiabilitiesFinanceLeaseObligations" xlink:to="ibio_DisposalGroupNoncurrentLiabilitiesFinanceLeaseObligations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DisposalGroupNoncurrentLiabilitiesFinanceLeaseObligations_lbl" xml:lang="en-US">Noncurrent finance lease obligations attributable to discontinued operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DisposalGroupNoncurrentLiabilitiesFinanceLeaseObligations_lbl" xml:lang="en-US">Disposal Group, Noncurrent Liabilities, Finance Lease Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DisposalGroupNoncurrentLiabilitiesFinanceLeaseObligations_lbl" xml:lang="en-US">Finance lease obligation</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_DisposalGroupNoncurrentOperatingLeaseObligations" xlink:label="ibio_DisposalGroupNoncurrentOperatingLeaseObligations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DisposalGroupNoncurrentOperatingLeaseObligations" xlink:to="ibio_DisposalGroupNoncurrentOperatingLeaseObligations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DisposalGroupNoncurrentOperatingLeaseObligations_lbl" xml:lang="en-US">Noncurrent operating lease obligations attributable to discontinued operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DisposalGroupNoncurrentOperatingLeaseObligations_lbl" xml:lang="en-US">Disposal Group, Noncurrent Operating Lease Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DisposalGroupNoncurrentOperatingLeaseObligations_lbl" xml:lang="en-US">Operating lease obligation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_lbl" xml:lang="en-US">Total long-term liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Discontinued Operations [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:label="us-gaap_DepreciationAndAmortizationDiscontinuedOperations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:to="us-gaap_DepreciationAndAmortizationDiscontinuedOperations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortizationDiscontinuedOperations_lbl" xml:lang="en-US">Depreciation and Amortization, Discontinued Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationAndAmortizationDiscontinuedOperations_lbl" xml:lang="en-US">Depreciation expense</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets" xlink:label="ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets" xlink:to="ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets_lbl" xml:lang="en-US">Amortization of finance lease ROU assets attributable to discontinued operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets_lbl" xml:lang="en-US">Disposal Group, Amortization Of Finance Lease Right Of Use Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets_lbl" xml:lang="en-US">Amortization of finance lease ROU assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpenditureDiscontinuedOperations" xlink:label="us-gaap_CapitalExpenditureDiscontinuedOperations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpenditureDiscontinuedOperations" xlink:to="us-gaap_CapitalExpenditureDiscontinuedOperations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpenditureDiscontinuedOperations_lbl" xml:lang="en-US">Capital Expenditure, Discontinued Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalExpenditureDiscontinuedOperations_lbl" xml:lang="en-US">Purchase of fixed assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Investing noncash transactions:</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod" xlink:label="ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod" xlink:to="ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod_lbl" xml:lang="en-US">Fixed asset charges incurred but not yet paid attributable to discontinued operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod_lbl" xml:lang="en-US">Disposal Group, Fixed Assets Incurred But Not Yet Paid In Current Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod_lbl" xml:lang="en-US">Fixed assets included in accounts payable in prior period, paid in current period</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations" xlink:label="ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations" xlink:to="ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations_lbl" xml:lang="en-US">Unpaid fixed assets included in accounts payable, attributable to discontinued operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations_lbl" xml:lang="en-US">Unpaid Fixed Assets Attributable To Discontinued Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations_lbl" xml:lang="en-US">Unpaid fixed assets included in accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntellectualPropertyMember" xlink:to="us-gaap_IntellectualPropertyMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntellectualPropertyMember_lbl" xml:lang="en-US">Intellectual Property [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="us-gaap_RevenueFromContractWithCustomerMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerMember" xlink:to="us-gaap_RevenueFromContractWithCustomerMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerMember_lbl" xml:lang="en-US">Revenue [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US">Concentration Risk Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:label="us-gaap_StatementOperatingActivitiesSegmentAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:to="us-gaap_StatementOperatingActivitiesSegmentAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOperatingActivitiesSegmentAxis_lbl" xml:lang="en-US">Operating Activities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentOperatingActivitiesDomain" xlink:label="us-gaap_SegmentOperatingActivitiesDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentOperatingActivitiesDomain" xlink:to="us-gaap_SegmentOperatingActivitiesDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentOperatingActivitiesDomain_lbl" xml:lang="en-US">Operating Activities [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentContinuingOperationsMember" xlink:label="us-gaap_SegmentContinuingOperationsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentContinuingOperationsMember" xlink:to="us-gaap_SegmentContinuingOperationsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentContinuingOperationsMember_lbl" xml:lang="en-US">Continuing Operations [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDiscontinuedOperationsMember" xlink:label="us-gaap_SegmentDiscontinuedOperationsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDiscontinuedOperationsMember" xlink:to="us-gaap_SegmentDiscontinuedOperationsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentDiscontinuedOperationsMember_lbl" xml:lang="en-US">Discontinued Operations [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_WoodforestMember" xlink:label="ibio_WoodforestMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_WoodforestMember" xlink:to="ibio_WoodforestMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_WoodforestMember_lbl" xml:lang="en-US">Woodforest [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_WoodforestMember_lbl" xml:lang="en-US">Woodforest [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_WoodforestMember_lbl" xml:lang="en-US">Woodforest Bank</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_AmendedCreditAgreementMember" xlink:label="ibio_AmendedCreditAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_AmendedCreditAgreementMember" xlink:to="ibio_AmendedCreditAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_AmendedCreditAgreementMember_lbl" xml:lang="en-US">Amended Credit Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_AmendedCreditAgreementMember_lbl" xml:lang="en-US">Amended Credit Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="ibio_SummaryOfSignificantAccountingPoliciesLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ibio_SummaryOfSignificantAccountingPoliciesLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" xml:lang="en-US">Contract with Customer, Asset, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" xml:lang="en-US">Contract assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xml:lang="en-US">Revenue recognized included in contract liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasePracticalExpedientsPackage" xlink:label="us-gaap_LeasePracticalExpedientsPackage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasePracticalExpedientsPackage" xlink:to="us-gaap_LeasePracticalExpedientsPackage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasePracticalExpedientsPackage_lbl" xml:lang="en-US">Lease, Practical Expedients, Package [true false]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US">Repayments of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US">Repayment of term loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Fixed assets, useful life</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Intangible asset, useful life</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashUninsuredAmount" xlink:to="us-gaap_CashUninsuredAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashUninsuredAmount_lbl" xml:lang="en-US">Cash, Uninsured Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashUninsuredAmount_lbl" xml:lang="en-US">Amount in excess of insured limit</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_NumberOfMajorCustomers" xlink:label="ibio_NumberOfMajorCustomers" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_NumberOfMajorCustomers" xlink:to="ibio_NumberOfMajorCustomers_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_NumberOfMajorCustomers_lbl" xml:lang="en-US">Represents the information pertaining to number of major customers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_NumberOfMajorCustomers_lbl" xml:lang="en-US">Number of Major Customers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_NumberOfMajorCustomers_lbl" xml:lang="en-US">Number of major customers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_lbl" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US">Cash and Cash Equivalents [Domain]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LetterOfCreditTermLoanMember" xlink:label="ibio_LetterOfCreditTermLoanMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LetterOfCreditTermLoanMember" xlink:to="ibio_LetterOfCreditTermLoanMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LetterOfCreditTermLoanMember_lbl" xml:lang="en-US">Represents the information pertaining to letter of credit term loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LetterOfCreditTermLoanMember_lbl" xml:lang="en-US">Letter Of Credit - Term Loan [Member]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LetterOfCreditSanDiegoLeaseMember" xlink:label="ibio_LetterOfCreditSanDiegoLeaseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LetterOfCreditSanDiegoLeaseMember" xlink:to="ibio_LetterOfCreditSanDiegoLeaseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LetterOfCreditSanDiegoLeaseMember_lbl" xml:lang="en-US">Represents the information pertaining to letter of credit for sandiego lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LetterOfCreditSanDiegoLeaseMember_lbl" xml:lang="en-US">Letter Of Credit - San Diego Lease [Member]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CompanyPurchasingCardMember" xlink:label="ibio_CompanyPurchasingCardMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CompanyPurchasingCardMember" xlink:to="ibio_CompanyPurchasingCardMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CompanyPurchasingCardMember_lbl" xml:lang="en-US">Information related to the Company purchasing card.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CompanyPurchasingCardMember_lbl" xml:lang="en-US">Company Purchasing Card [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_PercentageOfCollateralRequired" xlink:label="ibio_PercentageOfCollateralRequired" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_PercentageOfCollateralRequired" xlink:to="ibio_PercentageOfCollateralRequired_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_PercentageOfCollateralRequired_lbl" xml:lang="en-US">The percentage of collateral required to be held by the reporting entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_PercentageOfCollateralRequired_lbl" xml:lang="en-US">Percentage Of Collateral Required</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_PercentageOfCollateralRequired_lbl" xml:lang="en-US">Additional percentage of collateral held required by bank</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Collateral held</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xml:lang="en-US">Total cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US">Measurement Frequency [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsNonrecurringMember" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember_lbl" xml:lang="en-US">Fair Value, Nonrecurring [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingAndBuildingImprovementsMember" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember_lbl" xml:lang="en-US">Buildings and improvements [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xml:lang="en-US">Machinery and equipment [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure" xlink:to="ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure_lbl" xml:lang="en-US">Fair value portion of property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property Plant And Equipment Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure_lbl" xml:lang="en-US">Total Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure_lbl" xml:lang="en-US">Estimated fair values</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_Series2PreferredStockMember" xlink:label="ibio_Series2PreferredStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_Series2PreferredStockMember" xlink:to="ibio_Series2PreferredStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_Series2PreferredStockMember_lbl" xml:lang="en-US">Series A-2 Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_Series2PreferredStockMember_lbl" xml:lang="en-US">Series A-2 Preferred Stock [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CollaborationOptionAndLicenseAgreementMember" xlink:label="ibio_CollaborationOptionAndLicenseAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CollaborationOptionAndLicenseAgreementMember" xlink:to="ibio_CollaborationOptionAndLicenseAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CollaborationOptionAndLicenseAgreementMember_lbl" xml:lang="en-US">Collaboration, Option and License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CollaborationOptionAndLicenseAgreementMember_lbl" xml:lang="en-US">Collaboration, Option and License Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SeparationAgreementAndGeneralReleaseMember" xlink:label="ibio_SeparationAgreementAndGeneralReleaseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SeparationAgreementAndGeneralReleaseMember" xlink:to="ibio_SeparationAgreementAndGeneralReleaseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SeparationAgreementAndGeneralReleaseMember_lbl" xml:lang="en-US">Represents the member information pertaining to Separation Agreement and General Release.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SeparationAgreementAndGeneralReleaseMember_lbl" xml:lang="en-US">Separation Agreement and General Release [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ImmuneOncologyAntibodiesRtx003Member" xlink:label="ibio_ImmuneOncologyAntibodiesRtx003Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ImmuneOncologyAntibodiesRtx003Member" xlink:to="ibio_ImmuneOncologyAntibodiesRtx003Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ImmuneOncologyAntibodiesRtx003Member_lbl" xml:lang="en-US">Immune-Oncology Antibodies (RTX-003) [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ImmuneOncologyAntibodiesRtx003Member_lbl" xml:lang="en-US">Immune-Oncology Antibodies (RTX-003) [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario, Unspecified [Domain]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_NoBiosimilarProductHasBeenApprovedMember" xlink:label="ibio_NoBiosimilarProductHasBeenApprovedMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_NoBiosimilarProductHasBeenApprovedMember" xlink:to="ibio_NoBiosimilarProductHasBeenApprovedMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_NoBiosimilarProductHasBeenApprovedMember_lbl" xml:lang="en-US">No Biosimilar Product has been Approved [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_NoBiosimilarProductHasBeenApprovedMember_lbl" xml:lang="en-US">No Biosimilar Product has been Approved [Member]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_RubrycTheraputicsInc.Member" xlink:label="ibio_RubrycTheraputicsInc.Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_RubrycTheraputicsInc.Member" xlink:to="ibio_RubrycTheraputicsInc.Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_RubrycTheraputicsInc.Member_lbl" xml:lang="en-US">RubrYc Therapeutics, Inc. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_RubrycTheraputicsInc.Member_lbl" xml:lang="en-US">RubrYc Therapeutics, Inc. [Member]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" xlink:label="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" xlink:to="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_lbl" xml:lang="en-US">Represents the information pertaining to College Station Investors LLC And Bryan Capital.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_lbl" xml:lang="en-US">College Station Investors LLC And Bryan Capital [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_IbioCmoPreferredTrackingStockMember" xlink:label="ibio_IbioCmoPreferredTrackingStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IbioCmoPreferredTrackingStockMember" xlink:to="ibio_IbioCmoPreferredTrackingStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_IbioCmoPreferredTrackingStockMember_lbl" xml:lang="en-US">Represents the information pertaining to IBio CMO Preferred Tracking Stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IbioCmoPreferredTrackingStockMember_lbl" xml:lang="en-US">IBio CMO Preferred Tracking Stock</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SecuredTermLoanMember" xlink:label="ibio_SecuredTermLoanMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SecuredTermLoanMember" xlink:to="ibio_SecuredTermLoanMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SecuredTermLoanMember_lbl" xml:lang="en-US">Represents the information pertaining to secured term loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SecuredTermLoanMember_lbl" xml:lang="en-US">Secured Term Loan</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest" xlink:label="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest" xlink:to="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest_lbl" xml:lang="en-US">Total purchase price for the Property, the termination of the Sublease and other agreements among the parties, and the equity interests.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest_lbl" xml:lang="en-US">Purchase Price For Property, Termination of Sublease And Equity Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest_lbl" xml:lang="en-US">Total purchase price</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment" xlink:label="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment" xlink:to="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment_lbl" xml:lang="en-US">Cash payment for purchase price for the Property, the termination of the Sublease and other agreements among the parties, and the equity interests.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment_lbl" xml:lang="en-US">Purchase Price For Property, Termination of Sublease And Equity Interest, Cash Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment_lbl" xml:lang="en-US">Cash payment</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_FairMarketValueOfProperty" xlink:label="ibio_FairMarketValueOfProperty" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_FairMarketValueOfProperty" xlink:to="ibio_FairMarketValueOfProperty_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_FairMarketValueOfProperty_lbl" xml:lang="en-US">Fair market value of the property.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_FairMarketValueOfProperty_lbl" xml:lang="en-US">Fair Market Value of Property</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_FairMarketValueOfProperty_lbl" xml:lang="en-US">Fair market value of property</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_BaseRentPercentageOfFairMarketValueOfProperty" xlink:label="ibio_BaseRentPercentageOfFairMarketValueOfProperty" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_BaseRentPercentageOfFairMarketValueOfProperty" xlink:to="ibio_BaseRentPercentageOfFairMarketValueOfProperty_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_BaseRentPercentageOfFairMarketValueOfProperty_lbl" xml:lang="en-US">Amount of base rent payable on percentage of fair Market Value of the Property.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_BaseRentPercentageOfFairMarketValueOfProperty_lbl" xml:lang="en-US">Base Rent, Percentage of Fair Market Value of Property</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_BaseRentPercentageOfFairMarketValueOfProperty_lbl" xml:lang="en-US">Percentage of base rent</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired" xlink:label="ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired" xlink:to="ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired_lbl" xml:lang="en-US">Consideration transferred for equity interest acquired under the equity agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired_lbl" xml:lang="en-US">Equity Agreement, Consideration Transferred Equity Interests Acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired_lbl" xml:lang="en-US">Cash consideration for equity interest acquired</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_EquityAgreementWarrantsIssuedOrIssuable" xlink:label="ibio_EquityAgreementWarrantsIssuedOrIssuable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_EquityAgreementWarrantsIssuedOrIssuable" xlink:to="ibio_EquityAgreementWarrantsIssuedOrIssuable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_EquityAgreementWarrantsIssuedOrIssuable_lbl" xml:lang="en-US">Warrants issued or issuable under the equity agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_EquityAgreementWarrantsIssuedOrIssuable_lbl" xml:lang="en-US">Equity Agreement, Warrants Issued or Issuable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_EquityAgreementWarrantsIssuedOrIssuable_lbl" xml:lang="en-US">Warrants issuable</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable" xlink:label="ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable" xlink:to="ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable_lbl" xml:lang="en-US">Equity agreement, percentage of equity interest issued or issuable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable_lbl" xml:lang="en-US">Equity Agreement, Percentage of Equity Interest Issued or Issuable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable_lbl" xml:lang="en-US">Percentage of equity interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Debt Instrument, Face Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Secured term loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate (as percent)</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CreditAgreementThresholdLimitUnrestrictedCash" xlink:label="ibio_CreditAgreementThresholdLimitUnrestrictedCash" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CreditAgreementThresholdLimitUnrestrictedCash" xlink:to="ibio_CreditAgreementThresholdLimitUnrestrictedCash_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CreditAgreementThresholdLimitUnrestrictedCash_lbl" xml:lang="en-US">Threshold limit of unrestricted cash to be maintained.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CreditAgreementThresholdLimitUnrestrictedCash_lbl" xml:lang="en-US">Credit Agreement, Threshold Limit, Unrestricted Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_CreditAgreementThresholdLimitUnrestrictedCash_lbl" xml:lang="en-US">Unrestricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xml:lang="en-US">Debt Issuance Costs, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xml:lang="en-US">Deferred finance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xml:lang="en-US">Cost incurred to attain debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest Expense, Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Number of warrants issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants to purchase shares of Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Warrants, exercise price per share</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent" xlink:label="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent" xlink:to="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent_lbl" xml:lang="en-US">Number of warrants issued for the final payment of rent due under sublease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent_lbl" xml:lang="en-US">Warrants Issued for Final Payment of Sublease Rent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent_lbl" xml:lang="en-US">Shares issued under the Warrant</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue" xlink:label="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue" xlink:to="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue_lbl" xml:lang="en-US">Value of warrants issued for the final payment of rent due under sublease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue_lbl" xml:lang="en-US">Warrants Issued for Final Payment of Sublease Rent, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue_lbl" xml:lang="en-US">Fair value of the warrant</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US">Assets, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US">Estimated fair value</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CollaborativeArrangementMilestonePayments" xlink:label="ibio_CollaborativeArrangementMilestonePayments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CollaborativeArrangementMilestonePayments" xlink:to="ibio_CollaborativeArrangementMilestonePayments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CollaborativeArrangementMilestonePayments_lbl" xml:lang="en-US">Represents the amount of milestone payments based on different scenarios.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CollaborativeArrangementMilestonePayments_lbl" xml:lang="en-US">Collaborative Arrangement, Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_CollaborativeArrangementMilestonePayments_lbl" xml:lang="en-US">Milestone payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForAdvanceToAffiliate" xlink:label="us-gaap_PaymentsForAdvanceToAffiliate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForAdvanceToAffiliate" xlink:to="us-gaap_PaymentsForAdvanceToAffiliate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForAdvanceToAffiliate_lbl" xml:lang="en-US">Payments for Advance to Affiliate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForAdvanceToAffiliate_lbl" xml:lang="en-US">Amount advanced</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_AssetAcquisitionTransactionCosts" xlink:label="ibio_AssetAcquisitionTransactionCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_AssetAcquisitionTransactionCosts" xlink:to="ibio_AssetAcquisitionTransactionCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_AssetAcquisitionTransactionCosts_lbl" xml:lang="en-US">This element represents acquisition-related costs incurred to effect an asset acquisition.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_AssetAcquisitionTransactionCosts_lbl" xml:lang="en-US">Asset Acquisition, Transaction Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_AssetAcquisitionTransactionCosts_lbl" xml:lang="en-US">Transaction costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US">Finance Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US">Finance leases</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm" xlink:label="ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm" xlink:to="ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm_lbl" xml:lang="en-US">Collaboration and license agreement, royalty payment term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm_lbl" xml:lang="en-US">Collaboration and License Agreement, Royalty payment term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm_lbl" xml:lang="en-US">Collaboration and license agreement, royalty payment term</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CollaborationAndLicenseAgreementAgreementTerm" xlink:label="ibio_CollaborationAndLicenseAgreementAgreementTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CollaborationAndLicenseAgreementAgreementTerm" xlink:to="ibio_CollaborationAndLicenseAgreementAgreementTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CollaborationAndLicenseAgreementAgreementTerm_lbl" xml:lang="en-US">Collaboration and license agreement, agreement term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CollaborationAndLicenseAgreementAgreementTerm_lbl" xml:lang="en-US">Collaboration and license agreement, agreement term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_CollaborationAndLicenseAgreementAgreementTerm_lbl" xml:lang="en-US">Collaboration and license agreement, agreement term</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_StockPurchaseAgreementNumberOfSharesPurchased" xlink:label="ibio_StockPurchaseAgreementNumberOfSharesPurchased" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_StockPurchaseAgreementNumberOfSharesPurchased" xlink:to="ibio_StockPurchaseAgreementNumberOfSharesPurchased_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_StockPurchaseAgreementNumberOfSharesPurchased_lbl" xml:lang="en-US">Stock purchase agreement, number of shares purchased</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_StockPurchaseAgreementNumberOfSharesPurchased_lbl" xml:lang="en-US">Stock purchase agreement, number of shares purchased</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_StockPurchaseAgreementNumberOfSharesPurchased_lbl" xml:lang="en-US">Stock purchase agreement, number of shares purchased</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_StockPurchaseAgreementValueOfSharesPurchased" xlink:label="ibio_StockPurchaseAgreementValueOfSharesPurchased" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_StockPurchaseAgreementValueOfSharesPurchased" xlink:to="ibio_StockPurchaseAgreementValueOfSharesPurchased_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_StockPurchaseAgreementValueOfSharesPurchased_lbl" xml:lang="en-US">Stock purchase agreement, value of shares purchased</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_StockPurchaseAgreementValueOfSharesPurchased_lbl" xml:lang="en-US">Stock purchase agreement, value of shares purchased</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US">Preferred Stock, Dividend Rate, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US">Preferential dividend rate percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfInvestments" xlink:label="us-gaap_ImpairmentOfInvestments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfInvestments" xlink:to="us-gaap_ImpairmentOfInvestments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfInvestments_lbl" xml:lang="en-US">Other than Temporary Impairment Losses, Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ImpairmentOfInvestments_lbl" xml:lang="en-US">Impairment of investment in equity security</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ImpairmentOfPrepaidExpensesCurrent" xlink:label="ibio_ImpairmentOfPrepaidExpensesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ImpairmentOfPrepaidExpensesCurrent" xlink:to="ibio_ImpairmentOfPrepaidExpensesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ImpairmentOfPrepaidExpensesCurrent_lbl" xml:lang="en-US">Impairment of current prepaid expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ImpairmentOfPrepaidExpensesCurrent_lbl" xml:lang="en-US">Impairment Of Prepaid Expenses, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_ImpairmentOfPrepaidExpensesCurrent_lbl" xml:lang="en-US">Impairment of current prepaid expense</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ImpairmentOfPrepaidExpensesNonCurrent" xlink:label="ibio_ImpairmentOfPrepaidExpensesNonCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ImpairmentOfPrepaidExpensesNonCurrent" xlink:to="ibio_ImpairmentOfPrepaidExpensesNonCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ImpairmentOfPrepaidExpensesNonCurrent_lbl" xml:lang="en-US">Impairment of non-current prepaid expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ImpairmentOfPrepaidExpensesNonCurrent_lbl" xml:lang="en-US">Impairment Of Prepaid Expenses, Non Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_ImpairmentOfPrepaidExpensesNonCurrent_lbl" xml:lang="en-US">Impairment of non-current prepaid expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Number of shares issued</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary" xlink:label="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary" xlink:to="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary_lbl" xml:lang="en-US">Represents the period of bi-monthly installments of current base salary to be paid under severance benefits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary_lbl" xml:lang="en-US">Severance Benefits, Period of Bi-Monthly Installments of Current Base Salary</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary_lbl" xml:lang="en-US">Period of bi-monthly installments of current base salary</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus" xlink:label="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus" xlink:to="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus_lbl" xml:lang="en-US">Represents the period of bi-monthly installments of target bonus to be paid under severance benefits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus_lbl" xml:lang="en-US">Severance Benefits, Period of Bi-Monthly Installments of target Bonus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus_lbl" xml:lang="en-US">Period of bi-monthly installments of target bonus</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct" xlink:label="ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct" xlink:to="ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct_lbl" xml:lang="en-US">Represents the maximum period of coverage of health insurance under the Consolidated Omnibus Budget Reconciliation Act of 1985 ("COBRA").</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct_lbl" xml:lang="en-US">Severance Benefits, Maximum Period for Coverage of Health Insurance If Employer Elects Consolidated Omnibus Budget Reconciliation Act</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct_lbl" xml:lang="en-US">Maximum period for coverage of health insurance</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod" xlink:label="ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod" xlink:to="ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod_lbl" xml:lang="en-US">Represents the Consolidated Omnibus Budget Reconciliation Act of 1985 ("COBRA") subsidy period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod_lbl" xml:lang="en-US">Severance Benefits, Consolidated Omnibus Budget Reconciliation Act Subsidy Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod_lbl" xml:lang="en-US">COBRA subsidy period</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct" xlink:label="ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct" xlink:to="ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct_lbl" xml:lang="en-US">Represents the number of times on which the Company has to make lump sum cash payment if the employee not obtained health coverage under Consolidated Omnibus Budget Reconciliation Act of 1985 ("COBRA").</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct_lbl" xml:lang="en-US">Severance Benefits, Number of Times on Which Lum Sum Cash Payment to be Made if Health Coverage Not Made Under Consolidated Omnibus Budget Reconciliation Act</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct_lbl" xml:lang="en-US">Number of times on which lump sum cash payment tis o be made</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_AssetAcquisitionIntangibleAssetsMember" xlink:label="ibio_AssetAcquisitionIntangibleAssetsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_AssetAcquisitionIntangibleAssetsMember" xlink:to="ibio_AssetAcquisitionIntangibleAssetsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_AssetAcquisitionIntangibleAssetsMember_lbl" xml:lang="en-US">Asset Acquisition Intangible Assets [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_AssetAcquisitionIntangibleAssetsMember_lbl" xml:lang="en-US">Asset Acquisition Intangible Assets [Member]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_AssetAcquisitionFixedAssetsMember" xlink:label="ibio_AssetAcquisitionFixedAssetsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_AssetAcquisitionFixedAssetsMember" xlink:to="ibio_AssetAcquisitionFixedAssetsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_AssetAcquisitionFixedAssetsMember_lbl" xml:lang="en-US">Asset Acquisition Fixed Assets [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_AssetAcquisitionFixedAssetsMember_lbl" xml:lang="en-US">Asset Acquisition Fixed Assets [Member]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_AssetAcquisitionPrepaidExpensesMember" xlink:label="ibio_AssetAcquisitionPrepaidExpensesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_AssetAcquisitionPrepaidExpensesMember" xlink:to="ibio_AssetAcquisitionPrepaidExpensesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_AssetAcquisitionPrepaidExpensesMember_lbl" xml:lang="en-US">Asset Acquisition Prepaid Expenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_AssetAcquisitionPrepaidExpensesMember_lbl" xml:lang="en-US">Asset Acquisition Prepaid Expenses [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xml:lang="en-US">Asset Acquisition, Consideration Transferred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xml:lang="en-US">Purchase price allocated</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_lbl" xml:lang="en-US">Receivable Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_ReceivableTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivableTypeDomain_lbl" xml:lang="en-US">Receivable [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableMember" xlink:label="us-gaap_NotesReceivableMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesReceivableMember" xlink:to="us-gaap_NotesReceivableMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesReceivableMember_lbl" xml:lang="en-US">Convertible Promissory Note Receivable [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsNotesAndLoansReceivableLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems_lbl" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LoansReceivableAmountInvested" xlink:label="ibio_LoansReceivableAmountInvested" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LoansReceivableAmountInvested" xlink:to="ibio_LoansReceivableAmountInvested_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LoansReceivableAmountInvested_lbl" xml:lang="en-US">Represents the face amount of notes receivable invested.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LoansReceivableAmountInvested_lbl" xml:lang="en-US">Loans Receivable, Amount Invested</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LoansReceivableAmountInvested_lbl" xml:lang="en-US">Amount invested</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LoansReceivableFixedRatesOfInterest" xlink:label="ibio_LoansReceivableFixedRatesOfInterest" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LoansReceivableFixedRatesOfInterest" xlink:to="ibio_LoansReceivableFixedRatesOfInterest_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LoansReceivableFixedRatesOfInterest_lbl" xml:lang="en-US">Percentage of fixed rate of interest on notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LoansReceivableFixedRatesOfInterest_lbl" xml:lang="en-US">Loans Receivable, Fixed Rates of Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LoansReceivableFixedRatesOfInterest_lbl" xml:lang="en-US">Interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:label="us-gaap_NotesAndLoansReceivableNetNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:to="us-gaap_NotesAndLoansReceivableNetNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesAndLoansReceivableNetNoncurrent_lbl" xml:lang="en-US">Financing Receivable, after Allowance for Credit Loss, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesAndLoansReceivableNetNoncurrent_lbl" xml:lang="en-US">Note balance and accrued interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US">Adjusted cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xml:lang="en-US">Gross unrealized losses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract_lbl" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling Maturity, Fair Value [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_lbl" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling within One Year, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_lbl" xml:lang="en-US">2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling after Two Years, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" xml:lang="en-US">2024</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_FinanceLeaseRightOfUseAssetDisclosureTable" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureTable" xlink:to="ibio_FinanceLeaseRightOfUseAssetDisclosureTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureTable_lbl" xml:lang="en-US">Disclosure of information about activity in the balance of lessee's right to use underlying asset under finance lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureTable_lbl" xml:lang="en-US">Finance Lease, Right Of Use Asset, Disclosure [Table]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_FacilityMember" xlink:label="ibio_FacilityMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_FacilityMember" xlink:to="ibio_FacilityMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_FacilityMember_lbl" xml:lang="en-US">This member stands for facility.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_FacilityMember_lbl" xml:lang="en-US">Facility [Member]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems" xlink:to="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems_lbl" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems_lbl" xml:lang="en-US">Finance Lease, Right Of Use Asset, Disclosure [Line Items]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_FinanceLeaseRightOfUseAssetGross" xlink:label="ibio_FinanceLeaseRightOfUseAssetGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_FinanceLeaseRightOfUseAssetGross" xlink:to="ibio_FinanceLeaseRightOfUseAssetGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_FinanceLeaseRightOfUseAssetGross_lbl" xml:lang="en-US">Gross amount of lessee's right to use underlying asset under finance lease, before accumulated amortization.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_FinanceLeaseRightOfUseAssetGross_lbl" xml:lang="en-US">Finance Lease, Right Of Use Asset, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_FinanceLeaseRightOfUseAssetGross_lbl" xml:lang="en-US">ROU, gross</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_lbl" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Accumulated Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_lbl" xml:lang="en-US">Accumulated amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xml:lang="en-US">Area of Real Estate Property</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xml:lang="en-US">Area of lab and office</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_FixedAssetsHeldForSale" xlink:label="ibio_FixedAssetsHeldForSale" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_FixedAssetsHeldForSale" xlink:to="ibio_FixedAssetsHeldForSale_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_FixedAssetsHeldForSale_lbl" xml:lang="en-US">Amount of fixed assets held-for-sale.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_FixedAssetsHeldForSale_lbl" xml:lang="en-US">Fixed Assets Held-for-sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_FixedAssetsHeldForSale_lbl" xml:lang="en-US">Fixed assets held for sale</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office equipment and software [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US">Construction in progress [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Gross fixed assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PatentsMember_lbl" xml:lang="en-US">Patents and Licenses [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_StockPurchaseAgreementTotalInvestment" xlink:label="ibio_StockPurchaseAgreementTotalInvestment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_StockPurchaseAgreementTotalInvestment" xlink:to="ibio_StockPurchaseAgreementTotalInvestment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_StockPurchaseAgreementTotalInvestment_lbl" xml:lang="en-US">The amount of investment under the stock purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_StockPurchaseAgreementTotalInvestment_lbl" xml:lang="en-US">Stock Purchase Agreement, Total Investment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_StockPurchaseAgreementTotalInvestment_lbl" xml:lang="en-US">Investment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xml:lang="en-US">Impairment of Intangible Assets, Finite-Lived</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xml:lang="en-US">Impairment of intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, gross carrying value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, accumulated amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Total definite lived intangible assets, net of accumulated amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US">License - indefinite lived</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDeferredChargesAbstract" xlink:label="us-gaap_AmortizationOfDeferredChargesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDeferredChargesAbstract" xlink:to="us-gaap_AmortizationOfDeferredChargesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDeferredChargesAbstract_lbl" xml:lang="en-US">Amortization of Deferred Charges [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfDeferredChargesAbstract_lbl" xml:lang="en-US">Amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRollForward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRollForward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRollForward_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRollForward_lbl" xml:lang="en-US">Additions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="us-gaap_FinitelivedIntangibleAssetsAcquired1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="us-gaap_FinitelivedIntangibleAssetsAcquired1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinitelivedIntangibleAssetsAcquired1_lbl" xml:lang="en-US">Finite-Lived Intangible Assets Acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinitelivedIntangibleAssetsAcquired1_lbl" xml:lang="en-US">Additions to definite lived intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:label="us-gaap_IndefinitelivedIntangibleAssetsAcquired" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:to="us-gaap_IndefinitelivedIntangibleAssetsAcquired_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefinitelivedIntangibleAssetsAcquired_lbl" xml:lang="en-US">Indefinite-Lived Intangible Assets Acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IndefinitelivedIntangibleAssetsAcquired_lbl" xml:lang="en-US">Additions to licenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetImpairmentAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairmentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetImpairmentAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetImpairmentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairmentAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Asset Impairment [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairmentAbstract_lbl" xml:lang="en-US">Impairments</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ImpairmentOfIntangibleAssetsGrossOfReversals" xlink:label="ibio_ImpairmentOfIntangibleAssetsGrossOfReversals" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ImpairmentOfIntangibleAssetsGrossOfReversals" xlink:to="ibio_ImpairmentOfIntangibleAssetsGrossOfReversals_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ImpairmentOfIntangibleAssetsGrossOfReversals_lbl" xml:lang="en-US">Gross amount of intangible asset impairment before reversals.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ImpairmentOfIntangibleAssetsGrossOfReversals_lbl" xml:lang="en-US">Impairment Of Intangible Assets Gross Of Reversals</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ibio_ImpairmentOfIntangibleAssetsGrossOfReversals_lbl" xml:lang="en-US">Impairment of intangible assets - gross carrying value</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ReversalOfIntangibleAssetImpairment" xlink:label="ibio_ReversalOfIntangibleAssetImpairment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ReversalOfIntangibleAssetImpairment" xlink:to="ibio_ReversalOfIntangibleAssetImpairment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ReversalOfIntangibleAssetImpairment_lbl" xml:lang="en-US">Reversal of intangible asset impairment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ReversalOfIntangibleAssetImpairment_lbl" xml:lang="en-US">Reversal Of Intangible Asset Impairment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_ReversalOfIntangibleAssetImpairment_lbl" xml:lang="en-US">Intangible asset impairment - accumulated amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_LitigationCaseAxis_lbl" xml:lang="en-US">Litigation Case [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="srt_LitigationCaseTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_LitigationCaseTypeDomain_lbl" xml:lang="en-US">Litigation Case [Domain]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember" xlink:label="ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember" xlink:to="ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_lbl" xml:lang="en-US">I Bio Inc Versus Fraunhofer United States of America Incorporated [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_lbl" xml:lang="en-US">iBio, Inc. v. Fraunhofer USA, Inc. [Member]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_DateOfAmendmentMember" xlink:label="ibio_DateOfAmendmentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DateOfAmendmentMember" xlink:to="ibio_DateOfAmendmentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DateOfAmendmentMember_lbl" xml:lang="en-US">Date Of Amendment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DateOfAmendmentMember_lbl" xml:lang="en-US">Date Of Amendment [Member]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember" xlink:label="ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember" xlink:to="ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember_lbl" xml:lang="en-US">Within Two Business Days Of Frunhofer Legal Settlement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember_lbl" xml:lang="en-US">Within Two Business Days Of Frunhofer Legal Settlement [Member]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_OccurrenceOfSpecificMilestoneMember" xlink:label="ibio_OccurrenceOfSpecificMilestoneMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_OccurrenceOfSpecificMilestoneMember" xlink:to="ibio_OccurrenceOfSpecificMilestoneMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_OccurrenceOfSpecificMilestoneMember_lbl" xml:lang="en-US">Occurrence Of Specific Milestone [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_OccurrenceOfSpecificMilestoneMember_lbl" xml:lang="en-US">Occurrence Of Specific Milestone [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Debt Instrument [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl" xml:lang="en-US">Debt Instrument, Periodic Payment, Principal</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl" xml:lang="en-US">Principal payment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPayment" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US">Debt Instrument, Periodic Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US">Debt amortization payment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFeeAmount" xlink:to="us-gaap_DebtInstrumentFeeAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xml:lang="en-US">Debt Instrument, Fee Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xml:lang="en-US">Amendment fee</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_DebtCovenantLiquidityAmount" xlink:label="ibio_DebtCovenantLiquidityAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DebtCovenantLiquidityAmount" xlink:to="ibio_DebtCovenantLiquidityAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DebtCovenantLiquidityAmount_lbl" xml:lang="en-US">Amount of required liquidity per debt covenant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DebtCovenantLiquidityAmount_lbl" xml:lang="en-US">Debt Covenant, Liquidity Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DebtCovenantLiquidityAmount_lbl" xml:lang="en-US">Liquidity covenant, amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Long-Term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Debt balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLegalSettlements" xlink:label="us-gaap_ProceedsFromLegalSettlements" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLegalSettlements" xlink:to="us-gaap_ProceedsFromLegalSettlements_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLegalSettlements_lbl" xml:lang="en-US">Proceeds from Legal Settlements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromLegalSettlements_lbl" xml:lang="en-US">Settlement payment received</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_EquipmentFinancingAmountBorrowed" xlink:label="ibio_EquipmentFinancingAmountBorrowed" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_EquipmentFinancingAmountBorrowed" xlink:to="ibio_EquipmentFinancingAmountBorrowed_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_EquipmentFinancingAmountBorrowed_lbl" xml:lang="en-US">The amount borrowed under equipment financing as at the end of the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_EquipmentFinancingAmountBorrowed_lbl" xml:lang="en-US">Equipment Financing, Amount Borrowed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_EquipmentFinancingAmountBorrowed_lbl" xml:lang="en-US">Amount borrowed</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeEquipmentLeaseTermOfContract" xlink:label="ibio_LesseeEquipmentLeaseTermOfContract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeEquipmentLeaseTermOfContract" xlink:to="ibio_LesseeEquipmentLeaseTermOfContract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeEquipmentLeaseTermOfContract_lbl" xml:lang="en-US">Term of lessee equipment financing lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeEquipmentLeaseTermOfContract_lbl" xml:lang="en-US">Lessee, Equipment Lease, Term of Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LesseeEquipmentLeaseTermOfContract_lbl" xml:lang="en-US">Term of agreement</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_EquipmentFinancingLeaseImputedInterestRate" xlink:label="ibio_EquipmentFinancingLeaseImputedInterestRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_EquipmentFinancingLeaseImputedInterestRate" xlink:to="ibio_EquipmentFinancingLeaseImputedInterestRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_EquipmentFinancingLeaseImputedInterestRate_lbl" xml:lang="en-US">Percentage of imputed interest rate on equipment financing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_EquipmentFinancingLeaseImputedInterestRate_lbl" xml:lang="en-US">Equipment Financing Lease, Imputed Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_EquipmentFinancingLeaseImputedInterestRate_lbl" xml:lang="en-US">Imputed interest rate</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_EquipmentLeasingMonthlyInstallmentPayable" xlink:label="ibio_EquipmentLeasingMonthlyInstallmentPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_EquipmentLeasingMonthlyInstallmentPayable" xlink:to="ibio_EquipmentLeasingMonthlyInstallmentPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_EquipmentLeasingMonthlyInstallmentPayable_lbl" xml:lang="en-US">The amount of monthly installment payable under equipment leasing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_EquipmentLeasingMonthlyInstallmentPayable_lbl" xml:lang="en-US">Equipment Leasing Monthly Installment Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_EquipmentLeasingMonthlyInstallmentPayable_lbl" xml:lang="en-US">Monthly installment payable</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_EquipmentFinancingBalance" xlink:label="ibio_EquipmentFinancingBalance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_EquipmentFinancingBalance" xlink:to="ibio_EquipmentFinancingBalance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_EquipmentFinancingBalance_lbl" xml:lang="en-US">The amount of equipment financing balance under equipment leasing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_EquipmentFinancingBalance_lbl" xml:lang="en-US">Equipment Financing Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_EquipmentFinancingBalance_lbl" xml:lang="en-US">Balance owed under financing</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xml:lang="en-US">Lease Contractual Term [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xml:lang="en-US">Lease Contractual Term [Domain]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_PrincipalMember" xlink:label="ibio_PrincipalMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_PrincipalMember" xlink:to="ibio_PrincipalMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_PrincipalMember_lbl" xml:lang="en-US">Information pertaining to principal portion of the obligation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_PrincipalMember_lbl" xml:lang="en-US">Principal [Member]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_InterestMember" xlink:label="ibio_InterestMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_InterestMember" xlink:to="ibio_InterestMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_InterestMember_lbl" xml:lang="en-US">Information pertaining to interest portion of the obligation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_InterestMember_lbl" xml:lang="en-US">Interest [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl" xml:lang="en-US">Contractual Obligation, to be Paid, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl" xml:lang="en-US">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="us-gaap_ContractualObligationDueInSecondYear" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInSecondYear" xlink:to="us-gaap_ContractualObligationDueInSecondYear_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationDueInSecondYear_lbl" xml:lang="en-US">Contractual Obligation, to be Paid, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligationDueInSecondYear_lbl" xml:lang="en-US">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="us-gaap_ContractualObligationDueInThirdYear" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInThirdYear" xlink:to="us-gaap_ContractualObligationDueInThirdYear_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationDueInThirdYear_lbl" xml:lang="en-US">Contractual Obligation, to be Paid, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligationDueInThirdYear_lbl" xml:lang="en-US">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligation_lbl" xml:lang="en-US">Contractual Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ContractualObligation_lbl" xml:lang="en-US">Total minimum equipment financing payments</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ContractualObligationCurrent" xlink:label="ibio_ContractualObligationCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ContractualObligationCurrent" xlink:to="ibio_ContractualObligationCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ContractualObligationCurrent_lbl" xml:lang="en-US">The amount of current portion of contractual obligation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ContractualObligationCurrent_lbl" xml:lang="en-US">Contractual Obligation, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ibio_ContractualObligationCurrent_lbl" xml:lang="en-US">Less: current portion</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ContractualObligationNoncurrent" xlink:label="ibio_ContractualObligationNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ContractualObligationNoncurrent" xlink:to="ibio_ContractualObligationNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ContractualObligationNoncurrent_lbl" xml:lang="en-US">The amount of noncurrent portion of contractual obligation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ContractualObligationNoncurrent_lbl" xml:lang="en-US">Contractual Obligation, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_ContractualObligationNoncurrent_lbl" xml:lang="en-US">Long-term portion of minimum equipment financing obligation</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_PppLoanCaresActMember" xlink:label="ibio_PppLoanCaresActMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_PppLoanCaresActMember" xlink:to="ibio_PppLoanCaresActMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_PppLoanCaresActMember_lbl" xml:lang="en-US">PP Loans Cares Act.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_PppLoanCaresActMember_lbl" xml:lang="en-US">PPP Loan Cares Act [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermNotesPayable_lbl" xml:lang="en-US">Notes Payable, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_LongTermNotesPayable_lbl" xml:lang="en-US">Note payable, PPP loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDecreaseForgiveness" xlink:to="us-gaap_DebtInstrumentDecreaseForgiveness_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness_lbl" xml:lang="en-US">Debt Instrument, Decrease, Forgiveness</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness_lbl" xml:lang="en-US">Liability and accrued interest derecognized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party [Domain]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SecondEasternAffiliateMember" xlink:label="ibio_SecondEasternAffiliateMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SecondEasternAffiliateMember" xlink:to="ibio_SecondEasternAffiliateMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SecondEasternAffiliateMember_lbl" xml:lang="en-US">Represent information pertaining to Second Eastern Affiliate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SecondEasternAffiliateMember_lbl" xml:lang="en-US">Second Eastern Affiliate [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_NumberOfEquipmentLeases" xlink:label="ibio_NumberOfEquipmentLeases" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_NumberOfEquipmentLeases" xlink:to="ibio_NumberOfEquipmentLeases_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_NumberOfEquipmentLeases_lbl" xml:lang="en-US">Represents the number of equipment leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_NumberOfEquipmentLeases_lbl" xml:lang="en-US">Number of Equipment Leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_NumberOfEquipmentLeases_lbl" xml:lang="en-US">Number of equipment leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Other General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LeaseRentExpensePerMonth" xlink:label="ibio_LeaseRentExpensePerMonth" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LeaseRentExpensePerMonth" xlink:to="ibio_LeaseRentExpensePerMonth_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LeaseRentExpensePerMonth_lbl" xml:lang="en-US">The amount of lease rent expense per month during the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LeaseRentExpensePerMonth_lbl" xml:lang="en-US">Lease Rent Expense Per Month</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LeaseRentExpensePerMonth_lbl" xml:lang="en-US">Monthly rent</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LessorFinanceLeaseMonthlyRent" xlink:label="ibio_LessorFinanceLeaseMonthlyRent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LessorFinanceLeaseMonthlyRent" xlink:to="ibio_LessorFinanceLeaseMonthlyRent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LessorFinanceLeaseMonthlyRent_lbl" xml:lang="en-US">The amount of rent receivable monthly by the lessor under the finance lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LessorFinanceLeaseMonthlyRent_lbl" xml:lang="en-US">Lessor, Finance Lease Monthly Rent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LessorFinanceLeaseMonthlyRent_lbl" xml:lang="en-US">Mobile office trailer monthly rent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US">Lease, Cost [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US">Finance lease cost:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US">Finance Lease, Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US">Interest on lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Total lease cost</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_FinanceLeaseObligationOtherInformationAbstract" xlink:label="ibio_FinanceLeaseObligationOtherInformationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_FinanceLeaseObligationOtherInformationAbstract" xlink:to="ibio_FinanceLeaseObligationOtherInformationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_FinanceLeaseObligationOtherInformationAbstract_lbl" xml:lang="en-US">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_FinanceLeaseObligationOtherInformationAbstract_lbl" xml:lang="en-US">Finance Lease Obligation, Other Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_FinanceLeaseObligationOtherInformationAbstract_lbl" xml:lang="en-US">Other Information</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract" xlink:label="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract" xlink:to="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Cash Paid For Amounts Included In Measurement Lease Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement lease liabilities:</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_FinancingCashFlowsFromFinanceLeaseObligation" xlink:label="ibio_FinancingCashFlowsFromFinanceLeaseObligation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_FinancingCashFlowsFromFinanceLeaseObligation" xlink:to="ibio_FinancingCashFlowsFromFinanceLeaseObligation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_FinancingCashFlowsFromFinanceLeaseObligation_lbl" xml:lang="en-US">The amount of cash outflow for finance lease obligations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_FinancingCashFlowsFromFinanceLeaseObligation_lbl" xml:lang="en-US">Financing Cash Flows From Finance Lease Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_FinancingCashFlowsFromFinanceLeaseObligation_lbl" xml:lang="en-US">Financing cash flows from finance lease obligations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term - finance lease</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate - finance lease obligation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Finance Lease, Liability, Payments, Due Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Finance Lease, Liability, Payments, Due Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">Finance Lease, Liability, Payments, Due Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Finance Lease, Liability, Payment, Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total minimum lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsByNatureAxis" xlink:label="us-gaap_GuaranteeObligationsByNatureAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GuaranteeObligationsByNatureAxis" xlink:to="us-gaap_GuaranteeObligationsByNatureAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GuaranteeObligationsByNatureAxis_lbl" xml:lang="en-US">Guarantor Obligations, Nature [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsNatureDomain" xlink:label="us-gaap_GuaranteeObligationsNatureDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GuaranteeObligationsNatureDomain" xlink:to="us-gaap_GuaranteeObligationsNatureDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GuaranteeObligationsNatureDomain_lbl" xml:lang="en-US">Guarantor Obligations, Nature [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialStandbyLetterOfCreditMember" xlink:label="us-gaap_FinancialStandbyLetterOfCreditMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialStandbyLetterOfCreditMember" xlink:to="us-gaap_FinancialStandbyLetterOfCreditMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialStandbyLetterOfCreditMember_lbl" xml:lang="en-US">Letter of Credit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Term of lease</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseMonthlyRent" xlink:label="ibio_LesseeOperatingLeaseMonthlyRent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseMonthlyRent" xlink:to="ibio_LesseeOperatingLeaseMonthlyRent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseMonthlyRent_lbl" xml:lang="en-US">The amount of rent payable monthly by the lessee under the operating lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseMonthlyRent_lbl" xml:lang="en-US">Lessee, Operating Lease Monthly Rent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LesseeOperatingLeaseMonthlyRent_lbl" xml:lang="en-US">Operating lease monthly rent payable</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent" xlink:label="ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent" xlink:to="ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent_lbl" xml:lang="en-US">Lessee Operating Lease, Annual percentage increase in base rent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent_lbl" xml:lang="en-US">Lessee Operating Lease, Annual percentage increase in base rent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent_lbl" xml:lang="en-US">Annual percentage increase in base rent</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_BaseRentAbatementInFirstYearPeriod" xlink:label="ibio_BaseRentAbatementInFirstYearPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_BaseRentAbatementInFirstYearPeriod" xlink:to="ibio_BaseRentAbatementInFirstYearPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_BaseRentAbatementInFirstYearPeriod_lbl" xml:lang="en-US">Base rent abatement period in the first year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_BaseRentAbatementInFirstYearPeriod_lbl" xml:lang="en-US">Base Rent Abatement In the First Year, Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_BaseRentAbatementInFirstYearPeriod_lbl" xml:lang="en-US">Base rent abatement period in the first year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TenantImprovements" xlink:to="us-gaap_TenantImprovements_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TenantImprovements_lbl" xml:lang="en-US">Tenant Improvements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TenantImprovements_lbl" xml:lang="en-US">Tenant improvement allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsMaximumExposure" xlink:label="us-gaap_GuaranteeObligationsMaximumExposure" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GuaranteeObligationsMaximumExposure" xlink:to="us-gaap_GuaranteeObligationsMaximumExposure_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GuaranteeObligationsMaximumExposure_lbl" xml:lang="en-US">Guarantor Obligations, Maximum Exposure, Undiscounted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GuaranteeObligationsMaximumExposure_lbl" xml:lang="en-US">Irrevocable letter of credit</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_OperatingLeaseCostsAbstract" xlink:label="ibio_OperatingLeaseCostsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_OperatingLeaseCostsAbstract" xlink:to="ibio_OperatingLeaseCostsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_OperatingLeaseCostsAbstract_lbl" xml:lang="en-US">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_OperatingLeaseCostsAbstract_lbl" xml:lang="en-US">Operating Lease Costs [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_OperatingLeaseCostsAbstract_lbl" xml:lang="en-US">Operating lease cost:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating Lease, Cost</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_TotalOperatingLeaseCosts" xlink:label="ibio_TotalOperatingLeaseCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_TotalOperatingLeaseCosts" xlink:to="ibio_TotalOperatingLeaseCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_TotalOperatingLeaseCosts_lbl" xml:lang="en-US">Total operating lease costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_TotalOperatingLeaseCosts_lbl" xml:lang="en-US">Total Operating Lease Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_TotalOperatingLeaseCosts_lbl" xml:lang="en-US">Total lease cost</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_OperatingLeaseObligationOtherInformationAbstract" xlink:label="ibio_OperatingLeaseObligationOtherInformationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_OperatingLeaseObligationOtherInformationAbstract" xlink:to="ibio_OperatingLeaseObligationOtherInformationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_OperatingLeaseObligationOtherInformationAbstract_lbl" xml:lang="en-US">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_OperatingLeaseObligationOtherInformationAbstract_lbl" xml:lang="en-US">Operating Lease Obligation Other Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ibio_OperatingLeaseObligationOtherInformationAbstract_lbl" xml:lang="en-US">Other information:</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract" xlink:label="ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract" xlink:to="ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Cash Paid For Amounts Included In Measurement Operating Lease Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement lease liability:</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_OperatingCashFlowsFromOperatingLeaseObligation" xlink:label="ibio_OperatingCashFlowsFromOperatingLeaseObligation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_OperatingCashFlowsFromOperatingLeaseObligation" xlink:to="ibio_OperatingCashFlowsFromOperatingLeaseObligation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_OperatingCashFlowsFromOperatingLeaseObligation_lbl" xml:lang="en-US">Operating cash flows from operating lease obligation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_OperatingCashFlowsFromOperatingLeaseObligation_lbl" xml:lang="en-US">Operating Cash Flows From Operating Lease Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_OperatingCashFlowsFromOperatingLeaseObligation_lbl" xml:lang="en-US">Operating cash flows from operating lease obligation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US">Operating Lease Obligation, Principal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2027</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">2028</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Thereafter</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total minimum lease payments</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract" xlink:label="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract" xlink:to="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Imputed Interest Payment, Due [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract_lbl" xml:lang="en-US">Operating Lease Obligation, Imputed Interest</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, Year One.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne_lbl" xml:lang="en-US">2023</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo_lbl" xml:lang="en-US">2024</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree_lbl" xml:lang="en-US">2025</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, Year Four.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour_lbl" xml:lang="en-US">2026</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive_lbl" xml:lang="en-US">2027</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, After Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, After Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive_lbl" xml:lang="en-US">Thereafter</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal_lbl" xml:lang="en-US">Imputed Interest, Total</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest Payment, Due [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest Payment, Due [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract_lbl" xml:lang="en-US">Operating Lease Obligation, Total</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne_lbl" xml:lang="en-US">2023</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo_lbl" xml:lang="en-US">2024</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree_lbl" xml:lang="en-US">2025</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour_lbl" xml:lang="en-US">2026</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive_lbl" xml:lang="en-US">2027</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, After Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, After Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive_lbl" xml:lang="en-US">Thereafter</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest_lbl" xml:lang="en-US">Lessee Operating Lease Liability Principal And Imputed Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest_lbl" xml:lang="en-US">Lessee Operating Lease Liability Principal And Imputed Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest_lbl" xml:lang="en-US">Principal and imputed interest, Total</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_StockholdersEquityTable" xlink:label="ibio_StockholdersEquityTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_StockholdersEquityTable" xlink:to="ibio_StockholdersEquityTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_StockholdersEquityTable_lbl" xml:lang="en-US">Stockholders' Equity [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ExchangeAgreementMember" xlink:label="ibio_ExchangeAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ExchangeAgreementMember" xlink:to="ibio_ExchangeAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ExchangeAgreementMember_lbl" xml:lang="en-US">Exchange Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ExchangeAgreementMember_lbl" xml:lang="en-US">Exchange Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_EasternAffiliateMember" xlink:label="ibio_EasternAffiliateMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_EasternAffiliateMember" xlink:to="ibio_EasternAffiliateMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_EasternAffiliateMember_lbl" xml:lang="en-US">Information pertaining to Eastern affiliate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_EasternAffiliateMember_lbl" xml:lang="en-US">Eastern Affiliate [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_OmnibusIncentivePlanMember" xlink:label="ibio_OmnibusIncentivePlanMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_OmnibusIncentivePlanMember" xlink:to="ibio_OmnibusIncentivePlanMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_OmnibusIncentivePlanMember_lbl" xml:lang="en-US">Omnibus Incentive Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_OmnibusIncentivePlanMember_lbl" xml:lang="en-US">Omnibus Incentive (the 2020) Plan [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Award Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units [Member]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_PreferredTrackingStockMember" xlink:label="ibio_PreferredTrackingStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_PreferredTrackingStockMember" xlink:to="ibio_PreferredTrackingStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_PreferredTrackingStockMember_lbl" xml:lang="en-US">iBio CMO Preferred Tracking Stock [Member]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_Series2022ConvertiblePreferredStockMember" xlink:label="ibio_Series2022ConvertiblePreferredStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_Series2022ConvertiblePreferredStockMember" xlink:to="ibio_Series2022ConvertiblePreferredStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_Series2022ConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series 2022 Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_Series2022ConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series 2022 Convertible Preferred Stock [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_PreFundedWarrantsMember" xlink:label="ibio_PreFundedWarrantsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_PreFundedWarrantsMember" xlink:to="ibio_PreFundedWarrantsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_PreFundedWarrantsMember_lbl" xml:lang="en-US">Represents the information pertaining to Pre Funded Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_PreFundedWarrantsMember_lbl" xml:lang="en-US">Pre Funded Warrants [Member]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SeriesWarrantsMember" xlink:label="ibio_SeriesWarrantsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SeriesWarrantsMember" xlink:to="ibio_SeriesWarrantsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SeriesWarrantsMember_lbl" xml:lang="en-US">Represents information pertaining to series A warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SeriesWarrantsMember_lbl" xml:lang="en-US">Series A Warrants [Member]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SeriesBWarrantsMember" xlink:label="ibio_SeriesBWarrantsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SeriesBWarrantsMember" xlink:to="ibio_SeriesBWarrantsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SeriesBWarrantsMember_lbl" xml:lang="en-US">Represents information pertaining to series B warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SeriesBWarrantsMember_lbl" xml:lang="en-US">Series B Warrants [Member]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_RepresentativeWarrantsMember" xlink:label="ibio_RepresentativeWarrantsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_RepresentativeWarrantsMember" xlink:to="ibio_RepresentativeWarrantsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_RepresentativeWarrantsMember_lbl" xml:lang="en-US">Represents the information pertaining to representative warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_RepresentativeWarrantsMember_lbl" xml:lang="en-US">Representative Warrants [Member]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_H.c.WainwrightCo.LlcMember" xlink:label="ibio_H.c.WainwrightCo.LlcMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_H.c.WainwrightCo.LlcMember" xlink:to="ibio_H.c.WainwrightCo.LlcMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_H.c.WainwrightCo.LlcMember_lbl" xml:lang="en-US">Represents the information pertaining to H.C. Wainwright &amp; Co., LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_H.c.WainwrightCo.LlcMember_lbl" xml:lang="en-US">H.C. Wainwright &amp; Co., LLC [Member]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember" xlink:label="ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember" xlink:to="ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember_lbl" xml:lang="en-US">After Preferred Tracking Stock Exchanged for Units of Limited Liability Company Interests [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember_lbl" xml:lang="en-US">After Preferred Tracking Stock Exchanged for Units of Limited Liability Company Interests [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipAxis_lbl" xml:lang="en-US">Ownership [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipDomain_lbl" xml:lang="en-US">Ownership [Domain]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_IbioCdmoMember" xlink:label="ibio_IbioCdmoMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IbioCdmoMember" xlink:to="ibio_IbioCdmoMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_IbioCdmoMember_lbl" xml:lang="en-US">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IbioCdmoMember_lbl" xml:lang="en-US">Bioprocessing (iBio CDMO) [Member]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_StockholdersEquityLineItems" xlink:label="ibio_StockholdersEquityLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="ibio_StockholdersEquityLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_StockholdersEquityLineItems_lbl" xml:lang="en-US">Stockholders' Equity [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock" xlink:label="ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock" xlink:to="ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock_lbl" xml:lang="en-US">Number of Limited Liability Company interest units exchanged for each share of preferred tracking stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock_lbl" xml:lang="en-US">Number of Limited Liability Company interest units exchanged for each share of preferred tracking stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock_lbl" xml:lang="en-US">Number of LLC interest units exchanged for each share of preferred tracking stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Proceeds from sale of shares, net of issuance cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US">Shares issued upon conversion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsPerShareDeclared" xlink:label="us-gaap_PreferredStockDividendsPerShareDeclared" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsPerShareDeclared" xlink:to="us-gaap_PreferredStockDividendsPerShareDeclared_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendsPerShareDeclared_lbl" xml:lang="en-US">Preferred Stock, Dividends Per Share, Declared</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Number of shares reserved for future issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in Shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Shares available for grant under the plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Shares vested</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrants and Rights Outstanding, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Term of the warrants</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SalesAgreementMember" xlink:label="ibio_SalesAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SalesAgreementMember" xlink:to="ibio_SalesAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SalesAgreementMember_lbl" xml:lang="en-US">Represents information pertaining to Sales Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SalesAgreementMember_lbl" xml:lang="en-US">Sales Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US">Over-Allotment Option [Member]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CantorFitzgeraldMember" xlink:label="ibio_CantorFitzgeraldMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CantorFitzgeraldMember" xlink:to="ibio_CantorFitzgeraldMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CantorFitzgeraldMember_lbl" xml:lang="en-US">Cantor Fitzgerald [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CantorFitzgeraldMember_lbl" xml:lang="en-US">Cantor Fitzgerald [Member]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_AggregateCommonStockPurchased" xlink:label="ibio_AggregateCommonStockPurchased" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_AggregateCommonStockPurchased" xlink:to="ibio_AggregateCommonStockPurchased_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_AggregateCommonStockPurchased_lbl" xml:lang="en-US">The aggregate amount of common shares permitted to be issued by an entity's charter and bylaws.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_AggregateCommonStockPurchased_lbl" xml:lang="en-US">Aggregate Common Stock Purchased</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ibio_AggregateCommonStockPurchased_lbl" xml:lang="en-US">Aggregate offering price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Sale of preferred stock</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering" xlink:label="ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering" xlink:to="ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering_lbl" xml:lang="en-US">Percentage of underwriting discount paid on gross proceeds of offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering_lbl" xml:lang="en-US">Percentage of Underwriting Discount Paid on Gross Proceeds of Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering_lbl" xml:lang="en-US">Percentage of underwriting discount</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_NumberOfDaysOptionToPurchaseAdditionalShares" xlink:label="ibio_NumberOfDaysOptionToPurchaseAdditionalShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_NumberOfDaysOptionToPurchaseAdditionalShares" xlink:to="ibio_NumberOfDaysOptionToPurchaseAdditionalShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_NumberOfDaysOptionToPurchaseAdditionalShares_lbl" xml:lang="en-US">Number of days option to purchase additional shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_NumberOfDaysOptionToPurchaseAdditionalShares_lbl" xml:lang="en-US">Number of Days Option to Purchase Additional Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_NumberOfDaysOptionToPurchaseAdditionalShares_lbl" xml:lang="en-US">Number of days granted to purchase additional shares</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_NumberOfAdditionalSharesIssued" xlink:label="ibio_NumberOfAdditionalSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_NumberOfAdditionalSharesIssued" xlink:to="ibio_NumberOfAdditionalSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_NumberOfAdditionalSharesIssued_lbl" xml:lang="en-US">Number of additional shares issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_NumberOfAdditionalSharesIssued_lbl" xml:lang="en-US">Number of Additional Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_NumberOfAdditionalSharesIssued_lbl" xml:lang="en-US">Additional shares issued</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CommonWarrantsToPurchaseAdditionalShares" xlink:label="ibio_CommonWarrantsToPurchaseAdditionalShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CommonWarrantsToPurchaseAdditionalShares" xlink:to="ibio_CommonWarrantsToPurchaseAdditionalShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CommonWarrantsToPurchaseAdditionalShares_lbl" xml:lang="en-US">Number of common warrants to purchase additional shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CommonWarrantsToPurchaseAdditionalShares_lbl" xml:lang="en-US">Common Warrants to Purchase Additional Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_CommonWarrantsToPurchaseAdditionalShares_lbl" xml:lang="en-US">Warrants to purchase additional shares</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_PercentageOfAggregateNumberOfSharesOfCommonStock" xlink:label="ibio_PercentageOfAggregateNumberOfSharesOfCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_PercentageOfAggregateNumberOfSharesOfCommonStock" xlink:to="ibio_PercentageOfAggregateNumberOfSharesOfCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_PercentageOfAggregateNumberOfSharesOfCommonStock_lbl" xml:lang="en-US">Percentage of aggregate number of shares of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_PercentageOfAggregateNumberOfSharesOfCommonStock_lbl" xml:lang="en-US">Percentage of Aggregate Number of Shares of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_PercentageOfAggregateNumberOfSharesOfCommonStock_lbl" xml:lang="en-US">Percentage of number of shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Proceeds from Issuance of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Net proceeds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xml:lang="en-US">Basic and diluted numerator:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss available to iBio, Inc. stockholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xml:lang="en-US">Basic and diluted denominator:</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_EarningsLossPerCommonShareTable" xlink:label="ibio_EarningsLossPerCommonShareTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_EarningsLossPerCommonShareTable" xlink:to="ibio_EarningsLossPerCommonShareTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_EarningsLossPerCommonShareTable_lbl" xml:lang="en-US">Earnings Loss Per Common Share [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Stock Options [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_EarningsLossPerCommonShareLineItems" xlink:label="ibio_EarningsLossPerCommonShareLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_EarningsLossPerCommonShareLineItems" xlink:to="ibio_EarningsLossPerCommonShareLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_EarningsLossPerCommonShareLineItems_lbl" xml:lang="en-US">Earnings Loss Per Common Share [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ScenarioOneMember" xlink:label="ibio_ScenarioOneMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ScenarioOneMember" xlink:to="ibio_ScenarioOneMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ScenarioOneMember_lbl" xml:lang="en-US">This member stands for scenario one in which the value of maximum award in calendar year in which the applicable non-employee director is initially elected or appointed to the Board of Directors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ScenarioOneMember_lbl" xml:lang="en-US">Scenario One [Member]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ScenarioTwoMember" xlink:label="ibio_ScenarioTwoMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ScenarioTwoMember" xlink:to="ibio_ScenarioTwoMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ScenarioTwoMember_lbl" xml:lang="en-US">This represents Preferred tracking stock exchanged for units.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ScenarioTwoMember_lbl" xml:lang="en-US">Scenario Two [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Relationship to Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ConsultantsMember" xlink:label="ibio_ConsultantsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ConsultantsMember" xlink:to="ibio_ConsultantsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ConsultantsMember_lbl" xml:lang="en-US">Consultants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ConsultantsMember_lbl" xml:lang="en-US">Consultants [Member]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_VariousEmployeesMember" xlink:label="ibio_VariousEmployeesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_VariousEmployeesMember" xlink:to="ibio_VariousEmployeesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_VariousEmployeesMember_lbl" xml:lang="en-US">Various Employees [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_VariousEmployeesMember_lbl" xml:lang="en-US">Employees [Member]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_TwoThousandEighteenOmnibusEquityIncentivePlanMember" xlink:label="ibio_TwoThousandEighteenOmnibusEquityIncentivePlanMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_TwoThousandEighteenOmnibusEquityIncentivePlanMember" xlink:to="ibio_TwoThousandEighteenOmnibusEquityIncentivePlanMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_TwoThousandEighteenOmnibusEquityIncentivePlanMember_lbl" xml:lang="en-US">Information pertaining to Two thousand Eighteen Omnibus Equity Incentive Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_TwoThousandEighteenOmnibusEquityIncentivePlanMember_lbl" xml:lang="en-US">2018 Omnibus Equity Incentive Plan [Member]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_IbioInc.2020OmnibusEquityIncentivePlanMember" xlink:label="ibio_IbioInc.2020OmnibusEquityIncentivePlanMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IbioInc.2020OmnibusEquityIncentivePlanMember" xlink:to="ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_lbl" xml:lang="en-US">This member stands for iBio, Inc. 2020 Omnibus Equity Incentive Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_lbl" xml:lang="en-US">2020 Omnibus Equity Incentive Plan [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US">Vesting [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US">Vesting [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Share based award, vesting period</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized" xlink:label="ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized" xlink:to="ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Amount of Shares Authorized.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Amount of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized_lbl" xml:lang="en-US">Maximum value of all awards awarded under the Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Stock Options, Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-average exercise price per share, granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Share based payment plan term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Share-based award, Units to be issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Share-based award, Number of awards issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US">Grant date fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US">Share based payment award, Grant-date fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Stock options vesting percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and development Expense [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and administrative Expense [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Risk free interest rate, Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Risk free interest rate, Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Volatility, Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Volatility, Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term (in years)</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_Dr.MartinBrennerMember" xlink:label="ibio_Dr.MartinBrennerMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_Dr.MartinBrennerMember" xlink:to="ibio_Dr.MartinBrennerMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_Dr.MartinBrennerMember_lbl" xml:lang="en-US">Represents information relating to Dr. Martin Brenner, the Company's Chief Scientific Officer and Interim Chief Executive Officer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_Dr.MartinBrennerMember_lbl" xml:lang="en-US">Dr. Martin Brenner [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_Dr.MartinBrennerMember_lbl" xml:lang="en-US">Dr. Martin Brenner</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis" xlink:label="us-gaap_LitigationStatusAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationStatusAxis" xlink:to="us-gaap_LitigationStatusAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationStatusAxis_lbl" xml:lang="en-US">Litigation Status [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain" xlink:label="us-gaap_LitigationStatusDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationStatusDomain" xlink:to="us-gaap_LitigationStatusDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationStatusDomain_lbl" xml:lang="en-US">Litigation Status [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember" xlink:label="us-gaap_SettledLitigationMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SettledLitigationMember" xlink:to="us-gaap_SettledLitigationMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SettledLitigationMember_lbl" xml:lang="en-US">Settled Litigation [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioPlanMember" xlink:to="us-gaap_ScenarioPlanMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScenarioPlanMember_lbl" xml:lang="en-US">Scenario, Plan [Member]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ScenarioPlanExpectedLegalFeesMember" xlink:label="ibio_ScenarioPlanExpectedLegalFeesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ScenarioPlanExpectedLegalFeesMember" xlink:to="ibio_ScenarioPlanExpectedLegalFeesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ScenarioPlanExpectedLegalFeesMember_lbl" xml:lang="en-US">Scenario Plan, Expected Legal Fees [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ScenarioPlanExpectedLegalFeesMember_lbl" xml:lang="en-US">Scenario Plan Expected Legal Fees [Member]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ScenarioPlanExpectedPaymentOneMember" xlink:label="ibio_ScenarioPlanExpectedPaymentOneMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ScenarioPlanExpectedPaymentOneMember" xlink:to="ibio_ScenarioPlanExpectedPaymentOneMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ScenarioPlanExpectedPaymentOneMember_lbl" xml:lang="en-US">Scenario Plan Expected Payment One [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ScenarioPlanExpectedPaymentOneMember_lbl" xml:lang="en-US">Scenario Plan Expected Payment One [Member]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ScenarioPlanExpectedPaymentTwoMember" xlink:label="ibio_ScenarioPlanExpectedPaymentTwoMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ScenarioPlanExpectedPaymentTwoMember" xlink:to="ibio_ScenarioPlanExpectedPaymentTwoMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ScenarioPlanExpectedPaymentTwoMember_lbl" xml:lang="en-US">Scenario Plan Expected Payment Two [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ScenarioPlanExpectedPaymentTwoMember_lbl" xml:lang="en-US">Scenario Plan Expected Payment Two [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ServiceMember" xlink:to="us-gaap_ServiceMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ServiceMember_lbl" xml:lang="en-US">Service [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAndMaintenanceMember" xlink:label="us-gaap_LicenseAndMaintenanceMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAndMaintenanceMember" xlink:to="us-gaap_LicenseAndMaintenanceMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseAndMaintenanceMember_lbl" xml:lang="en-US">License and Maintenance [Member]</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CashPaymentsReceivablesRelatedToLitigationSettlement" xlink:label="ibio_CashPaymentsReceivablesRelatedToLitigationSettlement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CashPaymentsReceivablesRelatedToLitigationSettlement" xlink:to="ibio_CashPaymentsReceivablesRelatedToLitigationSettlement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CashPaymentsReceivablesRelatedToLitigationSettlement_lbl" xml:lang="en-US">Cash payments receivables related to litigation settlement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CashPaymentsReceivablesRelatedToLitigationSettlement_lbl" xml:lang="en-US">Cash Payments Receivables Related to Litigation Settlement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_CashPaymentsReceivablesRelatedToLitigationSettlement_lbl" xml:lang="en-US">Cash payments receivables related to litigation settlement</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_PercentageOfLegalFeesExpectedToBeReceived" xlink:label="ibio_PercentageOfLegalFeesExpectedToBeReceived" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_PercentageOfLegalFeesExpectedToBeReceived" xlink:to="ibio_PercentageOfLegalFeesExpectedToBeReceived_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_PercentageOfLegalFeesExpectedToBeReceived_lbl" xml:lang="en-US">Percentage of legal fees expected to be received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_PercentageOfLegalFeesExpectedToBeReceived_lbl" xml:lang="en-US">Percentage Of Legal Fees Expected to be Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_PercentageOfLegalFeesExpectedToBeReceived_lbl" xml:lang="en-US">Percentage of legal fees expected to be received</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SettlementAssetsNonCurrent" xlink:label="ibio_SettlementAssetsNonCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SettlementAssetsNonCurrent" xlink:to="ibio_SettlementAssetsNonCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SettlementAssetsNonCurrent_lbl" xml:lang="en-US">Settlement receivables, Non current portion.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SettlementAssetsNonCurrent_lbl" xml:lang="en-US">Settlement Assets Non Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_SettlementAssetsNonCurrent_lbl" xml:lang="en-US">Settlement receivable - noncurrent portion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyUnrecordedAmount" xlink:label="us-gaap_GainContingencyUnrecordedAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainContingencyUnrecordedAmount" xlink:to="us-gaap_GainContingencyUnrecordedAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainContingencyUnrecordedAmount_lbl" xml:lang="en-US">Gain Contingency, Unrecorded Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainContingencyUnrecordedAmount_lbl" xml:lang="en-US">Estimated net cash recovery</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedFromOtherParty" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:to="us-gaap_LitigationSettlementAmountAwardedFromOtherParty_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationSettlementAmountAwardedFromOtherParty_lbl" xml:lang="en-US">Litigation settlement, amount awarded from other party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LitigationSettlementAmountAwardedFromOtherParty_lbl" xml:lang="en-US">Settlement income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective income tax rate</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CroAgreementMember" xlink:label="ibio_CroAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CroAgreementMember" xlink:to="ibio_CroAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CroAgreementMember_lbl" xml:lang="en-US">Represents the information pertaining to CRO Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CroAgreementMember_lbl" xml:lang="en-US">CRO Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Other Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Costs incurred</label>
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_EstimatedAdditionalCostOnDevelopment" xlink:label="ibio_EstimatedAdditionalCostOnDevelopment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_EstimatedAdditionalCostOnDevelopment" xlink:to="ibio_EstimatedAdditionalCostOnDevelopment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_EstimatedAdditionalCostOnDevelopment_lbl" xml:lang="en-US">The amount of estimated additional cost on development as at end of the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_EstimatedAdditionalCostOnDevelopment_lbl" xml:lang="en-US">Estimated Additional Cost on Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_EstimatedAdditionalCostOnDevelopment_lbl" xml:lang="en-US">Additional costs committed</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Employer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>ibio-20230331_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.5.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/15/2023 1:23:55 PM-->
<!--Modified on: 5/15/2023 1:23:55 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#StatementCondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#StatementCondensedConsolidatedStatementsOfEquity" roleURI="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureNatureOfBusiness" roleURI="http://www.ibioinc.com/role/DisclosureNatureOfBusiness" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureBasisOfPresentation" roleURI="http://www.ibioinc.com/role/DisclosureBasisOfPresentation" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureDiscontinuedOperations" roleURI="http://www.ibioinc.com/role/DisclosureDiscontinuedOperations" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPolicies" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureFinancialInstrumentsAndFairValueMeasurement" roleURI="http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurement" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureSignificantTransactions" roleURI="http://www.ibioinc.com/role/DisclosureSignificantTransactions" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureConvertiblePromissoryNoteReceivable" roleURI="http://www.ibioinc.com/role/DisclosureConvertiblePromissoryNoteReceivable" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureInvestmentsInDebtSecurities" roleURI="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecurities" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureFinanceLeaseRouAssets" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssets" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureOperatingLeaseRouAssets" roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssets" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureFixedAssets" roleURI="http://www.ibioinc.com/role/DisclosureFixedAssets" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureIntangibleAssets" roleURI="http://www.ibioinc.com/role/DisclosureIntangibleAssets" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureDebt" roleURI="http://www.ibioinc.com/role/DisclosureDebt" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureFinanceLeaseObligation" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligation" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureOperatingLeaseObligation" roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligation" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureStockholdersEquity" roleURI="http://www.ibioinc.com/role/DisclosureStockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureEarningsLossPerCommonShare" roleURI="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShare" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureShareBasedCompensation" roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensation" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureFraunhoferSettlement" roleURI="http://www.ibioinc.com/role/DisclosureFraunhoferSettlement" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureIncomeTaxes" roleURI="http://www.ibioinc.com/role/DisclosureIncomeTaxes" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.ibioinc.com/role/DisclosureCommitmentsAndContingencies" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureEmployee401KPlan" roleURI="http://www.ibioinc.com/role/DisclosureEmployee401KPlan" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureSubsequentEvents" roleURI="http://www.ibioinc.com/role/DisclosureSubsequentEvents" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureDiscontinuedOperationsTables" roleURI="http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsTables" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureFinancialInstrumentsAndFairValueMeasurementTables" roleURI="http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementTables" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureSignificantTransactionsTables" roleURI="http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureInvestmentsInDebtSecuritiesTables" roleURI="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesTables" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureFinanceLeaseRouAssetsTables" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsTables" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureFixedAssetsTables" roleURI="http://www.ibioinc.com/role/DisclosureFixedAssetsTables" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureIntangibleAssetsTables" roleURI="http://www.ibioinc.com/role/DisclosureIntangibleAssetsTables" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureDebtTables" roleURI="http://www.ibioinc.com/role/DisclosureDebtTables" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureFinanceLeaseObligationTables" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationTables" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureOperatingLeaseObligationsTables" roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsTables" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureEarningsLossPerCommonShareTables" roleURI="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareTables" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureShareBasedCompensationTables" roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationTables" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureBasisOfPresentationNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureDiscontinuedOperationsNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails" roleURI="http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails" roleURI="http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureSignificantTransactionsNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails" roleURI="http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureConvertiblePromissoryNoteReceivableNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureConvertiblePromissoryNoteReceivableNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureInvestmentsInDebtSecuritiesNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureInvestmentsInDebtSecuritiesComponentsOfInvestmentsInDebtSecuritiesDetails" roleURI="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesComponentsOfInvestmentsInDebtSecuritiesDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureInvestmentsInDebtSecuritiesDebtSecuritiesContractualMaturityDetails" roleURI="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesDebtSecuritiesContractualMaturityDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureFinanceLeaseRouAssetsNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureOperatingLeaseRouAssetsNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssetsNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureFixedAssetsNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureFixedAssetsNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails" roleURI="http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureIntangibleAssetsNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails" roleURI="http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureDebtCreditAgreementDetails" roleURI="http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureDebtEquipmentFinancingDetails" roleURI="http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails" roleURI="http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureDebtNotePayablePppLoanDetails" roleURI="http://www.ibioinc.com/role/DisclosureDebtNotePayablePppLoanDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureFinanceLeaseObligationNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureOperatingLeaseObligationNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureOperatingLeaseObligationLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails" roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails" roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureStockholdersEquityNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails" roleURI="http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails" roleURI="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" roleURI="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureShareBasedCompensationNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureShareBasedCompensationStockOptionActivityDetails" roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureShareBasedCompensationFairValueOfOptionsGrantedDetails" roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationFairValueOfOptionsGrantedDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureShareBasedCompensationRsusDetails" roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationRsusDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureFraunhoferSettlementNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureIncomeTaxesNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureIncomeTaxesNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureCommitmentsAndContingenciesNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureEmployee401KPlanNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureEmployee401KPlanNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230331.xsd#DisclosureSubsequentEventsNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails" />
  <presentationLink xlink:role="http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document And Entity Information">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638197538276886500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_638197538276886500" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport_638197538276886500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport_638197538276886500" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638197538276886500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_638197538276886500" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638197538276886500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638197538276886500" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638197538276886500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_638197538276886500" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638197538276886500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_638197538276886500" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638197538276886500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638197538276886500" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638197538276896488" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638197538276896488" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638197538276896488" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638197538276896488" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638197538276896488" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638197538276896488" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638197538276896488" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638197538276896488" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638197538276896488" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638197538276896488" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638197538276896488" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_638197538276896488" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638197538276896488" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_638197538276896488" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638197538276896488" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_638197538276896488" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638197538276896488" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_638197538276896488" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638197538276896488" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_638197538276896488" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638197538276906380" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638197538276906380" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638197538276906380" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638197538276906380" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638197538276906380" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_638197538276906380" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638197538276906380" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_638197538276906380" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638197538276906380" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638197538276906380" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638197538276906380" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_638197538276906380" order="23" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638197538276916441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638197538276916441" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638197538276916441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638197538276916441" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638197538276916441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638197538276916441" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638197538276916441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638197538276916441" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638197538276916441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_638197538276916441" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638197538276916441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638197538276916441" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Condensed Consolidated Balance Sheets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_26" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638197538276926369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_26" xlink:to="us-gaap_AssetsAbstract_638197538276926369" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638197538276926369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638197538276926369" xlink:to="us-gaap_AssetsCurrentAbstract_638197538276926369" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638197538276926369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638197538276926369" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638197538276926369" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesCurrent" xlink:label="us-gaap_DebtSecuritiesCurrent_638197538276926369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638197538276926369" xlink:to="us-gaap_DebtSecuritiesCurrent_638197538276926369" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638197538276926369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638197538276926369" xlink:to="us-gaap_AccountsReceivableNetCurrent_638197538276926369" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SubscriptionReceivableCurrent" xlink:label="ibio_SubscriptionReceivableCurrent_638197538276926369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638197538276926369" xlink:to="ibio_SubscriptionReceivableCurrent_638197538276926369" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettlementAssetsCurrent" xlink:label="us-gaap_SettlementAssetsCurrent_638197538276926369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638197538276926369" xlink:to="us-gaap_SettlementAssetsCurrent_638197538276926369" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesAndLoansReceivableNetCurrent" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent_638197538276926369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638197538276926369" xlink:to="us-gaap_NotesAndLoansReceivableNetCurrent_638197538276926369" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638197538276926369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638197538276926369" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638197538276926369" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:label="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_638197538276926369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638197538276926369" xlink:to="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_638197538276926369" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638197538276936410" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638197538276926369" xlink:to="us-gaap_AssetsCurrent_638197538276936410" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638197538276936410" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638197538276926369" xlink:to="us-gaap_RestrictedCashNoncurrent_638197538276936410" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest" xlink:label="ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest_638197538276936410" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638197538276926369" xlink:to="ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest_638197538276936410" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_638197538276936410" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638197538276926369" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_638197538276936410" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638197538276936410" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638197538276926369" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638197538276936410" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638197538276936410" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638197538276926369" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638197538276936410" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_638197538276936410" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638197538276926369" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_638197538276936410" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit_638197538276936410" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638197538276926369" xlink:to="us-gaap_SecurityDeposit_638197538276936410" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="us-gaap_PrepaidExpenseNoncurrent_638197538276936410" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638197538276926369" xlink:to="us-gaap_PrepaidExpenseNoncurrent_638197538276936410" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_638197538276946368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638197538276926369" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_638197538276946368" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638197538276946368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638197538276926369" xlink:to="us-gaap_Assets_638197538276946368" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638197538276946368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_26" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638197538276946368" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638197538276946368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638197538276946368" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638197538276946368" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638197538276946368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638197538276946368" xlink:to="us-gaap_AccountsPayableCurrent_638197538276946368" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638197538276946368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638197538276946368" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638197538276946368" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_638197538276956402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638197538276946368" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_638197538276956402" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638197538276956402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638197538276946368" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638197538276956402" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_EquipmentFinancingPayableCurrent" xlink:label="ibio_EquipmentFinancingPayableCurrent_638197538276956402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638197538276946368" xlink:to="ibio_EquipmentFinancingPayableCurrent_638197538276956402" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent_638197538276956402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638197538276946368" xlink:to="us-gaap_NotesPayableCurrent_638197538276956402" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent_638197538276956402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638197538276946368" xlink:to="us-gaap_DeferredRevenueCurrent_638197538276956402" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale" xlink:label="ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale_638197538276956402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638197538276946368" xlink:to="ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale_638197538276956402" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638197538276966074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638197538276946368" xlink:to="us-gaap_LiabilitiesCurrent_638197538276966074" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_638197538276966074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638197538276946368" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_638197538276966074" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638197538276966074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638197538276946368" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638197538276966074" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_EquipmentFinancingPayableNoncurrent" xlink:label="ibio_EquipmentFinancingPayableNoncurrent_638197538276966074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638197538276946368" xlink:to="ibio_EquipmentFinancingPayableNoncurrent_638197538276966074" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_AccruedLiabilitiesNoncurrent" xlink:label="ibio_AccruedLiabilitiesNoncurrent_638197538276976074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638197538276946368" xlink:to="ibio_AccruedLiabilitiesNoncurrent_638197538276976074" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale" xlink:label="ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale_638197538276976074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638197538276946368" xlink:to="ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale_638197538276976074" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638197538276976074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638197538276946368" xlink:to="us-gaap_Liabilities_638197538276976074" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_638197538276976074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638197538276946368" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_638197538276976074" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638197538276976074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_638197538276976074" xlink:to="us-gaap_StockholdersEquityAbstract_638197538276976074" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638197538276986494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638197538276976074" xlink:to="us-gaap_PreferredStockValue_638197538276986494" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638197538276986494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638197538276976074" xlink:to="us-gaap_CommonStockValue_638197538276986494" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_638197538276986494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638197538276976074" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_638197538276986494" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638197538276986494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638197538276976074" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638197538276986494" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638197538276986494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638197538276976074" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638197538276986494" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638197538276996459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638197538276976074" xlink:to="us-gaap_StockholdersEquity_638197538276996459" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638197538276996459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638197538276946368" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638197538276996459" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638197538276996459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638197538276996459" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638197538276996459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_638197538276996459" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638197538276996459" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued_638197538276996459" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638197538277006474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding_638197538277006474" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638197538277006474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638197538277006474" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638197538277006474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_638197538277006474" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638197538277006474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_638197538277006474" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638197538277006474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_638197538277006474" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638197538277006474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638197538277006474" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract_636900514088604338" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638197538277006474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_Revenues_638197538277006474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_638197538277006474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_OperatingExpensesAbstract_638197538277006474" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638197538277006474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638197538277006474" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638197538277006474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638197538277016502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638197538277006474" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638197538277016502" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638197538277016502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638197538277006474" xlink:to="us-gaap_OperatingExpenses_638197538277016502" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638197538277016502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_OperatingIncomeLoss_638197538277016502" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_638197538277016502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_638197538277016502" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_638197538277016502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638197538277016502" xlink:to="us-gaap_InterestExpense_638197538277016502" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638197538277016502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638197538277016502" xlink:to="us-gaap_InvestmentIncomeInterest_638197538277016502" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleGainLoss_638197538277016502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638197538277016502" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleGainLoss_638197538277016502" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyIncomeNonoperating" xlink:label="us-gaap_RoyaltyIncomeNonoperating_638197538277016502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638197538277016502" xlink:to="us-gaap_RoyaltyIncomeNonoperating_638197538277016502" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638197538277016502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638197538277016502" xlink:to="us-gaap_NonoperatingIncomeExpense_638197538277016502" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_638197538277016502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_638197538277016502" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:label="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_638197538277016502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_638197538277016502" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="us-gaap_IncomeLossFromContinuingOperations_638197538277026475" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_IncomeLossFromContinuingOperations_638197538277026475" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPreferredStockStock" xlink:label="us-gaap_DividendsPreferredStockStock_638197538277026475" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_DividendsPreferredStockStock_638197538277026475" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_NetLossAvailableToStockholdersFromContinuingOperations" xlink:label="ibio_NetLossAvailableToStockholdersFromContinuingOperations_638197538277026475" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="ibio_NetLossAvailableToStockholdersFromContinuingOperations_638197538277026475" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_638197538277026475" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_638197538277026475" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_UnconsolidatedGainLossAttributableToStockholders" xlink:label="ibio_UnconsolidatedGainLossAttributableToStockholders_638197538277026475" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="ibio_UnconsolidatedGainLossAttributableToStockholders_638197538277026475" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_638197538277026475" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_638197538277026475" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638197538277026475" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_638197538277026475" xlink:to="us-gaap_ProfitLoss_638197538277026475" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_638197538277026475" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_638197538277026475" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_638197538277026475" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_638197538277036467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_638197538277026475" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_638197538277036467" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_638197538277036467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_638197538277036467" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_638197538277036467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_638197538277036467" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_638197538277036467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_638197538277036467" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_638197538277036467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_638197538277036467" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_638197538277036467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_638197538277036467" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638197538277036467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_EarningsPerShareBasic_638197538277036467" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638197538277046409" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_EarningsPerShareDiluted_638197538277046409" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638197538277046409" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638197538277046409" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638197538277046409" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638197538277046409" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity" xlink:type="extended" xlink:title="00300 - Statement - Condensed Consolidated Statements of Equity">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_637045036841541064" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638197538277046409" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract_637045036841541064" xlink:to="us-gaap_StatementTable_638197538277046409" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638197538277046409" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538277046409" xlink:to="us-gaap_StatementEquityComponentsAxis_638197538277046409" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember_638197538277056523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638197538277046409" xlink:to="us-gaap_PreferredStockMember_638197538277056523" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638197538277056523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638197538277046409" xlink:to="us-gaap_CommonStockMember_638197538277056523" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638197538277056523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638197538277046409" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638197538277056523" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638197538277056523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638197538277046409" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638197538277056523" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638197538277056523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638197538277046409" xlink:to="us-gaap_RetainedEarningsMember_638197538277056523" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember_638197538277056523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638197538277046409" xlink:to="us-gaap_NoncontrollingInterestMember_638197538277056523" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638197538277056523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638197538277046409" xlink:to="us-gaap_EquityComponentDomain_638197538277056523" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638197538277056523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538277046409" xlink:to="us-gaap_StatementLineItems_638197538277056523" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_638197538277116554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277056523" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_638197538277116554" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638197538277116554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277056523" xlink:to="us-gaap_SharesOutstanding_638197538277116554" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_StockIssuedDuringPeriodValueCapitalRaise" xlink:label="ibio_StockIssuedDuringPeriodValueCapitalRaise_638197538277116554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277056523" xlink:to="ibio_StockIssuedDuringPeriodValueCapitalRaise_638197538277116554" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638197538277126522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277056523" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638197538277126522" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638197538277126522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277056523" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638197538277126522" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_StockIssuedDuringPeriodSharesCapitalRaise" xlink:label="ibio_StockIssuedDuringPeriodSharesCapitalRaise_638197538277126522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277056523" xlink:to="ibio_StockIssuedDuringPeriodSharesCapitalRaise_638197538277126522" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_638197538277126522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277056523" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_638197538277126522" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_FractionalShareIssuedAfterReverseStockSplitValue" xlink:label="ibio_FractionalShareIssuedAfterReverseStockSplitValue_638197538277126522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277056523" xlink:to="ibio_FractionalShareIssuedAfterReverseStockSplitValue_638197538277126522" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_FractionalShareIssuedAfterReverseStockSplitShares" xlink:label="ibio_FractionalShareIssuedAfterReverseStockSplitShares_638197538277126522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277056523" xlink:to="ibio_FractionalShareIssuedAfterReverseStockSplitShares_638197538277126522" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638197538277126522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277056523" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638197538277126522" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CommonStockIssuedInRubrycTransactionValue" xlink:label="ibio_CommonStockIssuedInRubrycTransactionValue_638197538277136500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277056523" xlink:to="ibio_CommonStockIssuedInRubrycTransactionValue_638197538277136500" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CommonStockIssuedInRubrycTransactionInShares" xlink:label="ibio_CommonStockIssuedInRubrycTransactionInShares_638197538277136500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277056523" xlink:to="ibio_CommonStockIssuedInRubrycTransactionInShares_638197538277136500" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_638197538277136500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277056523" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_638197538277136500" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_638197538277136500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277056523" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_638197538277136500" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_638197538277136500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277056523" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_638197538277136500" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate" xlink:label="ibio_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate_638197538277146571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277056523" xlink:to="ibio_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate_638197538277146571" order="16" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638197538277146571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277056523" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638197538277146571" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_638197538277146571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277056523" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_638197538277146571" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities" xlink:label="ibio_ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities_638197538277146571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277056523" xlink:to="ibio_ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities_638197538277146571" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_638197538277146571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277056523" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_638197538277146571" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638197538277146571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277056523" xlink:to="us-gaap_NetIncomeLoss_638197538277146571" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_638197538277156510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277056523" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_638197538277156510" order="22" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638197538277156510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277056523" xlink:to="us-gaap_ProfitLoss_638197538277156510" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_638197538277156510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277056523" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_638197538277156510" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638197538277156510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277056523" xlink:to="us-gaap_SharesOutstanding_638197538277156510" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Condensed Consolidated Statements of Cash Flows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract_636900514800094338" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638197538277166168" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_636900514800094338" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638197538277166168" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638197538277166168" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638197538277166168" xlink:to="us-gaap_ProfitLoss_638197538277166168" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638197538277166168" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638197538277166168" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638197538277166168" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638197538277166168" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638197538277166168" xlink:to="us-gaap_ShareBasedCompensation_638197538277166168" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_638197538277166168" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638197538277166168" xlink:to="us-gaap_AmortizationOfIntangibleAssets_638197538277166168" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638197538277166168" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638197538277166168" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638197538277166168" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638197538277166168" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638197538277166168" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638197538277166168" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638197538277166168" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638197538277166168" xlink:to="us-gaap_Depreciation_638197538277166168" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:label="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_638197538277166168" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638197538277166168" xlink:to="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_638197538277166168" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable" xlink:label="ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable_638197538277176505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638197538277166168" xlink:to="ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable_638197538277176505" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_638197538277176505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638197538277166168" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_638197538277176505" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleGainLoss_638197538277176505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638197538277166168" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleGainLoss_638197538277176505" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_DeferredFinancingCostsAmortizationExpense" xlink:label="ibio_DeferredFinancingCostsAmortizationExpense_638197538277176505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638197538277166168" xlink:to="ibio_DeferredFinancingCostsAmortizationExpense_638197538277176505" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_IncreaseDecreaseInInventoryReserve" xlink:label="ibio_IncreaseDecreaseInInventoryReserve_638197538277176505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638197538277166168" xlink:to="ibio_IncreaseDecreaseInInventoryReserve_638197538277176505" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="us-gaap_TangibleAssetImpairmentCharges_638197538277176505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638197538277166168" xlink:to="us-gaap_TangibleAssetImpairmentCharges_638197538277176505" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_638197538277176505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638197538277166168" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_638197538277176505" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases" xlink:label="us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases_638197538277176505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638197538277166168" xlink:to="us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases_638197538277176505" order="14" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan" xlink:label="ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan_638197538277176505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638197538277166168" xlink:to="ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan_638197538277176505" order="15" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SettlementOfRevenueContract" xlink:label="ibio_SettlementOfRevenueContract_638197538277186484" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638197538277166168" xlink:to="ibio_SettlementOfRevenueContract_638197538277186484" order="16" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638197538277186484" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638197538277166168" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638197538277186484" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638197538277186484" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638197538277186484" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638197538277186484" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_IncreaseDecreaseInSettlementAssets" xlink:label="ibio_IncreaseDecreaseInSettlementAssets_638197538277186484" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638197538277186484" xlink:to="ibio_IncreaseDecreaseInSettlementAssets_638197538277186484" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories" xlink:label="us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories_638197538277186484" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638197538277186484" xlink:to="us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories_638197538277186484" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638197538277186484" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638197538277186484" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638197538277186484" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_638197538277186484" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638197538277186484" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_638197538277186484" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits_638197538277196519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638197538277186484" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits_638197538277196519" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638197538277196519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638197538277186484" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638197538277196519" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_638197538277196519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638197538277186484" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_638197538277196519" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent" xlink:label="ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent_638197538277196519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638197538277186484" xlink:to="ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent_638197538277196519" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638197538277196519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638197538277186484" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638197538277196519" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638197538277196519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638197538277186484" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638197538277196519" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638197538277206417" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638197538277166168" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638197538277206417" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638197538277206417" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_636900514800094338" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638197538277206417" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_638197538277206417" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638197538277206417" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_638197538277206417" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_638197538277206417" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638197538277206417" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_638197538277206417" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_638197538277206417" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638197538277206417" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_638197538277206417" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:label="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_638197538277206417" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638197538277206417" xlink:to="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_638197538277206417" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_638197538277216494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638197538277206417" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_638197538277216494" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638197538277216494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638197538277206417" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638197538277216494" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638197538277216494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638197538277206417" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638197538277216494" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_638197538277216494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638197538277206417" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_638197538277216494" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638197538277216494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638197538277206417" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638197538277216494" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638197538277216494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_636900514800094338" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638197538277216494" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ProceedsFromIssuanceOfPreferredAndCommonStock" xlink:label="ibio_ProceedsFromIssuanceOfPreferredAndCommonStock_638197538277226437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638197538277216494" xlink:to="ibio_ProceedsFromIssuanceOfPreferredAndCommonStock_638197538277226437" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_PaymentsForFractionalSharesAfterReverseStockSplit" xlink:label="ibio_PaymentsForFractionalSharesAfterReverseStockSplit_638197538277226437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638197538277216494" xlink:to="ibio_PaymentsForFractionalSharesAfterReverseStockSplit_638197538277226437" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="us-gaap_PaymentsToMinorityShareholders_638197538277226437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638197538277216494" xlink:to="us-gaap_PaymentsToMinorityShareholders_638197538277226437" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ProceedsFromEquipmentFinancingLoan" xlink:label="ibio_ProceedsFromEquipmentFinancingLoan_638197538277226437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638197538277216494" xlink:to="ibio_ProceedsFromEquipmentFinancingLoan_638197538277226437" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_PaymentOfEquipmentFinancingLoan" xlink:label="ibio_PaymentOfEquipmentFinancingLoan_638197538277226437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638197538277216494" xlink:to="ibio_PaymentOfEquipmentFinancingLoan_638197538277226437" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable_638197538277236438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638197538277216494" xlink:to="us-gaap_RepaymentsOfNotesPayable_638197538277236438" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638197538277236438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638197538277216494" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638197538277236438" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_PaymentsToAttainTermNote" xlink:label="ibio_PaymentsToAttainTermNote_638197538277236438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638197538277216494" xlink:to="ibio_PaymentsToAttainTermNote_638197538277236438" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments_638197538277236438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638197538277216494" xlink:to="us-gaap_FinanceLeasePrincipalPayments_638197538277236438" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638197538277236438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638197538277216494" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638197538277236438" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638197538277246729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_636900514800094338" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638197538277246729" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638197538277246729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_636900514800094338" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638197538277246729" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638197538277246729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_636900514800094338" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638197538277246729" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6381975382772467291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_636900514800094338" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6381975382772467291" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638197538277246729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_636900514800094338" xlink:to="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638197538277246729" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid" xlink:label="ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid_638197538277256520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638197538277246729" xlink:to="ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid_638197538277256520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_638197538277256520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638197538277246729" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_638197538277256520" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases" xlink:label="ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases_638197538277256520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638197538277246729" xlink:to="ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases_638197538277256520" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CommonStockIssuedInRubrycTransactionValue" xlink:label="ibio_CommonStockIssuedInRubrycTransactionValue_638197538277256520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638197538277246729" xlink:to="ibio_CommonStockIssuedInRubrycTransactionValue_638197538277256520" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CostToRaiseCapitalPaidDirectlyFromGrossProceeds" xlink:label="ibio_CostToRaiseCapitalPaidDirectlyFromGrossProceeds_638197538277266784" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638197538277246729" xlink:to="ibio_CostToRaiseCapitalPaidDirectlyFromGrossProceeds_638197538277266784" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_TerminationOfFinanceLeaseRightOfUseAssetIncludingIssuanceOfWarrant" xlink:label="ibio_TerminationOfFinanceLeaseRightOfUseAssetIncludingIssuanceOfWarrant_638197538277266784" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638197538277246729" xlink:to="ibio_TerminationOfFinanceLeaseRightOfUseAssetIncludingIssuanceOfWarrant_638197538277266784" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesIssued1" xlink:label="us-gaap_NotesIssued1_638197538277266784" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638197538277246729" xlink:to="us-gaap_NotesIssued1_638197538277266784" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities" xlink:label="ibio_NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities_638197538277276516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638197538277246729" xlink:to="ibio_NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities_638197538277276516" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_NonCashSettlementOfRevenueContract" xlink:label="ibio_NonCashSettlementOfRevenueContract_638197538277276516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638197538277246729" xlink:to="ibio_NonCashSettlementOfRevenueContract_638197538277276516" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_WarrantsIssuedForFinanceLeasePayment" xlink:label="ibio_WarrantsIssuedForFinanceLeasePayment_638197538277276516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638197538277246729" xlink:to="ibio_WarrantsIssuedForFinanceLeasePayment_638197538277276516" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LeaseIncentiveForConstructionInProgress" xlink:label="ibio_LeaseIncentiveForConstructionInProgress_638197538277276516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638197538277246729" xlink:to="ibio_LeaseIncentiveForConstructionInProgress_638197538277276516" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/documentation" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_NoncashOrPartNoncashAcquisitionNonControllingInterestAssumed" xlink:label="ibio_NoncashOrPartNoncashAcquisitionNonControllingInterestAssumed_638197538277286440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638197538277246729" xlink:to="ibio_NoncashOrPartNoncashAcquisitionNonControllingInterestAssumed_638197538277286440" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_638197538277286440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638197538277246729" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_638197538277286440" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_638197538277296098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_636900514800094338" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_638197538277296098" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_638197538277296098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638197538277296098" xlink:to="us-gaap_InterestPaidNet_638197538277296098" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureNatureOfBusiness" xlink:type="extended" xlink:title="10101 - Disclosure - Nature of Business">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations_638197538277306496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations_638197538277306496" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureBasisOfPresentation" xlink:type="extended" xlink:title="10201 - Disclosure - Basis of Presentation">
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_BasisOfPresentationAbstract" xlink:label="ibio_BasisOfPresentationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638197538277306496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_BasisOfPresentationAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638197538277306496" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureDiscontinuedOperations" xlink:type="extended" xlink:title="10301 - Disclosure - Discontinued Operations">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_638197538277306496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_638197538277306496" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10401 - Disclosure - Summary of Significant Accounting Policies">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_638197538277306496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_638197538277306496" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurement" xlink:type="extended" xlink:title="10501 - Disclosure - Financial Instruments and Fair Value Measurement">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_638197538277316524" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_638197538277316524" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureSignificantTransactions" xlink:type="extended" xlink:title="10601 - Disclosure - Significant Transactions">
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SignificantTransactionsAbstract" xlink:label="ibio_SignificantTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SignificantTransactionsTextBlock" xlink:label="ibio_SignificantTransactionsTextBlock_638197538277316524" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SignificantTransactionsAbstract" xlink:to="ibio_SignificantTransactionsTextBlock_638197538277316524" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureConvertiblePromissoryNoteReceivable" xlink:type="extended" xlink:title="10701 - Disclosure - Convertible Promissory Note Receivable">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_638197538277316524" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_638197538277316524" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecurities" xlink:type="extended" xlink:title="10801 - Disclosure - Investments in Debt Securities">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_638197538277316524" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_638197538277316524" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssets" xlink:type="extended" xlink:title="10901 - Disclosure - Finance Lease ROU Assets">
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock_638197538277326490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" xlink:to="ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock_638197538277326490" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssets" xlink:type="extended" xlink:title="11001 - Disclosure - Operating Lease ROU Assets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock" xlink:label="ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock_638197538277326490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock_638197538277326490" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFixedAssets" xlink:type="extended" xlink:title="11101 - Disclosure - Fixed Assets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638197538277326490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638197538277326490" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureIntangibleAssets" xlink:type="extended" xlink:title="11201 - Disclosure - Intangible Assets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_638197538277326490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_638197538277326490" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureDebt" xlink:type="extended" xlink:title="11301 - Disclosure - Debt">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock_638197538277336500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock_638197538277336500" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligation" xlink:type="extended" xlink:title="11401 - Disclosure - Finance Lease Obligation">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeasesTextBlock" xlink:label="us-gaap_LesseeFinanceLeasesTextBlock_638197538277336500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeFinanceLeasesTextBlock_638197538277336500" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligation" xlink:type="extended" xlink:title="11501 - Disclosure - Operating Lease Obligation">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_638197538277336500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_638197538277336500" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureStockholdersEquity" xlink:type="extended" xlink:title="11601 - Disclosure - Stockholders' Equity">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638197538277336500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638197538277336500" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShare" xlink:type="extended" xlink:title="11701 - Disclosure - Earnings (Loss) Per Common Share">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_638197538277346531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_638197538277346531" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureShareBasedCompensation" xlink:type="extended" xlink:title="11801 - Disclosure - Share-Based Compensation">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638197538277346531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638197538277346531" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFraunhoferSettlement" xlink:type="extended" xlink:title="11901 - Disclosure - Fraunhofer Settlement">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlementAbstract" xlink:label="us-gaap_GainLossRelatedToLitigationSettlementAbstract" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_GainLossRelatedToLitigationSettlementTextBlock" xlink:label="ibio_GainLossRelatedToLitigationSettlementTextBlock_638197538277346531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GainLossRelatedToLitigationSettlementAbstract" xlink:to="ibio_GainLossRelatedToLitigationSettlementTextBlock_638197538277346531" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="12001 - Disclosure - Income Taxes">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638197538277346531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638197538277346531" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="12101 - Disclosure - Commitments and Contingencies">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638197538277356447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638197538277356447" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureEmployee401KPlan" xlink:type="extended" xlink:title="12201 - Disclosure - Employee 401(K) Plan">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_638197538277356447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_638197538277356447" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="12301 - Disclosure - Subsequent Events">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_638197538277356447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_638197538277356447" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20402 - Disclosure - Summary of Significant Accounting Policies (Policies)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638197538277356447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_638197538277356447" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_638197538277356447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_638197538277356447" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_638197538277366741" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_638197538277366741" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ContractAssetsPolicyTextBlock" xlink:label="ibio_ContractAssetsPolicyTextBlock_638197538277366741" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ibio_ContractAssetsPolicyTextBlock_638197538277366741" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ContractLiabilitiesPolicyTextBlock" xlink:label="ibio_ContractLiabilitiesPolicyTextBlock_638197538277366741" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ibio_ContractLiabilitiesPolicyTextBlock_638197538277366741" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_638197538277366741" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_638197538277366741" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638197538277366741" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638197538277366741" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy" xlink:label="us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy_638197538277366741" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy_638197538277366741" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock_638197538277366741" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock_638197538277366741" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_638197538277366741" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_638197538277366741" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_RightOfUseAssetsPolicyPolicyTextBlock" xlink:label="ibio_RightOfUseAssetsPolicyPolicyTextBlock_638197538277366741" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ibio_RightOfUseAssetsPolicyPolicyTextBlock_638197538277366741" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638197538277366741" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638197538277366741" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_638197538277376513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_638197538277376513" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638197538277376513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638197538277376513" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_638197538277376513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk_638197538277376513" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638197538277376513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638197538277376513" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsTables" xlink:type="extended" xlink:title="30303 - Disclosure - Discontinued Operations (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_638197538277386524" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1" xlink:to="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_638197538277386524" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30403 - Disclosure - Summary of Significant Accounting Policies (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_638197538277386524" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_638197538277386524" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementTables" xlink:type="extended" xlink:title="30503 - Disclosure - Financial Instruments and Fair Value Measurement (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_638197538277386524" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_3" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_638197538277386524" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables" xlink:type="extended" xlink:title="30603 - Disclosure - Significant Transactions (Tables)">
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SignificantTransactionsAbstract" xlink:label="ibio_SignificantTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638197538277386524" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SignificantTransactionsAbstract" xlink:to="us-gaap_StatementTable_638197538277386524" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis_638197538277386524" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538277386524" xlink:to="us-gaap_AssetAcquisitionAxis_638197538277386524" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain_638197538277386524" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis_638197538277386524" xlink:to="us-gaap_AssetAcquisitionDomain_638197538277386524" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_StockPurchaseAgreementMember" xlink:label="ibio_StockPurchaseAgreementMember_638197538277396520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain_638197538277386524" xlink:to="ibio_StockPurchaseAgreementMember_638197538277396520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_AssetPurchaseAgreementMember" xlink:label="ibio_AssetPurchaseAgreementMember_638197538277396520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain_638197538277386524" xlink:to="ibio_AssetPurchaseAgreementMember_638197538277396520" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638197538277396520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538277386524" xlink:to="us-gaap_StatementLineItems_638197538277396520" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTableTextBlock" xlink:label="us-gaap_AssetAcquisitionTableTextBlock_638197538277396520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277396520" xlink:to="us-gaap_AssetAcquisitionTableTextBlock_638197538277396520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesTables" xlink:type="extended" xlink:title="30803 - Disclosure - Investments in Debt Securities (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_638197538277396520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_638197538277396520" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_638197538277396520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_638197538277396520" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_AvaliableForSaleDebtSecuritiesRealizedGainsLossesTableTextBlock" xlink:label="ibio_AvaliableForSaleDebtSecuritiesRealizedGainsLossesTableTextBlock_638197538277396520" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="ibio_AvaliableForSaleDebtSecuritiesRealizedGainsLossesTableTextBlock_638197538277396520" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsTables" xlink:type="extended" xlink:title="30903 - Disclosure - Finance Lease ROU Assets (Tables)">
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock" xlink:label="ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock_638197538277406525" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" xlink:to="ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock_638197538277406525" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFixedAssetsTables" xlink:type="extended" xlink:title="31103 - Disclosure - Fixed Assets (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_638197538277406525" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_638197538277406525" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureIntangibleAssetsTables" xlink:type="extended" xlink:title="31203 - Disclosure - Intangible Assets (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_638197538277406525" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_638197538277406525" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureDebtTables" xlink:type="extended" xlink:title="31303 - Disclosure - Debt (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableAbstract" xlink:label="us-gaap_NotesPayableAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_638197538277416546" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract_2" xlink:to="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_638197538277416546" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationTables" xlink:type="extended" xlink:title="31403 - Disclosure - Finance Lease Obligation (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock" xlink:label="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock_638197538277416546" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock_638197538277416546" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ScheduleOfFinanceLeaseRightOfUseAssetsAndObligationAndWeightedAverageInformationTableTextBlock" xlink:label="ibio_ScheduleOfFinanceLeaseRightOfUseAssetsAndObligationAndWeightedAverageInformationTableTextBlock_638197538277416546" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="ibio_ScheduleOfFinanceLeaseRightOfUseAssetsAndObligationAndWeightedAverageInformationTableTextBlock_638197538277416546" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_638197538277416546" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_638197538277416546" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsTables" xlink:type="extended" xlink:title="31503 - Disclosure - Operating Lease Obligations (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock" xlink:label="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock_638197538277416546" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock_638197538277416546" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638197538277416546" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638197538277416546" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareTables" xlink:type="extended" xlink:title="31703 - Disclosure - Earnings (Loss) Per Common Share (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638197538277426532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638197538277426532" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638197538277426532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638197538277426532" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureShareBasedCompensationTables" xlink:type="extended" xlink:title="31803 - Disclosure - Share-Based Compensation (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638197538277426532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638197538277426532" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638197538277426532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638197538277426532" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Basis of Presentation (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_BasisOfPresentationAbstract" xlink:label="ibio_BasisOfPresentationAbstract_637045036841780422" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_638197538277426532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_BasisOfPresentationAbstract_637045036841780422" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_638197538277426532" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_638197538277436509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_BasisOfPresentationAbstract_637045036841780422" xlink:to="us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_638197538277436509" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CashAndCashEquivalentsPlusDebtSecurities" xlink:label="ibio_CashAndCashEquivalentsPlusDebtSecurities_638197538277436509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_BasisOfPresentationAbstract_637045036841780422" xlink:to="ibio_CashAndCashEquivalentsPlusDebtSecurities_638197538277436509" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638197538277436509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_BasisOfPresentationAbstract_637045036841780422" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638197538277436509" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638197538277436509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_BasisOfPresentationAbstract_637045036841780422" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638197538277436509" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Discontinued Operations (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_638197538277436509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_3" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_638197538277436509" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_638197538277436509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_3" xlink:to="us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_638197538277436509" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_EmployeeReductionExpenses" xlink:label="ibio_EmployeeReductionExpenses_638197538277436509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_3" xlink:to="ibio_EmployeeReductionExpenses_638197538277436509" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_638197538277436509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_3" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_638197538277436509" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="us-gaap_TangibleAssetImpairmentCharges_638197538277436509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_3" xlink:to="us-gaap_TangibleAssetImpairmentCharges_638197538277436509" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown_638197538277446496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_3" xlink:to="ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown_638197538277446496" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance_638197538277446496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_3" xlink:to="ibio_DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance_638197538277446496" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638197538277446496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_3" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638197538277446496" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Discontinued Operations (Reconciliation and Classifications) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" xlink:label="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638197538277446496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_2" xlink:to="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638197538277446496" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_638197538277456376" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638197538277446496" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_638197538277456376" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_638197538277456376" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638197538277446496" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_638197538277456376" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_638197538277456376" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638197538277446496" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_638197538277456376" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses" xlink:label="ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses_638197538277456376" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638197538277446496" xlink:to="ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses_638197538277456376" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_638197538277456376" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638197538277446496" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_638197538277456376" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_TangibleAssetImpairmentChargesDiscontinuedOperations" xlink:label="ibio_TangibleAssetImpairmentChargesDiscontinuedOperations_638197538277456376" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638197538277446496" xlink:to="ibio_TangibleAssetImpairmentChargesDiscontinuedOperations_638197538277456376" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown_638197538277456376" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638197538277446496" xlink:to="ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown_638197538277456376" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_638197538277456376" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638197538277446496" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_638197538277456376" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_638197538277456376" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638197538277446496" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_638197538277456376" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_DisposalGroupInterestExpenseRelatedParty" xlink:label="ibio_DisposalGroupInterestExpenseRelatedParty_638197538277456376" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638197538277446496" xlink:to="ibio_DisposalGroupInterestExpenseRelatedParty_638197538277456376" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_DisposalGroupGainOnDebtForgiveness" xlink:label="ibio_DisposalGroupGainOnDebtForgiveness_638197538277466495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638197538277446496" xlink:to="ibio_DisposalGroupGainOnDebtForgiveness_638197538277466495" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_DiscontinuedOperationsMiscellaneousExpensesIncome" xlink:label="ibio_DiscontinuedOperationsMiscellaneousExpensesIncome_638197538277466495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638197538277446496" xlink:to="ibio_DiscontinuedOperationsMiscellaneousExpensesIncome_638197538277466495" order="12" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_638197538277466495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638197538277446496" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_638197538277466495" order="13" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_638197538277466495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638197538277446496" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_638197538277466495" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_638197538277466495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_2" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_638197538277466495" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_638197538277466495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_638197538277466495" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_638197538277466495" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_638197538277466495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_638197538277466495" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_638197538277466495" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_DisposalGroupOperatingLeaseRightOfUseAssets" xlink:label="ibio_DisposalGroupOperatingLeaseRightOfUseAssets_638197538277476563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_638197538277466495" xlink:to="ibio_DisposalGroupOperatingLeaseRightOfUseAssets_638197538277476563" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_638197538277476563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_638197538277466495" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_638197538277476563" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_638197538277476563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_638197538277466495" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_638197538277476563" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_638197538277476563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_638197538277466495" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_638197538277476563" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_638197538277476563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_638197538277476563" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_638197538277476563" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent" xlink:label="ibio_DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent_638197538277476563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_638197538277476563" xlink:to="ibio_DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent_638197538277476563" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_DisposalGroupNonCurrentAssetsFinanceLeaseRightOfUseAssets" xlink:label="ibio_DisposalGroupNonCurrentAssetsFinanceLeaseRightOfUseAssets_638197538277476563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_638197538277476563" xlink:to="ibio_DisposalGroupNonCurrentAssetsFinanceLeaseRightOfUseAssets_638197538277476563" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_638197538277476563" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_638197538277476563" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_638197538277476563" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_638197538277486497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_638197538277466495" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_638197538277486497" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_DisposalGroupCurrentLiabilitiesFinanceLeaseObligations" xlink:label="ibio_DisposalGroupCurrentLiabilitiesFinanceLeaseObligations_638197538277486497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_638197538277486497" xlink:to="ibio_DisposalGroupCurrentLiabilitiesFinanceLeaseObligations_638197538277486497" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations" xlink:label="ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations_638197538277486497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_638197538277486497" xlink:to="ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations_638197538277486497" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_638197538277486497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_638197538277486497" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_638197538277486497" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_638197538277486497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_638197538277466495" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_638197538277486497" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_DisposalGroupNoncurrentLiabilitiesFinanceLeaseObligations" xlink:label="ibio_DisposalGroupNoncurrentLiabilitiesFinanceLeaseObligations_638197538277486497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_638197538277486497" xlink:to="ibio_DisposalGroupNoncurrentLiabilitiesFinanceLeaseObligations_638197538277486497" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_DisposalGroupNoncurrentOperatingLeaseObligations" xlink:label="ibio_DisposalGroupNoncurrentOperatingLeaseObligations_638197538277496602" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_638197538277486497" xlink:to="ibio_DisposalGroupNoncurrentOperatingLeaseObligations_638197538277496602" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_638197538277496602" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_638197538277486497" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_638197538277496602" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_638197538277496602" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_638197538277466495" xlink:to="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_638197538277496602" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:label="us-gaap_DepreciationAndAmortizationDiscontinuedOperations_638197538277496602" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_638197538277496602" xlink:to="us-gaap_DepreciationAndAmortizationDiscontinuedOperations_638197538277496602" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets" xlink:label="ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets_638197538277496602" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_638197538277496602" xlink:to="ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets_638197538277496602" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpenditureDiscontinuedOperations" xlink:label="us-gaap_CapitalExpenditureDiscontinuedOperations_638197538277496602" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_638197538277496602" xlink:to="us-gaap_CapitalExpenditureDiscontinuedOperations_638197538277496602" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="us-gaap_TangibleAssetImpairmentCharges_638197538277506521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_638197538277496602" xlink:to="us-gaap_TangibleAssetImpairmentCharges_638197538277506521" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown_638197538277506521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_638197538277496602" xlink:to="ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown_638197538277506521" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638197538277506521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_638197538277496602" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638197538277506521" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638197538277506521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_638197538277496602" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638197538277506521" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod" xlink:label="ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod_638197538277506521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638197538277506521" xlink:to="ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod_638197538277506521" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations" xlink:label="ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations_638197538277506521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638197538277506521" xlink:to="ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations_638197538277506521" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_189" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638197538277516413" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_189" xlink:to="us-gaap_StatementTable_638197538277516413" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638197538277516413" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538277516413" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638197538277516413" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638197538277516413" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638197538277516413" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638197538277516413" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember_638197538277516413" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638197538277516413" xlink:to="us-gaap_IntellectualPropertyMember_638197538277516413" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638197538277526489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538277516413" xlink:to="srt_RangeAxis_638197538277526489" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638197538277526489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638197538277526489" xlink:to="srt_RangeMember_638197538277526489" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638197538277526489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638197538277526489" xlink:to="srt_MinimumMember_638197538277526489" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638197538277526489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638197538277526489" xlink:to="srt_MaximumMember_638197538277526489" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_638197538277526489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538277516413" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_638197538277526489" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_638197538277526489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis_638197538277526489" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_638197538277526489" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="us-gaap_RevenueFromContractWithCustomerMember_638197538277526489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain_638197538277526489" xlink:to="us-gaap_RevenueFromContractWithCustomerMember_638197538277526489" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_638197538277526489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538277516413" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_638197538277526489" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_638197538277526489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis_638197538277526489" xlink:to="us-gaap_ConcentrationRiskTypeDomain_638197538277526489" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember_638197538277526489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain_638197538277526489" xlink:to="us-gaap_CustomerConcentrationRiskMember_638197538277526489" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:label="us-gaap_StatementOperatingActivitiesSegmentAxis_638197538277526489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538277516413" xlink:to="us-gaap_StatementOperatingActivitiesSegmentAxis_638197538277526489" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentOperatingActivitiesDomain" xlink:label="us-gaap_SegmentOperatingActivitiesDomain_638197538277536588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOperatingActivitiesSegmentAxis_638197538277526489" xlink:to="us-gaap_SegmentOperatingActivitiesDomain_638197538277536588" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentContinuingOperationsMember" xlink:label="us-gaap_SegmentContinuingOperationsMember_638197538277536588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentOperatingActivitiesDomain_638197538277536588" xlink:to="us-gaap_SegmentContinuingOperationsMember_638197538277536588" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDiscontinuedOperationsMember" xlink:label="us-gaap_SegmentDiscontinuedOperationsMember_638197538277536588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentOperatingActivitiesDomain_638197538277536588" xlink:to="us-gaap_SegmentDiscontinuedOperationsMember_638197538277536588" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638197538277536588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538277516413" xlink:to="srt_CounterpartyNameAxis_638197538277536588" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638197538277536588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638197538277536588" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638197538277536588" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_WoodforestMember" xlink:label="ibio_WoodforestMember_638197538277536588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638197538277536588" xlink:to="ibio_WoodforestMember_638197538277536588" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638197538277536588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538277516413" xlink:to="us-gaap_DebtInstrumentAxis_638197538277536588" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638197538277536588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638197538277536588" xlink:to="us-gaap_DebtInstrumentNameDomain_638197538277536588" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_AmendedCreditAgreementMember" xlink:label="ibio_AmendedCreditAgreementMember_638197538277546500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638197538277536588" xlink:to="ibio_AmendedCreditAgreementMember_638197538277546500" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638197538277546500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538277516413" xlink:to="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638197538277546500" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_638197538277546500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638197538277546500" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent_638197538277546500" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent_638197538277546500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638197538277546500" xlink:to="us-gaap_DeferredRevenueCurrent_638197538277546500" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_638197538277546500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638197538277546500" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_638197538277546500" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasePracticalExpedientsPackage" xlink:label="us-gaap_LeasePracticalExpedientsPackage_638197538277546500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638197538277546500" xlink:to="us-gaap_LeasePracticalExpedientsPackage_638197538277546500" order="4" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt_638197538277546500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638197538277546500" xlink:to="us-gaap_RepaymentsOfDebt_638197538277546500" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_638197538277546500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638197538277546500" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_638197538277546500" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_638197538277556510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638197538277546500" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_638197538277556510" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638197538277556510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638197538277546500" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638197538277556510" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638197538277556510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638197538277546500" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638197538277556510" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount_638197538277556510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638197538277546500" xlink:to="us-gaap_CashUninsuredAmount_638197538277556510" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_NumberOfMajorCustomers" xlink:label="ibio_NumberOfMajorCustomers_638197538277556510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638197538277546500" xlink:to="ibio_NumberOfMajorCustomers_638197538277556510" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638197538277556510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638197538277546500" xlink:to="us-gaap_AccountsReceivableNetCurrent_638197538277556510" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyIncomeNonoperating" xlink:label="us-gaap_RoyaltyIncomeNonoperating_638197538277566532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638197538277546500" xlink:to="us-gaap_RoyaltyIncomeNonoperating_638197538277566532" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_638197538277566532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638197538277546500" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_638197538277566532" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Summary of Significant Accounting Policies (Cash, Cash Equivalents and Restricted Cash) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638197538277576431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable_638197538277576431" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_638197538277576431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538277576431" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_638197538277576431" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638197538277576431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_638197538277576431" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638197538277576431" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LetterOfCreditTermLoanMember" xlink:label="ibio_LetterOfCreditTermLoanMember_638197538277576431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638197538277576431" xlink:to="ibio_LetterOfCreditTermLoanMember_638197538277576431" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LetterOfCreditSanDiegoLeaseMember" xlink:label="ibio_LetterOfCreditSanDiegoLeaseMember_638197538277576431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638197538277576431" xlink:to="ibio_LetterOfCreditSanDiegoLeaseMember_638197538277576431" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CompanyPurchasingCardMember" xlink:label="ibio_CompanyPurchasingCardMember_638197538277576431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638197538277576431" xlink:to="ibio_CompanyPurchasingCardMember_638197538277576431" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638197538277576431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538277576431" xlink:to="us-gaap_StatementLineItems_638197538277576431" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638197538277576431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277576431" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638197538277576431" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_PercentageOfCollateralRequired" xlink:label="ibio_PercentageOfCollateralRequired_638197538277576431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638197538277576431" xlink:to="ibio_PercentageOfCollateralRequired_638197538277576431" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638197538277576431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638197538277576431" xlink:to="us-gaap_RestrictedCashNoncurrent_638197538277576431" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638197538277576431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638197538277576431" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638197538277576431" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_638197538277586515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638197538277576431" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_638197538277586515" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_638197538277586515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638197538277576431" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_638197538277586515" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Financial Instruments and Fair Value Measurement (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638197538277586515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_1" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638197538277586515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_638197538277586515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638197538277586515" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_638197538277586515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_638197538277586515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_638197538277586515" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_638197538277586515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember_638197538277586515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_638197538277586515" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember_638197538277586515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638197538277586515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638197538277586515" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638197538277586515" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638197538277586515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638197538277586515" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638197538277586515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember_638197538277596490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638197538277586515" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember_638197538277596490" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember_638197538277596490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638197538277586515" xlink:to="us-gaap_MachineryAndEquipmentMember_638197538277596490" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638197538277596490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638197538277586515" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638197538277596490" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure_638197538277596490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638197538277596490" xlink:to="ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure_638197538277596490" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="us-gaap_TangibleAssetImpairmentCharges_638197538277596490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638197538277596490" xlink:to="us-gaap_TangibleAssetImpairmentCharges_638197538277596490" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Financial Instruments and Fair Value Measurement (Non-recurring Basis) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638197538277596490" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_2" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638197538277596490" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_638197538277606496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638197538277596490" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_638197538277606496" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_638197538277606496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_638197538277606496" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_638197538277606496" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember_638197538277606496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_638197538277606496" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember_638197538277606496" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638197538277606496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638197538277596490" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638197538277606496" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638197538277606496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638197538277606496" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638197538277606496" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_638197538277606496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638197538277606496" xlink:to="us-gaap_FairValueInputsLevel3Member_638197538277606496" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638197538277606496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638197538277596490" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638197538277606496" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638197538277616450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638197538277606496" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638197538277616450" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember_638197538277616450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638197538277616450" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember_638197538277616450" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember_638197538277616450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638197538277616450" xlink:to="us-gaap_MachineryAndEquipmentMember_638197538277616450" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638197538277616450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638197538277596490" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638197538277616450" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure_638197538277616450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638197538277616450" xlink:to="ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure_638197538277616450" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="us-gaap_TangibleAssetImpairmentCharges_638197538277616450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638197538277616450" xlink:to="us-gaap_TangibleAssetImpairmentCharges_638197538277616450" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Significant Transactions (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SignificantTransactionsAbstract" xlink:label="ibio_SignificantTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638197538277616450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SignificantTransactionsAbstract" xlink:to="us-gaap_StatementTable_638197538277616450" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638197538277626402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538277616450" xlink:to="us-gaap_StatementClassOfStockAxis_638197538277626402" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638197538277626402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638197538277626402" xlink:to="us-gaap_ClassOfStockDomain_638197538277626402" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_Series2PreferredStockMember" xlink:label="ibio_Series2PreferredStockMember_638197538277626402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638197538277626402" xlink:to="ibio_Series2PreferredStockMember_638197538277626402" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638197538277626402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538277616450" xlink:to="us-gaap_TypeOfArrangementAxis_638197538277626402" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638197538277626402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638197538277626402" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638197538277626402" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CollaborationOptionAndLicenseAgreementMember" xlink:label="ibio_CollaborationOptionAndLicenseAgreementMember_638197538277626402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638197538277626402" xlink:to="ibio_CollaborationOptionAndLicenseAgreementMember_638197538277626402" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_StockPurchaseAgreementMember" xlink:label="ibio_StockPurchaseAgreementMember_638197538277626402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638197538277626402" xlink:to="ibio_StockPurchaseAgreementMember_638197538277626402" order="2" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SeparationAgreementAndGeneralReleaseMember" xlink:label="ibio_SeparationAgreementAndGeneralReleaseMember_638197538277626402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638197538277626402" xlink:to="ibio_SeparationAgreementAndGeneralReleaseMember_638197538277626402" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638197538277626402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538277616450" xlink:to="srt_ProductOrServiceAxis_638197538277626402" order="3" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638197538277626402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638197538277626402" xlink:to="srt_ProductsAndServicesDomain_638197538277626402" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ImmuneOncologyAntibodiesRtx003Member" xlink:label="ibio_ImmuneOncologyAntibodiesRtx003Member_638197538277626402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638197538277626402" xlink:to="ibio_ImmuneOncologyAntibodiesRtx003Member_638197538277626402" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638197538277626402" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538277616450" xlink:to="srt_StatementScenarioAxis_638197538277626402" order="4" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638197538277636501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638197538277626402" xlink:to="srt_ScenarioUnspecifiedDomain_638197538277636501" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_NoBiosimilarProductHasBeenApprovedMember" xlink:label="ibio_NoBiosimilarProductHasBeenApprovedMember_638197538277636501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638197538277636501" xlink:to="ibio_NoBiosimilarProductHasBeenApprovedMember_638197538277636501" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638197538277636501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538277616450" xlink:to="srt_CounterpartyNameAxis_638197538277636501" order="5" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638197538277636501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638197538277636501" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638197538277636501" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_RubrycTheraputicsInc.Member" xlink:label="ibio_RubrycTheraputicsInc.Member_638197538277636501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638197538277636501" xlink:to="ibio_RubrycTheraputicsInc.Member_638197538277636501" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" xlink:label="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_638197538277636501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638197538277636501" xlink:to="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_638197538277636501" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638197538277636501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538277616450" xlink:to="dei_LegalEntityAxis_638197538277636501" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638197538277636501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638197538277636501" xlink:to="dei_EntityDomain_638197538277636501" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_IbioCmoPreferredTrackingStockMember" xlink:label="ibio_IbioCmoPreferredTrackingStockMember_638197538277646681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638197538277636501" xlink:to="ibio_IbioCmoPreferredTrackingStockMember_638197538277646681" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638197538277646681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538277616450" xlink:to="us-gaap_DebtInstrumentAxis_638197538277646681" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638197538277646681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638197538277646681" xlink:to="us-gaap_DebtInstrumentNameDomain_638197538277646681" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SecuredTermLoanMember" xlink:label="ibio_SecuredTermLoanMember_638197538277646681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638197538277646681" xlink:to="ibio_SecuredTermLoanMember_638197538277646681" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638197538277646681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538277616450" xlink:to="us-gaap_StatementLineItems_638197538277646681" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest" xlink:label="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest_638197538277646681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277646681" xlink:to="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest_638197538277646681" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment" xlink:label="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment_638197538277646681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277646681" xlink:to="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment_638197538277646681" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_FairMarketValueOfProperty" xlink:label="ibio_FairMarketValueOfProperty_638197538277646681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277646681" xlink:to="ibio_FairMarketValueOfProperty_638197538277646681" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_BaseRentPercentageOfFairMarketValueOfProperty" xlink:label="ibio_BaseRentPercentageOfFairMarketValueOfProperty_638197538277656498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277646681" xlink:to="ibio_BaseRentPercentageOfFairMarketValueOfProperty_638197538277656498" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired" xlink:label="ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired_638197538277656498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277646681" xlink:to="ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired_638197538277656498" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_EquityAgreementWarrantsIssuedOrIssuable" xlink:label="ibio_EquityAgreementWarrantsIssuedOrIssuable_638197538277656498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277646681" xlink:to="ibio_EquityAgreementWarrantsIssuedOrIssuable_638197538277656498" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable" xlink:label="ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable_638197538277656498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277646681" xlink:to="ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable_638197538277656498" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638197538277656498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277646681" xlink:to="us-gaap_DebtInstrumentFaceAmount_638197538277656498" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638197538277656498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277646681" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638197538277656498" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CreditAgreementThresholdLimitUnrestrictedCash" xlink:label="ibio_CreditAgreementThresholdLimitUnrestrictedCash_638197538277666703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277646681" xlink:to="ibio_CreditAgreementThresholdLimitUnrestrictedCash_638197538277666703" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet_638197538277666703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277646681" xlink:to="us-gaap_DeferredFinanceCostsNet_638197538277666703" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_638197538277666703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277646681" xlink:to="us-gaap_InterestExpenseDebt_638197538277666703" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638197538277666703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277646681" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638197538277666703" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638197538277666703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277646681" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638197538277666703" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent" xlink:label="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent_638197538277676443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277646681" xlink:to="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent_638197538277676443" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue" xlink:label="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue_638197538277676443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277646681" xlink:to="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue_638197538277676443" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure_638197538277676443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277646681" xlink:to="us-gaap_AssetsFairValueDisclosure_638197538277676443" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CollaborativeArrangementMilestonePayments" xlink:label="ibio_CollaborativeArrangementMilestonePayments_638197538277676443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277646681" xlink:to="ibio_CollaborativeArrangementMilestonePayments_638197538277676443" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForAdvanceToAffiliate" xlink:label="us-gaap_PaymentsForAdvanceToAffiliate_638197538277676443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277646681" xlink:to="us-gaap_PaymentsForAdvanceToAffiliate_638197538277676443" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_AssetAcquisitionTransactionCosts" xlink:label="ibio_AssetAcquisitionTransactionCosts_638197538277676443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277646681" xlink:to="ibio_AssetAcquisitionTransactionCosts_638197538277676443" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability_638197538277686552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277646681" xlink:to="us-gaap_FinanceLeaseLiability_638197538277686552" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm" xlink:label="ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm_638197538277686552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277646681" xlink:to="ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm_638197538277686552" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CollaborationAndLicenseAgreementAgreementTerm" xlink:label="ibio_CollaborationAndLicenseAgreementAgreementTerm_638197538277686552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277646681" xlink:to="ibio_CollaborationAndLicenseAgreementAgreementTerm_638197538277686552" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_StockPurchaseAgreementNumberOfSharesPurchased" xlink:label="ibio_StockPurchaseAgreementNumberOfSharesPurchased_638197538277686552" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277646681" xlink:to="ibio_StockPurchaseAgreementNumberOfSharesPurchased_638197538277686552" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_StockPurchaseAgreementValueOfSharesPurchased" xlink:label="ibio_StockPurchaseAgreementValueOfSharesPurchased_638197538277696517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277646681" xlink:to="ibio_StockPurchaseAgreementValueOfSharesPurchased_638197538277696517" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage_638197538277696517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277646681" xlink:to="us-gaap_PreferredStockDividendRatePercentage_638197538277696517" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfInvestments" xlink:label="us-gaap_ImpairmentOfInvestments_638197538277696517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277646681" xlink:to="us-gaap_ImpairmentOfInvestments_638197538277696517" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638197538277696517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277646681" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638197538277696517" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ImpairmentOfPrepaidExpensesCurrent" xlink:label="ibio_ImpairmentOfPrepaidExpensesCurrent_638197538277696517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277646681" xlink:to="ibio_ImpairmentOfPrepaidExpensesCurrent_638197538277696517" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ImpairmentOfPrepaidExpensesNonCurrent" xlink:label="ibio_ImpairmentOfPrepaidExpensesNonCurrent_638197538277706420" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277646681" xlink:to="ibio_ImpairmentOfPrepaidExpensesNonCurrent_638197538277706420" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_638197538277706420" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277646681" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_638197538277706420" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638197538277706420" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277646681" xlink:to="us-gaap_CommonStockValue_638197538277706420" order="32" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary" xlink:label="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary_638197538277706420" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277646681" xlink:to="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary_638197538277706420" order="33" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus" xlink:label="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus_638197538277716404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277646681" xlink:to="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus_638197538277716404" order="34" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct" xlink:label="ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct_638197538277716404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277646681" xlink:to="ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct_638197538277716404" order="35" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod" xlink:label="ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod_638197538277716404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277646681" xlink:to="ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod_638197538277716404" order="36" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct" xlink:label="ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct_638197538277716404" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277646681" xlink:to="ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct_638197538277716404" order="37" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Significant Transactions (Summary of Asset Acquisition) (Details)">
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SignificantTransactionsAbstract" xlink:label="ibio_SignificantTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638197538277726501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SignificantTransactionsAbstract" xlink:to="us-gaap_StatementTable_638197538277726501" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis_638197538277726501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538277726501" xlink:to="us-gaap_AssetAcquisitionAxis_638197538277726501" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain_638197538277726501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis_638197538277726501" xlink:to="us-gaap_AssetAcquisitionDomain_638197538277726501" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_Series2PreferredStockMember" xlink:label="ibio_Series2PreferredStockMember_638197538277726501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain_638197538277726501" xlink:to="ibio_Series2PreferredStockMember_638197538277726501" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_AssetAcquisitionIntangibleAssetsMember" xlink:label="ibio_AssetAcquisitionIntangibleAssetsMember_638197538277726501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain_638197538277726501" xlink:to="ibio_AssetAcquisitionIntangibleAssetsMember_638197538277726501" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_AssetAcquisitionFixedAssetsMember" xlink:label="ibio_AssetAcquisitionFixedAssetsMember_638197538277726501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain_638197538277726501" xlink:to="ibio_AssetAcquisitionFixedAssetsMember_638197538277726501" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_AssetAcquisitionPrepaidExpensesMember" xlink:label="ibio_AssetAcquisitionPrepaidExpensesMember_638197538277736505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain_638197538277726501" xlink:to="ibio_AssetAcquisitionPrepaidExpensesMember_638197538277736505" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638197538277736505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538277726501" xlink:to="srt_CounterpartyNameAxis_638197538277736505" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638197538277736505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638197538277736505" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638197538277736505" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_RubrycTheraputicsInc.Member" xlink:label="ibio_RubrycTheraputicsInc.Member_638197538277736505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638197538277736505" xlink:to="ibio_RubrycTheraputicsInc.Member_638197538277736505" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638197538277736505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538277726501" xlink:to="us-gaap_StatementLineItems_638197538277736505" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_638197538277736505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277736505" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred_638197538277736505" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureConvertiblePromissoryNoteReceivableNarrativeDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Convertible Promissory Note Receivable (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_638197538277736505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_638197538277736505" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_638197538277746516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_638197538277736505" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_638197538277746516" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain_638197538277746516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_638197538277746516" xlink:to="us-gaap_ReceivableTypeDomain_638197538277746516" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableMember" xlink:label="us-gaap_NotesReceivableMember_638197538277746516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivableTypeDomain_638197538277746516" xlink:to="us-gaap_NotesReceivableMember_638197538277746516" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems_638197538277746516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_638197538277736505" xlink:to="us-gaap_AccountsNotesAndLoansReceivableLineItems_638197538277746516" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LoansReceivableAmountInvested" xlink:label="ibio_LoansReceivableAmountInvested_638197538277746516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems_638197538277746516" xlink:to="ibio_LoansReceivableAmountInvested_638197538277746516" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LoansReceivableFixedRatesOfInterest" xlink:label="ibio_LoansReceivableFixedRatesOfInterest_638197538277746516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems_638197538277746516" xlink:to="ibio_LoansReceivableFixedRatesOfInterest_638197538277746516" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638197538277746516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems_638197538277746516" xlink:to="us-gaap_InvestmentIncomeInterest_638197538277746516" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:label="us-gaap_NotesAndLoansReceivableNetNoncurrent_638197538277746516" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems_638197538277746516" xlink:to="us-gaap_NotesAndLoansReceivableNetNoncurrent_638197538277746516" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesNarrativeDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Investments in Debt Securities (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_638197538277826431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_638197538277826431" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesComponentsOfInvestmentsInDebtSecuritiesDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Investments in Debt Securities (Components of Investments in Debt Securities) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_638197538277826431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_638197538277826431" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_638197538277826431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_638197538277826431" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesCurrent" xlink:label="us-gaap_DebtSecuritiesCurrent_638197538277826431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesCurrent_638197538277826431" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesDebtSecuritiesContractualMaturityDetails" xlink:type="extended" xlink:title="40803 - Disclosure - Investments in Debt Securities (Debt Securities, Contractual Maturity) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract_638197538277836560" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract_638197538277836560" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_638197538277836560" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract_638197538277836560" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_638197538277836560" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_638197538277836560" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract_638197538277836560" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_638197538277836560" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesCurrent" xlink:label="us-gaap_DebtSecuritiesCurrent_638197538277836560" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract_638197538277836560" xlink:to="us-gaap_DebtSecuritiesCurrent_638197538277836560" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsNarrativeDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Finance Lease ROU Assets (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638197538277836560" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638197538277836560" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Finance Lease ROU Assets (Summary of Finance Lease ROU) (Details)">
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_FinanceLeaseRightOfUseAssetDisclosureTable" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureTable_638197538277846537" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" xlink:to="ibio_FinanceLeaseRightOfUseAssetDisclosureTable_638197538277846537" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638197538277846537" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureTable_638197538277846537" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638197538277846537" order="1" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638197538277846537" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638197538277846537" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638197538277846537" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_FacilityMember" xlink:label="ibio_FacilityMember_638197538277846537" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638197538277846537" xlink:to="ibio_FacilityMember_638197538277846537" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems_638197538277846537" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureTable_638197538277846537" xlink:to="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems_638197538277846537" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_FinanceLeaseRightOfUseAssetGross" xlink:label="ibio_FinanceLeaseRightOfUseAssetGross_638197538277846537" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems_638197538277846537" xlink:to="ibio_FinanceLeaseRightOfUseAssetGross_638197538277846537" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_638197538277846537" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems_638197538277846537" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_638197538277846537" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_638197538277846537" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems_638197538277846537" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_638197538277846537" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssetsNarrativeDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Operating Lease ROU Assets (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty_638197538277857377" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_AreaOfRealEstateProperty_638197538277857377" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638197538277857377" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638197538277857377" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFixedAssetsNarrativeDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Fixed Assets (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_637045036842019774" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638197538277857377" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_637045036842019774" xlink:to="us-gaap_Depreciation_638197538277857377" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_FixedAssetsHeldForSale" xlink:label="ibio_FixedAssetsHeldForSale_638197538277857377" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_637045036842019774" xlink:to="ibio_FixedAssetsHeldForSale_638197538277857377" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="us-gaap_TangibleAssetImpairmentCharges_638197538277857377" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_637045036842019774" xlink:to="us-gaap_TangibleAssetImpairmentCharges_638197538277857377" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Fixed Assets (Carrying Value and Accumulated Depreciation) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_637045036841999830" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638197538277866425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_637045036841999830" xlink:to="us-gaap_StatementTable_638197538277866425" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638197538277866425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538277866425" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638197538277866425" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638197538277866425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638197538277866425" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638197538277866425" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember_638197538277866425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638197538277866425" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember_638197538277866425" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember_638197538277866425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638197538277866425" xlink:to="us-gaap_MachineryAndEquipmentMember_638197538277866425" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember_638197538277866425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638197538277866425" xlink:to="us-gaap_OfficeEquipmentMember_638197538277866425" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember_638197538277866425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638197538277866425" xlink:to="us-gaap_ConstructionInProgressMember_638197538277866425" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638197538277896441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538277866425" xlink:to="us-gaap_StatementLineItems_638197538277896441" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638197538277896441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277896441" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638197538277896441" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638197538277896441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277896441" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638197538277896441" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638197538277896441" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538277896441" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638197538277896441" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Intangible Assets (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_637045036842069641" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638197538277906448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_637045036842069641" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638197538277906448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638197538277906448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638197538277906448" xlink:to="srt_CounterpartyNameAxis_638197538277906448" order="1" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638197538277906448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638197538277906448" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638197538277906448" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_RubrycTheraputicsInc.Member" xlink:label="ibio_RubrycTheraputicsInc.Member_638197538277906448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638197538277906448" xlink:to="ibio_RubrycTheraputicsInc.Member_638197538277906448" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638197538277906448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638197538277906448" xlink:to="srt_ProductOrServiceAxis_638197538277906448" order="2" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638197538277906448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638197538277906448" xlink:to="srt_ProductsAndServicesDomain_638197538277906448" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ImmuneOncologyAntibodiesRtx003Member" xlink:label="ibio_ImmuneOncologyAntibodiesRtx003Member_638197538277906448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638197538277906448" xlink:to="ibio_ImmuneOncologyAntibodiesRtx003Member_638197538277906448" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638197538277906448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638197538277906448" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638197538277906448" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638197538277906448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638197538277906448" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638197538277906448" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember_638197538277906448" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638197538277906448" xlink:to="us-gaap_PatentsMember_638197538277906448" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember_638197538277916437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638197538277906448" xlink:to="us-gaap_IntellectualPropertyMember_638197538277916437" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_638197538277916437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638197538277906448" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_638197538277916437" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_StockPurchaseAgreementTotalInvestment" xlink:label="ibio_StockPurchaseAgreementTotalInvestment_638197538277916437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638197538277916437" xlink:to="ibio_StockPurchaseAgreementTotalInvestment_638197538277916437" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_638197538277916437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638197538277916437" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_638197538277916437" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_638197538277916437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638197538277916437" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_638197538277916437" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_638197538277916437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638197538277916437" xlink:to="us-gaap_AmortizationOfIntangibleAssets_638197538277916437" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Intangible Assets (Carrying Value and Accumulated Amortization) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_637045036842049705" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638197538277926424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_637045036842049705" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638197538277926424" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638197538277926424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638197538277926424" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638197538277926424" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638197538277926424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638197538277926424" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638197538277926424" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember_638197538277926424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638197538277926424" xlink:to="us-gaap_IntellectualPropertyMember_638197538277926424" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember_638197538277926424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638197538277926424" xlink:to="us-gaap_PatentsMember_638197538277926424" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_638197538277926424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638197538277926424" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_638197538277926424" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_638197538277936446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638197538277926424" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_638197538277936446" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638197538277936446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638197538277926424" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638197538277936446" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_638197538277936446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638197538277926424" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_638197538277936446" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_638197538277936446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638197538277926424" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_638197538277936446" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_638197538277936446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638197538277926424" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_638197538277936446" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDeferredChargesAbstract" xlink:label="us-gaap_AmortizationOfDeferredChargesAbstract_638197538277936446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638197538277926424" xlink:to="us-gaap_AmortizationOfDeferredChargesAbstract_638197538277936446" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_638197538277936446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AmortizationOfDeferredChargesAbstract_638197538277936446" xlink:to="us-gaap_AmortizationOfIntangibleAssets_638197538277936446" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRollForward_638197538277936446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638197538277926424" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRollForward_638197538277936446" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="us-gaap_FinitelivedIntangibleAssetsAcquired1_638197538277936446" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsRollForward_638197538277936446" xlink:to="us-gaap_FinitelivedIntangibleAssetsAcquired1_638197538277936446" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:label="us-gaap_IndefinitelivedIntangibleAssetsAcquired_638197538277946553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsRollForward_638197538277936446" xlink:to="us-gaap_IndefinitelivedIntangibleAssetsAcquired_638197538277946553" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetImpairmentAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairmentAbstract_638197538277946553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638197538277926424" xlink:to="us-gaap_GoodwillAndIntangibleAssetImpairmentAbstract_638197538277946553" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ImpairmentOfIntangibleAssetsGrossOfReversals" xlink:label="ibio_ImpairmentOfIntangibleAssetsGrossOfReversals_638197538277946553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetImpairmentAbstract_638197538277946553" xlink:to="ibio_ImpairmentOfIntangibleAssetsGrossOfReversals_638197538277946553" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ReversalOfIntangibleAssetImpairment" xlink:label="ibio_ReversalOfIntangibleAssetImpairment_638197538277946553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetImpairmentAbstract_638197538277946553" xlink:to="ibio_ReversalOfIntangibleAssetImpairment_638197538277946553" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_638197538277946553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetImpairmentAbstract_638197538277946553" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_638197538277946553" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Debt (The Credit Agreement) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638197538277956529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_1" xlink:to="us-gaap_DebtInstrumentTable_638197538277956529" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638197538277956529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638197538277956529" xlink:to="srt_CounterpartyNameAxis_638197538277956529" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638197538277956529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638197538277956529" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638197538277956529" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" xlink:label="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_638197538277956529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638197538277956529" xlink:to="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_638197538277956529" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_WoodforestMember" xlink:label="ibio_WoodforestMember_638197538277956529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638197538277956529" xlink:to="ibio_WoodforestMember_638197538277956529" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638197538277956529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638197538277956529" xlink:to="us-gaap_DebtInstrumentAxis_638197538277956529" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638197538277956529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638197538277956529" xlink:to="us-gaap_DebtInstrumentNameDomain_638197538277956529" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SecuredTermLoanMember" xlink:label="ibio_SecuredTermLoanMember_638197538277956529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638197538277956529" xlink:to="ibio_SecuredTermLoanMember_638197538277956529" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_AmendedCreditAgreementMember" xlink:label="ibio_AmendedCreditAgreementMember_638197538277956529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638197538277956529" xlink:to="ibio_AmendedCreditAgreementMember_638197538277956529" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis_638197538277956529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638197538277956529" xlink:to="srt_LitigationCaseAxis_638197538277956529" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain_638197538277966542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis_638197538277956529" xlink:to="srt_LitigationCaseTypeDomain_638197538277966542" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember" xlink:label="ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_638197538277966542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseTypeDomain_638197538277966542" xlink:to="ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_638197538277966542" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638197538277966542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638197538277956529" xlink:to="srt_StatementScenarioAxis_638197538277966542" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638197538277966542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638197538277966542" xlink:to="srt_ScenarioUnspecifiedDomain_638197538277966542" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_DateOfAmendmentMember" xlink:label="ibio_DateOfAmendmentMember_638197538277966542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638197538277966542" xlink:to="ibio_DateOfAmendmentMember_638197538277966542" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember" xlink:label="ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember_638197538277966542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638197538277966542" xlink:to="ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember_638197538277966542" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_OccurrenceOfSpecificMilestoneMember" xlink:label="ibio_OccurrenceOfSpecificMilestoneMember_638197538277966542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638197538277966542" xlink:to="ibio_OccurrenceOfSpecificMilestoneMember_638197538277966542" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638197538277976175" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638197538277956529" xlink:to="us-gaap_DebtInstrumentLineItems_638197538277976175" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638197538277976175" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638197538277976175" xlink:to="us-gaap_DebtInstrumentFaceAmount_638197538277976175" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet_638197538277976175" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638197538277976175" xlink:to="us-gaap_DeferredFinanceCostsNet_638197538277976175" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_638197538277976175" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638197538277976175" xlink:to="us-gaap_InterestExpenseDebt_638197538277976175" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638197538277976175" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638197538277976175" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638197538277976175" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CreditAgreementThresholdLimitUnrestrictedCash" xlink:label="ibio_CreditAgreementThresholdLimitUnrestrictedCash_638197538277976175" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638197538277976175" xlink:to="ibio_CreditAgreementThresholdLimitUnrestrictedCash_638197538277976175" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_638197538277976175" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638197538277976175" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_638197538277976175" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_638197538277986549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638197538277976175" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_638197538277986549" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount_638197538277986549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638197538277976175" xlink:to="us-gaap_DebtInstrumentFeeAmount_638197538277986549" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_DebtCovenantLiquidityAmount" xlink:label="ibio_DebtCovenantLiquidityAmount_638197538277986549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638197538277976175" xlink:to="ibio_DebtCovenantLiquidityAmount_638197538277986549" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_638197538277986549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638197538277976175" xlink:to="us-gaap_LongTermDebt_638197538277986549" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLegalSettlements" xlink:label="us-gaap_ProceedsFromLegalSettlements_638197538277986549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638197538277976175" xlink:to="us-gaap_ProceedsFromLegalSettlements_638197538277986549" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638197538277986549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638197538277976175" xlink:to="us-gaap_RestrictedCashNoncurrent_638197538277986549" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638197538277986549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638197538277976175" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638197538277986549" order="13" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingDetails" xlink:type="extended" xlink:title="41302 - Disclosure - Debt (Equipment Financing) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableAbstract" xlink:label="us-gaap_NotesPayableAbstract_1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_EquipmentFinancingAmountBorrowed" xlink:label="ibio_EquipmentFinancingAmountBorrowed_638197538277996593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract_1" xlink:to="ibio_EquipmentFinancingAmountBorrowed_638197538277996593" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeEquipmentLeaseTermOfContract" xlink:label="ibio_LesseeEquipmentLeaseTermOfContract_638197538277996593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract_1" xlink:to="ibio_LesseeEquipmentLeaseTermOfContract_638197538277996593" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_EquipmentFinancingLeaseImputedInterestRate" xlink:label="ibio_EquipmentFinancingLeaseImputedInterestRate_638197538277996593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract_1" xlink:to="ibio_EquipmentFinancingLeaseImputedInterestRate_638197538277996593" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_EquipmentLeasingMonthlyInstallmentPayable" xlink:label="ibio_EquipmentLeasingMonthlyInstallmentPayable_638197538277996593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract_1" xlink:to="ibio_EquipmentLeasingMonthlyInstallmentPayable_638197538277996593" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_EquipmentFinancingBalance" xlink:label="ibio_EquipmentFinancingBalance_638197538278006438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract_1" xlink:to="ibio_EquipmentFinancingBalance_638197538278006438" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails" xlink:type="extended" xlink:title="41303 - Disclosure - Debt (Equipment Financing) (Future Minimum Payments) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableAbstract" xlink:label="us-gaap_NotesPayableAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638197538278006438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract_3" xlink:to="us-gaap_StatementTable_638197538278006438" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis_638197538278006438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538278006438" xlink:to="us-gaap_LeaseContractualTermAxis_638197538278006438" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_638197538278006438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis_638197538278006438" xlink:to="us-gaap_LeaseContractualTermDomain_638197538278006438" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_PrincipalMember" xlink:label="ibio_PrincipalMember_638197538278006438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain_638197538278006438" xlink:to="ibio_PrincipalMember_638197538278006438" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_InterestMember" xlink:label="ibio_InterestMember_638197538278006438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain_638197538278006438" xlink:to="ibio_InterestMember_638197538278006438" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638197538278006438" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538278006438" xlink:to="us-gaap_StatementLineItems_638197538278006438" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths_638197538278016542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538278006438" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths_638197538278016542" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="us-gaap_ContractualObligationDueInSecondYear_638197538278016542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538278006438" xlink:to="us-gaap_ContractualObligationDueInSecondYear_638197538278016542" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="us-gaap_ContractualObligationDueInThirdYear_638197538278016542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538278006438" xlink:to="us-gaap_ContractualObligationDueInThirdYear_638197538278016542" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation_638197538278016542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538278006438" xlink:to="us-gaap_ContractualObligation_638197538278016542" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ContractualObligationCurrent" xlink:label="ibio_ContractualObligationCurrent_638197538278016542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538278006438" xlink:to="ibio_ContractualObligationCurrent_638197538278016542" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ContractualObligationNoncurrent" xlink:label="ibio_ContractualObligationNoncurrent_638197538278016542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538278006438" xlink:to="ibio_ContractualObligationNoncurrent_638197538278016542" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureDebtNotePayablePppLoanDetails" xlink:type="extended" xlink:title="41304 - Disclosure - Debt (Note Payable - PPP Loan) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableAbstract" xlink:label="us-gaap_NotesPayableAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638197538278026540" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_StatementTable_638197538278026540" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638197538278026540" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538278026540" xlink:to="us-gaap_DebtInstrumentAxis_638197538278026540" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638197538278026540" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638197538278026540" xlink:to="us-gaap_DebtInstrumentNameDomain_638197538278026540" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_PppLoanCaresActMember" xlink:label="ibio_PppLoanCaresActMember_638197538278026540" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638197538278026540" xlink:to="ibio_PppLoanCaresActMember_638197538278026540" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638197538278026540" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538278026540" xlink:to="us-gaap_StatementLineItems_638197538278026540" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable_638197538278026540" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538278026540" xlink:to="us-gaap_LongTermNotesPayable_638197538278026540" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness_638197538278026540" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538278026540" xlink:to="us-gaap_DebtInstrumentDecreaseForgiveness_638197538278026540" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationNarrativeDetails" xlink:type="extended" xlink:title="41401 - Disclosure - Finance Lease Obligation (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638197538278036538" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638197538278036538" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638197538278036538" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638197538278036538" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638197538278036538" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638197538278036538" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638197538278036538" xlink:to="us-gaap_RelatedPartyDomain_638197538278036538" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SecondEasternAffiliateMember" xlink:label="ibio_SecondEasternAffiliateMember_638197538278036538" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638197538278036538" xlink:to="ibio_SecondEasternAffiliateMember_638197538278036538" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638197538278036538" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638197538278036538" xlink:to="srt_CounterpartyNameAxis_638197538278036538" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638197538278036538" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638197538278036538" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638197538278036538" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_RubrycTheraputicsInc.Member" xlink:label="ibio_RubrycTheraputicsInc.Member_638197538278036538" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638197538278036538" xlink:to="ibio_RubrycTheraputicsInc.Member_638197538278036538" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_638197538278036538" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638197538278036538" xlink:to="us-gaap_RelatedPartyTransactionLineItems_638197538278036538" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_NumberOfEquipmentLeases" xlink:label="ibio_NumberOfEquipmentLeases_638197538278036538" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638197538278036538" xlink:to="ibio_NumberOfEquipmentLeases_638197538278036538" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_638197538278036538" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638197538278036538" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_638197538278036538" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_638197538278036538" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638197538278036538" xlink:to="us-gaap_InterestExpenseDebt_638197538278036538" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability_638197538278046530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638197538278036538" xlink:to="us-gaap_FinanceLeaseLiability_638197538278046530" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LeaseRentExpensePerMonth" xlink:label="ibio_LeaseRentExpensePerMonth_638197538278046530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638197538278036538" xlink:to="ibio_LeaseRentExpensePerMonth_638197538278046530" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LessorFinanceLeaseMonthlyRent" xlink:label="ibio_LessorFinanceLeaseMonthlyRent_638197538278046530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638197538278036538" xlink:to="ibio_LessorFinanceLeaseMonthlyRent_638197538278046530" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails" xlink:type="extended" xlink:title="41402 - Disclosure - Finance Lease Obligation (Finance Lease Cost and Other Information) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract_638197538278046530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LeaseCostAbstract_638197538278046530" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638197538278046530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_638197538278046530" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638197538278046530" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense_638197538278046530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_638197538278046530" xlink:to="us-gaap_FinanceLeaseInterestExpense_638197538278046530" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost_638197538278056529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_638197538278046530" xlink:to="us-gaap_LeaseCost_638197538278056529" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_FinanceLeaseObligationOtherInformationAbstract" xlink:label="ibio_FinanceLeaseObligationOtherInformationAbstract_638197538278056529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="ibio_FinanceLeaseObligationOtherInformationAbstract_638197538278056529" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract" xlink:label="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract_638197538278056529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_FinanceLeaseObligationOtherInformationAbstract_638197538278056529" xlink:to="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract_638197538278056529" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_FinancingCashFlowsFromFinanceLeaseObligation" xlink:label="ibio_FinancingCashFlowsFromFinanceLeaseObligation_638197538278056529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract_638197538278056529" xlink:to="ibio_FinancingCashFlowsFromFinanceLeaseObligation_638197538278056529" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_638197538278056529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract_638197538278056529" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_638197538278056529" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_638197538278056529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract_638197538278056529" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_638197538278056529" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_638197538278056529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract_638197538278056529" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_638197538278056529" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_638197538278056529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract_638197538278056529" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_638197538278056529" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_638197538278056529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract_638197538278056529" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_638197538278056529" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails" xlink:type="extended" xlink:title="41403 - Disclosure - Finance Lease Obligation (Future Minimum Payments Under the Capitalized Lease Obligations) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638197538278066476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_StatementTable_638197538278066476" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis_638197538278066476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538278066476" xlink:to="us-gaap_LeaseContractualTermAxis_638197538278066476" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_638197538278066476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis_638197538278066476" xlink:to="us-gaap_LeaseContractualTermDomain_638197538278066476" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_PrincipalMember" xlink:label="ibio_PrincipalMember_638197538278066476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain_638197538278066476" xlink:to="ibio_PrincipalMember_638197538278066476" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_InterestMember" xlink:label="ibio_InterestMember_638197538278066476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain_638197538278066476" xlink:to="ibio_InterestMember_638197538278066476" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638197538278066476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538278066476" xlink:to="us-gaap_StatementLineItems_638197538278066476" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_638197538278066476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538278066476" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_638197538278066476" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_638197538278077211" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538278066476" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_638197538278077211" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_638197538278077211" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538278066476" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_638197538278077211" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_638197538278077211" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538278066476" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_638197538278077211" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_638197538278077211" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538278066476" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_638197538278077211" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_638197538278077211" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538278066476" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_638197538278077211" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails" xlink:type="extended" xlink:title="41501 - Disclosure - Operating Lease Obligation (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638197538278086819" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_StatementTable_638197538278086819" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638197538278086819" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538278086819" xlink:to="srt_CounterpartyNameAxis_638197538278086819" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638197538278086819" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638197538278086819" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638197538278086819" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" xlink:label="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_638197538278086819" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638197538278086819" xlink:to="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_638197538278086819" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638197538278086819" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538278086819" xlink:to="srt_RangeAxis_638197538278086819" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638197538278096553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638197538278086819" xlink:to="srt_RangeMember_638197538278096553" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638197538278096553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638197538278096553" xlink:to="srt_MinimumMember_638197538278096553" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638197538278096553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638197538278096553" xlink:to="srt_MaximumMember_638197538278096553" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsByNatureAxis" xlink:label="us-gaap_GuaranteeObligationsByNatureAxis_638197538278096553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538278086819" xlink:to="us-gaap_GuaranteeObligationsByNatureAxis_638197538278096553" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsNatureDomain" xlink:label="us-gaap_GuaranteeObligationsNatureDomain_638197538278096553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GuaranteeObligationsByNatureAxis_638197538278096553" xlink:to="us-gaap_GuaranteeObligationsNatureDomain_638197538278096553" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialStandbyLetterOfCreditMember" xlink:label="us-gaap_FinancialStandbyLetterOfCreditMember_638197538278096553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GuaranteeObligationsNatureDomain_638197538278096553" xlink:to="us-gaap_FinancialStandbyLetterOfCreditMember_638197538278096553" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638197538278096553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538278086819" xlink:to="us-gaap_StatementLineItems_638197538278096553" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_BaseRentPercentageOfFairMarketValueOfProperty" xlink:label="ibio_BaseRentPercentageOfFairMarketValueOfProperty_638197538278096553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538278096553" xlink:to="ibio_BaseRentPercentageOfFairMarketValueOfProperty_638197538278096553" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty_638197538278096553" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538278096553" xlink:to="us-gaap_AreaOfRealEstateProperty_638197538278096553" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_638197538278106521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538278096553" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_638197538278106521" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseMonthlyRent" xlink:label="ibio_LesseeOperatingLeaseMonthlyRent_638197538278106521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538278096553" xlink:to="ibio_LesseeOperatingLeaseMonthlyRent_638197538278106521" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent" xlink:label="ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent_638197538278106521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538278096553" xlink:to="ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent_638197538278106521" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_BaseRentAbatementInFirstYearPeriod" xlink:label="ibio_BaseRentAbatementInFirstYearPeriod_638197538278106521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538278096553" xlink:to="ibio_BaseRentAbatementInFirstYearPeriod_638197538278106521" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements_638197538278106521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538278096553" xlink:to="us-gaap_TenantImprovements_638197538278106521" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsMaximumExposure" xlink:label="us-gaap_GuaranteeObligationsMaximumExposure_638197538278106521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538278096553" xlink:to="us-gaap_GuaranteeObligationsMaximumExposure_638197538278106521" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails" xlink:type="extended" xlink:title="41502 - Disclosure - Operating Lease Obligation (Lease Expense and Supplemental Balance Sheet Information Related to the Operating Lease Obligation) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_OperatingLeaseCostsAbstract" xlink:label="ibio_OperatingLeaseCostsAbstract_638197538278116466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="ibio_OperatingLeaseCostsAbstract_638197538278116466" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_638197538278116466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_OperatingLeaseCostsAbstract_638197538278116466" xlink:to="us-gaap_OperatingLeaseCost_638197538278116466" order="1" use="optional" priority="5" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_TotalOperatingLeaseCosts" xlink:label="ibio_TotalOperatingLeaseCosts_638197538278116466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_OperatingLeaseCostsAbstract_638197538278116466" xlink:to="ibio_TotalOperatingLeaseCosts_638197538278116466" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_OperatingLeaseObligationOtherInformationAbstract" xlink:label="ibio_OperatingLeaseObligationOtherInformationAbstract_638197538278116466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="ibio_OperatingLeaseObligationOtherInformationAbstract_638197538278116466" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract" xlink:label="ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract_638197538278116466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_OperatingLeaseObligationOtherInformationAbstract_638197538278116466" xlink:to="ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract_638197538278116466" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_OperatingCashFlowsFromOperatingLeaseObligation" xlink:label="ibio_OperatingCashFlowsFromOperatingLeaseObligation_638197538278116466" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract_638197538278116466" xlink:to="ibio_OperatingCashFlowsFromOperatingLeaseObligation_638197538278116466" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails" xlink:type="extended" xlink:title="41503 - Disclosure - Operating Lease Obligation (Future Minimum Payments under the Operating Lease Obligation) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638197538278126559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638197538278126559" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638197538278126559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638197538278126559" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638197538278126559" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638197538278126559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638197538278126559" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638197538278126559" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638197538278126559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638197538278126559" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638197538278126559" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638197538278126559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638197538278126559" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638197538278126559" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638197538278126559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638197538278126559" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638197538278126559" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638197538278126559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638197538278126559" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638197538278126559" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638197538278126559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638197538278126559" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638197538278126559" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638197538278126559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638197538278126559" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638197538278126559" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638197538278126559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638197538278126559" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638197538278126559" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract" xlink:label="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract_638197538278136440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract_638197538278136440" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne_638197538278136440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract_638197538278136440" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne_638197538278136440" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo_638197538278136440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract_638197538278136440" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo_638197538278136440" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree_638197538278136440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract_638197538278136440" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree_638197538278136440" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour_638197538278136440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract_638197538278136440" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour_638197538278136440" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive_638197538278136440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract_638197538278136440" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive_638197538278136440" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive_638197538278136440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract_638197538278136440" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive_638197538278136440" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal_638197538278136440" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract_638197538278136440" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal_638197538278136440" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract_638197538278146455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract_638197538278146455" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne_638197538278146455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract_638197538278146455" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne_638197538278146455" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo_638197538278146455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract_638197538278146455" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo_638197538278146455" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree_638197538278146455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract_638197538278146455" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree_638197538278146455" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour_638197538278146455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract_638197538278146455" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour_638197538278146455" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive_638197538278146455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract_638197538278146455" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive_638197538278146455" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive_638197538278156544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract_638197538278146455" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive_638197538278156544" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest_638197538278156544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract_638197538278146455" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest_638197538278156544" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails" xlink:type="extended" xlink:title="41601 - Disclosure - Stockholders' Equity (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_355" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_StockholdersEquityTable" xlink:label="ibio_StockholdersEquityTable_638197538278166450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_355" xlink:to="ibio_StockholdersEquityTable_638197538278166450" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638197538278166450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityTable_638197538278166450" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638197538278166450" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638197538278166450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638197538278166450" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638197538278166450" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ExchangeAgreementMember" xlink:label="ibio_ExchangeAgreementMember_638197538278166450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638197538278166450" xlink:to="ibio_ExchangeAgreementMember_638197538278166450" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638197538278166450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityTable_638197538278166450" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638197538278166450" order="2" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638197538278166450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638197538278166450" xlink:to="us-gaap_RelatedPartyDomain_638197538278166450" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_EasternAffiliateMember" xlink:label="ibio_EasternAffiliateMember_638197538278166450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638197538278166450" xlink:to="ibio_EasternAffiliateMember_638197538278166450" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638197538278166450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityTable_638197538278166450" xlink:to="us-gaap_PlanNameAxis_638197538278166450" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638197538278166450" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638197538278166450" xlink:to="us-gaap_PlanNameDomain_638197538278166450" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_OmnibusIncentivePlanMember" xlink:label="ibio_OmnibusIncentivePlanMember_638197538278176554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638197538278166450" xlink:to="ibio_OmnibusIncentivePlanMember_638197538278176554" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638197538278176554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityTable_638197538278166450" xlink:to="us-gaap_AwardTypeAxis_638197538278176554" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638197538278176554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638197538278176554" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638197538278176554" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638197538278176554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638197538278176554" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638197538278176554" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638197538278176554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityTable_638197538278166450" xlink:to="us-gaap_StatementClassOfStockAxis_638197538278176554" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638197538278176554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638197538278176554" xlink:to="us-gaap_ClassOfStockDomain_638197538278176554" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_PreferredTrackingStockMember" xlink:label="ibio_PreferredTrackingStockMember_638197538278176554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638197538278176554" xlink:to="ibio_PreferredTrackingStockMember_638197538278176554" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_Series2022ConvertiblePreferredStockMember" xlink:label="ibio_Series2022ConvertiblePreferredStockMember_638197538278176554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638197538278176554" xlink:to="ibio_Series2022ConvertiblePreferredStockMember_638197538278176554" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638197538278186566" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityTable_638197538278166450" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638197538278186566" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638197538278186566" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638197538278186566" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638197538278186566" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_PreFundedWarrantsMember" xlink:label="ibio_PreFundedWarrantsMember_638197538278186566" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638197538278186566" xlink:to="ibio_PreFundedWarrantsMember_638197538278186566" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SeriesWarrantsMember" xlink:label="ibio_SeriesWarrantsMember_638197538278186566" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638197538278186566" xlink:to="ibio_SeriesWarrantsMember_638197538278186566" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SeriesBWarrantsMember" xlink:label="ibio_SeriesBWarrantsMember_638197538278186566" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638197538278186566" xlink:to="ibio_SeriesBWarrantsMember_638197538278186566" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_RepresentativeWarrantsMember" xlink:label="ibio_RepresentativeWarrantsMember_638197538278186566" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638197538278186566" xlink:to="ibio_RepresentativeWarrantsMember_638197538278186566" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638197538278186566" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityTable_638197538278166450" xlink:to="srt_CounterpartyNameAxis_638197538278186566" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638197538278186566" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638197538278186566" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638197538278186566" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" xlink:label="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_638197538278196542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638197538278186566" xlink:to="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_638197538278196542" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_H.c.WainwrightCo.LlcMember" xlink:label="ibio_H.c.WainwrightCo.LlcMember_638197538278196542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638197538278186566" xlink:to="ibio_H.c.WainwrightCo.LlcMember_638197538278196542" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638197538278196542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityTable_638197538278166450" xlink:to="srt_StatementScenarioAxis_638197538278196542" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638197538278196542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638197538278196542" xlink:to="srt_ScenarioUnspecifiedDomain_638197538278196542" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember" xlink:label="ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember_638197538278196542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638197538278196542" xlink:to="ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember_638197538278196542" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis_638197538278196542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityTable_638197538278166450" xlink:to="srt_OwnershipAxis_638197538278196542" order="9" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_638197538278196542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis_638197538278196542" xlink:to="srt_OwnershipDomain_638197538278196542" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_IbioCdmoMember" xlink:label="ibio_IbioCdmoMember_638197538278206549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain_638197538278196542" xlink:to="ibio_IbioCdmoMember_638197538278206549" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_StockholdersEquityLineItems" xlink:label="ibio_StockholdersEquityLineItems_638197538278206549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityTable_638197538278166450" xlink:to="ibio_StockholdersEquityLineItems_638197538278206549" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638197538278206549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638197538278206549" xlink:to="us-gaap_PreferredStockSharesAuthorized_638197538278206549" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_638197538278206549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638197538278206549" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_638197538278206549" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock" xlink:label="ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock_638197538278206549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638197538278206549" xlink:to="ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock_638197538278206549" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638197538278206549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638197538278206549" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638197538278206549" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_638197538278216732" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638197538278206549" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_638197538278216732" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_638197538278216732" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638197538278206549" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_638197538278216732" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_638197538278216732" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638197538278206549" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_638197538278216732" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage_638197538278216732" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638197538278206549" xlink:to="us-gaap_PreferredStockDividendRatePercentage_638197538278216732" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsPerShareDeclared" xlink:label="us-gaap_PreferredStockDividendsPerShareDeclared_638197538278216732" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638197538278206549" xlink:to="us-gaap_PreferredStockDividendsPerShareDeclared_638197538278216732" order="9" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638197538278226643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638197538278206549" xlink:to="us-gaap_PreferredStockSharesOutstanding_638197538278226643" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638197538278226643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638197538278206549" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638197538278226643" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638197538278226643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638197538278206549" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638197538278226643" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_638197538278226643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638197538278206549" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_638197538278226643" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638197538278226643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638197538278206549" xlink:to="us-gaap_CommonStockSharesAuthorized_638197538278226643" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638197538278236627" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638197538278206549" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638197538278236627" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638197538278236627" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638197538278206549" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638197538278236627" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638197538278236627" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638197538278206549" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638197538278236627" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638197538278236627" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638197538278206549" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638197538278236627" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638197538278236627" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638197538278206549" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638197538278236627" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_638197538278246692" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638197538278206549" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_638197538278246692" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638197538278246692" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638197538278206549" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638197538278246692" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638197538278256566" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638197538278206549" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638197538278256566" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails" xlink:type="extended" xlink:title="41602 - Disclosure - Stockholders' Equity (Cantor Fitzgerald Underwriting and RubrYc Transaction) (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638197538278256566" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StatementTable_638197538278256566" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638197538278266568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538278256566" xlink:to="us-gaap_TypeOfArrangementAxis_638197538278266568" order="1" use="optional" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638197538278266568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638197538278266568" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638197538278266568" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SalesAgreementMember" xlink:label="ibio_SalesAgreementMember_638197538278266568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638197538278266568" xlink:to="ibio_SalesAgreementMember_638197538278266568" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638197538278266568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538278256566" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638197538278266568" order="2" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638197538278266568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638197538278266568" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638197538278266568" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_638197538278266568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638197538278266568" xlink:to="us-gaap_OverAllotmentOptionMember_638197538278266568" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638197538278266568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538278256566" xlink:to="srt_CounterpartyNameAxis_638197538278266568" order="3" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638197538278266568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638197538278266568" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638197538278266568" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CantorFitzgeraldMember" xlink:label="ibio_CantorFitzgeraldMember_638197538278266568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638197538278266568" xlink:to="ibio_CantorFitzgeraldMember_638197538278266568" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_RubrycTheraputicsInc.Member" xlink:label="ibio_RubrycTheraputicsInc.Member_638197538278266568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638197538278266568" xlink:to="ibio_RubrycTheraputicsInc.Member_638197538278266568" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/documentation" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638197538278276568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538278256566" xlink:to="us-gaap_StatementLineItems_638197538278276568" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_AggregateCommonStockPurchased" xlink:label="ibio_AggregateCommonStockPurchased_638197538278276568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538278276568" xlink:to="ibio_AggregateCommonStockPurchased_638197538278276568" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638197538278276568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538278276568" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638197538278276568" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638197538278276568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538278276568" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638197538278276568" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_638197538278276568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538278276568" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_638197538278276568" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638197538278276568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538278276568" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638197538278276568" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SubscriptionReceivableCurrent" xlink:label="ibio_SubscriptionReceivableCurrent_638197538278276568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538278276568" xlink:to="ibio_SubscriptionReceivableCurrent_638197538278276568" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails" xlink:type="extended" xlink:title="41603 - Disclosure - Stockholders' Equity (Wainwright Underwriting and Vesting of RSUs) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638197538278286716" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_1" xlink:to="us-gaap_StatementTable_638197538278286716" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638197538278286716" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538278286716" xlink:to="srt_CounterpartyNameAxis_638197538278286716" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638197538278286716" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638197538278286716" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638197538278286716" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_H.c.WainwrightCo.LlcMember" xlink:label="ibio_H.c.WainwrightCo.LlcMember_638197538278286716" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638197538278286716" xlink:to="ibio_H.c.WainwrightCo.LlcMember_638197538278286716" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638197538278286716" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538278286716" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638197538278286716" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638197538278296478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638197538278286716" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638197538278296478" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_638197538278296478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638197538278296478" xlink:to="us-gaap_OverAllotmentOptionMember_638197538278296478" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638197538278296478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538278286716" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638197538278296478" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638197538278296478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638197538278296478" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638197538278296478" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_PreFundedWarrantsMember" xlink:label="ibio_PreFundedWarrantsMember_638197538278296478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638197538278296478" xlink:to="ibio_PreFundedWarrantsMember_638197538278296478" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SeriesWarrantsMember" xlink:label="ibio_SeriesWarrantsMember_638197538278296478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638197538278296478" xlink:to="ibio_SeriesWarrantsMember_638197538278296478" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SeriesBWarrantsMember" xlink:label="ibio_SeriesBWarrantsMember_638197538278296478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638197538278296478" xlink:to="ibio_SeriesBWarrantsMember_638197538278296478" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638197538278296478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538278286716" xlink:to="us-gaap_AwardTypeAxis_638197538278296478" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638197538278296478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638197538278296478" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638197538278296478" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638197538278296478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638197538278296478" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638197538278296478" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638197538278306456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538278286716" xlink:to="us-gaap_StatementLineItems_638197538278306456" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638197538278306456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538278306456" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638197538278306456" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638197538278306456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538278306456" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638197538278306456" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering" xlink:label="ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering_638197538278306456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538278306456" xlink:to="ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering_638197538278306456" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_NumberOfDaysOptionToPurchaseAdditionalShares" xlink:label="ibio_NumberOfDaysOptionToPurchaseAdditionalShares_638197538278306456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538278306456" xlink:to="ibio_NumberOfDaysOptionToPurchaseAdditionalShares_638197538278306456" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_NumberOfAdditionalSharesIssued" xlink:label="ibio_NumberOfAdditionalSharesIssued_638197538278306456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538278306456" xlink:to="ibio_NumberOfAdditionalSharesIssued_638197538278306456" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CommonWarrantsToPurchaseAdditionalShares" xlink:label="ibio_CommonWarrantsToPurchaseAdditionalShares_638197538278316453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538278306456" xlink:to="ibio_CommonWarrantsToPurchaseAdditionalShares_638197538278316453" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_PercentageOfAggregateNumberOfSharesOfCommonStock" xlink:label="ibio_PercentageOfAggregateNumberOfSharesOfCommonStock_638197538278316453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538278306456" xlink:to="ibio_PercentageOfAggregateNumberOfSharesOfCommonStock_638197538278316453" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_638197538278316453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538278306456" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_638197538278316453" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638197538278316453" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538278306456" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638197538278316453" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails" xlink:type="extended" xlink:title="41701 - Disclosure - Earnings (Loss) Per Common Share (Components of the Earnings (Loss) per Common Share ) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract_638197538278326554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_638197538278326554" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="us-gaap_IncomeLossFromContinuingOperations_638197538278326554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_638197538278326554" xlink:to="us-gaap_IncomeLossFromContinuingOperations_638197538278326554" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPreferredStockStock" xlink:label="us-gaap_DividendsPreferredStockStock_638197538278326554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_638197538278326554" xlink:to="us-gaap_DividendsPreferredStockStock_638197538278326554" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedNetLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638197538278326554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_638197538278326554" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638197538278326554" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_638197538278326554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_638197538278326554" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_638197538278326554" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_UnconsolidatedGainLossAttributableToStockholders" xlink:label="ibio_UnconsolidatedGainLossAttributableToStockholders_638197538278326554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_638197538278326554" xlink:to="ibio_UnconsolidatedGainLossAttributableToStockholders_638197538278326554" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract_638197538278326554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract_638197538278326554" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638197538278326554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract_638197538278326554" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638197538278326554" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638197538278326554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract_638197538278326554" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638197538278326554" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_638197538278326554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract_638197538278326554" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_638197538278326554" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_638197538278336620" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract_638197538278326554" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_638197538278336620" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_638197538278336620" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract_638197538278326554" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_638197538278336620" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_638197538278336620" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract_638197538278326554" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_638197538278336620" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638197538278336620" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract_638197538278326554" xlink:to="us-gaap_EarningsPerShareBasic_638197538278336620" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638197538278336620" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract_638197538278326554" xlink:to="us-gaap_EarningsPerShareDiluted_638197538278336620" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="extended" xlink:title="41702 - Disclosure - Earnings (Loss) Per Common Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_637045036842717904" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_EarningsLossPerCommonShareTable" xlink:label="ibio_EarningsLossPerCommonShareTable_638197538278346559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_637045036842717904" xlink:to="ibio_EarningsLossPerCommonShareTable_638197538278346559" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638197538278346559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_EarningsLossPerCommonShareTable_638197538278346559" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638197538278346559" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638197538278346559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638197538278346559" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638197538278346559" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638197538278346559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638197538278346559" xlink:to="us-gaap_EmployeeStockOptionMember_638197538278346559" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638197538278346559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638197538278346559" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638197538278346559" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_638197538278346559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638197538278346559" xlink:to="us-gaap_WarrantMember_638197538278346559" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_EarningsLossPerCommonShareLineItems" xlink:label="ibio_EarningsLossPerCommonShareLineItems_638197538278346559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_EarningsLossPerCommonShareTable_638197538278346559" xlink:to="ibio_EarningsLossPerCommonShareLineItems_638197538278346559" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638197538278346559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_EarningsLossPerCommonShareLineItems_638197538278346559" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638197538278346559" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638197538278346559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_EarningsLossPerCommonShareLineItems_638197538278346559" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638197538278346559" order="2" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails" xlink:type="extended" xlink:title="41801 - Disclosure - Share-Based Compensation (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_495" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638197538278356539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_495" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638197538278356539" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638197538278356539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638197538278356539" xlink:to="srt_StatementScenarioAxis_638197538278356539" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638197538278356539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638197538278356539" xlink:to="srt_ScenarioUnspecifiedDomain_638197538278356539" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ScenarioOneMember" xlink:label="ibio_ScenarioOneMember_638197538278356539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638197538278356539" xlink:to="ibio_ScenarioOneMember_638197538278356539" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ScenarioTwoMember" xlink:label="ibio_ScenarioTwoMember_638197538278356539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638197538278356539" xlink:to="ibio_ScenarioTwoMember_638197538278356539" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638197538278356539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638197538278356539" xlink:to="srt_TitleOfIndividualAxis_638197538278356539" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638197538278356539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638197538278356539" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638197538278356539" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ConsultantsMember" xlink:label="ibio_ConsultantsMember_638197538278356539" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638197538278356539" xlink:to="ibio_ConsultantsMember_638197538278356539" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_VariousEmployeesMember" xlink:label="ibio_VariousEmployeesMember_638197538278366598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638197538278356539" xlink:to="ibio_VariousEmployeesMember_638197538278366598" order="2" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638197538278366598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638197538278356539" xlink:to="srt_RangeAxis_638197538278366598" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638197538278366598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638197538278366598" xlink:to="srt_RangeMember_638197538278366598" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638197538278366598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638197538278366598" xlink:to="srt_MinimumMember_638197538278366598" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638197538278366598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638197538278366598" xlink:to="srt_MaximumMember_638197538278366598" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638197538278366598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638197538278356539" xlink:to="us-gaap_PlanNameAxis_638197538278366598" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638197538278366598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638197538278366598" xlink:to="us-gaap_PlanNameDomain_638197538278366598" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_TwoThousandEighteenOmnibusEquityIncentivePlanMember" xlink:label="ibio_TwoThousandEighteenOmnibusEquityIncentivePlanMember_638197538278366598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638197538278366598" xlink:to="ibio_TwoThousandEighteenOmnibusEquityIncentivePlanMember_638197538278366598" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_IbioInc.2020OmnibusEquityIncentivePlanMember" xlink:label="ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_638197538278366598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638197538278366598" xlink:to="ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_638197538278366598" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_638197538278376574" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638197538278356539" xlink:to="us-gaap_VestingAxis_638197538278376574" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_638197538278376574" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_638197538278376574" xlink:to="us-gaap_VestingDomain_638197538278376574" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638197538278376574" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638197538278376574" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638197538278376574" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638197538278376574" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638197538278376574" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638197538278376574" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638197538278376574" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638197538278356539" xlink:to="us-gaap_AwardTypeAxis_638197538278376574" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638197538278376574" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638197538278376574" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638197538278376574" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638197538278386243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638197538278376574" xlink:to="us-gaap_EmployeeStockOptionMember_638197538278386243" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638197538278386243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638197538278376574" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638197538278386243" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638197538278386243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638197538278356539" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638197538278386243" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638197538278386243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638197538278386243" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638197538278386243" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638197538278386243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638197538278386243" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638197538278386243" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638197538278386243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638197538278386243" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638197538278386243" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized" xlink:label="ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized_638197538278386243" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638197538278386243" xlink:to="ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized_638197538278386243" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638197538278396542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638197538278386243" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638197538278396542" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638197538278396542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638197538278386243" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638197538278396542" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638197538278396542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638197538278386243" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638197538278396542" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638197538278396542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638197538278386243" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638197538278396542" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_638197538278396542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638197538278386243" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_638197538278396542" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638197538278396542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638197538278386243" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638197538278396542" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638197538278406565" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638197538278386243" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638197538278406565" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="41802 - Disclosure - Share-Based Compensation (Share Based Compensation Expense) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637045036842727870" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638197538278416595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637045036842727870" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638197538278416595" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638197538278416595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638197538278416595" xlink:to="us-gaap_IncomeStatementLocationAxis_638197538278416595" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638197538278416595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638197538278416595" xlink:to="us-gaap_IncomeStatementLocationDomain_638197538278416595" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638197538278416595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638197538278416595" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638197538278416595" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_638197538278416595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638197538278416595" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_638197538278416595" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:label="us-gaap_StatementOperatingActivitiesSegmentAxis_638197538278416595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638197538278416595" xlink:to="us-gaap_StatementOperatingActivitiesSegmentAxis_638197538278416595" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentOperatingActivitiesDomain" xlink:label="us-gaap_SegmentOperatingActivitiesDomain_638197538278416595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOperatingActivitiesSegmentAxis_638197538278416595" xlink:to="us-gaap_SegmentOperatingActivitiesDomain_638197538278416595" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDiscontinuedOperationsMember" xlink:label="us-gaap_SegmentDiscontinuedOperationsMember_638197538278416595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentOperatingActivitiesDomain_638197538278416595" xlink:to="us-gaap_SegmentDiscontinuedOperationsMember_638197538278416595" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638197538278426606" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638197538278416595" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638197538278426606" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638197538278426606" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638197538278426606" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638197538278426606" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails" xlink:type="extended" xlink:title="41803 - Disclosure - Share-Based Compensation (Stock Option Activity) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638197538278426606" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638197538278426606" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638197538278426606" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638197538278426606" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638197538278426606" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638197538278426606" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638197538278426606" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638197538278426606" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638197538278436492" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638197538278436492" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureShareBasedCompensationFairValueOfOptionsGrantedDetails" xlink:type="extended" xlink:title="41805 - Disclosure - Share-Based Compensation (Fair Value of Options Granted) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637045036842777735" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_638197538278436492" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637045036842777735" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_638197538278436492" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_638197538278436492" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637045036842777735" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_638197538278436492" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638197538278436492" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637045036842777735" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638197538278436492" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_638197538278436492" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637045036842777735" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_638197538278436492" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_638197538278436492" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637045036842777735" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_638197538278436492" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638197538278436492" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637045036842777735" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638197538278436492" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureShareBasedCompensationRsusDetails" xlink:type="extended" xlink:title="41806 - Disclosure - Share-Based Compensation (RSUs) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638197538278446460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638197538278446460" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638197538278446460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638197538278446460" xlink:to="us-gaap_AwardTypeAxis_638197538278446460" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638197538278446460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638197538278446460" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638197538278446460" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638197538278446460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638197538278446460" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638197538278446460" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638197538278446460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638197538278446460" xlink:to="srt_TitleOfIndividualAxis_638197538278446460" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638197538278446460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638197538278446460" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638197538278446460" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_Dr.MartinBrennerMember" xlink:label="ibio_Dr.MartinBrennerMember_638197538278446460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638197538278446460" xlink:to="ibio_Dr.MartinBrennerMember_638197538278446460" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638197538278456492" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638197538278446460" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638197538278456492" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638197538278456492" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638197538278456492" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638197538278456492" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638197538278456492" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638197538278456492" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638197538278456492" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_638197538278456492" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638197538278456492" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_638197538278456492" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails" xlink:type="extended" xlink:title="41901 - Disclosure - Fraunhofer Settlement (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlementAbstract" xlink:label="us-gaap_GainLossRelatedToLitigationSettlementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638197538278456492" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GainLossRelatedToLitigationSettlementAbstract" xlink:to="us-gaap_StatementTable_638197538278456492" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis_638197538278456492" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538278456492" xlink:to="srt_LitigationCaseAxis_638197538278456492" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain_638197538278466472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis_638197538278456492" xlink:to="srt_LitigationCaseTypeDomain_638197538278466472" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember" xlink:label="ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_638197538278466472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseTypeDomain_638197538278466472" xlink:to="ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_638197538278466472" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis" xlink:label="us-gaap_LitigationStatusAxis_638197538278466472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538278456492" xlink:to="us-gaap_LitigationStatusAxis_638197538278466472" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain" xlink:label="us-gaap_LitigationStatusDomain_638197538278466472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationStatusAxis_638197538278466472" xlink:to="us-gaap_LitigationStatusDomain_638197538278466472" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember" xlink:label="us-gaap_SettledLitigationMember_638197538278466472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationStatusDomain_638197538278466472" xlink:to="us-gaap_SettledLitigationMember_638197538278466472" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638197538278466472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538278456492" xlink:to="srt_StatementScenarioAxis_638197538278466472" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638197538278466472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638197538278466472" xlink:to="srt_ScenarioUnspecifiedDomain_638197538278466472" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember_638197538278466472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638197538278466472" xlink:to="us-gaap_ScenarioPlanMember_638197538278466472" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ScenarioPlanExpectedLegalFeesMember" xlink:label="ibio_ScenarioPlanExpectedLegalFeesMember_638197538278466472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioPlanMember_638197538278466472" xlink:to="ibio_ScenarioPlanExpectedLegalFeesMember_638197538278466472" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ScenarioPlanExpectedPaymentOneMember" xlink:label="ibio_ScenarioPlanExpectedPaymentOneMember_638197538278466472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioPlanMember_638197538278466472" xlink:to="ibio_ScenarioPlanExpectedPaymentOneMember_638197538278466472" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_ScenarioPlanExpectedPaymentTwoMember" xlink:label="ibio_ScenarioPlanExpectedPaymentTwoMember_638197538278466472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioPlanMember_638197538278466472" xlink:to="ibio_ScenarioPlanExpectedPaymentTwoMember_638197538278466472" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638197538278476498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538278456492" xlink:to="srt_ProductOrServiceAxis_638197538278476498" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638197538278476498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638197538278476498" xlink:to="srt_ProductsAndServicesDomain_638197538278476498" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember_638197538278476498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638197538278476498" xlink:to="us-gaap_ServiceMember_638197538278476498" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAndMaintenanceMember" xlink:label="us-gaap_LicenseAndMaintenanceMember_638197538278476498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ServiceMember_638197538278476498" xlink:to="us-gaap_LicenseAndMaintenanceMember_638197538278476498" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638197538278476498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538278456492" xlink:to="us-gaap_StatementLineItems_638197538278476498" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CashPaymentsReceivablesRelatedToLitigationSettlement" xlink:label="ibio_CashPaymentsReceivablesRelatedToLitigationSettlement_638197538278476498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538278476498" xlink:to="ibio_CashPaymentsReceivablesRelatedToLitigationSettlement_638197538278476498" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_PercentageOfLegalFeesExpectedToBeReceived" xlink:label="ibio_PercentageOfLegalFeesExpectedToBeReceived_638197538278476498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538278476498" xlink:to="ibio_PercentageOfLegalFeesExpectedToBeReceived_638197538278476498" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettlementAssetsCurrent" xlink:label="us-gaap_SettlementAssetsCurrent_638197538278486483" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538278476498" xlink:to="us-gaap_SettlementAssetsCurrent_638197538278486483" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_SettlementAssetsNonCurrent" xlink:label="ibio_SettlementAssetsNonCurrent_638197538278486483" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538278476498" xlink:to="ibio_SettlementAssetsNonCurrent_638197538278486483" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyUnrecordedAmount" xlink:label="us-gaap_GainContingencyUnrecordedAmount_638197538278486483" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538278476498" xlink:to="us-gaap_GainContingencyUnrecordedAmount_638197538278486483" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedFromOtherParty_638197538278486483" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538278476498" xlink:to="us-gaap_LitigationSettlementAmountAwardedFromOtherParty_638197538278486483" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLegalSettlements" xlink:label="us-gaap_ProceedsFromLegalSettlements_638197538278486483" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538278476498" xlink:to="us-gaap_ProceedsFromLegalSettlements_638197538278486483" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638197538278486483" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538278476498" xlink:to="us-gaap_Revenues_638197538278486483" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638197538278486483" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538278476498" xlink:to="us-gaap_RestrictedCashNoncurrent_638197538278486483" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureIncomeTaxesNarrativeDetails" xlink:type="extended" xlink:title="42001 - Disclosure - Income Taxes (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_605" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638197538278556484" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_605" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638197538278556484" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638197538278556484" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_605" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638197538278556484" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" xlink:type="extended" xlink:title="42101 - Disclosure - Commitments and Contingencies (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638197538278556484" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1" xlink:to="us-gaap_StatementTable_638197538278556484" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638197538278556484" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538278556484" xlink:to="us-gaap_TypeOfArrangementAxis_638197538278556484" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638197538278556484" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638197538278556484" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638197538278556484" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_CroAgreementMember" xlink:label="ibio_CroAgreementMember_638197538278556484" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638197538278556484" xlink:to="ibio_CroAgreementMember_638197538278556484" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638197538278556484" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538278556484" xlink:to="us-gaap_StatementLineItems_638197538278556484" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_638197538278566471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538278556484" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_638197538278566471" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_EstimatedAdditionalCostOnDevelopment" xlink:label="ibio_EstimatedAdditionalCostOnDevelopment_638197538278566471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538278556484" xlink:to="ibio_EstimatedAdditionalCostOnDevelopment_638197538278566471" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureEmployee401KPlanNarrativeDetails" xlink:type="extended" xlink:title="42201 - Disclosure - Employee 401(K) Plan (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638197538278566471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_StatementTable_638197538278566471" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:label="us-gaap_StatementOperatingActivitiesSegmentAxis_638197538278576514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538278566471" xlink:to="us-gaap_StatementOperatingActivitiesSegmentAxis_638197538278576514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentOperatingActivitiesDomain" xlink:label="us-gaap_SegmentOperatingActivitiesDomain_638197538278576514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOperatingActivitiesSegmentAxis_638197538278576514" xlink:to="us-gaap_SegmentOperatingActivitiesDomain_638197538278576514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDiscontinuedOperationsMember" xlink:label="us-gaap_SegmentDiscontinuedOperationsMember_638197538278576514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentOperatingActivitiesDomain_638197538278576514" xlink:to="us-gaap_SegmentDiscontinuedOperationsMember_638197538278576514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638197538278576514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638197538278566471" xlink:to="us-gaap_StatementLineItems_638197538278576514" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_638197538278576514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538278576514" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_638197538278576514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_638197538278576514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538278576514" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_638197538278576514" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer_638197538278576514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638197538278576514" xlink:to="us-gaap_DefinedBenefitPlanContributionsByEmployer_638197538278576514" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails" xlink:type="extended" xlink:title="42301 - Disclosure - Subsequent Events (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_638197538278586488" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract_1" xlink:to="us-gaap_SubsequentEventTable_638197538278586488" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638197538278586488" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638197538278586488" xlink:to="srt_CounterpartyNameAxis_638197538278586488" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638197538278586488" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638197538278586488" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638197538278586488" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20230331.xsd#ibio_WoodforestMember" xlink:label="ibio_WoodforestMember_638197538278586488" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638197538278586488" xlink:to="ibio_WoodforestMember_638197538278586488" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_638197538278586488" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638197538278586488" xlink:to="us-gaap_SubsequentEventLineItems_638197538278586488" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638197538278586488" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638197538278586488" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638197538278586488" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638197538278586488" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638197538278586488" xlink:to="us-gaap_RestrictedCashNoncurrent_638197538278586488" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638197538278586488" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638197538278586488" xlink:to="us-gaap_DebtInstrumentFaceAmount_638197538278586488" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_638197538278586488" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638197538278586488" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_638197538278586488" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638197538278586488" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638197538278586488" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638197538278586488" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount_638197538278586488" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638197538278586488" xlink:to="us-gaap_DebtInstrumentFeeAmount_638197538278586488" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393612611312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>May 10, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document And Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">iBio,&#160;Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-2797813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">8800 HSC Parkway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Bryan<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">446-0027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IBIO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001420720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--06-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,798,014<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393612266320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 6,562,000<span></span>
</td>
<td class="nump">$ 22,676,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Investments in debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,845,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable - trade</a></td>
<td class="nump">70,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SubscriptionReceivableCurrent', window );">Subscription receivable</a></td>
<td class="nump">260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SettlementAssetsCurrent', window );">Settlement receivable - current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetCurrent', window );">Convertible promissory note receivable and accrued interest</a></td>
<td class="nump">912,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">921,000<span></span>
</td>
<td class="nump">1,549,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent', window );">Current assets held for sale</a></td>
<td class="nump">18,368,000<span></span>
</td>
<td class="nump">3,900,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">27,093,000<span></span>
</td>
<td class="nump">45,070,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">3,253,000<span></span>
</td>
<td class="nump">5,996,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest', window );">Convertible promissory note receivable and accrued interest</a></td>
<td class="nump">775,000<span></span>
</td>
<td class="nump">1,631,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use assets, net of accumulated amortization</a></td>
<td class="nump">678,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">2,786,000<span></span>
</td>
<td class="nump">3,068,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net of accumulated depreciation</a></td>
<td class="nump">4,358,000<span></span>
</td>
<td class="nump">1,373,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net of accumulated amortization</a></td>
<td class="nump">5,393,000<span></span>
</td>
<td class="nump">4,851,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposits</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">29,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Prepaid expenses - noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent', window );">Noncurrent assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,314,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">44,386,000<span></span>
</td>
<td class="nump">99,406,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,013,000<span></span>
</td>
<td class="nump">4,264,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">3,821,000<span></span>
</td>
<td class="nump">3,764,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease obligations - current portion</a></td>
<td class="nump">265,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease obligation - current portion</a></td>
<td class="nump">377,000<span></span>
</td>
<td class="nump">91,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EquipmentFinancingPayableCurrent', window );">Equipment financing payable - current portion</a></td>
<td class="nump">156,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Term note payable - net of deferred financing costs</a></td>
<td class="nump">13,700,000<span></span>
</td>
<td class="nump">22,161,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Contract liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale', window );">Current liabilities related to assets held for sale</a></td>
<td class="nump">1,944,000<span></span>
</td>
<td class="nump">56,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">22,276,000<span></span>
</td>
<td class="nump">30,436,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease obligations - net of current portion</a></td>
<td class="nump">422,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease obligation - net of current portion</a></td>
<td class="nump">3,225,000<span></span>
</td>
<td class="nump">3,514,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EquipmentFinancingPayableNoncurrent', window );">Equipment financing payable - net of current portion</a></td>
<td class="nump">283,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_AccruedLiabilitiesNoncurrent', window );">Accrued expenses - noncurrent</a></td>
<td class="nump">791,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale', window );">Noncurrent liabilities related to assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,971,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">26,997,000<span></span>
</td>
<td class="nump">35,921,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>iBio, Inc. Stockholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Series 2022 Convertible Preferred Stock - $0.001 par value; 1,000,000 shares authorized; 0 and 1,000 shares issued and outstanding as of March 31, 2023 and June 30, 2022, respectively</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock - $0.001 par value; 275,000,000 shares authorized at March 31, 2023 and June 30, 2022; 15,818,149 and 8,727,158 shares issued and outstanding as of March 31, 2023 and June 30, 2022, respectively</a></td>
<td class="nump">16,000<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">300,280,000<span></span>
</td>
<td class="nump">287,619,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(213,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(282,907,000)<span></span>
</td>
<td class="num">(223,930,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
<td class="nump">17,389,000<span></span>
</td>
<td class="nump">63,485,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity</a></td>
<td class="nump">$ 44,386,000<span></span>
</td>
<td class="nump">$ 99,406,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_AccruedLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of noncurrent portion of accrued expenses as at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_AccruedLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of convertible Promissory Note Receivable and Accrued Interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current liabilities related to assets held for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_EquipmentFinancingPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current portion of equipment financing payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_EquipmentFinancingPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_EquipmentFinancingPayableNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of noncurrent portion of equipment financing payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_EquipmentFinancingPayableNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncurrent liabilities related to assets held for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_SubscriptionReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of subscription receivables classified due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_SubscriptionReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 15<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982154&amp;loc=d3e400-110220<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity), and investment in debt security measured at fair value with change in fair value recognized in net income (trading), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2510-110228<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SettlementAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received or short term receivables for unsettled money transfers, money orders, consumer payments, or business to business payments. Settlement assets include clearing and settling customers payments due to and from financial institutions and may include cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SettlementAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393612577856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Condensed Consolidated Balance Sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">275,000,000<span></span>
</td>
<td class="nump">275,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">15,818,149<span></span>
</td>
<td class="nump">8,727,158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="nump">12,368,287<span></span>
</td>
<td class="nump">8,727,158<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393611767632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,884<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">2,644<span></span>
</td>
<td class="nump">3,272<span></span>
</td>
<td class="nump">$ 7,971<span></span>
</td>
<td class="nump">6,265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">3,525<span></span>
</td>
<td class="nump">5,316<span></span>
</td>
<td class="nump">16,407<span></span>
</td>
<td class="nump">14,863<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">6,169<span></span>
</td>
<td class="nump">8,588<span></span>
</td>
<td class="nump">24,378<span></span>
</td>
<td class="nump">21,128<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(6,169)<span></span>
</td>
<td class="num">(6,788)<span></span>
</td>
<td class="num">(24,378)<span></span>
</td>
<td class="num">(19,244)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(35)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(66)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="nump">163<span></span>
</td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleGainLoss', window );">Loss on sale of debt securities</a></td>
<td class="num">(98)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(98)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyIncomeNonoperating', window );">Royalty income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="num">(110)<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Consolidated net loss from continuing operations</a></td>
<td class="num">(6,279)<span></span>
</td>
<td class="num">(6,746)<span></span>
</td>
<td class="num">(24,379)<span></span>
</td>
<td class="num">(19,126)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity', window );">Net loss attributable to noncontrolling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net loss attributable to iBio, Inc. from continuing operations</a></td>
<td class="num">(6,279)<span></span>
</td>
<td class="num">(6,746)<span></span>
</td>
<td class="num">(24,379)<span></span>
</td>
<td class="num">(19,125)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockStock', window );">Preferred stock dividends - iBio CDMO Tracking Stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(88)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_NetLossAvailableToStockholdersFromContinuingOperations', window );">Net loss available to iBio, Inc. stockholders from continuing operations</a></td>
<td class="num">(6,279)<span></span>
</td>
<td class="num">(6,746)<span></span>
</td>
<td class="num">(24,379)<span></span>
</td>
<td class="num">(19,213)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Loss from discontinued operations</a></td>
<td class="num">(1,015)<span></span>
</td>
<td class="num">(5,644)<span></span>
</td>
<td class="num">(34,598)<span></span>
</td>
<td class="num">(14,124)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_UnconsolidatedGainLossAttributableToStockholders', window );">Net loss available to iBio, Inc. stockholders</a></td>
<td class="num">(7,294)<span></span>
</td>
<td class="num">(12,390)<span></span>
</td>
<td class="num">(58,977)<span></span>
</td>
<td class="num">(33,337)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Consolidated net loss</a></td>
<td class="num">(7,294)<span></span>
</td>
<td class="num">(12,390)<span></span>
</td>
<td class="num">(58,977)<span></span>
</td>
<td class="num">(33,250)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Other comprehensive income - unrealized gain (loss) on debt securities</a></td>
<td class="nump">134<span></span>
</td>
<td class="num">(103)<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="num">(131)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Other comprehensive income - foreign currency adjustment</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">$ (7,127)<span></span>
</td>
<td class="num">$ (12,493)<span></span>
</td>
<td class="num">$ (58,764)<span></span>
</td>
<td class="num">$ (33,381)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Loss per common share attributable to iBio, Inc. stockholders - basic - continuing operations</a></td>
<td class="num">$ (0.47)<span></span>
</td>
<td class="num">$ (0.77)<span></span>
</td>
<td class="num">$ (2.30)<span></span>
</td>
<td class="num">$ (2.20)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Loss per common share attributable to iBio, Inc. stockholders - diluted - continuing operations</a></td>
<td class="num">(0.47)<span></span>
</td>
<td class="num">(0.77)<span></span>
</td>
<td class="num">(2.30)<span></span>
</td>
<td class="num">(2.20)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Loss per common share attributable to iBio, Inc. stockholders - basic - discontinued operations</a></td>
<td class="num">(0.08)<span></span>
</td>
<td class="num">(0.65)<span></span>
</td>
<td class="num">(3.27)<span></span>
</td>
<td class="num">(1.62)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Loss per common share attributable to iBio, Inc. stockholders - diluted - discontinued operations</a></td>
<td class="num">(0.08)<span></span>
</td>
<td class="num">(0.65)<span></span>
</td>
<td class="num">(3.27)<span></span>
</td>
<td class="num">(1.62)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss per common share attributable to iBio, Inc. stockholders - basic - total</a></td>
<td class="num">(0.55)<span></span>
</td>
<td class="num">(1.42)<span></span>
</td>
<td class="num">(5.57)<span></span>
</td>
<td class="num">(3.82)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Loss per common share attributable to iBio, Inc. stockholders - diluted - total</a></td>
<td class="num">$ (0.55)<span></span>
</td>
<td class="num">$ (1.42)<span></span>
</td>
<td class="num">$ (5.57)<span></span>
</td>
<td class="num">$ (3.82)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic</a></td>
<td class="nump">13,184<span></span>
</td>
<td class="nump">8,719<span></span>
</td>
<td class="nump">10,592<span></span>
</td>
<td class="nump">8,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding - diluted</a></td>
<td class="nump">13,184<span></span>
</td>
<td class="nump">8,719<span></span>
</td>
<td class="nump">10,592<span></span>
</td>
<td class="nump">8,719<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_NetLossAvailableToStockholdersFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net loss available to stockholders from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_NetLossAvailableToStockholdersFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_UnconsolidatedGainLossAttributableToStockholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The unconsolidated net gain (loss) attributable to stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_UnconsolidatedGainLossAttributableToStockholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStockStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStockStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4613673-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393608128480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Equity - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Preferred Stock [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Noncontrolling Interest [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 282,266<span></span>
</td>
<td class="num">$ (63)<span></span>
</td>
<td class="num">$ (173,627)<span></span>
</td>
<td class="num">$ (17)<span></span>
</td>
<td class="nump">$ 108,568<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss', window );">Unrealized gain (loss) on available-for-sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,939)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss including portion attributable to noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,940)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">283,164<span></span>
</td>
<td class="num">(64)<span></span>
</td>
<td class="num">(182,566)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="nump">100,525<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">282,266<span></span>
</td>
<td class="num">(63)<span></span>
</td>
<td class="num">(173,627)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="nump">108,568<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CommonStockIssuedInRubrycTransactionValue', window );">Common stock issued - RubrYc transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss including portion attributable to noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,250)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">286,441<span></span>
</td>
<td class="num">(194)<span></span>
</td>
<td class="num">(206,876)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,380<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">283,164<span></span>
</td>
<td class="num">(64)<span></span>
</td>
<td class="num">(182,566)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="nump">100,525<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of RSU's (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrant issued for Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">967<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate', window );">Acquisition of remaining portion of iBio CDMO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(68)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss', window );">Unrealized gain (loss) on available-for-sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,920)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,920)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">285,166<span></span>
</td>
<td class="num">(91)<span></span>
</td>
<td class="num">(194,486)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,598<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Vesting of RSU's</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of RSU's (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss', window );">Unrealized gain (loss) on available-for-sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(103)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(103)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,390)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,390)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss including portion attributable to noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,390)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">286,441<span></span>
</td>
<td class="num">(194)<span></span>
</td>
<td class="num">(206,876)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,380<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">287,619<span></span>
</td>
<td class="num">(213)<span></span>
</td>
<td class="num">(223,930)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,485<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2022</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">8,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockIssuedDuringPeriodValueCapitalRaise', window );">Capital raise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockIssuedDuringPeriodSharesCapitalRaise', window );">Capital raise (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock (in shares)</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CommonStockIssuedInRubrycTransactionValue', window );">Common stock issued - RubrYc transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CommonStockIssuedInRubrycTransactionInShares', window );">Common stock issued - RubrYc transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of RSU's (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss', window );">Unrealized gain (loss) on available-for-sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,130)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,130)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">290,642<span></span>
</td>
<td class="num">(223)<span></span>
</td>
<td class="num">(242,060)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,368<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">287,619<span></span>
</td>
<td class="num">(213)<span></span>
</td>
<td class="num">(223,930)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,485<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2022</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">8,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CommonStockIssuedInRubrycTransactionValue', window );">Common stock issued - RubrYc transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss including portion attributable to noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(58,977)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">300,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(282,907)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,389<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">290,642<span></span>
</td>
<td class="num">(223)<span></span>
</td>
<td class="num">(242,060)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,368<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockIssuedDuringPeriodValueCapitalRaise', window );">Capital raise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">3,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockIssuedDuringPeriodSharesCapitalRaise', window );">Capital raise (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Cost to raise capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(636)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(636)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_FractionalShareIssuedAfterReverseStockSplitValue', window );">Payment for fractional shares after reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_FractionalShareIssuedAfterReverseStockSplitShares', window );">Payment for fractional shares after reverse stock split (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of RSU's (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss', window );">Unrealized gain (loss) on available-for-sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,553)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,553)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">294,591<span></span>
</td>
<td class="num">(167)<span></span>
</td>
<td class="num">(275,613)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,823<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockIssuedDuringPeriodValueCapitalRaise', window );">Capital raise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">4,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockIssuedDuringPeriodSharesCapitalRaise', window );">Capital raise (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of RSU's (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,596<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss', window );">Unrealized gain (loss) on available-for-sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities', window );">Reclassification adjustment for loss on available-for-sale debt securities realized in net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,294)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,294)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss including portion attributable to noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,294)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 300,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (282,907)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,389<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital acquisition of remaining portion of affiliate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CommonStockIssuedInRubrycTransactionInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares of common stock issued in the RubrYc transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CommonStockIssuedInRubrycTransactionInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CommonStockIssuedInRubrycTransactionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of common stock issued in the RubrYc transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CommonStockIssuedInRubrycTransactionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_FractionalShareIssuedAfterReverseStockSplitShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fractional shares after reverse stock split issued during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_FractionalShareIssuedAfterReverseStockSplitShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_FractionalShareIssuedAfterReverseStockSplitValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of fractional shares after reverse stock split issued during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_FractionalShareIssuedAfterReverseStockSplitValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The reclassification adjustment for the period on gains (losses) on avaliable for sale debt securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_StockIssuedDuringPeriodSharesCapitalRaise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new shares raised during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_StockIssuedDuringPeriodSharesCapitalRaise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_StockIssuedDuringPeriodValueCapitalRaise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of capital raise during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_StockIssuedDuringPeriodValueCapitalRaise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393607641456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Consolidated net loss</a></td>
<td class="num">$ (58,977,000)<span></span>
</td>
<td class="num">$ (33,250,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile consolidated net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">3,945,000<span></span>
</td>
<td class="nump">3,198,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">121,000<span></span>
</td>
<td class="nump">333,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of finance lease right-of-use assets</a></td>
<td class="nump">156,000<span></span>
</td>
<td class="nump">587,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of operating lease right-of-use assets</a></td>
<td class="nump">290,000<span></span>
</td>
<td class="nump">386,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation of fixed assets</a></td>
<td class="nump">508,000<span></span>
</td>
<td class="nump">1,532,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges', window );">Gain on sale of fixed assets</a></td>
<td class="num">(732,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable', window );">Accrued interest receivable on convertible promissory note receivable</a></td>
<td class="num">(56,000)<span></span>
</td>
<td class="num">(56,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of premiums on debt securities</a></td>
<td class="nump">67,000<span></span>
</td>
<td class="nump">269,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleGainLoss', window );">Loss on sale of debt securities</a></td>
<td class="nump">98,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DeferredFinancingCostsAmortizationExpense', window );">Amortization of deferred financing costs</a></td>
<td class="nump">160,000<span></span>
</td>
<td class="nump">67,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_IncreaseDecreaseInInventoryReserve', window );">Inventory reserve</a></td>
<td class="nump">4,915,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Impairment of fixed assets</a></td>
<td class="nump">17,600,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">565,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases', window );">Gain on disposition of finance lease ROU assets</a></td>
<td class="num">(5,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan', window );">Forgiveness of note payable and accrued interest - SBA loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(607,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SettlementOfRevenueContract', window );">Settlement of revenue contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(84,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable - trade</a></td>
<td class="nump">931,000<span></span>
</td>
<td class="num">(890,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_IncreaseDecreaseInSettlementAssets', window );">Settlement receivable</a></td>
<td class="nump">5,100,000<span></span>
</td>
<td class="nump">5,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories', window );">Inventory</a></td>
<td class="num">(1,015,000)<span></span>
</td>
<td class="num">(3,257,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">627,000<span></span>
</td>
<td class="num">(494,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses - noncurrent</a></td>
<td class="nump">74,000<span></span>
</td>
<td class="num">(975,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInSecurityDeposits', window );">Security deposit</a></td>
<td class="num">(21,000)<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(481,000)<span></span>
</td>
<td class="nump">1,649,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(18,000)<span></span>
</td>
<td class="nump">618,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent', window );">Accrued expenses - noncurrent</a></td>
<td class="nump">791,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease obligations</a></td>
<td class="num">(9,000)<span></span>
</td>
<td class="num">(12,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="num">(100,000)<span></span>
</td>
<td class="num">(86,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(25,466,000)<span></span>
</td>
<td class="num">(25,977,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,355,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Redemption of debt securities</a></td>
<td class="nump">4,100,000<span></span>
</td>
<td class="nump">9,711,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Sale of debt securities</a></td>
<td class="nump">6,739,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi', window );">Purchase of equity security</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,760,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Additions to intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,300,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of fixed assets</a></td>
<td class="num">(5,232,000)<span></span>
</td>
<td class="num">(3,900,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Sales of fixed assets</a></td>
<td class="nump">2,100,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Payment for RubrYc asset acquisition</a></td>
<td class="num">(692,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">7,015,000<span></span>
</td>
<td class="num">(5,604,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ProceedsFromIssuanceOfPreferredAndCommonStock', window );">Proceeds from sales of common stock</a></td>
<td class="nump">7,851,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_PaymentsForFractionalSharesAfterReverseStockSplit', window );">Payments for fractional shares after reverse stock split</a></td>
<td class="num">(39,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Acquisition of noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ProceedsFromEquipmentFinancingLoan', window );">Proceeds from equipment financing loan</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_PaymentOfEquipmentFinancingLoan', window );">Payment of equipment financing loan</a></td>
<td class="num">(62,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payment of term note payable</a></td>
<td class="num">(8,523,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_PaymentsToAttainTermNote', window );">Costs to attain term note</a></td>
<td class="num">(22,000)<span></span>
</td>
<td class="num">(322,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payment of finance lease obligation</a></td>
<td class="num">(144,000)<span></span>
</td>
<td class="num">(5,820,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in provided by financing activities</a></td>
<td class="num">(439,000)<span></span>
</td>
<td class="num">(6,115,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate changes</a></td>
<td class="nump">33,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(18,857,000)<span></span>
</td>
<td class="num">(37,696,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash - beginning</a></td>
<td class="nump">28,672,000<span></span>
</td>
<td class="nump">77,404,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash - end</a></td>
<td class="nump">9,815,000<span></span>
</td>
<td class="nump">39,708,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract', window );"><strong>Schedule of non-cash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid', window );">Fixed assets included in accounts payable in prior period, paid in current period</a></td>
<td class="nump">1,769,000<span></span>
</td>
<td class="nump">791,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Increase in finance lease ROU assets for new leases</a></td>
<td class="nump">814,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases', window );">Increase in finance lease obligation for new leases</a></td>
<td class="nump">814,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CommonStockIssuedInRubrycTransactionValue', window );">RubrYc asset acquisition by issuance of common stock</a></td>
<td class="nump">650,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CostToRaiseCapitalPaidDirectlyFromGrossProceeds', window );">Costs to raise capital paid directly from gross proceeds</a></td>
<td class="nump">636,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_TerminationOfFinanceLeaseRightOfUseAssetIncludingIssuanceOfWarrant', window );">Termination of finance ROU assets including issuance of warrant</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,386,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesIssued1', window );">Note payable to acquire Facility</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">22,375,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities', window );">Increase in operating lease ROU assets for new lease - net of lease incentive</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,570,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_NonCashSettlementOfRevenueContract', window );">Settlement of revenue contract</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">580,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_WarrantsIssuedForFinanceLeasePayment', window );">Issuance of warrant for final finance lease obligation payment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">217,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LeaseIncentiveForConstructionInProgress', window );">Lease incentive for construction in progress</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">82,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_NoncashOrPartNoncashAcquisitionNonControllingInterestAssumed', window );">Acquisition of noncontrolling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Unrealized (gain) loss on available-for-sale debt securities</a></td>
<td class="nump">159,000<span></span>
</td>
<td class="nump">131,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid during the period for interest</a></td>
<td class="nump">$ 523,000<span></span>
</td>
<td class="nump">$ 860,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued interest receivable on convertible promissory note receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount paid for capital expenditures incurred for intangible assets during the previous year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CommonStockIssuedInRubrycTransactionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of common stock issued in the RubrYc transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CommonStockIssuedInRubrycTransactionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CostToRaiseCapitalPaidDirectlyFromGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cost incurred to raise capital directly from gross proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CostToRaiseCapitalPaidDirectlyFromGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DeferredFinancingCostsAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization of loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DeferredFinancingCostsAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Forgiveness of note payable and accrued interest - SBA loan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of noncurrent expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in finance lease obligations for new leases incurred during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_IncreaseDecreaseInInventoryReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in inventory valuation reserve during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_IncreaseDecreaseInInventoryReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_IncreaseDecreaseInSettlementAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in cash received or short term receivables for unsettled money transfers, money orders, consumer payments, or business to business payments. Settlement assets include clearing and settling customers payments due to and from financial institutions and may include cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_IncreaseDecreaseInSettlementAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LeaseIncentiveForConstructionInProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease incentive for construction in progress</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LeaseIncentiveForConstructionInProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_NonCashSettlementOfRevenueContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash Settlement of revenue contract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_NonCashSettlementOfRevenueContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of increase in Right Of Use Assets under the ASU 842, for which no cash outflow was incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_NoncashOrPartNoncashAcquisitionNonControllingInterestAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non controlling interest that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_NoncashOrPartNoncashAcquisitionNonControllingInterestAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_PaymentOfEquipmentFinancingLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash outflow for equipment financing loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_PaymentOfEquipmentFinancingLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_PaymentsForFractionalSharesAfterReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash outflow for fractional shares after reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_PaymentsForFractionalSharesAfterReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_PaymentsToAttainTermNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred with attain term note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_PaymentsToAttainTermNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ProceedsFromEquipmentFinancingLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash inflow from equipment financing loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ProceedsFromEquipmentFinancingLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ProceedsFromIssuanceOfPreferredAndCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ProceedsFromIssuanceOfPreferredAndCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_SettlementOfRevenueContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Settlement of revenue contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_SettlementOfRevenueContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_TerminationOfFinanceLeaseRightOfUseAssetIncludingIssuanceOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of termination of finance lease right of use asset, including issuance of warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_TerminationOfFinanceLeaseRightOfUseAssetIncludingIssuanceOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_WarrantsIssuedForFinanceLeasePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of warrants issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_WarrantsIssuedForFinanceLeasePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net gain (loss) arising from the lessor's sale of assets held- or available-for-lease under contractual arrangements classified as operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 40<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=126905841&amp;loc=SL51729484-110225<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 40<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=123393937&amp;loc=d3e44908-112734<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the book value of finished goods inventory and work in process inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInSecurityDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in security deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInSecurityDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of notes issued in noncash investing and financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123583714&amp;loc=SL75117360-209713<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3444-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TangibleAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TangibleAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393617878128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Nature of Business [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Business</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">1.&#160;&#160;&#160;Nature of Business </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">iBio, Inc. (&#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;, &#8220;iBio&#8221;, &#8220;iBio, Inc&#8221; or the &#8220;Company&#8221;) is an Artificial Intelligence (&#8220;AI&#8221;)-driven innovator of precision antibody immunotherapies. The Company has a pipeline of innovative primarily immuno-oncology antibodies against hard-to-drug targets where it may face reduced competition and with antibodies that may be more selective. The Company plans to use its AI-driven discovery platform to continue adding antibodies against hard-to-drug targets or to work with partners on AI-driven drug development. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Therapeutics Pipeline </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><img alt="Graphic" src="ibio-20230331x10q001.jpg" style="display:inline-block;height:269.68pt;left:0%;padding-bottom:0.35pt;position:relative;top:0pt;width:531.75pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">IBIO-101: </b>an anti-CD25 molecule that works by depletion of immunosuppressive T-regulatory cells (&#8220;Tregs&#8221;) via antibody-dependent cellular cytotoxicity (&#8220;ADCC&#8221;), without disrupting activation of effector T-cells (&#8220;Teffs&#8221;) in the tumor microenvironment. IBIO-101 could potentially be used to treat solid tumors, hairy cell leukemia, relapsed multiple myeloma, lymphoma, or head and neck cancer. IBIO-101 is currently in the Investigational New Drug (&#8220;IND&#8221;) enabling stage. We have contracted with a contract research organization (&#8220;CRO&#8221;) to assist with the development of the manufacturing process, which includes but is not limited to process and cell line development for the production of the drug substance and drug product. IBIO-101 is strategically positioned as a fast follower to Hoffman-La Roche&#8217;s RG6292 molecule that recently released Phase 1 clinical data. While RG6292 showed signs of efficacy, especially in combination with PD-L1 monoclonal antibody, and was well tolerated, we anticipate additional clinical research will be needed to determine whether different cancer types are more efficacious than others. As a result, we have decided to pause the IND enabling studies until additional data is released on RG6292. This approach will allow us to gather more information, thoroughly evaluate the market potential and optimize our financial resources and the development plan for IBIO-101 to maximize its potential for success.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">CCR8:</b> targets depletion of highly immunosuppressive CCR8+ Tregs in the tumor microenvironment via an ADCC mechanism with selective binding to CCR8 over its closely related cousin, CCR4, to avoid off-target effects. A CCR8 program could potentially be broadly applicable in solid tumors and/or as a prospective combination therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">EGFRvIII: </b>binds a tumor-specific mutation of EGFR variant III with an afucosylated antibody for high ADCC. Because of its specificity binding to the tumor-specific mutation, it could potentially reduce toxicity and/or expand the therapeutic window compared to simple broad EGFR-targeted alternatives. EGFRvIII is constantly &#8220;switched on&#8221; which can lead to the development of a range of different cancers. An EGFRvIII antibody could potentially be used to treat glioblastoma, head and neck cancer or non-small cell lung cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">CD3 antibody panel:</b> provides a range of CD3 affinities with cross-reactivity to non-human primates and increased the humanness of the antibody sequences. The antibody panel is intended to serve as one arm of T-cell-redirecting bispecific antibodies, a new class of therapeutic antibodies designed to simultaneously bind to T-cells via CD3 and to tumor cells via tumor-specific antigens or tumor-associated antigens, inducing T-cell-mediated killing of tumor cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">MUC16:</b> a highly expressed target on ovarian cancer cells and an attractive tumor associated target for therapeutic antibodies. However, antibodies targeting MUC16 are prone to tumor resistance via epitope shedding and dysregulated glycosylation. Epitope-steered antibodies that bind to an epitope that avoids both of these tumor resistance mechanisms could potentially be used to treat MUC16 positive tumors, particularly those tumors that are resistant to other MUC16 antibodies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">PD-1 Agonist: </b>selectively binds PD-1 to suppress auto-reactive T-cells without PD-L1/PD-L2 blocking. A PD-1 agonist could potentially be used to treat inflammatory bowel disease, systemic lupus erythematosus, multiple sclerosis or other inflammatory diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In addition to the programs described above, the Company also has three additional early discovery programs that have the potential to advance into later stages of preclinical development and are designed to tackle hard-to-drug targets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">IBIO-100 and Endostatin E4</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our preclinical anti-fibrotic program, IBIO-100, has been undergoing a review process as part of our ongoing effort to prioritize our resources and focus on the most promising opportunities. The IBIO-100 program design is based upon work by Dr. Carol Feghali-Bostwick, Professor of Medicine at the Medical University of South Carolina and Vice-Chair of the Scleroderma Foundation. Her initial work was conducted at the University of Pittsburgh, and we have licensed the patents relevant for the continued development of the molecule from the university. &#160;After careful consideration, in February 2023, the Company terminated all efforts on IBIO-100 anti-fibrotic program and provided a six (6) month notice of termination of the license agreement to the University of Pittsburgh, as required by the license agreement. Pursuant to the license agreement with the University of Pittsburgh, the Company&#8217;s financial obligations for the management of the patents under the license will cease on August 14, 2023, and at such time, will transition back to the University of Pittsburgh.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As part of this decision, we are intending to complete the pre-clinical cancer studies we are conducting in collaboration with University of Texas Southwestern using E4 endostatin peptide, which is derived from IBIO-100. After the pre-clinical studies are completed, we will re-assess whether to further pursue the oncology program and have further discussions with the University of Pittsburgh. This approach allows us to gather valuable data and insights that will inform our future decisions regarding the potential of E4 endostatin peptide as an oncology program. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">AI Drug Discovery Platform</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In September 2022, the Company purchased substantially all of the assets of RubrYc Therapeutics (for a complete description of the transaction please see Note 6 &#8211; Significant Transactions). The AI Drug Discovery platform technology is designed to be used to discover antibodies that bind to hard-to-target subdominant and conformational epitopes for further development within our existing portfolio or in partnership with outside entities. The RubrYc AI platform is built upon three key technologies. </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Epitope Targeting Engine:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> A patented machine-learning platform that combines computational biology and 3D-modeling to identify molecules that mimic hard-to-target binding sites on target proteins, specifically, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">subdominant and conformational epitopes.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The creation of these small mimics enables the engineering of therapeutic antibody candidates that can selectively bind immune and cancer cells better than &#8221;trial and error&#8221; antibody engineering and screening methods that are traditionally focused on dominant epitopes.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">RubrYcHu</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">TM</sup><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"> Library:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> An </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">AI-generated human antibody library free of significant sequence liabilities that provides a unique pool of antibodies to screen. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The combination of the Epitope Targeting Engine and screening with the </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">RubrYcHu</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Library has been shown to reduce the discovery time from ideation to </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">in vivo</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> proof-of-concept (&#8220;PoC&#8217;) by up to four months. This has the potential to enable more, and better, therapeutic candidates to reach the clinic faster. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">StableHu</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">TM</sup><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"> Library:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> An </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">AI-powered sequence optimization library used to improve antibody performance</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. Once an antibody has been advanced to the lead optimization stage, </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">StableHu</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> allows precise and rapid optimization of the antibody binding regions to rapidly move a candidate molecule into the IND-enabling stage.</span></td></tr></table><div style="margin-top:10pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On January 3, 2023, the United States Patent and Trademark Office issued U.S. Patent No. 11,545,238, entitled &#8220;Machine Learning Method for Protein Modelling to Design Engineered Peptides,&#8221; which, among other claims, covers a machine learning model for </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">engineering peptides, including antibody epitope therapeutics. &#160;Subject to any potential patent term extensions, the patent will expire on May 13, 2040.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393617836080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_BasisOfPresentationAbstract', window );"><strong>Basis of Presentation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">2.&#160;&#160;&#160;Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Interim Consolidated Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The accompanying unaudited condensed consolidated financial statements have been prepared from the books and records of the Company and include all normal and recurring adjustments which, in the opinion of management, are necessary for a fair presentation in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) for interim consolidated financial information and Rule 8-03 of Regulation S-X promulgated by the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;). Accordingly, these interim financial statements do not include all of the information and footnotes required for complete annual consolidated financial statements. Interim results are not necessarily indicative of the results that may be expected for the full year. Interim unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and the notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the prior year ended June&#160;30,&#160;2022, filed with the SEC on October 11, 2022 (the &#8220;Annual Report&#8221;), from which the accompanying condensed consolidated balance sheet dated June&#160;30,&#160;2022 was derived.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Principles of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated as part of the consolidation. Non-controlling interest in the consolidated financial statements represented the share of the loss in iBio CDMO, LLC (&#8220;iBio CDMO&#8221;) for an affiliate of Eastern Capital Limited (&#8220;Eastern Capital&#8221;) through November 1, 2021, the date the Company acquired the remaining interest in iBio CDMO. &#160;See Note 6 &#8211; Significant Transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Going Concern </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The history of significant losses, the negative cash flow from operations, the limited cash resources on hand and the dependence by the Company on its ability to obtain additional financing to fund its operations after the current cash resources are exhausted raise substantial doubt about the Company's ability to continue as a going concern. In an effort to remain a going concern and increase cash reserves, the Company completed a public equity offering, reduced its work force by approximately 60% (a reduction of approximately 69 positions) in November 2022, and ceased operations of its CDMO facility thereby reducing annual spend on expenses by approximately 50%. &#160;Additionally, in July 2022, the Company initiated the selling of the CDMO assets and facility, and since then has sold a substantial portion of the CDMO assets. (See Note 3 &#8211; Discontinued Operations for more information.) Additional potential options being considered&#160;to further increase liquidity include lowering the Company&#8217;s expenses further, focusing product development on a select number of product candidates, the sale of the CDMO, the sale or out-licensing of certain product candidates, additional equipment sales, raising money from capital markets, grant revenue or collaborations, or a combination thereof. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">The Company&#8217;s cash, cash equivalents, and restricted cash of </span><span style="font-size:10pt;">$9.8</span><span style="font-size:10pt;"> million</span> <span style="font-size:10pt;">as of March&#160;31,&#160;2023, is not anticipated to be sufficient to support operations through the first quarter of Fiscal 2024</span><b style="font-size:10pt;font-weight:bold;"> </b><span style="font-size:10pt;">unless the Company reduces its burn rate further, sells the CDMO facility for amounts above its term note payable, or increases its capital as described above. Regardless of whether the Company is able to reduce its burn rate or sell or out-license certain assets or parts of the business, the Company will need to raise additional capital in order to fully execute its near and long-term business plan. It is the Company&#8217;s goal to implement one or more potential options described above to allow the Company to have a cash runway for at least 12 months from the date of the filing of this Quarterly Report on Form 10-Q. However, there can be no assurance that the Company will be successful in implementing any of the options that it is evaluating.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Reverse Stock Split </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 22, 2022, the Company's Board of Directors approved the implementation of a reverse stock split (the &#8220;Reverse Split&#8221;) at a ratio of one-for-twenty five (1:<span style="-sec-ix-hidden:Hidden_C8lqvEAS3E6y7jI9fK0gaA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">25</span></span>) shares of the Company's common stock, par value $0.001 (the &#8220;Common Stock&#8221;). The Reverse Split was effective as of October 7, 2022. All share and per share amounts of the Common Stock presented have been retroactively adjusted to reflect the Reverse Split. See Note 16 &#8211; Stockholders&#8217; Equity for more information. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_BasisOfPresentationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the information pertaining to Basis of Presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_BasisOfPresentationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393708056144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Discontinued Operations</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">3.&#160;&#160;&#160;Discontinued Operations </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On November 3, 2022, the Company announced it is seeking to divest its contract development and manufacturing organization (iBio CDMO, LLC) in order to complete its transformation into an antibody discovery and development company. In conjunction with the divestment, the Company commenced a workforce reduction of approximately 60% of the current Company staffing levels (a reduction of approximately 69 positions). The Company substantially completed the employee reduction by January 2, 2023. Through the process of seeking to divest its contract development and manufacturing organization, the Company continues to market for sale the 130,000-square-foot cGMP facility location in Bryan, Texas (the &#8220;Facility&#8221;). Additionally, on February 10, 2021, the Company, entered into an Auction Sale Agreement (the &#8220;Auction Sale Agreement&#8221;) with Holland Industrial Group, together with Federal Equipment Company and Capital Recovery Group LLC (collectively, the &#8220;Auctioneers&#8221;) for the sale at public auction of equipment and other tangible personal property (the &#8220;Equipment&#8221;) located at the Facility. &#160;The Auctioneer guaranteed an amount of gross proceeds from the sale of the equipment of $2.1 million, which was paid to the Company on February 17, 2023. The auction, which commenced on March 24, 2023 and concluded on March 30, 2023, resulted in total proceeds of approximately $2.9 million. &#160;In accordance with the Auction Sale Agreement, the Company received 80% of the excess proceeds, after Holland Industrial Group&#8217;s $0.2 million fee, which approximated $0.5 million during the fourth quarter of Fiscal 2023 and is included in prepaid and other assets as of March 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company incurred pre-tax charges of approximately $1.9 million for the employee reduction which consisted of severance obligations, continuation of salaries and benefits over a 60-day transitional period during which impacted employees remain employed but were not expected to provide active service, and other customary employee benefit payments in connection with an employee reduction. &#160;At March&#160;31,&#160;2023, $0.1 million remains in accrued expenses as a current liability. &#160;The Company recorded a charge in discontinued operations for $34.6 million for the nine months ended March&#160;31,&#160;2023, of which approximately $17.6 million was the result of a fixed asset impairment charge (see Note 11 &#8211; Fixed Assets for more information), approximately $4.9 million to write down inventory to its net realizable value, approximately $7.5 million of personnel costs including severance and the balance related to operational costs related to winding down the CDMO business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As such, the results of iBio CDMO's operations are reported as discontinued operations for the three and nine months ended March&#160;31,&#160;2023. The Company has retrospectively recast its condensed consolidated statement of operations for the three and nine months ended March&#160;31,&#160;2022 presented. In addition, those assets and liabilities associated with the discontinued operations of the CDMO that the Company intends to sell have been classified as &#8220;held for sale&#8221; as of March 31, 2023. The Company has retrospectively recast its consolidated balance sheet as of June 30, 2022 for assets and liabilities held for sale. The Company has chosen not to segregate the cash flows of iBio CDMO in the consolidated statement of cash flows. &#160;Supplemental disclosures related to discontinued operations for the statements of cash flows have been provided below. Unless noted otherwise, discussion in the Notes to the Condensed Consolidated Financial Statements refers to the Company's continuing operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">The following table presents a reconciliation of the major financial lines constituting the results of operations for discontinued operations to the loss from discontinued operations presented separately in the condensed consolidated statements of operations (in thousands):</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:61.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:0.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:15.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:61.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues</p></td><td style="vertical-align:middle;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:15.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 205</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 143</p></td></tr><tr><td style="vertical-align:middle;width:61.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of goods sold</p></td><td style="vertical-align:middle;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 48</p></td></tr><tr><td style="vertical-align:middle;width:61.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross profit</p></td><td style="vertical-align:middle;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 180</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 95</p></td></tr><tr><td style="vertical-align:middle;width:61.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:middle;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Research and development</span></p></td><td style="vertical-align:middle;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 837</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 2,278</p></td></tr><tr><td style="vertical-align:middle;width:61.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    General and administrative</span></p></td><td style="vertical-align:middle;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 929</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 3,211</p></td></tr><tr><td style="vertical-align:middle;width:61.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Gain on sale of fixed assets</span></p></td><td style="vertical-align:middle;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (732)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:61.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total operating expenses</p></td><td style="vertical-align:middle;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,034</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 5,489</p></td></tr><tr><td style="vertical-align:middle;width:61.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other expenses:</p></td><td style="vertical-align:middle;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Interest expense - term note payable</span></p></td><td style="vertical-align:middle;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (158)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (249)</p></td></tr><tr><td style="vertical-align:middle;width:61.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Other</span></p></td><td style="vertical-align:middle;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1)</p></td></tr><tr><td style="vertical-align:middle;width:61.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total other expenses</p></td><td style="vertical-align:middle;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (161)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (250)</p></td></tr><tr><td style="vertical-align:middle;width:61.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from discontinued operations</p></td><td style="vertical-align:middle;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:15.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,015)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,644)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:14.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues</p></td><td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 391</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 438</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of goods sold</p></td><td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 52</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 201</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross profit</p></td><td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 339</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 237</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Research and development</span></p></td><td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 6,361</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 5,128</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    General and administrative</span></p></td><td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 6,165</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 8,659</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Fixed asset impairments</span></p></td><td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 17,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Gain on sale of fixed assets</span></p></td><td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (732)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Inventory reserve</span></p></td><td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 4,933</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total operating expenses</p></td><td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 34,327</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 13,787</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other income (expenses):</p></td><td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Interest expense - term note payable</span></p></td><td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (606)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (372)</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Interest expense - related party</span></p></td><td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (810)</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Forgiveness of note payable and accrued interest - SBA loan</span></p></td><td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 607</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Other</span></p></td><td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total other income (expenses)</p></td><td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (610)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (574)</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from discontinued operations</p></td><td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:14.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (34,598)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (14,124)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table presents net carrying values related to the major classes of assets that were classified as held for sale at March&#160;31,&#160;2023 and June&#160;30,&#160;2022 (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Inventory</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 3,900</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Operating lease right-of-use assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,944</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Property and equipment, net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 16,424</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:14.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 18,368</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 3,900</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Property and equipment, net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 35,289</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Finance lease right-of-use assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 74</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Operating lease right-of-use assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,951</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 37,314</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Finance lease obligation</span></p></td><td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 46</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Operating lease obligation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,944</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 10</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:14.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,944</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 56</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Finance lease obligation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;">30</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Operating lease obligation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,941</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total long-term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,971</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table presents the supplemental disclosures related to discontinued operations for the statements of cash flows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Depreciation expense</p></td><td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 273</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,532</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization of finance lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 587</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Purchase of fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,041</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 28,384</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fixed asset impairments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 17,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Inventory reserve</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 4,933</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sales proceeds of fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 2,100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Investing non-cash transactions:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Fixed assets included in accounts payable in prior period, paid in current period</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,542</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 791</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Unpaid fixed assets included in accounts payable</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 2,193</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Sales of fixed assets receivable</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 460</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393615239504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">4.&#160;&#160;&#160;Summary of Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s significant accounting policies are described in Note&#160;3 of the Notes&#160;to Consolidated Financial Statements in the Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include liquidity assertions, the valuation of intellectual property and fixed assets held for sale, the incremental borrowing rate utilized in the finance and operating lease calculations, legal and contractual contingencies and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Accounts Receivable</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Accounts receivable are reported at their outstanding unpaid principal balances net of allowances for uncollectible accounts. The Company provides for allowances for uncollectible receivables based on its estimate of uncollectible amounts considering age, collection history, and other factors considered appropriate. Management&#8217;s policy is to write off accounts receivable against the allowance for doubtful accounts when a balance is determined to be uncollectible. At March&#160;31,&#160;2023 and June&#160;30,&#160;2022, the Company determined that an allowance for doubtful accounts was not needed. &#160;The Company had accounts receivable of $426,000 at June&#160;30,&#160;2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company accounts for its revenue recognition under Accounting Standards Codification ("ASC") 606, <i style="font-style:italic;">Revenue from Contracts with Customers</i>. Under this standard, the Company recognizes revenue when a customer obtains control of promised services or goods in an amount that reflects the consideration to which the Company expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer contracts. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s contract revenue consists primarily of amounts earned under contracts with third-party customers and reimbursed expenses under such contracts. The Company analyzes its agreements to determine whether the elements can be separated and accounted for individually or as a single unit of accounting. Allocation of revenue to individual elements that qualify for separate accounting is based on the separate selling prices determined for each component, and total contract consideration is then allocated pro rata across the components of the arrangement. If separate selling prices are not available, the Company will use its best estimate of such selling prices, consistent with the overall pricing strategy and after consideration of relevant market factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In general, the Company applies the following steps when recognizing revenue from contracts with customers: (i)&#160;identify the contract, (ii)&#160;identify the performance obligations, (iii)&#160;determine the transaction price, (iv)&#160;allocate the transaction price to the performance obligations and (v)&#160;recognize revenue when a performance obligation is satisfied. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Recognition of revenue is driven by satisfaction of the performance obligations using one of two methods: revenue is either recognized over time or at a point in time. Contracts containing multiple performance obligations classify those performance obligations into separate units of accounting either as standalone or combined units of accounting. For those performance obligations treated as a standalone unit of accounting, revenue is generally recognized based on the method appropriate for each standalone unit. For those performance obligations treated as a combined unit of accounting, revenue is generally recognized as the performance obligations are satisfied, which generally occurs when control of the goods or services have been transferred to the customer or client or once the client or customer is able to direct the use of those goods and/or services as well as obtaining substantially all of its benefits. As such, revenue for a combined unit of accounting is generally recognized based on the method appropriate for the last delivered item but due to the specific nature of certain project and contract items, management may determine an alternative revenue recognition method as appropriate, such as a contract whereby one deliverable in the arrangement clearly comprises the overwhelming majority of the value of the overall combined unit of accounting. Under this circumstance, management may determine revenue recognition for the combined unit of accounting based on the revenue recognition guidance otherwise applicable to the predominant deliverable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">If a loss on a contract is anticipated, such loss is recognized in its entirety when the loss becomes evident. When the current estimates of the amount of consideration that is expected to be received in exchange for transferring promised goods or services to the customer indicates a loss will be incurred, a provision for the entire loss on the contract is made. At March&#160;31,&#160;2023 and June&#160;30,&#160;2022, the Company had no contract loss provisions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Fixed-Fee </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Under a fixed-fee contract, the Company charges a fixed agreed upon amount for a deliverable. Fixed-fee contracts have fixed deliverables upon completion of the project. Typically, the Company recognizes revenue for fixed-fee contracts after projects are completed, delivery is made and title transfers to the customer, and collection is reasonably assured.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Revenue can be recognized either 1) over time or 2) at a point in time. &#160;All revenue was recognized at a point in time for all periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the three months ended March 31, 2022, revenue was recognized from a license agreement and for the nine months ended March&#160;31,&#160;2022, revenue was recognized from a license agreement and the settlement of a revenue contract. &#160;No revenue was recognized for all other periods presented. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Time and Materials</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Under a time and materials contract, the Company charges customers an hourly rate plus reimbursement for other project specific costs. The Company recognizes revenue for time and material contracts based on the number of hours devoted to the project multiplied by the customer&#8217;s billing rate plus other project specific costs incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;">Contract Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">A contract asset is an entity&#8217;s right to payment for goods and services already transferred to a customer if that right to payment is conditional on something other than the passage of time. Generally, an entity will recognize a contract asset when it has fulfilled a contract obligation but must perform other obligations before being entitled to payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Contract assets consist primarily of the cost of project contract work performed by third parties for which the Company expects to recognize any related revenue at a later date, upon satisfaction of the contract obligations. At March&#160;31,&#160;2023 and June&#160;30,&#160;2022, contract assets were $0.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Contract Liabilities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">A contract liability is an entity&#8217;s obligation to transfer goods or services to a customer at the earlier of (1) when the customer prepays consideration or (2) the time that the customer&#8217;s consideration is due for goods and services the entity will yet provide. Generally, an entity will recognize a contract liability when it receives a prepayment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Contract liabilities consist primarily of consideration received, usually in the form of payment, on project work to be performed whereby the Company expects to recognize any related revenue at a later date, upon satisfaction of the contract obligations. At March&#160;31,&#160;2023, June&#160;30,&#160;2022, and June&#160;30,&#160;2021, contract liabilities w<span style="background:#ffffff;">ere </span><span style="background:#ffffff;">$0</span><span style="background:#ffffff;">, </span><span style="background:#ffffff;">$100,000</span><span style="background:#ffffff;"> and </span><span style="background:#ffffff;">$423,000</span><span style="background:#ffffff;">, r</span>espectively. The Company recognized revenue of $53,000 and $100,000 during the three and nine months ended March&#160;31,&#160;2023, respectively, that was included in the contract liabilities balance as of June 30, 2022 and was reported in discontinued operations. The Company recognized revenue of $52,000 and $178,000 during the three and nine months ended March&#160;31,&#160;2022, respectively, that was included in the contract liabilities balance as of June&#160;30,&#160;2021 and was reported in discontinued operations. The Company recognized revenue of $0 and $84,000 during the three </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">and nine months ended March&#160;31,&#160;2022 that was included in the contract liabilities balance as of June&#160;30,&#160;2021 and reported as part of continuing operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Leases</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company accounts for leases under the guidance of Accounting Standards Codification ("ASC") 842, <i style="font-style:italic;">Leases</i> ("ASC 842"). The standard established a right-of-use (&#8220;ROU&#8221;) model requiring a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months and classified as either an operating or finance lease. The adoption of ASC 842 had a significant effect on the Company&#8217;s balance sheet, resulting in an increase in non-current assets and both current and non-current liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In accordance with ASC 842, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether the Company obtains the right to substantially all the economic benefit from the use of the asset, and whether the Company has the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. For contracts with lease and non-lease components, <span style="-sec-ix-hidden:Hidden_eZ239xUFfk2aM5khbNy0yg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Company has elected not to allocate the contract consideration and to account for the lease and non-lease components as a single lease component</span></span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The lease liabilities and the corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. The implicit rate within the Company&#8217;s existing finance (capital) lease was determinable and, therefore, used at the adoption date of ASC 842 to determine the present value of lease payments under the finance lease. The implicit rate within the Company&#8217;s operating lease was not determinable and, therefore, the Company used the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Company&#8217;s incremental borrowing rate requires judgment. The Company will determine the incremental borrowing rate for each new lease using its estimated borrowing rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain the Company will exercise that option. An option to terminate is considered unless it is reasonably certain the Company will not exercise the option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Cash, Cash Equivalents and Restricted Cash</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company considers all highly-liquid instruments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents at March&#160;31,&#160;2023 and June&#160;30,&#160;2022 consisted of money market accounts. Restricted cash consisted of $3.0 million held within a Company account at Woodforest Bank for the term note payable (see Note 6 &#8211; Significant Transactions and Note 13 - Debt), collateral for a letter of credit obtained related to the San Diego operating lease (see Note 15 &#8211; Operating Lease Obligations) and collateral for a Company purchasing card. The Company&#8217;s bank required an additional 5% collateral held above the actual letters of credit issued for the San Diego lease and Company purchasing card. Restricted cash was approximately $3.3 million at &#160;March&#160;31,&#160;2023 and $6.0 million on June&#160;30,&#160;2022. The reduction to the restricted cash occurred because on October 11, 2022, the Company, as part of the First Amendment to the Credit Agreement with Woodforest National Bank (&#8220;Woodforest&#8221;), paid down $5.5 million of the term loan and subsequently Woodforest cancelled the irrevocable letter of credit issued by JPMorgan Chase Bank upon closing of the amendment. &#160;In accordance with the Fourth Amendment with Woodforest, the Company deposited $3 million in a restricted account at Woodforest. (For a complete description of the transaction please see Note 6 &#8211; Significant Transactions and Note 13 - Debt). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table summarizes the components of total cash, cash equivalents and restricted cash in the condensed consolidated statements of cash flows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:58.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:16.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:58.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Cash and equivalents</p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,562</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 22,676</p></td></tr><tr><td style="vertical-align:middle;width:58.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Collateral held for letter of credit - term note payable</p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 5,743</p></td></tr><tr><td style="vertical-align:middle;width:58.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Collateral held for letter of credit - San Diego lease</p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 198</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 198</p></td></tr><tr><td style="vertical-align:middle;width:58.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Collateral held for Company purchasing card</p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 55</p></td></tr><tr><td style="vertical-align:middle;width:58.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Total cash, cash equivalents and restricted cash</p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,815</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,672</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Investments in Debt Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:normal;">Debt investments were classified as available-for-sale. Changes in fair value are recorded in other comprehensive income (loss). Fair value was calculated based on publicly available market information. Discounts and/or premiums paid when the debt securities were acquired are amortized to interest income over the terms of the debt securities. See Note 8 &#8211; Investments in Debt Securities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Inventory</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'TimesNewRomanPSMT';">Inventory is stated at the lower of cost or net realizable value on the first-in, first-out basis. &#160;Inventory held is related to the CDMO business and has been classified as held for sale. &#160;See Note 3 &#8211; Discontinued Operations for information on inventory reserved reflected in the period ended March&#160;31,&#160;2023.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'TimesNewRomanPSMT';visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Research and Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company accounts for research and development costs in accordance with the Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 730-10, <i style="font-style:italic;">Research and Development</i> (&#8220;ASC 730-10&#8221;). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved. For the nine months ended March&#160;31,&#160;2023 and 2022, research and development expense was reported in both continuing and discontinued operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Right-of-Use Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">Assets held under the terms of finance (capital) leases are amortized on a straight-line basis over the terms of the leases or the economic lives of the assets. Obligations for future lease payments under finance (capital) leases are shown within liabilities and are analyzed between amounts falling due within and after one year. See Note 9 </span><i style="font-family:'TimesNewRomanPSMT';">&#8211;</i><span style="font-style:normal;"> Finance Lease ROU Assets and Note 14 </span><i style="font-family:'TimesNewRomanPSMT';">&#8211;</i><span style="font-style:normal;"> Finance Lease Obligations for additional information.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Fixed Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Fixed assets are stated at cost net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets ranging from <span style="-sec-ix-hidden:Hidden_Eet2cSErQUWYG2NYDDLIPA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> to 39 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company monitors fixed assets for impairment indicators throughout the year. &#160;When necessary, charges for impairments of long-lived assets are recorded for the amount by which the fair value is less than the carrying value of these assets. &#160;Changes in the Company&#8217;s business strategy or adverse changes in market conditions could impact impairment analyses and require the recognition of an impairment charge. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">See Note 11 &#8211; Fixed Assets for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Intangible Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Identifiable intangible assets are comprised of definite life intangible assets and indefinite life intangible assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company accounts for definite life intangible assets at either their historical cost or allocated purchase price at asset acquisition and records amortization utilizing the straight-line method based upon their estimated useful lives. Intellectual property is amortized over <span style="-sec-ix-hidden:Hidden_5A4l74BAAkGpy-k8y3HFLw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">20&#160;years</span></span>. The Company reviews the carrying value of its definite life intangible assets for impairment whenever events or changes in business circumstances indicate the carrying amount of such assets may not be fully recoverable. &#160;The carrying value is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. An impairment loss is measured as the amount by which the carrying amount exceeds it fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For indefinite life intangible assets, the Company performs an impairment test annually and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. &#160;The Company determines the fair value of the asset quarterly or when triggering events are present, based on discounted cash flows and records an impairment loss if book value exceeds fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Evaluating for impairment requires judgment, including the estimation of future cash flows, future growth rates and profitability and the expected life over which cash flows will occur. Changes in the Company&#8217;s business strategy or adverse changes in market conditions could impact impairment analyses and require the recognition of an impairment charge. Although management bases its estimates on </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">See Note 12 &#8211; Intangible Assets for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Share-based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company recognizes the cost of all share-based payment transactions at fair value. Compensation cost, measured by the fair value of the equity instruments issued, adjusted for estimated forfeitures, is recognized in the financial statements as the respective awards are earned over the performance or service period. The Company uses historical data to estimate forfeiture rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The impact that share-based payment awards will have on the Company&#8217;s results of operations is a function of the number of shares awarded, the trading price of the Company&#8217;s stock at the date of grant or modification, the vesting schedule and forfeitures. Furthermore, the application of the Black-Scholes option pricing model employs weighted-average assumptions for expected volatility of the Company&#8217;s stock, expected term until exercise of the options, the risk-free interest rate, and dividends, if any, to determine fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Expected volatility is based on historical volatility of the Common Stock; the expected term until exercise represents the weighted-average period of time that options granted are expected to be outstanding giving consideration to vesting schedules and the Company&#8217;s historical exercise patterns; and the risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. The Company has not paid any dividends since its inception and does not anticipate paying any dividends for the foreseeable future, so the dividend yield is assumed to be zero. In addition, the Company estimates forfeitures at each reporting period, rather than electing to record the impact of such forfeitures as they occur. See Note 18 <span style="font-family:'TimesNewRomanPSMT';">&#8211;</span> Share-Based Compensation for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Concentrations of Credit Risk</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cash</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company maintains principally all cash balances in two financial institutions which, at times, may exceed the insured amounts. The exposure to the Company is solely dependent upon daily balances and the strength of the financial institutions. The Company has not incurred any losses on these accounts. At March&#160;31,&#160;2023 and June&#160;30,&#160;2022, amounts in excess of insured limits were approximately $6,300,000 and $18,200,000, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Revenue</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the three months ended March&#160;31,&#160;2023, the Company reported no revenue from continuing operations and generated 100% of its revenue reported in discontinued operations from two customers. During the three months ended March&#160;31,&#160;2022, the Company reported $1.8 million of license revenue from continuing operations and generated $144,000 of revenue reported in discontinued operations from two customers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the nine months ended March&#160;31,&#160;2023, the Company reported no revenue from continuing operations and generated 100% of its revenue reported in discontinued operations from two customers. During the nine months ended March&#160;31,&#160;2022, the Company reported revenue from continuing operations related to a license agreement and a settlement of a revenue contract. &#160;The Company also generated $438,000 of revenue reported in discontinued operations from six customers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Recently Issued Accounting Pronouncements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In June 2016, the FASB issued ASU 2016-13, <i style="font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i> (&#8220;ASU 2016-13&#8221;), which requires an entity to assess impairment of its financial instruments based on its estimate of expected credit losses. Since the issuance of ASU 2016-13, the FASB released several amendments to improve and clarify the implementation guidance. In November 2019, the FASB issued ASU 2019-10, <i style="font-style:italic;">Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates</i>, which amended the effective date of the various topics. As the Company is a smaller reporting company, the provisions of ASU 2016-13 and the related amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022 (quarter ending September 30, 2023, for the Company). Entities are required to apply these changes through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The Company does not expect the adoption of ASU 2016-13 to have a significant impact on the Company&#8217;s consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying condensed consolidated financial statements. Most of the newer standards issued represent </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">technical corrections to the accounting literature or application to specific industries which have no effect on the Company&#8217;s condensed consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393612600368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurement<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Financial Instruments and Fair Value Measurement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Financial Instruments and Fair Value Measurement</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">5.&#160;&#160;&#160;Financial Instruments and Fair Value Measurement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The carrying values of cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and term note payable in the Company&#8217;s condensed consolidated balance sheets approximated their fair values as of March&#160;31,&#160;2023 and June&#160;30,&#160;2022 due to their short-term nature. The carrying value of the convertible promissory note receivable, the term note payable and finance lease obligation approximated to fair value as of March&#160;31,&#160;2023 and June&#160;30,&#160;2022 as the interest rates related to the financial instruments approximated to market value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company accounts for its investments in debt securities at fair value. The following provides a description of the three levels of inputs that may be used to measure fair value under the standard, the types of investments that fall under each category, and the valuation methodologies used to measure these investments at fair value. </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Level 1</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8211; Inputs are based upon unadjusted quoted prices for identical instruments in active markets. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Level 2</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8211; Inputs to the valuation include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in inactive markets, inputs other than quoted prices that are observable for the asset or liability, and inputs that are derived principally from or corroborated by observable market data by correlation or other means. If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability. &#160;All debt securities were valued using Level 2 inputs.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Level 3</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8211; Inputs to the valuation methodology are unobservable and significant to the fair value measurement.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company&#8217;s fixed assets and amortizable intangible assets are measured at fair value on a nonrecurring basis; that is, these assets are not measured at fair value on an ongoing basis, but are subject to fair value adjustments in certain circumstances, such as when there is evidence of&#160;impairment. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company initially marketed the CDMO business and during the second quarter of Fiscal 2023, changed its strategy to selling the stand-alone CDMO assets. &#160;These assets were assessed for impairment and the analysis resulted in the expected future cash flows from the sale of the property and equipment falling below its current carrying value. The Company utilized a market approach, using independent third-party appraisals, including comparable assets, in addition to bids received from prospective buyers, to estimate the fair value of the property and equipment. As a result, the carrying value of the building and equipment was reduced to their estimated fair values of $16,350,000 and $2,100,000, respectively. &#160;In the second quarter of Fiscal 2023, impairment charges were recorded in discontinued operations under general and administrative expense of $6,300,000 and $11,300,000 for the building and machinery and equipment, respectively. &#160;The machinery and equipment were sold during the third quarter of Fiscal 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table shows the fair value of the Company's fixed assets included in Current Assets Held For Sale measured at fair value on a non-recurring basis as of March&#160;31,&#160;2023 (amounts in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:26.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:12.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:12.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:14.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:6.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">March 31, 2023</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Fair Value Hierarchy</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Quoted Prices in Active Markets for Identical Assets (Level 1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Significant Other Observable Inputs (Level 2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Significant Unobservable Inputs (Level 3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Total Fair Value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Total Impairments</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Building in Bryan, Texas</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 16,364</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 16,364</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 6,300</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the second quarter of Fiscal 2023, the Company re-evaluated its business strategy and reviewed its product portfolio. After such review, the Company identified intellectual property, patent and licenses that would no longer be utilized and therefore were fully impaired (Level 3). &#160;See Note 12 &#8211; Intangible Assets for additional information.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393611609696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Transactions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SignificantTransactionsAbstract', window );"><strong>Significant Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SignificantTransactionsTextBlock', window );">Significant Transactions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">6.   Significant Transactions </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Affiliates of Eastern Capital Limited</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 1, 2021, the Company and its subsidiary, iBio CDMO (&#8220;iBio CDMO&#8221;, and collectively with the Company, the &#8220;Purchaser&#8221;) entered into a series of agreements (the &#8220;Transaction&#8221;) with College Station Investors LLC (&#8220;College Station&#8221;), and Bryan Capital Investors LLC (&#8220;Bryan Capital&#8221; and, collectively with College Station, &#8220;Seller&#8221;), each affiliates of Eastern Capital Limited (&#8220;Eastern,&#8221; a former significant stockholder of the Company) described in more detail below whereby in exchange for a certain cash payment and a warrant the Company:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acquired both the Facility where iBio CDMO at that time and currently conducts business and also the rights as the tenant in the Facility&#8217;s ground lease;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acquired all of the equity owned by one of the affiliates of Eastern in the Company and iBio CDMO; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(iii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">otherwise terminated all agreements between the Company and the affiliates of Eastern.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Facility is a life sciences building located on land owned by the Board of Regents of the Texas A&amp;M University System (&#8220;Texas A&amp;M&#8221;) and is designed and equipped for the manufacture of plant-made biopharmaceuticals. iBio CDMO had held a sublease for the Facility through 2050, subject to extension until 2060 (the &#8220;Sublease&#8221;) until the purchase of the Facility described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The Purchase and Sale Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 1, 2021, the Purchaser entered into a Purchase and Sale Agreement (the &#8220;Purchase and Sale Agreement&#8221;) with the Seller pursuant to which: (i) the Seller sold to Purchaser all of its rights, title and interest as the tenant in the Ground Lease Agreement (the &#8220;Ground Lease Agreement&#8221;) that it entered into with Texas A&amp;M (the &#8220;Landlord&#8217;&#8217;) related to the property at which the Facility is located together with all improvements pertaining thereto (the &#8220;Property&#8221;), which previously had been the subject of the Sublease; (ii) the Seller sold to Purchaser all of its rights, title and interest to any tangible personal property owned by Seller and located on the Property including the Facility; (iii) the Seller sold to Purchaser all of its rights, title and interest to all licensed, permits and authorization for use of the Property; and (iv) College Station and iBio CDMO terminated the Sublease. The total purchase price for the Property, the termination of the Sublease and other agreements among the parties, and the equity described below is $28,750,000, which was paid $28,000,000 in cash and by the issuance to Seller of warrants (the &#8220;Warrant&#8221;) described below. As part of the transaction, iBio CDMO became the tenant under the Ground Lease Agreement for the Property until 2060 upon exercise of available extensions. The base rent payable under the Ground Lease Agreement, which was $151,450 for the current year, is 6.5% of the Fair Market Value (as defined in the Ground Lease Agreement) of the Property. The Ground Lease Agreement includes various covenants, indemnities, defaults, termination rights, and other provisions customary for lease transactions of this nature.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As discussed above, iBio CDMO is being accounted for as a discontinued operation. &#160;As such, the assets acquired and/or leased are now classified as assets held for sale on the March&#160;31,&#160;2023 and June&#160;30,&#160;2022 condensed consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The Equity Purchase Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company also entered into an Equity Purchase Agreement with Bryan Capital on November 1, 2021 (the &#8220;Equity Purchase Agreement&#8221;) pursuant to which the Company acquired for $50,000 cash, plus the Warrant, the one (1) share of iBio CMO Preferred Tracking Stock and the 0.01% interest in iBio CDMO owned by Bryan Capital. As a result, iBio CDMO is now a wholly-owned subsidiary of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The Credit Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the Purchase and Sale Agreement, iBio CDMO entered into a Credit Agreement, dated November 1, 2021, with Woodforest pursuant to which Woodforest provided iBio CDMO a $22,375,000 secured term loan to purchase the Facility, which Term Loan is evidenced by a term note. The term loan was advanced in full on the closing date. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">See Note 13 &#8211; Debt for further information of the Term Loan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The Warrant</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As part of the consideration for the purchase and sale of the rights set forth above, the Company issued to Bryan Capital a Warrant to purchase 51,583 shares of the Common Stock at an exercise price of $33.25 per share. The Warrant expires October 10, 2026, is exercisable immediately, provides for a cashless exercise at any time and automatic cashless exercise on the expiration date if on such date the exercise price of the Warrant exceeds its fair market value as determined in accordance with the terms of the Warrant and adjustments in the case of stock dividends and stock splits. Of the shares issued under the Warrant, 11,583, which were originally valued at $217,255, reflected the final payment of rent due under the Sublease. The Warrant, as shown on the condensed consolidated statements of equity, was recorded in additional paid-in capital with the corresponding activity included in the basis of the purchase price allocation of the Property acquired. &#160;See Note 16 &#8211; Stockholders&#8217; Equity for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">RubrYc</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On August 23, 2021, the Company entered into a series of agreements with RubrYc Therapeutics, Inc. (&#8220;RubrYc&#8221;) described in more detail below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Collaboration and License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company entered into a collaboration and licensing agreement (the &#8220;RTX-003 License Agreement&#8221;) with RubrYc to further develop RubrYc&#8217;s immune-oncology antibodies in its RTX-003 campaign. &#160;Under the terms of the agreement, the Company is solely responsible for worldwide research and development activities for development of the RTX-003 antibodies for use in pharmaceutical products in all fields<span style="color:#0000ff;">. &#160;</span>RubrYc was also entitled to receive royalties in the mid-single digits on net sales of RTX-003 antibodies, subject to adjustment under certain circumstances. The RTX-003 License Agreement was terminated when the Company acquired substantially all of the assets of RubrYc in September 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Collaboration, Option and License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company entered into an agreement with RubrYc (the &#8220;Collaboration, Option and License Agreement&#8221;) to collaborate for up to five years to discover and develop novel antibody therapeutics using RubrYc&#8217;s artificial intelligence discovery platform. The Company agreed to pay RubrYc for each Selected Compound as it achieves various milestones in addition to royalties if the Selected Compounds are commercialized. &#160;RubrYc was also entitled to receive tiered royalties ranging from low- to mid-single digits on net sales of Collaboration Products, subject to adjustment under certain circumstances. Royalties are payable on a country-by-country and collaboration product-by-collaboration product basis until the latest to occur of: (i) the last-to-expire of specified patent rights in such country; (ii) expiration of marketing or regulatory exclusivity in such country; or (iii) <span style="-sec-ix-hidden:Hidden_oSXmWjkN2kiwoY8AqAXFYw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ten</span></span> (10) years after the first commercial sale of a product in such country, provided that no biosimilar product has been approved in such country. &#160;With the exception of any obligations that survive the termination, the Collaboration, Option and License Agreement was terminated when the Company acquired substantially all of the assets of RubrYc in September 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 4.5pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock Purchase Agreement </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;padding-bottom:10pt;text-align:justify;margin:0pt;">In connection with the entry into the Collaboration, Option and License Agreement and RTX-003 License Agreement, the Company also entered into a Stock Purchase Agreement (&#8220;Stock Purchase Agreement&#8221;) with RubrYc whereby the Company purchased a total of 2,864,345 shares of RubrYc&#8217;s Series A-2 preferred stock (&#8220;Series A-2 Preferred&#8221;) for $7,500,000. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">The Company accounted for the agreements as an asset purchase and allocated the purchase price of $7,500,000 as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:74.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:17.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:74.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Preferred stock</p></td><td style="vertical-align:middle;width:4.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:4.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:17.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,760,000</p></td></tr><tr><td style="vertical-align:middle;width:74.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Intangible assets</p></td><td style="vertical-align:middle;width:4.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,300,000</p></td></tr><tr><td style="vertical-align:middle;width:74.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid expenses</p></td><td style="vertical-align:middle;width:4.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:4.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,440,000</p></td></tr><tr><td style="vertical-align:middle;width:74.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:4.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:17.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,500,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Subsequently after the Company acquired substantially all of the assets of RubrYc in September 2022, RubrYc ceased its operations, and accordingly, the Company recorded an impairment of the investment in the amount of $1,760,000 during the year ended June 30, 2022. The amount was recorded in the condensed consolidated statement of operations and comprehensive loss under general and administrative expense. The Company also recorded an impairment of current and non-current prepaid expense of $288,000 and $864,000, respectively, during the year ended June 30, 2022. The amount was recorded in the condensed consolidated statement of operations and comprehensive loss under research and development expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 16, 2022, the Company entered an Asset Purchase Agreement with RubrYc pursuant to which it acquired substantially all of the assets of RubrYc. &#160;The Company issued 102,354 shares of the Common Stock to RubrYc with an approximate market value of $1,000,000 (the &#8220;Closing Shares&#8221;). Pursuant to the Asset Purchase Agreement, the shares are subject to an initial lockup period and the estimated fair value was calculated as $650,000. The Company also agreed to make potential additional payments of up to $5,000,000 upon the achievement of specified developmental milestones on or before the fifth anniversary of the closing date, payable in cash or shares of the Common Stock, at the Company&#8217;s option. In addition, the Company had advanced RubrYc $484,000 to support their operation costs during the negotiation period and incurred transaction costs totaling $208,000, which were also capitalized as part of the assets acquired. &#160;The assets acquired include the patented AI drug discovery platform, all rights with no future milestone payments or royalty obligations, to IBIO-101, in addition to CCR8, EGFRvIII, MUC16, CD3 and one additional immuno-oncology candidate plus a PD-1 agonist. The Purchase Agreement contained representations, warranties and covenants of RubrYc and the Company. &#160;The acquisition closed on September 19, 2022 after receipt of approval of the NYSE American.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">The Company accounted for the agreements as an asset purchase and allocated the purchase price of approximately $1,342,000 as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:74.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:17.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:74.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible assets</p></td><td style="vertical-align:middle;width:4.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:4.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:17.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,228,000</p></td></tr><tr><td style="vertical-align:middle;width:74.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fixed assets</p></td><td style="vertical-align:middle;width:4.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:4.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 114,000</p></td></tr><tr><td style="vertical-align:middle;width:74.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:4.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:17.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,342,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, the Company assumed three equipment leases that were accounted for as finance leases totaling approximately $814,000. &#160;See Note 9 &#8211; Finance Lease ROU Assets and Note 14 &#8211; Finance Lease Obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Former CEO Departure</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Effective December 1, 2022, the Company and Mr. Thomas F. Isett, the former Chief Executive Officer (the &#8220;CEO) and former member of the Board of Directors (the &#8220;Board&#8221;), agreed for Mr. Isett to resign as a member of the Board and relinquish his duties, rights and obligations as the CEO of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Separation Agreement and General Release </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">In connection with Mr. Isett&#8217;s resignation, the Company entered into a separation agreement and general release with Mr. Isett effective December 1, 2022 (the &#8220;Agreement&#8221;). &#160;Pursuant to the Agreement, Mr. Isett resigned as CEO of the Company effective December 1, 2022, and will remain an employee of the Company until December 31, 2022, on which date his employment with the Company will automatically terminate. &#160;Following Mr. Isett&#8217;s termination of employment with the Company, pursuant to the Agreement, Mr. Isett will receive the severance benefits set forth in his employment agreement, as previously disclosed by the Company, including (i) an amount equal to his current base salary in equal bi-monthly installments for <span style="-sec-ix-hidden:Hidden_H20oJhWZMkiyeILxAMoOWg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">twenty-four</span></span> (24) months; (ii) an amount equal to a pro rata share of his target bonus for the current fiscal year; (iii) an amount equal to the target bonus in equal bi-monthly installments for the <span style="-sec-ix-hidden:Hidden_3XETezoZoE2Gln_IFI6pTg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">twenty-four</span></span> (24) month severance period and (iv) provided that he elects continuation coverage for health insurance under the Consolidated Omnibus Budget Reconciliation Act of 1985 (&#8220;COBRA&#8221;), the Company will pay the full cost of this benefit for up to <span style="-sec-ix-hidden:Hidden_YRBOV4wB5E2sgYw7SZXbjg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">eighteen</span></span> (18) months, or if he has not obtained alternative employer-provided health coverage by the end of the <span style="-sec-ix-hidden:Hidden_eUgWy76apU6hIb4U9tpWXg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">eighteen</span></span> (18) month COBRA subsidy period, the Company will provide him with a lump-sum cash payment equal to six (6) times the monthly amount paid by the Company for the COBRA subsidy. &#160;The Agreement includes a general release of claims by Mr. Isett. &#160;The Company accrued approximately $2.13 million to general and administrative expenses in the second quarter of Fiscal 2023. As of March 31, 2023, approximately $1.1 million is recorded in accrued expenses and $791,000 in accrued expenses &#8211; noncurrent. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_SignificantTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant Transactions [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_SignificantTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_SignificantTransactionsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant Transactions [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_SignificantTransactionsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393617841040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Promissory Note Receivable<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Convertible Promissory Note Receivable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">Convertible Promissory Note Receivable</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">7.&#160;&#160;&#160;Convertible Promissory Note Receivable </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On October 1, 2020, the Company entered into a master services agreement with Safi Biosolutions, Inc. (&#8220;Safi&#8221;). In addition, the Company invested $1.5 million in Safi in the form of a convertible promissory note (the "Note"). The Note bears interest at the rate of 5% per annum and is convertible into shares of Safi&#8217;s common stock (as defined). Principal and accrued interest mature on October 1, 2023. &#160;For the three months ended March&#160;31,&#160;2023 and 2022, interest income amounted to $18,000. For the nine months ended March&#160;31,&#160;2023 and 2022, interest income amounted to $56,000. As of March&#160;31,&#160;2023 and June&#160;30,&#160;2022, the Note balance and accrued interest totaled $1,687,000 and $1,631,000, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company is currently renegotiating the terms of the Note with Safi, which are expected to be finalized in the fourth quarter of Fiscal 2023. &#160;Proceeds expected to be received in the next twelve months are approximately $912,000 and accordingly, $775,000 has been classified to long term.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -URI https://asc.fasb.org/subtopic&amp;trid=2196772<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393617986672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Debt Securities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments in Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments in Debt Securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">8.&#160;&#160;&#160;Investments in Debt Securities </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company did not hold any investments in debt securities at March 31, 2023. The components of investments in debt securities are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:58.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:16.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:58.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Adjusted cost</p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:16.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,029</p></td></tr><tr><td style="vertical-align:middle;width:58.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Gross unrealized losses</p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (184)</p></td></tr><tr><td style="vertical-align:middle;width:58.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Fair value</p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:16.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,845</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The fair value of available-for-sale debt securities, by contractual maturity, was as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:59.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:15.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Fiscal period ending:</b></p></td><td style="vertical-align:middle;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:59.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2023</p></td><td style="vertical-align:middle;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:15.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">8,054</p></td></tr><tr><td style="vertical-align:middle;width:59.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2024</p></td><td style="vertical-align:middle;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,791</p></td></tr><tr><td style="vertical-align:middle;width:59.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:15.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10,845</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Amortization of premiums paid on the debt securities amounted to $7,000 and $74,000 for the three months ended March&#160;31,&#160;2023 and 2022, respectively, and $67,000 and $269,000 for the nine months ended March 31, 2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Realized gains on available-for-sale debt securities are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Proceeds from sale of debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,943</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Cost of debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,036</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Realized loss on sale of debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (93)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Proceeds from sale of debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,739</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Cost of debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,837</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Realized loss on sale of debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (98)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393617811504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Lease ROU Assets<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract', window );"><strong>Finance Lease ROU [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock', window );">Finance Lease ROU Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">9.&#160;&#160;&#160;Finance Lease ROU Assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As discussed above, the Company assumed three equipment leases as part of the RubrYc asset acquisition. &#160;In addition, the Company leased a mobile office trailer which is classified as part of assets held for sale. &#160;The lease was terminated in December 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">See Note 14 &#8211; Finance Lease Obligations for more details of the terms of the leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes by category the gross carrying value and accumulated amortization of finance lease ROU (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ROU - Equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 814</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (136)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net finance lease ROU</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 678</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Amortization of finance lease ROU assets was approximately $68,000 and $0 for the three months ended March&#160;31,&#160;2023 and 2022, respectively, and $136,000 and $0 for the nine months ended March&#160;31,&#160;2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee's right to use underlying asset under finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393617826592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Lease ROU Assets<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Operating Lease ROU Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock', window );">Operating Lease ROU Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">10.&#160;&#160;&#160;Operating Lease ROU Assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">San Diego, California</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 10, 2021, the Company entered into a lease for approximately 11,383 square feet of space in San Diego, California. &#160;Based on the terms of the lease payments, the Company recorded an operating lease ROU asset of $3,603,000. &#160;The net carrying amount of this ROU operating lease asset was <span style="-sec-ix-hidden:Hidden_iQoKre6X4UGSKRq8g3fedQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$2,798,000</span></span> and $3,068,000 at March&#160;31,&#160;2023 and June&#160;30,&#160;2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Bryan, Texas</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On November 1, 2021, as discussed above, iBio CDMO acquired the Facility and became the tenant under the ground lease for the Property upon which the Facility is located. Based on the terms of the lease payments, the Company recorded an operating lease ROU asset of $1,967,000. The net amount of this ROU operating lease asset is included in assets held for sale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> &#160; &#160;<span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">See Note 15 - Operating Lease Obligation for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393617897360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Fixed Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Fixed Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11.&#160;&#160;&#160;Fixed Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes by category the gross carrying value and accumulated depreciation of fixed assets (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Building and improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 695</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:61.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Machinery and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 3,461</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Office equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 403</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:61.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Construction in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,373</p></td></tr><tr><td style="vertical-align:bottom;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 4,593</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,373</p></td></tr><tr><td style="vertical-align:bottom;width:61.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (235)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 4,358</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,373</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Depreciation expense reported in continuing operations was approximately $120,000 and $235,000 for the three and nine months ended March&#160;31,&#160;2023, respectively, and $0 for both the three and nine months ended March&#160;31,&#160;2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Fixed assets held for sale at March&#160;31,&#160;2023 and June&#160;30,&#160;2022 in the amount of $16,424,000 and $35,289,000, respectively, are included in assets held for sale. &#160;The depreciation expense for the three months ended March&#160;31,&#160;2023 and 2022 and the nine months ended March&#160;31,&#160;2023 and 2022 is classified as part of loss from discontinued operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the third quarter of Fiscal 2023, the Company re-evaluated its business strategy and reviewed its product portfolio. After such review, the Company recorded an impairment charge of approximately $17.6 million for the three and nine months ended March&#160;31,&#160;2023, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">See Note 5 - Financial Instruments and Fair Value Measurement for more information.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393617981072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">12.&#160;&#160;&#160;Intangible Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has two categories of intangible assets&#160;&#8211; intellectual property and patents. Intellectual property consists of all technology, know-how, data, and protocols for producing targeted proteins in plants and related to any products and product formulations for pharmaceutical uses and for other applications. Intellectual property includes, but is not limited to, certain technology for the development and manufacture of novel vaccines and therapeutics for humans and certain veterinary applications acquired in December&#160;2003 from Fraunhofer USA&#160;Inc., acting through its Center for Molecular Biotechnology (&#8220;Fraunhofer&#8221;), pursuant to a Technology Transfer Agreement, as amended (the &#8220;TTA&#8221;). The Company designates such technology further developed and acquired from Fraunhofer as <i style="font-style:italic;">iBioLaunch</i><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> or <i style="font-style:italic;">LicKM</i><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> or <i style="font-style:italic;">FastPharming</i> Technology. The value on the Company&#8217;s books attributed to patents owned or controlled by the Company is based only on payments for services and fees related to the protection of the Company&#8217;s patent portfolio. The intellectual property also includes certain trademarks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On August 23, 2021, the Company entered into a series of agreements with RubrYc described in more detail above (see Note 6 &#8211; Significant Transactions) whereby in exchange for a $7.5 million investment in RubrYc, the Company acquired a worldwide exclusive license to certain antibodies that RubrYc develops under what it calls its RTX-003 campaign, which are promising immuno-oncology antibodies that bind to the CD25 protein without interfering with the IL-2 signaling pathway thereby potentially depleting T-regulatory (Tregs) cells while enhancing T effector (Teffs) cells and encouraging the immune system to attack cancer cells. The Company accounted for this license as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development efforts. &#160;In addition, the Company also received preferred shares and an option for future collaboration licenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 16, 2022, the Company entered into an Asset Purchase Agreement with RubrYc described in more detail above (see Note 6 &#8211; Significant Transactions) pursuant to which it acquired substantially all of the assets of RubrYc. &#160;The assets acquired include the patented AI drug discovery platform, all rights with no future milestone payments or royalty obligations, to IBIO-101, in addition to CCR8, EGFRvIII, MUC16, CD3, and one additional immuno-oncology candidate, plus a PD-1 agonist.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In January 2014, the Company entered into a license agreement with the University of Pittsburgh<i style="font-style:italic;"> </i>whereby the Company acquired exclusive worldwide rights to certain issued and pending patents covering specific candidate products for the treatment of fibrosis (the "Licensed Technology") which license agreement was amended in August 2016 and again in December 2020 and February 2022. The license agreement provides for payment by the Company of a license issue fee, annual license maintenance fees, reimbursement of prior patent costs incurred by the university, payment of a milestone payment upon regulatory approval for sale of a first product, and annual royalties on product sales. In addition, the Company has agreed to meet certain diligence milestones related to product development benchmarks. As part of its commitment to the diligence milestones, the Company successfully commenced production of a plant-made peptide comprising the Licensed Technology before March 31, 2014. The next milestone &#8211; filing an Investigational New Drug Application with the FDA or foreign equivalent covering the Licensed Technology ("IND") &#8211; initially was required to be met by December 1, 2015, and on November 2, 2020, was extended to be required to be met by December 31, 2021 and on February 8, 2022, was further extended to December 31, 2023. In addition, the amounts of the annual license maintenance fee and payment upon completion of various regulatory milestones were amended. On February 14, 2023, the Company provided notification to the University of Pittsburgh terminating the license agreement. Pursuant to the termination of the license agreement with the University of Pittsburgh, the Company&#8217;s financial obligations for the management of the patents under the license will cease on August 14, 2023, and at such time, will transition back to the University of Pittsburgh. As a result of the termination of the license agreement, the Company recorded a full impairment of the related intangible asset associated with IBIO-100 in the amount of $25,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">See Note 4 - Summary of Significant Accounting Policies for more information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table reflects changes in the carrying amount of intangible assets (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">June&#160;30,&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">March 31,</p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Additions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Impairments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2023</p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Intellectual property &#8211; gross carrying value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 3,100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,100)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 400</p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Patents and licenses &#8211; gross carrying value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 2,846</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,846)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 5,946</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,946)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 400</p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Intellectual property &#8211; accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,867)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (74)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 2,931</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10)</p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Patents and licenses &#8211; accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,403)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (47)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 2,450</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,270)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (121)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 5,381</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10)</p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Total definite lived intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 676</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (121)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (565)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 390</p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">License - indefinite lived</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 4,175</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 828</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 5,003</p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Total net intangible</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 4,851</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,228</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 5,393</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Amortization expense was approximately $5,000 and $122,000 for the three months ended March&#160;31,&#160;2023 and 2022, respectively. Amortization expense was approximately $121,000 and $333,000 for the nine months ended March&#160;31,&#160;2023 and 2022, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> <span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the second quarter of Fiscal 2023, the Company re-evaluated its business strategy and reviewed its product portfolio. After such review, the Company identified intellectual property, patent and licenses that will no longer be utilized and therefore were fully impaired. &#160;The Company recorded an impairment charge in general and administrative expenses of approximately $565,000 for the nine months ended March&#160;31,&#160;2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">See Note 4 - Summary of Significant Accounting Policies and Note 5 &#8211; Financial Instruments and Fair Value Measurement for more information.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393618042352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">13.&#160;&#160;&#160;Debt</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The Credit Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the Purchase and Sale Agreement, iBio CDMO entered into a Credit Agreement, dated November 1, 2021, with Woodforest pursuant to which Woodforest provided iBio CDMO a $22,375,000 secured term loan (the &#8220;Term Loan&#8221;) to purchase the Facility, which Term Loan is evidenced by a term note (the &#8220;Term Note&#8221;) (for a complete description of the transaction please see Note 6 &#8211; Significant Transactions). The Term Loan was advanced in full on the closing date. The Term Loan bears interest at a rate of 3.25%, with higher interest rates upon an event of default, which interest is payable monthly beginning November 5, 2021. Principal on the Term Loan was originally payable on November 1, 2023, subject to early termination upon events of default. The Term Loan provides that it may be prepaid by iBio CDMO at any time and provides for mandatory prepayment upon certain circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On October 11, 2022, iBio CDMO and Woodforest amended the Credit Agreement to: (i) include a payment of $5,500,000 of the outstanding principal balance owed under the Credit Agreement on the date of the amendment, (ii) include a payment of $5,100,000 of the outstanding principal balance owed under the Credit Agreement within two (2) business days upon our receipt of such amount owed to us by Fraunhofer as part of our legal settlement with them (the &#8220;Fraunhofer Settlement Funds&#8221;) (see Note 19 &#8211; Fraunhofer Settlement for more information), (iii) include principal payments of $250,000 per month in debt amortization for a six-month period commencing the date of the amendment through March 2023, (iv) include an amendment fee of $22,375 and all costs and expenses, (v) require delivery of a report detailing cash flow expenditures every two (2) weeks for the period prior to the delivery of the last report and a monthly 12-month forecast, (vi) reduce the liquidity covenant (the &#8220;Liquidity Covenant&#8221;) in the Guaranty (as defined in the Credit Agreement) from $10 million to $7.5 million with the ability to lower the liquidity covenant to $5.0 million upon the occurrence of a specific milestone in the Credit Agreement, and (vii) change the annual filing requirement solely for the fiscal year ended June 30, 2022, such that the filing is acceptable with or without a &#8220;going concern&#8221; designation. &#160;In addition, Woodforest cancelled the irrevocable letter of credit issued by JPMorgan Chase Bank upon closing of the amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In January 2023, the Company&#8217;s unrestricted cash decreased below the required $7,500,000, which created an event of default under the Credit Agreement and Guaranty as a result of not complying with the Liquidity Covenant. As a result, on February 9, 2023, iBio CDMO and Woodforest entered into a second amendment to the Credit Agreement (the &#8220;Second Amendment&#8221;), which amended, among other things, added a milestone that had to be met by a specified date, the failure of which would be an event of default. &#160;In addition, on February 9, 2023, the Company, as guarantor, entered into a second amendment to the Guaranty, which amended, among other things, allowed the Company to account for the Fraunhofer Settlement Funds in determining whether the Company is in compliance with the Liquidity Covenant until a specified period dependent upon the occurrence of a specific milestone in the Credit Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On February 20, 2023, iBio CDMO entered into a third amendment to the Credit Agreement (the &#8220;Third Amendment&#8221;), which removed the added milestone specified in the Second Amendment, the failure of which would be an event of default. &#160;In addition, the Guaranty was amended to allow the Company until February 28, 2023, to account for the Fraunhofer Settlement Funds in determining whether the Company is in compliance with the Liquidity Covenant without being dependent upon a specified milestone. &#160;In addition, the Company agreed that each time it consummates an at-the-market issuance of Equity Interests (as defined within the Credit Agreement), no later than five (5) days following such issuance of Equity Interests, it will (i) pay to Woodforest in immediately available cash funds, without setoff or counterclaim of any kind, forty percent (40%) of the Net Proceeds (as defined within the Credit Agreement) received by the Company for such issuance of Equity Interests; provided, any such payment would cease upon payment obligations in full and (ii) provide Woodforest with a detailed accounting of each such issuance of Equity Interests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On March 24, 2023, iBio CDMO and Woodforest entered into a fourth amendment to the Credit Agreement (the &#8220;Fourth Amendment&#8221;), which within the Fourth Amendment Woodforest agreed to (i) reduce the percentage of any payment to Woodforest the Company is required to make from the proceeds of sales of its common stock under its at-the-market facility from 40% to 20%, (ii) reduce the percentage of any payment to Woodforest the Company is required to make from the proceeds of sales of its equipment from 40% to </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">20%, and (iii) allowed the Company to retain $2,000,000 million of the $5,100,000 million that the Company received from the Fraunhofer Settlement Funds, with the remaining $3,000,000 million being held in a Company account at Woodforest. &#160;In addition, the Company is obligated to (y) deliver to Woodforest an executed copy of a purchase agreement (the &#8220;Purchase Agreement&#8221;) for the sale of the Facility, no later than April 14, 2023, and (z) pay to Woodforest a fee in the amount of $75,000 on the earlier of the date of the closing of the Purchase Agreement, or the Maturity Date (as defined in the Credit Agreement). &#160;In addition, on March 24, 2023, the Company, as guarantor, entered into a fourth amendment to the Guaranty, which reduced the Liquidity Covenant from $7,500,000 to $1,000,000. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On May 10, 2023, iBio CDMO and Woodforest entered into a fifth amendment to the Credit Agreement (the &#8220;Fifth Amendment&#8221;), which within the Fifth Amendment Woodforest agreed to: (i) waive our obligation to deliver to Woodforest an executed copy of a Purchase Agreement for the sale of the Facility no later than April 14, 2023 and, (ii) release $500,000 of the $3.0 million being held in a Company account at Woodforest when the outstanding principal amount is reduced to $10.0 million and for each additional $2.5 million reduction of the outstanding principal amount, an additional $750,00 will be released from the Company account at Woodforest.&#160; In addition, starting on the effective date of the Fifth Amendment, the interest on the Term Loan increased to 5.25%, and the Term Loan shall further accrue interest, payable in kind and added to the balance of the outstanding principal amount at a fixed rate per annum equal to (a) 1.00%, if the Facility is sold on or before June 30, 2023, (b) 2.00% if the Facility is sold after June 2023, but on or before September 30, 2023, or (c) 3:00%, if the Facility is sold after September 30, 2023, or not sold prior to the maturity date.&#160; The Company also agreed to pay Woodforest a fee in the amount of (x) $75,000 if the Facility is sold on or before June 30, 2023, (y) $100,000 if the Facility is sold after June 2023, but on or before September 30, 2023, or (x) $125,000, if the Facility is sold after September 30, 2023, or not sold prior to the maturity date. As of the date of the filing of this Quarterly Report on Form 10-Q, the Company is not in negotiations on a Purchase Agreement with a potential buyer of the Facility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">At March&#160;31,&#160;2023, the balance of the Term Loan was $13,700,000 which consisted of the Term Note of $13,852,000, net of approximately $152,000 of deferred finance costs. &#160;At June&#160;30,&#160;2022, the balance was $22,161,000 which consisted of the Term Note of $22,375,000, net of approximately $214,000 of deferred finance costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Equipment Financing</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On October 12, 2022, the Company entered into an equipment financing master lease agreement and a lease supplement whereby $500,000 was borrowed over 36 months at an imputed interest rate of 10.62% and securitized by certain assets purchased for the San Diego research site. &#160;The financing is payable in monthly installments of $16,230 through October 2025. &#160;At March&#160;31,&#160;2023, the balance owed under the financing was $438,000. &#160;Interest incurred under the financing for the three and nine months ended March&#160;31,&#160;2023 totaled approximately $12,000 and $19,000, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Future minimum payments under the finance lease obligation are due as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fiscal period ending on March 31:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 156</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 195</p></td></tr><tr><td style="vertical-align:bottom;width:65.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 173</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 195</p></td></tr><tr><td style="vertical-align:bottom;width:65.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 110</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 114</p></td></tr><tr><td style="vertical-align:bottom;width:65.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum equipment financing payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 439</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 504</p></td></tr><tr><td style="vertical-align:bottom;width:65.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (156)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term portion of minimum equipment financing obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 283</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Note Payable &#8211; PPP Loan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On April 16, 2020, the Company received $600,000 related to its filing under the Paycheck Protection Program (&#8220;PPP&#8221;) and Coronavirus Aid, Relief, and Economic Security Act (the "CARES Act"). The Company elected to treat the Small Business Administration (&#8220;SBA&#8221;) loans as debt under ASC 470, <i style="font-style:italic;">Debt</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On July 21, 2021, iBio was granted forgiveness in repaying the loan. &#160;In accordance with ASC 405-20-40, <i style="font-style:italic;">Liabilities - Extinguishments of Liabilities &#8211; Derecognition</i>, the Company derecognized the liability and accrued interest of approximately $7,000 in the first quarter of Fiscal 2022. &#160;The forgiveness is included in loss from discontinued operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">See Note 3 &#8211; Discontinued Operations.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393617791552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Lease Obligation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Finance Lease Obligation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Finance Lease Obligation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">14.&#160;&#160;&#160;Finance Lease Obligations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sublease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As discussed above, until November 1, 2021, iBio CDMO leased the Facility as well as certain equipment from College Station under the Sublease. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Sublease was terminated on November 1, 2021, when iBio CDMO acquired the Facility and became the tenant under the ground lease for the property upon which the Facility is located. &#160;See Note 15 &#8211; Operating Lease Obligations for additional information related to the ground lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">General and administrative expenses related to College Station, including rent related to the increases in the Consumer Price Index (&#8220;CPI&#8221;) and real estate taxes, were approximately $0 and $250,000 for the three and nine months ended March 31, 2022, respectively. Interest expense related to College Station was approximately $0 and $810,000 for the three and nine months ended March 31, 2022, respectively. Such expenses were classified as part of loss from discontinued operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Equipment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As discussed above, the Company assumed three equipment leases that were accounted for as finance leases totaling $813,822 as part of the RubrYc Asset Purchase Agreement. &#160;The monthly rental for the three leases is approximately $14,000 per month and all three expire on August 1, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Mobile Office Trailer</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Commencing April 1, 2021, the Company leased a mobile office trailer that was located at the Facility in Bryan, Texas, at a monthly rental of $3,819 through March 31, 2024. &#160;In December 2022, the Company terminated the lease and returned the mobile office trailer. Expenses related to the lease prior to its termination are included in discontinued operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following tables present the components of lease expense and supplemental balance sheet information related to the finance lease obligation (in thousands).</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Amortization of ROU assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest on lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for amounts included in the measurement lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating cash flows from finance lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Financing cash flows from finance lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finance lease cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Amortization of ROU assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 156</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest on lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 189</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash paid for amounts included in the measurement lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating cash flows from finance lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Financing cash flows from finance lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 144</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finance lease ROU assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 678</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finance lease obligation - current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 265</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finance lease obligation - noncurrent portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_ALMi0aoiGEux0RbmMQwClg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> 421</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average remaining lease term - finance lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 2.34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_UQCuo_IgjkapUCQ_dOiKtg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;width:54.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average discount rate - finance lease obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 9.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Future minimum payments under the finance lease obligation are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fiscal period ending on March 31:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 265</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 54</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 319</p></td></tr><tr><td style="vertical-align:bottom;width:65.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 292</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 28</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 320</p></td></tr><tr><td style="vertical-align:bottom;width:65.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 130</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 133</p></td></tr><tr><td style="vertical-align:bottom;width:65.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 687</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 772</p></td></tr><tr><td style="vertical-align:bottom;width:65.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (265)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term portion of minimum lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 422</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393617869904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Lease Obligation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Operating Lease, Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Operating Lease Obligation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">15.&#160;&#160;&#160;Operating Lease Obligations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Texas Ground Lease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As discussed above, as part of the Transaction, iBio CDMO became the tenant under the Ground Lease Agreement for the Property until 2060 upon exercise of available extensions. The base rent payable under the Ground Lease Agreement, which was $151,450 for the prior year, is 6.5% of the Fair Market Value (as defined in the Ground Lease Agreement) of the Property. The Ground Lease Agreement includes various covenants, indemnities, defaults, termination rights, and other provisions customary for lease transactions of this nature.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">San Diego</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;">On September 10, 2021, the Company entered into a lease for approximately 11,383 square feet of space in San Diego, California. &#160;Terms of the lease include the following: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:14pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The length of term of the lease is </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">88 months</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> from the lease commencement date (as defined).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The lease commencement date was estimated to be on or around January 1, 2022.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The monthly rent for the first year of the lease is </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$51,223</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and increases approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per year.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The lease provides for a base rent abatement for months </span><span style="-sec-ix-hidden:Hidden_fzpg5j2sZU2ExYr4_xtclw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> through </span><span style="-sec-ix-hidden:Hidden_JKyPk5I8s0q_VC6f1fzo2Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five</span></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> in the first year of the lease.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The landlord is providing a tenant improvement allowance of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$81,860</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> to be used for improvements as specified in the lease.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company is responsible for other expenses such as electric, janitorial, etc.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company opened an irrevocable letter of credit in the amount of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$188,844</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> in favor of the landlord. &#160;The letter of credit expires on October 8, 2023 and renews annually as required.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As discussed above, the lease provides for scheduled increases in base rent and scheduled rent abatements. Rent expense is charged to operations using the straight-line method over the term of the lease which results in rent expense being charged to operations at inception of the lease in excess of required lease payments. This excess (formerly classified as deferred rent) is shown as a reduction of the operating lease ROU asset in the accompanying balance sheet. &#160;As the Company has already started making improvements to the facility, the rent expense will be recognized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following tables present the components of lease expense and supplemental balance sheet information related to the operating lease obligation (in thousands).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 141</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 141</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 141</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 141</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for amounts included in the measurement lease liability:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating cash flows from operating lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 141</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 141</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating cash flows from operating lease obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 103</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 422</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 313</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 422</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 313</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for amounts included in the measurement lease liability:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating cash flows from operating lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 422</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 313</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating cash flows from operating lease obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 154</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Future minimum payments under the operating lease obligation are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fiscal period ending on December&#160;31:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Imputed Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 377</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 249</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 626</p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 424</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 220</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 644</p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 476</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 188</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 664</p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 532</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 151</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 683</p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 593</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 111</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 704</p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 82</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,282</p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 3,602</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,001</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 4,603</p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (377)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term portion of minimum lease obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 3,225</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393617986672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity [Member]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">16.&#160;&#160;&#160;Stockholders&#8217; Equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s Board is authorized to issue, at any time, without further stockholder approval, up to 1 million shares of preferred stock. The Board has the authority to fix and determine the voting rights, rights of redemption and other rights and preferences of preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Series 2022 Convertible Preferred Stock (&#8220;Series 2022 Preferred&#8221;)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May 9, 2022, the Board of the Company created the Series 2022 Preferred, par value $0.001 per share, out of the Company&#8217;s 1 million authorized shares of preferred stock. &#160;Each share of Series 2022 Preferred was convertible at a ratio of one-for-one (1:1) shares of the Common Stock on a pre-split basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company issued 1,000 shares of Series 2022 Preferred and received proceeds of $270. &#160;Pursuant to the terms of the preferred stock, the Company&#8217;s Board converted the Preferred Stock to 40 shares of Common Stock on July 19, 2022, on a post-split basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">iBio CMO Preferred Tracking Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On February 23, 2017, the Company entered into an exchange agreement with Bryan Capital pursuant to which the Company acquired substantially all of the interest in iBio CDMO held by Bryan Capital and issued one share of a newly created Preferred Tracking Stock, in exchange for 29,990,000 units of limited liability company interests of iBio CDMO held by Bryan Capital at an original issue price of $13 million. After giving effect to the transaction, the Company owned 99.99% and Bryan Capital owned 0.01% of iBio CDMO.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On February 23, 2017, the Board of the Company created the Preferred Tracking Stock out of the Company&#8217;s 1 million authorized shares of preferred stock. The Preferred Tracking Stock accrued dividends at the rate of 2% per annum on the original issue price. Accrued dividends were cumulative and were payable if and when declared by the Board, upon an exchange of the shares of Preferred Tracking Stock and upon a liquidation, winding up or deemed liquidation (such as a merger) of the Company. No dividends were declared through October 31, 2021. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On November 1, 2021, iBio purchased the iBio CMO Preferred Tracking Stock held by Bryan Capital. No iBio CMO Preferred Tracking Stock remains outstanding. As a result, the iBio CDMO subsidiary and its intellectual property are now wholly owned by iBio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The number of authorized shares of the Common Stock is 275 million. In addition, the Company has reserved 1,280,000 shares of Common Stock for issuance pursuant to the grant of new awards under the Company&#8217;s 2020 Omnibus Incentive Plan (the &#8220;2020 Plan&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Reverse Stock Split</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On June 30, 2022, the Company held a special meeting of its stockholders at which the stockholders approved a proposal to affect an amendment to the Company's certificate of incorporation, as amended, to implement a reverse stock split at a ratio of <span style="-sec-ix-hidden:Hidden_L9F1YPW0H0e_OcCFkVLlag;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span>-for-twenty-five (1:25). On September 22, 2022, the Company's Board approved the implementation of the reverse stock split of the Common Stock. As a result of the reverse stock split, every twenty-five (25) shares of the Common Stock either issued and outstanding or held by the Company in its treasury immediately prior to the effective time was, automatically and without any action on the part of the respective holders thereof, combined and converted into one (1) share of the Common Stock. No fractional shares were issued in connection with the reverse stock split. Stockholders who otherwise were entitled to receive a fractional share in connection with the reverse stock split instead were eligible to receive a cash payment, which was not material in the aggregate, instead of shares. On October 7, 2022, the Company filed a Certificate of Amendment of its Certificate of Incorporation, as amended with the Secretary of State of Delaware effecting a <span style="-sec-ix-hidden:Hidden_QTQry_EgBE-Zf0eAMcyRBw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span>-for-twenty-five (1:25) reverse stock split of the shares of the Common Stock, either issued or outstanding, effective October 7, 2022. The Common Stock began trading on a reverse split adjusted basis when the market opened Monday, October 10, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Recent issuances of Common Stock include the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;">Cantor Fitzgerald Underwriting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On November 25, 2020, the Company entered into a Controlled Equity Offering SM Sales Agreement (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald &amp; Co. ("Cantor Fitzgerald") to sell shares of Common Stock, from time to time, through an &#8220;at the market offering&#8221; program having an aggregate offering price of up to $100,000,000 through which Cantor Fitzgerald would act as sales agent. &#160;Between July 25, 2022, and March 31, 2023, Cantor Fitzgerald sold as sales agent pursuant to the Sales Agreement 1,551,879 shares of Common Stock. The Company received net proceeds of approximately $2.9 million during the nine months ended March 31, 2023 and holds a subscription receivable for $260,000 at March 31, 2023 for proceeds received on April 4, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">RubrYc Transaction</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 19, 2022, the Company issued 102,354 shares valued at approximately $1,000,000 to RubrYc as part of the payment for purchasing the assets of RubrYc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Wainwright Underwriting</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On December 6, 2022, the Company entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with H.C. Wainwright &amp; Co., LLC (&#8220;Wainwright&#8221;). Pursuant to the Underwriting Agreement, the Company agreed to sell to Wainwright, in a firm commitment underwritten offering (the &#8220;Offering&#8221;) (i) 1,530,769 shares of the Company&#8217;s Common Stock, (ii) pre-funded warrants (the &#8220;Pre-Funded Warrants&#8221;) to purchase up to 1,834,616 shares of Common Stock, (iii) Series A Common Stock purchase warrants (the &#8220;Series A Warrants&#8221;) to purchase up to 3,365,385 shares of Common Stock and (iv) Series B Common Stock purchase warrants (the &#8220;Series B Warrants&#8221; and together with the Series A Warrants, the &#8220;Common Warrants&#8221;) to purchase up to 3,365,385 shares of Common Stock. &#160;The offering closed on December 9, 2022. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Wainwright acted as the sole book-running manager for the Offering. The Company paid Wainwright an underwriting discount equal to 7.0% of the gross proceeds of the offering, and reimbursed Wainwright for the legal fees and certain expenses of the underwriter. &#160;Pursuant to the Underwriting Agreement, the Company has granted Wainwright a 30-day option to purchase up to an additional 504,807 shares of Common Stock and/or Common Warrants to purchase up to an additional 1,009,614 shares of Common Stock at the public offering price, less the underwriting discounts and commissions, solely to cover over-allotments. Wainwright elected to purchase 504,807 Series A Warrants and 504,807 Series B Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company has also agreed to issue to Wainwright, as the representative of the underwriters, warrants (the &#8220;Representative&#8217;s Warrants&#8221;) to purchase a number of shares of Common Stock equal to 6.0% of the aggregate number of shares of Common Stock and Pre-Funded Warrants being offered in the offering. Wainwright received warrants to purchase up to 201,923 shares of Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company received net proceeds of approximately $2,864,000 after deducting underwriting discounts, commissions and other issuance costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Vesting of Restricted Stock Units &#8220;RSUs&#8221;</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On August 23, 2022, RSUs for 1,057 shares of Common Stock were vested. On December 1, 2022, RSUs for 4,120 shares of Common Stock were vested. &#160;In addition, RSUs for 27,740 of Common Stock vested during the third quarter of Fiscal 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Warrants</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Bryan Capital </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> <span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As discussed above, the Company issued to Bryan Capital a Warrant to purchase 51,583 shares of the Common Stock of the Company at an exercise price of $33.25 per share. The Warrant expires October 10, 2026, is exercisable immediately, provides for a cashless exercise at any time and automatic cashless exercise on the expiration date if on such date the exercise price of the Warrant exceeds its fair market value as determined in accordance with the terms of the Warrant and adjustments in the case of stock dividends and stock splits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Wainwright</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> <span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As discussed above, the Company issued various warrants with the following terms:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Pre-Funded Warrants &#8211; Immediately exercisable at an exercise price of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.001</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per share. &#160;All of the Pre-Funded Warrants were exercised in December 2022.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Class A Warrants &#8211; Immediately exercisable at an exercise price of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$1.04</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per share for a term of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five years</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Class B Warrants &#8211; Immediately exercisable at an exercise price of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$1.04</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per share for a term of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two years</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Representative Warrants &#8211; Immediately exercisable at an exercise price of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$1.30</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per share for a term of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five years</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the third quarter of Fiscal 2023, 341,300 Class A Warrants and 1,704,916 Class B Warrants were exercised. &#160;On April 3, 2023, an additional 76,300 Class B Warrants were exercised. &#160;The total proceeds from Class A and B Warrants exercised during the third quarter of Fiscal 2023 and on April 3, 2023 were $2,207,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393617946672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Common Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings (Loss) Per Common Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings (Loss) Per Common Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">17.&#160;&#160;&#160;Earnings (Loss) Per Common Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Basic earnings (loss) per common share is computed by dividing the net income (loss) allocated to common stockholders by the weighted-average number of shares of Common Stock outstanding during the period. For purposes of calculating diluted earnings (loss) per common share, the denominator includes both the weighted-average number of shares of Common Stock outstanding during the period and the number of common stock equivalents if the inclusion of such common stock equivalents is dilutive. Dilutive common stock equivalents potentially include stock options and warrants using the treasury stock method. The following table summarizes the components of the earnings (loss) per common share calculation (in thousands, except per share amounts):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to iBio, Inc. from continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,279)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,746)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (24,379)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19,125)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Preferred stock dividends &#8211; iBio CMO Preferred Tracking Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (88)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss available to iBio, Inc. stockholders from continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,279)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,746)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (24,379)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19,213)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss available to iBio, Inc. stockholders from discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,015)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,644)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (34,598)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (14,124)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss available to iBio, Inc. stockholders - total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,294)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (12,390)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (58,977)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (33,337)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average common shares outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 13,184</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 8,719</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 10,592</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 8,719</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Per share amount - continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_wjVHAja0hk-ujBowM-xKHQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.47)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_yQjZFWrye0SmP2jIiPGrBA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.77)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_-JF8WUqQSkmfxC0R_OaSQA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.30)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_PwsJbaSoOUORrCdM232mAA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.20)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Per share amount - discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_9HqUV2MAckqjZOnis6YfZg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.08)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_U0bOGUWDzkuEeJ29Nf_EjQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.65)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_TmWH34FMsECu90mrUdyfXg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3.27)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_kDRlUx8GmUabgAhq5k_vvQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.62)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Per share amount - total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_Zp0MkR-0tUq910UPmXzGpA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.55)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_acVcgEcpAUW-LaSF7a3TxQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.42)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_wBTFuchxW0eQbgh0co0GoQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5.57)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_tJo2ezbm1Eau_et1XorUuA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3.82)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In Fiscal year 2023 and Fiscal year 2022, the Company incurred net losses which cannot be diluted; therefore, basic and diluted loss per common share is the same. As of March&#160;31,&#160;2023 and 2022, shares issuable which could potentially dilute future earnings were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:76.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 457</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 625</p></td></tr><tr><td style="vertical-align:bottom;width:76.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 443</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 22</p></td></tr><tr><td style="vertical-align:bottom;width:76.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 5,948</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 52</p></td></tr><tr><td style="vertical-align:bottom;width:76.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Shares excluded from the calculation of diluted loss per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 6,848</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 699</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393617899792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Compensation [Member]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">18.</b>&#160;&#160;&#160;<b style="font-weight:bold;">Share-Based Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes the components of share-based compensation expense in the condensed consolidated statements of operations (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 101</p></td></tr><tr><td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 345</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,112</p></td></tr><tr><td style="vertical-align:bottom;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 385</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,213</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 96</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 132</p></td></tr><tr><td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 2,330</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 2,761</p></td></tr><tr><td style="vertical-align:bottom;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 2,426</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 2,893</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In addition, share-based compensation expense included in loss from discontinued operations totaled approximately $1,211,000 and $62,000 for the three months ended March&#160;31,&#160;2023 and 2022, respectively, and $1,519,000 and $305,000 for the nine months ended March&#160;31,&#160;2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Stock Options</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">iBio, Inc. 2020 Omnibus Equity Incentive Plan (the &#8220;2020 Plan&#8221;)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On December 9, 2020, the Company adopted the 2020 Plan for employees, officers, directors and external service providers. The total number of shares of Common Stock reserved under the 2020 Plan is 1,280,000 shares of Common Stock for issuance pursuant to the grant of new awards under the 2020 Plan. The 2020 Plan allows for the award of stock options, stock appreciation rights, restricted stock, restricted stock units, unrestricted stock, cash-based awards, and dividend equivalent rights. The value of all awards awarded under the 2020 Plan and all other cash compensation paid by the Company to any non-employee director in any calendar year may not exceed $500,000; provided, however, that such amount shall be $750,000 for the calendar year in which the applicable non-employee director is initially elected or appointed to the Board and $1,500,000 for any non-executive chair of our Board should one be appointed. Notwithstanding the foregoing, the independent members of the Board may make exceptions to such limits in extraordinary circumstances. The term of the 2020 Plan will expire on the tenth anniversary of the date the Plan is approved by the stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Vesting of service awards are determined by the Board and stated in the award agreements. In general, vesting occurs ratably on the anniversary of the grant date over the service period, generally <span style="-sec-ix-hidden:Hidden_nzLgsplRfUCEtBruJ2QfKQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> or five years, as determined at the time of grant. Vesting of performance awards occurs when the performance criteria is satisfied. The Company uses historical data to estimate forfeiture rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock options issued</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the first quarter of Fiscal year 2023, the Company granted stock option agreements to various employees to purchase 303,869 shares of the Common Stock at exercise prices between $6.75 and $9.50 per share. The options vest 25% after one year and then in equal quarterly installments over a 36-month period and expire on the <span style="-sec-ix-hidden:Hidden_6UlFUOUwakC1Lx6RTBBOdg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">tenth</span></span> anniversary of the grant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the first quarter of Fiscal year 2023, the Company granted a stock option agreement to a consultant to purchase 4,000 shares of the Common Stock at an exercise price of $6.75 per share. The options vest in equal monthly installments, over a period of twelve months, starting after the second month and expire on the <span style="-sec-ix-hidden:Hidden_PqrGwNIVNUKtOSk9GN3hkQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">tenth</span></span> anniversary of the grant date. &#160;During the third quarter of Fiscal year 2023, the Company terminated the consultant&#8217;s services. &#160;As a result, none of the 4,000 shares pursuant to the stock option agreement were exercised and as such, all 4,000 shares will be forfeited. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">No stock options were granted in the second or third quarter of Fiscal year 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company estimated the fair value of options granted using the Black-Scholes option pricing model with the following assumptions:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">3.21% - 3.61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">115.52 - 116.93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">RSUs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On August 29, 2022, the Company issued RSUs to acquire 6,954 shares of common stock to various employees at a market value of $7.06 per share. &#160;The RSUs vest over a four-year period. &#160;The grant date fair value of the RSUs totaled approximately $49,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On November 10, 2022, as previously disclosed in relation to the Employment Agreement with Mr. Isett, the Company&#8217;s former CEO, dated April 30, 2021, the Company granted Mr. Isett RSUs to acquire 200,000 shares of Common Stock, on a post-split basis.&#160; The RSUs vest over a three-year period commencing April 30, 2021 provided the vesting is subject to the following performance conditions: (i) submission to the U.S. Food and Drug Administration (FDA) of an Investigational New Drug (IND) application, or alternatively, if the Board approves not to file an IND, (ii) consummation of a disposition of iBio CDMO, LLC, or (iii) out-licensing, with full global rights, any of its investigational product candidates prior to the submission to the FDA an IND application.&#160; The grant-date fair value of the RSUs totaled approximately $296,000. The performance conditions were not met and the RSUs did not vest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On November 11, 2022, the Company granted Mr. Robert Lutz, the Company&#8217;s Chief Financial and Business Officer at the time, RSUs to acquire 100,057 shares of the Company&#8217;s Common Stock in exchange for Mr. Lutz&#8217;s agreement to continue employment with the Company through July 1, 2023. &#160;The RSUs vest the earlier of: (i) July 1, 2023, or (ii) the successful achievement of the Company&#8217;s 2023 objectives, as defined by the Board. The grant-date fair value of the RSUs totaled approximately $175,100. Mr. Lutz resigned from the Company and was no longer an employee of the Company effective February 10, 2023; accordingly, the RSUs did not vest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 11, 2022, the Company granted Dr. Martin Brenner, the Company&#8217;s Chief Scientific Officer, RSUs to acquire 95,348 shares of the Company&#8217;s Common Stock in exchange for Mr. Brenner&#8217;s agreement to continue employment with the Company through July 1, 2023. &#160;The RSUs vest the earlier of: (i) July 1, 2023, or (ii) the successful achievement of the Company&#8217;s 2023 objectives, as defined by the Board. The grant-date fair value of the RSUs totaled approximately $167,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On January 20, 2023, the Board of the Company appointed Dr. Brenner to the position of Interim Chief Executive Officer, effective immediately. Dr. Brenner was granted RSUs to acquire 130,000 shares of the Company&#8217;s Common Stock, which RSUs shall vest pro rata over a twelve-month period, such vesting to terminate if Dr. Brenner is no longer the Company&#8217;s Interim Chief Executive Officer. The grant-date fair value of the RSUs totaled approximately $91,000. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 31, 2023, the Compensation Committee (the &#8220;Committee&#8221;) of the Board of the Company approved a special equity award program pursuant to which it awarded to its employees an aggregate of 225,000 RSUs under the Company&#8217;s 2020 Omnibus Equity Incentive Plan, as amended (the &#8220;Plan&#8221;), which awards included a grant of 50,000 and 37,500 restricted stock units to each of Dr. Brenner, and Felipe Duran, the Company&#8217;s Interim, Chief Financial Officer, respectively, vesting quarterly over 12 months commencing April 1, 2023. The grant-date fair value of the RSUs totaled approximately $468,000.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393617986672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fraunhofer Settlement<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlementAbstract', window );"><strong>Fraunhofer Settlement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_GainLossRelatedToLitigationSettlementTextBlock', window );">Fraunhofer Settlement</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">19.&#160;&#160;&#160;Fraunhofer Settlement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May 4, 2021, the Company and Fraunhofer USA, Inc. (&#8220;FhUSA&#8221;) entered into a Confidential Settlement Agreement and Mutual Release (the &#8220;Settlement Agreement&#8221;) to settle all claims and counterclaims in the litigation captioned iBio, Inc. v. Fraunhofer USA, Inc. (Case No. 10256-VCF) in Delaware Chancery Court (the &#8220;Lawsuit&#8221;). The Settlement Agreement, among other things, resolves the Company&#8217;s claims to ownership of certain plant-based technology developed by FhUSA from 2003 through 2014, and sets forth the terms of a license of intellectual property. The Lawsuit was commenced against FhUSA by the Company in March 2015 in the Court of Chancery of the State of Delaware and is described in more detail in the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended December 31, 2020. The Settlement Agreement is not an admission of liability or fault of the parties. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The terms of the Settlement Agreement provide for cash payments to the Company of $28,000,000 as follows: (i) $16,000,000 to be paid no later than May 14, 2021 (which is expected to be paid 100% to cover legal fees and expenses); (ii) <span style="-sec-ix-hidden:Hidden_PJle0PEsI0uXVu8jrliU2w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span> payments of $5,100,000 payable by March 31, 2022 and 2023 and (iii) as additional consideration for a license agreement, <span style="-sec-ix-hidden:Hidden__ic71Y4ppUShPuWLdTGl2Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span> payments of $900,000 due on March 1, 2022 and 2023. The license provides for a nonexclusive, nontransferable, worldwide, fully paid-up license to all intellectual property rights in and to certain plant-based technology developed by FhUSA from 2003 through 2014 that were the subject of the Lawsuit. After payment of the fees and expenses of its attorneys and others retained by the Company, including the litigation funding company, the Company&#8217;s estimated aggregate net cash recovery as a result of the Settlement Agreement will be approximately $10,200,000. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of June 30, 2021, the Company held receivables related to the settlement in the amount of $10,200,000. This amount was recorded in the consolidated statement of operations and comprehensive loss as settlement income in Fiscal 2021. &#160;During the quarter ended March 31, 2022, the Company received the first payment of $5,100,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 17, 2023, the Company received a payment of $5,100,000 from Fraunhofer related to the Fraunhofer Settlement Funds and in accordance with the Fourth Amendment to the Credit Agreement with Woodforest, transferred $3,000,0000 to a Company account at Woodforest on March 24, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company would recognize the $1.8 million of license revenue when it determines the collection of the license fees was reasonably assured in accordance with ASC 606. On February 9, 2022, the Company received the first $900,000 payment under the license agreement. &#160;As such, the Company determined that the collection of the license fees was reasonably assured, and the Company recognized license revenue related to the license fees and recorded a receivable for the second payment in the third quarter of 2022. &#160;The second $900,000 payment was received on February 17, 2023.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_GainLossRelatedToLitigationSettlementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entire disclosure on gain (Loss) related to litigation settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_GainLossRelatedToLitigationSettlementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393617871488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">20.&#160;&#160;&#160;Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company recorded no income tax expense for the three months ended March&#160;31,&#160;2023 because the estimated annual effective tax rate was zero. As of March&#160;31,&#160;2023, the Company continues to provide a valuation allowance against its net deferred tax assets since the Company believes it is more likely than not that its deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393615218112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">21.&#160;&#160;Commitments and Contingencies </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">CRO Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On October 10, 2022, the Company entered into an agreement with a CRO for cell line development and master cell banking to produce iBio-101 in addition to process development and GMP manufacturing of iBio-101 drug substance and drug product to support GLP toxicology and Phase 1 clinical studies. &#160;The Company has incurred costs totaling approximately $422,000 through March 31, 2023. &#160;The Company is committed to additional costs totaling approximately $958,000 as of the date of the filing of this report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Inflation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Although the Company has not experienced any material adverse effects on our business due to increasing inflation, it has raised operating costs for many businesses and, in the future, could impact demand or pricing of manufacturing services, foreign exchange rates or employee wages. We are actively monitoring the effects these disruptions and increasing inflation could have on the Company&#8217;s operations. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393617981072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee 401(K) Plan<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Employee 401(K) Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee 401(K) Plan</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">22.&#160;&#160;&#160;Employee 401(K)&#160;Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Commencing January&#160;1, 2018, the Company established the iBio,&#160;Inc. 401(K)&#160;Plan (the &#8220;Plan&#8221;). Eligible employees of the Company may participate in the Plan, whereby they may elect to make elective deferral contributions pursuant to a salary deduction agreement and receive matching contributions upon meeting age and length-of-service requirements. The Company will make a 100% matching contribution that is not in excess of 5% of an eligible employee&#8217;s compensation. In addition, the Company may make qualified non-elective contributions at its discretion. For the three months ended March&#160;31,&#160;2023 and 2022, employer contributions made to the Plan totaled approximately $56,000 and $54,000, respectively. For the nine months ended March&#160;31,&#160;2023 and 2022, employer contributions made to the Plan totaled approximately $200,000 and $116,000, respectively. In addition, employer contributions included in loss from discontinued operations totaled approximately $17,000 and $41,000 for the three months ended March&#160;31,&#160;2023 and 2022, respectively, and approximately $129,000 and $110,000 for the nine months ended March&#160;31,&#160;2023 and 2022, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393617946672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">23.&#160;&#160;&#160;Subsequent Events </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On April 3, 2023, 76,300 Class B Warrants were exercised, which resulted in proceeds of $79,352. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Between April 3 and April 17, 2023, Cantor Fitzgerald sold as sales agent pursuant to the Sales Agreement 892,194 shares of Common Stock. The Company received net proceeds of approximately $1.1 million during April 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May 10, 2023, iBio CDMO and Woodforest entered into a fifth amendment to the Credit Agreement (the &#8220;Fifth Amendment&#8221;), which within the Fifth Amendment Woodforest agreed to: (i) waive the obligation to deliver to Woodforest an executed copy of a Purchase Agreement for the sale of the 130,000 square foot cGMP manufacturing facility in Bryan, Texas, no later than April 14, 2023 and, (ii) release $500,000 of the $3.0 million being held in a Company account at Woodforest when the outstanding principal amount is reduced to $10.0 million and for each additional $2.5 million reduction of the outstanding principal amount, an additional $750,000 will be released from the Company account at Woodforest. &#160;In addition, starting on the effective date of the Fifth Amendment, the interest on the Term Loan increased to 5.25%, and the Term Loan shall further accrue interest, payable in kind and added to the balance of the outstanding principal amount at a fixed rate per annum equal to (a) 1.00%, if the Facility is sold on or before June 30, 2023, (b) 2.00% if the Facility is sold after June 2023, but on or before September 30, 2023, or (c) 3:00%, if the Facility is sold after September 30, 2023, or not sold prior to the maturity date. &#160;The Company also agreed to pay Woodforest a fee in the amount of (x) $75,000 if the Facility is sold on or before June 30, 2023, (y) $100,000 if the Facility is sold after June 2023, but on or before September 30, 2023, or (x) $125,000, if the Facility is sold after September 30, 2023, or not sold prior to the maturity date. &#160;After marketing the Facility with a real estate firm for approximately six months, in May 2023, the Company entered into a new agreement with a new global commercial real estate firm to remarket the Facility. &#160;As of the date of the filing of this Quarterly Report on Form 10-Q, the Company is not in negotiations on a Purchase Agreement with a potential buyer of the Facility.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393612622608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include liquidity assertions, the valuation of intellectual property and fixed assets held for sale, the incremental borrowing rate utilized in the finance and operating lease calculations, legal and contractual contingencies and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Accounts Receivable</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Accounts receivable are reported at their outstanding unpaid principal balances net of allowances for uncollectible accounts. The Company provides for allowances for uncollectible receivables based on its estimate of uncollectible amounts considering age, collection history, and other factors considered appropriate. Management&#8217;s policy is to write off accounts receivable against the allowance for doubtful accounts when a balance is determined to be uncollectible. At March&#160;31,&#160;2023 and June&#160;30,&#160;2022, the Company determined that an allowance for doubtful accounts was not needed. &#160;The Company had accounts receivable of $426,000 at June&#160;30,&#160;2021. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company accounts for its revenue recognition under Accounting Standards Codification ("ASC") 606, <i style="font-style:italic;">Revenue from Contracts with Customers</i>. Under this standard, the Company recognizes revenue when a customer obtains control of promised services or goods in an amount that reflects the consideration to which the Company expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer contracts. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s contract revenue consists primarily of amounts earned under contracts with third-party customers and reimbursed expenses under such contracts. The Company analyzes its agreements to determine whether the elements can be separated and accounted for individually or as a single unit of accounting. Allocation of revenue to individual elements that qualify for separate accounting is based on the separate selling prices determined for each component, and total contract consideration is then allocated pro rata across the components of the arrangement. If separate selling prices are not available, the Company will use its best estimate of such selling prices, consistent with the overall pricing strategy and after consideration of relevant market factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In general, the Company applies the following steps when recognizing revenue from contracts with customers: (i)&#160;identify the contract, (ii)&#160;identify the performance obligations, (iii)&#160;determine the transaction price, (iv)&#160;allocate the transaction price to the performance obligations and (v)&#160;recognize revenue when a performance obligation is satisfied. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Recognition of revenue is driven by satisfaction of the performance obligations using one of two methods: revenue is either recognized over time or at a point in time. Contracts containing multiple performance obligations classify those performance obligations into separate units of accounting either as standalone or combined units of accounting. For those performance obligations treated as a standalone unit of accounting, revenue is generally recognized based on the method appropriate for each standalone unit. For those performance obligations treated as a combined unit of accounting, revenue is generally recognized as the performance obligations are satisfied, which generally occurs when control of the goods or services have been transferred to the customer or client or once the client or customer is able to direct the use of those goods and/or services as well as obtaining substantially all of its benefits. As such, revenue for a combined unit of accounting is generally recognized based on the method appropriate for the last delivered item but due to the specific nature of certain project and contract items, management may determine an alternative revenue recognition method as appropriate, such as a contract whereby one deliverable in the arrangement clearly comprises the overwhelming majority of the value of the overall combined unit of accounting. Under this circumstance, management may determine revenue recognition for the combined unit of accounting based on the revenue recognition guidance otherwise applicable to the predominant deliverable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">If a loss on a contract is anticipated, such loss is recognized in its entirety when the loss becomes evident. When the current estimates of the amount of consideration that is expected to be received in exchange for transferring promised goods or services to the customer indicates a loss will be incurred, a provision for the entire loss on the contract is made. At March&#160;31,&#160;2023 and June&#160;30,&#160;2022, the Company had no contract loss provisions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Fixed-Fee </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Under a fixed-fee contract, the Company charges a fixed agreed upon amount for a deliverable. Fixed-fee contracts have fixed deliverables upon completion of the project. Typically, the Company recognizes revenue for fixed-fee contracts after projects are completed, delivery is made and title transfers to the customer, and collection is reasonably assured.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Revenue can be recognized either 1) over time or 2) at a point in time. &#160;All revenue was recognized at a point in time for all periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the three months ended March 31, 2022, revenue was recognized from a license agreement and for the nine months ended March&#160;31,&#160;2022, revenue was recognized from a license agreement and the settlement of a revenue contract. &#160;No revenue was recognized for all other periods presented. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Time and Materials</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Under a time and materials contract, the Company charges customers an hourly rate plus reimbursement for other project specific costs. The Company recognizes revenue for time and material contracts based on the number of hours devoted to the project multiplied by the customer&#8217;s billing rate plus other project specific costs incurred.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ContractAssetsPolicyTextBlock', window );">Contract Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;">Contract Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">A contract asset is an entity&#8217;s right to payment for goods and services already transferred to a customer if that right to payment is conditional on something other than the passage of time. Generally, an entity will recognize a contract asset when it has fulfilled a contract obligation but must perform other obligations before being entitled to payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Contract assets consist primarily of the cost of project contract work performed by third parties for which the Company expects to recognize any related revenue at a later date, upon satisfaction of the contract obligations. At March&#160;31,&#160;2023 and June&#160;30,&#160;2022, contract assets were $0.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ContractLiabilitiesPolicyTextBlock', window );">Contract Liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Contract Liabilities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">A contract liability is an entity&#8217;s obligation to transfer goods or services to a customer at the earlier of (1) when the customer prepays consideration or (2) the time that the customer&#8217;s consideration is due for goods and services the entity will yet provide. Generally, an entity will recognize a contract liability when it receives a prepayment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Contract liabilities consist primarily of consideration received, usually in the form of payment, on project work to be performed whereby the Company expects to recognize any related revenue at a later date, upon satisfaction of the contract obligations. At March&#160;31,&#160;2023, June&#160;30,&#160;2022, and June&#160;30,&#160;2021, contract liabilities w<span style="background:#ffffff;">ere </span><span style="background:#ffffff;">$0</span><span style="background:#ffffff;">, </span><span style="background:#ffffff;">$100,000</span><span style="background:#ffffff;"> and </span><span style="background:#ffffff;">$423,000</span><span style="background:#ffffff;">, r</span>espectively. The Company recognized revenue of $53,000 and $100,000 during the three and nine months ended March&#160;31,&#160;2023, respectively, that was included in the contract liabilities balance as of June 30, 2022 and was reported in discontinued operations. The Company recognized revenue of $52,000 and $178,000 during the three and nine months ended March&#160;31,&#160;2022, respectively, that was included in the contract liabilities balance as of June&#160;30,&#160;2021 and was reported in discontinued operations. The Company recognized revenue of $0 and $84,000 during the three </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">and nine months ended March&#160;31,&#160;2022 that was included in the contract liabilities balance as of June&#160;30,&#160;2021 and reported as part of continuing operations.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Leases</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company accounts for leases under the guidance of Accounting Standards Codification ("ASC") 842, <i style="font-style:italic;">Leases</i> ("ASC 842"). The standard established a right-of-use (&#8220;ROU&#8221;) model requiring a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months and classified as either an operating or finance lease. The adoption of ASC 842 had a significant effect on the Company&#8217;s balance sheet, resulting in an increase in non-current assets and both current and non-current liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In accordance with ASC 842, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether the Company obtains the right to substantially all the economic benefit from the use of the asset, and whether the Company has the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. For contracts with lease and non-lease components, <span style="-sec-ix-hidden:Hidden_eZ239xUFfk2aM5khbNy0yg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Company has elected not to allocate the contract consideration and to account for the lease and non-lease components as a single lease component</span></span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The lease liabilities and the corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. The implicit rate within the Company&#8217;s existing finance (capital) lease was determinable and, therefore, used at the adoption date of ASC 842 to determine the present value of lease payments under the finance lease. The implicit rate within the Company&#8217;s operating lease was not determinable and, therefore, the Company used the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Company&#8217;s incremental borrowing rate requires judgment. The Company will determine the incremental borrowing rate for each new lease using its estimated borrowing rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain the Company will exercise that option. An option to terminate is considered unless it is reasonably certain the Company will not exercise the option.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Cash, Cash Equivalents and Restricted Cash</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company considers all highly-liquid instruments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents at March&#160;31,&#160;2023 and June&#160;30,&#160;2022 consisted of money market accounts. Restricted cash consisted of $3.0 million held within a Company account at Woodforest Bank for the term note payable (see Note 6 &#8211; Significant Transactions and Note 13 - Debt), collateral for a letter of credit obtained related to the San Diego operating lease (see Note 15 &#8211; Operating Lease Obligations) and collateral for a Company purchasing card. The Company&#8217;s bank required an additional 5% collateral held above the actual letters of credit issued for the San Diego lease and Company purchasing card. Restricted cash was approximately $3.3 million at &#160;March&#160;31,&#160;2023 and $6.0 million on June&#160;30,&#160;2022. The reduction to the restricted cash occurred because on October 11, 2022, the Company, as part of the First Amendment to the Credit Agreement with Woodforest National Bank (&#8220;Woodforest&#8221;), paid down $5.5 million of the term loan and subsequently Woodforest cancelled the irrevocable letter of credit issued by JPMorgan Chase Bank upon closing of the amendment. &#160;In accordance with the Fourth Amendment with Woodforest, the Company deposited $3 million in a restricted account at Woodforest. (For a complete description of the transaction please see Note 6 &#8211; Significant Transactions and Note 13 - Debt). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table summarizes the components of total cash, cash equivalents and restricted cash in the condensed consolidated statements of cash flows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:58.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:16.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:58.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Cash and equivalents</p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,562</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 22,676</p></td></tr><tr><td style="vertical-align:middle;width:58.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Collateral held for letter of credit - term note payable</p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 5,743</p></td></tr><tr><td style="vertical-align:middle;width:58.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Collateral held for letter of credit - San Diego lease</p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 198</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 198</p></td></tr><tr><td style="vertical-align:middle;width:58.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Collateral held for Company purchasing card</p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 55</p></td></tr><tr><td style="vertical-align:middle;width:58.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Total cash, cash equivalents and restricted cash</p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,815</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,672</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy', window );">Investments in Debt Securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Investments in Debt Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:normal;">Debt investments were classified as available-for-sale. Changes in fair value are recorded in other comprehensive income (loss). Fair value was calculated based on publicly available market information. Discounts and/or premiums paid when the debt securities were acquired are amortized to interest income over the terms of the debt securities. See Note 8 &#8211; Investments in Debt Securities.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Inventory</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'TimesNewRomanPSMT';">Inventory is stated at the lower of cost or net realizable value on the first-in, first-out basis. &#160;Inventory held is related to the CDMO business and has been classified as held for sale. &#160;See Note 3 &#8211; Discontinued Operations for information on inventory reserved reflected in the period ended March&#160;31,&#160;2023.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'TimesNewRomanPSMT';visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Research and Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company accounts for research and development costs in accordance with the Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 730-10, <i style="font-style:italic;">Research and Development</i> (&#8220;ASC 730-10&#8221;). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved. For the nine months ended March&#160;31,&#160;2023 and 2022, research and development expense was reported in both continuing and discontinued operations.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_RightOfUseAssetsPolicyPolicyTextBlock', window );">Right-of-Use Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Right-of-Use Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">Assets held under the terms of finance (capital) leases are amortized on a straight-line basis over the terms of the leases or the economic lives of the assets. Obligations for future lease payments under finance (capital) leases are shown within liabilities and are analyzed between amounts falling due within and after one year. See Note 9 </span><i style="font-family:'TimesNewRomanPSMT';">&#8211;</i><span style="font-style:normal;"> Finance Lease ROU Assets and Note 14 </span><i style="font-family:'TimesNewRomanPSMT';">&#8211;</i><span style="font-style:normal;"> Finance Lease Obligations for additional information.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Fixed Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Fixed Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Fixed assets are stated at cost net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets ranging from <span style="-sec-ix-hidden:Hidden_Eet2cSErQUWYG2NYDDLIPA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> to 39 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company monitors fixed assets for impairment indicators throughout the year. &#160;When necessary, charges for impairments of long-lived assets are recorded for the amount by which the fair value is less than the carrying value of these assets. &#160;Changes in the Company&#8217;s business strategy or adverse changes in market conditions could impact impairment analyses and require the recognition of an impairment charge. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">See Note 11 &#8211; Fixed Assets for additional information.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intangible Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Intangible Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Identifiable intangible assets are comprised of definite life intangible assets and indefinite life intangible assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company accounts for definite life intangible assets at either their historical cost or allocated purchase price at asset acquisition and records amortization utilizing the straight-line method based upon their estimated useful lives. Intellectual property is amortized over <span style="-sec-ix-hidden:Hidden_5A4l74BAAkGpy-k8y3HFLw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">20&#160;years</span></span>. The Company reviews the carrying value of its definite life intangible assets for impairment whenever events or changes in business circumstances indicate the carrying amount of such assets may not be fully recoverable. &#160;The carrying value is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. An impairment loss is measured as the amount by which the carrying amount exceeds it fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For indefinite life intangible assets, the Company performs an impairment test annually and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. &#160;The Company determines the fair value of the asset quarterly or when triggering events are present, based on discounted cash flows and records an impairment loss if book value exceeds fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Evaluating for impairment requires judgment, including the estimation of future cash flows, future growth rates and profitability and the expected life over which cash flows will occur. Changes in the Company&#8217;s business strategy or adverse changes in market conditions could impact impairment analyses and require the recognition of an impairment charge. Although management bases its estimates on </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">See Note 12 &#8211; Intangible Assets for additional information.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Share-based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company recognizes the cost of all share-based payment transactions at fair value. Compensation cost, measured by the fair value of the equity instruments issued, adjusted for estimated forfeitures, is recognized in the financial statements as the respective awards are earned over the performance or service period. The Company uses historical data to estimate forfeiture rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The impact that share-based payment awards will have on the Company&#8217;s results of operations is a function of the number of shares awarded, the trading price of the Company&#8217;s stock at the date of grant or modification, the vesting schedule and forfeitures. Furthermore, the application of the Black-Scholes option pricing model employs weighted-average assumptions for expected volatility of the Company&#8217;s stock, expected term until exercise of the options, the risk-free interest rate, and dividends, if any, to determine fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Expected volatility is based on historical volatility of the Common Stock; the expected term until exercise represents the weighted-average period of time that options granted are expected to be outstanding giving consideration to vesting schedules and the Company&#8217;s historical exercise patterns; and the risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. The Company has not paid any dividends since its inception and does not anticipate paying any dividends for the foreseeable future, so the dividend yield is assumed to be zero. In addition, the Company estimates forfeitures at each reporting period, rather than electing to record the impact of such forfeitures as they occur. See Note 18 <span style="font-family:'TimesNewRomanPSMT';">&#8211;</span> Share-Based Compensation for additional information.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Concentrations of Credit Risk</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cash</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company maintains principally all cash balances in two financial institutions which, at times, may exceed the insured amounts. The exposure to the Company is solely dependent upon daily balances and the strength of the financial institutions. The Company has not incurred any losses on these accounts. At March&#160;31,&#160;2023 and June&#160;30,&#160;2022, amounts in excess of insured limits were approximately $6,300,000 and $18,200,000, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Revenue</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the three months ended March&#160;31,&#160;2023, the Company reported no revenue from continuing operations and generated 100% of its revenue reported in discontinued operations from two customers. During the three months ended March&#160;31,&#160;2022, the Company reported $1.8 million of license revenue from continuing operations and generated $144,000 of revenue reported in discontinued operations from two customers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the nine months ended March&#160;31,&#160;2023, the Company reported no revenue from continuing operations and generated 100% of its revenue reported in discontinued operations from two customers. During the nine months ended March&#160;31,&#160;2022, the Company reported revenue from continuing operations related to a license agreement and a settlement of a revenue contract. &#160;The Company also generated $438,000 of revenue reported in discontinued operations from six customers.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Recently Issued Accounting Pronouncements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In June 2016, the FASB issued ASU 2016-13, <i style="font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i> (&#8220;ASU 2016-13&#8221;), which requires an entity to assess impairment of its financial instruments based on its estimate of expected credit losses. Since the issuance of ASU 2016-13, the FASB released several amendments to improve and clarify the implementation guidance. In November 2019, the FASB issued ASU 2019-10, <i style="font-style:italic;">Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates</i>, which amended the effective date of the various topics. As the Company is a smaller reporting company, the provisions of ASU 2016-13 and the related amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022 (quarter ending September 30, 2023, for the Company). Entities are required to apply these changes through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The Company does not expect the adoption of ASU 2016-13 to have a significant impact on the Company&#8217;s consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying condensed consolidated financial statements. Most of the newer standards issued represent </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">technical corrections to the accounting literature or application to specific industries which have no effect on the Company&#8217;s condensed consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ContractAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for contract assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ContractAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ContractLiabilitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for contract liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ContractLiabilitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_RightOfUseAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of accounting policy for right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_RightOfUseAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for premium paid to acquire option for investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=6435544&amp;loc=d3e41834-113960<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393617981072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Schedule of discontinued operations</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">The following table presents a reconciliation of the major financial lines constituting the results of operations for discontinued operations to the loss from discontinued operations presented separately in the condensed consolidated statements of operations (in thousands):</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:61.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:0.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:15.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:61.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues</p></td><td style="vertical-align:middle;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:15.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 205</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 143</p></td></tr><tr><td style="vertical-align:middle;width:61.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of goods sold</p></td><td style="vertical-align:middle;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 48</p></td></tr><tr><td style="vertical-align:middle;width:61.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross profit</p></td><td style="vertical-align:middle;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 180</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 95</p></td></tr><tr><td style="vertical-align:middle;width:61.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:middle;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Research and development</span></p></td><td style="vertical-align:middle;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 837</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 2,278</p></td></tr><tr><td style="vertical-align:middle;width:61.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    General and administrative</span></p></td><td style="vertical-align:middle;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 929</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 3,211</p></td></tr><tr><td style="vertical-align:middle;width:61.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Gain on sale of fixed assets</span></p></td><td style="vertical-align:middle;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (732)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:61.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total operating expenses</p></td><td style="vertical-align:middle;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,034</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 5,489</p></td></tr><tr><td style="vertical-align:middle;width:61.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other expenses:</p></td><td style="vertical-align:middle;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Interest expense - term note payable</span></p></td><td style="vertical-align:middle;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (158)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (249)</p></td></tr><tr><td style="vertical-align:middle;width:61.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Other</span></p></td><td style="vertical-align:middle;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1)</p></td></tr><tr><td style="vertical-align:middle;width:61.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total other expenses</p></td><td style="vertical-align:middle;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (161)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (250)</p></td></tr><tr><td style="vertical-align:middle;width:61.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:0.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from discontinued operations</p></td><td style="vertical-align:middle;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:15.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,015)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,644)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:14.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues</p></td><td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 391</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 438</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of goods sold</p></td><td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 52</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 201</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross profit</p></td><td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 339</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 237</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Research and development</span></p></td><td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 6,361</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 5,128</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    General and administrative</span></p></td><td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 6,165</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 8,659</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Fixed asset impairments</span></p></td><td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 17,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Gain on sale of fixed assets</span></p></td><td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (732)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Inventory reserve</span></p></td><td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 4,933</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total operating expenses</p></td><td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 34,327</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 13,787</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other income (expenses):</p></td><td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Interest expense - term note payable</span></p></td><td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (606)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (372)</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Interest expense - related party</span></p></td><td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (810)</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Forgiveness of note payable and accrued interest - SBA loan</span></p></td><td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 607</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Other</span></p></td><td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total other income (expenses)</p></td><td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (610)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (574)</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from discontinued operations</p></td><td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:14.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (34,598)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (14,124)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table presents net carrying values related to the major classes of assets that were classified as held for sale at March&#160;31,&#160;2023 and June&#160;30,&#160;2022 (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Inventory</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 3,900</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Operating lease right-of-use assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,944</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Property and equipment, net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 16,424</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:14.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 18,368</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 3,900</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Property and equipment, net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 35,289</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Finance lease right-of-use assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 74</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Operating lease right-of-use assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,951</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 37,314</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Finance lease obligation</span></p></td><td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 46</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Operating lease obligation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,944</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 10</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:14.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,944</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 56</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Finance lease obligation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;">30</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Operating lease obligation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,941</p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total long-term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,971</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table presents the supplemental disclosures related to discontinued operations for the statements of cash flows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Depreciation expense</p></td><td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 273</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,532</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization of finance lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 587</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Purchase of fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,041</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 28,384</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fixed asset impairments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 17,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Inventory reserve</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 4,933</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sales proceeds of fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 2,100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Investing non-cash transactions:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Fixed assets included in accounts payable in prior period, paid in current period</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,542</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 791</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Unpaid fixed assets included in accounts payable</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 2,193</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Sales of fixed assets receivable</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 460</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1474-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721677-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721659-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721665-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721671-107760<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721663-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393609266576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of of total cash, cash equivalents and restricted cash</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table summarizes the components of total cash, cash equivalents and restricted cash in the condensed consolidated statements of cash flows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:58.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:16.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:58.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Cash and equivalents</p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,562</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 22,676</p></td></tr><tr><td style="vertical-align:middle;width:58.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Collateral held for letter of credit - term note payable</p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 5,743</p></td></tr><tr><td style="vertical-align:middle;width:58.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Collateral held for letter of credit - San Diego lease</p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 198</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 198</p></td></tr><tr><td style="vertical-align:middle;width:58.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Collateral held for Company purchasing card</p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 55</p></td></tr><tr><td style="vertical-align:middle;width:58.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Total cash, cash equivalents and restricted cash</p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,815</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,672</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393617876080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurement (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Financial Instruments and Fair Value Measurement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of fixed assets measured at fair value on a non-recurring basis</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table shows the fair value of the Company's fixed assets included in Current Assets Held For Sale measured at fair value on a non-recurring basis as of March&#160;31,&#160;2023 (amounts in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:26.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:12.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:12.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:14.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:6.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">March 31, 2023</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:70%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Fair Value Hierarchy</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Quoted Prices in Active Markets for Identical Assets (Level 1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Significant Other Observable Inputs (Level 2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Significant Unobservable Inputs (Level 3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Total Fair Value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Total Impairments</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Building in Bryan, Texas</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 16,364</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 16,364</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 6,300</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393615431024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=ibio_StockPurchaseAgreementMember', window );">Stock Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTableTextBlock', window );">Summary of Purchase Price Allocation of Asset Acquisition</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">The Company accounted for the agreements as an asset purchase and allocated the purchase price of $7,500,000 as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:74.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:17.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:74.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Preferred stock</p></td><td style="vertical-align:middle;width:4.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:4.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:17.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,760,000</p></td></tr><tr><td style="vertical-align:middle;width:74.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Intangible assets</p></td><td style="vertical-align:middle;width:4.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,300,000</p></td></tr><tr><td style="vertical-align:middle;width:74.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid expenses</p></td><td style="vertical-align:middle;width:4.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:4.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,440,000</p></td></tr><tr><td style="vertical-align:middle;width:74.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:4.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:17.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,500,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=ibio_AssetPurchaseAgreementMember', window );">Asset Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTableTextBlock', window );">Summary of Purchase Price Allocation of Asset Acquisition</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">The Company accounted for the agreements as an asset purchase and allocated the purchase price of approximately $1,342,000 as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:74.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:17.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:74.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible assets</p></td><td style="vertical-align:middle;width:4.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:4.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:17.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,228,000</p></td></tr><tr><td style="vertical-align:middle;width:74.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fixed assets</p></td><td style="vertical-align:middle;width:4.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:4.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 114,000</p></td></tr><tr><td style="vertical-align:middle;width:74.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:4.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:17.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,342,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 15<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6911878&amp;loc=d3e8732-128492<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ibio_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ibio_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ibio_AssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ibio_AssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393612621600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Debt Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments in Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of components of investments in debt securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company did not hold any investments in debt securities at March 31, 2023. The components of investments in debt securities are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:58.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:16.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:58.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Adjusted cost</p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:16.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,029</p></td></tr><tr><td style="vertical-align:middle;width:58.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Gross unrealized losses</p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (184)</p></td></tr><tr><td style="vertical-align:middle;width:58.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Fair value</p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:16.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,845</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of fair value of available-for-sale debt securities, by contractual maturity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The fair value of available-for-sale debt securities, by contractual maturity, was as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:59.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:15.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Fiscal period ending:</b></p></td><td style="vertical-align:middle;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:59.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2023</p></td><td style="vertical-align:middle;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:15.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">8,054</p></td></tr><tr><td style="vertical-align:middle;width:59.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2024</p></td><td style="vertical-align:middle;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,791</p></td></tr><tr><td style="vertical-align:middle;width:59.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:15.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10,845</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_AvaliableForSaleDebtSecuritiesRealizedGainsLossesTableTextBlock', window );">Schedule of realized gains on available-for-sale debt securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Realized gains on available-for-sale debt securities are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Proceeds from sale of debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,943</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Cost of debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,036</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Realized loss on sale of debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (93)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Proceeds from sale of debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,739</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Cost of debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,837</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Realized loss on sale of debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (98)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_AvaliableForSaleDebtSecuritiesRealizedGainsLossesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized gains (losses) on available for sale debt securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_AvaliableForSaleDebtSecuritiesRealizedGainsLossesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393609266576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Lease ROU Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract', window );"><strong>Finance Lease ROU [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock', window );">Summary of the gross carrying value and accumulated amortization of finance lease ROU</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes by category the gross carrying value and accumulated amortization of finance lease ROU (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ROU - Equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 814</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (136)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net finance lease ROU</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 678</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure for the gross carrying value and accumulated amortization of right-to-use assets under finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393617867904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Fixed Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of gross carrying value and accumulated depreciation of fixed assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes by category the gross carrying value and accumulated depreciation of fixed assets (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Building and improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 695</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:61.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Machinery and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 3,461</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Office equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 403</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:61.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Construction in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,373</p></td></tr><tr><td style="vertical-align:bottom;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 4,593</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,373</p></td></tr><tr><td style="vertical-align:bottom;width:61.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (235)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 4,358</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,373</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393617986672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Category the gross carrying value and accumulated amortization of intangible assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table reflects changes in the carrying amount of intangible assets (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">June&#160;30,&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">March 31,</p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Additions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Impairments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2023</p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Intellectual property &#8211; gross carrying value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 3,100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,100)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 400</p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Patents and licenses &#8211; gross carrying value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 2,846</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,846)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 5,946</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,946)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 400</p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Intellectual property &#8211; accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,867)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (74)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 2,931</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10)</p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Patents and licenses &#8211; accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,403)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (47)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 2,450</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,270)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (121)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 5,381</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10)</p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Total definite lived intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 676</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (121)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (565)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 390</p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">License - indefinite lived</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 4,175</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 828</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 5,003</p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Total net intangible</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 4,851</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,228</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 5,393</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393612814032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock', window );">Schedule of future minimum payments under the finance lease obligation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Future minimum payments under the finance lease obligation are due as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fiscal period ending on March 31:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 156</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 195</p></td></tr><tr><td style="vertical-align:bottom;width:65.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 173</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 195</p></td></tr><tr><td style="vertical-align:bottom;width:65.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 110</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 114</p></td></tr><tr><td style="vertical-align:bottom;width:65.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum equipment financing payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 439</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 504</p></td></tr><tr><td style="vertical-align:bottom;width:65.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (156)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term portion of minimum equipment financing obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 283</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 303<br> -Paragraph (a)<br> -Subparagraph (5)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393615303888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Lease Obligation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Finance Lease Obligation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock', window );">Schedule of components of lease expense and supplemental balance sheet information related to the finance lease obligation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following tables present the components of lease expense and supplemental balance sheet information related to the finance lease obligation (in thousands).</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Amortization of ROU assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest on lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for amounts included in the measurement lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating cash flows from finance lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Financing cash flows from finance lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finance lease cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Amortization of ROU assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 156</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest on lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 189</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash paid for amounts included in the measurement lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating cash flows from finance lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Financing cash flows from finance lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 144</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ScheduleOfFinanceLeaseRightOfUseAssetsAndObligationAndWeightedAverageInformationTableTextBlock', window );">Schedule of finance lease and weighted average information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Future Minimum Payments Under the Finance Lease Obligation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Future minimum payments under the finance lease obligation are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fiscal period ending on March 31:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 265</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 54</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 319</p></td></tr><tr><td style="vertical-align:bottom;width:65.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 292</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 28</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 320</p></td></tr><tr><td style="vertical-align:bottom;width:65.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 130</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 133</p></td></tr><tr><td style="vertical-align:bottom;width:65.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 687</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 772</p></td></tr><tr><td style="vertical-align:bottom;width:65.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (265)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term portion of minimum lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 422</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure for components of lease expense and supplemental balance sheet information related to the finance lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ScheduleOfFinanceLeaseRightOfUseAssetsAndObligationAndWeightedAverageInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents information pertaining to schedule of finance lease right of use assets and obligation and weighted average information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ScheduleOfFinanceLeaseRightOfUseAssetsAndObligationAndWeightedAverageInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393609277968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Lease Obligations (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Operating Lease, Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock', window );">Lease Expense and Supplemental Balance Sheet Information Related to the Operating Lease Obligation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following tables present the components of lease expense and supplemental balance sheet information related to the operating lease obligation (in thousands).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 141</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 141</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 141</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 141</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for amounts included in the measurement lease liability:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating cash flows from operating lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 141</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 141</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating cash flows from operating lease obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 103</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 422</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 313</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 422</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 313</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for amounts included in the measurement lease liability:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating cash flows from operating lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 422</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 313</p></td></tr><tr><td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating cash flows from operating lease obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 154</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Future Minimum Payments under the Operating Lease Obligation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Future minimum payments under the operating lease obligation are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fiscal period ending on December&#160;31:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Imputed Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 377</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 249</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 626</p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 424</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 220</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 644</p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 476</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 188</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 664</p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 532</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 151</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 683</p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 593</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 111</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 704</p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 82</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,282</p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 3,602</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,001</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 4,603</p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (377)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term portion of minimum lease obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 3,225</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of components of lease expense and supplemental balance sheet information related to the Operating lease obligation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393615217344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings (Loss) Per Common Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings (loss) Per Share, Basic and Diluted</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to iBio, Inc. from continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,279)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,746)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (24,379)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19,125)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Preferred stock dividends &#8211; iBio CMO Preferred Tracking Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (88)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss available to iBio, Inc. stockholders from continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,279)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,746)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (24,379)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19,213)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss available to iBio, Inc. stockholders from discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,015)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,644)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (34,598)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (14,124)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss available to iBio, Inc. stockholders - total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,294)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (12,390)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (58,977)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (33,337)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average common shares outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 13,184</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 8,719</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 10,592</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 8,719</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Per share amount - continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_wjVHAja0hk-ujBowM-xKHQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.47)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_yQjZFWrye0SmP2jIiPGrBA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.77)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_-JF8WUqQSkmfxC0R_OaSQA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.30)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_PwsJbaSoOUORrCdM232mAA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.20)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Per share amount - discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_9HqUV2MAckqjZOnis6YfZg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.08)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_U0bOGUWDzkuEeJ29Nf_EjQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.65)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_TmWH34FMsECu90mrUdyfXg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3.27)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_kDRlUx8GmUabgAhq5k_vvQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.62)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Per share amount - total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_Zp0MkR-0tUq910UPmXzGpA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.55)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_acVcgEcpAUW-LaSF7a3TxQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.42)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_wBTFuchxW0eQbgh0co0GoQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5.57)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_tJo2ezbm1Eau_et1XorUuA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3.82)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:76.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 457</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 625</p></td></tr><tr><td style="vertical-align:bottom;width:76.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 443</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 22</p></td></tr><tr><td style="vertical-align:bottom;width:76.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 5,948</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 52</p></td></tr><tr><td style="vertical-align:bottom;width:76.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Shares excluded from the calculation of diluted loss per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 6,848</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 699</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393612572352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Compensation [Member]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes the components of share-based compensation expense in the condensed consolidated statements of operations (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 101</p></td></tr><tr><td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 345</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,112</p></td></tr><tr><td style="vertical-align:bottom;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 385</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,213</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 96</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 132</p></td></tr><tr><td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 2,330</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 2,761</p></td></tr><tr><td style="vertical-align:bottom;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 2,426</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 2,893</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair value of options granted using the Black-Scholes option pricing model</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company estimated the fair value of options granted using the Black-Scholes option pricing model with the following assumptions:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">3.21% - 3.61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">115.52 - 116.93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393611797856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation (Narrative) (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th">
<div>Nov. 03, 2022 </div>
<div>position</div>
</th>
<th class="th"><div>Oct. 07, 2022</div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_BasisOfPresentationAbstract', window );"><strong>Basis of Presentation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Percentage of workforce reduction</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated', window );">Number of positions reduced | position</a></td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CashAndCashEquivalentsPlusDebtSecurities', window );">Cash and cash equivalents and marketable securities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split, shares received per share tendered</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_BasisOfPresentationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the information pertaining to Basis of Presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_BasisOfPresentationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CashAndCashEquivalentsPlusDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents plus debt securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CashAndCashEquivalentsPlusDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected number of positions to be eliminated as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393611817504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations (Narrative) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 03, 2022 </div>
<div>USD ($) </div>
<div>position</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Percentage of workforce reduction</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated', window );">Number of positions reduced | position</a></td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EmployeeReductionExpenses', window );">Expected employee reduction charges</a></td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Impairment of fixed assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,600<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown', window );">Inventory impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(732)<span></span>
</td>
<td class="nump">4,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance', window );">Personnel costs including severance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Sales of fixed assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount inventory written down in a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of personnel cost including severance incurred in a discontinuing operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_EmployeeReductionExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected amount of expenses to be incurred due to employee reductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_EmployeeReductionExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected number of positions to be eliminated as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TangibleAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TangibleAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393608263584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations (Reconciliation and Classifications) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract', window );"><strong>Results of operations for discontinued operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Revenues</a></td>
<td class="nump">$ 205<span></span>
</td>
<td class="nump">$ 143<span></span>
</td>
<td class="nump">$ 391<span></span>
</td>
<td class="nump">$ 438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold', window );">Cost of goods sold</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="nump">201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss', window );">Gross profit</a></td>
<td class="nump">180<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="nump">339<span></span>
</td>
<td class="nump">237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses', window );">Research and development</a></td>
<td class="nump">837<span></span>
</td>
<td class="nump">2,278<span></span>
</td>
<td class="nump">6,361<span></span>
</td>
<td class="nump">5,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">929<span></span>
</td>
<td class="nump">3,211<span></span>
</td>
<td class="nump">6,165<span></span>
</td>
<td class="nump">8,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_TangibleAssetImpairmentChargesDiscontinuedOperations', window );">Fixed assets impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown', window );">Inventory impairments</a></td>
<td class="num">(732)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense', window );">Total operating expenses</a></td>
<td class="nump">1,034<span></span>
</td>
<td class="nump">5,489<span></span>
</td>
<td class="nump">34,327<span></span>
</td>
<td class="nump">13,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense', window );">Interest expense - term note payable</a></td>
<td class="num">(158)<span></span>
</td>
<td class="num">(249)<span></span>
</td>
<td class="num">(606)<span></span>
</td>
<td class="num">(372)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupInterestExpenseRelatedParty', window );">Interest expense - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(810)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupGainOnDebtForgiveness', window );">Forgiveness of note payable and accrued interest - SBA loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DiscontinuedOperationsMiscellaneousExpensesIncome', window );">Other</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense', window );">Total other income (expenses)</a></td>
<td class="num">(161)<span></span>
</td>
<td class="num">(250)<span></span>
</td>
<td class="num">(610)<span></span>
</td>
<td class="num">(574)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Loss from discontinued operations</a></td>
<td class="num">(1,015)<span></span>
</td>
<td class="num">$ (5,644)<span></span>
</td>
<td class="num">(34,598)<span></span>
</td>
<td class="num">(14,124)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupOperatingLeaseRightOfUseAssets', window );">Operating lease right-of-use assets</a></td>
<td class="nump">1,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent', window );">Property and equipment, net</a></td>
<td class="nump">16,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total current assets</a></td>
<td class="nump">18,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract', window );"><strong>Other assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,951<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupNonCurrentAssetsFinanceLeaseRightOfUseAssets', window );">Finance lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent', window );">Total other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,314<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupCurrentLiabilitiesFinanceLeaseObligations', window );">Finance lease obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations', window );">Operating lease obligation</a></td>
<td class="nump">1,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract', window );"><strong>Long-term liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupNoncurrentLiabilitiesFinanceLeaseObligations', window );">Finance lease obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupNoncurrentOperatingLeaseObligations', window );">Operating lease obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,941<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent', window );">Total long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,971<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract', window );"><strong>Net Cash Provided by (Used in) Discontinued Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortizationDiscontinuedOperations', window );">Depreciation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">273<span></span>
</td>
<td class="nump">1,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets', window );">Amortization of finance lease ROU assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpenditureDiscontinuedOperations', window );">Purchase of fixed assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,041<span></span>
</td>
<td class="nump">28,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Fixed assets impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,600<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown', window );">Inventory impairments</a></td>
<td class="num">$ (732)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Sales of fixed assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Investing noncash transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod', window );">Fixed assets included in accounts payable in prior period, paid in current period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,542<span></span>
</td>
<td class="nump">$ 791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations', window );">Unpaid fixed assets included in accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DiscontinuedOperationsMiscellaneousExpensesIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Miscellaneous expenses (income) attributable to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DiscontinuedOperationsMiscellaneousExpensesIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development expenses attributable to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization of finance lease ROU assets attributable to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DisposalGroupCurrentLiabilitiesFinanceLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current finance lease obligations attributable to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DisposalGroupCurrentLiabilitiesFinanceLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current operating lease obligations attributable to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed asset charges incurred but not yet paid attributable to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DisposalGroupGainOnDebtForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on forgiveness of debt to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DisposalGroupGainOnDebtForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount inventory written down in a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DisposalGroupInterestExpenseRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest expense to related party from discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DisposalGroupInterestExpenseRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DisposalGroupNonCurrentAssetsFinanceLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as non current  assets attributable to disposal group held for sale or disposed of, expected to be disposed of more than one year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DisposalGroupNonCurrentAssetsFinanceLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DisposalGroupNoncurrentLiabilitiesFinanceLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncurrent finance lease obligations attributable to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DisposalGroupNoncurrentLiabilitiesFinanceLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DisposalGroupNoncurrentOperatingLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncurrent operating lease obligations attributable to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DisposalGroupNoncurrentOperatingLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DisposalGroupOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current operating lease ROU assets attributable to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DisposalGroupOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncurrent operating lease ROU assets attributable to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_TangibleAssetImpairmentChargesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the aggregate write down of tangible assets of discontinued operations from their carrying value to their fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_TangibleAssetImpairmentChargesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unpaid fixed assets included in accounts payable, attributable to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpenditureDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of capital expenditure attributable to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpenditureDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortizationDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deprecation and amortization expense attributable to property, plant and equipment and intangible assets of discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortizationDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2510-110228<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gross profit attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section S99<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=26872618&amp;loc=d3e7436-122677<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1063-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1060-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2510-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2510-110228<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TangibleAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TangibleAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393608801904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 11, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>customer </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>customer</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>customer </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>customer</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">423,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasePracticalExpedientsPackage', window );">Lease, Practical Expedients, Package [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Amount in excess of insured limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable - trade</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 426,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyIncomeNonoperating', window );">Royalty income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Revenue reported in discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205,000<span></span>
</td>
<td class="nump">143,000<span></span>
</td>
<td class="nump">391,000<span></span>
</td>
<td class="nump">438,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_WoodforestMember', window );">Woodforest [Member] | Amended Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of term loan</a></td>
<td class="nump">$ 5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember', window );">Continuing Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized included in contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">Discontinued Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized included in contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,000<span></span>
</td>
<td class="nump">$ 52,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 178,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_NumberOfMajorCustomers', window );">Number of major customers | customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Fixed assets, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Fixed assets, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">39 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember', window );">Intellectual Property [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">23 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_NumberOfMajorCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the information pertaining to number of major customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_NumberOfMajorCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasePracticalExpedientsPackage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether practical expedients are elected for not reassessing whether any expired or existing contract is or contains lease, lease classification for expired or existing lease, and initial direct cost for any existing lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL77916155-209984<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL77916155-209984<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasePracticalExpedientsPackage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibio_WoodforestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibio_WoodforestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ibio_AmendedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ibio_AmendedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393611816256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Cash, Cash Equivalents and Restricted Cash) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_PercentageOfCollateralRequired', window );">Additional percentage of collateral held required by bank</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">$ 3,253<span></span>
</td>
<td class="nump">$ 5,996<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">6,562<span></span>
</td>
<td class="nump">22,676<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">9,815<span></span>
</td>
<td class="nump">28,672<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ibio_LetterOfCreditTermLoanMember', window );">Letter Of Credit - Term Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Collateral held</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">5,743<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ibio_LetterOfCreditSanDiegoLeaseMember', window );">Letter Of Credit - San Diego Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Collateral held</a></td>
<td class="nump">198<span></span>
</td>
<td class="nump">198<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ibio_CompanyPurchasingCardMember', window );">Company Purchasing Card [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Collateral held</a></td>
<td class="nump">$ 55<span></span>
</td>
<td class="nump">$ 55<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_PercentageOfCollateralRequired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of collateral required to be held by the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_PercentageOfCollateralRequired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ibio_LetterOfCreditTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ibio_LetterOfCreditTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ibio_LetterOfCreditSanDiegoLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ibio_LetterOfCreditSanDiegoLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ibio_CompanyPurchasingCardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ibio_CompanyPurchasingCardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393612524480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurement (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Fixed assets impairments</a></td>
<td class="nump">$ 17,600,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Fair Value, Nonrecurring [Member] | Buildings and improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure', window );">Estimated fair values</a></td>
<td class="nump">16,364,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Fixed assets impairments</a></td>
<td class="nump">6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Fair Value, Nonrecurring [Member] | Machinery and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure', window );">Estimated fair values</a></td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Fixed assets impairments</a></td>
<td class="nump">$ 11,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TangibleAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TangibleAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393607213936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurement (Non-recurring Basis) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Fixed assets impairments</a></td>
<td class="nump">$ 17,600,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Fair Value, Nonrecurring [Member] | Buildings and improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure', window );">Total Fair Value</a></td>
<td class="nump">16,364,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Fixed assets impairments</a></td>
<td class="nump">6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Fair Value, Nonrecurring [Member] | Machinery and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure', window );">Total Fair Value</a></td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Fixed assets impairments</a></td>
<td class="nump">11,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Fair Value, Nonrecurring [Member] | Fair Value, Inputs, Level 3 [Member] | Buildings and improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure', window );">Total Fair Value</a></td>
<td class="nump">$ 16,364,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TangibleAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TangibleAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393606908272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Transactions (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 19, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 16, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 01, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 23, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,525,000<span></span>
</td>
<td class="nump">$ 5,316,000<span></span>
</td>
<td class="nump">$ 16,407,000<span></span>
</td>
<td class="nump">$ 14,863,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Value of common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ibio_SecuredTermLoanMember', window );">Secured Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Secured term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,852,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,852,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,375,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Cost incurred to attain debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 152,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_RubrycTheraputicsInc.Member', window );">RubrYc Therapeutics, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 650,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CollaborativeArrangementMilestonePayments', window );">Milestone payments</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForAdvanceToAffiliate', window );">Amount advanced</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">484,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_AssetAcquisitionTransactionCosts', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 813,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued | shares</a></td>
<td class="nump">102,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Value of common stock issued</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember', window );">College Station Investors LLC And Bryan Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest', window );">Total purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment', window );">Cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_FairMarketValueOfProperty', window );">Fair market value of property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 151,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_BaseRentPercentageOfFairMarketValueOfProperty', window );">Percentage of base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired', window );">Cash consideration for equity interest acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent', window );">Shares issued under the Warrant | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue', window );">Fair value of the warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 217,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember', window );">College Station Investors LLC And Bryan Capital [Member] | Secured Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Secured term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember', window );">College Station Investors LLC And Bryan Capital [Member] | IBio CMO Preferred Tracking Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EquityAgreementWarrantsIssuedOrIssuable', window );">Warrants issuable | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable', window );">Percentage of equity interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.01%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ibio_CollaborationOptionAndLicenseAgreementMember', window );">Collaboration, Option and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | RubrYc Therapeutics, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CollaborationAndLicenseAgreementAgreementTerm', window );">Collaboration and license agreement, agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ibio_CollaborationOptionAndLicenseAgreementMember', window );">Collaboration, Option and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | No Biosimilar Product has been Approved [Member] | RubrYc Therapeutics, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm', window );">Collaboration and license agreement, royalty payment term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ibio_StockPurchaseAgreementMember', window );">Stock Purchase Agreement [Member] | RubrYc Therapeutics, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 814,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ibio_SeparationAgreementAndGeneralReleaseMember', window );">Separation Agreement and General Release [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary', window );">Period of bi-monthly installments of current base salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus', window );">Period of bi-monthly installments of target bonus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct', window );">Maximum period for coverage of health insurance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod', window );">COBRA subsidy period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct', window );">Number of times on which lump sum cash payment tis o be made | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ibio_Series2PreferredStockMember', window );">Series A-2 Preferred Stock [Member] | Stock Purchase Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | RubrYc Therapeutics, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockPurchaseAgreementNumberOfSharesPurchased', window );">Stock purchase agreement, number of shares purchased | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,864,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockPurchaseAgreementValueOfSharesPurchased', window );">Stock purchase agreement, value of shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfInvestments', window );">Impairment of investment in equity security</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,760,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ImpairmentOfPrepaidExpensesCurrent', window );">Impairment of current prepaid expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">288,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ImpairmentOfPrepaidExpensesNonCurrent', window );">Impairment of non-current prepaid expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 864,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_AssetAcquisitionTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect an asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_AssetAcquisitionTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_BaseRentPercentageOfFairMarketValueOfProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of base rent payable on percentage of fair Market Value of the Property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_BaseRentPercentageOfFairMarketValueOfProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CollaborationAndLicenseAgreementAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration and license agreement, agreement term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CollaborationAndLicenseAgreementAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration and license agreement, royalty payment term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CollaborativeArrangementMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of milestone payments based on different scenarios.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CollaborativeArrangementMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consideration transferred for equity interest acquired under the equity agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity agreement, percentage of equity interest issued or issuable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_EquityAgreementWarrantsIssuedOrIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants issued or issuable under the equity agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_EquityAgreementWarrantsIssuedOrIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_FairMarketValueOfProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair market value of the property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_FairMarketValueOfProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ImpairmentOfPrepaidExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment of current prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ImpairmentOfPrepaidExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ImpairmentOfPrepaidExpensesNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment of non-current prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ImpairmentOfPrepaidExpensesNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total purchase price for the Property, the termination of the Sublease and other agreements among the parties, and the equity interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payment for purchase price for the Property, the termination of the Sublease and other agreements among the parties, and the equity interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the Consolidated Omnibus Budget Reconciliation Act of 1985 ("COBRA") subsidy period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum period of coverage of health insurance under the Consolidated Omnibus Budget Reconciliation Act of 1985 ("COBRA").</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of times on which the Company has to make lump sum cash payment if the employee not obtained health coverage under Consolidated Omnibus Budget Reconciliation Act of 1985 ("COBRA").</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the period of bi-monthly installments of current base salary to be paid under severance benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the period of bi-monthly installments of target bonus to be paid under severance benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_StockPurchaseAgreementNumberOfSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock purchase agreement, number of shares purchased</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_StockPurchaseAgreementNumberOfSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_StockPurchaseAgreementValueOfSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock purchase agreement, value of shares purchased</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_StockPurchaseAgreementValueOfSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants issued for the final payment of rent due under sublease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of warrants issued for the final payment of rent due under sublease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForAdvanceToAffiliate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from advancing money to an affiliate (an entity that is related but not strictly controlled by the entity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForAdvanceToAffiliate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ibio_SecuredTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ibio_SecuredTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibio_RubrycTheraputicsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibio_RubrycTheraputicsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ibio_IbioCmoPreferredTrackingStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ibio_IbioCmoPreferredTrackingStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ibio_CollaborationOptionAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ibio_CollaborationOptionAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ibio_ImmuneOncologyAntibodiesRtx003Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ibio_ImmuneOncologyAntibodiesRtx003Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_NoBiosimilarProductHasBeenApprovedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_NoBiosimilarProductHasBeenApprovedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ibio_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ibio_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ibio_SeparationAgreementAndGeneralReleaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ibio_SeparationAgreementAndGeneralReleaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ibio_Series2PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ibio_Series2PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393608617504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Transactions (Summary of Asset Acquisition) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 16, 2022</div></th>
<th class="th"><div>Aug. 23, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Purchase price allocated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_RubrycTheraputicsInc.Member', window );">RubrYc Therapeutics, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Purchase price allocated</a></td>
<td class="nump">$ 1,342,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=ibio_Series2PreferredStockMember', window );">Series A-2 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Purchase price allocated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,760,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=ibio_AssetAcquisitionIntangibleAssetsMember', window );">Asset Acquisition Intangible Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Purchase price allocated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=ibio_AssetAcquisitionIntangibleAssetsMember', window );">Asset Acquisition Intangible Assets [Member] | RubrYc Therapeutics, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Purchase price allocated</a></td>
<td class="nump">1,228,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=ibio_AssetAcquisitionFixedAssetsMember', window );">Asset Acquisition Fixed Assets [Member] | RubrYc Therapeutics, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Purchase price allocated</a></td>
<td class="nump">$ 114,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=ibio_AssetAcquisitionPrepaidExpensesMember', window );">Asset Acquisition Prepaid Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Purchase price allocated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,440,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 55<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6829253&amp;loc=SL6831962-166255<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibio_RubrycTheraputicsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibio_RubrycTheraputicsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ibio_Series2PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ibio_Series2PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ibio_AssetAcquisitionIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ibio_AssetAcquisitionIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ibio_AssetAcquisitionFixedAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ibio_AssetAcquisitionFixedAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ibio_AssetAcquisitionPrepaidExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ibio_AssetAcquisitionPrepaidExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393608614192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Promissory Note Receivable (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2020</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 163<span></span>
</td>
<td class="nump">$ 111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember', window );">Convertible Promissory Note Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LoansReceivableAmountInvested', window );">Amount invested</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LoansReceivableFixedRatesOfInterest', window );">Interest rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetNoncurrent', window );">Note balance and accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,631<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LoansReceivableAmountInvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the face amount of notes receivable invested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LoansReceivableAmountInvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LoansReceivableFixedRatesOfInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of fixed rate of interest on notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LoansReceivableFixedRatesOfInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393612541136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Debt Securities (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments in Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of premiums on debt securities</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 74<span></span>
</td>
<td class="nump">$ 67<span></span>
</td>
<td class="nump">$ 269<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393617878000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments in Debt Securities (Components of Investments in Debt Securities) (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments in Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Adjusted cost</a></td>
<td class="nump">$ 11,029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(184)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Fair value</a></td>
<td class="nump">$ 10,845<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity), and investment in debt security measured at fair value with change in fair value recognized in net income (trading), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393618006384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments in Debt Securities (Debt Securities, Contractual Maturity) (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling Maturity, Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue', window );">2023</a></td>
<td class="nump">$ 8,054<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">2024</a></td>
<td class="nump">2,791<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Fair value</a></td>
<td class="nump">$ 10,845<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity), and investment in debt security measured at fair value with change in fair value recognized in net income (trading), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393617888496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Lease ROU Assets (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract', window );"><strong>Finance Lease ROU [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of finance lease ROU assets</a></td>
<td class="nump">$ 68<span></span>
</td>
<td class="nump">$ 156<span></span>
</td>
<td class="nump">$ 587<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393615407008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Finance Lease ROU Assets (Summary of Finance Lease ROU) (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems', window );"><strong>Finance Lease, Right Of Use Asset, Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">$ (136)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use assets, net of accumulated amortization</a></td>
<td class="nump">678<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ibio_FacilityMember', window );">Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems', window );"><strong>Finance Lease, Right Of Use Asset, Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_FinanceLeaseRightOfUseAssetGross', window );">ROU, gross</a></td>
<td class="nump">$ 814<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_FinanceLeaseRightOfUseAssetGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of lessee's right to use underlying asset under finance lease, before accumulated amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_FinanceLeaseRightOfUseAssetGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ibio_FacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ibio_FacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393615251664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Lease ROU Assets (Narrative) (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 10, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Operating Lease ROU Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of lab and office | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset | $</a></td>
<td class="nump">$ 2,786,000<span></span>
</td>
<td class="nump">$ 3,068,000<span></span>
</td>
<td class="nump">$ 1,967,000<span></span>
</td>
<td class="nump">$ 3,603,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393615282224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Fixed Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 508,000<span></span>
</td>
<td class="nump">$ 1,532,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_FixedAssetsHeldForSale', window );">Fixed assets held for sale</a></td>
<td class="nump">16,424,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,289,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Impairment of fixed assets</a></td>
<td class="nump">$ 17,600,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_FixedAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of fixed assets held-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_FixedAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TangibleAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TangibleAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393608067280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fixed Assets (Carrying Value and Accumulated Depreciation) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross fixed assets</a></td>
<td class="nump">$ 4,593,000<span></span>
</td>
<td class="nump">$ 1,373,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(235,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net fixed assets</a></td>
<td class="nump">4,358,000<span></span>
</td>
<td class="nump">1,373,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings and improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross fixed assets</a></td>
<td class="nump">695,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross fixed assets</a></td>
<td class="nump">3,461,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment and software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross fixed assets</a></td>
<td class="nump">403,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross fixed assets</a></td>
<td class="nump">$ 34,000<span></span>
</td>
<td class="nump">$ 1,373,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393607549328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 14, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Aug. 23, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 565,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 122,000<span></span>
</td>
<td class="nump">121,000<span></span>
</td>
<td class="nump">$ 333,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents and Licenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember', window );">Intellectual Property [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_RubrycTheraputicsInc.Member', window );">RubrYc Therapeutics, Inc. [Member] | Immune-Oncology Antibodies (RTX-003) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockPurchaseAgreementTotalInvestment', window );">Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_StockPurchaseAgreementTotalInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investment under the stock purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_StockPurchaseAgreementTotalInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibio_RubrycTheraputicsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibio_RubrycTheraputicsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ibio_ImmuneOncologyAntibodiesRtx003Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ibio_ImmuneOncologyAntibodiesRtx003Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393607426144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Carrying Value and Accumulated Amortization) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, gross carrying value</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,946,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-Lived Intangible Assets, accumulated amortization</a></td>
<td class="num">(10,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,270,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total definite lived intangible assets, net of accumulated amortization</a></td>
<td class="nump">390,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">390,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">676,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">License - indefinite lived</a></td>
<td class="nump">5,003,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,003,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,175,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total net intangible assets</a></td>
<td class="nump">5,393,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,393,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,851,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDeferredChargesAbstract', window );"><strong>Amortization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of definite lived intangible assets</a></td>
<td class="num">(5,000)<span></span>
</td>
<td class="num">$ (122,000)<span></span>
</td>
<td class="num">(121,000)<span></span>
</td>
<td class="num">$ (333,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRollForward', window );"><strong>Additions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Additions to definite lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefinitelivedIntangibleAssetsAcquired', window );">Additions to licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">828,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairmentAbstract', window );"><strong>Impairments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ImpairmentOfIntangibleAssetsGrossOfReversals', window );">Impairment of intangible assets - gross carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,946,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ReversalOfIntangibleAssetImpairment', window );">Intangible asset impairment - accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,381,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(565,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember', window );">Intellectual Property [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, gross carrying value</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-Lived Intangible Assets, accumulated amortization</a></td>
<td class="num">$ (10,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,867,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDeferredChargesAbstract', window );"><strong>Amortization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of definite lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(74,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRollForward', window );"><strong>Additions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Additions to definite lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairmentAbstract', window );"><strong>Impairments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ImpairmentOfIntangibleAssetsGrossOfReversals', window );">Impairment of intangible assets - gross carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ReversalOfIntangibleAssetImpairment', window );">Intangible asset impairment - accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,931,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents and Licenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, gross carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,846,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-Lived Intangible Assets, accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,403,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDeferredChargesAbstract', window );"><strong>Amortization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of definite lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairmentAbstract', window );"><strong>Impairments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ImpairmentOfIntangibleAssetsGrossOfReversals', window );">Impairment of intangible assets - gross carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,846,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ReversalOfIntangibleAssetImpairment', window );">Intangible asset impairment - accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ImpairmentOfIntangibleAssetsGrossOfReversals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of intangible asset impairment before reversals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ImpairmentOfIntangibleAssetsGrossOfReversals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ReversalOfIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reversal of intangible asset impairment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ReversalOfIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDeferredChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDeferredChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefinitelivedIntangibleAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefinitelivedIntangibleAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393606794816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (The Credit Agreement) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 11, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Oct. 10, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Nov. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,996,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Amount released from restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,857,000<span></span>
</td>
<td class="nump">$ 37,696,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ibio_SecuredTermLoanMember', window );">Secured Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Secured term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,852,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,375,000<span></span>
</td>
<td class="nump">$ 22,375,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Deferred finance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Debt balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,161,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember', window );">College Station Investors LLC And Bryan Capital [Member] | Secured Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Secured term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,375,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_WoodforestMember', window );">Woodforest [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CreditAgreementThresholdLimitUnrestrictedCash', window );">Unrestricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_WoodforestMember', window );">Woodforest [Member] | Amended Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Debt amortization payment</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Amendment fee</a></td>
<td class="nump">22,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DebtCovenantLiquidityAmount', window );">Liquidity covenant, amount</a></td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_WoodforestMember', window );">Woodforest [Member] | Amended Credit Agreement [Member] | Date Of Amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Principal payment</a></td>
<td class="nump">5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_WoodforestMember', window );">Woodforest [Member] | Amended Credit Agreement [Member] | Within Two Business Days Of Frunhofer Legal Settlement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Principal payment</a></td>
<td class="nump">5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_WoodforestMember', window );">Woodforest [Member] | Amended Credit Agreement [Member] | Occurrence Of Specific Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DebtCovenantLiquidityAmount', window );">Liquidity covenant, amount</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CreditAgreementThresholdLimitUnrestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold limit of unrestricted cash to be maintained.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CreditAgreementThresholdLimitUnrestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DebtCovenantLiquidityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required liquidity per debt covenant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DebtCovenantLiquidityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to principal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ibio_SecuredTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ibio_SecuredTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibio_WoodforestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibio_WoodforestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ibio_AmendedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ibio_AmendedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_DateOfAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_DateOfAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_OccurrenceOfSpecificMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_OccurrenceOfSpecificMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393615216528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt (Equipment Financing) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Oct. 12, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EquipmentFinancingAmountBorrowed', window );">Amount borrowed</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeEquipmentLeaseTermOfContract', window );">Term of agreement</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EquipmentFinancingLeaseImputedInterestRate', window );">Imputed interest rate</a></td>
<td class="nump">10.62%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EquipmentLeasingMonthlyInstallmentPayable', window );">Monthly installment payable</a></td>
<td class="nump">$ 16,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EquipmentFinancingBalance', window );">Balance owed under financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 438,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_EquipmentFinancingAmountBorrowed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount borrowed under equipment financing as at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_EquipmentFinancingAmountBorrowed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_EquipmentFinancingBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equipment financing balance under equipment leasing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_EquipmentFinancingBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_EquipmentFinancingLeaseImputedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of imputed interest rate on equipment financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_EquipmentFinancingLeaseImputedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_EquipmentLeasingMonthlyInstallmentPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of monthly installment payable under equipment leasing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_EquipmentLeasingMonthlyInstallmentPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeEquipmentLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee equipment financing lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeEquipmentLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393611650736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt (Equipment Financing) (Future Minimum Payments) (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">2025</a></td>
<td class="nump">195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInThirdYear', window );">2026</a></td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Total minimum equipment financing payments</a></td>
<td class="nump">504<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=ibio_PrincipalMember', window );">Principal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">2024</a></td>
<td class="nump">156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">2025</a></td>
<td class="nump">173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInThirdYear', window );">2026</a></td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Total minimum equipment financing payments</a></td>
<td class="nump">439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ContractualObligationCurrent', window );">Less: current portion</a></td>
<td class="num">(156)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ContractualObligationNoncurrent', window );">Long-term portion of minimum equipment financing obligation</a></td>
<td class="nump">283<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=ibio_InterestMember', window );">Interest [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">2024</a></td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">2025</a></td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInThirdYear', window );">2026</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Total minimum equipment financing payments</a></td>
<td class="nump">$ 65<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ContractualObligationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current portion of contractual obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ContractualObligationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ContractualObligationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of noncurrent portion of contractual obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ContractualObligationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=ibio_PrincipalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=ibio_PrincipalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=ibio_InterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=ibio_InterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393612249360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Note Payable - PPP Loan) (Details) - PPP Loan Cares Act [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Apr. 16, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Note payable, PPP loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDecreaseForgiveness', window );">Liability and accrued interest derecognized</a></td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDecreaseForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDecreaseForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ibio_PppLoanCaresActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ibio_PppLoanCaresActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393612765744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Lease Obligation (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 01, 2021 </div>
<div>USD ($) </div>
<div>lease</div>
</th>
<th class="th">
<div>Apr. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LessorFinanceLeaseMonthlyRent', window );">Mobile office trailer monthly rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_RubrycTheraputicsInc.Member', window );">RubrYc Therapeutics, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_NumberOfEquipmentLeases', window );">Number of equipment leases | lease</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance leases</a></td>
<td class="nump">$ 813,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LeaseRentExpensePerMonth', window );">Monthly rent</a></td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ibio_SecondEasternAffiliateMember', window );">Second Eastern Affiliate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 810,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LeaseRentExpensePerMonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of lease rent expense per month during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LeaseRentExpensePerMonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LessorFinanceLeaseMonthlyRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of rent receivable monthly by the lessor under the finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LessorFinanceLeaseMonthlyRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_NumberOfEquipmentLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of equipment leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_NumberOfEquipmentLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibio_RubrycTheraputicsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibio_RubrycTheraputicsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ibio_SecondEasternAffiliateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ibio_SecondEasternAffiliateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393607291408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Lease Obligation (Finance Lease Cost and Other Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Finance lease cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of ROU assets</a></td>
<td class="nump">$ 68<span></span>
</td>
<td class="nump">$ 156<span></span>
</td>
<td class="nump">$ 587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract', window );"><strong>Cash paid for amounts included in the measurement lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_FinancingCashFlowsFromFinanceLeaseObligation', window );">Financing cash flows from finance lease obligations</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease ROU assets</a></td>
<td class="nump">678<span></span>
</td>
<td class="nump">678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease obligation - current portion</a></td>
<td class="nump">265<span></span>
</td>
<td class="nump">265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease obligation - non current portion</a></td>
<td class="nump">$ 422<span></span>
</td>
<td class="nump">$ 422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term - finance lease</a></td>
<td class="text">2 years 4 months 2 days<span></span>
</td>
<td class="text">2 years 4 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">0 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate - finance lease obligation</a></td>
<td class="nump">9.50%<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_FinancingCashFlowsFromFinanceLeaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash outflow for finance lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_FinancingCashFlowsFromFinanceLeaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393607424320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Finance Lease Obligation (Future Minimum Payments Under the Capitalized Lease Obligations) (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 319<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">772<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">(265)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term portion of minimum lease obligations</a></td>
<td class="nump">422<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=ibio_PrincipalMember', window );">Principal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">292<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">687<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">(265)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term portion of minimum lease obligations</a></td>
<td class="nump">422<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=ibio_InterestMember', window );">Interest [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">$ 85<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=ibio_PrincipalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=ibio_PrincipalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=ibio_InterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=ibio_InterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393606705168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Lease Obligation (Narrative) (Details)<br></strong></div></th>
<th class="th">
<div>Nov. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 10, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of lab and office | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">88 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseMonthlyRent', window );">Operating lease monthly rent payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent', window );">Annual percentage increase in base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TenantImprovements', window );">Tenant improvement allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,860<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsByNatureAxis=us-gaap_FinancialStandbyLetterOfCreditMember', window );">Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsMaximumExposure', window );">Irrevocable letter of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 188,844<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_BaseRentAbatementInFirstYearPeriod', window );">Base rent abatement period in the first year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_BaseRentAbatementInFirstYearPeriod', window );">Base rent abatement period in the first year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember', window );">College Station Investors LLC And Bryan Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_BaseRentPercentageOfFairMarketValueOfProperty', window );">Percentage of base rent</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseMonthlyRent', window );">Operating lease monthly rent payable</a></td>
<td class="nump">$ 151,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_BaseRentAbatementInFirstYearPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Base rent abatement period in the first year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_BaseRentAbatementInFirstYearPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_BaseRentPercentageOfFairMarketValueOfProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of base rent payable on percentage of fair Market Value of the Property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_BaseRentPercentageOfFairMarketValueOfProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating Lease, Annual percentage increase in base rent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseMonthlyRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of rent payable monthly by the lessee under the operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseMonthlyRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsMaximumExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12069-110248<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsMaximumExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsByNatureAxis=us-gaap_FinancialStandbyLetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsByNatureAxis=us-gaap_FinancialStandbyLetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393607215120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Lease Obligation (Lease Expense and Supplemental Balance Sheet Information Related to the Operating Lease Obligation) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_OperatingLeaseCostsAbstract', window );"><strong>Operating lease cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating Lease, Cost</a></td>
<td class="nump">$ 141<span></span>
</td>
<td class="nump">$ 141<span></span>
</td>
<td class="nump">$ 422<span></span>
</td>
<td class="nump">$ 313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_TotalOperatingLeaseCosts', window );">Total lease cost</a></td>
<td class="nump">141<span></span>
</td>
<td class="nump">$ 141<span></span>
</td>
<td class="nump">422<span></span>
</td>
<td class="nump">$ 313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract', window );"><strong>Cash paid for amounts included in the measurement lease liability:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_OperatingCashFlowsFromOperatingLeaseObligation', window );">Operating cash flows from operating lease obligation</a></td>
<td class="nump">$ 103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_OperatingCashFlowsFromOperatingLeaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating cash flows from operating lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_OperatingCashFlowsFromOperatingLeaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_OperatingLeaseCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_OperatingLeaseCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_TotalOperatingLeaseCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total operating lease costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_TotalOperatingLeaseCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393608782224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Lease Obligation (Future Minimum Payments under the Operating Lease Obligation) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Lease Obligation, Principal</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="nump">593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">3,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">(377)<span></span>
</td>
<td class="num">$ (91)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of minimum lease obligation</a></td>
<td class="nump">3,225<span></span>
</td>
<td class="nump">$ 3,514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract', window );"><strong>Operating Lease Obligation, Imputed Interest</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne', window );">2023</a></td>
<td class="nump">249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo', window );">2024</a></td>
<td class="nump">220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree', window );">2025</a></td>
<td class="nump">188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour', window );">2026</a></td>
<td class="nump">151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive', window );">2027</a></td>
<td class="nump">111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive', window );">Thereafter</a></td>
<td class="nump">82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal', window );">Imputed Interest, Total</a></td>
<td class="nump">1,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract', window );"><strong>Operating Lease Obligation, Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne', window );">2023</a></td>
<td class="nump">626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo', window );">2024</a></td>
<td class="nump">644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree', window );">2025</a></td>
<td class="nump">664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour', window );">2026</a></td>
<td class="nump">683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive', window );">2027</a></td>
<td class="nump">704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive', window );">Thereafter</a></td>
<td class="nump">1,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest', window );">Principal and imputed interest, Total</a></td>
<td class="nump">$ 4,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Imputed Interest, to be Paid, After Year Five</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Imputed Interest, to be Paid, Total</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Imputed Interest, to be Paid, Year Five</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Imputed Interest, to be Paid, Year Four.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Imputed Interest, to be Paid, Year One.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Imputed Interest, to be Paid, Year Three</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Imputed Interest, to be Paid, Year Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Imputed Interest Payment, Due [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating Lease Liability Principal And Imputed Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Principal and Imputed Interest Payment, Due [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, After Year Five</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Five</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year One</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Three</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393606160960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity (Narrative) (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 01, 2022 </div>
<div>shares</div>
</th>
<th class="th"><div>Oct. 07, 2022</div></th>
<th class="th">
<div>Aug. 23, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 09, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 23, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 06, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 19, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 01, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stockholders' Equity Note, Stock Split, Conversion Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember', window );">College Station Investors LLC And Bryan Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,583<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_H.c.WainwrightCo.LlcMember', window );">H.C. Wainwright &amp; Co., LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">201,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibio_PreFundedWarrantsMember', window );">Pre Funded Warrants [Member] | H.C. Wainwright &amp; Co., LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesWarrantsMember', window );">Series A Warrants [Member] | H.C. Wainwright &amp; Co., LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of the warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">504,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesBWarrantsMember', window );">Series B Warrants [Member] | H.C. Wainwright &amp; Co., LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of the warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">504,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibio_RepresentativeWarrantsMember', window );">Representative Warrants [Member] | H.C. Wainwright &amp; Co., LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of the warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ibio_PreferredTrackingStockMember', window );">iBio CMO Preferred Tracking Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred Stock, Dividend Rate, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsPerShareDeclared', window );">Preferred Stock, Dividends Per Share, Declared | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ibio_Series2022ConvertiblePreferredStockMember', window );">Series 2022 Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from sale of shares, net of issuance cost | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Shares issued upon conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stockholders' Equity Note, Stock Split, Conversion Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares vested</a></td>
<td class="nump">4,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ibio_OmnibusIncentivePlanMember', window );">Omnibus Incentive (the 2020) Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant under the plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,280,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ibio_ExchangeAgreementMember', window );">Exchange Agreement [Member] | iBio CMO Preferred Tracking Stock [Member] | Bioprocessing (iBio CDMO) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock Issued During Period, Shares, Acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock', window );">Number of LLC interest units exchanged for each share of preferred tracking stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,990,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from sale of shares, net of issuance cost | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ibio_ExchangeAgreementMember', window );">Exchange Agreement [Member] | iBio CMO Preferred Tracking Stock [Member] | After Preferred Tracking Stock Exchanged for Units of Limited Liability Company Interests [Member] | Bioprocessing (iBio CDMO) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Noncontrolling Interest, Ownership Percentage by Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ibio_ExchangeAgreementMember', window );">Exchange Agreement [Member] | Eastern Affiliate [Member] | iBio CMO Preferred Tracking Stock [Member] | After Preferred Tracking Stock Exchanged for Units of Limited Liability Company Interests [Member] | Bioprocessing (iBio CDMO) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.01%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Limited Liability Company interest units exchanged for each share of preferred tracking stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_StockholdersEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_StockholdersEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of preferred stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibio_H.c.WainwrightCo.LlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibio_H.c.WainwrightCo.LlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ibio_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ibio_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ibio_RepresentativeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ibio_RepresentativeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ibio_PreferredTrackingStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ibio_PreferredTrackingStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ibio_Series2022ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ibio_Series2022ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ibio_OmnibusIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ibio_OmnibusIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ibio_ExchangeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ibio_ExchangeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ibio_IbioCdmoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ibio_IbioCdmoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ibio_EasternAffiliateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ibio_EasternAffiliateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393607427680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Cantor Fitzgerald Underwriting and RubrYc Transaction) (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 19, 2022</div></th>
<th class="th"><div>Aug. 17, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Nov. 25, 2020</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SubscriptionReceivableCurrent', window );">Subscription receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_RubrycTheraputicsInc.Member', window );">RubrYc Therapeutics, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of preferred stock</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued</a></td>
<td class="nump">102,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ibio_SalesAgreementMember', window );">Sales Agreement | Cantor Fitzgerald [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_AggregateCommonStockPurchased', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,551,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from sale of shares, net of issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_AggregateCommonStockPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_AggregateCommonStockPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_SubscriptionReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of subscription receivables classified due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_SubscriptionReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibio_RubrycTheraputicsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibio_RubrycTheraputicsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ibio_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ibio_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibio_CantorFitzgeraldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibio_CantorFitzgeraldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393607238752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity (Wainwright Underwriting and Vesting of RSUs) (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 06, 2022 </div>
<div>USD ($) </div>
<div>D </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 01, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 23, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,120<span></span>
</td>
<td class="nump">1,057<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_H.c.WainwrightCo.LlcMember', window );">H.C. Wainwright &amp; Co., LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of Common Stock</a></td>
<td class="nump">201,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering', window );">Percentage of underwriting discount</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_NumberOfDaysOptionToPurchaseAdditionalShares', window );">Number of days granted to purchase additional shares | D</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_NumberOfAdditionalSharesIssued', window );">Additional shares issued</a></td>
<td class="nump">504,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CommonWarrantsToPurchaseAdditionalShares', window );">Warrants to purchase additional shares</a></td>
<td class="nump">1,009,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_PercentageOfAggregateNumberOfSharesOfCommonStock', window );">Percentage of number of shares</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Net proceeds | $</a></td>
<td class="nump">$ 2,864,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_H.c.WainwrightCo.LlcMember', window );">H.C. Wainwright &amp; Co., LLC [Member] | Series A Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of Common Stock</a></td>
<td class="nump">504,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_H.c.WainwrightCo.LlcMember', window );">H.C. Wainwright &amp; Co., LLC [Member] | Series B Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of Common Stock</a></td>
<td class="nump">504,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_H.c.WainwrightCo.LlcMember', window );">H.C. Wainwright &amp; Co., LLC [Member] | Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">1,530,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_H.c.WainwrightCo.LlcMember', window );">H.C. Wainwright &amp; Co., LLC [Member] | Over-Allotment Option [Member] | Pre Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of Common Stock</a></td>
<td class="nump">1,834,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_H.c.WainwrightCo.LlcMember', window );">H.C. Wainwright &amp; Co., LLC [Member] | Over-Allotment Option [Member] | Series A Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of Common Stock</a></td>
<td class="nump">3,365,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_H.c.WainwrightCo.LlcMember', window );">H.C. Wainwright &amp; Co., LLC [Member] | Over-Allotment Option [Member] | Series B Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of Common Stock</a></td>
<td class="nump">3,365,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CommonWarrantsToPurchaseAdditionalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common warrants to purchase additional shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CommonWarrantsToPurchaseAdditionalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_NumberOfAdditionalSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_NumberOfAdditionalSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_NumberOfDaysOptionToPurchaseAdditionalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of days option to purchase additional shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_NumberOfDaysOptionToPurchaseAdditionalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_PercentageOfAggregateNumberOfSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of aggregate number of shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_PercentageOfAggregateNumberOfSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of underwriting discount paid on gross proceeds of offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibio_H.c.WainwrightCo.LlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibio_H.c.WainwrightCo.LlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ibio_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ibio_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393605005968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Common Share (Components of the Earnings (Loss) per Common Share ) (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Basic and diluted numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net loss attributable to iBio, Inc.</a></td>
<td class="num">$ (6,279)<span></span>
</td>
<td class="num">$ (6,746)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (24,379)<span></span>
</td>
<td class="num">$ (19,125)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockStock', window );">Preferred stock dividends - iBio CMO Preferred Tracking Stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(88)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss available to iBio, Inc. stockholders</a></td>
<td class="num">(6,279)<span></span>
</td>
<td class="num">(6,746)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,379)<span></span>
</td>
<td class="num">(19,213)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Loss from discontinued operations</a></td>
<td class="num">(1,015)<span></span>
</td>
<td class="num">(5,644)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34,598)<span></span>
</td>
<td class="num">(14,124)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_UnconsolidatedGainLossAttributableToStockholders', window );">Net loss available to iBio, Inc. stockholders</a></td>
<td class="num">$ (7,294)<span></span>
</td>
<td class="num">$ (12,390)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (58,977)<span></span>
</td>
<td class="num">$ (33,337)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic and diluted denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic</a></td>
<td class="nump">13,184<span></span>
</td>
<td class="nump">8,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,592<span></span>
</td>
<td class="nump">8,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding - diluted</a></td>
<td class="nump">13,184<span></span>
</td>
<td class="nump">8,719<span></span>
</td>
<td class="nump">8,719<span></span>
</td>
<td class="nump">10,592<span></span>
</td>
<td class="nump">8,719<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Loss per common share attributable to iBio, Inc. stockholders - basic - continuing operations</a></td>
<td class="num">$ (0.47)<span></span>
</td>
<td class="num">$ (0.77)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.30)<span></span>
</td>
<td class="num">$ (2.20)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Loss per common share attributable to iBio, Inc. stockholders - diluted - continuing operations</a></td>
<td class="num">(0.47)<span></span>
</td>
<td class="num">(0.77)<span></span>
</td>
<td class="num">$ (2.20)<span></span>
</td>
<td class="num">(2.30)<span></span>
</td>
<td class="num">(2.20)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Loss per common share attributable to iBio, Inc. stockholders - basic - discontinued operations</a></td>
<td class="num">(0.08)<span></span>
</td>
<td class="num">(0.65)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.27)<span></span>
</td>
<td class="num">(1.62)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Loss per common share attributable to iBio, Inc. stockholders - diluted - discontinued operations</a></td>
<td class="num">(0.08)<span></span>
</td>
<td class="num">(0.65)<span></span>
</td>
<td class="num">(1.62)<span></span>
</td>
<td class="num">(3.27)<span></span>
</td>
<td class="num">(1.62)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Per share amount basic</a></td>
<td class="num">(0.55)<span></span>
</td>
<td class="num">(1.42)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.57)<span></span>
</td>
<td class="num">(3.82)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Per share amount diluted</a></td>
<td class="num">$ (0.55)<span></span>
</td>
<td class="num">$ (1.42)<span></span>
</td>
<td class="num">$ (3.82)<span></span>
</td>
<td class="num">$ (5.57)<span></span>
</td>
<td class="num">$ (3.82)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_UnconsolidatedGainLossAttributableToStockholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The unconsolidated net gain (loss) attributable to stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_UnconsolidatedGainLossAttributableToStockholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStockStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStockStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4613673-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393607293824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Common Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 07, 2022</div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EarningsLossPerCommonShareLineItems', window );"><strong>Earnings Loss Per Common Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,848<span></span>
</td>
<td class="nump">699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stockholders' Equity Note, Stock Split, Conversion Ratio</a></td>
<td class="nump">0.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EarningsLossPerCommonShareLineItems', window );"><strong>Earnings Loss Per Common Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">457<span></span>
</td>
<td class="nump">625<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EarningsLossPerCommonShareLineItems', window );"><strong>Earnings Loss Per Common Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">443<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EarningsLossPerCommonShareLineItems', window );"><strong>Earnings Loss Per Common Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,948<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_EarningsLossPerCommonShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_EarningsLossPerCommonShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393606872128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 09, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ibio_IbioInc.2020OmnibusEquityIncentivePlanMember', window );">2020 Omnibus Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,280,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized', window );">Maximum value of all awards awarded under the Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | 2018 Omnibus Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share based award, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | 2018 Omnibus Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share based award, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ibio_ConsultantsMember', window );">Consultants [Member] | 2020 Omnibus Equity Incentive Plan [Member] | Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share based award, vesting period</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price per share, granted</a></td>
<td class="nump">$ 6.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share based payment plan term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ibio_VariousEmployeesMember', window );">Employees [Member] | 2020 Omnibus Equity Incentive Plan [Member] | Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="nump">303,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share based payment plan term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ibio_VariousEmployeesMember', window );">Employees [Member] | 2020 Omnibus Equity Incentive Plan [Member] | Share-Based Payment Arrangement, Tranche One [Member] | Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share based award, vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Stock options vesting percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ibio_VariousEmployeesMember', window );">Employees [Member] | 2020 Omnibus Equity Incentive Plan [Member] | Share-Based Payment Arrangement, Tranche Two [Member] | Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share based award, vesting period</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ibio_VariousEmployeesMember', window );">Employees [Member] | Minimum [Member] | 2020 Omnibus Equity Incentive Plan [Member] | Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price per share, granted</a></td>
<td class="nump">$ 6.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ibio_VariousEmployeesMember', window );">Employees [Member] | Maximum [Member] | 2020 Omnibus Equity Incentive Plan [Member] | Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price per share, granted</a></td>
<td class="nump">$ 9.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ibio_ScenarioOneMember', window );">Scenario One [Member] | 2020 Omnibus Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized', window );">Maximum value of all awards awarded under the Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ibio_ScenarioTwoMember', window );">Scenario Two [Member] | 2020 Omnibus Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized', window );">Maximum value of all awards awarded under the Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Amount of Shares Authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ibio_IbioInc.2020OmnibusEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ibio_IbioInc.2020OmnibusEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ibio_TwoThousandEighteenOmnibusEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ibio_TwoThousandEighteenOmnibusEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ibio_ConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ibio_ConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ibio_VariousEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ibio_VariousEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_ScenarioOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_ScenarioOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_ScenarioTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_ScenarioTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393605015632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Share Based Compensation Expense) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="nump">$ 385<span></span>
</td>
<td class="nump">$ 1,213<span></span>
</td>
<td class="nump">$ 2,426<span></span>
</td>
<td class="nump">$ 2,893<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">Discontinued Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="nump">1,211<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="nump">1,519<span></span>
</td>
<td class="nump">305<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">101<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="nump">$ 345<span></span>
</td>
<td class="nump">$ 1,112<span></span>
</td>
<td class="nump">$ 2,330<span></span>
</td>
<td class="nump">$ 2,761<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393615222672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Fair Value of Options Granted) (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Compensation [Member]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk free interest rate, Minimum</a></td>
<td class="nump">3.21%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk free interest rate, Maximum</a></td>
<td class="nump">3.61%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility, Minimum</a></td>
<td class="nump">115.52%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility, Maximum</a></td>
<td class="nump">116.93%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393618008112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share-Based Compensation (RSUs) (Details) - Restricted Stock Units [Member] - Dr. Martin Brenner<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jan. 20, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based award, Units to be issued | shares</a></td>
<td class="nump">130,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share based award, vesting period</a></td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Grant date fair value | $</a></td>
<td class="nump">$ 91<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ibio_Dr.MartinBrennerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ibio_Dr.MartinBrennerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393608693040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fraunhofer Settlement (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 09, 2022</div></th>
<th class="th"><div>May 04, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 01, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 01, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SettlementAssetsCurrent', window );">Settlement receivable - current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="nump">$ 1,884,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,996,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember', window );">iBio, Inc. v. Fraunhofer USA, Inc. [Member] | Settled Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CashPaymentsReceivablesRelatedToLitigationSettlement', window );">Cash payments receivables related to litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_PercentageOfLegalFeesExpectedToBeReceived', window );">Percentage of legal fees expected to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainContingencyUnrecordedAmount', window );">Estimated net cash recovery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLegalSettlements', window );">Settlement payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember', window );">iBio, Inc. v. Fraunhofer USA, Inc. [Member] | Settled Litigation [Member] | License and Maintenance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty', window );">Settlement income</a></td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLegalSettlements', window );">Settlement payment received</a></td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember', window );">iBio, Inc. v. Fraunhofer USA, Inc. [Member] | Settled Litigation [Member] | Scenario, Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CashPaymentsReceivablesRelatedToLitigationSettlement', window );">Cash payments receivables related to litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember', window );">iBio, Inc. v. Fraunhofer USA, Inc. [Member] | Settled Litigation [Member] | Scenario Plan Expected Legal Fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CashPaymentsReceivablesRelatedToLitigationSettlement', window );">Cash payments receivables related to litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember', window );">iBio, Inc. v. Fraunhofer USA, Inc. [Member] | Settled Litigation [Member] | Scenario Plan Expected Payment One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CashPaymentsReceivablesRelatedToLitigationSettlement', window );">Cash payments receivables related to litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember', window );">iBio, Inc. v. Fraunhofer USA, Inc. [Member] | Settled Litigation [Member] | Scenario Plan Expected Payment One [Member] | License and Maintenance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SettlementAssetsCurrent', window );">Settlement receivable - current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember', window );">iBio, Inc. v. Fraunhofer USA, Inc. [Member] | Settled Litigation [Member] | Scenario Plan Expected Payment Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CashPaymentsReceivablesRelatedToLitigationSettlement', window );">Cash payments receivables related to litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember', window );">iBio, Inc. v. Fraunhofer USA, Inc. [Member] | Settled Litigation [Member] | Scenario Plan Expected Payment Two [Member] | License and Maintenance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SettlementAssetsNonCurrent', window );">Settlement receivable - noncurrent portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CashPaymentsReceivablesRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments receivables related to litigation settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CashPaymentsReceivablesRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_PercentageOfLegalFeesExpectedToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of legal fees expected to be received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_PercentageOfLegalFeesExpectedToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_SettlementAssetsNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Settlement receivables, Non current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_SettlementAssetsNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingencyUnrecordedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount or range of possible amounts of gain that could be realized upon the resolution of a contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6397426&amp;loc=d3e17499-108355<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingencyUnrecordedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded from other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedFromOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received for the settlement of litigation during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SettlementAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received or short term receivables for unsettled money transfers, money orders, consumer payments, or business to business payments. Settlement assets include clearing and settling customers payments due to and from financial institutions and may include cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SettlementAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndMaintenanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndMaintenanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_ScenarioPlanExpectedLegalFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_ScenarioPlanExpectedLegalFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_ScenarioPlanExpectedPaymentOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_ScenarioPlanExpectedPaymentOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_ScenarioPlanExpectedPaymentTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_ScenarioPlanExpectedPaymentTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393612715888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393615347520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Narrative) (Details) - CRO Agreement [Member]<br></strong></div></th>
<th class="th">
<div>Oct. 10, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Costs incurred</a></td>
<td class="nump">$ 422,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EstimatedAdditionalCostOnDevelopment', window );">Additional costs committed</a></td>
<td class="nump">$ 958,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_EstimatedAdditionalCostOnDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated additional cost on development as at end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_EstimatedAdditionalCostOnDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ibio_CroAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ibio_CroAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393612212304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee 401(K) Plan (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Defined Benefit Plan, Plan Assets, Contributions by Employer</a></td>
<td class="nump">$ 56,000<span></span>
</td>
<td class="nump">$ 54,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 116,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">Discontinued Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Defined Benefit Plan, Plan Assets, Contributions by Employer</a></td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="nump">$ 41,000<span></span>
</td>
<td class="nump">$ 129,000<span></span>
</td>
<td class="nump">$ 110,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140393618931984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Amount released from restricted cash</a></td>
<td class="nump">$ 18,857<span></span>
</td>
<td class="nump">$ 37,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">$ 3,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,996<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>ibio-20230331x10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:ibio="http://www.ibioinc.com/20230331"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ibio-20230331.xsd" xlink:type="simple"/>
    <context id="Duration_7_1_2022_To_3_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_GWDLoqc91Eylj7aqLB53AA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_3_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_OScbop6D_EyFbi9oWinyQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uJ57OeAa6Em8d-wBmehB4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7S5LrOv4UU-uYc7t0vEohw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ydfUDabqlkij0w-BBn4BJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_6_2022_To_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_KH2r3-L2ZEmEEfMT1ZNKKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-06</startDate>
            <endDate>2022-12-06</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_qNVa23oLakSTWA8v85-VDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_7_2022_To_10_7_2022_Slp385Pip0S6eRadEDIyaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <startDate>2022-10-07</startDate>
            <endDate>2022-10-07</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_a8XYRnY0YEqjr3LZjT16ww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Dq6r99N510C1DCNhsL8h9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_aXxc-Org7Umr-wR0vxLYGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ljAxJwch6kazqell6E9urQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Zo82mtQMNE2WG6FBhO9Gxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_OyKJ3tL-Q06qZ-tFHs9gXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_btFG4i_i4UifFBqeFaAOYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tl2lar8KpUyhhXZisj7IKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Pbu5fuCUvkqtV3iKXcXZgg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_FQYWefjPT06gXbntJAGaLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_JyoJW5xFA02SvXgMgzGBBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sIGvof6AoUegd5YJhRXoGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_eeBEWZpzDEuzNagWju7iXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_abZOLroj_UO6rIP7k3Bifg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tF8wULMhbkG99rPul9KSrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_PWObTblql0OvdhYq9X8sSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZL8l8ThJZ0-W7M_aNkuPyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_XTKrAoBNIEahMhTSx3nvGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_q6a6n0hytkGjctTlsPRp-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_3LjjH4Oi8EqKlNswnjVbLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_gOfCh-hUOkaoojsAe2NwmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_eTEPnd7U0k2A3wEuB687aA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_hsH-C_nn7UGLsToocSuw0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_jVGpJMpt70iwB6r1klHOKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_6xZdpSuxG02KaCdJhSlZ7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HFSiWMrWY0ej62GFJxBZIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_3WIr_ndZqka5CsSKIRQ3fA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_oxzaYxve7U-k1xy12FFQvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_pVa8MvgG4kWQa5aMi-i-SQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_G5vLxz-NeEqgDIsG6nvKaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8ASi2S5ht0qWY7QQf1HPIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_84GMwaIsm0KxnvZMEZe9PA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_302kYRWtf0SLrzPv4HomVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_UH3i88_6M0mId27kV_1YRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_swlXLlVROkCjZl5I0-C9RQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vSAxS0YAgUqgjKsUyRNznw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QXzbdBTf7UyvyFsCyM5MpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__ZOGluhSl0G7K2wu1sD4IQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember__h4euJzls0O2OyXOl4zqpA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_vETdeXuor0693SHSOmu6TA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_PlanNameAxis_ibio_OmnibusIncentivePlanMember_KOZgQdvqsU-8te5q0_AgpA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:OmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_BcLE-e5aOUawYtWYzbYpuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2022_To_12_1_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_hQgfyxu2uUOmIRU8B4Fklw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-01</endDate>
        </period>
    </context>
    <context id="Duration_8_23_2022_To_8_23_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_lmnxjWAiuES8yulA3DkvLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-23</startDate>
            <endDate>2022-08-23</endDate>
        </period>
    </context>
    <context id="Duration_1_20_2023_To_1_20_2023_srt_TitleOfIndividualAxis_ibio_Dr.MartinBrennerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_N9G2vRJjBkiY4CVMVYrH_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:Dr.MartinBrennerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-20</startDate>
            <endDate>2023-01-20</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_3_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_ibio_TwoThousandEighteenOmnibusEquityIncentivePlanMember_RgnWTUvfSUmaNbGh5cYapQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:TwoThousandEighteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_3_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_ibio_TwoThousandEighteenOmnibusEquityIncentivePlanMember_B8y79W7GIkih4LgR3vQBOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:TwoThousandEighteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_fmpgVBKP1km0zpZ63FGixw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_OhlEn2kqNUmaT0Hh--g1yg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_ConsultantsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_yuIW9ztkf0mAQBCgQQaTxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:ConsultantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentOneMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_NmtkHB0kdUyIGd_4OxJpew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndMaintenanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioPlanExpectedPaymentOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="Duration_7_25_2022_To_8_17_2022_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_ggLswlBXtkqHIYFVDHZ-Zg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CantorFitzgeraldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-25</startDate>
            <endDate>2022-08-17</endDate>
        </period>
    </context>
    <context id="Duration_5_9_2022_To_5_9_2022_us-gaap_StatementClassOfStockAxis_ibio_Series2022ConvertiblePreferredStockMember_IRKi-LuHkUq15KpdZkL8TA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:Series2022ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-09</startDate>
            <endDate>2022-05-09</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditTermLoanMember_pkYNKGm7FE-AjzorOXr0XA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ibio:LetterOfCreditTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditSanDiegoLeaseMember_wcNGCEcPbEm21StpOapKJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ibio:LetterOfCreditSanDiegoLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_CompanyPurchasingCardMember_ZTE2EhC6DUi3V8Us5_uTEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ibio:CompanyPurchasingCardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditTermLoanMember_ZKZXpDTWYkGA9VMDpyQWng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ibio:LetterOfCreditTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditSanDiegoLeaseMember_yPkVHgiNf0eqnma-vd44Og">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ibio:LetterOfCreditSanDiegoLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_CompanyPurchasingCardMember_jAg6eAzyCE6hspA3-EkVZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ibio:CompanyPurchasingCardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_3_31_2023_srt_RangeAxis_srt_MinimumMember_iZJ0-KgMMEWGQBeszyazgg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_3_31_2023_srt_RangeAxis_srt_MaximumMember_qkTv4t_oSEqp0FIe4NY8bw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_6QB18MmXqEK9CBa2yX9t0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_yqfA3UgBD0GxUlVv1J1aZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_lgu0RKVqRUy0scLhwVYi5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_ThM6Q7i9IU-hcgFbdInU_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_NSlKXkd1_ky6H3FWqPfqaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_6pSybpjm2Em9u1qgqtHc8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_11_1_2021_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_Nh5Sltvg50S1MDQaPh-wrw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:PreferredTrackingStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-01</instant>
        </period>
    </context>
    <context id="As_Of_2_23_2017_lMLzTmFjFUeEaGVOB1WIPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <instant>2017-02-23</instant>
        </period>
    </context>
    <context id="As_Of_5_9_2022_vsP8EMdp9kqoJCsGc37KdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <instant>2022-05-09</instant>
        </period>
    </context>
    <context id="Duration_10_31_2021_To_10_31_2021_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_47o5yRKDNE6T9LQPWz8erA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:PreferredTrackingStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-31</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="Duration_2_23_2017_To_2_23_2017_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_hlhl6dJdp0if7Q1n3P67xA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:PreferredTrackingStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-02-23</startDate>
            <endDate>2017-02-23</endDate>
        </period>
    </context>
    <context id="Duration_10_10_2022_To_10_10_2022_us-gaap_TypeOfArrangementAxis_ibio_CroAgreementMember_58YO1TPUFEKbnaIFe8Kesw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:CroAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-10</startDate>
            <endDate>2022-10-10</endDate>
        </period>
    </context>
    <context id="As_Of_11_1_2021_klJV-onJz0KrNHSyhYX8GA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <instant>2021-11-01</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_1HkfNu-AM0mxZ7COThJZjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_gf874UKLE0GViq4jrr0myw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_s9UOO5awBEKLVvHLUhhOvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_QiAZnlfbxEmMw0lCHMl5EA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZuedCxHLfEuQdq1I8bADJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ll59BJ1LzUSofhSUma-j9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ogcZKKYW_Eir0iTTRpyFTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_reQq62UAKUWWMC0PAA6-mQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_aWjmWshK0UmxjFzpIuJKUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_srt_StatementScenarioAxis_ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_1x-cfjUThkKbcg8PyPRDEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ibio:IbioCdmoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:PreferredTrackingStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibio:ExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-02-23</instant>
        </period>
    </context>
    <context id="As_Of_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_srt_StatementScenarioAxis_ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ibio_EasternAffiliateMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_qFx6baRFl0K1AnDbITGYjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ibio:IbioCdmoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibio:EasternAffiliateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:PreferredTrackingStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibio:ExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-02-23</instant>
        </period>
    </context>
    <context id="As_Of_4_16_2020_us-gaap_DebtInstrumentAxis_ibio_PppLoanCaresActMember_arEPE-gVxE-EC-ffEJt_Mw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:PppLoanCaresActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-16</instant>
        </period>
    </context>
    <context id="Duration_2_9_2022_To_2_9_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_jUBQVMVhmEuilj8unuIy3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndMaintenanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-09</startDate>
            <endDate>2022-02-09</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_3ufJCLpgP0Khx5n03TYFHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_3_31_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_WSwD-_QeQUyXYX-UiYDXDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_AXcDgcQQBEGgUeelykng1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_3_31_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_7hfM841DCUy3t_UYmcPmTA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ibio_SecondEasternAffiliateMember_KNUp6QEjNk2k0RVdB9kesQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibio:SecondEasternAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_3_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ibio_SecondEasternAffiliateMember_NrQUiMJSu0yMjFFmZyMHLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibio:SecondEasternAffiliateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_2_14_2023_To_2_14_2023_TnhaetjjP06Trcv9WL2o_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <startDate>2023-02-14</startDate>
            <endDate>2023-02-14</endDate>
        </period>
    </context>
    <context id="As_Of_9_10_2021_us-gaap_GuaranteeObligationsByNatureAxis_us-gaap_FinancialStandbyLetterOfCreditMember_KIF7AjbiKESPVs3YPPPkKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">us-gaap:FinancialStandbyLetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-10</instant>
        </period>
    </context>
    <context id="As_Of_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_DniZqopZZkSjp3fXCv6SrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-04</instant>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_3_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_7qvwM12szUub7e7UoiuztA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_5pgV7l8BAkeLqa2TtOfOrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_3xQ4GPFAFEWXC_8Y-7ecig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_h4ptg2J5jEab7-ozoqAPPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementMember_k1dUagvh-06HXU6xBQefUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-16</instant>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_FGJtC-Cca0ywdM4SzNVWpg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_JJDtYxXNZUqTS9r_Ytu0CA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_huTLj4Tyh0uE8TfHbS9zCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_wmQZYW3PoEyWWUp8Dmyyyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Tqrr8xcQvkaRlWyBfJNZbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_11_2022_To_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_uQ72oafLtUqgFnnzbdiAsw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-11</startDate>
            <endDate>2022-10-11</endDate>
        </period>
    </context>
    <context id="Duration_10_11_2022_To_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_DateOfAmendmentMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_ymy8A_X8_EK1tvCrHTVuEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:DateOfAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-11</startDate>
            <endDate>2022-10-11</endDate>
        </period>
    </context>
    <context id="Duration_10_11_2022_To_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_SmV5R4SrNkmUCX3FsbIGLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-11</startDate>
            <endDate>2022-10-11</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_co4oLbGgmE-T18TcXR1zRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:SecuredTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_Vft8wC26KU20m86L9BIQqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:SecuredTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_jDRo_Tn2dEiaxaJsfTrTaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CollegeStationInvestorsLlcAndBryanCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:SecuredTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-01</instant>
        </period>
    </context>
    <context id="As_Of_11_1_2021_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_LgWNkAEXrEOd4Kk1fbDdsQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:SecuredTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-01</instant>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_ibio_PppLoanCaresActMember_fyRImC3heEeL4wSzPLvcgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:PppLoanCaresActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_7_19_2022_us-gaap_StatementClassOfStockAxis_ibio_Series2022ConvertiblePreferredStockMember_qeFYBi3PAUWnjNGHYNci7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:Series2022ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-19</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentContinuingOperationsMember_Cex7NDVXOEO89CLJRQZTuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_3_31_2022_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentContinuingOperationsMember_h7DRj5r8q0CCEDp9Wg0n4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_ELLu56FrAUeDrqmkxHQWOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibio:InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_9_19_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_8ARQ_UpEmkSNVg45b4FndQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-19</instant>
        </period>
    </context>
    <context id="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_J-u4uOUfG0ORoIm4jvgctQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-06</instant>
        </period>
    </context>
    <context id="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_cBAtqPpEJUqEJd0c0GaR7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesBWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-06</instant>
        </period>
    </context>
    <context id="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_InpkTkfz_02nABMpU6azWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-06</instant>
        </period>
    </context>
    <context id="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_A4kvDn5x20q7_8fIvjOF-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-06</instant>
        </period>
    </context>
    <context id="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_BCjemMCehUOFvWDV-Z5NgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-06</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_nMTFluJjHUGsVU2uJ_O6bQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_MA5Y7fHH4E6vZRFVAPWBvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_RepresentativeWarrantsMember_L0HxhOr8_0eWqjfa9gKftw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:RepresentativeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_PreFundedWarrantsMember_AmjIXMsiE020WBD4cpXPjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_xGREzJg85k2rOyE5lH-V2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-16</instant>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_3_31_2023_us-gaap_AssetAcquisitionAxis_ibio_StockPurchaseAgreementMember_3-07kxSNOkaDZSJYQDyQdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibio:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_3_31_2023_us-gaap_AssetAcquisitionAxis_ibio_AssetPurchaseAgreementMember_W13nwak_50mao3LDEg0jzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibio:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_9_16_2022_To_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionIntangibleAssetsMember_yQ9fxKqDbkGLPQucgu0SgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibio:AssetAcquisitionIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-16</startDate>
            <endDate>2022-09-16</endDate>
        </period>
    </context>
    <context id="Duration_9_16_2022_To_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionFixedAssetsMember_vLthqkkiPEekVSsXm4z-Wg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibio:AssetAcquisitionFixedAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-16</startDate>
            <endDate>2022-09-16</endDate>
        </period>
    </context>
    <context id="Duration_8_23_2021_To_8_23_2021_ibio_AssetAcquisitionAxis_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionPrepaidExpensesMember_ZiSAVMfDE0OuOIvWRTPOkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibio:AssetAcquisitionPrepaidExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-23</startDate>
            <endDate>2021-08-23</endDate>
        </period>
    </context>
    <context id="Duration_8_23_2021_To_8_23_2021_ibio_AssetAcquisitionAxis_us-gaap_FiniteLivedIntangibleAssetsMember_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionIntangibleAssetsMember__yJ7v5TK2km2wwhoqTq5Cw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibio:AssetAcquisitionIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-23</startDate>
            <endDate>2021-08-23</endDate>
        </period>
    </context>
    <context id="Duration_8_23_2021_To_8_23_2021_ibio_AssetAcquisitionAxis_ibio_Series2PreferredStockMember_us-gaap_AssetAcquisitionAxis_ibio_Series2PreferredStockMember_VOoG9DcOHkek5MqvabkkeA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibio:Series2PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-23</startDate>
            <endDate>2021-08-23</endDate>
        </period>
    </context>
    <context id="Duration_8_23_2021_To_8_23_2021_HiZIlu8ubEeyewTLP3230g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <startDate>2021-08-23</startDate>
            <endDate>2021-08-23</endDate>
        </period>
    </context>
    <context id="As_Of_9_10_2021_fOp8nNM7xESd6X0-jbcuDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <instant>2021-09-10</instant>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_3_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_-vyQFO66V0-VnP5O63-I_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_3_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_gE-bXUQhFkqJyMBuH9S0rQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_3_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_uH1aZ6v5zUW5U0OYeCYCVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_3_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_zQX7x8UMbk6gJSsI7k7Ecw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_3_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_52A2X6mgk0CFvchRmy-_Xw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_3_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_wGAzW97TrUSXKPZdUccZUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_qwQKiC4qEkiqgQ5177TkpA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_0YZIOq7O40ivJtfSHHkoMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_qY2IkD16B0qsnL9JdcbhWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_3_31_2023_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_uXNvRGR-RESDya9s9QmQmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_j5YNxf9-9UOgFjDrRr3Uog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_8W6InNkO50yKpr_pjkqq9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_RaNGnKpnsEaTsjOvOslUxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_qBMqGNRQFUWB9ZObqlDu1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_e_Rq4byCpkSvRJ7e4WS-Ew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_3_31_2022_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_GqDXZ6lLOEyUlH87AA2kZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_T5bdyp2yw0iUue1_r7FPew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_aJI5vfPiSkWbqmmaBoEKtQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_PuLylut6L0y-PztjYjnBWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gnv2jc0O2EKruqChBGMUTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_vL3rOPanq0GYnPOprKHLGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2022_-w0U61DdKUWU0kwbv1xmfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_RvsAx0CeVUiEHjFvD-Jmkw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_vI4fmkUg3kuCuyZ_zK8brg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ibio:ImmuneOncologyAntibodiesRtx003Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-23</instant>
        </period>
    </context>
    <context id="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_us-gaap_StatementClassOfStockAxis_ibio_Series2PreferredStockMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementMember_YCIyuJUGskWd66faz53YYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ibio:ImmuneOncologyAntibodiesRtx003Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:Series2PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-23</startDate>
            <endDate>2021-08-23</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_o6HWlvHmjUS2rzS8fnoWuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MWdz4lqoIEShu4AoC1KFyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_9_2020_srt_StatementScenarioAxis_ibio_ScenarioTwoMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_JVZ6u6vkRkGYKXk3HmaqFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-09</instant>
        </period>
    </context>
    <context id="As_Of_12_9_2020_srt_StatementScenarioAxis_ibio_ScenarioOneMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_tZmDg9QDo0iz01RbPbZOcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-09</instant>
        </period>
    </context>
    <context id="As_Of_12_9_2020_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_x5WH3KDAZkGbq_aE3REdDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-09</instant>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_3_31_2023_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_7N6sRqj9kEWZRTEMclg2yA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:SeparationAgreementAndGeneralReleaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentTwoMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_KtCuFsBjc0WIUmqqIyBxaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndMaintenanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioPlanExpectedPaymentTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_YZMShz8Rh0u-FmqZPOXdfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_5_4_2021_To_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_eCKkBDi1PUu1tOF1oLvpIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-04</startDate>
            <endDate>2021-05-04</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_R1fh5LInTEmTcImaZYCq4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_3_31_2023_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_ARnE75gvP0qnPbmgOAREKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_7ZRgVsYP8kOQ3Ji8AiOywQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_3_31_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_yRWAOjfd2Ue7tGm5AdoU8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_2_23_2017_To_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_oc0tqqFKsk-LEKQxwyeAOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ibio:IbioCdmoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:PreferredTrackingStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibio:ExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-02-23</startDate>
            <endDate>2017-02-23</endDate>
        </period>
    </context>
    <context id="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_aNeIbxhhIUWzr_C1HYpBqQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-01</instant>
        </period>
    </context>
    <context id="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_t_boUVr6WkyudoVlOiImcQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-06</instant>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_10_1_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_zTgxHY80r0C6Oan6do8BOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-01</endDate>
        </period>
    </context>
    <context id="As_Of_10_1_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_VyVmxesCq0KMm1BWB8Egcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-01</instant>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_4_1_2021_34XjF-RfakO2aPg-6ZHbIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-01</endDate>
        </period>
    </context>
    <context id="Duration_9_10_2021_To_9_10_2021_nXnIcEGZ8UGqkU29lvwVJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <startDate>2021-09-10</startDate>
            <endDate>2021-09-10</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_GnYUgnieSE-ivQH2Syhl-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-01</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_us-gaap_StatementClassOfStockAxis_ibio_Series2PreferredStockMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementMember_GiIiWNIPGEib_sv1KnwHFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ibio:ImmuneOncologyAntibodiesRtx003Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:Series2PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_3_31_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_9dyJeVMv1ki5yRGsbgJw-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_3_31_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_V386ndKYUkuQBZjgR9D61w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_05inVfs2x0qofUiIplZIZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_12_31_2022_cYAWIZbIyEWUA55EtH7XHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uUZOjGeySkC0V7oyrpt9UA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ibio_FacilityMember_K0EB_c8dT0OHjVuRMWJAdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ibio:FacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_p-vKhEHGAUG72E1kGh9gmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CollegeStationInvestorsLlcAndBryanCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-01</instant>
        </period>
    </context>
    <context id="As_Of_10_10_2022_us-gaap_TypeOfArrangementAxis_ibio_CroAgreementMember_Bo_t44xgLU28rjco1A0Xvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:CroAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-10</instant>
        </period>
    </context>
    <context id="Duration_11_1_2021_To_11_1_2021_dei_LegalEntityAxis_ibio_IbioCmoPreferredTrackingStockMember_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_Fd00xECGqUS_feybjJADgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CollegeStationInvestorsLlcAndBryanCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibio:IbioCmoPreferredTrackingStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-01</endDate>
        </period>
    </context>
    <context id="Duration_10_12_2022_To_10_12_2022_fUvngAqb2k-xursF14pifg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <startDate>2022-10-12</startDate>
            <endDate>2022-10-12</endDate>
        </period>
    </context>
    <context id="As_Of_10_12_2022_0w4cNGT5qUGNwBnB1qrjUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <instant>2022-10-12</instant>
        </period>
    </context>
    <context id="Duration_11_3_2022_To_11_3_2022_B-3zxmk-RECRSqI6e6Ttyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <startDate>2022-11-03</startDate>
            <endDate>2022-11-03</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_ECHSceNMpEGQENNfII3BMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_c19oJcuBhUqWIDNcmlXJ7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_LfJb0Ctu7kiams8KPEcLPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_OccurrenceOfSpecificMilestoneMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_RDzgSGSsy0qENkxPgtYl4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:OccurrenceOfSpecificMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-11</instant>
        </period>
    </context>
    <context id="As_Of_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_O-zm2Doh6EmpqJ14OI8KEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-11</instant>
        </period>
    </context>
    <context id="As_Of_10_10_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_dl3OmSiDBEKFtrzke4LxUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-10</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_87cTBGu9gE-x613iWJyDyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_Q7qov9TaRUq6PVlJRwP10w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibio:PrincipalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="Duration_12_6_2022_To_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_sbC4xz-l302ta9iq3YNsng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-06</startDate>
            <endDate>2022-12-06</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VgtORRQXUEmi1Rl7s04fXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_goiPae-IiUSx1NtZV7V7cg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HD3iLrT9BUSp3VUMVRBnVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_9_19_2022_To_9_19_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_wXZQoYO-rEO6uGxtBLB7Ag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-19</startDate>
            <endDate>2022-09-19</endDate>
        </period>
    </context>
    <context id="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_srt_StatementScenarioAxis_ibio_NoBiosimilarProductHasBeenApprovedMember_us-gaap_TypeOfArrangementAxis_ibio_CollaborationOptionAndLicenseAgreementMember_ou4zV9VwTU-c00lddvVKIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ibio:ImmuneOncologyAntibodiesRtx003Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:NoBiosimilarProductHasBeenApprovedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-23</startDate>
            <endDate>2021-08-23</endDate>
        </period>
    </context>
    <context id="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_us-gaap_TypeOfArrangementAxis_ibio_CollaborationOptionAndLicenseAgreementMember_ajEqmB0rDEiBS1559tP2SQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ibio:ImmuneOncologyAntibodiesRtx003Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-23</startDate>
            <endDate>2021-08-23</endDate>
        </period>
    </context>
    <context id="As_Of_3_1_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentTwoMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_d6E-TSK80kuu0sljeRCUGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioPlanExpectedPaymentTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-01</instant>
        </period>
    </context>
    <context id="As_Of_3_1_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentOneMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_-rTyVybeQkylV5wAH1QWrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioPlanExpectedPaymentOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-01</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_CoaZKFcMoUunX2IienHmqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_iqiKw6Sqfk-mWIZ8WFtzQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-04</instant>
        </period>
    </context>
    <context id="As_Of_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedLegalFeesMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_c-4YxyJ_jk-9z62ejKBbXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioPlanExpectedLegalFeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-04</instant>
        </period>
    </context>
    <context id="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_0-dXyj2LIE2MJCZBHgv0hw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CollegeStationInvestorsLlcAndBryanCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-01</endDate>
        </period>
    </context>
    <context id="Duration_9_10_2021_To_9_10_2021_srt_RangeAxis_srt_MinimumMember_FVB8Duxb3Eaig4ikvWE2OQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-10</startDate>
            <endDate>2021-09-10</endDate>
        </period>
    </context>
    <context id="Duration_9_10_2021_To_9_10_2021_srt_RangeAxis_srt_MaximumMember_mW7qNF6ZRUyagUbuT2sblQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-10</startDate>
            <endDate>2021-09-10</endDate>
        </period>
    </context>
    <context id="Duration_9_16_2022_To_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_QdOFAORoNkObDq7whbxqtQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-16</startDate>
            <endDate>2022-09-16</endDate>
        </period>
    </context>
    <context id="As_Of_11_25_2020_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_R42dgLYX1k2Ix5l9AuMByA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CantorFitzgeraldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-25</instant>
        </period>
    </context>
    <context id="Duration_10_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_Xf6pRLT-l0WeqW9gCVshUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_h7U0v0axEUSvtq7AMRXwhw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2021_To_12_31_2021_WNPh7gwO_06OGSGOzOxzNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_5_10_2023_1kydZmm4_EeBJVujDl0wBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <instant>2023-05-10</instant>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_position_V29P0pRPvUyM5A0t2OFq5g">
        <measure>ibio:position</measure>
    </unit>
    <unit id="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_D_NZPLSJv9m0GC4_X7zPjKmg">
        <measure>ibio:D</measure>
    </unit>
    <unit id="Unit_Standard_lease_8Woavb0ETUO8s9ODCurHtQ">
        <measure>ibio:lease</measure>
    </unit>
    <unit id="Unit_Standard_customer_yQcExGHKGkW8YXSDfuntYQ">
        <measure>ibio:customer</measure>
    </unit>
    <unit id="Unit_Standard_item_ITzkWC4v7UGBZiwOGBFemw">
        <measure>ibio:item</measure>
    </unit>
    <unit id="Unit_Standard_sqft_3kWp_fWhaEWbENPWsKzOnw">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      id="Hidden_Mmhw1Jx8RkCtn1jI8k-39w"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      id="Hidden_N_j11tLD2kCEU98JvTtlWA"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="2"
      id="Hidden_uMJ7rDsFFEe-PYrwZsUJbg"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">-0.47</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="2"
      id="Hidden_4R874yyR00-lQ-gPK5aVDQ"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">-0.77</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="2"
      id="Hidden_4cohup_Xe0im-EU-Ng1hmQ"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">-2.30</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="2"
      id="Hidden_alkmQJ0-3EK_SSHZA_FGwg"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">-2.20</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="2"
      id="Hidden_s2ZDVjJuBUuX5ocrOsoaJA"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">-0.08</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="2"
      id="Hidden_pvbUml_Xr02ereqyMzgIaA"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">-0.65</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="2"
      id="Hidden_tZ68DHnAh0ewkHu2Z17AYg"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">-3.27</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="2"
      id="Hidden_UcSIW9AD8UiR_O8CKdfyGg"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">-1.62</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="2"
      id="Hidden_KoisN5HwMUirJemjndgMlQ"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">-0.55</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="2"
      id="Hidden_3P92l1MxxUySgIWVF8sauw"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">-1.42</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="2"
      id="Hidden_CHdwpyqz5UmsdxMQu01lmA"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">-5.57</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="2"
      id="Hidden_Y9WTzYNp-UiQOB98sjcuIw"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">-3.82</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Hidden_X1igTQcX2UyKMX7R8gIL5Q"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">13184000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="-3"
      id="Hidden_H4VP7sY7u0-Nc2YmbPLNbg"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">8719000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Hidden_d1Pfavst9UCfkWrvh4C2fA"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">10592000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Hidden_N_ufrc8wzUOepnKRl3ROPA"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">8719000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Hidden_L-Jh2gUQ20aXNcKW4O9D8A"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">13184000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="-3"
      id="Hidden_Sd0Sn95nhESiByEw7rkSOw"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">8719000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Hidden_8NBIqXmdCESiQWM1l4UUWw"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">10592000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2021_To_9_30_2021_vL3rOPanq0GYnPOprKHLGg"
      decimals="-3"
      id="Hidden_cDAb6ZuFx0WK18wMCd_ivg"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">8719000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="2"
      id="Hidden_wjVHAja0hk-ujBowM-xKHQ"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">-0.47</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="2"
      id="Hidden_yQjZFWrye0SmP2jIiPGrBA"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">-0.77</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="2"
      id="Hidden_-JF8WUqQSkmfxC0R_OaSQA"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">-2.30</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="Duration_7_1_2021_To_9_30_2021_vL3rOPanq0GYnPOprKHLGg"
      decimals="2"
      id="Hidden_PwsJbaSoOUORrCdM232mAA"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">-2.20</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="2"
      id="Hidden_9HqUV2MAckqjZOnis6YfZg"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">-0.08</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="2"
      id="Hidden_U0bOGUWDzkuEeJ29Nf_EjQ"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">-0.65</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="2"
      id="Hidden_TmWH34FMsECu90mrUdyfXg"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">-3.27</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="Duration_7_1_2021_To_9_30_2021_vL3rOPanq0GYnPOprKHLGg"
      decimals="2"
      id="Hidden_kDRlUx8GmUabgAhq5k_vvQ"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">-1.62</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="2"
      id="Hidden_Zp0MkR-0tUq910UPmXzGpA"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">-0.55</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="2"
      id="Hidden_acVcgEcpAUW-LaSF7a3TxQ"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">-1.42</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="2"
      id="Hidden_wBTFuchxW0eQbgh0co0GoQ"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">-5.57</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2021_To_9_30_2021_vL3rOPanq0GYnPOprKHLGg"
      decimals="2"
      id="Hidden_tJo2ezbm1Eau_et1XorUuA"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">-3.82</us-gaap:EarningsPerShareDiluted>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_7_1_2022_To_3_31_2023_srt_RangeAxis_srt_MinimumMember_iZJ0-KgMMEWGQBeszyazgg"
      id="Hidden_Eet2cSErQUWYG2NYDDLIPA">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="Duration_7_1_2022_To_3_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_7qvwM12szUub7e7UoiuztA"
      id="Hidden_5A4l74BAAkGpy-k8y3HFLw">P23Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <dei:EntityCentralIndexKey
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tc_s0P44FTMQESws8USVI0JYA_2_1">0001420720</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tc_zckhK2d-j0mrNXCfAWreBQ_3_1">--06-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tc_hZBWLIhR80OijMhMqCjy_g_4_1">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tc_9tqFbpgFckS4rj5HeafPtw_5_1">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tc_nDMQDrLQsE-wJcCtxBXxPg_6_1">false</dei:AmendmentFlag>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Hidden_ALMi0aoiGEux0RbmMQwClg"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">422000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      id="Hidden_UQCuo_IgjkapUCQ_dOiKtg">P0Y</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <ibio:CollaborationAndLicenseAgreementRoyaltyPaymentTerm
      contextRef="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_srt_StatementScenarioAxis_ibio_NoBiosimilarProductHasBeenApprovedMember_us-gaap_TypeOfArrangementAxis_ibio_CollaborationOptionAndLicenseAgreementMember_ou4zV9VwTU-c00lddvVKIg"
      id="Hidden_oSXmWjkN2kiwoY8AqAXFYw">P10Y</ibio:CollaborationAndLicenseAgreementRoyaltyPaymentTerm>
    <us-gaap:SettlementAssetsCurrent
      contextRef="As_Of_3_31_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentOneMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_NmtkHB0kdUyIGd_4OxJpew"
      decimals="0"
      id="Hidden_PJle0PEsI0uXVu8jrliU2w"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">5100000</us-gaap:SettlementAssetsCurrent>
    <ibio:CashPaymentsReceivablesRelatedToLitigationSettlement
      contextRef="As_Of_3_1_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentOneMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_-rTyVybeQkylV5wAH1QWrQ"
      decimals="0"
      id="Hidden__ic71Y4ppUShPuWLdTGl2Q"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">900000</ibio:CashPaymentsReceivablesRelatedToLitigationSettlement>
    <ibio:BaseRentAbatementInFirstYearPeriod
      contextRef="Duration_9_10_2021_To_9_10_2021_srt_RangeAxis_srt_MinimumMember_FVB8Duxb3Eaig4ikvWE2OQ"
      id="Hidden_fzpg5j2sZU2ExYr4_xtclw">P2Y</ibio:BaseRentAbatementInFirstYearPeriod>
    <ibio:BaseRentAbatementInFirstYearPeriod
      contextRef="Duration_9_10_2021_To_9_10_2021_srt_RangeAxis_srt_MaximumMember_mW7qNF6ZRUyagUbuT2sblQ"
      id="Hidden_JKyPk5I8s0q_VC6f1fzo2Q">P5Y</ibio:BaseRentAbatementInFirstYearPeriod>
    <us-gaap:LeasePracticalExpedientsPackage
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Hidden_eZ239xUFfk2aM5khbNy0yg">false</us-gaap:LeasePracticalExpedientsPackage>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_10_7_2022_To_10_7_2022_Slp385Pip0S6eRadEDIyaA"
      decimals="2"
      id="Hidden_C8lqvEAS3E6y7jI9fK0gaA"
      unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg">0.04</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="INF"
      id="Hidden_WwbDRZXCKEm0c75aLXR51A"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">1000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="INF"
      id="Hidden_N7VJDuA9s0SBMrSoQpnaMA"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="0"
      id="Hidden_iQoKre6X4UGSKRq8g3fedQ"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">2786000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="INF"
      id="Hidden_4-uRaCb8LEyTO1qExlEmGw"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">8727158</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="INF"
      id="Hidden_x71a3m4K-ki3BoetvIms3g"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">12368287</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_10_7_2022_To_10_7_2022_Slp385Pip0S6eRadEDIyaA"
      decimals="2"
      id="Hidden_L9F1YPW0H0e_OcCFkVLlag"
      unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg">0.04</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_10_7_2022_To_10_7_2022_Slp385Pip0S6eRadEDIyaA"
      decimals="2"
      id="Hidden_QTQry_EgBE-Zf0eAMcyRBw"
      unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg">0.04</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_7_1_2022_To_3_31_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_ibio_TwoThousandEighteenOmnibusEquityIncentivePlanMember_RgnWTUvfSUmaNbGh5cYapQ"
      id="Hidden_nzLgsplRfUCEtBruJ2QfKQ">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_BcLE-e5aOUawYtWYzbYpuQ"
      id="Hidden_6UlFUOUwakC1Lx6RTBBOdg">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_ConsultantsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_yuIW9ztkf0mAQBCgQQaTxw"
      id="Hidden_PqrGwNIVNUKtOSk9GN3hkQ">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <ibio:SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary
      contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_7N6sRqj9kEWZRTEMclg2yA"
      id="Hidden_H20oJhWZMkiyeILxAMoOWg">P24M</ibio:SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary>
    <ibio:SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus
      contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_7N6sRqj9kEWZRTEMclg2yA"
      id="Hidden_3XETezoZoE2Gln_IFI6pTg">P24M</ibio:SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus>
    <ibio:SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct
      contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_7N6sRqj9kEWZRTEMclg2yA"
      id="Hidden_YRBOV4wB5E2sgYw7SZXbjg">P18M</ibio:SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct>
    <ibio:SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod
      contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_7N6sRqj9kEWZRTEMclg2yA"
      id="Hidden_eUgWy76apU6hIb4U9tpWXg">P18M</ibio:SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod>
    <dei:DocumentType
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Narr_o6mHoMtUw0WMff6IvdNl2Q">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tc_VZNONDB5FUuis5CS4w0q2w_1_0">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Narr_Y0tpL-Ffik-sQokYvqLFhQ">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tc_2itkjY7XMUeAjEISSFlWfA_1_0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Narr_Az8vKbcouUCLfy21djprjg">001-35023</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Narr_TrK5w7J6wkGoiKHtNsg4iw">iBio,&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tc_39qpsAOIak-X5WYqVUMYow_0_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tc_lDMOM0k3yEuCut1p3YVwIA_0_2">26-2797813</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Narr_ETTPvafiCkKvBG-c4CoXow">8800 HSC Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Narr_l8HydpBPbkSN5WVARUZHyw">Bryan</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Narr_OEnZ6w8CyUeF4b1hCx7JMg">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Narr_lHXH4Ypnf0iQMp6MT2JzNw">77807</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Narr_72Ucj5zaP0afitPp-eFeVg">979</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Narr___VyigrJuk-pSzwjQoQwTg">446-0027</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tc_M9LtKRTFwUGF-r9UiW1z6Q_2_0">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tc_Hb12vT3VRk23NCZ-e7G3yQ_2_2">IBIO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tc_0_mnYiUsN02DTEcVbGLOyQ_2_4">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Narr_0aHOd91z00GexDLWRKzgjQ">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Narr_jTqVCzMAuUGf2tSEVkwNWA">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Narr_erVoDxhSc02HkvYhUnLzVg">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Narr_NZ2O17yy2EGwyaCS8fM0qQ">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Narr_FjbMm_xHu0uQm5t66_uKjw">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Narr_UCbSYMbLtk-omf1nKapTWA">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_5_10_2023_1kydZmm4_EeBJVujDl0wBA"
      decimals="INF"
      id="Narr_W42B6utcREK6zJHJcIpNxA"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">16798014</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_s88ototjB0aqygIcjYTuAw_6_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">6562000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_CULjBccjlEaHD75wz6RHtw_6_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">22676000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_xwy80zCLFkypVh67Bj53Kw_7_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">10845000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_I1S7eWhn-k2n9Z2c7RJdKA_8_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">70000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_VjsmiIs0p02Ho5cu5-2gIQ_8_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1000000</us-gaap:AccountsReceivableNetCurrent>
    <ibio:SubscriptionReceivableCurrent
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_15OaVR0rm0a-CIhnBuL7iw_9_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">260000</ibio:SubscriptionReceivableCurrent>
    <us-gaap:SettlementAssetsCurrent
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_86pKZoc0fEmQWuZzygFm0Q_10_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">5100000</us-gaap:SettlementAssetsCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_DKhoXoLRiEK4q8g2CUghfg_11_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">912000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_WnMcTMmBlkKJ3KGjbVTuVA_12_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">921000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_aLYME3ls8keFQoQUrrUI_w_12_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1549000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_NTrYaEtJGkmeiXwOmDMZAQ_13_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">18368000</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent>
    <us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_KeR5umeqXE67BIQRqQp-Gw_13_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">3900000</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_3lMiRGtndUSBWStZiRvXJg_14_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">27093000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_FrDU-cVJ5Eyh2Tz2pdaFjQ_14_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">45070000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_kkh_YvD6t0KUr_rLPlN7Lg_16_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">3253000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_a7w3eGeb6UqZufRUxZm9kg_16_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">5996000</us-gaap:RestrictedCashNoncurrent>
    <ibio:ConvertiblePromissoryNoteReceivableAndAccruedInterest
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_e0-OmfxZ9EaWGpY-Jfydwg_17_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">775000</ibio:ConvertiblePromissoryNoteReceivableAndAccruedInterest>
    <ibio:ConvertiblePromissoryNoteReceivableAndAccruedInterest
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_SjOIZAlpQkOTcoa7251CkA_17_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1631000</ibio:ConvertiblePromissoryNoteReceivableAndAccruedInterest>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_tppJfvfOXk2Rnb0hgMhvVQ_18_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">678000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_jyVooTVfhEmt8c3inY-YUg_19_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">2786000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_7CHtNIQU6UCEAf5CxhRHxw_19_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">3068000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_9mHx-Imi40-b0UQYmuiFqQ_20_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">4358000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_JPnH5m0xuUiMfJPHXRv_nA_20_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1373000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_vGXg5Jie3EeePAWzTKgCBQ_21_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">5393000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_F58MpnjqgES5MNaGW8aIpA_21_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">4851000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:SecurityDeposit
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc__PmeNcZLFEOyy-zDF3voPw_22_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">50000</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_0EXT15_DPky9XT1I5ZThrA_22_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">29000</us-gaap:SecurityDeposit>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_PnRMyidZ0UqLRVM-ovxbdA_23_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">74000</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_yXMUt5o-qUOg_i8D2tBwhg_24_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">37314000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_6WvFgPmtrU2UZ9Azm1AEfw_25_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">44386000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_2bH3OutPIEO7ZFQ7jaGQEA_25_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">99406000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_vzpN7AvfxkyIw73sShaIYQ_29_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">2013000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_eiF9apP5nUG6FvduHeoYlw_29_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">4264000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_w7iucYSoRkKgNPyQ3b3BUw_30_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">3821000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_HWM3ykO6NkiDQdRbmKTs4g_30_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">3764000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_JmyrWKkuWUOMUnZe9xYgYQ_31_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">265000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_kqITfLuYTESU9UXNFPib5A_32_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">377000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_xdVumVfIZUOuqKWYIR09cw_32_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">91000</us-gaap:OperatingLeaseLiabilityCurrent>
    <ibio:EquipmentFinancingPayableCurrent
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_Y6d-ErsAlEiPtE76Qo4Zsg_33_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">156000</ibio:EquipmentFinancingPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_JOxp3uu29Ue5v1anSIQl8w_34_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">13700000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_8XSx77QBWEOerH82bZPlnw_34_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">22161000</us-gaap:NotesPayableCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_0AN5D-wuP06_qKeuEoQUoA_35_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">100000</us-gaap:DeferredRevenueCurrent>
    <ibio:CurrentLiabilitiesRelatedToAssetsHeldForSale
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_zYIwHpHTk0WzaKFnUQbJLA_36_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1944000</ibio:CurrentLiabilitiesRelatedToAssetsHeldForSale>
    <ibio:CurrentLiabilitiesRelatedToAssetsHeldForSale
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_x0ZyHdAb5kimjvdcHl2zPA_36_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">56000</ibio:CurrentLiabilitiesRelatedToAssetsHeldForSale>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_ou9xvJYdj02Q9Aku65jEiQ_37_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">22276000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_Dk-wsZ3dVUyVsuFLrpk8vA_37_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">30436000</us-gaap:LiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_hAO25xUyQUCTiArslGnAZA_39_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">422000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_3LnICue8Jkqs5zAx1CTksQ_40_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">3225000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_ZDRFtsm8vU2TSEz9AWklEg_40_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">3514000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <ibio:EquipmentFinancingPayableNoncurrent
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_zcULuyMaBUWjfTVN-gKm2g_41_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">283000</ibio:EquipmentFinancingPayableNoncurrent>
    <ibio:AccruedLiabilitiesNoncurrent
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_Y7NuIiY3_0OXX6oUQ5oUAQ_42_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">791000</ibio:AccruedLiabilitiesNoncurrent>
    <ibio:NoncurrentLiabilitiesRelatedToAssetsHeldForSale
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_7FxhGJGA00SKu4sgrkZmcw_43_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1971000</ibio:NoncurrentLiabilitiesRelatedToAssetsHeldForSale>
    <us-gaap:Liabilities
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_CC1ykaf4UEOv3m4-OwxPhg_45_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">26997000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_oMaGSxazK0O_HgowJr8oyA_45_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">35921000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="INF"
      id="Narr_p9rb5jJIhUaDss0l0UYP6w"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="INF"
      id="Narr_QyAo8U5xXkS-StafUPgp-Q"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="INF"
      id="Narr_DX8CGX1xHECHWjc1dCRSQA"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="INF"
      id="Narr_KPGveXqpV0eWR1BuZJ4JVw"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="INF"
      id="Narr_YG-Eswwbyk26gW_K0Gfzcw"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="INF"
      id="Narr_ZPl3Z4lwH0OQ8axNSOZVyA"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">1000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="INF"
      id="Narr_ftuKYvVLKk-oxoU6HLYP9Q"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="INF"
      id="Narr_K2Zbi1wiPE6wQRHbva8MNA"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="0"
      id="Narr_Ah8Z8hI9_kChEO0IWg8u7Q"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">275000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="0"
      id="Narr_wlqE7fdn40utyCKmpWU4Xg"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">275000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="INF"
      id="Narr_FVPCoeSXvEK3_cfOHfDZqg"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">15818149</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="INF"
      id="Narr_cj-9Av5pikCC7_6VCJYIFQ"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">8727158</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_YlE-INmkE0uc31WbXvLjrg_49_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">16000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_vKmQJKujrEeP7E0ptTz0IQ_49_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">9000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_IQuUFxVCuEmRUnby06fy9A_50_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">300280000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_-UL7-cxMBEyJg9OPQzXESw_50_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">287619000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_hVsQU8DXA0-m2OkBmiLTNw_51_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-213000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_q41KgZWxJkKM7KGMiyQunw_52_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-282907000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_1xKzZJye6kyWxDv-sLvLqA_52_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-223930000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_BH_TcF4ZVkaLmYyh3wNaEA_53_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">17389000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_Zz6flBgPTk66PEGS5n5tPA_53_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">63485000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_aN47aWwzmkOIrPlWj-OYgA_54_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">44386000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_WQ4hf6WHfUW5PyMkgmqCMQ_54_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">99406000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Tc_Pdqvlad84EqCs5rzRaQ3lg_5_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="-3"
      id="Tc_19Dgy2otzUKIaPDqoz5EFw_5_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_FMbLgsOhOUOfG1gHJujK3g_5_12"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1884000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Tc_yliNjXUcO0mnxP6edm9W9A_8_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">2644000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="-3"
      id="Tc_83IOdDjjp0yYIw811NRLCg_8_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">3272000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_4QqqwxXsS0SQIlfuLoCuYA_8_9"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">7971000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_Bzi8_YIJk06ZGr6rd23I6A_8_12"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">6265000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Tc_CW7Njiutp0-LlK909WSwRQ_9_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">3525000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="-3"
      id="Tc_i5Ibdp7FsUmGaeKbn6kwhw_9_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">5316000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_qqJ6XKIsZEyOqXCGIUR38w_9_9"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">16407000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_24nbE7BJD0ivq6TEDYHsZQ_9_12"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">14863000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Tc_XWDbNuqNPUKVTfc_-L5KyQ_10_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">6169000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="-3"
      id="Tc_i00J9cW4OESUOLCW5vPGIg_10_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">8588000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_DOAC88r1hEOZIIsQwy0Dmg_10_9"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">24378000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_gbmNwuDCs06Kxl-5gzqxnA_10_12"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">21128000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Tc_iVHTVYEeO0C-r84Kd042YQ_12_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-6169000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="-3"
      id="Tc_FRQIOuev6EKOVgpHHhtTkw_12_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-6788000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_T2ZHlopK20CJwNcLlKgWwQ_12_9"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-24378000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_b0MNztITmkSD6imhB8IEcg_12_12"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-19244000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Tc_fJPC63O9bkGZ65ppd_IMuA_15_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">35000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="-3"
      id="Tc_oXEMjdiIfE6oGTZ9O8Mc7A_15_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_KgWFf1t94UazeBXQGDERMw_15_9"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">66000</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Tc_1n3U72d5g0quO4W7Ofl7KA_16_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">23000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="-3"
      id="Tc_AA85FXXzAkSoFibrVZCPnw_16_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">40000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_MDsivovyu0mtyyhlal36mQ_16_9"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">163000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_0cnkO7hhz0aR7sU4Tfa5uw_16_12"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">111000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleGainLoss
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Tc_tydLgSwpQ0KxNeAtY4Tpsw_17_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-98000</us-gaap:DebtSecuritiesAvailableForSaleGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleGainLoss
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="-3"
      id="Tc_l09Dhs9zREKc8a57PMLOEw_17_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">0</us-gaap:DebtSecuritiesAvailableForSaleGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleGainLoss
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_V4uHOfnha0qD86-K2SBfog_17_9"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-98000</us-gaap:DebtSecuritiesAvailableForSaleGainLoss>
    <us-gaap:RoyaltyIncomeNonoperating
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Tc_uho2-HG7A0aY2J1fXx0KYQ_18_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">0</us-gaap:RoyaltyIncomeNonoperating>
    <us-gaap:RoyaltyIncomeNonoperating
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="-3"
      id="Tc_Wwa10ZgyqUCQoR3_pX3qKA_18_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">2000</us-gaap:RoyaltyIncomeNonoperating>
    <us-gaap:RoyaltyIncomeNonoperating
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_S1KUGCvB-UOgMTAANebsqg_18_12"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">7000</us-gaap:RoyaltyIncomeNonoperating>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Tc_pvxWTkROl0as6ba0s0UT2g_19_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-110000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="-3"
      id="Tc_WWK8mDcbIkmxmuMb3-6n9Q_19_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">42000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_4wY12rA-lEGsGYjJ4X-Xaw_19_9"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-1000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_wPhf1aXNpUexg-xK5kCpww_19_12"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">118000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Tc_YgS82KFCd0CANUghMGOFiA_21_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-6279000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="-3"
      id="Tc_7qJr5DkzxkSjD4mVfEzymQ_21_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-6746000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_mCFD-SeWJEqtTQVp5O8HKQ_21_9"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-24379000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_TgVXC2n-LUmD96QjUvbMDA_21_12"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-19126000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Tc_VgWU5qJjO0uSPkE44lSIPg_22_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">0</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="-3"
      id="Tc_c5_VwaTQpUCzZ3V5TJwc1g_22_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">0</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_wNnvhtQGJESeofnfZMepuQ_22_12"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-1000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Tc_Ppl2nqQf3EGjmCD9gDiKPA_23_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-6279000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="-3"
      id="Tc_Jt1DV4iXF0mzDJBkayoX9g_23_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-6746000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_xAQgv45p_kmQPDMCJRsMGw_23_9"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-24379000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_OhxST6aiN0yPQpqh8MuATw_23_12"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-19125000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:DividendsPreferredStockStock
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Tc_yypIbOim8EikM39QIf6LKA_25_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">0</us-gaap:DividendsPreferredStockStock>
    <us-gaap:DividendsPreferredStockStock
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="-3"
      id="Tc_zNoQYLNEG0-CnshffoZMZg_25_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">0</us-gaap:DividendsPreferredStockStock>
    <us-gaap:DividendsPreferredStockStock
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_P3mOBGtx9ESa92OoOvtN7Q_25_12"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">88000</us-gaap:DividendsPreferredStockStock>
    <ibio:NetLossAvailableToStockholdersFromContinuingOperations
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Tc_OeKAkTvz50GA0s0Tb6DWpA_26_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-6279000</ibio:NetLossAvailableToStockholdersFromContinuingOperations>
    <ibio:NetLossAvailableToStockholdersFromContinuingOperations
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="-3"
      id="Tc_LAZ6MsUZ6UuSM4ROyBQenA_26_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-6746000</ibio:NetLossAvailableToStockholdersFromContinuingOperations>
    <ibio:NetLossAvailableToStockholdersFromContinuingOperations
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_eR2cFR4f7EKWLwCepiHITg_26_9"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-24379000</ibio:NetLossAvailableToStockholdersFromContinuingOperations>
    <ibio:NetLossAvailableToStockholdersFromContinuingOperations
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_AWOO-nrav0qpxILH4EUeGA_26_12"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-19213000</ibio:NetLossAvailableToStockholdersFromContinuingOperations>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Tc_UPxQ8KETdkazLR1ES0MJ_g_28_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-1015000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="-3"
      id="Tc_vVZ_Q8KblUO5zIXz7tFTwQ_28_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-5644000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_gZt0vZjWu0CNLlYXoLegVQ_28_9"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-34598000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_PsHr1B6lmU2_r-NHp8ueNQ_28_12"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-14124000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <ibio:UnconsolidatedGainLossAttributableToStockholders
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Tc_o2Owa36fJUCRat9-otlhJQ_30_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-7294000</ibio:UnconsolidatedGainLossAttributableToStockholders>
    <ibio:UnconsolidatedGainLossAttributableToStockholders
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="-3"
      id="Tc_gqyCwbilXUaAavP8WCcxTA_30_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-12390000</ibio:UnconsolidatedGainLossAttributableToStockholders>
    <ibio:UnconsolidatedGainLossAttributableToStockholders
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_5wVDvzJhqku-0Kk6IZwIrg_30_9"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-58977000</ibio:UnconsolidatedGainLossAttributableToStockholders>
    <ibio:UnconsolidatedGainLossAttributableToStockholders
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_zUeYebMud06IbpJkt_JVJA_30_12"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-33337000</ibio:UnconsolidatedGainLossAttributableToStockholders>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Tc_wJeTQDGEEECcVgmfavvXZQ_33_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-7294000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="-3"
      id="Tc_LWR_BJTC7kium3eirPY49g_33_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-12390000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_T2_qpgstWU67lMNjdcl1xw_33_9"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-58977000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_l1ZJSYGsM0GhGkRCkdWmPw_33_12"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-33250000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Tc_fG8e_sJQnUuZAzdtWvlGLg_34_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">134000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="-3"
      id="Tc_SoklsFCDrU2SxgInve6mJQ_34_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-103000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_suoD5akzh0mHi9LfrLCHiQ_34_9"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">180000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_RMovBs15wkaYgwhgC0KiAQ_34_12"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-131000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Tc_ncQKXytNN0eamBV3EtvAVQ_35_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">33000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="-3"
      id="Tc_xW792NPVqUSKJ931fBTXHg_35_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_d916kj6HyEyyfhcVGEIQsg_35_9"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">33000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Tc_spTeRAjiK0eXbc-J2MxqAQ_37_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-7127000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="-3"
      id="Tc_Wkto6q4lhUq9kE9FJH7qVw_37_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-12493000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_XM_m5Py68Uq7xxc4mjFdDQ_37_9"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-58764000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_-qxBKxrFLU-syo-oPmH5wg_37_12"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-33381000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="2"
      id="Tc_RilchKoS4UCJaPFwuDZM1A_39_3"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">-0.47</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="2"
      id="Tc_5G6DgJzK7ESE_RaTei5-Sg_39_6"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">-0.77</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="2"
      id="Tc_oBuy8t_nzka5lH2_gjqYvA_39_9"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">-2.30</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="2"
      id="Tc_VUbiBod6ukK1c330zq7CfQ_39_12"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">-2.20</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="2"
      id="Tc_re-rJSKGDk-ia_p_-3l5ag_40_3"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">-0.08</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="2"
      id="Tc_Ed24NtwATES_S41t6SC_ew_40_6"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">-0.65</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="2"
      id="Tc__gF5KQ2JL0mmdw1b8ZG_bQ_40_9"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">-3.27</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="2"
      id="Tc_uTpEwlUeQ0mWV6XUFoHIxA_40_12"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">-1.62</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="2"
      id="Tc_Tw6nnJ6DUk6LCWnDIy5A0Q_41_3"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">-0.55</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="2"
      id="Tc_SqmavZBF9kyRCWsanPSJgg_41_6"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">-1.42</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="2"
      id="Tc_6GGqdelwYEqoCYRXMXKn5g_41_9"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">-5.57</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="2"
      id="Tc_avtP0lVylEyRn117FbNoNg_41_12"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">-3.82</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Tc_bFu57BPFek2kZ-K-6wqZMg_43_3"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">13184000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="-3"
      id="Tc_gZ9FgyqWxUGMW-ouf22GfQ_43_6"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">8719000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_I2yZAS3AwEqPM-8kN4rx-g_43_9"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">10592000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_l112lJjdHkGW3My9bqHyjg_43_12"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">8719000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_302kYRWtf0SLrzPv4HomVw"
      decimals="-3"
      id="Tc_UEQD0GJzPkW7yjNYWVirWA_5_3"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">1000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_UH3i88_6M0mId27kV_1YRQ"
      decimals="-3"
      id="Tc_KqWt_9FeZUqwb0SfUDANqg_5_8"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">8727000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_UH3i88_6M0mId27kV_1YRQ"
      decimals="-3"
      id="Tc_kMsKjbE0dEuGWDue5bP-cQ_5_11"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">9000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sIGvof6AoUegd5YJhRXoGA"
      decimals="-3"
      id="Tc_APQ5V8oVIkidHETHsr_F9Q_5_14"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">287619000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_eeBEWZpzDEuzNagWju7iXA"
      decimals="-3"
      id="Tc_Dt0U_qo5hkKRUuIrWnadog_5_17"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-213000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_JyoJW5xFA02SvXgMgzGBBQ"
      decimals="-3"
      id="Tc_QkJ66Rh4FE6UbSw1mM2YCw_5_20"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-223930000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_jXB0mJimHkK9bgFzYBz_Mg_5_23"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">63485000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <ibio:StockIssuedDuringPeriodSharesCapitalRaise
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HD3iLrT9BUSp3VUMVRBnVA"
      decimals="-3"
      id="Tc_LXUOzDdCm0i2CRtj3yrndg_7_8"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">176000</ibio:StockIssuedDuringPeriodSharesCapitalRaise>
    <ibio:StockIssuedDuringPeriodValueCapitalRaise
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VgtORRQXUEmi1Rl7s04fXA"
      decimals="-3"
      id="Tc_DT3n_LaSq0-rjUhxFDEOdw_7_14"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1151000</ibio:StockIssuedDuringPeriodValueCapitalRaise>
    <ibio:StockIssuedDuringPeriodValueCapitalRaise
      contextRef="Duration_7_1_2022_To_9_30_2022_goiPae-IiUSx1NtZV7V7cg"
      decimals="-3"
      id="Tc_AJT33ejfz0adv6NmiAl2Fw_7_23"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1151000</ibio:StockIssuedDuringPeriodValueCapitalRaise>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_qNVa23oLakSTWA8v85-VDQ"
      decimals="-3"
      id="Tc_IhRHdtm2vkGLXm040I-MNQ_8_3"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">-1000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <ibio:CommonStockIssuedInRubrycTransactionInShares
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HD3iLrT9BUSp3VUMVRBnVA"
      decimals="-3"
      id="Tc_vzFSCcALUU-_-fT3xo8pmQ_9_8"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">102000</ibio:CommonStockIssuedInRubrycTransactionInShares>
    <ibio:CommonStockIssuedInRubrycTransactionValue
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VgtORRQXUEmi1Rl7s04fXA"
      decimals="-3"
      id="Tc_RkS8cV8V4EWEw5Jv4DR1Lw_9_14"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">650000</ibio:CommonStockIssuedInRubrycTransactionValue>
    <ibio:CommonStockIssuedInRubrycTransactionValue
      contextRef="Duration_7_1_2022_To_9_30_2022_goiPae-IiUSx1NtZV7V7cg"
      decimals="-3"
      id="Tc_LJVbZRr9M0SXaebi3Cos1w_9_23"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">650000</ibio:CommonStockIssuedInRubrycTransactionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HD3iLrT9BUSp3VUMVRBnVA"
      decimals="-3"
      id="Tc_moXR8fWTZ0Ss3iSTSTqVQw_10_8"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">1000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VgtORRQXUEmi1Rl7s04fXA"
      decimals="-3"
      id="Tc_FF1rq18Fn0yLg7Wc_jaxzQ_11_14"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1222000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2022_To_9_30_2022_goiPae-IiUSx1NtZV7V7cg"
      decimals="-3"
      id="Tc_8RPSpzupPEGNphu9xYn9kw_11_23"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1222000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_JJDtYxXNZUqTS9r_Ytu0CA"
      decimals="-3"
      id="Tc_18VTyRga4kKTF74w_Iyc2g_12_17"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-10000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="Duration_7_1_2022_To_9_30_2022_goiPae-IiUSx1NtZV7V7cg"
      decimals="-3"
      id="Tc_VB98PcRaGECsXOH2rKMmcg_12_23"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-10000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ll59BJ1LzUSofhSUma-j9g"
      decimals="-3"
      id="Tc_WZk5HBniCkaiH-kouHDybw_13_20"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-18130000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2022_To_9_30_2022_goiPae-IiUSx1NtZV7V7cg"
      decimals="-3"
      id="Tc_ertEIEyeNU22xh2kOPDSLQ_13_23"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-18130000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_84GMwaIsm0KxnvZMEZe9PA"
      decimals="-3"
      id="Tc_6oyE0u7h5kqgwHkzuCfnIg_15_8"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">9006000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_84GMwaIsm0KxnvZMEZe9PA"
      decimals="-3"
      id="Tc_LyGtaUgWI06rmt1ChMP87w_15_11"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">9000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tl2lar8KpUyhhXZisj7IKA"
      decimals="-3"
      id="Tc_IKiwHBL4I0KoitcIYJDwJA_15_14"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">290642000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Pbu5fuCUvkqtV3iKXcXZgg"
      decimals="-3"
      id="Tc_9FbEgwGeTkOjgdhOP9ciLQ_15_17"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-223000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_btFG4i_i4UifFBqeFaAOYw"
      decimals="-3"
      id="Tc_tFfmu65RN0yusd03e-AlUA_15_20"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-242060000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_9_30_2022_FQYWefjPT06gXbntJAGaLQ"
      decimals="-3"
      id="Tc_oodOclsf6UWEoUChA_JB5A_15_23"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">48368000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <ibio:StockIssuedDuringPeriodSharesCapitalRaise
      contextRef="Duration_10_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uUZOjGeySkC0V7oyrpt9UA"
      decimals="-3"
      id="Tc_J-lyjXVGcU-3b4-2rdsxFQ_17_8"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">3366000</ibio:StockIssuedDuringPeriodSharesCapitalRaise>
    <ibio:StockIssuedDuringPeriodValueCapitalRaise
      contextRef="Duration_10_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uUZOjGeySkC0V7oyrpt9UA"
      decimals="-3"
      id="Tc_W0JDAbLnH0qj7FfsDE4wrA_17_11"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">3000</ibio:StockIssuedDuringPeriodValueCapitalRaise>
    <ibio:StockIssuedDuringPeriodValueCapitalRaise
      contextRef="Duration_10_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_05inVfs2x0qofUiIplZIZw"
      decimals="-3"
      id="Tc_GrlKzva4EE6Lyviw6zEtMg_17_14"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">3497000</ibio:StockIssuedDuringPeriodValueCapitalRaise>
    <ibio:StockIssuedDuringPeriodValueCapitalRaise
      contextRef="Duration_10_1_2022_To_12_31_2022_cYAWIZbIyEWUA55EtH7XHg"
      decimals="-3"
      id="Tc_m2Y47du4Okupnd6aAZtJ9A_17_23"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">3500000</ibio:StockIssuedDuringPeriodValueCapitalRaise>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_10_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_05inVfs2x0qofUiIplZIZw"
      decimals="-3"
      id="Tc_l2K7b2N9nkyTBnJgALXaTQ_18_14"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">636000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_10_1_2022_To_12_31_2022_cYAWIZbIyEWUA55EtH7XHg"
      decimals="-3"
      id="Tc_u7etNgEqv0WTZ5DoMpuY5g_18_23"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">636000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <ibio:FractionalShareIssuedAfterReverseStockSplitShares
      contextRef="Duration_10_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uUZOjGeySkC0V7oyrpt9UA"
      decimals="-3"
      id="Tc_k1umYGO_30mKtRmnFp0uRA_19_8"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">-8000</ibio:FractionalShareIssuedAfterReverseStockSplitShares>
    <ibio:FractionalShareIssuedAfterReverseStockSplitValue
      contextRef="Duration_10_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_05inVfs2x0qofUiIplZIZw"
      decimals="-3"
      id="Tc_sv2Q6jxnBkWZWVkuefQOyA_19_14"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-39000</ibio:FractionalShareIssuedAfterReverseStockSplitValue>
    <ibio:FractionalShareIssuedAfterReverseStockSplitValue
      contextRef="Duration_10_1_2022_To_12_31_2022_cYAWIZbIyEWUA55EtH7XHg"
      decimals="-3"
      id="Tc_YACjxM1loUClsOcAJOPaww_19_23"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-39000</ibio:FractionalShareIssuedAfterReverseStockSplitValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_10_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uUZOjGeySkC0V7oyrpt9UA"
      decimals="-3"
      id="Tc_-kMxTgJA6E68P38tcprqNA_20_8"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">4000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_10_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_05inVfs2x0qofUiIplZIZw"
      decimals="-3"
      id="Tc_zPQbotzf7kKhKhNrwWQuqw_21_14"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1127000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_10_1_2022_To_12_31_2022_cYAWIZbIyEWUA55EtH7XHg"
      decimals="-3"
      id="Tc_hxT0VfUH30yD2U7FcFfiwg_21_23"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1127000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="Duration_10_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_FGJtC-Cca0ywdM4SzNVWpg"
      decimals="-3"
      id="Tc_voRmpczuSUWz09HtgayIcQ_22_17"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">56000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="Duration_10_1_2022_To_12_31_2022_cYAWIZbIyEWUA55EtH7XHg"
      decimals="-3"
      id="Tc_2dxLH-n9_EeD3RGX2T8giA_22_23"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">56000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_10_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZuedCxHLfEuQdq1I8bADJg"
      decimals="-3"
      id="Tc_4w4snGLOLUaWz-kp_dbB2Q_23_20"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-33553000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_10_1_2022_To_12_31_2022_cYAWIZbIyEWUA55EtH7XHg"
      decimals="-3"
      id="Tc_Ai2dAuPAfUihWY5mPl9wUg_23_23"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-33553000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8ASi2S5ht0qWY7QQf1HPIA"
      decimals="-3"
      id="Tc_7u7VS-R7S0aH1K6oMnQGuQ_25_8"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">12368000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_8ASi2S5ht0qWY7QQf1HPIA"
      decimals="-3"
      id="Tc_EWwh0UeZT0GbAU1epGGLLw_25_11"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">12000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ljAxJwch6kazqell6E9urQ"
      decimals="-3"
      id="Tc_oarCkqXZ7ka4O1LKUYZ_JA_25_14"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">294591000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Zo82mtQMNE2WG6FBhO9Gxw"
      decimals="-3"
      id="Tc_P_q0hcn8TkGLtPhE8WhNLQ_25_17"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-167000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_aXxc-Org7Umr-wR0vxLYGg"
      decimals="-3"
      id="Tc_Eufh1h0gw0yU0Wv3mNPXFQ_25_20"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-275613000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2022_OyKJ3tL-Q06qZ-tFHs9gXQ"
      decimals="-3"
      id="Tc_BJpC_fePFkOFQQkbP86avg_25_23"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">18823000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MWdz4lqoIEShu4AoC1KFyw"
      decimals="-3"
      id="Tc__WEjtC_I30C6eWIpRvg6_Q_27_8"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">28000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <ibio:StockIssuedDuringPeriodSharesCapitalRaise
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MWdz4lqoIEShu4AoC1KFyw"
      decimals="-3"
      id="Tc_Q1Iosb-GXkWTSR6haHio9Q_28_8"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">3422000</ibio:StockIssuedDuringPeriodSharesCapitalRaise>
    <ibio:StockIssuedDuringPeriodValueCapitalRaise
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MWdz4lqoIEShu4AoC1KFyw"
      decimals="-3"
      id="Tc_0COs9epdt0eQFq88HYVPNw_28_11"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">4000</ibio:StockIssuedDuringPeriodValueCapitalRaise>
    <ibio:StockIssuedDuringPeriodValueCapitalRaise
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_o6HWlvHmjUS2rzS8fnoWuw"
      decimals="-3"
      id="Tc_F2SDmEzkWUuVASRc4x1baw_28_14"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">4093000</ibio:StockIssuedDuringPeriodValueCapitalRaise>
    <ibio:StockIssuedDuringPeriodValueCapitalRaise
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Tc_tdGxeJvQWE2JcyC1aBjI7g_28_23"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">4097000</ibio:StockIssuedDuringPeriodValueCapitalRaise>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_o6HWlvHmjUS2rzS8fnoWuw"
      decimals="-3"
      id="Tc_kkV9HLQtqkiBl1m2QwVbaw_29_14"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1596000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Tc_tMmR8II-oU6zZPzwV6HrCQ_29_23"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1596000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_YZMShz8Rh0u-FmqZPOXdfA"
      decimals="-3"
      id="Tc_F-klo3k5x0C2g3HbpffCwQ_30_17"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">113000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Tc_Rm-foUWBOU-C5qJi-hy_UQ_30_23"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">113000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <ibio:ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_YZMShz8Rh0u-FmqZPOXdfA"
      decimals="-3"
      id="Tc_tEYOAHBJ9E-s0qCB7h4_rw_31_17"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">21000</ibio:ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities>
    <ibio:ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Tc_sbeXa_3RgkK2HRYCyfApsg_31_23"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">21000</ibio:ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_YZMShz8Rh0u-FmqZPOXdfA"
      decimals="-3"
      id="Tc_7lOVEYLmikymQoHBQjT4Dg_32_17"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">33000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Tc_4q5T7TFfT0q1H3yWu_Tcow_32_23"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">33000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_QiAZnlfbxEmMw0lCHMl5EA"
      decimals="-3"
      id="Tc_3jGDbbRq50axmyZ-0NA7OQ_33_20"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-7294000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Tc_G5jLXeM43kyL8HjGSBSSwA_33_23"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-7294000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_G5vLxz-NeEqgDIsG6nvKaA"
      decimals="-3"
      id="Tc_NRWjaij06UKQ60HNf8szKg_35_8"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">15818000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_G5vLxz-NeEqgDIsG6nvKaA"
      decimals="-3"
      id="Tc_b7J3U6a_4kemXh8DhJ6_wA_35_11"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">16000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Dq6r99N510C1DCNhsL8h9g"
      decimals="-3"
      id="Tc_J21wzIsDpU-JryeexKsakA_35_14"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">300280000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_a8XYRnY0YEqjr3LZjT16ww"
      decimals="-3"
      id="Tc_zHsDbcuTu0GCZkSKZnXhqA_35_20"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-282907000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_DmhBoT7zlU-HV0ioP1liyg_35_23"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">17389000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__ZOGluhSl0G7K2wu1sD4IQ"
      decimals="-3"
      id="Tc_3NR69hkmJkuV3anSFyN8-g_5_8"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">8715000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__ZOGluhSl0G7K2wu1sD4IQ"
      decimals="-3"
      id="Tc_EjBcch8DJ06uz5zjhq9Xxg_5_11"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">9000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_oxzaYxve7U-k1xy12FFQvw"
      decimals="-3"
      id="Tc_66dfaVOvG0WXmuYTHDIh_A_5_14"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">282266000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_pVa8MvgG4kWQa5aMi-i-SQ"
      decimals="-3"
      id="Tc_Km7v8l9yP0qbIxflPgByrA_5_17"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-63000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HFSiWMrWY0ej62GFJxBZIg"
      decimals="-3"
      id="Tc_6wIqzY5CYE2j3TDLQYZkFQ_5_20"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-173627000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_3WIr_ndZqka5CsSKIRQ3fA"
      decimals="-3"
      id="Tc_qc89S7guoEmda5oXX19i1g_5_23"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-17000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2021_RvsAx0CeVUiEHjFvD-Jmkw"
      decimals="-3"
      id="Tc_x1UFppHhB0u45pg4AXC3yw_5_26"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">108568000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uJ57OeAa6Em8d-wBmehB4A"
      decimals="-3"
      id="Tc_9BmMk-ZZskqn1MUJGySciw_7_8"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">3000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gnv2jc0O2EKruqChBGMUTg"
      decimals="-3"
      id="Tc_rJFxwCKwMUe_ncAirJbsQQ_7_14"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">77000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_7_1_2021_To_9_30_2021_vL3rOPanq0GYnPOprKHLGg"
      decimals="-3"
      id="Tc_AkLOSIEf30CGbGFdFSTStQ_7_26"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">77000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gnv2jc0O2EKruqChBGMUTg"
      decimals="-3"
      id="Tc_6449CZetDUi6suTkaiWx5Q_8_14"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">821000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2021_To_9_30_2021_vL3rOPanq0GYnPOprKHLGg"
      decimals="-3"
      id="Tc_6RCtt1totEaXgCWkj2znJA_8_26"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">821000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Tqrr8xcQvkaRlWyBfJNZbQ"
      decimals="-3"
      id="Tc_SkIvZv-03UCt7krk3nUHlQ_9_17"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-1000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="Duration_7_1_2021_To_9_30_2021_vL3rOPanq0GYnPOprKHLGg"
      decimals="-3"
      id="Tc_v68lyXQsg0OpU1A4bbGkMw_9_26"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-1000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_aWjmWshK0UmxjFzpIuJKUg"
      decimals="-3"
      id="Tc_x7OP3GSh20CfW1htQpoyig_10_20"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-8939000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_s9UOO5awBEKLVvHLUhhOvQ"
      decimals="-3"
      id="Tc_ATirVQlqQUGXqRc8MyXWlA_10_23"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="Duration_7_1_2021_To_9_30_2021_vL3rOPanq0GYnPOprKHLGg"
      decimals="-3"
      id="Tc_7RO69URuQ0-EXiCK74oqSg_10_26"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-8940000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QXzbdBTf7UyvyFsCyM5MpQ"
      decimals="-3"
      id="Tc_TSsD94KmrUmPquF5HCSfnQ_12_8"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">8718000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QXzbdBTf7UyvyFsCyM5MpQ"
      decimals="-3"
      id="Tc_0admOlRw5EixuAj1Bnloqg_12_11"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">9000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_hsH-C_nn7UGLsToocSuw0g"
      decimals="-3"
      id="Tc_d76U8Q1u3U-Rvqfdq0WR7A_12_14"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">283164000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_jVGpJMpt70iwB6r1klHOKA"
      decimals="-3"
      id="Tc_3uq5jPgSyUS4IUchTIOolw_12_17"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-64000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_gOfCh-hUOkaoojsAe2NwmQ"
      decimals="-3"
      id="Tc_PEm66rYnoku6woNQhmNZyA_12_20"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-182566000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_eTEPnd7U0k2A3wEuB687aA"
      decimals="-3"
      id="Tc_-Zvmbch2fU-XbcGxWI4kPQ_12_23"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-18000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_9_30_2021_6xZdpSuxG02KaCdJhSlZ7A"
      decimals="-3"
      id="Tc_Sr06ebgs406ZuDc6FET-IA_12_26"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">100525000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_10_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ydfUDabqlkij0w-BBn4BJA"
      decimals="-3"
      id="Tc_jb-WS4aXZUOZ-OuLtkj0cQ_14_8"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">4000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_10_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_h7U0v0axEUSvtq7AMRXwhw"
      decimals="-3"
      id="Tc_sMRBOJX0ZUmv2wJWyU3kYg_15_14"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">967000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="Duration_10_1_2021_To_12_31_2021_WNPh7gwO_06OGSGOzOxzNw"
      decimals="-3"
      id="Tc_5zBictjKAkyf3SDMIT5XuQ_15_26"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">967000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <ibio:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate
      contextRef="Duration_10_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_h7U0v0axEUSvtq7AMRXwhw"
      decimals="-3"
      id="Tc_YxJAX4G5D0-17EVMnacbow_16_14"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">68000</ibio:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate>
    <ibio:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate
      contextRef="Duration_10_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_Xf6pRLT-l0WeqW9gCVshUA"
      decimals="-3"
      id="Tc_J2d28V-xF0W4qiLc6ThAVw_16_23"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-18000</ibio:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate>
    <ibio:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate
      contextRef="Duration_10_1_2021_To_12_31_2021_WNPh7gwO_06OGSGOzOxzNw"
      decimals="-3"
      id="Tc_QcgGt0jUPEe773tHCyoALg_16_26"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">50000</ibio:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_10_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_h7U0v0axEUSvtq7AMRXwhw"
      decimals="-3"
      id="Tc_VmzKG3VRGUGfSZZdtmPYSg_17_14"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1103000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_10_1_2021_To_12_31_2021_WNPh7gwO_06OGSGOzOxzNw"
      decimals="-3"
      id="Tc_5tkeuA-60066K9XlQmP3TA_17_26"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1103000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="Duration_10_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_wmQZYW3PoEyWWUp8Dmyyyg"
      decimals="-3"
      id="Tc_me3JV3yei0CVxDefjkFL9A_18_17"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-27000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="Duration_10_1_2021_To_12_31_2021_WNPh7gwO_06OGSGOzOxzNw"
      decimals="-3"
      id="Tc_l7YiXkoIp0O5wfo21vNZow_18_26"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-27000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_10_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_reQq62UAKUWWMC0PAA6-mQ"
      decimals="-3"
      id="Tc_i_Cehr8NsUKBp99AU4RkgA_19_20"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-11920000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_10_1_2021_To_12_31_2021_WNPh7gwO_06OGSGOzOxzNw"
      decimals="-3"
      id="Tc_SmTXp2qTQ0uL8kEs-UAgDA_19_26"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-11920000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vSAxS0YAgUqgjKsUyRNznw"
      decimals="-3"
      id="Tc_ak7ImX92w0uxEawUbf_faw_21_8"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">8722000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vSAxS0YAgUqgjKsUyRNznw"
      decimals="-3"
      id="Tc_bm2MtIiFAE-Ma8REYscohA_21_11"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">9000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_XTKrAoBNIEahMhTSx3nvGA"
      decimals="-3"
      id="Tc_Wr9-2RTRWE2fxX1fO9OAKg_21_14"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">285166000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_q6a6n0hytkGjctTlsPRp-Q"
      decimals="-3"
      id="Tc_Jn1TslrH_UuF2Y6RCsID9w_21_17"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-91000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZL8l8ThJZ0-W7M_aNkuPyg"
      decimals="-3"
      id="Tc_vHdlJAuL00W3HcHkgAlejQ_21_20"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-194486000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2021_3LjjH4Oi8EqKlNswnjVbLw"
      decimals="-3"
      id="Tc_IWjVIZxsvkS36Yf8AxnbGA_21_26"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">90598000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7S5LrOv4UU-uYc7t0vEohw"
      decimals="-3"
      id="Tc_hZgMQ8qjqEKFFJfQU9YdbQ_23_8"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">4000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_PuLylut6L0y-PztjYjnBWw"
      decimals="-3"
      id="Tc_4-Ow8-Vo3kGS6G8jE0b-og_23_14"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="-3"
      id="Tc_za685tnvvku0BEtXAab4Ig_23_26"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_PuLylut6L0y-PztjYjnBWw"
      decimals="-3"
      id="Tc_7qbIWAfEFUS-A-QJ4d5p7g_26_14"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1274000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="-3"
      id="Tc_fefUCcOSCE2mJDHLCLouTQ_26_26"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1274000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_huTLj4Tyh0uE8TfHbS9zCQ"
      decimals="-3"
      id="Tc_LSZijCzi_Ei02Hj36wbYfQ_28_17"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-103000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="-3"
      id="Tc_1llsh3wFb0e5PrhSmoMqRA_28_26"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-103000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ogcZKKYW_Eir0iTTRpyFTw"
      decimals="-3"
      id="Tc__8mZTU2BJkKLS9O4WHTsLQ_29_20"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-12390000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="-3"
      id="Tc_bzUCZS8eEEKmXLJUc4DDVA_29_26"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-12390000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_swlXLlVROkCjZl5I0-C9RQ"
      decimals="-3"
      id="Tc_gCM0iQ72vECVC_YdxIPnzw_31_8"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">8726000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_swlXLlVROkCjZl5I0-C9RQ"
      decimals="-3"
      id="Tc_20qDUDdaI02GYXikX5WPsg_31_11"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">9000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tF8wULMhbkG99rPul9KSrQ"
      decimals="-3"
      id="Tc_zC3Flss6SUmK9Q7wuJ9N1g_31_14"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">286441000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_PWObTblql0OvdhYq9X8sSA"
      decimals="-3"
      id="Tc_GvL954xfU0uh49oeef4Eiw_31_17"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-194000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_abZOLroj_UO6rIP7k3Bifg"
      decimals="-3"
      id="Tc_YetIzcIeYU6WDX5nui40wg_31_20"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-206876000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_3_31_2022_-w0U61DdKUWU0kwbv1xmfg"
      decimals="-3"
      id="Tc_bqCNOF3hHE-ePClQjuXbFw_31_26"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">79380000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_khQgursIN0yO8ahkh-ZaZA_6_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-58977000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_a5wNQa9RlkyVWGRsLCPLaw_6_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-33250000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_lxWZozlJ5kuNIw19qftGtA_8_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">3945000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_TFYBbxBd7kGsqYtaS6Qbdw_8_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">3198000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_kTPQ1XIt4U66J6cn749--A_9_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">121000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc__vohrUfukkSnhG_jc5LLgA_9_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">333000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_2FUegZtetUa3dSPgClZwyg_10_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">156000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_5mmZXfcVhkmxxfuoyrlJDw_10_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">587000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_DcdHbHF74UWa1KwnlcIm0g_11_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">290000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_PVl7Ig5SsECvuWkIlSvvTQ_11_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">386000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:Depreciation
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_BKkZaT7qF0aTTsUmqrdwGw_12_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">508000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_BOU5Ucl43Ui4OLK5zax6ug_12_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1532000</us-gaap:Depreciation>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_w_G_FCcUlUCtbzqE_p55hA_13_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">732000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_fuMFGqXxkkCtkv3-g2G3tA_13_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">0</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <ibio:AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_xGzevSI4tEm5CnohzUWjbQ_14_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">56000</ibio:AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable>
    <ibio:AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_mMM5TI4a3EuK6tyIyumchw_14_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">56000</ibio:AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_cp0iTU4mykmBMJxfRJI0DA_15_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">67000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_VZNl-8iWnEe0SaKnpewVgw_15_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">269000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:DebtSecuritiesAvailableForSaleGainLoss
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_MrkGoOqDrEWWYwUT85SkgQ_16_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-98000</us-gaap:DebtSecuritiesAvailableForSaleGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleGainLoss
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_drGrEsIGBkiHO_gX1C4LjA_16_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">0</us-gaap:DebtSecuritiesAvailableForSaleGainLoss>
    <ibio:DeferredFinancingCostsAmortizationExpense
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_uDHgnP3OGEGYZMM0vL2xtw_17_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">160000</ibio:DeferredFinancingCostsAmortizationExpense>
    <ibio:DeferredFinancingCostsAmortizationExpense
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_dSkSB4QvTkOU7K1xRCoqpw_17_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">67000</ibio:DeferredFinancingCostsAmortizationExpense>
    <ibio:IncreaseDecreaseInInventoryReserve
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_ITeJCo4eWkmEvHq-kmbkYQ_18_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">4915000</ibio:IncreaseDecreaseInInventoryReserve>
    <ibio:IncreaseDecreaseInInventoryReserve
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_zkG8Ukfd4067GilNBRCuxA_18_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">0</ibio:IncreaseDecreaseInInventoryReserve>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_bdBQHKdgYUK7Wa_3U6UsKg_19_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">17600000</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_cj5zSDDXOUissqJUtVhwzA_19_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">0</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_wJKRChNLIkOE3jHR1vje0w_20_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">565000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_aXeC-RpywEOywOUUaUwaZg_20_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:GainLossOnSaleOfLeasedAssetsNetOperatingLeases
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_HeyXR5OU4EOEQXQS8GSlxg_21_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">5000</us-gaap:GainLossOnSaleOfLeasedAssetsNetOperatingLeases>
    <us-gaap:GainLossOnSaleOfLeasedAssetsNetOperatingLeases
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_mLgjY5wIrE-x6-rDsLxMuQ_21_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">0</us-gaap:GainLossOnSaleOfLeasedAssetsNetOperatingLeases>
    <ibio:ForgivenessOfNotePayableAndAccruedInterestSbaLoan
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_XKNnOOK2AkiRHj5fw18_oQ_22_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">607000</ibio:ForgivenessOfNotePayableAndAccruedInterestSbaLoan>
    <ibio:SettlementOfRevenueContract
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_Rf2eBNLshE6ucP_vbEvy2Q_23_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">84000</ibio:SettlementOfRevenueContract>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_CDgSNW2P5kGCa9ctP-16Ug_25_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-931000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_3PUV-7tzBU-JZtnC7IMeQg_25_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">890000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <ibio:IncreaseDecreaseInSettlementAssets
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_ttqIZYalJUyYErgM4Iv7oQ_26_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-5100000</ibio:IncreaseDecreaseInSettlementAssets>
    <ibio:IncreaseDecreaseInSettlementAssets
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_erDNxm4dIEu4nlR9o5sPmQ_26_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-5100000</ibio:IncreaseDecreaseInSettlementAssets>
    <us-gaap:IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_XktYm1aN4U-61om_eu9yNg_27_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1015000</us-gaap:IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories>
    <us-gaap:IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_Aov-fiO1oU-hQiw3N7o4HA_27_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">3257000</us-gaap:IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_KvihGiut1EGcICpXdZVAoA_28_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-627000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_h07VThkxnUuswDwxw9k_pg_28_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">494000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_4UmB4ilivkK38k211EiBtA_29_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-74000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_6V9sPJN2TUeeJ2q86EUzcQ_29_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">975000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInSecurityDeposits
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_4s7XHKNtK02Y62eZxkqbKg_30_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-21000</us-gaap:IncreaseDecreaseInSecurityDeposits>
    <us-gaap:IncreaseDecreaseInSecurityDeposits
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_i77-31WBdkGPqXiDjfOyeA_30_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-5000</us-gaap:IncreaseDecreaseInSecurityDeposits>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_BWmcU63IuEiEF43fuDmarw_31_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-481000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_OGV0xpNODkey0gr0UGYCwg_31_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1649000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_Aso4Wf7gXkWFEXl325eoGw_32_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-18000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_MIWLCdeOKU2Lka3nM8k_Og_32_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">618000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <ibio:IncreaseDecreaseInAccruedLiabilitiesNoncurrent
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_hQ43xbZ800GAOyoigJgXGw_33_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">791000</ibio:IncreaseDecreaseInAccruedLiabilitiesNoncurrent>
    <ibio:IncreaseDecreaseInAccruedLiabilitiesNoncurrent
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_L3RH-cJsKUeLQ0dspuWkVw_33_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">0</ibio:IncreaseDecreaseInAccruedLiabilitiesNoncurrent>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_Dx__jB5TJEmsHcgSO4CFpg_34_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-9000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_e0zqImcLWkePpyUUTSCjZA_34_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-12000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc__mK7zt4x0UiIYuRs6udM0g_35_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-100000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_RmuYADqX-Uuh4_6BMYeQSg_35_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-86000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_gw9OIxyrkE60KWZDLssHfw_36_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-25466000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_WCXVteXIxU2ep7fovcCITw_36_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-25977000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_xRMZO3LQA0OM0pdB2Or3uQ_39_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">5355000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_RsQhyDlqokOBPSFZ9IRhxA_40_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">4100000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_pirdJLxm8kuxKnZDr_lPwQ_40_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">9711000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_satvE27kxUOXRnjYhvS0Yg_41_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">6739000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_cyq6BC91406QaLezJ9buiA_41_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_11cs0S7dakK2pN8ExprQGA_42_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1760000</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_JGHWux3tkU-N3l979gartw_43_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">4300000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_cMLinalO-U6cPHno6FysEA_44_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">5232000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_pw_eChb00kKFKEN9xKiQnw_44_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">3900000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_34Gp_WfJYk6b5gsW2NngPg_45_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">2100000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_VEvn-BJpBkm_hDojpD6YkA_45_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_XNktqvMOj0KI62knRg7iag_46_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">692000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_Q11mQSU5KEmBc1hfXHT0Xw_46_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_pX7LSInpq0mD9S8D-_IzpA_48_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">7015000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_GmtREfiBrU2lB15Qo7p_Mw_48_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-5604000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <ibio:ProceedsFromIssuanceOfPreferredAndCommonStock
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_MvoMFo3naUCrOJwqPp4DuQ_51_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">7851000</ibio:ProceedsFromIssuanceOfPreferredAndCommonStock>
    <ibio:ProceedsFromIssuanceOfPreferredAndCommonStock
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_S8XyFADNiE-ew3eED9ztPg_51_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">0</ibio:ProceedsFromIssuanceOfPreferredAndCommonStock>
    <ibio:PaymentsForFractionalSharesAfterReverseStockSplit
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_fs_AqQRIUkGSZ_oAHqVq4g_52_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">39000</ibio:PaymentsForFractionalSharesAfterReverseStockSplit>
    <ibio:PaymentsForFractionalSharesAfterReverseStockSplit
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc__E5TH91jwkuirnrvlA4VFw_52_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">0</ibio:PaymentsForFractionalSharesAfterReverseStockSplit>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc__lRG6lp7yk6ZRkJyb_6QBA_53_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">50000</us-gaap:PaymentsToMinorityShareholders>
    <ibio:ProceedsFromEquipmentFinancingLoan
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_NGsSOzcWl0m9-wTmtSnCXA_54_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">500000</ibio:ProceedsFromEquipmentFinancingLoan>
    <ibio:ProceedsFromEquipmentFinancingLoan
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_AYpP1kOiFUG0VfpWCL-c_w_54_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">0</ibio:ProceedsFromEquipmentFinancingLoan>
    <ibio:PaymentOfEquipmentFinancingLoan
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_OCWVxn743kCU6S8KfiNsyw_55_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">62000</ibio:PaymentOfEquipmentFinancingLoan>
    <ibio:PaymentOfEquipmentFinancingLoan
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_1R3B_IeSSk-3Hc1crXUjYg_55_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">0</ibio:PaymentOfEquipmentFinancingLoan>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_ge3XwCFEXUexe8ib6prx4Q_56_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">8523000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_j41puXX25E-8rJbCLz8Erw_56_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">0</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_8WM6D5I_0EaKV1t3nV12Jw_57_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">77000</us-gaap:ProceedsFromStockOptionsExercised>
    <ibio:PaymentsToAttainTermNote
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_zA-u05S5S06YU9Dmx-DrdQ_58_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">22000</ibio:PaymentsToAttainTermNote>
    <ibio:PaymentsToAttainTermNote
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_MuD4RQQYe0GXQk9K_2ZFpw_58_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">322000</ibio:PaymentsToAttainTermNote>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_doi9Gi1IS0OnJldRudu-8A_59_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">144000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_BMgW_GAqq0KaciR_Se5D0w_59_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">5820000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_3k4axUkP1EaDKGtvgoBDuA_60_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-439000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_3vZ8TdlVYEuh4rHqqxPHXQ_60_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-6115000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_VLhUnPoSyUC4vFa_3PKJ1g_62_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">33000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_swKqIuDrUU2W8bj12FcyhQ_62_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_e_kJ8s8AqkWmTvEcQbgv1w_64_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-18857000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_EvHH-KIpAkeJXvzxEP9afQ_64_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-37696000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_4FYGDuxHJ0eReM-3hdMItg_65_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">28672000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_6_30_2021_RvsAx0CeVUiEHjFvD-Jmkw"
      decimals="-3"
      id="Tc_SEzVfgqzT0ePJcOGgHghCA_65_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">77404000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_UyO2Zj5IK0W_vpgjlXrXEg_66_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">9815000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_3_31_2022_-w0U61DdKUWU0kwbv1xmfg"
      decimals="-3"
      id="Tc_lE0287lz3ECXZ-lQDavldA_66_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">39708000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <ibio:CapitalExpenditureIncurredForIntangibleAssetsPaid
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_OsQt9lfZa0iBk_p5VjI1Ug_5_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1769000</ibio:CapitalExpenditureIncurredForIntangibleAssetsPaid>
    <ibio:CapitalExpenditureIncurredForIntangibleAssetsPaid
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_FLuB7YrU70iVrk-KSoVpIw_5_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">791000</ibio:CapitalExpenditureIncurredForIntangibleAssetsPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_9heWDc-dTUaKs5KZvlA1CA_6_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">814000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_NBeABZ7p_k6qsmcqHqA5Qw_6_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <ibio:IncreaseDecreaseInFinanceLeaseObligationsForNewLeases
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_w3Zb3S8TyUu2RpZ5MHv_7w_7_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">814000</ibio:IncreaseDecreaseInFinanceLeaseObligationsForNewLeases>
    <ibio:IncreaseDecreaseInFinanceLeaseObligationsForNewLeases
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_Q-e5CEzFPk-dCMyFi2JPsw_7_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">0</ibio:IncreaseDecreaseInFinanceLeaseObligationsForNewLeases>
    <ibio:CommonStockIssuedInRubrycTransactionValue
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_GrbdDPlQ2U2BEWhSoa-JBA_8_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">650000</ibio:CommonStockIssuedInRubrycTransactionValue>
    <ibio:CommonStockIssuedInRubrycTransactionValue
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_-Buic0FefUWk1iX9G9XRsg_8_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">0</ibio:CommonStockIssuedInRubrycTransactionValue>
    <ibio:CostToRaiseCapitalPaidDirectlyFromGrossProceeds
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_ytpeX1Zr-EGcGbOtyRuAKg_9_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">636000</ibio:CostToRaiseCapitalPaidDirectlyFromGrossProceeds>
    <ibio:CostToRaiseCapitalPaidDirectlyFromGrossProceeds
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_lAYcHpqjoEeJehf420dIgA_9_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">0</ibio:CostToRaiseCapitalPaidDirectlyFromGrossProceeds>
    <ibio:TerminationOfFinanceLeaseRightOfUseAssetIncludingIssuanceOfWarrant
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_senshscGSke7Dp0zVR65TQ_14_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">0</ibio:TerminationOfFinanceLeaseRightOfUseAssetIncludingIssuanceOfWarrant>
    <ibio:TerminationOfFinanceLeaseRightOfUseAssetIncludingIssuanceOfWarrant
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_axE8hBNV5ESmMdP2NGPUJg_14_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">25386000</ibio:TerminationOfFinanceLeaseRightOfUseAssetIncludingIssuanceOfWarrant>
    <us-gaap:NotesIssued1
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_lWHlQ3Z0LEqWVJgRxsUzfA_15_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">0</us-gaap:NotesIssued1>
    <us-gaap:NotesIssued1
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_aB1jma_l_k2uvHzADP9lEA_15_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">22375000</us-gaap:NotesIssued1>
    <ibio:NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_3w_wZgF8qkWD6VEjKjeQkw_16_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">0</ibio:NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities>
    <ibio:NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_e7_L-7Z7q0eyBrVqcKUyug_16_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">5570000</ibio:NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities>
    <ibio:NonCashSettlementOfRevenueContract
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_csxh8rSsr06kCSuRWj_NjA_17_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">0</ibio:NonCashSettlementOfRevenueContract>
    <ibio:NonCashSettlementOfRevenueContract
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_NOsl1V2wZk-rMqU2swMsnw_17_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">580000</ibio:NonCashSettlementOfRevenueContract>
    <ibio:WarrantsIssuedForFinanceLeasePayment
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_6aDcdT2xI0-rbDOsnCdzzg_18_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">0</ibio:WarrantsIssuedForFinanceLeasePayment>
    <ibio:WarrantsIssuedForFinanceLeasePayment
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_qdV-eVfdEUKd_4dLAvutWw_18_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">217000</ibio:WarrantsIssuedForFinanceLeasePayment>
    <ibio:LeaseIncentiveForConstructionInProgress
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_Y7Ae9kfP80KLs8VQdRHkeQ_19_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">0</ibio:LeaseIncentiveForConstructionInProgress>
    <ibio:LeaseIncentiveForConstructionInProgress
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_cFSlIqmPK0GzMhsWZltTyg_19_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">82000</ibio:LeaseIncentiveForConstructionInProgress>
    <ibio:NoncashOrPartNoncashAcquisitionNonControllingInterestAssumed
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_MTtcGTTSC0uiotrjLcw63w_20_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">0</ibio:NoncashOrPartNoncashAcquisitionNonControllingInterestAssumed>
    <ibio:NoncashOrPartNoncashAcquisitionNonControllingInterestAssumed
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_NkJ8zFzrL0Wa49yVEV6OGQ_20_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">18000</ibio:NoncashOrPartNoncashAcquisitionNonControllingInterestAssumed>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_v8lBuw1bvUObFCamQjMV6Q_21_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">159000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_zlf2qVqIWEGpwMM1qvwvCg_21_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">131000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:InterestPaidNet
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_dAFo8lmVoUKvrrhWtf0T1A_23_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">523000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_cheu2D2nE0qYxOn_o1wlyw_23_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">860000</us-gaap:InterestPaidNet>
    <us-gaap:NatureOfOperations
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      id="Tb_-XgXDlkNEUaEbuvFCo_11g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;1.&#160;&#160;&#160;Nature of Business &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;iBio, Inc. (&#x201c;we&#x201d;, &#x201c;us&#x201d;, &#x201c;our&#x201d;, &#x201c;iBio&#x201d;, &#x201c;iBio, Inc&#x201d; or the &#x201c;Company&#x201d;) is an Artificial Intelligence (&#x201c;AI&#x201d;)-driven innovator of precision antibody immunotherapies. The Company has a pipeline of innovative primarily immuno-oncology antibodies against hard-to-drug targets where it may face reduced competition and with antibodies that may be more selective. The Company plans to use its AI-driven discovery platform to continue adding antibodies against hard-to-drug targets or to work with partners on AI-driven drug development. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Therapeutics Pipeline &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;img alt="Graphic" src="ibio-20230331x10q001.jpg" style="display:inline-block;height:269.68pt;left:0%;padding-bottom:0.35pt;position:relative;top:0pt;width:531.75pt;"/&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;IBIO-101: &lt;/b&gt;an anti-CD25 molecule that works by depletion of immunosuppressive T-regulatory cells (&#x201c;Tregs&#x201d;) via antibody-dependent cellular cytotoxicity (&#x201c;ADCC&#x201d;), without disrupting activation of effector T-cells (&#x201c;Teffs&#x201d;) in the tumor microenvironment. IBIO-101 could potentially be used to treat solid tumors, hairy cell leukemia, relapsed multiple myeloma, lymphoma, or head and neck cancer. IBIO-101 is currently in the Investigational New Drug (&#x201c;IND&#x201d;) enabling stage. We have contracted with a contract research organization (&#x201c;CRO&#x201d;) to assist with the development of the manufacturing process, which includes but is not limited to process and cell line development for the production of the drug substance and drug product. IBIO-101 is strategically positioned as a fast follower to Hoffman-La Roche&#x2019;s RG6292 molecule that recently released Phase 1 clinical data. While RG6292 showed signs of efficacy, especially in combination with PD-L1 monoclonal antibody, and was well tolerated, we anticipate additional clinical research will be needed to determine whether different cancer types are more efficacious than others. As a result, we have decided to pause the IND enabling studies until additional data is released on RG6292. This approach will allow us to gather more information, thoroughly evaluate the market potential and optimize our financial resources and the development plan for IBIO-101 to maximize its potential for success.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;CCR8:&lt;/b&gt; targets depletion of highly immunosuppressive CCR8+ Tregs in the tumor microenvironment via an ADCC mechanism with selective binding to CCR8 over its closely related cousin, CCR4, to avoid off-target effects. A CCR8 program could potentially be broadly applicable in solid tumors and/or as a prospective combination therapy.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EGFRvIII: &lt;/b&gt;binds a tumor-specific mutation of EGFR variant III with an afucosylated antibody for high ADCC. Because of its specificity binding to the tumor-specific mutation, it could potentially reduce toxicity and/or expand the therapeutic window compared to simple broad EGFR-targeted alternatives. EGFRvIII is constantly &#x201c;switched on&#x201d; which can lead to the development of a range of different cancers. An EGFRvIII antibody could potentially be used to treat glioblastoma, head and neck cancer or non-small cell lung cancer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;CD3 antibody panel:&lt;/b&gt; provides a range of CD3 affinities with cross-reactivity to non-human primates and increased the humanness of the antibody sequences. The antibody panel is intended to serve as one arm of T-cell-redirecting bispecific antibodies, a new class of therapeutic antibodies designed to simultaneously bind to T-cells via CD3 and to tumor cells via tumor-specific antigens or tumor-associated antigens, inducing T-cell-mediated killing of tumor cells.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;MUC16:&lt;/b&gt; a highly expressed target on ovarian cancer cells and an attractive tumor associated target for therapeutic antibodies. However, antibodies targeting MUC16 are prone to tumor resistance via epitope shedding and dysregulated glycosylation. Epitope-steered antibodies that bind to an epitope that avoids both of these tumor resistance mechanisms could potentially be used to treat MUC16 positive tumors, particularly those tumors that are resistant to other MUC16 antibodies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;PD-1 Agonist: &lt;/b&gt;selectively binds PD-1 to suppress auto-reactive T-cells without PD-L1/PD-L2 blocking. A PD-1 agonist could potentially be used to treat inflammatory bowel disease, systemic lupus erythematosus, multiple sclerosis or other inflammatory diseases.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In addition to the programs described above, the Company also has three additional early discovery programs that have the potential to advance into later stages of preclinical development and are designed to tackle hard-to-drug targets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;IBIO-100 and Endostatin E4&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Our preclinical anti-fibrotic program, IBIO-100, has been undergoing a review process as part of our ongoing effort to prioritize our resources and focus on the most promising opportunities. The IBIO-100 program design is based upon work by Dr. Carol Feghali-Bostwick, Professor of Medicine at the Medical University of South Carolina and Vice-Chair of the Scleroderma Foundation. Her initial work was conducted at the University of Pittsburgh, and we have licensed the patents relevant for the continued development of the molecule from the university. &#160;After careful consideration, in February 2023, the Company terminated all efforts on IBIO-100 anti-fibrotic program and provided a six (6) month notice of termination of the license agreement to the University of Pittsburgh, as required by the license agreement. Pursuant to the license agreement with the University of Pittsburgh, the Company&#x2019;s financial obligations for the management of the patents under the license will cease on August 14, 2023, and at such time, will transition back to the University of Pittsburgh.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;As part of this decision, we are intending to complete the pre-clinical cancer studies we are conducting in collaboration with University of Texas Southwestern using E4 endostatin peptide, which is derived from IBIO-100. After the pre-clinical studies are completed, we will re-assess whether to further pursue the oncology program and have further discussions with the University of Pittsburgh. This approach allows us to gather valuable data and insights that will inform our future decisions regarding the potential of E4 endostatin peptide as an oncology program. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;AI Drug Discovery Platform&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In September 2022, the Company purchased substantially all of the assets of RubrYc Therapeutics (for a complete description of the transaction please see Note 6 &#x2013; Significant Transactions). The AI Drug Discovery platform technology is designed to be used to discover antibodies that bind to hard-to-target subdominant and conformational epitopes for further development within our existing portfolio or in partnership with outside entities. The RubrYc AI platform is built upon three key technologies. &lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;1.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;Epitope Targeting Engine:&lt;/b&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; A patented machine-learning platform that combines computational biology and 3D-modeling to identify molecules that mimic hard-to-target binding sites on target proteins, specifically, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;subdominant and conformational epitopes.&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The creation of these small mimics enables the engineering of therapeutic antibody candidates that can selectively bind immune and cancer cells better than &#x201d;trial and error&#x201d; antibody engineering and screening methods that are traditionally focused on dominant epitopes.&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;2.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;"&gt;RubrYcHu&lt;/span&gt;&lt;sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;"&gt;TM&lt;/sup&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt; Library:&lt;/b&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; An &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;AI-generated human antibody library free of significant sequence liabilities that provides a unique pool of antibodies to screen. &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The combination of the Epitope Targeting Engine and screening with the &lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;RubrYcHu&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; Library has been shown to reduce the discovery time from ideation to &lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;in vivo&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; proof-of-concept (&#x201c;PoC&#x2019;) by up to four months. This has the potential to enable more, and better, therapeutic candidates to reach the clinic faster. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;3.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;"&gt;StableHu&lt;/span&gt;&lt;sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;"&gt;TM&lt;/sup&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt; Library:&lt;/b&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; An &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;AI-powered sequence optimization library used to improve antibody performance&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;. Once an antibody has been advanced to the lead optimization stage, &lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;StableHu&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; allows precise and rapid optimization of the antibody binding regions to rapidly move a candidate molecule into the IND-enabling stage.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On January 3, 2023, the United States Patent and Trademark Office issued U.S. Patent No. 11,545,238, entitled &#x201c;Machine Learning Method for Protein Modelling to Design Engineered Peptides,&#x201d; which, among other claims, covers a machine learning model for &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;engineering peptides, including antibody epitope therapeutics. &#160;Subject to any potential patent term extensions, the patent will expire on May 13, 2040.&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_4RTLL7EZIE2-SZCqH8ijHg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;2.&#160;&#160;&#160;Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"&gt;Interim Consolidated Financial Statements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared from the books and records of the Company and include all normal and recurring adjustments which, in the opinion of management, are necessary for a fair presentation in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;) for interim consolidated financial information and Rule 8-03 of Regulation S-X promulgated by the U.S. Securities and Exchange Commission (the &#x201c;SEC&#x201d;). Accordingly, these interim financial statements do not include all of the information and footnotes required for complete annual consolidated financial statements. Interim results are not necessarily indicative of the results that may be expected for the full year. Interim unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and the notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the prior year ended June&#160;30,&#160;2022, filed with the SEC on October 11, 2022 (the &#x201c;Annual Report&#x201d;), from which the accompanying condensed consolidated balance sheet dated June&#160;30,&#160;2022 was derived.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"&gt;Principles of Consolidation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated as part of the consolidation. Non-controlling interest in the consolidated financial statements represented the share of the loss in iBio CDMO, LLC (&#x201c;iBio CDMO&#x201d;) for an affiliate of Eastern Capital Limited (&#x201c;Eastern Capital&#x201d;) through November 1, 2021, the date the Company acquired the remaining interest in iBio CDMO. &#160;See Note 6 &#x2013; Significant Transactions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"&gt;Going Concern &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The history of significant losses, the negative cash flow from operations, the limited cash resources on hand and the dependence by the Company on its ability to obtain additional financing to fund its operations after the current cash resources are exhausted raise substantial doubt about the Company's ability to continue as a going concern. In an effort to remain a going concern and increase cash reserves, the Company completed a public equity offering, reduced its work force by approximately 60% (a reduction of approximately 69 positions) in November 2022, and ceased operations of its CDMO facility thereby reducing annual spend on expenses by approximately 50%. &#160;Additionally, in July 2022, the Company initiated the selling of the CDMO assets and facility, and since then has sold a substantial portion of the CDMO assets. (See Note 3 &#x2013; Discontinued Operations for more information.) Additional potential options being considered&#160;to further increase liquidity include lowering the Company&#x2019;s expenses further, focusing product development on a select number of product candidates, the sale of the CDMO, the sale or out-licensing of certain product candidates, additional equipment sales, raising money from capital markets, grant revenue or collaborations, or a combination thereof. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;The Company&#x2019;s cash, cash equivalents, and restricted cash of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$9.8&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million&lt;/span&gt; &lt;span style="font-size:10pt;"&gt;as of March&#160;31,&#160;2023, is not anticipated to be sufficient to support operations through the first quarter of Fiscal 2024&lt;/span&gt;&lt;b style="font-size:10pt;font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-size:10pt;"&gt;unless the Company reduces its burn rate further, sells the CDMO facility for amounts above its term note payable, or increases its capital as described above. Regardless of whether the Company is able to reduce its burn rate or sell or out-license certain assets or parts of the business, the Company will need to raise additional capital in order to fully execute its near and long-term business plan. It is the Company&#x2019;s goal to implement one or more potential options described above to allow the Company to have a cash runway for at least 12 months from the date of the filing of this Quarterly Report on Form 10-Q. However, there can be no assurance that the Company will be successful in implementing any of the options that it is evaluating.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying consolidated financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Reverse Stock Split &lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On September 22, 2022, the Company's Board of Directors approved the implementation of a reverse stock split (the &#x201c;Reverse Split&#x201d;) at a ratio of one-for-twenty five (1:&lt;span style="-sec-ix-hidden:Hidden_C8lqvEAS3E6y7jI9fK0gaA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;25&lt;/span&gt;&lt;/span&gt;) shares of the Company's common stock, par value $0.001 (the &#x201c;Common Stock&#x201d;). The Reverse Split was effective as of October 7, 2022. All share and per share amounts of the Common Stock presented have been retroactively adjusted to reflect the Reverse Split. See Note 16 &#x2013; Stockholders&#x2019; Equity for more information. &lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <ibio:CashAndCashEquivalentsPlusDebtSecurities
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-5"
      id="Narr_8vn33m0oh0C8DGH5Xv-gJw"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">9800000</ibio:CashAndCashEquivalentsPlusDebtSecurities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="INF"
      id="Narr_TQ2Ei7lmZUWTCFjqX1MX1g"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_vjNUY7z2SEqlEKH3y7Z5Vg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;3.&#160;&#160;&#160;Discontinued Operations &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On November 3, 2022, the Company announced it is seeking to divest its contract development and manufacturing organization (iBio CDMO, LLC) in order to complete its transformation into an antibody discovery and development company. In conjunction with the divestment, the Company commenced a workforce reduction of approximately 60% of the current Company staffing levels (a reduction of approximately 69 positions). The Company substantially completed the employee reduction by January 2, 2023. Through the process of seeking to divest its contract development and manufacturing organization, the Company continues to market for sale the 130,000-square-foot cGMP facility location in Bryan, Texas (the &#x201c;Facility&#x201d;). Additionally, on February 10, 2021, the Company, entered into an Auction Sale Agreement (the &#x201c;Auction Sale Agreement&#x201d;) with Holland Industrial Group, together with Federal Equipment Company and Capital Recovery Group LLC (collectively, the &#x201c;Auctioneers&#x201d;) for the sale at public auction of equipment and other tangible personal property (the &#x201c;Equipment&#x201d;) located at the Facility. &#160;The Auctioneer guaranteed an amount of gross proceeds from the sale of the equipment of $2.1 million, which was paid to the Company on February 17, 2023. The auction, which commenced on March 24, 2023 and concluded on March 30, 2023, resulted in total proceeds of approximately $2.9 million. &#160;In accordance with the Auction Sale Agreement, the Company received 80% of the excess proceeds, after Holland Industrial Group&#x2019;s $0.2 million fee, which approximated $0.5 million during the fourth quarter of Fiscal 2023 and is included in prepaid and other assets as of March 31, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company incurred pre-tax charges of approximately $1.9 million for the employee reduction which consisted of severance obligations, continuation of salaries and benefits over a 60-day transitional period during which impacted employees remain employed but were not expected to provide active service, and other customary employee benefit payments in connection with an employee reduction. &#160;At March&#160;31,&#160;2023, $0.1 million remains in accrued expenses as a current liability. &#160;The Company recorded a charge in discontinued operations for $34.6 million for the nine months ended March&#160;31,&#160;2023, of which approximately $17.6 million was the result of a fixed asset impairment charge (see Note 11 &#x2013; Fixed Assets for more information), approximately $4.9 million to write down inventory to its net realizable value, approximately $7.5 million of personnel costs including severance and the balance related to operational costs related to winding down the CDMO business.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;As such, the results of iBio CDMO's operations are reported as discontinued operations for the three and nine months ended March&#160;31,&#160;2023. The Company has retrospectively recast its condensed consolidated statement of operations for the three and nine months ended March&#160;31,&#160;2022 presented. In addition, those assets and liabilities associated with the discontinued operations of the CDMO that the Company intends to sell have been classified as &#x201c;held for sale&#x201d; as of March 31, 2023. The Company has retrospectively recast its consolidated balance sheet as of June 30, 2022 for assets and liabilities held for sale. The Company has chosen not to segregate the cash flows of iBio CDMO in the consolidated statement of cash flows. &#160;Supplemental disclosures related to discontinued operations for the statements of cash flows have been provided below. Unless noted otherwise, discussion in the Notes to the Condensed Consolidated Financial Statements refers to the Company's continuing operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;The following table presents a reconciliation of the major financial lines constituting the results of operations for discontinued operations to the loss from discontinued operations presented separately in the condensed consolidated statements of operations (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:61.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenues&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 205&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 143&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cost of goods sold&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 48&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gross profit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 180&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 95&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating expenses:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 837&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 2,278&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 929&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 3,211&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Gain on sale of fixed assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (732)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total operating expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,034&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 5,489&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other expenses:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Interest expense - term note payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (158)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (249)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total other expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (161)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (250)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Loss from discontinued operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,015)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,644)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenues&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 391&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 438&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cost of goods sold&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 52&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 201&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gross profit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 339&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 237&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating expenses:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 6,361&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 5,128&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 6,165&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 8,659&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Fixed asset impairments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 17,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Gain on sale of fixed assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (732)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Inventory reserve&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 4,933&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total operating expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 34,327&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 13,787&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other income (expenses):&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Interest expense - term note payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (606)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (372)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Interest expense - related party&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (810)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Forgiveness of note payable and accrued interest - SBA loan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 607&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total other income (expenses)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (610)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (574)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Loss from discontinued operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (34,598)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (14,124)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table presents net carrying values related to the major classes of assets that were classified as held for sale at March&#160;31,&#160;2023 and June&#160;30,&#160;2022 (in thousands): &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Current assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Inventory&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 3,900&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,944&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 16,424&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 18,368&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 3,900&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 35,289&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Finance lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 74&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,951&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total other assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 37,314&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Current liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Finance lease obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 46&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Operating lease obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,944&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 10&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total current liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,944&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 56&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Long-term liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Finance lease obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt;30&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Operating lease obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,941&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total long-term liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,971&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The following table presents the supplemental disclosures related to discontinued operations for the statements of cash flows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Depreciation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 273&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,532&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Amortization of finance lease right-of-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 587&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Purchase of fixed assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,041&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 28,384&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Fixed asset impairments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 17,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Inventory reserve&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 4,933&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Sales proceeds of fixed assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 2,100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Investing non-cash transactions:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Fixed assets included in accounts payable in prior period, paid in current period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,542&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 791&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Unpaid fixed assets included in accounts payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 2,193&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Sales of fixed assets receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 460&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="Duration_11_3_2022_To_11_3_2022_B-3zxmk-RECRSqI6e6Ttyg"
      decimals="2"
      id="Narr_1fBedorh_0WhkDGZfaEFuQ"
      unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg">0.60</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated
      contextRef="Duration_11_3_2022_To_11_3_2022_B-3zxmk-RECRSqI6e6Ttyg"
      decimals="INF"
      id="Narr_pOGDtvayTEuzxUujXdhAMQ"
      unitRef="Unit_Standard_position_V29P0pRPvUyM5A0t2OFq5g">69</us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated>
    <ibio:EmployeeReductionExpenses
      contextRef="Duration_11_3_2022_To_11_3_2022_B-3zxmk-RECRSqI6e6Ttyg"
      decimals="-5"
      id="Narr_kvXmfJdPE0uCp-t1jspnPQ"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1900000</ibio:EmployeeReductionExpenses>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-5"
      id="Narr__ZEcBVa8FkGpFde_CTtQng"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">100000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent>
    <ibio:EmployeeReductionExpenses
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-5"
      id="Narr_NrFLBXXwpkCAbU5aKKxRTw"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">34600000</ibio:EmployeeReductionExpenses>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-5"
      id="Narr_Q5kOWRKjykiCEjswWhTwNg"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">17600000</us-gaap:TangibleAssetImpairmentCharges>
    <ibio:DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-5"
      id="Narr_xwRr7BMujEe0x6dZTl7fMQ"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">4900000</ibio:DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown>
    <ibio:DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-5"
      id="Narr_DVjv9HDNtE-vznpcyU9EEA"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">7500000</ibio:DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_fhkmsCG_B0a91HXa6X0jKA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;The following table presents a reconciliation of the major financial lines constituting the results of operations for discontinued operations to the loss from discontinued operations presented separately in the condensed consolidated statements of operations (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:61.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenues&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 205&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 143&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cost of goods sold&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 48&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gross profit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 180&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 95&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating expenses:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 837&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 2,278&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 929&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 3,211&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Gain on sale of fixed assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (732)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total operating expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,034&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 5,489&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other expenses:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Interest expense - term note payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (158)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (249)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total other expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (161)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (250)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Loss from discontinued operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,015)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,644)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenues&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 391&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 438&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cost of goods sold&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 52&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 201&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gross profit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 339&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 237&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating expenses:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 6,361&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 5,128&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 6,165&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 8,659&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Fixed asset impairments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 17,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Gain on sale of fixed assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (732)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Inventory reserve&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 4,933&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total operating expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 34,327&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 13,787&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other income (expenses):&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Interest expense - term note payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (606)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (372)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Interest expense - related party&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (810)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Forgiveness of note payable and accrued interest - SBA loan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 607&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total other income (expenses)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (610)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (574)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Loss from discontinued operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (34,598)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (14,124)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table presents net carrying values related to the major classes of assets that were classified as held for sale at March&#160;31,&#160;2023 and June&#160;30,&#160;2022 (in thousands): &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Current assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Inventory&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 3,900&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,944&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 16,424&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 18,368&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 3,900&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 35,289&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Finance lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 74&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,951&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total other assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 37,314&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Current liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Finance lease obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 46&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Operating lease obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,944&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 10&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total current liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,944&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 56&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Long-term liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Finance lease obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt;30&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Operating lease obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,941&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total long-term liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,971&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The following table presents the supplemental disclosures related to discontinued operations for the statements of cash flows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Depreciation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 273&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,532&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Amortization of finance lease right-of-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 587&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Purchase of fixed assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,041&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 28,384&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Fixed asset impairments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 17,600&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Inventory reserve&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 4,933&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Sales proceeds of fixed assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 2,100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Investing non-cash transactions:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Fixed assets included in accounts payable in prior period, paid in current period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,542&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 791&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Unpaid fixed assets included in accounts payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 2,193&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Sales of fixed assets receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 460&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Tc_X3VbJSYQ-0-_6YfEISLeSA_4_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">205000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="-3"
      id="Tc_MITVCm85VEuybu2KUSLBTQ_4_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">143000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Tc_iV5NOnh0AESI9pSyWDjKrw_5_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">25000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="-3"
      id="Tc_0b3TJmyyNUmE29RsZzR1dw_5_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">48000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Tc_ZNBojOkqJEyJ2d6yy73wAg_6_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">180000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="-3"
      id="Tc_2TvSrgx0bUCdw96CZWr35Q_6_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">95000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss>
    <ibio:DiscontinuedOperationsResearchAndDevelopmentExpenses
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Tc_kSVrGv72L0SXa4LzPj5wIA_8_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">837000</ibio:DiscontinuedOperationsResearchAndDevelopmentExpenses>
    <ibio:DiscontinuedOperationsResearchAndDevelopmentExpenses
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="-3"
      id="Tc_Vncq_hslbkmU1bee_e_9vA_8_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">2278000</ibio:DiscontinuedOperationsResearchAndDevelopmentExpenses>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Tc_cj9cxxOvgk6p90qvhXuzWw_9_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">929000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="-3"
      id="Tc_Wiveo7HxtkavTRORVEpouw_9_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">3211000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <ibio:DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Tc_bpMIncSDzkmh2an40preTw_10_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-732000</ibio:DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Tc_iHCAYFCoNk-9eVR9jDEwPA_11_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1034000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="-3"
      id="Tc_-SYNbbot-U60n9dd1TfEOA_11_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">5489000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Tc_IwhO18AvXUits91JF-Lb3A_14_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">158000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="-3"
      id="Tc_5F_TNv_ki0CfPbJscwFCOQ_14_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">249000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense>
    <ibio:DiscontinuedOperationsMiscellaneousExpensesIncome
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Tc_4ZenPpYICkmA5LhDDr88GA_15_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">3000</ibio:DiscontinuedOperationsMiscellaneousExpensesIncome>
    <ibio:DiscontinuedOperationsMiscellaneousExpensesIncome
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="-3"
      id="Tc_rdOrXJRlK0Ssynqcvk_yiQ_15_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1000</ibio:DiscontinuedOperationsMiscellaneousExpensesIncome>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Tc_UdO0U6YXS02vU23F0Xe7xg_16_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">161000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="-3"
      id="Tc_huyzL1WyXE691q0b19XFOQ_16_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">250000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Tc_W3TTPyCEtUunHkbMyOm92g_18_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-1015000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="-3"
      id="Tc_Rf4MwXqG7kyxdMrWRlyQTA_18_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-5644000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_XAXuG185rk68azDa1vNy_Q_4_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">391000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_YOBSZZGpukGVFcYMdY8EoQ_4_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">438000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_9GDse8Auz0iKU2paFf05qg_5_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">52000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_ZWI4mxp590W2s4PxYbmv6A_5_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">201000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_j1IiUkEZFUSijrpI7w-BwQ_6_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">339000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_dB-qaSKgNUmAvbgpD-Lgpg_6_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">237000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss>
    <ibio:DiscontinuedOperationsResearchAndDevelopmentExpenses
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_mEjE1IqdmUerf_4U_O6MHg_8_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">6361000</ibio:DiscontinuedOperationsResearchAndDevelopmentExpenses>
    <ibio:DiscontinuedOperationsResearchAndDevelopmentExpenses
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_qvKaRf4Rskm0MErLirlctw_8_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">5128000</ibio:DiscontinuedOperationsResearchAndDevelopmentExpenses>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_t7CBEMVWlEWS-fCbuWhCMw_9_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">6165000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_l-_WtYqjjECBebYyoDMUZw_9_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">8659000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <ibio:TangibleAssetImpairmentChargesDiscontinuedOperations
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_MXhCvYbaAkGEapvNR9M5Vg_10_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">17600000</ibio:TangibleAssetImpairmentChargesDiscontinuedOperations>
    <ibio:DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_aCNReGcpyUGEaaoLiY_QtA_12_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">4933000</ibio:DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_KRxrRsk4akatUz05pX2kZQ_13_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">34327000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_pB9Z_HP1vkaaMSfU0meImA_13_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">13787000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_7NjoyUaP40GkniATxT_jmw_16_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">606000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_Ct7GyEbMr0mnjHhrEQPEMQ_16_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">372000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense>
    <ibio:DisposalGroupInterestExpenseRelatedParty
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_K_edmUvdF0KF3F5WZzj5aQ_17_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">810000</ibio:DisposalGroupInterestExpenseRelatedParty>
    <ibio:DisposalGroupGainOnDebtForgiveness
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_SvzoSoCYJU2E1vjuTdVb-Q_18_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">607000</ibio:DisposalGroupGainOnDebtForgiveness>
    <ibio:DiscontinuedOperationsMiscellaneousExpensesIncome
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_oSugKgwZP0KzIFJnZmwKHA_19_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">4000</ibio:DiscontinuedOperationsMiscellaneousExpensesIncome>
    <ibio:DiscontinuedOperationsMiscellaneousExpensesIncome
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_-5X8K-L35EKZFw4HcH9xSA_19_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-1000</ibio:DiscontinuedOperationsMiscellaneousExpensesIncome>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_HJqw12rxrEyARg97U3a_dQ_20_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">610000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_36w7PYWQWEq1iH1gB6mM9w_20_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">574000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_ygupZ6luQ02CAuyXBEqWWw_22_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-34598000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_bAngYwK1VEmpUMwkeDedbg_22_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-14124000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_7ZGc89kQfkKtjv3-Q0i1xA_4_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">3900000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent>
    <ibio:DisposalGroupOperatingLeaseRightOfUseAssets
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_CCs6R1m5QUSuqDe4qbKPqw_5_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1944000</ibio:DisposalGroupOperatingLeaseRightOfUseAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_rT4iqBjLdEOK_4rVlxz1TA_6_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">16424000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_RR7AXOBXl02oURYtXzaSIw_7_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">18368000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_MfEafO9YkU6jTQkQztVXHQ_7_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">3900000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_YwGmWKbD8Eefu-etn4KrRg_10_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">35289000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent>
    <ibio:DisposalGroupNonCurrentAssetsFinanceLeaseRightOfUseAssets
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_5WSzUR_W9k-pnmV_nvyBJA_11_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">74000</ibio:DisposalGroupNonCurrentAssetsFinanceLeaseRightOfUseAssets>
    <ibio:DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_IvuP5Uc-d0KP7_W0ANVBXA_12_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1951000</ibio:DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_0HrPalRgd0ehLPUbsVHwKA_13_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">37314000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <ibio:DisposalGroupCurrentLiabilitiesFinanceLeaseObligations
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_0R3REXoidUm7qI-_rTPhaA_16_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">46000</ibio:DisposalGroupCurrentLiabilitiesFinanceLeaseObligations>
    <ibio:DisposalGroupCurrentLiabilitiesOperatingLeaseObligations
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_37IrJ6QnLEGf4dXsmwG_Yg_17_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1944000</ibio:DisposalGroupCurrentLiabilitiesOperatingLeaseObligations>
    <ibio:DisposalGroupCurrentLiabilitiesOperatingLeaseObligations
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_ZYodlYOsfUuD_CeH1TRgZw_17_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">10000</ibio:DisposalGroupCurrentLiabilitiesOperatingLeaseObligations>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_v6s8JJw-2kmKqJxSuuJByQ_18_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1944000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_bl2_IU5a9UKaK1mNcvNx-g_18_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">56000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <ibio:DisposalGroupNoncurrentLiabilitiesFinanceLeaseObligations
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_5jnBGlaaHUegVzpu6lOu0w_21_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">30000</ibio:DisposalGroupNoncurrentLiabilitiesFinanceLeaseObligations>
    <ibio:DisposalGroupNoncurrentOperatingLeaseObligations
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_H5E9ZRLRNEygKIT-Q87kbA_22_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1941000</ibio:DisposalGroupNoncurrentOperatingLeaseObligations>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_tyBWYoqgjEiTela-q4nyvA_23_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1971000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent>
    <us-gaap:DepreciationAndAmortizationDiscontinuedOperations
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_fwACq1u-ZEq1H3GxdtJhfA_4_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">273000</us-gaap:DepreciationAndAmortizationDiscontinuedOperations>
    <us-gaap:DepreciationAndAmortizationDiscontinuedOperations
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_1nmPxrb5ak-kriRJTsGYzA_4_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1532000</us-gaap:DepreciationAndAmortizationDiscontinuedOperations>
    <ibio:DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_o4Vm7RARJUCIMq5Pt8thQQ_5_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">20000</ibio:DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets>
    <ibio:DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_GM37i_NetE-dQ4-ZWIuM7g_5_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">587000</ibio:DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets>
    <us-gaap:CapitalExpenditureDiscontinuedOperations
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_txSwrvhrh0qxcqTJG33kYw_6_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1041000</us-gaap:CapitalExpenditureDiscontinuedOperations>
    <us-gaap:CapitalExpenditureDiscontinuedOperations
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_1i_4kEHfikiA835VTncrpQ_6_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">28384000</us-gaap:CapitalExpenditureDiscontinuedOperations>
    <ibio:TangibleAssetImpairmentChargesDiscontinuedOperations
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_bIZlkdVyNkSn5orWAZ0mhw_7_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">17600000</ibio:TangibleAssetImpairmentChargesDiscontinuedOperations>
    <ibio:DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_xiZ8PZAGEUqjVNpJHF37Fg_8_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">4933000</ibio:DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown>
    <ibio:DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_ocl9q5wYF02Pw3qPyc7rYQ_11_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1542000</ibio:DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod>
    <ibio:DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_g6yRetR-aEm5bUjO95ogjQ_11_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">791000</ibio:DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod>
    <ibio:UnpaidFixedAssetsAttributableToDiscontinuedOperations
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_bDzkbhsVL0yTsduFsXzGAA_13_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">460000</ibio:UnpaidFixedAssetsAttributableToDiscontinuedOperations>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_adn3R_PFpki_rEn3dlfjdg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;4.&#160;&#160;&#160;Summary of Significant Accounting Policies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company&#x2019;s significant accounting policies are described in Note&#160;3 of the Notes&#160;to Consolidated Financial Statements in the Annual Report.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include liquidity assertions, the valuation of intellectual property and fixed assets held for sale, the incremental borrowing rate utilized in the finance and operating lease calculations, legal and contractual contingencies and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Accounts Receivable&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Accounts receivable are reported at their outstanding unpaid principal balances net of allowances for uncollectible accounts. The Company provides for allowances for uncollectible receivables based on its estimate of uncollectible amounts considering age, collection history, and other factors considered appropriate. Management&#x2019;s policy is to write off accounts receivable against the allowance for doubtful accounts when a balance is determined to be uncollectible. At March&#160;31,&#160;2023 and June&#160;30,&#160;2022, the Company determined that an allowance for doubtful accounts was not needed. &#160;The Company had accounts receivable of $426,000 at June&#160;30,&#160;2021. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Revenue Recognition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company accounts for its revenue recognition under Accounting Standards Codification ("ASC") 606, &lt;i style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/i&gt;. Under this standard, the Company recognizes revenue when a customer obtains control of promised services or goods in an amount that reflects the consideration to which the Company expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer contracts. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company&#x2019;s contract revenue consists primarily of amounts earned under contracts with third-party customers and reimbursed expenses under such contracts. The Company analyzes its agreements to determine whether the elements can be separated and accounted for individually or as a single unit of accounting. Allocation of revenue to individual elements that qualify for separate accounting is based on the separate selling prices determined for each component, and total contract consideration is then allocated pro rata across the components of the arrangement. If separate selling prices are not available, the Company will use its best estimate of such selling prices, consistent with the overall pricing strategy and after consideration of relevant market factors.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In general, the Company applies the following steps when recognizing revenue from contracts with customers: (i)&#160;identify the contract, (ii)&#160;identify the performance obligations, (iii)&#160;determine the transaction price, (iv)&#160;allocate the transaction price to the performance obligations and (v)&#160;recognize revenue when a performance obligation is satisfied. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Recognition of revenue is driven by satisfaction of the performance obligations using one of two methods: revenue is either recognized over time or at a point in time. Contracts containing multiple performance obligations classify those performance obligations into separate units of accounting either as standalone or combined units of accounting. For those performance obligations treated as a standalone unit of accounting, revenue is generally recognized based on the method appropriate for each standalone unit. For those performance obligations treated as a combined unit of accounting, revenue is generally recognized as the performance obligations are satisfied, which generally occurs when control of the goods or services have been transferred to the customer or client or once the client or customer is able to direct the use of those goods and/or services as well as obtaining substantially all of its benefits. As such, revenue for a combined unit of accounting is generally recognized based on the method appropriate for the last delivered item but due to the specific nature of certain project and contract items, management may determine an alternative revenue recognition method as appropriate, such as a contract whereby one deliverable in the arrangement clearly comprises the overwhelming majority of the value of the overall combined unit of accounting. Under this circumstance, management may determine revenue recognition for the combined unit of accounting based on the revenue recognition guidance otherwise applicable to the predominant deliverable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;If a loss on a contract is anticipated, such loss is recognized in its entirety when the loss becomes evident. When the current estimates of the amount of consideration that is expected to be received in exchange for transferring promised goods or services to the customer indicates a loss will be incurred, a provision for the entire loss on the contract is made. At March&#160;31,&#160;2023 and June&#160;30,&#160;2022, the Company had no contract loss provisions. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration-line:underline;text-decoration-style:solid;"&gt;Fixed-Fee &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Under a fixed-fee contract, the Company charges a fixed agreed upon amount for a deliverable. Fixed-fee contracts have fixed deliverables upon completion of the project. Typically, the Company recognizes revenue for fixed-fee contracts after projects are completed, delivery is made and title transfers to the customer, and collection is reasonably assured.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Revenue can be recognized either 1) over time or 2) at a point in time. &#160;All revenue was recognized at a point in time for all periods presented.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;For the three months ended March 31, 2022, revenue was recognized from a license agreement and for the nine months ended March&#160;31,&#160;2022, revenue was recognized from a license agreement and the settlement of a revenue contract. &#160;No revenue was recognized for all other periods presented. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration-line:underline;text-decoration-style:solid;"&gt;Time and Materials&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Under a time and materials contract, the Company charges customers an hourly rate plus reimbursement for other project specific costs. The Company recognizes revenue for time and material contracts based on the number of hours devoted to the project multiplied by the customer&#x2019;s billing rate plus other project specific costs incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Contract Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;A contract asset is an entity&#x2019;s right to payment for goods and services already transferred to a customer if that right to payment is conditional on something other than the passage of time. Generally, an entity will recognize a contract asset when it has fulfilled a contract obligation but must perform other obligations before being entitled to payment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Contract assets consist primarily of the cost of project contract work performed by third parties for which the Company expects to recognize any related revenue at a later date, upon satisfaction of the contract obligations. At March&#160;31,&#160;2023 and June&#160;30,&#160;2022, contract assets were $0.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Contract Liabilities&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;A contract liability is an entity&#x2019;s obligation to transfer goods or services to a customer at the earlier of (1) when the customer prepays consideration or (2) the time that the customer&#x2019;s consideration is due for goods and services the entity will yet provide. Generally, an entity will recognize a contract liability when it receives a prepayment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Contract liabilities consist primarily of consideration received, usually in the form of payment, on project work to be performed whereby the Company expects to recognize any related revenue at a later date, upon satisfaction of the contract obligations. At March&#160;31,&#160;2023, June&#160;30,&#160;2022, and June&#160;30,&#160;2021, contract liabilities w&lt;span style="background:#ffffff;"&gt;ere &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$0&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;, &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$100,000&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; and &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$423,000&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;, r&lt;/span&gt;espectively. The Company recognized revenue of $53,000 and $100,000 during the three and nine months ended March&#160;31,&#160;2023, respectively, that was included in the contract liabilities balance as of June 30, 2022 and was reported in discontinued operations. The Company recognized revenue of $52,000 and $178,000 during the three and nine months ended March&#160;31,&#160;2022, respectively, that was included in the contract liabilities balance as of June&#160;30,&#160;2021 and was reported in discontinued operations. The Company recognized revenue of $0 and $84,000 during the three &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;and nine months ended March&#160;31,&#160;2022 that was included in the contract liabilities balance as of June&#160;30,&#160;2021 and reported as part of continuing operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Leases&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company accounts for leases under the guidance of Accounting Standards Codification ("ASC") 842, &lt;i style="font-style:italic;"&gt;Leases&lt;/i&gt; ("ASC 842"). The standard established a right-of-use (&#x201c;ROU&#x201d;) model requiring a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months and classified as either an operating or finance lease. The adoption of ASC 842 had a significant effect on the Company&#x2019;s balance sheet, resulting in an increase in non-current assets and both current and non-current liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In accordance with ASC 842, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether the Company obtains the right to substantially all the economic benefit from the use of the asset, and whether the Company has the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. For contracts with lease and non-lease components, &lt;span style="-sec-ix-hidden:Hidden_eZ239xUFfk2aM5khbNy0yg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;the Company has elected not to allocate the contract consideration and to account for the lease and non-lease components as a single lease component&lt;/span&gt;&lt;/span&gt;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The lease liabilities and the corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. The implicit rate within the Company&#x2019;s existing finance (capital) lease was determinable and, therefore, used at the adoption date of ASC 842 to determine the present value of lease payments under the finance lease. The implicit rate within the Company&#x2019;s operating lease was not determinable and, therefore, the Company used the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Company&#x2019;s incremental borrowing rate requires judgment. The Company will determine the incremental borrowing rate for each new lease using its estimated borrowing rate.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain the Company will exercise that option. An option to terminate is considered unless it is reasonably certain the Company will not exercise the option.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers all highly-liquid instruments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents at March&#160;31,&#160;2023 and June&#160;30,&#160;2022 consisted of money market accounts. Restricted cash consisted of $3.0 million held within a Company account at Woodforest Bank for the term note payable (see Note 6 &#x2013; Significant Transactions and Note 13 - Debt), collateral for a letter of credit obtained related to the San Diego operating lease (see Note 15 &#x2013; Operating Lease Obligations) and collateral for a Company purchasing card. The Company&#x2019;s bank required an additional 5% collateral held above the actual letters of credit issued for the San Diego lease and Company purchasing card. Restricted cash was approximately $3.3 million at &#160;March&#160;31,&#160;2023 and $6.0 million on June&#160;30,&#160;2022. The reduction to the restricted cash occurred because on October 11, 2022, the Company, as part of the First Amendment to the Credit Agreement with Woodforest National Bank (&#x201c;Woodforest&#x201d;), paid down $5.5 million of the term loan and subsequently Woodforest cancelled the irrevocable letter of credit issued by JPMorgan Chase Bank upon closing of the amendment. &#160;In accordance with the Fourth Amendment with Woodforest, the Company deposited $3 million in a restricted account at Woodforest. (For a complete description of the transaction please see Note 6 &#x2013; Significant Transactions and Note 13 - Debt). &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes the components of total cash, cash equivalents and restricted cash in the condensed consolidated statements of cash flows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:58.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,562&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 22,676&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Collateral held for letter of credit - term note payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 5,743&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Collateral held for letter of credit - San Diego lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 198&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 198&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Collateral held for Company purchasing card&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 55&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 55&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total cash, cash equivalents and restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,815&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,672&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"&gt;Investments in Debt Securities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:normal;"&gt;Debt investments were classified as available-for-sale. Changes in fair value are recorded in other comprehensive income (loss). Fair value was calculated based on publicly available market information. Discounts and/or premiums paid when the debt securities were acquired are amortized to interest income over the terms of the debt securities. See Note 8 &#x2013; Investments in Debt Securities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"&gt;Inventory&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-family:'TimesNewRomanPSMT';"&gt;Inventory is stated at the lower of cost or net realizable value on the first-in, first-out basis. &#160;Inventory held is related to the CDMO business and has been classified as held for sale. &#160;See Note 3 &#x2013; Discontinued Operations for information on inventory reserved reflected in the period ended March&#160;31,&#160;2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-family:'TimesNewRomanPSMT';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"&gt;Research and Development&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company accounts for research and development costs in accordance with the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) ASC 730-10, &lt;i style="font-style:italic;"&gt;Research and Development&lt;/i&gt; (&#x201c;ASC 730-10&#x201d;). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved. For the nine months ended March&#160;31,&#160;2023 and 2022, research and development expense was reported in both continuing and discontinued operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Right-of-Use Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;"&gt;Assets held under the terms of finance (capital) leases are amortized on a straight-line basis over the terms of the leases or the economic lives of the assets. Obligations for future lease payments under finance (capital) leases are shown within liabilities and are analyzed between amounts falling due within and after one year. See Note 9 &lt;/span&gt;&lt;i style="font-family:'TimesNewRomanPSMT';"&gt;&#x2013;&lt;/i&gt;&lt;span style="font-style:normal;"&gt; Finance Lease ROU Assets and Note 14 &lt;/span&gt;&lt;i style="font-family:'TimesNewRomanPSMT';"&gt;&#x2013;&lt;/i&gt;&lt;span style="font-style:normal;"&gt; Finance Lease Obligations for additional information.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Fixed Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Fixed assets are stated at cost net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets ranging from &lt;span style="-sec-ix-hidden:Hidden_Eet2cSErQUWYG2NYDDLIPA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;three&lt;/span&gt;&lt;/span&gt; to 39 years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company monitors fixed assets for impairment indicators throughout the year. &#160;When necessary, charges for impairments of long-lived assets are recorded for the amount by which the fair value is less than the carrying value of these assets. &#160;Changes in the Company&#x2019;s business strategy or adverse changes in market conditions could impact impairment analyses and require the recognition of an impairment charge. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;See Note 11 &#x2013; Fixed Assets for additional information.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Intangible Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Identifiable intangible assets are comprised of definite life intangible assets and indefinite life intangible assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for definite life intangible assets at either their historical cost or allocated purchase price at asset acquisition and records amortization utilizing the straight-line method based upon their estimated useful lives. Intellectual property is amortized over &lt;span style="-sec-ix-hidden:Hidden_5A4l74BAAkGpy-k8y3HFLw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;20&#160;years&lt;/span&gt;&lt;/span&gt;. The Company reviews the carrying value of its definite life intangible assets for impairment whenever events or changes in business circumstances indicate the carrying amount of such assets may not be fully recoverable. &#160;The carrying value is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. An impairment loss is measured as the amount by which the carrying amount exceeds it fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;For indefinite life intangible assets, the Company performs an impairment test annually and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. &#160;The Company determines the fair value of the asset quarterly or when triggering events are present, based on discounted cash flows and records an impairment loss if book value exceeds fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Evaluating for impairment requires judgment, including the estimation of future cash flows, future growth rates and profitability and the expected life over which cash flows will occur. Changes in the Company&#x2019;s business strategy or adverse changes in market conditions could impact impairment analyses and require the recognition of an impairment charge. Although management bases its estimates on &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;See Note 12 &#x2013; Intangible Assets for additional information.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Share-based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes the cost of all share-based payment transactions at fair value. Compensation cost, measured by the fair value of the equity instruments issued, adjusted for estimated forfeitures, is recognized in the financial statements as the respective awards are earned over the performance or service period. The Company uses historical data to estimate forfeiture rates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The impact that share-based payment awards will have on the Company&#x2019;s results of operations is a function of the number of shares awarded, the trading price of the Company&#x2019;s stock at the date of grant or modification, the vesting schedule and forfeitures. Furthermore, the application of the Black-Scholes option pricing model employs weighted-average assumptions for expected volatility of the Company&#x2019;s stock, expected term until exercise of the options, the risk-free interest rate, and dividends, if any, to determine fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Expected volatility is based on historical volatility of the Common Stock; the expected term until exercise represents the weighted-average period of time that options granted are expected to be outstanding giving consideration to vesting schedules and the Company&#x2019;s historical exercise patterns; and the risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. The Company has not paid any dividends since its inception and does not anticipate paying any dividends for the foreseeable future, so the dividend yield is assumed to be zero. In addition, the Company estimates forfeitures at each reporting period, rather than electing to record the impact of such forfeitures as they occur. See Note 18 &lt;span style="font-family:'TimesNewRomanPSMT';"&gt;&#x2013;&lt;/span&gt; Share-Based Compensation for additional information.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Concentrations of Credit Risk&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company maintains principally all cash balances in two financial institutions which, at times, may exceed the insured amounts. The exposure to the Company is solely dependent upon daily balances and the strength of the financial institutions. The Company has not incurred any losses on these accounts. At March&#160;31,&#160;2023 and June&#160;30,&#160;2022, amounts in excess of insured limits were approximately $6,300,000 and $18,200,000, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;During the three months ended March&#160;31,&#160;2023, the Company reported no revenue from continuing operations and generated 100% of its revenue reported in discontinued operations from two customers. During the three months ended March&#160;31,&#160;2022, the Company reported $1.8 million of license revenue from continuing operations and generated $144,000 of revenue reported in discontinued operations from two customers.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;During the nine months ended March&#160;31,&#160;2023, the Company reported no revenue from continuing operations and generated 100% of its revenue reported in discontinued operations from two customers. During the nine months ended March&#160;31,&#160;2022, the Company reported revenue from continuing operations related to a license agreement and a settlement of a revenue contract. &#160;The Company also generated $438,000 of revenue reported in discontinued operations from six customers.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Recently Issued Accounting Pronouncements&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;i style="font-style:italic;"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/i&gt; (&#x201c;ASU 2016-13&#x201d;), which requires an entity to assess impairment of its financial instruments based on its estimate of expected credit losses. Since the issuance of ASU 2016-13, the FASB released several amendments to improve and clarify the implementation guidance. In November 2019, the FASB issued ASU 2019-10, &lt;i style="font-style:italic;"&gt;Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates&lt;/i&gt;, which amended the effective date of the various topics. As the Company is a smaller reporting company, the provisions of ASU 2016-13 and the related amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022 (quarter ending September 30, 2023, for the Company). Entities are required to apply these changes through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The Company does not expect the adoption of ASU 2016-13 to have a significant impact on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying condensed consolidated financial statements. Most of the newer standards issued represent &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;technical corrections to the accounting literature or application to specific industries which have no effect on the Company&#x2019;s condensed consolidated financial statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_azSXl0Y530OdIghiWsHDDQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include liquidity assertions, the valuation of intellectual property and fixed assets held for sale, the incremental borrowing rate utilized in the finance and operating lease calculations, legal and contractual contingencies and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_UHQRFwr6EU6rNOScFO_5BA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Accounts Receivable&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Accounts receivable are reported at their outstanding unpaid principal balances net of allowances for uncollectible accounts. The Company provides for allowances for uncollectible receivables based on its estimate of uncollectible amounts considering age, collection history, and other factors considered appropriate. Management&#x2019;s policy is to write off accounts receivable against the allowance for doubtful accounts when a balance is determined to be uncollectible. At March&#160;31,&#160;2023 and June&#160;30,&#160;2022, the Company determined that an allowance for doubtful accounts was not needed. &#160;The Company had accounts receivable of $426,000 at June&#160;30,&#160;2021. &lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_6_30_2021_RvsAx0CeVUiEHjFvD-Jmkw"
      decimals="0"
      id="Narr_V-lVNi1WpkW1d4bjhYNUQw"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">426000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_q_XWXtJTlE-_lyjuxQVZyg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Revenue Recognition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company accounts for its revenue recognition under Accounting Standards Codification ("ASC") 606, &lt;i style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/i&gt;. Under this standard, the Company recognizes revenue when a customer obtains control of promised services or goods in an amount that reflects the consideration to which the Company expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer contracts. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company&#x2019;s contract revenue consists primarily of amounts earned under contracts with third-party customers and reimbursed expenses under such contracts. The Company analyzes its agreements to determine whether the elements can be separated and accounted for individually or as a single unit of accounting. Allocation of revenue to individual elements that qualify for separate accounting is based on the separate selling prices determined for each component, and total contract consideration is then allocated pro rata across the components of the arrangement. If separate selling prices are not available, the Company will use its best estimate of such selling prices, consistent with the overall pricing strategy and after consideration of relevant market factors.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In general, the Company applies the following steps when recognizing revenue from contracts with customers: (i)&#160;identify the contract, (ii)&#160;identify the performance obligations, (iii)&#160;determine the transaction price, (iv)&#160;allocate the transaction price to the performance obligations and (v)&#160;recognize revenue when a performance obligation is satisfied. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Recognition of revenue is driven by satisfaction of the performance obligations using one of two methods: revenue is either recognized over time or at a point in time. Contracts containing multiple performance obligations classify those performance obligations into separate units of accounting either as standalone or combined units of accounting. For those performance obligations treated as a standalone unit of accounting, revenue is generally recognized based on the method appropriate for each standalone unit. For those performance obligations treated as a combined unit of accounting, revenue is generally recognized as the performance obligations are satisfied, which generally occurs when control of the goods or services have been transferred to the customer or client or once the client or customer is able to direct the use of those goods and/or services as well as obtaining substantially all of its benefits. As such, revenue for a combined unit of accounting is generally recognized based on the method appropriate for the last delivered item but due to the specific nature of certain project and contract items, management may determine an alternative revenue recognition method as appropriate, such as a contract whereby one deliverable in the arrangement clearly comprises the overwhelming majority of the value of the overall combined unit of accounting. Under this circumstance, management may determine revenue recognition for the combined unit of accounting based on the revenue recognition guidance otherwise applicable to the predominant deliverable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;If a loss on a contract is anticipated, such loss is recognized in its entirety when the loss becomes evident. When the current estimates of the amount of consideration that is expected to be received in exchange for transferring promised goods or services to the customer indicates a loss will be incurred, a provision for the entire loss on the contract is made. At March&#160;31,&#160;2023 and June&#160;30,&#160;2022, the Company had no contract loss provisions. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration-line:underline;text-decoration-style:solid;"&gt;Fixed-Fee &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Under a fixed-fee contract, the Company charges a fixed agreed upon amount for a deliverable. Fixed-fee contracts have fixed deliverables upon completion of the project. Typically, the Company recognizes revenue for fixed-fee contracts after projects are completed, delivery is made and title transfers to the customer, and collection is reasonably assured.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Revenue can be recognized either 1) over time or 2) at a point in time. &#160;All revenue was recognized at a point in time for all periods presented.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;For the three months ended March 31, 2022, revenue was recognized from a license agreement and for the nine months ended March&#160;31,&#160;2022, revenue was recognized from a license agreement and the settlement of a revenue contract. &#160;No revenue was recognized for all other periods presented. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration-line:underline;text-decoration-style:solid;"&gt;Time and Materials&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Under a time and materials contract, the Company charges customers an hourly rate plus reimbursement for other project specific costs. The Company recognizes revenue for time and material contracts based on the number of hours devoted to the project multiplied by the customer&#x2019;s billing rate plus other project specific costs incurred.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <ibio:ContractAssetsPolicyTextBlock
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_R6Ywaxw_R0mSwl_kxgI62A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Contract Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;A contract asset is an entity&#x2019;s right to payment for goods and services already transferred to a customer if that right to payment is conditional on something other than the passage of time. Generally, an entity will recognize a contract asset when it has fulfilled a contract obligation but must perform other obligations before being entitled to payment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Contract assets consist primarily of the cost of project contract work performed by third parties for which the Company expects to recognize any related revenue at a later date, upon satisfaction of the contract obligations. At March&#160;31,&#160;2023 and June&#160;30,&#160;2022, contract assets were $0.&lt;/p&gt;</ibio:ContractAssetsPolicyTextBlock>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="As_Of_6_30_2021_RvsAx0CeVUiEHjFvD-Jmkw"
      decimals="0"
      id="Narr_OAlu573U3ky6lx_Ld3glTg"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="0"
      id="Narr_EYTru7PojEiyxXVzf5G2_g"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="0"
      id="Narr_S5jYEx3AzUevf9K1xYOGCQ"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <ibio:ContractLiabilitiesPolicyTextBlock
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_ZPCk-06WHUyJ6--qXvzlUQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Contract Liabilities&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;A contract liability is an entity&#x2019;s obligation to transfer goods or services to a customer at the earlier of (1) when the customer prepays consideration or (2) the time that the customer&#x2019;s consideration is due for goods and services the entity will yet provide. Generally, an entity will recognize a contract liability when it receives a prepayment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Contract liabilities consist primarily of consideration received, usually in the form of payment, on project work to be performed whereby the Company expects to recognize any related revenue at a later date, upon satisfaction of the contract obligations. At March&#160;31,&#160;2023, June&#160;30,&#160;2022, and June&#160;30,&#160;2021, contract liabilities w&lt;span style="background:#ffffff;"&gt;ere &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$0&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;, &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$100,000&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; and &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$423,000&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;, r&lt;/span&gt;espectively. The Company recognized revenue of $53,000 and $100,000 during the three and nine months ended March&#160;31,&#160;2023, respectively, that was included in the contract liabilities balance as of June 30, 2022 and was reported in discontinued operations. The Company recognized revenue of $52,000 and $178,000 during the three and nine months ended March&#160;31,&#160;2022, respectively, that was included in the contract liabilities balance as of June&#160;30,&#160;2021 and was reported in discontinued operations. The Company recognized revenue of $0 and $84,000 during the three &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;and nine months ended March&#160;31,&#160;2022 that was included in the contract liabilities balance as of June&#160;30,&#160;2021 and reported as part of continuing operations.&lt;/p&gt;</ibio:ContractLiabilitiesPolicyTextBlock>
    <us-gaap:DeferredRevenueCurrent
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="0"
      id="Narr_IFbkSUQjhk-wskYYsFI-Rg"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">0</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="0"
      id="Narr__hQl1FflmkSM1zkRAvyoZQ"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">100000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="As_Of_6_30_2021_RvsAx0CeVUiEHjFvD-Jmkw"
      decimals="0"
      id="Narr_TfdeV_r890GVh9_tgy0Qew"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">423000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_qwQKiC4qEkiqgQ5177TkpA"
      decimals="0"
      id="Narr_NEo0qFwncECSgETdXnBj4Q"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">53000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_uXNvRGR-RESDya9s9QmQmA"
      decimals="0"
      id="Narr_YJ0oW45npE6WAdRseDvq4A"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">100000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_RaNGnKpnsEaTsjOvOslUxA"
      decimals="0"
      id="Narr_iLWJ8v-qhEG3vbDUxpTYdg"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">52000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="Duration_7_1_2021_To_3_31_2022_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_GqDXZ6lLOEyUlH87AA2kZw"
      decimals="0"
      id="Narr_C9E32KKbL0eNuCjXmbBZkw"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">178000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentContinuingOperationsMember_Cex7NDVXOEO89CLJRQZTuQ"
      decimals="0"
      id="Narr_NL2uS3D_tkGX9TwrAs58-g"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="Duration_7_1_2021_To_3_31_2022_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentContinuingOperationsMember_h7DRj5r8q0CCEDp9Wg0n4A"
      decimals="0"
      id="Narr_ng8ZsqgAIkybbHVlmG94ew"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">84000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_mVnt28z-aUGz6gPcHfhjHw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Leases&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company accounts for leases under the guidance of Accounting Standards Codification ("ASC") 842, &lt;i style="font-style:italic;"&gt;Leases&lt;/i&gt; ("ASC 842"). The standard established a right-of-use (&#x201c;ROU&#x201d;) model requiring a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months and classified as either an operating or finance lease. The adoption of ASC 842 had a significant effect on the Company&#x2019;s balance sheet, resulting in an increase in non-current assets and both current and non-current liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In accordance with ASC 842, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether the Company obtains the right to substantially all the economic benefit from the use of the asset, and whether the Company has the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. For contracts with lease and non-lease components, &lt;span style="-sec-ix-hidden:Hidden_eZ239xUFfk2aM5khbNy0yg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;the Company has elected not to allocate the contract consideration and to account for the lease and non-lease components as a single lease component&lt;/span&gt;&lt;/span&gt;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The lease liabilities and the corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. The implicit rate within the Company&#x2019;s existing finance (capital) lease was determinable and, therefore, used at the adoption date of ASC 842 to determine the present value of lease payments under the finance lease. The implicit rate within the Company&#x2019;s operating lease was not determinable and, therefore, the Company used the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Company&#x2019;s incremental borrowing rate requires judgment. The Company will determine the incremental borrowing rate for each new lease using its estimated borrowing rate.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain the Company will exercise that option. An option to terminate is considered unless it is reasonably certain the Company will not exercise the option.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_LkhtSHTHGkulumI0VGTBOg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers all highly-liquid instruments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents at March&#160;31,&#160;2023 and June&#160;30,&#160;2022 consisted of money market accounts. Restricted cash consisted of $3.0 million held within a Company account at Woodforest Bank for the term note payable (see Note 6 &#x2013; Significant Transactions and Note 13 - Debt), collateral for a letter of credit obtained related to the San Diego operating lease (see Note 15 &#x2013; Operating Lease Obligations) and collateral for a Company purchasing card. The Company&#x2019;s bank required an additional 5% collateral held above the actual letters of credit issued for the San Diego lease and Company purchasing card. Restricted cash was approximately $3.3 million at &#160;March&#160;31,&#160;2023 and $6.0 million on June&#160;30,&#160;2022. The reduction to the restricted cash occurred because on October 11, 2022, the Company, as part of the First Amendment to the Credit Agreement with Woodforest National Bank (&#x201c;Woodforest&#x201d;), paid down $5.5 million of the term loan and subsequently Woodforest cancelled the irrevocable letter of credit issued by JPMorgan Chase Bank upon closing of the amendment. &#160;In accordance with the Fourth Amendment with Woodforest, the Company deposited $3 million in a restricted account at Woodforest. (For a complete description of the transaction please see Note 6 &#x2013; Significant Transactions and Note 13 - Debt). &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes the components of total cash, cash equivalents and restricted cash in the condensed consolidated statements of cash flows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:58.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,562&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 22,676&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Collateral held for letter of credit - term note payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 5,743&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Collateral held for letter of credit - San Diego lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 198&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 198&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Collateral held for Company purchasing card&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 55&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 55&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total cash, cash equivalents and restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,815&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,672&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <ibio:PercentageOfCollateralRequired
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="INF"
      id="Narr_DQ4OuCTaB0iw3tKJzxuEYQ"
      unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg">0.05</ibio:PercentageOfCollateralRequired>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-5"
      id="Narr_1i70k72QH0edboQnRqkyfA"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">3300000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-5"
      id="Narr_vjIgHb6Ka0WIHLLcFrnoaA"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">6000000.0</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_10_11_2022_To_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_SmV5R4SrNkmUCX3FsbIGLA"
      decimals="-5"
      id="Narr_c0uoj2eKzUy7ZULPYBRLAg"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">5500000</us-gaap:RepaymentsOfDebt>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_W6UuzIWN2UeSrrcPK9eEgQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes the components of total cash, cash equivalents and restricted cash in the condensed consolidated statements of cash flows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:58.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,562&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 22,676&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Collateral held for letter of credit - term note payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 5,743&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Collateral held for letter of credit - San Diego lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 198&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 198&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Collateral held for Company purchasing card&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 55&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 55&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total cash, cash equivalents and restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,815&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,672&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_y-nwbhNzlU6IrRk6o8df9g_3_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">6562000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_LAKoUBSkZkyMUr8_O8NNVw_3_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">22676000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_3_31_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditTermLoanMember_pkYNKGm7FE-AjzorOXr0XA"
      decimals="-3"
      id="Tc_dVh5rk2GvkmcZYwyyUVxKQ_4_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">3000000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_6_30_2022_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditTermLoanMember_ZKZXpDTWYkGA9VMDpyQWng"
      decimals="-3"
      id="Tc_8-LbPHEcmkOkhcB_0Bk0TA_4_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">5743000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_3_31_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditSanDiegoLeaseMember_wcNGCEcPbEm21StpOapKJw"
      decimals="-3"
      id="Tc_Okp55T8ALk-B9TxBy72cBw_5_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">198000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_6_30_2022_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditSanDiegoLeaseMember_yPkVHgiNf0eqnma-vd44Og"
      decimals="-3"
      id="Tc_mhJ9jDA9c0qegenXeSPuag_5_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">198000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_3_31_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_CompanyPurchasingCardMember_ZTE2EhC6DUi3V8Us5_uTEg"
      decimals="-3"
      id="Tc_ooAwW-2nbkWhsZVO5yrmCA_6_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">55000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_6_30_2022_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_CompanyPurchasingCardMember_jAg6eAzyCE6hspA3-EkVZw"
      decimals="-3"
      id="Tc_yyuV7Ddzj0arkhjZQTRwQw_6_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">55000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_gXuEleZ0_EW5XykaBlWpMQ_7_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">9815000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_1WqZkojip0m6TAgln9pdWw_7_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">28672000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:AvailableForSaleSecuritiesPurchasedOptionsPricePolicy
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_Q7YpYezfakqnoxt2R7eT7Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"&gt;Investments in Debt Securities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:normal;"&gt;Debt investments were classified as available-for-sale. Changes in fair value are recorded in other comprehensive income (loss). Fair value was calculated based on publicly available market information. Discounts and/or premiums paid when the debt securities were acquired are amortized to interest income over the terms of the debt securities. See Note 8 &#x2013; Investments in Debt Securities.&lt;/span&gt;&lt;/p&gt;</us-gaap:AvailableForSaleSecuritiesPurchasedOptionsPricePolicy>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_VzsQ913b2kuNm4rpzLa54w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"&gt;Inventory&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-family:'TimesNewRomanPSMT';"&gt;Inventory is stated at the lower of cost or net realizable value on the first-in, first-out basis. &#160;Inventory held is related to the CDMO business and has been classified as held for sale. &#160;See Note 3 &#x2013; Discontinued Operations for information on inventory reserved reflected in the period ended March&#160;31,&#160;2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-family:'TimesNewRomanPSMT';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_AUVWTs1jJ0yn9AScW39HpQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"&gt;Research and Development&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company accounts for research and development costs in accordance with the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) ASC 730-10, &lt;i style="font-style:italic;"&gt;Research and Development&lt;/i&gt; (&#x201c;ASC 730-10&#x201d;). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved. For the nine months ended March&#160;31,&#160;2023 and 2022, research and development expense was reported in both continuing and discontinued operations.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <ibio:RightOfUseAssetsPolicyPolicyTextBlock
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_cDBqCxaQz0-Tuz_ZWYZuAQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Right-of-Use Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;"&gt;Assets held under the terms of finance (capital) leases are amortized on a straight-line basis over the terms of the leases or the economic lives of the assets. Obligations for future lease payments under finance (capital) leases are shown within liabilities and are analyzed between amounts falling due within and after one year. See Note 9 &lt;/span&gt;&lt;i style="font-family:'TimesNewRomanPSMT';"&gt;&#x2013;&lt;/i&gt;&lt;span style="font-style:normal;"&gt; Finance Lease ROU Assets and Note 14 &lt;/span&gt;&lt;i style="font-family:'TimesNewRomanPSMT';"&gt;&#x2013;&lt;/i&gt;&lt;span style="font-style:normal;"&gt; Finance Lease Obligations for additional information.&lt;/span&gt;&lt;/p&gt;</ibio:RightOfUseAssetsPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_5KkxvNm4Nkmv_L55GrQLSA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Fixed Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Fixed assets are stated at cost net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets ranging from &lt;span style="-sec-ix-hidden:Hidden_Eet2cSErQUWYG2NYDDLIPA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;three&lt;/span&gt;&lt;/span&gt; to 39 years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company monitors fixed assets for impairment indicators throughout the year. &#160;When necessary, charges for impairments of long-lived assets are recorded for the amount by which the fair value is less than the carrying value of these assets. &#160;Changes in the Company&#x2019;s business strategy or adverse changes in market conditions could impact impairment analyses and require the recognition of an impairment charge. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;See Note 11 &#x2013; Fixed Assets for additional information.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_7_1_2022_To_3_31_2023_srt_RangeAxis_srt_MaximumMember_qkTv4t_oSEqp0FIe4NY8bw"
      id="Narr_e959wg9ykEuCujOYmJE7bQ">P39Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_u-now5XBekGI7cFpD6sZBw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Intangible Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Identifiable intangible assets are comprised of definite life intangible assets and indefinite life intangible assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for definite life intangible assets at either their historical cost or allocated purchase price at asset acquisition and records amortization utilizing the straight-line method based upon their estimated useful lives. Intellectual property is amortized over &lt;span style="-sec-ix-hidden:Hidden_5A4l74BAAkGpy-k8y3HFLw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;20&#160;years&lt;/span&gt;&lt;/span&gt;. The Company reviews the carrying value of its definite life intangible assets for impairment whenever events or changes in business circumstances indicate the carrying amount of such assets may not be fully recoverable. &#160;The carrying value is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. An impairment loss is measured as the amount by which the carrying amount exceeds it fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;For indefinite life intangible assets, the Company performs an impairment test annually and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. &#160;The Company determines the fair value of the asset quarterly or when triggering events are present, based on discounted cash flows and records an impairment loss if book value exceeds fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Evaluating for impairment requires judgment, including the estimation of future cash flows, future growth rates and profitability and the expected life over which cash flows will occur. Changes in the Company&#x2019;s business strategy or adverse changes in market conditions could impact impairment analyses and require the recognition of an impairment charge. Although management bases its estimates on &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;See Note 12 &#x2013; Intangible Assets for additional information.&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_06wvhCAEeEWyEhNo-zW2pQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Share-based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes the cost of all share-based payment transactions at fair value. Compensation cost, measured by the fair value of the equity instruments issued, adjusted for estimated forfeitures, is recognized in the financial statements as the respective awards are earned over the performance or service period. The Company uses historical data to estimate forfeiture rates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The impact that share-based payment awards will have on the Company&#x2019;s results of operations is a function of the number of shares awarded, the trading price of the Company&#x2019;s stock at the date of grant or modification, the vesting schedule and forfeitures. Furthermore, the application of the Black-Scholes option pricing model employs weighted-average assumptions for expected volatility of the Company&#x2019;s stock, expected term until exercise of the options, the risk-free interest rate, and dividends, if any, to determine fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Expected volatility is based on historical volatility of the Common Stock; the expected term until exercise represents the weighted-average period of time that options granted are expected to be outstanding giving consideration to vesting schedules and the Company&#x2019;s historical exercise patterns; and the risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. The Company has not paid any dividends since its inception and does not anticipate paying any dividends for the foreseeable future, so the dividend yield is assumed to be zero. In addition, the Company estimates forfeitures at each reporting period, rather than electing to record the impact of such forfeitures as they occur. See Note 18 &lt;span style="font-family:'TimesNewRomanPSMT';"&gt;&#x2013;&lt;/span&gt; Share-Based Compensation for additional information.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="2"
      id="Narr_dZRlZm_3dEyetEjhbq3AjQ"
      unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_8DWFv54dVES3pvyTAya_AA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Concentrations of Credit Risk&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company maintains principally all cash balances in two financial institutions which, at times, may exceed the insured amounts. The exposure to the Company is solely dependent upon daily balances and the strength of the financial institutions. The Company has not incurred any losses on these accounts. At March&#160;31,&#160;2023 and June&#160;30,&#160;2022, amounts in excess of insured limits were approximately $6,300,000 and $18,200,000, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;During the three months ended March&#160;31,&#160;2023, the Company reported no revenue from continuing operations and generated 100% of its revenue reported in discontinued operations from two customers. During the three months ended March&#160;31,&#160;2022, the Company reported $1.8 million of license revenue from continuing operations and generated $144,000 of revenue reported in discontinued operations from two customers.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;During the nine months ended March&#160;31,&#160;2023, the Company reported no revenue from continuing operations and generated 100% of its revenue reported in discontinued operations from two customers. During the nine months ended March&#160;31,&#160;2022, the Company reported revenue from continuing operations related to a license agreement and a settlement of a revenue contract. &#160;The Company also generated $438,000 of revenue reported in discontinued operations from six customers.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashUninsuredAmount
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="0"
      id="Narr_530hsNS8aUGfSGj7B0_Dgg"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">6300000</us-gaap:CashUninsuredAmount>
    <us-gaap:CashUninsuredAmount
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="0"
      id="Narr_h69Rm3lLdkCvNIcsKaaxdw"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">18200000</us-gaap:CashUninsuredAmount>
    <ibio:NumberOfMajorCustomers
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_R1fh5LInTEmTcImaZYCq4w"
      decimals="0"
      id="Narr_aI4Q-qCcvk6NezyHvWlCNw"
      unitRef="Unit_Standard_customer_yQcExGHKGkW8YXSDfuntYQ">2</ibio:NumberOfMajorCustomers>
    <ibio:NumberOfMajorCustomers
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_7ZRgVsYP8kOQ3Ji8AiOywQ"
      decimals="0"
      id="Narr__Wm0JN7HhkyhmKvk2ynWHA"
      unitRef="Unit_Standard_customer_yQcExGHKGkW8YXSDfuntYQ">2</ibio:NumberOfMajorCustomers>
    <ibio:NumberOfMajorCustomers
      contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_ARnE75gvP0qnPbmgOAREKg"
      decimals="0"
      id="Narr_Pg_RCsQcV0yt7kOArtYgYg"
      unitRef="Unit_Standard_customer_yQcExGHKGkW8YXSDfuntYQ">2</ibio:NumberOfMajorCustomers>
    <ibio:NumberOfMajorCustomers
      contextRef="Duration_7_1_2021_To_3_31_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_yRWAOjfd2Ue7tGm5AdoU8A"
      decimals="0"
      id="Narr_LUt5ipb340ea-p4c833KYQ"
      unitRef="Unit_Standard_customer_yQcExGHKGkW8YXSDfuntYQ">6</ibio:NumberOfMajorCustomers>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_qutn5niG2UO4thm5VBO6-Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Recently Issued Accounting Pronouncements&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;i style="font-style:italic;"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/i&gt; (&#x201c;ASU 2016-13&#x201d;), which requires an entity to assess impairment of its financial instruments based on its estimate of expected credit losses. Since the issuance of ASU 2016-13, the FASB released several amendments to improve and clarify the implementation guidance. In November 2019, the FASB issued ASU 2019-10, &lt;i style="font-style:italic;"&gt;Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates&lt;/i&gt;, which amended the effective date of the various topics. As the Company is a smaller reporting company, the provisions of ASU 2016-13 and the related amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022 (quarter ending September 30, 2023, for the Company). Entities are required to apply these changes through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The Company does not expect the adoption of ASU 2016-13 to have a significant impact on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying condensed consolidated financial statements. Most of the newer standards issued represent &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;technical corrections to the accounting literature or application to specific industries which have no effect on the Company&#x2019;s condensed consolidated financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_rxpXPlWmVkiM7wUPu5gvHA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;5.&#160;&#160;&#160;Financial Instruments and Fair Value Measurement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The carrying values of cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and term note payable in the Company&#x2019;s condensed consolidated balance sheets approximated their fair values as of March&#160;31,&#160;2023 and June&#160;30,&#160;2022 due to their short-term nature. The carrying value of the convertible promissory note receivable, the term note payable and finance lease obligation approximated to fair value as of March&#160;31,&#160;2023 and June&#160;30,&#160;2022 as the interest rates related to the financial instruments approximated to market value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company accounts for its investments in debt securities at fair value. The following provides a description of the three levels of inputs that may be used to measure fair value under the standard, the types of investments that fall under each category, and the valuation methodologies used to measure these investments at fair value. &lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x2022;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Level 1&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2013; Inputs are based upon unadjusted quoted prices for identical instruments in active markets. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x2022;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Level 2&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2013; Inputs to the valuation include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in inactive markets, inputs other than quoted prices that are observable for the asset or liability, and inputs that are derived principally from or corroborated by observable market data by correlation or other means. If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability. &#160;All debt securities were valued using Level 2 inputs.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x2022;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Level 3&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2013; Inputs to the valuation methodology are unobservable and significant to the fair value measurement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company&#x2019;s fixed assets and amortizable intangible assets are measured at fair value on a nonrecurring basis; that is, these assets are not measured at fair value on an ongoing basis, but are subject to fair value adjustments in certain circumstances, such as when there is evidence of&#160;impairment. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company initially marketed the CDMO business and during the second quarter of Fiscal 2023, changed its strategy to selling the stand-alone CDMO assets. &#160;These assets were assessed for impairment and the analysis resulted in the expected future cash flows from the sale of the property and equipment falling below its current carrying value. The Company utilized a market approach, using independent third-party appraisals, including comparable assets, in addition to bids received from prospective buyers, to estimate the fair value of the property and equipment. As a result, the carrying value of the building and equipment was reduced to their estimated fair values of $16,350,000 and $2,100,000, respectively. &#160;In the second quarter of Fiscal 2023, impairment charges were recorded in discontinued operations under general and administrative expense of $6,300,000 and $11,300,000 for the building and machinery and equipment, respectively. &#160;The machinery and equipment were sold during the third quarter of Fiscal 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table shows the fair value of the Company's fixed assets included in Current Assets Held For Sale measured at fair value on a non-recurring basis as of March&#160;31,&#160;2023 (amounts in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:14.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:70%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;March 31, 2023&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:70%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Fair Value Hierarchy&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Quoted Prices in Active Markets for Identical Assets (Level 1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Significant Other Observable Inputs (Level 2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:14.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Significant Unobservable Inputs (Level 3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:6.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Total Fair Value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Total Impairments&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Building in Bryan, Texas&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 16,364&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 16,364&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 6,300&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;During the second quarter of Fiscal 2023, the Company re-evaluated its business strategy and reviewed its product portfolio. After such review, the Company identified intellectual property, patent and licenses that would no longer be utilized and therefore were fully impaired (Level 3). &#160;See Note 12 &#x2013; Intangible Assets for additional information.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <ibio:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure
      contextRef="As_Of_3_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_c19oJcuBhUqWIDNcmlXJ7Q"
      decimals="0"
      id="Narr_w4vNATbkrEaXs4QUDqykMg"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">2100000</ibio:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_OScbop6D_EyFbi9oWinyQQ"
      decimals="0"
      id="Narr_q5CjbeTfpkWUEpMrlr7OpQ"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">6300000</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_GWDLoqc91Eylj7aqLB53AA"
      decimals="0"
      id="Narr_phSRxINAEka9wpDwrrSh2w"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">11300000</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_rsNfdSjvIUS9KYs4qarwoQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table shows the fair value of the Company's fixed assets included in Current Assets Held For Sale measured at fair value on a non-recurring basis as of March&#160;31,&#160;2023 (amounts in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:14.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:70%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;March 31, 2023&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:70%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Fair Value Hierarchy&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Quoted Prices in Active Markets for Identical Assets (Level 1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Significant Other Observable Inputs (Level 2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:14.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Significant Unobservable Inputs (Level 3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:6.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Total Fair Value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Total Impairments&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:26.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Building in Bryan, Texas&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 16,364&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 16,364&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 6,300&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <ibio:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure
      contextRef="As_Of_3_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_ECHSceNMpEGQENNfII3BMg"
      decimals="-3"
      id="Tc_LS8gMm8kN0O95Nq_RSvajg_4_9"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">16364000</ibio:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure>
    <ibio:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure
      contextRef="As_Of_3_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_LfJb0Ctu7kiams8KPEcLPg"
      decimals="-3"
      id="Tc_D8L3LM_Z5kKhANNNL-b-Bg_4_12"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">16364000</ibio:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_OScbop6D_EyFbi9oWinyQQ"
      decimals="-3"
      id="Tc_cBzCXWyopECfPMVBc_bCRQ_4_15"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">6300000</us-gaap:TangibleAssetImpairmentCharges>
    <ibio:SignificantTransactionsTextBlock
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_I9DG71wPZUW0G9l5TM2FcA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;white-space:pre-wrap;"&gt;6.   Significant Transactions &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Affiliates of Eastern Capital Limited&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On November 1, 2021, the Company and its subsidiary, iBio CDMO (&#x201c;iBio CDMO&#x201d;, and collectively with the Company, the &#x201c;Purchaser&#x201d;) entered into a series of agreements (the &#x201c;Transaction&#x201d;) with College Station Investors LLC (&#x201c;College Station&#x201d;), and Bryan Capital Investors LLC (&#x201c;Bryan Capital&#x201d; and, collectively with College Station, &#x201c;Seller&#x201d;), each affiliates of Eastern Capital Limited (&#x201c;Eastern,&#x201d; a former significant stockholder of the Company) described in more detail below whereby in exchange for a certain cash payment and a warrant the Company:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(i)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;acquired both the Facility where iBio CDMO at that time and currently conducts business and also the rights as the tenant in the Facility&#x2019;s ground lease;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(ii)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;acquired all of the equity owned by one of the affiliates of Eastern in the Company and iBio CDMO; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(iii)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;otherwise terminated all agreements between the Company and the affiliates of Eastern.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Facility is a life sciences building located on land owned by the Board of Regents of the Texas A&amp;amp;M University System (&#x201c;Texas A&amp;amp;M&#x201d;) and is designed and equipped for the manufacture of plant-made biopharmaceuticals. iBio CDMO had held a sublease for the Facility through 2050, subject to extension until 2060 (the &#x201c;Sublease&#x201d;) until the purchase of the Facility described below.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;The Purchase and Sale Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On November 1, 2021, the Purchaser entered into a Purchase and Sale Agreement (the &#x201c;Purchase and Sale Agreement&#x201d;) with the Seller pursuant to which: (i) the Seller sold to Purchaser all of its rights, title and interest as the tenant in the Ground Lease Agreement (the &#x201c;Ground Lease Agreement&#x201d;) that it entered into with Texas A&amp;amp;M (the &#x201c;Landlord&#x2019;&#x2019;) related to the property at which the Facility is located together with all improvements pertaining thereto (the &#x201c;Property&#x201d;), which previously had been the subject of the Sublease; (ii) the Seller sold to Purchaser all of its rights, title and interest to any tangible personal property owned by Seller and located on the Property including the Facility; (iii) the Seller sold to Purchaser all of its rights, title and interest to all licensed, permits and authorization for use of the Property; and (iv) College Station and iBio CDMO terminated the Sublease. The total purchase price for the Property, the termination of the Sublease and other agreements among the parties, and the equity described below is $28,750,000, which was paid $28,000,000 in cash and by the issuance to Seller of warrants (the &#x201c;Warrant&#x201d;) described below. As part of the transaction, iBio CDMO became the tenant under the Ground Lease Agreement for the Property until 2060 upon exercise of available extensions. The base rent payable under the Ground Lease Agreement, which was $151,450 for the current year, is 6.5% of the Fair Market Value (as defined in the Ground Lease Agreement) of the Property. The Ground Lease Agreement includes various covenants, indemnities, defaults, termination rights, and other provisions customary for lease transactions of this nature.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As discussed above, iBio CDMO is being accounted for as a discontinued operation. &#160;As such, the assets acquired and/or leased are now classified as assets held for sale on the March&#160;31,&#160;2023 and June&#160;30,&#160;2022 condensed consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;The Equity Purchase Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company also entered into an Equity Purchase Agreement with Bryan Capital on November 1, 2021 (the &#x201c;Equity Purchase Agreement&#x201d;) pursuant to which the Company acquired for $50,000 cash, plus the Warrant, the one (1) share of iBio CMO Preferred Tracking Stock and the 0.01% interest in iBio CDMO owned by Bryan Capital. As a result, iBio CDMO is now a wholly-owned subsidiary of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;The Credit Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In connection with the Purchase and Sale Agreement, iBio CDMO entered into a Credit Agreement, dated November 1, 2021, with Woodforest pursuant to which Woodforest provided iBio CDMO a $22,375,000 secured term loan to purchase the Facility, which Term Loan is evidenced by a term note. The term loan was advanced in full on the closing date. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;See Note 13 &#x2013; Debt for further information of the Term Loan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;The Warrant&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As part of the consideration for the purchase and sale of the rights set forth above, the Company issued to Bryan Capital a Warrant to purchase 51,583 shares of the Common Stock at an exercise price of $33.25 per share. The Warrant expires October 10, 2026, is exercisable immediately, provides for a cashless exercise at any time and automatic cashless exercise on the expiration date if on such date the exercise price of the Warrant exceeds its fair market value as determined in accordance with the terms of the Warrant and adjustments in the case of stock dividends and stock splits. Of the shares issued under the Warrant, 11,583, which were originally valued at $217,255, reflected the final payment of rent due under the Sublease. The Warrant, as shown on the condensed consolidated statements of equity, was recorded in additional paid-in capital with the corresponding activity included in the basis of the purchase price allocation of the Property acquired. &#160;See Note 16 &#x2013; Stockholders&#x2019; Equity for additional information.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;RubrYc&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On August 23, 2021, the Company entered into a series of agreements with RubrYc Therapeutics, Inc. (&#x201c;RubrYc&#x201d;) described in more detail below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Collaboration and License Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company entered into a collaboration and licensing agreement (the &#x201c;RTX-003 License Agreement&#x201d;) with RubrYc to further develop RubrYc&#x2019;s immune-oncology antibodies in its RTX-003 campaign. &#160;Under the terms of the agreement, the Company is solely responsible for worldwide research and development activities for development of the RTX-003 antibodies for use in pharmaceutical products in all fields&lt;span style="color:#0000ff;"&gt;. &#160;&lt;/span&gt;RubrYc was also entitled to receive royalties in the mid-single digits on net sales of RTX-003 antibodies, subject to adjustment under certain circumstances. The RTX-003 License Agreement was terminated when the Company acquired substantially all of the assets of RubrYc in September 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Collaboration, Option and License Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company entered into an agreement with RubrYc (the &#x201c;Collaboration, Option and License Agreement&#x201d;) to collaborate for up to five years to discover and develop novel antibody therapeutics using RubrYc&#x2019;s artificial intelligence discovery platform. The Company agreed to pay RubrYc for each Selected Compound as it achieves various milestones in addition to royalties if the Selected Compounds are commercialized. &#160;RubrYc was also entitled to receive tiered royalties ranging from low- to mid-single digits on net sales of Collaboration Products, subject to adjustment under certain circumstances. Royalties are payable on a country-by-country and collaboration product-by-collaboration product basis until the latest to occur of: (i) the last-to-expire of specified patent rights in such country; (ii) expiration of marketing or regulatory exclusivity in such country; or (iii) &lt;span style="-sec-ix-hidden:Hidden_oSXmWjkN2kiwoY8AqAXFYw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;ten&lt;/span&gt;&lt;/span&gt; (10) years after the first commercial sale of a product in such country, provided that no biosimilar product has been approved in such country. &#160;With the exception of any obligations that survive the termination, the Collaboration, Option and License Agreement was terminated when the Company acquired substantially all of the assets of RubrYc in September 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 4.5pt 0pt 0pt;"&gt;&lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Stock Purchase Agreement &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt;"&gt;&lt;span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;padding-bottom:10pt;text-align:justify;margin:0pt;"&gt;In connection with the entry into the Collaboration, Option and License Agreement and RTX-003 License Agreement, the Company also entered into a Stock Purchase Agreement (&#x201c;Stock Purchase Agreement&#x201d;) with RubrYc whereby the Company purchased a total of 2,864,345 shares of RubrYc&#x2019;s Series A-2 preferred stock (&#x201c;Series A-2 Preferred&#x201d;) for $7,500,000. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;The Company accounted for the agreements as an asset purchase and allocated the purchase price of $7,500,000 as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:74.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:74.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,760,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:74.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,300,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:74.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,440,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:74.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 7,500,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Subsequently after the Company acquired substantially all of the assets of RubrYc in September 2022, RubrYc ceased its operations, and accordingly, the Company recorded an impairment of the investment in the amount of $1,760,000 during the year ended June 30, 2022. The amount was recorded in the condensed consolidated statement of operations and comprehensive loss under general and administrative expense. The Company also recorded an impairment of current and non-current prepaid expense of $288,000 and $864,000, respectively, during the year ended June 30, 2022. The amount was recorded in the condensed consolidated statement of operations and comprehensive loss under research and development expense.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On September 16, 2022, the Company entered an Asset Purchase Agreement with RubrYc pursuant to which it acquired substantially all of the assets of RubrYc. &#160;The Company issued 102,354 shares of the Common Stock to RubrYc with an approximate market value of $1,000,000 (the &#x201c;Closing Shares&#x201d;). Pursuant to the Asset Purchase Agreement, the shares are subject to an initial lockup period and the estimated fair value was calculated as $650,000. The Company also agreed to make potential additional payments of up to $5,000,000 upon the achievement of specified developmental milestones on or before the fifth anniversary of the closing date, payable in cash or shares of the Common Stock, at the Company&#x2019;s option. In addition, the Company had advanced RubrYc $484,000 to support their operation costs during the negotiation period and incurred transaction costs totaling $208,000, which were also capitalized as part of the assets acquired. &#160;The assets acquired include the patented AI drug discovery platform, all rights with no future milestone payments or royalty obligations, to IBIO-101, in addition to CCR8, EGFRvIII, MUC16, CD3 and one additional immuno-oncology candidate plus a PD-1 agonist. The Purchase Agreement contained representations, warranties and covenants of RubrYc and the Company. &#160;The acquisition closed on September 19, 2022 after receipt of approval of the NYSE American.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;The Company accounted for the agreements as an asset purchase and allocated the purchase price of approximately $1,342,000 as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:74.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:74.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,228,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:74.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Fixed assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 114,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:74.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,342,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In addition, the Company assumed three equipment leases that were accounted for as finance leases totaling approximately $814,000. &#160;See Note 9 &#x2013; Finance Lease ROU Assets and Note 14 &#x2013; Finance Lease Obligations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Former CEO Departure&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Effective December 1, 2022, the Company and Mr. Thomas F. Isett, the former Chief Executive Officer (the &#x201c;CEO) and former member of the Board of Directors (the &#x201c;Board&#x201d;), agreed for Mr. Isett to resign as a member of the Board and relinquish his duties, rights and obligations as the CEO of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Separation Agreement and General Release &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;In connection with Mr. Isett&#x2019;s resignation, the Company entered into a separation agreement and general release with Mr. Isett effective December 1, 2022 (the &#x201c;Agreement&#x201d;). &#160;Pursuant to the Agreement, Mr. Isett resigned as CEO of the Company effective December 1, 2022, and will remain an employee of the Company until December 31, 2022, on which date his employment with the Company will automatically terminate. &#160;Following Mr. Isett&#x2019;s termination of employment with the Company, pursuant to the Agreement, Mr. Isett will receive the severance benefits set forth in his employment agreement, as previously disclosed by the Company, including (i) an amount equal to his current base salary in equal bi-monthly installments for &lt;span style="-sec-ix-hidden:Hidden_H20oJhWZMkiyeILxAMoOWg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;twenty-four&lt;/span&gt;&lt;/span&gt; (24) months; (ii) an amount equal to a pro rata share of his target bonus for the current fiscal year; (iii) an amount equal to the target bonus in equal bi-monthly installments for the &lt;span style="-sec-ix-hidden:Hidden_3XETezoZoE2Gln_IFI6pTg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;twenty-four&lt;/span&gt;&lt;/span&gt; (24) month severance period and (iv) provided that he elects continuation coverage for health insurance under the Consolidated Omnibus Budget Reconciliation Act of 1985 (&#x201c;COBRA&#x201d;), the Company will pay the full cost of this benefit for up to &lt;span style="-sec-ix-hidden:Hidden_YRBOV4wB5E2sgYw7SZXbjg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;eighteen&lt;/span&gt;&lt;/span&gt; (18) months, or if he has not obtained alternative employer-provided health coverage by the end of the &lt;span style="-sec-ix-hidden:Hidden_eUgWy76apU6hIb4U9tpWXg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;eighteen&lt;/span&gt;&lt;/span&gt; (18) month COBRA subsidy period, the Company will provide him with a lump-sum cash payment equal to six (6) times the monthly amount paid by the Company for the COBRA subsidy. &#160;The Agreement includes a general release of claims by Mr. Isett. &#160;The Company accrued approximately $2.13 million to general and administrative expenses in the second quarter of Fiscal 2023. As of March 31, 2023, approximately $1.1 million is recorded in accrued expenses and $791,000 in accrued expenses &#x2013; noncurrent. &lt;/p&gt;</ibio:SignificantTransactionsTextBlock>
    <ibio:PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest
      contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_p-vKhEHGAUG72E1kGh9gmg"
      decimals="0"
      id="Narr_c35m5Rq9hUmL7KGY2l9mag"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">28750000</ibio:PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest>
    <ibio:PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment
      contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_0-dXyj2LIE2MJCZBHgv0hw"
      decimals="0"
      id="Narr_wyXaGY1hj0-jbxEUk5urmg"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">28000000</ibio:PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment>
    <ibio:FairMarketValueOfProperty
      contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_p-vKhEHGAUG72E1kGh9gmg"
      decimals="0"
      id="Narr_SE3oJopWBUy2AkE-Yjvbkw"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">151450</ibio:FairMarketValueOfProperty>
    <ibio:BaseRentPercentageOfFairMarketValueOfProperty
      contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_0-dXyj2LIE2MJCZBHgv0hw"
      decimals="3"
      id="Narr_7eNyzIYL5UiqlVXsUtGP9A"
      unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg">0.065</ibio:BaseRentPercentageOfFairMarketValueOfProperty>
    <ibio:EquityAgreementConsiderationTransferredEquityInterestsAcquired
      contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_0-dXyj2LIE2MJCZBHgv0hw"
      decimals="0"
      id="Narr_VZMHv9wYW0mXMudRrP9VVw"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">50000</ibio:EquityAgreementConsiderationTransferredEquityInterestsAcquired>
    <ibio:EquityAgreementWarrantsIssuedOrIssuable
      contextRef="Duration_11_1_2021_To_11_1_2021_dei_LegalEntityAxis_ibio_IbioCmoPreferredTrackingStockMember_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_Fd00xECGqUS_feybjJADgA"
      decimals="INF"
      id="Narr_Dbujxdiw_kqusUM3gFSIpA"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">1</ibio:EquityAgreementWarrantsIssuedOrIssuable>
    <ibio:EquityAgreementPercentageOfEquityInterestIssuedOrIssuable
      contextRef="Duration_11_1_2021_To_11_1_2021_dei_LegalEntityAxis_ibio_IbioCmoPreferredTrackingStockMember_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_Fd00xECGqUS_feybjJADgA"
      decimals="4"
      id="Narr_0uqWqpHSz0eTcbhtKXxulA"
      unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg">0.0001</ibio:EquityAgreementPercentageOfEquityInterestIssuedOrIssuable>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_jDRo_Tn2dEiaxaJsfTrTaQ"
      decimals="0"
      id="Narr_HuC1-zR7xku2xtT4c6UXkw"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">22375000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_p-vKhEHGAUG72E1kGh9gmg"
      decimals="INF"
      id="Narr_IKmk-eOCj0Snmgruk4OxVQ"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">51583</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_p-vKhEHGAUG72E1kGh9gmg"
      decimals="2"
      id="Narr_pwVB13hfPkG3orWZJeAxSg"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">33.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ibio:WarrantsIssuedForFinalPaymentOfSubleaseRent
      contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_0-dXyj2LIE2MJCZBHgv0hw"
      decimals="INF"
      id="Narr_r4MaBUzh0EK8GRDq1mfJ7g"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">11583</ibio:WarrantsIssuedForFinalPaymentOfSubleaseRent>
    <ibio:WarrantsIssuedForFinalPaymentOfSubleaseRentValue
      contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_p-vKhEHGAUG72E1kGh9gmg"
      decimals="0"
      id="Narr_CLMuDV2410mw6hlmw0-Esw"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">217255</ibio:WarrantsIssuedForFinalPaymentOfSubleaseRentValue>
    <ibio:CollaborationAndLicenseAgreementAgreementTerm
      contextRef="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_us-gaap_TypeOfArrangementAxis_ibio_CollaborationOptionAndLicenseAgreementMember_ajEqmB0rDEiBS1559tP2SQ"
      id="Narr_LucSxRjHIUaXli40Nremaw">P5Y</ibio:CollaborationAndLicenseAgreementAgreementTerm>
    <ibio:StockPurchaseAgreementNumberOfSharesPurchased
      contextRef="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_us-gaap_StatementClassOfStockAxis_ibio_Series2PreferredStockMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementMember_YCIyuJUGskWd66faz53YYA"
      decimals="INF"
      id="Narr_PF3bV4dPpEGw5Fx2T7XsJQ"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">2864345</ibio:StockPurchaseAgreementNumberOfSharesPurchased>
    <ibio:StockPurchaseAgreementValueOfSharesPurchased
      contextRef="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_us-gaap_StatementClassOfStockAxis_ibio_Series2PreferredStockMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementMember_YCIyuJUGskWd66faz53YYA"
      decimals="0"
      id="Narr_tdFTjayjfkyxFwaWSgVYpg"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">7500000</ibio:StockPurchaseAgreementValueOfSharesPurchased>
    <us-gaap:AssetAcquisitionTableTextBlock
      contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_AssetAcquisitionAxis_ibio_StockPurchaseAgreementMember_3-07kxSNOkaDZSJYQDyQdQ"
      id="Tb_THO5zO_xZUe_EXmMFNHfAA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;The Company accounted for the agreements as an asset purchase and allocated the purchase price of $7,500,000 as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:74.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:74.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,760,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:74.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,300,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:74.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,440,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:74.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 7,500,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AssetAcquisitionTableTextBlock>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="Duration_8_23_2021_To_8_23_2021_HiZIlu8ubEeyewTLP3230g"
      decimals="0"
      id="Narr_ZkhmKvNjrUqSSaxOMOAAJQ"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">7500000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="Duration_8_23_2021_To_8_23_2021_ibio_AssetAcquisitionAxis_ibio_Series2PreferredStockMember_us-gaap_AssetAcquisitionAxis_ibio_Series2PreferredStockMember_VOoG9DcOHkek5MqvabkkeA"
      decimals="0"
      id="Tc_5cOdzhs_RUmDKqNo9aeW8A_1_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1760000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="Duration_8_23_2021_To_8_23_2021_ibio_AssetAcquisitionAxis_us-gaap_FiniteLivedIntangibleAssetsMember_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionIntangibleAssetsMember__yJ7v5TK2km2wwhoqTq5Cw"
      decimals="0"
      id="Tc_t4cXIBNH20uALgAFeBypBQ_2_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">4300000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="Duration_8_23_2021_To_8_23_2021_ibio_AssetAcquisitionAxis_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionPrepaidExpensesMember_ZiSAVMfDE0OuOIvWRTPOkA"
      decimals="0"
      id="Tc_VqpN7vCtn0mlyM0vbHOrsw_3_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1440000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="Duration_8_23_2021_To_8_23_2021_HiZIlu8ubEeyewTLP3230g"
      decimals="0"
      id="Tc_jrIfCXwOCEKhkr6nSyrQvg_4_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">7500000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:ImpairmentOfInvestments
      contextRef="Duration_7_1_2021_To_6_30_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_us-gaap_StatementClassOfStockAxis_ibio_Series2PreferredStockMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementMember_GiIiWNIPGEib_sv1KnwHFw"
      decimals="0"
      id="Narr_Fvww1RpDzkem6ij8dpmcgA"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1760000</us-gaap:ImpairmentOfInvestments>
    <ibio:ImpairmentOfPrepaidExpensesCurrent
      contextRef="Duration_7_1_2021_To_6_30_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_us-gaap_StatementClassOfStockAxis_ibio_Series2PreferredStockMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementMember_GiIiWNIPGEib_sv1KnwHFw"
      decimals="0"
      id="Narr_mFjSXLYA4UepuFAdsQn9ww"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">288000</ibio:ImpairmentOfPrepaidExpensesCurrent>
    <ibio:ImpairmentOfPrepaidExpensesNonCurrent
      contextRef="Duration_7_1_2021_To_6_30_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_us-gaap_StatementClassOfStockAxis_ibio_Series2PreferredStockMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementMember_GiIiWNIPGEib_sv1KnwHFw"
      decimals="0"
      id="Narr_tMeA9GimhEevEGsKbe8y4A"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">864000</ibio:ImpairmentOfPrepaidExpensesNonCurrent>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="Duration_9_19_2022_To_9_19_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_wXZQoYO-rEO6uGxtBLB7Ag"
      decimals="INF"
      id="Narr_vPqpfdpcl0q76nU-8R49gQ"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">102354</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:CommonStockValue
      contextRef="As_Of_9_19_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_8ARQ_UpEmkSNVg45b4FndQ"
      decimals="0"
      id="Narr_G_ehDlbqSUmAZijeIzvmIw"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1000000</us-gaap:CommonStockValue>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_xGREzJg85k2rOyE5lH-V2A"
      decimals="0"
      id="Narr_f0pDy_8eFE26JeGv8CspZQ"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">650000000</us-gaap:AssetsFairValueDisclosure>
    <ibio:CollaborativeArrangementMilestonePayments
      contextRef="Duration_9_19_2022_To_9_19_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_wXZQoYO-rEO6uGxtBLB7Ag"
      decimals="0"
      id="Narr_x6FByO4HAkGC_GEynDvp-w"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">5000000</ibio:CollaborativeArrangementMilestonePayments>
    <us-gaap:PaymentsForAdvanceToAffiliate
      contextRef="Duration_9_16_2022_To_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_QdOFAORoNkObDq7whbxqtQ"
      decimals="0"
      id="Narr_UXrcC-Kf-0u5gQ8yxwv86A"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">484000000</us-gaap:PaymentsForAdvanceToAffiliate>
    <ibio:AssetAcquisitionTransactionCosts
      contextRef="Duration_9_16_2022_To_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_QdOFAORoNkObDq7whbxqtQ"
      decimals="0"
      id="Narr_D9bsrdWi3UqNuAqjy0ifew"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">208000000</ibio:AssetAcquisitionTransactionCosts>
    <us-gaap:AssetAcquisitionTableTextBlock
      contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_AssetAcquisitionAxis_ibio_AssetPurchaseAgreementMember_W13nwak_50mao3LDEg0jzw"
      id="Tb_QNviURTzA0Ka3CzH1HjRBg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;The Company accounted for the agreements as an asset purchase and allocated the purchase price of approximately $1,342,000 as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:74.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:74.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,228,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:74.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Fixed assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 114,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:74.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,342,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AssetAcquisitionTableTextBlock>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="Duration_9_16_2022_To_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_QdOFAORoNkObDq7whbxqtQ"
      decimals="0"
      id="Narr_iZw4Mx31nEyk1lBs0PJeRA"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1342000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="Duration_9_16_2022_To_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionIntangibleAssetsMember_yQ9fxKqDbkGLPQucgu0SgA"
      decimals="0"
      id="Tc_H8d0HaEcZkyMb7uXzNLkGg_1_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1228000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="Duration_9_16_2022_To_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionFixedAssetsMember_vLthqkkiPEekVSsXm4z-Wg"
      decimals="0"
      id="Tc_QgTrzYdDfUObgDu6tU-O2A_2_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">114000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="Duration_9_16_2022_To_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_QdOFAORoNkObDq7whbxqtQ"
      decimals="0"
      id="Tc_XsGkA4D-Lki2Nl0gmrumZw_3_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1342000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:FinanceLeaseLiability
      contextRef="As_Of_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementMember_k1dUagvh-06HXU6xBQefUQ"
      decimals="0"
      id="Narr_fLAbKmyBLkGYM6q62vsaRw"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">814000</us-gaap:FinanceLeaseLiability>
    <ibio:SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct
      contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_7N6sRqj9kEWZRTEMclg2yA"
      decimals="INF"
      id="Narr_g0ndatGlE0Ki-cfkEHQ3rQ"
      unitRef="Unit_Standard_item_ITzkWC4v7UGBZiwOGBFemw">6</ibio:SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_7N6sRqj9kEWZRTEMclg2yA"
      decimals="-4"
      id="Narr_3JCmJT_BBkyazUcvFSNifA"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">2130000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_Ef67qn-mQEWTXAhKiIfGgA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;7.&#160;&#160;&#160;Convertible Promissory Note Receivable &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On October 1, 2020, the Company entered into a master services agreement with Safi Biosolutions, Inc. (&#x201c;Safi&#x201d;). In addition, the Company invested $1.5 million in Safi in the form of a convertible promissory note (the "Note"). The Note bears interest at the rate of 5% per annum and is convertible into shares of Safi&#x2019;s common stock (as defined). Principal and accrued interest mature on October 1, 2023. &#160;For the three months ended March&#160;31,&#160;2023 and 2022, interest income amounted to $18,000. For the nine months ended March&#160;31,&#160;2023 and 2022, interest income amounted to $56,000. As of March&#160;31,&#160;2023 and June&#160;30,&#160;2022, the Note balance and accrued interest totaled $1,687,000 and $1,631,000, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company is currently renegotiating the terms of the Note with Safi, which are expected to be finalized in the fourth quarter of Fiscal 2023. &#160;Proceeds expected to be received in the next twelve months are approximately $912,000 and accordingly, $775,000 has been classified to long term.&lt;/p&gt;</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <ibio:LoansReceivableAmountInvested
      contextRef="As_Of_10_1_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_VyVmxesCq0KMm1BWB8Egcw"
      decimals="-5"
      id="Narr_2sXQ1GcXUkiNLJRRWnMgjQ"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1500000</ibio:LoansReceivableAmountInvested>
    <ibio:LoansReceivableFixedRatesOfInterest
      contextRef="Duration_10_1_2020_To_10_1_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_zTgxHY80r0C6Oan6do8BOw"
      decimals="2"
      id="Narr_s9yp0QZHnUe6UPPLoZgF5Q"
      unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg">0.05</ibio:LoansReceivableFixedRatesOfInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_AXcDgcQQBEGgUeelykng1A"
      decimals="-3"
      id="Narr_vZ2jtgBZX0i-APs96KuMBg"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">18000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_3ufJCLpgP0Khx5n03TYFHw"
      decimals="-3"
      id="Narr_0DR1Rpk9zEKYvrlHxDU3ZA"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">18000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_7_1_2021_To_3_31_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_7hfM841DCUy3t_UYmcPmTA"
      decimals="-3"
      id="Narr_mLocBu93u0ybE0Cwm4xE-A"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">56000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_WSwD-_QeQUyXYX-UiYDXDA"
      decimals="-3"
      id="Narr_6W0Vcb1UBkCyI8Y_K67yxw"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">56000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:NotesAndLoansReceivableNetNoncurrent
      contextRef="As_Of_3_31_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_1HkfNu-AM0mxZ7COThJZjg"
      decimals="-3"
      id="Narr_0stJSXljr0OYE6WiXtdCqA"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1687000</us-gaap:NotesAndLoansReceivableNetNoncurrent>
    <us-gaap:NotesAndLoansReceivableNetNoncurrent
      contextRef="As_Of_6_30_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_gf874UKLE0GViq4jrr0myw"
      decimals="-3"
      id="Narr_5eSMpjQiR0CM01qBVLpSbQ"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1631000</us-gaap:NotesAndLoansReceivableNetNoncurrent>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_DXSGjOiLakGW3cX2lxBW4w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;8.&#160;&#160;&#160;Investments in Debt Securities &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company did not hold any investments in debt securities at March 31, 2023. The components of investments in debt securities are as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:58.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;Adjusted cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,029&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;Gross unrealized losses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"&gt; (184)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;Fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,845&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The fair value of available-for-sale debt securities, by contractual maturity, was as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:59.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fiscal period ending:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:59.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;8,054&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:59.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2,791&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:59.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;10,845&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Amortization of premiums paid on the debt securities amounted to $7,000 and $74,000 for the three months ended March&#160;31,&#160;2023 and 2022, respectively, and $67,000 and $269,000 for the nine months ended March 31, 2023 and 2022, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Realized gains on available-for-sale debt securities are as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;Proceeds from sale of debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; 5,943&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;Cost of debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; 6,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;Realized loss on sale of debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; (93)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;Proceeds from sale of debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; 6,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;Cost of debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; 6,837&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;Realized loss on sale of debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; (98)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_9YYy015_hUyeosoAaZQrzw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company did not hold any investments in debt securities at March 31, 2023. The components of investments in debt securities are as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:58.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;Adjusted cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,029&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;Gross unrealized losses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"&gt; (184)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;Fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,845&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_ig0Kbjcg5UaWjbTb_SxfMg_3_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">11029000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_N2vdO0cxTU-lHyJs0D3WAQ_4_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">184000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_1F_uO6gXC06SrX47LOvydg_5_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">10845000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_6oFlvpvV-0u64XdiVcugDQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The fair value of available-for-sale debt securities, by contractual maturity, was as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:59.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fiscal period ending:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:59.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;8,054&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:59.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2,791&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:59.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;10,845&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_nkkYPyQxd06aHTAvp5jj2w_3_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">8054000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_xl3-0FThQ0merF-UPWMbJQ_4_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">2791000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_czerRu9kwE64lHYgALZrjQ_5_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">10845000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Narr_0VHYOx-KL0O59hepQipT3Q"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">7000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="-3"
      id="Narr_B7raERMHkk-8rKsBAGDgWA"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">74000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Narr__7yyJg5AOUewT-eMwV2CXg"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">67000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Narr_nRWfrlf-mEy6yTti8e80mA"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">269000</us-gaap:AmortizationOfDebtDiscountPremium>
    <ibio:AvaliableForSaleDebtSecuritiesRealizedGainsLossesTableTextBlock
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_wSknUKOhaUOvu2vrPEiPXA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Realized gains on available-for-sale debt securities are as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;Proceeds from sale of debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; 5,943&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;Cost of debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; 6,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;Realized loss on sale of debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; (93)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;Proceeds from sale of debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; 6,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;Cost of debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; 6,837&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;Realized loss on sale of debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; (98)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; &#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ibio:AvaliableForSaleDebtSecuritiesRealizedGainsLossesTableTextBlock>
    <ibio:FinanceLeaseRightOfUseAssetDisclosureTextBlock
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_l6QJ4jhuAUSvf0rCP8bgFA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;9.&#160;&#160;&#160;Finance Lease ROU Assets&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;As discussed above, the Company assumed three equipment leases as part of the RubrYc asset acquisition. &#160;In addition, the Company leased a mobile office trailer which is classified as part of assets held for sale. &#160;The lease was terminated in December 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;See Note 14 &#x2013; Finance Lease Obligations for more details of the terms of the leases.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table summarizes by category the gross carrying value and accumulated amortization of finance lease ROU (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;ROU - Equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 814&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accumulated amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (136)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net finance lease ROU&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 678&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Amortization of finance lease ROU assets was approximately $68,000 and $0 for the three months ended March&#160;31,&#160;2023 and 2022, respectively, and $136,000 and $0 for the nine months ended March&#160;31,&#160;2023 and 2022, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</ibio:FinanceLeaseRightOfUseAssetDisclosureTextBlock>
    <ibio:SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_kfzKjlcBOUSRyqLvbwAcUg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table summarizes by category the gross carrying value and accumulated amortization of finance lease ROU (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;ROU - Equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 814&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accumulated amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (136)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net finance lease ROU&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 678&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</ibio:SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock>
    <ibio:FinanceLeaseRightOfUseAssetGross
      contextRef="As_Of_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ibio_FacilityMember_K0EB_c8dT0OHjVuRMWJAdA"
      decimals="-3"
      id="Tc_GFeo5LTQ_UWht7BCE8FuXw_3_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">814000</ibio:FinanceLeaseRightOfUseAssetGross>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_7RHg-X7zJkKzU1FV6q0yhA_4_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">136000</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_FI826uy3KUO-m9EixjDxWA_5_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">678000</us-gaap:FinanceLeaseRightOfUseAsset>
    <ibio:OperatingLeaseRightOfUseAssetDisclosureTextBlock
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_uGtKOkXz2EuS2MIqLh385Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;10.&#160;&#160;&#160;Operating Lease ROU Assets&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;San Diego, California&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On September 10, 2021, the Company entered into a lease for approximately 11,383 square feet of space in San Diego, California. &#160;Based on the terms of the lease payments, the Company recorded an operating lease ROU asset of $3,603,000. &#160;The net carrying amount of this ROU operating lease asset was &lt;span style="-sec-ix-hidden:Hidden_iQoKre6X4UGSKRq8g3fedQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$2,798,000&lt;/span&gt;&lt;/span&gt; and $3,068,000 at March&#160;31,&#160;2023 and June&#160;30,&#160;2022, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Bryan, Texas&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On November 1, 2021, as discussed above, iBio CDMO acquired the Facility and became the tenant under the ground lease for the Property upon which the Facility is located. Based on the terms of the lease payments, the Company recorded an operating lease ROU asset of $1,967,000. The net amount of this ROU operating lease asset is included in assets held for sale.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt; &#160; &#160;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;See Note 15 - Operating Lease Obligation for additional information.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</ibio:OperatingLeaseRightOfUseAssetDisclosureTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="As_Of_9_10_2021_fOp8nNM7xESd6X0-jbcuDQ"
      decimals="INF"
      id="Narr_B846z8ldt0iIgq9_ETtgSA"
      unitRef="Unit_Standard_sqft_3kWp_fWhaEWbENPWsKzOnw">11383</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_9_10_2021_fOp8nNM7xESd6X0-jbcuDQ"
      decimals="0"
      id="Narr_hsRo-_cZI0K_ZlEzy--RaQ"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">3603000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="0"
      id="Narr_bZZlgiZPOUashncbb3B9CQ"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">3068000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_11_1_2021_klJV-onJz0KrNHSyhYX8GA"
      decimals="0"
      id="Narr_FHQXFrY2cEWRg4s83-4ybg"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1967000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_vdfruBHf60i889TOzr5V_Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;11.&#160;&#160;&#160;Fixed Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table summarizes by category the gross carrying value and accumulated depreciation of fixed assets (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Building and improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 695&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Machinery and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 3,461&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Office equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 403&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 34&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,373&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 4,593&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,373&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (235)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net fixed assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 4,358&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,373&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Depreciation expense reported in continuing operations was approximately $120,000 and $235,000 for the three and nine months ended March&#160;31,&#160;2023, respectively, and $0 for both the three and nine months ended March&#160;31,&#160;2022. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Fixed assets held for sale at March&#160;31,&#160;2023 and June&#160;30,&#160;2022 in the amount of $16,424,000 and $35,289,000, respectively, are included in assets held for sale. &#160;The depreciation expense for the three months ended March&#160;31,&#160;2023 and 2022 and the nine months ended March&#160;31,&#160;2023 and 2022 is classified as part of loss from discontinued operations. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;During the third quarter of Fiscal 2023, the Company re-evaluated its business strategy and reviewed its product portfolio. After such review, the Company recorded an impairment charge of approximately $17.6 million for the three and nine months ended March&#160;31,&#160;2023, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;See Note 5 - Financial Instruments and Fair Value Measurement for more information.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_ugQyFffa7029J342EhdZ9Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table summarizes by category the gross carrying value and accumulated depreciation of fixed assets (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Building and improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 695&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Machinery and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 3,461&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Office equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 403&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 34&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,373&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 4,593&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,373&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (235)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net fixed assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 4,358&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,373&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_ThM6Q7i9IU-hcgFbdInU_Q"
      decimals="-3"
      id="Tc_h9ZDwiArxk6xsONmYwVYLA_4_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">695000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_yqfA3UgBD0GxUlVv1J1aZg"
      decimals="-3"
      id="Tc_7P5Mdj-4b060qRMd-T9QWg_5_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">3461000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_6QB18MmXqEK9CBa2yX9t0w"
      decimals="-3"
      id="Tc_SJk8PlZhtEu91Wbft_dRwA_6_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">403000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_3_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_lgu0RKVqRUy0scLhwVYi5A"
      decimals="-3"
      id="Tc_KNEj4gqndk6MaN3GhChFbw_7_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">34000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_6_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_NSlKXkd1_ky6H3FWqPfqaQ"
      decimals="-3"
      id="Tc_zOkCdUCwTU-ovzBum4h9ZQ_7_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1373000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_xiWADLT9JUSXXhY4HnsmzA_8_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">4593000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_1iUMKj_1fkeCO6sCPiXpTA_8_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1373000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_bjQnmRqB4UilTtedXHIJDg_9_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">235000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_ImyBH8dAYEOt_Kb8kn1tPQ_10_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">4358000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_qwA0jErzF0uBmLsoKDs5Wg_10_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1373000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_3_31_2022_-w0U61DdKUWU0kwbv1xmfg"
      decimals="0"
      id="Narr_kJg3iZDObkyzV99IDY7Ngw"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">0</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_3_31_2022_-w0U61DdKUWU0kwbv1xmfg"
      decimals="0"
      id="Narr_ck2tWKIuOkS853pAMtmBsg"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">0</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <ibio:FixedAssetsHeldForSale
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="0"
      id="Narr__5QW1rgNvECycQVQnZz5ug"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">16424000</ibio:FixedAssetsHeldForSale>
    <ibio:FixedAssetsHeldForSale
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="0"
      id="Narr_Rh7CKI_44UWqw4YXJwxXlg"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">35289000</ibio:FixedAssetsHeldForSale>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-5"
      id="Narr_onZblSPmYUeP3OEbWSgLKQ"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">17600000</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_aB5KzA-dWkGaYz1o51HWhg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;12.&#160;&#160;&#160;Intangible Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company has two categories of intangible assets&#160;&#x2013; intellectual property and patents. Intellectual property consists of all technology, know-how, data, and protocols for producing targeted proteins in plants and related to any products and product formulations for pharmaceutical uses and for other applications. Intellectual property includes, but is not limited to, certain technology for the development and manufacture of novel vaccines and therapeutics for humans and certain veterinary applications acquired in December&#160;2003 from Fraunhofer USA&#160;Inc., acting through its Center for Molecular Biotechnology (&#x201c;Fraunhofer&#x201d;), pursuant to a Technology Transfer Agreement, as amended (the &#x201c;TTA&#x201d;). The Company designates such technology further developed and acquired from Fraunhofer as &lt;i style="font-style:italic;"&gt;iBioLaunch&lt;/i&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;TM&lt;/sup&gt; or &lt;i style="font-style:italic;"&gt;LicKM&lt;/i&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;TM&lt;/sup&gt; or &lt;i style="font-style:italic;"&gt;FastPharming&lt;/i&gt; Technology. The value on the Company&#x2019;s books attributed to patents owned or controlled by the Company is based only on payments for services and fees related to the protection of the Company&#x2019;s patent portfolio. The intellectual property also includes certain trademarks.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On August 23, 2021, the Company entered into a series of agreements with RubrYc described in more detail above (see Note 6 &#x2013; Significant Transactions) whereby in exchange for a $7.5 million investment in RubrYc, the Company acquired a worldwide exclusive license to certain antibodies that RubrYc develops under what it calls its RTX-003 campaign, which are promising immuno-oncology antibodies that bind to the CD25 protein without interfering with the IL-2 signaling pathway thereby potentially depleting T-regulatory (Tregs) cells while enhancing T effector (Teffs) cells and encouraging the immune system to attack cancer cells. The Company accounted for this license as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development efforts. &#160;In addition, the Company also received preferred shares and an option for future collaboration licenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On September 16, 2022, the Company entered into an Asset Purchase Agreement with RubrYc described in more detail above (see Note 6 &#x2013; Significant Transactions) pursuant to which it acquired substantially all of the assets of RubrYc. &#160;The assets acquired include the patented AI drug discovery platform, all rights with no future milestone payments or royalty obligations, to IBIO-101, in addition to CCR8, EGFRvIII, MUC16, CD3, and one additional immuno-oncology candidate, plus a PD-1 agonist.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In January 2014, the Company entered into a license agreement with the University of Pittsburgh&lt;i style="font-style:italic;"&gt; &lt;/i&gt;whereby the Company acquired exclusive worldwide rights to certain issued and pending patents covering specific candidate products for the treatment of fibrosis (the "Licensed Technology") which license agreement was amended in August 2016 and again in December 2020 and February 2022. The license agreement provides for payment by the Company of a license issue fee, annual license maintenance fees, reimbursement of prior patent costs incurred by the university, payment of a milestone payment upon regulatory approval for sale of a first product, and annual royalties on product sales. In addition, the Company has agreed to meet certain diligence milestones related to product development benchmarks. As part of its commitment to the diligence milestones, the Company successfully commenced production of a plant-made peptide comprising the Licensed Technology before March 31, 2014. The next milestone &#x2013; filing an Investigational New Drug Application with the FDA or foreign equivalent covering the Licensed Technology ("IND") &#x2013; initially was required to be met by December 1, 2015, and on November 2, 2020, was extended to be required to be met by December 31, 2021 and on February 8, 2022, was further extended to December 31, 2023. In addition, the amounts of the annual license maintenance fee and payment upon completion of various regulatory milestones were amended. On February 14, 2023, the Company provided notification to the University of Pittsburgh terminating the license agreement. Pursuant to the termination of the license agreement with the University of Pittsburgh, the Company&#x2019;s financial obligations for the management of the patents under the license will cease on August 14, 2023, and at such time, will transition back to the University of Pittsburgh. As a result of the termination of the license agreement, the Company recorded a full impairment of the related intangible asset associated with IBIO-100 in the amount of $25,000.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;See Note 4 - Summary of Significant Accounting Policies for more information.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table reflects changes in the carrying amount of intangible assets (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;June&#160;30,&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;March 31,&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Additions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Impairments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Intellectual property &#x2013; gross carrying value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 3,100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,100)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 400&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Patents and licenses &#x2013; gross carrying value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 2,846&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,846)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 5,946&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,946)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 400&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Intellectual property &#x2013; accumulated amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,867)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (74)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 2,931&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (10)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Patents and licenses &#x2013; accumulated amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,403)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (47)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 2,450&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,270)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (121)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 5,381&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (10)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total definite lived intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 676&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (121)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (565)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 390&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;License - indefinite lived&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 4,175&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 828&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 5,003&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total net intangible&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 4,851&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,228&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 5,393&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Amortization expense was approximately $5,000 and $122,000 for the three months ended March&#160;31,&#160;2023 and 2022, respectively. Amortization expense was approximately $121,000 and $333,000 for the nine months ended March&#160;31,&#160;2023 and 2022, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt; &lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;During the second quarter of Fiscal 2023, the Company re-evaluated its business strategy and reviewed its product portfolio. After such review, the Company identified intellectual property, patent and licenses that will no longer be utilized and therefore were fully impaired. &#160;The Company recorded an impairment charge in general and administrative expenses of approximately $565,000 for the nine months ended March&#160;31,&#160;2023. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;See Note 4 - Summary of Significant Accounting Policies and Note 5 &#x2013; Financial Instruments and Fair Value Measurement for more information.&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <ibio:StockPurchaseAgreementTotalInvestment
      contextRef="As_Of_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_vI4fmkUg3kuCuyZ_zK8brg"
      decimals="-5"
      id="Narr_M9z9BGqBR0yWut7pSW7RKA"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">7500000</ibio:StockPurchaseAgreementTotalInvestment>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="Duration_2_14_2023_To_2_14_2023_TnhaetjjP06Trcv9WL2o_A"
      decimals="0"
      id="Narr_gabpU9Y0GUm7DxEP8okS4w"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">25000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_zhQLQdvP6EWVMnhhpRTsHQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table reflects changes in the carrying amount of intangible assets (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;June&#160;30,&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;March 31,&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Additions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Impairments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Intellectual property &#x2013; gross carrying value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 3,100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,100)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 400&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Patents and licenses &#x2013; gross carrying value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 2,846&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,846)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 5,946&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,946)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 400&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Intellectual property &#x2013; accumulated amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,867)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (74)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 2,931&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (10)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Patents and licenses &#x2013; accumulated amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,403)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (47)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 2,450&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,270)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (121)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 5,381&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (10)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total definite lived intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 676&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (121)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (565)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 390&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;License - indefinite lived&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 4,175&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 828&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 5,003&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total net intangible&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 4,851&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,228&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 5,393&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_h4ptg2J5jEab7-ozoqAPPA"
      decimals="-3"
      id="Tc_uDuiqWzM4UW6j3A5fqy9Tw_3_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">3100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_V386ndKYUkuQBZjgR9D61w"
      decimals="-3"
      id="Tc_sQiZCLyJaE-8zgvliyZk6w_3_9"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">400000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <ibio:ImpairmentOfIntangibleAssetsGrossOfReversals
      contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_V386ndKYUkuQBZjgR9D61w"
      decimals="-3"
      id="Tc_gD8vjbiKi0OZeU-qnQBxPQ_3_12"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">3100000</ibio:ImpairmentOfIntangibleAssetsGrossOfReversals>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_3_31_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_5pgV7l8BAkeLqa2TtOfOrg"
      decimals="-3"
      id="Tc_3dEqidnwKUmElk3-GZnBAA_3_15"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">400000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_3xQ4GPFAFEWXC_8Y-7ecig"
      decimals="-3"
      id="Tc_QMd3MYnh_Emcfg-hZ15lbQ_4_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">2846000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <ibio:ImpairmentOfIntangibleAssetsGrossOfReversals
      contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_9dyJeVMv1ki5yRGsbgJw-Q"
      decimals="-3"
      id="Tc_3EFnOQnsfEGnleHXbsr5qw_4_12"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">2846000</ibio:ImpairmentOfIntangibleAssetsGrossOfReversals>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_VtLxoXRTqU2SA2qBwvHXVQ_5_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">5946000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc__hMYb9q8P0yjchJrWWvZqg_5_9"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">400000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <ibio:ImpairmentOfIntangibleAssetsGrossOfReversals
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_H2bECi1sSUq3wNq_dUMb0Q_5_12"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">5946000</ibio:ImpairmentOfIntangibleAssetsGrossOfReversals>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_rwVC6hrXTUWaFsbpYTCoRQ_5_15"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">400000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_h4ptg2J5jEab7-ozoqAPPA"
      decimals="-3"
      id="Tc_r4fFPv4dMkeivKIv67f4Ug_6_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">2867000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_V386ndKYUkuQBZjgR9D61w"
      decimals="-3"
      id="Tc_ECv8lsjGyUuSO-zYV0GXQw_6_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">74000</us-gaap:AmortizationOfIntangibleAssets>
    <ibio:ReversalOfIntangibleAssetImpairment
      contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_V386ndKYUkuQBZjgR9D61w"
      decimals="-3"
      id="Tc_BkVM9LOO306UyMphs6HjIA_6_12"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">2931000</ibio:ReversalOfIntangibleAssetImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_3_31_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_5pgV7l8BAkeLqa2TtOfOrg"
      decimals="-3"
      id="Tc_f5lZALBgV0GbGqGmfj-mXg_6_15"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">10000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_3xQ4GPFAFEWXC_8Y-7ecig"
      decimals="-3"
      id="Tc_u-S9-y0xpUWLPLAY4wOItQ_7_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">2403000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_9dyJeVMv1ki5yRGsbgJw-Q"
      decimals="-3"
      id="Tc_4D0nYfD3606yo0FR6Z0z4Q_7_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">47000</us-gaap:AmortizationOfIntangibleAssets>
    <ibio:ReversalOfIntangibleAssetImpairment
      contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_9dyJeVMv1ki5yRGsbgJw-Q"
      decimals="-3"
      id="Tc_Z-x4mpFS8UGObFy2JY-7Xg_7_12"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">2450000</ibio:ReversalOfIntangibleAssetImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_kR_IUoa_Mkiwgw9foyTM3Q_8_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">5270000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_1hClUXxaqU6SBWScluCa4g_8_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">121000</us-gaap:AmortizationOfIntangibleAssets>
    <ibio:ReversalOfIntangibleAssetImpairment
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_vCnyQSY-uk-psyNwv_GPHQ_8_12"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">5381000</ibio:ReversalOfIntangibleAssetImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_NVaJFduVD0mKVQJHQA-7AQ_8_15"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">10000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_UyUKdLoCvk6r9vCsAAM8dg_9_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">676000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_QQSAS4Je70O4sgiPG8awFA_9_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">121000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_Uku7jNr8zkqRB3JNQbV85Q_9_9"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">400000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_6MHbE5Aq40WzHQQJUrSNLw_9_12"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">565000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_AzAkt6XVs0CrXKRL2yReZg_9_15"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">390000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw"
      decimals="-3"
      id="Tc_snc7Ig2CPE6zVUxRF3Gcow_11_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">4175000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefinitelivedIntangibleAssetsAcquired
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_vAxMAWzxg0ejjTCIiZp0LA_11_9"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">828000</us-gaap:IndefinitelivedIntangibleAssetsAcquired>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_r1lNqFFe8UGoscuTpLp8SA_11_15"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">5003000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="0"
      id="Narr_-KEMU6FAq0SAc2AZqepQaQ"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">5000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="0"
      id="Narr_Fi_fyesQAkiNY9dwLLajFQ"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">122000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="0"
      id="Narr_ckxgk6jYfkSMHk9BY63kWA"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">121000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="0"
      id="Narr_bZUudpfNtU-LHZGf_USidw"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">333000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="0"
      id="Narr_ucdLRNlvPk6j8-oM8J0Ogw"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">565000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_BFnhxF-yiE2VcEa8tBDnkQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;13.&#160;&#160;&#160;Debt&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;The Credit Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In connection with the Purchase and Sale Agreement, iBio CDMO entered into a Credit Agreement, dated November 1, 2021, with Woodforest pursuant to which Woodforest provided iBio CDMO a $22,375,000 secured term loan (the &#x201c;Term Loan&#x201d;) to purchase the Facility, which Term Loan is evidenced by a term note (the &#x201c;Term Note&#x201d;) (for a complete description of the transaction please see Note 6 &#x2013; Significant Transactions). The Term Loan was advanced in full on the closing date. The Term Loan bears interest at a rate of 3.25%, with higher interest rates upon an event of default, which interest is payable monthly beginning November 5, 2021. Principal on the Term Loan was originally payable on November 1, 2023, subject to early termination upon events of default. The Term Loan provides that it may be prepaid by iBio CDMO at any time and provides for mandatory prepayment upon certain circumstances.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On October 11, 2022, iBio CDMO and Woodforest amended the Credit Agreement to: (i) include a payment of $5,500,000 of the outstanding principal balance owed under the Credit Agreement on the date of the amendment, (ii) include a payment of $5,100,000 of the outstanding principal balance owed under the Credit Agreement within two (2) business days upon our receipt of such amount owed to us by Fraunhofer as part of our legal settlement with them (the &#x201c;Fraunhofer Settlement Funds&#x201d;) (see Note 19 &#x2013; Fraunhofer Settlement for more information), (iii) include principal payments of $250,000 per month in debt amortization for a six-month period commencing the date of the amendment through March 2023, (iv) include an amendment fee of $22,375 and all costs and expenses, (v) require delivery of a report detailing cash flow expenditures every two (2) weeks for the period prior to the delivery of the last report and a monthly 12-month forecast, (vi) reduce the liquidity covenant (the &#x201c;Liquidity Covenant&#x201d;) in the Guaranty (as defined in the Credit Agreement) from $10 million to $7.5 million with the ability to lower the liquidity covenant to $5.0 million upon the occurrence of a specific milestone in the Credit Agreement, and (vii) change the annual filing requirement solely for the fiscal year ended June 30, 2022, such that the filing is acceptable with or without a &#x201c;going concern&#x201d; designation. &#160;In addition, Woodforest cancelled the irrevocable letter of credit issued by JPMorgan Chase Bank upon closing of the amendment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In January 2023, the Company&#x2019;s unrestricted cash decreased below the required $7,500,000, which created an event of default under the Credit Agreement and Guaranty as a result of not complying with the Liquidity Covenant. As a result, on February 9, 2023, iBio CDMO and Woodforest entered into a second amendment to the Credit Agreement (the &#x201c;Second Amendment&#x201d;), which amended, among other things, added a milestone that had to be met by a specified date, the failure of which would be an event of default. &#160;In addition, on February 9, 2023, the Company, as guarantor, entered into a second amendment to the Guaranty, which amended, among other things, allowed the Company to account for the Fraunhofer Settlement Funds in determining whether the Company is in compliance with the Liquidity Covenant until a specified period dependent upon the occurrence of a specific milestone in the Credit Agreement. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On February 20, 2023, iBio CDMO entered into a third amendment to the Credit Agreement (the &#x201c;Third Amendment&#x201d;), which removed the added milestone specified in the Second Amendment, the failure of which would be an event of default. &#160;In addition, the Guaranty was amended to allow the Company until February 28, 2023, to account for the Fraunhofer Settlement Funds in determining whether the Company is in compliance with the Liquidity Covenant without being dependent upon a specified milestone. &#160;In addition, the Company agreed that each time it consummates an at-the-market issuance of Equity Interests (as defined within the Credit Agreement), no later than five (5) days following such issuance of Equity Interests, it will (i) pay to Woodforest in immediately available cash funds, without setoff or counterclaim of any kind, forty percent (40%) of the Net Proceeds (as defined within the Credit Agreement) received by the Company for such issuance of Equity Interests; provided, any such payment would cease upon payment obligations in full and (ii) provide Woodforest with a detailed accounting of each such issuance of Equity Interests.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On March 24, 2023, iBio CDMO and Woodforest entered into a fourth amendment to the Credit Agreement (the &#x201c;Fourth Amendment&#x201d;), which within the Fourth Amendment Woodforest agreed to (i) reduce the percentage of any payment to Woodforest the Company is required to make from the proceeds of sales of its common stock under its at-the-market facility from 40% to 20%, (ii) reduce the percentage of any payment to Woodforest the Company is required to make from the proceeds of sales of its equipment from 40% to &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;20%, and (iii) allowed the Company to retain $2,000,000 million of the $5,100,000 million that the Company received from the Fraunhofer Settlement Funds, with the remaining $3,000,000 million being held in a Company account at Woodforest. &#160;In addition, the Company is obligated to (y) deliver to Woodforest an executed copy of a purchase agreement (the &#x201c;Purchase Agreement&#x201d;) for the sale of the Facility, no later than April 14, 2023, and (z) pay to Woodforest a fee in the amount of $75,000 on the earlier of the date of the closing of the Purchase Agreement, or the Maturity Date (as defined in the Credit Agreement). &#160;In addition, on March 24, 2023, the Company, as guarantor, entered into a fourth amendment to the Guaranty, which reduced the Liquidity Covenant from $7,500,000 to $1,000,000. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On May 10, 2023, iBio CDMO and Woodforest entered into a fifth amendment to the Credit Agreement (the &#x201c;Fifth Amendment&#x201d;), which within the Fifth Amendment Woodforest agreed to: (i) waive our obligation to deliver to Woodforest an executed copy of a Purchase Agreement for the sale of the Facility no later than April 14, 2023 and, (ii) release $500,000 of the $3.0 million being held in a Company account at Woodforest when the outstanding principal amount is reduced to $10.0 million and for each additional $2.5 million reduction of the outstanding principal amount, an additional $750,00 will be released from the Company account at Woodforest.&#160; In addition, starting on the effective date of the Fifth Amendment, the interest on the Term Loan increased to 5.25%, and the Term Loan shall further accrue interest, payable in kind and added to the balance of the outstanding principal amount at a fixed rate per annum equal to (a) 1.00%, if the Facility is sold on or before June 30, 2023, (b) 2.00% if the Facility is sold after June 2023, but on or before September 30, 2023, or (c) 3:00%, if the Facility is sold after September 30, 2023, or not sold prior to the maturity date.&#160; The Company also agreed to pay Woodforest a fee in the amount of (x) $75,000 if the Facility is sold on or before June 30, 2023, (y) $100,000 if the Facility is sold after June 2023, but on or before September 30, 2023, or (x) $125,000, if the Facility is sold after September 30, 2023, or not sold prior to the maturity date. As of the date of the filing of this Quarterly Report on Form 10-Q, the Company is not in negotiations on a Purchase Agreement with a potential buyer of the Facility.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;At March&#160;31,&#160;2023, the balance of the Term Loan was $13,700,000 which consisted of the Term Note of $13,852,000, net of approximately $152,000 of deferred finance costs. &#160;At June&#160;30,&#160;2022, the balance was $22,161,000 which consisted of the Term Note of $22,375,000, net of approximately $214,000 of deferred finance costs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Equipment Financing&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On October 12, 2022, the Company entered into an equipment financing master lease agreement and a lease supplement whereby $500,000 was borrowed over 36 months at an imputed interest rate of 10.62% and securitized by certain assets purchased for the San Diego research site. &#160;The financing is payable in monthly installments of $16,230 through October 2025. &#160;At March&#160;31,&#160;2023, the balance owed under the financing was $438,000. &#160;Interest incurred under the financing for the three and nine months ended March&#160;31,&#160;2023 totaled approximately $12,000 and $19,000, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Future minimum payments under the finance lease obligation are due as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fiscal period ending on March 31:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Principal&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Interest&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 156&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 39&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 195&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 173&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 22&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 195&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 110&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 114&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total minimum equipment financing payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 439&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 65&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 504&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (156)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Long-term portion of minimum equipment financing obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 283&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Note Payable &#x2013; PPP Loan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;On April 16, 2020, the Company received $600,000 related to its filing under the Paycheck Protection Program (&#x201c;PPP&#x201d;) and Coronavirus Aid, Relief, and Economic Security Act (the "CARES Act"). The Company elected to treat the Small Business Administration (&#x201c;SBA&#x201d;) loans as debt under ASC 470, &lt;i style="font-style:italic;"&gt;Debt&lt;/i&gt;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On July 21, 2021, iBio was granted forgiveness in repaying the loan. &#160;In accordance with ASC 405-20-40, &lt;i style="font-style:italic;"&gt;Liabilities - Extinguishments of Liabilities &#x2013; Derecognition&lt;/i&gt;, the Company derecognized the liability and accrued interest of approximately $7,000 in the first quarter of Fiscal 2022. &#160;The forgiveness is included in loss from discontinued operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;See Note 3 &#x2013; Discontinued Operations.&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_11_1_2021_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_LgWNkAEXrEOd4Kk1fbDdsQ"
      decimals="0"
      id="Narr_ZtqYl9pyrEOQZQWx1IhakQ"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">22375000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_11_1_2021_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_LgWNkAEXrEOd4Kk1fbDdsQ"
      decimals="4"
      id="Narr_zqXUcwvD0UKvnHWS-_DG2g"
      unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg">0.0325</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="Duration_10_11_2022_To_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_DateOfAmendmentMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_ymy8A_X8_EK1tvCrHTVuEQ"
      decimals="0"
      id="Narr_WUnC40JDfE6jX1M8NPdAqQ"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">5500000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="Duration_10_11_2022_To_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_uQ72oafLtUqgFnnzbdiAsw"
      decimals="0"
      id="Narr_f28vH5JCpk-M4trV9KWheg"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">5100000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="Duration_10_11_2022_To_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_SmV5R4SrNkmUCX3FsbIGLA"
      decimals="0"
      id="Narr_BW2RdnQHYUqVP2jI1pmWKg"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">250000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="As_Of_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_O-zm2Doh6EmpqJ14OI8KEw"
      decimals="0"
      id="Narr_vM9ewdRhhUWxrPGyS-uRpQ"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">22375</us-gaap:DebtInstrumentFeeAmount>
    <ibio:DebtCovenantLiquidityAmount
      contextRef="As_Of_10_10_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_dl3OmSiDBEKFtrzke4LxUw"
      decimals="-6"
      id="Narr_BvaL5Qacr0O0dRFb2fc5Lw"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">10000000</ibio:DebtCovenantLiquidityAmount>
    <ibio:DebtCovenantLiquidityAmount
      contextRef="As_Of_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_O-zm2Doh6EmpqJ14OI8KEw"
      decimals="-5"
      id="Narr_RudUF6_0u0WdrCkTAt9J6w"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">7500000</ibio:DebtCovenantLiquidityAmount>
    <ibio:DebtCovenantLiquidityAmount
      contextRef="As_Of_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_OccurrenceOfSpecificMilestoneMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_RDzgSGSsy0qENkxPgtYl4w"
      decimals="-5"
      id="Narr_WW8db3gWcUGzP7OywFMYgQ"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">5000000.0</ibio:DebtCovenantLiquidityAmount>
    <ibio:CreditAgreementThresholdLimitUnrestrictedCash
      contextRef="As_Of_1_31_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_87cTBGu9gE-x613iWJyDyg"
      decimals="0"
      id="Narr_7rvypUBypkemXf40ShuFXw"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">7500000</ibio:CreditAgreementThresholdLimitUnrestrictedCash>
    <us-gaap:LongTermDebt
      contextRef="As_Of_3_31_2023_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_co4oLbGgmE-T18TcXR1zRA"
      decimals="0"
      id="Narr_4IOUiGH_jEe3yHB3khQFuA"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">13700000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_3_31_2023_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_co4oLbGgmE-T18TcXR1zRA"
      decimals="0"
      id="Narr_lbv1tpIZ_E6glF8_J3EKKA"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">13852000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="As_Of_3_31_2023_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_co4oLbGgmE-T18TcXR1zRA"
      decimals="0"
      id="Narr_LiWuh9-4S0ubSOwKTX04lg"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">152000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_Vft8wC26KU20m86L9BIQqA"
      decimals="0"
      id="Narr_0XhaGohGLE6j1khbtgtT4A"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">22161000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_Vft8wC26KU20m86L9BIQqA"
      decimals="0"
      id="Narr_G15SqtPMHU21METdl-0dNQ"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">22375000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="As_Of_6_30_2022_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_Vft8wC26KU20m86L9BIQqA"
      decimals="0"
      id="Narr_80y2Hfv7gkq-kGEBh_bbfg"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">214000</us-gaap:DeferredFinanceCostsNet>
    <ibio:EquipmentFinancingAmountBorrowed
      contextRef="As_Of_10_12_2022_0w4cNGT5qUGNwBnB1qrjUA"
      decimals="0"
      id="Narr_zrCS5fiZnE-WA86tWFFM1A"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">500000</ibio:EquipmentFinancingAmountBorrowed>
    <ibio:LesseeEquipmentLeaseTermOfContract
      contextRef="Duration_10_12_2022_To_10_12_2022_fUvngAqb2k-xursF14pifg"
      id="Narr_Kj3Rc964-0-Sv2iQEnJR3Q">P36M</ibio:LesseeEquipmentLeaseTermOfContract>
    <ibio:EquipmentFinancingLeaseImputedInterestRate
      contextRef="Duration_10_12_2022_To_10_12_2022_fUvngAqb2k-xursF14pifg"
      decimals="4"
      id="Narr_IIn3ZyLRSEuN6sPi8vmwyw"
      unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg">0.1062</ibio:EquipmentFinancingLeaseImputedInterestRate>
    <ibio:EquipmentLeasingMonthlyInstallmentPayable
      contextRef="As_Of_10_12_2022_0w4cNGT5qUGNwBnB1qrjUA"
      decimals="0"
      id="Narr_gScY4u1Y60etIss3r0A08Q"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">16230</ibio:EquipmentLeasingMonthlyInstallmentPayable>
    <ibio:EquipmentFinancingBalance
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="0"
      id="Narr__EtQVjIykkC24lRmvCsm4Q"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">438000</ibio:EquipmentFinancingBalance>
    <srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_O4z0w5hcUEWH-JcsCPR7UQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Future minimum payments under the finance lease obligation are due as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fiscal period ending on March 31:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Principal&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Interest&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 156&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 39&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 195&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 173&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 22&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 195&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 110&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 114&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total minimum equipment financing payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 439&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 65&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 504&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (156)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Long-term portion of minimum equipment financing obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 283&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock>
    <us-gaap:ContractualObligationDueInNextTwelveMonths
      contextRef="As_Of_3_31_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_Q7qov9TaRUq6PVlJRwP10w"
      decimals="0"
      id="Tc_T8gW3oO93UGgX23FETHzDg_2_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">156</us-gaap:ContractualObligationDueInNextTwelveMonths>
    <us-gaap:ContractualObligationDueInNextTwelveMonths
      contextRef="As_Of_3_31_2023_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_ELLu56FrAUeDrqmkxHQWOw"
      decimals="0"
      id="Tc_ovITMRoH90imcAJwO9uc8w_2_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">39</us-gaap:ContractualObligationDueInNextTwelveMonths>
    <us-gaap:ContractualObligationDueInNextTwelveMonths
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="0"
      id="Tc_kyyFWRWOkEq1rmA5iCK-1Q_2_9"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">195</us-gaap:ContractualObligationDueInNextTwelveMonths>
    <us-gaap:ContractualObligationDueInSecondYear
      contextRef="As_Of_3_31_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_Q7qov9TaRUq6PVlJRwP10w"
      decimals="0"
      id="Tc__n8dMwhngkGH06u5Y7MnSQ_3_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">173</us-gaap:ContractualObligationDueInSecondYear>
    <us-gaap:ContractualObligationDueInSecondYear
      contextRef="As_Of_3_31_2023_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_ELLu56FrAUeDrqmkxHQWOw"
      decimals="0"
      id="Tc_vvCh3Rz-jkSAe6OWwHYqdA_3_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">22</us-gaap:ContractualObligationDueInSecondYear>
    <us-gaap:ContractualObligationDueInSecondYear
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="0"
      id="Tc_APz5CILUjkuhPHcrsaYf0w_3_9"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">195</us-gaap:ContractualObligationDueInSecondYear>
    <us-gaap:ContractualObligationDueInThirdYear
      contextRef="As_Of_3_31_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_Q7qov9TaRUq6PVlJRwP10w"
      decimals="0"
      id="Tc_Ot9pNXknv0qNCoIMsKeTUw_4_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">110</us-gaap:ContractualObligationDueInThirdYear>
    <us-gaap:ContractualObligationDueInThirdYear
      contextRef="As_Of_3_31_2023_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_ELLu56FrAUeDrqmkxHQWOw"
      decimals="0"
      id="Tc_Wte3AIHnxky-sUrVTbGNSw_4_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">4</us-gaap:ContractualObligationDueInThirdYear>
    <us-gaap:ContractualObligationDueInThirdYear
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="0"
      id="Tc_MgQ5bVy3406nuC9a5f5VCw_4_9"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">114</us-gaap:ContractualObligationDueInThirdYear>
    <us-gaap:ContractualObligation
      contextRef="As_Of_3_31_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_Q7qov9TaRUq6PVlJRwP10w"
      decimals="0"
      id="Tc_GYBS3uZ9Kk6My2y2dmuC6Q_6_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">439</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligation
      contextRef="As_Of_3_31_2023_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_ELLu56FrAUeDrqmkxHQWOw"
      decimals="0"
      id="Tc_WehArT2Hp0C8D6hzEX6O9A_6_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">65</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligation
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="0"
      id="Tc_2-jUOS9bb0y89OU5rbPc_A_6_9"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">504</us-gaap:ContractualObligation>
    <ibio:ContractualObligationCurrent
      contextRef="As_Of_3_31_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_Q7qov9TaRUq6PVlJRwP10w"
      decimals="0"
      id="Tc_6GJUzt5Afk2mhz1m42DO6Q_7_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">156</ibio:ContractualObligationCurrent>
    <ibio:ContractualObligationNoncurrent
      contextRef="As_Of_3_31_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_Q7qov9TaRUq6PVlJRwP10w"
      decimals="0"
      id="Tc_Rk3bTzdPd0eST75acaCiVQ_8_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">283</ibio:ContractualObligationNoncurrent>
    <us-gaap:LongTermNotesPayable
      contextRef="As_Of_4_16_2020_us-gaap_DebtInstrumentAxis_ibio_PppLoanCaresActMember_arEPE-gVxE-EC-ffEJt_Mw"
      decimals="0"
      id="Narr_3UeAXG6ahk-z5hylcU3PaA"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">600000</us-gaap:LongTermNotesPayable>
    <us-gaap:DebtInstrumentDecreaseForgiveness
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_ibio_PppLoanCaresActMember_fyRImC3heEeL4wSzPLvcgw"
      decimals="0"
      id="Narr_LMEh6iFXh0i6jO0DvkdOqA"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">7000</us-gaap:DebtInstrumentDecreaseForgiveness>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_MCSuS7GO2UymFneAPFtn9w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;14.&#160;&#160;&#160;Finance Lease Obligations&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Sublease&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As discussed above, until November 1, 2021, iBio CDMO leased the Facility as well as certain equipment from College Station under the Sublease. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Sublease was terminated on November 1, 2021, when iBio CDMO acquired the Facility and became the tenant under the ground lease for the property upon which the Facility is located. &#160;See Note 15 &#x2013; Operating Lease Obligations for additional information related to the ground lease.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;General and administrative expenses related to College Station, including rent related to the increases in the Consumer Price Index (&#x201c;CPI&#x201d;) and real estate taxes, were approximately $0 and $250,000 for the three and nine months ended March 31, 2022, respectively. Interest expense related to College Station was approximately $0 and $810,000 for the three and nine months ended March 31, 2022, respectively. Such expenses were classified as part of loss from discontinued operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As discussed above, the Company assumed three equipment leases that were accounted for as finance leases totaling $813,822 as part of the RubrYc Asset Purchase Agreement. &#160;The monthly rental for the three leases is approximately $14,000 per month and all three expire on August 1, 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Mobile Office Trailer&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Commencing April 1, 2021, the Company leased a mobile office trailer that was located at the Facility in Bryan, Texas, at a monthly rental of $3,819 through March 31, 2024. &#160;In December 2022, the Company terminated the lease and returned the mobile office trailer. Expenses related to the lease prior to its termination are included in discontinued operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following tables present the components of lease expense and supplemental balance sheet information related to the finance lease obligation (in thousands).&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finance lease cost:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Amortization of ROU assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Interest on lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 84&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other information:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash paid for amounts included in the measurement lease liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Operating cash flows from finance lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Financing cash flows from finance lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 62&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finance lease cost:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Amortization of ROU assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 156&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Interest on lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 33&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 189&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other information:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash paid for amounts included in the measurement lease liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Operating cash flows from finance lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Financing cash flows from finance lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 144&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finance lease ROU assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 678&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finance lease obligation - current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 265&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finance lease obligation - noncurrent portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_ALMi0aoiGEux0RbmMQwClg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; 421&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average remaining lease term - finance lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 2.34&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_UQCuo_IgjkapUCQ_dOiKtg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average discount rate - finance lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 9.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Future minimum payments under the finance lease obligation are as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fiscal period ending on March 31:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Principal&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Interest&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 265&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 54&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 319&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 292&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 28&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 320&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 130&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 133&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 687&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 85&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 772&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (265)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Long-term portion of minimum lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 422&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:65.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ibio_SecondEasternAffiliateMember_KNUp6QEjNk2k0RVdB9kesQ"
      decimals="0"
      id="Narr_vffNdhoDPUSeHmqJWGVysA"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">0</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2021_To_3_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ibio_SecondEasternAffiliateMember_NrQUiMJSu0yMjFFmZyMHLQ"
      decimals="0"
      id="Narr_J_oqSF9jzESyo9JHtNExZQ"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">250000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ibio_SecondEasternAffiliateMember_KNUp6QEjNk2k0RVdB9kesQ"
      decimals="0"
      id="Narr_aJfX-5vb9kWt3nFIq9rXag"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">0</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_7_1_2021_To_3_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ibio_SecondEasternAffiliateMember_NrQUiMJSu0yMjFFmZyMHLQ"
      decimals="0"
      id="Narr_-Ubh6uVdEEiNkawVPWNamA"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">810000</us-gaap:InterestExpenseDebt>
    <ibio:NumberOfEquipmentLeases
      contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_aNeIbxhhIUWzr_C1HYpBqQ"
      decimals="0"
      id="Narr_mQlZ9iByLkO5o8cPEzkyxA"
      unitRef="Unit_Standard_lease_8Woavb0ETUO8s9ODCurHtQ">3</ibio:NumberOfEquipmentLeases>
    <us-gaap:FinanceLeaseLiability
      contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_aNeIbxhhIUWzr_C1HYpBqQ"
      decimals="0"
      id="Narr_wzZgRp8zo0-aO82swz_3uQ"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">813822</us-gaap:FinanceLeaseLiability>
    <ibio:NumberOfEquipmentLeases
      contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_aNeIbxhhIUWzr_C1HYpBqQ"
      decimals="0"
      id="Narr_QI9yY5RGnUONApCqkaJSrw"
      unitRef="Unit_Standard_lease_8Woavb0ETUO8s9ODCurHtQ">3</ibio:NumberOfEquipmentLeases>
    <ibio:LeaseRentExpensePerMonth
      contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_GnYUgnieSE-ivQH2Syhl-Q"
      decimals="0"
      id="Narr_Vh1Sr9_tJkeknjEMlKZLcg"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">14000</ibio:LeaseRentExpensePerMonth>
    <ibio:NumberOfEquipmentLeases
      contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_aNeIbxhhIUWzr_C1HYpBqQ"
      decimals="0"
      id="Narr_BaVTKOA_LUywjY-Kb_SJmg"
      unitRef="Unit_Standard_lease_8Woavb0ETUO8s9ODCurHtQ">3</ibio:NumberOfEquipmentLeases>
    <ibio:LessorFinanceLeaseMonthlyRent
      contextRef="Duration_4_1_2021_To_4_1_2021_34XjF-RfakO2aPg-6ZHbIA"
      decimals="0"
      id="Narr_4_Fc4XR1XU--g2Ng5pXQkg"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">3819</ibio:LessorFinanceLeaseMonthlyRent>
    <ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_KZw9oG81OUCwOnq9fYqECg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following tables present the components of lease expense and supplemental balance sheet information related to the finance lease obligation (in thousands).&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finance lease cost:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Amortization of ROU assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Interest on lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 84&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other information:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash paid for amounts included in the measurement lease liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Operating cash flows from finance lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Financing cash flows from finance lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 62&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finance lease cost:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Amortization of ROU assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 156&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Interest on lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 33&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 189&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other information:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash paid for amounts included in the measurement lease liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Operating cash flows from finance lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Financing cash flows from finance lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 144&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Tc_SLTufxOjhk2h0WzJKbuyuw_5_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">68000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Tc_2JLXvhy9Ak2cg1q0gclHWg_6_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">16000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Tc_IHQOy81d1kyh95cL5sRKYw_7_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">84000</us-gaap:LeaseCost>
    <ibio:FinancingCashFlowsFromFinanceLeaseObligation
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Tc_ubI8cPr_4Uq09pmBiBngEg_12_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">62000</ibio:FinancingCashFlowsFromFinanceLeaseObligation>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_Trt3xKPH80qnq0tW8tqJdA_5_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">156000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_pWHlL015mECuTqQO6VmTnA_6_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">33000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:LeaseCost
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_id_5qfFj_kSKM8mT8BAVuA_7_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">189000</us-gaap:LeaseCost>
    <ibio:FinancingCashFlowsFromFinanceLeaseObligation
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_7A9J8k72I02YgR-4jbgOOA_12_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">144000</ibio:FinancingCashFlowsFromFinanceLeaseObligation>
    <ibio:ScheduleOfFinanceLeaseRightOfUseAssetsAndObligationAndWeightedAverageInformationTableTextBlock
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_PKRUVgdyvkCPffEBu_ESGA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</ibio:ScheduleOfFinanceLeaseRightOfUseAssetsAndObligationAndWeightedAverageInformationTableTextBlock>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_lZ2wf76nOk2lqd-6ECGkTw_3_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">678000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_K70LcCwwF0WBUZf4DmeNKg_4_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">265000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      id="Tc_A2T_pWSg5EC7IZoPCGZJzA_6_3">P2Y4M2D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="4"
      id="Tc_MdaMg13aREmov-Xx-Jz8Ng_7_3"
      unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg">0.0950</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb__4z9wyJVvU29zPpfOzqoIw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Future minimum payments under the finance lease obligation are as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fiscal period ending on March 31:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Principal&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Interest&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 265&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 54&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 319&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 292&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 28&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 320&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 130&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 133&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 687&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 85&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 772&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (265)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Long-term portion of minimum lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 422&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:65.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_3_31_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_Q7qov9TaRUq6PVlJRwP10w"
      decimals="-3"
      id="Tc_D0UCSQb2ZUWNNgFDwff04w_2_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">265000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_3_31_2023_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_ELLu56FrAUeDrqmkxHQWOw"
      decimals="-3"
      id="Tc_Q_yEt2gfUEGJLnqZMzEA2w_2_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">54000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_kt_KNPWmIUSg6WoSr9Wmlg_2_9"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">319000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_3_31_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_Q7qov9TaRUq6PVlJRwP10w"
      decimals="-3"
      id="Tc_HAeS69HCI0yC5JqeaA9yXg_3_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">292000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_3_31_2023_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_ELLu56FrAUeDrqmkxHQWOw"
      decimals="-3"
      id="Tc_wcGHaXS4YEiYK1fU6ZD5Cw_3_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">28000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_H8v6lhCL4UaieSj2GtJPRA_3_9"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">320000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_3_31_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_Q7qov9TaRUq6PVlJRwP10w"
      decimals="-3"
      id="Tc_saiMO_xSZUmBAxl3zJgBpA_4_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">130000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_3_31_2023_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_ELLu56FrAUeDrqmkxHQWOw"
      decimals="-3"
      id="Tc_MulEN7xmRUipgd4VX3dUVQ_4_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">3000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_nJ57tnhebk-qjkOr28U7tw_4_9"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">133000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="As_Of_3_31_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_Q7qov9TaRUq6PVlJRwP10w"
      decimals="-3"
      id="Tc_52oIY6b-r0GnQDOhPtmHSg_6_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">687000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="As_Of_3_31_2023_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_ELLu56FrAUeDrqmkxHQWOw"
      decimals="-3"
      id="Tc_XuOmy2P1fUK0F-jyBdRgDQ_6_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">85000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_lQvoaMc3IUmExWHFJr2DTw_6_9"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">772000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="As_Of_3_31_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_Q7qov9TaRUq6PVlJRwP10w"
      decimals="-3"
      id="Tc_h5MzqZ4F_k2Q4-10kMj9vg_7_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">265000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="As_Of_3_31_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_Q7qov9TaRUq6PVlJRwP10w"
      decimals="-3"
      id="Tc_221yWiw8r0Wb6LuJ86GEbw_8_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">422000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_4FruKkOrYkKh_FrP_hF0wA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;15.&#160;&#160;&#160;Operating Lease Obligations&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Texas Ground Lease&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As discussed above, as part of the Transaction, iBio CDMO became the tenant under the Ground Lease Agreement for the Property until 2060 upon exercise of available extensions. The base rent payable under the Ground Lease Agreement, which was $151,450 for the prior year, is 6.5% of the Fair Market Value (as defined in the Ground Lease Agreement) of the Property. The Ground Lease Agreement includes various covenants, indemnities, defaults, termination rights, and other provisions customary for lease transactions of this nature.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;San Diego&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;"&gt;On September 10, 2021, the Company entered into a lease for approximately 11,383 square feet of space in San Diego, California. &#160;Terms of the lease include the following: &lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:14pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The length of term of the lease is &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;88 months&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; from the lease commencement date (as defined).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The lease commencement date was estimated to be on or around January 1, 2022.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The monthly rent for the first year of the lease is &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$51,223&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; and increases approximately &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;3%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; per year.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The lease provides for a base rent abatement for months &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_fzpg5j2sZU2ExYr4_xtclw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; through &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_JKyPk5I8s0q_VC6f1fzo2Q;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;five&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; in the first year of the lease.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The landlord is providing a tenant improvement allowance of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$81,860&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; to be used for improvements as specified in the lease.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The Company is responsible for other expenses such as electric, janitorial, etc.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The Company opened an irrevocable letter of credit in the amount of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$188,844&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; in favor of the landlord. &#160;The letter of credit expires on October 8, 2023 and renews annually as required.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As discussed above, the lease provides for scheduled increases in base rent and scheduled rent abatements. Rent expense is charged to operations using the straight-line method over the term of the lease which results in rent expense being charged to operations at inception of the lease in excess of required lease payments. This excess (formerly classified as deferred rent) is shown as a reduction of the operating lease ROU asset in the accompanying balance sheet. &#160;As the Company has already started making improvements to the facility, the rent expense will be recognized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following tables present the components of lease expense and supplemental balance sheet information related to the operating lease obligation (in thousands).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease cost:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 141&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 141&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 141&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 141&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other information:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash paid for amounts included in the measurement lease liability:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Operating cash flows from operating lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 141&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 141&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Operating cash flows from operating lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 103&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease cost:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 422&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 313&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 422&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 313&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other information:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash paid for amounts included in the measurement lease liability:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Operating cash flows from operating lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 422&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 313&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Operating cash flows from operating lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 154&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Future minimum payments under the operating lease obligation are as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fiscal period ending on December&#160;31:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Principal&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Imputed Interest&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 377&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 249&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 626&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 424&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 220&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 644&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 476&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 188&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 664&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 532&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 151&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 683&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 593&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 111&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 704&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,200&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 82&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,282&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 3,602&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,001&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 4,603&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (377)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Long-term portion of minimum lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 3,225&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <ibio:LesseeOperatingLeaseMonthlyRent
      contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_0-dXyj2LIE2MJCZBHgv0hw"
      decimals="0"
      id="Narr_hexVf_8etUe4a4O0r-CWuA"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">151450</ibio:LesseeOperatingLeaseMonthlyRent>
    <ibio:BaseRentPercentageOfFairMarketValueOfProperty
      contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_0-dXyj2LIE2MJCZBHgv0hw"
      decimals="3"
      id="Narr_iBsKxPpld0C9gBlYcATSlA"
      unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg">0.065</ibio:BaseRentPercentageOfFairMarketValueOfProperty>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="As_Of_9_10_2021_fOp8nNM7xESd6X0-jbcuDQ"
      decimals="0"
      id="Narr_ESwvanexM0uDPvfOtlaKDg"
      unitRef="Unit_Standard_sqft_3kWp_fWhaEWbENPWsKzOnw">11383</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="As_Of_9_10_2021_fOp8nNM7xESd6X0-jbcuDQ"
      id="Narr_hctCYZ27JEmg_oNBRnY3YQ">P88M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <ibio:LesseeOperatingLeaseMonthlyRent
      contextRef="Duration_9_10_2021_To_9_10_2021_nXnIcEGZ8UGqkU29lvwVJQ"
      decimals="0"
      id="Narr_tFJIA75J5kOF5Tc-Dc_r-g"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">51223</ibio:LesseeOperatingLeaseMonthlyRent>
    <ibio:LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent
      contextRef="Duration_9_10_2021_To_9_10_2021_nXnIcEGZ8UGqkU29lvwVJQ"
      decimals="2"
      id="Narr_pwzJpv-GUUufLrU8GhfZVQ"
      unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg">0.03</ibio:LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent>
    <us-gaap:TenantImprovements
      contextRef="As_Of_9_10_2021_fOp8nNM7xESd6X0-jbcuDQ"
      decimals="0"
      id="Narr_Q1q5uqu9AkufnjDkhL2Pfg"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">81860</us-gaap:TenantImprovements>
    <us-gaap:GuaranteeObligationsMaximumExposure
      contextRef="As_Of_9_10_2021_us-gaap_GuaranteeObligationsByNatureAxis_us-gaap_FinancialStandbyLetterOfCreditMember_KIF7AjbiKESPVs3YPPPkKQ"
      decimals="0"
      id="Narr_bWZtxsCAP0utvWtsp297bQ"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">188844</us-gaap:GuaranteeObligationsMaximumExposure>
    <ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_MSo5llzMu0ObY48RKasMOA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following tables present the components of lease expense and supplemental balance sheet information related to the operating lease obligation (in thousands).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease cost:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 141&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 141&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 141&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 141&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other information:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash paid for amounts included in the measurement lease liability:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Operating cash flows from operating lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 141&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 141&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Operating cash flows from operating lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 103&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease cost:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 422&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 313&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 422&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 313&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other information:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash paid for amounts included in the measurement lease liability:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Operating cash flows from operating lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 422&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 313&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Operating cash flows from operating lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 154&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Tc_rSD0SXh9-EWiKbzVbYWnYg_4_2"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">141000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="-3"
      id="Tc__peCmcUscEWjhBOWu9qtGg_4_5"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">141000</us-gaap:OperatingLeaseCost>
    <ibio:TotalOperatingLeaseCosts
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Tc_ME-SQiAVpU62kh46EDGTUQ_5_2"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">141000</ibio:TotalOperatingLeaseCosts>
    <ibio:TotalOperatingLeaseCosts
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="-3"
      id="Tc_ChtO1kPlEk2t83I-IzFzBg_5_5"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">141000</ibio:TotalOperatingLeaseCosts>
    <ibio:OperatingCashFlowsFromOperatingLeaseObligation
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Tc_oGOSYYXv00OQqZGKCdJQkw_10_2"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">103000</ibio:OperatingCashFlowsFromOperatingLeaseObligation>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_Gml3MSjWQE-ztk6sVU5tlg_16_2"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">422000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_qpCEx-vwy02U_fjCVKT6qQ_16_5"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">313000</us-gaap:OperatingLeaseCost>
    <ibio:TotalOperatingLeaseCosts
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_IfvwFib4qEayE1fIQ7E-Ag_17_2"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">422000</ibio:TotalOperatingLeaseCosts>
    <ibio:TotalOperatingLeaseCosts
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_Z0I9wlHXXkKckAT6BCt1og_17_5"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">313000</ibio:TotalOperatingLeaseCosts>
    <ibio:OperatingCashFlowsFromOperatingLeaseObligation
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_ir5a-q8FmU2v_mSbccaniQ_22_2"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">154000</ibio:OperatingCashFlowsFromOperatingLeaseObligation>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_Bd9JXPMWFU6UiRug0OWNfA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Future minimum payments under the operating lease obligation are as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fiscal period ending on December&#160;31:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Principal&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Imputed Interest&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 377&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 249&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 626&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 424&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 220&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 644&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 476&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 188&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 664&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 532&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 151&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 683&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 593&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 111&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 704&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,200&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 82&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,282&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 3,602&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,001&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 4,603&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (377)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Long-term portion of minimum lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 3,225&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_LZPd_PGF3kylVKbzYW4qFQ_2_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">377000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <ibio:LesseeOperatingLeaseImputedInterestToBePaidYearOne
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc__sSaDB4PiEqwmIrkJ6_K8w_2_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">249000</ibio:LesseeOperatingLeaseImputedInterestToBePaidYearOne>
    <ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_SDgPe1zRn061O5V4vr-Kqg_2_9"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">626000</ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_aPKNd8yR00WcBRZ_lcSZjQ_3_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">424000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <ibio:LesseeOperatingLeaseImputedInterestToBePaidYearTwo
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_2ZFTu9WYGkyEFzd_ZKhU-g_3_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">220000</ibio:LesseeOperatingLeaseImputedInterestToBePaidYearTwo>
    <ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_eBTYeX1odUiE8Xk4KeORfA_3_9"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">644000</ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_yykC0QNx-kuwQnCo7X9jIQ_4_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">476000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <ibio:LesseeOperatingLeaseImputedInterestToBePaidYearThree
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_AwI3CGIulUOaih78T4kzIA_4_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">188000</ibio:LesseeOperatingLeaseImputedInterestToBePaidYearThree>
    <ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_K6U1QRmEFkCYz3HKDxS4VA_4_9"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">664000</ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_49HELDPt_UOdIS4iYsqbdw_5_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">532000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <ibio:LesseeOperatingLeaseImputedInterestToBePaidYearFour
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_EekqHlKgvU2endLujYQReA_5_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">151000</ibio:LesseeOperatingLeaseImputedInterestToBePaidYearFour>
    <ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_2dZhyU3gIEWLXLigVywHvQ_5_9"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">683000</ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_U292ARCeHEWXDcP8NIXbzw_6_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">593000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <ibio:LesseeOperatingLeaseImputedInterestToBePaidYearFive
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_iRuSTDYNRkmdB6IgeA5klQ_6_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">111000</ibio:LesseeOperatingLeaseImputedInterestToBePaidYearFive>
    <ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_vcdTjkV5pUOqcx0UHX822w_6_9"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">704000</ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_UgXXLvX7EECkaYO39rg0Ow_7_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1200000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <ibio:LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_zthvIJ5N3kWoe85DOkuR0Q_7_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">82000</ibio:LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive>
    <ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_hZ-Te9Qdwk-1EZX00aUM-Q_7_9"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1282000</ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_Inm78xIa-06a5ZDxlAHWPQ_9_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">3602000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <ibio:LesseeOperatingLeaseImputedInterestToBePaidTotal
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_5O4tvu8hSE--xoXOuRHttw_9_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1001000</ibio:LesseeOperatingLeaseImputedInterestToBePaidTotal>
    <ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_MuNtJjg0kkqW2yOD1ev0dg_9_9"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">4603000</ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_rZItyn40KkurpnECMmI5Wg_10_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">377000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-3"
      id="Tc_vcZ7zFjzn0-IxopJyO3n7g_11_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">3225000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_loV9x29FtEyJx_azkAKJ0g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;16.&#160;&#160;&#160;Stockholders&#x2019; Equity&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Preferred Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s Board is authorized to issue, at any time, without further stockholder approval, up to 1 million shares of preferred stock. The Board has the authority to fix and determine the voting rights, rights of redemption and other rights and preferences of preferred stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Series 2022 Convertible Preferred Stock (&#x201c;Series 2022 Preferred&#x201d;)&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On May 9, 2022, the Board of the Company created the Series 2022 Preferred, par value $0.001 per share, out of the Company&#x2019;s 1 million authorized shares of preferred stock. &#160;Each share of Series 2022 Preferred was convertible at a ratio of one-for-one (1:1) shares of the Common Stock on a pre-split basis.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company issued 1,000 shares of Series 2022 Preferred and received proceeds of $270. &#160;Pursuant to the terms of the preferred stock, the Company&#x2019;s Board converted the Preferred Stock to 40 shares of Common Stock on July 19, 2022, on a post-split basis.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;iBio CMO Preferred Tracking Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On February 23, 2017, the Company entered into an exchange agreement with Bryan Capital pursuant to which the Company acquired substantially all of the interest in iBio CDMO held by Bryan Capital and issued one share of a newly created Preferred Tracking Stock, in exchange for 29,990,000 units of limited liability company interests of iBio CDMO held by Bryan Capital at an original issue price of $13 million. After giving effect to the transaction, the Company owned 99.99% and Bryan Capital owned 0.01% of iBio CDMO.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On February 23, 2017, the Board of the Company created the Preferred Tracking Stock out of the Company&#x2019;s 1 million authorized shares of preferred stock. The Preferred Tracking Stock accrued dividends at the rate of 2% per annum on the original issue price. Accrued dividends were cumulative and were payable if and when declared by the Board, upon an exchange of the shares of Preferred Tracking Stock and upon a liquidation, winding up or deemed liquidation (such as a merger) of the Company. No dividends were declared through October 31, 2021. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On November 1, 2021, iBio purchased the iBio CMO Preferred Tracking Stock held by Bryan Capital. No iBio CMO Preferred Tracking Stock remains outstanding. As a result, the iBio CDMO subsidiary and its intellectual property are now wholly owned by iBio.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Common Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The number of authorized shares of the Common Stock is 275 million. In addition, the Company has reserved 1,280,000 shares of Common Stock for issuance pursuant to the grant of new awards under the Company&#x2019;s 2020 Omnibus Incentive Plan (the &#x201c;2020 Plan&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Reverse Stock Split&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On June 30, 2022, the Company held a special meeting of its stockholders at which the stockholders approved a proposal to affect an amendment to the Company's certificate of incorporation, as amended, to implement a reverse stock split at a ratio of &lt;span style="-sec-ix-hidden:Hidden_L9F1YPW0H0e_OcCFkVLlag;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt;-for-twenty-five (1:25). On September 22, 2022, the Company's Board approved the implementation of the reverse stock split of the Common Stock. As a result of the reverse stock split, every twenty-five (25) shares of the Common Stock either issued and outstanding or held by the Company in its treasury immediately prior to the effective time was, automatically and without any action on the part of the respective holders thereof, combined and converted into one (1) share of the Common Stock. No fractional shares were issued in connection with the reverse stock split. Stockholders who otherwise were entitled to receive a fractional share in connection with the reverse stock split instead were eligible to receive a cash payment, which was not material in the aggregate, instead of shares. On October 7, 2022, the Company filed a Certificate of Amendment of its Certificate of Incorporation, as amended with the Secretary of State of Delaware effecting a &lt;span style="-sec-ix-hidden:Hidden_QTQry_EgBE-Zf0eAMcyRBw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt;-for-twenty-five (1:25) reverse stock split of the shares of the Common Stock, either issued or outstanding, effective October 7, 2022. The Common Stock began trading on a reverse split adjusted basis when the market opened Monday, October 10, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Recent issuances of Common Stock include the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Cantor Fitzgerald Underwriting&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On November 25, 2020, the Company entered into a Controlled Equity Offering SM Sales Agreement (the &#x201c;Sales Agreement&#x201d;) with Cantor Fitzgerald &amp;amp; Co. ("Cantor Fitzgerald") to sell shares of Common Stock, from time to time, through an &#x201c;at the market offering&#x201d; program having an aggregate offering price of up to $100,000,000 through which Cantor Fitzgerald would act as sales agent. &#160;Between July 25, 2022, and March 31, 2023, Cantor Fitzgerald sold as sales agent pursuant to the Sales Agreement 1,551,879 shares of Common Stock. The Company received net proceeds of approximately $2.9 million during the nine months ended March 31, 2023 and holds a subscription receivable for $260,000 at March 31, 2023 for proceeds received on April 4, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;RubrYc Transaction&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On September 19, 2022, the Company issued 102,354 shares valued at approximately $1,000,000 to RubrYc as part of the payment for purchasing the assets of RubrYc.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Wainwright Underwriting&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;background:#ffff00;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On December 6, 2022, the Company entered into an underwriting agreement (the &#x201c;Underwriting Agreement&#x201d;) with H.C. Wainwright &amp;amp; Co., LLC (&#x201c;Wainwright&#x201d;). Pursuant to the Underwriting Agreement, the Company agreed to sell to Wainwright, in a firm commitment underwritten offering (the &#x201c;Offering&#x201d;) (i) 1,530,769 shares of the Company&#x2019;s Common Stock, (ii) pre-funded warrants (the &#x201c;Pre-Funded Warrants&#x201d;) to purchase up to 1,834,616 shares of Common Stock, (iii) Series A Common Stock purchase warrants (the &#x201c;Series A Warrants&#x201d;) to purchase up to 3,365,385 shares of Common Stock and (iv) Series B Common Stock purchase warrants (the &#x201c;Series B Warrants&#x201d; and together with the Series A Warrants, the &#x201c;Common Warrants&#x201d;) to purchase up to 3,365,385 shares of Common Stock. &#160;The offering closed on December 9, 2022. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Wainwright acted as the sole book-running manager for the Offering. The Company paid Wainwright an underwriting discount equal to 7.0% of the gross proceeds of the offering, and reimbursed Wainwright for the legal fees and certain expenses of the underwriter. &#160;Pursuant to the Underwriting Agreement, the Company has granted Wainwright a 30-day option to purchase up to an additional 504,807 shares of Common Stock and/or Common Warrants to purchase up to an additional 1,009,614 shares of Common Stock at the public offering price, less the underwriting discounts and commissions, solely to cover over-allotments. Wainwright elected to purchase 504,807 Series A Warrants and 504,807 Series B Warrants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company has also agreed to issue to Wainwright, as the representative of the underwriters, warrants (the &#x201c;Representative&#x2019;s Warrants&#x201d;) to purchase a number of shares of Common Stock equal to 6.0% of the aggregate number of shares of Common Stock and Pre-Funded Warrants being offered in the offering. Wainwright received warrants to purchase up to 201,923 shares of Common Stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company received net proceeds of approximately $2,864,000 after deducting underwriting discounts, commissions and other issuance costs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Vesting of Restricted Stock Units &#x201c;RSUs&#x201d;&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On August 23, 2022, RSUs for 1,057 shares of Common Stock were vested. On December 1, 2022, RSUs for 4,120 shares of Common Stock were vested. &#160;In addition, RSUs for 27,740 of Common Stock vested during the third quarter of Fiscal 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Warrants&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Bryan Capital &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt; &lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;As discussed above, the Company issued to Bryan Capital a Warrant to purchase 51,583 shares of the Common Stock of the Company at an exercise price of $33.25 per share. The Warrant expires October 10, 2026, is exercisable immediately, provides for a cashless exercise at any time and automatic cashless exercise on the expiration date if on such date the exercise price of the Warrant exceeds its fair market value as determined in accordance with the terms of the Warrant and adjustments in the case of stock dividends and stock splits.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Wainwright&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt; &lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;As discussed above, the Company issued various warrants with the following terms:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;1.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Pre-Funded Warrants &#x2013; Immediately exercisable at an exercise price of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$0.001&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; per share. &#160;All of the Pre-Funded Warrants were exercised in December 2022.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;2.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Class A Warrants &#x2013; Immediately exercisable at an exercise price of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$1.04&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; per share for a term of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;five years&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;3.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Class B Warrants &#x2013; Immediately exercisable at an exercise price of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$1.04&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; per share for a term of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;two years&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;4.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Representative Warrants &#x2013; Immediately exercisable at an exercise price of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$1.30&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; per share for a term of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;five years&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;During the third quarter of Fiscal 2023, 341,300 Class A Warrants and 1,704,916 Class B Warrants were exercised. &#160;On April 3, 2023, an additional 76,300 Class B Warrants were exercised. &#160;The total proceeds from Class A and B Warrants exercised during the third quarter of Fiscal 2023 and on April 3, 2023 were $2,207,000.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-6"
      id="Narr_9i9VV6pF7kq3Kctbf0-Sug"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_5_9_2022_vsP8EMdp9kqoJCsGc37KdQ"
      decimals="INF"
      id="Narr_GIw5xluf0Ue_k5DQ_V4PKQ"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_5_9_2022_vsP8EMdp9kqoJCsGc37KdQ"
      decimals="-6"
      id="Narr_gmdXwquc4keoie0kuef9uQ"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_5_9_2022_To_5_9_2022_us-gaap_StatementClassOfStockAxis_ibio_Series2022ConvertiblePreferredStockMember_IRKi-LuHkUq15KpdZkL8TA"
      decimals="0"
      id="Narr_2KjXBoiT7k6cw2YYecJcNA"
      unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg">1</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_5_9_2022_To_5_9_2022_us-gaap_StatementClassOfStockAxis_ibio_Series2022ConvertiblePreferredStockMember_IRKi-LuHkUq15KpdZkL8TA"
      decimals="INF"
      id="Narr_0tfQ5g_BSUmVRIDSBe6_mw"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">1000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_5_9_2022_To_5_9_2022_us-gaap_StatementClassOfStockAxis_ibio_Series2022ConvertiblePreferredStockMember_IRKi-LuHkUq15KpdZkL8TA"
      decimals="0"
      id="Narr_F_GTJgT2nUSX80LULqpjGA"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">270</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="As_Of_7_19_2022_us-gaap_StatementClassOfStockAxis_ibio_Series2022ConvertiblePreferredStockMember_qeFYBi3PAUWnjNGHYNci7Q"
      decimals="INF"
      id="Narr_GPCXa8UxFEyqSii9wjmHzQ"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">40</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="Duration_2_23_2017_To_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_oc0tqqFKsk-LEKQxwyeAOw"
      decimals="INF"
      id="Narr_fob72mPae0qRrsGQZNXP9Q"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">1</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <ibio:NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock
      contextRef="Duration_2_23_2017_To_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_oc0tqqFKsk-LEKQxwyeAOw"
      decimals="INF"
      id="Narr_qklJg84qa0Wd8DEGwTdWBA"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">29990000</ibio:NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_2_23_2017_To_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_oc0tqqFKsk-LEKQxwyeAOw"
      decimals="-6"
      id="Narr_zaSPK_9O1k2JQxhPE2MkgQ"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">13000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="As_Of_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_srt_StatementScenarioAxis_ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_1x-cfjUThkKbcg8PyPRDEg"
      decimals="4"
      id="Narr_RSJVANoWF0SD6lFBp8SrCA"
      unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg">0.9999</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="As_Of_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_srt_StatementScenarioAxis_ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ibio_EasternAffiliateMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_qFx6baRFl0K1AnDbITGYjg"
      decimals="4"
      id="Narr_yJJPB7Ei_0KYEleNz24_4g"
      unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg">0.0001</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_2_23_2017_lMLzTmFjFUeEaGVOB1WIPA"
      decimals="-6"
      id="Narr_VPaQc1_aUUq1ZBGMCIPmmA"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="Duration_2_23_2017_To_2_23_2017_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_hlhl6dJdp0if7Q1n3P67xA"
      decimals="2"
      id="Narr_D6u7FMk_-ka86-2PeXuSkw"
      unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg">0.02</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockDividendsPerShareDeclared
      contextRef="Duration_10_31_2021_To_10_31_2021_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_47o5yRKDNE6T9LQPWz8erA"
      decimals="INF"
      id="Narr_dwbDH7vudE6QbxEcysrbEA"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">0</us-gaap:PreferredStockDividendsPerShareDeclared>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_11_1_2021_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_Nh5Sltvg50S1MDQaPh-wrw"
      decimals="INF"
      id="Narr_yr6g1TC1q0yXaaAChy64yw"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg"
      decimals="-6"
      id="Narr_kfLYRjfMsUKgvDDa2R64hQ"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">275000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_3_31_2023_us-gaap_PlanNameAxis_ibio_OmnibusIncentivePlanMember_KOZgQdvqsU-8te5q0_AgpA"
      decimals="INF"
      id="Narr_AeUkr_RI4Eqbd6QcDtCU-g"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">1280000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <ibio:AggregateCommonStockPurchased
      contextRef="As_Of_11_25_2020_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_R42dgLYX1k2Ix5l9AuMByA"
      decimals="0"
      id="Narr_xdPINAI6NkKJlzPBkmEgGQ"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">100000000</ibio:AggregateCommonStockPurchased>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="Duration_7_25_2022_To_8_17_2022_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_ggLswlBXtkqHIYFVDHZ-Zg"
      decimals="INF"
      id="Narr_rhZQCatEh0OtATyVjThQhg"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">1551879</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_7_25_2022_To_8_17_2022_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_ggLswlBXtkqHIYFVDHZ-Zg"
      decimals="-5"
      id="Narr_DAOTiRlO0kCs8LUewOuBJQ"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">2900000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="Duration_9_19_2022_To_9_19_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_wXZQoYO-rEO6uGxtBLB7Ag"
      decimals="INF"
      id="Narr_l87vlbKHxUyocHNadFC8Cw"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">102354</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_9_19_2022_To_9_19_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_wXZQoYO-rEO6uGxtBLB7Ag"
      decimals="0"
      id="Narr_2x_xAp8J_Uy16xOdLEq_Og"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_12_6_2022_To_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_KH2r3-L2ZEmEEfMT1ZNKKw"
      decimals="INF"
      id="Narr_IYolcbaWj0KAzUIGbGXmaA"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">1530769</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_InpkTkfz_02nABMpU6azWQ"
      decimals="INF"
      id="Narr_FklHTk98D0y3-4a0bBvZGg"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">1834616</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_J-u4uOUfG0ORoIm4jvgctQ"
      decimals="INF"
      id="Narr_F_xkh3b4cUuoMJagkKPr5w"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">3365385</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_cBAtqPpEJUqEJd0c0GaR7w"
      decimals="INF"
      id="Narr_XT_XaaZm7UOnKLdpmoj-9Q"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">3365385</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <ibio:PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering
      contextRef="Duration_12_6_2022_To_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_sbC4xz-l302ta9iq3YNsng"
      decimals="3"
      id="Narr_sHJFjA2fU0aKizQcrvJSEQ"
      unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg">0.070</ibio:PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering>
    <ibio:NumberOfDaysOptionToPurchaseAdditionalShares
      contextRef="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_t_boUVr6WkyudoVlOiImcQ"
      decimals="INF"
      id="Narr_WehFIvXP3Ey6KYU8IG99ug"
      unitRef="Unit_Standard_D_NZPLSJv9m0GC4_X7zPjKmg">30</ibio:NumberOfDaysOptionToPurchaseAdditionalShares>
    <ibio:NumberOfAdditionalSharesIssued
      contextRef="Duration_12_6_2022_To_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_sbC4xz-l302ta9iq3YNsng"
      decimals="INF"
      id="Narr_71YaRJSkCk6rl16z_SdJMQ"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">504807</ibio:NumberOfAdditionalSharesIssued>
    <ibio:CommonWarrantsToPurchaseAdditionalShares
      contextRef="Duration_12_6_2022_To_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_sbC4xz-l302ta9iq3YNsng"
      decimals="INF"
      id="Narr_pMKZ9Uw5AUqR_N4jecmmnQ"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">1009614</ibio:CommonWarrantsToPurchaseAdditionalShares>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_A4kvDn5x20q7_8fIvjOF-g"
      decimals="INF"
      id="Narr_kC3Wn3vdFUONp8wJkeQmPg"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">504807</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_BCjemMCehUOFvWDV-Z5NgA"
      decimals="INF"
      id="Narr_RgYzDgBVIk-LgBjMqnDO5g"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">504807</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <ibio:PercentageOfAggregateNumberOfSharesOfCommonStock
      contextRef="Duration_12_6_2022_To_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_sbC4xz-l302ta9iq3YNsng"
      decimals="3"
      id="Narr_Y5KuARgib0iRtalxW3sUUg"
      unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg">0.060</ibio:PercentageOfAggregateNumberOfSharesOfCommonStock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_t_boUVr6WkyudoVlOiImcQ"
      decimals="INF"
      id="Narr_lRtDPabCp0SniP2x0VvoLw"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">201923</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="Duration_12_6_2022_To_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_sbC4xz-l302ta9iq3YNsng"
      decimals="0"
      id="Narr_vxg1YmiXmUandO8TNmnw4Q"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">2864000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_8_23_2022_To_8_23_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_lmnxjWAiuES8yulA3DkvLA"
      decimals="INF"
      id="Narr_m7pNGF3dzkGi9dFIRCS90w"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">1057</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_12_1_2022_To_12_1_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_hQgfyxu2uUOmIRU8B4Fklw"
      decimals="INF"
      id="Narr_xjuK8UcN8k-puL1U4_ChOQ"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">4120</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_p-vKhEHGAUG72E1kGh9gmg"
      decimals="INF"
      id="Narr_7HX1cxRmB0OeO4Ou9dbhQA"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">51583</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_p-vKhEHGAUG72E1kGh9gmg"
      decimals="2"
      id="Narr_7Tabihv1HkOJKPb8uczZ_A"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">33.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_31_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_PreFundedWarrantsMember_AmjIXMsiE020WBD4cpXPjg"
      decimals="3"
      id="Narr_BS7l0T1UnkWJ7PMFT_W4_w"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_31_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_nMTFluJjHUGsVU2uJ_O6bQ"
      decimals="2"
      id="Narr_o-2KTPyYIEmtHYDjVk5QDw"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">1.04</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_3_31_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_nMTFluJjHUGsVU2uJ_O6bQ"
      id="Narr_9Zac9cb3vEC3yjGa-34Smg">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_31_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_MA5Y7fHH4E6vZRFVAPWBvA"
      decimals="2"
      id="Narr_xFRdUBF3TUStkCKmcJ_rPQ"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">1.04</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_3_31_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_MA5Y7fHH4E6vZRFVAPWBvA"
      id="Narr_io3MZFnexkiTo45E9NuJ3g">P2Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_31_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_RepresentativeWarrantsMember_L0HxhOr8_0eWqjfa9gKftw"
      decimals="2"
      id="Narr_DSNqOUOU1EK6G0HApVcRpQ"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">1.30</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_3_31_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_RepresentativeWarrantsMember_L0HxhOr8_0eWqjfa9gKftw"
      id="Narr_GXfBT0qO_EO_3H7LZnJx8Q">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_Fb7R_KTVVU2ZCgrio0GBBw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;17.&#160;&#160;&#160;Earnings (Loss) Per Common Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Basic earnings (loss) per common share is computed by dividing the net income (loss) allocated to common stockholders by the weighted-average number of shares of Common Stock outstanding during the period. For purposes of calculating diluted earnings (loss) per common share, the denominator includes both the weighted-average number of shares of Common Stock outstanding during the period and the number of common stock equivalents if the inclusion of such common stock equivalents is dilutive. Dilutive common stock equivalents potentially include stock options and warrants using the treasury stock method. The following table summarizes the components of the earnings (loss) per common share calculation (in thousands, except per share amounts):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Basic and diluted numerator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss attributable to iBio, Inc. from continuing operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,279)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,746)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (24,379)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (19,125)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Preferred stock dividends &#x2013; iBio CMO Preferred Tracking Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (88)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss available to iBio, Inc. stockholders from continuing operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,279)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,746)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (24,379)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (19,213)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss available to iBio, Inc. stockholders from discontinued operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,015)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,644)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (34,598)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (14,124)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss available to iBio, Inc. stockholders - total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,294)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (12,390)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (58,977)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (33,337)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Basic and diluted denominator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-average common shares outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 13,184&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 8,719&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 10,592&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 8,719&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Per share amount - continuing operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_wjVHAja0hk-ujBowM-xKHQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.47)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_yQjZFWrye0SmP2jIiPGrBA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.77)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_-JF8WUqQSkmfxC0R_OaSQA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2.30)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_PwsJbaSoOUORrCdM232mAA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2.20)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Per share amount - discontinued operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_9HqUV2MAckqjZOnis6YfZg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.08)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_U0bOGUWDzkuEeJ29Nf_EjQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.65)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_TmWH34FMsECu90mrUdyfXg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3.27)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_kDRlUx8GmUabgAhq5k_vvQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.62)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Per share amount - total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_Zp0MkR-0tUq910UPmXzGpA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.55)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_acVcgEcpAUW-LaSF7a3TxQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.42)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_wBTFuchxW0eQbgh0co0GoQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5.57)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_tJo2ezbm1Eau_et1XorUuA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3.82)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In Fiscal year 2023 and Fiscal year 2022, the Company incurred net losses which cannot be diluted; therefore, basic and diluted loss per common share is the same. As of March&#160;31,&#160;2023 and 2022, shares issuable which could potentially dilute future earnings were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="5" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 457&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 625&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 443&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 22&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 5,948&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 52&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Shares excluded from the calculation of diluted loss per share&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 6,848&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 699&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_GOEnFK17Vkm0o6xMm9Mhig">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Basic and diluted numerator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss attributable to iBio, Inc. from continuing operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,279)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,746)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (24,379)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (19,125)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Preferred stock dividends &#x2013; iBio CMO Preferred Tracking Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (88)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss available to iBio, Inc. stockholders from continuing operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,279)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,746)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (24,379)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (19,213)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss available to iBio, Inc. stockholders from discontinued operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,015)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,644)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (34,598)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (14,124)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss available to iBio, Inc. stockholders - total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,294)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (12,390)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (58,977)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (33,337)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Basic and diluted denominator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-average common shares outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 13,184&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 8,719&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 10,592&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 8,719&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:55.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Per share amount - continuing operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_wjVHAja0hk-ujBowM-xKHQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.47)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_yQjZFWrye0SmP2jIiPGrBA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.77)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_-JF8WUqQSkmfxC0R_OaSQA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2.30)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_PwsJbaSoOUORrCdM232mAA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2.20)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Per share amount - discontinued operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_9HqUV2MAckqjZOnis6YfZg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.08)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_U0bOGUWDzkuEeJ29Nf_EjQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.65)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_TmWH34FMsECu90mrUdyfXg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3.27)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_kDRlUx8GmUabgAhq5k_vvQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.62)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Per share amount - total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_Zp0MkR-0tUq910UPmXzGpA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.55)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_acVcgEcpAUW-LaSF7a3TxQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.42)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_wBTFuchxW0eQbgh0co0GoQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5.57)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_tJo2ezbm1Eau_et1XorUuA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3.82)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Tc_hzVmml4HYESwaYILa0wC3Q_6_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-6279000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="-3"
      id="Tc_-n2mFY4t8UaLSt05w02FQQ_6_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-6746000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_5RheRb5Jk0Guw6NDAs0FvA_6_9"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-24379000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_5bmaJJiR6kCOjd0GsiqvnA_6_12"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-19125000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:DividendsPreferredStockStock
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_7bKjXxcsWEiAn5YUSlY0-g_7_9"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">0</us-gaap:DividendsPreferredStockStock>
    <us-gaap:DividendsPreferredStockStock
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_Yw6kWRvqj062X5TDoi8FNQ_7_12"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">88000</us-gaap:DividendsPreferredStockStock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Tc_eq_NG0pTqk2fzjcbhynN7g_8_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-6279000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="-3"
      id="Tc_OVVQ0QqRbk6RoxZ6IKbZcw_8_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-6746000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_cI2y7cxPck2jKe_Z2nOgXw_8_9"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-24379000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_WlbLXj1kq0CiA449_iKktw_8_12"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-19213000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Tc_qdn-WhX9KkeuMBRAK4fYAw_10_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-1015000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="-3"
      id="Tc_qj_JDBLdM0q-3evr4D9Z2A_10_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-5644000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc__yTeiC9ZC0uzgDC2xzRiiA_10_9"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-34598000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_yprmAT0-YUK57VFsrkDCcw_10_12"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-14124000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <ibio:UnconsolidatedGainLossAttributableToStockholders
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Tc_GvpYuHBdsUGnWyrzvfmYdg_12_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-7294000</ibio:UnconsolidatedGainLossAttributableToStockholders>
    <ibio:UnconsolidatedGainLossAttributableToStockholders
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="-3"
      id="Tc_0teAQDP3tkK6MY4RPr_Ulg_12_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-12390000</ibio:UnconsolidatedGainLossAttributableToStockholders>
    <ibio:UnconsolidatedGainLossAttributableToStockholders
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_1vJsmrMybk-4FdiPTrOIPw_12_9"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-58977000</ibio:UnconsolidatedGainLossAttributableToStockholders>
    <ibio:UnconsolidatedGainLossAttributableToStockholders
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_-tx0-E5b2kalbs8Uyu2Wgw_12_12"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">-33337000</ibio:UnconsolidatedGainLossAttributableToStockholders>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Tc_ayL3huDlXE66wzyy_DgCjw_16_3"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">13184000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="-3"
      id="Tc_9zILRcazVkGWeJCkHOZc1g_16_6"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">8719000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_NaaOtZZfI0mvwrDOY7nBAA_16_9"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">10592000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_H7x__8YIcUySjiGvbbJvzQ_16_12"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">8719000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="2"
      id="Tc_lWWloV0UtkyBfBiiNRSaRg_18_3"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">-0.47</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="2"
      id="Tc_EDGauNFFBkaqU6uAL3d_0A_18_6"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">-0.77</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="2"
      id="Tc_wLQqonYOtE-EAqJ7RAyVXg_18_9"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">-2.30</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="2"
      id="Tc_KzFjCg6hoUSzoZZHMJcbYQ_18_12"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">-2.20</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="2"
      id="Tc_Mmee8DqHxUS55T7RRwXHgA_19_3"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">-0.08</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="2"
      id="Tc_8zcMN0DjXkOvj_7-hCoRCg_19_6"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">-0.65</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="2"
      id="Tc_GULP1gfMZk2tWGjb_G0FZg_19_9"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">-3.27</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="2"
      id="Tc_s8roW3CkL0uKtNusmA2L2g_19_12"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">-1.62</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="2"
      id="Tc_CC1jkLFcB0WipDJMD-8N6Q_20_3"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">-0.55</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="2"
      id="Tc_ubyF2mtHpUCD0gqp86cnxA_20_6"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">-1.42</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="2"
      id="Tc_hAcacMq6QUmWewMnshMIwQ_20_9"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">-5.57</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="2"
      id="Tc_S21jD0LPzk2PPdPTEO7EHQ_20_12"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">-3.82</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_rLy__zaz8kixEBQ575DJYw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="5" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 457&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 625&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 443&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 22&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 5,948&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 52&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Shares excluded from the calculation of diluted loss per share&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 6,848&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 699&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_uH1aZ6v5zUW5U0OYeCYCVA"
      decimals="-3"
      id="Tc_FhGoM2nwo06qU1S4gPBRjQ_4_2"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">457000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2021_To_3_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_wGAzW97TrUSXKPZdUccZUQ"
      decimals="-3"
      id="Tc_HFt7PkZSJk6JVQ0TPC4gjA_4_4"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">625000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_gE-bXUQhFkqJyMBuH9S0rQ"
      decimals="-3"
      id="Tc_626QYxhVzUSS-EKoP80GHg_5_2"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">443000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2021_To_3_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_52A2X6mgk0CFvchRmy-_Xw"
      decimals="-3"
      id="Tc_EpqNH86j0UKnnYJymfbN1Q_5_4"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">22000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_-vyQFO66V0-VnP5O63-I_g"
      decimals="-3"
      id="Tc_WF0zSk5jC0COELd5xIAyjg_6_2"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">5948000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2021_To_3_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_zQX7x8UMbk6gJSsI7k7Ecw"
      decimals="-3"
      id="Tc_kE_xkF9ai0uGhsMr2nPXAQ_6_4"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">52000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_VblNbVliK0-SJvrFIqMMXQ_7_2"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">6848000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_kN_eLP3NYEqD5vWP12cwEA_7_4"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">699000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_xvNkkpsGMEeCBidFKktokw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;18.&lt;/b&gt;&#160;&#160;&#160;&lt;b style="font-weight:bold;"&gt;Share-Based Compensation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table summarizes the components of share-based compensation expense in the condensed consolidated statements of operations (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 101&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 345&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,112&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 385&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,213&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 96&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 132&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 2,330&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 2,761&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 2,426&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 2,893&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In addition, share-based compensation expense included in loss from discontinued operations totaled approximately $1,211,000 and $62,000 for the three months ended March&#160;31,&#160;2023 and 2022, respectively, and $1,519,000 and $305,000 for the nine months ended March&#160;31,&#160;2023 and 2022, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Stock Options&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;iBio, Inc. 2020 Omnibus Equity Incentive Plan (the &#x201c;2020 Plan&#x201d;)&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On December 9, 2020, the Company adopted the 2020 Plan for employees, officers, directors and external service providers. The total number of shares of Common Stock reserved under the 2020 Plan is 1,280,000 shares of Common Stock for issuance pursuant to the grant of new awards under the 2020 Plan. The 2020 Plan allows for the award of stock options, stock appreciation rights, restricted stock, restricted stock units, unrestricted stock, cash-based awards, and dividend equivalent rights. The value of all awards awarded under the 2020 Plan and all other cash compensation paid by the Company to any non-employee director in any calendar year may not exceed $500,000; provided, however, that such amount shall be $750,000 for the calendar year in which the applicable non-employee director is initially elected or appointed to the Board and $1,500,000 for any non-executive chair of our Board should one be appointed. Notwithstanding the foregoing, the independent members of the Board may make exceptions to such limits in extraordinary circumstances. The term of the 2020 Plan will expire on the tenth anniversary of the date the Plan is approved by the stockholders.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Vesting of service awards are determined by the Board and stated in the award agreements. In general, vesting occurs ratably on the anniversary of the grant date over the service period, generally &lt;span style="-sec-ix-hidden:Hidden_nzLgsplRfUCEtBruJ2QfKQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;three&lt;/span&gt;&lt;/span&gt; or five years, as determined at the time of grant. Vesting of performance awards occurs when the performance criteria is satisfied. The Company uses historical data to estimate forfeiture rates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Stock options issued&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;During the first quarter of Fiscal year 2023, the Company granted stock option agreements to various employees to purchase 303,869 shares of the Common Stock at exercise prices between $6.75 and $9.50 per share. The options vest 25% after one year and then in equal quarterly installments over a 36-month period and expire on the &lt;span style="-sec-ix-hidden:Hidden_6UlFUOUwakC1Lx6RTBBOdg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;tenth&lt;/span&gt;&lt;/span&gt; anniversary of the grant date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;During the first quarter of Fiscal year 2023, the Company granted a stock option agreement to a consultant to purchase 4,000 shares of the Common Stock at an exercise price of $6.75 per share. The options vest in equal monthly installments, over a period of twelve months, starting after the second month and expire on the &lt;span style="-sec-ix-hidden:Hidden_PqrGwNIVNUKtOSk9GN3hkQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;tenth&lt;/span&gt;&lt;/span&gt; anniversary of the grant date. &#160;During the third quarter of Fiscal year 2023, the Company terminated the consultant&#x2019;s services. &#160;As a result, none of the 4,000 shares pursuant to the stock option agreement were exercised and as such, all 4,000 shares will be forfeited. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;No stock options were granted in the second or third quarter of Fiscal year 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company estimated the fair value of options granted using the Black-Scholes option pricing model with the following assumptions:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;3.21% - 3.61&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;115.52 - 116.93&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;RSUs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On August 29, 2022, the Company issued RSUs to acquire 6,954 shares of common stock to various employees at a market value of $7.06 per share. &#160;The RSUs vest over a four-year period. &#160;The grant date fair value of the RSUs totaled approximately $49,000.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On November 10, 2022, as previously disclosed in relation to the Employment Agreement with Mr. Isett, the Company&#x2019;s former CEO, dated April 30, 2021, the Company granted Mr. Isett RSUs to acquire 200,000 shares of Common Stock, on a post-split basis.&#160; The RSUs vest over a three-year period commencing April 30, 2021 provided the vesting is subject to the following performance conditions: (i) submission to the U.S. Food and Drug Administration (FDA) of an Investigational New Drug (IND) application, or alternatively, if the Board approves not to file an IND, (ii) consummation of a disposition of iBio CDMO, LLC, or (iii) out-licensing, with full global rights, any of its investigational product candidates prior to the submission to the FDA an IND application.&#160; The grant-date fair value of the RSUs totaled approximately $296,000. The performance conditions were not met and the RSUs did not vest.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On November 11, 2022, the Company granted Mr. Robert Lutz, the Company&#x2019;s Chief Financial and Business Officer at the time, RSUs to acquire 100,057 shares of the Company&#x2019;s Common Stock in exchange for Mr. Lutz&#x2019;s agreement to continue employment with the Company through July 1, 2023. &#160;The RSUs vest the earlier of: (i) July 1, 2023, or (ii) the successful achievement of the Company&#x2019;s 2023 objectives, as defined by the Board. The grant-date fair value of the RSUs totaled approximately $175,100. Mr. Lutz resigned from the Company and was no longer an employee of the Company effective February 10, 2023; accordingly, the RSUs did not vest.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On November 11, 2022, the Company granted Dr. Martin Brenner, the Company&#x2019;s Chief Scientific Officer, RSUs to acquire 95,348 shares of the Company&#x2019;s Common Stock in exchange for Mr. Brenner&#x2019;s agreement to continue employment with the Company through July 1, 2023. &#160;The RSUs vest the earlier of: (i) July 1, 2023, or (ii) the successful achievement of the Company&#x2019;s 2023 objectives, as defined by the Board. The grant-date fair value of the RSUs totaled approximately $167,000.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On January 20, 2023, the Board of the Company appointed Dr. Brenner to the position of Interim Chief Executive Officer, effective immediately. Dr. Brenner was granted RSUs to acquire 130,000 shares of the Company&#x2019;s Common Stock, which RSUs shall vest pro rata over a twelve-month period, such vesting to terminate if Dr. Brenner is no longer the Company&#x2019;s Interim Chief Executive Officer. The grant-date fair value of the RSUs totaled approximately $91,000. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On March 31, 2023, the Compensation Committee (the &#x201c;Committee&#x201d;) of the Board of the Company approved a special equity award program pursuant to which it awarded to its employees an aggregate of 225,000 RSUs under the Company&#x2019;s 2020 Omnibus Equity Incentive Plan, as amended (the &#x201c;Plan&#x201d;), which awards included a grant of 50,000 and 37,500 restricted stock units to each of Dr. Brenner, and Felipe Duran, the Company&#x2019;s Interim, Chief Financial Officer, respectively, vesting quarterly over 12 months commencing April 1, 2023. The grant-date fair value of the RSUs totaled approximately $468,000.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_jhpVZGYF-UaFMIbuFiJv1w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table summarizes the components of share-based compensation expense in the condensed consolidated statements of operations (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 101&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 345&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,112&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 385&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,213&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 96&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 132&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 2,330&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 2,761&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 2,426&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 2,893&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_0YZIOq7O40ivJtfSHHkoMQ"
      decimals="-3"
      id="Tc_Zg77W993pk2G9Lo0OBtQ-Q_4_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">40000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_qBMqGNRQFUWB9ZObqlDu1g"
      decimals="-3"
      id="Tc_rsx-TzYqNkq9nxGov2RIbw_4_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">101000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_qY2IkD16B0qsnL9JdcbhWg"
      decimals="-3"
      id="Tc_T7exz_sUPEOLOGUv6hSFPQ_5_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">345000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_e_Rq4byCpkSvRJ7e4WS-Ew"
      decimals="-3"
      id="Tc_XCKMQrNsyEivcfNNbLHp6w_5_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1112000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="-3"
      id="Tc_Lg96nj-F80WP0q0uVj1D3g_6_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">385000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="-3"
      id="Tc_ly4BAtGc3U67bdZXw9zuVA_6_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1213000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_j5YNxf9-9UOgFjDrRr3Uog"
      decimals="-3"
      id="Tc_qDhbGuMFfk6FtgJmZpCSWA_4_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">96000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2021_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_T5bdyp2yw0iUue1_r7FPew"
      decimals="-3"
      id="Tc_lR6_WHVZFESuFRUz5V-PcQ_4_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">132000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_8W6InNkO50yKpr_pjkqq9w"
      decimals="-3"
      id="Tc_CkpUNS83A0qxU-2x9_-E_Q_5_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">2330000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2021_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_aJI5vfPiSkWbqmmaBoEKtQ"
      decimals="-3"
      id="Tc_2-Hnh9GOUkCGWkwi5v1K4w_5_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">2761000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="-3"
      id="Tc_ztZc-lQvJkaIgTdwQtDM-A_6_3"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">2426000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="-3"
      id="Tc_2WeVYxtStEO86fYfU2hJsg_6_6"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">2893000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_qwQKiC4qEkiqgQ5177TkpA"
      decimals="-3"
      id="Narr_41fSsTjaE0qNQu4s5FfmpA"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1211000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_RaNGnKpnsEaTsjOvOslUxA"
      decimals="-3"
      id="Narr_h60vEgQkukKa6Dp826HlKQ"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">62000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_uXNvRGR-RESDya9s9QmQmA"
      decimals="-3"
      id="Narr_LpqAGMr9Ik-odSxMH8FX7A"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1519000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2021_To_3_31_2022_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_GqDXZ6lLOEyUlH87AA2kZw"
      decimals="-3"
      id="Narr_yIoe3tvbQkebTFys6wMpYw"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">305000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_9_2020_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_x5WH3KDAZkGbq_aE3REdDQ"
      decimals="-6"
      id="Narr_-W_uzhzydke7ZmAR4tOlGg"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">1280000000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <ibio:ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized
      contextRef="As_Of_12_9_2020_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_x5WH3KDAZkGbq_aE3REdDQ"
      decimals="0"
      id="Narr_o1FOSSg8P0ezJ3LrOAL8Yg"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">500000</ibio:ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized>
    <ibio:ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized
      contextRef="As_Of_12_9_2020_srt_StatementScenarioAxis_ibio_ScenarioOneMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_tZmDg9QDo0iz01RbPbZOcw"
      decimals="0"
      id="Narr_PBT6RlAIFU2833263GTwgQ"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">750000</ibio:ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized>
    <ibio:ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized
      contextRef="As_Of_12_9_2020_srt_StatementScenarioAxis_ibio_ScenarioTwoMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_JVZ6u6vkRkGYKXk3HmaqFA"
      decimals="2"
      id="Narr_amt07L16IEKMNbf7-nSQBg"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1500000</ibio:ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_7_1_2022_To_3_31_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_ibio_TwoThousandEighteenOmnibusEquityIncentivePlanMember_B8y79W7GIkih4LgR3vQBOw"
      id="Narr_CSKU14zRB0OxTP_bZzVSAA">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_BcLE-e5aOUawYtWYzbYpuQ"
      decimals="INF"
      id="Narr_ZId_ow8qvkm_0n_SdS4YEw"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">303869</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember__h4euJzls0O2OyXOl4zqpA"
      decimals="2"
      id="Narr_j3PbY3C2l0Cyk8W3SwTp1A"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">6.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_vETdeXuor0693SHSOmu6TA"
      decimals="2"
      id="Narr_4MnaGkxf50mK2KbmfE-qJw"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">9.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_OhlEn2kqNUmaT0Hh--g1yg"
      decimals="2"
      id="Narr_09Qlycs3aEKW0Am7I2eofA"
      unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_OhlEn2kqNUmaT0Hh--g1yg"
      id="Narr_vVulWTfSDEWaII7V344YMg">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_fmpgVBKP1km0zpZ63FGixw"
      id="Narr_VFV09sjlq0OdGnoTTM0mzg">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_ConsultantsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_yuIW9ztkf0mAQBCgQQaTxw"
      decimals="INF"
      id="Narr_1VcjwvBUq0WnX0MiO1Hwvg"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">4000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_ConsultantsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_yuIW9ztkf0mAQBCgQQaTxw"
      decimals="2"
      id="Narr_iSnLRz9Cc0eHBlXI2lKksw"
      unitRef="Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA">6.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_ConsultantsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_yuIW9ztkf0mAQBCgQQaTxw"
      id="Narr_UirB_vocvkCuPeq1a6fnSA">P12M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_hT2YZ3L5oUmhKKFafj4Dnw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company estimated the fair value of options granted using the Black-Scholes option pricing model with the following assumptions:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;3.21% - 3.61&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;115.52 - 116.93&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="4"
      id="Narr_VtlcwNPlo065-EY0TDiG6Q"
      unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg">0.0321</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="4"
      id="Narr_KZ7epdNEokKo93Wq0Yt5lw"
      unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg">0.0361</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="2"
      id="Tc_FrcaXW2gAUW5-3ztwH2J3Q_3_3"
      unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="4"
      id="Narr_Y8cG6sW2lEayYU4r9GYzlg"
      unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg">1.1552</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="4"
      id="Narr_kmx9GDiHt0K5Dt8LzBuKcg"
      unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg">1.1693</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tc_d2qNBBkwrkembDdRz3OvJQ_5_3">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_20_2023_To_1_20_2023_srt_TitleOfIndividualAxis_ibio_Dr.MartinBrennerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_N9G2vRJjBkiY4CVMVYrH_Q"
      decimals="INF"
      id="Narr_xOrb0Io2SE227kIwVO4pJQ"
      unitRef="Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA">130000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_20_2023_To_1_20_2023_srt_TitleOfIndividualAxis_ibio_Dr.MartinBrennerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_N9G2vRJjBkiY4CVMVYrH_Q"
      id="Narr_L1M1gvHvF0mtkcegsegemg">P12M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="Duration_1_20_2023_To_1_20_2023_srt_TitleOfIndividualAxis_ibio_Dr.MartinBrennerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_N9G2vRJjBkiY4CVMVYrH_Q"
      decimals="-3"
      id="Narr_QqsuvscWy0mnYtvNfbz3aQ"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">91000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <ibio:GainLossRelatedToLitigationSettlementTextBlock
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_VgWcfGoqO0iG_HgKRmcSpQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;19.&#160;&#160;&#160;Fraunhofer Settlement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On May 4, 2021, the Company and Fraunhofer USA, Inc. (&#x201c;FhUSA&#x201d;) entered into a Confidential Settlement Agreement and Mutual Release (the &#x201c;Settlement Agreement&#x201d;) to settle all claims and counterclaims in the litigation captioned iBio, Inc. v. Fraunhofer USA, Inc. (Case No. 10256-VCF) in Delaware Chancery Court (the &#x201c;Lawsuit&#x201d;). The Settlement Agreement, among other things, resolves the Company&#x2019;s claims to ownership of certain plant-based technology developed by FhUSA from 2003 through 2014, and sets forth the terms of a license of intellectual property. The Lawsuit was commenced against FhUSA by the Company in March 2015 in the Court of Chancery of the State of Delaware and is described in more detail in the Company&#x2019;s Quarterly Report on Form 10-Q for the quarter ended December 31, 2020. The Settlement Agreement is not an admission of liability or fault of the parties. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The terms of the Settlement Agreement provide for cash payments to the Company of $28,000,000 as follows: (i) $16,000,000 to be paid no later than May 14, 2021 (which is expected to be paid 100% to cover legal fees and expenses); (ii) &lt;span style="-sec-ix-hidden:Hidden_PJle0PEsI0uXVu8jrliU2w;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;two&lt;/span&gt;&lt;/span&gt; payments of $5,100,000 payable by March 31, 2022 and 2023 and (iii) as additional consideration for a license agreement, &lt;span style="-sec-ix-hidden:Hidden__ic71Y4ppUShPuWLdTGl2Q;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;two&lt;/span&gt;&lt;/span&gt; payments of $900,000 due on March 1, 2022 and 2023. The license provides for a nonexclusive, nontransferable, worldwide, fully paid-up license to all intellectual property rights in and to certain plant-based technology developed by FhUSA from 2003 through 2014 that were the subject of the Lawsuit. After payment of the fees and expenses of its attorneys and others retained by the Company, including the litigation funding company, the Company&#x2019;s estimated aggregate net cash recovery as a result of the Settlement Agreement will be approximately $10,200,000. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As of June 30, 2021, the Company held receivables related to the settlement in the amount of $10,200,000. This amount was recorded in the consolidated statement of operations and comprehensive loss as settlement income in Fiscal 2021. &#160;During the quarter ended March 31, 2022, the Company received the first payment of $5,100,000.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On March 17, 2023, the Company received a payment of $5,100,000 from Fraunhofer related to the Fraunhofer Settlement Funds and in accordance with the Fourth Amendment to the Credit Agreement with Woodforest, transferred $3,000,0000 to a Company account at Woodforest on March 24, 2023. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company would recognize the $1.8 million of license revenue when it determines the collection of the license fees was reasonably assured in accordance with ASC 606. On February 9, 2022, the Company received the first $900,000 payment under the license agreement. &#160;As such, the Company determined that the collection of the license fees was reasonably assured, and the Company recognized license revenue related to the license fees and recorded a receivable for the second payment in the third quarter of 2022. &#160;The second $900,000 payment was received on February 17, 2023.&lt;/p&gt;</ibio:GainLossRelatedToLitigationSettlementTextBlock>
    <ibio:CashPaymentsReceivablesRelatedToLitigationSettlement
      contextRef="As_Of_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_iqiKw6Sqfk-mWIZ8WFtzQA"
      decimals="0"
      id="Narr_z1YkMoNMP0mEsN-lQHOMog"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">28000000</ibio:CashPaymentsReceivablesRelatedToLitigationSettlement>
    <ibio:CashPaymentsReceivablesRelatedToLitigationSettlement
      contextRef="As_Of_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedLegalFeesMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_c-4YxyJ_jk-9z62ejKBbXQ"
      decimals="0"
      id="Narr_Fg78nAsSX0yHCH9uhDa3KQ"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">16000000</ibio:CashPaymentsReceivablesRelatedToLitigationSettlement>
    <ibio:PercentageOfLegalFeesExpectedToBeReceived
      contextRef="Duration_5_4_2021_To_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_eCKkBDi1PUu1tOF1oLvpIQ"
      decimals="2"
      id="Narr_uYeaL_wTsECIU534LyvGjw"
      unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg">1</ibio:PercentageOfLegalFeesExpectedToBeReceived>
    <ibio:SettlementAssetsNonCurrent
      contextRef="As_Of_3_31_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentTwoMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_KtCuFsBjc0WIUmqqIyBxaQ"
      decimals="0"
      id="Narr_CroCfNCc9kmeZIvs8pMmDA"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">5100000</ibio:SettlementAssetsNonCurrent>
    <ibio:CashPaymentsReceivablesRelatedToLitigationSettlement
      contextRef="As_Of_3_1_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentTwoMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_d6E-TSK80kuu0sljeRCUGw"
      decimals="0"
      id="Narr_cQS5iSwvpUqrS5WJcDK78w"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">900000</ibio:CashPaymentsReceivablesRelatedToLitigationSettlement>
    <us-gaap:GainContingencyUnrecordedAmount
      contextRef="As_Of_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_DniZqopZZkSjp3fXCv6SrQ"
      decimals="0"
      id="Narr_5V4ZKpiSr0efxipuhN-bUw"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">10200000</us-gaap:GainContingencyUnrecordedAmount>
    <ibio:CashPaymentsReceivablesRelatedToLitigationSettlement
      contextRef="As_Of_6_30_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_CoaZKFcMoUunX2IienHmqw"
      decimals="0"
      id="Narr_qdhUZGjOqk6Jt025sPAdaw"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">10200000</ibio:CashPaymentsReceivablesRelatedToLitigationSettlement>
    <us-gaap:ProceedsFromLegalSettlements
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_6pSybpjm2Em9u1qgqtHc8Q"
      decimals="0"
      id="Narr_iCr0GgwzZUS0VJKxjcilIQ"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">5100000</us-gaap:ProceedsFromLegalSettlements>
    <us-gaap:LitigationSettlementAmountAwardedFromOtherParty
      contextRef="Duration_2_9_2022_To_2_9_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_jUBQVMVhmEuilj8unuIy3A"
      decimals="-5"
      id="Narr_mIz43m0XN0uOxN6BvhdiIg"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">1800000</us-gaap:LitigationSettlementAmountAwardedFromOtherParty>
    <us-gaap:ProceedsFromLegalSettlements
      contextRef="Duration_2_9_2022_To_2_9_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_jUBQVMVhmEuilj8unuIy3A"
      decimals="0"
      id="Narr_Md8xcyGbDESuekoScqDDSQ"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">900000</us-gaap:ProceedsFromLegalSettlements>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_o_FytRbVLU6Rza4WS8kABA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;20.&#160;&#160;&#160;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company recorded no income tax expense for the three months ended March&#160;31,&#160;2023 because the estimated annual effective tax rate was zero. As of March&#160;31,&#160;2023, the Company continues to provide a valuation allowance against its net deferred tax assets since the Company believes it is more likely than not that its deferred tax assets will not be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="0"
      id="Narr_c4C_PvL6IEuUXkF0mSDY1g"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="2"
      id="Narr_fKFBYkIMyUqfULLClhlJ8Q"
      unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_srLb1d2QX06KtPNaSlsgQw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;21.&#160;&#160;Commitments and Contingencies &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;CRO Agreement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On October 10, 2022, the Company entered into an agreement with a CRO for cell line development and master cell banking to produce iBio-101 in addition to process development and GMP manufacturing of iBio-101 drug substance and drug product to support GLP toxicology and Phase 1 clinical studies. &#160;The Company has incurred costs totaling approximately $422,000 through March 31, 2023. &#160;The Company is committed to additional costs totaling approximately $958,000 as of the date of the filing of this report.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Inflation&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;Although the Company has not experienced any material adverse effects on our business due to increasing inflation, it has raised operating costs for many businesses and, in the future, could impact demand or pricing of manufacturing services, foreign exchange rates or employee wages. We are actively monitoring the effects these disruptions and increasing inflation could have on the Company&#x2019;s operations. &lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="Duration_10_10_2022_To_10_10_2022_us-gaap_TypeOfArrangementAxis_ibio_CroAgreementMember_58YO1TPUFEKbnaIFe8Kesw"
      decimals="0"
      id="Narr_CRjdnlbwe0a-crjUFDhTsQ"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">422000</us-gaap:OtherResearchAndDevelopmentExpense>
    <ibio:EstimatedAdditionalCostOnDevelopment
      contextRef="As_Of_10_10_2022_us-gaap_TypeOfArrangementAxis_ibio_CroAgreementMember_Bo_t44xgLU28rjco1A0Xvw"
      decimals="0"
      id="Narr_FMymwXG7bU6arr6cvuxV0w"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">958000</ibio:EstimatedAdditionalCostOnDevelopment>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_60M6jZsajUGVZTVm2gDyuQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;22.&#160;&#160;&#160;Employee 401(K)&#160;Plan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Commencing January&#160;1, 2018, the Company established the iBio,&#160;Inc. 401(K)&#160;Plan (the &#x201c;Plan&#x201d;). Eligible employees of the Company may participate in the Plan, whereby they may elect to make elective deferral contributions pursuant to a salary deduction agreement and receive matching contributions upon meeting age and length-of-service requirements. The Company will make a 100% matching contribution that is not in excess of 5% of an eligible employee&#x2019;s compensation. In addition, the Company may make qualified non-elective contributions at its discretion. For the three months ended March&#160;31,&#160;2023 and 2022, employer contributions made to the Plan totaled approximately $56,000 and $54,000, respectively. For the nine months ended March&#160;31,&#160;2023 and 2022, employer contributions made to the Plan totaled approximately $200,000 and $116,000, respectively. In addition, employer contributions included in loss from discontinued operations totaled approximately $17,000 and $41,000 for the three months ended March&#160;31,&#160;2023 and 2022, respectively, and approximately $129,000 and $110,000 for the nine months ended March&#160;31,&#160;2023 and 2022, respectively.&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="2"
      id="Narr_RgckjiRlJUq03TKkZkvPEg"
      unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg">1</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="2"
      id="Narr_5xxuElLbVEq0TMjWoaEtqg"
      unitRef="Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg">0.05</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA"
      decimals="0"
      id="Narr_rnQROXfy4Uu8mKFMHf9vdg"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">56000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="Duration_1_1_2022_To_3_31_2022_VIy98qperkebIEUpLvJxNg"
      decimals="0"
      id="Narr_O1kOYbXnxUeedfrbccqtXg"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">54000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      decimals="0"
      id="Narr_tSqUaUVqe0u2ws-CcB_rMA"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">200000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ"
      decimals="0"
      id="Narr_txulreCGR0GjfatJGBUO1w"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">116000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_qwQKiC4qEkiqgQ5177TkpA"
      decimals="0"
      id="Narr_ZBaVg6nGH0SFioOmzcZNKw"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">17000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_RaNGnKpnsEaTsjOvOslUxA"
      decimals="0"
      id="Narr_yS2wBaL_IUqwE91qwIDsMQ"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">41000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="Duration_7_1_2022_To_3_31_2023_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_uXNvRGR-RESDya9s9QmQmA"
      decimals="0"
      id="Narr_PnJZyYKbik6du6s3dMCXbA"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">129000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="Duration_7_1_2021_To_3_31_2022_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_GqDXZ6lLOEyUlH87AA2kZw"
      decimals="0"
      id="Narr_VYijXZXIEEO6CxeRWQ-eNQ"
      unitRef="Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog">110000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg"
      id="Tb_YqPnqmpEeUuR2j64PGMYGw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;23.&#160;&#160;&#160;Subsequent Events &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On April 3, 2023, 76,300 Class B Warrants were exercised, which resulted in proceeds of $79,352. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Between April 3 and April 17, 2023, Cantor Fitzgerald sold as sales agent pursuant to the Sales Agreement 892,194 shares of Common Stock. The Company received net proceeds of approximately $1.1 million during April 2023. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On May 10, 2023, iBio CDMO and Woodforest entered into a fifth amendment to the Credit Agreement (the &#x201c;Fifth Amendment&#x201d;), which within the Fifth Amendment Woodforest agreed to: (i) waive the obligation to deliver to Woodforest an executed copy of a Purchase Agreement for the sale of the 130,000 square foot cGMP manufacturing facility in Bryan, Texas, no later than April 14, 2023 and, (ii) release $500,000 of the $3.0 million being held in a Company account at Woodforest when the outstanding principal amount is reduced to $10.0 million and for each additional $2.5 million reduction of the outstanding principal amount, an additional $750,000 will be released from the Company account at Woodforest. &#160;In addition, starting on the effective date of the Fifth Amendment, the interest on the Term Loan increased to 5.25%, and the Term Loan shall further accrue interest, payable in kind and added to the balance of the outstanding principal amount at a fixed rate per annum equal to (a) 1.00%, if the Facility is sold on or before June 30, 2023, (b) 2.00% if the Facility is sold after June 2023, but on or before September 30, 2023, or (c) 3:00%, if the Facility is sold after September 30, 2023, or not sold prior to the maturity date. &#160;The Company also agreed to pay Woodforest a fee in the amount of (x) $75,000 if the Facility is sold on or before June 30, 2023, (y) $100,000 if the Facility is sold after June 2023, but on or before September 30, 2023, or (x) $125,000, if the Facility is sold after September 30, 2023, or not sold prior to the maturity date. &#160;After marketing the Facility with a real estate firm for approximately six months, in May 2023, the Company entered into a new agreement with a new global commercial real estate firm to remarket the Facility. &#160;As of the date of the filing of this Quarterly Report on Form 10-Q, the Company is not in negotiations on a Purchase Agreement with a potential buyer of the Facility.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>104
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M,>DM'#0//KA9Y:K!.?*/6^8?]\1DS3O&_?QE)>4)NZ]&1ES4E+',/RZ>5L8
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M3(@'C.?A\N8$2N>_]3[_ZMY/R/ .&O*J>-[_JB%(%76_/MROKJ$W8ILNZ-U
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MT5.19V>HIV,O2I!^1>Q,8A49/7N>^MM)\:)^+/*M3#?PSD6RR@11BIBYYAJ
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MGP],B$UQZ/)6<\>8"F6M::? _KRA3K0*N87&D>Y*D*))HQK$H<BRMI^&(MP
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MW@LLBMBY"_PK?F_Y]XZ3FVO+.K"@N"-Z;?GU-HQG[R([0-(Z= INW%((=V5
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MGD1\6U2WDJPHPZ2*K N+A27L"FE=JYJ&;M2$VQL0G6=L _YB"0A4W*V%&0_
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;.T\68\;-YI_A>CQ#-R
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MRGKWM[]<SV<_/'7"9>_(],XVO".M B5RA=4+50I=BU],H\0Y'M? =OC)B<;
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MBFAMM0I WDL@;@N+ 'H[(%R@7@M5:>!6B0*Y0,9(9VJYJ ![L,N6I4';HMT
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M;Q$!FUJ "\4-N[""?:S0KY*G-F@_^"BU]4;,*^KOY-]SG>NI0A3_)^*Q/A4
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MQ5BN<\4B3B#EM[#SOIG+Q:G$2V?8!0HWP!*\K)^QL2>IYPY$'"*T!XZTD::
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M3WA..WQHS)9^B'!A&E!,^G.M)(33N "^7QJ(B/P'/"#^,N6+_P902P,$%
M  @ >$NO5K1)\QT+"   Z14  !D   !X;"]W;W)K<VAE971S+W-H965T,3$N
M>&ULS5A;<]LV%OXK&#73369DZ^:XV?@R8SO-Q#OK)ENGW8>=?8!(4$)# @P
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MKP?"Q0^+\2;8FC_FS6T(MN++I9)H"+0 [PL+[](-*>B^[E[^ 5!+ P04
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M&?8]4-6[O!H8N7)OX;DT]+)VW8Q^95#9!32_D-+L!G:#^N=H]@]02P,$%
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M#_W0Z_DD)^^7PG(%\&1QS?LC$ NA87E]L^)B]JT57F%/\0,60@JW9VHEK*G
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M)@'\GBOTM]N0@7Y"7OP#4$L#!!0    ( 'A+KU;F#!H^^P@    8   9
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M'M=#\QD:T%R,H\^RX7[;%FLE]\[>I<+@ IVTGXSZ*H9&7]IU')LM^T9?\?
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;,U86V_;.!;^*X2;*1K
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MR1$Q^&B;0 ;1=:3\RDHKG#ZH]3/V\L7I_.3TM8^Q$L7:;3P;^!^P6[98L#P
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MS51@&4$\33V) DK#*^=379<E2BMX"=2MB0AP1HO#(1-77&8#H3NYFTF3JAJ
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M]ZJ+]_+:-%2XMXP/S&5YSD><!?' ?PV?%S#A(Y=:XLS(NO;GTUT0O<H5=68
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M!)%,[$P'FG%(BZ!T\44.#I='4IRA-G\H@*LC::9X+\"/QU#8#9- [_\,XW5
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M_L#))<@^/B'J"CY]4T*%LV69"VE!7VSP: L'RUK(Q0($&G;85 8/EVN\((N
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MM][5;*.4@$XH0",F-&PI*29[ZM!$I=0YY\%PMI!^*)32#G,U**G GB-@90T
MQXVJ+ /SQ!Q.\ED5GB.7%;"9(!UN;DCAK>0-!@:PE(0+_'K#_A1)MY-\ND50
M)L!L\%>%\-#/X:NP$# B'P?-&H3!&?MVC771)I*/80#JGJ1P ,JWH#GQWVKN
M>=<V<[R'6A->J#$Q_"/56ZJ%1AM[94GM1IJ2\SQ$_I_B#?P)Y*4&[56 Z".M
MP,%=BWD#7S5!']F-RM"[$:6L(3BGV!RB5$ +[=7O2)<T8*0]0#$F\=]:)OXH
M>Z+P ;:#4WM=+0^P36$>L4UR'.D. \8P"E06\K9#@^[,1;Z)J80;!A\)J(0&
MU6CKK DJ(MBD6)-^D;]#0%IO/8MAJ!YR"][0#5S'6'QUP2?<2QI]#I"C#W]_
M.T,WW[KAODV6C<Y9W%"5W0+&;$8SS]0U)XWR:HWY@3JE'_D54A3HA&!2-KE=
M9/=:8Z!8H\#2G= Z;5,&U"Z(@[5&86H))9@X#M?.8>$:;D#=D)4=B]_\SR#N
M!HF49 J<UT..KLL,)>X$N71H8\!_S>HD(8 Q"@.BOF<K9 .FJU<-[-@ \DC'
M767251OH3F:<\&(<R'^:4R(&809:2 Y[;7J%3(! R=3/0*C7,O^1Z [#L;**
M.]'VX7!0)>\P>W3\3BG'D9+S2<<+E?HYZ99 (K,D[%SF"?UZX+P-WC_3GM51
MBTW>[>SJU#!ODJRUO!5*7Z%:G@4K$0@QMAM,!A7;-F"!J6Q++^[B8YV[Z39D
MV^+.P^MQP&P]W=E#UW6A E/L7/O(Z;:05R N=[DFRNV!2B2WR@5I'. D@N \
MB>E1V^>9'?6Z/1#-1+=.MB1J=[E/KKAD)'* L@HC*6_BT;;!-8HUI_45IO7;
MK#8;[3N/W&?@=9"&$G6'C_,X.^FV+U&%_=MWYZBKKCEL(\67AL%TVV/Q:[5W
M<T<7SOOT4.<+4@]/^@ 2#=:EL$%.:O_3.OPT+#!I1"U658,VAOS*3='8&&$3
M)@B8 \J9SF!=L\IVX^P]G+\#82(!+:M0-NLY.CP+ @L#UINJCAZ1!\%YU1K=
MAFV+^T,R8JXY$(QX#6$15.)0!O5Q2  ]'LS=^$  O"-,A?<E?QZT@;B*:I.R
MZVS22%'7,?UBL$Z(E-K(;;BZX.XEOEZ!5=9MU^.4B>%8L(W:V5$39^5DK>$2
MX=)LA9X/!50N=R+Y)C< *;@/I#))3_S=.WVC"#M;I!@>RBZB9(/!D5B!M"R:
M8@'+4:_$94G4B$[@&E#PCKN#*'7=YPI^0(>; J:2-&F>(!B#.%_&</F#=@:+
M3:(E,??\%/V[RGSS('C^U"87F,S2+I_,,4,JFNP+D#)/R$$255!8X\6)="I^
M9:B,-&(;U1?_]M#(WM-P9QTJW(++*AY-AH3C,@C'Y?UX^Y=8%^N3D(?ODHJ)
M+[IM^T4EX1K4+$X0^EVJ1"Y<^0Z=<LU:ZA",Y&UT!-TZJFMN;<?M@WT/P8:2
MB4-]2"+6J[MVDFZYTZ,]TNP]-B],6U7[4L:#92Y2S<N=\TDM.8IJ5TK2XF:O
MJ+11\2XN<*WE=*FO]Y&\+KP<CD050S42*':1HUCY*.H_0X9&70'JRM1TM$ME
MI-FM8,D2(_%H.IEP40*>?70&F^('\$;HB[N\%N8F="I<.3>44GO/]74<2<%*
M"U*79??E-TN**Y:W&]+U&W>C@Q7')T$E/!D4YE^PK-NK!.[SW/ZR2,&_Q^IJ
MC"\7#ZB*7)[!A;JSWI=TA.%M*#\+BWB)DV:@O]IX'L+,00SH]]2[;*ORD"8
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M:]^E6=-P;,(XWF%,9K1</M8-[4C?7$7.N-6AD,:":[V-9&W&D]F#.HPC",K
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M%1UG>BL88U[HM?;EK4[GQ,7H-.UPGUZ.9OQYE/@/Q39.)KZ);S&[:R;PM#N
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MQ\>L,>,67@'1)4AE$2IVYR_B3X>27A1%#[C#WLD@^5LC2R;A-<>UHD,:A _
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M'+PXBZ/DXK___A;.+K6-,K[FJ!WH::?RIUI9NM:IYBGZBQGY!]39NG=IH($
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MY'Q]][X77[]@:(=GKD$(G))J>')*/RJ]?A6L":OFY4U\HBS=Z\MI1@\IU$Z
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M3D[['E'-F] 81E:N#\^DP:[NI@4^HZ"L ^YG4IJU80.T#W/\!U!+ P04
M" !X2Z]6=U&5;)0#  !D"P  &0   'AL+W=O<FMS:&5E=',O<VAE970S."YX
M;6S-5M]OVS80_E<(M2AL0(LD2O*/Q#;@9!N6H06")FL?ACW0$BT1E4B-I.)F
M?WV/E"W+CJWZJ=V+J2/OOOL^\DC?;"/D%Y53JM'7LN!J[N1:5]>>IY*<ED1=
MB8IR6%D+61(-ILP\54E*4AM4%A[V_9%7$L:=Q<S./<C%3-2Z8)P^2*3JLB3R
MY9868C-W F<W\9%EN383WF)6D8P^4OU7]2#!\EJ4E)64*R8XDG0]=Y;!]6UD
M_*W#)T8WJO.-C)*5$%^,<9_.'=\0H@5-M$$@,#S3.UH4!@AH_+O%=-J4)K#[
MO4/_W6H'+2NBZ)TH/K-4YW-GXJ"4KDE=Z(]B\P?=ZHD-7B(*97_19NOK.RBI
ME1;E-A@8E(PW(_FZW8=+ O V %O>32++\E>BR6(FQ09)XPUHYL-*M=% CG%S
M*(]:PBJ#.+VXYYKPC*T*BI9*4:W0X(F I88S3P.^\?*2+=9M@X7/8$W1!\%U
MKM!O/*7I8;P'O%IR>$?N%O<"?B#R"H6!B["/PQZ\L!4;6KSP8K%_+U=*2RB-
M?T[);="BTVCFNERKBB1T[L!]4%0^4V?Q[DTP\F]ZN$8MUZ@/??$(UR^M@:E8
MHSNB:2;D"](Y19D42J&$2/G">(:>25%31'@*!9[495V +WR70FKV'[&5#PAL
MKYQ8Y:?D]A-Z@MQK4< M-FFU*1)S*\WU CHYP%,%>2S'EAWPJ+D^R0 -K+.H
M%9!7PVOT[LT$^^'-_V;\L^84A;Y[U@'*,\EM?1ZO0+WBUEAVSZ*=3%-F)E0[
M<U]6A$EX[[3JXH0(JA8>+=CFFA2HDO >2_UB78+@YG0Y[.+?HM -?+]CVS!\
MTYF)#M8'-F!XM/X 165XF3(K6 )O,E67,<#N)!H=[$\W^[$]L.[#7G\SQNZT
M![6K:&!=AP=K_1MZ]AIU28[&>\C!.#K/&+O3,-B[!K"UO9MY2?;(#SO9HW%?
M]BCVO[N;L$=XW#GS08"#\YBQ&TZ.%#T)#3L)_X6,,TU!U#.P?WWA]S4U&H\Z
MUF&^5Q49C^+N:CCU7RGXT>/[YMC0+Z#R2'9'AAN,XY,0AQ=P@B<7>,6N[X<_
M77ASTAR:Q<[Q=B5/XN"[(&]1X.(SH@_]H-:FK>A3?ZI>I_,IJ<QL?P>/D?G7
M:9J@=K9M(9=-Y[1W;_I/>,TS!N]Q0=<0ZE^-8P?)IJ=K#"TJVT>MA(:NS'[F
MT 93:1Q@?2V$WADF0=M8+[X!4$L#!!0    ( 'A+KU8G=-X/[ (  $8'   9
M    >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;*U5;4_;,!#^*Z=L0B!MY+6E
ME+82+T-#@JD"MGV8]L%-+HU%8@?;H?#O=T[2$-322=.^)#[[GN>>L\_GR4JJ
M!YTA&G@N<J&G3F9,.79='6=8,'TH2Q2TDDI5,$.F6KJZ5,B2&E3D;N!Y0[=@
M7#BS23TW5[.)K$S.!<X5Z*HHF'HYPURNIH[OK"=N^3(S=L*=34JVQ#LTW\NY
M(LOM6!)>H-!<"E"83IU3?WP66?_:X0?'E>Z-P6:RD/+!&E?)U/&L(,PQ-I:!
MT>\)SS'/+1')>&PYG2ZD!?;':_;+.G?*9<$TGLO\)T],-G5&#B28LBHWMW+U
M%=M\!I8OEKFNO[!J?(\H8EQI(XL63';!1?-GS^T^]  C[QU T *"6G<3J%9Y
MP0R;391<@;+>Q&8'=:HUFL1Q80_ESBA:Y80SLPM<&-B_9XL<]<'$-41I%]RX
MA9\U\. =^#'<2&$R#5]$@LE;O$M2.CW!6L]9L)/PAJE#"/U/$'A!N(,O[/(+
M:[[P';YOTJ"&.7NQ&<*OTX4VBBKA][94&Z9H.Y.]'6-=LABG#I6_1O6$SFSO
M@S_T3G;HC#J=T2[VV1W=MJ0BB3*%M#*50GO:O*@**-D+W0*CH:(]5F RA)0+
M)F*$'*D@02YROF2VR+=EM3ONY3_' D:XI$)@&E*9T^W6L,\%862EF4CTP1CV
M/HP"+SSY[_]+KF.60XF*RP10)%PL@211]<09E<\8YHJ+F)?D="4,TGD9N)>&
M3*JKJ./Y"/Y@V+/"X_[2\<!Z#S:B^T?AQEP0;+HU^%=^W_>Z<=2;C?Z:;R-]
M?4CX6/'2'E-[-C;Y[N"Z &]R&0YZQL"+X!JU'E.#4<KRE%+51[KVV:=M.=A0
M<2W%\C-M9M'Y4['N$M4KEM?HP6AS]]K_MGOD]GI;@6I9=W -L:R$:=I<-]L]
M$J=-;WQU;UX8JHXE%YHJ.26H=W@T<$ U7;LQC"SK3KF0AOIN/<SHH4-E'6@]
ME=1-6L,&Z)[.V1]02P,$%     @ >$NO5BU+%"PZ!   6P\  !D   !X;"]W
M;W)K<VAE971S+W-H965T-# N>&UL[5?;;N,V$/T50ELL$J"-+,EV',<VD*0-
M=H%-8^32/A1]H*6Q12PO*DG%V7Y]AY0ER^M+DFU1]*$OIDC.Y<S,&=(<+97^
M;'( 2YX%EV8<Y-86PS T:0Z"FA-5@,2=N=*"6ISJ16@*#33S2H*'<:?3#P5E
M,IB,_-I43T:JM)Q)F&IB2B&H_G()7"W'0134"W=LD5NW$$Y&!5W /=C'8JIQ
M%C96,B9 &J8DT3 ?!Q?1\++OY+W +PR6IO5-7"0SI3Z[R<=L''0<(."06F>!
MXO $5\"Y,X0P_EC9#!J73K']75N_]K%C+#-JX$KQ7UEF\W$P"$@&<UIR>Z>6
M'V 53\_92Q4W_I<L5[*=@*2EL4JLE!&!8+(:Z?,J#Z]1B%<*L<==.?(H?Z26
M3D9:+8EVTFC-??A0O3:"8](5Y=YJW&6H9R?73%*9 OD$&!JYG7&VH#Y=1P]T
MQL$<CT*+;IQPF*Y,7E8FXSTFS\B-DC8WY">90;:I'R*\!F-<8[R,#QJ\H?J$
M)-'W).[$R0%[21-SXNTE;XWYMXN9L1J)\ONNJ"NCW=U&7?,,34%3& ?8'0;T
M$P23]^^B?N?\ .1N [E[R/KD'ILQ*SD0-2>I$H62(*UQ,^Z#@&?L4ARIS+"_
MBH(#-HZE'!G+?:Q5AS-9M7'549Q:R(A5Q.9 YJND5/94DY1=F3B,]?V[0=Q)
MSLF#LZHXMCV3"V(]G8C/C;3>Y;\;"#EB$@54:="V.3XA-<YO'1]R#;#!]==L
MU2.2.LT]J_>OU*/C?7L2D^N-(%-E[' OS@NAM&5_5DG 1-_=/A)J#&#::Y'O
M2'_0FKBO*#XG'Z4%K)<EJ%AYXHS.&&>6P5HYZF^X=(H/RI5L#:YE>]#=X6@?
M]%LLJ&X7>SO**VIR4E"6(=<TH4*5CD],IKQT:?<U!R(02JD]E[8CV39Z6X!&
M?TC;U)F?(X<-F6LEOF+7_DC6*U6I7K:U9NI&7>(WI.M;QY^Q@W>S=?_.?Y3'
M4:^_(V&O(W*2;/A\@<C1X.Q_)K^!R5'W0.<?N")[S179>_45N8G'W25+__<,
MTTB?,"$+:)=BUQ5WV-?+J/L-ZOY!2]>EQ6J2&R:9* 69TB_"7XB/V&S:%WS?
MOY5=J%_E2ZQ\%;6OLO&U]^ZDJ$?-ZCHW7UVE^UOV[X[7S*38?\AAIC(",G/D
M0SCU$3,D4XT-P@H4:GJ\ZED\7MI\B_N]UJS7WDJB,R?=V_(>G\7;:X.MI23N
M./WUN1,EG?5F:S5Y,=X*>EV@J@I-F6JA_N"T?9^VXSH]C9$G!L^!M-3:'1&%
M.S,Q8[7,$2;B>,OO)R47/V#Z1"./3;0)8W=3=^/M%/W#XZXF"UL/'@%ZX9]U
M!D]H/#*KMT^SVKP<+ZH'TUJ\>G8BE18,8^(P1]7.R2EVOJZ><M7$JL(_GV;*
MXF/,?^;X^@7M!'!_KI2M)\Y!\YZ>_ 502P,$%     @ >$NO5F-I,I(V!
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ME^^.V#\U?H6G0GL:(DH)-JN53A!(<<0FC-OH2Y4Z:"YXB5*X$E;5X)L('A%
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M+)XS41G([Q><EZ\7E8/=6Z>N_@)02P,$%     @ >$NO5K._7SQ5"   \D\
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M^X@AB_-J,=!BG1_Y%D+C 3*_3?",#]($X/Q2"/TT,*?(ZE^#R0]02P,$%
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MU1$-N%Z@GL\9DYN!=E >^L9_ 5!+ P04    " !X2Z]6GM9-S:X#  !9$0
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M-%4DV8]_2ZA1^53"X_L7>I /7@YFB3G,:?IW$HO-U!@9*(85WJ7BB1Y^@W)
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M23K@_GK'?N6S4Y8EMW"IY3>18S$+I@'+8<5KB;=Z^Q':/-Y@IJ7U5[9M>Z.
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M14=AQ84*LM2?W9HLU0U*H>#6,-M4%3?/YR#U9AY,@I>#.[$NT1V$65KS-2P
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M!TR;G*,MIM'X=#?144=TM)\H22FC^@4>;Y$O4.ZLY%Z(OZQDU!&,_F-/1O]
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M%R(O5U"_WV>9?/Y2&FQ?UC']'U!+ P04    " !X2Z]6UNW;6H@'  !M3
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MJE5JI:A=MX=I#TYR2:R"36V3M/]^-A"2E8].F?:28.Q[SKGV]>$&6RX>Y1I
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MSL[5*H_7IWIU0;*R.K::,RE94=VN &? =07U?L&8W!5T ^W9:O0O4$L#!!0
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M)](8P/N%$'KS8!Q4?P2&OP%02P,$%     @ >$NO5L-EKWYL!   T!<  !D
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MNSTM.D+[A/D-".$50 $*+>'W[O"_\U2%!T4X.@SW5=^JYJ&J>:C(%_YT\Z[
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MU7Q4"U M1+6(TKKY;<MQIKH<M_?T?V6!^<,VAAQMO:&:A6HVJCFHYC;:RMZ
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MP6O,DA"Y^!G\SP657^'JGF22<?A Y3\1<I*$\)*I%7M.)<TB(%D(S\6&_QG
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M"ZCW<\;DVX/NH+U3&_\+4$L#!!0    ( 'A+KU9TU$]-T0,  -43   9
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M5\,<+S[0+@"_KY2RQXD3:*[2Y"=02P,$%     @ >$NO5M7A88IS @  F04
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MU'..CJEWG"O/*1IA\K.N^J1AA2"MW?+*[X.%:>E;_;'7=ZVZ2X>CB'])N#O
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M.>.9,W:&X8ZR7WP-(-!]$A,^,M9"I /3Y,$:$LS;- 4BWRPI2["04[8R><H
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M(-)'8_IHC(\*(6/WP?*$8S)[A5>:94F2IMB.CL=!!6-LW](4?L)LF#:(P/)
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MHKC9,KRJB^(<CMT:2+R6^Q\([G_<^.$_4$L#!!0    ( 'A+KU9 RG71C@(
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M*^JM!'HKZJT$>NMDLX1 ;T6]E4!O1;V50&]%O95 ;T6]E4!O1;V50&]%O95
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M;W!S+V%P<"YX;6Q02P$"% ,4    " !X2Z]6'! G.N\    K @  $0
M        @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " !X2Z]6
MF5R<(Q &  "<)P  $P              @ '- 0  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    ( 'A+KU9G@I=;J@4  ,@>   8              "
M@0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " !X2Z]6
MH\A 2-D'  !J)P  &               @('N#0  >&PO=V]R:W-H965T<R]S
M:&5E=#(N>&UL4$L! A0#%     @ >$NO5K0% Z[K @  0PH  !@
M     ("!_14  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    (
M 'A+KU:_7[PHP@<  /XJ   8              " @1X9  !X;"]W;W)K<VAE
M971S+W-H965T-"YX;6Q02P$"% ,4    " !X2Z]6B)X4+^D/  #9M0  &
M            @($6(0  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#
M%     @ >$NO5L@IZ?2$"P  .#P  !@              ("!-3$  'AL+W=O
M<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( 'A+KU;FNZ(3+0H   88
M   8              " @>\\  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q0
M2P$"% ,4    " !X2Z]63YDB:5$)  #(%@  &               @(%21P
M>&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ >$NO5AKXLM2I
M"P  HRD  !@              ("!V5   'AL+W=O<FMS:&5E=',O<VAE970Y
M+GAM;%!+ 0(4 Q0    ( 'A+KU9_- <3L1D  *52   9              "
M@;A<  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ >$NO
M5K1)\QT+"   Z14  !D              ("!H'8  'AL+W=O<FMS:&5E=',O
M<VAE970Q,2YX;6Q02P$"% ,4    " !X2Z]6CON/XD,1  #9,0  &0
M        @('B?@  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0
M   ( 'A+KU8F,>VNY@,  /4(   9              " @5R0  !X;"]W;W)K
M<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ >$NO5IO9K=;= P  * T
M !D              ("!>90  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q0
M2P$"% ,4    " !X2Z]6%>;'H*$#  "Q"   &0              @(&-F
M>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( 'A+KU9L9H+Q
M70,   4(   9              " @66<  !X;"]W;W)K<VAE971S+W-H965T
M,38N>&UL4$L! A0#%     @ >$NO5G/V24)G!   +0L  !D
M ("!^9\  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " !X
M2Z]6Y@P:/OL(    &   &0              @(&7I   >&PO=V]R:W-H965T
M<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( 'A+KU;3(=0/4 X  *DJ   9
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M970R,RYX;6Q02P$"% ,4    " !X2Z]6[OBY'34+  !?(   &0
M    @($6W0  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    (
M 'A+KU;D8!6]T@4  .L-   9              " @8+H  !X;"]W;W)K<VAE
M971S+W-H965T,C4N>&UL4$L! A0#%     @ >$NO5J$_=-JR @  _@4  !D
M             ("!B^X  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"
M% ,4    " !X2Z]69)-8#]<#  "6"   &0              @(%T\0  >&PO
M=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( 'A+KU:@!H\6M ,
M #X)   9              " @8+U  !X;"]W;W)K<VAE971S+W-H965T,C@N
M>&UL4$L! A0#%     @ >$NO5EAO;!64!0  @0T  !D              ("!
M;?D  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " !X2Z]6
MD1AAVX$:   ;6@  &0              @($X_P  >&PO=V]R:W-H965T<R]S
M:&5E=#,P+GAM;%!+ 0(4 Q0    ( 'A+KU93E9!_I 8   0;   9
M      " @? 9 0!X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%
M  @ >$NO5K@QV8,7 P  R <  !D              ("!RR ! 'AL+W=O<FMS
M:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " !X2Z]6.H.J&2X#  !#"
M&0              @($9) $ >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+
M 0(4 Q0    ( 'A+KU;[:ZN_^0(  (0(   9              " @7XG 0!X
M;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ >$NO5LJ-S>NL
M P  I@T  !D              ("!KBH! 'AL+W=O<FMS:&5E=',O<VAE970S
M-2YX;6Q02P$"% ,4    " !X2Z]6]KFR7Z@"  "'!@  &0
M@(&1+@$ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( 'A+
MKU9\)M^=_0(  *0'   9              " @7 Q 0!X;"]W;W)K<VAE971S
M+W-H965T,S<N>&UL4$L! A0#%     @ >$NO5G=1E6R4 P  9 L  !D
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M=#0R+GAM;%!+ 0(4 Q0    ( 'A+KU8:]&";N ,  /$)   9
M  " @0M) 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @
M>$NO5GYE:7QZ P  >@T  !D              ("!^DP! 'AL+W=O<FMS:&5E
M=',O<VAE970T-"YX;6Q02P$"% ,4    " !X2Z]6BI):3_0#  !Q$0  &0
M            @(&K4 $ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4
M Q0    ( 'A+KU8<:'SNM@D  (%*   9              " @=94 0!X;"]W
M;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ >$NO5K._7SQ5"
M\D\  !D              ("!PUX! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX
M;6Q02P$"% ,4    " !X2Z]6B^Q 5,H#  !!$   &0              @(%/
M9P$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( 'A+KU:$
MH@]O9P,    .   9              " @5!K 0!X;"]W;W)K<VAE971S+W-H
M965T-#DN>&UL4$L! A0#%     @ >$NO5I[63<VN P  61$  !D
M     ("![FX! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4
M" !X2Z]6#'MJH)(-   6F@  &0              @('3<@$ >&PO=V]R:W-H
M965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( 'A+KU95N1P,3P,  *,/   9
M              " @9R  0!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L!
M A0#%     @ >$NO5L\KTJ;V P  O!4  !D              ("!(H0! 'AL
M+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    " !X2Z]6 Z+<V*H"
M  #[!P  &0              @(%/B $ >&PO=V]R:W-H965T<R]S:&5E=#4T
M+GAM;%!+ 0(4 Q0    ( 'A+KU::29""40(  %<%   9              "
M@3"+ 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ >$NO
M5@!3^")G @  >04  !D              ("!N(T! 'AL+W=O<FMS:&5E=',O
M<VAE970U-BYX;6Q02P$"% ,4    " !X2Z]6;)N3Z8 "  #D!@  &0
M        @(%6D $ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0
M   ( 'A+KU9#.#U8D@(  .0&   9              " @0V3 0!X;"]W;W)K
M<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ >$NO5C@<"(NO @  ? @
M !D              ("!UI4! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q0
M2P$"% ,4    " !X2Z]62/NV#K\"  "2"   &0              @(&\F $
M>&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( 'A+KU;UU)U^
M:@,  #00   9              " @;*; 0!X;"]W;W)K<VAE971S+W-H965T
M-C$N>&UL4$L! A0#%     @ >$NO5K*1WX66!   AR$  !D
M ("!4Y\! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"% ,4    " !X
M2Z]6*,AX?SP'  "X0P  &0              @($@I $ >&PO=V]R:W-H965T
M<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( 'A+KU;6[=M:B <  &U,   9
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M970V."YX;6Q02P$"% ,4    " !X2Z]6#S=)(%$$  !H%   &0
M    @(%EP $ >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    (
M 'A+KU;Z!9][2@,   4,   9              " @>W$ 0!X;"]W;W)K<VAE
M971S+W-H965T-S N>&UL4$L! A0#%     @ >$NO5IP);V;/ P  "1   !D
M             ("!;L@! 'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6Q02P$"
M% ,4    " !X2Z]6;$=\:4D#   4#   &0              @(%TS $ >&PO
M=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+ 0(4 Q0    ( 'A+KU;#9:]^; 0
M - 7   9              " @?3/ 0!X;"]W;W)K<VAE971S+W-H965T-S,N
M>&UL4$L! A0#%     @ >$NO5L>-K+8A#P  )]\  !D              ("!
ME]0! 'AL+W=O<FMS:&5E=',O<VAE970W-"YX;6Q02P$"% ,4    " !X2Z]6
MXQ2Q1\<#  #:$   &0              @('OXP$ >&PO=V]R:W-H965T<R]S
M:&5E=#<U+GAM;%!+ 0(4 Q0    ( 'A+KU:;'"RB^@0  .8?   9
M      " @>WG 0!X;"]W;W)K<VAE971S+W-H965T-S8N>&UL4$L! A0#%
M  @ >$NO5L*&UW1K!0  7QL  !D              ("!'NT! 'AL+W=O<FMS
M:&5E=',O<VAE970W-RYX;6Q02P$"% ,4    " !X2Z]6=-1/3=$#  #5$P
M&0              @(' \@$ >&PO=V]R:W-H965T<R]S:&5E=#<X+GAM;%!+
M 0(4 Q0    ( 'A+KU8:LR8Z@0<   U*   9              " @<CV 0!X
M;"]W;W)K<VAE971S+W-H965T-SDN>&UL4$L! A0#%     @ >$NO5KE@$0+X
M P  ;A4  !D              ("!@/X! 'AL+W=O<FMS:&5E=',O<VAE970X
M,"YX;6Q02P$"% ,4    " !X2Z]6A4!Q<*X"  !6!P  &0
M@(&O @( >&PO=V]R:W-H965T<R]S:&5E=#@Q+GAM;%!+ 0(4 Q0    ( 'A+
MKU;5X6&*<P(  )D%   9              " @90% @!X;"]W;W)K<VAE971S
M+W-H965T.#(N>&UL4$L! A0#%     @ >$NO5BW=6W\=!P  >D\  !D
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M=#@W+GAM;%!+ 0(4 Q0    ( 'A+KU:BR:.\.P,  .P3   -
M  "  7(: @!X;"]S='EL97,N>&UL4$L! A0#%     @ >$NO5I>*NQS
M$P(   L              ( !V!T" %]R96QS+RYR96QS4$L! A0#%     @
M>$NO5BK6+>U.!@  8#D   \              ( !P1X" 'AL+W=O<FMB;V]K
M+GAM;%!+ 0(4 Q0    ( 'A+KU9 RG71C@(  $PS   :              "
M 3PE @!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( 'A+
MKU8AV_FQ,0(  ,TQ   3              "  0(H @!;0V]N=&5N=%]4>7!E
<<UTN>&UL4$L%!@    !? %\ $!H  &0J @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>240</ContextCount>
  <ElementCount>469</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>90</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - Condensed Consolidated Statements of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity</Role>
      <ShortName>Condensed Consolidated Statements of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00400 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureNatureOfBusiness</Role>
      <ShortName>Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureBasisOfPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Discontinued Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureDiscontinuedOperations</Role>
      <ShortName>Discontinued Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Financial Instruments and Fair Value Measurement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurement</Role>
      <ShortName>Financial Instruments and Fair Value Measurement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Significant Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureSignificantTransactions</Role>
      <ShortName>Significant Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Convertible Promissory Note Receivable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureConvertiblePromissoryNoteReceivable</Role>
      <ShortName>Convertible Promissory Note Receivable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Investments in Debt Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecurities</Role>
      <ShortName>Investments in Debt Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Finance Lease ROU Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssets</Role>
      <ShortName>Finance Lease ROU Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Operating Lease ROU Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssets</Role>
      <ShortName>Operating Lease ROU Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Fixed Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFixedAssets</Role>
      <ShortName>Fixed Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11201 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureIntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11301 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureDebt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11401 - Disclosure - Finance Lease Obligation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFinanceLeaseObligation</Role>
      <ShortName>Finance Lease Obligation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>11501 - Disclosure - Operating Lease Obligation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureOperatingLeaseObligation</Role>
      <ShortName>Operating Lease Obligation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>11601 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>11701 - Disclosure - Earnings (Loss) Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShare</Role>
      <ShortName>Earnings (Loss) Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>11801 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>11901 - Disclosure - Fraunhofer Settlement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFraunhoferSettlement</Role>
      <ShortName>Fraunhofer Settlement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>12001 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>12101 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>12201 - Disclosure - Employee 401(K) Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureEmployee401KPlan</Role>
      <ShortName>Employee 401(K) Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>12301 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>20402 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Discontinued Operations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsTables</Role>
      <ShortName>Discontinued Operations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureDiscontinuedOperations</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Financial Instruments and Fair Value Measurement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementTables</Role>
      <ShortName>Financial Instruments and Fair Value Measurement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurement</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Significant Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables</Role>
      <ShortName>Significant Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureSignificantTransactions</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>30803 - Disclosure - Investments in Debt Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesTables</Role>
      <ShortName>Investments in Debt Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecurities</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>30903 - Disclosure - Finance Lease ROU Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsTables</Role>
      <ShortName>Finance Lease ROU Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssets</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>31103 - Disclosure - Fixed Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFixedAssetsTables</Role>
      <ShortName>Fixed Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureFixedAssets</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>31203 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureIntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureIntangibleAssets</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>31303 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureDebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureDebt</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>31403 - Disclosure - Finance Lease Obligation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationTables</Role>
      <ShortName>Finance Lease Obligation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureFinanceLeaseObligation</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>31503 - Disclosure - Operating Lease Obligations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsTables</Role>
      <ShortName>Operating Lease Obligations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureOperatingLeaseObligation</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>31703 - Disclosure - Earnings (Loss) Per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareTables</Role>
      <ShortName>Earnings (Loss) Per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShare</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>31803 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureShareBasedCompensation</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Basis of Presentation (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails</Role>
      <ShortName>Basis of Presentation (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureBasisOfPresentation</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Discontinued Operations (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails</Role>
      <ShortName>Discontinued Operations (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40302 - Disclosure - Discontinued Operations (Reconciliation and Classifications) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails</Role>
      <ShortName>Discontinued Operations (Reconciliation and Classifications) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>40402 - Disclosure - Summary of Significant Accounting Policies (Cash, Cash Equivalents and Restricted Cash) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Cash, Cash Equivalents and Restricted Cash) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Financial Instruments and Fair Value Measurement (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails</Role>
      <ShortName>Financial Instruments and Fair Value Measurement (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>40502 - Disclosure - Financial Instruments and Fair Value Measurement (Non-recurring Basis) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails</Role>
      <ShortName>Financial Instruments and Fair Value Measurement (Non-recurring Basis) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Significant Transactions (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails</Role>
      <ShortName>Significant Transactions (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>40602 - Disclosure - Significant Transactions (Summary of Asset Acquisition) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails</Role>
      <ShortName>Significant Transactions (Summary of Asset Acquisition) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Convertible Promissory Note Receivable (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureConvertiblePromissoryNoteReceivableNarrativeDetails</Role>
      <ShortName>Convertible Promissory Note Receivable (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureConvertiblePromissoryNoteReceivable</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Investments in Debt Securities (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesNarrativeDetails</Role>
      <ShortName>Investments in Debt Securities (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>40802 - Disclosure - Investments in Debt Securities (Components of Investments in Debt Securities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesComponentsOfInvestmentsInDebtSecuritiesDetails</Role>
      <ShortName>Investments in Debt Securities (Components of Investments in Debt Securities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>40803 - Disclosure - Investments in Debt Securities (Debt Securities, Contractual Maturity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesDebtSecuritiesContractualMaturityDetails</Role>
      <ShortName>Investments in Debt Securities (Debt Securities, Contractual Maturity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Finance Lease ROU Assets (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsNarrativeDetails</Role>
      <ShortName>Finance Lease ROU Assets (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>40902 - Disclosure - Finance Lease ROU Assets (Summary of Finance Lease ROU) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails</Role>
      <ShortName>Finance Lease ROU Assets (Summary of Finance Lease ROU) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Operating Lease ROU Assets (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssetsNarrativeDetails</Role>
      <ShortName>Operating Lease ROU Assets (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssets</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Fixed Assets (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFixedAssetsNarrativeDetails</Role>
      <ShortName>Fixed Assets (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureFixedAssetsTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>41102 - Disclosure - Fixed Assets (Carrying Value and Accumulated Depreciation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails</Role>
      <ShortName>Fixed Assets (Carrying Value and Accumulated Depreciation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureFixedAssetsTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>41201 - Disclosure - Intangible Assets (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails</Role>
      <ShortName>Intangible Assets (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureIntangibleAssetsTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>41202 - Disclosure - Intangible Assets (Carrying Value and Accumulated Amortization) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails</Role>
      <ShortName>Intangible Assets (Carrying Value and Accumulated Amortization) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureIntangibleAssetsTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>41301 - Disclosure - Debt (The Credit Agreement) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails</Role>
      <ShortName>Debt (The Credit Agreement) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureDebtTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>41302 - Disclosure - Debt (Equipment Financing) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingDetails</Role>
      <ShortName>Debt (Equipment Financing) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureDebtTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>41303 - Disclosure - Debt (Equipment Financing) (Future Minimum Payments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails</Role>
      <ShortName>Debt (Equipment Financing) (Future Minimum Payments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureDebtTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>41304 - Disclosure - Debt (Note Payable - PPP Loan) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureDebtNotePayablePppLoanDetails</Role>
      <ShortName>Debt (Note Payable - PPP Loan) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureDebtTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>41401 - Disclosure - Finance Lease Obligation (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationNarrativeDetails</Role>
      <ShortName>Finance Lease Obligation (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>41402 - Disclosure - Finance Lease Obligation (Finance Lease Cost and Other Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails</Role>
      <ShortName>Finance Lease Obligation (Finance Lease Cost and Other Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>41403 - Disclosure - Finance Lease Obligation (Future Minimum Payments Under the Capitalized Lease Obligations) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails</Role>
      <ShortName>Finance Lease Obligation (Future Minimum Payments Under the Capitalized Lease Obligations) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>41501 - Disclosure - Operating Lease Obligation (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails</Role>
      <ShortName>Operating Lease Obligation (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>41502 - Disclosure - Operating Lease Obligation (Lease Expense and Supplemental Balance Sheet Information Related to the Operating Lease Obligation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails</Role>
      <ShortName>Operating Lease Obligation (Lease Expense and Supplemental Balance Sheet Information Related to the Operating Lease Obligation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>41503 - Disclosure - Operating Lease Obligation (Future Minimum Payments under the Operating Lease Obligation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails</Role>
      <ShortName>Operating Lease Obligation (Future Minimum Payments under the Operating Lease Obligation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>41601 - Disclosure - Stockholders' Equity (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureStockholdersEquity</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>41602 - Disclosure - Stockholders' Equity (Cantor Fitzgerald Underwriting and RubrYc Transaction) (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails</Role>
      <ShortName>Stockholders' Equity (Cantor Fitzgerald Underwriting and RubrYc Transaction) (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureStockholdersEquity</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>41603 - Disclosure - Stockholders' Equity (Wainwright Underwriting and Vesting of RSUs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails</Role>
      <ShortName>Stockholders' Equity (Wainwright Underwriting and Vesting of RSUs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureStockholdersEquity</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>41701 - Disclosure - Earnings (Loss) Per Common Share (Components of the Earnings (Loss) per Common Share ) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails</Role>
      <ShortName>Earnings (Loss) Per Common Share (Components of the Earnings (Loss) per Common Share ) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>41702 - Disclosure - Earnings (Loss) Per Common Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails</Role>
      <ShortName>Earnings (Loss) Per Common Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>41801 - Disclosure - Share-Based Compensation (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails</Role>
      <ShortName>Share-Based Compensation (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureShareBasedCompensationTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>41802 - Disclosure - Share-Based Compensation (Share Based Compensation Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails</Role>
      <ShortName>Share-Based Compensation (Share Based Compensation Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureShareBasedCompensationTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>41805 - Disclosure - Share-Based Compensation (Fair Value of Options Granted) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureShareBasedCompensationFairValueOfOptionsGrantedDetails</Role>
      <ShortName>Share-Based Compensation (Fair Value of Options Granted) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureShareBasedCompensationTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>41806 - Disclosure - Share-Based Compensation (RSUs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureShareBasedCompensationRsusDetails</Role>
      <ShortName>Share-Based Compensation (RSUs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureShareBasedCompensationTables</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>41901 - Disclosure - Fraunhofer Settlement (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails</Role>
      <ShortName>Fraunhofer Settlement (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureFraunhoferSettlement</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>42001 - Disclosure - Income Taxes (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureIncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>42101 - Disclosure - Commitments and Contingencies (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>42201 - Disclosure - Employee 401(K) Plan (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureEmployee401KPlanNarrativeDetails</Role>
      <ShortName>Employee 401(K) Plan (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureEmployee401KPlan</ParentRole>
      <Position>86</Position>
    </Report>
    <Report instance="ibio-20230331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>42301 - Disclosure - Subsequent Events (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails</Role>
      <ShortName>Subsequent Events (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>87</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 57 fact(s) appearing in ix:hidden were eligible for transformation: ibio:BaseRentAbatementInFirstYearPeriod, ibio:CashPaymentsReceivablesRelatedToLitigationSettlement, ibio:CollaborationAndLicenseAgreementRoyaltyPaymentTerm, ibio:SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod, ibio:SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct, ibio:SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary, ibio:SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus, us-gaap:CommonStockSharesIssued, us-gaap:CommonStockSharesOutstanding, us-gaap:EarningsPerShareDiluted, us-gaap:FinanceLeaseLiabilityNoncurrent, us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1, us-gaap:FiniteLivedIntangibleAssetUsefulLife, us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare, us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare, us-gaap:LeasePracticalExpedientsPackage, us-gaap:OperatingLeaseRightOfUseAsset, us-gaap:PreferredStockSharesOutstanding, us-gaap:PropertyPlantAndEquipmentUsefulLife, us-gaap:SettlementAssetsCurrent, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod, us-gaap:StockholdersEquityNoteStockSplitConversionRatio1, us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding -  ibio-20230331x10q.htm 9</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="ibio-20230331x10q.htm">ibio-20230331x10q.htm</File>
    <File>ibio-20230331.xsd</File>
    <File>ibio-20230331_cal.xml</File>
    <File>ibio-20230331_def.xml</File>
    <File>ibio-20230331_lab.xml</File>
    <File>ibio-20230331_pre.xml</File>
    <File>ibio-20230331xex10d7.htm</File>
    <File>ibio-20230331xex10d8.htm</File>
    <File>ibio-20230331xex31d1.htm</File>
    <File>ibio-20230331xex31d2.htm</File>
    <File>ibio-20230331xex32d1.htm</File>
    <File>ibio-20230331xex32d2.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ibio-20230331x10q001.jpg</File>
    <File>ibio-20230331x10q002.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2022</BaseTaxonomy>
    <BaseTaxonomy items="807">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>110
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ibio-20230331x10q.htm": {
   "axisCustom": 0,
   "axisStandard": 33,
   "baseTaxonomies": {
    "http://fasb.org/srt/2022": 1,
    "http://fasb.org/us-gaap/2022": 807,
    "http://xbrl.sec.gov/dei/2022": 29
   },
   "contextCount": 240,
   "dts": {
    "calculationLink": {
     "local": [
      "ibio-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ibio-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ibio-20230331x10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ibio-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ibio-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ibio-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 716,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 51,
    "http://www.ibioinc.com/20230331": 8,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 64
   },
   "keyCustom": 145,
   "keyStandard": 324,
   "memberCustom": 53,
   "memberStandard": 33,
   "nsprefix": "ibio",
   "nsuri": "http://www.ibioinc.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document And Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - Financial Instruments and Fair Value Measurement",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurement",
     "shortName": "Financial Instruments and Fair Value Measurement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ibio:SignificantTransactionsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - Significant Transactions",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.ibioinc.com/role/DisclosureSignificantTransactions",
     "shortName": "Significant Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ibio:SignificantTransactionsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - Convertible Promissory Note Receivable",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.ibioinc.com/role/DisclosureConvertiblePromissoryNoteReceivable",
     "shortName": "Convertible Promissory Note Receivable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - Investments in Debt Securities",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecurities",
     "shortName": "Investments in Debt Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ibio:FinanceLeaseRightOfUseAssetDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - Finance Lease ROU Assets",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssets",
     "shortName": "Finance Lease ROU Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ibio:FinanceLeaseRightOfUseAssetDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ibio:OperatingLeaseRightOfUseAssetDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - Operating Lease ROU Assets",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssets",
     "shortName": "Operating Lease ROU Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ibio:OperatingLeaseRightOfUseAssetDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11101 - Disclosure - Fixed Assets",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.ibioinc.com/role/DisclosureFixedAssets",
     "shortName": "Fixed Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11201 - Disclosure - Intangible Assets",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.ibioinc.com/role/DisclosureIntangibleAssets",
     "shortName": "Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11301 - Disclosure - Debt",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.ibioinc.com/role/DisclosureDebt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - Condensed Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:NotesAndLoansReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11401 - Disclosure - Finance Lease Obligation",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligation",
     "shortName": "Finance Lease Obligation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11501 - Disclosure - Operating Lease Obligation",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligation",
     "shortName": "Operating Lease Obligation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11601 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.ibioinc.com/role/DisclosureStockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11701 - Disclosure - Earnings (Loss) Per Common Share",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShare",
     "shortName": "Earnings (Loss) Per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11801 - Disclosure - Share-Based Compensation",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://www.ibioinc.com/role/DisclosureShareBasedCompensation",
     "shortName": "Share-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ibio:GainLossRelatedToLitigationSettlementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11901 - Disclosure - Fraunhofer Settlement",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://www.ibioinc.com/role/DisclosureFraunhoferSettlement",
     "shortName": "Fraunhofer Settlement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ibio:GainLossRelatedToLitigationSettlementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "12001 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "26",
     "role": "http://www.ibioinc.com/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "12101 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "27",
     "role": "http://www.ibioinc.com/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "12201 - Disclosure - Employee 401(K) Plan",
     "menuCat": "Notes",
     "order": "28",
     "role": "http://www.ibioinc.com/role/DisclosureEmployee401KPlan",
     "shortName": "Employee 401(K) Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "12301 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "29",
     "role": "http://www.ibioinc.com/role/DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_LjJQ2Y3_rE6yr0k8ceA1YA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:PreferredStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20402 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "30",
     "role": "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - Discontinued Operations (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsTables",
     "shortName": "Discontinued Operations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30503 - Disclosure - Financial Instruments and Fair Value Measurement (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementTables",
     "shortName": "Financial Instruments and Fair Value Measurement (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_us-gaap_AssetAcquisitionAxis_ibio_StockPurchaseAgreementMember_3-07kxSNOkaDZSJYQDyQdQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetAcquisitionTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30603 - Disclosure - Significant Transactions (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables",
     "shortName": "Significant Transactions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_us-gaap_AssetAcquisitionAxis_ibio_StockPurchaseAgreementMember_3-07kxSNOkaDZSJYQDyQdQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetAcquisitionTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30803 - Disclosure - Investments in Debt Securities (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesTables",
     "shortName": "Investments in Debt Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ibio:SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30903 - Disclosure - Finance Lease ROU Assets (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsTables",
     "shortName": "Finance Lease ROU Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ibio:SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31103 - Disclosure - Fixed Assets (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://www.ibioinc.com/role/DisclosureFixedAssetsTables",
     "shortName": "Fixed Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31203 - Disclosure - Intangible Assets (Tables)",
     "menuCat": "Tables",
     "order": "38",
     "role": "http://www.ibioinc.com/role/DisclosureIntangibleAssetsTables",
     "shortName": "Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31303 - Disclosure - Debt (Tables)",
     "menuCat": "Tables",
     "order": "39",
     "role": "http://www.ibioinc.com/role/DisclosureDebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31403 - Disclosure - Finance Lease Obligation (Tables)",
     "menuCat": "Tables",
     "order": "40",
     "role": "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationTables",
     "shortName": "Finance Lease Obligation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31503 - Disclosure - Operating Lease Obligations (Tables)",
     "menuCat": "Tables",
     "order": "41",
     "role": "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsTables",
     "shortName": "Operating Lease Obligations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31703 - Disclosure - Earnings (Loss) Per Common Share (Tables)",
     "menuCat": "Tables",
     "order": "42",
     "role": "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareTables",
     "shortName": "Earnings (Loss) Per Common Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31803 - Disclosure - Share-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "43",
     "role": "http://www.ibioinc.com/role/DisclosureShareBasedCompensationTables",
     "shortName": "Share-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_11_3_2022_To_11_3_2022_B-3zxmk-RECRSqI6e6Ttyg",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
      "reportCount": 1,
      "unitRef": "Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - Basis of Presentation (Narrative) (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails",
     "shortName": "Basis of Presentation (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg",
      "decimals": "-5",
      "lang": null,
      "name": "ibio:CashAndCashEquivalentsPlusDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_11_3_2022_To_11_3_2022_B-3zxmk-RECRSqI6e6Ttyg",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
      "reportCount": 1,
      "unitRef": "Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - Discontinued Operations (Narrative) (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails",
     "shortName": "Discontinued Operations (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_11_3_2022_To_11_3_2022_B-3zxmk-RECRSqI6e6Ttyg",
      "decimals": "-5",
      "lang": null,
      "name": "ibio:EmployeeReductionExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40302 - Disclosure - Discontinued Operations (Reconciliation and Classifications) (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails",
     "shortName": "Discontinued Operations (Reconciliation and Classifications) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ContractWithCustomerAssetNetCurrent",
       "p",
       "ibio:ContractAssetsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerAssetNetCurrent",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Summary of Significant Accounting Policies (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ContractWithCustomerAssetNetCurrent",
       "us-gaap:ContractWithCustomerAssetNetCurrent",
       "p",
       "ibio:ContractAssetsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ContractWithCustomerAssetNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ibio:PercentageOfCollateralRequired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40402 - Disclosure - Summary of Significant Accounting Policies (Cash, Cash Equivalents and Restricted Cash) (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails",
     "shortName": "Summary of Significant Accounting Policies (Cash, Cash Equivalents and Restricted Cash) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ibio:PercentageOfCollateralRequired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:TangibleAssetImpairmentCharges",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - Financial Instruments and Fair Value Measurement (Narrative) (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails",
     "shortName": "Financial Instruments and Fair Value Measurement (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__ZOGluhSl0G7K2wu1sD4IQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - Condensed Consolidated Statements of Equity",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity",
     "shortName": "Condensed Consolidated Statements of Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gnv2jc0O2EKruqChBGMUTg",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:TangibleAssetImpairmentCharges",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40502 - Disclosure - Financial Instruments and Fair Value Measurement (Non-recurring Basis) (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails",
     "shortName": "Financial Instruments and Fair Value Measurement (Non-recurring Basis) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "As_Of_3_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_ECHSceNMpEGQENNfII3BMg",
      "decimals": "-3",
      "lang": null,
      "name": "ibio:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - Significant Transactions (Narrative) (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
     "shortName": "Significant Transactions (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "As_Of_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_xGREzJg85k2rOyE5lH-V2A",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:AssetAcquisitionTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_8_23_2021_To_8_23_2021_HiZIlu8ubEeyewTLP3230g",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetAcquisitionConsiderationTransferred",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40602 - Disclosure - Significant Transactions (Summary of Asset Acquisition) (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails",
     "shortName": "Significant Transactions (Summary of Asset Acquisition) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:AssetAcquisitionTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_8_23_2021_To_8_23_2021_HiZIlu8ubEeyewTLP3230g",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetAcquisitionConsiderationTransferred",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - Convertible Promissory Note Receivable (Narrative) (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.ibioinc.com/role/DisclosureConvertiblePromissoryNoteReceivableNarrativeDetails",
     "shortName": "Convertible Promissory Note Receivable (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "As_Of_10_1_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_VyVmxesCq0KMm1BWB8Egcw",
      "decimals": "-5",
      "lang": null,
      "name": "ibio:LoansReceivableAmountInvested",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfDebtDiscountPremium",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - Investments in Debt Securities (Narrative) (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesNarrativeDetails",
     "shortName": "Investments in Debt Securities (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40802 - Disclosure - Investments in Debt Securities (Components of Investments in Debt Securities) (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesComponentsOfInvestmentsInDebtSecuritiesDetails",
     "shortName": "Investments in Debt Securities (Components of Investments in Debt Securities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40803 - Disclosure - Investments in Debt Securities (Debt Securities, Contractual Maturity) (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesDebtSecuritiesContractualMaturityDetails",
     "shortName": "Investments in Debt Securities (Debt Securities, Contractual Maturity) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock",
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - Finance Lease ROU Assets (Narrative) (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsNarrativeDetails",
     "shortName": "Finance Lease ROU Assets (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ibio:SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40902 - Disclosure - Finance Lease ROU Assets (Summary of Finance Lease ROU) (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails",
     "shortName": "Finance Lease ROU Assets (Summary of Finance Lease ROU) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ibio:SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ibio:OperatingLeaseRightOfUseAssetDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "As_Of_9_10_2021_fOp8nNM7xESd6X0-jbcuDQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AreaOfRealEstateProperty",
      "reportCount": 1,
      "unitRef": "Unit_Standard_sqft_3kWp_fWhaEWbENPWsKzOnw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41001 - Disclosure - Operating Lease ROU Assets (Narrative) (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssetsNarrativeDetails",
     "shortName": "Operating Lease ROU Assets (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ibio:OperatingLeaseRightOfUseAssetDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "As_Of_11_1_2021_klJV-onJz0KrNHSyhYX8GA",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - Condensed Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41101 - Disclosure - Fixed Assets (Narrative) (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.ibioinc.com/role/DisclosureFixedAssetsNarrativeDetails",
     "shortName": "Fixed Assets (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg",
      "decimals": "0",
      "lang": null,
      "name": "ibio:FixedAssetsHeldForSale",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41102 - Disclosure - Fixed Assets (Carrying Value and Accumulated Depreciation) (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails",
     "shortName": "Fixed Assets (Carrying Value and Accumulated Depreciation) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41201 - Disclosure - Intangible Assets (Narrative) (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails",
     "shortName": "Intangible Assets (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_2_14_2023_To_2_14_2023_TnhaetjjP06Trcv9WL2o_A",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41202 - Disclosure - Intangible Assets (Carrying Value and Accumulated Amortization) (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails",
     "shortName": "Intangible Assets (Carrying Value and Accumulated Amortization) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestrictedCashNoncurrent",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41301 - Disclosure - Debt (The Credit Agreement) (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
     "shortName": "Debt (The Credit Agreement) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "As_Of_3_31_2023_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_co4oLbGgmE-T18TcXR1zRA",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "As_Of_10_12_2022_0w4cNGT5qUGNwBnB1qrjUA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ibio:EquipmentFinancingAmountBorrowed",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41302 - Disclosure - Debt (Equipment Financing) (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingDetails",
     "shortName": "Debt (Equipment Financing) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "As_Of_10_12_2022_0w4cNGT5qUGNwBnB1qrjUA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ibio:EquipmentFinancingAmountBorrowed",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractualObligationDueInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41303 - Disclosure - Debt (Equipment Financing) (Future Minimum Payments) (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails",
     "shortName": "Debt (Equipment Financing) (Future Minimum Payments) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractualObligationDueInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "As_Of_4_16_2020_us-gaap_DebtInstrumentAxis_ibio_PppLoanCaresActMember_arEPE-gVxE-EC-ffEJt_Mw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermNotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41304 - Disclosure - Debt (Note Payable - PPP Loan) (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.ibioinc.com/role/DisclosureDebtNotePayablePppLoanDetails",
     "shortName": "Debt (Note Payable - PPP Loan) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "As_Of_4_16_2020_us-gaap_DebtInstrumentAxis_ibio_PppLoanCaresActMember_arEPE-gVxE-EC-ffEJt_Mw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermNotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_4_1_2021_To_4_1_2021_34XjF-RfakO2aPg-6ZHbIA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ibio:LessorFinanceLeaseMonthlyRent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41401 - Disclosure - Finance Lease Obligation (Narrative) (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationNarrativeDetails",
     "shortName": "Finance Lease Obligation (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_4_1_2021_To_4_1_2021_34XjF-RfakO2aPg-6ZHbIA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ibio:LessorFinanceLeaseMonthlyRent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock",
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41402 - Disclosure - Finance Lease Obligation (Finance Lease Cost and Other Information) (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails",
     "shortName": "Finance Lease Obligation (Finance Lease Cost and Other Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock",
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:FinanceLeaseInterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - Nature of Business",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.ibioinc.com/role/DisclosureNatureOfBusiness",
     "shortName": "Nature of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41403 - Disclosure - Finance Lease Obligation (Future Minimum Payments Under the Capitalized Lease Obligations) (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails",
     "shortName": "Finance Lease Obligation (Future Minimum Payments Under the Capitalized Lease Obligations) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ibio:OperatingLeaseRightOfUseAssetDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "As_Of_9_10_2021_fOp8nNM7xESd6X0-jbcuDQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AreaOfRealEstateProperty",
      "reportCount": 1,
      "unitRef": "Unit_Standard_sqft_3kWp_fWhaEWbENPWsKzOnw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41501 - Disclosure - Operating Lease Obligation (Narrative) (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails",
     "shortName": "Operating Lease Obligation (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "As_Of_9_10_2021_fOp8nNM7xESd6X0-jbcuDQ",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41502 - Disclosure - Operating Lease Obligation (Lease Expense and Supplemental Balance Sheet Information Related to the Operating Lease Obligation) (Details)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails",
     "shortName": "Operating Lease Obligation (Lease Expense and Supplemental Balance Sheet Information Related to the Operating Lease Obligation) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41503 - Disclosure - Operating Lease Obligation (Future Minimum Payments under the Operating Lease Obligation) (Details)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails",
     "shortName": "Operating Lease Obligation (Future Minimum Payments under the Operating Lease Obligation) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "As_Of_5_9_2022_vsP8EMdp9kqoJCsGc37KdQ",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41601 - Disclosure - Stockholders' Equity (Narrative) (Details)",
     "menuCat": "Details",
     "order": "74",
     "role": "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
     "shortName": "Stockholders' Equity (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "As_Of_5_9_2022_vsP8EMdp9kqoJCsGc37KdQ",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "As_Of_3_31_2023_VGPfrwQQ3EitfLkpKM2nDg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ibio:SubscriptionReceivableCurrent",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41602 - Disclosure - Stockholders' Equity (Cantor Fitzgerald Underwriting and RubrYc Transaction) (Narrative) (Details)",
     "menuCat": "Details",
     "order": "75",
     "role": "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails",
     "shortName": "Stockholders' Equity (Cantor Fitzgerald Underwriting and RubrYc Transaction) (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_9_19_2022_To_9_19_2022_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_wXZQoYO-rEO6uGxtBLB7Ag",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_12_1_2022_To_12_1_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_hQgfyxu2uUOmIRU8B4Fklw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41603 - Disclosure - Stockholders' Equity (Wainwright Underwriting and Vesting of RSUs) (Details)",
     "menuCat": "Details",
     "order": "76",
     "role": "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails",
     "shortName": "Stockholders' Equity (Wainwright Underwriting and Vesting of RSUs) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_12_6_2022_To_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_sbC4xz-l302ta9iq3YNsng",
      "decimals": "3",
      "lang": null,
      "name": "ibio:PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperations",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41701 - Disclosure - Earnings (Loss) Per Common Share (Components of the Earnings (Loss) per Common Share ) (Details)",
     "menuCat": "Details",
     "order": "77",
     "role": "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails",
     "shortName": "Earnings (Loss) Per Common Share (Components of the Earnings (Loss) per Common Share ) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41702 - Disclosure - Earnings (Loss) Per Common Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)",
     "menuCat": "Details",
     "order": "78",
     "role": "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
     "shortName": "Earnings (Loss) Per Common Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2021_To_3_31_2022_d8VT6ABEaUiFtodTBJMZXQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromStockOptionsExercised",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41801 - Disclosure - Share-Based Compensation (Narrative) (Details)",
     "menuCat": "Details",
     "order": "79",
     "role": "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
     "shortName": "Share-Based Compensation (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "As_Of_12_9_2020_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_x5WH3KDAZkGbq_aE3REdDQ",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - Basis of Presentation",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.ibioinc.com/role/DisclosureBasisOfPresentation",
     "shortName": "Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41802 - Disclosure - Share-Based Compensation (Share Based Compensation Expense) (Details)",
     "menuCat": "Details",
     "order": "80",
     "role": "http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails",
     "shortName": "Share-Based Compensation (Share Based Compensation Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41805 - Disclosure - Share-Based Compensation (Fair Value of Options Granted) (Details)",
     "menuCat": "Details",
     "order": "81",
     "role": "http://www.ibioinc.com/role/DisclosureShareBasedCompensationFairValueOfOptionsGrantedDetails",
     "shortName": "Share-Based Compensation (Fair Value of Options Granted) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_1_20_2023_To_1_20_2023_srt_TitleOfIndividualAxis_ibio_Dr.MartinBrennerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_N9G2vRJjBkiY4CVMVYrH_Q",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41806 - Disclosure - Share-Based Compensation (RSUs) (Details)",
     "menuCat": "Details",
     "order": "82",
     "role": "http://www.ibioinc.com/role/DisclosureShareBasedCompensationRsusDetails",
     "shortName": "Share-Based Compensation (RSUs) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_1_20_2023_To_1_20_2023_srt_TitleOfIndividualAxis_ibio_Dr.MartinBrennerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_N9G2vRJjBkiY4CVMVYrH_Q",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_hICJ_ZBbVUKnEkJV7ietAA",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "As_Of_6_30_2022_J7aJ0e6kE0WrdrCV-hOktw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SettlementAssetsCurrent",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41901 - Disclosure - Fraunhofer Settlement (Narrative) (Details)",
     "menuCat": "Details",
     "order": "83",
     "role": "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails",
     "shortName": "Fraunhofer Settlement (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ibio:GainLossRelatedToLitigationSettlementTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "As_Of_6_30_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_CoaZKFcMoUunX2IienHmqw",
      "decimals": "0",
      "lang": null,
      "name": "ibio:CashPaymentsReceivablesRelatedToLitigationSettlement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "42001 - Disclosure - Income Taxes (Narrative) (Details)",
     "menuCat": "Details",
     "order": "84",
     "role": "http://www.ibioinc.com/role/DisclosureIncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_nkGsrB5FMUC463n9cjjZgA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_10_10_2022_To_10_10_2022_us-gaap_TypeOfArrangementAxis_ibio_CroAgreementMember_58YO1TPUFEKbnaIFe8Kesw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "42101 - Disclosure - Commitments and Contingencies (Narrative) (Details)",
     "menuCat": "Details",
     "order": "85",
     "role": "http://www.ibioinc.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
     "shortName": "Commitments and Contingencies (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_10_10_2022_To_10_10_2022_us-gaap_TypeOfArrangementAxis_ibio_CroAgreementMember_58YO1TPUFEKbnaIFe8Kesw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "42201 - Disclosure - Employee 401(K) Plan (Narrative) (Details)",
     "menuCat": "Details",
     "order": "86",
     "role": "http://www.ibioinc.com/role/DisclosureEmployee401KPlanNarrativeDetails",
     "shortName": "Employee 401(K) Plan (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_OE-xA8ReJ0aE9KawFPBgeg",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_XKoUs_deL0aWOL8ZreyFog",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "42301 - Disclosure - Subsequent Events (Narrative) (Details)",
     "menuCat": "Details",
     "order": "87",
     "role": "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails",
     "shortName": "Subsequent Events (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - Discontinued Operations",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.ibioinc.com/role/DisclosureDiscontinuedOperations",
     "shortName": "Discontinued Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20230331x10q.htm",
      "contextRef": "Duration_7_1_2022_To_3_31_2023_eDlUufR7M0Cyfnb-8D4AIg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 90,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document And Entity Information"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued interest receivable on convertible promissory note receivable.",
        "label": "Accrued Interest Receivable on Convertible Promissory Note Receivable",
        "negatedLabel": "Accrued interest receivable on convertible promissory note receivable"
       }
      }
     },
     "localname": "AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_AccruedLiabilitiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of noncurrent portion of accrued expenses as at the end of the reporting period.",
        "label": "Accrued Liabilities, Noncurrent",
        "terseLabel": "Accrued expenses - noncurrent"
       }
      }
     },
     "localname": "AccruedLiabilitiesNoncurrent",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid in capital acquisition of remaining portion of affiliate.",
        "label": "Adjustments to additional paid in capital acquisition of remaining portion of affiliate",
        "negatedLabel": "Acquisition of remaining portion of iBio CDMO"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalAcquisitionOfRemainingPortionOfAffiliate",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "After Preferred Tracking Stock Exchanged for Units of Limited Liability Company Interests [Member]",
        "label": "After Preferred Tracking Stock Exchanged for Units of Limited Liability Company Interests [Member]"
       }
      }
     },
     "localname": "AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_AggregateCommonStockPurchased": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Aggregate Common Stock Purchased",
        "verboseLabel": "Aggregate offering price"
       }
      }
     },
     "localname": "AggregateCommonStockPurchased",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_AmendedCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Credit Agreement [Member]",
        "label": "Amended Credit Agreement [Member]"
       }
      }
     },
     "localname": "AmendedCreditAgreementMember",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_AssetAcquisitionFixedAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition Fixed Assets [Member]",
        "label": "Asset Acquisition Fixed Assets [Member]"
       }
      }
     },
     "localname": "AssetAcquisitionFixedAssetsMember",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_AssetAcquisitionIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition Intangible Assets [Member]",
        "label": "Asset Acquisition Intangible Assets [Member]"
       }
      }
     },
     "localname": "AssetAcquisitionIntangibleAssetsMember",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_AssetAcquisitionPrepaidExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition Prepaid Expenses [Member]",
        "label": "Asset Acquisition Prepaid Expenses [Member]"
       }
      }
     },
     "localname": "AssetAcquisitionPrepaidExpensesMember",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_AssetAcquisitionTransactionCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect an asset acquisition.",
        "label": "Asset Acquisition, Transaction Costs",
        "terseLabel": "Transaction costs"
       }
      }
     },
     "localname": "AssetAcquisitionTransactionCosts",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_AssetPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Purchase Agreement [Member]",
        "label": "Asset Purchase Agreement [Member]"
       }
      }
     },
     "localname": "AssetPurchaseAgreementMember",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_AvaliableForSaleDebtSecuritiesRealizedGainsLossesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of realized gains (losses) on available for sale debt securities.",
        "label": "Avaliable For Sale Debt Securities Realized Gains (Losses) [Table Text Block]",
        "terseLabel": "Schedule of realized gains on available-for-sale debt securities"
       }
      }
     },
     "localname": "AvaliableForSaleDebtSecuritiesRealizedGainsLossesTableTextBlock",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ibio_BaseRentAbatementInFirstYearPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Base rent abatement period in the first year.",
        "label": "Base Rent Abatement In the First Year, Period",
        "terseLabel": "Base rent abatement period in the first year"
       }
      }
     },
     "localname": "BaseRentAbatementInFirstYearPeriod",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ibio_BaseRentPercentageOfFairMarketValueOfProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of base rent payable on percentage of fair Market Value of the Property.",
        "label": "Base Rent, Percentage of Fair Market Value of Property",
        "terseLabel": "Percentage of base rent"
       }
      }
     },
     "localname": "BaseRentPercentageOfFairMarketValueOfProperty",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ibio_BasisOfPresentationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Basis of Presentation.",
        "label": "Basis of Presentation [Abstract]"
       }
      }
     },
     "localname": "BasisOfPresentationAbstract",
     "nsuri": "http://www.ibioinc.com/20230331",
     "xbrltype": "stringItemType"
    },
    "ibio_CantorFitzgeraldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cantor Fitzgerald [Member]",
        "label": "Cantor Fitzgerald [Member]"
       }
      }
     },
     "localname": "CantorFitzgeraldMember",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount paid for capital expenditures incurred for intangible assets during the previous year.",
        "label": "Capital Expenditure Incurred For Intangible Assets Paid",
        "terseLabel": "Fixed assets included in accounts payable in prior period, paid in current period"
       }
      }
     },
     "localname": "CapitalExpenditureIncurredForIntangibleAssetsPaid",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_CashAndCashEquivalentsPlusDebtSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalents plus debt securities",
        "label": "Cash and cash equivalents plus debt securities",
        "terseLabel": "Cash and cash equivalents and marketable securities"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPlusDebtSecurities",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Cash Paid For Amounts Included In Measurement Lease Liabilities [Abstract]",
        "terseLabel": "Cash paid for amounts included in the measurement lease liabilities:"
       }
      }
     },
     "localname": "CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Cash Paid For Amounts Included In Measurement Operating Lease Liabilities [Abstract]",
        "terseLabel": "Cash paid for amounts included in the measurement lease liability:"
       }
      }
     },
     "localname": "CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ibio_CashPaymentsReceivablesRelatedToLitigationSettlement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash payments receivables related to litigation settlement.",
        "label": "Cash Payments Receivables Related to Litigation Settlement",
        "terseLabel": "Cash payments receivables related to litigation settlement"
       }
      }
     },
     "localname": "CashPaymentsReceivablesRelatedToLitigationSettlement",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_CollaborationAndLicenseAgreementAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and license agreement, agreement term",
        "label": "Collaboration and license agreement, agreement term",
        "terseLabel": "Collaboration and license agreement, agreement term"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementAgreementTerm",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and license agreement, royalty payment term",
        "label": "Collaboration and License Agreement, Royalty payment term",
        "terseLabel": "Collaboration and license agreement, royalty payment term"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementRoyaltyPaymentTerm",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ibio_CollaborationOptionAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration, Option and License Agreement [Member]",
        "label": "Collaboration, Option and License Agreement [Member]"
       }
      }
     },
     "localname": "CollaborationOptionAndLicenseAgreementMember",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_CollaborativeArrangementMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of milestone payments based on different scenarios.",
        "label": "Collaborative Arrangement, Milestone Payments",
        "terseLabel": "Milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementMilestonePayments",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_CollegeStationInvestorsLlcAndBryanCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to College Station Investors LLC And Bryan Capital.",
        "label": "College Station Investors LLC And Bryan Capital [Member]"
       }
      }
     },
     "localname": "CollegeStationInvestorsLlcAndBryanCapitalMember",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_CommonStockIssuedInRubrycTransactionInShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares of common stock issued in the RubrYc transaction.",
        "label": "Common Stock Issued In RubrYc Transaction (In Shares)",
        "terseLabel": "Common stock issued - RubrYc transaction (in shares)"
       }
      }
     },
     "localname": "CommonStockIssuedInRubrycTransactionInShares",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "ibio_CommonStockIssuedInRubrycTransactionValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of common stock issued in the RubrYc transaction.",
        "label": "Common Stock Issued In RubrYc Transaction, Value",
        "terseLabel": "Common stock issued - RubrYc transaction",
        "verboseLabel": "RubrYc asset acquisition by issuance of common stock"
       }
      }
     },
     "localname": "CommonStockIssuedInRubrycTransactionValue",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_CommonWarrantsToPurchaseAdditionalShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common warrants to purchase additional shares.",
        "label": "Common Warrants to Purchase Additional Shares",
        "terseLabel": "Warrants to purchase additional shares"
       }
      }
     },
     "localname": "CommonWarrantsToPurchaseAdditionalShares",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ibio_CompanyPurchasingCardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the Company purchasing card.",
        "label": "Company Purchasing Card [Member]"
       }
      }
     },
     "localname": "CompanyPurchasingCardMember",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_ConsultantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consultants [Member]",
        "label": "Consultants [Member]"
       }
      }
     },
     "localname": "ConsultantsMember",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_ContractAssetsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for contract assets.",
        "label": "Contract Assets [Policy Text Block]",
        "terseLabel": "Contract Assets"
       }
      }
     },
     "localname": "ContractAssetsPolicyTextBlock",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ibio_ContractLiabilitiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for contract liabilities.",
        "label": "Contract Liabilities [Policy Text Block]",
        "terseLabel": "Contract Liabilities"
       }
      }
     },
     "localname": "ContractLiabilitiesPolicyTextBlock",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ibio_ContractualObligationCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of current portion of contractual obligation.",
        "label": "Contractual Obligation, Current",
        "negatedLabel": "Less: current portion"
       }
      }
     },
     "localname": "ContractualObligationCurrent",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_ContractualObligationNoncurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of noncurrent portion of contractual obligation.",
        "label": "Contractual Obligation, Noncurrent",
        "terseLabel": "Long-term portion of minimum equipment financing obligation"
       }
      }
     },
     "localname": "ContractualObligationNoncurrent",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of convertible Promissory Note Receivable and Accrued Interest.",
        "label": "Convertible Promissory Note Receivable and Accrued Interest",
        "terseLabel": "Convertible promissory note receivable and accrued interest"
       }
      }
     },
     "localname": "ConvertiblePromissoryNoteReceivableAndAccruedInterest",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_CostToRaiseCapitalPaidDirectlyFromGrossProceeds": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cost incurred to raise capital directly from gross proceeds.",
        "label": "Cost to Raise Capital paid Directly from Gross Proceeds",
        "terseLabel": "Costs to raise capital paid directly from gross proceeds"
       }
      }
     },
     "localname": "CostToRaiseCapitalPaidDirectlyFromGrossProceeds",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_CreditAgreementThresholdLimitUnrestrictedCash": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold limit of unrestricted cash to be maintained.",
        "label": "Credit Agreement, Threshold Limit, Unrestricted Cash",
        "terseLabel": "Unrestricted cash"
       }
      }
     },
     "localname": "CreditAgreementThresholdLimitUnrestrictedCash",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_CroAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to CRO Agreement.",
        "label": "CRO Agreement [Member]"
       }
      }
     },
     "localname": "CroAgreementMember",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current liabilities related to assets held for sale.",
        "label": "Current Liabilities Related To Assets Held For Sale",
        "terseLabel": "Current liabilities related to assets held for sale"
       }
      }
     },
     "localname": "CurrentLiabilitiesRelatedToAssetsHeldForSale",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_DateOfAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date Of Amendment [Member]",
        "label": "Date Of Amendment [Member]"
       }
      }
     },
     "localname": "DateOfAmendmentMember",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_DebtCovenantLiquidityAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required liquidity per debt covenant.",
        "label": "Debt Covenant, Liquidity Amount",
        "terseLabel": "Liquidity covenant, amount"
       }
      }
     },
     "localname": "DebtCovenantLiquidityAmount",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_DeferredFinancingCostsAmortizationExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization of loan and debt issuance costs.",
        "label": "Deferred Financing Costs, Amortization Expense",
        "terseLabel": "Amortization of deferred financing costs"
       }
      }
     },
     "localname": "DeferredFinancingCostsAmortizationExpense",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_DiscontinuedOperationsMiscellaneousExpensesIncome": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Miscellaneous expenses (income) attributable to discontinued operations.",
        "label": "Discontinued Operations, Miscellaneous Expenses (Income)",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "DiscontinuedOperationsMiscellaneousExpensesIncome",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development expenses attributable to discontinued operations.",
        "label": "Discontinued Operations, Research And Development Expenses",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "DiscontinuedOperationsResearchAndDevelopmentExpenses",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization of finance lease ROU assets attributable to discontinued operations.",
        "label": "Disposal Group, Amortization Of Finance Lease Right Of Use Assets",
        "terseLabel": "Amortization of finance lease ROU assets"
       }
      }
     },
     "localname": "DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_DisposalGroupCurrentLiabilitiesFinanceLeaseObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current finance lease obligations attributable to discontinued operations.",
        "label": "Disposal Group, Current Liabilities, Finance Lease Obligations",
        "terseLabel": "Finance lease obligation"
       }
      }
     },
     "localname": "DisposalGroupCurrentLiabilitiesFinanceLeaseObligations",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current operating lease obligations attributable to discontinued operations.",
        "label": "Disposal Group, Current Liabilities, Operating Lease Obligations",
        "terseLabel": "Operating lease obligation"
       }
      }
     },
     "localname": "DisposalGroupCurrentLiabilitiesOperatingLeaseObligations",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed asset charges incurred but not yet paid attributable to discontinued operations.",
        "label": "Disposal Group, Fixed Assets Incurred But Not Yet Paid In Current Period",
        "terseLabel": "Fixed assets included in accounts payable in prior period, paid in current period"
       }
      }
     },
     "localname": "DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_DisposalGroupGainOnDebtForgiveness": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (loss) on forgiveness of debt to discontinued operations.",
        "label": "Disposal Group, Gain On Debt Forgiveness",
        "terseLabel": "Forgiveness of note payable and accrued interest - SBA loan"
       }
      }
     },
     "localname": "DisposalGroupGainOnDebtForgiveness",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount inventory written down in a discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Inventory Write down",
        "terseLabel": "Inventory impairments"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of personnel cost including severance incurred in a discontinuing operation.",
        "label": "Disposal Group, Including Discontinued Operation, Personnel Costs Including Severance",
        "terseLabel": "Personnel costs including severance"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Property Plant And Equipment Fair Value Disclosure",
        "terseLabel": "Total Fair Value",
        "verboseLabel": "Estimated fair values"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_DisposalGroupInterestExpenseRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest expense to related party from discontinued operations.",
        "label": "Disposal Group, Interest Expense, Related Party",
        "negatedLabel": "Interest expense - related party"
       }
      }
     },
     "localname": "DisposalGroupInterestExpenseRelatedParty",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_DisposalGroupNonCurrentAssetsFinanceLeaseRightOfUseAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as non current  assets attributable to disposal group held for sale or disposed of, expected to be disposed of more than one year.",
        "label": "Disposal Group, Non Current Assets, Finance Lease Right of Use Assets",
        "terseLabel": "Finance lease right-of-use assets"
       }
      }
     },
     "localname": "DisposalGroupNonCurrentAssetsFinanceLeaseRightOfUseAssets",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_DisposalGroupNoncurrentLiabilitiesFinanceLeaseObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncurrent finance lease obligations attributable to discontinued operations.",
        "label": "Disposal Group, Noncurrent Liabilities, Finance Lease Obligations",
        "terseLabel": "Finance lease obligation"
       }
      }
     },
     "localname": "DisposalGroupNoncurrentLiabilitiesFinanceLeaseObligations",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_DisposalGroupNoncurrentOperatingLeaseObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncurrent operating lease obligations attributable to discontinued operations.",
        "label": "Disposal Group, Noncurrent Operating Lease Obligations",
        "terseLabel": "Operating lease obligation"
       }
      }
     },
     "localname": "DisposalGroupNoncurrentOperatingLeaseObligations",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_DisposalGroupOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current operating lease ROU assets attributable to discontinued operations.",
        "label": "Disposal Group, Operating Lease Right Of Use Assets",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "DisposalGroupOperatingLeaseRightOfUseAssets",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncurrent operating lease ROU assets attributable to discontinued operations.",
        "label": "Disposal Group, Operating Lease Right Of Use Assets, Noncurrent",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_Dr.MartinBrennerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to Dr. Martin Brenner, the Company's Chief Scientific Officer and Interim Chief Executive Officer.",
        "label": "Dr. Martin Brenner [Member]",
        "terseLabel": "Dr. Martin Brenner"
       }
      }
     },
     "localname": "Dr.MartinBrennerMember",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationRsusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_EarningsLossPerCommonShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Loss Per Common Share [Line Items]"
       }
      }
     },
     "localname": "EarningsLossPerCommonShareLineItems",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ibio_EarningsLossPerCommonShareTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Loss Per Common Share [Table]"
       }
      }
     },
     "localname": "EarningsLossPerCommonShareTable",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ibio_EasternAffiliateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to Eastern affiliate.",
        "label": "Eastern Affiliate [Member]"
       }
      }
     },
     "localname": "EasternAffiliateMember",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_EmployeeReductionExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected amount of expenses to be incurred due to employee reductions.",
        "label": "Employee Reduction Expenses",
        "terseLabel": "Expected employee reduction charges"
       }
      }
     },
     "localname": "EmployeeReductionExpenses",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_EquipmentFinancingAmountBorrowed": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount borrowed under equipment financing as at the end of the reporting period.",
        "label": "Equipment Financing, Amount Borrowed",
        "terseLabel": "Amount borrowed"
       }
      }
     },
     "localname": "EquipmentFinancingAmountBorrowed",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_EquipmentFinancingBalance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of equipment financing balance under equipment leasing.",
        "label": "Equipment Financing Balance",
        "terseLabel": "Balance owed under financing"
       }
      }
     },
     "localname": "EquipmentFinancingBalance",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_EquipmentFinancingLeaseImputedInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of imputed interest rate on equipment financing.",
        "label": "Equipment Financing Lease, Imputed Interest Rate",
        "terseLabel": "Imputed interest rate"
       }
      }
     },
     "localname": "EquipmentFinancingLeaseImputedInterestRate",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ibio_EquipmentFinancingPayableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of current portion of equipment financing payable.",
        "label": "Equipment Financing Payable, Current",
        "terseLabel": "Equipment financing payable - current portion"
       }
      }
     },
     "localname": "EquipmentFinancingPayableCurrent",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_EquipmentFinancingPayableNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of noncurrent portion of equipment financing payable.",
        "label": "Equipment Financing Payable, Noncurrent",
        "terseLabel": "Equipment financing payable - net of current portion"
       }
      }
     },
     "localname": "EquipmentFinancingPayableNoncurrent",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_EquipmentLeasingMonthlyInstallmentPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of monthly installment payable under equipment leasing.",
        "label": "Equipment Leasing Monthly Installment Payable",
        "terseLabel": "Monthly installment payable"
       }
      }
     },
     "localname": "EquipmentLeasingMonthlyInstallmentPayable",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consideration transferred for equity interest acquired under the equity agreement.",
        "label": "Equity Agreement, Consideration Transferred Equity Interests Acquired",
        "terseLabel": "Cash consideration for equity interest acquired"
       }
      }
     },
     "localname": "EquityAgreementConsiderationTransferredEquityInterestsAcquired",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity agreement, percentage of equity interest issued or issuable.",
        "label": "Equity Agreement, Percentage of Equity Interest Issued or Issuable",
        "terseLabel": "Percentage of equity interest"
       }
      }
     },
     "localname": "EquityAgreementPercentageOfEquityInterestIssuedOrIssuable",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ibio_EquityAgreementWarrantsIssuedOrIssuable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants issued or issuable under the equity agreement.",
        "label": "Equity Agreement, Warrants Issued or Issuable",
        "terseLabel": "Warrants issuable"
       }
      }
     },
     "localname": "EquityAgreementWarrantsIssuedOrIssuable",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ibio_EstimatedAdditionalCostOnDevelopment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of estimated additional cost on development as at end of the reporting period.",
        "label": "Estimated Additional Cost on Development",
        "terseLabel": "Additional costs committed"
       }
      }
     },
     "localname": "EstimatedAdditionalCostOnDevelopment",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_ExchangeAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange Agreement [Member]",
        "label": "Exchange Agreement [Member]"
       }
      }
     },
     "localname": "ExchangeAgreementMember",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_FacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for facility.",
        "label": "Facility [Member]"
       }
      }
     },
     "localname": "FacilityMember",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_FairMarketValueOfProperty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair market value of the property.",
        "label": "Fair Market Value of Property",
        "terseLabel": "Fair market value of property"
       }
      }
     },
     "localname": "FairMarketValueOfProperty",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_FinanceLeaseObligationOtherInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Finance Lease Obligation, Other Information [Abstract]",
        "terseLabel": "Other Information"
       }
      }
     },
     "localname": "FinanceLeaseObligationOtherInformationAbstract",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Finance Lease ROU [Abstract]"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetDisclosureAbstract",
     "nsuri": "http://www.ibioinc.com/20230331",
     "xbrltype": "stringItemType"
    },
    "ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finance Lease, Right Of Use Asset, Disclosure [Line Items]"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetDisclosureLineItems",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ibio_FinanceLeaseRightOfUseAssetDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about activity in the balance of lessee's right to use underlying asset under finance lease.",
        "label": "Finance Lease, Right Of Use Asset, Disclosure [Table]"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetDisclosureTable",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for lessee's right to use underlying asset under finance lease.",
        "label": "Finance Lease, Right Of Use Asset, Disclosure [Text Block]",
        "terseLabel": "Finance Lease ROU Assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetDisclosureTextBlock",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ibio_FinanceLeaseRightOfUseAssetGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of lessee's right to use underlying asset under finance lease, before accumulated amortization.",
        "label": "Finance Lease, Right Of Use Asset, Gross",
        "terseLabel": "ROU, gross"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetGross",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_FinancingCashFlowsFromFinanceLeaseObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash outflow for finance lease obligations.",
        "label": "Financing Cash Flows From Finance Lease Obligation",
        "terseLabel": "Financing cash flows from finance lease obligations"
       }
      }
     },
     "localname": "FinancingCashFlowsFromFinanceLeaseObligation",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_FixedAssetsHeldForSale": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of fixed assets held-for-sale.",
        "label": "Fixed Assets Held-for-sale",
        "terseLabel": "Fixed assets held for sale"
       }
      }
     },
     "localname": "FixedAssetsHeldForSale",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFixedAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forgiveness of note payable and accrued interest - SBA loan",
        "label": "Forgiveness of note payable and accrued interest - SBA loan",
        "negatedLabel": "Forgiveness of note payable and accrued interest - SBA loan"
       }
      }
     },
     "localname": "ForgivenessOfNotePayableAndAccruedInterestSbaLoan",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_FractionalShareIssuedAfterReverseStockSplitShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fractional shares after reverse stock split issued during period.",
        "label": "Fractional Share Issued After Reverse Stock Split, Shares",
        "terseLabel": "Payment for fractional shares after reverse stock split (in shares)"
       }
      }
     },
     "localname": "FractionalShareIssuedAfterReverseStockSplitShares",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "ibio_FractionalShareIssuedAfterReverseStockSplitValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of fractional shares after reverse stock split issued during period.",
        "label": "Fractional Share Issued After Reverse Stock Split, Value",
        "terseLabel": "Payment for fractional shares after reverse stock split"
       }
      }
     },
     "localname": "FractionalShareIssuedAfterReverseStockSplitValue",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_GainLossRelatedToLitigationSettlementTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entire disclosure on gain (Loss) related to litigation settlement.",
        "label": "Gain Loss Related To Litigation Settlement [Text Block]",
        "terseLabel": "Fraunhofer Settlement"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlementTextBlock",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ibio_H.c.WainwrightCo.LlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to H.C. Wainwright &amp; Co., LLC.",
        "label": "H.C. Wainwright &amp; Co., LLC [Member]"
       }
      }
     },
     "localname": "H.c.WainwrightCo.LlcMember",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "I Bio Inc Versus Fraunhofer United States of America Incorporated [Member].",
        "label": "iBio, Inc. v. Fraunhofer USA, Inc. [Member]"
       }
      }
     },
     "localname": "IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_IbioCdmoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Bioprocessing (iBio CDMO) [Member]"
       }
      }
     },
     "localname": "IbioCdmoMember",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_IbioCmoPreferredTrackingStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to IBio CMO Preferred Tracking Stock.",
        "label": "IBio CMO Preferred Tracking Stock"
       }
      }
     },
     "localname": "IbioCmoPreferredTrackingStockMember",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_IbioInc.2020OmnibusEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for iBio, Inc. 2020 Omnibus Equity Incentive Plan.",
        "label": "2020 Omnibus Equity Incentive Plan [Member]"
       }
      }
     },
     "localname": "IbioInc.2020OmnibusEquityIncentivePlanMember",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_ImmuneOncologyAntibodiesRtx003Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immune-Oncology Antibodies (RTX-003) [Member]",
        "label": "Immune-Oncology Antibodies (RTX-003) [Member]"
       }
      }
     },
     "localname": "ImmuneOncologyAntibodiesRtx003Member",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_ImpairmentOfIntangibleAssetsGrossOfReversals": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of intangible asset impairment before reversals.",
        "label": "Impairment Of Intangible Assets Gross Of Reversals",
        "negatedLabel": "Impairment of intangible assets - gross carrying value"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsGrossOfReversals",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_ImpairmentOfPrepaidExpensesCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairment of current prepaid expenses.",
        "label": "Impairment Of Prepaid Expenses, Current",
        "terseLabel": "Impairment of current prepaid expense"
       }
      }
     },
     "localname": "ImpairmentOfPrepaidExpensesCurrent",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_ImpairmentOfPrepaidExpensesNonCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairment of non-current prepaid expenses.",
        "label": "Impairment Of Prepaid Expenses, Non Current",
        "terseLabel": "Impairment of non-current prepaid expense"
       }
      }
     },
     "localname": "ImpairmentOfPrepaidExpensesNonCurrent",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 24.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of noncurrent expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities, Noncurrent",
        "terseLabel": "Accrued expenses - noncurrent"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesNoncurrent",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) in finance lease obligations for new leases incurred during the period.",
        "label": "Increase (Decrease) In Finance Lease Obligations For New Leases",
        "terseLabel": "Increase in finance lease obligation for new leases"
       }
      }
     },
     "localname": "IncreaseDecreaseInFinanceLeaseObligationsForNewLeases",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_IncreaseDecreaseInInventoryReserve": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) in inventory valuation reserve during the period.",
        "label": "Increase (Decrease) In Inventory Reserve",
        "terseLabel": "Inventory reserve"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventoryReserve",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_IncreaseDecreaseInSettlementAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in cash received or short term receivables for unsettled money transfers, money orders, consumer payments, or business to business payments. Settlement assets include clearing and settling customers payments due to and from financial institutions and may include cash and cash equivalents.",
        "label": "Increase (Decrease) In Settlement Assets",
        "negatedLabel": "Settlement receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInSettlementAssets",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_InterestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to interest portion of the obligation.",
        "label": "Interest [Member]"
       }
      }
     },
     "localname": "InterestMember",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails",
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_LeaseIncentiveForConstructionInProgress": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease incentive for construction in progress",
        "label": "Lease incentive for construction in progress"
       }
      }
     },
     "localname": "LeaseIncentiveForConstructionInProgress",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_LeaseRentExpensePerMonth": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of lease rent expense per month during the reporting period.",
        "label": "Lease Rent Expense Per Month",
        "terseLabel": "Monthly rent"
       }
      }
     },
     "localname": "LeaseRentExpensePerMonth",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_LesseeEquipmentLeaseTermOfContract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee equipment financing lease.",
        "label": "Lessee, Equipment Lease, Term of Contract",
        "terseLabel": "Term of agreement"
       }
      }
     },
     "localname": "LesseeEquipmentLeaseTermOfContract",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee Operating Lease, Annual percentage increase in base rent",
        "label": "Lessee Operating Lease, Annual percentage increase in base rent",
        "verboseLabel": "Annual percentage increase in base rent"
       }
      }
     },
     "localname": "LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "order": 1.0,
       "parentTag": "ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal",
       "weight": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "order": 2.0,
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Imputed Interest, to be Paid, After Year Five",
        "label": "Lessee, Operating Lease, Imputed Interest, to be Paid, After Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "order": 1.0,
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Imputed Interest, to be Paid, Total",
        "label": "Lessee, Operating Lease, Imputed Interest, to be Paid, Total",
        "totalLabel": "Imputed Interest, Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseImputedInterestToBePaidTotal",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "order": 2.0,
       "parentTag": "ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal",
       "weight": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "order": 1.0,
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Imputed Interest, to be Paid, Year Five",
        "label": "Lessee, Operating Lease, Imputed Interest, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseImputedInterestToBePaidYearFive",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "order": 3.0,
       "parentTag": "ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal",
       "weight": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "order": 1.0,
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Imputed Interest, to be Paid, Year Four.",
        "label": "Lessee, Operating Lease, Imputed Interest, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseImputedInterestToBePaidYearFour",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "order": 4.0,
       "parentTag": "ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal",
       "weight": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "order": 1.0,
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Imputed Interest, to be Paid, Year One.",
        "label": "Lessee, Operating Lease, Imputed Interest, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseImputedInterestToBePaidYearOne",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "order": 5.0,
       "parentTag": "ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal",
       "weight": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "order": 1.0,
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Imputed Interest, to be Paid, Year Three",
        "label": "Lessee, Operating Lease, Imputed Interest, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseImputedInterestToBePaidYearThree",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "order": 6.0,
       "parentTag": "ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal",
       "weight": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "order": 1.0,
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Imputed Interest, to be Paid, Year Two",
        "label": "Lessee, Operating Lease, Imputed Interest, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseImputedInterestToBePaidYearTwo",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Imputed Interest Payment, Due [Abstract]",
        "label": "Operating Lease Obligation, Imputed Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee Operating Lease Liability Principal And Imputed Interest",
        "label": "Lessee Operating Lease Liability Principal And Imputed Interest",
        "totalLabel": "Principal and imputed interest, Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Principal and Imputed Interest Payment, Due [Abstract]",
        "label": "Lessee, Operating Lease, Liability, Principal and Imputed Interest Payment, Due [Abstract]",
        "terseLabel": "Operating Lease Obligation, Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "order": 1.0,
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest",
       "weight": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, After Year Five",
        "label": "Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, After Year Five",
        "totalLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "order": 2.0,
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest",
       "weight": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Five",
        "label": "Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Five",
        "totalLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "order": 3.0,
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest",
       "weight": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Four",
        "label": "Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Four",
        "totalLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "order": 4.0,
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest",
       "weight": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year One",
        "label": "Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year One",
        "totalLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "order": 5.0,
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest",
       "weight": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Three",
        "label": "Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Three",
        "totalLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "order": 6.0,
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest",
       "weight": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Two",
        "label": "Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Two",
        "totalLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_LesseeOperatingLeaseMonthlyRent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of rent payable monthly by the lessee under the operating lease.",
        "label": "Lessee, Operating Lease Monthly Rent",
        "terseLabel": "Operating lease monthly rent payable"
       }
      }
     },
     "localname": "LesseeOperatingLeaseMonthlyRent",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_LessorFinanceLeaseMonthlyRent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of rent receivable monthly by the lessor under the finance lease.",
        "label": "Lessor, Finance Lease Monthly Rent",
        "terseLabel": "Mobile office trailer monthly rent"
       }
      }
     },
     "localname": "LessorFinanceLeaseMonthlyRent",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_LetterOfCreditSanDiegoLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to letter of credit for sandiego lease.",
        "label": "Letter Of Credit - San Diego Lease [Member]"
       }
      }
     },
     "localname": "LetterOfCreditSanDiegoLeaseMember",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_LetterOfCreditTermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to letter of credit term loan.",
        "label": "Letter Of Credit - Term Loan [Member]"
       }
      }
     },
     "localname": "LetterOfCreditTermLoanMember",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_LoansReceivableAmountInvested": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the face amount of notes receivable invested.",
        "label": "Loans Receivable, Amount Invested",
        "terseLabel": "Amount invested"
       }
      }
     },
     "localname": "LoansReceivableAmountInvested",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureConvertiblePromissoryNoteReceivableNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_LoansReceivableFixedRatesOfInterest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of fixed rate of interest on notes.",
        "label": "Loans Receivable, Fixed Rates of Interest",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "LoansReceivableFixedRatesOfInterest",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureConvertiblePromissoryNoteReceivableNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ibio_NetLossAvailableToStockholdersFromContinuingOperations": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "ibio_UnconsolidatedGainLossAttributableToStockholders",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net loss available to stockholders from continuing operations.",
        "label": "Net Loss Available To Stockholders from Continuing Operations",
        "totalLabel": "Net loss available to iBio, Inc. stockholders from continuing operations"
       }
      }
     },
     "localname": "NetLossAvailableToStockholdersFromContinuingOperations",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_NoBiosimilarProductHasBeenApprovedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No Biosimilar Product has been Approved [Member]",
        "label": "No Biosimilar Product has been Approved [Member]"
       }
      }
     },
     "localname": "NoBiosimilarProductHasBeenApprovedMember",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_NonCashSettlementOfRevenueContract": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash Settlement of revenue contract",
        "label": "Non cash Settlement of revenue contract",
        "verboseLabel": "Settlement of revenue contract"
       }
      }
     },
     "localname": "NonCashSettlementOfRevenueContract",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of increase in Right Of Use Assets under the ASU 842, for which no cash outflow was incurred.",
        "label": "Non Cash Transaction Increase In Right Of Use Assets And Liabilities",
        "terseLabel": "Increase in operating lease ROU assets for new lease - net of lease incentive"
       }
      }
     },
     "localname": "NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_NoncashOrPartNoncashAcquisitionNonControllingInterestAssumed": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of non controlling interest that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Non Controlling Interest Assumed",
        "terseLabel": "Acquisition of noncontrolling interest"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionNonControllingInterestAssumed",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncurrent liabilities related to assets held for sale.",
        "label": "Noncurrent Liabilities Related To Assets Held For Sale",
        "terseLabel": "Noncurrent liabilities related to assets held for sale"
       }
      }
     },
     "localname": "NoncurrentLiabilitiesRelatedToAssetsHeldForSale",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_NumberOfAdditionalSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares issued.",
        "label": "Number of Additional Shares Issued",
        "terseLabel": "Additional shares issued"
       }
      }
     },
     "localname": "NumberOfAdditionalSharesIssued",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ibio_NumberOfDaysOptionToPurchaseAdditionalShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of days option to purchase additional shares.",
        "label": "Number of Days Option to Purchase Additional Shares",
        "terseLabel": "Number of days granted to purchase additional shares"
       }
      }
     },
     "localname": "NumberOfDaysOptionToPurchaseAdditionalShares",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ibio_NumberOfEquipmentLeases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of equipment leases.",
        "label": "Number of Equipment Leases",
        "terseLabel": "Number of equipment leases"
       }
      }
     },
     "localname": "NumberOfEquipmentLeases",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Limited Liability Company interest units exchanged for each share of preferred tracking stock.",
        "label": "Number of Limited Liability Company interest units exchanged for each share of preferred tracking stock",
        "terseLabel": "Number of LLC interest units exchanged for each share of preferred tracking stock"
       }
      }
     },
     "localname": "NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ibio_NumberOfMajorCustomers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to number of major customers.",
        "label": "Number of Major Customers",
        "terseLabel": "Number of major customers"
       }
      }
     },
     "localname": "NumberOfMajorCustomers",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ibio_OccurrenceOfSpecificMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Occurrence Of Specific Milestone [Member]",
        "label": "Occurrence Of Specific Milestone [Member]"
       }
      }
     },
     "localname": "OccurrenceOfSpecificMilestoneMember",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_OmnibusIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Omnibus Incentive Plan [Member]",
        "label": "Omnibus Incentive (the 2020) Plan [Member]"
       }
      }
     },
     "localname": "OmnibusIncentivePlanMember",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_OperatingCashFlowsFromOperatingLeaseObligation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating cash flows from operating lease obligation.",
        "label": "Operating Cash Flows From Operating Lease Obligation",
        "terseLabel": "Operating cash flows from operating lease obligation"
       }
      }
     },
     "localname": "OperatingCashFlowsFromOperatingLeaseObligation",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_OperatingLeaseCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Operating Lease Costs [Abstract]",
        "terseLabel": "Operating lease cost:"
       }
      }
     },
     "localname": "OperatingLeaseCostsAbstract",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ibio_OperatingLeaseObligationOtherInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Operating Lease Obligation Other Information [Abstract]",
        "verboseLabel": "Other information:"
       }
      }
     },
     "localname": "OperatingLeaseObligationOtherInformationAbstract",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease Right Of Use Asset Disclosure [Text Block]",
        "terseLabel": "Operating Lease ROU Assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetDisclosureTextBlock",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ibio_PaymentOfEquipmentFinancingLoan": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash outflow for equipment financing loan.",
        "label": "Payment of Equipment Financing Loan",
        "negatedLabel": "Payment of equipment financing loan"
       }
      }
     },
     "localname": "PaymentOfEquipmentFinancingLoan",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_PaymentsForFractionalSharesAfterReverseStockSplit": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash outflow for fractional shares after reverse stock split.",
        "label": "Payments for Fractional Shares after Reverse Stock Split",
        "negatedLabel": "Payments for fractional shares after reverse stock split"
       }
      }
     },
     "localname": "PaymentsForFractionalSharesAfterReverseStockSplit",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_PaymentsToAttainTermNote": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred with attain term note.",
        "label": "Payments To Attain Term Note",
        "negatedLabel": "Costs to attain term note"
       }
      }
     },
     "localname": "PaymentsToAttainTermNote",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_PercentageOfAggregateNumberOfSharesOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of aggregate number of shares of common stock.",
        "label": "Percentage of Aggregate Number of Shares of Common Stock",
        "terseLabel": "Percentage of number of shares"
       }
      }
     },
     "localname": "PercentageOfAggregateNumberOfSharesOfCommonStock",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ibio_PercentageOfCollateralRequired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of collateral required to be held by the reporting entity.",
        "label": "Percentage Of Collateral Required",
        "terseLabel": "Additional percentage of collateral held required by bank"
       }
      }
     },
     "localname": "PercentageOfCollateralRequired",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ibio_PercentageOfLegalFeesExpectedToBeReceived": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of legal fees expected to be received.",
        "label": "Percentage Of Legal Fees Expected to be Received",
        "terseLabel": "Percentage of legal fees expected to be received"
       }
      }
     },
     "localname": "PercentageOfLegalFeesExpectedToBeReceived",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of underwriting discount paid on gross proceeds of offering.",
        "label": "Percentage of Underwriting Discount Paid on Gross Proceeds of Offering",
        "terseLabel": "Percentage of underwriting discount"
       }
      }
     },
     "localname": "PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ibio_PppLoanCaresActMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PP Loans Cares Act.",
        "label": "PPP Loan Cares Act [Member]"
       }
      }
     },
     "localname": "PppLoanCaresActMember",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtNotePayablePppLoanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_PreFundedWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Pre Funded Warrants.",
        "label": "Pre Funded Warrants [Member]"
       }
      }
     },
     "localname": "PreFundedWarrantsMember",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_PreferredTrackingStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "iBio CMO Preferred Tracking Stock [Member]"
       }
      }
     },
     "localname": "PreferredTrackingStockMember",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_PrincipalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to principal portion of the obligation.",
        "label": "Principal [Member]"
       }
      }
     },
     "localname": "PrincipalMember",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails",
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_ProceedsFromEquipmentFinancingLoan": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash inflow from equipment financing loan.",
        "label": "Proceeds from Equipment Financing Loan",
        "terseLabel": "Proceeds from equipment financing loan"
       }
      }
     },
     "localname": "ProceedsFromEquipmentFinancingLoan",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_ProceedsFromIssuanceOfPreferredAndCommonStock": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds From Issuance Of Preferred And Common Stock",
        "terseLabel": "Proceeds from sales of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPreferredAndCommonStock",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total purchase price for the Property, the termination of the Sublease and other agreements among the parties, and the equity interests.",
        "label": "Purchase Price For Property, Termination of Sublease And Equity Interest",
        "terseLabel": "Total purchase price"
       }
      }
     },
     "localname": "PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash payment for purchase price for the Property, the termination of the Sublease and other agreements among the parties, and the equity interests.",
        "label": "Purchase Price For Property, Termination of Sublease And Equity Interest, Cash Payment",
        "terseLabel": "Cash payment"
       }
      }
     },
     "localname": "PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The reclassification adjustment for the period on gains (losses) on avaliable for sale debt securities.",
        "label": "Reclassficiation Adjustment, Gain (Loss) On Available For Sale Debt Securities",
        "terseLabel": "Reclassification adjustment for loss on available-for-sale debt securities realized in net income"
       }
      }
     },
     "localname": "ReclassficiationAdjustmentGainLossOnAvailableForSaleDebtSecurities",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_RepresentativeWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to representative warrants.",
        "label": "Representative Warrants [Member]"
       }
      }
     },
     "localname": "RepresentativeWarrantsMember",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_ReversalOfIntangibleAssetImpairment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reversal of intangible asset impairment.",
        "label": "Reversal Of Intangible Asset Impairment",
        "terseLabel": "Intangible asset impairment - accumulated amortization"
       }
      }
     },
     "localname": "ReversalOfIntangibleAssetImpairment",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_RightOfUseAssetsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of accounting policy for right-of-use assets.",
        "label": "Right Of Use Assets Policy [Policy Text Block]",
        "terseLabel": "Right-of-Use Assets"
       }
      }
     },
     "localname": "RightOfUseAssetsPolicyPolicyTextBlock",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ibio_RubrycTheraputicsInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RubrYc Therapeutics, Inc. [Member]",
        "label": "RubrYc Therapeutics, Inc. [Member]"
       }
      }
     },
     "localname": "RubrycTheraputicsInc.Member",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_SalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Sales Agreement.",
        "label": "Sales Agreement"
       }
      }
     },
     "localname": "SalesAgreementMember",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_ScenarioOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for scenario one in which the value of maximum award in calendar year in which the applicable non-employee director is initially elected or appointed to the Board of Directors.",
        "label": "Scenario One [Member]"
       }
      }
     },
     "localname": "ScenarioOneMember",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_ScenarioPlanExpectedLegalFeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario Plan, Expected Legal Fees [Member].",
        "label": "Scenario Plan Expected Legal Fees [Member]"
       }
      }
     },
     "localname": "ScenarioPlanExpectedLegalFeesMember",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_ScenarioPlanExpectedPaymentOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario Plan Expected Payment One [Member].",
        "label": "Scenario Plan Expected Payment One [Member]"
       }
      }
     },
     "localname": "ScenarioPlanExpectedPaymentOneMember",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_ScenarioPlanExpectedPaymentTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario Plan Expected Payment Two [Member].",
        "label": "Scenario Plan Expected Payment Two [Member]"
       }
      }
     },
     "localname": "ScenarioPlanExpectedPaymentTwoMember",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_ScenarioTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This represents Preferred tracking stock exchanged for units.",
        "label": "Scenario Two [Member]"
       }
      }
     },
     "localname": "ScenarioTwoMember",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure for components of lease expense and supplemental balance sheet information related to the finance lease obligation.",
        "label": "Schedule Of Components Of Lease Expense And Supplemental Balance Sheet Information Related To Finance Lease Obligation [Table Text Block]",
        "terseLabel": "Schedule of components of lease expense and supplemental balance sheet information related to the finance lease obligation"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of components of lease expense and supplemental balance sheet information related to the Operating lease obligation",
        "label": "Schedule of components of lease expense and supplemental balance sheet information related to the Operating lease obligation [Table Text Block]",
        "terseLabel": "Lease Expense and Supplemental Balance Sheet Information Related to the Operating Lease Obligation"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ibio_ScheduleOfFinanceLeaseRightOfUseAssetsAndObligationAndWeightedAverageInformationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to schedule of finance lease right of use assets and obligation and weighted average information.",
        "label": "Schedule of Finance Lease Right of use Assets and Obligation and Weighted average Information [Table Text Block]",
        "terseLabel": "Schedule of finance lease and weighted average information"
       }
      }
     },
     "localname": "ScheduleOfFinanceLeaseRightOfUseAssetsAndObligationAndWeightedAverageInformationTableTextBlock",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ibio_SecondEasternAffiliateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent information pertaining to Second Eastern Affiliate.",
        "label": "Second Eastern Affiliate [Member]"
       }
      }
     },
     "localname": "SecondEasternAffiliateMember",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_SecuredTermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to secured term loan.",
        "label": "Secured Term Loan"
       }
      }
     },
     "localname": "SecuredTermLoanMember",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_SeparationAgreementAndGeneralReleaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the member information pertaining to Separation Agreement and General Release.",
        "label": "Separation Agreement and General Release [Member]"
       }
      }
     },
     "localname": "SeparationAgreementAndGeneralReleaseMember",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_Series2022ConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series 2022 Convertible Preferred Stock [Member]",
        "label": "Series 2022 Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "Series2022ConvertiblePreferredStockMember",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_Series2PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A-2 Preferred Stock [Member]",
        "label": "Series A-2 Preferred Stock [Member]"
       }
      }
     },
     "localname": "Series2PreferredStockMember",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_SeriesBWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to series B warrants.",
        "label": "Series B Warrants [Member]"
       }
      }
     },
     "localname": "SeriesBWarrantsMember",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_SeriesWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to series A warrants.",
        "label": "Series A Warrants [Member]"
       }
      }
     },
     "localname": "SeriesWarrantsMember",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_SettlementAssetsNonCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settlement receivables, Non current portion.",
        "label": "Settlement Assets Non Current",
        "terseLabel": "Settlement receivable - noncurrent portion"
       }
      }
     },
     "localname": "SettlementAssetsNonCurrent",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_SettlementOfRevenueContract": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settlement of revenue contract.",
        "label": "Settlement of revenue contract",
        "negatedLabel": "Settlement of revenue contract"
       }
      }
     },
     "localname": "SettlementOfRevenueContract",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Consolidated Omnibus Budget Reconciliation Act of 1985 (\"COBRA\") subsidy period.",
        "label": "Severance Benefits, Consolidated Omnibus Budget Reconciliation Act Subsidy Period",
        "terseLabel": "COBRA subsidy period"
       }
      }
     },
     "localname": "SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum period of coverage of health insurance under the Consolidated Omnibus Budget Reconciliation Act of 1985 (\"COBRA\").",
        "label": "Severance Benefits, Maximum Period for Coverage of Health Insurance If Employer Elects Consolidated Omnibus Budget Reconciliation Act",
        "terseLabel": "Maximum period for coverage of health insurance"
       }
      }
     },
     "localname": "SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of times on which the Company has to make lump sum cash payment if the employee not obtained health coverage under Consolidated Omnibus Budget Reconciliation Act of 1985 (\"COBRA\").",
        "label": "Severance Benefits, Number of Times on Which Lum Sum Cash Payment to be Made if Health Coverage Not Made Under Consolidated Omnibus Budget Reconciliation Act",
        "terseLabel": "Number of times on which lump sum cash payment tis o be made"
       }
      }
     },
     "localname": "SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the period of bi-monthly installments of current base salary to be paid under severance benefits.",
        "label": "Severance Benefits, Period of Bi-Monthly Installments of Current Base Salary",
        "terseLabel": "Period of bi-monthly installments of current base salary"
       }
      }
     },
     "localname": "SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the period of bi-monthly installments of target bonus to be paid under severance benefits.",
        "label": "Severance Benefits, Period of Bi-Monthly Installments of target Bonus",
        "terseLabel": "Period of bi-monthly installments of target bonus"
       }
      }
     },
     "localname": "SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Amount of Shares Authorized.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Amount of Shares Authorized",
        "terseLabel": "Maximum value of all awards awarded under the Plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_SignificantTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant Transactions [Abstract]",
        "label": "Significant Transactions [Abstract]"
       }
      }
     },
     "localname": "SignificantTransactionsAbstract",
     "nsuri": "http://www.ibioinc.com/20230331",
     "xbrltype": "stringItemType"
    },
    "ibio_SignificantTransactionsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant Transactions [Text Block]",
        "label": "Significant Transactions [Text Block]",
        "verboseLabel": "Significant Transactions"
       }
      }
     },
     "localname": "SignificantTransactionsTextBlock",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ibio_StockIssuedDuringPeriodSharesCapitalRaise": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new shares raised during the period.",
        "label": "Stock Issued During Period, Shares, Capital Raise",
        "terseLabel": "Capital raise (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesCapitalRaise",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "ibio_StockIssuedDuringPeriodValueCapitalRaise": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of capital raise during the period.",
        "label": "Stock Issued During Period, Value, Capital Raise",
        "terseLabel": "Capital raise"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueCapitalRaise",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_StockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Purchase Agreement [Member]",
        "label": "Stock Purchase Agreement [Member]"
       }
      }
     },
     "localname": "StockPurchaseAgreementMember",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_StockPurchaseAgreementNumberOfSharesPurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock purchase agreement, number of shares purchased",
        "label": "Stock purchase agreement, number of shares purchased",
        "terseLabel": "Stock purchase agreement, number of shares purchased"
       }
      }
     },
     "localname": "StockPurchaseAgreementNumberOfSharesPurchased",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ibio_StockPurchaseAgreementTotalInvestment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of investment under the stock purchase agreement.",
        "label": "Stock Purchase Agreement, Total Investment",
        "terseLabel": "Investment"
       }
      }
     },
     "localname": "StockPurchaseAgreementTotalInvestment",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_StockPurchaseAgreementValueOfSharesPurchased": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock purchase agreement, value of shares purchased",
        "label": "Stock purchase agreement, value of shares purchased"
       }
      }
     },
     "localname": "StockPurchaseAgreementValueOfSharesPurchased",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_StockholdersEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity [Line Items]"
       }
      }
     },
     "localname": "StockholdersEquityLineItems",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ibio_StockholdersEquityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity [Table]"
       }
      }
     },
     "localname": "StockholdersEquityTable",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ibio_SubscriptionReceivableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of subscription receivables classified due within one year or the normal operating cycle, if longer.",
        "label": "Subscription Receivable Current",
        "terseLabel": "Subscription receivable"
       }
      }
     },
     "localname": "SubscriptionReceivableCurrent",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure for the gross carrying value and accumulated amortization of right-to-use assets under finance lease.",
        "label": "Summary Of Gross Carrying Value And Accumulated Amortization Of Finance Lease, Right Of Use Assets [Table Text Block]",
        "terseLabel": "Summary of the gross carrying value and accumulated amortization of finance lease ROU"
       }
      }
     },
     "localname": "SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ibio_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ibio_TangibleAssetImpairmentChargesDiscontinuedOperations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets of discontinued operations from their carrying value to their fair value.",
        "label": "Tangible Asset Impairment Charges, Discontinued Operations",
        "terseLabel": "Fixed assets impairments"
       }
      }
     },
     "localname": "TangibleAssetImpairmentChargesDiscontinuedOperations",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_TerminationOfFinanceLeaseRightOfUseAssetIncludingIssuanceOfWarrant": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of termination of finance lease right of use asset, including issuance of warrant.",
        "label": "Termination Of Finance Lease Right Of Use Asset, Including Issuance Of Warrant",
        "terseLabel": "Termination of finance ROU assets including issuance of warrant"
       }
      }
     },
     "localname": "TerminationOfFinanceLeaseRightOfUseAssetIncludingIssuanceOfWarrant",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_TotalOperatingLeaseCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total operating lease costs.",
        "label": "Total Operating Lease Costs",
        "terseLabel": "Total lease cost"
       }
      }
     },
     "localname": "TotalOperatingLeaseCosts",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_TwoThousandEighteenOmnibusEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to Two thousand Eighteen Omnibus Equity Incentive Plan.",
        "label": "2018 Omnibus Equity Incentive Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandEighteenOmnibusEquityIncentivePlanMember",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_UnconsolidatedGainLossAttributableToStockholders": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The unconsolidated net gain (loss) attributable to stockholders.",
        "label": "Unconsolidated Gain (Loss) Attributable To Stockholders",
        "totalLabel": "Net loss available to iBio, Inc. stockholders"
       }
      }
     },
     "localname": "UnconsolidatedGainLossAttributableToStockholders",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unpaid fixed assets included in accounts payable, attributable to discontinued operations.",
        "label": "Unpaid Fixed Assets Attributable To Discontinued Operations",
        "terseLabel": "Unpaid fixed assets included in accounts payable"
       }
      }
     },
     "localname": "UnpaidFixedAssetsAttributableToDiscontinuedOperations",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_VariousEmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Various Employees [Member]",
        "label": "Employees [Member]"
       }
      }
     },
     "localname": "VariousEmployeesMember",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants issued for the final payment of rent due under sublease.",
        "label": "Warrants Issued for Final Payment of Sublease Rent",
        "terseLabel": "Shares issued under the Warrant"
       }
      }
     },
     "localname": "WarrantsIssuedForFinalPaymentOfSubleaseRent",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of warrants issued for the final payment of rent due under sublease.",
        "label": "Warrants Issued for Final Payment of Sublease Rent, Value",
        "terseLabel": "Fair value of the warrant"
       }
      }
     },
     "localname": "WarrantsIssuedForFinalPaymentOfSubleaseRentValue",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_WarrantsIssuedForFinanceLeasePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of warrants issued in noncash financing activities.",
        "label": "Warrants Issued for Finance Lease Payment",
        "terseLabel": "Issuance of warrant for final finance lease obligation payment"
       }
      }
     },
     "localname": "WarrantsIssuedForFinanceLeasePayment",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Within Two Business Days Of Frunhofer Legal Settlement [Member]",
        "label": "Within Two Business Days Of Frunhofer Legal Settlement [Member]"
       }
      }
     },
     "localname": "WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_WoodforestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Woodforest [Member]",
        "label": "Woodforest [Member]",
        "terseLabel": "Woodforest Bank"
       }
      }
     },
     "localname": "WoodforestMember",
     "nsuri": "http://www.ibioinc.com/20230331",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": {
     "auth_ref": [
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.",
        "label": "Contractual Obligation, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Schedule of future minimum payments under the finance lease obligation"
       }
      }
     },
     "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r257",
      "r258",
      "r357",
      "r385",
      "r594",
      "r596",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim.",
        "label": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information.",
        "label": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r341",
      "r342",
      "r343",
      "r344",
      "r434",
      "r549",
      "r576",
      "r590",
      "r591",
      "r609",
      "r615",
      "r624",
      "r666",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r341",
      "r342",
      "r343",
      "r344",
      "r434",
      "r549",
      "r576",
      "r590",
      "r591",
      "r609",
      "r615",
      "r624",
      "r666",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.",
        "label": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.",
        "label": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r314",
      "r552",
      "r610",
      "r623",
      "r660",
      "r661",
      "r668",
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by product and service, or group of similar products and similar services.",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r314",
      "r552",
      "r610",
      "r623",
      "r660",
      "r661",
      "r668",
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product or service, or a group of similar products or similar services.",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r341",
      "r342",
      "r343",
      "r344",
      "r415",
      "r434",
      "r466",
      "r467",
      "r468",
      "r548",
      "r549",
      "r576",
      "r590",
      "r591",
      "r609",
      "r615",
      "r624",
      "r658",
      "r666",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r341",
      "r342",
      "r343",
      "r344",
      "r415",
      "r434",
      "r466",
      "r467",
      "r468",
      "r548",
      "r549",
      "r576",
      "r590",
      "r591",
      "r609",
      "r615",
      "r624",
      "r658",
      "r666",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r257",
      "r258",
      "r357",
      "r385",
      "r597",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r273",
      "r435",
      "r632",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario, Unspecified [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r273",
      "r435",
      "r632",
      "r633",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r654",
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationRsusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of individual, or nature of relationship to individual or group of individuals.",
        "label": "Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationRsusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]"
       }
      }
     },
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureConvertiblePromissoryNoteReceivableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of receivable.",
        "label": "Receivable Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureConvertiblePromissoryNoteReceivableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r42",
      "r622"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r317",
      "r318"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, Net, Current",
        "verboseLabel": "Accounts receivable - trade"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "verboseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r117",
      "r220"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r56",
      "r57",
      "r58",
      "r226",
      "r572",
      "r581",
      "r582"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r55",
      "r58",
      "r158",
      "r539",
      "r577",
      "r578",
      "r637",
      "r638",
      "r639",
      "r647",
      "r648",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Loss [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "verboseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r474",
      "r475",
      "r476",
      "r647",
      "r648",
      "r649",
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r148",
      "r149",
      "r438"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r132",
      "r138"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "negatedLabel": "Cost to raise capital"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r130",
      "r132",
      "r138"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Warrant issued for Transaction"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile consolidated net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r470"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share-based Compensation Expense",
        "verboseLabel": "Allocated Share-based Compensation Expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r67",
      "r80",
      "r173",
      "r376"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Amortization of premiums on debt securities",
        "verboseLabel": "Amortization of premiums on debt securities"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDeferredChargesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Deferred Charges [Abstract]",
        "terseLabel": "Amortization"
       }
      }
     },
     "localname": "AmortizationOfDeferredChargesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r80",
      "r102",
      "r108"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "negatedLabel": "Amortization of definite lived intangible assets",
        "verboseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails",
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "verboseLabel": "Area of lab and office"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssetsNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "auth_ref": [
      "r618",
      "r697",
      "r698",
      "r699"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.",
        "label": "Asset Acquisition, Consideration Transferred",
        "terseLabel": "Purchase price allocated"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferred",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionTableTextBlock": {
     "auth_ref": [
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of asset acquisition.",
        "label": "Asset Acquisition [Table Text Block]",
        "terseLabel": "Summary of Purchase Price Allocation of Asset Acquisition"
       }
      }
     },
     "localname": "AssetAcquisitionTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r180",
      "r194",
      "r222",
      "r254",
      "r305",
      "r308",
      "r312",
      "r325",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r495",
      "r499",
      "r513",
      "r622",
      "r664",
      "r665",
      "r713"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r215",
      "r228",
      "r254",
      "r325",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r495",
      "r499",
      "r513",
      "r622",
      "r664",
      "r665",
      "r713"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total Current Assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r165"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Estimated fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent": {
     "auth_ref": [
      "r112",
      "r622"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer.",
        "label": "Assets Held-for-sale, Not Part of Disposal Group, Current",
        "terseLabel": "Current assets held for sale"
       }
      }
     },
     "localname": "AssetsHeldForSaleNotPartOfDisposalGroupCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r21",
      "r114",
      "r120",
      "r213",
      "r214"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Current",
        "terseLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Assets, Noncurrent [Abstract]",
        "terseLabel": "Other assets:"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesComponentsOfInvestmentsInDebtSecurities2Details": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesComponentsOfInvestmentsInDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r323",
      "r327"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesComponentsOfInvestmentsInDebtSecurities2Details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Adjusted cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesComponentsOfInvestmentsInDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss": {
     "auth_ref": [
      "r98"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss",
        "terseLabel": "Unrealized (gain) loss on available-for-sale debt securities"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesDebtSecuritiesContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling within One Year, Fair Value",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesDebtSecuritiesContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling Maturity, Fair Value [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesDebtSecuritiesContractualMaturityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesDebtSecuritiesContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling after Two Years, Fair Value",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesDebtSecuritiesContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for premium paid to acquire option for investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Premium on Purchased Options [Policy Text Block]",
        "verboseLabel": "Investments in Debt Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesPurchasedOptionsPricePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r441",
      "r442",
      "r443",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationRsusDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Buildings and improvements [Member]"
       }
      }
     },
     "localname": "BuildingAndBuildingImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails",
      "http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalExpenditureDiscontinuedOperations": {
     "auth_ref": [
      "r20"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of capital expenditure attributable to discontinued operations.",
        "label": "Capital Expenditure, Discontinued Operations",
        "terseLabel": "Purchase of fixed assets"
       }
      }
     },
     "localname": "CapitalExpenditureDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r82",
      "r218",
      "r595"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments",
       "weight": 1.0
      },
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r636"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r76",
      "r82",
      "r87"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash - end",
        "periodStartLabel": "Cash, cash equivalents and restricted cash - beginning"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r76",
      "r172"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "negatedLabel": "Amount released from restricted cash",
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashUninsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.",
        "label": "Cash, Uninsured Amount",
        "verboseLabel": "Amount in excess of insured limit"
       }
      }
     },
     "localname": "CashUninsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r223",
      "r224",
      "r225",
      "r254",
      "r277",
      "r278",
      "r281",
      "r283",
      "r291",
      "r292",
      "r325",
      "r345",
      "r347",
      "r348",
      "r349",
      "r352",
      "r353",
      "r383",
      "r384",
      "r387",
      "r391",
      "r398",
      "r513",
      "r592",
      "r631",
      "r644",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r140",
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrants, exercise price per share"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of warrants issued",
        "verboseLabel": "Warrants to purchase shares of Common Stock"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r124",
      "r339",
      "r340",
      "r586",
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "verboseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Number of shares reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r647",
      "r648",
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)",
        "verboseLabel": "Common Stock, Par or Stated Value Per Share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)",
        "verboseLabel": "Common Stock, Shares Authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common Stock, Shares, Issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r35",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common Stock, Shares, Outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r35",
      "r622"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Value of common stock issued",
        "verboseLabel": "Common stock - $0.001 par value; 275,000,000 shares authorized at March 31, 2023 and June 30, 2022; 15,818,149 and 8,727,158 shares issued and outstanding as of March 31, 2023 and June 30, 2022, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee 401(K) Plan [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r156",
      "r161",
      "r233",
      "r235",
      "r241",
      "r568",
      "r573"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r91",
      "r92",
      "r170",
      "r171",
      "r316",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r91",
      "r92",
      "r170",
      "r171",
      "r316",
      "r583",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r91",
      "r92",
      "r170",
      "r171",
      "r316",
      "r585",
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r192",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r91",
      "r92",
      "r170",
      "r171",
      "r316",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in progress [Member]"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "auth_ref": [
      "r401",
      "r402",
      "r411"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.",
        "label": "Contract with Customer, Asset, Net, Current",
        "verboseLabel": "Contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r412"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Revenue recognized included in contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "Contractual Obligation",
        "verboseLabel": "Total minimum equipment financing payments"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligationDueInNextTwelveMonths": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Contractual Obligation, to be Paid, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "ContractualObligationDueInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligationDueInSecondYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Contractual Obligation, to be Paid, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "ContractualObligationDueInSecondYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligationDueInThirdYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Contractual Obligation, to be Paid, Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "ContractualObligationDueInThirdYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r33",
      "r34",
      "r133",
      "r134",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Shares issued upon conversion"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r90",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r131",
      "r252",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r370",
      "r377",
      "r378",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r30",
      "r31",
      "r32",
      "r181",
      "r182",
      "r193",
      "r259",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r360",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r522",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureDebtNotePayablePppLoanDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentDecreaseForgiveness": {
     "auth_ref": [
      "r645"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.",
        "label": "Debt Instrument, Decrease, Forgiveness",
        "terseLabel": "Liability and accrued interest derecognized"
       }
      }
     },
     "localname": "DebtInstrumentDecreaseForgiveness",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtNotePayablePppLoanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r174",
      "r176",
      "r354",
      "r522",
      "r605",
      "r606"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "verboseLabel": "Secured term loan"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "auth_ref": [
      "r48"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.",
        "label": "Debt Instrument, Fee Amount",
        "terseLabel": "Amendment fee"
       }
      }
     },
     "localname": "DebtInstrumentFeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r47",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate (as percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r49",
      "r259",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r360",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r522",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureDebtNotePayablePppLoanDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPayment": {
     "auth_ref": [
      "r49",
      "r190"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payments including both interest and principal payments.",
        "label": "Debt Instrument, Periodic Payment",
        "terseLabel": "Debt amortization payment"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPayment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": {
     "auth_ref": [
      "r49"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payments applied to principal.",
        "label": "Debt Instrument, Periodic Payment, Principal",
        "terseLabel": "Principal payment"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentPrincipal",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r49",
      "r133",
      "r135",
      "r136",
      "r137",
      "r173",
      "r174",
      "r176",
      "r191",
      "r259",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r360",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r379",
      "r522",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 26.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Gain (Loss)",
        "negatedLabel": "Loss on sale of debt securities",
        "terseLabel": "Loss on sale of debt securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Unrealized Gain (Loss)",
        "terseLabel": "Unrealized gain (loss) on available-for-sale debt securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesComponentsOfInvestmentsInDebtSecurities2Details": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesDebtSecuritiesContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity), and investment in debt security measured at fair value with change in fair value recognized in net income (trading), classified as current.",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair value",
        "totalLabel": "Fair value",
        "verboseLabel": "Investments in debt securities"
       }
      }
     },
     "localname": "DebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesComponentsOfInvestmentsInDebtSecuritiesDetails",
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesDebtSecuritiesContractualMaturityDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r175",
      "r667"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "terseLabel": "Deferred finance costs",
        "verboseLabel": "Cost incurred to attain debt"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r635"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred Revenue",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "auth_ref": [
      "r414",
      "r417",
      "r430",
      "r611",
      "r612",
      "r613",
      "r614"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer"
       }
      }
     },
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEmployee401KPlanNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEmployee401KPlanNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEmployee401KPlanNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r80",
      "r115"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense",
        "verboseLabel": "Depreciation of fixed assets"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFixedAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortizationDiscontinuedOperations": {
     "auth_ref": [
      "r212",
      "r642"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deprecation and amortization expense attributable to property, plant and equipment and intangible assets of discontinued operations.",
        "label": "Depreciation and Amortization, Discontinued Operations",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "DepreciationAndAmortizationDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r440",
      "r471",
      "r472",
      "r473",
      "r478",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation [Member]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease ROU Assets [Abstract]"
       }
      }
     },
     "localname": "DisclosureTextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r21",
      "r114",
      "r120"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r21",
      "r113",
      "r120",
      "r213",
      "r214"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Noncurrent",
        "terseLabel": "Noncurrent assets held for sale",
        "verboseLabel": "Total other assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Balance Sheet Disclosures [Abstract]"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": {
     "auth_ref": [
      "r19",
      "r214"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r19"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss": {
     "auth_ref": [
      "r19",
      "r214"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gross profit attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Gross Profit (Loss)",
        "terseLabel": "Gross profit"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense": {
     "auth_ref": [
      "r10",
      "r11",
      "r19",
      "r27"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Interest Expense",
        "negatedLabel": "Interest expense - term note payable"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r21",
      "r114",
      "r120"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Inventory, Current",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationInventoryCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": {
     "auth_ref": [
      "r19"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Operating Expense",
        "terseLabel": "Total operating expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense": {
     "auth_ref": [
      "r19"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Other Expense",
        "negatedLabel": "Total other income (expenses)"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r21",
      "r114",
      "r120"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r21",
      "r113",
      "r120"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": {
     "auth_ref": [
      "r19",
      "r214"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Revenue",
        "terseLabel": "Revenues",
        "verboseLabel": "Revenue reported in discontinued operations"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]",
        "terseLabel": "Results of operations for discontinued operations"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r28",
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Discontinued Operations"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DividendsPreferredStockStock": {
     "auth_ref": [
      "r138",
      "r189"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "ibio_NetLossAvailableToStockholdersFromContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in stock.",
        "label": "Dividends, Preferred Stock, Stock",
        "negatedLabel": "Preferred stock dividends - iBio CDMO Tracking Stock",
        "negatedNetLabel": "Preferred stock dividends - iBio CMO Preferred Tracking Stock"
       }
      }
     },
     "localname": "DividendsPreferredStockStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings (Loss) Per Common Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r242",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r274",
      "r277",
      "r281",
      "r282",
      "r283",
      "r287",
      "r503",
      "r504",
      "r569",
      "r574",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Loss per common share attributable to iBio, Inc. stockholders - basic - total",
        "verboseLabel": "Per share amount basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Basic and diluted denominator:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r242",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r277",
      "r281",
      "r282",
      "r283",
      "r287",
      "r503",
      "r504",
      "r569",
      "r574",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Loss per common share attributable to iBio, Inc. stockholders - diluted - total",
        "verboseLabel": "Per share amount diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r284",
      "r285",
      "r286",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings (Loss) Per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r704"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "terseLabel": "Effect of exchange rate changes"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "verboseLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]",
        "verboseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Stock Options [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r132",
      "r210",
      "r236",
      "r237",
      "r238",
      "r260",
      "r261",
      "r262",
      "r264",
      "r270",
      "r272",
      "r290",
      "r326",
      "r400",
      "r474",
      "r475",
      "r476",
      "r484",
      "r485",
      "r502",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r539",
      "r577",
      "r578",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r505",
      "r506",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r168",
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Schedule of fixed assets measured at fair value on a non-recurring basis"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r368",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r506",
      "r545",
      "r546",
      "r547",
      "r605",
      "r606",
      "r611",
      "r612",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r505",
      "r506",
      "r507",
      "r508",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments and Fair Value Measurement [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Financial Instruments and Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r368",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r506",
      "r547",
      "r605",
      "r606",
      "r611",
      "r612",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r368",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r545",
      "r546",
      "r547",
      "r605",
      "r606",
      "r611",
      "r612",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsNonrecurringMember": {
     "auth_ref": [
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value.",
        "label": "Fair Value, Nonrecurring [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsNonrecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r527",
      "r530",
      "r621"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest on lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r526",
      "r537"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "terseLabel": "Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r526"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderFinanceLeaseObligationDetailsCalc2": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "negatedLabel": "Less: current portion",
        "terseLabel": "Finance lease obligations - current portion",
        "verboseLabel": "Finance lease obligation - current portion"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails",
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.",
        "label": "Finance Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Future Minimum Payments Under the Finance Lease Obligation"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r526"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderFinanceLeaseObligationDetailsCalc2": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "netLabel": "Long-term portion of minimum lease obligations",
        "presentationGuidance": "Finance lease obligation - non current portion",
        "terseLabel": "Finance lease obligations - net of current portion"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails",
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r537"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderFinanceLeaseObligationDetailsCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Payment, Due",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r537"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, Payments, Due Next Twelve Months",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r537"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, Payments, Due Year Three",
        "verboseLabel": "2026"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r537"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, Payments, Due Year Two",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r528",
      "r532"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Payment of finance lease obligation"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r525"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset",
        "terseLabel": "Finance lease right-of-use assets, net of accumulated amortization",
        "verboseLabel": "Finance lease ROU assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails",
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization": {
     "auth_ref": [
      "r705",
      "r708"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated amortization of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Accumulated Amortization",
        "negatedLabel": "Accumulated amortization"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r527",
      "r530",
      "r621"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "presentationGuidance": "Amortization of ROU assets",
        "terseLabel": "Amortization of finance lease right-of-use assets",
        "verboseLabel": "Amortization of finance lease ROU assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails",
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r535",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate - finance lease obligation"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r534",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term - finance lease"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FinancialStandbyLetterOfCreditMember": {
     "auth_ref": [
      "r125",
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An irrevocable undertaking (typically by a financial institution) to guarantee payment of a specified financial obligation if defined events occur or fail to occur.",
        "label": "Letter of Credit"
       }
      }
     },
     "localname": "FinancialStandbyLetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Intangible asset, useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r221",
      "r334"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Finite-Lived Intangible Assets, accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r331",
      "r333",
      "r334",
      "r335",
      "r553",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails",
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r107",
      "r554"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "verboseLabel": "Finite-Lived Intangible Assets, gross carrying value"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails",
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r103",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails",
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r107",
      "r553"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Total definite lived intangible assets, net of accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Finite-Lived Intangible Assets [Roll Forward]",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r332"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.",
        "label": "Finite-Lived Intangible Assets Acquired",
        "terseLabel": "Additions to definite lived intangible assets"
       }
      }
     },
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainContingencyUnrecordedAmount": {
     "auth_ref": [
      "r662"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount or range of possible amounts of gain that could be realized upon the resolution of a contingency.",
        "label": "Gain Contingency, Unrecorded Amount",
        "terseLabel": "Estimated net cash recovery"
       }
      }
     },
     "localname": "GainContingencyUnrecordedAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases": {
     "auth_ref": [
      "r209",
      "r336"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net gain (loss) arising from the lessor's sale of assets held- or available-for-lease under contractual arrangements classified as operating leases.",
        "label": "Gain (Loss) on Sale of Leased Assets, Net, Operating Leases",
        "negatedLabel": "Gain on disposition of finance lease ROU assets"
       }
      }
     },
     "localname": "GainLossOnSaleOfLeasedAssetsNetOperatingLeases",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": {
     "auth_ref": [
      "r642"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 23.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.",
        "label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges",
        "negatedLabel": "Gain on sale of fixed assets"
       }
      }
     },
     "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossRelatedToLitigationSettlementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fraunhofer Settlement [Abstract]"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative expenses",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and administrative Expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetImpairmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Asset Impairment [Abstract]",
        "terseLabel": "Impairments"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetImpairmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GuaranteeObligationsByNatureAxis": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by nature of guarantee.",
        "label": "Guarantor Obligations, Nature [Axis]"
       }
      }
     },
     "localname": "GuaranteeObligationsByNatureAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GuaranteeObligationsMaximumExposure": {
     "auth_ref": [
      "r127"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions.",
        "label": "Guarantor Obligations, Maximum Exposure, Undiscounted",
        "verboseLabel": "Irrevocable letter of credit"
       }
      }
     },
     "localname": "GuaranteeObligationsMaximumExposure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GuaranteeObligationsNatureDomain": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents a description of the nature of the guarantee or each group of similar guarantees.",
        "label": "Guarantor Obligations, Nature [Domain]"
       }
      }
     },
     "localname": "GuaranteeObligationsNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r80",
      "r110"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "negatedLabel": "Impairment of intangible assets",
        "verboseLabel": "Impairment of intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails",
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r642",
      "r657"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment of Intangible Assets, Finite-Lived",
        "terseLabel": "Impairment of intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfInvestments": {
     "auth_ref": [
      "r322"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.",
        "label": "Other than Temporary Impairment Losses, Investments",
        "verboseLabel": "Impairment of investment in equity security"
       }
      }
     },
     "localname": "ImpairmentOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "auth_ref": [
      "r63",
      "r81",
      "r155",
      "r265",
      "r266",
      "r267",
      "r268",
      "r279",
      "r283"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "ibio_NetLossAvailableToStockholdersFromContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent",
        "terseLabel": "Net loss attributable to iBio, Inc.",
        "totalLabel": "Net loss attributable to iBio, Inc. from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity": {
     "auth_ref": [
      "r153",
      "r156"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest",
        "negatedLabel": "Net loss attributable to noncontrolling interest"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r156",
      "r254",
      "r263",
      "r305",
      "r307",
      "r311",
      "r313",
      "r325",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r504",
      "r513",
      "r603",
      "r664"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Consolidated Gain (Loss) From Continuing Operations",
        "totalLabel": "Consolidated net loss from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r59",
      "r184",
      "r185",
      "r200",
      "r242",
      "r263",
      "r265",
      "r266",
      "r267",
      "r268",
      "r277",
      "r281",
      "r282",
      "r504",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Loss per common share attributable to iBio, Inc. stockholders - basic - continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r59",
      "r200",
      "r203",
      "r242",
      "r263",
      "r265",
      "r266",
      "r267",
      "r268",
      "r277",
      "r281",
      "r282",
      "r283",
      "r504",
      "r569",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Loss per common share attributable to iBio, Inc. stockholders - diluted - continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r9",
      "r12",
      "r23",
      "r201",
      "r214",
      "r490"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "ibio_UnconsolidatedGainLossAttributableToStockholders",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Loss from discontinued operations"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails",
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "auth_ref": [
      "r60",
      "r201",
      "r203",
      "r242",
      "r278",
      "r281",
      "r282",
      "r722",
      "r723"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
        "terseLabel": "Loss per common share attributable to iBio, Inc. stockholders - basic - discontinued operations"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "auth_ref": [
      "r162",
      "r278",
      "r281",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
        "terseLabel": "Loss per common share attributable to iBio, Inc. stockholders - diluted - discontinued operations"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Statements of Operations and Comprehensive Loss"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r337",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r255",
      "r481",
      "r482",
      "r483",
      "r486",
      "r488",
      "r491",
      "r492",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r256",
      "r271",
      "r272",
      "r304",
      "r479",
      "r487",
      "r489",
      "r575"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "verboseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable - trade"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 27.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r550",
      "r641"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 28.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "verboseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the book value of finished goods inventory and work in process inventory.",
        "label": "Increase (Decrease) in Finished Goods and Work in Process Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r641",
      "r709"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 25.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease obligations"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses - noncurrent"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInSecurityDeposits": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in security deposits.",
        "label": "Increase (Decrease) in Security Deposits",
        "terseLabel": "Security deposit"
       }
      }
     },
     "localname": "IncreaseDecreaseInSecurityDeposits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "License - indefinite lived"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefinitelivedIntangibleAssetsAcquired": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition.",
        "label": "Indefinite-Lived Intangible Assets Acquired",
        "terseLabel": "Additions to licenses"
       }
      }
     },
     "localname": "IndefinitelivedIntangibleAssetsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r101",
      "r105"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "totalLabel": "Total net intangible assets",
        "verboseLabel": "Intangible assets, net of accumulated amortization"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntellectualPropertyMember": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights.",
        "label": "Intellectual Property [Member]"
       }
      }
     },
     "localname": "IntellectualPropertyMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails",
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r175",
      "r187",
      "r239",
      "r303",
      "r521"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r67",
      "r374",
      "r382",
      "r607",
      "r608"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r245",
      "r249",
      "r250"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Net",
        "terseLabel": "Cash paid during the period for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r217",
      "r227",
      "r289",
      "r328",
      "r329",
      "r330",
      "r551",
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r65",
      "r302"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income",
        "verboseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureConvertiblePromissoryNoteReceivableNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "verboseLabel": "Schedule of fair value of available-for-sale debt securities, by contractual maturity"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments in Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r100",
      "r179",
      "r188",
      "r204",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "verboseLabel": "Investments in Debt Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails",
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails",
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r536",
      "r621"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "terseLabel": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Finance lease cost:"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeasePracticalExpedientsPackage": {
     "auth_ref": [
      "r523",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether practical expedients are elected for not reassessing whether any expired or existing contract is or contains lease, lease classification for expired or existing lease, and initial direct cost for any existing lease.",
        "label": "Lease, Practical Expedients, Package [true false]"
       }
      }
     },
     "localname": "LeasePracticalExpedientsPackage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease Obligation [Abstract]"
       }
      }
     },
     "localname": "LesseeDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "auth_ref": [
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.",
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "Finance Lease Obligation"
       }
      }
     },
     "localname": "LesseeFinanceLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "verboseLabel": "Future Minimum Payments under the Operating Lease Obligation"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r537"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "order": 2.0,
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r537"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "order": 1.0,
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "verboseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r537"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "order": 2.0,
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r537"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "order": 2.0,
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "verboseLabel": "2028"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r537"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "order": 2.0,
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "verboseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r537"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "order": 2.0,
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "verboseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r537"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "order": 2.0,
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Term of lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "verboseLabel": "Operating Lease Obligation"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r44",
      "r254",
      "r325",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r496",
      "r499",
      "r500",
      "r513",
      "r602",
      "r664",
      "r713",
      "r714"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r40",
      "r183",
      "r197",
      "r622",
      "r646",
      "r656",
      "r703"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r46",
      "r216",
      "r254",
      "r325",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r496",
      "r499",
      "r500",
      "r513",
      "r622",
      "r664",
      "r713",
      "r714"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r21",
      "r114",
      "r120",
      "r213",
      "r214"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current",
        "terseLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r21",
      "r113",
      "r120",
      "r213",
      "r214"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent",
        "terseLabel": "Total long-term liabilities"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Long-term liabilities:"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAndMaintenanceMember": {
     "auth_ref": [
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset and process of preserving asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License and Maintenance [Member]"
       }
      }
     },
     "localname": "LicenseAndMaintenanceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedFromOtherParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded from other party in judgment or settlement of litigation.",
        "label": "Litigation settlement, amount awarded from other party",
        "terseLabel": "Settlement income"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedFromOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationStatusAxis": {
     "auth_ref": [
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Axis]"
       }
      }
     },
     "localname": "LitigationStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusDomain": {
     "auth_ref": [
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Domain]"
       }
      }
     },
     "localname": "LitigationStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "auth_ref": [
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.",
        "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]",
        "terseLabel": "Convertible Promissory Note Receivable"
       }
      }
     },
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureConvertiblePromissoryNoteReceivable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r32",
      "r182",
      "r195",
      "r367",
      "r381",
      "r605",
      "r606"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "verboseLabel": "Debt balance"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermNotesPayable": {
     "auth_ref": [
      "r49"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Notes Payable, Noncurrent",
        "netLabel": "Note payable, PPP loan"
       }
      }
     },
     "localname": "LongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtNotePayablePppLoanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and equipment [Member]"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails",
      "http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.",
        "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r293",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Nature of Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureNatureOfBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Discontinued Operations [Abstract]"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInDiscontinuedOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r248"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r248"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r76",
      "r78",
      "r81"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r61",
      "r81",
      "r186",
      "r202",
      "r214",
      "r232",
      "r234",
      "r238",
      "r254",
      "r263",
      "r265",
      "r266",
      "r267",
      "r268",
      "r271",
      "r272",
      "r279",
      "r305",
      "r307",
      "r311",
      "r313",
      "r325",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r504",
      "r513",
      "r603",
      "r664"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Basic and diluted numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r157",
      "r160",
      "r232",
      "r234",
      "r271",
      "r272",
      "r639"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedLabel": "Net loss attributable to noncontrolling interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r265",
      "r266",
      "r267",
      "r268",
      "r274",
      "r275",
      "r280",
      "r283",
      "r305",
      "r307",
      "r311",
      "r313",
      "r603"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss available to iBio, Inc. stockholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Investing noncash transactions:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r153",
      "r400",
      "r647",
      "r648",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesAndLoansReceivableNetCurrent": {
     "auth_ref": [
      "r317",
      "r318",
      "r567"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease.",
        "label": "Financing Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Convertible promissory note receivable and accrued interest"
       }
      }
     },
     "localname": "NotesAndLoansReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesAndLoansReceivableNetNoncurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of financing receivable, classified as noncurrent.",
        "label": "Financing Receivable, after Allowance for Credit Loss, Noncurrent",
        "terseLabel": "Note balance and accrued interest"
       }
      }
     },
     "localname": "NotesAndLoansReceivableNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureConvertiblePromissoryNoteReceivableNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesIssued1": {
     "auth_ref": [
      "r84",
      "r85",
      "r86"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of notes issued in noncash investing and financing activities.",
        "label": "Notes Issued",
        "terseLabel": "Note payable to acquire Facility"
       }
      }
     },
     "localname": "NotesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable [Abstract]"
       }
      }
     },
     "localname": "NotesPayableAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "Term note payable - net of deferred financing costs"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An amount representing an agreement for an unconditional promise by the maker to pay the Entity (holder) a definite sum of money at a future date(s) within one year of the balance sheet date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.",
        "label": "Convertible Promissory Note Receivable [Member]"
       }
      }
     },
     "localname": "NotesReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureConvertiblePromissoryNoteReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office equipment and software [Member]"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r305",
      "r307",
      "r311",
      "r313",
      "r603"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r531",
      "r621"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Obligation, Principal"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r526"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedLabel": "Less: current portion",
        "verboseLabel": "Operating lease obligation - current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r526"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc2": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease obligation - net of current portion",
        "verboseLabel": "Long-term portion of minimum lease obligation"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r525"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r642"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "verboseLabel": "Amortization of operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Business [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r29",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "verboseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r229",
      "r230",
      "r231"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Other comprehensive income - unrealized gain (loss) on debt securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustment",
        "verboseLabel": "Other comprehensive income - foreign currency adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of general and administrative expense classified as other.",
        "label": "Other General and Administrative Expense",
        "verboseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "OtherGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Noncash Investing and Financing Items [Abstract]",
        "verboseLabel": "Schedule of non-cash activities:"
       }
      }
     },
     "localname": "OtherNoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r150"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other research and development expense.",
        "label": "Other Research and Development Expense",
        "terseLabel": "Costs incurred"
       }
      }
     },
     "localname": "OtherResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PatentsMember": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Patents and Licenses [Member]"
       }
      }
     },
     "localname": "PatentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails",
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForAdvanceToAffiliate": {
     "auth_ref": [
      "r70"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from advancing money to an affiliate (an entity that is related but not strictly controlled by the entity).",
        "label": "Payments for Advance to Affiliate",
        "terseLabel": "Amount advanced"
       }
      }
     },
     "localname": "PaymentsForAdvanceToAffiliate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r70",
      "r97",
      "r243"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedLabel": "Purchases of debt securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Payment for RubrYc asset acquisition"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquitySecuritiesFvNi": {
     "auth_ref": [
      "r246",
      "r324"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.",
        "label": "Payments to Acquire Equity Securities, FV-NI",
        "negatedLabel": "Purchase of equity security"
       }
      }
     },
     "localname": "PaymentsToAcquireEquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Additions to intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of fixed assets"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToMinorityShareholders": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.",
        "label": "Payments to Noncontrolling Interests",
        "negatedLabel": "Acquisition of noncontrolling interest"
       }
      }
     },
     "localname": "PaymentsToMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r415",
      "r416",
      "r422",
      "r423",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r431",
      "r432",
      "r433",
      "r436",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Pension and Other Postretirement Benefits Disclosure [Text Block]",
        "terseLabel": "Employee 401(K) Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEmployee401KPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock.",
        "label": "Preferred Stock, Dividend Rate, Percentage",
        "verboseLabel": "Preferential dividend rate percentage"
       }
      }
     },
     "localname": "PreferredStockDividendRatePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_PreferredStockDividendsPerShareDeclared": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of preferred stock outstanding.",
        "label": "Preferred Stock, Dividends Per Share, Declared"
       }
      }
     },
     "localname": "PreferredStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r34",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "verboseLabel": "Preferred Stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r34",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r34",
      "r622"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Series 2022 Convertible Preferred Stock - $0.001 par value; 1,000,000 shares authorized; 0 and 1,000 shares issued and outstanding as of March 31, 2023 and June 30, 2022, respectively"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r636"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "verboseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseNoncurrent": {
     "auth_ref": [
      "r634"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.",
        "label": "Prepaid Expense, Noncurrent",
        "verboseLabel": "Prepaid expenses - noncurrent"
       }
      }
     },
     "localname": "PrepaidExpenseNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "auth_ref": [
      "r73"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).",
        "label": "Proceeds from Issuance of Warrants",
        "terseLabel": "Net proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLegalSettlements": {
     "auth_ref": [
      "r77"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received for the settlement of litigation during the current period.",
        "label": "Proceeds from Legal Settlements",
        "terseLabel": "Settlement payment received"
       }
      }
     },
     "localname": "ProceedsFromLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r97",
      "r243",
      "r244"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale",
        "verboseLabel": "Redemption of debt securities"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r68",
      "r97",
      "r243"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-Sale",
        "terseLabel": "Sale of debt securities"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Sales of fixed assets"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r73",
      "r146"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r214",
      "r232",
      "r234",
      "r247",
      "r254",
      "r263",
      "r271",
      "r272",
      "r305",
      "r307",
      "r311",
      "r313",
      "r325",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r494",
      "r497",
      "r498",
      "r504",
      "r513",
      "r570",
      "r603",
      "r619",
      "r620",
      "r639",
      "r664"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Consolidated net loss",
        "disclosureGuidance": "Net loss including portion attributable to noncontrolling interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Consolidated net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fixed Assets [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails",
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails",
      "http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r123",
      "r587",
      "r588",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Fixed Assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFixedAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r116",
      "r219"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Gross fixed assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r118",
      "r198",
      "r571",
      "r622"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Net fixed assets",
        "verboseLabel": "Fixed assets, net of accumulated depreciation"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r118",
      "r587",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Fixed Assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of gross carrying value and accumulated depreciation of fixed assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFixedAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails",
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails",
      "http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "verboseLabel": "Fixed assets, useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReceivableTypeDomain": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.",
        "label": "Receivable [Domain]"
       }
      }
     },
     "localname": "ReceivableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureConvertiblePromissoryNoteReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Promissory Note Receivable [Abstract]"
       }
      }
     },
     "localname": "ReceivablesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r424",
      "r540",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r424",
      "r540",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r640"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "terseLabel": "Repayment of term loan"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedLabel": "Payment of term note payable"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r150",
      "r205",
      "r721"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r82",
      "r87",
      "r218"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "terseLabel": "Collateral held"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage.",
        "label": "Restricted Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r584",
      "r634",
      "r643"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 9.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "verboseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationRsusDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expected number of positions to be eliminated as a result of restructuring activities.",
        "label": "Restructuring and Related Cost, Expected Number of Positions Eliminated",
        "terseLabel": "Number of positions reduced"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "terseLabel": "Percentage of workforce reduction"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r37",
      "r138",
      "r196",
      "r580",
      "r582",
      "r622"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r210",
      "r260",
      "r261",
      "r262",
      "r264",
      "r270",
      "r272",
      "r326",
      "r474",
      "r475",
      "r476",
      "r484",
      "r485",
      "r502",
      "r577",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated Deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r316",
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue [Member]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r413",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue Recognition, Policy [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r240",
      "r254",
      "r300",
      "r301",
      "r306",
      "r309",
      "r310",
      "r314",
      "r315",
      "r316",
      "r325",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r513",
      "r570",
      "r664"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r533",
      "r621"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Increase in finance lease ROU assets for new leases"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyIncomeNonoperating": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources.",
        "label": "Royalty Income, Nonoperating",
        "terseLabel": "Royalty income"
       }
      }
     },
     "localname": "RoyaltyIncomeNonoperating",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Proceeds from sale of shares, net of issuance cost"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares issued"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ScenarioPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The scenario under which facts represent plans as distinct from actual.",
        "label": "Scenario, Plan [Member]"
       }
      }
     },
     "localname": "ScenarioPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureConvertiblePromissoryNoteReceivableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "verboseLabel": "Schedule of components of investments in debt securities"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of of total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "auth_ref": [
      "r1",
      "r13",
      "r14",
      "r15",
      "r16",
      "r17",
      "r18",
      "r22",
      "r24",
      "r25",
      "r26",
      "r121",
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "terseLabel": "Schedule of discontinued operations"
       }
      }
     },
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Earnings (loss) Per Share, Basic and Diluted"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r144",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r103",
      "r106",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails",
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r103",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "verboseLabel": "Schedule of Category the gross carrying value and accumulated amortization of intangible assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r177",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r437",
      "r439",
      "r441",
      "r442",
      "r443",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "verboseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationRsusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Fair value of options granted using the Black-Scholes option pricing model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r634"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security Deposit",
        "verboseLabel": "Security deposits"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SegmentContinuingOperationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component of an entity expected to operate in the foreseeable future.",
        "label": "Continuing Operations [Member]"
       }
      }
     },
     "localname": "SegmentContinuingOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentDiscontinuedOperationsMember": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of or classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale.",
        "label": "Discontinued Operations [Member]"
       }
      }
     },
     "localname": "SegmentDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEmployee401KPlanNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentOperatingActivitiesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operations of an entity including continuing and discontinued operations.",
        "label": "Operating Activities [Domain]"
       }
      }
     },
     "localname": "SegmentOperatingActivitiesDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEmployee401KPlanNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServiceMember": {
     "auth_ref": [
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
        "label": "Service [Member]"
       }
      }
     },
     "localname": "ServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SettledLitigationMember": {
     "auth_ref": [
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval.",
        "label": "Settled Litigation [Member]"
       }
      }
     },
     "localname": "SettledLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SettlementAssetsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received or short term receivables for unsettled money transfers, money orders, consumer payments, or business to business payments. Settlement assets include clearing and settling customers payments due to and from financial institutions and may include cash and cash equivalents.",
        "label": "Settlement Assets, Current",
        "verboseLabel": "Settlement receivable - current portion"
       }
      }
     },
     "localname": "SettlementAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Compensation.",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Share based award, vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationRsusDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Share-based award, Units to be issued",
        "verboseLabel": "Share-based award, Number of awards issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationRsusDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "terseLabel": "Shares vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r460"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Grant date fair value",
        "verboseLabel": "Share based payment award, Grant-date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationRsusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend rate",
        "verboseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationFairValueOfOptionsGrantedDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "verboseLabel": "Volatility, Maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationFairValueOfOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "verboseLabel": "Volatility, Minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationFairValueOfOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk free interest rate, Maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationFairValueOfOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk free interest rate, Minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationFairValueOfOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationRsusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in Shares)",
        "verboseLabel": "Shares available for grant under the plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of options granted",
        "verboseLabel": "Stock Options, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r441",
      "r442",
      "r443",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationRsusDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Weighted-average exercise price per share, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r444",
      "r463",
      "r464",
      "r465",
      "r466",
      "r469",
      "r477",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]",
        "terseLabel": "Share-based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "verboseLabel": "Stock options vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Share based payment plan term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "verboseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationFairValueOfOptionsGrantedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r88",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r223",
      "r224",
      "r225",
      "r254",
      "r277",
      "r278",
      "r281",
      "r283",
      "r291",
      "r292",
      "r325",
      "r345",
      "r347",
      "r348",
      "r349",
      "r352",
      "r353",
      "r383",
      "r384",
      "r387",
      "r391",
      "r398",
      "r513",
      "r592",
      "r631",
      "r644",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r52",
      "r132",
      "r210",
      "r236",
      "r237",
      "r238",
      "r260",
      "r261",
      "r262",
      "r264",
      "r270",
      "r272",
      "r290",
      "r326",
      "r400",
      "r474",
      "r475",
      "r476",
      "r484",
      "r485",
      "r502",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r539",
      "r577",
      "r578",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "verboseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails",
      "http://www.ibioinc.com/role/DisclosureDebtNotePayablePppLoanDetails",
      "http://www.ibioinc.com/role/DisclosureEmployee401KPlanNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails",
      "http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails",
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Balance Sheets"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "verboseLabel": "Comprehensive loss:"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Stockholders' Equity"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOperatingActivitiesSegmentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by continuing and discontinuing operations.",
        "label": "Operating Activities [Axis]"
       }
      }
     },
     "localname": "StatementOperatingActivitiesSegmentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEmployee401KPlanNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r260",
      "r261",
      "r262",
      "r290",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails",
      "http://www.ibioinc.com/role/DisclosureDebtNotePayablePppLoanDetails",
      "http://www.ibioinc.com/role/DisclosureEmployee401KPlanNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails",
      "http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails",
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r34",
      "r35",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r51",
      "r132",
      "r133",
      "r138",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "verboseLabel": "Conversion of preferred stock to common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r34",
      "r35",
      "r132",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r34",
      "r35",
      "r132",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "verboseLabel": "Vesting of RSU's (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r34",
      "r35",
      "r132",
      "r138",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Stock Options, Exercised",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r34",
      "r35",
      "r132",
      "r138"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "positiveLabel": "Sale of preferred stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r132",
      "r138"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "verboseLabel": "Vesting of RSU's"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r52",
      "r132",
      "r138"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r35",
      "r38",
      "r39",
      "r96",
      "r622",
      "r646",
      "r656",
      "r703"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "iBio, Inc. Stockholders' Equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r153",
      "r154",
      "r159",
      "r210",
      "r211",
      "r237",
      "r260",
      "r261",
      "r262",
      "r264",
      "r270",
      "r326",
      "r400",
      "r474",
      "r475",
      "r476",
      "r484",
      "r485",
      "r502",
      "r514",
      "r515",
      "r519",
      "r539",
      "r578",
      "r579",
      "r646",
      "r656",
      "r703"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity [Member]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r141",
      "r253",
      "r384",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r395",
      "r396",
      "r397",
      "r400",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split, shares received per share tendered"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r520",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r542",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TangibleAssetImpairmentCharges": {
     "auth_ref": [
      "r12",
      "r119"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.",
        "label": "Tangible Asset Impairment Charges",
        "terseLabel": "Impairment of fixed assets",
        "verboseLabel": "Fixed assets impairments"
       }
      }
     },
     "localname": "TangibleAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails",
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails",
      "http://www.ibioinc.com/role/DisclosureFixedAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TenantImprovements": {
     "auth_ref": [
      "r199"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.",
        "label": "Tenant Improvements",
        "verboseLabel": "Tenant improvement allowance"
       }
      }
     },
     "localname": "TenantImprovements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r319",
      "r320",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Trade and Other Accounts Receivable, Policy [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r700"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r294",
      "r295",
      "r297",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Term of the warrants"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r276",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding - diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r274",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding - basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1060-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1063-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126982154&loc=d3e400-110220",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2510-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2473-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907419&loc=d3e10037-110241",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907907&loc=d3e12803-110250",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "44",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5558-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613673-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.E)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120398118&loc=d3e355146-122828",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=6435544&loc=d3e41834-113960",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL7498348-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "https://asc.fasb.org/subtopic&trid=2176304",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/subtopic&trid=2209399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(f))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721491-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "https://asc.fasb.org/subtopic&trid=2324412",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "30",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123393937&loc=d3e44908-112734",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3444-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=26872618&loc=d3e7436-122677",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/subtopic&trid=2122178",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=SL6284422-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=123583714&loc=SL75117360-209713",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905841&loc=SL51729484-110225",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721501-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721503-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL77916155-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL77916155-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(7))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868656-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(m)",
   "Publisher": "SEC",
   "Section": "4",
   "Subparagraph": "(1)(iii)",
   "Subsection": "08",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(14))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6829253&loc=SL6831962-166255",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r625": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r626": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r627": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r628": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r629": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.13)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/subtopic&trid=2196772",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=6397426&loc=d3e17499-108355",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r726": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "303",
   "Subparagraph": "(5)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>111
<FILENAME>0001558370-23-009707-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-23-009707-xbrl.zip
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M'-,JUTNF8[E?4/ XB3=_YVX IS(*1',J_LCP[RGG]^,3:'/[_+M1KA=(QTY
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M9_2VLZK@4 _F[L16>-B31ZZ$4'0571+*DG]A;@E%'0675I N[$^JQI'IFM8
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MGUSDO@+Q_Y?*<_UA3RWO%3QB2J\G$V S':DM(['M,V<0$ISQ9"!)9<[%XD=
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M4[+\)\SE('18!51Q(Y6^3I6+-LEB/$DKO)8P^G=8/]3P(M4.@<<V.EO:;##
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M!?D5L^0;6UHR)-]Z),\@.5#.IM61%PB0%T>L-MJOF@WD%I?3S<4E ]R GD'
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MEIJQA%B0-/K44T*H3C\MZ8Y]YM[+C*( )S./TMV2T"SSIL)3+BLO7R-4-<!
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MGV9)-E R7UX3ND0X28]9W%^SXW*^E3>H/[#P!2(7W?XEPJ;=<45B"$^2#5I
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M4GI<1K7RAV@Q .+*?II?O6SYA0"N R0<$98<EQNMO!5*^@%QHKC55EBI<[K
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M=&BK0#-=V'(8L%WAG#X@^LRV\!*])2X&Z&)\:[TE1N:,$3R:LJ DENHI15D
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MVKB\[,$+IX<$B&U"P3M8.LAG^B?!*)YY88B"RUU3!FVFK4VKXS*]!\==9\2
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MH6>WV]GM]BVE#^[5_39R^N#S&>?YC/-\QGD^X_QFSSB[!AV?S.-@UJ>?!C
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MJ9\OLX\2=O;0[NG8]#V !>0Z;X^F=UDXA;U$'RCA<?\21>R'A".H4AQ?[O:
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MOKO2<O&7%JX2Z/M9J2SZ%!:NU!6+4&9:OT_N1';@UJ/U@9DB.HI:&;*D5Q@
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M!KP.C++C"G91H$6XPM8INQI")@!TO;&H)J0?C:D;=I5Y) "?B@LY\U&1'C>
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M:ER&#5529),**3F]!.8FS>128B2."<%;%>@T"K<!!.2:;)LE2;5+XHE-,JW
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MZL-V4"&&O2V74!MVM[5;L<^Y!+"O\RNN&AUT8;_O,>Y!2&89YOM?7?)H+ 7
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ML'=P$GA>QS$O4C9)@X.$1U[D$8;QHEYE$@C;5*,D+Z+B"*LJMJ!]<&KPPQK
M+_D/T/'A)8@Y4=@W^L[?MG6C+ZTH3FV':5Q)Y"/G O=9N(R2*'^F(5PLP-./
MW]+LCZOD-DNW3*BK9(1^9?XY$/KB6K@N@=GAL,7F@1OB1JJM<U)AY9>%PD8!
M8OA3B9I(N/WQ6R:O1IFXXXEBWV84VKE5>8EE]B'CZZ9XIIFQ=--89+XHM OK
M9F6VP>2!(MN3::O$)<8JH99K,4>&7%QI5MXK)LN'T,)6I9S+[3'+&@?.+Y4V
ME]@8!O-,30TE-(9@_%$]<W*WG9)YIU-FIGK:<\:+T@O%\41CRLXOI_>4W[C;
M;WA]0%^T1L>266^Z4!YHCIHD6]VIH$D%CI/0.IJMFOY0C/-$8:J87'G'[!ST
MJ^%\41<-0W9!XQ+( V514N0<+BZA?5$5.Z9JZ@]JZO$T!=(EKIL;(!>^>Z >
MZ8N&K4&5Z<#YH35*HAP4AZ?$2 @\TAT[UBH>*C=MT:N5/E6?:I?0+J1JQN#%
ME8L-DX;K%Q.X+U<QPS1:/SZ47A>R P,\<F7_*AMR,A6#WP=/3QD_II"@KL/2
M'"6: T8D?A62QV,!^6OD1 L"9Q#TZXT1ZV5O<C;DD_9<M:SYF8_;KA7R\;#8
MSN*NN#NYYY9TX7W9VP<8M$Q@:@-[L,L;*7-/7^)8:OWKA?.Q-GPW+F\ZQ4C3
MQSAZXAN +\',*NOQMZAXOBAOP-UU;@"++YIGQ:Q9_XPH/-!""_IL=;%"1;XP
M7*1"MEE8)T?E$X[ANF8OUA\K/&NNJ%D/%P2^-U-4::$]M,?-$^=KFKC,5I@6
M06Q2NEDX'>P>YI,"0BI!/D=W4R,BKQ32@F4+Q31@\45!!TET5=0:H4_=!&=C
MOMO=-*JYQ6[\=UOF:CZDY]O_/$89/7\)HA@"U)=I!J^$[^NR?E K4+-0SEAP
MM'8DL[+*.J)875]'T=>_%*\R>(N4E'A$@<X&>D-JS&>[-#N#NME85_\S,<TH
M>PX@JL,+UTTN:3E=-R%ICX;Y)1/BCT%1DL(3%@2_YTEX$<0QU#S7,JQ;LGEP
M(^GQG O3TNXY$*^O\_-1K4B/$;C%OM5@WQ )/\\XXS/4E7S7-!3V)]\E5^J.
MAG1_: I?^F4_1,&/<9N[,QI\J^#"KLX V.! U75[ @?4NJI=,Z"Y]TMI[J C
M/A/7%9]>*&?79_G _K<X-7Q<OGR*;/T=-:PG3K:),:-KK0+$=ZCU5%FYT0*\
MI667OYY]NO+&=W;AK_280:>HX*O4*ISG(SU>+)M\6\!YHDLVK;X'@?!UR++C
MLDI_O&F0/9:I\S",Q+M7QI4?M0U[K+#]]D"SXG3+*"^83PPVX;#O9S^-0>")
M)@VR:%0I+32^;@V09J5D%0YVR@,L&W[ JQ$MJ7$/@Z[@9'[E, ]Z*\:^9^NL
M>RX8?#F9N6F?/;@'YS%G>50>Q=;4P/&G,%=>>8=&/_2N:T;>E14P**^$NH,;
MF_(OH:TE,J+P9-NS8-.X\1G@\;>^0>*L-K\&"R_?"^+*[^\J5-XXG*/9Y=5C
M[HZ/V5^W0@=) '"BF*_G*023KVK]3QF8EBK@<8K ?*D!7N7PN''*<W@.,J?'
MBE-56H!/ZEAW!9N:T6-$Y)5Z6K!LH:8&++ZHZR")KFK;M+A;+Z/'X@IP-O:[
M.3U-A[N).3V:9VJR]WU5-D$$#[RL& (WE^E^GR;W1;K]H\/\& 0(C]1&L5B_
M47."QGFB-H)$Y0LUOH=$"4B?$#[^_JP,+ 8Q^[NH7<O+*T>/O,X>N+@PC-$7
M%:>5WYK-P7A]4 8DI,)";N"P7+69/(=$!(Z)<%0(#\UF995_W+PZ-6\%9[F*
MLRF6I3Q87*;9)1@\+D/WSP%;F_,=8Q8*?#...<'WASA2OH$=@03#PHQEM;$R
MKAB0+,TX,I76IGG.RNU.>BR$X6&'R%V-F^0<.0D .Z_OSM +424Y3+"VQ9EI
M >H( ;#;8"+W,KLE,F%S"$>'4MMS$:8=OC%R*.]CE*1P^<PY?DYCJ'X[&$Q1
M V&'ZTRLJ -T*@C$D)R>'&,0#IY@@].2QC&XTE5/& ]N>1T8.F^B:541 (FG
MJC/-0F>#.@9?'VETK;!LH)!/ 69FE*Z_&@3?WS?19;/MRNX^K7!)IT[H<(3H
MU3NQU_9O:U I9G"]5&,N>^=] D>Z[S._TWZS<]#W(1 \AWR(C:[[K1N/ZFR;
MB7)UK7W1\5&\51=-C+%UM-O-01[/S9R:/=GSO:O?+8B6>@/U#O7#<;S=(?)E
M/U<W=G4/UTR(XE5(_4B&20\'6*9^H;U+Z\B!)/R\"XG<<1$_90K.GC?\U4W^
MX2O-ME&NS]<8AO,@/<K$D#8I2@6$FPJEIV@H 8I'$TI04L-ZD/$TFB5:C@85
M$L&2]#"ZAM% #/<A/2^*($H>F*J"<INB1/VQB!%9'>&]P&MW(&Y\54V-_M)&
M]O"V:5XTU0!YE:" (VL,+5+0U)*K.G#SD!(!0 "";W.H\4]+^B_8!^!1I^ZR
MH^QKPA.EO##:;<;D(CH$<<61QD -P.#L9U:,R'N9$6#U?<R"FGY7:@$CJN[!
MV^@2C%1P6,[>&&8DCV]7\M4MO^=Y5M+DW __LY"F91]YG'4T7[:15TF";IRV
M"GW)R8*J+",49?RPV]$M!%*^;GEWX3MFB6X2X!S^_T/3M/&.YD46;9F=X@G*
M2=C^A33RBO=_9+R]C_)#F@?Q+UEZ/# (]F^X0(F2(PW+@FG,>]:LOP^$X1@/
M'SCO&R5\JE8W=KZPW#,M@C >E2U)(T ;21-N6S?"PDK3;DA#D?@CO$/J_JX%
M4%-**E()IY5#RM22AER<T_TK^$RT^DP9?";Q,XZ]G[0LM[Q0?K_N;+E8\@<0
MO&N^V-I$X-AQG*66;?:Z%*QNGS'84^:/SV)P!4%$485:-L9M@R\HPSJ4>K'^
MY^+J-:/\;%MV*,^:A087'.<$X<7RP"FD:G]2-:;?]#JR<^D<6#3_MZ<EOL.K
MW#QFWPM>EVE?UE(O8DQ$"Z(/R7+VUK@H-O: G!&:+'.!)[B_+X*L\)K_1_H4
M)0DSORBVD;>0AL1:1DSS5C4)ZY#454'W0R\Y79'@6+]QK,KFS@W#ZO9M#'G]
MMCJ\.7B)17I?#<+;!%(Y)@]>;,["\OWVF89'45LE29,SSODR#S4OQ.,[WG8Z
MC(HC5 83=[R7:=8M$G8;1-U\E;%($"[O1[-:W^H[8\"Y[A])IBGGDW<=YVD
MY6--VB"7F@3"B%Z5.+D=X2&C+U%ZS,F)!MG*^0)S+4N)ATB(2(6),%3]JG\$
ML"$DB,_%\:54  D^-CN=B<N>H-,G6%P 16P-A+.S$8(#)[*RL:3X/4X":O3T
M7-SL/N>"X9M'2*. VZ[JF D/T:0;Z*'.:!/P(:6P3EV 5H[K6&3K)\%.H[2?
M)0OXSM+=&<,H%)Q4.$'2Z]@5?X,IIUI@-SB<>R'J(![CNIU[<7?SN3(7L H)
M_2+^L&PG9)GVFZ;Y(N/J$_W"?]L-GDQ!Y$5?9 >6#>V1+;#XTB79FE3K9LD]
MX97Z=G:DMW%T9)>&[VCH[9#'+XRJ(^15TC%=$DKNXS"DXB\K7X<NQ[U!#I8S
M8I#4^9#>!5%.2V<-W+#W44:W17R"3.Y?LC3/JQ1MI9/GB@+CZ#6.S>;@Y0:/
M=.P:0^300[M6UG61D@S0UZ>PL$0N[H.> #TD8''\:Y^N9N$>L ";' ^I3EK\
M$/&^Q2M'1BIL&&>KV?C-^]^5,VSZN#.:($@[9W8/I/IF)]O1CKM8W\HU=8)^
M"[(LZ-5ZG@TK@J&:;S%JVS4=)8XYFXMNW5UV^42OG**?OYW!-/#K8UY&DC9E
M[('7I:@J:K$!7\1T*QN\Q=9'0@SUPMI^&$<.OZX/GW+>A%QGK)P$P32NLC*2
MO$BG3:. X+P#@$>KP" -W^J2L%M#D'+Y%62VLO6EOZ^?C]^;O)\!PA\KBS%(
M_7?MB*Q#I?"2JRSB?1ELE6&A";OZIY3GACXPN<]%1:SJH'.5=-00^@A6H9[^
M<Y3)V!!V\>G,U[OW>%0XN_94>@?.(Y%T6NYO13DY)B'->%CD_/XS^?,__[CA
M9^<OS]'VF21I^UGIEZ")J*R\><^^3)_*K'0BH6RR'*_4JP4%0"74"%OU[.L@
MAU-2D3H.14>,46%RQG[FXA67H%LFXM'+J)>M9GMX3XLBIJ*J"M073([T JJ=
M]5-)K*'P[)L%,UT[9@!!M5>#="D5CEN3!A0D*!/ HIAP,'?6L*59>5W<&+):
MIC'EQLL$Y2Y/#:7WU;G%*A\(JSBS@T-0<!>&:A6W <)1<GO*E.['+H@R\A+$
M1_DPE_,3GKAR3<KD,-5[TY4=BPFL5J#E*49Q?US"(_@)$]BZZA_$1:7>"(KT
M:J]<#FI>)UB)Z_)M@? M& _,?.5%=BS=GMLL?6(+ISS_6(,BV I'MFIS80F'
M8S&<B.N)W'7;C2SKUS0(RG?J',6ZY@&/KVF^,YC7F^PVR(KR'U+58/ /FHK!
M51%D=F9@GUB9+CH-'XZ_/7D!9$]\-#(T'WTBQ0-1A02\7T71:5(\!P4)$O*!
MMP&!PR/#F8O,0PB=\:V>/):MY0C//N4:$87EJV6N(PR#Z!R7T2UEBB-R%VNW
MX0WD*S+6JE]\*W>8^ZY./8]R$M(=3_,*<E(T1^8ZPS4HDT%*NL7#:#9G^I1$
M?V\R*-ET<7.09N27C(8IU'."%QG'N*B>L0F:#P*,_Z*NT0A%H)H$%/+-K<3#
M-X3W\,A%(Q6&_)!F5=P<@"3RI4G%XKO-N_H):VY9K+XOXY.O8/5O">V&\/B.
MHM8[*7'CQ&[F7HKE:L%/OD<Y?PFB& +G;-.$SJSOZ6-Q3[=,\4")^%W[YR2C
M00R:=IWV_+@)>'!N9$8S+%_;."-9_6YG)(4]T04XT@!N2(WXC&T!9]"6:$,:
M3 10X5P4S<6QQ,R;IP#J2L60(L)4-^BQSG8NMCQY/0N*"M\?#P<1#PIBB"A=
MQNF7JX21N.=;]<";/FMH''5U9$Y64DO0U573B:Y^]$^"%E<C $\D!$L_UQO4
MQ!D9%/$G8#!J$(QZJ#=9S:JM'O+1/E&=.O5&X:B-AEA9/3I#5E<#Y?R*BZ_2
M(81AO!<WCDS;47LA'/I(D<E>/>+#<_5NLJ> '9BX"D%\)(VC4"AD$MXRJJJS
M:I5<% 7Q/?L-5\7!E^'SX$9Z,#[GPK3>D<^!>/WGY?-1W3\4!OQ=)SL$58WK
M#;O5.HEDG**;W6!-2=5 I*0R+<FMU++>J/43S#0D&,2B&4I^?Z!?"_*.??8_
MD!R9$?178CUCG/A=D$<Y[QY;JY[&&@\/1XCR6I!?!W$-8W%BM(,$J9J]B,$Y
MW_PEMQ4< 7@:ROV"E'#4(#(R\I7#?N[L*:G&MN&3=BRHRLE.^$Q_P=YP<[/$
MQJB<YA7Z.X;EFLWU4<SQNKP@+0/],CS2-!O2FHB7XFFI65H]6XB@^7 ]&VFF
M6W[3M"G6L\[2*4T1BOU1%_85%7^;"L!#9RAG+#C68R2SLG%P1+&Z[H^BKQ\Z
M5]>YKFI@2V6QT0]!;;[D M:*=;#?,*>C11/Q69:C(_.3<&(HP0P$J[1"EOQ.
MK7B5PFQ6W=\&#X7+K8M-5?QU+H5%_2G&U2W;N[<1'=JZ3 !(U[R#++3N<[6C
MU[^X'2!%<5^RWP?9"1RA^^@IB7;1%G)!&SRD0H2]RTCD];D<VDML@9&N*9U8
M:]U26D&N?TGI0%9?)(?D$-V(3V//6N-P>@@&4?8KI/4WF\^0_3:#('40M&"C
MU4#0,'[]_H&#Q&C:!\+)_HJG'N_K6M* C'!LY",- !=__(-LS54L#AGQ 1A_
M!,UHLHT 7HC:D 63)$J"\L NCV+&47%FO)J1S+_TUE=G;>U $*YH+-FHKVD&
MQN-<U5@197159+"EDZBT5S*KL3&_V.NLOR6,/X*OM/Y6 %Z)OHN;WA::I?<!
M5^GWEY.A5]XS,X13X9L_[X'$YZ%SA'(D4E5N/=&M>MO]8>M7TM;1H*AKF#"!
M*W@-_%O&;I3G*3N(\@)(#1;LD\%UR@26UVUBHAO2\R3D[3LD-NVO$$;BPI&Y
M28S+4CD*T>IR.X'*_AM<P+7ADLS^P_%Q%UZTJ9%0^G49,.<2V"DW4NX[M-P1
M]_/TL6!L0G.LXM2\KQG8&%P08&7,N[+83J:WA4;(LW<C39&"7R. -ZK\11BH
MID C/0[#WG<D0J^2DM>/0?8'+4!Q>EPGX85(R /5A792_!FQ_=:TW'3H&K#(
M\FGT9=:Y,+5K 4:L=;&94J&6;V!$.2\I)RYKY7WK6^Z8!^MY/^DYIR9D8JC7
MVU!KBALZ(D (IHQBL8ZL.$'CA%E&D*BHBB"J78AB /6+XI7SON?@I%- ^^;S
M,K%&*U*-D4=7#+ZJCCXJZ0;NL?(,F6NH;P-%FMAF%3;[%KRL9">MG-)_RLOZ
M]D7*Z]OSNKGQB1>1X95J1"'=5G4T'U7/[LJKU+V-LGJ]%\?DA3CFUD9L]6CY
MWAVR+7*[M1!X>=P#3'1SMC7#4?*SC;3TGUG4-9.[ K3,KE7/-V'?<L>!L'.-
M9;3>NUP1X.Q>XZA<:O_J5 !?>0>;:2UZ*MG;Q#S:PY;B&7<?N\U DHK3;0QY
MD"(P>  ]&-C-+.!P]C1KAN2=;1!H]?W-DB)-0^E9]K7E9,L^P.J&PC.)LPR$
MNL#[(X?V%J]"L2$<27UQP-'X8>!GY%960!2M^R5-PR]1'#/RNXWH!\.,(W'@
MZ-TH1F7%<T*PNN:-H$Y5.JL$]&1+L&)J:%-P1>*Q>!HW!C<,?@KHD+FLD/!=
MH2^N7NT.LS#<XQ$G?$4?AR^=A@8C!:V,I+?B5<J1ZX>J#&2HB^W*4H]<%:!%
M^^!C?]UH'R3%_#1?/1195@8?C'>%!=U$NM./DY[*0VW6!E _'"G)=(#\5AZI
M9NSZJ:)&0@9N>VZ:]D78F<V<#?E":_#)HQD$4X3,;/3%2#T>291,Q"@:_ #(
MIMWVRX?GCB-XT:D&3N&]5EB\:F-Z&BH6/ 2%5!;/CIE6E3LSR/I%ZVSH&;J5
MV-3-<T]^V-LV5Y865P^$:7.'6.E;71T$DMTUDZ.UO!T1PWV8-XFC[A4>L@6^
M+QBISVD<LJU&9,?">Y&AGA\#0$@U=*Q8:=7.,4*L7S/'@IS^2T\)Z)^JY.W?
M/]+](\V0RC0IV; /!#C ^R1HEL$":V!/Q,_^0*Z41/[ZS*LHPQ)LHNC9AR"#
M6N#Y+<WNGX/!.(1^.(X6#9$O*XUN[.HZ8B:D)RO5</(&&H9]2Q@8N4CW^S0A
M'!S;/^ZR,V2:#>/]$"*CZ=4.1A>C(9M3RQ$(4"DYZ(9T-!,:94!.Q;[9,6(.
M-,FY,WY'XZ"@X46:%SFG[I$YZV'94MVF$O<4I-@)W5.60IWS/08C8EKX>'+[
M[@( G+T#""(CQ?71K5E])[-J4:][&E;/!=^\&*,D7XW27]$WT:NL25WZ_>FN
M+?TE8L(Q;\0&<,;UBE38/=CBEED6G4G 2:H*H@3VXY*EA_0Z*LJ U#TM"M%)
M<RCCSPT'4DK5&$9;&54N"-9/J'*GKG\WE 7'Y#G=@9-9PRSSP,F*7./S)E<,
M"(^;QC%9/VUR \=YV#2&QO[)H/>DB>T0T#N[.BIDY6Y1I"2N\9.\GF#E%TRS
M, U(>+OS>B]\2$F#J*6!N(^79F%7:5N0ROQLTSU]"+Y:I_ 8(;"*[0PRT:Z7
MHQV.4/)F@!9%VBM $ ;B0Y&H'O7#A9Y,(-[(ST#!)?UX'R1H.'.Z$B&_;B,F
ML8+4( *"=I$H>@0%E'C7H2>:0,,*:Y/JB -'248Q*FN-$X+5U6@$=8JBDS4.
M_@JCA07;5ELQ.&2]79%X+*I&"^^&P4]A'2Z1:I)6STK9+<\QEE+6$2_&UQV%
MLU_[F>SPWF&/ 4T=79GLZ*(M.(8BNM'6/^[O#W%ZHI3\\P]OW_R/;_G+;NRM
MXI:Q)!CB!9AO4T9,S=D[FM!=Y/+*=#PZI#($$]EOE208B6O]\@23".V7*A#H
MI++C;8RD0NG7"63F55 I-TX:XO$QI_]Y9$Q\>+&XL]</1THR'""_E5.H&;M^
M"J&1$$4CQ&HX$>.Q=X$N_8.IJOKQ?DB-.155-QA=;@9O4/N"@VY')_. (O&?
M<WJS^Y 7T3XH:*YAK3L(1[;5I,H"W1ZQNA2KIN]]=JA.E^Y(/6PCFKV>R._E
M?]$%>10;*,+;ZIE2ML_-FU8G8D$U7%K"XHBZ$V.R!E@!KJX8#E3U2UYV6OE4
MX%)+&_]4: K#"@:1NK:Q7>E(+YE@0M (G++?HN+YXI@7Z1[."<##D(/DB@2K
MU]L85MMMX%PP('2(<R>O)Y@E$I#+]$DT(/!/\Y;B=,;4IXHN4<')K$<V  B)
M358LU'E,QM$X:4L6) UDLP;"3,-#WH.0?2C#O"WQBG++^<IY26.XJF#J&G_8
MFCP7)PMH;%77(*(N:FN"0M3=869Z"JP'P=7B(;JFJ7+<8$?29V?^:E60(#W3
M[%EX0BPJ(JH]V'G!1@C,<B)&)OJU1)3#D0J)&&C15A&I:H=@*\(43F LSKU]
MD#]#'@+[#SQZ?PEB"%K:*8 E+-)=O0MCK5MZ&\#U[^?MJ>K;6 8DTD3@!PG<
MOX/>5#8W/1XYXW<T+[)HRY^FL;^C:-IYU=7O,LWN&6U-0\E;MHS/\&[LY@ ^
M47[+2#6'.4?BPM'$28S+FCD*T>J:.H%*=377!L&&U,C/F#-[E@<\3)K1?73<
MP^N:>@923K&:9EMDOLVY,/-W:)WA"0'<]Z79R6[SU _'Z_-L(K_;IUDU%J7/
MLIX0I=3PX?YM?&,Y0;I$R"D3+=BIW],7&J>\(<J'KY!!:-ZXK""QK@NLF6K?
M$0R"(5P,6-*DB)$+2.XU2;"D!/9/<>;G=<808Z<E7.G(6D09+0$1 HU.+-6Q
M1BLHG'"C VG*SHVA1=21MV\\2W=GT+X1Y1)A"I?]'HRY-V9@'N;@TS3,^=49
MS\Z=M ?WK".>A;MI"^M/)SP[T3-VP?-OIYW(K<]=\+K_-OJP(_!XUV[,S+!E
MQS$U$I^:CIDH=.P[ME']RC<5G6LI_.A(UM3@DE^GB1@1YW#+C$_T0L$@F55V
M%":D7/_Q3+=> ;BC6?]]P%@:-;77'GNUUS9E'+14Z1(?WV[]<6'76PZDE\&<
M\$R4V(OR/RXR&D8%_*2[!#)!8+W\'62B_=)7.QSA9>\ +:J<C :"P, -$4#E
M/WS3G(DLYKR.9<,@BII\HE_.Z]@!<[43]N.6O]:TBAJ-1X.C4&/9E;7,%<?J
MJC>.P)ZP,C2DP4/:B/S3QIFXAH<221&?R%6>'^'DJ%L!'-]T^TS#8TQO=N^C
M_)#F0?Q+EAX/S,W>QL>0$0G)B+PJQQ&N-6EI:425I_LB*,1#[""&MFWWSY3"
MB?H\#'E:>A WJ8S#KU4Q*$'RC?$6O>5;KT_&^KXY%H^JK%X^/Q$$P#F\)('(
M-)"&"/+[ Z09X%M"?Q:QH@0\G5!>M;2>%=F,JC._^(>TMX!V2+"-EPNK:KMC
M@P'19-B39Q14;=ZBAPH^$\OL_XJT8,9NRY,9X7\)[20S9DTRXQ8KF?$RB+)?
M@_A8!A,9YU+^_D<:@%$*;Y([2,G*F*%C SZE25;]\UV01W:ZO<1$./J_W)+)
M-F+^65:W(TNQT+^18A,1/A,IT98GJAHUUS<9N3>69[5%DJW3CE_AB?P%LB\G
M(4%!=K"2+WPE(=A*DC0Y:];L$2;#R;D&4L^WS(#FW&<Z_QKIJJ&HAR)E3!O(
M;B5$*\:MG^^L):)?! &&$FDL^1U&XU2%ZM+]/MT'43=#:&BP'_+1)MTD(6(D
MNHS(9-A(B1@_9Z<2WN^SRCL_?\HHM_VB>9<JQ<@\'B$/SX:!.OW.-!@GZVZ8
M(G6+UOJ) ZF!M#W7ELVH6X.#"0+.M<A!P,WC$03<AH%:P$V#<01\F"*-X?-&
MP-?@ &6GMSIX#@'YL?,/'PC-$.B>@-491.$1>'(,&\7._7&_#[(3G*AJ5>%/
MWLAYS#4 .&1_[+&-'*+5/^"#DDK)EIT^ VO]FHX6.XP[;3G4@=UQ.!%#O5,(
M-L8:^B]=I0>>I(U\+7-@\<AUA979IOM#FO!P,/M7U'X)&\)+V!S_)6Q)TD4<
MY'FTBVCX[E25>CD&\<>@  )/[X."6EF+:2CQ7M1.78;NJ]NQ^%!>YDXCUOCF
MN\%)'D]$PDHJM 3P>F08%EB05FA6BL#N2- WGAW#L(%UVTKKMB]GG_,(RNB)
M) L(K_1E*\C^^G<:0A_*'!I14O.-T#PH,0ZR\RQ#<]:=A@_I.#P'T?WWE\'C
M,0ZRSAO,K,3&F\WFY$W,$7[+KR8JQ>#/,E6*L?*[S&76I<9*&%H">+LE,DB%
MFOPB%NFZ7"3LD]6"JR+;RXZ,R**AM9ESAI_%$?!F]TO&Z+\(LNP4)4_B0B\)
MS[=,FXZ\+>_Y/LV*Z._B*<#N,DH@%8C7"^L^>ATVGBM,BA$(7VLIFVCZTC,B
MA>3784OYB+[H&W(PT 7[TQ-00[8E.:6/ _?R04,1"222N'KS5]U%*CVX)\<D
MI!G9"7))#/2N;.RQ5K@*.-WL")^95%.7V0]L<B+-3N3I :@D0%1:W!!5/0 O
MM@WL]87LK;$2VY)+<G?SV:\J!*/K#Z ?P^U9LJHYX&&U@4EU!M U=S)[LEMG
MI7HA/61T&TFJUZ0U(8?8F2F*"GH=O=#> V['J+H#)NQ NC/3ZMBY-1K$<+DC
MC499%[C..+)^<0*/0E_+L'_!=/DI9;ONZ"TW:M8,4?D_I07-;X,3\#_0S5(]
M%.D!IX'LUB--Q;CU'V)JB>@_MH2AI!R[2.?*/"LDN6#_:F2"_>-O4D3XYC&.
MGKBX7K)S41#_E099%26N5,&X+<R ;UWIFFT!0 0G(UM-3F>B5-M= 0+\#=(-
M$6@)X&TN3+ =P:46H75-<BP@MK!G^]#^N">'X"3NDT1L ':2]CDLK8F8,_C7
MO!JJKW)O=OSX6=:M9.[O_?%PB'GR5!#++P"ODEV:[46E \KWM8=4/L VRV81
M$,0A!"-(B+GD3> 0@PJD8"(>JRX!QG8NA=!Y*NCC[F,N44@>!8DD!QJ9]U@3
M23)!)2E2HPU9.]SHT3>HC?#-CC34P+\XMJJ^, ]%RB21DB;"B2(25:0DBSRD
M[0"EM-.A[VG^?H=>(M'2PK_(!FH*W4*GUGIV]H_?* R@X3D[L@9/5%I8EYUR
MF1E1M\0E%U&Q]RTQ'?8FMQQ/BKHX!\9,F>_7:"'$3@/FUB9/H(AYZ]6FK)#\
M9@Q^+=V,@;(WBLK_^:4DD@2"2GDNM&ULQ57N!-JDW>5.7L#S9@%OV@OX6W<!
MY:W+LVT):5W;@CDD=3AU#J25J1Y8GZI3J%T! Q<,2)4)W)ELE1RP!U^_EH K
M;8JRU:V[[QK)QI_ R8S,BO#(QS(\<EN%1S[7X1&=I^US>*2LK)0\X0=(;$GY
M1PB1N"W[<D$2.SJP/4@$9A$.AS5Y@\?#5Q8:>;7KCKY[>?@]VB&IP#TDU5OU
M.;;+F5I<MU=FG%,["A-F2^Q13/=;93NA06JA/8)&;6OMC@"CNK\6B2;S+8#.
M$6[N"3W3[<: ?@@RB +EMS2K.@I$6^B.%\5',(UN:62.V+!3R48QKTXG<T*%
MF%(V@DZC U+A(PPAX1@WA.,4?1(%5G2O8<5UX._'OC4N!W9AAJ2(0J D>I&>
MF7_X"E6&:7C)= 6\JF-1YKMW5\JA5,-L$V$;BKF73%/.8:99, L\S,J"N>2#
M-)7\5+&:C,#')-)T:G/EH6UZ?8N([<3L#W%ZHFRQLI<(CGFJUDA-M9R;'=34
M>$K@12=C(4K9N+QP:)TP^WS8]FVA!=2X2O-.ANE,+<&)V<TH9R3EE$3?RZQ=
M':J9F8BI"9_;0^OW^A<5V1HV*U8>1,^_!%G(JTF*]G YO'$4RYCGQ[WXG>-)
M;YY)L.W>G$NE-G9SS(!HX>8CWZB!LL*5$Q$^TX:(*JCE9!M23T>D^3RT8BLM
MW&6KD$]:+L=3%B1P[#[F/,'GF;)%";9_G#%(QD9>CB.'+-K"@'T:TAC%:-U!
M<XKC%D)MO.A\&1$'*_KI""5 ;W:WJ:AFF'^(HWV4P)^%K67_"RV_-%]B%LPX
MYFG&19%MT@QH5S=$L]&LR(N3,//@3'4; \@W1*#G13>K"4@SPZ;:[\M)<*S-
M<JM3_A5RJM@*?$FS/W8I^PW)F.'9HD6M#?S"[1OTN#'P[;Z(5DB]LQ$.2V%I
M'BPP^F09K,EU-@H5Y@'KX)TU&+\B#:.'FE%N!,9%L34Y7.IV6+?Q,6^7\E+E
M MC#(F1)N3)6IS79 N+D(;E1UW]G6G5JZS4L.S 40W74EDWU>?VLF5-G%N,/
M?KD/LC]HP8]BZ$6%G9MBOCLYM=WD1S6-*5YM=JQ2Q:LN;KNJ\2I3(Q1 7I&O
M^9KFXG3H6'ZQKJ.$7C'LNO9OJU+PCZKDO45>5]'KZ?\!E;W#FZ(X.E! :A(V
MG2Q5V,P;.HA$"!0"'V,N@"+"29JS;55U<W-7Q27*+%SE2<$P&.%H,$AZ?1;0
MCL1Q_@?(Z<E:?6@.]NDQX6\ARPSU'#*?'^'9'O3^A%)[1PJ_HM5]7!UN6KO.
MMC./%<4U0)4/CN'CC_Y"_84GV^<@>T)RXELFSVSQSK?;C/U;ZFI[ 2*EO1Z8
M!S7.SCSGLLA;[AQX5]]+YR-ZP"L>WN4VI)R!2%-L2#D)3E!PP>6IF*4:0S=A
M6W>@&AJE) SOZ;<L*NC[](MRSYJ($,$]F&4):A=B$C8<-V,&DI6EG4HO)*I@
MR!<&5-"$A P.>F(%O.I3K=YI-<O*+L@2_+M;M!HUX;CY(B%X-$LL1L-:M#\$
M4<:?[. 8L5O&?)HD-.;I8_78>PIU+9)M-\PX/WJ_#9SM\HPQ=T.XO3=^=@R8
M3"%<[E5(R)9A@0-9:1?R"DUS2.N82!CU"FSDR&5RMYCU1&6";0-1S^6W 1VY
M4K<M$<I5,H1_B/R4%II-HQ61D^)= S6V9\/NP5%R^N)H3Y/C4>,>**?2/8L'
MU@[5MH*Q^H+C",?+V1?KCN;'6%2VJ'>8G!=B57OHWD>I[I@E9+^8?E:O$7E@
M-IQ8'AEO*K'X'%UJD3B#WI?X/-#K*7R7?UTF"FY1XV%N1DA&#VE6"#?XE5HA
M[M?=['Y)TS"_3V-=8NPDC-[;)=TBC#10770^6RHUK3.8+''@8;LU1TT M_?F
MRW(Q8!CO&,8YRQ6<^:;EO*GA;9;NH@*:WDY?J1Y"[W5<LP0C5;R#S6<-5Y(Z
M@X*+=J "L>@!_:WW"FZW%H*S Q\V;PQ8D9W#SC6423SDX;YG;D6<\L:%IM25
M<7APHKJC&9;#M\Y(T.*T(RE5'78Y$,^]"ANP)EDF*(HL>CR*_.HBU;F?Z\=@
MYUH"3?(8G(7*M8%^'Q(^S"2;%3Z]]RX&3=A/,<]9A!Y9$,R!0C(ENS/8[J$)
M_'=![)9HK$MBQNZUBV)#^APNBYBGS&B59ZJ,A_\>S*BEDAD/6G S^C</<E/6
MJ_H:_4(D#:I-I,J8CL.#X-],8;CV;\8@P?%OQE.JO' 6R:0D> JBA)VG:55'
M+..!?E!C7FX,"E8$3T\9?0H*RO-S1.()', [/7CA5QH_J,859=U6OZ+@,OO]
MKBZ?L;+7-.?"MCHYDP89*;%M=%GY"%[3C'Q?2GW8IZ;PK.DUU:6 9W.3^AB]
M]XMTBS#2$>JB\]GS4=,Z@ZO3U)A^+9Z-Y5(\I%!'/ZW9FY)QO*:F7R5LL6A>
MS*;H/83>Z[EF"4:J>0>;SUJN)'66=!"!=QD=_XM8@X1[7N%,6FZW%#5C5?N2
M,\)^L2=)RKR_0W""J-=RV;DM"LO**;=!5IPLDND,L/AYM8.,Z9)FM8!>9,0.
M4#<L7>P(4#6].0"<."UX$U*=PFO?J+1-QJ:N:L2QK&U!%OF<9^VON92A^(4=
M7&\2J)1RR?B-7FA">U>KUE#8QL'(C-HL*$$\, @&NOJ!,3:VZM*0)I!.6 'P
M8 )4Z/'I<F4<DUT;P)F^20A $PD<.Q7=A:?+]I>2'0,1Y2P?)$:5<3@C]^_.
M29P&<_:;5,<H/K+?TIB12]-C7EWWB,17^\LC(Q)O+G,M6!VXR35@\.D:=Y#,
MGH2V()J+VS<1!_KV5=W@NG.OO;YM+\N'>ED$MIE32.P=D%F8OBF>:>9[(((3
M.5^XL87-^Q"$BOFQ848)E<_!ASZ=<X07 >DK"CM8+$(96.2,"1M-WE16NV>6
M?%-JN6S4^W$/UB9.X+WJ6R[12&LP@-UG V%%^@PVHUU53)K)\')M%3WC]X_Y
MS<YAS<IJ* /Z-0=B'+V:;TED?9J.=74]FHOD.0H*<5+J&D+H[ST76YJ*07&=
M_[/O>V]=.V2V*F-]C-[OKKI%&'VYUT;G\_ZIIG7.>CNOIVZ8Y5K4PY:*S=?)
M!+S#]EWT]%S<[#[G(M5H.$@_!(X=K;=C3QVV-\-Z$+^W(5"[9S2)(3'OK7YW
M\[E*"_,VX#:1]:YA:5)_1'MYCH;<[ A#5#H1V)'^47S>=#YM!F!GZ>[LF%<9
MH+Z["K<9R%EQNF6,07EGZ+K 7W?,YCH,S^"]*V&[2"-=BR'T/KL:=K3/4;BJ
MG(C]!%/Q*[5ZLM?CCHQ<KPJ,LTT;MA.*\PQK_$EK]J/;ZPM(S!N(>$4!B*4"
M#Z\MVF",]V];L8;7HMV?TF2[5 12A?O5Z+Q^82:J?Q_Q:[ $.JIG- K-%*\Q
M(&F]0.+"\Y5$)+5N3\/N@KZ5/,GK/6STEVKN\T8SPZL\<G3)7_[4T<SX>@\>
M@ZLV\]EC>K!4:S.F(/([@*K6_?%8O ^J#DJEM,O_(T=8G6V:1:P5SV[-SOU"
M$5@;&_6IN3SF\UQ&"223C+O><4.&;:O&L*ZV5RZ8/+!9[N3V^Q*)K@;;F$EG
MM(MXC0"20"NSTIH93)=0]">@A#S3..3%IMFO*!%%I]G?P:SM-CRYF_=,$RWL
MI+^1?9HQ?,]!0M*$DA,-,DSK-\.*=BT@0UEGI%0&KT3;LHFI3_=/,ZQ#Q:-?
M=U%2PZX%\MEFPXYS+)QY<>3SX$RH5S\(SDKW#"= 5;,\]+C2LHM4<1DWLXP*
M,-EX4>5<$D.RY;MYC*.G0%N7:RPF;/_)F6FU\V2-Q@//R9%6K4SN6IM<VL"]
MAJ/>U$7H6J]J45HVJNWJ2$BQ79RIW%]J/OUZIJE]6)UFG RX_#-/@XS;&B@M
M(B]-U "UUBE_K]Y,N2Z$E:'J1JJ\-E6N*] -3$TS5]BGL&7<T%=ZZEK@M/7:
M3EF+GJY>Y9'**J5'.E"]*BM@G=PSYP2ORS;8I?G,A_W56(P%$WY:QL.CK)_%
ME^HZ39[.>/G!-4(T#5DS1&G<D&&?A,:PKKWHLL;DP5G(G5S3!?VK#MK,L!2*
M&ZJMZD3D;>AFAC58.WK3D#P^:F.%PQ\;-3)*8X' *XOD>A0W9 J]6E,T-2 C
MK8G'89CQ_/Z#A%\&LZ/G0/Q:#UK+'+!>X<%JZ0/5:SU%&6,RL>H,A6(</M'B
M(LB?;[/T)0II^.[T.:?A5:)D;JA^VDA<."9@$N.RUH]"M+JB3Z"R[]/0@@ R
M4F$CCR?R!A"2*/E6UU$)NZS9>WK(Z#;BQ$"_N'V:%='?^3_5JZ!9R1%XD)[]
MC&6X];+'%<GZCW?&4=C?L20\HB6BA,F3/F&+\DS5Y4OG.A/+1-[L)B6LNZ#"
M/B&[LZT^*-OC\>"\[$JL*E&]1@"YTNT@WNMZ8S-Y,;J^=&MQ;G;*_'*OZANM
M)@XHCL5%<(B84\_+*8=1<<RHDS]A#X[C1KBR)WL/MK"K.PUNA/5SK00XD> ]
M\Q F,GC+"'KFL2M0MJ:9*,X9E0DI.VY E<0<PFK,XQ$VA/U\5=#]X+G4'A[I
M+.K*8.O\:0N\_IG3C3)E[!R.F34"[I;7* C'@7[A/I7+AKNDY)>-3G(& /JY
MV,4Z;Q$L-MTK$;,*WQV+3VGQ5UK<!E%X5247W=(L2L/!/=X9'[9C/G(!U-ZY
M(S(/7/11%)L:39<=S'/H%L'1$>:60R<J<F)_/#"4K\%9GV=9NAZ[6":!EE1X
M"4-,&&;"4!/ S?Y2)RL+]-B.^^Q"PJ4C/H8\5 A=R> ]<EZW*F._.S!$&3EP
M?!LA-E'S/OF@7)8)-O%S E-(?)Y+,OJ06GGR4Q A6,%)+-?F;Q06'+LW@=2>
M+ M<+9_8*-(;3XW> FO2,G(R.O*0^G$X0I<&E.,3\T:C@EY'+W#A4S#R(T:)
M8/W=Z6/PO]+L NI!G'^-="$*)PPX1Z@13,J'* ?PU8]1SK2ITM\8AC..@C0X
M*EU]/!&.AG \[$#%,.'<T1E8;1C]%.SI^W0?1%UC/QJ+=R)K8M92;%4H?!)=
M/7V.XKMI"2\@([\+=#@R#/VWXYANBV,05]7K/M+](\TTBV0"P)',819D(=2/
M7EW>ADA1-DNO .IZB^1W 3.C_.19(<D.^U<C-^P??[MC-%'%!MSYV[K2H"0,
M/GSK#ZM]8\6LO<_)_S[[!F;S\90:WOLKT@?LZV[G3^M_1*-6EI]Q=BL^\"$_
MLGUF?]QK/V7G[^M_3"6!U>=L_7'5#ZJ86='^FX]9W[1^#+Z:/VK[[P@?545@
M_5'E/Z[[4?LS]S^J&+/ 1W6Y?H?E30IQ4+^+\C_>G=[19/N\#[(_#&?:83"D
MZW9+=EK7[ ,PZU^O6Q'4OU:7P0C D1H,\UC:9Z>BRG@.'0;S1<34[)A%K WC
M@8BI"'(4,<QSXQU]H<F17K)/Q8CD-\:_1<7SQ3$OTCW-C$=(2U@<<7-B3)8Y
M*\#5!<^!JKYC*V"]VS ?V'1N>V4#X8L-ZS$QL$-6PSVP7!U:;(P60'BU)0)!
M;KNA#.&)$/69, I1,QQ?B+JTV L1YJ976<T>.\;M;A *29SLF&F)E!ED?;&R
MH4=1>E! $86,H6YU]T50T+W\A/M\6T0O_+GE/7V"OQBV/6MH''%S9$X6.TO0
MU<7/B2[#N_L&"G./+"E6\&+<*(?!D.3-DIV6H W K"]A5@19BA;FSEDR<B%R
M51AE3;**<>^T@$,5KV&&%/*E!\(2L"&*5.Y9"=!Z,XVZ>PI6U!E1-D)FAD05
M,QNF%()F L,2M6&:5/G)ZB?Z:]_.7$!Z',T.05:<('5#<P>N'K;^78V)W.K*
M1C5FU9L;/0$*H],,+5-G5KX[IX?RI=GY4T:IL)QM\I6^DB,LPKV[*V/UK;PM
MX+IW]FY4V0C:!.=)D\O_6YJ&NY2Q72@W)\T8A Q\':%U<GUW $[>O)J*WK=M
MAFGWC\5DTT<ZS>GG[L2^"Y(_D"KF/!9725YDQX% B6H@5LT;'<GMHC;=40A5
M:]0D*$JT/!:D&8D9SVC3/)B&K1_N@VR8$ZMU8Y'E9'"?[4C+9K&]]IRA#VEX
MD=$P*FJ?0+_OFL<C[,$V#-3[L6DPSMX\3)&BB H'(0*&U$!(N_8:'$P0\/OC
M?A]DIYO=??241+MH"YWKQ7.N*'FZ3>-H&]'\.DHH?^2OXM 9!8(:C&2SU@Q'
M^-7LYWCB>E)78H&22A(>TB B%2;R.^ 2=2G0KN5[&2G\F0S4?S06\[6"1+NF
MMV6J<UT_!(9Q;6]'DS(^#)#D"P,E%>Q&/()B^SS\SY(]C%YH]I@.U!R:SAQF
M&2\%]549X%.9N'5'MRFS '^GW7HH8Y'XHU##K [IEAZ#%VHV1)ZUQM6(-J3*
MYVMP(57[FH/?BIFL'MAZR[ZME@.[9#4O''@+I+"-F%<X"R-F6O+;8/M'\$0U
M2S0(A52)WHZ95IEY,\CZ->1MZ.FWD0*H#:GA2 /(?BM R>_L'$O)+HASBI64
M?0A.<,2 ,O#L;*U9@OXPK%1K-;GMK.KV&(0$:A4!"G-4#8,BA# 0Q[:ZD@O4
MBM+^:8#3\*-ZQWP;PWDG"3_\YS$Z &F?<[H[QM?13F<DK2!Q1-N!*5G:+<!6
M5P!KFOIE.4M(9B$!EM=#K*$W1, 30(!U!AC/FUPE;$..@I58P0IR)9)!);(#
M]:WFB%F-;. \JBYB(6R&DB++*]+@IC.!-8F;0'"#K4OWST%&WS%W+[Q(]]!C
M0/0MR#)XY@^VX=VI&7(K=M'S+T$67@91]FL0'X'SX_[ <Y3 3=P6-'P?0>N1
M)+P+"ITBKC O4@[;6@O:RH!;>M+U\^?6X:@?4 :D9X^ E<@S$VEJ*,HECRNG
M)WS^#0$*"">!2#1L2$4%J<@@0 >.#<-:WIKU;"G6+?P@=.9/$8U'%4J=H1]"
M_OPYB9+\F%%H37/4WSFH1F)U.= 2W6YHT!N&T+M 0X.B34'^S)R9:BP1@]&N
M!ZSI%G^$H"/]NJ4Y#P!4/,31/NJQ,.&>]],1;HYO=J(>71D[55[GZD8BW-J:
MB:XO9]7#<!(63+2H@BF,"![[*9ZA+/0NS?9BCX339<"\X^0)BNDF'"O(QYX7
M =Q6B%<NI^O$W:>:Z+)R834>(1UQ).&=U4:*S>9%%L&^");E/.'_@7C#2Q"#
MZ*A_:TACG((0*]X[=0G:D>&QV!!BR--(55B<"J%H;0F1-?Z#!(Z9>SF.X8&B
M,5-0OB:!-Y68&8_OE0B]^=6A7M;GSQF]ID4!>XU(WWN@V?XZ#1)]SJAY/(+;
M9<- [7R9!N.X8,,4C7?$8HX;7(.M2,ZLK\!6]L1&,"E (+^O3"P](P!' '")
MU-(VB?=!\CZB3RF_$+=5!B40ND886-&HA0+"!]W0DC6C@K"!)&>F%^81C2Q1
M-<6>986Z,&#"H<L>I LH#831@N14-B9DBWH19*%>78S#$13%@OQ:10QC<91C
MD"#%)52C!QF- _"KF1* BI3(R*'&1K8,W<K"[\Y217<#0@ &N98?<]LZ_E[/
M2VS_0CX.F=MFSH0;+YX[V\)T(\"3$:/$C&>B6A-E[AX@(#FV?Z3N_JY]NM8U
M\IRP;=S2#"J2!4^4;71I#)8H"^([RN;->EG<5A (FX<=$_7^81Z.LX78T-23
MK >V71QJ0.X[U:!L6Q&PL*\\4O),XQ N36&+R>@!^H4S"\T@H^*T\MXRBM<&
MB'M6#9\5'$)P>!0CYR'S"9D4,-*UWXY_K/H#LJ_VB/7&?2BF<EZP33X[,5GB
ME[(C(S,]+'Y&SS3,N@3,.BB\BY$IZ1L5#5[VN95%6O(<C%ZT==(7'Y:Q<__,
M3#B$841_;)Z ;>_<:!%XXXT.L#C@<FJ@?? KC:19.X^@<1S-&0\D2HB64;>T
M".*AY(5)C#[ #&3+V>5=WJGD^@*W66-SX.\X6<]2\A'E'%XWC[T^TH"G8-PD
M=Q3Z,8M>]Y_2)*O^^8X=B_,':'2J6<49\2/E3\^]0*TDZ[F0KY^)/2_E_73M
M.MT1CI4E%-<:&0WYG>- :EU:+<&[4\DP6(-+<')ILCV9NNO:0"*+^S!32D'6
M@^&)Z!!-_2Y7S7!2CT?MDENQHF+$W!G7!A)9U(:94HJ:'@Q/U(9HLA4US#K3
M*F9RV>H:<TRLH?T1.@-S0X*G /5"^+1T&3?:]M:*><NA?50XV+G("M*S!ZWF
M3D868/X\:!WL;#3PH!6@,7=:+6- F'&GM8+T3/#Z3%D)7@/FC^!U:1HG>)C[
M[KMC%(?BJ%3]>+4_9.F+L.C&7=<2%D?\G!B3!= *<'41=*"J)X05@ @ 11(8
M[G[[,=@^1PG-3K)*&27."($C9Q9,R-)E&+ZZ3 W2HNC$7$)P2:(5#*X8S1$5
MNM84V%QHCM<;5>PMU-R1Q>O5:W@N2+WQX".FX9HD342JF0BTMM,'(?ETDRN!
M:M)9WD?Y(<V#^)<L/1ZN>'4V-J>R XS6-ZJ7$\#B%'A27?XO-A5" LW"RU9G
MWBPT#T[*SJ+,J!7PA5<TX,D[3,G2'3G4;OJA=M.;W2THBBQZ/!80]8<TH+"D
MF#P!R2++1*19L[^S_XJ_@P;O-H16I1)$_I#T-U[P,6+S,PT^T2 #4$@K2B"E
M-29IW0MN>]K&S%Y$.Q*GR1/-5LXS6O<#5;,1/MV&U!,2=3<IJ.TG)BV/6.?R
M$4NN8-%,C9#CM.XBBEO@AO>UW^(CL/PA+Z(]3P#?U2J.\V!8N@*J?_SWB'&:
M;9]/U_2%;496MW1&8/2+.@O6-'=U!DC,Z[I!L@S.'*EAA*-V_JMO%W=YGSWG
M*SP##H_N5888';Q=T2'PXX[%3)VCC'IQXW>5'(Y%SI7M)[M;/A4$L@3JF5#*
M6W\XGG3I:#$>7@70AG P\I,G_=<OXB#/;W;W1;K]PZ;C>G\\<H]U'0/*KNK=
MP7A]U-64]+,P81B<?/A S"U2)MBX#ZH&(B7W:DEN)?'V1JV?K*LA85 <YB\%
M<4^SB.8_WK(Q-,MHR"?2O^8U#L?HFC1,?M,A23\6)ZXS2%"_8"6'(.=G/Y(:
MJI(-E-YAJ["PBKV#B^:;G507TK [:L;B6#TCX;+A4PY<W?89J% _BGE,(0+R
M0EM%6<$_E_]]4SQ3B T&"6D#(>Z@$GVYN D)FM\\L)]RZ+C1:W;?62]G+#A2
M.))963X=4:PNN:/H6T2FYW<#I G2Y(87N^6W>UN:2)W&354^7.!1RGZX,RC5
M ;$'QBH,XDJA23#ASD @*>]>.1KT1J6>,#G)VSX$8NYZ&L;!+S01S[EC<^4I
M%V@47]R5.<DUMP7%\M3=Z!NJ3K7G8PU%JIH))8$$,2WG).6D*U]T3EX'6[X6
M. OD62%Y;>Q?C<?&_@$9K.%Q6]QD[(#RPFR!POW7#UM7VX;(!;72C5G-:S(3
MH$H#AJ'BN;$8/;OO;B<!_#FQH"!7!KX&QJ+)@I[PCD#T!V)(A8X*.]&8WP6^
MVN^/";U)MFF</IW.DR)Z3,.(YG?%5\:2?E>V@T/8CUT8JG=B&R"</=B>LGX1
M/ YZ5L&2!IB\N7OXCS,&_RV23XO%U6)6M+[QN&?^=)!%J68CU8Q;WWH:":XL
MIW+0JE;30$'?RRJ'K+V#5O-^3O(#W4:[B(;:'=0P%D$&A@BOY4 W<%U9,%.A
ME0=H05-#++&'?DK?16D>[:,XR,IM^]^#_!VER?F!OZDQ%(JUA\7H\^+(6-/Y
MQ1(0J1>,$W7]-B0I:>!)Y:<]!SEY9"A(A0-I:T5F;H(:W1T?L]/VX9F=B _'
M(MKF5\GV.[WF&(<C*(L%^;5^&,;BJ,0@0?W8#H/XZY8($,IA>%+V=TAROP8'
M$Z\:Z!.]%Y] U.M*L_PZWL++S>P4)!?!(2J"V'S;X(0"Z<)A!)NM.P<'>+QK
M!V<BQY?N+Z<CY7RDGI!<7U_P9PU\3E).NGHE\SD6PY''^0YX.=U^]Y2^?!_2
M2/CX[(?&O6?_^-LU?0KB#[R0K^)0IQRQKN(9B 2]4OQY-;==.[>BJP,;1<2P
MN0YPP]]6S*<\K?7_O/Y759%7?5+Y;ZM^S_[$_3<WY6=<(%S)_N=BG]8Y5 ]9
ML/V#V<F!!#XK,(Q@I3T[3:QR& 8I5&E+V/BM\(J=3<C%QQLIB:Z:1633K;SY
MC6=YD)-9[]^W\'!\N..99B#*K;J!9.D"73$*ZZY<2\IX<<\%4K1F9BY,E6.;
MUF5S=M$0/6_H;19MZ66:5<]"8:XH$8DQN_OC([]$+Y^)%J>KA*T;\R)5G$W%
MB-&%8Y9%:+IT3$*'U,5C!IHU;Z++=E"4'  W?[8/NMG4Z8)_%<T\\#P!?E7-
MQN]I4YZ[&%0I'CD)]BEH,O01"3*HXB$JB\,O**>-*;\@;NV.T8LL9864<*R$
MH946\*&]>/7"5>_RV6)4Z#%ZC:PE6MZ812@G?QN<0%#G7Y 6\E=G+!5+,Y/=
ME#"_1A/:(U_=T?<@AG K^O\;UGD7>"X;6W:]*"=[=1;731)G-+KPV/ECD/U!
M"_[B^697T:WBT3 8P2@.DEX;.>U('*,U0([Z0?J> Y0UG4JC4M5S6MDFC*)?
M )0U&AC]%0R"JLZR_@<-_1-T\1VS#'=,<.1&<4[ZZ8@ 06='L5CKL1,TCFZ/
M(+'?\V^?'IF[P83L$78[Z(H&EI_791-!%:D/X$ZE7+)+LK)QF&,!  <!)!MR
MVV+6-TLR![-M#NLO/J-=$:Y&_53C(DWR*"Q+DO$GCR)BV_9(\O.MOJOK5(P(
MEF>>1:A-T31T.+9I#IH55]T2%E(T:/C9J'-Z(4&)C!R3D&;R :<^#:ULKQ99
ME/)P4F-EIY/6,DF(NP>9G%2X$>S9,A(")Y=MBW^3:"QG^'[C3[V+_"K/H2IC
M!O]5M-=S \4W94-LZ6R6#LX+XV0FKB=CU7 2\?%08S8J(;PU-8XL]FU*S?15
MS72% ]]V3/F *@[F,P.RL]:V9",,@PLR?%/ASKK.>-AC\L*<N)*KT[Z@T;[V
M,:R[F_7M$*ZQF6L!)//3/KATW!@O;=+D1;@U?7.4^D3OZ6-QE>1%=A1UI+=4
M1 \ZJS$\'*?BT!#Y<FDAW=C5:PB9">F7>F?#23-^0P""")"U*Y:/9.&^F[GC
M@:Q7JGL7%#Q=FX:-=EIQ;4;@@S[8L*C7$!,TLLX,DS:L1?5. T@V1*"1-J5U
MMYO9^*S98D=E2MX$>>5H?#OG\QVFS%%1[XL/;'#^G,;A=;2/BL\)S)]%T,X#
MSNZJC=41 <;3G3$L-@]W7*"1GNVXD]C/Z*F 2 Q0X-0<)4BRA="-Z.@"J>^0
MRTG#M5_DS,"GP"$[KPWG' \\JI;X!E0([NH<K'[N?C^DK5I$"B^C)&!Z>I'F
M1?Z)ZKU2S6BL3=A(?'O'50Y%V%X-=&CV4CCJL+&$#]X0-AQKRW2CO;I>$,/)
M%L;C^=$NM,.?V7$1>MN)3EE! 2:5A.Q[H*AIY6Q\^'J NHD@%QI&E2-QU--
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M_6ARCKTL!,AWI/+!8$4P^[V@>/6.SLNL6(V75(AY;*U<MG?168F=7'66K9R
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M>NS/Y]]E;I/]3,S$TVIEE%@,=RB&V78[^(C,]YPIBP7G+?AE&+%5/)T==X@
M;[OC1&'94S5]89$^C6F)+K1;CBE/,<?C?9'DUPF9EO76<.&M 81XEC&QW#W.
MJ*" GFCTK R?-1X0A:T0@T8$?.G7%R]F.;<=L[!WWDTJX.>BQI4Z%M$,"IL'
MJF);E0\JPX'EA0Z9&*@' VEBY>;ST>UVJS8=ESSY;H+B5H@J>4:4/()R&C=X
M6])'^EM")7W#M'J?1EH'O!A*;!@$TA?;4" !E]W0<F0OP-&@KI"$'$,M#G>9
M[M/D.<UH\C_MZI5LM^5)#D+?D?]MBY<\_2=0T^ZF3P+MP,.::#PD9?W^5))5
MEFS::'N\J_?>+X9E8R0M&%N;)+AL?Z,(+6Z3$[@T]M80.(@A(9G>"CV_G_T<
MO-N&AZ*[B6T(VO0A */2_B+*>NR.O;CR^K*F:(O44T.XF$^97V.LIPH07JOT
ML9U#*% M,<9RGFE#^!!._M3\,:G(*I^O]WNR 2 #ZJ\/S/  MP@N K27"29@
MF#L%.T<*G3@25NB=4JJ-N.-DD:"+6L(+7T*,D$['.>R-A,:MWULJ-=O1X!VE
M21R'1?<>K(BS&T,6ERHA3J[KK'&QGT]4;S?[?K$ 95=?+2B 8[6PW?I4#1R,
M.S4RH_>D%0M'SAER/XN.%<Q8NMVNGQ2?6[;/"F4L?/\PB?7S&0?Q\ANB!>6O
M.,=E0CN&KW?T&8<V!Z_3-_SQ^Q'GE>Y"P0T5QMO[B"5[?!>\Q;V^.U/#'A 4
M%0E<=LG5QT8"'2H2:()HLE!)7RC,$4-&!#&;?B3&*IAZP"6+\58Y!#TL2)4H
M,^-2;2@U(%1%*!,WEM@!YD\1BQT0JL"*Z[(2$&AW*MF) ;[8FZ>,/,F1PC=6
M2TN_\R(/(.6@O+AOJC>H'M$F5G0K2IZ9CAE+8J!'3="/!0&HCIM5A%X)-RTT
M7/4V"TL6@V6FRNMZLH(L3;&6YW=FIQD;0-02H/_ (TLP6&TW7VDYSDJ4<\!\
MK]J69WF$B?T9(\BGXCEE3PO[E(A!UEORM[+]7&-M.U2R?E6OGRM5&4<#'&AJ
M_I!A149^!P25B'_.@7II6B$*B7YO8.=IE&9]"W;E^5;V(6A+$/X,HKNR 3;Y
MM^:#EQ$#1I\=A) UVP"^N(Y;>=%J3E.$KPD7F/,L955[?S%:OHM<&$$FPB%2
MH,N(UG1MI@WNMHWN&LY-V]TSL$\V)OETGCC@ 4&VBR[$F=T[2-4;-/N&410
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M_@B>:^2IX%L^O+]X!JX1\;S;O+IVA=1S?^^/R-G#3N7=AX-Z"J#;#_/-<-:
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MM(,>11NI>J3V&:1.Q3DFWO3K5VR1KFO>_L/4>R/NB2_ .ZZ12%5X=>-!:E>
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M1/.2/IM-QY=#!5]=:71^'TNJ$UE=_,P._?Q3J2I[S=MW*/!HSG3G%6 E),%
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M><D%LB GWG?2'9@PH6, ER2II*A3GLN\\RR'>'.'_P_[Y-X-&WMVYVCO#_S
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M%Q>GO8Y1S2]9E'=*Y8;:J+W^\BO(W( TS7Q\1&JNN=8Y%MQ:'*JUNL_ 1"<
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MZ[=@L?KF@SD25##?N%X _Z*]SN+LK2$2>+1+W\F)\BL)*UEI?0FA%><K.RP
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MNUJK2B,N562Q5*+FF ]J-!*KFW9JKJ4Q/L4S^=8EYBQY[6C8"/..];I[ $&
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M9>M@WVAX.J"SIM1WQ[!=+W@KO%C=.Q9^K1P:-F%MJFRGC:*Z6)OX):*5?O^
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M#BSU$!5*X:?7#Y<(LR*"/9H9:/:0KO-J4- 5#A3EE@'1E-^!PX5T\UB#PI'
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M.LVN(]_9^/./@B/ZKT<Z]_[K?U!+ P04    " !X2Z]6S1GQWD$\ P#O\24
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MHHFNE=][>)MXUH;MD-79#6WS#>(2O9@ %.1J\#YJO+.WN_=LYH=Z] ZS\]K
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MXF]+GF_\O1%_-X+3(MXK1BLY:J@5A"G'T]$6+=V_6L9[+>$7Y_&%N9#GUJ<
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M)(#D;05PLYL6WONCLA8_K.3%FL5Z9I\LJ< L&M-O\_6H^"5NNR'Z$=>?O6Q
MMMC=4T.WP+PZ52OS1'LJ:YC1*PU3O;R[;(8NQAQ*S)^Q&%O /^/6EQ.Q_5O7
M'EO$7O31@@//>0"<6PB<B,4&"[_,C34LO4R08%S)"/UO%^U>+MH1[[[%[PZE
M;=]:Z@#'I+X_)JLEFJR5L\-,49GAHU#Z6=\U!]Y50QK!I17<0X(P@C[55%,U
M/&,-@'PWD\IY"R%*\ZH24[59CR:94.K [2Q^_(,^'DSCGE'*SRMN?3E+^<4>
M2XU><EK/)X8MUN<55O ZI"/H#\'2_6E\698F]G,1+LH"/+<SU)28/,6TK+K&
M"+EI<CX2%E,WE,P.92["A7F !TUO<%\2&5_=HO&*,8<>A&7G57>I0,KH;]CL
M1U=2.<\.CL5(2:D.^H1&EA9Q/4UYM8P?RO7E.5M_DB;WW2\[1<T[N9'H0 U&
MQF_I1N+[;N2F&B;QQHRXNF6BWFWH::%CQH@[NW,1?3DQ:54[F([WP+275K)=
M9_3PA3'/S?B>'N2E-3*)N]5-O0XIY].31TD6G^'\@F;;,W>:I&JM_CQ\ZXV'
M2$\.)59Z]<8HJ<P9#D\PA7:!63*+93T,IW,^G73'1WFZA89LSYO-**VZ<E6;
M5&JDF0M#*O==3\&<OI-82G4["2I#\ZR:=RVIDRG7AO</Q+UCX?#A5]=N@K&K
MM5^4(S1?&AI&C*-!IMSUQCD=GV?"4 _C$#7QVY8,/7WQ LCIK">WDC4\Z\NF
M@*5R,>K^2:KO6&=\R(T#GJFNJ(9BO\A6FQ)O2]S$<@+;Q'7)= .?M!HSUJ_%
M*=PEF?PTOJ.6L:ILLW)X-P]M7K7Y<?,9O>N5]SHC'OI+W*B4+7/#C-!E*R:M
ME;M)%;@4]>RM:]H$SUSQ4K:=X_H5BW4X"51QOL=44T,;^'GKQ#P=*T82R5_P
MD2M>.('M.8;&%E2J!<HX3Z<K_#S?R"C@^1O73(1_7O'"'%<?-JKM\BQMX(5L
MC.LGEXUQQ7B!C]=,34?',+E4S^)G DYW6";EI)E<UK.+>^&%@[<%3USQ1G%]
M)3GG-T5Z42A6"EHO->BW<S)<#0Y>>.GFH2O>JT(?CRMUEEHO&YLEV4)FJ,Z9
M0B8/C/GI=Z('KA&-J>QR4:TWX>3>B*=[ EUO])S*DC&?O\]S[5^H_=M?EU-G
M4&T%(K&6Q>JXW"0'4<ZF$[Z-:RD14,1@)XM2\,!^9W4/$I:'R^UW"L^SY]&7
M.6!:AFJ>ZO92+7#0Q<_#T1_0Y:>Z^ 7[LCQ;!,[JXPCP4J#&X0/__ 7_$W%<
M7X?6P. 7V%R5W-$O L?_[Y\37D(%M3 =R.ZOV%,LN?LJ.*NZ^6ZM*>%K=&BK
M9N#/'T>]VHIJ8JXU^95\(B?NGW#<V @$/9#X$Q&'7^V]%3X\V3PJ0_V.R;RA
MZOZO?W?@XL2)U,$\TK(,WOSW?U??P'\=:!7D?_\9M';4)8 =H=<$[_T%_XR@
M_T^L_D7]\Y&1#>2_?_RKPV3A1V?"FP=O#/[^95JVP>NK7N>KX:Z_^O%/!]U,
M&K'D"#JDC59#?_U$O4":\O#_)R=H*T+58/\2+'?TYS&93]'O-B38L N^%FJ(
M7\3>5X@=Z#.RGQBOJXKY2P1HA?^G8-D0'KMG%A''TE4I\B\\^-_F=]1!] E1
M]O#G'=G_/$G;8'#PQWVZ"I8NK1_<OA<A9:8Z4-N@6QE^C50)>B"PR__Y5XK$
MHW]N"3ZY/5Y>'GCB\D'Q@1[B0$R.)8% <$F"CW(Q*1GGTB(?XPA"D' ^F4RG
MH_*/%6ZNGD;Z)#\/YR4<O&2?_C_^8>NE#IV+M#M4AV[_]5.X$76O'5:;SK*M
M4J=$MR-4/1>A^]DB52_0D2Q3JY7:[1)3_[BQ!JJ$P'>ZY-S >[PS@K+F(B]2
M^.>_D;.-<T_9IPB)QV/IV\TFP/45T]F2Y,1X\TRK]C__(A+XG\%XH5TQ+3,P
M=ZH863OF+:1EW[>$B9@\6J"@"O\Y2PPJ\*#X](] JNJ\;7-6PBA:-9>=X[V:
M+"=*,ZFND\TWS8' L>:*V@?#/Q#@9$I.B^DTX&(\(7*Q!)_@H,SR7"J=$G%!
M$E)Q":P%>/5$1^3JHV%=QUN9'-WN))G.?-ALMZ)S5*9PW=(-[,=ZF&N%*J(C
M*1,'_-K\L<](I'C6-A.9#W%E=C8Z,[#0O.=:FR]6]CGXYL"*[QN%51O\F?5U
M[<W UB\D5M!PI<WW,V"[JLCK:U1!2[#N(OI$DO]W7[+7[]I(^9X]W.O;@OW)
MNC7?J-/-9VQN\Y-?@@UX#9M#&KWJ:6Q_YP5HDSP7_(F,U/,9KHSS^K^N=-'4
MTHFG9/(1Y_;3M1%/;\*_>QC:0\4A(P_+_?N'"G66 T0HJ)8N\+INN8*U^'$?
MO=+T>!NJ1=UO@8EENS\V4MP=UIEZ+A//LY[JQ+/MV!R?DDB*\6=*9D.*-E L
M$&%+D;9O0!US;%E.J*#_^5<Z&4O\^:(6NAD^;V(:+S?:399J=>A6=1!IT0VF
MU8DTV%:;I>J=2(>)0(O>@69[93Z(:(1I18CX'])_5E\P^4BG2$?VS/[6Y%/9
M3@3^3*2CL:V5W*'\9Z!6[^\/?JA;^B;S?=IK30<_YBT[XHY 9+J!>V0538L$
MQ>PBFY&_*(^_)+03!#L=2;SOP]4,,.\DD(U@7/0J]K=G\0>X.ZEB>5G5,*=I
M:8/9M)H?08M?0U<DK+ 3)?Z[^@.]\J1 A<M%9%I;'*_]#3)&)B0AGN:D9 SZ
M&R"6@JY&-,41<4!*4*23?$HX]C>&*4.7XXM96C/\INC-L*4?HYO?_D98;?*W
MO_$[^QL=FS=7Q#UR.$C5U<:#9+_& FI,PZ5M7N_)U#T<CMC7<S@Z+:K>+B&W
MXMOC^##;MO$IW"VD-TZ%;%M&A..XB&NA?\(?ST"5P%0');]$\BHTEE H4$K,
MO8,;=+")BMZX>N&>NT,M4[.*(%H>FZW*/DE(XXD]5MXT*1Q5H(T'KM +XGX]
M3\@+PGMW)V +**J#4.BB9,D](G;L2GR>+"?F6L%2*T6W[B@Q=?Z*+E$SJK7V
M(U$:[OV(]U9Y^X->\*(;S![M/MC;64=X)^*L2OM#7UXU(ZKK1,11X.G_9]^]
M3,1$,4H"GL.CDLS%)!#G4D(ZR8&H3/ $CTN 2!R[ER9G<(LZI6A:I6YV4E)B
M$J-Z&[MTT))I8\MI=R*)+)^:$&P!YRV74Q!GCULFZD2[;U6(!5M9U+ETI3:B
M^IX".?^L3TS-5VLY![?IA)/U\%D4V S;1-<"'K>L<C.MLUS&/0U$F44C4XC6
MDER3BSWOD_!B5,Q36GD-2^?X7'2AX+VA@L[[/83#?,9 K[9/UD_$4D_I]/T=
MK+=)_['+Y: ,0U2:"Z'ZYFO*E7K8G?M;GY0#07ZU[6<M"6S]KVAZ.G$HI@1]
MY'Z\-YAVV=K FG/X"?_KG-+-08]ZSJ,<ARM=K/OZQA=LRVSB^Z^.^1!UH8/<
M'1#5X1>E=4J4&/2W;[XAEO1<C:GA6M2GO:SG$I/HH#LO41!+Y)NP1"8P,IE.
MIHB7+?B%JZX/5@P7H.N/0! CT(6TH ]I1\:>K3J2*@9N)+1NZK[0!LULA3?5
M9?#Y/]^2]"$\*CVUGMI/$=J8Z)8/F70(^DC=>OK/8Z/P8LY\H^GFXPX=7L)A
M6RA)LH'CK/^IJB8@]E8T=*?3F/&RFM4JLTP!$V-9JV\]7]&<LRJI%(Y'BNUL
MI,';VISW3]J6R[O[[P>MDM<$R<(_&;MCS<T]JNBIHB]-,@U!:]?CO2[58H=%
M_VU4"8[)/Q8I @O*H$*W,V@M]]>]#&T.$_-4UF=!/B80H^PB6:Z]+7C0Z7][
ML%]?RS0LN #3A^IDMQ1:"52Q7XP-)J:,J\W:)%'KD.75,:;+ 91,IO#DE0*%
M$<2FC]!:C4O\J#6UD5\[V5S?$P$+('IH\P5^#5TJX'Q[M1_##0CW",+[L>_Z
MU>+Y%VF:RX7QCWL;-V3:*1OP1[HH2;+B.+[D&SCT>]S&! -YT'V;,4LGTU=J
MHO_<W;17+2@QC9%E/M\+X+BNKRIVV=.P27LY'S>MYKSS-@K$8@D,Q\EK%7+D
M\Y)M_]A%^9&P$,D_G8@+=#!!)(N8 <W^B\(&NH<T2H2'2((<VHCYQX\W;]F0
MO@&'_QO$/>$'?FT(>%/:?"6K#F1\!.74P.'+*&YO*@#J4N33173><2-VL%-\
MPWF\/.HVNM%==578VVI_ =AP+!//=CRTT>!:$=@B6/P3Y!_"?Y!%0UN E.C^
M.MAH2,<2*3X-.$&,I[D8+A"<("4(#B?$%(BE4Z*(;[)3=ML'DCMH*G1<9<FA
M.=&'=MY,2<U3&PT+I]4PRE769S&\[+4Y(98Q6LU3&PVYIBO84Z69TBHL6==E
M.M]<*&A+(O80H?XWYL8<&%HR<<[0OL%BXZ]X4&_HBDC?KJ\;#BM^UI=ZC]N)
MB"_PHJ;8EF=*O_XE!_\[/EUS_@#-)[A&YW,L5'=U[ GPXB@B0LWD'+KF;^';
MFX@3)!A,4,ZA^Y ^[QKV7PX0-A]86B?(/OH#K5^^X7"ANOEJ6*BODQ("W0 6
M*R<F MV$^4B%W^Q\B:M6\R^HU2\<K5G[8SY!"H'^W6XQUM)5M]+JY.=L(8_9
M:5;M$<M$DR,#;^E<)OCJTL-(<.OA=KGYYBC?93+\D?F!MU;-7QA4:\6]RAK=
M(JHH$.2L$^VV-#):SPXQD"Q$?80H\A5$E3(EYAM)+VCU<,'H./T&:>J[9-YL
M]!:]-@6[Q#R(-)PSS('*.G6<S'5HL2L4JDR M-@K2*L/VG1D7<W;?!5R'QK4
M.QSJ)Z7LCCW'567_<)@E4T(;]B B^!%Q!$0M G_6H&$&0>(%6K[OI1+^0:S3
MHD>\$Y%5':[^>5U?AR!04&#JJ2@DX%H1 :P;P([748%MBK5E[Z=8KZ,$>\&%
M#2Y0Y #Y#2C%.B+!7Z$_B9I.;"""P+LDR%4?P>$C)_('[!FB..)XT*UP1A;*
M<=RD';LCWCV>SYP_'#0:\>KA]93^\]\@&O,'N3=O 0H$;"2,X:S00T%[^"0:
MS[HSE,OO!",)AHO"-&E\U8/$^\[3?4*XSQG\+.GY[EM'6<]&KO?J^ (R(T'M
M^;UP)<X7&2E-+'&\ !:Y:J]562KCYBNB/0#.2P)][K$5Q;?GUYXU7=/\B.1_
M/N\FE4ZG_WRQF[VFD=4K5_^M6Z^^^AF[3[P\G21#KQB07$"1,%37A9($="@:
MMF4B:ZC[$0 MHQ\)BH3R8K"GE>-=?I5+?Z0R=GWL1Q5;G@Y6)(WA<:006D#Q
M]%6:41OK1/Y /R;_)*/DT[J!.U*#).<)2G+^$-6Q&OE6&0#G/U]8RO=XB5BY
M%OH]*1]WIMWLLD9Y;$$FW3;=U>;U'O4MY1\MY5>(-!0@/J+#YP&T@:((93JX
M&R4 MXW,XLEO(Y!KV,D?' ,J _@:>V,:(# -.%L?N0.P-V@TT5B5"/21Y^YH
M\^L3= Q ,#8)R*H9G"0*]LJ1QT3B?[XXPN!WXL]-NV<-CGY_<7B;=L@/6+=]
M8:B;EJH9:"RH802,W&R"[/LT'Z897O9#4UMPO*>LTJTV1NYSP&&DN@"#@Q51
MI2YTNG43($H^1>^?&'% _2I"YP$X\ROLK536BPKCV>'-O=.9.S9<M@!]D1Q/
M^..EB;PX&?R)"$%JULM6X_W"=C67B6\N?W/YD;B<>"(_?3;4/77VY3L;GV?+
M+O,N7HD@!JN%P-U"CJ=BV?Z=CO$%+,JNW[&W$ %VU\HM1FT1)XO:;#!BS>HR
MR \[&TD\\F&#SM^_-+EP@?):Q8:]BE /XP(\JCK]MC.?9&<>E2[?@/D&3+A\
MG"L)\^.?]LL1D9U5>[4VW-UK)ZWL?S#8C.>H)G#VMQOJ0Y(ADKY/TH6YSV?;
M*;F&3T]N-[S;"E]_\#I$ 8O;.?'?T870SN9++1:_61/:R83?QM&'D?S5U$-L
MYC;C+03#S:X&NF?N\F.A9G"+HH=[32/N)A*<5QG/KS=WL0O-W<<GU*0N]]CN
MOV]^O!-;DL_L;*'S2"<WY%3YU/9ZL*D.I(AI!7OBGK/:%8/#657I/5%HS[*#
M=^D^>OE<A:]&VVTFG*J%W#I(MF SS.1-4>5UM$V!2A\%6=OKZWB<""J_I$JG
MC_EL$GK^X ]3>0[VNLY$S)YMBSY*ND.P-^J,@*YO-S'_@"P*=BA71=9V*0LO
M[@)^8H+ *[OPKU=\_BBO'I'XN99CLT)[4!.JKH99ADR8%7[2.9U=<"LM=W$V
M0*1NW3/<]_$JK!U<.+6ZT&B7&QZQ/#?0$<%ARN#G&N_#Y_X;00S^M;::*RKF
M@U01^"BZ=RJ QUMNPSLH-&YZAF2Y$A!5N-[[$4&'(R$Q\$/P77@M9&3=C?/W
MCU(]?R*5+9AO,-T5$9C=G/? V(N1F83GBBVZDEB6BV6Q-*DO(!B)Q'^3Z=1_
M<2*V0=.&#G<ZP?U&N7]_Y./#;J Z//1RZDJIO1NGGE]']68%2%P5$-J215*=
MB<[[B.7K)(B+::1#^[&Y >U2#PC]&'S:/W1S:1!K5Z/[?_^O_2+?NV1UE-AA
MV;\V1-V[K6QS4UO .05@JQKBO Q=\%^\/N=]9U,0FGC"T>&<@%F_MHR)(H8$
M-\5%=G\&ARK?<OU<_"F5.KY^;OW=6Z^?^X"[YJ)[('R R^;6)[8)',0!GDYP
M$L!C7(R0HYR0E 6.C\73@.!E,2;PZS/3'U7)F;SL%H6@7F]D5ZIW>PI]1?,0
MCKA#9:HT*BR>9>H=NM[97;?VI8ZC[VK5))[BJ4>\SN""J:623P]Y4\,%4XL_
M)<_&=L(ZM?VH/)09I"[__D'^>'6^Z=@3>1:F]PAY;"U$@VIU2OE2G:IG2U05
MNJM,JT:A:PNX!)$@TZGWF0_4Z[J6^5-DVWMDK_MG]N1&Z/B0R%_T]%Y,V+G^
MCK*CH2#WVTMX7FX#[BI<)1<81'X3!@L*)P8'N+A4(AI-Q]\G6ZC3=0#HZ;U2
M])KYN -5H",9+**"O*<[DVC;7V378>0/UN0]286O_\]75#ZA%P2RQIMP,1<P
M(Z<ZHA=<?,*;$F7RNN^HCB7GKY4(\I$DXJ/(L^MX6\%L]X+@],GF%6C!MY,=
M*+'2*NR/VK2 X^ENT(29@%40]OFJ\*$$*?F@DA1MHNT2U0W<5\@;^%%??T*,
MU2W'LZ^5I.@>:Y\>2Y+N1Y[]C@.AV.LZLNT;SH,2+,^-U'A; VZDI3K:0PM*
M+/Z@@A)#T2L;>N605PW;$H&$N,/%8W$B&;U60F*/:VON0)=-CX%8[/K\QGUH
MEW:?@,*ON  -^Z+_*-138CI%NG40Y\'Q)/%.J=^+\Y2>(D'77R;($TL\)L._
MHI"%4.,>A3"J0.'UP.X%14 <+ADEHL0[PZ</&N*Y)TF"SB)[O7U)W1)^G%-H
M-9/G1=>R'8Y,QLD;A#&I!P;YS>B!^HFL._K&]F?P,LZ@C,R2N4H+0SF&1"I!
M1M/7XCO^N/"^+4F"SB)[O3TTSN/$@^(\02]&JJ"Z#A=-)E/)Q+7X3CPNOF]#
MBDTG7Q+.W\N=[YC"RT+4+A7J5(=MT6V.()*Q%/$^"=IU\]@R1'[ZJ264"_4L
M]^]#TZ]?&64(Q_6FE.;3*:^;S.R WT>IWB3QA/(E#?C-.F'M5%+P7K\'G6$B
MT/4_SQ:3OVE:\8L0)V/K?%-\FVY*'J=ZWSWA.Y5Z(F,O)'P'N=F1W9_?"=\A
M3/@&44)(\J+ $4(\RL621)3CDWB42\1P,95,2T(Z):W3IU=/7)"@>+M<ZV<:
MZN54Z[W0]^H?[*5$QVUF^.NY3A\RDZ, X_J46>0@0>NU#*H//F%(GCY@$^(K
M+4\<%EBCQ12?@DW2MB<XJJ3RM@J<V]UO>/504=8/,-'YW0- 9'B=1S<#MD<
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MY0_]B\I<D6%MQ5>?QW!CR--'SE4'DO"&)*"?R=/>UO#[DM"(W.<)RAA<$ 2
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M2\KSS<%)EKOQ A., [GKO,WU8R'(]YS$*7I1\\I!RX\@H=QS](XZ:U7Y;I)
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M3+F"!,T%$:^P7##'$ZC"8\[K^$!5N*$(^_"&M\99/#=V/MB9C?OPW:^> R!
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M@2K&I;LJ'BEI<76KOY)RQEFZ*UYCY $UOYT1_6D%8[W=C8=6OVO#2D#.%3B
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M^YTU6%5P9[3@]XDC9OA!9OA!X:>:8'Y;^'%EY>5[ !1PYOX<$Q+/C2<.5ZU
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ME*#@?*\%YRL"PY.V[J=[Y7U)U3UKP&%?E'WH#5[I]Q_UY>A-UAIN]P1<8^$
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M.W5&S$@+3! 8V=EJNCR0N-BOC%I6OUGMQAEID0FU>#;;]8)RAT=#$5FUA,6
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M,="T)X.\.A[.<-ZE-'[(#S>C_DXD\*@:>+E:X"-'%_!+,OD%9I"4W>&49 !
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MT"E;6NW;A&$+)</MRFRCVY-VNS /C21JK^:AJ1.HC9#K!;\O8ZN9 2^XT-L
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MHT4(3$#W2Z7O[*UQP[.977%9+S7$67$^$IH6IS=&C(8\EOVYO89UQ:[Z\2[
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MD)Q"2Q,@ 'H1D%&!Y!0DI\"5P)7 E1 6$!;@%+=& "2G(#F%J #)*4A.(2Q
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M=P;\Y)UAI3G3H 1:$K,Z,B?+?'G9H,6P/S G$D1 2S1<KY(H7=P],M*[-''
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MLLD^?2/SY!>2IH%RKJ93CA0Q#T YT8WUR6*<V'=F_BM9?/-WOWATT,9/BH*
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M$GJ14GJ<2=/.U+)UG][9G?[2[,P.4?H2GBU!Y,DO.9H&7KG0V1'WQRSGSHT
M9OFTDR+0D.M9"B/@.LE2.\XOTGE&2G+*@LVVYEQ>DJJ 3>9R=3^N9_5>M'L;
MG2,1W[L%:H%-E_<?$9$L:KG%G@N]GREKWM]7<;(IE93&DC=F3 (8(7;WEX/3
M:+YPLS@]\\LR7>&&6/V4:(3W*.#XEQR9>V6?!(Z2>,!#$F[67)@JE. HB<2@
ME+:^5.C>38SK@#KY'EWGIOU/X$O@2P^'$I!U8E!*F^M @"7&=6 &NT?7N4V
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M?--/5V55-8B%X+/.+.>G^P8[R59S91PC&&[4MB1Y;N]$@H[*M71*;_9*'YF
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M"1^]# ($.>[I3>J6;/BA'7JV$R+ >IZCS7TO/+9K:'=L*_P\QS:,8$@]^-"
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M0$*6B]$6<LKS(X?ULY46+1? CCT#E3)MSZ-LBU+!V*<\H 2N[NO@XZK(7JA
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M@ J6Z!8ACZX]UGW+*,3[\21F)20040RB&(3,N6TRA\W@5^!;Y^BQ'%9IG#O
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M^M6DG!""&N]OJIM@KDQ7"!?XD^$"(4$OF@1]G3'IN&"N!W,/.9DJ&/N4!Y3
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M=ENK82H?H$P@(X)M#$<@?^@EZS?B\W\\>7!+]\Y<W.@ORY"<=HLV3,\!=80
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MR_!7YS%:1TQ/LO18+@;K"NQC%S3HQ%1M5/V)Q..;+[C,'9\^K+=P@PA# (4
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M&-HSL;\N6Q5ME4--#SK0E@9= (RV*^AFOY!<;[+%:1HV/6)9:HL*WQ,J[%P
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M&FC=3IMA\\%ST]0M0#7@YU./$BP5H 3E\4<(R<6F&F4_)-7HBP &_]9,1%O
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M ^:9UKL=#/_I5@DF23>JF,>/I"V%PR^.^.ON)LX'4\(;.!GJ_*V@VP5]33!
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MV:(=,7!*H,S7(1R."#EWUK\0I:!(7L F/Y)-WA9R4&]EFSX!JUUMAX=_C,<
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M@AA%.B5YLZEU99I*M?3AMD5RB%- 72CJUTW@EIPQ!:<V""\8M^&0N8RJ=,5
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M'A.2]Y]P@>;S$"%@B %#_!8,L8J:=/_['V2<^!TA[ZP/ 4_\GCSQ95P(V&+
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M7.\+YGH_F]Q04Y7QLZ[-IU5![I='N20->#,,#"5:UEH3AL1=32*Q.RJ9"A+
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ME\]<\4N]_K9Y*F>KT.GE3!]3D&\9UY.ETBI,B7)Y45JW3;.4V309,OD)&D]
MXE^*Q'U2S[\MA9\M$^WC*7PD44RQ&V-3W3);)N7:>%E;AR>(PJ%:$OM>;J)/
M3$Z[>3!\^V!ID"P0N#.^,_X'R0+799-75&42-H FGR?[[;90.:C&>XWY!%<
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MZ-I2O8*6#B_N&1IJZ,O_^T']>#]5DI][^V;?:^T/DM'>2VU7Z$B5./AC35!
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M#;S:GC/6[96VG&I38K$>+SJE0B0B/JW056-DSQ$GZW4$OIN (P2>GFM2DSZ
M(9 "$Q7I1UX0A70R$NMUE+$V;S*X<RZ5O(LD3W4]N@D/3WZG_H0$><X*FFS=
M90[\.(&5%_AQSN['Z;#*1!A)EO56= DP.X4[!OJK&=FH.)1$KK>IB6TEIFK]
M])"0IRO&ZE>;N(L3@2,G(/&O[,@Y*JEUJ[Z)HK*$]*]JFQ"ZCJXM7Y,/$C@E
M A,D<$I<1RSF=!$QE[K[&CRQG+I2?(3Y6A@F&\-T@>XN9KW:O/28CR3R$P:W
M8HW>I2)!BDG ([ZEF^)\2L E3[P-R5\/S3450IW3SQ:3N"VD_O9J^I5:XM0=
MB6S-P+0,<#8P+:],M4#*IX[[L4#=,8SKD>&*&)82^8$M0J]LWQ=JI!A X2J-
MS]. V4V4G+^^]D=@>04T<\/&V,?!Y28,MM>W*-V9<2$!^X7@WX(28L=C>+;P
MRSF[P64_X7=S35"UT!PN1N7NX \"'FE7G+>_#VY/!^KUUS,);\2QBZG92K(M
M6IT@N(QIU%3C"1@-2*Y%)6L1:P/3JE^F_5A*+6*KISQ!-5:116,S3FA/N)@T
MSC^+14_=)PHLZ8#4K]V2_I)I9.>@]$E\TP)&*\S2<FS4G=53,74RPY0>__$G
MD?J[OG!?T_GP6J6IJV#=AW^M[A3T>P\B8+?IJ A:RP7H_GU\#,]%DU*1;^H]
ML,+"!]'@D ;&0%B>0_!=#4P""R%P!ERA,\!23#VV0=HP-&%DXL8]'?7UJ=JY
MK3B:ZKT*L>GHG)G7!]M".HUZ+Z'TKGB0J!U0^%?V ?A'TYWNIL=-0C^A^=?S
M,3[2/56W2B+UAK#?)3:#4>\OF[=:#*9FRO#UXX_@I_L7\MIPY0(/45DQTI:U
M#M&RH4K"6 !Z![XJ(ZEC\8?3'8[EE$B+:>3GHL!HM!+A)'[&V7P>L].T<6(<
M[B)'_@@!R&CG<!&&9H(/PW[\I[=XX>$Y$.XY1.^MXK[>?]NF#!_8("7. Y/0
M#B@A!RKX6#X->W:K1GWPLJH,,6.#"3?Q6P_IGJ6RNZ7.[:6&6 U  :J/H?"S
M7#(UU0!VB6.T5=3Z#GVE6]\9*NJ0BBN/XL9Y5O4*@95"[5U_/-P0#X32"B0E
M*=0"<U4S[C\#5[LZJ/,T!!/4 ("^P\EM>R 13[$(4>>*DZG0UQ]SN>8YL0Q/
M]( NL@KC$P?6M:I6N"N^).) @V7.:FYQ,'2 8^])\^Y)ZWLG#0<AE0MRJ=!*
M,*:A[GW[/@1UH :T;A:F@+HLPO6R$_P$:K0HLR(( 6?+(:@C(G/(E.=6OT5C
MRD),Y7DP-N ,"'60O21;;D*X,-MT0H])N^;?=WMM'5&#1LQO)NB=_D^$X&O0
M)M'N7KWA.SP+&NJW- TL 61QUJOL K!ZB#,UW);2?0C3'W8VWX<@Y'4O-&SG
M*%PHA!V'@(I6KV'0W.$YEJQDNJ<D0 *2) @J1&AS#;6M1(\H!R[7*9 XW,A2
MA^JK-0U\D>9TQ!RIFF;USM00,$P#@FAK<0,TU*D3AZ:U&V/"H5;5.*CAC$V)
MM=<G@0F<#HU#X$<J+UJ7>Q06PX&_ZE/(=L(C. $:*2- X2GN0VD)M=*<3+TX
M@\9!R,!][. $MS\5=$/5D(Z%8:T)P%GDDH7 ->$@N'K-![D@RQL!28"GA3M_
MCM#!L+JJX.B]J7# ZO@Y%K2Q*</#A_.BD[=V _'+E.!:("N%0.4$B*E:B-=4
M&3WC/<M[5ZW8L;RS<\".QG(@K7!UM'5;-.DMU\V )=3&98S=QV8KO]+B=#>N
MU>KM<;[.Q#+I,S'&-W&D_PK[^IV7G_[XXVPLU/(X4(0_EV*?[G)V_AR,9#L>
M@5F-H(54TT#XA#1[B&@X-C*'W&$LS!$9LA)&M9 "#,SI4$=;ZQM$NZ:"&L="
M6A?P_/8[,0MQI#YB 4N!LQ\X^?QNJ7K((D34X==#8V@%!Z^T.1WBDO EF*M!
M&KT+.8-<HMQ8?-*B/QX2CJKM'D/PF"->I0GP-?>AJDOIKM*"M9--2- 1>:[0
MY2JX&GX7+?+"><(*BFZQ<G?#>+^<:HX,WI1VCZVF0 FQ#IS1]!PP )1=BLL(
M]G8,V9$!EW?<\P$1)-YAR50<98G8_499+-8Y%.]+,/]17EXI"[% -2 F  Y
M,6%-[3WI*<OYP@.>VC\_V"V3UIDZC^KJ$%;<MK74TVLB"WI=@7Z<Y9>Y<$D6
M5UX_#/&&@A_'3*H&##LDZSI<"(MEU5A-8WIAJ5<3R/Y<[)-<=#2;/M6ZS174
MV:GX'>%S-1Y1G_\YD?>A2_#HEJ4FY*',R-IBL@\UIRSD,RI\I<6CCRVK!3/H
M#XQ21Z+#C+29F>MF;[CQL:S\QYW?LMKCT6_BGS9 $#=7H;6" 'P%)M2.O!"-
M"IC,K'5JNW7:ZH+'"'3(2X?S<-CRPN-^_GMAJL;O=#MK??@5BA/QN]!I.><
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MS,,.N14RYL=6R-G: [9>1S@4BJ\%W2'9B0(HNA=S+ "XD/1:6FC5,LM]5)P
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MF/($"W/-:-W,=M@,(:PB1KFT79OT$\KC.HH3_LL+9HR([ AJ@)::995FMQ!
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ME4VX_:Y"GN9)B&1VE<5_XN=44X=SZK\>,"K8R[/S=G".31AK07,=/#@?O.!
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M'2=MN(NH ($#XD4'!.7)FCJP<5_EA?C4),<VE#H@@[04)!>!HN,IK;Q&[)M
MO!02 G*0'GHBB/AJ.<VF:4#W-_2TIH:W?>J"R1:>LT";"ENZEW=;UV!TVSK
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M=O,O'CCUR<G]SV5T+WGHE@<Z/E2?-,C$D9M]@?N4 #FU\!SIA+75 _H[- O
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M!-ONHD\B5/2E5@W[=A#%0)Y!Q/,*5[!+[I^.O@)W/THS/W\159RYX$F:PY6
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M_F'P.C3@R-78/2#Y;]LKD$AC_.1YUW1X% Y]4X1C:Y#&?>3(.?YT 72(7VB
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M"4;^>V]+J8;;=\5MN/0/#RU(6=7VDWG#+\[/8^4#W\ S]]L=A682&]Z NB!
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MQ*I\NOLT);ER,M_*KJFE7$J ^T&%<S,_#P"6@NA 8,&W+1Q,/"(DZ*_E?_C
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MS&QW"0>\Q',FBK!CBKXB]@2#:@J!FF9K4D37(!905QA+G>BBB@<M0<W(>Z/
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M)<19Z+G'=T>WP:1L"5@)2)Y, ')EV!T IH$ #@.>#V!T=,+ F%F84V9(&SB
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M"PVT!89EV$#;ML=/TJZ$]4KI$([K6A_J$Q5[V;:7&0!+-]N_HZ>E*B]*1;F
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M(("4$*:$:A+" CQ;E56X=O]J]#Z3F$H+$8T0A(:+]\H.> MZ.K$%WP#": D
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M0X?80/"@6<_\'D $'X 09&&RJYXL?$WZ>X[\=:42DFV\;>G>'[!D0W_YO*G
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MHRL>Z8N/P$H-6P+08ZJFA=[!+Q:$)0E3#=@!BO- S#5]&YGJVP="Y"T>!Z[
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MYR%O/-,A&<MXSUQI:,IS%_ SO92*_]G;CX@&"*A3BFJNC/:KVNDF''V*Y/=
M16K&@:K:IE^]?#(]!\CU4.F::OA6@DW ;K6:BS("SN<1S\2SS:]A/P7&8R*K
MG.5Q>P>]KK'SM')H" )[7UDG(3Y@=38FO\I>B*LJ(I_KL<)^L*R<A/P>NV="
MG-#+/Q6<V@?0P$Z?MH+T->4(0EENJ@U,]97S!0N[<HY7@RM!WB(?@1,.!PNV
MLIK3G]#GI1) "H.*OPS0?8 '<#O1C2]D(21W/31Z_[73JTT8O+?O;+QT-?\O
M$",BZ^FI22>Z!C]+]VNL-LA\]$3!NE:P(6YOUQ1)_$?"O\"*8HD;ZKWT UWJ
M39+Y1:&9TL:=V/S;;S8>6$U\L%AKV\];U=/%J C5L2<3K.S .7^LD7$"8JRN
M30W$2G;=BN!*NCUOH77X$1)L!35$AP4US()M[I!:G=U]M.=1J]829LU$H7]7
M5T<CO=TU;UJ[^VC!X_:ZC_96&(IML0AANC9WMGJP-D)\C].K)N5D!TU/_W@0
MP"4QSRM%W-F[HKZ3P6 *0 7-'S_/K][4H8%70N<<$B6)#-U$/[T?_'/#-89N
M:A^78_%.&==F@9OO$*E;WD;OU*I9AO=6;Z/ 6=:?]8"(I:ZCT=>:H/@*R'S/
MQ]Z1"-SW2.+]'L%G:'\ZU8 0"@EO%N*YE"8O]H9R0U-3; L=HBCO3VZ'9]YQ
MU-%?6OF79Z^3(5].DB]T,N3+Z?$E>1U[]9:JD"\ACH5\\?.%>?6&NI OQ\*Q
M9,B7$^1+B&.GRI?7FSB&?#F:/_9J%^*0+T?#L="^G"1?0AP[1;Z$.'::? EQ
M[%3Y$N+8*?(E>1U-AWS9&U_>V7K[S6V7OR9"^@T:4,=H)_MZ"/TI:WZQ'T:P
M) PWWND_.>A=A[C[[S__'6Z2 Y]^ QK]WS?VVP=)D[J.LR=&FH".=)<I R^S
M^9-9G#K ;1/O%/]@($R_ PA#:?BHPK_JOGY1:=@O34)I"*7A+*0AME]+\?Z5
MKVJQ/WS9S/X]WH^Z_9=C[3Y7RW<\XG<2Z;.\XB/>R_1^1<%UI%]/5(X@&=B9
M/BO)\'=[#R7D$-AQW(ON/B A[CF;S[CR;._>4R@>AQ:/]?F/4$ .(2"Q<[,P
M^-C*W_KGA[WS[*TD=7#[+N^@I80OVUX?+R$]BS[-LI[RY6^?ZZ=_>)\O>6KB
M\ADWOSEUY(=?UZE=Z^8><!N\<JPMNZQS3YJ1PS=UD+9*WG?\:NM=;.3V4QK%
M=$MB*_&G C=,1K1G;9II-C,?OBWNE=F5,#H$W!AGYVUYVG^NQWK]Q%,T$Q>G
MRS3I4!S]]CMZQ02<A@PQY6"8P@3?-WGVF)(\RKK^_D;I4.#W;40/?L_L@8SH
MP2\6/P4C^L:1\CW9U+MH*J$*U8?>V&YE'Y^D=CJ?8#Y^ ZNOE\#V[#)NPR,F
MP*Z:+?DQ5UM6N$(D]2S-%'GY.$Y@NYK^]CNV-ZMZ<%P-028$F9=!9F>AU/<0
M8K;:H+[6QX0X[0VQC7"O&7AN ,Y(^=3L:2A79;KQB'J1J=K*+IKDVA#V)0?^
M1X@U(=9\0O7L:6'-X;(">X>7N"[=)954-C-&M2G'=@$9&EM=EO><%8@*A:DL
MJ/-J;U)0QM%(Z5'-9O"M2?@NCM?=EY,KA'A+(9INQS#< ,SKKGN8I&J(E;L9
MU./N,+Q=[O1Y.=63V4LY^P2KJ\$N>D87K5BI6<P4"_W[W"#U$$D"+!X4/5MU
M(5I_4$>#PH07I<CHD8DK0WR76O3;;_8J%=N]I3:$E#TF4+\$I"2/O]*CYU=#
MX=^-/;Z$\)/,QU<6_@/4KH3"'PK_E\L!;GJ6:6%907?U&3.6X\MVR1Q*E7FD
M=92T7[105!LMU10+)55!-_=#TXA/Y_@27O8E'_/STGXAU'Q1J"%9O].%FC^S
ML^=0"7@FAW?.AR@G5A7X->#BA=+!<T.0/6>^*DFN0J/$N$#W#<'(W45&C;'U
MM_4*[\I7W5FUA7;?[DY[;"?#3K/SV<W]76L0Q_FJ^%5ZG_FJ$$$^6 /X-1#D
MA4WF<T.0L)#P1/;=OX;6O% (=&Y:<]@TP4L7W!RV;' PJC\,T]-4DUX^\:.*
MT>_/'J<2F.*P;#"$E!!2SBGO^$F \AG9PAMV6,C)C-GI3:/SV^E Z-6'-';P
M<;8PV,,/BP1#9#E<3O'D%G]L9V6[TO"NU!2->:L5+<B66!OKU3JKY@]:U&+,
M[W*)D7'?[?6YHCG4'[HYK4TPY/)* E\_:,WQO#VQG>LWN7-L8W)N\/CJ#6/G
MA'6OW\EU 2[1Q1V;SJQUW=^Q* @?8V*Q.8L)]3&29]7R+)$48ST)TX)LR":2
M^W*Q0L!XWU5>YP08A^WY>'HQU&F?W_+PPX\,N_%9 %84<K.48CZ5ECV[TX@\
M/]S1I?O6'+ B\>UW,A8"Q2$#K\L BM=O9;F 78^P["@4WC..Y\_:SI$4I)=?
MW#%PZ]QD@*7+CN_JZ5JC$:43O65='YF)FZ=R!BR=4Z>8CC+[V]((\>)"\>+U
MJWLNP"N^N'/&?QY&BW'E,5/+2N 2#TO3TD1\BDSN<1B-TXS,J\T,SJ&P\Z\.
M(^\]\1ANU83UG!=5SWE>&<]CG6/^<W2V(YUT9$DO]%Z_UJQE'F+S1MEJ@5-+
MDIPQ.KK'W$4(3F&IZ$65BIYU=G4O)^,^G%"-Y6GU0<Q'$W1BJ='%=N*1?HYA
M7$I\^QW;Y\Y+"$IA<<M%E<T=)),;:DVH-9>O-5_<F/]%UO@QLHA-]&(GU2LU
MAL4E6X'@YU[""R=9XU@\+(0/L2DL5SW^J?@3U8P+NK_RW+ A[.%X&EI_^,SG
MX<ZQ_WF^<MP>E'L:-ZB/Y;DT3XO:LEN/M@8IYV0[F]Q;<^P0&<)6C%\6&0Y[
MTO;=R4)FE%-Z]PMNVDMTLOT.K]@Y+B8!*"2^_6;8W8*4$!+"QEF7W:,O+-\,
MA3\4_K/O/?$7&;=93EVV.@\1>QS1S>7M?#8H-6^PH^R<$(^FPCK-$!CVDDL[
M76 X5 A]C%/>?QY"W]YQE:)@W^7I2?6N5;EI92+)#$&&+U&0V=4L3@$&B(26
M%&GH0\DK:E(<(6=83W#L"LPCBDAXS_8Y)A%O49 ?U%OVJD)-R\W&"2,]RYF9
M3#TE2(,T3A@FDF$CS&,G$"]0\4_O,NPOGR%LM3J93JR"DG0C9DIRLY3BYL4,
MH,#>,X0A#'RP^N#L8>#T;N^]G,3(7S;E[(WMY-.MD7H>3]O9:.6V-;Q+Q5L
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MLL';$]/"&F%>'\LT-52JP5L:(:1#2=9O>_"Z?$8")),$/U: C06Z_Z2^RS]
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ME^$E3G$.4Y:<=(^WH5X&IT802''BE3^/P>.805'<3(8,%)II/'FE GZU4XK
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MEY*E&5U=/EGT0UI(+,DS=^;Y;"YKBFHH-X5<_[%F6--%XRDOP<C$#N4S*;G
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M'F^&Y<P'0= T-</O!=2=Q;4#CA@2I8T-BGSLOLW<]R(1B;V5XOI]:PQ*"UX
ML]M4$,<XFBV--N.9F*_T.(]X)RWKQ#E^[OGRMZ0$F.1 G82=91NJ^W$@:Z^I
M0D!6<?T4$!GL53@E[MY[,.,X VU4J;X:-NUI8XEPIL./D& KJ"%B<F@J+F!J
MB(1%[M(RJM"Q=5TA_A.G9#D%,[$S0L@JK[/!;AC=U?Q,7B>229'4[G95]7&>
MUDHIIM'+S1OJ-"T^3 LY:7>[*GC<7K>K/AYEGGI5IU,PK2C:G)3I8\Z #PV1
M/XYEL.SR*TD@L3V19"^KAO7"](D#-73D@3*Q0+RV/[ 1 _GZ#5#?23)=LTUX
MMOG#$7DRJU4=I'-H'.R>PNDF^NG]X%\X+A1U:R%Q31WOU.)M5BGZCMFY-8KT
M3L&A97AO=9_&. S^PV80,5+T^/*Q/E\5H._Y$*4;(O##$P[O]P@^0_C3*>G$
M7M";U92NS)$7>T.Y(5A[VT*'J*Q\^12I[WOO+1QV__W+8[:O-A\)V7(<MC#7
M\9 OI\B7Z/6K?8="OAP+QIB0+R?(EQ#'3I0OT>L$&S)F;XQY;Z^TM]SCHQ$A
M]0XB[-,1_6L"I%X[B19(D=U*RX"^)Q!R80K\WS?VVT=5,7[-GMK2_QF^V&4$
MA\EXV[SN[)87R&[Y/_\=?HX,O&[%]WP>\;UZL4.;=RK*I\C.GBEV:-D)@?/4
M@/-S=>88*G)>\$HR]8ZEB3)7GLD)\37$UT\1GA!@0X#=!\ >\6*%3]8AO$,8
M NY1 ?>BA(G]#  ^L0Z@Q8T]2UXSK9^?A;0GMM)/O*0G?GJK.T)#6[*#<IXM
M7__2#ISZHH_1W3C4B74V_M3EXW.N!3EF0)$@K\A,\-4?SYQW_4>[T</'/] G
MW=!]@&CAQ,3WC4V^\[B:XZVM_<NX9F/[_&5TLS!2'9=,(QLOUGNY6"*JIOFG
MIT=IH[0U$OW@\98V7FY#[)F(G$'Q*^&JT#6ZNDNC4^O:XJ+Q-!JS([K_7*D.
M[:6-&XI%O_U.I/9SE<:!8[73-<@7H,JO[VX?29=)7PGVKVWGR?A+CCE='3 '
M='+B067=</I"H\(3<I6/?:/I88+GEZ+&8Z_^Z]KSK>/Y 3:<K=3N9Z-E.C-F
M>8F9TA*OW/1Q6TY\6^ON9:UAG!V"Q[[ XX7P^MC+/Y8'<4RV=O$9?U_B.(RY
M_T*CCWUKY&&"\J,O\VM9>??*3=,*L.GEFU9CF6($9KP<I>-\+6ZVJP]SYP;V
M5"R,RT-U_PQ+?>QU?OG(_EAR'L;Z)[LMMO]8_J0P/MP!#D4]W-@]K]"2M&7U
MMUKXM**DKVA_+D4#3RUZV(ME.:D5AA)[WIN7>S40)V;K<YPYHG1.=EN23G '
MO\V+4DF3*\29MH'674W]>YR76OH:>H-AX!,&/J&HAX'/Z08^3@G.^J(:'ILS
MW)+#;3N_T5PNC(;"W/O%;;7MI-[#2"J4]G"GZ5RB,,> .85E;QHP7W?4L++T
MP,5AEPD"?U)5>@ZP<)8%)Z31]DKU<2:FB!6_"'H?W"T[H"#%'I93?-,8Q'I3
M.JU/LG)6E0KD4EM\4F3W7I0PI V!9&_>Q DN_9,<C/^2QN-'N??"^<OQVL:_
M/+,_G$;8L_W<>H1N,]HW\,^E+VS2?FE\^+K=C$^-$5^V#?N),>+K]ET_,4:$
MT'0JC/BZG=7WPXE3WXU[>=47TZ'RK9YX6SNI%]TL_=<;#?]N\57BE]D<_75)
MWZ'%%^S6^[?"$6+=T;'N+[7@"_8W?TOHZY?<T#S$Q/V+1XB*(2I>7%/RM]3B
MHKJ0GPE*GK>XG'^?\5^7VUC\4XNKCU\Z?ISZ@A,\/_%B$?E%59><5CG)Y8OY
MZ9V=>%'.3]TYI[S_+J_W]Q&U\J"+O*SNWONOV4PZ-9OL9LTFRBL]6VPGZW1N
M*:K#2"H?RY2E([3V[AI6=%%MWJ3HJ3JEK7[*FE:$C-/:FXGOL2_HUS2@YZBJ
MQSX OZNKEW/L0O\Z?;M/RVT]=K/9/06CY]R9^P)M\=MMN?7^C5*CF?BDD+.[
MTU8C<3?IJAFG+7<T^E4.3(38<!!L../&VY]N_ _*Q/-OLWU,#3WVJ9T]Q;]'
M7]<7,LJO==&6A4%\*A:?!N-.M9Z:=%/9S)V=<;IH,ZET& *'ZGPY[0LN*X@^
MBAB'H?1%[-N&^Y=?T/9<D/2&VY*?R9E+Z%;]5?8U+J<?];X _VNB^]D*X9%W
MV#X9MX]M9,,FTL=7Q6.O.PP3PC AE-XP3-AGR<;%]GD.D\-??:_G@MHXA\(<
M[G1<P$['ENWYJBV:3\LI/+H>[,M:G>!2OT"QPF=T8$YFTI74.,F6:?9!:D=B
M3T.IT<BX'9B9V!XO!3^Y(",$B@-X B>XUL]P#KP.RZZVW-H3>!4?\#MIC>;K
M^,:#W34P]4:_!-G4%6[YDSS*G81'%I:YQH9\ I^X?>>2U[B7\F9/.-]S-QX6
MX9&B_'K-9?G<KG(OGH5G8S[/Q"$HF]KM'(?__=__V6B,MY(;W'Q9,WYZPN&C
MGTL8ELB)A").WSU.A/?_Y)0YMS3=Q:92UVS,\TI_K@0LBB<5QZX;M?X1$V6'
M:;BOLX]N&ZV=G6]M-G=V/WNC^9_+<4O3 YF[%P\QNF;$/QPU,K#Q^E>WD0ML
M^8!_!FD&JZ1LM'UP/_KVNTMZ96LBE=-(TVMS!97<;Q^7@\5_FZA!U.(\LW53
M&>GE\FUSWENF8R,Z0P]'S4D&&]MOSMM6(Y/5FW*ZJ%>'O9RF/"TJDM&]45LP
M,K$]<OZ0JG:$NQNKEQ ZVGB@B"GZ,3-@=Y\Y+?.]2&ZN\+W<I--/U2/)^'*(
M1^X\4S/9QYO9F--IKASM)BRKV\_I<W %Z.V1TLV87R[[S$-!INOVN%RUH@_/
M$HS<?;NM%\2.E)#'D26=;(PB.>-.P<_<>?M=UAA)C'+/CR-#2T\8S/UR+N.1
MR>V1Z>*P)BSOK,RX] 1/-0M]MFUE!K'=><[["V4XR?"U7O59G2"AGKO-Q5LP
M<F>>8_K!FF32_4)A.2[;3'TLW*92^)D[\ZQ/)RVI)Z AG2@^)IFHP'6,ZAQ&
M[LRS$:TUIZ:RO.MUTJ6G>KQ)E]0I/GZX,\_H:/:<2#0>DW3U3HW=6]EZ>UIJ
MP<B=>6:K9G-X%\]K8_LIPW4;D\=83\8C=^:)%KFGIXCX^-"KRNS@N8>JW/,2
MOWUGGD*^P;:7L^JT4$+S%,<HF=YL+ T2N_.\TZ>E1'':KQ>F5:%DL_;B5J^T
M8&1L>^2MW"AF%3H5[57K\X>*]F#GV3P^^I':'MFVZV79B/3$WF1Z__2<K=TT
MFS=S<$9WWC[4;TMTMC]#O5S_H9FP9G-U4I-@Y,[;I_;"$#HWJ7$O<:_?C![,
MA930<-7KSMIC\;1L]V55+RQGXYM:*MD=VTH+1F[.<X $FDL)"6$0X]GX();D
MN0$7$\1!BDD.:9$3.89-;S];'Y079;3(ML;5F^>YWJ_E;U/I.6CSSLKRC51V
MNDQ-8L"!Q]DD(0AUS*L A+@9V6.M4A^D>K;*%5)5N]2M<!*,C.]H<V3<SZCY
M8KJ7R"<UIAK)/6M-/'*' \^C8K94;L9H>EI-Q::Y0M.NE^: $#OS;#SFY:5V
M?].@Y>+3P[RU$.F8+06A3JUC:ZU^FV?&?8$7*XU.HU&XQ\_<F6<VL[2FU7A9
M'',C>32(HV&WMFS!R)UY#A^42H-)W47&G)5Z&!N#0=)XR 3A4[,AU&\SG5:$
M;DAZ,B6J8[8]"T2(E)*>W+;O"PIM<U*Q&H^5Q7BZ%23[MXGXA+EC2XEQ1&B,
M\BF^.LP+6*)W5M1Z3CT\1 J/!CWIH<Q8K:9CIM(*DGU:SQ4?*NTG?3Q)C<1,
MUG@N,^E6D.R/%P^ZG2HHY5["[ \?[](W[2@@66IWY%(OQ9@[58F/$YVF6J@5
M._5>#X_T> 1>'@[_9-5V>A.0[PT']5S'[B1+#;:WG!15E&D6+16D%0]EOKWX
MK>KC/*V54DRCEYLWU&E:?)@6<I+_6VN/\C.B3E\PV>%'2+ 5U!!?.2%N9E1A
M'5/"+WWB!B A QXF.%[E=5$4<0BZ,+^LHO'C;]X*F]5V[TX2 !YR35$L9.U!
MH5/*?*,0A*<ZS,4R;'1"R:  G][/M\^[(\3U (D?R=F6YGW@>)'DDP-?(Q*/
M7:?"AM@^'_B(S?I3L9 1)\ (YCH9WIIP$HR(7L>9D!,GP(G8=3J\:^H4&!%B
M4\B(D!&AD3A%3H1&XG,9\<ZBE#<CN8MLK/YZS'38)?NW3/ZJ4W;THYVR6?J:
M/??[!/9FDB^FD?H%BT?%5A$5I:_^JEEZB(1GMN1/D^SSOB+@LVZ4"('P*XK+
MQT#RV,6[FS=*?'*_;PR)QU[@,8H.D\>IOMQ'32&.[4^KD'3_Q<49<] 0??NZ
M=Z6F:,Q;K6A!ML3:6*_6636_E][@ ?7#RB,[%Y,)M3%FE:D0211RI7$7EQA%
MO_U.)%/[*!]V$@G'%N"OJKA?==U?"; ^[SC?F>OJ&426Q1?.;U$1BK<- [>K
MT/&-#IIZ 6'D ?'F7,'EM)#D?%V?FMO=99ESM"C ]ZDFZ1J?F\^+=#_;>Q1C
M^0FZK4J#&/9]V$1\?[Y/J(#A(D.4V9^_<AZB=PD9G0U_!;!R7R[+L5<=1DT7
M'S5ML#AB(CXB+R(.?W_>D/\-,K6Z3'.:7"K8"[H]G-1;\YPB!6;#/SKE/SRI
M1\589B5KGR5R9Q[LG;FJ?=5U?R&("1,S9Y28\4Y%49QS+(HRT(235=R#Q_%]
M+&1,P.OY_.9O88[FU)LLGEX(]<JQPC]-NOC2+-C]^2G8QA)QQFM)EJV3@VU/
M0\@?NZ ?S"K9DF&[ [W?D>*%7++\J#5SI<?*LWOQ'7L=C>T>TSO'8! 3[#,V
MM\,42@@"^XA@>JV<K0W*TM.8TWNYUD!HR%7K.!',RA?:2Q1S3*T_S\3.CK\C
MR":/>ZE3!F>A;4?'E_D)DSQG'H%]-BB>?!CVA[M:NFV@0:,06612;52AN4*Z
MRLV+S:R$_GI;*_;!7:TMAROOJF@;-+2)#-Z_SQ5A5[Y77>#J$A/EVH6)-HO<
M+R*5Y]2MY-QXF+Z.TY=;Y?.?BU'2$)R^"#A=6H[H/UN.D==J\41T9$_M>%XM
M2:ASEFW _U]HKS.(/:?GR\K=K,>FGYNZV'B>:N7YGMKK^(3SR38M65QN[??9
M,%=$32"NG]@32N>6^ H=$VRF@ QRL\Y+?B'%P?<X$PR=0MI5?R<W\6BV">;5
M_.%<N7.8-6S(A?.7U:D W*CQ#T7E<ML$)>+7\<37/-SK0.\U'0\.HWW?^W-!
M^<RN0?07[1ITVGQAKMDO>AC^M/F2NF9>O3HGY,O1<"P:\N7T^,*\<6(\Y$N(
M8R%?0AP[=;Z$.'::? EQ;*]\>>_%9DZ8?\2^"&\3Z;6N"$49[VU0.CQ5$RBD
MXJE1FDK5<=<A*LK\_*0.&V]%W?OOL/%.POCO5]V\:W6+'JO>&NQ'>VNDKV.Q
MXXO0)]*N:<@J+^N<\GG"\ZJ+<'($.*SP1"]*>,KXZ\BT0MD)9>>]M.MJUC;H
M?-">'_^B4O^B69J-?9H1/NYV[9^P^ C[\NQQMG7?1YC/.-?AA \GNF7O7^R^
M#\J[V\D#LH^,;V?#[[$Y!==89Q:R.<#7OPQ6KDP=38;(&+224VV6[G+MWC31
MO%,J[7F3H>>?>[R^Z6X(YVUT"[/OSI$R0W68X<@,.'*?IWNY3FO(/O;ZM[=2
M,3\713J&[T#:WY%[QZ:>O+H<!4>.?HUKB".GB".>5^O"2*%6L^.)HI'IH;PQ
MG8P7-ZU^XZ@PTAHL"Q8KB;U"J5)3IX_UYT*&G3L7.,;W=.=QB"(ABH0H<K"V
M/>\#A+$UJ-XV^Y-RKR,E^EK'2/<G"KZ%,?WM=Y1)OX(('PNYCAQ?Q2\UR7FD
M8.JK4^&M;9K+A+&S"*H>$&=TYUH YMUD4">1OLF5Z64N7IDB+I->WDM.ZU8V
MS>[/"_KJVO+69O/7H$*(&:<:0+T,&7.^=,/==V(/!?FARHB]Q&,^GG.OGF?W
MTNPY1(P0,;XV8APX6'K%7TC-$LHH5XOU.!EUGMB256FV\5WQ.$9B7SL$>BG;
M4HESWI9Z;6V?=TCRI;VE$]IWW='JDX&V,Z/;Z?I/IQ!SC0R$ E#4Y.1Z8[#H
M//8FV<Q"B3Y7I*R><9I&,]&]'*4_6N[Y4) 3G$ ^MNJ$"'/!"',"$=H+ %.W
ME<)M<C%I]V1=$F)W]U&A=]<"@($8+1K"2P@O(;Q\M7#N!:10*_&DI8[0<!R9
M/HT;!IOJ):TY($4:NR*O8<7Y;7H=7B,.LS]VP*@N#-&.G'UZ@<&?QN;#Y%H/
M:+6_%N"$ AH*:"B@GR&@%Y&O)L=#5GVWG.9:7O>M,(]]!F<D3M<).C&ZG&Z6
MZ,AYZ("8+\YJY8?$,&+0);65;XR:UN2F(SEM]!.IY)?)#YU0H?-FAB2J+RA!
MLW&GP%/().VU[OGH*S]/5#EN[CD 5.[MQF3)-AFQ5Z6+D:=E5FA+^1: 2N+;
M[]1E'<H*,27$E//"E ,GG /@06G--*[.1\N]26'1ORE6##;?G0,\I+_]3B9?
M*S0^OSQS#9GFS[W<O'YAV>13WA<Z 61W\>V<B$1]/PGOZ!@QU\MWQ(_B]>?I
M8ZPX&+.M6(2AQ_6G],R].B/HP/J/BTB37FJ%]$'P\6S2I*& A@)ZT@)ZANZC
MIDH1<C&LZSI2FKB5PU]?D/%Y:?POIXH[#NCEALC'7N:IQ<.GZT7>:BK_HB/)
MLLRR+\]3!MT?)FIV)94H%8;S00H[DC'VC$_KGAPVA&8Z]"-# 0T%]"-^Y$M+
M/0'7\J7VX>_I'WY)KN8Q2'"80MJ3)L%AE/ZD27!B9NM(BG!*Y8^A(H2*$"I"
MJ A_28*-^XG_NW$S\%&NJO5]=T6!CUQ<BY>"4RJR:G-.<N&,%[/G"YMQ 0!"
M#1WA9ZD2R?"8NW<TQXJ&71TWC(=Q=30H&LW!J$C/,T[F"LB,A(SURK@!'L;L
MZ49G\JO_JH$W>.(.57'N2_D+QNQ]]D3Q\8Q<M6?BU[LW3ZPX1Q'648VM=/L!
M)'][GALD)]\4$*\YLHHOD-:,GUXR=_NOBJRBG^2J;?S3SI_),W^2F@)\8@ M
M.),JD7HJ9_6?SYYW+3QC4H)L\C9HE$!Q0VV&KO"%X#IG6'A?!%\>WC4XU712
MGE>4G)4U*I>O-Z@AXD$KR0@+J9QJ^>X;]R^0RD@&0KAV">=NR9^;A@8B8"WA
M&Y:L4"R=H"E;UU0*+9#!RW@'1J2X&2<KY#IO6 ]232P>UU07OC[$3W6*?[@E
M&?'6FZ\H,(W\B)K#TO[]R<GO%:0QC(-I#,:T]2^F80UR,"D+&9BJRUN@VCH)
MGM,4!4D(WHJ?459GR+0TPZPI?$85LL:24W.<+ENK)#D=$>Z73VRM7&#KE=QC
M]D::T:.-)#G]!SER_.I &"7=>Y5EVY\@IQU$O>4,8S!"BSMQD$)6#\6X6(,V
M(KF^G<%ZSES%XKNM558LUPT9?EHBS@ 9,O]T T*W#31H%"*+3*J-*C172%>Y
M>;&9E="),^%/-BH($[) =$SM)@@^_(^34$,L<K)1YXPQLNXXQ88//'U9L23"
M^G@B9\WJHJDK IU+2UGE@<]T.PKP)'&]6_OR'T^I\3LHYR44>0OU'71#0")@
MF$#)ZBO*],-[AC<M1RM?T'E9Y15;  ";<2 "M@ELFQ&X,$$00&TGP' 9P2_P
M;LY6\,=X<U96"2\HDD^$ST @* U>:H D:=C: 1I0 %M@ 3EC2<3,V;NUUFAE
M.A,%<8.'@21=7[IUZ<!;\C*2M$,:%2;F^?NK]394JH-TBR@+Q=!7%-;!*R(S
M.6T",UM2I/DAD31+HSB7=YB+G X,7H">6$A9_BE.F%/1&D3'?7T@]D=<H3\L
MW#;[9O6YH<Z#=BK3 X9V<$%LZ"GUMIY<%#I"XIZ./ UY.]]Z+YQZCFG&0%Q#
M;"-.*9B )6A';_U06NC,9YR*%G7:SC=G8L-2N&I> BAEKJ*IW<X0E#FU.0-H
MA!"QS"3*PXJZ8OH5E0,&P615F;NF'%<+[[B:GKXZ1'85DGPB O!I<QP(4D16
M2%SER8N[K0WRJ7"ZB7YZ/_SZA"#1<UY]GUB:3F3I%YE$1.&6FFW]%.4%$H*D
MSW<UJ#-1SWG>W$1PAZ6<OVU%T7^UD*T0G$P1UO!*'B*U$WC_OW^E$\GTK^UY
M;47G.^' 7SGN#F2XH41 = %.*I$55;)&1')PJ<RF!(']=@'FY4CO3S7-IUP1
M$_$_!=O ]\::2/V3L _+=T/T2@S\C@IOY1X>V62E,)$&VFVVK3Y$'UI'(&8J
M14VP4V6N,'DK:7'H"5&BH4U\W.2U"1AJWK'6 J"6WQ/X<;V:]D[VY=A@08=8
M<2I8$2Q'.-H"3YK8<H$".S]$^"I@;.0=7['"J3;VWACB(;"AK(6R]I:L39P
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MDOP(9N7LS6A.$@]7S=@F=M[Q%$S+X+!<D3(4:H*LD290,$'#+?O;WAEVJNQ
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M^4RB.D)#3T5IV)_)XV)3YYWAV-FLAN.$9+E#3^:Z8O+0*YUW1GRIGI%7/7Q
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M_D)?\+,*W7'HTVTFX241\TV%+L$J:WE?#F<#H'-LX)//S5KZRDQ,SUXJ.CK
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M!3/1W%LP$ACW85L90%,'QO !G0\.%-U?P%-2D)L:X:9X;K,,SV]OU<"&OA:
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MJ:74*3O*H=07PG5AS[NQ6QI[6OZ4P9:&@_P/Y"5 ;\-E3G$$%[R->*< U#W
M3]7U90,J>61:540XVVV(//)PYN&6@9Y]\-P3G_E86*Z8 ACWF<;-R4\(9-S[
MY4LY:#0J6TLMU;75>;[0R[8S^3[>'WTBC/*4K7 8&/%R/@NO9NR;XWX]+=KL
MF.#L9&O=GK3&];$;&HG%R(=$_#2SY1F(V9D(+F#NBBUT""3[!1>N)[12IIZ#
M<+7$N^]!:SSVI<ESF2374AH:1ZAI*U'FP9)S4D44MGP\0^7M\;OLI@V[LJJC
MRGU(<'ML89X]?H@!+BP@;P=YJ.AP0#(5KXS?8P?WH!9%T/Y%T2Y>H5C!T2/0
MGW?\LN,B^(@DU"P:%O6&W<PZO&27H+ EP4E+ C)L21"V)'AC2P+1!38AKZF)
M.!FC:(;YY3W\_;T*+M=]0(,0N95*\I&B+QK*=@9F3\+V4/[K(]E/04^2.1?Q
MN7Z)#[.KMH.:_>F7ES4[VKJU! T44YPY$/C0$=>CKZ:7W7[=Z'&XR7*TDUO9
MJ7(JGKRE2:8EX@MM4,JO^+4AY:NBG$TGTJCVE: >(K'HLP:9VY5!=N/O7V-D
MW8 4[ZY>/ZU]<CL]O%Q]3*V$57*6* K\FJ17G%QFYP(W\JN/GW&T#,R73^CP
M[(>J_4"K9]AX#M[6GA(M"WCE*]Y7OZ%5\T63?1$7.Z*B+UWE>A1 ^E)P?"6W
M9+^1^Q#^#YHKM\WARD#;V@5R^AR.'Q>4.GL;NU=4NA_:VM_[YR)<^<?T([9'
MKUU\ZP$KE].[1CI/(W9GWMAQF?CYUQVNPIVHO(N-P?\^/=FM/A2QH6).T9'1
M5+'=%>T6"FV6IZC6_CJYP[#8W]A?RM_75'@D)= [E'WZY664S3]*CT]KA1M<
MUJ0WESQL1W#02TAJFN'N#.=Z<MMLD#QE1O RU6>G+#NLM,A^M53Z0#7B!3I%
M%'J&)@W$SH0H)3=\(3?(=:=BT@U@1(B'./UB .-<7L9AW/0O!5(7-1T9.MX)
ME(C\?XC:^RQ1@W_/>G_O^'_?<8?]E!=YY?:"%^0-/Q_27PQG-M#(@\1(;[G;
MU5Z0M0KZ3&VIPXU 4'HR59GQM+CI?*;EP;FE[ PS(#D(0H"5%E$X/[7>KL@?
M>)[GLJJ6;ZE,(D.L(WA4) :I13_GV@>)2/2!)NFW!LU<_H(,YG<M21X>X.SX
MYBS3[;[S(UC.6^T5^*V(.U&'XX<Y@FL8A6ETLAA)=M#X35BIX\@@*O&.42F*
M([54,V-+=&=!A(X]1!)GL@Z?R5]#$;J_E,6.XU(?X+C4,<>Y3[6-$7#/EO?.
MZ(\8U%/._L/\]_X@YDU=@7NE5-*>UV9LD9^S19F0B)S8B']"$5^#>[LMH2N*
M_6F<Y_1269Y-C0F.NDB\FWNWAU+HH&%GFJ$>T5Z$>&?1,MNDA;!J8S>S/:,;
M;C)PS^7<9!%# ]C ,%3<='0=;2A\FSB"NX@<5C1B:^\>'O#,1$7>M^2/?019
ML20D41B8.UXVXM5J["YM(%N#='2UP;4(0=DBH\PCO:JE'T0AWGRS[%/M'#?<
M=U@R_NZ@BZ0Y/6<:EE7S#SVXX7;#SY?;6?EB=I*DACPAEI1-73(7Q28+I2G^
M>!J5^/?6QAVA-QR<P]E[,O3@]T=3I@/H9($#NFZY0 ,C2,8A %X+9I0Q*KKM
M6U#N]I,QO>,!8#[7W^LMCAO*B'>SJ0\G([Z5B3)"M5\K-XL+9DKDTE&A&]_4
M)J7I^62"SW.,+0P,OFW2'77MR$9;XY3"5/J #7'0G"4CKBT/ZUO&-C,@Z=</
MB)KG&IW%VPX89PN+;BW"KNE2CT\4<@R#6GM'3AD$E\4U9GAG=*>*5WPJ6("T
M_T8N[NL2_ %Z'.^]YZZ>I4"<[(F-8E--J[2ID?1&:,K%"I31&!%]2!"GUYV^
M8*W]!\K?D:D44NH92GG[M-VF=TK-K%+J,_PREN3G#:$:G0!I.M7K7LR7@3[=
M\W'W$ZIY650S9Z ITE%FU ,$4LLZA,I]=>FC*XI'6:C['K29D8;6W#;ZDK%
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M(+)@TY'U)"?BD6AS.KH!&KF=5M= -)^ZUAS0Z>MG%*K.H*C.2#!59RI4G0%
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M-VC=\7%8$=8MH*29?IIP-J-,FEIM&HKBP@KSZT\D^A!CKE83$'!<"6$DA)$
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M-M7OV6--*KIGBGD<%XF<IO.A?__O_SG(5MP)%BJ:,<S?6^G9VS]_8RA7D$8
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M=+U]K!9$ZI@4$_8G]:.ZONYC7$>RO\6%Q5JKO5+C"+?#-K3'L3_O@X[][5'
M@\+K!QR!\_8PM*=C>YL,G-B2B E6:G(6RS+S4<:PAHS-&.*A"#WQPZ38UQK3
M<K"8$G/T3,R1XH=,;^X$8T;ZV0[1DXW:&-2DS8L@PQ9QH#&R<NP829P*IVR\
M!^O"+9C3FI,FY]2>NAH%"27%B9:?UF*A\739..?>R?#*H_=P*1R[-Q)Q @0O
MW>&[Y%>$?V[<_#M?P/ 38/C5%S#\"QC^4<'P$^;PG7+ZKFN$Z!)RCG[[ZY#8
M N H,FG?U'M4VI3B:6U[WQ!)0!3G;!J>,GI^8"-)>^!<'R(!;^9]R+.? MX]
M#93+.(A'^SI"<A =PR=[4I 4NU'__)\^_0?&4W/Z:AAHG>XI@Z:L&6YK<>IP
MUV,_P=II;Y,*[ZC:>32*$9[4(SSD'K7R\-83%47*M";0<H1W[J(N"H;R55O4
MZ07')!_B#M,,J.&"SG".ME48P,&.G;&BVO5OL7-7\1:FP+-3TM93\L7 IQ#H
MJ.$ZPN' Z JA#8"?IWP.P^12@LG5:(9D:@S=Q2WF1LP/A&KJ7C$&V,VKD+IC
MJC]!2<-LE%"E8#X9ZF[?P9BN%D1^>E,EH1&.D0[TVKY*M/;")UQY0;%!$JZC
MIGB-$VGNT5-]/P\-7/-#<)X'/82M;8"E3.E$8>Q CS@ PUR2X4Q!2>A,VP#*
M@>II'B'!J<")T>5W,Q36]VQA>Q#"-&"-HF89+7V&M$0*BD4)&)7,(YS!)&".
M8C^%+<"CI7')@.]Y+)=$<FK:#]$^#743'MCJE^R4YT32M)WX>70:(S5M"6X>
MJ@&"%%4&SE !?SOT7AN05'/5H*2<)QW9F_KQ)/T)S90F?*&<@  <#=:305L!
MU5:8A,'DRM.\P\2/\$F98!131:A=(EK%QD(!HY["N.L[0'#=HJ3&W(T=HD'(
M**I")^?KA<;O<UKF"EW3-'?-R ]ZI<9=FN\;5-/K9F/.ZX&UY_#S<VZ_9R'B
M$=>O&5W&[=]D[7NL[%\'%]ALBSU\U'-][ _#Q)4.DZC(C071*J=)FLLFYV)A
MD02&N"_'7D>.TQ=(967[.0>*?T,]Z2.0.>G=LOG<,=TSM?D<RP'K4F[#9?5!
M0>U5:6FVI?I^$.9,3RP-[72C"*RRO!!@O"C=RFYE^)0=ID\>4Y6%T?"Q)3]B
M+6>G;<7$:^*"9J*]6*DYMG.L\+LG36%* +DC74GC^L[DF0FM_/9+99IQ8<J6
MTT.8IKODCAHYUN]Q1#2;AZ',"Z$3QIUTG[0M&!P,;5>:K*7>:Q_/(VHZ[+8,
M* O*7+DW7Q]UP.O%"3U#9\NL-UJ0.9Z]V%.LJ,=@ ,%0*!@0<7L!,D-.%9Y@
M7A\7QG+JP0D1]_MX7M.J@OXDIF,A5<:N<;59NO4CS,Z!UJTWG0G;T!*3@*DF
ML)K]U6],!8PT*J CV!_SX4:[@(L]2";T']PB$AA./P]#T<LX=?S \AD  @5"
MZU-_$1%VP7*1P%P[TL>L":'>FFC/MQ9NK-DPX7K[OII\TXT::Y8NK>RL2;+K
MY,U%NGPF<J' IBQAZ9!64K4M%4I$BW;F%&JY_5'E1&8JI"[W5TVQOZJ4"^&O
MBSO=--:DYX&DXPM:V#90VF8^XH"M]3,Q&!%A&)'+5Y<HLII>M:@W'W;_TTTS
M=7?/Q5JS]!=2A*XG9O:F&> ,!5^S6AO[W;&6?]6>>/^M.HE.5=V)L9E$A,9S
MM^K!JFL2G*HT5\0G&^49FLL':-5JZ#2U+6MWU*P>KK+V/ZL4_Y1^DKJ7I&Y/
MZB=A8+O]N0T(D7O.PE8K.@<282F5@.IFC9MXNZOXIRG]RE6-*]77#?65MF*L
M>25]9:MM")+G5\LUW?&6VL]J27WLQM-W-)^EZ]O;\*S9;J^V5Y=:J_?:J.U&
MQXW;ROGZP^99]7"F0NR'[N%L^I.^]&*^02_FEU;,+ZV87UHQ/^M6S _=A'GB
MR(\F&R_?K.ER9<OE^VBV+.;G0S59?KX6QR-E2VVXSEINJ"(W_!$"P; OF9"C
M/.)\H?K@[H'C<AT &,K4I)#CRP,.Z')\!?TQ.L+<?HB$H1-2>[K,LKV _)SZ
M<B*0D$IT"\X"H=_0*@P[M:+'RLM&28H.>7S.J2K\&8QEPE@/W6*'(NJ K'W)
MU93&@W*NKDY]F!$Z7P+X4+>(V^O%>2=#=J:\X#G^[_^T5]\41F=[H&!>C^EO
M" 2>8/W#M1E?I.5Q"#_P3NY22SXK4^;@-^!C>3W*\V[F%-TQ(3=@DA@^'ZB5
MG"D#<==7FE12'DN3RIGEG7P/S5+%)+W =F;!=A8:+["=%]C.L^*PO%XKL=Y#
M[7,S36=<Q @;2S=;8@*)'G;CR$7Z([<A+6I"/P<=3X 5-&1-QV[R5+%;!!,/
MCOP$3"=_=$I9 .*]TM8,=6"]OFVX-%3LF7&76G%K^[$UT<"5["C;)7.L\1LO
M.4G->1@Y[&\<+YV0%I>'W)S,2"'.:1_#-$3AS$X8=+$3!&.)X6F;JNORL&CO
M'I>>6-7@Y6Q6%"WS)?#S7OM%=[YTQ:H!^J0$ /@87[AOXNX\W%_%'HLBU)3%
M-G'03#+V]#;&.U.7UW1$V?7(M(">'.=BXW<PYWNV/EWF1#8?<:((J9J&$ICW
M"]L,2;8="ED$E(I$[KF,4U*.T0%?^BX/R5%IO?%.-24V?0/A-+ -#O5 0BA7
M5QDC0T<U!,V$%'$!U?B'VH.:.BH?TQ 7<4(:%?RR+L'#^^3UAV'=>WVD\1MM
M ]\@]AI-:&<[]U8"..ISSARZ]$W2K)9#39K03O785G+HJXQ\AL96%WWD47LD
MMU,K+:3<6&,Z >D!A;)6Y-ZC5"ZW:[4]D?65MK2OYD3<$@R4S#/EF[AS&CQ2
M=2.)A)[\FI-AH<1+C>PX!NM'2G) 7?% V+6$:P9)R4 L,)*EY%;[$\U25-S_
M;[AZUXULD],B[((G:>:=L^?-7:E3I%:C$\>$!AR55TC5:;W'NX>"&,WEQ=KJ
M<AMC<0GGT38XZ7>$23]"1)KT5@$5-*'O7C7K+1WFK'O.F%.&9=QBT!-ZF@N&
M M25 VQ.,6L8;2?:JI4'A4<&2,+&T8QVK;VT6&NO+#K?/9'P?$V(/#6/+B&F
MY_T$Q9B2XF&@<BVC<S7O"$8)#UFSUV"X3,<WN&:W75M9;M2:U*),O[+P.OQ&
M>=#ZKSR(REVXQ Z;P%CGM32I-:]GUXBA.S.7J+W0K+4;#6^#.FNL>5_T$''@
MS=IR8Z&VVER2/Z_;/]-AH:XP!)5B/^U]'==OV_2<ZXXO+SFOF?$<&Z_,8M0V
M1B1(!^E1$G+:/L3<?Y./UTD'(L-TA\QC>=6JM1K+G I; POSMA-ZRXU::^-6
M;2SI9<=S2K([SAXM;8:6S4\8$M:",=!1V256+\KWT?LD[>)"V&\QT)75%DCG
M@B.=UXZR66_:4=JSNNDPTJ%DG\+C'1BU@$BFG-?_]I-C]1=JQB0SB=X-(73)
M:,:3_0+.=+VE2SA>2HNOUE?T0AE/9>8[V#>BA#5+7[M9XQ]8M*1YI6VCJ+D"
MTQP!\('D/Y'NGGPR:Z9EI]1/L/I4[!<WVT)-3WUGRDBK2K6K2[3=KY,F]I>6
M>530+FC*=7+P33!,5K*A#(ECHN-L I]!(T@@R\3C+J'-CLFO]0V$-W8L2G)2
MQ>+R)\C@Z]XA48^&TI6IA"<D@]G2<13&C6]AA\ U&96Q%NUW( C79 PTL-9B
M[B))(''(S^V3*<-&<L:DIPE?0VK<0ZEDQF7'T4 E\U2DJ1].W1[KWBYE9/&B
M0<Q)/&J9)K8Q?0&IADF+O31-!2@G,5!*?3%ZDWETZ<OZ9%B=FKI!"9-ZO6NF
MQ&D;=%<?R7PTVSICDQ$=Z;WB&U25=-_$1A#/KECD*2M#4- *>11'UW"'#(HB
MP=S#;',/8/![B^@(EU/;R926D1N47[,"R(A?/Z"E/%(<3EBJ3V5A=5I:7@1Q
MZ)L$8P6"Q^E?96!GV%\0_C1@+) R0DNJYE*9[8KY7@2ZFK^Y*M=%;Q@5%B?N
M_=.V^W_#J9LX4720VRUGOF[XA]34EU2KC5#P^3G/2:0D2!UV7R*?%<7$\<=I
M1R^).(9H'G8Q*N+!Q?4)*H+FPF.!GT\1 ^*L^"_(S!TF4*;(00"AB>'H+K*P
M+FWT&[6-&_DJI?[0&NLD\9G"Z#=BW3$\3E:Z-D*FAMMUNPYS1@>ZVB8HTF(&
M<^4&$JA&1\%(4:/R@F/3BVE(&!?KVA 2A7SA,1*C7]N=[R$1?>1VLQ'"6@IA
M#/TQ'^GZ 489SKI5@UN8S1TM*9EK,=VF;3</=IK$^ZDS1*CM6M^S83?;&.*)
M=^ _2=JO4Q=2J8OBX52">ULZJJH!Q(?_ZP]';S8U3/*_K&"*VH3GQ0E#7R/J
MLTX6'26I+Q4@DJ_:];;^14TGPXC#M^;-3*B\?M6H+\_90,$QV27B!<%6G1@\
MZ!],&&&3JYPL?.VY9'YZ)CT_TQ1+B3A^+P13I"3G3V/L":WU$#7M5&!N48=8
M1!H2]$-*%OW"."@K0SCVF-.'U%R6/27-*H_Y*<Q2_#=LH6M'-G-;[Q#<A(N0
MUGI8%Y=F"<.'],9FZ=.[>X<$8>V!=O<_84[+"#&9D?O<US.B[K3+%V?M<K-=
M$##ZJEE?F;&MW>ULS0GLU!MT\DP',+B>1NL.:J22@&6,W:6[,54 WGV3UB0>
MQIEA?P@>O$-9%D1PXR# <4A$!!U$*ER2>/"G5E4 N/X"<:J&.#5?($XO$*?G
M W&::- X\[ ZIER4..M("2W:ZS%-S/*(>4RQ&9/6J#5&+$A#'*-:L;N0F%*H
M]\IG1^U.AT?5F;%D$\8URC#Y4NU9NF[%L2"Q2V!1D;8>IE_H[99]"ICD*5=]
MWT4<U6R;*4OO1%YWZ#.S)NQ!*N5AR!L86"6H"8I"L4PS3@9^I _"UX9\H^9]
M^+ Q5XCIFXY4F&.G%E0F4V?*%ZPCSBRA;$@(K:/US7$8[K"ZC*2N>[O(C!#]
M@"^S7>XH<DG?98EB')0!XKL8WC4+QM7XG5_JKG IR*)3J^78BP#6J(>RZC'2
ML3KXHB,9U=&5#P+5AGTW"[5TGP8=6F6-N8))]QILNJ6Y:J/.*2V[Y2AJC"_O
M%7P_HKE <@GF%L]'HQ!Q$<84K/ -F_6F,S;7P)QUY83Y1Y'_"?O/M1Q[B@24
METU&Q':LZYX6[RD9HW3M4G%V?8+7#%!>)C$M#<>ZIDB?;\55:%-E;QA\UKWR
MVMQ5+2+7!0JOMV88-3!'!ZJBIN6E6W>3^T^J,7&T6!7A\']4C#9U1GNWHQ K
MV5\MU]N.L&!I&J[R(G$[,7:B[CW*@#A*.;%)6O4%*Z TO&9]H548WC\\6Q)A
ML/DE6?(O"BK]0Y(E>ABX[X@+^Q(3I0$Q*6%7LO]H.F7*?BQF4R2@^Y)4>4FJ
M/.,IOUE2Y0X'D.145DJT$^!*3X^V1@Y6K *TO5P,O9IK<;=9?2.[6LIK@T@[
M52D[< 6-8WGYI24X;."-C<,5CJ-N[6P?7NSN[EI&")@8GYCWM>Z:J44R4\IE
MQIJZZ1]K:PM-TQ',P&:@!K$#H+,$%::&!NPKXVG4Z%_&EOX#M4Z&B)JN=%(R
MD)?$I32Q;\H4-NO6$.4@+4TK4FY0L\BXWT^QX>FX[/Z8^'0<7>N?O"217I)(
M3YE$NK,>*^NBI?I"4:TU%^JK-]1KH,D6IVBRHN&D;3_[YTG_G.@5$9/I<[L?
MS/X0@M2MM;M^[^)CF%58N@/C-J8_J$?<M2\![&D![)L+;JU28%L+5F!G1K!;
M3H6#-H-3?Z@T(3:,^"62?<^1;*[G>HEDWTLDFYE\+A\UE'U/Q\KK5^V%<K#U
M-9XLS6MBV=MWT!)$6H,1.QM"(#  F\I4F7)%T\>E$Q7!Z>5"C-U&P5.I<T?"
M:F'7*=\+AZ5SJSW3M+/,9QN%JI?KBW..0M+VNCGSK'%N24KY=IIAL]@:S?T"
M8YB ,;1>8 PO,(9'A3$\7I9&:FQCTR;G>1@*OY ON<5AP_F;Q54G/RH)G,7Z
MXO)])7!N/*#J_$V[[>27>'3M^LJ#Y6]NYX!,[^[UVU\GDM_=P-([/(20-1M%
M[)#IP(>\_^ZUL=>O;!P:YTG*R0+K-JVA,4&][I]Z0U -8RX#M#Z4;P98*3^M
M1=="N/TN81<\9]^<AE",)Y;QFWU99;0<([UK]&O92WH.WI%9\0/IK(#N_RY%
M0Y_AJH^<009FD,[*3\:#EYW(\AUUX[4@736DNE2F#) Z0BHP3)&<T(SL5;-9
M"G-SMD>!\9QPN]8,RPN:16B$6YU8L+8#HI/2R FBB\#B;4Z-^6X\A]DRA'6C
MPFA'3=]R(,NO#U6?_4/B+7!H"Z:4<-+4<M%G>K]<!?>FRK8-*^8S$VJMRBQM
MIR/0#@/'K8([%1JPX0(@4/J<]&.58!?Y1UPI=-E9:I;:Q7"1U!S1DXX8&,B
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M">9/[@(7--?(0I)W@AFE:6]3I@LA*(#\]6AKPV!O$CO;PKLU!$MT\WI1DQQ
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M+<I8'FUG%SX[K_$0'.U8X+V=4))&!"R)KKH:!476=$*V,O[[<<ZI^P_ZFR-
MUWJYK21G1_FIV2.VTYE6?%H@Y'Q^,?4;S8]>U6<P^!MI-SD*!>[M4#B@&NG
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MF^GLN7:?T2-@*D-Q4FPH=V?]:NW6=19?2$8MT'^R1L%WZZ+C0-BP6ZA*C=H
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M-GIE>EC-H&F/ GPR'*7W<HG)OU'YG0TR%GP]N><B6V#@JO=4WP<#CL"FA3"
M<R^LV[=-462KVV@?_HN:[-X,Q_895/$6_D&S87J&/F-Q#NHX5>C89N-L1;]-
MGX\^*\5>WZE8N>^PSX<E<;X/9F?S.Y+-?U*UG[:LDF@\<C7'!&PF-W(@[$0Z
MI_DIU-TN^(;A7<:2A&6'.LZ'N+*LY'?GD$3?6#QVSN]B-EQ ;XBU4_&[ZS#F
M4!S8>.27?QMDSNDO*\@1=S)T!S.MK<%XW0;CDHWB"7,NIAR*'>HH'Z*YL')_
MF3Y73<<<^=J24Q/:EFN[^G#$@NR,+^N[GZ,XGXR"V1E>6CM:\+U&IWJ<T&WX
M<UM_[;Z5FYV$;#3ZN29+NG/M#L_LA/1;&G40R;'MDZATKP7\_/=_V^@H1).?
M$(R/D^&6G9!O)1CRYY\%H_M@ELO#P5[#;ZDC$:4YF]"I=J/7^XM3_EIZ5+3>
M@'-.DUO%^4:MJNXW\=D:!X]V=+1H<)]Z#N,8-+5%$@C*P__X\O%\X;$)_+Z2
ML/ +.CS3H7-.GLM\C@]PQ?2O"W61M/;;HVJU[;/U>17-)8#T\ONW8<C5!-]!
MW:Y1Q7MRC/2BY^C>_AR";M4I:T[GS&GS&<RIKB[)EE7T9>4C,%]-=Z$-_I;&
MT1(37)Y;#-)HQO^[*\:C7_X?4$L#!!0    ( 'A+KU:?6XN>C]\  &,X 0 8
M    :6)I;RTR,#(S,#,S,7@Q,'$P,#$N:G!G[+P'6%-KES:\$1&E17HO"@J*
M@"!%:1$1:0("TIM()P)*D4X4I(@4 0$%(11ITJ1+C720WB74 -)+0@T0DC]X
MSGF/I\SW?S/SS_6_,_-&<EW;G?W<ZUYKW6L]ZP$4_PT_#9Q5N:-\!R Z 0!$
MA#\ ?@R0!XA/G#C^(KQ.$KY(3I.0G#Q)0D9*>NHT!1D%!3D9.3DE%<U92BIJ
M*G+RLPQGJ6GIZ.GI*4",3 QT3#1T]'3'($3$A#4G2<Z0D)RAHR2GI/MWO_!?
M .K3)SA.7B$F.@^<H"8BIB;"-P&<!)XD1#]>P*\OHA,$CJ=(3Y\A(R<\4'86
M.$%$3'SB)/$Q:\*GOH3/@9/4)#3GA.5.T6J:DYY_0B?R/"KU-/>MHGIZK3X4
MS[6'SOYGR!@8F9A9+ESDY;MT651,7.+Z#4GYVPIW%)645;3OZ^CJZ1L86EA:
M6=O8VMF[N+H]=??P] IX$1@4'/(R-#KF36Q<_-MW"6GI'S(RL[)S/A:7E):5
M5WRNK&IH;&IN:6UK_]H_,#@T//)M%(&<F9W[/K^PN+2,WMS:WMG=P^P?'/M%
M!! 3_?;Z6[^H"7Z=.'F2^"3IL5]$)]R/'Z ^27).^!2-G":I^1/:\R+/3]/=
MBDHMJC_#?4T+1?_0N8^,@4<4>0%][-H/S_[O'//_#WGV#\=^]PL!4! 3$9)'
M3 V @2.E#VFA@.$EOA22M.A?+D[$'5]<4U8 !.C>:]XD3SC^L(ONS;T3_9K'
M]P@7?<H_7S!_2'O&$!WQ*\0ENY^P?EEW_)2@+>$I1E$M N"=WYXP_B/.!;K?
M31 E&*KP$1VO80CK)ZQ1N$ 'E%J_[OOERCHN^B?2?X1A/NCOU]Q.(?F+7S\]
M>]&6@!M*,.!RC*9U;$!9D>XG&K\C)AS3Z.(EW)O_QX)2K5\95:9%QX0";G0/
M0X$N-,EPKDUF:8)@XJE\'^9;8\:FOK%D"S%PBVWV\JTUXPHL#R<U=/%./QB5
M <:^- 7C 1)Z=%:(--&AR+(7/,BM5K[QX*/]4^'\]<3'O7<_]B/?2+Y^K'A2
M[SLC5DRO!7K SW$-#]1/M.(!>I/!Q^MYGK$1]K'WV2/'IC!*?N?Q0&_X!RA2
M!;I/$XE1DOWY[_"S<.3'.L+B/GTT#$>U#L9\!/_YQM2RUB;V+NY33<\QG.Q_
M%DXV0TBH2?9?:/\IM/]T4O\+T?Z9/?TS-[]_8K1_IBS\=\KIO]#^^ZOWGUDA
M_[6]]W]/1_IGXO;/K+=_9K0?<7OUIYR^^I^HD/\]D\,_<RW\=^J]_TQQ^]^#
M]J_SPO\\;O_,'>E?GOXSH/T7QJV:7<2H<GO%4V@MO;C6MCYA\E+-]W#TUV!$
M];.=+ST9?F= B-Q9646L220S='H=BKL,MX-;33AIHH56%U!3.D.%!6(RZEMR
M)<GSF^OR/"5*??[=JYX\R1]&Q+RHHM42!CYFKGJ%TVFY&-O<+-4,%;[)>0%:
M?P\/S/7O.!V2V^&! TDX"V37#$<6C <NQN="OQEI$(@/8?I,Y\DQ9M>ZFGS,
M54[- ,L>'S)T$5]]J2 U\U)39WW.HC6"A*0](;[TKQ/K^1T17T)7K\N)YM#Y
M&1#OP41SWEL0R\9>K$;Q-_NQ#]5 LDP;+2MDSPX@A\0TV;]9Z5\X^T;XO<_:
M(6:3]"Y,91OZ$@^4VX34\2V!:44=[O WIGKD7QE0'\BH48Q4W.0-U;H?4A_S
M.*3PD6//]8^F,D>9I3V,&)MFZY[ZPDR/GN8#A[C80HB6?1#$[EP%-<78F*?%
M5SOID J:U5-4P@GUDDEZ.UE86B/YRG=X@ **EL+1WD&U[LI4[/HO0E%1S'7#
M<.M#!ED\D!CFV--1P=S#L=/B 9E>"/4Q0?4TF<H,7$E/;$P@OU-17%IOM5\>
MK25;0"<9S[T>='*D3.[0W2.4\VR<Y$TGBL26&EP'(Y=&W$!=^W?/0_"0TQ&N
MZ_/$_H@,:F\WSRPXF1:5]2(?RYAIAK'0**HI'3Y?TSBQK/:4S$3:9>WHBVV3
M"B/$HH/Y8K2;PT=R^<HV6W")3:2T:BJ&V^#3 %>\"CH<FV =[^$(A!ESB[R=
MOW[4=\'(T>O9$^-X?Q_B7.Q-^&#>MNOS^8'ME20MJ*PYTUFC5$\EWAP$%:G7
M+C1@JOQB*NIY#0CBD!*N+=_K(.@@5-J1FUIR3\AU[VIGEOEF1N!;!Q_AZ6T*
M!<^1+W@@3,_L9(U)CD=0"T)YHT#TU83DI)(UM5AI3(NF]<E<XD^OQYYT2X;F
M#HYHR!E*TF!L=OW09J$+J ]/"S\@6F=,!#?TBRKK!AE.:PU_^_QNWEF88TJ@
MY\:TSG4<^8ID<),#:[VD> X2#] L'Q3).<D&?\R8>"M0+36O^0)!5V*S7GBQ
M5OOV48D;#SK^F;3R#+N4YO".!J6M9-!+-V^&M-?&DXDQ@KR*FP8/+6D (MWN
M7@BLY"A-%$KI<PO-&;8-HK!GE)S,S5"V8)N\/,0]&*;]]:F&U O_<URVT*>T
MQ*POVY=4=L1ZGP:[!%5CA&=><=)A6AM'&#[)?_10[Y_9TPY?(-)E>AIO.\8I
M*W_)V'=:CA[<(.1?-=*2KSM[M]?-C&K4GIHBHZ B5]&*9Q9RS5/N^539O;A6
M.=, /$ ID[YB*EPU@E68CD\J,SLC$5CV5M1$[I'""!'-S)6F&9KSM]4^FV\2
M)P^U8/AG8,$X5A_S4K1[$%8B6SX-T7Q9\<,RR\=QC7=<'F_?-5T^W;%.;//(
M>Z!F=7M0-[Q3S0DI6YBV>#"?5X$0S_VPQ!)8_DX&%Y.=WTFC)OT(O:^>3O7Y
M#DGP+6$#/QF4;"YJK!D1&516&B2C]26MNWSSY3W&<$OCJRN;5;@;!2/(R#7*
M&:$74"HW/$#E83V_HC+HYJ#>O5]F9/"&+N)DK"%-6+ 4]HM+5'@M%81T5J\I
M$U./5C1#OS(0?W]06O1UN.?JFU1]K6OQ9)7MMR9(C74$'2$R+_8=,A>H%>AT
M7Y#0:=YDYVSL(;*'TV(M,CTL;C-,(1("WB(/C6>8GI/IQ[F\3B?S+)CG'(6V
M2"3SHM;#+3R1M>HR?E+OKHAY4SI>VEXBJ6)\+]: "J2S])<*G:\CPZJ"27&\
MMJ9"1K0YXO'\7\L[^$(JA8M!;W.)_$<7O?1,I@L1D<T(WJ8CQA:_\_ :M$)+
MI(.;DY433\Z)^H7;2Y4G,NN#'K1^WR^?'M9:@%<9?B_/U!E91<[>1H.#MXWH
M^MT&"N4N#,-R; _R),1IY:G/VU%^.:=I43]IQ/I$!ZMP*(MIE!O"RE@X,"3-
MZ* I6L94ZE"3J1RI=NY7N415+[.1&H<%M1#UJ$.*/Q_E[E#J->'H1]R2Z"",
MXBP4./9AAXQJX;'EN/YUBKXTOD/I0+,XX^^Q1NP*]\T0XAT-$G7DP5\XZ"1/
M!2.35-1,',1\;R[33HXK^4ML69UA(O\>_NQRF.7[&*TD]69#4J$9V'.6O4"W
M)$957Z-&EMKY7,\C&(MMPD[M1I3+:PIM3QOAUQH\_C)+4S1U1!Z)R*?OW2AO
MK=P:RM,Z*LU9%Z4TY/]>7GU/V?_!9SZ,[G0D4@R!"=A-[#=20&4&(&&DX[8'
MIU[E*>2Q.LC?-QHM865@0*F<DV>[87W=8=6C_7I.C<NA@3+ZUM;MF.8JRI;<
M4[$S=CMM:_W[YLKYEE*!'SX6F;\[363=\C2.:?[%LEV*(2GI#&QTJR69$BWT
M8EO L 4QI8F6UE3.RJ[2-9ND)^(QQ^4/%J]K?YVS+ER&EY V"5!Q<JA"/S1#
M0/ZAE(;*@H#QIZ\AZF#OV/W/:R:.\$.3"<RP"<M&DRG]P(<A42BM4,BC==?7
MY19VW-W^"HBQCL#(A;9ZN?ILK,:AN4=PBQ=#==H* _^33%.[O5WQJ ]CIIRE
MQF=TE8V<-@Q%.;2V]WTOF18DD*2.3_NXH"2:.*FVK^^PVQ\VHM6USESHYQHV
MC]&L,'@C?4?UL3MP/Z#E\>EN_A[(I(_;X5T#3 F2V.,B)V@YHCNN+9YEO>(H
M@P'V_:QR,259.P/V05#4,ZV;3"W2+*4!,:9HFHJ;::'\MVZ%\J6<J((&<X+$
MS$)-KY2AUD-W-<W&>:+/B)%'.9VX?.ZIS6M4RN48XV8OT!=HZ"N4V8QUXDSK
MI\^#<7T7Y9T@K@(9LI:/$N-N1="%CY[,6=+F'QUSCBW,H8.?VO'T\4S#*"H/
M^<C,^.KIN48@-$#+[9Z.S!$G:CY>S:KLD>LR'8#;;-!/^2@/^X"$^TMK+92"
M5!/;RZ1V*DHCZ&[.:UP/HT/(D:;2#QOZ]7F!@_UXEI,E>K'".9.0>$/+\B=J
M,_F&,HH=G]V^V3R.0Y.>D,Z^2Z7N@BA0.#0RKI\E-V.40[:);M!F!66BL".&
MCU[1436KU$O>TO3WM+WU9DZ\KRVO4#L-#P0+]JX_1FRL'LU,@4SL-;NK3 89
M#&^,U$V89[<^<7"Q9'5Z=_)5$TR":1H%(6Z 4>QLL-DF#&>DCC5G4YZS\,Z]
MGM$U$K=Z5BG*0O!Y"(7BW;"1?(U#S:5)'K1?3KY'8<-!1#Y5$?(%:C<#8I4G
M4&1M;.UQ)C#N[)B<<" WSVO/ E4DO,5$"$G:HB1M@61GO%_<GQ*J%*-:-?2B
MY#6:3BI+_\W5]F[QIZVUH@L.NFGV$KW?=\"!"?,Q:!9.XJY=7C1%/+6AZ-4)
MTHA+'UJXW8F)XKFN+MBUK9GPAL&M>Y@]+J]_Y0_J*S/RSE<]Y%ZKNIA+OU;#
M^*[>WUK]H4] (U'O".?T!E,',I)S29;O\\N=2WEE)P=YPK\C!C[Y+@C*U?-*
M3^\4&J"=UH32)\;5. .EF9\@C\"::!:/1#W& _A8@9 @S1VW<./;K^@>5#\@
MX1U,<.@2>V!<JV[:L^N(MFHN+W1Q=T>N,4RI#UKUWT6TE%&F&4^TG/%(L4&V
M$<L$U]Y'N7\!T6)Z&K.,0S<:#V03MMH=[ 2K\^LM=O=C-EH=V7"HB!M,;!&0
M/A_R0X-1#-@(K9Y)Z&"9OC8ZB=KBXI/G-E<O4BF?-3&2IHK.[IE4"_.RKI0!
MSRJ^V(DD-;3E$$=1)*QZF4Q,3$8?J']".'\19+I6?W[?J8[K9@O9IY9KVEY)
MP;;N(EC:0TE,=:OAU2$!J][M#H,"TZ\=AQ #__8RUA>'?4:DX%KSM5;N9 @+
M-*".O[R/*NOB>P;18? GZXHM4@17S1I;U([Q]#,O&OXB5' +'B ?];"XU>^C
M-ZWL<QO'6AVW<3NY1Q\BQ*=4WRE!W $5O_HURS^\U=1^HQ&&B-YJX!!&Q]7F
M>W@--!'&P)Y=/%!4FGSW:47VX722"*NLP:S=LM2 8V856=^Z)0+7:<KK.C)7
M.R)]+LUH,7Y6M;IR: >3GR9Q0<+S2263\RFYUL<*BM,;HXG-R3=ZN8=*NQ0;
MR4F:L0B'-Q()<[I;9N-W1-H=P\">46WU\U6<@=#2H0K_.DZ/](:#]7>%RS9F
M@]!21Z=2-4>I,SP7]"65YXVZ*O6+>)G$($CWM2>>*%A#E5G0=CB#1;J1?;Q[
MO*:R1YU5)ZUBT4,:3\^(VTSG==8ER>*65RRUYI8?>S&N[L]JT!C9Z4GZAI?N
MCNQ),#A<K[H7I_7E3*QC)+;H"TFQ!Q>;7E(/8Y1TU$ON> OZK?,.;=^N?TV>
MWA5;]*/!='A/XX$3/C=1S0F3B6;T'VS-UCYXGK,<5PV'UURIU/+HUBC@[^;7
MZ7)WD7!\KD"G$TVGJ0#0]]IQD ZYP<^LU'&7*:F_2WNKBTZ^5R ]C$C4PU2N
M+!D?>4$;8*&RK"CH"ZP>$DZ'L=%$,\06^KZOV#7-J_+Y5*KQF7V-(B5@Z;DV
M?T:JRL1=IT \0.JCB0[" UHEJ.;W>EI+N_F>CVW>WDXE?=#JWYIBFEF&8\("
M(WY7[*K"YV/R,7H:N&Z]Z.4QPQ'NXL^AHH?];[_1G(5Z9[B"06"[ZSB07<5P
M,B4JX[V#>VYKMO3!5OYAR/EY/L6V9U<?Q7"QH;_DY0J%E[-HA..X5A*@P1S#
M \U/&75?FN]^\6L9F"XY-;H%C)Y[+#DKENCB7GR);\E9@'?7;41,@[QCAA<M
M%"#:Q63:E=7HEH,)XG>KBCL7O^D,]KAZY_2*\50C+!!1T0PZ.['$HC89"[F0
M45KA,K%<T0&!L&D>+8A\^L*QLP0%P>UDA!KP /$'C%.N;?*YRE+OZE?O!$75
MO/CIWZND^E1JKF5<26=&QGV&!L!H2B.#)L\/.[HYD&T8]^VHB<_>C?LZ<(\A
MYHHS.NI2>,M-/&"3("0E(T,\T9N\L>N)3HI_*>BJ5S$PERP@J&8M5>U[ZT:^
MH,-9JXP@RZ]MUQ=O]&3(%_J0HQF#I%D=9@2.CY1&B4H;Z?V60TB6&*.VQ]&O
M++;H94=EAT::#U40=@?C-JHHV"XT.*_FAAMR0N(NKE>D@^PNU9+5NYB]\,]S
MSSY*4=PO]NO??8G2-3O1F+)<TGXAP9#?OFIA[)$#L[X$S(&XL>Z2B.29IV&H
M2Z:9"52]-V2\=[W1&H%8[J/:CQ.V#(("T>A2@[)JMR%=TL-H5BWWZ1WB#8LR
MP^JC=S5.5D@[L7>T2G8SQ2QOJMB\2@5R%6SOW%ZSI4*]71AAF\GSN85I1 J%
M'+@F)*=.JX;X<:DZ4=! 'D/NEENEWTLSAWQ?Z#QWD[MS;,V$?6I-+D-E+YDG
MH%Y+#GUY2P77!C.1+(((! DSOW.0KGFI0N'\W7OFU6#YU,@D_^UI ;^3F.(]
M_7Y1S+GB-\L)VA#=/557V9Y='2T#Q%USE6E_D'RSP:#?"8@D^/EJC6:V1T"#
M+L/(L!F"H<JWNYK%GK8QFDC568+FR9=\$^[=D,K^NE,F'L2'S!<'#4S[Q\P@
M ?-&^FWU&>7W6\^]I7)IE=8=(9R.;2<86\ DKAHG[ U!(<-JY[\8WMQ-P&I^
MDTY]:9 \CHCCL4EYHUVKNLKPLML>7J+X:AMVNGWF5&6O(#) XY5.Y<":6,@<
MO*PT9KU+H([XLE?R$P/$PA<A1HR+QE 9*^9*:G_IRG4A(ZU#PT1(R#P>N,_E
MX[<S=I@>%?#^874AK=\P(CZTCL/>E+QJP)&[C[=O=7O%TG^->FT^("_PA7>R
MQ ;U];T"4!.,:0.KB((TP$#SJE$.*9/&)E=Z7 UOG'R+\)?VJ?:L;U]!!*Y)
M!LPM>D[0:1HQ!Q).""1.&(TO!X7A>OH. N>>9.@K9X_O%Z\V\=U\6./LR:9+
MXL59#WV9H->H9F3LZR1?A3X5FV>GM:3'4*ZW8G55CVO=@,(9N .NLK?RMA6#
M+.MBG%!0/4RB>9[9MV4OJO L.W[FZEKTJ>RXLUEO'S^3.G&&M\P 9?.ED!8K
MC\[,1492UL7F32Y]4GXBT%60$FZ["-_J=HS04"#.F:F&!\)*]0)Q-#VSY":@
M1@[>XMZ=Q91PFI&FUQD[\#CE1]W#87FL,M)%D88]*+,U3B=4P4@3^?04N0+[
M<'Y.L^<NC+HSX97"21OGYN=L#^JPY3CP1-Y83G[4TXB$]SV->."9WP5,>,9R
MQ:Y> E6,4Y9)_HM6LZ&9@0YCB8F7TMW,$<)A$9 W@S6@@B4.X?B&"D-+-"9(
M*M7Z$4!Y[LWK$V&/7:+\K\_7AH(1W/7N*[/D#B[(B9WCK02U8F=E7O!*P1_)
M.*\U*<\0GLA+; ?,RJP\&\:)0B1;6Q0P89_&$,M%IJV>),4G>INXORCMSX6G
M,TL/J#M4I]B+B]:8'4IXM-8GF(VM6_;N\#VLBFC9$?5]R-HNNO*2BD;JC?S;
ME[QL<V[S>9B>W8=H]^<.R;/W!J6O23/L1>E/U095TN&!T>(V$?]%@(+K("IT
M&,VY1H(<[MM)-#OCP>)$->$1BB,_<IQ9T9=X=2E4X]K7"@T!GP\",5N,TCMY
M3A&<I<&A.+'ED9F->]4EJ/$]\B>G@BSOA-+0\75<ON0L7/]H)T<]W7[6YR6#
MM.*A(":KT7V2I=C7J8$E=B$D(T)&G%*HB=JXYN/^F" P<RU@:SOO+:$31K*-
M>ZAK4(_9/9FT>[+"*_>T_+U4_N3:,WK"$65:0J66,#L,09$B&+L"//"P7)K5
MQLG> 3<([L>FJ4^/R=Y=R&2E[_=PWZT>P=(C#U^!J+Y="-MC1,2.%X^K7+QC
M5/?L8E]PV&9A<FT@8S8'L@V3ONN*A@4X8;5M<N6SQM20L>4.2D=E*DV\UR-)
M.27@&==:.8&=J1,>YT>:XUFF LO"&>875J-44R&:D]6J8;&(%-])S-)D%9C&
MKP_MD3#2\LG$EM:B:3C!+:] *&BQKM//NKOG+5PVT64RWT<.LS(-8I[PN&6D
M$7PPG A!#OM?=ZV45F KOSA!M1#.S?!5YX-YG'.GAHRM>F:\G*W[]4)&GS-H
MO6?K-0*@$*U&10WJ!M[2S]6U]X,N\)+V/ 2[*CZ>X$\=@5LY,2Q*$@9UT3O#
M/MS9RW5<40P-(W='9CZ[ZVEU\ .R^FVDH-ZAR%><I1-3+68D4XL)>T';8]Z%
M:_(Y=B,(8XBC0Z/@2(0"L%])Y/<H9S9#-W(W0!]WV8.TQ>R;NE[#L&ZY=<>:
MA83L72L)TM%-FQLM5#*+M:JDE2[7ZJ$EL%<U3[(ZO!W$ S/&?,NV5VR&=T(>
M^4VY!E-2?GH]K]O#]L RPCZI\ N(W=3#HLEPVXN?7 AD?R;3/J2?2"RO\R9)
M3$'G:W)7YH+T1BA'C3B",B)^5HAXW"-!AO,^3*=OLD=?_")#G(9PZGM/C?G6
M:M+P_)&$_E[H(Q"UK6%03D[&"Q%[KZP0JA(O"MABQ=FW#3+I3??7;Z7G2#]@
ML]3T2CIK2!KNT=I@&/G<1RW;5O)C4T)X6/+]CI/^MRF?>9B/Y%OHF:!M6NW0
M4C.R\)FWI<@/K1]-Q!J^Y24_>,:)I'S^6M:_DF7(%/&N=IN,+RU;3H'NWLFX
M7IFAIGN* 3P%107JIY2_'*EY62VL3LQ6JPFUL/@O?3(Q\E!9EE(S6JTX<2?P
M_0DF0-:2F=E\0&Q^6 )L45O^>0S>'LLS]MX&0AS97[LKA, #VOUN\+/+58*1
MN^3Y9F:1^JX)<ZJTM\YO?BB+%0<)L[O$M Z$=AM/698Y9@EE^75R7(4/^2B8
MBVT$;;\49?3G;]_Q=>17DFZ/=U6*OH[H;*R@7S 50B7G3H-I3!<E=U('RHQN
M2%>F1+V9WN4*"#KI?)KG+&2\+!+AU% G/%QW7FT&"IA.+N($JDMK3"341DC>
ME=G2/Y/G?7WX>ET:R&)?>8EF7 /-4%HTX[B&UUS7:+[*F- 0V[AD&$V]\M 4
MOQ-5V^3X]=8SB4LGD^T?+KO)V\N0;?D0#Z_6D&1Y%.,!4U1RO%7VMZ0[7PF#
MOTD$Z^%;.6[A+W?THT\#'$,R"ZL#LV.G18U>;K=QEPZ+VKFM\*<[2^<XI)MT
M2UB\!+CGI+=,3(L.E1=Q/!CZ-!_I(5%.:AOE 5PK6QP+]IY^%Y^U98*JBWVG
MDD"OTG7ZU'2_4<FXF'1[%NY%5>_4"8\GHO=+/U=2.#CJ4C,B9AQ@YZPX1:A2
MJ#RZU):?LJ>.;^8*!7!<'I2EF\0J^'^50-5F?"N.<[KN67W@2#U[@:@A;O%,
MLV/]H1BF;J7^*B9N<E;N<ZB)0-F'_@'=R,/;HY<:U7:=B1 @4TA>/]Q^KM_G
MDLWT',HT2>@%=Z]EGZ/ W .G3/>.TH8%IX[#5>42.S8+F15MC:-/7 ,X$,*#
M'T<]H?L]I1<F+]R5S[MKG/KRO'OY62>12UR1D\]?7T^M2F+$7KU E8>*9/3@
MO8]2[H>6T=#A!@:0@VO8=[??^6N^X66GDHP8&NLY%/' W9"VH).TJEV=I"T.
MN#=TOK3*@)TKUIT_A5CH>0=1?Q9ZI%GC)&:OWE F8R&@+%O:(,-V]^ N2ZGA
M)KG(>8 4XE2R?H-YMI/=:T35]]!X^3$FL5D2%YBAG&[OU6@720&#T)!#B[FY
M^<,#.@V(S^H]]U<44^M&G#.4,6A:FBH9"1/CI!M?]!;M4+ZRO>@&F;BU=R^"
MG%7*0-. )^%I0X%\=BLO+]O(A5DS4A,,8Q.MG41\@FGJ%?L"P5*'6_QC=O1!
M.M'Z[2>IM[D_TZ\95JR9V\UPAOA=&MH1.O418]-4+J[K7G6!<,B(XA&R9_P:
M-^ETY05A;\TX75_?8SCM)X6UCIG5"WVT<RX3:F6@;Y 17BJB4J+>5BDU'ZMY
M,EJ8)YH.)'?;>&.#RUZ\=\N0+ZW\&J&8G_W^SD@!J?02-I\>NI5DRN"FH)6;
M_0Z"*='+#0,&PRG%-8/G(Z7F*H)ND6<COG!<"P@;$9CI(5J>).O'WLBVMSMA
M!#FP7QZ^R/PB,$6PC9QHSXAO2JB_N@0-;9 ]AY)]E8%I_!+/LEZ;LM25L920
MD5PZ?.^M_#6%W9#;#O.B5MUDQ0O$-[(PA3-3_C4.J(Y&28;\Z0E+3$PC@JGO
M41G$Q).[C$NJJFVW93SN>[?BVVLK!KQ2R_#"FOZ^\N^L&J.YK55AD^>".N[Z
MXV9O]:V5C;4).)Z,]HVV;0II2_%9/?O]C?-5KYD2(3]2CUR-$GA5 O\YRK@
MAQGED.J3KRZ-ZHH3L]496TF&;M#N%@Z6YFN8#;D*B#MPZL+[MR'D1I\WB%GU
M/IV6;A"G7+G80/;D61.-W10UV-ZC!OK1HVK;0X6=BS U[R:S'PHDM9U%O+54
M%$E;/<R[]RRI9"_BLI/6(55O^0)[GE^/WV44'@B ([F&!%TI;P3FN2_<KAI.
MB=1EZ F/\7V==*@N1[SQ("#TZY L)297$:.3@;U=613N(Y ]7I;'2,XGXLCZ
M3(!31U?XLZXT>V959 B4J887+:6<J#E<0_[8CZO+AN1#PEIY:=]HR>U73)\/
M>>.@7IH =^?H%'V?!VRW(+*ICF88RS9)-N!0<\XE=<SVP+?&TK>J*Q_E,.^=
M!*]%S.ORE[G,5W#G2_6HD=CN2;NW))\9DB;.;<Q<7B(S4;-Q\O%GOOWJNP9-
M!W-/P0@S>R3]<]-JM/9,A;_?13OQ"C-4T(HA-(QKX)'KQAIWX8>XVT8-48Z'
M$J.-/E^3I+O/;)@J&"J4EUU ')#0:=Y7TE2@ ]*S"R=[1LEQ:BY(LZ-7<68'
MER"HNV[TAZ.'7'B@O<"''P\4.7?@ 04!S\\;S[V2/)Q>)M<J,*73SW(\6X6^
MUXS<"A6^P\>SSXLC"P'/TNR8_>.'A(]]*:'R4/IM-?(F#JJ$GB93"B<.NW#1
M1P@1A(*K28!/8;&NCI3&C1[VW"8H\K[/>3R0;@C# V?R)?! Y$A&<$%.8VQZ
M7#[O#=.%F3A0:CII[\B:$_9RY NS;8@V'D"*9>(!] 'XKTLUAD<V<7=,Z_?
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M"1M+#$$&PS$<<*S^@97"$Z[4NQ$J>VG+%D8?RO34T@$)479PWW: ZWE<RKA
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MOF*PS,&Y0S;BJ#3>LH:7'HN,9@J-D1I(Z!:^B=;M8ULL/M)U&GS=S$Q:H"#
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MSM[=-2[CF@SREI4-=J4$>,#JYJS.^]JRUR*@8M[B@Y*9S@E\9;T [2;!H?F
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M?#C?_6'Y<:S<LKHJ0[O%KKST9[:B\/"9I%"=B^<=L+VS@3_#%\I.JN=_!HF
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MP$!UEN#;>C),>-9F\ISZ$41:18PI3W29N*54S#%B"P(YKTX",?'AQ$F@ZXJ
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M96FHBG(O@[V;FTWAU/OAE;8"\YO</-/Z*S1^]YS;3MU?P1NRTPHK_2.>G/A
MKM4 _4]-],\XQ0%=2-$ 6,T_8UTF8NCM![G&4@\FNU78SOT3:OE_@UPTQL.
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M^N\>5?MX8&'.A($/IA 'Q_+*^'^O"/QOX_ZS\U3B\-@P?+'['PQ(<AEA!&!
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MQ D9WE13ART5E7V%._QLH?8)4HLCKBTI;!EI.;8_WDVK'BL\(AH;(]<BEV=
M I5*^%U0D)@!GV"P;,U<E+RN>*@..UMCIW#^$CW+DQ^,,1?&/\[-N5+JMEUH
M_&':=2LUK>*MR6BKL.&U90ZQ4/U U:?7%WUR-5Z^_%^H0=%ZM'T7E[<>SFJJ
M0[M%Z5@MILJVZ@)"9GXGL\)&89!%:I-2BSLW4GJOND^)%E>"I6M ,#SVUL)2
MW +D<J>/E6-F;SZ*U[:D34RR[=1;[YV8&]122H_]]D-[HRNWSLK%K7H1V+96
MB*-*Q^(;&YGM1B1"R]Z30"?4/6".Z4L'ZC&;Y]=NL32*>06VF$3B-A*#6B 5
M-"\5>%SSCU\"G[*/YQ*+'EU.+'R?]NYQ?B$8MB[PYM.1EBD.^A=WCJ<-=WUR
M;OV\K<(V736Y%C#E2-=\2OY>>>).<T!$$[MG0K"XRT#L[=["<[1ZYQ=HYF'O
MG%_<6.<\6XQB]^TS0C0QC="UD$!,ZPJG\H?LJBY%JSADOV>G?956(M-^JD%T
MC=!-\>-T]^J\PY#<K!=8N1O*-^G;BSH;.VL87"/M-+M!Y7ZCH=$D2K.T:,#%
M.,?F\]W3L-BG)6*WOIG&N1WIK?7QT-!Q*FOE//\8D +7U?X"*9:][\[4"M7S
M\J &9=H72]=$6@03O=Y%LK'"I=<F/L/^E(%P!EZOI\1O-C*$NUMOT*-@X!:H
M=6/#X:'ZIP 5_LKV)P=^9H%T]-BX%-7=:KA3 :W92*Y?&-:&2&M5:.\VR(YF
M+%T1E[YS.W=9OE1<O FQ)N9!^_'@\NPV4AR"T4&'?_?[X1ZEI;#;/=T&[D&9
MV8A^?VWOJ#0T 57F7/ ".4,S]=H_W9OYF".TC-Q'Z)Y6Y,@3YE]V(=0JR9B,
M)@0U<SW'=K9T?^3</>VL/[A+P T?$76:\9&$<M(1HFB4>S\\*G*%#,LVVQ@G
M,E [*.IU\CW)WG,K>M!^J<<XY)MN6L6W&['?MR+[*>$EVA&NQ@_6#!@XV0;.
M/ZI.N.__Y<VM>8O[EIT#Y_Q,* 9#%2,-^OO,]_@VS=V*\0Q>DSAA6$O<>W;B
MV=ZO1UYVI-6WX7-+X/7*Q"M,^V^W)_$L]42V!IS_KBT6'51PX<F3@GPN;B^/
M)X)>/C?.O_2XG2/"_"I*\L$;MI4.FETCW*O=DMMB+E/8A)OECG?8DI_?C[>^
MGR; R:%:-^4UH-<XWVYVW[B;L\K=9Q5-40G&Z#)%JA&M%64!7(N!!USYV2V
ME5NSX%/)3!BD6!_QJ/OH+<PJ5TV5AO;I,+K:B*2OVCY'VXD9&>4W+*_M<S^3
M^[*4N$@\[<WZ8JE"?B^R3!--/=3XO)Q]H,=.6W%NCTH3,?99*SOWN)CV=RY$
MWI2XZS'T3<2<A(VRK_X>;PA@5%"!<+WBN8#>O\UB(X9,JP-!VQ-+:/"L%+/,
M)IKH)B/O[K3'5UW>4BMR9\E\Q87M*F.#=N.FN\_UEG$+12LUNYV;,\C<5C"S
M#YZ)KI!F(Y[LO%YX5Y6 J'FD&I>DU TK4X6*WHG5\WOR[>;K<[9T-/>N:G]S
MKQ.8,HA.B]>8F%.:,PKDW(;Z+1JB,3J02 .W9TW>:EDG\I\C5FVIU2QZ8D9W
M 62RX2Y@6W,]BS7<:FB)?4IX;^;S^ZAAKV;/ !3R64^SEP_7M9''GH^+QHTG
MCY\[:2ZHVOI%6\'IH,^)V$&\_!*RNNA8FMFD9Z*4P9M%,82,KU-:>3UZ+X=/
M(_F9&HV,2*#1^&>+O;,^R5R'$G4KAN3^?@@.3?#WWI'W2ZL_<.HP[26!8%T1
ML;>.8*G?77H\5MECKI?6%V[X=AE: HO<)MSX.F(L:E>X?H'^Z"W8V1C6V*];
M*!L:6A2THQ+SU,&O5ZQCKB3GG?B7,915->^M1;5'HK;F%]F4:)W@ B9VYO.8
M9NG)#<A4"I23[\.Q&GUS*<>Y"&80A:=EI%JM/!-.&-J2<TP<:=<(*H<4G]DG
M5#E!KQ!>U0L^$X@&TX.^ '"GK\+P]F;)P_BN"2L*  :O&+1?:'#- ']F_]2'
MCO9I'8-3H:>R$OWZ'5TF0SP54XI>!W>6I*?Q-SGOI0?''-L14544W>;6Z%\M
M6[LPJ-M;:%%35!5A'3C#/A;#QTG)181/OO;R,EP"3@++#!L)%$QD<_ ]71N7
M&7:C6M?^VS.#\T>N2B\>NW(PV+H@9RIR"55TW6BT,"@ZO/'&R=W7!DHQ. "U
MG&6%[Q"\ ,@@90@WH:DC@?9/I/U1$W" 6_*^C37X(OS?W/%/E0!T%U/Q1^3;
MK;\.9T'4F P')AU +IG4M-8<Y]GY;^@.:$=^0-C0<VXX!Q+(/ @0C@QFB?*&
M[[P!11H].8TD! )#OBGC:;MDL'NS8*@4D+O_Y.T^8@;'DD#$6ZV_[FY 7D-"
M<"00"21@0:X42#C05YNYV6[]W%,"_U(,_C.OL[!?_-]!FL9?+FWXQZ9$+E,,
M)H%^%@:<)!<&I/Y-XN92UR_G/V ]F7-+$+A$?T!P@H;X!%,O8O,P>CMU K5!
M 2R+R 1R6W$9O"Z]3PQ:1#9)4-C!611.%KH;&D6D]^QXJ8NM'SU]T=#$2MN:
MY_KJ-20'H+F]]; #(4Q^-8ZSXHQ[=;K[3A/C2^4LRGD.[-CB:,JYSZ%GIAZI
MAC,WGJ$:;^UF-6S,N;+J?1AJ\V*2V%G5//A"P>IC)O)1A?QDQ"SV-G,IK%C8
M8'=D]JMY'^J,>73+K3Q?=IST+)2>0;N^K7 Q%B]56XG^D#?\348_<FT^1O/I
M=),[\^TFC>N/0;1[2.=41&E\PYQ:QPA\=6]V[49KH^>I$ 7=E'%W>/UNB7*J
M8L"K:%.S6X_G2@/6BYM/"#PK-^ +>N*KVVSP'6(C$0QFW!:^M$&#>]^(C3!L
M'+$.*53*L[B4>;Q G*IBQ/'YI_$W)%"\'C:.1B$:JJ6K/7)+[B0VJBF*8GD2
M=(E@T9A,T_<$Z>BM/#TD9E52A:G=S1#MH,HIBYA*'CHVH*9_S>)M;DXC17@H
M0@,'\9F)"H,REEJ5]:VZ=+ T5CW"31Q?'1<K+!2+EQ/C4P^FD\XOG"]GY[Y+
M&1FW>UDX=[>PZ? 2Z*%>M\I#^W\W CPJ_N.F#'7DW^"T9\/,/^M9=)N];7#D
MOQ5PFX:%U'"Y,JTBU_(XQ5 C?%LU2;/<Y4],A[:_(.5Q%8<7M;"B=42*[^98
M@<N <1EV+.YCG\N6FWGVJQ<JAX=.(BR]S_!XL-%>KDC?/$^(D[;S#[@_M.@U
M3GU&FWIY$A,O")SG8SL#2.===Q=T2?KD$WW3O,.!(?[1UHFN.Z)-<%M8@)*L
MORYVL'$#9(QKV;N)-<MASQ)$2 2FQMX^O%D8(9V9;DTM3#0I+K6<>\A%H$ZO
M*V"S.^^L>,NE/S\J!@E_:"HR.Z.R$&)1^_W"8QG-;%@9PU43S(P]BT!NKH"Q
ME[^(A^VA\\L"_R](?<Q@78%V/0G$BU>?71-MP@J&S5QYJ*5Y_;T6_?Q4>+H6
M6]WKQZ?G7@9=65E:O72O*L;SLMXK@U8_[WN$9&\[K/VL;G=95(@N&&0O&SW6
ME5;H=Z(FXF3<*\GQXR!:#<*/\$]M/VJ7.0PF6$.H3[**A"^ GI[?OB=W.;\E
MQ@C@N9XN8*C]*?IP'3B=Z7BYVJI>O.BL@^V$\57^<P$_NJ-Y-VDEMSE-T7JB
M*QM_RN?0#E40SW ?;*P8X:VP8D_+F+SY?<SXME1A%H#Z5@937C;5\-@:E*V2
M0!1&;(H1^M(8H0VNY('I_'7^1 58A#_]-K(2=0%>+U%V**[GA0[R'$].R;S5
M'*O5/W>QZQBDX1PHSV_YJ8^S&2#]&&=Q@R30M0Y X%'G$-D.5!1Z::YLB81X
M+OJ(.=TS0DM^43F\ZQZS26R8^2$NS[FZ/E,;$%#-NL5?<2B_OE\2D53KD;]/
ME,<5MS=6F05'+W5D#G$P5/M\2%"ZMR9ON;ZP8)$L=]K0?1)S1R+B%0GT14(5
ML"%SX0&V2VB,]F3D99"H'9<8EO$H*O^##^-Y-;;XM?-J&\KZ3T<O1[(THDMA
MP>+3:,U11Z[=3KO"A<J2FA()2A+(SLJ.[<73I[0O/YY0E4],R?7M,Y- 8WD"
M/XEO!]M\JDY<'[F2_R7"Z!;[44GT1Q4.SJDMLRA ^5!NXGI=U!+2;#]ERXG(
M6,X1]>\2>=JP2*)?(H3(<!=_7O-D/*0"7'N\KU$I>[,#MOL2:U"14AO9<?4.
M*OD*7_7 ]HH%=9K'Z2N;\>K^<,93<;1WNF.<=-RALXA@/,3.RRJ[U7R61VG3
MLC*FM_EB[4'^EXLQ:=)!!J#HQH>1QY F8,P=[8C[)-!K,\!J][]' M%"IL?@
M7/!%3N#L3/5#&F*:YMN>;;5,9)OU,CDX\[_6'G%KJNK;E3VUH!U#;-<W-3IR
M#C44KQ_U]:8.QQ$NY!&(D8Q$E*]([Y/2).M9]>_0)G;QN=9\'H7WG_FX@_V&
MRKD4)$W8VF@X"TL!IE\ARH#W VT!=".CC2F8/01Y/ZKJ=71\<LGT]-M)9[G^
MUW-,#8E-5M7.9/Y?'._^\1Q1)A2VC8M7E.]5^7X)I\\^T*[5NZM,/4SYZHRU
M0A'X\HS[;.BR@MSAK?<5%U>XK *3INW.QLN5^H!OJ3O.2YWXML'R]?.CKUG/
M,:K4HOEHX!!XX_43Z!@CTDZ?IZN^>RW7]^U<M\TA!=ZZ]]+NRXE&=:FV>N?<
M,R-7X4R7QKV+\IQ;-PQW=KB3.0GISR8D"-FEAP3NUKSI=D5-K5HLZ^6!BZU/
MHP78X[&J_%)\E''1"<_6:$"\F:AG1;86.L4FC[\<IJA3#,V@/O:AIY(AG.N-
M<3W;CIUU256I1UJ]+6IMX(V51)FH_8#%7QQ)C9<X$MB3=(M -#C6GZ(]'7/8
ME60Y.._O.8+/J+0[3=WUW2+TXZ#4;?152[_P/9GM-F ^3MX.D"WZ;C3&'C%]
M@\QB%$ PT';R)X>3K0)@N*+#;NB#=&*/DKDOE6\R\!5)%"\4YS!M4#9S=2B1
M8V>E[')N(U5J^$GTHOJ5 T,JC#'Q>(A[8D%Y!E;"L,SARENY;I<$&ZDIPK#@
MF8>> 9Q[R.\\$NHEWTO;'2':Y9&=+0,RH1Q\ICE<1UZ MI'QG<X:,CD$,__:
M/1\F"<[05[.KTSDMWDP JJ']5R2BD&(*C@_6_16(?]-F2O!^C!)TS[,$],L_
M5RA6@NGA;<98!.$I&7585R]/>9-K;F!_)%EDE)Q;CSP(%<X1_J<(![EM@4,G
M-Z_B94B@3X",7 Q$:O&(?D.)PK]L8 :)C;_^/N&22Y[768-5(^'4CQ__2UGF
MOZ.MGW69_Y9G0:ZQL2KY)Z_8?_7B_7_E%2/?G77B'^_.0OVE!%/K[P!!7OR7
MN#Z RR]?AIZ7OD:G<H[S(U5J[*72/\#O7Q14]<Z2R9^+--UV/Q(^.L)M$($)
M7).O*T8ZVGW>:Q5;-)6<>&J,Z@?%KHIZWLLRTLW2,BV_HM+I732>G)?K<)F+
MIV)$AGO4B\Y[MJ/JW:/;!U;!;)%*@CB%9 7#5/!A<".Y_G)&HFDCA%<<5S'#
M609G6T[P[/B6]2S]F_?;ZT2.V<-LFH_@I&?/RU6LE7=U:)0W:0]IO65<:C.T
MO!/P+".1QEFUXCY,$S#< Q039$MF$8&3#")7(Q+9;?Q;\1U&0D1Z<Q)H)@^C
MRWQQ]B1?HP6?BI83J^8E_Z]W/A^F E+08(D$ZAK<@]>+'EZ&=.# -6A,B0(?
MP'V#$$ D<\!QN3&08!3KN_+6&4>>T<)3.L$( BV:2I^_ZR"=!$*IV-VW/VZ9
M$B-> KKQY0530\[3#L!TEX".DPN,Q,,.X7Z'^;X"[K>8(=/"W<57^ ]O@(DB
M?EAP@PW1VH<;4+$G2""L/DY=E-.YBK)-3JB=0F@S:[3YU+=./WV/Z6MY)I):
M)%#[K_%)0;IPX&IM+$M#] ?9D%+7*YT,>&42R#J3!&KX@DD@,'#)$NGY?LYV
M8@GBP1DO&9-E)XI7K.J-;\Z\20?C\N]<)Q<AVL.W]@GD M,X\ *>:0R&NT]D
M(8%2TLB*^!4$KR^,BYA6[FTZ^(/:@'"_I? 7/[_6<;:A)25F_]4<9R^QY],M
M%K>%A;9R$/1Z+P=*#M%3(?-.4!@&8MW:!*:+]9O1.H/0KF@F%ZA'@7$/%WCY
M>^Y E@XDB")H9N9I]NWXD2/.\74\! =#S?M/RB E'M$?GZHE5IJ_5%R&TE]W
M6/O)0EY#-G(-ZZX_D1T< %^TZ@: J!) (I;(+A$ 6;0FOS<_10*Q02/E@_Q[
M5SMD/G2/.<ZEZ"\LJCP3/S&F_N*R(JLN+V>&8AZDFGA,K%ABC4BS-@U,\/K@
M'Q/,X9Z1?=4PAT.H4DSJD'</LG'80,9 2;5!NETXCROL8W'IT1_\FX1)T?5#
MESP22#_GMRT#WC6!(S"0ATIT@+QI9$^FBA#"\D;3$<HQ:S'$<U=DF4_6PS36
M)V<@KV8%9$.VK?B+^OC AS*^IXW-"FK"SL1+GTWF;B<&V+GR7'<]/N+F3ID/
M2"T#R:C,$3#]W2?$?F"1;A97%LB1JWB9@!W]"K)HWPW!6 #2D$T-+]9U#/Z]
M/Q4^U0)L*33=?21^NPRR^P6.O=18<3@ WUN#XQ(1.X\0> +<#7\2;JVV3Z9C
M^#=T:$B@[X._$SK^]?S*KC0)! )/:YW,])U_1P*]8,)D$//ODD (Y#J@Y,##
MT41X'6&4! I(F#Y" DG_<51@>+')/Q$[5I@DX$9'?T2;\W[=E]R)VQX_A$F@
MC6@=G'TB"93PDYIFNP6Y\'0V$S?:6-7QI:)W9TV*Z-PC:OQESADGRF+LBC\<
M4;^ <&9K3I,I:+)YID7A\22K[V(]-?HZW!PR*FHT6'/= ;/5ZNF_K/VTVJ7
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M,7!\33N?J'"^+J),XC*[KA8Z-,"_S;A+&QJ5X[9U!.\]JCO4$;$&CQ[LR4;
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M,Y"%T!VW:QOKW9KA>[35QU"2A+EP>@^]TIS&@*;)75^;+Z%9TZ432'5OE@S
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M-G8H=L]H$D!P+^:EB?XP4HR[E+"*IQQYU-2.+.F 7?<X547)YEVN0C!!QTV
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M@M*CU0V1=,%\+L:0%E]^G6J[,H/)SL^C:^LR5[^()+X<%%Z]3ND\)@])*N*
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MPBS3D,F"A]$U6%32\N4*JBAV(/;7R=(9^<X=CY ]?KSK_D)TNG 63HAWZ@.
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M='N@;.V9@.$R+#GA8A''6Z)P$,8TZ@\H>]G1,&WZ_ ^ASG\9) PBX,-:.]A
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M]R\YI)'A!*QDZTT4T8;[257AW@'4&DK_.QU(.'.WV7=Y%V,9J[ALO>9?LV7
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MUA1'4>M;1GFAZ8%R<^:\6,LWK;FMH,#**:?3QW _<- 61?N+]NE;D9%7 3?
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M<) NGC*VP0_FY$V]565:@< 6T!5YS"UN\&GA5T7/9ON./Z+QF]_8'JYZ'^!
M=$'Q[CW+=Y##NCL^5*E*.B7#9V;'"Y:9Z7X8V@?<P>Z%"RR\[]AV90VK3 %'
M%E:DLAAL*%\N,M%S97X!K)F\7)DTF:PMFL0??[UCZ4!O1]Y([82+P8<@6^^Y
M<S8M)BEEJP.CN)QUC$8OD%VN34/!73]-!.@99YT#$>B6BN%^ONN%*/_A\XE
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M;]_' O7N&AAAQ3]K+WLBHTR-!Q8@0#)CJ*%!.*74=+# .55;C+CB'W">0MO
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MA=/_0=.:'49OG_A3O./_R6**@W/HHDW*1U>7T:]:&(J&8"ASRI';F%?6ME@
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M/PGZQ_O?"6J$$]0-)Y7V<0QL67$0!B?]1<X_M?Q.S J<F'LXJF4><4-_1!1
MI^E.F*;UUY:]"BS =^1W2B ['('6,(RJR+LXMH ,<&P1^)E ?VGZ'8%F<00:
M0E^/7T_"L46V%,<6@Y\)])>FWPCD?T*@(I2YX(@4YI6G%8XOI3\1Z$\-OQ&(
M](1 IO!OIE]<CL\>#F'PK'"$N4FYWG1T>=RHVY;>;T_9YN+8TIVXJA'(/EGA
M-#T[>U1RR>]@[/P?&/\9C* _W__FA_0G?@B;>0-[LG5(M5>$QO_9#?]P__^
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M.A6,$J6^ &?G&%=4CVZ%^CKH6IN,K<#F-08O=13&R\KTK$L?9;QN5>).U,W
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M%GJT^O,)/11%I]H_"\8"I^IK'#D0HKLWS0[WV)8616D/'?[:1?%DH:W?5IX
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M77AVBCI2BN[TK!Q&G"9Z'M+<8'@<) 5S>'+.E5/BSCA-F>WF$U60_!Y8>K?
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M+!JTS1SA%,2\(^PJ0$<I\MVA-?Q^I>6FR0%[J?90P>@W1^DK$F3^[B''U[!
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M4A;<E!>\2;.V0E1:X6#8-X9,I2.9[IQSS#_#6<\*PP,C;]1#$L] ,5[]7);
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M -4P0$0T__LRE=_"8P*_F,(?\:F358=&/ZG$KRS6K)2RN*4;_XE^_.W*!DL
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MZK.VR!^;6&I3N&@V]GE4$ "5\!P .XX] 5"1\LAVUP6,T..U  XS'GD#O@!
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M_VSCY/#@) VKX7"C!78@3+FFK7#/GB>#CC(G*J+2_L=()QH1E-*[LWEFR4L
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M%5$ W>9BNQ2@>);LN"1M_'[P%+T.Z\U@$LC28'*M,CM G;YJ "WG+V%!IAY
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M*,%O[JA7]J6@T.W.)?%&Q"2&T+IK%3%SDY4&[2G/V-D\/R@_>"D"O5831]7
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M]UZT-/MIQD?EG])@O!KXJ$'44AP.4,()-!PCACXZ)3(=)L\'1@>Z6@_F-I-
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M_G80J[-OB:65_UBK48OH^X5P:Q-?#<,[2I>^*S'.#<)B9RGGK\+1:=BW?+$
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MGVP^TR6_ +(RV'!"%!/$=WA1M &!.FZ#VAA)Z\BM9MAF0-]6 %Z!;PI()Q<
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M(2,,* +W"#D;D1)?2NO".V^M:MF62\>LTAF;3_P>%3B7CMNUV55SVN2IZUR
MV77+B9Q(8EV:9T1C6BFGG?W:Y 32J26JD[JJ- EYL-"R7T_-FWM<Y2(3562@
M7V-J W+B\]:R*AA8U)Z\2G,BP7R/UND3F]U<!=T8;I1P9/!S<1)=:.(D2N=?
M<;Y]\&:+I6C#_0Q @J=R EZ6XQ6*^3HUZTSA$R"1&9*SYA50(5GAF=9S-Q;
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M00^6]\N,IJL/!JA*W=YFV964:74&J(U6PET/#<%/@,I\"S#0CNKDB+L?E8.
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M:JK YOI$TKW&Q&T8MX6RPV\O044\.2\5Q>.8P&LS-XX6">-O*''R@T8< 8O
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M1U 4. )*C2/-GO!_:8.V/U36HYC1%6P[+>BUE5;UK.A^DZ/_H((5"KR+W7?
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MQA>7W%\X&W1/JT!#R,:HI_ZFOXHU6KT(^LD_-YWYA]RK=[<'4FYW,5@]Y0@
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M5)_.3!#0J8P$#-I7,T:E ^W)/"R!;C)">;'BH&;A2%&M-MQU9++;!YE;8V<
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M2Z,4_T)W2PX$#0D0)M]\D(5+XJC<E75=2,J9#F@[-F&FX !<)@'VUQ CN23
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M)]+O-\O2/>X_H[DW#:D3S#R].WIFHLSS<P[\T/_U66RZ[,/,4XYHXKUSYOW
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M>R_.DT0E:$7Z[>6%9'6QT2-,*8SA%6[>\:1GF8:T;LPGK*\6QC^+D9L>*5U
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MM1'G4;=]#]="(44/!;ZN5)IM^;C(GD.C.\&T%4^8./X[[4OU1K2E+&]\5>[
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M=MP]G6K7T#(.6O#ZQ74O^&&0,#?4]WZ4.1AO *@3UD";L?&B^^S5#-C;F7J
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M]5)EXH%(?>SQB_"/>$-Q1@1* 1\C= &"9&?TN#[QG5DU+MZ94;)2C<=5K)
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M <K^RIQ2XU-J_",5=EI5\AE"E9VC2N.\3*QR&.LFL<J[<KM1;GS*C7]T\I:
M\A,SFP!E54#)Y0J9#.7&W^G:V;ANIA3*\):HD/_^-S6O7!*0)#J1[;[C.]]-
MFW5>/)^/+EG%&8TG6&:=77=3^<6"]D0IFSQ^/-1=BWNL;8(P:;<GT1!._GW
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M8"'<?MYI\[O,BP/K*F1>&J@[,B]EB&Q+A4U7D6>XO\/ ,R5D7IQ_+R9V9%Y
M.$V1?&/FI1#, V"0>6F$QD"5G\^\P-)J%Y96L+2"I56IEE;<Q')(3WIW?4&*
MQ0\6/W66?#6]RVW2/?[KX_'^=_G=W\G>Q^/N_O'I(6'D9.]=;Y]T6WO?IWL+
M?3:P6D*ZM]JZ(]U;AL@.=YQG9I -Z5X;V]>EI'O=?R\F=J1[03Q-D7QCNA<
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MOR=[[/ODRVT6&(RC=!?(4G.-N>]2RREHF@9D4446R_3Y^IX%JEO*!)9"R40
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M'(/.>"SBRR2] J1HA133P_D]W0)_.'.IYYCK,P80!8C2)(V!*$"47V<,@"A
ME*8(W#TVJ<_-];-E0)2R$86\/15WA7;? 2JH+ZF,Q'DKK6"8D6_>1S,JZ3],
M,C$"E^A5/A)&+TA'!;?00":J#TYYM<ZLKQ#H1)O(W*;MGDE=MNZ_ S8IL=H'
MN1.TIJB[QOTL".-(Y.T^,R$BTO_?:9 *,LA/_(%)JAG=P)$2- :,_)3$ !&
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MGAC>CH*8M)/I[)3,>9(E*?BCFF$-_@!_5$-?QC_:+N4< %*_( >  $"JHS$
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M@([*QS>@ ]!1'8W[63"\G8[)43)*KD4LOY.2()YY.X=Q)J[3O'25 $:J&>>
M$<!(=?4%C%0^O@$C@)'J:-S/2U3'LSK5:2SOA^3X(?Y%>LDD(\?Q51AE\H4P
MB<$CU0QU\ AXI+KZ@D<J']_@$?!(=31^Y)&KZ420B^0>X%'-F 9X #RJJR_
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M^C7^]/F<G(MAF ZG$=IK5SBDL<Y1U9@QUSW9Q_I&I\34\RCU*-*L ) &"PP
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MICGZH3I%+X(G41"FQ&3/%'Z"3UY/9^8P1BUJK6\RP/F@7$C!-@\@I>8: U(
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M>84LF79)__CTL-O)]XI/3SM=(L.^,QAT?B>S^,>6,=9%=1:X+X4+LFDJR*=
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M#7"P3:2-56 X#%9IF.;JK +#861::JSO8Z9%!OL__\$\]AXI%MTI%MND=/U
M)S:(R@87&^ "<&F6YB\IQX7K,-"EQOH"7;91W&*;%E/.NH!=M+$+C(?!+@W3
MG.ZP6=9EQ_XANL!Y6&_+Q/%8Q)=)>@6 T=E,2UR)5,3#0M,*J$4YX4(YHVY+
MM8^V^;(^VF 6=6:! S&8I6&:JQ;DPG\8P%)[E0$LI<AL^K;'U('%0I)%%[#
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M$_!(ONA"%_1T +HT3/.7H MZ.@!=:JPOT&5+Z.*R];3M\^AB,E3JZH(7]'4
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MC$VAAFENOV!/")XN8);:JXPD2VE=O2W'44^RF!34HH=:8-%2SB8S>&7K12P
M% !*W57^-I^<%,L1@D\4A3ZR+=-B&Q(K:-6 5@UHU8!6#6C5\..5V(89GWZ;
M[:MNBHY6#6C5T/A;1:N&FMWJAF(D&[73%7?V1NX,K1HJ+/MWK1H*)HB1-D.O
MAE]'=2357EUVX$W9&X$P/4;Y4L,T_V^=V[^C'+@>Z_4N":-)$@-I=,[B1?VD
M0"^*"O]UZIH.LU59Q4=?*5VL J]CL$K#-.=SU\ ?DPJ,CE'&5'N581I8%K,P
MQFWO"*:!6X<6!J]C0$O#-%?W.BX6_< 68$N55$8OS#(;2[FF"[?C"H +W(X!
M+@W3_"5NQ\7B'^@"=*F2RD"7\CQY+)/ZGC*ZN+.#&B 7#>0"NV.02\,T5V[D
M73#ZP2W@EBJIC)VBLIZ8%O-=4]F0!YV\M5&+"6H!M31+<_5*W&+1#VH!M51)
M95!+63:"C'NF>FLIY%JT40M:-8!:&J;YBW:)T+,!W%)[E<$MI?68XLSR7\ M
M*&_1!2[K![H +@"76FM.=]BL,'?'_C&W% I_< NXI4HJ@UO*$MID/F4;N 6V
MR+!%ABTR;)%_15OD%[<!=O"\45ZBH;4>EF@-TUS5[Z%8[&-]5M;ZS,&ZH9P%
M&G16T?E$ J1G:_-[ +2H0PLZZP%:&J;Y"_P>8!L.;*F_S,"6DKKM,9,S]2.3
M+[36!+6H4PMLP$$M#=/\165\, +7^T -PC@L:@0.:%&;R/-)Q>B&F2!?NGUP
MBT:IV]1TJ>6XIBY7<*"+.KK %1SHTC#-7Y!P@2\XP*7F&C\!%R./>O"+=G[Q
M&#,M<_WT$OBE9'[A, @'OS1,<]4JEV*Q#WH!O51'8Z1=2L86YCCKBY[7L:L"
MMJAC"^S!]>Y>< /(4J+>YBSE8LY3+HQO A:8@J.^I?XROX8K.)164?K,\IBG
MWL_DA8WNP2OJO )3<*19&J:Y<IH%EN"@EOK+#&HIK96)7 ?YH)8*4 M,P4$M
M#=-<O;BE6/2#6\ ME9(9W%*6TL?<=!QU;N'@%EW< EMP<$O#-'_)>:)B\0]R
M ;E42F:02VGD8MD^]3>02Q4--F%M"6M+6%LVVMH2:5UMRR,T'\#RJ&&:*V]&
MH_, ED;UEQE+H[*4/K0<DS+EI"Z\+?5A"PRY@2T-T_P%N]&PY :XU%]F@$MI
MX,*I:=D E^V#BPF/!8!+PS1_R79TL?@'N@!=*B4ST*4LI;N6[?K6"XRYT01-
M%[K 9P'HTC#-Z8X]1Y<?@PO\%@ N]9<9X%*:WP*GMJ?<4<2DL]H9<(L&;H'?
M KBE89J_@%O@N !NJ;_,X):RE/Y@.K:'(I<J@ N.+FJ>4\8BR$0*9"E#;9N.
M)*J\&BN"4$ HE9+YVVS2*>85 CY1U-ETN455^80Y.#JD"T]P= AYE89I+B]H
M5H3[X[0*S@[IK5@,HTF"?B'Z^X6,@ICTT%M>I\XG'USF6^M4"&(IFUAP:@C$
MTC#-U8D%AX9 +#77&,12CLY_26)QK?6*-Q!+V<3B@EA +,W2G*E6KA2*?0 +
M@*4Z&C\""RMV\ W$HD@L1[9I<P^NE7"MA&LE7"NKX%J)99&^9='Z1(]E$99%
MM=9<>5E4*/:Q+,*RJ#H:8UE4UK*H;4LL12)W^\3B@UA +,W27)E8"L4^B 7$
M4AV-02RE)G+73[Z!6$HF%@M.E2"6AFFN2BS%8A_$ F*ICL:SB#YIG8)8= O]
MP38="F+9/K' H!+$TC#-E8D%]I0@EIIK#&(I,\?RC+L0B*5L8H$U)8BE89HK
M$PN,*4$L-=?X&[$<YLQR"&C1OC$$%X7M0TLA?S- "Z"ENIJKMHPO%ON %D!+
M=31>,5% FD6K4V7;Y0Y#\>WVB05&VB"6AFFN3"R%8A_$ F*ICL8@EK*(I>6:
M_C.^*R"6LHD%WMH@EH9IKDPLL-8&L=1<8Q!+F<3BJ1*+:8%8=!$+O+5!+ W3
MG-%Y+<MSS )& :/46^/5<EM BEX[;4[M9^K=8$X)<TJ84\*<<AOFE/:.BY70
MZT[TJO&(M5&E9<?RZ"4 ^9BV17^A^@0Y5DG;D1TKIM=6_?E$+W=W?&1Z-65Z
MT9,(F=Z&:<[I?'.:DFGT@]UI="5"YK?F&J_N3B/SJU7IMLM<93=+;@%9]" +
M^H4 61JF^0JR_*B@#AU#@"PUUQC(4N*I1<OQUBW[@2SE(@L:A@!9&J;Y"Y %
M+4. +#77&,A2*K(XJM900!9-R&*C8PB0I6&:JR-+L>@'L@!9JJ,QD*5$9#$M
M6WECR-]A@!8]T(*F(8"6AFF>GUB<'US\<3U+L?@'M@!;JJ/Q:G-6<(MVOP6'
MKCNTH RW='!![Q" 2\,T?P(N/\JWH'\(P*7F&@-<2I/Z](/+/$?5C)L[.Q;
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MJU;H%HM]X OPI3H:?X\OH)=2Z(4YEBJ]F!2%NKK@!<U% "\-T_PENT;%XA\
M X"ICL9/ 686]D 8[0CC4LMQ/.6&KC8\O'4A##J. &$:IKER_@6=1]#0M<X"
MMX,LB))K<IKL$-=ACF]PLY@K/=!%<6IAMY1ZZ^Y1<,>$.R;<,>&.N0UW3"R.
MM"V.T. (BZ.&:;Z2WU58(:''$59(=1;XF1625:QH%"LDQ142WZ.2V]1=I%!:
MIXM>T.8(]-(PS5]P-@ 6WT"7.@O\7'*WF,$(T$4=75QS0W)W/>_BHJY.%[G
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MB;5>0A^+899.1Z0;R!L*LB0-1;%C;^ 81<E]2@WF,%3%:3TLF^=J3?H,+&X
M&6?' LEH(1FT5]<KL?QEDRR(Y!N 8+2K?1),,I%>1>*>=-_U"PL.0"D@^,4#
M:2>1,'I!.A(I.8XG.;D(^8_;R0Z816ONQ>:6@;TAO9&>(POC;'WEOZ'9.MU!
MNW4MQ()FZR 6J U< :[4=!1<UV+48. 5G2(?L!Q8/%>55U#-HHM7"GF @%?
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MYK2+#AK1.CM/\^J0"_(QRM( 3*)1Z8^'A]SU;1<XLM5A.#\R*!IZ $=JKO%
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MT__^-<;I)]3'ZBU)2=)87AV01:LCF>M1XP#=Q71J+&'%HLS!Z>*MPTJA?K^
M%<!*=31>P,H@S/*#.LBD()/21+DMAR.+HA6NF>=QQJC)F(FFIVAZBJ:G:'KZ
M&.7;;'IJ,BQ_-"U_7"Q_L/QI@L;D;19&&?*O>I<\1YWSDS/2;Q]W3@?'!\=M
M+'GT+GG,]?-J6/*\YI+'<3Q&Y9K'\MSU1R'*VDJF$0\T AJIM\;=?F?CMC'@
M!'X%-1<9?@6E^17D&3 ?M?;;AA*T!@.;-$1C' ?$1G'SY4;)?:DE]YYJ?R\@
MBI;G9@\U;+HESL)%717PI(0ZMI/@.L[?A/R<[N 3\$DEY>[WY#.3VW^!3[3N
M[+C<9@ZUJ.WZZ\]'$$JYA((R$Q!* W0&H8!0?@&Y02AE$PIJ3[9-*"@] :$T
M0.=O6SQ E'*%__2Y6#T$H$118-^E%C=<J]!$#2I15#D'$N;39[I& 4C*!9)U
M;P@ "8"DQCJ_)WMH8ZZY K;;(;W6^4D'+*)5:&HY#C-XH2D:**(J,J.<\3:U
M7(82DRW3""MT#@TT AJIEL[/;>"DJ']%:J36 C/N<&KX?J&N . 15949M>7_
MGEF8 T;*A1&T- >,-$!G[-5L*T\"&^DR;*1]VW 8W0>4Z(02TW09I<RC'*W-
MM\LE;>.973. R2MJ_,]_,(>^!Y1HC>.Q&&9I,KY)I$0B0VY$K]Q[8G@["F+2
M3J914;&!)*K _9&X<%33S".<<1<';K:.(NN-T( B0)%::;R&(N_E8W(TGN;6
MZ:3;VBMH\0 V 9M43VS))AX%FVAE$^H[YC.;!V"35QV#<,, S+_,O[6;I[W#
MX3=4^??^P# EL(2@%=!*737>%Y-;>0NDW?OXGAS'DRR=CD2<[9+B. Y441<_
MBL G.A4^&V?A.!+WQ/= *3J%-GUW[_04E++U#$JA:BHP"9BD.AJW;Z(D3Z \
M1!$YP6:.=E/,)):_FIR$<1)E 7A$[Q3=VC=LRDDOFDX )'I[E5/?,T$D6R>2
M0OEN$ F(I#H:'P7QY8V(+LGGX*N(1'R=W9!N?L?@$_WBYYJ3XRB:CL(XR%O'
M E&TRMWZU#D\,SX=]R6H %%T*LV83RW*71P4WCJDP(P>D%)SC5$#NX6NPF@J
M7([:AYW33O_O/D$AK%Z[NA;[FW'&-GF7O,N"BTC(/R_#KZ]^I=]?W==P$EZ$
M49@][-Z$EY<BGCU(/$[-IT^2V;7,_WOS#9DN@N'M=9I,XTMCF$1)NKL<BV$D
M@G17!L'-^Z??6$!6+D04QL)8?+T<O67<F(\7/0\5.6-ZORU?F8?'DY?RD##G
M0W\MC(M4!+=&<)67 P;17? P6<2HY^WPQP?=_#6:2R)O;'E3H^!^\1U&Z6_+
M6%J]C.5+J]<Q3B9AOF[:344D%U!?Q=IO?7J=*^_P6N&8B?ML\:D<BC@OBGPZ
M[.'HFDS2X1]OY( G!J?<S/M(WHM[1B]=2MG.?\;7;T@097^\.4R#\4TX?+.\
MK,MP,HZ"A]TPGHW:190,;Y=CZ9@[KK5R1^X.-^=OF >.YO!]_,$<VE\4S"N#
MLQ*NWX_^AF&5,V+^(?WV09@'E(SU*!A/Q.[R+ZLWXL@+7$B6O\E0?D>.TI,H
M#Z99\C3(9Z\\"4%SQWF<X18_-1O]_'H,.4C)=/'/5D.,S.)"WNDL,-X\M^YY
MR:+'_FW3=$N_3;6V/_^-*SJOO%4B?_U5E-PM!VKYM7$G0V]W_@&^DZK^\(/U
M[?O!A7P>3#/Q/O^,K7_$5F>P%ZX]?HE;G2\!?H5;7>#W+W&K?.=7N5-SQ_,;
M<*NODY2R >*J22GT'T)2JN8:(RE5QZ04Q"XE)^4A*?62I-0SW6Z>1Q++!))H
M0A(T' *2U%SCSM=\U2,70(0[E.R%"?GX*2]W.-[K_O_VSH:I<5Q;UW]%Q3Z]
MJZ<.#O[(=Y^^52$$R!X(["1TS^Q;MW8ICD@\.':V[0 YO_Y*LAT2H&>"&SN.
M>:=J&G ^++UK67JTM"1UR."ZTQ[VKZ[/KX97EYUAIW\8KH2JKZ_B/ADJM61M
M/D#F32!#3KL#_@L!T&0B>KVL*J*?3;RB&T"SE<Z55O5WHM8,[97<V->)1B_+
MT#J()O5EW?5_1ZT[EG6#<?968[&RF$1KNU]9UYWL-#K RQO4!ZCDL@D!I/RD
MQC^(N& 2**6(2^^HA9!+FB*?V@O72SXW 2;95NA_+D86?S?Y2<&!(5O'4*;,
MF[GDU/+Y+V1@6AP K5O+!)KL@9>#4[847#=TO:IK:DW5&FFM]@:N;(<K@R%.
M$\CMT >DLO4&-$+"6XN-29_=,H\Y)B.7E+?D_.;)=NT LVPI/?]V>T:)./%R
MR6^23&VPRI: N)PS4JW6E)MOJFH 4]+4NN<Z+\]' YUD32<X8 !TLN<:@TY
M)Q]![(A.JLHIT 1H4F0#A&B2R,N!)D"3_&@,- &:? 2QG]!$;R!7%G!29 .$
M<()C!0 G>ZXQX&1W;4A /8<B!26C93PUO5Y7^+\-!$[2/?3(4.LO)0:<9 TG
M.&$ <++G&@-. "<?0NUZS= T1?R;['!1P,D;X"2M@P4 )ULU+ -DPZ8L<6L1
MN*9-[U^&"$$G[RCS=;][>3,@*[6_D.-$C@TH>9OB()$T)1X,ZLJQPH>0)R"1
M-(76:M57DAM (MF2"#)?02(?7&;@Q]8-!G66+N@C184O+P:*4:MKR@7@(]4P
MB%HM8UGPKN$#N:WY[14!'X"/7,D,^ !\%$-G 1\OQ]T_V.*U6BJ#/MZ_,1FV
MCC$-D[+(7<=<C&C@8@>UM#,5PB,D27M*9R/FD<]ZA;3)$:FJGTC_G AG[UYT
MA[^3]GGK\KC3_P6DDJ9!CEOGO<%5CW1ZW[K]J]YEIS=L71!QAD"W=3'L=C"!
MD^I!#@.=EY>T3RZ59.<"@&.V5%ILKZ8;Y;K^\D2ZUV'&4+%??5HL@XD<L,S^
MR_PZRP!7,L05P G@I !*K^"D^CJ<',GCY_]/=)+Q.Y?T>>GN+=\*V[7XG&:Q
M?J*NJ\;& HI\E&+]A.?I"N%&U+R;>.["&2NF:[M>,_8(TV;4:W)7G'[9?"&.
M8/&"V);#E.COV(=B[S6>"ATZ+&^XZ_&YV)&3;EP2CFF$#CAA2GC$-;T51[!1
M^X$N_>A1J==+^E.G&UY3A21KAU[/Z*.R=KQUY-'KQ8@OK9?CKX[2?E[.S0.T
MW\7( 7L,HL;!9 ZO^S.S6[,)\3WSZP$WN*OHJFZHAJ$]LD=-'==452O],9\<
M$&H'7P_./#J?6N9!7*RQY<]MNFQ:CK3:R';-N]B65:-4*Z_5J%;2C?"&&;CO
MTQM%0/1-SKQFG#5W?6[]'YB5-\RBJ5@]"*%#<5^WZ=QGS?B7]8J(44XDF;B)
MR5_A5MKP<KH(W$TGEU<V7-"0PZ5-%Y36%^51N)'<1?2Q=1<CTB]X3:5C'+PV
MH_W&0=@/&GUUU>#G[(SZS!Q1>ZLC1O^^;7@&^7<D?SAL@_R[D3\:P4'^'<DO
MQW10?T?JAP,]R)^"_ A.9S4,W]9""%?G6G:$K[<,.F'2?7?):YAEW]L&!E'M
M]Y<=D)/AK.5WY!*F+/%5,,5)K"E[,2\U(]^I-\,1K"GO,>"QF<6\9 M&0"C;
MB?S;N:*KR=*BP"-;#WC^3F?S+ZT;35.UZK8+*@V#@P4HY-VWG^\HQLMD!U (
M]KS<*XV';#9OV5Q',NQ<7G?ZK>%-OT,&G=[@JG]($CLYZ&1K#KQL]8=2\ X9
M+<E)]ZP+4$ES_7!;&5Y>5ZZ[O9-N+YEO@U>VS0JLG[8:U9.RVA#EQ@80.\:5
MEPM'@"O E;W2^*]Q)9&3 U> *_G4&[B2):XT5%T'KN3 %+PEKV##*O#*OFL\
MI,X=X9Y,^FRRL).N: 6>I._3()(M)>X=M8 A60L,]LBPS3X]18))^AH#/%(=
MI\^9&7B+&?EU>*IHO.ADL/0#-@-^I*EZOW-]T3WK8%>'5%W[]\BE@2&I1D-4
MK:IHNJ*KRFN)/2"2K(GDW\-?P27@DOT6>,4EH4^3P<*;,"+#)$ 3H,F>B_RO
MEJ8;9;W> )JD>GZM6E4US:@#2G8-)=@'$SBRSP(C3 (6*:C(")-D'R;!(6>[
M)Q(9)@&7@$OV6>#-,(F., G0I$ B_ZNE:N5Z%622091$JX!)=LTD2&0%C>RS
MP+]ZKG]JN^37RVM+$ F")""18HC\$_G"X)!MQS)'O29I<YW5<G4U,?:GG_B?
MD3@R9(LW7E Q++I>S.;D\_4U'RC]0I[N9JCU^OO>;C"CMKUV.VW]=EI#+Y//
ME^Z8V:2AJHI6U8Q?WO?^Q]2\(]<>\_V%Q\@WRJT6%N"'*<,X=P7GKN#<%9R[
M\B'/77GC@+:*WGS; 6T9 UH,:/=8X-6 MJ]C0+LG ]HJ1EO;J"R''O5&HI C
M']-"Y&U$ED- .?(ZEN-:]6F7O)1'>M?M;_R.?&Q9T?1W'MQRCV"\0ORK#:->
M+:>U 08P:VO,>CEU \P"9NV/P, L8%9!509F92#R/S0N<[E>2VNA!U!D:Q3!
M5N= D7T6&"D,0)&"JBQ1I&$D77,*D;<1^4*@B*%J:6V$ 139&D6PC3E09)\%
M!HH 10JJ,E D0Q39=K&I7GO;*;1 D:U1Y&5@"B@"%-DK@<G@CI?\\R7E#.*=
MVNSQER\D)I2+DU.C!D0!HA1(Y<'OOUXHFJXIJM8CKD>BOW7Q]_LF5'P.NXA_
M7]_(E0+7S)LQ&H3+%9JDU1;7HW)\OF#,=QWRG?K3R8)Z8W+"?&[A+R1<3] N
MJUJM]VNEIK[SBH*XC-]:LHPB[62^D742%?2TGJ) 9^'-3ZR)%5#[*>WETG6L
MP/6B(NBJIH KTSQJ2!.[Q91KY;@WN.6] 3D^&JXLPYUQ85./G'C6/?OE=?S,
MXXH3K/7 6@^L]2CR6@^]6BHCWO[.7<*V#HEQ;ZYEQVAX%[)CW+L;V3$0WA+W
MY;@SWF?L@H[\:+#9C%:OJ[67A(_AUB[<_@=A?2!/:G']1!-8X!O$]7,B<)_-
MN7;,D=M:ZQ7L:HWX?5%4EMM:<Y<&FZ2ZJ;5:U:MOV- :.09IL8B6R-/!(F"1
MG B\P2+5U0D;V,<:,++W*DL8J28^8@,B;PTCE11/UP",; TC.'X4,++/ F-'
M"K!(057&CA19K;VH5 QLCK5S%,$17T"1?19X<XY&Q=&C8)'"J!Q.TJ@(C*0=
M&#%T X&1W?>4BH8COD C^RPP B. D8*JC,!(!B+?.'>.^^  1'8-(CB:!2"R
MSP(_#XL 1  B!5$YCHH 1-(-BE0:]2KR179MB.&E\HH% "/O*?&4>3-WQ@+F
M 4K2%#K> "44W'07<YN1GU0?=+*M^J?VXHX!3=*4N))H-AU0LJ6\-;U>5K7R
MR_.\ "39 @F21@ D11!Z$TC (&"0_9>XHI%N%QB2HL*:4:FH9>/E65[ D&PQ
M!*>I 4.*(/3%5>],&0P[E^2D>]8=MB[(\+S3O[RZ[ P[_4.2V-7!)=M:X-OW
M/J@D38&KFJZK2EE+YL<@DRW)I*H:=:VNO\Q> )IDBR;8^@QH4@2A![QH-B/M
M*74<9I,3&E#;G?!OFB!HDI4-VOR"Y]JD[<[FU%D"5-(%%:VJ*<8KHWN RCN"
MBJ95M(K>P +@'8.*]G(R#: "4-D_H74P"@(H!1984]5R7:EBQ]9T5:ZIAJZ6
M:T@QV367X'AZ<$D1A :7@$N*+#"X)"LNJ>G:*Z-U<$FV7(*SZL$E11 :7 (N
M*;+ X)(LN02YL+OF$B2<@$N*(#2X!%Q29($C+JF"2U+FDK):J]60"+MC+M&Q
M5!A<4@2A+ZS_+'BY+8><V=3W020@DH((7-54K:PT=!!)FBKW7.?EPG<)(T<!
M'=F,_QQ;]^]>QN?ENK=\:V395K!L3JWQF#G\#7__6UU7C2\;I9-E"?^=KF!I
M1,V[B><NG+%BNK;K-6,KF#:C7I.;?_IE\X7X7&->$-MRF!+]'=LM]ACCJ="A
MD_#6L?XIOA(ZQL8EX0Q&:/0)4T8>HW<*O>5M<9/:#W3I1]Y9KY?TI^XMO*8*
M27C%XDK-Z&/T"D?S3[$7K1<COK1>CKGK6X'E.DV/V32P[MF+;]TLY]H=WLL1
M _881,^CR1Q>]V=FMV83XGOFUP-N<%?15=U0#4-[9(^:.JZIJE;Z8SXY(-0.
MOAZ<>70^M<R#N%ACRY_;=-FT'&FUD>V:=[$MJT:I5EZK4:VD&^$-A>.D[+Y/
M;Q2X_B9G7C/.FKL^M_X/S,K;0O&0KAZ$T*&XK]MT[K-F_,MZ1<1!WI%DXB8F
M?X5;:</+Z2)P-YU<7MEP04.>"+[I@M+ZHCP*-Y*[B#ZV[F)$^@6OJ72, XQX
M,ASQ(*,>(YXB"(T1#T8\Q108(Y[=CG@ (YG!"+9( HP406C R(Z$/U>. 2.
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M< HXY4.I#D[)CE.JV*)IUYR"K23!*440&IP"3OE0JH-3,N04;-&T:TZI@5/
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MP"$%TA<<DFD\!/N@[II#7CD*$!P"#MDGB9$3 O8H@KY@CTS7X6(?U)VS!_8
M 7L40&+$0, A!=(7'))I# 3K8G;.(=@/!!Q2 (G!(>"0 ND+#LDT'O+R4'AP
M2,8<@KU!P"$%D!@< @XID+[@D"QS4RM8([/3!GRHZ%BJFZK$?_^;5E6_@$-2
M=6,VFS./!@N/D9;-]02"I"GW2?>L"P9)TY\OE7]=&QQ#!OW.MQ9 )$VM-:U:
MK8:%UJKU:D/5#.R;NFLFP;)=,,F>:PPF 9,426 PR5XPB6& 2%(@DE?T!Y&
M2/9*8T$DDD3(]VZ_<]$9#,BP<WG=Z;>&-_T. 9^D*?[@LM4?DD&G-^B0T9(
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M^JK?(8/NV>7+8P0 *N\I=FL@5C-\.P6GI'KDB*;7D72R<T)!ABP(I0A"@U!
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M1LLT&\VH\A+_(.(*(MD9D1@@DM2\OL]N>0691P,7FSRFV[Z0P"5U<M(Y(VV
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MEV<&[#&('E"3.;SNS\QNS2;$]\RO!]S@KJ*KNJ$:AO;('C5U7%-5K?3'?')
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M*),K<P!E4D09U[Q+TIV"91(*/GQPB;GD*,.K1NR$Z@-F #.%UALP Y@IICD
M,VENS6'> 64R#<OTH[#,;&$'%@DL#C4S%G@N\1+9 F #L"FTW@";E,$&._#E
MU?>!-0GU'DSYW7AI0399*1Y,/2:V6Z>68S/?Y[\Q9D>,XW-KW(H-^&RR<*S
M/R0CU[T35^\9@"?OC1" !\"SKW(CDI,K<P!Y4IPE$:N*$<K)-)3S''>"9#8
MT8!H"JTWB 9$4TQS@&C2SAD&TF2[08TU8M[$IKY_M-I>F,/-'%G$>]+< &X
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MPS*&"I(!R11*;RS<SG33X$7@_F=AS8EVR*M![!$QZ9R:5K"4R[BQ-<T^M3D
M'*0([ZO<B-7DRAP@G!1W@&N1P=(/V R8D_$BJ)'[2)*K#YQ)J/YW&B0Y"00X
MDS0G^ZA'*H:AJGJID2!1$EB33'8NN:X8:DT#V>3$(B ;Q&Z*J_8J=J,?5L+8
M#7;>VX7^ )O,)J*&'4-5](J"$[JSDES7-$VMUQJ FKQ8!%"3<>8DOR;VMT5Z
M389=ZZ-E3CUW1BZI'S"/F,EM +SY21L ;[)2W%!511P>#;C)2/ RSNC.BRE
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MR[-!,(54&P23ER8>!),_O4$P()C]-X<@&+4!@@'!%%%M$$Q>FG@03/[T!L&
M8/;?'-=8BI3U\FH 3%9J:T?Z^34Q74=*.[(9>6"V+==6EPB()KNMDY8. ]
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MY*XK_>&.)P;QR?'N^_?9(R6'H_19H)=VHH3'8WDCL.]<KXXGN#KI!_'H='J
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MJN!&NL*B,JF=H'**[\))$.*N$H!8#J"9X3"] P :"B<FV .HB[@GK$0CSV3
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MT>YH]^A91;LFN96B)72&5>0Z3?&T=P4% 27@.!UD;F2&CLSB@3ZA5@U]2"6
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M9O>NU>MCK\3<YO=;6(A;+?5C5C;PA0R9; 8BCFFFF%?^4Q_5+BB)[ W'K2^
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M%7(RIT99'I$( ^V1&\["^H%*QW3O<DC99FO E%]6Z&\_!O\ 4$L! A0#%
M  @ >$NO5@L0%R F(0  ")8! !$              ( !     &EB:6\M,C R
M,S S,S$N>'-D4$L! A0#%     @ >$NO5M61';Z[%@  6WD! !4
M     ( !52$  &EB:6\M,C R,S S,S%?8V%L+GAM;%!+ 0(4 Q0    ( 'A+
MKU8/6M=_>TH   NX!  5              "  4,X  !I8FEO+3(P,C,P,S,Q
M7V1E9BYX;6Q02P$"% ,4    " !X2Z]6J1^!_]&N  "+O D %0
M    @ 'Q@@  :6)I;RTR,#(S,#,S,5]L86(N>&UL4$L! A0#%     @ >$NO
M5CFZ[ ?L?P  >_P( !4              ( !]3$! &EB:6\M,C R,S S,S%?
M<')E+GAM;%!+ 0(4 Q0    ( 'A+KU;-&?'>03P# ._Q)0 5
M  "  12R 0!I8FEO+3(P,C,P,S,Q>#$P<2YH=&U02P$"% ,4    " !X2Z]6
MGUN+GH_?  !C. $ &               @ &([@0 :6)I;RTR,#(S,#,S,7@Q
M,'$P,#$N:G!G4$L! A0#%     @ >$NO5DE$QT^8[0  2TL! !@
M     ( !3<X% &EB:6\M,C R,S S,S%X,3!Q,# R+FIP9U!+ 0(4 Q0    (
M 'E+KU:RQ[!<D"@! %3M)  8              "  1N\!@!I8FEO+3(P,C,P
M,S,Q>&5X,3!D-RYH=&U02P$"% ,4    " !Y2Z]6C4DSS.,<  "6YP  &
M            @ 'AY < :6)I;RTR,#(S,#,S,7AE>#$P9#@N:'1M4$L! A0#
M%     @ >4NO5A9S-,$3"@  DD<  !@              ( !^@$( &EB:6\M
M,C R,S S,S%X97@S,60Q+FAT;5!+ 0(4 Q0    ( 'E+KU8G'YP]Y0D  /-(
M   8              "  4,," !I8FEO+3(P,C,P,S,Q>&5X,S%D,BYH=&U0
M2P$"% ,4    " !Y2Z]6K JB3A4&  #U*   &               @ %>%@@
M:6)I;RTR,#(S,#,S,7AE>#,R9#$N:'1M4$L! A0#%     @ >4NO5G5/\4/
M!0  T1D  !@              ( !J1P( &EB:6\M,C R,S S,S%X97@S,F0R
:+FAT;5!+!08     #@ . +X#  "?(@@    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
